ID APC_HUMAN Reviewed; 2843 AA. AC P25054; B7Z2B6; D3DT03; Q15162; Q15163; Q93042; DT 01-MAY-1992, integrated into UniProtKB/Swiss-Prot. DT 16-MAY-2006, sequence version 2. DT 28-JAN-2026, entry version 276. DE RecName: Full=Adenomatous polyposis coli protein; DE Short=Protein APC; DE AltName: Full=Deleted in polyposis 2.5; GN Name=APC {ECO:0000312|HGNC:HGNC:583}; Synonyms=DP2.5; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1A AND 2), AND VARIANT ASP-1822. RC TISSUE=Fetal brain; RX PubMed=1678319; DOI=10.1016/0092-8674(81)90022-2; RA Joslyn G., Carlson M., Thliveris A., Albertsen H., Gelbert L., Samowitz W., RA Groden J., Stevens J., Spirio L., Robertson M., Sargeant L., Krapcho K., RA Wolff E., Burt R., Hughes J.P., Warrington J., McPherson J.D., RA Wasmuth J.J., le Paslier D., Abderrahim H., Cohen D., Leppert M., White R.; RT "Identification of deletion mutations and three new genes at the familial RT polyposis locus."; RL Cell 66:601-613(1991). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1A), AND VARIANT ASP-1822. RX PubMed=1651562; DOI=10.1126/science.1651562; RA Kinzler K.W., Nilbert M.C., Su L.-K., Vogelstein B., Bryan T.M., Levy D.B., RA Smith K.J., Preisinger A.C., Hedge P., McKechnie D., Finniear R., RA Markham A., Groffen J., Boguski M.S., Altschul S.F., Horii A.K., Ando H., RA Miyoshi Y., Miki Y., Nishisho I., Nakamura Y.; RT "Identification of FAP locus genes from chromosome 5q21."; RL Science 253:661-665(1991). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1A), FUNCTION, SUBCELLULAR LOCATION, RP INTERACTION WITH ARHGEF4, AND IDENTIFICATION IN A COMPLEX WITH ARHGEF4 AND RP CTNNB1. RX PubMed=10947987; DOI=10.1126/science.289.5482.1194; RA Kawasaki Y., Senda T., Ishidate T., Koyama R., Morishita T., Iwayama Y., RA Higuchi O., Akiyama T.; RT "Asef, a link between the tumor suppressor APC and G-protein signaling."; RL Science 289:1194-1197(2000). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15372022; DOI=10.1038/nature02919; RA Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S., RA Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M., RA She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S., RA Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M., RA Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M., RA Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T., RA Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., RA Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R., RA Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L., RA Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N., RA Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., RA Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., RA Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.; RT "The DNA sequence and comparative analysis of human chromosome 5."; RL Nature 431:268-274(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ASP-1822. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-1135 (ISOFORM 1B). RC TISSUE=Amygdala {ECO:0000312|EMBL:BAH11802.1}; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1506-1524. RX PubMed=1310068; RA Miki Y., Nishisho I., Horii A., Miyoshi Y., Utsunomiya J., Kinzler K.W., RA Vogelstein B., Nakamura Y.; RT "Disruption of the APC gene by a retrotransposal insertion of L1 sequence RT in a colon cancer."; RL Cancer Res. 52:643-645(1992). RN [8] RP INTERACTION WITH ALPHA- AND BETA-CATENINS. RX PubMed=8259519; DOI=10.1126/science.8259519; RA Su L.-K., Vogelstein B., Kinzler K.W.; RT "Association of the APC tumor suppressor protein with catenins."; RL Science 262:1734-1737(1993). RN [9] RP INTERACTION WITH DLG1. RX PubMed=8638125; DOI=10.1126/science.272.5264.1020; RA Matsumine A., Ogai A., Senda T., Okumura N., Satoh K., Baeg G.-H., RA Kawahara T., Kobayashi S., Okada M., Toyoshima K., Akiyama T.; RT "Binding of APC to the human homolog of the Drosophila discs large tumor RT suppressor protein."; RL Science 272:1020-1023(1996). RN [10] RP INTERACTION WITH DLG3. RC TISSUE=Fetal brain; RX PubMed=9188857; DOI=10.1038/sj.onc.1201087; RA Makino K., Kuwahara H., Masuko N., Nishiyama Y., Morisaki T., Sasaki J., RA Nakao M., Kuwano A., Nakata M., Ushio Y., Saya H.; RT "Cloning and characterization of NE-dlg: a novel human homolog of the RT Drosophila discs large (dlg) tumor suppressor protein interacts with the RT APC protein."; RL Oncogene 14:2425-2433(1997). RN [11] RP INTERACTION WITH APC2. RX PubMed=11691822; RA Jarrett C.R., Blancato J., Cao T., Bressette D.S., Cepeda M., Young P.E., RA King C.R., Byers S.W.; RT "Human APC2 localization and allelic imbalance."; RL Cancer Res. 61:7978-7984(2001). RN [12] RP INTERACTION WITH MAPRE1; MAPRE2 AND MAPRE3. RX PubMed=14514668; DOI=10.1074/jbc.m306194200; RA Bu W., Su L.-K.; RT "Characterization of functional domains of human EB1 family proteins."; RL J. Biol. Chem. 278:49721-49731(2003). RN [13] RP UBIQUITINATION. RX PubMed=15355978; DOI=10.1074/jbc.m404655200; RA Choi J., Park S.Y., Costantini F., Jho E.-H., Joo C.-K.; RT "Adenomatous polyposis coli is down-regulated by the ubiquitin-proteasome RT pathway in a process facilitated by Axin."; RL J. Biol. Chem. 279:49188-49198(2004). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [15] RP SUBCELLULAR LOCATION, INTERACTION WITH SCRIB, AND MUTAGENESIS OF THR-2841 RP AND VAL-2843. RX PubMed=16611247; DOI=10.1111/j.1365-2443.2006.00954.x; RA Takizawa S., Nagasaka K., Nakagawa S., Yano T., Nakagawa K., Yasugi T., RA Takeuchi T., Kanda T., Huibregtse J.M., Akiyama T., Taketani Y.; RT "Human scribble, a novel tumor suppressor identified as a target of high- RT risk HPV E6 for ubiquitin-mediated degradation, interacts with adenomatous RT polyposis coli."; RL Genes Cells 11:453-464(2006). RN [16] RP FUNCTION, INTERACTION WITH MAPRE1 AND ACTIN, AND PHOSPHORYLATION. RX PubMed=17293347; DOI=10.1074/jbc.m610615200; RA Moseley J.B., Bartolini F., Okada K., Wen Y., Gundersen G.G., Goode B.L.; RT "Regulated binding of adenomatous polyposis coli protein to actin."; RL J. Biol. Chem. 282:12661-12668(2007). RN [17] RP FUNCTION, AND INTERACTION WITH SPATA13. RX PubMed=17599059; DOI=10.1038/sj.onc.1210574; RA Kawasaki Y., Sagara M., Shibata Y., Shirouzu M., Yokoyama S., Akiyama T.; RT "Identification and characterization of Asef2, a guanine-nucleotide RT exchange factor specific for Rac1 and Cdc42."; RL Oncogene 26:7620-7627(2007). RN [18] RP DEUBIQUITINATION. RX PubMed=18281465; DOI=10.1101/gad.463208; RA Tran H., Hamada F., Schwarz-Romond T., Bienz M.; RT "Trabid, a new positive regulator of Wnt-induced transcription with RT preference for binding and cleaving K63-linked ubiquitin chains."; RL Genes Dev. 22:528-542(2008). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2671, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-780; SER-1042; SER-1360; RP SER-1861; SER-1863; SER-1864; THR-2151; SER-2260; SER-2270; SER-2283; RP SER-2473; SER-2535; SER-2671; SER-2674; THR-2679 AND SER-2789, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [22] RP ALTERNATIVE PROMOTER USAGE, AND TISSUE SPECIFICITY. RX PubMed=19527921; DOI=10.1016/j.canlet.2009.05.016; RA Hosoya K., Yamashita S., Ando T., Nakajima T., Itoh F., Ushijima T.; RT "Adenomatous polyposis coli 1A is likely to be methylated as a passenger in RT human gastric carcinogenesis."; RL Cancer Lett. 285:182-189(2009). RN [23] RP INTERACTION WITH MAPRE1, AND SUBCELLULAR LOCATION. RX PubMed=19632184; DOI=10.1016/j.cell.2009.04.065; RA Honnappa S., Gouveia S.M., Weisbrich A., Damberger F.F., Bhavesh N.S., RA Jawhari H., Grigoriev I., van Rijssel F.J., Buey R.M., Lawera A., RA Jelesarov I., Winkler F.K., Wuthrich K., Akhmanova A., Steinmetz M.O.; RT "An EB1-binding motif acts as a microtubule tip localization signal."; RL Cell 138:366-376(2009). RN [24] RP FUNCTION. RX PubMed=19893577; DOI=10.1038/embor.2009.233; RA Kawasaki Y., Tsuji S., Muroya K., Furukawa S., Shibata Y., Okuno M., RA Ohwada S., Akiyama T.; RT "The adenomatous polyposis coli-associated exchange factors Asef and Asef2 RT are required for adenoma formation in Apc(Min/+)mice."; RL EMBO Rep. 10:1355-1362(2009). RN [25] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=19151759; DOI=10.1038/onc.2008.478; RA Sagara M., Kawasaki Y., Iemura S.I., Natsume T., Takai Y., Akiyama T.; RT "Asef2 and Neurabin2 cooperatively regulate actin cytoskeletal organization RT and are involved in HGF-induced cell migration."; RL Oncogene 28:1357-1365(2009). RN [26] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [27] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=20937854; DOI=10.1073/pnas.1000975107; RA Zaoui K., Benseddik K., Daou P., Salaun D., Badache A.; RT "ErbB2 receptor controls microtubule capture by recruiting ACF7 to the RT plasma membrane of migrating cells."; RL Proc. Natl. Acad. Sci. U.S.A. 107:18517-18522(2010). RN [28] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-744 AND SER-780, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [29] RP INTERACTION WITH AMER1. RX PubMed=21498506; DOI=10.1074/jbc.m111.224881; RA Tanneberger K., Pfister A.S., Kriz V., Bryja V., Schambony A., Behrens J.; RT "Structural and functional characterization of the Wnt inhibitor APC RT membrane recruitment 1 (Amer1)."; RL J. Biol. Chem. 286:19204-19214(2011). RN [30] RP ALTERNATIVE PROMOTER USAGE, TISSUE SPECIFICITY, AND INVOLVEMENT IN FAP1. RX PubMed=21643010; DOI=10.1038/onc.2011.201; RA Rohlin A., Engwall Y., Fritzell K., Goeransson K., Bergsten A., RA Einbeigi Z., Nilbert M., Karlsson P., Bjoerk J., Nordling M.; RT "Inactivation of promoter 1B of APC causes partial gene silencing: evidence RT for a significant role of the promoter in regulation and causative of RT familial adenomatous polyposis."; RL Oncogene 30:4977-4989(2011). RN [31] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1861; SER-1863 AND SER-1864, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [32] RP INTERACTION WITH AMER2. RX PubMed=22128170; DOI=10.1074/jbc.m111.308650; RA Pfister A.S., Tanneberger K., Schambony A., Behrens J.; RT "Amer2 protein is a novel negative regulator of Wnt/beta-Catenin signaling RT involved in neuroectodermal patterning."; RL J. Biol. Chem. 287:1734-1741(2012). RN [33] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [34] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-744; SER-748; SER-908; RP SER-1042; SER-1371; SER-1385; THR-1438; SER-1774; SER-1861; SER-2260; RP SER-2283; SER-2569; SER-2674; SER-2724 AND SER-2789, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [35] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-780, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [36] RP INTERACTION WITH JPT1. RX PubMed=25169422; DOI=10.1002/jcb.24956; RA Varisli L., Ozturk B.E., Akyuz G.K., Korkmaz K.S.; RT "HN1 negatively influences the beta-catenin/E-cadherin interaction, and RT contributes to migration in prostate cells."; RL J. Cell. Biochem. 116:170-178(2015). RN [37] RP ALTERNATIVE PROMOTER USAGE, TISSUE SPECIFICITY, AND INVOLVEMENT IN FAP1. RX PubMed=27217144; DOI=10.1038/srep26011; RA Yamaguchi K., Nagayama S., Shimizu E., Komura M., Yamaguchi R., Shibuya T., RA Arai M., Hatakeyama S., Ikenoue T., Ueno M., Miyano S., Imoto S., RA Furukawa Y.; RT "Reduced expression of APC-1B but not APC-1A by the deletion of promoter 1B RT is responsible for familial adenomatous polyposis."; RL Sci. Rep. 6:26011-26011(2016). RN [38] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 2-55. RX PubMed=10926498; DOI=10.1006/jmbi.2000.3895; RA Day C.L., Alber T.; RT "Crystal structure of the amino-terminal coiled-coil domain of the APC RT tumor suppressor."; RL J. Mol. Biol. 301:147-156(2000). RN [39] RP X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 1021-1035 IN COMPLEX WITH CTNNB1. RX PubMed=11707392; DOI=10.1093/emboj/20.22.6203; RA Eklof Spink K., Fridman S.G., Weis W.I.; RT "Molecular mechanisms of beta-catenin recognition by adenomatous polyposis RT coli revealed by the structure of an APC-beta-catenin complex."; RL EMBO J. 20:6203-6212(2001). RN [40] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 2034-2049 IN COMPLEX WITH AXIN1, RP AND INTERACTION WITH AXIN1. RX PubMed=10811618; DOI=10.1093/emboj/19.10.2270; RA Spink K.E., Polakis P., Weis W.I.; RT "Structural basis of the axin-adenomatous polyposis coli interaction."; RL EMBO J. 19:2270-2279(2000). RN [41] RP STRUCTURE BY NMR OF 1578-1596 IN COMPLEX WITH ASAP1, AND INTERACTION WITH RP ASAP1. RX PubMed=20509626; DOI=10.1021/bi100563z; RA Kaieda S., Matsui C., Mimori-Kiyosue Y., Ikegami T.; RT "Structural basis of the recognition of the SAMP motif of adenomatous RT polyposis coli by the Src-homology 3 domain."; RL Biochemistry 49:5143-5153(2010). RN [42] RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 407-775, AND DOMAIN ARM REPEATS. RX PubMed=21871439; DOI=10.1016/j.bbrc.2011.08.044; RA Zhang Z., Lin K., Gao L., Chen L., Shi X., Wu G.; RT "Crystal structure of the armadillo repeat domain of adenomatous polyposis RT coli which reveals its inherent flexibility."; RL Biochem. Biophys. Res. Commun. 412:732-736(2011). RN [43] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 396-732 IN COMPLEX WITH KHDRBS1, RP INTERACTION WITH KHDRBS1, AND MUTAGENESIS OF LYS-516 AND ARG-549. RX PubMed=22000517; DOI=10.1016/j.str.2011.07.013; RA Morishita E.C., Murayama K., Kato-Murayama M., Ishizuka-Katsura Y., RA Tomabechi Y., Hayashi T., Terada T., Handa N., Shirouzu M., Akiyama T., RA Yokoyama S.; RT "Crystal structures of the armadillo repeat domain of adenomatous polyposis RT coli and its complex with the tyrosine-rich domain of Sam68."; RL Structure 19:1496-1508(2011). RN [44] RP VARIANTS FAP1. RX PubMed=1651563; DOI=10.1126/science.1651563; RA Nishisho I., Nakamura Y., Miyoshi Y., Miki Y., Ando H., Horii A., RA Koyama K., Utsunomiya J., Baba S., Hedge P., Markham A., Krush A.J., RA Petersen G.M., Hamilton S.R., Nilbert M.C., Levy D.B., Bryan T.M., RA Preisinger A.C., Smith K.J., Su L.-K., Kinzler K.W., Vogelstein B.; RT "Mutations of chromosome 5q21 genes in FAP and colorectal cancer RT patients."; RL Science 253:665-669(1991). RN [45] RP VARIANT FAP1 GLY-911. RX PubMed=1338904; DOI=10.1093/hmg/1.4.229; RA Miyoshi Y., Nagase H., Ando H., Ichii S., Nakatsuru S., Aoki T., Miki Y., RA Mori T., Nakamura Y.; RT "Somatic mutations of the APC gene in colorectal tumors: mutation cluster RT region in the APC gene."; RL Hum. Mol. Genet. 1:229-233(1992). RN [46] RP VARIANTS FAP1. RX PubMed=1338691; DOI=10.1093/hmg/1.8.559; RA Nakatsuru S., Yanagisawa A., Ichii S., Tahara E., Kato Y., Nakamura Y., RA Horii A.; RT "Somatic mutation of the APC gene in gastric cancer: frequent mutations in RT very well differentiated adenocarcinoma and signet-ring cell carcinoma."; RL Hum. Mol. Genet. 1:559-563(1992). RN [47] RP VARIANTS FAP1 MET-1292 AND TRP-1348, AND VARIANTS ASP-1118; VAL-1304 AND RP SER-2502. RX PubMed=1338764; DOI=10.1002/humu.1380010603; RA Nagase H., Miyoshi Y., Horii A., Aoki T., Petersen G.M., Vogelstein B., RA Maher E., Ogawa M., Maruyama M., Utsunomiya J., Baba S., Nakamura Y.; RT "Screening for germ-line mutations in familial adenomatous polyposis RT patients: 61 new patients and a summary of 150 unrelated patients."; RL Hum. Mutat. 1:467-473(1992). RN [48] RP VARIANTS FAP1 CYS-2621 AND PHE-2839. RX PubMed=1316610; DOI=10.1073/pnas.89.10.4452; RA Miyoshi Y., Ando H., Nagase H., Nishisho I., Horii A., Miki Y., Mori T., RA Utsunomiya J., Baba S., Petersen G.; RT "Germ-line mutations of the APC gene in 53 familial adenomatous polyposis RT patients."; RL Proc. Natl. Acad. Sci. U.S.A. 89:4452-4456(1992). RN [49] RP VARIANTS FAP1 CYS-414; THR-784 AND LEU-1176. RX PubMed=8111410; DOI=10.1002/humu.1380020602; RA Nagase H., Nakamura Y.; RT "Mutations of the APC (adenomatous polyposis coli) gene."; RL Hum. Mutat. 2:425-434(1993). RN [50] RP VARIANT FAP1 TRP-99. RC TISSUE=Peripheral blood lymphocyte; RX PubMed=7833149; DOI=10.1016/0959-8049(94)00294-f; RA Dobbie Z., Spycher M., Huerliman R., Ammann R., Ammann T., Roth J., RA Mueller A., Mueller H., Scott R.J.; RT "Mutational analysis of the first 14 exons of the adenomatous polyposis RT coli (APC) gene."; RL Eur. J. Cancer 30A:1709-1713(1994). RN [51] RP VARIANT FAP1 GLY-722. RX PubMed=7833931; DOI=10.1093/hmg/3.9.1687; RA Stella A., Montera M., Resta N., Marchese C., Susca F., Gentile M., RA Romio L., Pilia S., Prete F., Mareni C., Guanti G.; RT "Four novel mutations of the APC (adenomatous polyposis coli) gene in FAP RT patients."; RL Hum. Mol. Genet. 3:1687-1688(1994). RN [52] RP ERRATUM OF PUBMED:7833931. RA Stella A., Montera M., Resta N., Marchese C., Susca F., Gentile M., RA Romio L., Pilia S., Prete F., Mareni C., Guanti G.; RL Hum. Mol. Genet. 3:1918-1918(1994). RN [53] RP INVOLVEMENT IN FAP1. RX PubMed=7661930; DOI=10.1056/nejm199503303321302; RA Hamilton S.R., Liu B., Parsons R.E., Papadopoulos N., Jen J., Powell S.M., RA Krush A.J., Berk T., Cohen Z., Tetu B., Burger P.C., Wood P.A., Taqi F., RA Booker S.V., Petersen G.M., Offerhaus G.J.A., Tersmette A.C., RA Giardiello F.M., Vogelstein B., Kinzler K.W.; RT "The molecular basis of Turcot's syndrome."; RL N. Engl. J. Med. 332:839-847(1995). RN [54] RP INVOLVEMENT IN DESMD. RX PubMed=8940264; RA Eccles D.M., van der Luijt R.B., Breukel C., Bullman H., Bunyan D., RA Fisher A., Barber J., du Boulay C., Primrose J., Burn J., Fodde R.; RT "Hereditary desmoid disease due to a frameshift mutation at codon 1924 of RT the APC gene."; RL Am. J. Hum. Genet. 59:1193-1201(1996). RN [55] RP VARIANT HEPATOBLASTOMA CYS-1395. RX PubMed=8764128; RA Oda H., Imai Y., Nakatsuru Y., Hata J., Ishikawa T.; RT "Somatic mutations of the APC gene in sporadic hepatoblastomas."; RL Cancer Res. 56:3320-3323(1996). RN [56] RP VARIANT FAP1 ILE-171. RX PubMed=8990002; RX DOI=10.1002/(sici)1098-1004(1997)9:1<7::aid-humu2>3.0.co;2-8; RA van der Luijt R.B., Meera Khan P., Vasen H.F.A., Tops C.M.J., RA van Leeuwen-Cornelisse I.S.J., Wijnen J.T., van der Klift H.M., Plug R.J., RA Griffioen G., Fodde R.; RT "Molecular analysis of the APC gene in 105 Dutch kindreds with familial RT adenomatous polyposis: 67 germline mutations identified by DGGE, PTT, and RT southern analysis."; RL Hum. Mutat. 9:7-16(1997). RN [57] RP VARIANTS COLORECTAL CARCINOMA THR-880; ILE-890 AND VAL-1508. RX PubMed=9419979; DOI=10.1038/sj.onc.1201668; RA Miyaki M., Nishio J., Konishi M., Kikuchi-Yanoshita R., Tanaka K., RA Muraoka M., Nagato M., Chong J.-M., Koike M., Terada T., Kawahara Y., RA Fukutome A., Tomiyama J., Chuganji Y., Momoi M., Utsunomiya J.; RT "Drastic genetic instability of tumors and normal tissues in Turcot RT syndrome."; RL Oncogene 15:2877-2881(1997). RN [58] RP VARIANT LYS-1307. RX PubMed=9731522; DOI=10.1038/1666; RA Redston M., Nathanson K.L., Yuan Z.Q., Neuhausen S.L., Satagopan J., RA Wong N., Yang D., Nafa D., Abrahamson J., Ozcelik H., Antin-Ozerkis D., RA Andrulis I., Daly M., Pinsky L., Schrag D., Gallinger S., Kaback M., RA King M.-C., Woodage T., Brody L.C., Godwin A., Warner E., Weber B., RA Foulkes W., Offit K.; RT "The APC I1307K allele and breast cancer risk."; RL Nat. Genet. 20:13-14(1998). RN [59] RP VARIANTS LYS-1307 AND GLN-1317. RC TISSUE=Peripheral blood; RX PubMed=9724771; DOI=10.1073/pnas.95.18.10722; RA Frayling I.M., Beck N.E., Ilyas M., Dove-Edwin I., Goodman P., Pack K., RA Bell J.A., Williams C.B., Hodgson S.V., Thomas H.J.W., Talbot I.C., RA Bodmer W.F., Tomlinson I.P.M.; RT "The APC variants I1307K and E1317Q are associated with colorectal tumors, RT but not always with a family history."; RL Proc. Natl. Acad. Sci. U.S.A. 95:10722-10727(1998). RN [60] RP VARIANT LYS-1307. RX PubMed=9731533; DOI=10.1038/1722; RA Woodage T., King S.M., Wacholder S., Hartge P., Struewing J.P., McAdams M., RA Laken S.J., Tucker M.A., Brody L.C.; RT "The APC I1307K allele and cancer risk in a community-based study of RT Ashkenazi Jews."; RL Nat. Genet. 20:62-65(1998). RN [61] RP VARIANT LYS-1307. RX PubMed=9973276; DOI=10.1086/302262; RA Gryfe R., Di Nicola N., Lal G., Gallinger S., Redston M.; RT "Inherited colorectal polyposis and cancer risk of the APC I1307K RT polymorphism."; RL Am. J. Hum. Genet. 64:378-384(1999). RN [62] RP VARIANTS GLY-1057; CYS-1171; ASP-1822 AND THR-2738. RX PubMed=9950360; RA Wallis Y.L., Morton D.G., McKeown C.M., Macdonald F.; RT "Molecular analysis of the APC gene in 205 families: extended genotype- RT phenotype correlations in FAP and evidence for the role of APC amino acid RT changes in colorectal cancer predisposition."; RL J. Med. Genet. 36:14-20(1999). RN [63] RP VARIANT FAP1 PRO-1184. RX PubMed=10470088; DOI=10.1038/12511; RA Lamlum H., Ilyas M., Rowan A., Clark S., Johnson V., Bell J.A., RA Frayling I.M., Efstathiou J., Pack K., Payne S., Roylance R., Gorman P., RA Sheer D., Neale K., Phillips R., Talbot I.C., Bodmer W.F., RA Tomlinson I.P.M.; RT "The type of somatic mutation at APC in familial adenomatous polyposis is RT determined by the site of the germline mutation: a new facet to Knudson's RT 'two-hit' hypothesis."; RL Nat. Med. 5:1071-1075(1999). RN [64] RP VARIANTS MDB VAL-1296; ILE-1472 AND GLY-1495. RX PubMed=10666372; DOI=10.1016/s0002-9440(10)64747-5; RA Huang H., Mahler-Araujo B.M., Sankila A., Chimelli L., Yonekawa Y., RA Kleihues P., Ohgaki H.; RT "APC mutations in sporadic medulloblastomas."; RL Am. J. Pathol. 156:433-437(2000). RN [65] RP INVOLVEMENT IN DESMD. RX PubMed=10782927; DOI=10.1034/j.1399-0004.2000.570306.x; RA Couture J., Mitri A., Lagace R., Smits R., Berk T., Bouchard H.-L., RA Fodde R., Alman B., Bapat B.; RT "A germline mutation at the extreme 3' end of the APC gene results in a RT severe desmoid phenotype and is associated with overexpression of beta- RT catenin in the desmoid tumor."; RL Clin. Genet. 57:205-212(2000). RN [66] RP VARIANT [LARGE SCALE ANALYSIS] PHE-1254. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [67] RP INVOLVEMENT IN GAPPS. RX PubMed=27087319; DOI=10.1016/j.ajhg.2016.03.001; RA Li J., Woods S.L., Healey S., Beesley J., Chen X., Lee J.S., RA Sivakumaran H., Wayte N., Nones K., Waterfall J.J., Pearson J., Patch A.M., RA Senz J., Ferreira M.A., Kaurah P., Mackenzie R., Heravi-Moussavi A., RA Hansford S., Lannagan T.R.M., Spurdle A.B., Simpson P.T., da Silva L., RA Lakhani S.R., Clouston A.D., Bettington M., Grimpen F., Busuttil R.A., RA Di Costanzo N., Boussioutas A., Jeanjean M., Chong G., Fabre A., RA Olschwang S., Faulkner G.J., Bellos E., Coin L., Rioux K., Bathe O.F., RA Wen X., Martin H.C., Neklason D.W., Davis S.R., Walker R.L., Calzone K.A., RA Avital I., Heller T., Koh C., Pineda M., Rudloff U., Quezado M., RA Pichurin P.N., Hulick P.J., Weissman S.M., Newlin A., Rubinstein W.S., RA Sampson J.E., Hamman K., Goldgar D., Poplawski N., Phillips K., RA Schofield L., Armstrong J., Kiraly-Borri C., Suthers G.K., Huntsman D.G., RA Foulkes W.D., Carneiro F., Lindor N.M., Edwards S.L., French J.D., RA Waddell N., Meltzer P.S., Worthley D.L., Schrader K.A., Chenevix-Trench G.; RT "Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and RT Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis RT Variant."; RL Am. J. Hum. Genet. 98:830-842(2016). RN [68] RP INVOLVEMENT IN GAPPS. RX PubMed=27343414; DOI=10.1016/j.gie.2016.06.023; RA Repak R., Kohoutova D., Podhola M., Rejchrt S., Minarik M., Benesova L., RA Lesko M., Bures J.; RT "The first European family with gastric adenocarcinoma and proximal RT polyposis of the stomach: case report and review of the literature."; RL Gastrointest. Endosc. 84:718-725(2016). RN [69] RP INVOLVEMENT IN MDB. RX PubMed=29753700; DOI=10.1016/s1470-2045(18)30242-0; RA Waszak S.M., Northcott P.A., Buchhalter I., Robinson G.W., Sutter C., RA Groebner S., Grund K.B., Brugieres L., Jones D.T.W., Pajtler K.W., RA Morrissy A.S., Kool M., Sturm D., Chavez L., Ernst A., Brabetz S., Hain M., RA Zichner T., Segura-Wang M., Weischenfeldt J., Rausch T., Mardin B.R., RA Zhou X., Baciu C., Lawerenz C., Chan J.A., Varlet P., Guerrini-Rousseau L., RA Fults D.W., Grajkowska W., Hauser P., Jabado N., Ra Y.S., Zitterbart K., RA Shringarpure S.S., De La Vega F.M., Bustamante C.D., Ng H.K., Perry A., RA MacDonald T.J., Hernaiz Driever P., Bendel A.E., Bowers D.C., McCowage G., RA Chintagumpala M.M., Cohn R., Hassall T., Fleischhack G., Eggen T., RA Wesenberg F., Feychting M., Lannering B., Schuez J., Johansen C., RA Andersen T.V., Roeoesli M., Kuehni C.E., Grotzer M., Kjaerheim K., RA Monoranu C.M., Archer T.C., Duke E., Pomeroy S.L., Shelagh R., Frank S., RA Sumerauer D., Scheurlen W., Ryzhova M.V., Milde T., Kratz C.P., Samuel D., RA Zhang J., Solomon D.A., Marra M., Eils R., Bartram C.R., von Hoff K., RA Rutkowski S., Ramaswamy V., Gilbertson R.J., Korshunov A., Taylor M.D., RA Lichter P., Malkin D., Gajjar A., Korbel J.O., Pfister S.M.; RT "Spectrum and prevalence of genetic predisposition in medulloblastoma: a RT retrospective genetic study and prospective validation in a clinical trial RT cohort."; RL Lancet Oncol. 19:785-798(2018). RN [70] RP INVOLVEMENT IN GAPPS. RX PubMed=33242120; DOI=10.1007/s12328-020-01290-6; RA Kanemitsu K., Iwatsuki M., Yamashita K., Komohara Y., Morinaga T., RA Iwagami S., Eto K., Nagai Y., Kurashige J., Baba Y., Yoshida N., Baba H.; RT "Two Asian families with gastric adenocarcinoma and proximal polyposis of RT the stomach successfully treated via laparoscopic total gastrectomy."; RL Clin. J. Gastroenterol. 14:92-97(2021). CC -!- FUNCTION: Tumor suppressor. Promotes rapid degradation of CTNNB1 and CC participates in Wnt signaling as a negative regulator. APC activity is CC correlated with its phosphorylation state. Activates the GEF activity CC of SPATA13 and ARHGEF4. Plays a role in hepatocyte growth factor (HGF)- CC induced cell migration. Required for MMP9 up-regulation via the JNK CC signaling pathway in colorectal tumor cells. Associates with both CC microtubules and actin filaments, components of the cytoskeleton CC (PubMed:17293347). Plays a role in mediating the organization of F- CC actin into ordered bundles (PubMed:17293347). Functions downstream of CC Rho GTPases and DIAPH1 to selectively stabilize microtubules (By CC similarity). Acts as a mediator of ERBB2-dependent stabilization of CC microtubules at the cell cortex. It is required for the localization of CC MACF1 to the cell membrane and this localization of MACF1 is critical CC for its function in microtubule stabilization. CC {ECO:0000250|UniProtKB:Q61315, ECO:0000269|PubMed:10947987, CC ECO:0000269|PubMed:17293347, ECO:0000269|PubMed:17599059, CC ECO:0000269|PubMed:19151759, ECO:0000269|PubMed:19893577, CC ECO:0000269|PubMed:20937854}. CC -!- SUBUNIT: Forms homooligomers (Probable). Found in a complex consisting CC of ARHGEF4, APC and CTNNB1 (PubMed:10947987). Found in a complex CC composed of MACF1, APC, AXIN1, CTNNB1 and GSK3B (By similarity). The CC complex composed, at least, of APC, CTNNB1 and GSK3B interacts with CC JPT1; the interaction requires the inactive form of GSK3B CC (phosphorylated at 'Ser-9') (PubMed:25169422). Interacts with APC2 CC (PubMed:11691822). Interacts with DLG1 (via PDZ domains) and DLG3 (via CC PDZ domains) (PubMed:8638125, PubMed:9188857). Interacts with CC alpha- and beta-catenins (PubMed:8259519). Interacts with AXIN1 (via CC RGS domain) (PubMed:10811618). Interacts with ARHGEF4 (via N-terminus) CC (PubMed:10947987). Interacts (via C-terminal residues 2674-2843) with CC MAPRE1 (via C-terminal residues 206-211); the interaction inhibits CC association with and bundling of F-actin (PubMed:14514668, CC PubMed:17293347, PubMed:19632184). Interacts with MAPRE2 and MAPRE3 CC (via C-terminus) (PubMed:14514668). Interacts with DIAPH1; DIAPH1 acts CC as a scaffold protein for MAPRE1 and APC to stabilize microtubules and CC promote cell migration (By similarity). Interacts with DIAPH2 (By CC similarity). Interacts with SCRIB; may mediate APC targeting to CC adherens junctions of epithelial cells (PubMed:16611247). Interacts CC with SPATA13 (via N-terminus and SH3 domain) (PubMed:17599059). CC Interacts with ASAP1 (via SH3 domain) (PubMed:20509626). Interacts (at CC the cell membrane) with AMER1 and AMER2 (via ARM repeats) CC (PubMed:21498506, PubMed:22128170). Interacts with KHDRBS1 CC (PubMed:22000517). Interacts with actin; binds both to F-actin and CC actin filament bundles (PubMed:17293347). CC {ECO:0000250|UniProtKB:P70478, ECO:0000250|UniProtKB:Q61315, CC ECO:0000269|PubMed:10811618, ECO:0000269|PubMed:10947987, CC ECO:0000269|PubMed:11691822, ECO:0000269|PubMed:11707392, CC ECO:0000269|PubMed:14514668, ECO:0000269|PubMed:16611247, CC ECO:0000269|PubMed:17293347, ECO:0000269|PubMed:17599059, CC ECO:0000269|PubMed:19632184, ECO:0000269|PubMed:20509626, CC ECO:0000269|PubMed:21498506, ECO:0000269|PubMed:22000517, CC ECO:0000269|PubMed:22128170, ECO:0000269|PubMed:25169422, CC ECO:0000269|PubMed:8259519, ECO:0000269|PubMed:8638125, CC ECO:0000269|PubMed:9188857, ECO:0000305}. CC -!- INTERACTION: CC P25054; Q5JTC6: AMER1; NbExp=4; IntAct=EBI-727707, EBI-6169747; CC P25054; Q8N944: AMER3; NbExp=8; IntAct=EBI-727707, EBI-8869590; CC P25054; Q9NR80-3: ARHGEF4; NbExp=5; IntAct=EBI-727707, EBI-13639160; CC P25054; O15169: AXIN1; NbExp=17; IntAct=EBI-727707, EBI-710484; CC P25054; O14936: CASK; NbExp=2; IntAct=EBI-727707, EBI-1215506; CC P25054; P60953: CDC42; NbExp=9; IntAct=EBI-727707, EBI-81752; CC P25054; P49674: CSNK1E; NbExp=8; IntAct=EBI-727707, EBI-749343; CC P25054; P35221: CTNNA1; NbExp=3; IntAct=EBI-727707, EBI-701918; CC P25054; P35222: CTNNB1; NbExp=22; IntAct=EBI-727707, EBI-491549; CC P25054; Q12959: DLG1; NbExp=11; IntAct=EBI-727707, EBI-357481; CC P25054; Q15700: DLG2; NbExp=2; IntAct=EBI-727707, EBI-80426; CC P25054; Q92796: DLG3; NbExp=2; IntAct=EBI-727707, EBI-80440; CC P25054; P78352: DLG4; NbExp=3; IntAct=EBI-727707, EBI-80389; CC P25054; O14640: DVL1; NbExp=6; IntAct=EBI-727707, EBI-723489; CC P25054; P54792: DVL1P1; NbExp=2; IntAct=EBI-727707, EBI-7848109; CC P25054; O14641: DVL2; NbExp=2; IntAct=EBI-727707, EBI-740850; CC P25054; Q96RT1: ERBIN; NbExp=2; IntAct=EBI-727707, EBI-993903; CC P25054; P14923: JUP; NbExp=3; IntAct=EBI-727707, EBI-702484; CC P25054; Q07666: KHDRBS1; NbExp=4; IntAct=EBI-727707, EBI-1364; CC P25054; Q14114: LRP8; NbExp=2; IntAct=EBI-727707, EBI-2681187; CC P25054; Q86UL8: MAGI2; NbExp=5; IntAct=EBI-727707, EBI-311035; CC P25054; Q15691: MAPRE1; NbExp=6; IntAct=EBI-727707, EBI-1004115; CC P25054; Q14160: SCRIB; NbExp=8; IntAct=EBI-727707, EBI-357345; CC P25054; Q96N96: SPATA13; NbExp=5; IntAct=EBI-727707, EBI-13618641; CC P25054; Q96N96-1: SPATA13; NbExp=5; IntAct=EBI-727707, EBI-13638906; CC P25054; Q96N96-2: SPATA13; NbExp=2; IntAct=EBI-727707, EBI-13639118; CC P25054; O14907: TAX1BP3; NbExp=5; IntAct=EBI-727707, EBI-723259; CC P25054; P63104: YWHAZ; NbExp=2; IntAct=EBI-727707, EBI-347088; CC P25054; Q02248: Ctnnb1; Xeno; NbExp=8; IntAct=EBI-727707, EBI-397872; CC -!- SUBCELLULAR LOCATION: Cell junction, adherens junction CC {ECO:0000269|PubMed:16611247}. Cytoplasm, cytoskeleton CC {ECO:0000269|PubMed:19632184, ECO:0000269|PubMed:20937854}. Cell CC projection, lamellipodium {ECO:0000269|PubMed:19151759}. Cell CC projection, ruffle membrane {ECO:0000269|PubMed:19151759}. Cytoplasm CC {ECO:0000269|PubMed:10947987}. Cell membrane CC {ECO:0000269|PubMed:10947987, ECO:0000269|PubMed:16611247, CC ECO:0000269|PubMed:20937854}. Note=Associated with the microtubule CC network at the growing distal tip of microtubules (PubMed:19632184). CC MAPRE1 may be required for targeting to the growing microtubule plus CC ends (PubMed:19632184). Accumulates in the lamellipodium and ruffle CC membrane in response to hepatocyte growth factor (HGF) treatment CC (PubMed:19151759). The MEMO1-RHOA-DIAPH1 signaling pathway controls CC localization of the phosphorylated form to the cell membrane CC (PubMed:20937854). {ECO:0000269|PubMed:19151759, CC ECO:0000269|PubMed:19632184, ECO:0000269|PubMed:20937854}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative promoter usage, Alternative splicing; Named isoforms=3; CC Name=1A {ECO:0000303|PubMed:19527921}; Synonyms=Long CC {ECO:0000303|PubMed:1678319}; CC IsoId=P25054-1; Sequence=Displayed; CC Name=2; Synonyms=Short {ECO:0000303|PubMed:1678319}; CC IsoId=P25054-2; Sequence=VSP_004115; CC Name=1B {ECO:0000303|PubMed:19527921}; CC IsoId=P25054-3; Sequence=VSP_059027, VSP_059028; CC -!- TISSUE SPECIFICITY: Expressed in a variety of tissues: brain, small CC intestine, colon, thymus, skeletal muscle, heart, prostate, lung, CC spleen, ovary, testis kidney, placenta, blood and liver CC (PubMed:21643010, PubMed:27217144). Isoform 1A: Very strongly expressed CC in brain but has relatively low expression levels in other tissues CC (PubMed:19527921, PubMed:21643010, PubMed:27217144). Isoform 1B: CC Predominant form in all tissues except for brain, including gastric CC mucosa and blood (PubMed:19527921, PubMed:21643010, PubMed:27217144). CC {ECO:0000269|PubMed:19527921, ECO:0000269|PubMed:21643010, CC ECO:0000269|PubMed:27217144}. CC -!- DOMAIN: The microtubule tip localization signal (MtLS) motif; mediates CC interaction with MAPRE1 and targeting to the growing microtubule plus CC ends. {ECO:0000250}. CC -!- DOMAIN: The basic region (residues 2167-2674) mediates the association CC with both microtubule and actin proteins and promotes the bundling of CC F-actin. {ECO:0000269|PubMed:17293347}. CC -!- PTM: Phosphorylated; phosphorylation enhances the F-actin bundling CC activity (PubMed:17293347). Phosphorylated by GSK3B. CC {ECO:0000269|PubMed:17293347}. CC -!- PTM: Ubiquitinated, leading to its degradation by the proteasome. CC Ubiquitination is facilitated by Axin. Deubiquitinated by CC ZRANB1/TRABID. {ECO:0000269|PubMed:15355978, CC ECO:0000269|PubMed:18281465}. CC -!- DISEASE: Familial adenomatous polyposis 1 (FAP1) [MIM:175100]: An CC autosomal dominant cancer predisposition syndrome characterized by CC adenomatous polyps of the colon and rectum, but also of upper CC gastrointestinal tract (ampullary, duodenal and gastric adenomas). This CC is a viciously premalignant disease with one or more polyps progressing CC through dysplasia to malignancy in untreated gene carriers with a CC median age at diagnosis of 40 years. {ECO:0000269|PubMed:10470088, CC ECO:0000269|PubMed:1316610, ECO:0000269|PubMed:1338691, CC ECO:0000269|PubMed:1338764, ECO:0000269|PubMed:1338904, CC ECO:0000269|PubMed:1651563, ECO:0000269|PubMed:21643010, CC ECO:0000269|PubMed:27217144, ECO:0000269|PubMed:7661930, CC ECO:0000269|PubMed:7833149, ECO:0000269|PubMed:7833931, CC ECO:0000269|PubMed:8111410, ECO:0000269|PubMed:8990002}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Desmoid disease, hereditary (DESMD) [MIM:135290]: An autosomal CC dominant disease characterized by multifocal fibromatosis of the CC abdominal wall and mesentery. Desmoid tumors can also affect paraspinal CC muscles, breast, occiput, arms, and lower ribs. CC {ECO:0000269|PubMed:10782927, ECO:0000269|PubMed:8940264}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Medulloblastoma (MDB) [MIM:155255]: Malignant, invasive CC embryonal tumor of the cerebellum with a preferential manifestation in CC children. {ECO:0000269|PubMed:10666372, ECO:0000269|PubMed:29753700}. CC Note=The gene represented in this entry may be involved in disease CC pathogenesis. CC -!- DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which CC starts in the stomach, can spread to the esophagus or the small CC intestine, and can extend through the stomach wall to nearby lymph CC nodes and organs. It also can metastasize to other parts of the body. CC The term gastric cancer or gastric carcinoma refers to adenocarcinoma CC of the stomach that accounts for most of all gastric malignant tumors. CC Two main histologic types are recognized, diffuse type and intestinal CC type carcinomas. Diffuse tumors are poorly differentiated infiltrating CC lesions, resulting in thickening of the stomach. In contrast, CC intestinal tumors are usually exophytic, often ulcerating, and CC associated with intestinal metaplasia of the stomach, most often CC observed in sporadic disease. Note=The gene represented in this entry CC may be involved in disease pathogenesis. CC -!- DISEASE: Hepatocellular carcinoma (HCC) [MIM:114550]: A primary CC malignant neoplasm of epithelial liver cells. The major risk factors CC for HCC are chronic hepatitis B virus (HBV) infection, chronic CC hepatitis C virus (HCV) infection, prolonged dietary aflatoxin CC exposure, alcoholic cirrhosis, and cirrhosis due to other causes. CC Note=The gene represented in this entry may be involved in disease CC pathogenesis. CC -!- DISEASE: Gastric adenocarcinoma and proximal polyposis of the stomach CC (GAPPS) [MIM:619182]: A familial gastric polyposis syndrome CC characterized by autosomal dominant transmission of fundic gland CC polyposis with occasional hyperplastic and adenomatous polyps, sparing CC of the gastric antrum, and a significant risk of intestinal-type CC gastric adenocarcinoma development. Colorectal polyposis is not CC observed, and family history does not include colorectal cancer. CC {ECO:0000269|PubMed:27087319, ECO:0000269|PubMed:27343414, CC ECO:0000269|PubMed:33242120}. Note=The gene represented in this entry CC may be involved in disease pathogenesis. CC -!- MISCELLANEOUS: APC mutations have led to some interesting observations. CC (1) the great majority of the mutations found to date would result in CC truncation of the APC product. (2) almost all the mutations have CC occurred within the first half of the coding sequence, and somatic CC mutations in colorectal tumors are further clustered in a particular CC region, called MCR (mutation cluster region). (3) most identified point CC mutations in the APC gene are transitions from cytosine to other CC nucleotides. (4) the location of germline mutations tends to correlate CC with the number of colorectal polyps in FAP1 patients. Inactivation of CC both alleles of the APC gene seems to be required as an early event to CC develop most adenomas and carcinomas in the colon and rectum as well as CC some of those in the stomach. CC -!- MISCELLANEOUS: [Isoform 1B]: Produced by alternative promoter usage. CC {ECO:0000269|PubMed:19527921}. CC -!- SIMILARITY: Belongs to the adenomatous polyposis coli (APC) family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Colon cancer gene variant databases Adenomatous CC Polyposis Coli (APC); Note=Leiden Open Variation Database (LOVD); CC URL="https://databases.lovd.nl/shared/genes/APC"; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/118/APC"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M73548; AAA60353.1; -; mRNA. DR EMBL; M73548; AAA60354.1; -; mRNA. DR EMBL; M74088; AAA03586.1; -; mRNA. DR EMBL; AC008575; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC136500; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471086; EAW49002.1; -; Genomic_DNA. DR EMBL; CH471086; EAW49007.1; -; Genomic_DNA. DR EMBL; AK294544; BAH11802.1; -; mRNA. DR EMBL; S78214; AAB21145.2; ALT_SEQ; Genomic_DNA. DR CCDS; CCDS4107.1; -. [P25054-1] DR PIR; A37261; RBHUAP. DR RefSeq; NP_000029.2; NM_000038.5. [P25054-1] DR RefSeq; NP_001120982.1; NM_001127510.3. [P25054-1] DR RefSeq; NP_001120983.2; NM_001127511.3. [P25054-3] DR RefSeq; NP_001341824.1; NM_001354895.2. [P25054-1] DR RefSeq; NP_001341832.1; NM_001354903.2. [P25054-2] DR RefSeq; NP_001394379.1; NM_001407450.1. [P25054-1] DR RefSeq; NP_001394387.1; NM_001407458.1. [P25054-2] DR RefSeq; NP_001394388.1; NM_001407459.1. [P25054-2] DR RefSeq; NP_001394389.1; NM_001407460.1. [P25054-2] DR PDB; 1DEB; X-ray; 2.40 A; A/B=2-55. DR PDB; 1EMU; X-ray; 1.90 A; B=2034-2049. DR PDB; 1JPP; X-ray; 3.10 A; C/D=1021-1035. DR PDB; 1M5I; X-ray; 2.00 A; A=126-250. DR PDB; 1T08; X-ray; 2.10 A; C=1484-1498. DR PDB; 1TH1; X-ray; 2.50 A; C/D=1362-1540. DR PDB; 1V18; X-ray; 2.10 A; B=1482-1528. DR PDB; 2RQU; NMR; -; B=1578-1596. DR PDB; 3AU3; X-ray; 2.10 A; A=396-732. DR PDB; 3NMW; X-ray; 1.60 A; A/B=407-751. DR PDB; 3NMX; X-ray; 2.30 A; A/B/C=407-751. DR PDB; 3NMZ; X-ray; 3.01 A; A/B=303-739. DR PDB; 3QHE; X-ray; 2.40 A; A/C=396-732. DR PDB; 3RL7; X-ray; 2.30 A; G/H/I/J/K/L=2833-2843. DR PDB; 3RL8; X-ray; 2.20 A; F=2833-2843. DR PDB; 3T7U; X-ray; 2.90 A; A/B=407-775. DR PDB; 4G69; X-ray; 2.00 A; B=2833-2843. DR PDB; 4YJE; X-ray; 1.90 A; A=407-751. DR PDB; 4YJL; X-ray; 2.10 A; A/B/C/D/E/F=407-751. DR PDB; 4YK6; X-ray; 1.70 A; A=407-751. DR PDB; 5B6G; X-ray; 1.99 A; A=407-751. DR PDB; 5IZ6; X-ray; 2.15 A; A=407-751. DR PDB; 5IZ8; X-ray; 3.06 A; A/B=407-751. DR PDB; 5IZ9; X-ray; 2.93 A; A=407-751. DR PDB; 5IZA; X-ray; 1.50 A; A=407-751. DR PDB; 5Z8H; X-ray; 1.79 A; A=407-741. DR PDB; 7F6M; X-ray; 2.40 A; A=407-751. DR PDB; 7F7O; X-ray; 2.80 A; A=407-738. DR PDB; 7XTY; X-ray; 2.10 A; C/D=2833-2843. DR PDB; 8GSJ; X-ray; 2.10 A; A=407-738. DR PDB; 8X2Q; X-ray; 2.00 A; A=126-250. DR PDBsum; 1DEB; -. DR PDBsum; 1EMU; -. DR PDBsum; 1JPP; -. DR PDBsum; 1M5I; -. DR PDBsum; 1T08; -. DR PDBsum; 1TH1; -. DR PDBsum; 1V18; -. DR PDBsum; 2RQU; -. DR PDBsum; 3AU3; -. DR PDBsum; 3NMW; -. DR PDBsum; 3NMX; -. DR PDBsum; 3NMZ; -. DR PDBsum; 3QHE; -. DR PDBsum; 3RL7; -. DR PDBsum; 3RL8; -. DR PDBsum; 3T7U; -. DR PDBsum; 4G69; -. DR PDBsum; 4YJE; -. DR PDBsum; 4YJL; -. DR PDBsum; 4YK6; -. DR PDBsum; 5B6G; -. DR PDBsum; 5IZ6; -. DR PDBsum; 5IZ8; -. DR PDBsum; 5IZ9; -. DR PDBsum; 5IZA; -. DR PDBsum; 5Z8H; -. DR PDBsum; 7F6M; -. DR PDBsum; 7F7O; -. DR PDBsum; 7XTY; -. DR PDBsum; 8GSJ; -. DR PDBsum; 8X2Q; -. DR BMRB; P25054; -. DR SMR; P25054; -. DR BioGRID; 106821; 370. DR ComplexPortal; CPX-107; Beta-catenin destruction core complex, APC-AXIN1-GSK3A variant. DR ComplexPortal; CPX-109; Beta-catenin destruction core complex, APC-AXIN1-GSK3B variant. DR ComplexPortal; CPX-439; Beta-catenin destruction core complex, APC-AXIN2-GSK3B variant. DR ComplexPortal; CPX-441; Beta-catenin destruction core complex, APC-AXIN2-GSK3A variant. DR CORUM; P25054; -. DR DIP; DIP-33556N; -. DR FunCoup; P25054; 1537. DR IntAct; P25054; 301. DR MINT; P25054; -. DR STRING; 9606.ENSP00000257430; -. DR BindingDB; P25054; -. DR ChEMBL; CHEMBL3233; -. DR GlyCosmos; P25054; 3 sites, 2 glycans. DR GlyGen; P25054; 8 sites, 3 N-linked glycans (3 sites), 1 O-linked glycan (4 sites). DR iPTMnet; P25054; -. DR PhosphoSitePlus; P25054; -. DR BioMuta; APC; -. DR DMDM; 97535708; -. DR jPOST; P25054; -. DR MassIVE; P25054; -. DR PaxDb; 9606-ENSP00000257430; -. DR PeptideAtlas; P25054; -. DR ProteomicsDB; 54247; -. [P25054-1] DR ProteomicsDB; 54248; -. [P25054-2] DR ProteomicsDB; 6428; -. DR Pumba; P25054; -. DR Antibodypedia; 1054; 757 antibodies from 45 providers. DR DNASU; 324; -. DR Ensembl; ENST00000257430.9; ENSP00000257430.4; ENSG00000134982.20. [P25054-1] DR Ensembl; ENST00000507379.6; ENSP00000423224.2; ENSG00000134982.20. [P25054-3] DR Ensembl; ENST00000508376.6; ENSP00000427089.2; ENSG00000134982.20. [P25054-1] DR Ensembl; ENST00000509732.6; ENSP00000426541.2; ENSG00000134982.20. [P25054-1] DR Ensembl; ENST00000512211.7; ENSP00000423828.3; ENSG00000134982.20. [P25054-1] DR GeneID; 324; -. DR KEGG; hsa:324; -. DR MANE-Select; ENST00000257430.9; ENSP00000257430.4; NM_000038.6; NP_000029.2. DR UCSC; uc003kpy.5; human. [P25054-1] DR UCSC; uc063gan.1; human. DR AGR; HGNC:583; -. DR CIViC; 324; 4 evidence items across 2 molecular profiles. DR ClinPGx; PA24875; -. DR CTD; 324; -. DR DisGeNET; 324; -. DR GeneCards; APC; -. DR GeneReviews; APC; -. DR HGNC; HGNC:583; APC. DR HPA; ENSG00000134982; Tissue enhanced (brain). DR MalaCards; APC; -. DR MIM; 114550; phenotype. DR MIM; 135290; phenotype. DR MIM; 155255; phenotype. DR MIM; 175100; phenotype. DR MIM; 611731; gene. DR MIM; 613659; phenotype. DR MIM; 619182; phenotype. DR OpenTargets; ENSG00000134982; -. DR Orphanet; 261584; 5q22 microdeletion syndrome. DR Orphanet; 220460; Attenuated familial adenomatous polyposis. DR Orphanet; 3258; Cenani-Lenz syndrome. DR Orphanet; 873; Desmoid tumor. DR Orphanet; 314022; Gastric adenocarcinoma and proximal polyposis of the stomach. DR VEuPathDB; HostDB:ENSG00000134982; -. DR eggNOG; KOG2122; Eukaryota. DR GeneTree; ENSGT00530000063749; -. DR HOGENOM; CLU_001012_0_0_1; -. DR InParanoid; P25054; -. DR OMA; DHEKHSP; -. DR OrthoDB; 5918429at2759; -. DR PAN-GO; P25054; 14 GO annotations based on evolutionary models. DR PhylomeDB; P25054; -. DR BioCyc; MetaCyc:ENSG00000134982-MONOMER; -. DR PathwayCommons; P25054; -. DR Reactome; R-HSA-111465; Apoptotic cleavage of cellular proteins. DR Reactome; R-HSA-195253; Degradation of beta-catenin by the destruction complex. DR Reactome; R-HSA-196299; Beta-catenin phosphorylation cascade. DR Reactome; R-HSA-3769402; Deactivation of the beta-catenin transactivating complex. DR Reactome; R-HSA-4641262; Disassembly of the destruction complex and recruitment of AXIN to the membrane. DR Reactome; R-HSA-5339716; Signaling by GSK3beta mutants. DR Reactome; R-HSA-5358747; CTNNB1 S33 mutants aren't phosphorylated. DR Reactome; R-HSA-5358749; CTNNB1 S37 mutants aren't phosphorylated. DR Reactome; R-HSA-5358751; CTNNB1 S45 mutants aren't phosphorylated. DR Reactome; R-HSA-5358752; CTNNB1 T41 mutants aren't phosphorylated. DR Reactome; R-HSA-5467333; APC truncation mutants are not K63 polyubiquitinated. DR Reactome; R-HSA-5467337; APC truncation mutants have impaired AXIN binding. DR Reactome; R-HSA-5467340; AXIN missense mutants destabilize the destruction complex. DR Reactome; R-HSA-5467348; Truncations of AMER1 destabilize the destruction complex. DR Reactome; R-HSA-5689896; Ovarian tumor domain proteases. DR SignaLink; P25054; -. DR SIGNOR; P25054; -. DR Agora; ENSG00000134982; -. DR BioGRID-ORCS; 324; 172 hits in 1170 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; D8D47D1F; Synthetic Condensate 000297. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; APC; human. DR EvolutionaryTrace; P25054; -. DR GeneWiki; Adenomatous_polyposis_coli; -. DR GenomeRNAi; 324; -. DR Pharos; P25054; Tchem. DR PRO; PR:P25054; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; P25054; protein. DR Bgee; ENSG00000134982; Expressed in substantia nigra pars compacta and 207 other cell types or tissues. DR ExpressionAtlas; P25054; baseline and differential. DR GO; GO:0005912; C:adherens junction; IEA:UniProtKB-SubCell. DR GO; GO:0030877; C:beta-catenin destruction complex; IDA:UniProtKB. DR GO; GO:0005923; C:bicellular tight junction; IDA:UniProtKB. DR GO; GO:0016342; C:catenin complex; IDA:CACAO. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005794; C:Golgi apparatus; IDA:HPA. DR GO; GO:0000776; C:kinetochore; IDA:UniProtKB. DR GO; GO:0030027; C:lamellipodium; IDA:UniProtKB. DR GO; GO:0016328; C:lateral plasma membrane; IDA:MGI. DR GO; GO:0005874; C:microtubule; IEA:UniProtKB-KW. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:MGI. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0032587; C:ruffle membrane; IDA:UniProtKB. DR GO; GO:1990909; C:Wnt signalosome; NAS:ParkinsonsUK-UCL. DR GO; GO:0008013; F:beta-catenin binding; IDA:BHF-UCL. DR GO; GO:0070840; F:dynein complex binding; IPI:CAFA. DR GO; GO:0045295; F:gamma-catenin binding; IPI:BHF-UCL. DR GO; GO:0008017; F:microtubule binding; IDA:UniProtKB. DR GO; GO:0051010; F:microtubule plus-end binding; IDA:UniProtKB. DR GO; GO:0019901; F:protein kinase binding; IDA:DisProt. DR GO; GO:0019887; F:protein kinase regulator activity; IDA:UniProtKB. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IDA:MGI. DR GO; GO:0070830; P:bicellular tight junction assembly; NAS:UniProtKB. DR GO; GO:0007155; P:cell adhesion; NAS:UniProtKB. DR GO; GO:0001708; P:cell fate specification; IBA:GO_Central. DR GO; GO:0016477; P:cell migration; IMP:UniProtKB. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0003203; P:endocardial cushion morphogenesis; ISS:BHF-UCL. DR GO; GO:0003170; P:heart valve development; ISS:BHF-UCL. DR GO; GO:0008286; P:insulin receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0000281; P:mitotic cytokinesis; IMP:MGI. DR GO; GO:0007094; P:mitotic spindle assembly checkpoint signaling; IMP:MGI. DR GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IMP:UniProtKB. DR GO; GO:1902807; P:negative regulation of cell cycle G1/S phase transition; IDA:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:UniProtKB. DR GO; GO:0045736; P:negative regulation of cyclin-dependent protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; IMP:UniProtKB. DR GO; GO:0007026; P:negative regulation of microtubule depolymerization; IDA:UniProtKB. DR GO; GO:0007399; P:nervous system development; IBA:GO_Central. DR GO; GO:0007389; P:pattern specification process; IBA:GO_Central. DR GO; GO:0043065; P:positive regulation of apoptotic process; IMP:MGI. DR GO; GO:0030335; P:positive regulation of cell migration; IMP:MGI. DR GO; GO:0120162; P:positive regulation of cold-induced thermogenesis; ISS:YuBioLab. DR GO; GO:0045732; P:positive regulation of protein catabolic process; IGI:MGI. DR GO; GO:1904781; P:positive regulation of protein localization to centrosome; IMP:CAFA. DR GO; GO:0031274; P:positive regulation of pseudopodium assembly; IMP:MGI. DR GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; NAS:ComplexPortal. DR GO; GO:0065003; P:protein-containing complex assembly; IDA:UniProtKB. DR GO; GO:0051988; P:regulation of attachment of spindle microtubules to kinetochore; IMP:MGI. DR GO; GO:0060632; P:regulation of microtubule-based movement; IEP:UniProtKB. DR GO; GO:0032886; P:regulation of microtubule-based process; IMP:UniProtKB. DR GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW. DR DisProt; DP00519; -. DR FunFam; 1.25.10.10:FF:000035; adenomatous polyposis coli protein 2; 1. DR FunFam; 1.10.287.450:FF:000001; adenomatous polyposis coli protein isoform X1; 1. DR Gene3D; 1.20.5.10; -; 1. DR Gene3D; 1.10.287.450; Helix hairpin bin; 1. DR Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 1. DR IDEAL; IID00035; -. DR InterPro; IPR009240; APC_15aa_rpt. DR InterPro; IPR009234; APC_basic_dom. DR InterPro; IPR026831; APC_dom. DR InterPro; IPR026818; Apc_fam. DR InterPro; IPR032038; APC_N. DR InterPro; IPR036149; APC_N_sf. DR InterPro; IPR041257; APC_rep. DR InterPro; IPR009223; APC_rpt. DR InterPro; IPR011989; ARM-like. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR000225; Armadillo. DR InterPro; IPR009232; EB1-bd. DR InterPro; IPR009224; SAMP. DR PANTHER; PTHR12607:SF11; ADENOMATOUS POLYPOSIS COLI PROTEIN; 1. DR PANTHER; PTHR12607; ADENOMATOUS POLYPOSIS COLI PROTEIN FAMILY; 1. DR Pfam; PF05972; APC_15aa; 4. DR Pfam; PF05956; APC_basic; 1. DR Pfam; PF16689; APC_N_CC; 1. DR Pfam; PF05923; APC_r; 7. DR Pfam; PF18797; APC_rep; 1. DR Pfam; PF16634; APC_u13; 1. DR Pfam; PF16635; APC_u14; 1. DR Pfam; PF16636; APC_u15; 1. DR Pfam; PF16630; APC_u5; 1. DR Pfam; PF16633; APC_u9; 1. DR Pfam; PF00514; Arm; 3. DR Pfam; PF16629; Arm_APC_u3; 1. DR Pfam; PF05937; EB1_binding; 1. DR Pfam; PF05924; SAMP; 3. DR Pfam; PF11414; Suppressor_APC; 1. DR SMART; SM00185; ARM; 7. DR SUPFAM; SSF48371; ARM repeat; 1. DR SUPFAM; SSF58050; N-terminal coiled coil domain from apc; 1. DR SUPFAM; SSF82931; Tumor suppressor gene product Apc; 1. DR PROSITE; PS50176; ARM_REPEAT; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative promoter usage; KW Alternative splicing; Cell junction; Cell membrane; Cell projection; KW Coiled coil; Cytoplasm; Cytoskeleton; Disease variant; Membrane; KW Microtubule; Phosphoprotein; Proteomics identification; Reference proteome; KW Repeat; Tumor suppressor; Ubl conjugation; Wnt signaling pathway. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..2843 FT /note="Adenomatous polyposis coli protein" FT /id="PRO_0000064627" FT REPEAT 453..495 FT /note="ARM 1" FT REPEAT 505..547 FT /note="ARM 2" FT REPEAT 548..591 FT /note="ARM 3" FT REPEAT 592..638 FT /note="ARM 4" FT REPEAT 639..683 FT /note="ARM 5" FT REPEAT 684..725 FT /note="ARM 6" FT REPEAT 726..767 FT /note="ARM 7" FT REGION 239..305 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 828..878 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 923..943 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 958..987 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 960..1337 FT /note="Responsible for down-regulation through a process FT mediated by direct ubiquitination" FT REGION 1020..1169 FT /note="Interaction with catenins" FT /evidence="ECO:0000269|PubMed:8259519" FT REGION 1099..1169 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1190..1244 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1311..1376 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1403..1475 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1526..1569 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1583..1611 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1664..1717 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1729..1836 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1866..1893 FT /note="Highly charged" FT REGION 1881..1950 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1965..2011 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2035..2059 FT /note="Interaction with AXIN1" FT /evidence="ECO:0000269|PubMed:10811618" FT REGION 2043..2072 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2147..2635 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2167..2674 FT /note="Basic region" FT /evidence="ECO:0000269|PubMed:17293347" FT REGION 2475..2843 FT /note="Interaction with DLG1" FT /evidence="ECO:0000269|PubMed:8638125" FT REGION 2667..2714 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2674..2843 FT /note="Interaction with MAPRE1" FT /evidence="ECO:0000269|PubMed:17293347" FT REGION 2729..2843 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 2..61 FT /evidence="ECO:0000255" FT COILED 127..248 FT /evidence="ECO:0000255" FT MOTIF 2803..2806 FT /note="Microtubule tip localization signal" FT MOTIF 2841..2843 FT /note="PDZ-binding" FT COMPBIAS 241..261 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 271..282 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 290..299 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 833..843 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 844..857 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 869..878 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 927..943 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 961..971 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1107..1130 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1146..1159 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1190..1224 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1225..1244 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1335..1345 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1355..1366 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1448..1466 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1540..1564 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1683..1698 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1735..1744 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1785..1794 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1804..1813 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1881..1896 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1897..1913 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1928..1938 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1939..1950 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1979..1991 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2169..2187 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2203..2223 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2257..2271 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2286..2331 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2348..2369 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2370..2409 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2418..2427 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2459..2477 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2518..2535 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2555..2568 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2569..2579 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2580..2592 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2593..2608 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2620..2635 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2668..2679 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2741..2757 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2763..2774 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2784..2812 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 107 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 111 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 744 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163" FT MOD_RES 748 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 780 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:24275569" FT MOD_RES 908 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 987 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 1038 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 1042 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1360 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 1371 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1385 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1392 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 1395 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 1438 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1567 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 1774 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1861 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 1863 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692" FT MOD_RES 1864 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692" FT MOD_RES 1971 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 1973 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 2088 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 2093 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 2125 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 2129 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 2130 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 2132 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 2151 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2260 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2270 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2283 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2473 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2535 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2569 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2671 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18220336, FT ECO:0007744|PubMed:18669648" FT MOD_RES 2674 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2679 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2710 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 2724 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2789 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..45 FT /note="MAAASYDQLLKQVEALKMENSNLRQELEDNSNHLTKLETEASNMK -> MYA FT SLGSGPVAPLPASVPPSVLGSWSTGGSRSCVRQETKSPGGARTSGHWASVWQ (in FT isoform 1B)" FT /id="VSP_059027" FT VAR_SEQ 217..244 FT /note="Missing (in isoform 1B)" FT /id="VSP_059028" FT VAR_SEQ 312..412 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:1678319" FT /id="VSP_004115" FT VARIANT 99 FT /note="R -> W (in FAP1; benign; dbSNP:rs139196838)" FT /evidence="ECO:0000269|PubMed:7833149" FT /id="VAR_009613" FT VARIANT 171 FT /note="S -> I (in FAP1)" FT /evidence="ECO:0000269|PubMed:8990002" FT /id="VAR_005032" FT VARIANT 414 FT /note="R -> C (in FAP1; benign; dbSNP:rs137854567)" FT /evidence="ECO:0000269|PubMed:8111410" FT /id="VAR_005033" FT VARIANT 722 FT /note="S -> G (in FAP1)" FT /evidence="ECO:0000269|PubMed:7833931" FT /id="VAR_009614" FT VARIANT 784 FT /note="S -> T (in FAP1)" FT /evidence="ECO:0000269|PubMed:8111410" FT /id="VAR_005034" FT VARIANT 817 FT /note="G -> C (in gastric cancer)" FT /id="VAR_005035" FT VARIANT 870 FT /note="P -> S (in dbSNP:rs33974176)" FT /id="VAR_053976" FT VARIANT 880 FT /note="I -> T (in colorectal carcinoma and gastric cancer; FT from a patient with MMRCS; dbSNP:rs1400295986)" FT /evidence="ECO:0000269|PubMed:9419979" FT /id="VAR_005036" FT VARIANT 890 FT /note="V -> I (in colorectal carcinoma; from a patient with FT MMRCS; dbSNP:rs779998847)" FT /evidence="ECO:0000269|PubMed:9419979" FT /id="VAR_012975" FT VARIANT 906 FT /note="S -> Y (in colorectal tumor)" FT /id="VAR_005037" FT VARIANT 911 FT /note="E -> G (in FAP1 and colorectal tumor)" FT /evidence="ECO:0000269|PubMed:1338904" FT /id="VAR_005038" FT VARIANT 942 FT /note="N -> D (in gastric cancer)" FT /id="VAR_005039" FT VARIANT 1027 FT /note="Y -> C (in colorectal tumor; dbSNP:rs869312784)" FT /id="VAR_005040" FT VARIANT 1057 FT /note="E -> G (found in a family whose members exhibit FT gastrointestinal cancers and multiple pigmented cutaneous FT lesions; uncertain significance)" FT /evidence="ECO:0000269|PubMed:9950360" FT /id="VAR_009615" FT VARIANT 1118 FT /note="N -> D (in dbSNP:rs140493115)" FT /evidence="ECO:0000269|PubMed:1338764" FT /id="VAR_005041" FT VARIANT 1120 FT /note="G -> E (in gastric cancer; dbSNP:rs28933379)" FT /id="VAR_005042" FT VARIANT 1171 FT /note="R -> C (in dbSNP:rs201830995)" FT /evidence="ECO:0000269|PubMed:9950360" FT /id="VAR_008992" FT VARIANT 1171 FT /note="R -> H (in gastric cancer; dbSNP:rs372481703)" FT /id="VAR_005043" FT VARIANT 1176 FT /note="P -> L (in FAP1)" FT /evidence="ECO:0000269|PubMed:8111410" FT /id="VAR_005044" FT VARIANT 1184 FT /note="A -> P (in FAP1)" FT /evidence="ECO:0000269|PubMed:10470088" FT /id="VAR_009616" FT VARIANT 1197 FT /note="F -> S (in gastric cancer)" FT /id="VAR_005045" FT VARIANT 1254 FT /note="I -> F (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035794" FT VARIANT 1259 FT /note="I -> T (in gastric cancer)" FT /id="VAR_005046" FT VARIANT 1292 FT /note="T -> M (in FAP1; uncertain significance; FT dbSNP:rs371113837)" FT /evidence="ECO:0000269|PubMed:1338764" FT /id="VAR_005047" FT VARIANT 1296 FT /note="A -> V (in MDB; sporadic; dbSNP:rs1291513037)" FT /evidence="ECO:0000269|PubMed:10666372" FT /id="VAR_017653" FT VARIANT 1304 FT /note="I -> V (in dbSNP:rs770157475)" FT /evidence="ECO:0000269|PubMed:1338764" FT /id="VAR_005048" FT VARIANT 1307 FT /note="I -> K (probable risk factor for colon and breast FT cancer; dbSNP:rs1801155)" FT /evidence="ECO:0000269|PubMed:9724771, FT ECO:0000269|PubMed:9731522, ECO:0000269|PubMed:9731533, FT ECO:0000269|PubMed:9973276" FT /id="VAR_005049" FT VARIANT 1312 FT /note="G -> E (in gastric cancer)" FT /id="VAR_005050" FT VARIANT 1313 FT /note="T -> A (in FAP1 and colorectal tumor; FT dbSNP:rs863225349)" FT /id="VAR_005051" FT VARIANT 1317 FT /note="E -> Q (may contribute to colorectal tumor FT development; dbSNP:rs1801166)" FT /evidence="ECO:0000269|PubMed:9724771" FT /id="VAR_009617" FT VARIANT 1326 FT /note="V -> A (in gastric cancer)" FT /id="VAR_005052" FT VARIANT 1348 FT /note="R -> W (in FAP1)" FT /evidence="ECO:0000269|PubMed:1338764" FT /id="VAR_005053" FT VARIANT 1395 FT /note="S -> C (in hepatoblastoma; dbSNP:rs137854578)" FT /evidence="ECO:0000269|PubMed:8764128" FT /id="VAR_065133" FT VARIANT 1422 FT /note="D -> H (in colorectal tumor)" FT /id="VAR_005054" FT VARIANT 1472 FT /note="V -> I (in MDB; sporadic; dbSNP:rs878853445)" FT /evidence="ECO:0000269|PubMed:10666372" FT /id="VAR_017654" FT VARIANT 1495 FT /note="S -> G (in MDB; sporadic)" FT /evidence="ECO:0000269|PubMed:10666372" FT /id="VAR_017655" FT VARIANT 1496 FT /note="T -> S (in dbSNP:rs2229996)" FT /id="VAR_020141" FT VARIANT 1508 FT /note="A -> V (in colorectal carcinoma from a patient with FT MMRCS)" FT /evidence="ECO:0000269|PubMed:9419979" FT /id="VAR_012976" FT VARIANT 1822 FT /note="V -> D (in dbSNP:rs459552)" FT /evidence="ECO:0000269|PubMed:1651562, FT ECO:0000269|PubMed:1678319, ECO:0000269|PubMed:9950360, FT ECO:0000269|Ref.5" FT /id="VAR_008993" FT VARIANT 1882 FT /note="R -> T (in dbSNP:rs34157245)" FT /id="VAR_053977" FT VARIANT 1973 FT /note="S -> T (in dbSNP:rs4987109)" FT /id="VAR_020142" FT VARIANT 2499 FT /note="V -> L (in dbSNP:rs33941929)" FT /id="VAR_053978" FT VARIANT 2502 FT /note="G -> S (in dbSNP:rs2229995)" FT /evidence="ECO:0000269|PubMed:1338764" FT /id="VAR_005055" FT VARIANT 2621 FT /note="S -> C (in FAP1; benign; dbSNP:rs72541816)" FT /evidence="ECO:0000269|PubMed:1316610" FT /id="VAR_005056" FT VARIANT 2738 FT /note="I -> T (in dbSNP:rs863224552)" FT /evidence="ECO:0000269|PubMed:9950360" FT /id="VAR_008994" FT VARIANT 2839 FT /note="L -> F (in FAP1; dbSNP:rs876658156)" FT /evidence="ECO:0000269|PubMed:1316610" FT /id="VAR_005057" FT MUTAGEN 516 FT /note="K->E: Impairs interaction with KHDRBS1." FT /evidence="ECO:0000269|PubMed:22000517" FT MUTAGEN 549 FT /note="R->E: Impairs interaction with KHDRBS1." FT /evidence="ECO:0000269|PubMed:22000517" FT MUTAGEN 2841 FT /note="T->L: Loss of interaction with SCRIB." FT /evidence="ECO:0000269|PubMed:16611247" FT MUTAGEN 2843 FT /note="V->Q: Loss of interaction with SCRIB." FT /evidence="ECO:0000269|PubMed:16611247" FT CONFLICT 184 FT /note="M -> L (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 970 FT /note="S -> N (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 1309 FT /note="E -> G (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 1325..1331 FT /note="AVSQHPR -> SSVHSTLE (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 1355 FT /note="S -> P (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 1591 FT /note="A -> G (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 2723 FT /note="N -> T (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 2755 FT /note="S -> P (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT HELIX 6..53 FT /evidence="ECO:0007829|PDB:1DEB" FT HELIX 132..169 FT /evidence="ECO:0007829|PDB:1M5I" FT HELIX 176..178 FT /evidence="ECO:0007829|PDB:8X2Q" FT HELIX 180..204 FT /evidence="ECO:0007829|PDB:1M5I" FT HELIX 208..238 FT /evidence="ECO:0007829|PDB:1M5I" FT HELIX 328..338 FT /evidence="ECO:0007829|PDB:3NMZ" FT HELIX 343..350 FT /evidence="ECO:0007829|PDB:3NMZ" FT HELIX 353..360 FT /evidence="ECO:0007829|PDB:3NMZ" FT HELIX 377..393 FT /evidence="ECO:0007829|PDB:3NMZ" FT HELIX 407..426 FT /evidence="ECO:0007829|PDB:5IZA" FT STRAND 429..431 FT /evidence="ECO:0007829|PDB:3AU3" FT TURN 433..435 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 441..444 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 446..456 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 460..468 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 471..486 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 492..509 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 513..521 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 523..531 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 532..534 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 538..552 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 557..565 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 568..578 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 582..596 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 600..607 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 612..619 FT /evidence="ECO:0007829|PDB:5IZA" FT STRAND 625..627 FT /evidence="ECO:0007829|PDB:3NMW" FT HELIX 629..646 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 650..658 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 661..668 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 674..687 FT /evidence="ECO:0007829|PDB:5IZA" FT STRAND 688..690 FT /evidence="ECO:0007829|PDB:5IZ8" FT HELIX 692..700 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 703..708 FT /evidence="ECO:0007829|PDB:5IZA" FT TURN 709..712 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 716..731 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 735..737 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 739..742 FT /evidence="ECO:0007829|PDB:5IZA" FT TURN 1027..1030 FT /evidence="ECO:0007829|PDB:1JPP" FT HELIX 1470..1479 FT /evidence="ECO:0007829|PDB:1TH1" FT HELIX 1520..1524 FT /evidence="ECO:0007829|PDB:1V18" FT HELIX 2036..2045 FT /evidence="ECO:0007829|PDB:1EMU" FT STRAND 2841..2843 FT /evidence="ECO:0007829|PDB:7XTY" SQ SEQUENCE 2843 AA; 311646 MW; 77E194AE4A91DC5A CRC64; MAAASYDQLL KQVEALKMEN SNLRQELEDN SNHLTKLETE ASNMKEVLKQ LQGSIEDEAM ASSGQIDLLE RLKELNLDSS NFPGVKLRSK MSLRSYGSRE GSVSSRSGEC SPVPMGSFPR RGFVNGSRES TGYLEELEKE RSLLLADLDK EEKEKDWYYA QLQNLTKRID SLPLTENFSL QTDMTRRQLE YEARQIRVAM EEQLGTCQDM EKRAQRRIAR IQQIEKDILR IRQLLQSQAT EAERSSQNKH ETGSHDAERQ NEGQGVGEIN MATSGNGQGS TTRMDHETAS VLSSSSTHSA PRRLTSHLGT KVEMVYSLLS MLGTHDKDDM SRTLLAMSSS QDSCISMRQS GCLPLLIQLL HGNDKDSVLL GNSRGSKEAR ARASAALHNI IHSQPDDKRG RREIRVLHLL EQIRAYCETC WEWQEAHEPG MDQDKNPMPA PVEHQICPAV CVLMKLSFDE EHRHAMNELG GLQAIAELLQ VDCEMYGLTN DHYSITLRRY AGMALTNLTF GDVANKATLC SMKGCMRALV AQLKSESEDL QQVIASVLRN LSWRADVNSK KTLREVGSVK ALMECALEVK KESTLKSVLS ALWNLSAHCT ENKADICAVD GALAFLVGTL TYRSQTNTLA IIESGGGILR NVSSLIATNE DHRQILRENN CLQTLLQHLK SHSLTIVSNA CGTLWNLSAR NPKDQEALWD MGAVSMLKNL IHSKHKMIAM GSAAALRNLM ANRPAKYKDA NIMSPGSSLP SLHVRKQKAL EAELDAQHLS ETFDNIDNLS PKASHRSKQR HKQSLYGDYV FDTNRHDDNR SDNFNTGNMT VLSPYLNTTV LPSSSSSRGS LDSSRSEKDR SLERERGIGL GNYHPATENP GTSSKRGLQI STTAAQIAKV MEEVSAIHTS QEDRSSGSTT ELHCVTDERN ALRRSSAAHT HSNTYNFTKS ENSNRTCSMP YAKLEYKRSS NDSLNSVSSS DGYGKRGQMK PSIESYSEDD ESKFCSYGQY PADLAHKIHS ANHMDDNDGE LDTPINYSLK YSDEQLNSGR QSPSQNERWA RPKHIIEDEI KQSEQRQSRN QSTTYPVYTE STDDKHLKFQ PHFGQQECVS PYRSRGANGS ETNRVGSNHG INQNVSQSLC QEDDYEDDKP TNYSERYSEE EQHEEEERPT NYSIKYNEEK RHVDQPIDYS LKYATDIPSS QKQSFSFSKS SSGQSSKTEH MSSSSENTST PSSNAKRQNQ LHPSSAQSRS GQPQKAATCK VSSINQETIQ TYCVEDTPIC FSRCSSLSSL SSAEDEIGCN QTTQEADSAN TLQIAEIKEK IGTRSAEDPV SEVPAVSQHP RTKSSRLQGS SLSSESARHK AVEFSSGAKS PSKSGAQTPK SPPEHYVQET PLMFSRCTSV SSLDSFESRS IASSVQSEPC SGMVSGIISP SDLPDSPGQT MPPSRSKTPP PPPQTAQTKR EVPKNKAPTA EKRESGPKQA AVNAAVQRVQ VLPDADTLLH FATESTPDGF SCSSSLSALS LDEPFIQKDV ELRIMPPVQE NDNGNETESE QPKESNENQE KEAEKTIDSE KDLLDDSDDD DIEILEECII SAMPTKSSRK AKKPAQTASK LPPPVARKPS QLPVYKLLPS QNRLQPQKHV SFTPGDDMPR VYCVEGTPIN FSTATSLSDL TIESPPNELA AGEGVRGGAQ SGEFEKRDTI PTEGRSTDEA QGGKTSSVTI PELDDNKAEE GDILAECINS AMPKGKSHKP FRVKKIMDQV QQASASSSAP NKNQLDGKKK KPTSPVKPIP QNTEYRTRVR KNADSKNNLN AERVFSDNKD SKKQNLKNNS KVFNDKLPNN EDRVRGSFAF DSPHHYTPIE GTPYCFSRND SLSSLDFDDD DVDLSREKAE LRKAKENKES EAKVTSHTEL TSNQQSANKT QAIAKQPINR GQPKPILQKQ STFPQSSKDI PDRGAATDEK LQNFAIENTP VCFSHNSSLS SLSDIDQENN NKENEPIKET EPPDSQGEPS KPQASGYAPK SFHVEDTPVC FSRNSSLSSL SIDSEDDLLQ ECISSAMPKK KKPSRLKGDN EKHSPRNMGG ILGEDLTLDL KDIQRPDSEH GLSPDSENFD WKAIQEGANS IVSSLHQAAA AACLSRQASS DSDSILSLKS GISLGSPFHL TPDQEEKPFT SNKGPRILKP GEKSTLETKK IESESKGIKG GKKVYKSLIT GKVRSNSEIS GQMKQPLQAN MPSISRGRTM IHIPGVRNSS SSTSPVSKKG PPLKTPASKS PSEGQTATTS PRGAKPSVKS ELSPVARQTS QIGGSSKAPS RSGSRDSTPS RPAQQPLSRP IQSPGRNSIS PGRNGISPPN KLSQLPRTSS PSTASTKSSG SGKMSYTSPG RQMSQQNLTK QTGLSKNASS IPRSESASKG LNQMNNGNGA NKKVELSRMS STKSSGSESD RSERPVLVRQ STFIKEAPSP TLRRKLEESA SFESLSPSSR PASPTRSQAQ TPVLSPSLPD MSLSTHSSVQ AGGWRKLPPN LSPTIEYNDG RPAKRHDIAR SHSESPSRLP INRSGTWKRE HSKHSSSLPR VSTWRRTGSS SSILSASSES SEKAKSEDEK HVNSISGTKQ SKENQVSAKG TWRKIKENEF SPTNSTSQTV SSGATNGAES KTLIYQMAPA VSKTEDVWVR IEDCPINNPR SGRSPTGNTP PVIDSVSEKA NPNIKDSKDN QAKQNVGNGS VPMRTVGLEN RLNSFIQVDA PDQKGTEIKP GQNNPVPVSE TNESSIVERT PFSSSSSSKH SSPSGTVAAR VTPFNYNPSP RKSSADSTSA RPSQIPTPVN NNTKKRDSKT DSTESSGTQS PKRHSGSYLV TSV // ID ATM_HUMAN Reviewed; 3056 AA. AC Q13315; B2RNX5; O15429; Q12758; Q16551; Q93007; Q9NP02; Q9UCX7; DT 27-APR-2001, integrated into UniProtKB/Swiss-Prot. DT 22-JAN-2014, sequence version 4. DT 28-JAN-2026, entry version 269. DE RecName: Full=Serine-protein kinase ATM; DE EC=2.7.11.1 {ECO:0000269|PubMed:15448695, ECO:0000269|PubMed:15790808, ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:28508083, ECO:0000269|PubMed:30886146, ECO:0000269|PubMed:8988033, ECO:0000269|PubMed:9843217}; DE AltName: Full=Ataxia telangiectasia mutated; DE Short=A-T mutated; GN Name=ATM; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT AT ASP-3003. RX PubMed=8589678; DOI=10.1093/hmg/4.11.2025; RA Savitsky K., Sfez S., Tagle D.A., Ziv Y., Sartiel A., Collins F.S., RA Shiloh Y., Rotman G.; RT "The complete sequence of the coding region of the ATM gene reveals RT similarity to cell cycle regulators in different species."; RL Hum. Mol. Genet. 4:2025-2032(1995). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], VARIANT AT ASP-3003, AND VARIANTS RP CYS-49; ARG-1054; PHE-1420; ILE-2079 AND ALA-2287. RX PubMed=8665503; RA Vorechovsky I., Rasio D., Luo L., Monaco C., Hammarstroem L., RA Webster A.D.B., Zaloudik J., Barbanti-Brodano G., James M.R., Russo G., RA Croce C.M., Negrini M.; RT "The ATM gene and susceptibility to breast cancer: analysis of 38 breast RT tumors reveals no evidence for mutation."; RL Cancer Res. 56:2726-2732(1996). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9199932; DOI=10.1101/gr.7.6.592; RA Platzer M., Rotman G., Bauer D., Uziel T., Savitsky K., Bar-Shira A., RA Gilad S., Shiloh Y., Rosenthal A.; RT "Ataxia-telangiectasia locus: sequence analysis of 184 kb of human genomic RT DNA containing the entire ATM gene."; RL Genome Res. 7:592-605(1997). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ASN-1983. RX PubMed=16554811; DOI=10.1038/nature04632; RA Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K., RA Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T., RA Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G., RA Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C., RA Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A., RA Hattori M., Rogers J., Lander E.S., Sakaki Y.; RT "Human chromosome 11 DNA sequence and analysis including novel gene RT identification."; RL Nature 440:497-500(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-2756. RG NIEHS SNPs program; RL Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-1369, AND VARIANT AT 2546-SER--ILE-2548 RP DEL. RX PubMed=8789452; DOI=10.1093/hmg/5.1.145; RA Byrd P.J., McConville C.M., Cooper P., Parkhill J., Stankovic T., RA McGuire G.M., Thick J.A., Taylor A.M.R.; RT "Mutations revealed by sequencing the 5' half of the gene for ataxia RT telangiectasia."; RL Hum. Mol. Genet. 5:145-149(1996). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-24. RX PubMed=9108147; DOI=10.1093/nar/25.9.1678; RA Savitsky K., Platzer M., Uziel T., Gilad S., Sartiel A., Rosenthal A., RA Elroy-Stein O., Shiloh Y., Rotman G.; RT "Ataxia-telangiectasia: structural diversity of untranslated sequences RT suggests complex post-transcriptional regulation of ATM gene expression."; RL Nucleic Acids Res. 25:1678-1684(1997). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1332-3056, AND VARIANTS 2427-LEU-ARG-2428 RP DEL; 2546-SER--ILE-2548 DEL; SER-2860 DEL AND ASP-3003. RC TISSUE=Fibroblast; RX PubMed=7792600; DOI=10.1126/science.7792600; RA Savitsky K., Bar-Shira A., Gilad S., Rotman G., Ziv Y., Vanagaite L., RA Tagle D.A., Smith S., Uziel T., Sfez S., Ashkenazi M., Pecker I., RA Frydman M., Harnik R., Patanjali S.R., Simmons A., Clines G.A., Sartiel A., RA Gatti R.A., Chessa L., Sanal O., Lavin M.F., Jaspers N.G.J., Taylor A.M.R., RA Arlett C.F., Miki T., Weissman S.M., Lovett M., Collins F.S., Shiloh Y.; RT "A single ataxia telangiectasia gene with a product similar to PI-3 RT kinase."; RL Science 268:1749-1753(1995). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1332-3056. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1349-3056. RX PubMed=8521392; RA Rasio D., Negrini M., Croce C.M.; RT "Genomic organization of the ATM locus involved in ataxia-telangiectasia."; RL Cancer Res. 55:6053-6057(1995). RN [12] RP PHOSPHORYLATION. RX PubMed=8969240; DOI=10.1074/jbc.271.52.33693; RA Chen G., Lee E.Y.-H.P.; RT "The product of the ATM gene is a 370-kDa nuclear phosphoprotein."; RL J. Biol. Chem. 271:33693-33697(1996). RN [13] RP SUBCELLULAR LOCATION. RX PubMed=9050866; DOI=10.1073/pnas.94.5.1840; RA Brown K.D., Ziv Y., Sadanandan S.N., Chessa L., Collins F.S., Shiloh Y., RA Tagle D.A.; RT "The ataxia-telangiectasia gene product, a constitutively expressed nuclear RT protein that is not up-regulated following genome damage."; RL Proc. Natl. Acad. Sci. U.S.A. 94:1840-1845(1997). RN [14] RP SUBCELLULAR LOCATION, AND VARIANTS 2546-SER--ILE-2548 DEL AND TYR-2824. RX PubMed=9150358; DOI=10.1038/sj.onc.1201037; RA Watters D., Khanna K.K., Beamish H., Birrell G., Spring K., Kedar P., RA Gatei M., Stenzel D., Hobson K., Kozlov S., Zhang N., Farrell A., RA Ramsay J., Gatti R.A., Lavin M.F.; RT "Cellular localisation of the ataxia-telangiectasia (ATM) gene product and RT discrimination between mutated and normal forms."; RL Oncogene 14:1911-1921(1997). RN [15] RP CATALYTIC ACTIVITY. RX PubMed=8988033; RA Jung M., Kondratyev A., Lee S.A., Dimtchev A., Dritschilo A.; RT "ATM gene product phosphorylates I kappa B-alpha."; RL Cancer Res. 57:24-27(1997). RN [16] RP INTERACTION WITH ABL1. RX PubMed=9168117; DOI=10.1038/387520a0; RA Shafman T., Khanna K.K., Kedar P., Spring K., Kozlov S., Yen T., Hobson K., RA Gatei M., Zhang N., Watters D., Egerton M., Shiloh Y., Kharbanda S., RA Kufe D., Lavin M.F.; RT "Interaction between ATM protein and c-Abl in response to DNA damage."; RL Nature 387:520-523(1997). RN [17] RP ACTIVITY REGULATION. RX PubMed=9766667; RA Sarkaria J.N., Tibbetts R.S., Busby E.C., Kennedy A.P., Hill D.E., RA Abraham R.T.; RT "Inhibition of phosphoinositide 3-kinase related kinases by the RT radiosensitizing agent wortmannin."; RL Cancer Res. 58:4375-4382(1998). RN [18] RP FUNCTION, INTERACTION WITH TP53, AND CATALYTIC ACTIVITY. RX PubMed=9843217; DOI=10.1038/3882; RA Khanna K.K., Keating K.E., Kozlov S., Scott S., Gatei M., Hobson K., RA Taya Y., Gabrielli B., Chan D., Lees-Miller S.P., Lavin M.F.; RT "ATM associates with and phosphorylates p53: mapping the region of RT interaction."; RL Nat. Genet. 20:398-400(1998). RN [19] RP SUBCELLULAR LOCATION. RX PubMed=9707615; DOI=10.1073/pnas.95.17.10146; RA Lim D.-S., Kirsch D.G., Canman C.E., Ahn J.-H., Ziv Y., Newman L.S., RA Darnell R.B., Shiloh Y., Kastan M.B.; RT "ATM binds to beta-adaptin in cytoplasmic vesicles."; RL Proc. Natl. Acad. Sci. U.S.A. 95:10146-10151(1998). RN [20] RP FUNCTION IN PHOSPHORYLATION OF TP53. RX PubMed=9733514; DOI=10.1126/science.281.5383.1674; RA Banin S., Moyal L., Shieh S.-Y., Taya Y., Anderson C.W., Chessa L., RA Smorodinsky N.I., Prives C., Reiss Y., Shiloh Y., Ziv Y.; RT "Enhanced phosphorylation of p53 by ATM in response to DNA damage."; RL Science 281:1674-1677(1998). RN [21] RP FUNCTION IN PHOSPHORYLATION OF TP53, AND MUTAGENESIS OF ASP-2870 AND RP ASN-2875. RX PubMed=9733515; DOI=10.1126/science.281.5383.1677; RA Canman C.E., Lim D.-S., Cimprich K.A., Taya Y., Tamai K., Sakaguchi K., RA Appella E., Kastan M.B., Siliciano J.D.; RT "Activation of the ATM kinase by ionizing radiation and phosphorylation of RT p53."; RL Science 281:1677-1679(1998). RN [22] RP DNA-BINDING. RX PubMed=10500142; DOI=10.1073/pnas.96.20.11134; RA Smith G.C.M., Cary R.B., Lakin N.D., Hann B.C., Teo S.-H., Chen D.J., RA Jackson S.P.; RT "Purification and DNA binding properties of the ataxia-telangiectasia gene RT product ATM."; RL Proc. Natl. Acad. Sci. U.S.A. 96:11134-11139(1999). RN [23] RP FUNCTION IN PHOSPHORYLATION OF BRCA1. RX PubMed=10550055; DOI=10.1126/science.286.5442.1162; RA Cortez D., Wang Y., Qin J., Elledge S.J.; RT "Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage RT response to double-strand breaks."; RL Science 286:1162-1166(1999). RN [24] RP IDENTIFICATION OF ATM AS MEMBER OF BASC. RX PubMed=10783165; RA Wang Y., Cortez D., Yazdi P., Neff N., Elledge S.J., Qin J.; RT "BASC, a super complex of BRCA1-associated proteins involved in the RT recognition and repair of aberrant DNA structures."; RL Genes Dev. 14:927-939(2000). RN [25] RP FUNCTION IN PHOSPHORYLATION OF NBN. RX PubMed=10766245; DOI=10.1038/35007091; RA Lim D.-S., Kim S.-T., Xu B., Maser R.S., Lin J., Petrini J.H.J., RA Kastan M.B.; RT "ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway."; RL Nature 404:613-617(2000). RN [26] RP FUNCTION IN PHOSPHORYLATION OF NBN. RX PubMed=10839545; DOI=10.1038/35013089; RA Wu X., Ranganathan V., Weisman D.S., Heine W.F., Ciccone D.N., RA O'Neill T.B., Crick K.E., Pierce K.A., Lane W.S., Rathbun G., RA Livingston D.M., Weaver D.T.; RT "ATM phosphorylation of Nijmegen breakage syndrome protein is required in a RT DNA damage response."; RL Nature 405:477-482(2000). RN [27] RP FUNCTION IN PHOSPHORYLATION OF CTIP. RX PubMed=10910365; DOI=10.1038/35018134; RA Li S., Ting N.S.Y., Zheng L., Chen P.-L., Ziv Y., Shiloh Y., Lee E.Y.-H.P., RA Lee W.-H.; RT "Functional link of BRCA1 and ataxia telangiectasia gene product in DNA RT damage response."; RL Nature 406:210-215(2000). RN [28] RP FUNCTION IN PHOSPHORYLATION OF NBN. RX PubMed=10802669; DOI=10.1038/75508; RA Gatei M., Young D., Cerosaletti K.M., Desai-Mehta A., Spring K., Kozlov S., RA Lavin M.F., Gatti R.A., Concannon P., Khanna K.K.; RT "ATM-dependent phosphorylation of nibrin in response to radiation RT exposure."; RL Nat. Genet. 25:115-119(2000). RN [29] RP FUNCTION IN PHOSPHORYLATION OF CHEK2. RX PubMed=10973490; DOI=10.1073/pnas.190030497; RA Matsuoka S., Rotman G., Ogawa A., Shiloh Y., Tamai K., Elledge S.J.; RT "Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro."; RL Proc. Natl. Acad. Sci. U.S.A. 97:10389-10394(2000). RN [30] RP FUNCTION IN PHOSPHORYLATION OF TERF1. RX PubMed=11375976; DOI=10.1074/jbc.m011534200; RA Kishi S., Zhou X.Z., Ziv Y., Khoo C., Hill D.E., Shiloh Y., Lu K.P.; RT "Telomeric protein Pin2/TRF1 as an important ATM target in response to RT double strand DNA breaks."; RL J. Biol. Chem. 276:29282-29291(2001). RN [31] RP INTERACTION WITH RAD17. RX PubMed=11418864; DOI=10.1038/35082110; RA Bao S., Tibbetts R.S., Brumbaugh K.M., Fang Y., Richardson D.A., Ali A., RA Chen S.M., Abraham R.T., Wang X.-F.; RT "ATR/ATM-mediated phosphorylation of human Rad17 is required for genotoxic RT stress responses."; RL Nature 411:969-974(2001). RN [32] RP FUNCTION IN PHOSPHORYLATION OF FANCD2. RX PubMed=12086603; DOI=10.1016/s0092-8674(02)00747-x; RA Taniguchi T., Garcia-Higuera I., Xu B., Andreassen P.R., Gregory R.C., RA Kim S.-T., Lane W.S., Kastan M.B., D'Andrea A.D.; RT "Convergence of the Fanconi anemia and ataxia telangiectasia signaling RT pathways."; RL Cell 109:459-472(2002). RN [33] RP PHOSPHORYLATION BY NUAK1. RX PubMed=12409306; DOI=10.1074/jbc.m206025200; RA Suzuki A., Kusakai G., Kishimoto A., Lu J., Ogura T., Lavin M.F., Esumi H.; RT "Identification of a novel protein kinase mediating Akt survival signaling RT to the ATM protein."; RL J. Biol. Chem. 278:48-53(2003). RN [34] RP PHOSPHORYLATION AT SER-1981, SUBUNIT, FUNCTION, AND MUTAGENESIS OF RP SER-1981. RX PubMed=12556884; DOI=10.1038/nature01368; RA Bakkenist C.J., Kastan M.B.; RT "DNA damage activates ATM through intermolecular autophosphorylation and RT dimer dissociation."; RL Nature 421:499-506(2003). RN [35] RP FUNCTION IN DNA DAMAGE RESPONSE. RX PubMed=14871926; DOI=10.1101/gad.1176004; RA Ali A., Zhang J., Bao S., Liu I., Otterness D., Dean N.M., Abraham R.T., RA Wang X.F.; RT "Requirement of protein phosphatase 5 in DNA-damage-induced ATM RT activation."; RL Genes Dev. 18:249-254(2004). RN [36] RP FUNCTION IN PHOSPHORYLATION OF DCLRE1C. RX PubMed=15456891; DOI=10.1128/mcb.24.20.9207-9220.2004; RA Zhang X., Succi J., Feng Z., Prithivirajsingh S., Story M.D., RA Legerski R.J.; RT "Artemis is a phosphorylation target of ATM and ATR and is involved in the RT G2/M DNA damage checkpoint response."; RL Mol. Cell. Biol. 24:9207-9220(2004). RN [37] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=15448695; DOI=10.1038/ncb1170; RA Demonacos C., Krstic-Demonacos M., Smith L., Xu D., O'Connor D.P., RA Jansson M., La Thangue N.B.; RT "A new effector pathway links ATM kinase with the DNA damage response."; RL Nat. Cell Biol. 6:968-976(2004). RN [38] RP FUNCTION, AND ACTIVITY REGULATION. RX PubMed=15064416; DOI=10.1126/science.1091496; RA Lee J.-H., Paull T.T.; RT "Direct activation of the ATM protein kinase by the Mre11/Rad50/Nbs1 RT complex."; RL Science 304:93-96(2004). RN [39] RP INTERACTION WITH EEF1E1. RX PubMed=15680327; DOI=10.1016/j.cell.2004.11.054; RA Park B.-J., Kang J.W., Lee S.W., Choi S.-J., Shin Y.K., Ahn Y.H., RA Choi Y.H., Choi D., Lee K.S., Kim S.; RT "The haploinsufficient tumor suppressor p18 upregulates p53 via RT interactions with ATM/ATR."; RL Cell 120:209-221(2005). RN [40] RP FUNCTION. RX PubMed=15916964; DOI=10.1016/j.molcel.2005.04.015; RA Bhoumik A., Takahashi S., Breitweiser W., Shiloh Y., Jones N., Ronai Z.; RT "ATM-dependent phosphorylation of ATF2 is required for the DNA damage RT response."; RL Mol. Cell 18:577-587(2005). RN [41] RP INTERACTION WITH KAT8. RX PubMed=15923642; DOI=10.1128/mcb.25.12.5292-5305.2005; RA Gupta A., Sharma G.G., Young C.S.H., Agarwal M., Smith E.R., Paull T.T., RA Lucchesi J.C., Khanna K.K., Ludwig T., Pandita T.K.; RT "Involvement of human MOF in ATM function."; RL Mol. Cell. Biol. 25:5292-5305(2005). RN [42] RP FUNCTION IN HISTONE MRNA DEGRADATION ACTIVITY. RX PubMed=16086026; DOI=10.1038/nsmb972; RA Kaygun H., Marzluff W.F.; RT "Regulated degradation of replication-dependent histone mRNAs requires both RT ATR and Upf1."; RL Nat. Struct. Mol. Biol. 12:794-800(2005). RN [43] RP PHOSPHORYLATION AT SER-1981, AND ACETYLATION. RX PubMed=16141325; DOI=10.1073/pnas.0504211102; RA Sun Y., Jiang X., Chen S., Fernandes N., Price B.D.; RT "A role for the Tip60 histone acetyltransferase in the acetylation and RT activation of ATM."; RL Proc. Natl. Acad. Sci. U.S.A. 102:13182-13187(2005). RN [44] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, SUBUNIT, AND RP PHOSPHORYLATION AT SER-1981. RX PubMed=15790808; DOI=10.1126/science.1108297; RA Lee J.H., Paull T.T.; RT "ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 RT complex."; RL Science 308:551-554(2005). RN [45] RP PHOSPHORYLATION AT SER-367; SER-1893 AND SER-1981, FUNCTION, CATALYTIC RP ACTIVITY, MUTAGENESIS OF SER-367; SER-1893 AND SER-1981, AND IDENTIFICATION RP BY MASS SPECTROMETRY. RX PubMed=16858402; DOI=10.1038/sj.emboj.7601231; RA Kozlov S.V., Graham M.E., Peng C., Chen P., Robinson P.J., Lavin M.F.; RT "Involvement of novel autophosphorylation sites in ATM activation."; RL EMBO J. 25:3504-3514(2006). RN [46] RP INTERACTION WITH ATMIN. RX PubMed=17525732; DOI=10.1038/sj.emboj.7601733; RA Kanu N., Behrens A.; RT "ATMIN defines an NBS1-independent pathway of ATM signalling."; RL EMBO J. 26:2933-2941(2007). RN [47] RP ACETYLATION AT LYS-3016, FUNCTION, AND MUTAGENESIS OF LYS-3016 AND RP LYS-3018. RX PubMed=17923702; DOI=10.1128/mcb.01382-07; RA Sun Y., Xu Y., Roy K., Price B.D.; RT "DNA damage-induced acetylation of lysine 3016 of ATM activates ATM kinase RT activity."; RL Mol. Cell. Biol. 27:8502-8509(2007). RN [48] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1981 AND SER-1983, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [49] RP INTERACTION WITH CEP164. RX PubMed=18283122; DOI=10.1101/gad.1627708; RA Sivasubramaniam S., Sun X., Pan Y.R., Wang S., Lee E.Y.; RT "Cep164 is a mediator protein required for the maintenance of genomic RT stability through modulation of MDC1, RPA, and CHK1."; RL Genes Dev. 22:587-600(2008). RN [50] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2996, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [51] RP INTERACTION WITH NABP2. RX PubMed=18449195; DOI=10.1038/nature06883; RA Richard D.J., Bolderson E., Cubeddu L., Wadsworth R.I.M., Savage K., RA Sharma G.G., Nicolette M.L., Tsvetanov S., McIlwraith M.J., Pandita R.K., RA Takeda S., Hay R.T., Gautier J., West S.C., Paull T.T., Pandita T.K., RA White M.F., Khanna K.K.; RT "Single-stranded DNA-binding protein hSSB1 is critical for genomic RT stability."; RL Nature 453:677-681(2008). RN [52] RP INTERACTION WITH DDX1. RX PubMed=18710941; DOI=10.1128/mcb.01053-08; RA Li L., Monckton E.A., Godbout R.; RT "A role for DEAD box 1 at DNA double-strand breaks."; RL Mol. Cell. Biol. 28:6413-6425(2008). RN [53] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2996, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [54] RP FUNCTION AS DYRK2 KINASE. RX PubMed=19965871; DOI=10.1074/jbc.m109.042341; RA Taira N., Yamamoto H., Yamaguchi T., Miki Y., Yoshida K.; RT "ATM augments nuclear stabilization of DYRK2 by inhibiting MDM2 in the RT apoptotic response to DNA damage."; RL J. Biol. Chem. 285:4909-4919(2010). RN [55] RP INTERACTION WITH TTI1. RX PubMed=20810650; DOI=10.1101/gad.1934210; RA Hurov K.E., Cotta-Ramusino C., Elledge S.J.; RT "A genetic screen identifies the Triple T complex required for DNA damage RT signaling and ATM and ATR stability."; RL Genes Dev. 24:1939-1950(2010). RN [56] RP INTERACTION WITH TELO2. RX PubMed=20801936; DOI=10.1101/gad.1956410; RA Takai H., Xie Y., de Lange T., Pavletich N.P.; RT "Tel2 structure and function in the Hsp90-dependent maturation of mTOR and RT ATR complexes."; RL Genes Dev. 24:2019-2030(2010). RN [57] RP INTERACTION WITH TELO2 AND TTI1. RX PubMed=20427287; DOI=10.1074/jbc.m110.121699; RA Kaizuka T., Hara T., Oshiro N., Kikkawa U., Yonezawa K., Takehana K., RA Iemura S., Natsume T., Mizushima N.; RT "Tti1 and Tel2 are critical factors in mammalian target of rapamycin RT complex assembly."; RL J. Biol. Chem. 285:20109-20116(2010). RN [58] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [59] RP PHOSPHORYLATION AT SER-1981. RX PubMed=21144835; DOI=10.1016/j.bbrc.2010.12.005; RA Kang Y., Cheong H.M., Lee J.H., Song P.I., Lee K.H., Kim S.Y., Jun J.Y., RA You H.J.; RT "Protein phosphatase 5 is necessary for ATR-mediated DNA repair."; RL Biochem. Biophys. Res. Commun. 404:476-481(2011). RN [60] RP INTERACTION WITH BRAT1. RX PubMed=22977523; DOI=10.3892/etm.2011.232; RA So E.Y., Ouchi T.; RT "Functional interaction of BRCA1/ATM-associated BAAT1 with the DNA-PK RT catalytic subunit."; RL Exp. Ther. Med. 2:443-447(2011). RN [61] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=21757780; DOI=10.1074/jbc.m111.258152; RA Gatei M., Jakob B., Chen P., Kijas A.W., Becherel O.J., Gueven N., RA Birrell G., Lee J.H., Paull T.T., Lerenthal Y., Fazry S., RA Taucher-Scholz G., Kalb R., Schindler D., Waltes R., Doerk T., Lavin M.F.; RT "ATM protein-dependent phosphorylation of Rad50 protein regulates DNA RT repair and cell cycle control."; RL J. Biol. Chem. 286:31542-31556(2011). RN [62] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22223895; DOI=10.1074/mcp.m111.015131; RA Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T., RA Giglione C.; RT "Comparative large-scale characterisation of plant vs. mammal proteins RT reveals similar and idiosyncratic N-alpha acetylation features."; RL Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012). RN [63] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [64] RP FUNCTION. RX PubMed=24534091; DOI=10.1002/embj.201386064; RA Wang Q., Goldstein M., Alexander P., Wakeman T.P., Sun T., Feng J., Lou Z., RA Kastan M.B., Wang X.F.; RT "Rad17 recruits the MRE11-RAD50-NBS1 complex to regulate the cellular RT response to DNA double-strand breaks."; RL EMBO J. 33:862-877(2014). RN [65] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [66] RP FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, INTERACTION WITH PEX5, RP AND MUTAGENESIS OF ARG-3047. RX PubMed=26344566; DOI=10.1038/ncb3230; RA Zhang J., Tripathi D.N., Jing J., Alexander A., Kim J., Powell R.T., RA Dere R., Tait-Mulder J., Lee J.H., Paull T.T., Pandita R.K., Charaka V.K., RA Pandita T.K., Kastan M.B., Walker C.L.; RT "ATM functions at the peroxisome to induce pexophagy in response to ROS."; RL Nat. Cell Biol. 17:1259-1269(2015). RN [67] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=26240375; DOI=10.1093/nar/gkv754; RA Kijas A.W., Lim Y.C., Bolderson E., Cerosaletti K., Gatei M., Jakob B., RA Tobias F., Taucher-Scholz G., Gueven N., Oakley G., Concannon P., RA Wolvetang E., Khanna K.K., Wiesmueller L., Lavin M.F.; RT "ATM-dependent phosphorylation of MRE11 controls extent of resection during RT homology directed repair by signalling through Exonuclease 1."; RL Nucleic Acids Res. 43:8352-8367(2015). RN [68] RP FUNCTION IN PHOSPHORYLATION OF FBXW7. RX PubMed=26774286; DOI=10.1016/j.molcel.2015.12.010; RA Zhang Q., Karnak D., Tan M., Lawrence T.S., Morgan M.A., Sun Y.; RT "FBXW7 facilitates nonhomologous end-joining via K63-linked RT polyubiquitylation of XRCC4."; RL Mol. Cell 61:419-433(2016). RN [69] RP FUNCTION. RX PubMed=29203878; DOI=10.1038/s41467-017-02114-x; RA Batenburg N.L., Walker J.R., Noordermeer S.M., Moatti N., Durocher D., RA Zhu X.D.; RT "ATM and CDK2 control chromatin remodeler CSB to inhibit RIF1 in DSB repair RT pathway choice."; RL Nat. Commun. 8:1921-1921(2017). RN [70] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=30171069; DOI=10.1074/jbc.ra118.005354; RA Choppara S., Ganga S., Manne R., Dutta P., Singh S., Santra M.K.; RT "The SCFFBXO46 ubiquitin ligase complex mediates degradation of the tumor RT suppressor FBXO31 and thereby prevents premature cellular senescence."; RL J. Biol. Chem. 293:16291-16306(2018). RN [71] RP FUNCTION. RX PubMed=30612738; DOI=10.1016/j.cell.2018.11.024; RA Jachimowicz R.D., Beleggia F., Isensee J., Velpula B.B., Goergens J., RA Bustos M.A., Doll M.A., Shenoy A., Checa-Rodriguez C., Wiederstein J.L., RA Baranes-Bachar K., Bartenhagen C., Hertwig F., Teper N., Nishi T., RA Schmitt A., Distelmaier F., Luedecke H.J., Albrecht B., Krueger M., RA Schumacher B., Geiger T., Hoon D.S.B., Huertas P., Fischer M., Hucho T., RA Peifer M., Ziv Y., Reinhardt H.C., Wieczorek D., Shiloh Y.; RT "UBQLN4 represses homologous recombination and is overexpressed in RT aggressive tumors."; RL Cell 0:0-0(2019). RN [72] RP FUNCTION IN PHOSPHORYLATION OF UFL1, AND CATALYTIC ACTIVITY. RX PubMed=30886146; DOI=10.1038/s41467-019-09175-0; RA Qin B., Yu J., Nowsheen S., Wang M., Tu X., Liu T., Li H., Wang L., Lou Z.; RT "UFL1 promotes histone H4 ufmylation and ATM activation."; RL Nat. Commun. 10:1242-1242(2019). RN [73] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=30952868; DOI=10.1038/s41467-019-09641-9; RA Ha G.H., Ji J.H., Chae S., Park J., Kim S., Lee J.K., Kim Y., Min S., RA Park J.M., Kang T.H., Lee H., Cho H., Lee C.W.; RT "Pellino1 regulates reversible ATM activation via NBS1 ubiquitination at RT DNA double-strand breaks."; RL Nat. Commun. 10:1577-1577(2019). RN [74] RP ACETYLATION AT LYS-3016, PHOSPHORYLATION AT SER-1981, AND MUTAGENESIS OF RP LYS-3016. RX PubMed=30944854; DOI=10.1126/sciadv.aav1118; RA Tang M., Li Z., Zhang C., Lu X., Tu B., Cao Z., Li Y., Chen Y., Jiang L., RA Wang H., Wang L., Wang J., Liu B., Xu X., Wang H., Zhu W.G.; RT "SIRT7-mediated ATM deacetylation is essential for its deactivation and DNA RT damage repair."; RL Sci. Adv. 5:EAAV1118-EAAV1118(2019). RN [75] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=38128537; DOI=10.1016/j.cell.2023.11.022; RA Chen Y., Wu J., Zhai L., Zhang T., Yin H., Gao H., Zhao F., Wang Z., RA Yang X., Jin M., Huang B., Ding X., Li R., Yang J., He Y., Wang Q., RA Wang W., Kloeber J.A., Li Y., Hao B., Zhang Y., Wang J., Tan M., Li K., RA Wang P., Lou Z., Yuan J.; RT "Metabolic regulation of homologous recombination repair by MRE11 RT lactylation."; RL Cell 187:294-311(2024). RN [76] {ECO:0007744|PDB:5NP0, ECO:0007744|PDB:5NP1} RP STRUCTURE BY ELECTRON MICROSCOPY (5.70 ANGSTROMS), CATALYTIC ACTIVITY, AND RP SUBUNIT. RX PubMed=28508083; DOI=10.1126/sciadv.1700933; RA Baretic D., Pollard H.K., Fisher D.I., Johnson C.M., Santhanam B., RA Truman C.M., Kouba T., Fersht A.R., Phillips C., Williams R.L.; RT "Structures of closed and open conformations of dimeric human ATM."; RL Sci. Adv. 3:E1700933-E1700933(2017). RN [77] {ECO:0007744|PDB:7SIC, ECO:0007744|PDB:7SID} RP STRUCTURE BY ELECTRON MICROSCOPY (2.51 ANGSTROMS) IN COMPLEX WITH NBN, RP FUNCTION, INTERACTION WITH NBN, AND ACTIVITY REGULATION. RX PubMed=35076389; DOI=10.7554/elife.74218; RA Warren C., Pavletich N.P.; RT "Structure of the human ATM kinase and mechanism of Nbs1 binding."; RL Elife 11:0-0(2022). RN [78] RP VARIANTS GLY-2424; 2546-SER--ILE-2548 DEL AND CYS-2827. RX PubMed=8755918; RA McConville C.M., Stankovic T., Byrd P.J., McGuire G.M., Yao Q.-Y., RA Lennox G.G., Taylor A.M.R.; RT "Mutations associated with variant phenotypes in ataxia-telangiectasia."; RL Am. J. Hum. Genet. 59:320-330(1996). RN [79] RP VARIANT AT 2546-SER--ILE-2548 DEL, AND VARIANT ILE-2438. RX PubMed=8808599; RA Wright J., Teraoka S., Onengut S., Tolun A., Gatti R.A., Ochs H.D., RA Concannon P.; RT "A high frequency of distinct ATM gene mutations in ataxia- RT telangiectasia."; RL Am. J. Hum. Genet. 59:839-846(1996). RN [80] RP VARIANTS 705-TYR--SER-707 DELINS PHE-ILE-PRO AND 2546-SER--ILE-2548 DEL, RP AND VARIANTS CYS-49; LEU-858; ARG-1054; PHE-1420 AND ARG-1691. RX PubMed=8797579; RA Vorechovsky I., Luo L., Lindblom A., Negrini M., Webster A.D.B., RA Croce C.M., Hammarstroem L.; RT "ATM mutations in cancer families."; RL Cancer Res. 56:4130-4133(1996). RN [81] RP VARIANT AT 705-TYR--SER-707 DELINS PHE-ILE-PRO, AND VARIANTS LEU-858 AND RP ARG-1054. RX PubMed=9043869; DOI=10.1159/000472231; RA Vorechovsky I., Luo L., Prudente S., Chessa L., Russo G., Kanariou M., RA James M.R., Negrini M., Webster A.D.B., Hammarstroem L.; RT "Exon-scanning mutation analysis of the ATM gene in patients with ataxia- RT telangiectasia."; RL Eur. J. Hum. Genet. 4:352-355(1996). RN [82] RP VARIANT AT ARG-2867. RX PubMed=8698354; DOI=10.1007/s004390050202; RA Baumer A., Bernthaler U., Wolz W., Hoehn H., Schindler D.; RT "New mutations in the ataxia telangiectasia gene."; RL Hum. Genet. 98:246-249(1996). RN [83] RP VARIANTS 2427-LEU-ARG-2428 DEL; 2546-SER--ILE-2548 DEL; SER-2860 DEL AND RP GLY-2904. RX PubMed=8845835; DOI=10.1093/hmg/5.4.433; RA Gilad S., Khosravi R., Shkedy D., Uziel T., Ziv Y., Savitsky K., Rotman G., RA Smith S., Chessa L., Jorgensen T.J., Harnik R., Frydman M., Sanal O., RA Portnoi S., Goldwicz Z., Jaspers N.G.J., Gatti R.A., Lenoir G., Lavin M.F., RA Tatsumi K., Wegner R.-D., Shiloh Y., Bar-Shira A.; RT "Predominance of null mutations in ataxia-telangiectasia."; RL Hum. Mol. Genet. 5:433-439(1996). RN [84] RP POSSIBLE INVOLVEMENT IN TPLL AND BNHL, AND VARIANTS VAL-1040; THR-1407; RP SER-1463; HIS-1682; HIS-1910; LYS-2164; SER-2396; GLY-2424; PRO-2442; RP 2546-SER--ILE-2548 DEL; ALA-2695; ARG-2722; VAL-2725; LEU-2732; LYS-2810 RP DEL; CYS-2832 AND 2871-ARG-HIS-2872 DELINS SER AND VAL-2890. RX PubMed=9288106; DOI=10.1038/ng0997-96; RA Vorechovsky I., Luo L., Dyer M.J.S., Catovsky D., Amlot P.L., Yaxley J.C., RA Foroni L., Hammarstroem L., Webster A.D.B., Yuille M.A.R.; RT "Clustering of missense mutations in the ataxia-telangiectasia gene in a RT sporadic T-cell leukaemia."; RL Nat. Genet. 17:96-99(1997). RN [85] RP POSSIBLE INVOLVEMENT IN TPLL, AND VARIANTS GLY-2725; PRO-3006 AND CYS-3008. RX PubMed=9334731; DOI=10.1038/nm1097-1155; RA Stilgenbauer S., Schaffner C., Litterst A., Liebisch P., Gilad S., RA Bar-Shira A., James M.R., Lichter P., Doehner H.; RT "Biallelic mutations in the ATM gene in T-prolymphocytic leukemia."; RL Nat. Med. 3:1155-1159(1997). RN [86] RP VARIANT AT CYS-2832. RX PubMed=9443866; DOI=10.1086/301673; RA Telatar M., Teraoka S., Wang Z., Chun H.H., Liang T., Castellvi-Bel S., RA Udar N., Boerresen-Dale A.-L., Chessa L., Bernatowska-Matuszkiewicz E., RA Porras O., Watanabe M., Junker A., Concannon P., Gatti R.A.; RT "Ataxia-telangiectasia: identification and detection of founder-effect RT mutations in the ATM gene in ethnic populations."; RL Am. J. Hum. Genet. 62:86-97(1998). RN [87] RP POSSIBLE INVOLVEMENT IN TALL, AND VARIANTS AT LEU-292; ASP-768; GLN-1001; RP ARG-1691; ILE-1743; GLY-2424; 2427-LEU-ARG-2428 DEL; 2546-SER--ILE-2548 RP DEL; ASP-2554; GLY-2668 AND CYS-2827. RX PubMed=9463314; DOI=10.1086/301706; RA Stankovic T., Kidd A.M.J., Sutcliffe A., McGuire G.M., Robinson P., RA Weber P., Bedenham T., Bradwell A.R., Easton D.F., Lennox G.G., Haites N., RA Byrd P.J., Taylor A.M.R.; RT "ATM mutations and phenotypes in ataxia-telangiectasia families in the RT British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, RT and breast cancer."; RL Am. J. Hum. Genet. 62:334-345(1998). RN [88] RP VARIANT AT 1812-ALA-PHE-1813 DELINS VAL. RX PubMed=9497252; DOI=10.1086/301755; RA Gilad S., Chessa L., Khosravi R., Russell P., Galanty Y., Piane M., RA Gatti R.A., Jorgensen T.J., Shiloh Y., Bar-Shira A.; RT "Genotype-phenotype relationships in ataxia-telangiectasia and variants."; RL Am. J. Hum. Genet. 62:551-561(1998). RN [89] RP VARIANT AT PRO-2656. RX PubMed=9450874; RX DOI=10.1002/(sici)1096-8628(19980113)75:2<141::aid-ajmg4>3.3.co;2-8; RA Toyoshima M., Hara T., Zhang H., Yamamoto T., Akaboshi S., Nanba E., RA Ohno K., Hori N., Sato K., Takeshita K.; RT "Ataxia-telangiectasia without immunodeficiency: novel point mutations RT within and adjacent to the phosphatidylinositol 3-kinase-like domain."; RL Am. J. Med. Genet. 75:141-144(1998). RN [90] RP VARIANT TPLL GLY-2486. RX PubMed=9573030; RA Stoppa-Lyonnet D., Soulier J., Lauge A., Dastot H., Garand R., Sigaux F., RA Stern M.-H.; RT "Inactivation of the ATM gene in T-cell prolymphocytic leukemias."; RL Blood 91:3920-3926(1998). RN [91] RP VARIANTS 2855-SER-VAL-2856 DELINS ARG-ILE AND CYS-3008, AND VARIANT RP VAL-1853. RX PubMed=9872980; DOI=10.1101/gr.8.12.1245; RA Hacia J.G., Sun B., Hunt N., Edgemon K., Mosbrook D., Robbins C., RA Fodor S.P.A., Tagle D.A., Collins F.S.; RT "Strategies for mutational analysis of the large multiexon ATM gene using RT high-density oligonucleotide arrays."; RL Genome Res. 8:1245-1258(1998). RN [92] RP VARIANT AT 2625-ASP-ALA-2626 DELINS GLU-PRO. RX PubMed=9521587; DOI=10.1007/s004390050675; RA van Belzen M.J., Hiel J.A.P., Weemaes C.M.R., Gabreeels F.J.M., RA van Engelen B.G.M., Smeets D.F.C.M., van den Heuvel L.P.W.J.; RT "A double missense mutation in the ATM gene of a Dutch family with ataxia RT telangiectasia."; RL Hum. Genet. 102:187-191(1998). RN [93] RP VARIANT AT LEU-2829, AND VARIANTS GLU-126; ASP-514 AND ASN-1853. RX PubMed=9711876; RX DOI=10.1002/(sici)1098-1004(1998)12:3<186::aid-humu6>3.0.co;2-f; RA Sasaki T., Tian H., Kukita Y., Inazuka M., Tahira T., Imai T., Yamauchi M., RA Saito T., Hori T., Hashimoto-Tamaoki T., Komatsu K., Nikaido O., RA Hayashi K.; RT "ATM mutations in patients with ataxia telangiectasia screened by a RT hierarchical strategy."; RL Hum. Mutat. 12:186-195(1998). RN [94] RP VARIANTS AT LEU-858; ARG-1054; ASP-1091 AND ARG-1566. RX PubMed=9792409; RX DOI=10.1002/(sici)1098-1004(1998)12:5<330::aid-humu6>3.0.co;2-h; RA Broeks A., de Klein A., Floore A.N., Muijtjens M., Kleijer W.J., RA Jaspers N.G.J., van 't Veer L.J.; RT "ATM germline mutations in classical ataxia-telangiectasia patients in the RT Dutch population."; RL Hum. Mutat. 12:330-337(1998). RN [95] RP VARIANTS AT ARG-2491 AND GLY-2909. RX PubMed=9792410; RX DOI=10.1002/(sici)1098-1004(1998)12:5<338::aid-humu7>3.0.co;2-9; RA Fukao T., Song X.-Q., Yoshida T., Tashita H., Kaneko H., Teramoto T., RA Inoue R., Katamura K., Mayumi M., Hiratani M., Taniguchi N., Arai J., RA Wakiguchi H., Bar-Shira A., Shiloh Y., Kondo N.; RT "Ataxia-telangiectasia in the Japanese population: identification of RT R1917X, W2491R, R2909G, IVS33+2T-->A, and 7883del5, the latter two being RT relatively common mutations."; RL Hum. Mutat. 12:338-343(1998). RN [96] RP VARIANTS TPLL GLY-2139; VAL-2890 AND CYS-3008. RX PubMed=9488043; DOI=10.1038/sj.onc.1201603; RA Yuille M.A.R., Coignet L.J.A., Abraham S.M., Yaqub F., Luo L., Matutes E., RA Brito-Babapulle V., Vorechovsky I., Dyer M.J.S., Catovsky D.; RT "ATM is usually rearranged in T-cell prolymphocytic leukaemia."; RL Oncogene 16:789-796(1998). RN [97] RP ERRATUM OF PUBMED:9488043. RA Yuille M.A.R., Coignet L.J.A., Abraham S.M., Yaqub F., Luo L., Matutes E., RA Brito-Babapulle V., Vorechovsky I., Dyer M.J.S., Catovsky D.; RL Oncogene 16:2955-2955(1998). RN [98] RP POSSIBLE INVOLVEMENT IN BCLL AND MCL, AND VARIANTS ASN-1853; VAL-1853; RP ARG-1953; LYS-2418 INS; PRO-2420; GLY-2423; HIS-3008 AND ASN-3018. RX PubMed=10397742; RA Schaffner C., Stilgenbauer S., Rappold G.A., Doehner H., Lichter P.; RT "Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic RT lymphocytic leukemia."; RL Blood 94:748-753(1999). RN [99] RP POSSIBLE INVOLVEMENT IN BCLL, AND VARIANTS CYS-332; ARG-1691 AND GLY-2424. RX PubMed=9892178; RA Bullrich F., Rasio D., Kitada S., Starostik P., Kipps T., Keating M., RA Albitar M., Reed J.C., Croce C.M.; RT "ATM mutations in B-cell chronic lymphocytic leukemia."; RL Cancer Res. 59:24-27(1999). RN [100] RP VARIANT AT PRO-1465. RX PubMed=10234507; DOI=10.1038/sj.ejhg.5200288; RA Izatt L., Vessey C., Hodgson S.V., Solomon E.; RT "Rapid and efficient ATM mutation detection by fluorescent chemical RT cleavage of mismatch: identification of four novel mutations."; RL Eur. J. Hum. Genet. 7:310-320(1999). RN [101] RP VARIANTS CYS-49; LEU-182; PRO-707; LEU-858; PHE-1420; ALA-1570; ASN-1853 RP AND SER-2765. RX PubMed=10534763; RX DOI=10.1002/(sici)1098-2264(199912)26:4<286::aid-gcc2>3.3.co;2-o; RA Izatt L., Greenman J., Hodgson S.V., Ellis D., Watts S., Scott G., RA Jacobs C., Liebmann R., Zvelebil M.J., Mathew C., Solomon E.; RT "Identification of germline missense mutations and rare allelic variants in RT the ATM gene in early-onset breast cancer."; RL Genes Chromosomes Cancer 26:286-294(1999). RN [102] RP VARIANTS AT SER-570; CYS-785; GLY-1913; GLY-2016; ASP-2067; CYS-2227; RP ASP-2470; VAL-2662 DEL; PRO-2849 AND ARG-2867, AND VARIANTS CYS-49; RP LEU-858; ARG-1054; ASN-1853 AND VAL-1853. RX PubMed=9887333; DOI=10.1093/hmg/8.1.69; RA Sandoval N., Platzer M., Rosenthal A., Doerk T., Bendix R., Skawran B., RA Stuhrmann M., Wegner R.-D., Sperling K., Banin S., Shiloh Y., Baumer A., RA Bernthaler U., Sennefelder H., Brohm M., Weber B.H.F., Schindler D.; RT "Characterization of ATM gene mutations in 66 ataxia telangiectasia RT families."; RL Hum. Mol. Genet. 8:69-79(1999). RN [103] RP VARIANTS AT 375-GLN--VAL-3056 DEL; 1466-ARG--VAL-3056 DEL; RP 1730-ARG--VAL-3056 DEL; GLY-2016; 2224-MET--ARG-2227 DELINS ILE-SER; RP 2246-CYS--THR-2252 DELINS HIS; VAL-2664 DEL; VAL-2726; 2849-ARG--VAL-3056 RP DEL AND ARG-2855, AND VARIANT CYS-49. RX PubMed=10425038; RX DOI=10.1002/(sici)1098-1004(1999)14:2<156::aid-humu7>3.0.co;2-e; RA Castellvi-Bel S., Sheikhavandi S., Telatar M., Tai L.-Q., Hwang M.J., RA Wang Z., Yang Z., Cheng R., Gatti R.A.; RT "New mutations, polymorphisms, and rare variants in the ATM gene detected RT by a novel SSCP strategy."; RL Hum. Mutat. 14:156-162(1999). RN [104] RP POSSIBLE INVOLVEMENT IN BCLL, AND VARIANTS THR-350; THR-352; ARG-1054; RP THR-2274 AND ALA-2695. RX PubMed=10023947; DOI=10.1016/s0140-6736(98)10117-4; RA Stankovic T., Weber P., Stewart G., Bedenham T., Murray J., Byrd P.J., RA Moss P.A.H., Taylor A.M.R.; RT "Inactivation of ataxia telangiectasia mutated gene in B-cell chronic RT lymphocytic leukaemia."; RL Lancet 353:26-29(1999). RN [105] RP VARIANT ARG-1054. RX PubMed=10217116; DOI=10.1016/s0140-6736(05)75199-0; RA Vorechovsky I., Luo L., Ortmann E., Steinmann D., Doerk T.; RT "Missense mutations at ATM gene and cancer risk."; RL Lancet 353:1276-1276(1999). RN [106] RP ERRATUM OF PUBMED:10217116. RA Vorechovsky I., Luo L., Ortmann E., Steinmann D., Doerk T.; RL Lancet 354:780-780(1999). RN [107] RP VARIANTS AT GLU-224; VAL-323; PRO-1420; CYS-2218; 2546-SER--ILE-2548 DEL; RP GLN-2625; CYS-2832; 2855-SER-VAL-2856 DELINS ARG-ILE AND CYS-3008, AND RP VARIANTS VAL-1853 AND ILE-2438. RX PubMed=10817650; RX DOI=10.1002/(sici)1096-8628(20000529)92:3<170::aid-ajmg3>3.0.co;2-#; RA Li A., Swift M.; RT "Mutations at the ataxia-telangiectasia locus and clinical phenotypes of A- RT T patients."; RL Am. J. Med. Genet. 92:170-177(2000). RN [108] RP VARIANTS AT 35-ARG--VAL-3056 DEL; LEU-292; 393-TRP--VAL-3056 DEL; ARG-950; RP LEU-1082; 1171-GLN--VAL-3056 DEL; 1839-GLN--VAL-3056 DEL; GLU-2063; RP CYS-2227; 2246-CYS--THR-2252 DELINS HIS; 2547-ARG--SER-2549 DEL; GLU-2625; RP PRO-2626 AND ARG-2702, AND VARIANT CYS-49. RX PubMed=10873394; DOI=10.1006/mgme.2000.2998; RA Becker-Catania S.G., Chen G., Hwang M.J., Wang Z., Sun X., Sanal O., RA Bernatowska-Matuszkiewicz E., Chessa L., Lee E.Y.-H.P., Gatti R.A.; RT "Ataxia-telangiectasia: phenotype/genotype studies of ATM protein RT expression, mutations, and radiosensitivity."; RL Mol. Genet. Metab. 70:122-133(2000). RN [109] RP VARIANTS MCL LYS-2418 INS; GLY-2423 AND CYS-3008. RX PubMed=10706620; DOI=10.1073/pnas.050400997; RA Schaffner C., Idler I., Stilgenbauer S., Doehner H., Lichter P.; RT "Mantle cell lymphoma is characterized by inactivation of the ATM gene."; RL Proc. Natl. Acad. Sci. U.S.A. 97:2773-2778(2000). RN [110] RP VARIANTS TRP-45 AND CYS-49. RX PubMed=11897822; DOI=10.1136/jmg.39.3.192; RA Allinen M., Launonen V., Laake K., Jansen L., Huusko P., Kaeaeriaeinen H., RA Boerresen-Dale A.L., Winqvist R.; RT "ATM mutations in Finnish breast cancer patients."; RL J. Med. Genet. 39:192-196(2002). RN [111] RP VARIANTS [LARGE SCALE ANALYSIS] GLN-23; CYS-49; GLU-126; HIS-140; GLN-250; RP PHE-333; CYS-337; HIS-337; ALA-410; SER-504; ASP-514; TYR-540; VAL-546; RP LEU-582; PRO-707; GLN-848; LEU-858; SER-872; TRP-924; ALA-935; ARG-1054; RP PHE-1179; ILE-1321; TYR-1380; SER-1382; PHE-1420; MET-1469; CYS-1475; RP SER-1650; THR-1739; ASN-1853; VAL-1853; ILE-1916; THR-1945; CYS-1961; RP ASP-1991; PHE-2307; PRO-2332; PHE-2356; LEU-2408; PRO-2442; GLN-2443; RP ARG-2464; ARG-2492; ALA-2666; HIS-2719; ARG-2842 AND ASN-2870. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [112] RP VARIANTS CYS-49; LEU-858; ARG-1054; VAL-1255; ASN-1853; THR-2105; SER-2396 RP AND HIS-2719. RX PubMed=18384426; DOI=10.1111/j.1399-0004.2008.00987.x; RA Brunet J., Gutierrez-Enriquez S., Torres A., Berez V., Sanjose S., RA Galceran J., Izquierdo A., Menendez J.A., Guma J., Borras J.; RT "ATM germline mutations in Spanish early-onset breast cancer patients RT negative for BRCA1/BRCA2 mutations."; RL Clin. Genet. 73:465-473(2008). RN [113] RP FUNCTION, CHARACTERIZATION OF VARIANTS AT LEU-292; PRO-1465; ILE-1743; RP THR-2274; GLY-2424; 2427-LEU-ARG-2428 DEL; 2546-SER--ILE-2548 DEL; RP ASP-2554; GLY-2668; CYS-2827; 2855-SER-VAL-2856 DELINS ARG-ILE AND RP CYS-3008, CHARACTERIZATION OF VARIANTS VAL-546; ARG-1054; ILE-1322; RP ARG-1691; CYS-1961 AND SER-2765, VARIANT ILE-1322, AND MUTAGENESIS OF RP LYS-1807; VAL-1941; TYR-2019; GLU-2039; LEU-2338; SER-2394; LEU-2452; RP SER-2685; PRO-2699; ASP-2708 AND GLN-2730. RX PubMed=19431188; DOI=10.1002/humu.21034; RA Barone G., Groom A., Reiman A., Srinivasan V., Byrd P.J., Taylor A.M.; RT "Modeling ATM mutant proteins from missense changes confirms retained RT kinase activity."; RL Hum. Mutat. 30:1222-1230(2009). RN [114] RP VARIANTS ALA-661; PRO-707; LEU-858; TRP-924; ARG-1054; ARG-1691 AND RP VAL-1853. RX PubMed=28202063; DOI=10.1186/s12920-017-0244-7; RA Jalkh N., Chouery E., Haidar Z., Khater C., Atallah D., Ali H., RA Marafie M.J., Al-Mulla M.R., Al-Mulla F., Megarbane A.; RT "Next-generation sequencing in familial breast cancer patients from RT Lebanon."; RL BMC Med. Genomics 10:8-8(2017). RN [115] RP VARIANTS AT VAL-323; PRO-1046; ARG-2023; SER-2068; ASP-2080; HIS-2627; RP LEU-2834 AND ASP-3003, CHARACTERIZATION OF VARIANTS AT VAL-323; PRO-1046; RP ARG-2023; SER-2068; ASP-2080; HIS-2627; LEU-2834 AND ASP-3003, AND RP PHOSPHORYLATION. RX PubMed=27664052; DOI=10.1007/s12017-016-8440-8; RA Carranza D., Vega A.K., Torres-Rusillo S., Montero E., Martinez L.J., RA Santamaria M., Santos J.L., Molina I.J.; RT "Molecular and functional characterization of a cohort of Spanish patients RT with ataxia-telangiectasia."; RL NeuroMolecular Med. 19:161-174(2017). RN [116] RP VARIANTS VAL-68; ILE-341; LEU-597; GLY-699; GLY-759; SER-813; GLY-869; RP ILE-897; ASP-1474; VAL-1488; CYS-1961; ALA-2287; PHE-2307; ARG-2464; RP PRO-2524; THR-2531; GLN-2810; HIS-2832; LEU-2974; ASP-3029 AND LEU-3056. RX PubMed=28726808; DOI=10.1038/gim.2017.85; RA Chaffee K.G., Oberg A.L., McWilliams R.R., Majithia N., Allen B.A., RA Kidd J., Singh N., Hartman A.R., Wenstrup R.J., Petersen G.M.; RT "Prevalence of germ-line mutations in cancer genes among pancreatic cancer RT patients with a positive family history."; RL Genet. Med. 20:119-127(2018). CC -!- FUNCTION: Serine/threonine protein kinase which activates checkpoint CC signaling upon double strand breaks (DSBs), apoptosis and genotoxic CC stresses such as ionizing ultraviolet A light (UVA), thereby acting as CC a DNA damage sensor (PubMed:10550055, PubMed:10839545, PubMed:10910365, CC PubMed:12556884, PubMed:14871926, PubMed:15064416, PubMed:15448695, CC PubMed:15456891, PubMed:15790808, PubMed:15916964, PubMed:17923702, CC PubMed:21757780, PubMed:24534091, PubMed:35076389, PubMed:9733514). CC Recognizes the substrate consensus sequence [ST]-Q (PubMed:10550055, CC PubMed:10839545, PubMed:10910365, PubMed:12556884, PubMed:14871926, CC PubMed:15448695, PubMed:15456891, PubMed:15916964, PubMed:17923702, CC PubMed:24534091, PubMed:9733514). Phosphorylates 'Ser-139' of histone CC variant H2AX at double strand breaks (DSBs), thereby regulating DNA CC damage response mechanism (By similarity). Also plays a role in pre-B CC cell allelic exclusion, a process leading to expression of a single CC immunoglobulin heavy chain allele to enforce clonality and monospecific CC recognition by the B-cell antigen receptor (BCR) expressed on CC individual B-lymphocytes. After the introduction of DNA breaks by the CC RAG complex on one immunoglobulin allele, acts by mediating a CC repositioning of the second allele to pericentromeric heterochromatin, CC preventing accessibility to the RAG complex and recombination of the CC second allele. Also involved in signal transduction and cell cycle CC control. May function as a tumor suppressor. Necessary for activation CC of ABL1 and SAPK. Phosphorylates DYRK2, CHEK2, p53/TP53, FBXW7, FANCD2, CC NFKBIA, BRCA1, CREBBP/CBP, RBBP8/CTIP, FBXO46, MRE11, nibrin (NBN), CC RAD50, RAD17, PELI1, TERF1, UFL1, RAD9, UBQLN4 and DCLRE1C CC (PubMed:10550055, PubMed:10766245, PubMed:10802669, PubMed:10839545, CC PubMed:10910365, PubMed:10973490, PubMed:11375976, PubMed:12086603, CC PubMed:15456891, PubMed:19965871, PubMed:21757780, PubMed:24534091, CC PubMed:26240375, PubMed:26774286, PubMed:30171069, PubMed:30612738, CC PubMed:30886146, PubMed:30952868, PubMed:38128537, PubMed:9733515, CC PubMed:9843217). May play a role in vesicle and/or protein transport. CC Could play a role in T-cell development, gonad and neurological CC function. Plays a role in replication-dependent histone mRNA CC degradation. Binds DNA ends. Phosphorylation of DYRK2 in nucleus in CC response to genotoxic stress prevents its MDM2-mediated ubiquitination CC and subsequent proteasome degradation (PubMed:19965871). Phosphorylates CC ATF2 which stimulates its function in DNA damage response CC (PubMed:15916964). Phosphorylates ERCC6 which is essential for its CC chromatin remodeling activity at DNA double-strand breaks CC (PubMed:29203878). Phosphorylates TTC5/STRAP at 'Ser-203' in the CC cytoplasm in response to DNA damage, which promotes TTC5/STRAP nuclear CC localization (PubMed:15448695). Also involved in pexophagy by mediating CC phosphorylation of PEX5: translocated to peroxisomes in response to CC reactive oxygen species (ROS), and catalyzes phosphorylation of PEX5, CC promoting PEX5 ubiquitination and induction of pexophagy CC (PubMed:26344566). {ECO:0000250|UniProtKB:Q62388, CC ECO:0000269|PubMed:10550055, ECO:0000269|PubMed:10766245, CC ECO:0000269|PubMed:10802669, ECO:0000269|PubMed:10839545, CC ECO:0000269|PubMed:10910365, ECO:0000269|PubMed:10973490, CC ECO:0000269|PubMed:11375976, ECO:0000269|PubMed:12086603, CC ECO:0000269|PubMed:12556884, ECO:0000269|PubMed:14871926, CC ECO:0000269|PubMed:15448695, ECO:0000269|PubMed:15456891, CC ECO:0000269|PubMed:15916964, ECO:0000269|PubMed:16086026, CC ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:17923702, CC ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:19965871, CC ECO:0000269|PubMed:21757780, ECO:0000269|PubMed:24534091, CC ECO:0000269|PubMed:26240375, ECO:0000269|PubMed:26344566, CC ECO:0000269|PubMed:26774286, ECO:0000269|PubMed:29203878, CC ECO:0000269|PubMed:30171069, ECO:0000269|PubMed:30612738, CC ECO:0000269|PubMed:30886146, ECO:0000269|PubMed:30952868, CC ECO:0000269|PubMed:35076389, ECO:0000269|PubMed:38128537, CC ECO:0000269|PubMed:9733514, ECO:0000269|PubMed:9733515, CC ECO:0000269|PubMed:9843217}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:15448695, ECO:0000269|PubMed:15790808, CC ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:26240375, CC ECO:0000269|PubMed:26344566, ECO:0000269|PubMed:28508083, CC ECO:0000269|PubMed:30171069, ECO:0000269|PubMed:30886146, CC ECO:0000269|PubMed:30952868, ECO:0000269|PubMed:38128537, CC ECO:0000269|PubMed:8988033, ECO:0000269|PubMed:9843217}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990; CC Evidence={ECO:0000269|PubMed:15790808, ECO:0000269|PubMed:21757780, CC ECO:0000269|PubMed:26240375, ECO:0000269|PubMed:30952868, CC ECO:0000269|PubMed:9843217, ECO:0000305|PubMed:15448695}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:24534091, ECO:0000269|PubMed:28508083, CC ECO:0000269|PubMed:30952868, ECO:0000269|PubMed:8988033, CC ECO:0000269|PubMed:9843217}; CC -!- ACTIVITY REGULATION: Activated by the MRN (MRE11-RAD50-NBS1) complex in CC response to DNA double strand breaks (DSBs), which recruits ATM to DSBs CC and promotes its activation (PubMed:15064416, PubMed:15790808, CC PubMed:35076389). Inhibited by wortmannin (PubMed:9766667). CC {ECO:0000269|PubMed:15064416, ECO:0000269|PubMed:15790808, CC ECO:0000269|PubMed:35076389, ECO:0000269|PubMed:9766667}. CC -!- SUBUNIT: Homodimer (PubMed:12556884, PubMed:15790808, PubMed:28508083). CC Dimers or tetramers in inactive state (PubMed:12556884, CC PubMed:15790808, PubMed:28508083). On DNA damage, autophosphorylation CC dissociates ATM into monomers rendering them catalytically active CC (PubMed:12556884, PubMed:28508083). Binds p53/TP53, ABL1, BRCA1 and CC TERF1 (PubMed:15790808, PubMed:9168117, PubMed:9843217). Interacts with CC NBN (via FxF/Y motif) (PubMed:35076389). Part of the BRCA1-associated CC genome surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, CC MLH1, ATM, BLM, PMS2 and the RAD50-MRE11-NBN protein complex CC (PubMed:10783165). This association could be a dynamic process changing CC throughout the cell cycle and within subnuclear domains CC (PubMed:10783165). Interacts with RAD17; DNA damage promotes the CC association (PubMed:11418864). Interacts with EEF1E1; the interaction, CC induced on DNA damage, up-regulates TP53 (PubMed:15680327). Interacts CC with KAT8, NABP2, ATMIN and CEP164 (PubMed:15923642, PubMed:17525732, CC PubMed:18283122, PubMed:18449195). Interacts with AP2B1 and AP3B2; the CC interaction occurs in cytoplasmic vesicles (By similarity). Interacts CC with TELO2 and TTI1 (PubMed:20427287, PubMed:20801936, CC PubMed:20810650). Interacts with DDX1 (PubMed:18710941). Interacts with CC BRAT1 (PubMed:22977523). Interacts with CYREN (via XLF motif) (By CC similarity). Interacts (via microbody targeting signal) with PEX5; CC promoting translocation to peroxisomes in response to reactive oxygen CC species (ROS) (PubMed:26344566). {ECO:0000250|UniProtKB:Q62388, CC ECO:0000269|PubMed:10783165, ECO:0000269|PubMed:11418864, CC ECO:0000269|PubMed:12556884, ECO:0000269|PubMed:15680327, CC ECO:0000269|PubMed:15790808, ECO:0000269|PubMed:15923642, CC ECO:0000269|PubMed:17525732, ECO:0000269|PubMed:18283122, CC ECO:0000269|PubMed:18449195, ECO:0000269|PubMed:18710941, CC ECO:0000269|PubMed:20427287, ECO:0000269|PubMed:20801936, CC ECO:0000269|PubMed:20810650, ECO:0000269|PubMed:22977523, CC ECO:0000269|PubMed:26344566, ECO:0000269|PubMed:28508083, CC ECO:0000269|PubMed:35076389, ECO:0000269|PubMed:9168117, CC ECO:0000269|PubMed:9843217}. CC -!- INTERACTION: CC Q13315; Q9NY61: AATF; NbExp=3; IntAct=EBI-495465, EBI-372428; CC Q13315; P00519: ABL1; NbExp=4; IntAct=EBI-495465, EBI-375543; CC Q13315; P31749: AKT1; NbExp=5; IntAct=EBI-495465, EBI-296087; CC Q13315; O43313: ATMIN; NbExp=5; IntAct=EBI-495465, EBI-7422202; CC Q13315; Q6PJG6: BRAT1; NbExp=3; IntAct=EBI-495465, EBI-10826195; CC Q13315; P62508-3: ESRRG; NbExp=3; IntAct=EBI-495465, EBI-12001340; CC Q13315; Q5XUX0: FBXO31; NbExp=2; IntAct=EBI-495465, EBI-6162477; CC Q13315; Q9Y6K9: IKBKG; NbExp=4; IntAct=EBI-495465, EBI-81279; CC Q13315; Q13007: IL24; NbExp=2; IntAct=EBI-495465, EBI-3915542; CC Q13315; Q14676: MDC1; NbExp=3; IntAct=EBI-495465, EBI-495644; CC Q13315; Q9BQ15: NABP2; NbExp=4; IntAct=EBI-495465, EBI-2120336; CC Q13315; P11245: NAT2; NbExp=2; IntAct=EBI-495465, EBI-9057228; CC Q13315; O60934: NBN; NbExp=2; IntAct=EBI-495465, EBI-494844; CC Q13315; P46531: NOTCH1; NbExp=8; IntAct=EBI-495465, EBI-636374; CC Q13315; Q9BZ95: NSD3; NbExp=3; IntAct=EBI-495465, EBI-3390132; CC Q13315; Q7LG56: RRM2B; NbExp=3; IntAct=EBI-495465, EBI-9009083; CC Q13315; Q9Y4R8: TELO2; NbExp=4; IntAct=EBI-495465, EBI-1043674; CC Q13315; P54274: TERF1; NbExp=3; IntAct=EBI-495465, EBI-710997; CC Q13315; P54274-2: TERF1; NbExp=5; IntAct=EBI-495465, EBI-711018; CC Q13315; Q15554: TERF2; NbExp=2; IntAct=EBI-495465, EBI-706637; CC Q13315; Q12888: TP53BP1; NbExp=2; IntAct=EBI-495465, EBI-396540; CC Q13315; O43156: TTI1; NbExp=5; IntAct=EBI-495465, EBI-1055680; CC Q13315; PRO_0000037577 [P27958]; Xeno; NbExp=3; IntAct=EBI-495465, EBI-6904388; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9050866, CC ECO:0000269|PubMed:9150358}. Cytoplasmic vesicle CC {ECO:0000269|PubMed:9050866, ECO:0000269|PubMed:9150358}. Cytoplasm, CC cytoskeleton, microtubule organizing center, centrosome CC {ECO:0000250|UniProtKB:Q62388}. Peroxisome matrix CC {ECO:0000269|PubMed:26344566}. Note=Primarily nuclear (PubMed:9050866, CC PubMed:9150358). Found also in endocytic vesicles in association with CC beta-adaptin (PubMed:9707615). Translocated to peroxisomes in response CC to reactive oxygen species (ROS) by PEX5 (PubMed:26344566). CC {ECO:0000269|PubMed:26344566, ECO:0000269|PubMed:9050866, CC ECO:0000269|PubMed:9150358, ECO:0000269|PubMed:9707615}. CC -!- TISSUE SPECIFICITY: Found in pancreas, kidney, skeletal muscle, liver, CC lung, placenta, brain, heart, spleen, thymus, testis, ovary, small CC intestine, colon and leukocytes. CC -!- INDUCTION: By ionizing radiation. CC -!- DOMAIN: The FATC domain is required for interaction with KAT5. CC {ECO:0000269|PubMed:16141325}. CC -!- PTM: Phosphorylated by NUAK1/ARK5 (PubMed:12409306). CC Autophosphorylation on Ser-367, Ser-1893, Ser-1981 correlates with DNA CC damage-mediated activation of the kinase (PubMed:12556884, CC PubMed:15790808, PubMed:16141325, PubMed:16858402, PubMed:21144835, CC PubMed:27664052). During the late stages of DNA damage response, CC dephosphorylated following deacetylation by SIRT7, leading to ATM CC deactivation (PubMed:30944854). {ECO:0000269|PubMed:12409306, CC ECO:0000269|PubMed:12556884, ECO:0000269|PubMed:15790808, CC ECO:0000269|PubMed:16141325, ECO:0000269|PubMed:16858402, CC ECO:0000269|PubMed:21144835, ECO:0000269|PubMed:27664052, CC ECO:0000269|PubMed:30944854}. CC -!- PTM: Acetylation, on DNA damage, is required for activation of the CC kinase activity, dimer-monomer transition, and subsequent CC autophosphorylation on Ser-1981 (PubMed:12556884, PubMed:16141325, CC PubMed:16858402, PubMed:17923702, PubMed:21144835). Acetylated in vitro CC by KAT5/TIP60 (PubMed:16141325). Deacetylated by SIRT7 during the late CC stages of DNA damage response, promoting ATM dephosphorylation and CC subsequent deactivation (PubMed:30944854). CC {ECO:0000269|PubMed:12556884, ECO:0000269|PubMed:16141325, CC ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:17923702, CC ECO:0000269|PubMed:21144835, ECO:0000269|PubMed:30944854}. CC -!- DISEASE: Ataxia telangiectasia (AT) [MIM:208900]: A rare recessive CC disorder characterized by progressive cerebellar ataxia, dilation of CC the blood vessels in the conjunctiva and eyeballs, immunodeficiency, CC growth retardation and sexual immaturity. Patients have a strong CC predisposition to cancer; about 30% of patients develop tumors, CC particularly lymphomas and leukemias. Cells from affected individuals CC are highly sensitive to damage by ionizing radiation and resistant to CC inhibition of DNA synthesis following irradiation. CC {ECO:0000269|PubMed:10234507, ECO:0000269|PubMed:10425038, CC ECO:0000269|PubMed:10817650, ECO:0000269|PubMed:10873394, CC ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:27664052, CC ECO:0000269|PubMed:7792600, ECO:0000269|PubMed:8589678, CC ECO:0000269|PubMed:8665503, ECO:0000269|PubMed:8698354, CC ECO:0000269|PubMed:8755918, ECO:0000269|PubMed:8789452, CC ECO:0000269|PubMed:8797579, ECO:0000269|PubMed:8808599, CC ECO:0000269|PubMed:8845835, ECO:0000269|PubMed:9043869, CC ECO:0000269|PubMed:9150358, ECO:0000269|PubMed:9443866, CC ECO:0000269|PubMed:9450874, ECO:0000269|PubMed:9463314, CC ECO:0000269|PubMed:9497252, ECO:0000269|PubMed:9521587, CC ECO:0000269|PubMed:9711876, ECO:0000269|PubMed:9792409, CC ECO:0000269|PubMed:9792410, ECO:0000269|PubMed:9872980, CC ECO:0000269|PubMed:9887333}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Note=Defects in ATM may contribute to T-cell acute CC lymphoblastic leukemia (TALL) and T-prolymphocytic leukemia (TPLL). CC TPLL is characterized by a high white blood cell count, with a CC predominance of prolymphocytes, marked splenomegaly, lymphadenopathy, CC skin lesions and serous effusion. The clinical course is highly CC aggressive, with poor response to chemotherapy and short survival time. CC TPLL occurs both in adults as a sporadic disease and in younger AT CC patients. {ECO:0000269|PubMed:9288106, ECO:0000269|PubMed:9334731, CC ECO:0000269|PubMed:9463314, ECO:0000269|PubMed:9488043, CC ECO:0000269|PubMed:9573030}. CC -!- DISEASE: Note=Defects in ATM may contribute to B-cell non-Hodgkin CC lymphomas (BNHL), including mantle cell lymphoma (MCL). CC {ECO:0000269|PubMed:10397742, ECO:0000269|PubMed:10706620, CC ECO:0000269|PubMed:9288106}. CC -!- DISEASE: Note=Defects in ATM may contribute to B-cell chronic CC lymphocytic leukemia (BCLL). BCLL is the commonest form of leukemia in CC the elderly. It is characterized by the accumulation of mature CD5+ B- CC lymphocytes, lymphadenopathy, immunodeficiency and bone marrow failure. CC {ECO:0000269|PubMed:10023947, ECO:0000269|PubMed:10397742, CC ECO:0000269|PubMed:9892178}. CC -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. ATM subfamily. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAA86520.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=AAA86520.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305}; CC Sequence=AAI37170.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=AAI37170.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305}; CC Sequence=EAW67111.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/123/ATM"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=Ataxia telangiectasia mutated entry; CC URL="https://en.wikipedia.org/wiki/Ataxia_telangiectasia_mutated"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U33841; AAC50289.1; -; mRNA. DR EMBL; U55757; AAB38309.1; -; Genomic_DNA. DR EMBL; U55704; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55705; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55707; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55708; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55709; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55710; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55711; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55712; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55713; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55714; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55715; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55716; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55717; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55718; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55719; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55720; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55721; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55722; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55723; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55724; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55725; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55726; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55727; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55728; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55729; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55730; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55731; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55732; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55733; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55734; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55735; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55736; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55737; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55738; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55739; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55740; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55741; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55742; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55743; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55744; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55745; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55746; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55747; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55748; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55749; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55750; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55751; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55752; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55753; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55754; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55755; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55756; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55757; AAB38310.1; -; Genomic_DNA. DR EMBL; U55726; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55727; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55728; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55729; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55730; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55731; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55732; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55733; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55734; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55735; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55736; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55737; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55738; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55739; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55740; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55741; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55742; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55743; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55744; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55745; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55746; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55747; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55748; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55749; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55750; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55751; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55752; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55753; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55754; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55755; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55756; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U82828; AAB65827.1; -; Genomic_DNA. DR EMBL; AP001925; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AP005718; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; KF455499; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471065; EAW67111.1; ALT_SEQ; Genomic_DNA. DR EMBL; X91196; CAA62603.1; -; mRNA. DR EMBL; U67092; AAC51298.1; -; Genomic_DNA. DR EMBL; AY220758; AAO26044.1; -; Genomic_DNA. DR EMBL; U26455; AAA86520.1; ALT_SEQ; mRNA. DR EMBL; BC137169; AAI37170.1; ALT_SEQ; mRNA. DR CCDS; CCDS31669.1; -. DR PIR; A43100; A43100. DR RefSeq; NP_000042.3; NM_000051.3. DR RefSeq; NP_001338763.1; NM_001351834.2. DR RefSeq; XP_005271619.2; XM_005271562.6. DR RefSeq; XP_006718906.1; XM_006718843.5. DR RefSeq; XP_006718908.1; XM_006718845.1. DR RefSeq; XP_011541142.1; XM_011542840.4. DR RefSeq; XP_016873279.1; XM_017017790.3. DR RefSeq; XP_047282931.1; XM_047426975.1. DR RefSeq; XP_047282932.1; XM_047426976.1. DR RefSeq; XP_054224846.1; XM_054368871.1. DR RefSeq; XP_054224847.1; XM_054368872.1. DR RefSeq; XP_054224848.1; XM_054368873.1. DR RefSeq; XP_054224849.1; XM_054368874.1. DR RefSeq; XP_054224850.1; XM_054368875.1. DR RefSeq; XP_054224851.1; XM_054368876.1. DR PDB; 5NP0; EM; 5.70 A; A/B=1-3056. DR PDB; 5NP1; EM; 5.70 A; A=1-3056. DR PDB; 6HKA; NMR; -; A=3024-3056. DR PDB; 6K9K; EM; 7.82 A; A=1-3056. DR PDB; 6K9L; EM; 4.27 A; A/B=1-3056. DR PDB; 7NI4; EM; 3.00 A; A/B=1-3056. DR PDB; 7NI5; EM; 2.78 A; A/B=1-3056. DR PDB; 7NI6; EM; 2.80 A; A/B=1-3056. DR PDB; 7SIC; EM; 2.51 A; A/B=1-3056. DR PDB; 7SID; EM; 2.53 A; A/C=1-3056. DR PDB; 8OXM; EM; 3.30 A; A/B=1-3056. DR PDB; 8OXO; EM; 3.00 A; A/B=1-3056. DR PDB; 8OXP; EM; 2.60 A; A/B=1-3056. DR PDB; 8OXQ; EM; 2.50 A; A/B=1-3056. DR PDBsum; 5NP0; -. DR PDBsum; 5NP1; -. DR PDBsum; 6HKA; -. DR PDBsum; 6K9K; -. DR PDBsum; 6K9L; -. DR PDBsum; 7NI4; -. DR PDBsum; 7NI5; -. DR PDBsum; 7NI6; -. DR PDBsum; 7SIC; -. DR PDBsum; 7SID; -. DR PDBsum; 8OXM; -. DR PDBsum; 8OXO; -. DR PDBsum; 8OXP; -. DR PDBsum; 8OXQ; -. DR EMDB; EMD-12350; -. DR EMDB; EMD-12351; -. DR EMDB; EMD-12352; -. DR EMDB; EMD-17265; -. DR EMDB; EMD-17266; -. DR EMDB; EMD-17267; -. DR EMDB; EMD-17268; -. DR EMDB; EMD-25140; -. DR EMDB; EMD-25141; -. DR EMDB; EMD-3669; -. DR EMDB; EMD-3672; -. DR EMDB; EMD-9949; -. DR EMDB; EMD-9950; -. DR SMR; Q13315; -. DR BioGRID; 106962; 345. DR CORUM; Q13315; -. DR DIP; DIP-182N; -. DR FunCoup; Q13315; 3527. DR IntAct; Q13315; 175. DR MINT; Q13315; -. DR STRING; 9606.ENSP00000278616; -. DR BindingDB; Q13315; -. DR ChEMBL; CHEMBL3797; -. DR DrugBank; DB02289; 2-Aminopropanedioic Acid. DR DrugBank; DB00201; Caffeine. DR GuidetoPHARMACOLOGY; 1934; -. DR GlyCosmos; Q13315; 4 sites, 2 glycans. DR GlyGen; Q13315; 7 sites, 2 O-linked glycans (6 sites). DR iPTMnet; Q13315; -. DR PhosphoSitePlus; Q13315; -. DR BioMuta; ATM; -. DR DMDM; 317373479; -. DR CPTAC; CPTAC-2874; -. DR CPTAC; CPTAC-2875; -. DR CPTAC; CPTAC-2876; -. DR CPTAC; CPTAC-3210; -. DR CPTAC; CPTAC-3211; -. DR CPTAC; CPTAC-3212; -. DR CPTAC; CPTAC-3213; -. DR CPTAC; CPTAC-5976; -. DR CPTAC; CPTAC-5977; -. DR CPTAC; CPTAC-5978; -. DR CPTAC; CPTAC-5979; -. DR CPTAC; CPTAC-912; -. DR CPTAC; CPTAC-913; -. DR jPOST; Q13315; -. DR MassIVE; Q13315; -. DR PaxDb; 9606-ENSP00000278616; -. DR PeptideAtlas; Q13315; -. DR ProteomicsDB; 59303; -. DR Pumba; Q13315; -. DR Antibodypedia; 3596; 1462 antibodies from 49 providers. DR CPTC; Q13315; 4 antibodies. DR DNASU; 472; -. DR Ensembl; ENST00000278616.10; ENSP00000278616.4; ENSG00000149311.23. DR Ensembl; ENST00000452508.7; ENSP00000388058.2; ENSG00000149311.23. DR Ensembl; ENST00000601453.3; ENSP00000469471.2; ENSG00000149311.23. DR Ensembl; ENST00000675843.1; ENSP00000501606.1; ENSG00000149311.23. DR Ensembl; ENST00000713844.1; ENSP00000519149.1; ENSG00000149311.23. DR GeneID; 472; -. DR KEGG; hsa:472; -. DR MANE-Select; ENST00000675843.1; ENSP00000501606.1; NM_000051.4; NP_000042.3. DR UCSC; uc001pkb.1; human. DR AGR; HGNC:795; -. DR CIViC; 472; 50 evidence items across 37 molecular profiles. DR ClinPGx; PA61; -. DR CTD; 472; -. DR DisGeNET; 472; -. DR GeneCards; ATM; -. DR GeneReviews; ATM; -. DR HGNC; HGNC:795; ATM. DR HPA; ENSG00000149311; Low tissue specificity. DR MalaCards; ATM; -. DR MIM; 208900; phenotype. DR MIM; 607585; gene. DR OpenTargets; ENSG00000149311; -. DR Orphanet; 100; Ataxia-telangiectasia. DR Orphanet; 370109; Ataxia-telangiectasia variant. DR Orphanet; 67038; B-cell chronic lymphocytic leukemia. DR Orphanet; 440437; Familial colorectal cancer Type X. DR Orphanet; 1331; Familial prostate cancer. DR Orphanet; 145; Hereditary breast and/or ovarian cancer syndrome. DR Orphanet; 227535; Hereditary breast cancer. DR Orphanet; 52416; Mantle cell lymphoma. DR VEuPathDB; HostDB:ENSG00000149311; -. DR eggNOG; KOG0892; Eukaryota. DR GeneTree; ENSGT00670000098061; -. DR HOGENOM; CLU_000178_3_1_1; -. DR InParanoid; Q13315; -. DR OMA; SEVYMKW; -. DR OrthoDB; 381190at2759; -. DR PAN-GO; Q13315; 7 GO annotations based on evolutionary models. DR PhylomeDB; Q13315; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; Q13315; -. DR Reactome; R-HSA-2559586; DNA Damage/Telomere Stress Induced Senescence. DR Reactome; R-HSA-3371453; Regulation of HSF1-mediated heat shock response. DR Reactome; R-HSA-349425; Autodegradation of the E3 ubiquitin ligase COP1. DR Reactome; R-HSA-5685938; HDR through Single Strand Annealing (SSA). DR Reactome; R-HSA-5685942; HDR through Homologous Recombination (HRR). DR Reactome; R-HSA-5693548; Sensing of DNA Double Strand Breaks. DR Reactome; R-HSA-5693554; Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA). DR Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks. DR Reactome; R-HSA-5693568; Resolution of D-loop Structures through Holliday Junction Intermediates. DR Reactome; R-HSA-5693571; Nonhomologous End-Joining (NHEJ). DR Reactome; R-HSA-5693579; Homologous DNA Pairing and Strand Exchange. DR Reactome; R-HSA-5693607; Processing of DNA double-strand break ends. DR Reactome; R-HSA-5693616; Presynaptic phase of homologous DNA pairing and strand exchange. DR Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes. DR Reactome; R-HSA-6803204; TP53 Regulates Transcription of Genes Involved in Cytochrome C Release. DR Reactome; R-HSA-6803207; TP53 Regulates Transcription of Caspase Activators and Caspases. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-6804757; Regulation of TP53 Degradation. DR Reactome; R-HSA-6804760; Regulation of TP53 Activity through Methylation. DR Reactome; R-HSA-69473; G2/M DNA damage checkpoint. DR Reactome; R-HSA-69541; Stabilization of p53. DR Reactome; R-HSA-912446; Meiotic recombination. DR Reactome; R-HSA-9664873; Pexophagy. DR Reactome; R-HSA-9701192; Defective homologous recombination repair (HRR) due to BRCA1 loss of function. DR Reactome; R-HSA-9704331; Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function. DR Reactome; R-HSA-9704646; Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function. DR Reactome; R-HSA-9709570; Impaired BRCA2 binding to RAD51. DR Reactome; R-HSA-9709603; Impaired BRCA2 binding to PALB2. DR SignaLink; Q13315; -. DR SIGNOR; Q13315; -. DR Agora; ENSG00000149311; -. DR BioGRID-ORCS; 472; 54 hits in 1215 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; A0DCDA94; DNA damage foci. DR ChiTaRS; ATM; human. DR GeneWiki; Ataxia_telangiectasia_mutated; -. DR GenomeRNAi; 472; -. DR Pharos; Q13315; Tchem. DR PRO; PR:Q13315; -. DR Proteomes; UP000005640; Chromosome 11. DR RNAct; Q13315; protein. DR Bgee; ENSG00000149311; Expressed in calcaneal tendon and 207 other cell types or tissues. DR ExpressionAtlas; Q13315; baseline and differential. DR GO; GO:0005813; C:centrosome; ISS:UniProtKB. DR GO; GO:0005694; C:chromosome; IBA:GO_Central. DR GO; GO:0005737; C:cytoplasm; ISS:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:1990391; C:DNA repair complex; IDA:MGI. DR GO; GO:0098850; C:extrinsic component of synaptic vesicle membrane; IEA:Ensembl. DR GO; GO:0005730; C:nucleolus; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:ParkinsonsUK-UCL. DR GO; GO:0005782; C:peroxisomal matrix; IDA:UniProtKB. DR GO; GO:0035861; C:site of double-strand break; IDA:UniProtKB. DR GO; GO:0005819; C:spindle; IEA:Ensembl. DR GO; GO:0016303; F:1-phosphatidylinositol-3-kinase activity; IMP:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW. DR GO; GO:0004677; F:DNA-dependent protein kinase activity; IDA:BHF-UCL. DR GO; GO:0035979; F:histone H2AXS139 kinase activity; ISS:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:BHF-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0044877; F:protein-containing complex binding; IDA:BHF-UCL. DR GO; GO:0007420; P:brain development; IEA:Ensembl. DR GO; GO:0071480; P:cellular response to gamma radiation; IDA:CAFA. DR GO; GO:0071500; P:cellular response to nitrosative stress; IDA:ParkinsonsUK-UCL. DR GO; GO:0034614; P:cellular response to reactive oxygen species; IDA:UniProt. DR GO; GO:0071300; P:cellular response to retinoic acid; ISS:ARUK-UCL. DR GO; GO:0033554; P:cellular response to stress; IDA:UniProt. DR GO; GO:0071481; P:cellular response to X-ray; IDA:ParkinsonsUK-UCL. DR GO; GO:0090398; P:cellular senescence; TAS:Reactome. DR GO; GO:0008340; P:determination of adult lifespan; IEA:Ensembl. DR GO; GO:0000077; P:DNA damage checkpoint signaling; IDA:UniProtKB. DR GO; GO:0006974; P:DNA damage response; IDA:CAFA. DR GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0000729; P:DNA double-strand break processing; IDA:UniProt. DR GO; GO:0006302; P:double-strand break repair; IDA:UniProtKB. DR GO; GO:0000724; P:double-strand break repair via homologous recombination; IDA:UniProt. DR GO; GO:0006303; P:double-strand break repair via nonhomologous end joining; TAS:Reactome. DR GO; GO:0097695; P:establishment of protein-containing complex localization to telomere; IMP:BHF-UCL. DR GO; GO:0097694; P:establishment of RNA localization to telomere; IMP:BHF-UCL. DR GO; GO:0007143; P:female meiotic nuclear division; IEA:Ensembl. DR GO; GO:0007507; P:heart development; IEA:Ensembl. DR GO; GO:0071044; P:histone mRNA catabolic process; IDA:UniProtKB. DR GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IBA:GO_Central. DR GO; GO:0042159; P:lipoprotein catabolic process; IEA:Ensembl. DR GO; GO:0007140; P:male meiotic nuclear division; IEA:Ensembl. DR GO; GO:0045141; P:meiotic telomere clustering; IEA:Ensembl. DR GO; GO:0007095; P:mitotic G2 DNA damage checkpoint signaling; IMP:BHF-UCL. DR GO; GO:0007094; P:mitotic spindle assembly checkpoint signaling; IMP:UniProtKB. DR GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl. DR GO; GO:0030889; P:negative regulation of B cell proliferation; IMP:UniProtKB. DR GO; GO:1904354; P:negative regulation of telomere capping; IMP:BHF-UCL. DR GO; GO:1904262; P:negative regulation of TORC1 signaling; IMP:ParkinsonsUK-UCL. DR GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl. DR GO; GO:0048599; P:oocyte development; IEA:Ensembl. DR GO; GO:0001541; P:ovarian follicle development; IEA:Ensembl. DR GO; GO:0036289; P:peptidyl-serine autophosphorylation; IMP:MGI. DR GO; GO:0000425; P:pexophagy; IDA:UniProtKB. DR GO; GO:0043065; P:positive regulation of apoptotic process; IMP:UniProtKB. DR GO; GO:0045785; P:positive regulation of cell adhesion; ISS:ARUK-UCL. DR GO; GO:0030335; P:positive regulation of cell migration; IMP:BHF-UCL. DR GO; GO:0043517; P:positive regulation of DNA damage response, signal transduction by p53 class mediator; IMP:BHF-UCL. DR GO; GO:2000781; P:positive regulation of double-strand break repair; IMP:BHF-UCL. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:1904884; P:positive regulation of telomerase catalytic core complex assembly; IMP:BHF-UCL. DR GO; GO:0032212; P:positive regulation of telomere maintenance via telomerase; ISS:BHF-UCL. DR GO; GO:1904358; P:positive regulation of telomere maintenance via telomere lengthening; IMP:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISS:ARUK-UCL. DR GO; GO:0009791; P:post-embryonic development; IEA:Ensembl. DR GO; GO:0002331; P:pre-B cell allelic exclusion; ISS:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0050821; P:protein stabilization; IDA:UniProt. DR GO; GO:0007131; P:reciprocal meiotic recombination; TAS:ProtInc. DR GO; GO:0042981; P:regulation of apoptotic process; TAS:Reactome. DR GO; GO:2000785; P:regulation of autophagosome assembly; IC:UniProt. DR GO; GO:0010506; P:regulation of autophagy; IMP:ParkinsonsUK-UCL. DR GO; GO:0051726; P:regulation of cell cycle; IMP:BHF-UCL. DR GO; GO:1900034; P:regulation of cellular response to heat; TAS:Reactome. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0032210; P:regulation of telomere maintenance via telomerase; IGI:BHF-UCL. DR GO; GO:0090399; P:replicative senescence; IMP:BHF-UCL. DR GO; GO:0010212; P:response to ionizing radiation; IDA:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0042770; P:signal transduction in response to DNA damage; IDA:UniProtKB. DR GO; GO:0001756; P:somitogenesis; IEA:Ensembl. DR GO; GO:0000723; P:telomere maintenance; IBA:GO_Central. DR GO; GO:0048538; P:thymus development; IEA:Ensembl. DR GO; GO:0033151; P:V(D)J recombination; IEA:Ensembl. DR CDD; cd05171; PIKKc_ATM; 1. DR FunFam; 1.10.1070.11:FF:000011; Serine-protein kinase ATM; 1. DR FunFam; 3.30.1010.10:FF:000015; Serine-protein kinase ATM; 1. DR Gene3D; 1.10.1070.11; Phosphatidylinositol 3-/4-kinase, catalytic domain; 1. DR Gene3D; 3.30.1010.10; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 4; 1. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR038980; ATM_plant. DR InterPro; IPR003152; FATC_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000403; PI3/4_kinase_cat_dom. DR InterPro; IPR036940; PI3/4_kinase_cat_sf. DR InterPro; IPR018936; PI3/4_kinase_CS. DR InterPro; IPR003151; PIK-rel_kinase_FAT. DR InterPro; IPR014009; PIK_FAT. DR InterPro; IPR044107; PIKKc_ATM. DR InterPro; IPR021668; TAN. DR PANTHER; PTHR37079; SERINE/THREONINE-PROTEIN KINASE ATM; 1. DR PANTHER; PTHR37079:SF4; SERINE_THREONINE-PROTEIN KINASE ATM; 1. DR Pfam; PF02259; FAT; 1. DR Pfam; PF02260; FATC; 1. DR Pfam; PF00454; PI3_PI4_kinase; 1. DR Pfam; PF11640; TAN; 1. DR SMART; SM01343; FATC; 1. DR SMART; SM00146; PI3Kc; 1. DR SMART; SM01342; TAN; 1. DR SUPFAM; SSF48371; ARM repeat; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51189; FAT; 1. DR PROSITE; PS51190; FATC; 1. DR PROSITE; PS00915; PI3_4_KINASE_1; 1. DR PROSITE; PS00916; PI3_4_KINASE_2; 1. DR PROSITE; PS50290; PI3_4_KINASE_3; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; ATP-binding; Cell cycle; Cytoplasm; KW Cytoplasmic vesicle; Cytoskeleton; Disease variant; DNA damage; KW DNA-binding; Kinase; Neurodegeneration; Nucleotide-binding; Nucleus; KW Peroxisome; Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Tumor suppressor. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22223895" FT CHAIN 2..3056 FT /note="Serine-protein kinase ATM" FT /id="PRO_0000088840" FT DOMAIN 1940..2566 FT /note="FAT" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534" FT DOMAIN 2686..2998 FT /note="PI3K/PI4K catalytic" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT DOMAIN 3024..3056 FT /note="FATC" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534, FT ECO:0000255|PROSITE-ProRule:PRU00535" FT REGION 1373..1382 FT /note="Interaction with ABL1" FT /evidence="ECO:0000269|PubMed:9168117" FT REGION 2692..2698 FT /note="G-loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 2867..2875 FT /note="Catalytic loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 2887..2911 FT /note="Activation loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT MOTIF 3046..3048 FT /note="Microbody targeting signal; atypical" FT /evidence="ECO:0000269|PubMed:26344566" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:22223895" FT MOD_RES 367 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:16858402" FT MOD_RES 1893 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:16858402" FT MOD_RES 1981 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12556884, FT ECO:0000269|PubMed:15790808, ECO:0000269|PubMed:16141325, FT ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:21144835, FT ECO:0000269|PubMed:30944854, ECO:0007744|PubMed:17525332" FT MOD_RES 1983 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17525332" FT MOD_RES 2996 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195" FT MOD_RES 3016 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:17923702, FT ECO:0000269|PubMed:30944854" FT VARIANT 23 FT /note="R -> Q (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs587779858)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041545" FT VARIANT 35..3056 FT /note="Missing (in AT; dbSNP:rs55861249)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085060" FT VARIANT 45 FT /note="R -> W (found in a patient with breast cancer; FT uncertain significance; dbSNP:rs3218684)" FT /evidence="ECO:0000269|PubMed:11897822" FT /id="VAR_056678" FT VARIANT 49 FT /note="S -> C (in dbSNP:rs1800054)" FT /evidence="ECO:0000269|PubMed:10425038, FT ECO:0000269|PubMed:10534763, ECO:0000269|PubMed:10873394, FT ECO:0000269|PubMed:11897822, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:18384426, ECO:0000269|PubMed:8665503, FT ECO:0000269|PubMed:8797579, ECO:0000269|PubMed:9887333" FT /id="VAR_010798" FT VARIANT 68 FT /note="I -> V (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083373" FT VARIANT 126 FT /note="D -> E (in dbSNP:rs2234997)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:9711876" FT /id="VAR_010799" FT VARIANT 140 FT /note="D -> H (in dbSNP:rs55633650)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041546" FT VARIANT 182 FT /note="V -> L (in dbSNP:rs3218707)" FT /evidence="ECO:0000269|PubMed:10534763" FT /id="VAR_010800" FT VARIANT 224 FT /note="K -> E (in AT; uncertain significance; FT dbSNP:rs145053092)" FT /evidence="ECO:0000269|PubMed:10817650" FT /id="VAR_010801" FT VARIANT 250 FT /note="R -> Q (in dbSNP:rs56123940)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041547" FT VARIANT 292 FT /note="P -> L (in AT; decrease phosphorylation of target FT proteins; increases protein abundance; dbSNP:rs747727055)" FT /evidence="ECO:0000269|PubMed:10873394, FT ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:9463314" FT /id="VAR_010802" FT VARIANT 323 FT /note="I -> V (in AT; loss of protein expression; FT dbSNP:rs587781511)" FT /evidence="ECO:0000269|PubMed:10817650, FT ECO:0000269|PubMed:27664052" FT /id="VAR_010803" FT VARIANT 332 FT /note="Y -> C (in B-cell chronic lymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9892178" FT /id="VAR_010804" FT VARIANT 333 FT /note="S -> F (in dbSNP:rs28904919)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041548" FT VARIANT 337 FT /note="R -> C (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs138398778)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041549" FT VARIANT 337 FT /note="R -> H (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs202160435)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041550" FT VARIANT 341 FT /note="V -> I (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083374" FT VARIANT 350 FT /note="A -> T (in B-cell chronic lymphocytic leukemia; FT dbSNP:rs371713984)" FT /evidence="ECO:0000269|PubMed:10023947" FT /id="VAR_010805" FT VARIANT 352 FT /note="I -> T (in B-cell chronic lymphocytic leukemia; FT dbSNP:rs369203092)" FT /evidence="ECO:0000269|PubMed:10023947" FT /id="VAR_010806" FT VARIANT 374..3056 FT /note="Missing (in AT; uncertain significance)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_085061" FT VARIANT 393..3056 FT /note="Missing (in AT; uncertain significance; FT dbSNP:rs587776547)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085062" FT VARIANT 410 FT /note="V -> A (in dbSNP:rs56128736)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041551" FT VARIANT 504 FT /note="N -> S (in dbSNP:rs56365018)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041552" FT VARIANT 514 FT /note="G -> D (in dbSNP:rs2235000)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:9711876" FT /id="VAR_010807" FT VARIANT 540 FT /note="C -> Y (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041553" FT VARIANT 546 FT /note="L -> V (no effect on phosphorylation of target FT proteins; dbSNP:rs2227924)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:19431188" FT /id="VAR_041554" FT VARIANT 570 FT /note="F -> S (in AT; dbSNP:rs777301065)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010808" FT VARIANT 582 FT /note="F -> L (in dbSNP:rs2235006)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041555" FT VARIANT 597 FT /note="P -> L (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083375" FT VARIANT 661 FT /note="D -> A (found in a patient with familial breast FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28202063" FT /id="VAR_083376" FT VARIANT 699 FT /note="E -> G (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083377" FT VARIANT 705..707 FT /note="YSS -> FIP (in AT)" FT /evidence="ECO:0000269|PubMed:8797579, FT ECO:0000269|PubMed:9043869" FT /id="VAR_010809" FT VARIANT 707 FT /note="S -> P (in dbSNP:rs4986761)" FT /evidence="ECO:0000269|PubMed:10534763, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:28202063" FT /id="VAR_010810" FT VARIANT 759 FT /note="S -> G (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083378" FT VARIANT 761 FT /note="T -> S (in dbSNP:rs2235011)" FT /id="VAR_056679" FT VARIANT 768 FT /note="N -> D (in AT)" FT /evidence="ECO:0000269|PubMed:9463314" FT /id="VAR_010812" FT VARIANT 785 FT /note="R -> C (in AT; dbSNP:rs587778065)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010813" FT VARIANT 788 FT /note="S -> R (in dbSNP:rs641252)" FT /id="VAR_056680" FT VARIANT 813 FT /note="N -> S (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083379" FT VARIANT 814 FT /note="D -> E (in dbSNP:rs3218695)" FT /id="VAR_056681" FT VARIANT 848 FT /note="E -> Q (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs879254046)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041556" FT VARIANT 858 FT /note="F -> L (in dbSNP:rs1800056)" FT /evidence="ECO:0000269|PubMed:10534763, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:18384426, FT ECO:0000269|PubMed:28202063, ECO:0000269|PubMed:8797579, FT ECO:0000269|PubMed:9043869, ECO:0000269|PubMed:9792409, FT ECO:0000269|PubMed:9887333" FT /id="VAR_010814" FT VARIANT 869 FT /note="A -> G (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083380" FT VARIANT 872 FT /note="P -> S (in dbSNP:rs3218673)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041557" FT VARIANT 897 FT /note="F -> I (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083381" FT VARIANT 924 FT /note="R -> W (found in a patient with familial breast FT cancer; uncertain significance; dbSNP:rs55723361)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:28202063" FT /id="VAR_041558" FT VARIANT 935 FT /note="T -> A (in dbSNP:rs35813135)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041559" FT VARIANT 935 FT /note="T -> M (in dbSNP:rs3218708)" FT /id="VAR_056682" FT VARIANT 942 FT /note="L -> F (in dbSNP:rs3218688)" FT /id="VAR_056683" FT VARIANT 950 FT /note="L -> R (in AT; dbSNP:rs786203054)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_010815" FT VARIANT 1001 FT /note="L -> Q (in AT; risk factor for T-cell acute FT lymphoblastic leukemia)" FT /evidence="ECO:0000269|PubMed:9463314" FT /id="VAR_010816" FT VARIANT 1040 FT /note="M -> V (in dbSNP:rs3092857)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010817" FT VARIANT 1046 FT /note="L -> P (in AT; loss of protein expression; FT dbSNP:rs568461905)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077237" FT VARIANT 1054 FT /note="P -> R (in AT; likely benign; no effect on FT phosphorylation of target proteins; dbSNP:rs1800057)" FT /evidence="ECO:0000269|PubMed:10023947, FT ECO:0000269|PubMed:10217116, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:18384426, ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:28202063, ECO:0000269|PubMed:8665503, FT ECO:0000269|PubMed:8797579, ECO:0000269|PubMed:9043869, FT ECO:0000269|PubMed:9792409, ECO:0000269|PubMed:9887333" FT /id="VAR_010818" FT VARIANT 1082 FT /note="H -> L (in AT; uncertain significance)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_010819" FT VARIANT 1091 FT /note="E -> D (in AT)" FT /evidence="ECO:0000269|PubMed:9792409" FT /id="VAR_010820" FT VARIANT 1171..3056 FT /note="Missing (in AT; uncertain significance; increases FT protein abundance)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085063" FT VARIANT 1179 FT /note="S -> F (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041560" FT VARIANT 1255 FT /note="L -> V (found in a patient with early-onset breast FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:18384426" FT /id="VAR_083382" FT VARIANT 1313 FT /note="E -> Q (in dbSNP:rs3092841)" FT /id="VAR_056684" FT VARIANT 1321 FT /note="M -> I (in dbSNP:rs35184530)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041561" FT VARIANT 1322 FT /note="L -> I (no effect on phosphorylation of target FT proteins; dbSNP:rs144535256)" FT /evidence="ECO:0000269|PubMed:19431188" FT /id="VAR_080300" FT VARIANT 1380 FT /note="H -> Y (in dbSNP:rs3092856)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041562" FT VARIANT 1382 FT /note="P -> S (in dbSNP:rs55859590)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041563" FT VARIANT 1407 FT /note="I -> T (in T-prolymphocytic leukemia; FT dbSNP:rs1234250980)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010821" FT VARIANT 1420 FT /note="L -> F (in dbSNP:rs1800058)" FT /evidence="ECO:0000269|PubMed:10534763, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:8665503, FT ECO:0000269|PubMed:8797579" FT /id="VAR_010822" FT VARIANT 1420 FT /note="L -> P (in AT)" FT /evidence="ECO:0000269|PubMed:10817650" FT /id="VAR_010823" FT VARIANT 1427 FT /note="A -> T (in dbSNP:rs2229021)" FT /id="VAR_056685" FT VARIANT 1463 FT /note="F -> S (found in B-cell non-Hodgkin lymphoma; FT uncertain significance)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010825" FT VARIANT 1465 FT /note="L -> P (in AT; decreased phosphorylation of target FT proteins; dbSNP:rs730881391)" FT /evidence="ECO:0000269|PubMed:10234507, FT ECO:0000269|PubMed:19431188" FT /id="VAR_010826" FT VARIANT 1466..3056 FT /note="Missing (in AT; uncertain significance; FT dbSNP:rs730881369)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_085064" FT VARIANT 1469 FT /note="I -> M (in a renal papillary cancer sample; somatic FT mutation; dbSNP:rs775047783)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041564" FT VARIANT 1474 FT /note="H -> D (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083383" FT VARIANT 1475 FT /note="Y -> C (in dbSNP:rs34640941)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041565" FT VARIANT 1488 FT /note="L -> V (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083384" FT VARIANT 1541 FT /note="L -> F (in dbSNP:rs3092849)" FT /id="VAR_056686" FT VARIANT 1566 FT /note="P -> R (in AT)" FT /evidence="ECO:0000269|PubMed:9792409" FT /id="VAR_010827" FT VARIANT 1570 FT /note="V -> A (in dbSNP:rs140856217)" FT /evidence="ECO:0000269|PubMed:10534763" FT /id="VAR_010828" FT VARIANT 1650 FT /note="N -> S (in dbSNP:rs55870064)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041566" FT VARIANT 1682 FT /note="D -> H (in T-prolymphocytic leukemia; FT dbSNP:rs121434217)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010829" FT VARIANT 1691 FT /note="S -> R (in AT, B-cell chronic lymphocytic leukemia FT and familial cancer patients; no effect on phosphorylation FT of target proteins; dbSNP:rs1800059)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:28202063, ECO:0000269|PubMed:8797579, FT ECO:0000269|PubMed:9463314, ECO:0000269|PubMed:9892178" FT /id="VAR_010830" FT VARIANT 1729 FT /note="V -> L (in dbSNP:rs3092907)" FT /id="VAR_056687" FT VARIANT 1730..3056 FT /note="Missing (in AT; uncertain significance; FT dbSNP:rs764389018)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_085065" FT VARIANT 1739 FT /note="N -> T (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041567" FT VARIANT 1743 FT /note="T -> I (in AT; decreased phosphorylation of target FT proteins; dbSNP:rs587779844)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:9463314" FT /id="VAR_010831" FT VARIANT 1812..1813 FT /note="AF -> V (in AT)" FT /evidence="ECO:0000269|PubMed:9497252" FT /id="VAR_010832" FT VARIANT 1839..3056 FT /note="Missing (in AT; uncertain significance; reduces FT protein abundance)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085066" FT VARIANT 1853 FT /note="D -> N (in dbSNP:rs1801516)" FT /evidence="ECO:0000269|PubMed:10397742, FT ECO:0000269|PubMed:10425038, ECO:0000269|PubMed:10534763, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:18384426, FT ECO:0000269|PubMed:9711876, ECO:0000269|PubMed:9887333" FT /id="VAR_010833" FT VARIANT 1853 FT /note="D -> V (might contribute to B-cell chronic FT lymphocytic leukemia; dbSNP:rs1801673)" FT /evidence="ECO:0000269|PubMed:10397742, FT ECO:0000269|PubMed:10817650, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:28202063, ECO:0000269|PubMed:9872980, FT ECO:0000269|PubMed:9887333" FT /id="VAR_010834" FT VARIANT 1910 FT /note="L -> H (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010835" FT VARIANT 1913 FT /note="V -> G (in AT; dbSNP:rs1060501688)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010836" FT VARIANT 1916 FT /note="M -> I (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041568" FT VARIANT 1945 FT /note="A -> T (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041569" FT VARIANT 1953 FT /note="T -> R (in B-cell chronic lymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:10397742" FT /id="VAR_010837" FT VARIANT 1961 FT /note="Y -> C (found in a patient with familial pancreatic FT cancer; uncertain significance; also found in a lung FT adenocarcinoma sample; uncertain significance; decreased FT phosphorylation of target proteins; dbSNP:rs56399311)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:28726808" FT /id="VAR_041570" FT VARIANT 1983 FT /note="S -> N (in dbSNP:rs659243)" FT /evidence="ECO:0000269|PubMed:16554811" FT /id="VAR_041571" FT VARIANT 1991 FT /note="E -> D (in a renal clear cell carcinoma sample; FT somatic mutation; dbSNP:rs587782274)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041572" FT VARIANT 2016 FT /note="D -> G (in AT; uncertain significance; FT dbSNP:rs587781302)" FT /evidence="ECO:0000269|PubMed:10425038, FT ECO:0000269|PubMed:9887333" FT /id="VAR_010838" FT VARIANT 2023 FT /note="G -> R (in AT; loss of protein expression; FT dbSNP:rs11212587)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077238" FT VARIANT 2034 FT /note="R -> Q (in dbSNP:rs3218670)" FT /id="VAR_056688" FT VARIANT 2063 FT /note="G -> E (in AT; uncertain significance; reduces FT protein abundance; dbSNP:rs866290641)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_010839" FT VARIANT 2067 FT /note="A -> D (in AT; dbSNP:rs397514577)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010840" FT VARIANT 2068 FT /note="L -> S (in AT; decreased protein abundance; loss of FT DNA damage induced protein autophosphorylation; FT dbSNP:rs1555114558)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077239" FT VARIANT 2079 FT /note="V -> I (in dbSNP:rs1800060)" FT /evidence="ECO:0000269|PubMed:8665503" FT /id="VAR_010841" FT VARIANT 2080 FT /note="Y -> D (in AT; loss of DNA damage induced protein FT autophosphorylation; dbSNP:rs1064795467)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077240" FT VARIANT 2105 FT /note="R -> T (found in a patient with early-onset breast FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:18384426" FT /id="VAR_083385" FT VARIANT 2139 FT /note="E -> G (in T-prolymphocytic leukemia; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:9488043" FT /id="VAR_010842" FT VARIANT 2164 FT /note="E -> K (in T-prolymphocytic leukemia; FT dbSNP:rs1317619286)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010843" FT VARIANT 2218 FT /note="S -> C (in AT)" FT /evidence="ECO:0000269|PubMed:10817650" FT /id="VAR_010844" FT VARIANT 2224..2227 FT /note="MALR -> IS (in AT; uncertain significance)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_010845" FT VARIANT 2227 FT /note="R -> C (in AT; uncertain significance; reduces FT protein abundance; dbSNP:rs564652222)" FT /evidence="ECO:0000269|PubMed:10873394, FT ECO:0000269|PubMed:9887333" FT /id="VAR_010846" FT VARIANT 2246..2252 FT /note="CIKDILT -> H (in AT; uncertain significance)" FT /evidence="ECO:0000269|PubMed:10425038, FT ECO:0000269|PubMed:10873394" FT /id="VAR_010847" FT VARIANT 2274 FT /note="A -> T (in B-cell chronic lymphocytic leukemia; FT uncertain significance; no effect on phosphorylation of FT target proteins; dbSNP:rs567060474)" FT /evidence="ECO:0000269|PubMed:10023947, FT ECO:0000269|PubMed:19431188" FT /id="VAR_010848" FT VARIANT 2287 FT /note="G -> A (found in a patient with familial pancreatic FT cancer; uncertain significance; dbSNP:rs1800061)" FT /evidence="ECO:0000269|PubMed:28726808, FT ECO:0000269|PubMed:8665503" FT /id="VAR_010849" FT VARIANT 2307 FT /note="L -> F (found in patients with familial pancreatic FT cancer; uncertain significance; also found in a lung FT adenocarcinoma sample; uncertain significance; FT dbSNP:rs56009889)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:28726808" FT /id="VAR_041573" FT VARIANT 2332 FT /note="L -> P (in dbSNP:rs4988111)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041574" FT VARIANT 2335 FT /note="T -> K (in dbSNP:rs3092831)" FT /id="VAR_056689" FT VARIANT 2356 FT /note="I -> F (in a renal clear cell carcinoma sample; FT somatic mutation; dbSNP:rs876658517)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041575" FT VARIANT 2396 FT /note="T -> S (found in a patient with T-prolymphocytic FT leukemia; uncertain significance; also found in a patient FT with early-onset breast cancer; uncertain significance; FT dbSNP:rs370559102)" FT /evidence="ECO:0000269|PubMed:18384426, FT ECO:0000269|PubMed:9288106" FT /id="VAR_010850" FT VARIANT 2408 FT /note="S -> L (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs730881315)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041576" FT VARIANT 2418 FT /note="K -> KK (in mantle cell lymphoma)" FT /evidence="ECO:0000269|PubMed:10397742, FT ECO:0000269|PubMed:10706620" FT /id="VAR_010851" FT VARIANT 2420 FT /note="A -> P (in B-cell chronic lymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:10397742" FT /id="VAR_010852" FT VARIANT 2423 FT /note="E -> G (in mantle cell lymphoma; dbSNP:rs121434221)" FT /evidence="ECO:0000269|PubMed:10397742, FT ECO:0000269|PubMed:10706620" FT /id="VAR_010853" FT VARIANT 2424 FT /note="V -> G (in AT; also found in B-cell chronic FT lymphocytic leukemia and T-prolymphocytic leukemia; risk FT factor for breast cancer; decreased phosphorylation of FT target proteins; dbSNP:rs28904921)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:8755918, ECO:0000269|PubMed:9288106, FT ECO:0000269|PubMed:9463314, ECO:0000269|PubMed:9892178" FT /id="VAR_010854" FT VARIANT 2427..2428 FT /note="Missing (in AT; also found in T-prolymphocytic FT leukemia; lack of phosphorylation of target proteins)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:7792600, ECO:0000269|PubMed:8845835, FT ECO:0000269|PubMed:9463314" FT /id="VAR_010855" FT VARIANT 2438 FT /note="T -> I (in dbSNP:rs147604227)" FT /evidence="ECO:0000269|PubMed:10817650, FT ECO:0000269|PubMed:8808599" FT /id="VAR_010856" FT VARIANT 2442 FT /note="Q -> P (in T-prolymphocytic leukemia; also in a lung FT adenocarcinoma sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:9288106" FT /id="VAR_010857" FT VARIANT 2443 FT /note="R -> Q (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs587782310)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041577" FT VARIANT 2464 FT /note="C -> R (found in patients with familial pancreatic FT cancer; uncertain significance; also found in a small cell FT lung cancer sample; uncertain significance; FT dbSNP:rs55801750)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:28726808" FT /id="VAR_041578" FT VARIANT 2470 FT /note="Y -> D (in AT; dbSNP:rs876659365)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010858" FT VARIANT 2486 FT /note="R -> G (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9573030" FT /id="VAR_010859" FT VARIANT 2491 FT /note="W -> R (in AT)" FT /evidence="ECO:0000269|PubMed:9792410" FT /id="VAR_010860" FT VARIANT 2492 FT /note="L -> R (in dbSNP:rs56399857)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041579" FT VARIANT 2524 FT /note="A -> P (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083386" FT VARIANT 2531 FT /note="M -> T (found in patients with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083387" FT VARIANT 2546..2548 FT /note="Missing (in AT; also found in T-prolymphocytic FT leukemia and T-cell acute lymphoblastic leukemia; lack of FT phosphorylation of target proteins)" FT /evidence="ECO:0000269|PubMed:10817650, FT ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:7792600, FT ECO:0000269|PubMed:8755918, ECO:0000269|PubMed:8789452, FT ECO:0000269|PubMed:8797579, ECO:0000269|PubMed:8808599, FT ECO:0000269|PubMed:8845835, ECO:0000269|PubMed:9150358, FT ECO:0000269|PubMed:9288106, ECO:0000269|PubMed:9463314" FT /id="VAR_010861" FT VARIANT 2547..2549 FT /note="Missing (in AT; dbSNP:rs587776547)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085067" FT VARIANT 2554 FT /note="H -> D (in AT; lack of phosphorylation of target FT proteins)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:9463314" FT /id="VAR_010862" FT VARIANT 2570 FT /note="E -> G (in dbSNP:rs28904920)" FT /id="VAR_056690" FT VARIANT 2625..2626 FT /note="DA -> EP (in AT; dbSNP:rs267606668)" FT /evidence="ECO:0000269|PubMed:9521587" FT /id="VAR_010864" FT VARIANT 2625 FT /note="D -> E (in AT; uncertain significance; FT dbSNP:rs1196903858)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085068" FT VARIANT 2625 FT /note="D -> Q (in AT; requires 2 nucleotide substitutions)" FT /evidence="ECO:0000269|PubMed:10817650" FT /id="VAR_010863" FT VARIANT 2626 FT /note="A -> P (in AT; uncertain significance; FT dbSNP:rs267606669)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085069" FT VARIANT 2627 FT /note="Y -> H (in AT; loss of protein expression)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077241" FT VARIANT 2640 FT /note="T -> I (in dbSNP:rs4988125)" FT /id="VAR_056691" FT VARIANT 2656 FT /note="L -> P (in AT; dbSNP:rs121434218)" FT /evidence="ECO:0000269|PubMed:9450874" FT /id="VAR_010865" FT VARIANT 2662 FT /note="Missing (in AT)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010866" FT VARIANT 2664 FT /note="Missing (in AT; uncertain significance; FT dbSNP:rs1471563800)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_085070" FT VARIANT 2666 FT /note="T -> A (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs745775382)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041580" FT VARIANT 2668 FT /note="E -> G (in AT; uncertain significance; no effect on FT phosphorylation of target proteins)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:9463314" FT /id="VAR_010868" FT VARIANT 2695 FT /note="G -> A (in T-prolymphocytic leukemia and B-cell FT chronic lymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:10023947, FT ECO:0000269|PubMed:9288106" FT /id="VAR_010869" FT VARIANT 2702 FT /note="I -> R (in AT; dbSNP:rs876659735)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_010870" FT VARIANT 2709 FT /note="G -> S (in dbSNP:rs3218680)" FT /id="VAR_056692" FT VARIANT 2719 FT /note="R -> H (found in a patient with early-onset breast FT cancer; uncertain significance; dbSNP:rs55982963)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:18384426" FT /id="VAR_041581" FT VARIANT 2722 FT /note="L -> R (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010871" FT VARIANT 2725 FT /note="D -> G (found in T-prolymphocytic leukemia; FT uncertain significance; dbSNP:rs1555128314)" FT /evidence="ECO:0000269|PubMed:9334731" FT /id="VAR_010872" FT VARIANT 2725 FT /note="D -> V (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010873" FT VARIANT 2726 FT /note="A -> V (in AT; uncertain significance)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_010874" FT VARIANT 2732 FT /note="F -> L (in T-prolymphocytic leukemia; FT dbSNP:rs876659619)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010875" FT VARIANT 2765 FT /note="G -> S (may contribute to breast cancer; lack of FT phosphorylation of target proteins; dbSNP:rs748634900)" FT /evidence="ECO:0000269|PubMed:10534763, FT ECO:0000269|PubMed:19431188" FT /id="VAR_010876" FT VARIANT 2810 FT /note="K -> Q (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083388" FT VARIANT 2810 FT /note="Missing (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010877" FT VARIANT 2824 FT /note="C -> Y (in AT; dbSNP:rs876660927)" FT /evidence="ECO:0000269|PubMed:9150358" FT /id="VAR_010878" FT VARIANT 2827 FT /note="F -> C (in AT; mild; decreased phosphorylation of FT target proteins; dbSNP:rs121434216)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:8755918, ECO:0000269|PubMed:9463314" FT /id="VAR_010879" FT VARIANT 2829 FT /note="P -> L (in AT; dbSNP:rs938431501)" FT /evidence="ECO:0000269|PubMed:9711876" FT /id="VAR_010880" FT VARIANT 2832 FT /note="R -> C (in AT; also found in B-cell non-Hodgkin FT lymphoma; increases protein abundance; dbSNP:rs587779872)" FT /evidence="ECO:0000269|PubMed:10817650, FT ECO:0000269|PubMed:10873394, ECO:0000269|PubMed:9288106, FT ECO:0000269|PubMed:9443866" FT /id="VAR_010881" FT VARIANT 2832 FT /note="R -> H (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083389" FT VARIANT 2834 FT /note="F -> L (in AT; decreased protein abundance)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077242" FT VARIANT 2842 FT /note="P -> R (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs879254065)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041582" FT VARIANT 2849..3056 FT /note="Missing (in AT; uncertain significance; FT dbSNP:rs587778080)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_085071" FT VARIANT 2849 FT /note="R -> P (in AT; dbSNP:rs587782202)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010882" FT VARIANT 2855..2856 FT /note="SV -> RI (in AT; lack of phosphorylation of target FT proteins; dbSNP:rs587781353)" FT /evidence="ECO:0000269|PubMed:10817650, FT ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:9872980" FT /id="VAR_010884" FT VARIANT 2855 FT /note="S -> R (in AT; uncertain significance; FT dbSNP:rs780905851)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_010883" FT VARIANT 2860 FT /note="Missing (in AT)" FT /evidence="ECO:0000269|PubMed:7792600, FT ECO:0000269|PubMed:8845835" FT /id="VAR_010885" FT VARIANT 2867 FT /note="G -> R (in AT)" FT /evidence="ECO:0000269|PubMed:8698354, FT ECO:0000269|PubMed:9887333" FT /id="VAR_010886" FT VARIANT 2870 FT /note="D -> N (in dbSNP:rs55798854)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041583" FT VARIANT 2871..2872 FT /note="RH -> S (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010887" FT VARIANT 2890 FT /note="L -> V (in T-prolymphocytic leukemia; FT dbSNP:rs587779874)" FT /evidence="ECO:0000269|PubMed:9288106, FT ECO:0000269|PubMed:9488043" FT /id="VAR_010888" FT VARIANT 2904 FT /note="E -> G (in AT; dbSNP:rs786202826)" FT /evidence="ECO:0000269|PubMed:8845835" FT /id="VAR_010889" FT VARIANT 2909 FT /note="R -> G (in AT)" FT /evidence="ECO:0000269|PubMed:9792410" FT /id="VAR_010890" FT VARIANT 2974 FT /note="P -> L (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083390" FT VARIANT 3003 FT /note="N -> D (in AT; decreased protein abundance; FT dbSNP:rs1137889)" FT /evidence="ECO:0000269|PubMed:27664052, FT ECO:0000269|PubMed:7792600, ECO:0000269|PubMed:8589678, FT ECO:0000269|PubMed:8665503" FT /id="VAR_077243" FT VARIANT 3006 FT /note="A -> P (found in T-prolymphocytic leukemia; FT uncertain significance; dbSNP:rs876658767)" FT /evidence="ECO:0000269|PubMed:9334731" FT /id="VAR_010892" FT VARIANT 3008 FT /note="R -> C (in AT; also found in T-prolymphocytic FT leukemia and mantle cell lymphoma; lack of phosphorylation FT of target proteins; dbSNP:rs587782292)" FT /evidence="ECO:0000269|PubMed:10706620, FT ECO:0000269|PubMed:10817650, ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:9334731, ECO:0000269|PubMed:9488043, FT ECO:0000269|PubMed:9872980" FT /id="VAR_010893" FT VARIANT 3008 FT /note="R -> H (in B-cell chronic lymphocytic leukemia; FT dbSNP:rs587781894)" FT /evidence="ECO:0000269|PubMed:10397742" FT /id="VAR_010894" FT VARIANT 3018 FT /note="K -> N (in B-cell chronic lymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:10397742" FT /id="VAR_010895" FT VARIANT 3029 FT /note="G -> D (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083391" FT VARIANT 3056 FT /note="V -> L (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083392" FT MUTAGEN 367 FT /note="S->A: Loss of IR-induced S-367 autophosphorylation. FT Reduced correction of cell cycle checkpoint defects and FT DNA-repair activity. No effect on S-1893 nor S-1981 FT autophosphorylation." FT /evidence="ECO:0000269|PubMed:16858402" FT MUTAGEN 1807 FT /note="K->E: Decreased phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 1893 FT /note="S->A: Loss of IR-induced S-1893 autophosphorylation. FT Reduced correction of cell cycle checkpoint defects and FT DNA-repair activity. No effect on S-367 nor S-1981 FT autophosphorylation." FT /evidence="ECO:0000269|PubMed:16858402" FT MUTAGEN 1941 FT /note="V->L: Decreased phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 1981 FT /note="S->A: Loss of IR-induced S-1981 autophosphorylation. FT Reduced correction of cell cycle checkpoint defects and FT DNA-repair activity. No effect on S-367 nor S-1893 FT autophosphorylation. No dimer disruption." FT /evidence="ECO:0000269|PubMed:12556884, FT ECO:0000269|PubMed:16858402" FT MUTAGEN 1981 FT /note="S->D,E: Disrupts the dimer." FT /evidence="ECO:0000269|PubMed:12556884, FT ECO:0000269|PubMed:16858402" FT MUTAGEN 2019 FT /note="Y->C: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2039 FT /note="E->K: Decreased phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2338 FT /note="L->P: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2394 FT /note="S->L: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2452 FT /note="L->P: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2685 FT /note="S->T: No effect on phosphorylation of target FT proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2699 FT /note="P->L: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2708 FT /note="D->N: Decreased phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2730 FT /note="Q->P: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2870 FT /note="D->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:9733515" FT MUTAGEN 2875 FT /note="N->K: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:9733515" FT MUTAGEN 3016 FT /note="K->Q: Mimics acetylation, preventing FT dephosphorylation and subsequent ATM deactivation during FT the late stage of DNA damage response." FT /evidence="ECO:0000269|PubMed:30944854" FT MUTAGEN 3016 FT /note="K->R: Loss of DNA damage-inducible acetylation. FT Retains constitutive kinase activity, but blocks DNA FT damage-induced kinase activation. Disrupts dimer and FT abolishes S-1981 autophosphorylation." FT /evidence="ECO:0000269|PubMed:17923702" FT MUTAGEN 3018 FT /note="K->R: Retains DNA damage-inducible acetylation and FT S-1981 autophosphorylation." FT /evidence="ECO:0000269|PubMed:17923702" FT MUTAGEN 3047 FT /note="R->Q: Abolished interaction with PEX5 and FT translocation to peroxisomes in response to reactive oxygen FT species (ROS)." FT /evidence="ECO:0000269|PubMed:26344566" FT CONFLICT 46 FT /note="H -> N (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 56 FT /note="N -> I (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 313 FT /note="Y -> N (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 488 FT /note="W -> G (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 554 FT /note="T -> A (in Ref. 1; AAC50289)" FT /evidence="ECO:0000305" FT CONFLICT 750 FT /note="K -> N (in Ref. 1; AAC50289)" FT /evidence="ECO:0000305" FT CONFLICT 754 FT /note="Q -> K (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 887 FT /note="E -> G (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 1003 FT /note="Q -> L (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 1049 FT /note="L -> W (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 1089 FT /note="A -> V (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT HELIX 6..17 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 20..33 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 36..41 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 57..73 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 90..108 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 109..112 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 117..129 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 130..133 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 135..148 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 149..151 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 153..158 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 161..176 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 183..201 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 207..209 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 210..222 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 223..225 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 229..242 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 244..246 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 248..268 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 273..290 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 292..294 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 298..300 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 306..323 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 324..326 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 343..356 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 393..402 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 407..409 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 410..422 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 424..426 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 429..431 FT /evidence="ECO:0007829|PDB:7SID" FT HELIX 432..442 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 445..447 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 452..466 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 474..492 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 493..496 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 498..500 FT /evidence="ECO:0007829|PDB:7SID" FT HELIX 501..513 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 521..524 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 525..527 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 528..530 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 536..548 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 572..580 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 597..600 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 605..607 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 608..615 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 617..619 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 620..628 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 634..636 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 646..655 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 684..704 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 707..709 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 713..731 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 732..735 FT /evidence="ECO:0007829|PDB:8OXP" FT HELIX 737..741 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 744..765 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 771..786 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 792..794 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 795..806 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 809..822 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 887..889 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 892..911 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 920..930 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 933..935 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 941..953 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 957..959 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 963..970 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 973..979 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 980..982 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 984..994 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 995..997 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 998..1002 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1009..1030 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 1031..1033 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 1036..1052 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 1060..1063 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 1066..1069 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1070..1076 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1077..1079 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1083..1092 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1093..1096 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1113..1132 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 1136..1138 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 1144..1164 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1169..1181 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1187..1201 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1206..1212 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1214..1223 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1227..1229 FT /evidence="ECO:0007829|PDB:7NI5" FT TURN 1231..1233 FT /evidence="ECO:0007829|PDB:7SID" FT HELIX 1236..1238 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1244..1261 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1265..1275 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1279..1285 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1287..1294 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1295..1297 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 1299..1303 FT /evidence="ECO:0007829|PDB:8OXM" FT HELIX 1306..1322 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 1325..1327 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1328..1330 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1332..1338 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1340..1348 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1383..1396 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 1397..1399 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1404..1408 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1413..1428 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1432..1450 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1453..1455 FT /evidence="ECO:0007829|PDB:7SID" FT TURN 1456..1460 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 1461..1477 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1485..1508 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1513..1515 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1517..1527 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 1528..1530 FT /evidence="ECO:0007829|PDB:7SID" FT HELIX 1532..1545 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 1546..1551 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1553..1560 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1567..1569 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1572..1582 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 1583..1585 FT /evidence="ECO:0007829|PDB:7NI6" FT HELIX 1590..1601 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1607..1610 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1611..1623 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1625..1634 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1635..1637 FT /evidence="ECO:0007829|PDB:8OXP" FT HELIX 1639..1641 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1643..1658 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1661..1663 FT /evidence="ECO:0007829|PDB:8OXM" FT HELIX 1664..1677 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1694..1702 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1706..1721 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1723..1725 FT /evidence="ECO:0007829|PDB:8OXO" FT HELIX 1727..1742 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1744..1753 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1754..1756 FT /evidence="ECO:0007829|PDB:7NI4" FT HELIX 1759..1763 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 1764..1767 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 1785..1789 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1792..1795 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1802..1815 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1822..1825 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1828..1831 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1835..1851 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1857..1874 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1903..1917 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1922..1924 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1927..1930 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1938..1947 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1951..1973 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1986..1997 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2001..2012 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2016..2019 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2023..2028 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 2029..2038 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2042..2051 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2057..2070 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2074..2087 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2093..2105 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2124..2136 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2140..2159 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2166..2168 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2170..2190 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2195..2210 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2211..2214 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2217..2236 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2240..2242 FT /evidence="ECO:0007829|PDB:8OXP" FT HELIX 2245..2264 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2269..2281 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2290..2301 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2305..2322 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2328..2348 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2353..2359 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2361..2370 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2377..2406 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2408..2421 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2437..2475 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2481..2483 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2484..2493 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2494..2496 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2498..2507 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2508..2510 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2513..2516 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2520..2525 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2529..2531 FT /evidence="ECO:0007829|PDB:7SID" FT STRAND 2533..2535 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2537..2551 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2553..2564 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2565..2567 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2568..2572 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2593..2612 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2614..2632 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2637..2640 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2652..2655 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2659..2663 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2665..2667 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2673..2675 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2682..2686 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2688..2692 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2695..2697 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2700..2706 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2707..2709 FT /evidence="ECO:0007829|PDB:7NI4" FT STRAND 2711..2717 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2723..2740 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2743..2748 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2757..2759 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2761..2763 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2765..2768 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2773..2775 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2776..2780 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2783..2785 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2787..2791 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2798..2807 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2808..2810 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2813..2825 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2833..2838 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2842..2866 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2873..2875 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2876..2879 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2880..2882 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2885..2887 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2894..2899 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2900..2902 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2906..2908 FT /evidence="ECO:0007829|PDB:8OXP" FT HELIX 2912..2916 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2920..2925 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2926..2940 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2942..2953 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2964..2970 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 3002..3017 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 3020..3025 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 3028..3040 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 3042..3047 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 3050..3052 FT /evidence="ECO:0007829|PDB:8OXQ" SQ SEQUENCE 3056 AA; 350687 MW; C0B4866E1E3199E2 CRC64; MSLVLNDLLI CCRQLEHDRA TERKKEVEKF KRLIRDPETI KHLDRHSDSK QGKYLNWDAV FRFLQKYIQK ETECLRIAKP NVSASTQASR QKKMQEISSL VKYFIKCANR RAPRLKCQEL LNYIMDTVKD SSNGAIYGAD CSNILLKDIL SVRKYWCEIS QQQWLELFSV YFRLYLKPSQ DVHRVLVARI IHAVTKGCCS QTDGLNSKFL DFFSKAIQCA RQEKSSSGLN HILAALTIFL KTLAVNFRIR VCELGDEILP TLLYIWTQHR LNDSLKEVII ELFQLQIYIH HPKGAKTQEK GAYESTKWRS ILYNLYDLLV NEISHIGSRG KYSSGFRNIA VKENLIELMA DICHQVFNED TRSLEISQSY TTTQRESSDY SVPCKRKKIE LGWEVIKDHL QKSQNDFDLV PWLQIATQLI SKYPASLPNC ELSPLLMILS QLLPQQRHGE RTPYVLRCLT EVALCQDKRS NLESSQKSDL LKLWNKIWCI TFRGISSEQI QAENFGLLGA IIQGSLVEVD REFWKLFTGS ACRPSCPAVC CLTLALTTSI VPGTVKMGIE QNMCEVNRSF SLKESIMKWL LFYQLEGDLE NSTEVPPILH SNFPHLVLEK ILVSLTMKNC KAAMNFFQSV PECEHHQKDK EELSFSEVEE LFLQTTFDKM DFLTIVRECG IEKHQSSIGF SVHQNLKESL DRCLLGLSEQ LLNNYSSEIT NSETLVRCSR LLVGVLGCYC YMGVIAEEEA YKSELFQKAK SLMQCAGESI TLFKNKTNEE FRIGSLRNMM QLCTRCLSNC TKKSPNKIAS GFFLRLLTSK LMNDIADICK SLASFIKKPF DRGEVESMED DTNGNLMEVE DQSSMNLFND YPDSSVSDAN EPGESQSTIG AINPLAEEYL SKQDLLFLDM LKFLCLCVTT AQTNTVSFRA ADIRRKLLML IDSSTLEPTK SLHLHMYLML LKELPGEEYP LPMEDVLELL KPLSNVCSLY RRDQDVCKTI LNHVLHVVKN LGQSNMDSEN TRDAQGQFLT VIGAFWHLTK ERKYIFSVRM ALVNCLKTLL EADPYSKWAI LNVMGKDFPV NEVFTQFLAD NHHQVRMLAA ESINRLFQDT KGDSSRLLKA LPLKLQQTAF ENAYLKAQEG MREMSHSAEN PETLDEIYNR KSVLLTLIAV VLSCSPICEK QALFALCKSV KENGLEPHLV KKVLEKVSET FGYRRLEDFM ASHLDYLVLE WLNLQDTEYN LSSFPFILLN YTNIEDFYRS CYKVLIPHLV IRSHFDEVKS IANQIQEDWK SLLTDCFPKI LVNILPYFAY EGTRDSGMAQ QRETATKVYD MLKSENLLGK QIDHLFISNL PEIVVELLMT LHEPANSSAS QSTDLCDFSG DLDPAPNPPH FPSHVIKATF AYISNCHKTK LKSILEILSK SPDSYQKILL AICEQAAETN NVYKKHRILK IYHLFVSLLL KDIKSGLGGA WAFVLRDVIY TLIHYINQRP SCIMDVSLRS FSLCCDLLSQ VCQTAVTYCK DALENHLHVI VGTLIPLVYE QVEVQKQVLD LLKYLVIDNK DNENLYITIK LLDPFPDHVV FKDLRITQQK IKYSRGPFSL LEEINHFLSV SVYDALPLTR LEGLKDLRRQ LELHKDQMVD IMRASQDNPQ DGIMVKLVVN LLQLSKMAIN HTGEKEVLEA VGSCLGEVGP IDFSTIAIQH SKDASYTKAL KLFEDKELQW TFIMLTYLNN TLVEDCVKVR SAAVTCLKNI LATKTGHSFW EIYKMTTDPM LAYLQPFRTS RKKFLEVPRF DKENPFEGLD DINLWIPLSE NHDIWIKTLT CAFLDSGGTK CEILQLLKPM CEVKTDFCQT VLPYLIHDIL LQDTNESWRN LLSTHVQGFF TSCLRHFSQT SRSTTPANLD SESEHFFRCC LDKKSQRTML AVVDYMRRQK RPSSGTIFND AFWLDLNYLE VAKVAQSCAA HFTALLYAEI YADKKSMDDQ EKRSLAFEEG SQSTTISSLS EKSKEETGIS LQDLLLEIYR SIGEPDSLYG CGGGKMLQPI TRLRTYEHEA MWGKALVTYD LETAIPSSTR QAGIIQALQN LGLCHILSVY LKGLDYENKD WCPELEELHY QAAWRNMQWD HCTSVSKEVE GTSYHESLYN ALQSLRDREF STFYESLKYA RVKEVEEMCK RSLESVYSLY PTLSRLQAIG ELESIGELFS RSVTHRQLSE VYIKWQKHSQ LLKDSDFSFQ EPIMALRTVI LEILMEKEMD NSQRECIKDI LTKHLVELSI LARTFKNTQL PERAIFQIKQ YNSVSCGVSE WQLEEAQVFW AKKEQSLALS ILKQMIKKLD ASCAANNPSL KLTYTECLRV CGNWLAETCL ENPAVIMQTY LEKAVEVAGN YDGESSDELR NGKMKAFLSL ARFSDTQYQR IENYMKSSEF ENKQALLKRA KEEVGLLREH KIQTNRYTVK VQRELELDEL ALRALKEDRK RFLCKAVENY INCLLSGEEH DMWVFRLCSL WLENSGVSEV NGMMKRDGMK IPTYKFLPLM YQLAARMGTK MMGGLGFHEV LNNLISRISM DHPHHTLFII LALANANRDE FLTKPEVARR SRITKNVPKQ SSQLDEDRTE AANRIICTIR SRRPQMVRSV EALCDAYIIL ANLDATQWKT QRKGINIPAD QPITKLKNLE DVVVPTMEIK VDHTGEYGNL VTIQSFKAEF RLAGGVNLPK IIDCVGSDGK ERRQLVKGRD DLRQDAVMQQ VFQMCNTLLQ RNTETRKRKL TICTYKVVPL SQRSGVLEWC TGTVPIGEFL VNNEDGAHKR YRPNDFSAFQ CQKKMMEVQK KSFEEKYEVF MDVCQNFQPV FRYFCMEKFL DPAIWFEKRL AYTRSVATSS IVGYILGLGD RHVQNILINE QSAELVHIDL GVAFEQGKIL PTPETVPFRL TRDIVDGMGI TGVEGVFRRC CEKTMEVMRN SQETLLTIVE VLLYDPLFDW TMNPLKALYL QQRPEDETEL HPTLNADDQE CKRNLSDIDQ SFNKVAERVL MRLQEKLKGV EEGTVLSVGG QVNLLIQQAI DPKNLSRLFP GWKAWV // ID AURKA_HUMAN Reviewed; 403 AA. AC O14965; E1P5F9; O60445; O75873; Q9BQD6; Q9UPG5; DT 27-JAN-2003, integrated into UniProtKB/Swiss-Prot. DT 23-FEB-2022, sequence version 3. DT 28-JAN-2026, entry version 254. DE RecName: Full=Aurora kinase A {ECO:0000312|HGNC:HGNC:11393}; DE EC=2.7.11.1 {ECO:0000269|PubMed:12237287, ECO:0000269|PubMed:16337122, ECO:0000269|PubMed:19140666, ECO:0000269|PubMed:19402633, ECO:0000269|PubMed:27192185, ECO:0000269|PubMed:27837025, ECO:0000269|PubMed:28218735}; DE AltName: Full=Aurora 2 {ECO:0000303|PubMed:10851084}; DE AltName: Full=Aurora/IPL1-related kinase 1 {ECO:0000303|PubMed:9153231}; DE Short=ARK-1 {ECO:0000303|PubMed:9153231}; DE Short=Aurora-related kinase 1 {ECO:0000303|PubMed:9514916}; DE AltName: Full=Breast tumor-amplified kinase {ECO:0000303|PubMed:11790771}; DE AltName: Full=Ipl1- and aurora-related kinase 1 {ECO:0000250|UniProtKB:P97477}; DE AltName: Full=Serine/threonine-protein kinase 15 {ECO:0000303|PubMed:15867347, ECO:0000303|PubMed:16011022}; DE AltName: Full=Serine/threonine-protein kinase 6 {ECO:0000303|PubMed:9771714}; DE AltName: Full=Serine/threonine-protein kinase Ayk1 {ECO:0000250|UniProtKB:P97477}; DE AltName: Full=Serine/threonine-protein kinase aurora-A {ECO:0000250|UniProtKB:P59241}; GN Name=AURKA {ECO:0000312|HGNC:HGNC:11393}; GN Synonyms=AIK {ECO:0000303|PubMed:9153231}, GN AIRK1 {ECO:0000312|HGNC:HGNC:11393}, ARK1 {ECO:0000312|HGNC:HGNC:11393}, GN AURA {ECO:0000312|HGNC:HGNC:11393}, AYK1 {ECO:0000250|UniProtKB:P97477}, GN BTAK {ECO:0000303|PubMed:9771714}, IAK1 {ECO:0000250|UniProtKB:P97477}, GN STK15 {ECO:0000303|PubMed:15867347, ECO:0000303|PubMed:16011022}, GN STK6 {ECO:0000303|PubMed:9771714}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], INDUCTION, SUBCELLULAR LOCATION, AND VARIANT RP VAL-57. RC TISSUE=Blood; RX PubMed=9153231; DOI=10.1074/jbc.272.21.13766; RA Kimura M., Kotani S., Hattori T., Sumi N., Yoshioka T., Todokoro K., RA Okano Y.; RT "Cell cycle-dependent expression and spindle pole localization of a novel RT human protein kinase, Aik, related to Aurora of Drosophila and yeast RT Ipl1."; RL J. Biol. Chem. 272:13766-13771(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT VAL-57. RX PubMed=9514916; DOI=10.1006/bbrc.1998.8250; RA Shindo M., Nakano H., Kuroyanagi H., Shirasawa T., Mihara M., Gilbert D.J., RA Jenkins N.A., Copeland N.G., Yagita H., Okumura K.; RT "cDNA cloning, expression, subcellular localization, and chromosomal RT assignment of mammalian aurora homologues, aurora-related kinase (ARK) 1 RT and 2."; RL Biochem. Biophys. Res. Commun. 244:285-292(1998). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS ILE-31 AND VAL-57. RC TISSUE=Mammary gland; RX PubMed=9771714; DOI=10.1038/2496; RA Zhou H., Kuang J., Zhong L., Kuo W.-L., Gray J.W., Sahin A., Brinkley B.R., RA Sen S.; RT "Tumour amplified kinase STK15/BTAK induces centrosome amplification, RT aneuploidy and transformation."; RL Nat. Genet. 20:189-193(1998). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Wang L., Thibodeau S.N.; RT "Mutational analysis of the STK15 gene in human tumors."; RL Submitted (OCT-1999) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=11780052; DOI=10.1038/414865a; RA Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R., RA Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L., RA Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P., RA Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D., RA Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G., RA Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E., RA Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D., RA Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P., RA Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E., RA Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J., RA Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D., RA Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S., RA Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D., RA Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A., RA Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T., RA Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I., RA Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M., RA Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D., RA Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M., RA Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A., RA Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L., RA Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L., RA Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 20."; RL Nature 414:865-871(2001). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT VAL-57. RC TISSUE=Cervix, Colon, Kidney, and Muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP INDUCTION, AND SUBCELLULAR LOCATION. RX PubMed=9606188; DOI=10.1093/emboj/17.11.3052; RA Bischoff J.R., Anderson L., Zhu Y., Mossie K., Ng L., Souza B., RA Schryver B., Flanagan P., Clairvoyant F., Ginther C., Chan C.S., RA Novotny M., Slamon D.J., Plowman G.D.; RT "A homologue of Drosophila aurora kinase is oncogenic and amplified in RT human colorectal cancers."; RL EMBO J. 17:3052-3065(1998). RN [9] RP UBIQUITINATION, PROTEASOMAL DEGRADATION, AND MUTAGENESIS OF ARG-205. RX PubMed=10851084; DOI=10.1038/sj.onc.1203609; RA Honda K., Mihara H., Kato Y., Yamaguchi A., Tanaka H., Yasuda H., RA Furukawa K., Urano T.; RT "Degradation of human Aurora2 protein kinase by the anaphase-promoting RT complex-ubiquitin-proteasome pathway."; RL Oncogene 19:2812-2819(2000). RN [10] RP FUNCTION, PHOSPHORYLATION AT THR-288, MUTAGENESIS OF THR-288, RP UBIQUITINATION, AND ACTIVITY REGULATION. RX PubMed=11039908; DOI=10.1038/sj.onc.1203847; RA Walter A.O., Seghezzi W., Korver W., Sheung J., Lees E.; RT "The mitotic serine/threonine kinase Aurora2/AIK is regulated by RT phosphorylation and degradation."; RL Oncogene 19:4906-4916(2000). RN [11] RP FUNCTION, INTERACTION WITH PPP1CA; PPP1CB AND PPP1CC, MUTAGENESIS OF RP PHE-165 AND PHE-346, AND PHOSPHORYLATION. RX PubMed=11551964; DOI=10.1074/jbc.m107540200; RA Katayama H., Zhou H., Li Q., Tatsuka M., Sen S.; RT "Interaction and feedback regulation between STK15/BTAK/Aurora-A kinase and RT protein phosphatase 1 through mitotic cell division cycle."; RL J. Biol. Chem. 276:46219-46224(2001). RN [12] RP SUBCELLULAR LOCATION. RX PubMed=12576638; DOI=10.1247/csf.27.457; RA Sugimoto K., Urano T., Zushi H., Inoue K., Tasaka H., Tachibana M., RA Dotsu M.; RT "Molecular dynamics of Aurora-A kinase in living mitotic cells RT simultaneously visualized with histone H3 and nuclear membrane protein RT importinalpha."; RL Cell Struct. Funct. 27:457-467(2002). RN [13] RP FUNCTION, INDUCTION, PHOSPHORYLATION, AND ACTIVITY REGULATION. RX PubMed=12390251; DOI=10.1046/j.1365-2443.2002.00592.x; RA Marumoto T., Hirota T., Morisaki T., Kunitoku N., Zhang D., Ichikawa Y., RA Sasayama T., Kuninaka S., Mimori T., Tamaki N., Kimura M., Okano Y., RA Saya H.; RT "Roles of aurora-A kinase in mitotic entry and G2 checkpoint in mammalian RT cells."; RL Genes Cells 7:1173-1182(2002). RN [14] RP INDUCTION. RX PubMed=11790771; DOI=10.1074/jbc.m108252200; RA Tanaka M., Ueda A., Kanamori H., Ideguchi H., Yang J., Kitajima S., RA Ishigatsubo Y.; RT "Cell-cycle-dependent regulation of human aurora A transcription is RT mediated by periodic repression of E4TF1."; RL J. Biol. Chem. 277:10719-10726(2002). RN [15] RP FUNCTION, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT THR-288. RX PubMed=13678582; DOI=10.1016/s0092-8674(03)00642-1; RA Hirota T., Kunitoku N., Sasayama T., Marumoto T., Zhang D., Nitta M., RA Hatakeyama K., Saya H.; RT "Aurora-A and an interacting activator, the LIM protein Ajuba, are required RT for mitotic commitment in human cells."; RL Cell 114:585-598(2003). RN [16] RP FUNCTION. RX PubMed=14523000; DOI=10.1074/jbc.m306275200; RA Marumoto T., Honda S., Hara T., Nitta M., Hirota T., Kohmura E., Saya H.; RT "Aurora-A kinase maintains the fidelity of early and late mitotic events in RT HeLa cells."; RL J. Biol. Chem. 278:51786-51795(2003). RN [17] RP INTERACTION WITH TACC1. RX PubMed=14603251; DOI=10.1038/sj.onc.1206972; RA Conte N., Delaval B., Ginestier C., Ferrand A., Isnardon D., Larroque C., RA Prigent C., Seraphin B., Jacquemier J., Birnbaum D.; RT "TACC1-chTOG-Aurora A protein complex in breast cancer."; RL Oncogene 22:8102-8116(2003). RN [18] RP FUNCTION. RX PubMed=15147269; DOI=10.1111/j.1356-9597.2004.00732.x; RA Toji S., Yabuta N., Hosomi T., Nishihara S., Kobayashi T., Suzuki S., RA Tamai K., Nojima H.; RT "The centrosomal protein Lats2 is a phosphorylation target of Aurora-A RT kinase."; RL Genes Cells 9:383-397(2004). RN [19] RP RETRACTED PAPER. RX PubMed=14990569; DOI=10.1074/jbc.m311780200; RA Ouchi M., Fujiuchi N., Sasai K., Katayama H., Minamishima Y.A., RA Ongusaha P.P., Deng C., Sen S., Lee S.W., Ouchi T.; RT "BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M RT transition."; RL J. Biol. Chem. 279:19643-19648(2004). RN [20] RP RETRACTION NOTICE OF PUBMED:14990569. RX PubMed=26341884; DOI=10.1074/jbc.a115.311780; RA Ouchi M., Fujiuchi N., Sasai K., Katayama H., Minamishima Y.A., RA Ongusaha P.P., Deng C., Sen S., Lee S.W., Ouchi T.; RL J. Biol. Chem. 290:22311-22311(2015). RN [21] RP FUNCTION. RX PubMed=15128871; DOI=10.1242/jcs.01108; RA Dutertre S., Cazales M., Quaranta M., Froment C., Trabut V., Dozier C., RA Mirey G., Bouche J.P., Theis-Febvre N., Schmitt E., Monsarrat B., RA Prigent C., Ducommun B.; RT "Phosphorylation of CDC25B by Aurora-A at the centrosome contributes to the RT G2-M transition."; RL J. Cell Sci. 117:2523-2531(2004). RN [22] RP FUNCTION, MUTAGENESIS OF LYS-162, AND INTERACTION WITH TP53. RX PubMed=14702041; DOI=10.1038/ng1279; RA Katayama H., Sasai K., Kawai H., Yuan Z.M., Bondaruk J., Suzuki F., RA Fujii S., Arlinghaus R.B., Czerniak B.A., Sen S.; RT "Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization RT and inhibition of p53."; RL Nat. Genet. 36:55-62(2004). RN [23] RP INTERACTION WITH CPEB1. RX PubMed=15966895; DOI=10.1111/j.1365-2443.2005.00870.x; RA Sasayama T., Marumoto T., Kunitoku N., Zhang D., Tamaki N., Kohmura E., RA Saya H., Hirota T.; RT "Over-expression of Aurora-A targets cytoplasmic polyadenylation element RT binding protein and promotes mRNA polyadenylation of Cdk1 and cyclin B1."; RL Genes Cells 10:627-638(2005). RN [24] RP PHOSPHORYLATION AT THR-288 AND SER-342. RX PubMed=16246726; DOI=10.1016/j.molcel.2005.08.035; RA Zhao Z.S., Lim J.P., Ng Y.W., Lim L., Manser E.; RT "The GIT-associated kinase PAK targets to the centrosome and regulates RT Aurora-A."; RL Mol. Cell 20:237-249(2005). RN [25] RP INDUCTION, AND FUNCTION. RX PubMed=15987997; DOI=10.1128/mcb.25.14.5789-5800.2005; RA Yu C.T., Hsu J.M., Lee Y.C., Tsou A.P., Chou C.K., Huang C.Y.; RT "Phosphorylation and stabilization of HURP by Aurora-A: implication of HURP RT as a transforming target of Aurora-A."; RL Mol. Cell. Biol. 25:5789-5800(2005). RN [26] RP INTERACTION WITH BORA. RX PubMed=16890155; DOI=10.1016/j.devcel.2006.06.002; RA Hutterer A., Berdnik D., Wirtz-Peitz F., Zigman M., Schleiffer A., RA Knoblich J.A.; RT "Mitotic activation of the kinase Aurora-A requires its binding partner RT Bora."; RL Dev. Cell 11:147-157(2006). RN [27] RP FUNCTION. RX PubMed=18056443; DOI=10.1158/0008-5472.can-07-2578; RA Sankaran S., Crone D.E., Palazzo R.E., Parvin J.D.; RT "Aurora-A kinase regulates breast cancer associated gene 1 inhibition of RT centrosome-dependent microtubule nucleation."; RL Cancer Res. 67:11186-11194(2007). RN [28] RP FUNCTION, INTERACTION WITH HDAC6, SUBCELLULAR LOCATION, AND MUTAGENESIS OF RP ASP-274 AND THR-288. RX PubMed=17604723; DOI=10.1016/j.cell.2007.04.035; RA Pugacheva E.N., Jablonski S.A., Hartman T.R., Henske E.P., Golemis E.A.; RT "HEF1-dependent Aurora A activation induces disassembly of the primary RT cilium."; RL Cell 129:1351-1363(2007). RN [29] RP INTERACTION WITH ARHGEF2. RX PubMed=17488622; DOI=10.1016/j.devcel.2007.03.014; RA Birkenfeld J., Nalbant P., Bohl B.P., Pertz O., Hahn K.M., Bokoch G.M.; RT "GEF-H1 modulates localized RhoA activation during cytokinesis under the RT control of mitotic kinases."; RL Dev. Cell 12:699-712(2007). RN [30] RP SUBCELLULAR LOCATION, INTERACTION WITH PPP2CA, AND PHOSPHORYLATION AT RP SER-51. RX PubMed=17229885; DOI=10.1091/mbc.e06-12-1152; RA Horn V., Thelu J., Garcia A., Albiges-Rizo C., Block M.R., Viallet J.; RT "Functional interaction of Aurora-A and PP2A during mitosis."; RL Mol. Biol. Cell 18:1233-1241(2007). RN [31] RP INTERACTION WITH SIRT2, AND SUBCELLULAR LOCATION. RX PubMed=17726514; DOI=10.1371/journal.pone.0000784; RA North B.J., Verdin E.; RT "Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during RT mitosis."; RL PLoS ONE 2:E784-E784(2007). RN [32] RP FUNCTION, AND ACTIVITY REGULATION. RX PubMed=17360485; DOI=10.1073/pnas.0608798104; RA Manfredi M.G., Ecsedy J.A., Meetze K.A., Balani S.K., Burenkova O., RA Chen W., Galvin K.M., Hoar K.M., Huck J.J., LeRoy P.J., Ray E.T., RA Sells T.B., Stringer B., Stroud S.G., Vos T.J., Weatherhead G.S., RA Wysong D.R., Zhang M., Bolen J.B., Claiborne C.F.; RT "Antitumor activity of MLN8054, an orally active small-molecule inhibitor RT of Aurora A kinase."; RL Proc. Natl. Acad. Sci. U.S.A. 104:4106-4111(2007). RN [33] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-41, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [34] RP FUNCTION. RX PubMed=18615013; DOI=10.1038/nature07185; RA Macurek L., Lindqvist A., Lim D., Lampson M.A., Klompmaker R., Freire R., RA Clouin C., Taylor S.S., Yaffe M.B., Medema R.H.; RT "Polo-like kinase-1 is activated by aurora A to promote checkpoint RT recovery."; RL Nature 455:119-123(2008). RN [35] RP FUNCTION, AUTOPHOSPHORYLATION, AND INTERACTION WITH PARD3. RX PubMed=19812038; DOI=10.1074/jbc.m109.055897; RA Khazaei M.R., Puschel A.W.; RT "Phosphorylation of the par polarity complex protein Par3 at serine 962 is RT mediated by aurora A and regulates its function in neuronal polarity."; RL J. Biol. Chem. 284:33571-33579(2009). RN [36] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH KIF2A. RX PubMed=19351716; DOI=10.1242/jcs.044321; RA Jang C.Y., Coppinger J.A., Seki A., Yates J.R. III, Fang G.; RT "Plk1 and Aurora A regulate the depolymerase activity and the cellular RT localization of Kif2a."; RL J. Cell Sci. 122:1334-1341(2009). RN [37] RP FUNCTION, INTERACTION WITH TPX2, PHOSPHORYLATION AT THR-287 AND THR-288, RP AND MUTAGENESIS OF THR-287. RX PubMed=19668197; DOI=10.1038/ncb1919; RA Mori D., Yamada M., Mimori-Kiyosue Y., Shirai Y., Suzuki A., Ohno S., RA Saya H., Wynshaw-Boris A., Hirotsune S.; RT "An essential role of the aPKC-Aurora A-NDEL1 pathway in neurite elongation RT by modulation of microtubule dynamics."; RL Nat. Cell Biol. 11:1057-1068(2009). RN [38] RP INTERACTION WITH TPX2, MUTAGENESIS OF GLY-198, AND SUBCELLULAR LOCATION. RX PubMed=19357306; DOI=10.1073/pnas.0900833106; RA Fu J., Bian M., Liu J., Jiang Q., Zhang C.; RT "A single amino acid change converts Aurora-A into Aurora-B-like kinase in RT terms of partner specificity and cellular function."; RL Proc. Natl. Acad. Sci. U.S.A. 106:6939-6944(2009). RN [39] RP FUNCTION, INTERACTION WITH CIMAP3, AND ACTIVATION BY CIMAP3. RX PubMed=20643351; DOI=10.1016/j.devcel.2010.06.005; RA Kinzel D., Boldt K., Davis E.E., Burtscher I., Trumbach D., Diplas B., RA Attie-Bitach T., Wurst W., Katsanis N., Ueffing M., Lickert H.; RT "Pitchfork regulates primary cilia disassembly and left-right asymmetry."; RL Dev. Cell 19:66-77(2010). RN [40] RP IDENTIFICATION IN A COMPLEX WITH AUNIP AND NIN. RX PubMed=20596670; DOI=10.3892/ijo_00000691; RA Lieu A.S., Cheng T.S., Chou C.H., Wu C.H., Hsu C.Y., Huang C.Y., RA Chang L.K., Loh J.K., Chang C.S., Hsu C.M., Howng S.L., Hong Y.R.; RT "Functional characterization of AIBp, a novel Aurora-A binding protein in RT centrosome structure and spindle formation."; RL Int. J. Oncol. 37:429-436(2010). RN [41] RP INTERACTION WITH GADD45A. RX PubMed=20460379; DOI=10.1074/jbc.m109.069344; RA Sanchez R., Pantoja-Uceda D., Prieto J., Diercks T., Marcaida M.J., RA Montoya G., Campos-Olivas R., Blanco F.J.; RT "Solution structure of human growth arrest and DNA damage 45alpha RT (Gadd45alpha) and its interactions with proliferating cell nuclear antigen RT (PCNA) and Aurora A kinase."; RL J. Biol. Chem. 285:22196-22201(2010). RN [42] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [43] RP SUBCELLULAR LOCATION, AND INTERACTION WITH JTB. RX PubMed=21225229; DOI=10.3892/ijo.2011.900; RA Platica M., Ionescu A., Ivan E., Holland J.F., Mandeli J., Platica O.; RT "PAR, a protein involved in the cell cycle, is functionally related to RT chromosomal passenger proteins."; RL Int. J. Oncol. 38:777-785(2011). RN [44] RP REVIEW ON FUNCTION. RX PubMed=14625535; DOI=10.1038/nrm1245; RA Carmena M., Earnshaw W.C.; RT "The cellular geography of aurora kinases."; RL Nat. Rev. Mol. Cell Biol. 4:842-854(2003). RN [45] RP REVIEW ON FUNCTION. RX PubMed=19774610; DOI=10.1002/em.20533; RA Lukasiewicz K.B., Lingle W.L.; RT "Aurora A, centrosome structure, and the centrosome cycle."; RL Environ. Mol. Mutagen. 50:602-619(2009). RN [46] RP INTERACTION WITH SIRT2, AND SUBCELLULAR LOCATION. RX PubMed=22014574; DOI=10.1016/j.ccr.2011.09.004; RA Kim H.S., Vassilopoulos A., Wang R.H., Lahusen T., Xiao Z., Xu X., Li C., RA Veenstra T.D., Li B., Yu H., Ji J., Wang X.W., Park S.H., Cha Y.I., RA Gius D., Deng C.X.; RT "SIRT2 maintains genome integrity and suppresses tumorigenesis through RT regulating APC/C activity."; RL Cancer Cell 20:487-499(2011). RN [47] RP INTERACTION WITH HNRNPU. RX PubMed=21242313; DOI=10.1242/jcs.063347; RA Ma N., Matsunaga S., Morimoto A., Sakashita G., Urano T., Uchiyama S., RA Fukui K.; RT "The nuclear scaffold protein SAF-A is required for kinetochore-microtubule RT attachment and contributes to the targeting of Aurora-A to mitotic RT spindles."; RL J. Cell Sci. 124:394-404(2011). RN [48] RP INTERACTION WITH KLHL18 AND CUL3, UBIQUITINATION, AND SUBCELLULAR LOCATION. RX PubMed=23213400; DOI=10.1242/bio.2011018; RA Moghe S., Jiang F., Miura Y., Cerny R.L., Tsai M.Y., Furukawa M.; RT "The CUL3-KLHL18 ligase regulates mitotic entry and ubiquitylates Aurora- RT A."; RL Biol. Open 1:82-91(2012). RN [49] RP INTERACTION WITH FRY. RX PubMed=22753416; DOI=10.1074/jbc.m112.378968; RA Ikeda M., Chiba S., Ohashi K., Mizuno K.; RT "Furry protein promotes Aurora A-mediated polo-like kinase 1 activation."; RL J. Biol. Chem. 287:27670-27681(2012). RN [50] RP SUBCELLULAR LOCATION. RX PubMed=25657325; DOI=10.1091/mbc.e14-09-1366; RA Ohta S., Wood L., Toramoto I., Yagyu K., Fukagawa T., Earnshaw W.C.; RT "CENP-32 is required to maintain centrosomal dominance in bipolar spindle RT assembly."; RL Mol. Biol. Cell 26:1225-1237(2015). RN [51] RP INTERACTION WITH HNRNPU. RX PubMed=25986610; DOI=10.1128/mcb.01312-14; RA Douglas P., Ye R., Morrice N., Britton S., Trinkle-Mulcahy L., RA Lees-Miller S.P.; RT "Phosphorylation of SAF-A/hnRNP-U serine 59 by polo-like kinase 1 is RT required for mitosis."; RL Mol. Cell. Biol. 35:2699-2713(2015). RN [52] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=27192185; DOI=10.1080/15384101.2016.1187342; RA Meunier S., Timon K., Vernos I.; RT "Aurora-A regulates MCRS1 function during mitosis."; RL Cell Cycle 15:1779-1786(2016). RN [53] RP FUNCTION. RX PubMed=27335426; DOI=10.1242/jcs.184416; RA Kotak S., Afshar K., Busso C., Goenczy P.; RT "Aurora A kinase regulates proper spindle positioning in C. elegans and in RT human cells."; RL J. Cell Sci. 129:3015-3025(2016). RN [54] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-258, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [55] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND INTERACTION WITH RP FOXP1. RX PubMed=28218735; DOI=10.1038/oncsis.2016.80; RA Kamran M., Long Z.J., Xu D., Lv S.S., Liu B., Wang C.L., Xu J., Lam E.W., RA Liu Q.; RT "Aurora kinase A regulates Survivin stability through targeting FBXL7 in RT gastric cancer drug resistance and prognosis."; RL Oncogenesis 6:E298-E298(2017). RN [56] RP SUBCELLULAR LOCATION. RX PubMed=30538148; DOI=10.1261/rna.069773.118; RA Jiao A.L., Perales R., Umbreit N.T., Haswell J.R., Piper M.E., Adams B.D., RA Pellman D., Kennedy S., Slack F.J.; RT "Human nuclear RNAi-defective 2 (NRDE2) is an essential RNA splicing RT factor."; RL RNA 25:352-363(2019). RN [57] RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 107-403 IN COMPLEX WITH ADENOSINE, RP AND CATALYTIC ACTIVITY. RX PubMed=12237287; DOI=10.1074/jbc.c200426200; RA Cheetham G.M., Knegtel R.M., Coll J.T., Renwick S.B., Swenson L., Weber P., RA Lippke J.A., Austen D.A.; RT "Crystal structure of aurora-2, an oncogenic serine/threonine kinase."; RL J. Biol. Chem. 277:42419-42422(2002). RN [58] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 125-391 IN COMPLEX WITH ADP. RX PubMed=12467573; DOI=10.1016/s0969-2126(02)00907-3; RA Nowakowski J., Cronin C.N., McRee D.E., Knuth M.W., Nelson C.G., RA Pavletich N.P., Rogers J., Sang B.C., Scheibe D.N., Swanson R.V., RA Thompson D.A.; RT "Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases RT from nanovolume crystallography."; RL Structure 10:1659-1667(2002). RN [59] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 122-403 IN COMPLEX WITH TPX2, RP MUTAGENESIS OF ASP-274, ACTIVE SITE, PHOSPHORYLATION AT THR-287 AND RP THR-288, AND REGION ACTIVATION SEGMENT. RX PubMed=14580337; DOI=10.1016/s1097-2765(03)00392-7; RA Bayliss R., Sardon T., Vernos I., Conti E.; RT "Structural basis of Aurora-A activation by TPX2 at the mitotic spindle."; RL Mol. Cell 12:851-862(2003). RN [60] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 123-401 IN COMPLEXES WITH ADPNP RP AND 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR, AND CATALYTIC ACTIVITY. RX PubMed=16337122; DOI=10.1016/j.bmcl.2005.11.053; RA Heron N.M., Anderson M., Blowers D.P., Breed J., Eden J.M., Green S., RA Hill G.B., Johnson T., Jung F.H., McMiken H.H., Mortlock A.A., RA Pannifer A.D., Pauptit R.A., Pink J., Roberts N.J., Rowsell S.; RT "SAR and inhibitor complex structure determination of a novel class of RT potent and specific Aurora kinase inhibitors."; RL Bioorg. Med. Chem. Lett. 16:1320-1323(2006). RN [61] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 100-403 IN COMPLEXES WITH RP SYNTHETIC INHIBITORS, AND FUNCTION. RX PubMed=17125279; DOI=10.1021/jm060897w; RA Fancelli D., Moll J., Varasi M., Bravo R., Artico R., Berta D., Bindi S., RA Cameron A., Candiani I., Cappella P., Carpinelli P., Croci W., Forte B., RA Giorgini M.L., Klapwijk J., Marsiglio A., Pesenti E., Rocchetti M., RA Roletto F., Severino D., Soncini C., Storici P., Tonani R., Zugnoni P., RA Vianello P.; RT "1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent RT aurora kinase inhibitor with a favorable antitumor kinase inhibition RT profile."; RL J. Med. Chem. 49:7247-7251(2006). RN [62] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 125-391 IN COMPLEX WITH VX-680 AND RP TPX2, PHOSPHORYLATION AT THR-288, IDENTIFICATION BY MASS SPECTROMETRY, AND RP SUBUNIT. RX PubMed=18662907; DOI=10.1110/ps.036590.108; RA Zhao B., Smallwood A., Yang J., Koretke K., Nurse K., Calamari A., RA Kirkpatrick R.B., Lai Z.; RT "Modulation of kinase-inhibitor interactions by auxiliary protein binding: RT crystallography studies on Aurora A interactions with VX-680 and with RT TPX2."; RL Protein Sci. 17:1791-1797(2008). RN [63] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 127-388 IN COMPLEX WITH ADP, RP CHARACTERIZATION OF VARIANTS ARG-155 AND MET-174, AND INTERACTION WITH RP TPX2. RX PubMed=19801554; DOI=10.1074/jbc.m109.032722; RA Bibby R.A., Tang C., Faisal A., Drosopoulos K., Lubbe S., Houlston R., RA Bayliss R., Linardopoulos S.; RT "A cancer-associated aurora A mutant is mislocalized and misregulated due RT to loss of interaction with TPX2."; RL J. Biol. Chem. 284:33177-33184(2009). RN [64] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 123-401 IN COMPLEX WITH SYNTHETIC RP INHIBITOR, AND CATALYTIC ACTIVITY. RX PubMed=19140666; DOI=10.1021/jm801270e; RA Coumar M.S., Leou J.S., Shukla P., Wu J.S., Dixit A.K., Lin W.H., RA Chang C.Y., Lien T.W., Tan U.K., Chen C.H., Hsu J.T., Chao Y.S., Wu S.Y., RA Hsieh H.P.; RT "Structure-based drug design of novel Aurora kinase A inhibitors: RT structural basis for potency and specificity."; RL J. Med. Chem. 52:1050-1062(2009). RN [65] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 125-391 IN COMPLEX WITH SYNTHETIC RP INHIBITOR, AND CATALYTIC ACTIVITY. RX PubMed=19402633; DOI=10.1021/jm9000314; RA Aliagas-Martin I., Burdick D., Corson L., Dotson J., Drummond J., RA Fields C., Huang O.W., Hunsaker T., Kleinheinz T., Krueger E., Liang J., RA Moffat J., Phillips G., Pulk R., Rawson T.E., Ultsch M., Walker L., RA Wiesmann C., Zhang B., Zhu B.Y., Cochran A.G.; RT "A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually RT high selectivity against Aurora B."; RL J. Med. Chem. 52:3300-3307(2009). RN [66] RP X-RAY CRYSTALLOGRAPHY (1.72 ANGSTROMS) OF 122-403 OF MUTANTS ALA-290 AND RP ALA-393 IN COMPLEX WITH ADP, INTERACTION WITH MYCN AND TPX2, MUTAGENESIS OF RP CYS-290; TYR-334; GLN-335 AND CYS-393, AND CATALYTIC ACTIVITY. RX PubMed=27837025; DOI=10.1073/pnas.1610626113; RA Richards M.W., Burgess S.G., Poon E., Carstensen A., Eilers M., Chesler L., RA Bayliss R.; RT "Structural basis of N-Myc binding by Aurora-A and its destabilization by RT kinase inhibitors."; RL Proc. Natl. Acad. Sci. U.S.A. 113:13726-13731(2016). RN [67] RP VARIANTS ILE-31 AND VAL-57, AND CHARACTERIZATION OF VARIANT VAL-57. RX PubMed=15867347; DOI=10.1158/0008-5472.can-04-2149; RA Kimura M.T., Mori T., Conroy J., Nowak N.J., Satomi S., Tamai K., RA Nagase H.; RT "Two functional coding single nucleotide polymorphisms in STK15 (Aurora-A) RT coordinately increase esophageal cancer risk."; RL Cancer Res. 65:3548-3554(2005). RN [68] RP VARIANTS ILE-31 AND VAL-57. RX PubMed=16011022; RA Chen L., Ao X., Ren Q., Wang Z.N., Lu C., Xu Y., Jiang L., Luo Y., Xu H.M., RA Zhang X.; RT "Linkage disequilibrium and haplotype analysis of two single nucleotide RT polymorphisms in STK15 in Chinese."; RL Yi Chuan Xue Bao 32:331-336(2005). RN [69] RP VARIANT ILE-31. RX PubMed=16762494; DOI=10.1016/j.canlet.2006.05.002; RA Tchatchou S., Wirtenberger M., Hemminki K., Sutter C., Meindl A., RA Wappenschmidt B., Kiechle M., Bugert P., Schmutzler R.K., Bartram C.R., RA Burwinkel B.; RT "Aurora kinases A and B and familial breast cancer risk."; RL Cancer Lett. 247:266-272(2007). RN [70] RP VARIANTS [LARGE SCALE ANALYSIS] ILE-31; LEU-50; VAL-57; ARG-155; MET-174 RP AND VAL-373. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [71] RP IDENTIFICATION IN A COMPLEX WITH NEDD9 AND CTTN. RX PubMed=24574519; DOI=10.1158/1541-7786.mcr-13-0654; RA Kozyreva V.K., McLaughlin S.L., Livengood R.H., Calkins R.A., Kelley L.C., RA Rajulapati A., Ice R.J., Smolkin M.B., Weed S.A., Pugacheva E.N.; RT "NEDD9 regulates actin dynamics through cortactin deacetylation in an RT AURKA/HDAC6-dependent manner."; RL Mol. Cancer Res. 12:681-693(2014). RN [72] RP FUNCTION, INTERACTION WITH AAAS, SUBCELLULAR LOCATION, AND PHOSPHORYLATION RP AT THR-288. RX PubMed=26246606; DOI=10.1091/mbc.e15-02-0113; RA Carvalhal S., Ribeiro S.A., Arocena M., Kasciukovic T., Temme A., RA Koehler K., Huebner A., Griffis E.R.; RT "The nucleoporin ALADIN regulates Aurora A localization to ensure robust RT mitotic spindle formation."; RL Mol. Biol. Cell 26:3424-3438(2015). CC -!- FUNCTION: Mitotic serine/threonine kinase that contributes to the CC regulation of cell cycle progression (PubMed:11039908, PubMed:12390251, CC PubMed:17125279, PubMed:17360485, PubMed:18615013, PubMed:26246606). CC Associates with the centrosome and the spindle microtubules during CC mitosis and plays a critical role in various mitotic events including CC the establishment of mitotic spindle, centrosome duplication, CC centrosome separation as well as maturation, chromosomal alignment, CC spindle assembly checkpoint, and cytokinesis (PubMed:14523000, CC PubMed:26246606). Required for normal spindle positioning during CC mitosis and for the localization of NUMA1 and DCTN1 to the cell cortex CC during metaphase (PubMed:27335426). Required for initial activation of CC CDK1 at centrosomes (PubMed:13678582, PubMed:15128871). Phosphorylates CC numerous target proteins, including ARHGEF2, BORA, BRCA1, CDC25B, CC DLGP5, HDAC6, KIF2A, LATS2, NDEL1, PARD3, PPP1R2, PLK1, RASSF1, TACC3, CC p53/TP53 and TPX2 (PubMed:11551964, PubMed:14702041, PubMed:15128871, CC PubMed:15147269, PubMed:15987997, PubMed:17604723, PubMed:18056443, CC PubMed:18615013). Phosphorylates MCRS1 which is required for MCRS1- CC mediated kinetochore fiber assembly and mitotic progression CC (PubMed:27192185). Regulates KIF2A tubulin depolymerase activity CC (PubMed:19351716). Important for microtubule formation and/or CC stabilization (PubMed:18056443). Required for normal axon formation CC (PubMed:19812038). Plays a role in microtubule remodeling during CC neurite extension (PubMed:19668197). Also acts as a key regulatory CC component of the p53/TP53 pathway, and particularly the checkpoint- CC response pathways critical for oncogenic transformation of cells, by CC phosphorylating and destabilizing p53/TP53 (PubMed:14702041). CC Phosphorylates its own inhibitors, the protein phosphatase type 1 (PP1) CC isoforms, to inhibit their activity (PubMed:11551964). Inhibits cilia CC outgrowth (By similarity). Required for cilia disassembly via CC phosphorylation of HDAC6 and subsequent deacetylation of alpha-tubulin CC (PubMed:17604723, PubMed:20643351). Regulates protein levels of the CC anti-apoptosis protein BIRC5 by suppressing the expression of the CC SCF(FBXL7) E3 ubiquitin-protein ligase substrate adapter FBXL7 through CC the phosphorylation of the transcription factor FOXP1 CC (PubMed:28218735). {ECO:0000250|UniProtKB:A0A8I3S724, CC ECO:0000269|PubMed:11039908, ECO:0000269|PubMed:11551964, CC ECO:0000269|PubMed:12390251, ECO:0000269|PubMed:13678582, CC ECO:0000269|PubMed:14523000, ECO:0000269|PubMed:14702041, CC ECO:0000269|PubMed:15128871, ECO:0000269|PubMed:15147269, CC ECO:0000269|PubMed:15987997, ECO:0000269|PubMed:17125279, CC ECO:0000269|PubMed:17360485, ECO:0000269|PubMed:17604723, CC ECO:0000269|PubMed:18056443, ECO:0000269|PubMed:18615013, CC ECO:0000269|PubMed:19351716, ECO:0000269|PubMed:19668197, CC ECO:0000269|PubMed:19812038, ECO:0000269|PubMed:20643351, CC ECO:0000269|PubMed:26246606, ECO:0000269|PubMed:27192185, CC ECO:0000269|PubMed:27335426, ECO:0000269|PubMed:28218735}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12237287, ECO:0000269|PubMed:16337122, CC ECO:0000269|PubMed:19140666, ECO:0000269|PubMed:19402633, CC ECO:0000269|PubMed:27192185, ECO:0000269|PubMed:27837025, CC ECO:0000269|PubMed:28218735}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12237287, ECO:0000269|PubMed:16337122, CC ECO:0000269|PubMed:19140666, ECO:0000269|PubMed:19402633, CC ECO:0000269|PubMed:27837025, ECO:0000269|PubMed:28218735}; CC -!- ACTIVITY REGULATION: Activation of CDK1, appears to be an upstream CC event of AURKA activation. Phosphatase inhibitor-2 (PPP1R2) and TPX2 CC act also as activators. Inactivated by the G2 checkpoint. Inhibited by CC GADD45A and p53/TP53, and through dephosphorylation by protein CC phosphatase type 1 (PP1). MLN8054 is also a potent and selective CC inhibitor. Activated during the early phase of cilia disassembly in the CC presence of CIMAP3. Inhibited by the small molecule inhibitor VX-680 CC (PubMed:28218735). {ECO:0000269|PubMed:11039908, CC ECO:0000269|PubMed:12390251, ECO:0000269|PubMed:17360485, CC ECO:0000269|PubMed:28218735}. CC -!- SUBUNIT: Part of a complex composed of NEDD9, AURKA and CTTN; within CC the complex NEDD9 acts as a scaffold protein and is required for CC complex formation (PubMed:24574519). Identified in a complex with AUNIP CC and NIN (PubMed:20596670). Interacts with FBXL7 (By similarity). CC Interacts with CPEB1, JTB, TACC1, TPX2, PPP2CA, as well as with the CC protein phosphatase type 1 (PP1) isoforms PPP1CA, PPP1CB and PPP1CC CC (PubMed:11551964, PubMed:14580337, PubMed:14603251, PubMed:15966895, CC PubMed:17229885, PubMed:18662907, PubMed:19357306, PubMed:19668197, CC PubMed:19801554, PubMed:21225229, PubMed:27837025). Also interacts with CC its substrates ARHGEF2, BORA, KIF2A, PARD3, and p53/TP53 CC (PubMed:14702041, PubMed:16890155, PubMed:17488622, PubMed:19351716, CC PubMed:19812038). Interaction with BORA promotes phosphorylation of CC PLK1 (By similarity). Interacts with CIMAP3 (PubMed:20643351). CC Interacts with GADD45A, competing with its oligomerization CC (PubMed:20460379). Interacts (via C-terminus) with AUNIP (via C- CC terminus) (PubMed:20596670). Interacts with FRY; this interaction CC facilitates AURKA-mediated PLK1 phosphorylation (PubMed:22753416). CC Interacts with SIRT2 (PubMed:17726514, PubMed:22014574). Interacts with CC MYCN; interaction is phospho-independent and triggers AURKA activation; CC AURKA competes with FBXW7 for binding to unphosphorylated MYCN but not CC for binding to phosphorylated MYCN (PubMed:27837025). Interacts with CC HNRNPU (PubMed:21242313, PubMed:25986610). Interacts with AAAS CC (PubMed:26246606). Interacts with KLHL18 and CUL3 (PubMed:23213400). CC Interacts with FOXP1 (PubMed:28218735). Interacts with HDAC6; AURKA- CC mediated phosphorylation of HDAC6 promotes deacetylation of alpha- CC tubulin (PubMed:17604723). {ECO:0000250|UniProtKB:P97477, CC ECO:0000269|PubMed:11551964, ECO:0000269|PubMed:12237287, CC ECO:0000269|PubMed:12467573, ECO:0000269|PubMed:14580337, CC ECO:0000269|PubMed:14603251, ECO:0000269|PubMed:14702041, CC ECO:0000269|PubMed:15966895, ECO:0000269|PubMed:16890155, CC ECO:0000269|PubMed:17229885, ECO:0000269|PubMed:17488622, CC ECO:0000269|PubMed:17604723, ECO:0000269|PubMed:17726514, CC ECO:0000269|PubMed:18662907, ECO:0000269|PubMed:19140666, CC ECO:0000269|PubMed:19351716, ECO:0000269|PubMed:19357306, CC ECO:0000269|PubMed:19402633, ECO:0000269|PubMed:19668197, CC ECO:0000269|PubMed:19801554, ECO:0000269|PubMed:19812038, CC ECO:0000269|PubMed:20460379, ECO:0000269|PubMed:20596670, CC ECO:0000269|PubMed:20643351, ECO:0000269|PubMed:21225229, CC ECO:0000269|PubMed:21242313, ECO:0000269|PubMed:22014574, CC ECO:0000269|PubMed:22753416, ECO:0000269|PubMed:23213400, CC ECO:0000269|PubMed:24574519, ECO:0000269|PubMed:25986610, CC ECO:0000269|PubMed:26246606, ECO:0000269|PubMed:27837025, CC ECO:0000269|PubMed:28218735}. CC -!- INTERACTION: CC O14965; Q9NWT8: AURKAIP1; NbExp=2; IntAct=EBI-448680, EBI-448665; CC O14965; O15392: BIRC5; NbExp=2; IntAct=EBI-448680, EBI-518823; CC O14965; Q6PGQ7: BORA; NbExp=3; IntAct=EBI-448680, EBI-719836; CC O14965; P15056: BRAF; NbExp=5; IntAct=EBI-448680, EBI-365980; CC O14965; P00533: EGFR; NbExp=5; IntAct=EBI-448680, EBI-297353; CC O14965; P06730: EIF4E; NbExp=2; IntAct=EBI-448680, EBI-73440; CC O14965; P61978: HNRNPK; NbExp=2; IntAct=EBI-448680, EBI-304185; CC O14965; Q13123: IK; NbExp=3; IntAct=EBI-448680, EBI-713456; CC O14965; O14920: IKBKB; NbExp=2; IntAct=EBI-448680, EBI-81266; CC O14965; Q9NQS7: INCENP; NbExp=2; IntAct=EBI-448680, EBI-307907; CC O14965; Q9NQS7-1: INCENP; NbExp=2; IntAct=EBI-448680, EBI-15767972; CC O14965; P04198: MYCN; NbExp=12; IntAct=EBI-448680, EBI-878369; CC O14965; P06748: NPM1; NbExp=3; IntAct=EBI-448680, EBI-78579; CC O14965; P53350: PLK1; NbExp=4; IntAct=EBI-448680, EBI-476768; CC O14965; P23468: PTPRD; NbExp=2; IntAct=EBI-448680, EBI-2682990; CC O14965; Q96R06: SPAG5; NbExp=3; IntAct=EBI-448680, EBI-413317; CC O14965; O15350: TP73; NbExp=11; IntAct=EBI-448680, EBI-389606; CC O14965; Q9ULW0: TPX2; NbExp=10; IntAct=EBI-448680, EBI-1037322; CC O14965; Q8VDQ8: Sirt2; Xeno; NbExp=5; IntAct=EBI-448680, EBI-911012; CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule organizing CC center, centrosome {ECO:0000269|PubMed:12576638, CC ECO:0000269|PubMed:13678582, ECO:0000269|PubMed:17229885, CC ECO:0000269|PubMed:17726514, ECO:0000269|PubMed:19357306, CC ECO:0000269|PubMed:21225229, ECO:0000269|PubMed:22014574, CC ECO:0000269|PubMed:23213400, ECO:0000269|PubMed:25657325, CC ECO:0000269|PubMed:30538148, ECO:0000269|PubMed:9153231}. Cytoplasm, CC cytoskeleton, spindle pole {ECO:0000269|PubMed:12576638, CC ECO:0000269|PubMed:13678582, ECO:0000269|PubMed:17726514, CC ECO:0000269|PubMed:19351716, ECO:0000269|PubMed:25657325, CC ECO:0000269|PubMed:26246606, ECO:0000269|PubMed:9153231, CC ECO:0000269|PubMed:9606188}. Cytoplasm, cytoskeleton, microtubule CC organizing center, centrosome, centriole CC {ECO:0000250|UniProtKB:P97477}. Cell projection, neuron projection CC {ECO:0000250|UniProtKB:P97477}. Cell projection, cilium CC {ECO:0000269|PubMed:17604723}. Cytoplasm, cytoskeleton, cilium basal CC body {ECO:0000269|PubMed:17604723}. Basolateral cell membrane CC {ECO:0000250|UniProtKB:F1PNY0}. Note=Detected at the neurite hillock in CC developing neurons (By similarity). Localizes at the centrosome in CC mitotic cells from early prophase until telophase, but also localizes CC to the spindle pole MTs from prophase to anaphase (PubMed:17229885, CC PubMed:21225229, PubMed:9606188). Colocalized with SIRT2 at centrosome CC (PubMed:22014574). Moves to the midbody during both telophase and CC cytokinesis (PubMed:17726514). Associates with both the pericentriolar CC material (PCM) and centrioles (PubMed:22014574). The localization to CC the spindle poles is regulated by AAAS (PubMed:26246606). CC {ECO:0000250|UniProtKB:P97477, ECO:0000269|PubMed:17229885, CC ECO:0000269|PubMed:17726514, ECO:0000269|PubMed:21225229, CC ECO:0000269|PubMed:22014574, ECO:0000269|PubMed:26246606, CC ECO:0000269|PubMed:9606188}. CC -!- TISSUE SPECIFICITY: Highly expressed in testis and weakly in skeletal CC muscle, thymus and spleen. Also highly expressed in colon, ovarian, CC prostate, neuroblastoma, breast and cervical cancer cell lines. CC -!- INDUCTION: Expression is cell-cycle regulated, low in G1/S, accumulates CC during G2/M, and decreases rapidly after. {ECO:0000269|PubMed:11790771, CC ECO:0000269|PubMed:12390251, ECO:0000269|PubMed:15987997, CC ECO:0000269|PubMed:9153231, ECO:0000269|PubMed:9606188}. CC -!- PTM: Activated by phosphorylation at Thr-288; this brings about a CC change in the conformation of the activation segment. Phosphorylation CC at Thr-288 varies during the cell cycle and is highest during M phase. CC Autophosphorylated at Thr-288 upon TPX2 binding. Thr-288 can be CC phosphorylated by several kinases, including PAK and PKA. Protein CC phosphatase type 1 (PP1) binds AURKA and inhibits its activity by CC dephosphorylating Thr-288 during mitosis. Phosphorylation at Ser-342 CC decreases the kinase activity. PPP2CA controls degradation by CC dephosphorylating Ser-51 at the end of mitosis. CC {ECO:0000269|PubMed:11039908, ECO:0000269|PubMed:11551964, CC ECO:0000269|PubMed:12390251, ECO:0000269|PubMed:13678582, CC ECO:0000269|PubMed:14580337, ECO:0000269|PubMed:16246726, CC ECO:0000269|PubMed:17229885, ECO:0000269|PubMed:18662907, CC ECO:0000269|PubMed:19668197}. CC -!- PTM: Ubiquitinated by the E3 ubiquitin-protein ligase complex CC SCF(FBXL7) during mitosis, leading to its degradation by the proteasome CC (By similarity). Ubiquitinated by CHFR, leading to its degradation by CC the proteasome (By similarity). Ubiquitinated by the anaphase-promoting CC complex (APC), leading to its degradation by the proteasome CC (PubMed:10851084, PubMed:11039908). Ubiquitinated by the CUL3-KLHL18 CC ligase leading to its activation at the centrosome which is required CC for initiating mitotic entry (PubMed:23213400). Ubiquitination mediated CC by CUL3-KLHL18 ligase does not lead to its degradation by the CC proteasome (PubMed:23213400). {ECO:0000250|UniProtKB:P97477, CC ECO:0000269|PubMed:10851084, ECO:0000269|PubMed:11039908, CC ECO:0000269|PubMed:23213400}. CC -!- MISCELLANEOUS: Centrosome amplification can occur when the cycles are CC uncoupled, and this amplification is associated with cancer and with an CC increase in the levels of chromosomal instability. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. Aurora subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- CAUTION: Authors initially considered AURKA/STK6 and STK15 as 2 CC different proteins (PubMed:9771714). It is clear that they are the same CC protein. {ECO:0000305|PubMed:9771714}. CC -!- CAUTION: An article that concluded that AURKA-mediated phosphorylation CC of BRCA1 'Ser-308' plays a role in the normal cell cycle G2/M CC transition was withdrawn due to data manipulation of flow cytometry CC data. {ECO:0000305|PubMed:14990569, ECO:0000305|PubMed:26341884}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA23592.1; Type=Frameshift; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/730/AURKA"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D84212; BAA23592.1; ALT_FRAME; mRNA. DR EMBL; AF008551; AAC12708.1; -; mRNA. DR EMBL; AF011467; AAC23448.1; -; Genomic_DNA. DR EMBL; AF011468; AAC63902.1; -; mRNA. DR EMBL; AF195947; AAF29508.1; -; Genomic_DNA. DR EMBL; AF195942; AAF29508.1; JOINED; Genomic_DNA. DR EMBL; AF195943; AAF29508.1; JOINED; Genomic_DNA. DR EMBL; AF195944; AAF29508.1; JOINED; Genomic_DNA. DR EMBL; AF195945; AAF29508.1; JOINED; Genomic_DNA. DR EMBL; AF195946; AAF29508.1; JOINED; Genomic_DNA. DR EMBL; AL121914; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471077; EAW75550.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75551.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75552.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75553.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75554.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75555.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75556.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75557.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75558.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75559.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75561.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75562.1; -; Genomic_DNA. DR EMBL; BC001280; AAH01280.1; -; mRNA. DR EMBL; BC002499; AAH02499.1; -; mRNA. DR EMBL; BC006423; AAH06423.1; -; mRNA. DR EMBL; BC027464; AAH27464.1; -; mRNA. DR CCDS; CCDS13451.1; -. DR PIR; JC5974; JC5974. DR RefSeq; NP_001310232.1; NM_001323303.2. DR RefSeq; NP_001310233.1; NM_001323304.2. DR RefSeq; NP_001310234.1; NM_001323305.2. DR RefSeq; NP_001411346.1; NM_001424417.1. DR RefSeq; NP_003591.2; NM_003600.3. DR RefSeq; NP_940835.1; NM_198433.3. DR RefSeq; NP_940836.1; NM_198434.3. DR RefSeq; NP_940837.1; NM_198435.3. DR RefSeq; NP_940838.1; NM_198436.3. DR RefSeq; NP_940839.1; NM_198437.3. DR PDB; 1MQ4; X-ray; 1.90 A; A=125-391. DR PDB; 1MUO; X-ray; 2.90 A; A=107-403. DR PDB; 1OL5; X-ray; 2.50 A; A=122-403. DR PDB; 1OL6; X-ray; 3.00 A; A=122-403. DR PDB; 1OL7; X-ray; 2.75 A; A=122-403. DR PDB; 2BMC; X-ray; 2.60 A; A/B/C/D/E/F=100-403. DR PDB; 2C6D; X-ray; 2.20 A; A=124-398. DR PDB; 2C6E; X-ray; 2.10 A; A/B=123-401. DR PDB; 2DWB; X-ray; 2.50 A; A=122-403. DR PDB; 2J4Z; X-ray; 2.00 A; A/B=100-403. DR PDB; 2J50; X-ray; 3.00 A; A/B=126-403. DR PDB; 2NP8; X-ray; 2.25 A; A=125-391. DR PDB; 2W1C; X-ray; 3.24 A; A=122-389. DR PDB; 2W1D; X-ray; 2.97 A; A=122-389. DR PDB; 2W1E; X-ray; 2.93 A; A=122-389. DR PDB; 2W1F; X-ray; 2.85 A; A=122-389. DR PDB; 2W1G; X-ray; 2.71 A; A=122-389. DR PDB; 2WQE; X-ray; 2.50 A; A=127-388. DR PDB; 2WTV; X-ray; 2.40 A; A/B/C/D=122-403. DR PDB; 2WTW; X-ray; 3.30 A; A=122-403. DR PDB; 2X6D; X-ray; 2.80 A; A=122-403. DR PDB; 2X6E; X-ray; 3.35 A; A=122-403. DR PDB; 2X81; X-ray; 2.91 A; A=126-391. DR PDB; 2XNE; X-ray; 2.80 A; A=122-392. DR PDB; 2XNG; X-ray; 2.60 A; A=122-403. DR PDB; 2XRU; X-ray; 2.90 A; A=126-403. DR PDB; 3COH; X-ray; 2.70 A; A/B=124-391. DR PDB; 3E5A; X-ray; 2.30 A; A=125-391. DR PDB; 3EFW; X-ray; 2.29 A; A/B=125-391. DR PDB; 3FDN; X-ray; 1.90 A; A=123-401. DR PDB; 3H0Y; X-ray; 2.50 A; A=124-391. DR PDB; 3H0Z; X-ray; 2.92 A; A/B/C=124-391. DR PDB; 3H10; X-ray; 2.20 A; A/B/D=124-391. DR PDB; 3HA6; X-ray; 2.36 A; A=125-391. DR PDB; 3K5U; X-ray; 2.35 A; A=123-401. DR PDB; 3LAU; X-ray; 2.10 A; A=125-399. DR PDB; 3M11; X-ray; 2.75 A; A=123-401. DR PDB; 3MYG; X-ray; 2.40 A; A=125-391. DR PDB; 3NRM; X-ray; 3.05 A; A=126-403. DR PDB; 3O50; X-ray; 2.00 A; A/B=125-391. DR PDB; 3O51; X-ray; 3.20 A; A=125-391. DR PDB; 3P9J; X-ray; 2.80 A; A=125-391. DR PDB; 3QBN; X-ray; 3.50 A; A=124-403. DR PDB; 3R21; X-ray; 2.90 A; A=126-391. DR PDB; 3R22; X-ray; 2.90 A; A=126-391. DR PDB; 3UNZ; X-ray; 2.80 A; A/B=123-401. DR PDB; 3UO4; X-ray; 2.45 A; A=123-401. DR PDB; 3UO5; X-ray; 2.70 A; A=123-401. DR PDB; 3UO6; X-ray; 2.80 A; A/B=123-401. DR PDB; 3UOD; X-ray; 2.50 A; A=123-401. DR PDB; 3UOH; X-ray; 2.80 A; A/B=123-401. DR PDB; 3UOJ; X-ray; 2.90 A; A/B=123-401. DR PDB; 3UOK; X-ray; 2.95 A; A/B=123-401. DR PDB; 3UOL; X-ray; 2.40 A; A/B=123-401. DR PDB; 3UP2; X-ray; 2.30 A; A=123-401. DR PDB; 3UP7; X-ray; 3.05 A; A=123-401. DR PDB; 3VAP; X-ray; 2.66 A; A=125-391. DR PDB; 3W10; X-ray; 2.70 A; A=126-403. DR PDB; 3W16; X-ray; 2.80 A; A=126-403. DR PDB; 3W18; X-ray; 2.50 A; A/B=126-403. DR PDB; 3W2C; X-ray; 2.45 A; A/C/E/G=128-388. DR PDB; 4B0G; X-ray; 2.50 A; A=122-403. DR PDB; 4BN1; X-ray; 2.50 A; A=122-403. DR PDB; 4BYI; X-ray; 2.60 A; A=122-403. DR PDB; 4BYJ; X-ray; 2.75 A; A=122-403. DR PDB; 4C3P; X-ray; 2.69 A; A/D=122-403. DR PDB; 4C3R; X-ray; 2.79 A; A=122-403. DR PDB; 4CEG; X-ray; 2.10 A; A=122-403. DR PDB; 4DEA; X-ray; 2.45 A; A=123-401. DR PDB; 4DEB; X-ray; 3.05 A; A=123-401. DR PDB; 4DED; X-ray; 3.05 A; A=123-401. DR PDB; 4DEE; X-ray; 2.30 A; A=123-401. DR PDB; 4DHF; X-ray; 2.80 A; A/B=126-391. DR PDB; 4J8M; X-ray; 1.85 A; A=123-401. DR PDB; 4J8N; X-ray; 3.14 A; A/B/C/D=123-401. DR PDB; 4JAI; X-ray; 3.20 A; A=122-396. DR PDB; 4JAJ; X-ray; 2.70 A; A=122-396. DR PDB; 4JBO; X-ray; 2.49 A; A=123-401. DR PDB; 4JBP; X-ray; 2.45 A; A=123-401. DR PDB; 4JBQ; X-ray; 2.30 A; A=123-401. DR PDB; 4O0S; X-ray; 2.50 A; A=122-403. DR PDB; 4O0U; X-ray; 2.60 A; A=122-403. DR PDB; 4O0W; X-ray; 2.60 A; A=122-403. DR PDB; 4PRJ; X-ray; 2.80 A; A=124-391. DR PDB; 4UYN; X-ray; 1.90 A; A=125-399. DR PDB; 4UZD; X-ray; 3.20 A; A/B=125-399. DR PDB; 4UZH; X-ray; 2.00 A; A=125-399. DR PDB; 4ZS0; X-ray; 3.00 A; A=122-403. DR PDB; 4ZTQ; X-ray; 2.80 A; A=122-403. DR PDB; 4ZTR; X-ray; 2.85 A; A=122-403. DR PDB; 4ZTS; X-ray; 2.90 A; A=122-403. DR PDB; 5AAD; X-ray; 3.10 A; A=122-403. DR PDB; 5AAE; X-ray; 3.11 A; A=122-403. DR PDB; 5AAF; X-ray; 2.78 A; A=122-403. DR PDB; 5AAG; X-ray; 2.85 A; A=122-403. DR PDB; 5DN3; X-ray; 2.05 A; A=125-391. DR PDB; 5DNR; X-ray; 1.95 A; A=125-391. DR PDB; 5DOS; X-ray; 2.98 A; A=126-390. DR PDB; 5DPV; X-ray; 2.29 A; A=126-390. DR PDB; 5DR2; X-ray; 2.46 A; A=128-390. DR PDB; 5DR6; X-ray; 2.53 A; A=126-390. DR PDB; 5DR9; X-ray; 2.47 A; A=126-390. DR PDB; 5DRD; X-ray; 2.13 A; A=126-390. DR PDB; 5DT0; X-ray; 2.15 A; A=126-390. DR PDB; 5DT3; X-ray; 2.33 A; A=126-390. DR PDB; 5DT4; X-ray; 2.86 A; A=126-390. DR PDB; 5EW9; X-ray; 2.18 A; A=123-390. DR PDB; 5G15; X-ray; 2.06 A; A=122-403. DR PDB; 5G1X; X-ray; 1.72 A; A=122-403. DR PDB; 5L8J; X-ray; 1.68 A; A=122-403. DR PDB; 5L8K; X-ray; 1.79 A; A=122-403. DR PDB; 5L8L; X-ray; 1.67 A; A=122-403. DR PDB; 5LXM; X-ray; 2.08 A; A=122-403. DR PDB; 5OBJ; X-ray; 2.90 A; A=125-391. DR PDB; 5OBR; X-ray; 2.62 A; A=125-391. DR PDB; 5ODT; X-ray; 2.02 A; A=122-403. DR PDB; 5ONE; X-ray; 2.60 A; A=122-403. DR PDB; 5ORL; X-ray; 1.69 A; A=127-391. DR PDB; 5ORN; X-ray; 2.19 A; A=127-391. DR PDB; 5ORO; X-ray; 2.12 A; A=127-391. DR PDB; 5ORP; X-ray; 2.19 A; A=127-391. DR PDB; 5ORR; X-ray; 2.09 A; A=127-391. DR PDB; 5ORS; X-ray; 1.98 A; A=127-391. DR PDB; 5ORT; X-ray; 2.56 A; A=127-391. DR PDB; 5ORV; X-ray; 1.88 A; A=127-391. DR PDB; 5ORW; X-ray; 2.00 A; A=127-391. DR PDB; 5ORX; X-ray; 1.88 A; A=127-391. DR PDB; 5ORY; X-ray; 1.99 A; A=127-391. DR PDB; 5ORZ; X-ray; 1.92 A; A=127-391. DR PDB; 5OS0; X-ray; 1.74 A; A=127-391. DR PDB; 5OS1; X-ray; 1.90 A; A=127-391. DR PDB; 5OS2; X-ray; 1.92 A; A=127-391. DR PDB; 5OS3; X-ray; 1.81 A; A=127-391. DR PDB; 5OS4; X-ray; 1.88 A; A=127-391. DR PDB; 5OS5; X-ray; 1.74 A; A=125-392. DR PDB; 5OS6; X-ray; 2.20 A; A=127-391. DR PDB; 5OSD; X-ray; 1.99 A; A=125-391. DR PDB; 5OSE; X-ray; 1.90 A; A=127-391. DR PDB; 5OSF; X-ray; 1.89 A; A=127-391. DR PDB; 5ZAN; X-ray; 2.85 A; A=123-403. DR PDB; 6C2R; X-ray; 1.96 A; A=125-391. DR PDB; 6C2T; X-ray; 1.73 A; A=125-391. DR PDB; 6C83; X-ray; 2.55 A; A/B=122-403. DR PDB; 6CPE; X-ray; 2.45 A; A=122-403. DR PDB; 6CPF; X-ray; 2.30 A; A=122-403. DR PDB; 6CPG; X-ray; 2.80 A; A/D=122-403. DR PDB; 6GRA; X-ray; 2.60 A; A=122-403. DR PDB; 6HJJ; X-ray; 2.13 A; A=122-403. DR PDB; 6HJK; X-ray; 2.40 A; A=122-403. DR PDB; 6I2U; X-ray; 2.50 A; A=122-403. DR PDB; 6R49; X-ray; 2.21 A; A=122-403. DR PDB; 6R4A; X-ray; 1.94 A; A=122-403. DR PDB; 6R4B; X-ray; 2.15 A; A=122-403. DR PDB; 6R4C; X-ray; 2.04 A; A=122-403. DR PDB; 6R4D; X-ray; 2.01 A; A=122-403. DR PDB; 6VPG; X-ray; 2.64 A; A=117-389. DR PDB; 6VPH; X-ray; 2.14 A; A=117-389. DR PDB; 6VPI; X-ray; 2.00 A; A=117-389. DR PDB; 6VPJ; X-ray; 2.10 A; A=117-389. DR PDB; 6VPL; X-ray; 1.86 A; A/B=117-389. DR PDB; 6VPM; X-ray; 1.58 A; A/B=117-389. DR PDB; 6XKA; X-ray; 2.65 A; A=117-389. DR PDB; 6Z4Y; X-ray; 2.25 A; A=122-403. DR PDB; 7AYH; X-ray; 2.80 A; A=122-403. DR PDB; 7AYI; X-ray; 2.86 A; A=122-403. DR PDB; 7FIC; X-ray; 2.32 A; A=127-391. DR PDB; 7O2V; X-ray; 3.10 A; A=116-403. DR PDB; 7ZTL; X-ray; 1.90 A; A=122-403. DR PDB; 8C14; X-ray; 1.93 A; A=125-391. DR PDB; 8C15; X-ray; 2.41 A; A=126-388. DR PDB; 8C1D; X-ray; 2.12 A; A=126-388. DR PDB; 8C1E; X-ray; 2.80 A; A=125-391. DR PDB; 8C1F; X-ray; 1.92 A; A=126-388. DR PDB; 8C1G; X-ray; 1.96 A; A=126-388. DR PDB; 8C1H; X-ray; 2.23 A; A=126-388. DR PDB; 8C1I; X-ray; 2.81 A; A=126-388. DR PDB; 8C1K; X-ray; 2.43 A; A=126-390. DR PDB; 8C1M; X-ray; 2.84 A; A=125-391. DR PDB; 8GUW; X-ray; 2.70 A; A/B/C=123-403. DR PDB; 8JF4; X-ray; 2.89 A; A=127-389. DR PDB; 8JG8; X-ray; 2.90 A; A=127-389. DR PDB; 8JMX; X-ray; 2.95 A; A=127-389. DR PDB; 8OF5; X-ray; 1.97 A; A=122-403. DR PDB; 8PR7; X-ray; 2.76 A; A/D=122-403. DR PDB; 8SSO; X-ray; 1.97 A; A/D=122-403. DR PDB; 8SSP; X-ray; 2.60 A; A=122-403. DR PDB; 9BZG; X-ray; 1.80 A; A=122-403. DR PDB; 9BZL; X-ray; 1.81 A; B=122-403. DR PDBsum; 1MQ4; -. DR PDBsum; 1MUO; -. DR PDBsum; 1OL5; -. DR PDBsum; 1OL6; -. DR PDBsum; 1OL7; -. DR PDBsum; 2BMC; -. DR PDBsum; 2C6D; -. DR PDBsum; 2C6E; -. DR PDBsum; 2DWB; -. DR PDBsum; 2J4Z; -. DR PDBsum; 2J50; -. DR PDBsum; 2NP8; -. DR PDBsum; 2W1C; -. DR PDBsum; 2W1D; -. DR PDBsum; 2W1E; -. DR PDBsum; 2W1F; -. DR PDBsum; 2W1G; -. DR PDBsum; 2WQE; -. DR PDBsum; 2WTV; -. DR PDBsum; 2WTW; -. DR PDBsum; 2X6D; -. DR PDBsum; 2X6E; -. DR PDBsum; 2X81; -. DR PDBsum; 2XNE; -. DR PDBsum; 2XNG; -. DR PDBsum; 2XRU; -. DR PDBsum; 3COH; -. DR PDBsum; 3E5A; -. DR PDBsum; 3EFW; -. DR PDBsum; 3FDN; -. DR PDBsum; 3H0Y; -. DR PDBsum; 3H0Z; -. DR PDBsum; 3H10; -. DR PDBsum; 3HA6; -. DR PDBsum; 3K5U; -. DR PDBsum; 3LAU; -. DR PDBsum; 3M11; -. DR PDBsum; 3MYG; -. DR PDBsum; 3NRM; -. DR PDBsum; 3O50; -. DR PDBsum; 3O51; -. DR PDBsum; 3P9J; -. DR PDBsum; 3QBN; -. DR PDBsum; 3R21; -. DR PDBsum; 3R22; -. DR PDBsum; 3UNZ; -. DR PDBsum; 3UO4; -. DR PDBsum; 3UO5; -. DR PDBsum; 3UO6; -. DR PDBsum; 3UOD; -. DR PDBsum; 3UOH; -. DR PDBsum; 3UOJ; -. DR PDBsum; 3UOK; -. DR PDBsum; 3UOL; -. DR PDBsum; 3UP2; -. DR PDBsum; 3UP7; -. DR PDBsum; 3VAP; -. DR PDBsum; 3W10; -. DR PDBsum; 3W16; -. DR PDBsum; 3W18; -. DR PDBsum; 3W2C; -. DR PDBsum; 4B0G; -. DR PDBsum; 4BN1; -. DR PDBsum; 4BYI; -. DR PDBsum; 4BYJ; -. DR PDBsum; 4C3P; -. DR PDBsum; 4C3R; -. DR PDBsum; 4CEG; -. DR PDBsum; 4DEA; -. DR PDBsum; 4DEB; -. DR PDBsum; 4DED; -. DR PDBsum; 4DEE; -. DR PDBsum; 4DHF; -. DR PDBsum; 4J8M; -. DR PDBsum; 4J8N; -. DR PDBsum; 4JAI; -. DR PDBsum; 4JAJ; -. DR PDBsum; 4JBO; -. DR PDBsum; 4JBP; -. DR PDBsum; 4JBQ; -. DR PDBsum; 4O0S; -. DR PDBsum; 4O0U; -. DR PDBsum; 4O0W; -. DR PDBsum; 4PRJ; -. DR PDBsum; 4UYN; -. DR PDBsum; 4UZD; -. DR PDBsum; 4UZH; -. DR PDBsum; 4ZS0; -. DR PDBsum; 4ZTQ; -. DR PDBsum; 4ZTR; -. DR PDBsum; 4ZTS; -. DR PDBsum; 5AAD; -. DR PDBsum; 5AAE; -. DR PDBsum; 5AAF; -. DR PDBsum; 5AAG; -. DR PDBsum; 5DN3; -. DR PDBsum; 5DNR; -. DR PDBsum; 5DOS; -. DR PDBsum; 5DPV; -. DR PDBsum; 5DR2; -. DR PDBsum; 5DR6; -. DR PDBsum; 5DR9; -. DR PDBsum; 5DRD; -. DR PDBsum; 5DT0; -. DR PDBsum; 5DT3; -. DR PDBsum; 5DT4; -. DR PDBsum; 5EW9; -. DR PDBsum; 5G15; -. DR PDBsum; 5G1X; -. DR PDBsum; 5L8J; -. DR PDBsum; 5L8K; -. DR PDBsum; 5L8L; -. DR PDBsum; 5LXM; -. DR PDBsum; 5OBJ; -. DR PDBsum; 5OBR; -. DR PDBsum; 5ODT; -. DR PDBsum; 5ONE; -. DR PDBsum; 5ORL; -. DR PDBsum; 5ORN; -. DR PDBsum; 5ORO; -. DR PDBsum; 5ORP; -. DR PDBsum; 5ORR; -. DR PDBsum; 5ORS; -. DR PDBsum; 5ORT; -. DR PDBsum; 5ORV; -. DR PDBsum; 5ORW; -. DR PDBsum; 5ORX; -. DR PDBsum; 5ORY; -. DR PDBsum; 5ORZ; -. DR PDBsum; 5OS0; -. DR PDBsum; 5OS1; -. DR PDBsum; 5OS2; -. DR PDBsum; 5OS3; -. DR PDBsum; 5OS4; -. DR PDBsum; 5OS5; -. DR PDBsum; 5OS6; -. DR PDBsum; 5OSD; -. DR PDBsum; 5OSE; -. DR PDBsum; 5OSF; -. DR PDBsum; 5ZAN; -. DR PDBsum; 6C2R; -. DR PDBsum; 6C2T; -. DR PDBsum; 6C83; -. DR PDBsum; 6CPE; -. DR PDBsum; 6CPF; -. DR PDBsum; 6CPG; -. DR PDBsum; 6GRA; -. DR PDBsum; 6HJJ; -. DR PDBsum; 6HJK; -. DR PDBsum; 6I2U; -. DR PDBsum; 6R49; -. DR PDBsum; 6R4A; -. DR PDBsum; 6R4B; -. DR PDBsum; 6R4C; -. DR PDBsum; 6R4D; -. DR PDBsum; 6VPG; -. DR PDBsum; 6VPH; -. DR PDBsum; 6VPI; -. DR PDBsum; 6VPJ; -. DR PDBsum; 6VPL; -. DR PDBsum; 6VPM; -. DR PDBsum; 6XKA; -. DR PDBsum; 6Z4Y; -. DR PDBsum; 7AYH; -. DR PDBsum; 7AYI; -. DR PDBsum; 7FIC; -. DR PDBsum; 7O2V; -. DR PDBsum; 7ZTL; -. DR PDBsum; 8C14; -. DR PDBsum; 8C15; -. DR PDBsum; 8C1D; -. DR PDBsum; 8C1E; -. DR PDBsum; 8C1F; -. DR PDBsum; 8C1G; -. DR PDBsum; 8C1H; -. DR PDBsum; 8C1I; -. DR PDBsum; 8C1K; -. DR PDBsum; 8C1M; -. DR PDBsum; 8GUW; -. DR PDBsum; 8JF4; -. DR PDBsum; 8JG8; -. DR PDBsum; 8JMX; -. DR PDBsum; 8OF5; -. DR PDBsum; 8PR7; -. DR PDBsum; 8SSO; -. DR PDBsum; 8SSP; -. DR PDBsum; 9BZG; -. DR PDBsum; 9BZL; -. DR AlphaFoldDB; O14965; -. DR SMR; O14965; -. DR BioGRID; 112666; 697. DR CORUM; O14965; -. DR DIP; DIP-33068N; -. DR ELM; O14965; -. DR FunCoup; O14965; 1695. DR IntAct; O14965; 219. DR MINT; O14965; -. DR STRING; 9606.ENSP00000216911; -. DR BindingDB; O14965; -. DR ChEMBL; CHEMBL4722; -. DR DrugBank; DB07362; 1-(5-{2-[(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea. DR DrugBank; DB07360; 1-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}-3-[3-(trifluoromethyl)phenyl]urea. DR DrugBank; DB08065; 2-(1H-pyrazol-3-yl)-1H-benzimidazole. DR DrugBank; DB07186; 4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE. DR DrugBank; DB07266; AKI-001. DR DrugBank; DB05220; Alisertib. DR DrugBank; DB17197; AMG-900. DR DrugBank; DB05169; AT9283. DR DrugBank; DB06347; Cenisertib. DR DrugBank; DB05198; CYC116. DR DrugBank; DB11778; Danusertib. DR DrugBank; DB16891; ENMD-981693. DR DrugBank; DB06486; Enzastaurin. DR DrugBank; DB18019; Erbumine. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB11694; Ilorasertib. DR DrugBank; DB12556; MK-5108. DR DrugBank; DB13061; MLN8054. DR DrugBank; DB08066; N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE. DR DrugBank; DB07801; N-butyl-3-{[6-(9H-purin-6-ylamino)hexanoyl]amino}benzamide. DR DrugBank; DB07545; N-{3-[(4-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-2-YL)AMINO]PHENYL}CYCLOPROPANECARBOXAMIDE. DR DrugBank; DB12072; Orantinib. DR DrugBank; DB13059; PF-03814735. DR DrugBank; DB02482; Phosphonothreonine. DR DrugBank; DB06134; SNS-314. DR DrugCentral; O14965; -. DR GuidetoPHARMACOLOGY; 1936; -. DR GlyGen; O14965; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; O14965; -. DR PhosphoSitePlus; O14965; -. DR BioMuta; AURKA; -. DR CPTAC; CPTAC-1341; -. DR CPTAC; CPTAC-3083; -. DR CPTAC; CPTAC-3084; -. DR jPOST; O14965; -. DR MassIVE; O14965; -. DR PaxDb; 9606-ENSP00000216911; -. DR PeptideAtlas; O14965; -. DR ProteomicsDB; 48339; -. DR Pumba; O14965; -. DR ABCD; O14965; 7 sequenced antibodies. DR Antibodypedia; 1129; 1084 antibodies from 47 providers. DR DNASU; 6790; -. DR Ensembl; ENST00000312783.10; ENSP00000321591.6; ENSG00000087586.19. DR Ensembl; ENST00000347343.6; ENSP00000216911.2; ENSG00000087586.19. DR Ensembl; ENST00000371356.6; ENSP00000360407.2; ENSG00000087586.19. DR Ensembl; ENST00000395911.5; ENSP00000379247.1; ENSG00000087586.19. DR Ensembl; ENST00000395913.7; ENSP00000379249.3; ENSG00000087586.19. DR Ensembl; ENST00000395914.5; ENSP00000379250.1; ENSG00000087586.19. DR Ensembl; ENST00000395915.8; ENSP00000379251.3; ENSG00000087586.19. DR GeneID; 6790; -. DR KEGG; hsa:6790; -. DR MANE-Select; ENST00000395915.8; ENSP00000379251.3; NM_198437.3; NP_940839.1. DR UCSC; uc002xxe.1; human. DR AGR; HGNC:11393; -. DR CIViC; 6790; 8 evidence items across 3 molecular profiles. DR ClinPGx; PA36201; -. DR CTD; 6790; -. DR DisGeNET; 6790; -. DR GeneCards; AURKA; -. DR HGNC; HGNC:11393; AURKA. DR HPA; ENSG00000087586; Tissue enhanced (lymphoid tissue, testis). DR MalaCards; AURKA; -. DR MIM; 603072; gene. DR OpenTargets; ENSG00000087586; -. DR VEuPathDB; HostDB:ENSG00000087586; -. DR eggNOG; KOG0580; Eukaryota. DR GeneTree; ENSGT00940000154900; -. DR InParanoid; O14965; -. DR OMA; KIMNLMF; -. DR OrthoDB; 377346at2759; -. DR PAN-GO; O14965; 6 GO annotations based on evolutionary models. DR PhylomeDB; O14965; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; O14965; -. DR Reactome; R-HSA-174178; APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1. DR Reactome; R-HSA-2565942; Regulation of PLK1 Activity at G2/M Transition. DR Reactome; R-HSA-4615885; SUMOylation of DNA replication proteins. DR Reactome; R-HSA-6804114; TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-8854050; FBXL7 down-regulates AURKA during mitotic entry and in early mitosis. DR Reactome; R-HSA-8854518; AURKA Activation by TPX2. DR Reactome; R-HSA-8854521; Interaction between PHLDA1 and AURKA. DR SignaLink; O14965; -. DR SIGNOR; O14965; -. DR Agora; ENSG00000087586; -. DR BioGRID-ORCS; 6790; 713 hits in 1214 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; AURKA; human. DR EvolutionaryTrace; O14965; -. DR GeneWiki; Aurora_A_kinase; -. DR GenomeRNAi; 6790; -. DR Pharos; O14965; Tchem. DR PRO; PR:O14965; -. DR Proteomes; UP000005640; Chromosome 20. DR RNAct; O14965; protein. DR Bgee; ENSG00000087586; Expressed in oocyte and 159 other cell types or tissues. DR ExpressionAtlas; O14965; baseline and differential. DR GO; GO:0043203; C:axon hillock; IEA:Ensembl. DR GO; GO:0016323; C:basolateral plasma membrane; ISS:UniProtKB. DR GO; GO:0005814; C:centriole; IEA:UniProtKB-SubCell. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0032133; C:chromosome passenger complex; IBA:GO_Central. DR GO; GO:0036064; C:ciliary basal body; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0042585; C:germinal vesicle; IEA:Ensembl. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0000776; C:kinetochore; IBA:GO_Central. DR GO; GO:0072687; C:meiotic spindle; IEA:Ensembl. DR GO; GO:0005874; C:microtubule; IEA:UniProtKB-KW. DR GO; GO:0015630; C:microtubule cytoskeleton; IDA:BHF-UCL. DR GO; GO:0030496; C:midbody; TAS:UniProtKB. DR GO; GO:0072686; C:mitotic spindle; IDA:HPA. DR GO; GO:0097431; C:mitotic spindle pole; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:BHF-UCL. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL. DR GO; GO:0014069; C:postsynaptic density; IEA:Ensembl. DR GO; GO:0045120; C:pronucleus; IEA:Ensembl. DR GO; GO:0005819; C:spindle; TAS:UniProtKB. DR GO; GO:0051233; C:spindle midzone; IBA:GO_Central. DR GO; GO:0000922; C:spindle pole; IBA:GO_Central. DR GO; GO:0031616; C:spindle pole centrosome; IDA:BHF-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0035175; F:histone H3S10 kinase activity; IEA:Ensembl. DR GO; GO:0140677; F:molecular function activator activity; EXP:DisProt. DR GO; GO:0046982; F:protein heterodimerization activity; IPI:CAFA. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IMP:UniProtKB. DR GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; TAS:UniProtKB. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IEA:Ensembl. DR GO; GO:0009948; P:anterior/posterior axis specification; IEA:Ensembl. DR GO; GO:0006915; P:apoptotic process; IEA:Ensembl. DR GO; GO:0051301; P:cell division; IEA:UniProtKB-KW. DR GO; GO:0051642; P:centrosome localization; IEA:Ensembl. DR GO; GO:0061523; P:cilium disassembly; IMP:UniProtKB. DR GO; GO:0000086; P:G2/M transition of mitotic cell cycle; TAS:Reactome. DR GO; GO:0097421; P:liver regeneration; IDA:MGI. DR GO; GO:0000278; P:mitotic cell cycle; TAS:ProtInc. DR GO; GO:0007100; P:mitotic centrosome separation; IEA:Ensembl. DR GO; GO:0007052; P:mitotic spindle organization; IBA:GO_Central. DR GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl. DR GO; GO:0010629; P:negative regulation of gene expression; IMP:UniProtKB. DR GO; GO:0032091; P:negative regulation of protein binding; IDA:UniProtKB. DR GO; GO:1990138; P:neuron projection extension; IEA:Ensembl. DR GO; GO:0018105; P:peptidyl-serine phosphorylation; IMP:UniProtKB. DR GO; GO:0090141; P:positive regulation of mitochondrial fission; IMP:UniProtKB. DR GO; GO:0045931; P:positive regulation of mitotic cell cycle; ISS:UniProtKB. DR GO; GO:0045840; P:positive regulation of mitotic nuclear division; TAS:UniProtKB. DR GO; GO:1900195; P:positive regulation of oocyte maturation; IEA:Ensembl. DR GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IEA:Ensembl. DR GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IEA:Ensembl. DR GO; GO:0046777; P:protein autophosphorylation; TAS:UniProtKB. DR GO; GO:0071539; P:protein localization to centrosome; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0046605; P:regulation of centrosome cycle; TAS:UniProtKB. DR GO; GO:0032465; P:regulation of cytokinesis; IBA:GO_Central. DR GO; GO:0010389; P:regulation of G2/M transition of mitotic cell cycle; TAS:Reactome. DR GO; GO:0031647; P:regulation of protein stability; IMP:UniProtKB. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0009611; P:response to wounding; IDA:MGI. DR GO; GO:0007057; P:spindle assembly involved in female meiosis I; IEA:Ensembl. DR GO; GO:0007051; P:spindle organization; IMP:UniProtKB. DR CDD; cd14116; STKc_Aurora-A; 1. DR DisProt; DP03125; -. DR FunFam; 3.30.200.20:FF:000042; Aurora kinase A; 1. DR FunFam; 1.10.510.10:FF:000235; Serine/threonine-protein kinase ark1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR030616; Aur-like. DR InterPro; IPR030611; AURKA. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24350; SERINE/THREONINE-PROTEIN KINASE IAL-RELATED; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; ATP-binding; Cell cycle; Cell division; Cell membrane; KW Cell projection; Cilium; Cilium biogenesis/degradation; Cytoplasm; KW Cytoskeleton; Isopeptide bond; Kinase; Membrane; Microtubule; Mitosis; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Proto-oncogene; Reference proteome; Serine/threonine-protein kinase; KW Transferase; Ubl conjugation. FT CHAIN 1..403 FT /note="Aurora kinase A" FT /id="PRO_0000086692" FT DOMAIN 133..383 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..125 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 280..293 FT /note="Activation segment" FT /evidence="ECO:0000269|PubMed:14580337" FT COMPBIAS 27..83 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 91..101 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 114..125 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 256 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027, FT ECO:0000269|PubMed:14580337" FT BINDING 143 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27837025, FT ECO:0007744|PDB:5G1X" FT BINDING 162 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27837025, FT ECO:0007744|PDB:5G1X" FT BINDING 211..213 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27837025, FT ECO:0007744|PDB:5G1X" FT BINDING 260..261 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27837025, FT ECO:0007744|PDB:5G1X" FT BINDING 274 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27837025, FT ECO:0007744|PDB:5G1X" FT MOD_RES 41 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 51 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17229885" FT MOD_RES 287 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:14580337, FT ECO:0000269|PubMed:19668197" FT MOD_RES 288 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:11039908, FT ECO:0000269|PubMed:13678582, ECO:0000269|PubMed:14580337, FT ECO:0000269|PubMed:16246726, ECO:0000269|PubMed:18662907, FT ECO:0000269|PubMed:19668197, ECO:0000269|PubMed:26246606" FT MOD_RES 342 FT /note="Phosphoserine; by PKA and PAK" FT /evidence="ECO:0000269|PubMed:16246726" FT CROSSLNK 258 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VARIANT 11 FT /note="G -> R (in dbSNP:rs6069717)" FT /id="VAR_030840" FT VARIANT 31 FT /note="F -> I (in dbSNP:rs2273535)" FT /evidence="ECO:0000269|PubMed:15867347, FT ECO:0000269|PubMed:16011022, ECO:0000269|PubMed:16762494, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:9771714" FT /id="VAR_030841" FT VARIANT 50 FT /note="P -> L (in dbSNP:rs34572020)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041127" FT VARIANT 57 FT /note="I -> V (increased kinase activity; dbSNP:rs1047972)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:15867347, ECO:0000269|PubMed:16011022, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:9153231, FT ECO:0000269|PubMed:9514916, ECO:0000269|PubMed:9771714" FT /id="VAR_030842" FT VARIANT 104 FT /note="S -> L (in dbSNP:rs2230743)" FT /id="VAR_061745" FT VARIANT 155 FT /note="S -> R (in a colorectal adenocarcinoma sample; FT somatic mutation; reduces interaction with TPX2)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:19801554" FT /id="VAR_041128" FT VARIANT 174 FT /note="V -> M (in a metastatic melanoma sample; somatic FT mutation; constitutively enhanced kinase activity)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:19801554" FT /id="VAR_041129" FT VARIANT 373 FT /note="M -> V (in dbSNP:rs33923703)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041130" FT MUTAGEN 162 FT /note="K->R: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:14702041" FT MUTAGEN 165 FT /note="F->A: Decreases the interaction with phosphatase FT type 1 isoforms." FT /evidence="ECO:0000269|PubMed:11551964" FT MUTAGEN 198 FT /note="G->N: Reduces interaction with TPX2. Reduces kinase FT activity tenfold. Promotes interaction with the AURKB FT binding partners INCENP and BIRC5 that are normally not FT bound by AURKA." FT /evidence="ECO:0000269|PubMed:19357306" FT MUTAGEN 205 FT /note="R->A: Reduces ubiquitination and proteasomal FT degradation." FT /evidence="ECO:0000269|PubMed:10851084" FT MUTAGEN 274 FT /note="D->N: Abolishes cilia disassembly and kinase FT activity." FT /evidence="ECO:0000269|PubMed:14580337, FT ECO:0000269|PubMed:17604723" FT MUTAGEN 287 FT /note="T->A: No direct effect on catalytic activity." FT /evidence="ECO:0000269|PubMed:19668197" FT MUTAGEN 287 FT /note="T->E: Enhances interaction with TPX2." FT /evidence="ECO:0000269|PubMed:19668197" FT MUTAGEN 288 FT /note="T->A: Reduces cilia disassembly and kinase FT activity." FT /evidence="ECO:0000269|PubMed:17604723" FT MUTAGEN 288 FT /note="T->D: Mimics phosphorylation state and increases FT kinase activity." FT /evidence="ECO:0000269|PubMed:11039908" FT MUTAGEN 290 FT /note="C->A: Enhances stability; when associated with A- FT 393." FT /evidence="ECO:0000269|PubMed:27837025" FT MUTAGEN 334 FT /note="Y->A: Reduces binding to MYCN." FT /evidence="ECO:0000269|PubMed:27837025" FT MUTAGEN 335 FT /note="Q->A: Reduces binding to MYCN." FT /evidence="ECO:0000269|PubMed:27837025" FT MUTAGEN 346 FT /note="F->A: Decreases the interaction with phosphatase FT type 1 isoforms." FT /evidence="ECO:0000269|PubMed:11551964" FT MUTAGEN 393 FT /note="C->A: Enhances stability; when associated with A- FT 290." FT /evidence="ECO:0000269|PubMed:27837025" FT HELIX 130..132 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 133..141 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 143..152 FT /evidence="ECO:0007829|PDB:6VPM" FT TURN 153..156 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 157..165 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 166..172 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 175..185 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 191..193 FT /evidence="ECO:0007829|PDB:3UO6" FT STRAND 196..201 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 203..210 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 214..217 FT /evidence="ECO:0007829|PDB:2J50" FT HELIX 218..225 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 230..249 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 252..254 FT /evidence="ECO:0007829|PDB:6XKA" FT HELIX 259..261 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 262..264 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 266..268 FT /evidence="ECO:0007829|PDB:3UOL" FT STRAND 270..272 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 275..277 FT /evidence="ECO:0007829|PDB:5ORL" FT STRAND 280..283 FT /evidence="ECO:0007829|PDB:5L8L" FT HELIX 288..291 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 293..295 FT /evidence="ECO:0007829|PDB:5L8J" FT HELIX 298..302 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 304..306 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 307..309 FT /evidence="ECO:0007829|PDB:6C2T" FT HELIX 310..324 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 334..342 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 350..352 FT /evidence="ECO:0007829|PDB:8JF4" FT HELIX 354..363 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 368..370 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 374..378 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 381..386 FT /evidence="ECO:0007829|PDB:6VPM" SQ SEQUENCE 403 AA; 45823 MW; 7C2E7B438D969187 CRC64; MDRSKENCIS GPVKATAPVG GPKRVLVTQQ FPCQNPLPVN SGQAQRVLCP SNSSQRIPLQ AQKLVSSHKP VQNQKQKQLQ ATSVPHPVSR PLNNTQKSKQ PLPSAPENNP EEELASKQKN EESKKRQWAL EDFEIGRPLG KGKFGNVYLA REKQSKFILA LKVLFKAQLE KAGVEHQLRR EVEIQSHLRH PNILRLYGYF HDATRVYLIL EYAPLGTVYR ELQKLSKFDE QRTATYITEL ANALSYCHSK RVIHRDIKPE NLLLGSAGEL KIADFGWSVH APSSRRTTLC GTLDYLPPEM IEGRMHDEKV DLWSLGVLCY EFLVGKPPFE ANTYQETYKR ISRVEFTFPD FVTEGARDLI SRLLKHNPSQ RPMLREVLEH PWITANSSKP SNCQNKESAS KQS // ID AURKC_HUMAN Reviewed; 309 AA. AC Q9UQB9; O60681; O75442; Q6AZY8; Q6DLZ0; Q9UPK5; DT 17-JAN-2003, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-2000, sequence version 1. DT 28-JAN-2026, entry version 213. DE RecName: Full=Aurora kinase C; DE EC=2.7.11.1; DE AltName: Full=Aurora 3; DE AltName: Full=Aurora/IPL1-related kinase 3; DE Short=ARK-3; DE Short=Aurora-related kinase 3; DE AltName: Full=Aurora/IPL1/Eg2 protein 2; DE AltName: Full=Serine/threonine-protein kinase 13; DE AltName: Full=Serine/threonine-protein kinase aurora-C; GN Name=AURKC; Synonyms=AIE2, AIK3, AIRK3, ARK3, STK13; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND SUBCELLULAR LOCATION. RC TISSUE=Testis; RX PubMed=9809744; DOI=10.1089/dna.1998.17.823; RA Tseng T.-C., Chen S.-H., Hsu Y.-P.P., Tang T.K.; RT "Protein kinase profile of sperm and eggs: cloning and characterization of RT two novel testis-specific protein kinases (AIE1, AIE2) related to yeast and RT fly chromosome segregation regulators."; RL DNA Cell Biol. 17:823-833(1998). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RC TISSUE=Placenta; RX PubMed=9799611; DOI=10.1006/geno.1998.5522; RA Bernard M., Sanseau P., Henry C., Couturier A., Prigent C.; RT "Cloning of STK13, a third human protein kinase related to Drosophila RT aurora and budding yeast Ipl1 that maps on chromosome 19q13.3-ter."; RL Genomics 53:406-409(1998). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INDUCTION, AND SUBCELLULAR RP LOCATION. RC TISSUE=Testis; RX PubMed=10066797; DOI=10.1074/jbc.274.11.7334; RA Kimura M., Matsuda Y., Yoshioka T., Okano Y.; RT "Cell cycle-dependent expression and centrosome localization of a third RT human Aurora/Ipl1-related protein kinase, AIK3."; RL J. Biol. Chem. 274:7334-7340(1999). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), TISSUE SPECIFICITY, FUNCTION, RP MUTAGENESIS OF THR-198, AND SUBCELLULAR LOCATION. RX PubMed=15670791; DOI=10.1016/j.bbrc.2004.12.168; RA Yan X., Wu Y., Li Q., Cao L., Liu X., Saiyin H., Yu L.; RT "Cloning and characterization of a novel human Aurora C splicing variant."; RL Biochem. Biophys. Res. Commun. 328:353-361(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP INDUCTION, FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH INCENP, AND RP MUTAGENESIS OF LYS-72. RX PubMed=15499654; DOI=10.1002/cm.20039; RA Sasai K., Katayama H., Stenoien D.L., Fujii S., Honda R., Kimura M., RA Okano Y., Tatsuka M., Suzuki F., Nigg E.A., Earnshaw W.C., Brinkley W.R., RA Sen S.; RT "Aurora-C kinase is a novel chromosomal passenger protein that can RT complement Aurora-B kinase function in mitotic cells."; RL Cell Motil. Cytoskeleton 59:249-263(2004). RN [9] RP IDENTIFICATION IN THE CDC COMPLEX, SUBCELLULAR LOCATION, ACTIVITY RP REGULATION, FUNCTION, AND MUTAGENESIS OF LYS-72 AND THR-198. RX PubMed=15316025; DOI=10.1074/jbc.m403029200; RA Li X., Sakashita G., Matsuzaki H., Sugimoto K., Kimura K., Hanaoka F., RA Taniguchi H., Furukawa K., Urano T.; RT "Direct association with inner centromere protein (INCENP) activates the RT novel chromosomal passenger protein, Aurora-C."; RL J. Biol. Chem. 279:47201-47211(2004). RN [10] RP IDENTIFICATION IN THE CDC COMPLEX, INTERACTION WITH BIRC5, SUBCELLULAR RP LOCATION, FUNCTION, AND MUTAGENESIS OF ASP-166. RX PubMed=15938719; DOI=10.1111/j.1365-2443.2005.00863.x; RA Yan X., Cao L., Li Q., Wu Y., Zhang H., Saiyin H., Liu X., Zhang X., RA Shi Q., Yu L.; RT "Aurora C is directly associated with Survivin and required for RT cytokinesis."; RL Genes Cells 10:617-626(2005). RN [11] RP INVOLVEMENT IN SPGF5. RX PubMed=17435757; DOI=10.1038/ng2027; RA Dieterich K., Soto Rifo R., Faure A.K., Hennebicq S., Ben Amar B., Zahi M., RA Perrin J., Martinez D., Sele B., Jouk P.-S., Ohlmann T., Rousseaux S., RA Lunardi J., Ray P.F.; RT "Homozygous mutation of AURKC yields large-headed polyploid spermatozoa and RT causes male infertility."; RL Nat. Genet. 39:661-665(2007). RN [12] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH TACC1. RX PubMed=21531210; DOI=10.1016/j.bbrc.2011.04.078; RA Gabillard J.C., Ulisse S., Baldini E., Sorrenti S., Cremet J.Y., RA Coccaro C., Prigent C., D'Armiento M., Arlot-Bonnemains Y.; RT "Aurora-C interacts with and phosphorylates the transforming acidic coiled- RT coil 1 protein."; RL Biochem. Biophys. Res. Commun. 408:647-653(2011). RN [13] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=21493633; DOI=10.1093/humrep/der111; RA Avo Santos M., van de Werken C., de Vries M., Jahr H., Vromans M.J., RA Laven J.S., Fauser B.C., Kops G.J., Lens S.M., Baart E.B.; RT "A role for Aurora C in the chromosomal passenger complex during human RT preimplantation embryo development."; RL Hum. Reprod. 26:1868-1881(2011). RN [14] RP INVOLVEMENT IN SPGF5. RX PubMed=21733974; DOI=10.1093/molehr/gar050; RA Ben Khelifa M., Zouari R., Harbuz R., Halouani L., Arnoult C., Lunardi J., RA Ray P.F.; RT "A new AURKC mutation causing macrozoospermia: implications for human RT spermatogenesis and clinical diagnosis."; RL Mol. Hum. Reprod. 17:762-768(2011). RN [15] RP INTERACTION WITH BIRC5, SUBUNIT, FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=27332895; DOI=10.1371/journal.pone.0157305; RA Sasai K., Katayama H., Hawke D.H., Sen S.; RT "Aurora-C interactions with survivin and INCENP reveal shared and distinct RT features compared with Aurora-B chromosome passenger protein complex."; RL PLoS ONE 11:E0157305-E0157305(2016). RN [16] RP VARIANTS [LARGE SCALE ANALYSIS] GLU-52; GLN-148 AND GLN-244. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase component of the chromosomal CC passenger complex (CPC), a complex that acts as a key regulator of CC mitosis. The CPC complex has essential functions at the centromere in CC ensuring correct chromosome alignment and segregation and is required CC for chromatin-induced microtubule stabilization and spindle assembly. CC Also plays a role in meiosis and more particularly in spermatogenesis. CC Has redundant cellular functions with AURKB and can rescue an AURKB CC knockdown. Like AURKB, AURKC phosphorylates histone H3 at 'Ser-10' and CC 'Ser-28'. AURKC phosphorylates the CPC complex subunits BIRC5/survivin CC and INCENP leading to increased AURKC activity. Phosphorylates TACC1, CC another protein involved in cell division, at 'Ser-228'. CC {ECO:0000269|PubMed:15316025, ECO:0000269|PubMed:15499654, CC ECO:0000269|PubMed:15670791, ECO:0000269|PubMed:15938719, CC ECO:0000269|PubMed:21493633, ECO:0000269|PubMed:21531210, CC ECO:0000269|PubMed:27332895}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- ACTIVITY REGULATION: Okadaic acid, an inhibitor of protein phosphatase CC 1 (PP1), protein phosphatase 2A (PP2A) and protein phosphatase 5 (PP5), CC increases AURKC activity. AURKC is also stabilized through its CC interaction with INCENP, which also acts as an activator. CC {ECO:0000269|PubMed:15316025}. CC -!- SUBUNIT: Component of the chromosomal passenger complex (CPC) composed CC of at least BIRC5/survivin, CDCA8/borealin, INCENP, AURKB or AURKC; CC predominantly independent AURKB- and AURKC-containing complexes exist; CC in the complex interacts directly with BIRC5/survivin and INCENP. CC Interacts with TACC1. {ECO:0000269|PubMed:15316025, CC ECO:0000269|PubMed:15499654, ECO:0000269|PubMed:15938719, CC ECO:0000269|PubMed:21531210, ECO:0000269|PubMed:27332895}. CC -!- INTERACTION: CC Q9UQB9; O15392: BIRC5; NbExp=10; IntAct=EBI-3926851, EBI-518823; CC Q9UQB9; Q96CA5: BIRC7; NbExp=3; IntAct=EBI-3926851, EBI-517623; CC Q9UQB9; A2RRN7: CADPS; NbExp=3; IntAct=EBI-3926851, EBI-10179719; CC Q9UQB9; Q9NQS7: INCENP; NbExp=20; IntAct=EBI-3926851, EBI-307907; CC Q9UQB9; P32243-2: OTX2; NbExp=4; IntAct=EBI-3926851, EBI-9087860; CC -!- SUBCELLULAR LOCATION: Nucleus. Chromosome. Chromosome, centromere CC {ECO:0000269|PubMed:27332895}. Cytoplasm, cytoskeleton, spindle CC {ECO:0000269|PubMed:15938719}. Note=Distributes in the condensed CC chromosomes during prophase to metaphase. After entering anaphase, CC there is a dissociation from separated chromosomes and a redistribution CC to midzone microtubules, and finally remains in the midbody during CC cytokinesis. {ECO:0000269|PubMed:21531210}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q9UQB9-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9UQB9-2; Sequence=VSP_004872; CC Name=3; Synonyms=Aurora C-SV; CC IsoId=Q9UQB9-3; Sequence=VSP_041095; CC -!- TISSUE SPECIFICITY: Isoform 1 and isoform 2 are expressed in testis. CC Elevated expression levels were seen only in a subset of cancer cell CC lines such as Hep-G2, Huh-7 and HeLa. Expression is maximum at M phase. CC {ECO:0000269|PubMed:15670791}. CC -!- INDUCTION: Expression is cell cycle-regulated, with an increase during CC G2 and M phases. {ECO:0000269|PubMed:10066797, CC ECO:0000269|PubMed:15499654}. CC -!- DISEASE: Spermatogenic failure 5 (SPGF5) [MIM:243060]: An infertility CC disorder caused by spermatogenesis defects. Semen from affected men CC show close to 100% morphologically abnormal multiflagellar spermatozoa CC with low motility, oversized irregular heads, and abnormal midpiece and CC acrosome. {ECO:0000269|PubMed:17435757, ECO:0000269|PubMed:21733974}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. Aurora subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF054621; AAC25955.1; -; mRNA. DR EMBL; AF059681; AAC77369.1; -; mRNA. DR EMBL; AB017332; BAA76292.1; -; mRNA. DR EMBL; AY661554; AAT64422.1; -; mRNA. DR EMBL; AC005261; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471135; EAW72485.1; -; Genomic_DNA. DR EMBL; BC075064; AAH75064.2; -; mRNA. DR CCDS; CCDS33128.1; -. [Q9UQB9-1] DR CCDS; CCDS46205.1; -. [Q9UQB9-3] DR CCDS; CCDS46206.1; -. [Q9UQB9-2] DR RefSeq; NP_001015878.1; NM_001015878.2. [Q9UQB9-1] DR RefSeq; NP_001015879.1; NM_001015879.2. [Q9UQB9-3] DR RefSeq; NP_003151.2; NM_003160.3. [Q9UQB9-2] DR PDB; 6GR8; X-ray; 1.75 A; A=36-305. DR PDB; 6GR9; X-ray; 2.25 A; A=36-305. DR PDB; 9ESA; X-ray; 2.80 A; AAA/BBB=13-309. DR PDBsum; 6GR8; -. DR PDBsum; 6GR9; -. DR PDBsum; 9ESA; -. DR AlphaFoldDB; Q9UQB9; -. DR SMR; Q9UQB9; -. DR BioGRID; 112671; 42. DR FunCoup; Q9UQB9; 312. DR IntAct; Q9UQB9; 31. DR STRING; 9606.ENSP00000302898; -. DR BindingDB; Q9UQB9; -. DR ChEMBL; CHEMBL3935; -. DR DrugBank; DB08039; (3Z)-N,N-DIMETHYL-2-OXO-3-(4,5,6,7-TETRAHYDRO-1H-INDOL-2-YLMETHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE. DR DrugBank; DB17197; AMG-900. DR DrugBank; DB11778; Danusertib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB11694; Ilorasertib. DR DrugBank; DB08454; N-(5-METHYL-1H-PYRAZOL-3-YL)-2-PHENYLQUINAZOLIN-4-AMINE. DR DrugBank; DB07545; N-{3-[(4-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-2-YL)AMINO]PHENYL}CYCLOPROPANECARBOXAMIDE. DR DrugBank; DB06134; SNS-314. DR DrugCentral; Q9UQB9; -. DR GuidetoPHARMACOLOGY; 1938; -. DR iPTMnet; Q9UQB9; -. DR PhosphoSitePlus; Q9UQB9; -. DR BioMuta; AURKC; -. DR DMDM; 27805738; -. DR jPOST; Q9UQB9; -. DR MassIVE; Q9UQB9; -. DR PaxDb; 9606-ENSP00000302898; -. DR PeptideAtlas; Q9UQB9; -. DR ProteomicsDB; 85538; -. [Q9UQB9-1] DR ProteomicsDB; 85539; -. [Q9UQB9-2] DR ProteomicsDB; 85540; -. [Q9UQB9-3] DR Pumba; Q9UQB9; -. DR Antibodypedia; 33237; 506 antibodies from 29 providers. DR DNASU; 6795; -. DR Ensembl; ENST00000302804.12; ENSP00000302898.6; ENSG00000105146.15. [Q9UQB9-1] DR Ensembl; ENST00000415300.6; ENSP00000407162.1; ENSG00000105146.15. [Q9UQB9-3] DR Ensembl; ENST00000598785.5; ENSP00000471830.1; ENSG00000105146.15. [Q9UQB9-2] DR GeneID; 6795; -. DR KEGG; hsa:6795; -. DR MANE-Select; ENST00000302804.12; ENSP00000302898.6; NM_001015878.2; NP_001015878.1. DR UCSC; uc002qoc.4; human. [Q9UQB9-1] DR AGR; HGNC:11391; -. DR ClinPGx; PA36200; -. DR CTD; 6795; -. DR DisGeNET; 6795; -. DR GeneCards; AURKC; -. DR HGNC; HGNC:11391; AURKC. DR HPA; ENSG00000105146; Tissue enriched (testis). DR MalaCards; AURKC; -. DR MIM; 243060; phenotype. DR MIM; 603495; gene. DR OpenTargets; ENSG00000105146; -. DR Orphanet; 137893; Male infertility due to large-headed multiflagellar polyploid spermatozoa. DR VEuPathDB; HostDB:ENSG00000105146; -. DR eggNOG; KOG0580; Eukaryota. DR GeneTree; ENSGT00940000161619; -. DR HOGENOM; CLU_000288_63_0_1; -. DR InParanoid; Q9UQB9; -. DR OMA; KELQKCH; -. DR OrthoDB; 377346at2759; -. DR PAN-GO; Q9UQB9; 7 GO annotations based on evolutionary models. DR PhylomeDB; Q9UQB9; -. DR PathwayCommons; Q9UQB9; -. DR SignaLink; Q9UQB9; -. DR SIGNOR; Q9UQB9; -. DR Agora; ENSG00000105146; -. DR BioGRID-ORCS; 6795; 17 hits in 1190 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR GeneWiki; AURKC; -. DR GenomeRNAi; 6795; -. DR Pharos; Q9UQB9; Tchem. DR PRO; PR:Q9UQB9; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q9UQB9; protein. DR Bgee; ENSG00000105146; Expressed in oocyte and 101 other cell types or tissues. DR ExpressionAtlas; Q9UQB9; baseline and differential. DR GO; GO:0005813; C:centrosome; IBA:GO_Central. DR GO; GO:0032133; C:chromosome passenger complex; IBA:GO_Central. DR GO; GO:0000793; C:condensed chromosome; IDA:UniProtKB. DR GO; GO:0000776; C:kinetochore; IBA:GO_Central. DR GO; GO:0030496; C:midbody; IDA:UniProtKB. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0005819; C:spindle; TAS:UniProtKB. DR GO; GO:0005876; C:spindle microtubule; IBA:GO_Central. DR GO; GO:0051233; C:spindle midzone; IDA:UniProtKB. DR GO; GO:0000922; C:spindle pole; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; TAS:UniProtKB. DR GO; GO:0008608; P:attachment of spindle microtubules to kinetochore; TAS:UniProtKB. DR GO; GO:0051301; P:cell division; IEA:UniProtKB-KW. DR GO; GO:0051321; P:meiotic cell cycle; IEA:UniProtKB-KW. DR GO; GO:0051256; P:mitotic spindle midzone assembly; TAS:UniProtKB. DR GO; GO:0007052; P:mitotic spindle organization; IBA:GO_Central. DR GO; GO:0032467; P:positive regulation of cytokinesis; TAS:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0032465; P:regulation of cytokinesis; IBA:GO_Central. DR CDD; cd14117; STKc_Aurora-B_like; 1. DR FunFam; 1.10.510.10:FF:000887; Aurora B kinase; 1. DR FunFam; 3.30.200.20:FF:000042; Aurora kinase A; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR030616; Aur-like. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24350; SERINE/THREONINE-PROTEIN KINASE IAL-RELATED; 1. DR Pfam; PF00069; Pkinase; 1. DR PIRSF; PIRSF000654; Integrin-linked_kinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell cycle; Cell division; KW Centromere; Chromosome; Cytoplasm; Cytoskeleton; Kinase; Meiosis; Mitosis; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase. FT CHAIN 1..309 FT /note="Aurora kinase C" FT /id="PRO_0000085660" FT DOMAIN 43..293 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..33 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 292..309 FT /note="Interaction with BIRC5" FT /evidence="ECO:0000269|PubMed:27332895" FT COMPBIAS 22..32 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 166 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 49..57 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 72 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 198 FT /note="Phosphothreonine; by PKA" FT /evidence="ECO:0000250|UniProtKB:O88445" FT VAR_SEQ 1..34 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:9799611" FT /id="VSP_004872" FT VAR_SEQ 1..20 FT /note="MSSPRAVVQLGKAQPAGEEL -> M (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15670791" FT /id="VSP_041095" FT VARIANT 52 FT /note="G -> E (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs2122802401)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040385" FT VARIANT 148 FT /note="E -> Q (in a lung squamous cell carcinoma sample; FT somatic mutation; dbSNP:rs2087514266)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040386" FT VARIANT 244 FT /note="H -> Q (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040387" FT MUTAGEN 72 FT /note="K->R: Impairs kinase activity." FT /evidence="ECO:0000269|PubMed:15316025, FT ECO:0000269|PubMed:15499654" FT MUTAGEN 166 FT /note="D->Y: Impairs kinase activity, and keeps AURKC with FT the chromosomes until the end of mitosis." FT /evidence="ECO:0000269|PubMed:15938719" FT MUTAGEN 198 FT /note="T->A: Impairs kinase activity." FT /evidence="ECO:0000269|PubMed:15316025, FT ECO:0000269|PubMed:15670791" FT CONFLICT 109 FT /note="Y -> H (in Ref. 1; AAC25955)" FT /evidence="ECO:0000305" FT CONFLICT 150 FT /note="L -> V (in Ref. 2; AAC77369)" FT /evidence="ECO:0000305" FT CONFLICT 193..195 FT /note="SLR -> LPE (in Ref. 2; AAC77369)" FT /evidence="ECO:0000305" FT HELIX 40..42 FT /evidence="ECO:0007829|PDB:6GR8" FT STRAND 43..52 FT /evidence="ECO:0007829|PDB:6GR8" FT STRAND 55..62 FT /evidence="ECO:0007829|PDB:6GR8" FT TURN 63..65 FT /evidence="ECO:0007829|PDB:6GR8" FT STRAND 68..75 FT /evidence="ECO:0007829|PDB:6GR8" FT HELIX 76..82 FT /evidence="ECO:0007829|PDB:6GR8" FT HELIX 85..97 FT /evidence="ECO:0007829|PDB:6GR8" FT STRAND 106..111 FT /evidence="ECO:0007829|PDB:6GR8" FT STRAND 113..120 FT /evidence="ECO:0007829|PDB:6GR8" FT HELIX 128..135 FT /evidence="ECO:0007829|PDB:6GR8" FT HELIX 140..159 FT /evidence="ECO:0007829|PDB:6GR8" FT HELIX 169..171 FT /evidence="ECO:0007829|PDB:6GR8" FT STRAND 172..174 FT /evidence="ECO:0007829|PDB:6GR8" FT STRAND 180..182 FT /evidence="ECO:0007829|PDB:6GR8" FT HELIX 203..205 FT /evidence="ECO:0007829|PDB:6GR8" FT HELIX 208..211 FT /evidence="ECO:0007829|PDB:6GR8" FT HELIX 220..234 FT /evidence="ECO:0007829|PDB:6GR8" FT HELIX 244..252 FT /evidence="ECO:0007829|PDB:6GR8" FT HELIX 264..273 FT /evidence="ECO:0007829|PDB:6GR8" FT HELIX 278..280 FT /evidence="ECO:0007829|PDB:6GR8" FT HELIX 284..289 FT /evidence="ECO:0007829|PDB:6GR8" FT HELIX 291..296 FT /evidence="ECO:0007829|PDB:6GR8" SQ SEQUENCE 309 AA; 35591 MW; 41B7DFCA91704201 CRC64; MSSPRAVVQL GKAQPAGEEL ATANQTAQQP SSPAMRRLTV DDFEIGRPLG KGKFGNVYLA RLKESHFIVA LKVLFKSQIE KEGLEHQLRR EIEIQAHLQH PNILRLYNYF HDARRVYLIL EYAPRGELYK ELQKSEKLDE QRTATIIEEL ADALTYCHDK KVIHRDIKPE NLLLGFRGEV KIADFGWSVH TPSLRRKTMC GTLDYLPPEM IEGRTYDEKV DLWCIGVLCY ELLVGYPPFE SASHSETYRR ILKVDVRFPL SMPLGARDLI SRLLRYQPLE RLPLAQILKH PWVQAHSRRV LPPCAQMAS // ID BIRC5_HUMAN Reviewed; 142 AA. AC O15392; A2SUH6; B2R4R1; Q2I3N8; Q4VGX0; Q53F61; Q5MGC6; Q6FHL2; Q75SP2; AC Q9P2W8; DT 30-MAY-2000, integrated into UniProtKB/Swiss-Prot. DT 21-MAR-2012, sequence version 3. DT 28-JAN-2026, entry version 252. DE RecName: Full=Baculoviral IAP repeat-containing protein 5; DE AltName: Full=Apoptosis inhibitor 4; DE AltName: Full=Apoptosis inhibitor survivin; GN Name=BIRC5; Synonyms=API4, IAP4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1). RX PubMed=9256286; DOI=10.1038/nm0897-917; RA Ambrosini G., Adida C., Altieri D.C.; RT "A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma."; RL Nat. Med. 3:917-921(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 3), FUNCTION, AND TISSUE RP SPECIFICITY. RX PubMed=10626797; RA Mahotka C., Wenzel M., Springer E., Gabbert H.E., Gerharz C.D.; RT "Survivin-deltaEx3 and survivin-2B: two novel splice variants of the RT apoptosis inhibitor survivin with different antiapoptotic properties."; RL Cancer Res. 59:6097-6102(1999). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND SUBCELLULAR LOCATION. RX PubMed=11084331; DOI=10.1016/s0960-9822(00)00769-7; RA Uren A.G., Wong L., Pakusch M., Fowler K.J., Burrows F.J., Vaux D.L., RA Choo K.H.; RT "Survivin and the inner centromere protein INCENP show similar cell-cycle RT localization and gene knockout phenotype."; RL Curr. Biol. 10:1319-1328(2000). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), AND TISSUE SPECIFICITY. RC TISSUE=Myeloid leukemia cell; RX PubMed=14741722; DOI=10.1016/j.bbrc.2003.12.178; RA Badran A., Yoshida A., Ishikawa K., Goi T., Yamaguchi A., Ueda T., RA Inuzuka M.; RT "Identification of a novel splice variant of the human anti-apoptosis gene RT survivin."; RL Biochem. Biophys. Res. Commun. 314:902-907(2004). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5), AND TISSUE SPECIFICITY. RC TISSUE=Mammary cancer; RX PubMed=16329164; DOI=10.1080/10425170500226490; RA Zheng W., Ma X., Wei D., Wang T., Ma Y., Yang S.; RT "Molecular cloning and bioinformatics analysis of a novel spliced variant RT of survivin from human breast cancer cells."; RL DNA Seq. 16:321-328(2005). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RC TISSUE=Neuroblastoma; RA Kageyama H., Islam A., Takayasu H., Nakagawara A.; RT "An isoform of survivin (survivin-beta) which has 23 amino acids insertion RT into the BIR domain."; RL Submitted (JUN-1999) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 7). RA Caldas H., Honsey L.E., Altura R.A.; RT "Survivin 2 alpha: a novel survivin splice variant expressed in human RT malignancies."; RL Submitted (FEB-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 6). RC TISSUE=Myeloid leukemia cell; RA Vietri M.T., Cioffi M., Sessa M., Sica V., Molinari A.M.; RT "Identification of a novel survivin splicing variant 3alpha in acute RT myeloid leukemia."; RL Submitted (NOV-2005) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.; RL Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases. RN [13] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT GLU-129. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [14] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [15] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Lung, Mammary gland, and Muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [16] RP FUNCTION. RX PubMed=9859993; DOI=10.1038/25141; RA Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C., RA Altieri D.C.; RT "Control of apoptosis and mitotic spindle checkpoint by survivin."; RL Nature 396:580-584(1998). RN [17] RP PHOSPHORYLATION AT THR-34. RX PubMed=11069302; DOI=10.1073/pnas.240390697; RA O'Connor D.S., Grossman D., Plescia J., Li F., Zhang H., Villa A., RA Tognin S., Marchisio P.C., Altieri D.C.; RT "Regulation of apoptosis at cell division by p34cdc2 phosphorylation of RT survivin."; RL Proc. Natl. Acad. Sci. U.S.A. 97:13103-13107(2000). RN [18] RP FUNCTION IN APOPTOSIS SUPPRESSION, INTERACTION WITH LAMTOR5/HBXIP, RP MUTAGENESIS OF THR-34, AND SUBCELLULAR LOCATION. RX PubMed=12773388; DOI=10.1093/emboj/cdg263; RA Marusawa H., Matsuzawa S., Welsh K., Zou H., Armstrong R., Tamm I., RA Reed J.C.; RT "HBXIP functions as a cofactor of survivin in apoptosis suppression."; RL EMBO J. 22:2729-2740(2003). RN [19] RP INTERACTION WITH INCENP, SUBCELLULAR LOCATION, PHOSPHORYLATION AT THR-117, RP AND MUTAGENESIS OF THR-117. RX PubMed=14610074; DOI=10.1074/jbc.m311299200; RA Wheatley S.P., Henzing A.J., Dodson H., Khaled W., Earnshaw W.C.; RT "Aurora-B phosphorylation in vitro identifies a residue of survivin that is RT essential for its localization and binding to inner centromere protein RT (INCENP) in vivo."; RL J. Biol. Chem. 279:5655-5660(2004). RN [20] RP INTERACTION WITH CDCA8. RX PubMed=15249581; DOI=10.1083/jcb.200404001; RA Gassmann R., Carvalho A., Henzing A.J., Ruchaud S., Hudson D.F., Honda R., RA Nigg E.A., Gerloff D.L., Earnshaw W.C.; RT "Borealin: a novel chromosomal passenger required for stability of the RT bipolar mitotic spindle."; RL J. Cell Biol. 166:179-191(2004). RN [21] RP SUBCELLULAR LOCATION, AND INTERACTION WITH BIRC2/C-IAP1. RX PubMed=15665297; DOI=10.1158/0008-5472.210.65.1; RA Samuel T., Okada K., Hyer M., Welsh K., Zapata J.M., Reed J.C.; RT "cIAP1 Localizes to the nuclear compartment and modulates the cell cycle."; RL Cancer Res. 65:210-218(2005). RN [22] RP REVIEW ON FUNCTION. RX PubMed=16344111; DOI=10.1016/s0074-7696(05)47002-3; RA Wheatley S.P., McNeish I.A.; RT "Survivin: a protein with dual roles in mitosis and apoptosis."; RL Int. Rev. Cytol. 247:35-88(2005). RN [23] RP FUNCTION, INTERACTION WITH USP9X, SUBCELLULAR LOCATION, UBIQUITINATION, AND RP MUTAGENESIS OF LYS-23; LYS-62; LYS-78 AND LYS-79. RX PubMed=16322459; DOI=10.1126/science.1120160; RA Vong Q.P., Cao K., Li H.Y., Iglesias P.A., Zheng Y.; RT "Chromosome alignment and segregation regulated by ubiquitination of RT survivin."; RL Science 310:1499-1504(2005). RN [24] RP MUTAGENESIS OF ASP-70; ASP-71 AND 70-ASP--ASP-71. RX PubMed=16762323; DOI=10.1016/j.bbrc.2006.05.131; RA Cao L., Yan X., Wu Y., Hu H., Li Q., Zhou T., Jiang S., Yu L.; RT "Survivin mutant (Surv-DD70, 71AA) disrupts the interaction of Survivin RT with Aurora B and causes multinucleation in HeLa cells."; RL Biochem. Biophys. Res. Commun. 346:400-407(2006). RN [25] RP INTERACTION WITH CDCA8. RX PubMed=16239925; DOI=10.1038/sj.embor.7400562; RA Vader G., Kauw J.J.W., Medema R.H., Lens S.M.A.; RT "Survivin mediates targeting of the chromosomal passenger complex to the RT centromere and midbody."; RL EMBO Rep. 7:85-92(2006). RN [26] RP INTERACTION WITH CDCA8. RX PubMed=16427043; DOI=10.1016/j.yexcr.2005.12.015; RA Chang J.-L., Chen T.-H., Wang C.-F., Chiang Y.-H., Huang Y.-L., Wong F.-H., RA Chou C.-K., Chen C.-M.; RT "Borealin/Dasra B is a cell cycle-regulated chromosomal passenger protein RT and its nuclear accumulation is linked to poor prognosis for human gastric RT cancer."; RL Exp. Cell Res. 312:962-973(2006). RN [27] RP INTERACTION WITH EVI5. RX PubMed=16764853; DOI=10.1016/j.yexcr.2006.03.032; RA Faitar S.L., Sossey-Alaoui K., Ranalli T.A., Cowell J.K.; RT "EVI5 protein associates with the INCENP-aurora B kinase-survivin RT chromosomal passenger complex and is involved in the completion of RT cytokinesis."; RL Exp. Cell Res. 312:2325-2335(2006). RN [28] RP FUNCTION, AND INTERACTION WITH CDCA8. RX PubMed=16291752; DOI=10.1074/jbc.m508773200; RA Noton E.A., Colnaghi R., Tate S., Starck C., Carvalho A., Ko Ferrigno P., RA Wheatley S.P.; RT "Molecular analysis of survivin isoforms: evidence that alternatively RT spliced variants do not play a role in mitosis."; RL J. Biol. Chem. 281:1286-1295(2006). RN [29] RP INTERACTION WITH CDCA8. RX PubMed=16436504; DOI=10.1091/mbc.e05-08-0727; RA Lens S.M.A., Rodriguez J.A., Vader G., Span S.W., Giaccone G., Medema R.H.; RT "Uncoupling the central spindle-associated function of the chromosomal RT passenger complex from its role at centromeres."; RL Mol. Biol. Cell 17:1897-1909(2006). RN [30] RP INTERACTION WITH BIRC6/BRUCE. RX PubMed=18329369; DOI=10.1016/j.cell.2008.01.012; RA Pohl C., Jentsch S.; RT "Final stages of cytokinesis and midbody ring formation are controlled by RT BRUCE."; RL Cell 132:832-845(2008). RN [31] RP INDUCTION. RX PubMed=17993464; DOI=10.1074/jbc.m704035200; RA Gagarina V., Carlberg A.L., Pereira-Mouries L., Hall D.J.; RT "Cartilage oligomeric matrix protein protects cells against death by RT elevating members of the IAP family of survival proteins."; RL J. Biol. Chem. 283:648-659(2008). RN [32] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-34, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [33] RP FUNCTION, INTERACTION WITH RAN; AURKB AND CDCA8, SUBCELLULAR LOCATION, RP DEVELOPMENTAL STAGE, AND MUTAGENESIS OF GLU-65. RX PubMed=18591255; DOI=10.1128/mcb.02039-07; RA Xia F., Canovas P.M., Guadagno T.M., Altieri D.C.; RT "A survivin-ran complex regulates spindle formation in tumor cells."; RL Mol. Cell. Biol. 28:5299-5311(2008). RN [34] RP FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=21364656; DOI=10.1038/cddis.2010.25; RA Knauer S.K., Heinrich U.R., Bier C., Habtemichael N., Docter D., RA Helling K., Mann W.J., Stauber R.H.; RT "An otoprotective role for the apoptosis inhibitor protein survivin."; RL Cell Death Dis. 1:E51-E51(2010). RN [35] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH STAT3 AND XPO1/CRM1, RP ACETYLATION AT LYS-23; LYS-90; LYS-110; LYS-112; LYS-115; LYS-121 AND RP LYS-129, MUTAGENESIS OF LYS-129, AND CHARACTERIZATION OF VARIANT GLU-129. RX PubMed=20826784; DOI=10.1074/jbc.m110.152777; RA Wang H., Holloway M.P., Ma L., Cooper Z.A., Riolo M., Samkari A., RA Elenitoba-Johnson K.S., Chin Y.E., Altura R.A.; RT "Acetylation directs survivin nuclear localization to repress STAT3 RT oncogenic activity."; RL J. Biol. Chem. 285:36129-36137(2010). RN [36] RP FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=20627126; DOI=10.1016/j.mcn.2010.07.003; RA Habtemichael N., Heinrich U.R., Knauer S.K., Schmidtmann I., Bier C., RA Docter D., Brochhausen C., Helling K., Brieger J., Stauber R.H., Mann W.J.; RT "Expression analysis suggests a potential cytoprotective role of Birc5 in RT the inner ear."; RL Mol. Cell. Neurosci. 45:297-305(2010). RN [37] RP FUNCTION, HISTONE-BINDING, AND MUTAGENESIS OF ARG-18; TRP-25; CYS-33; RP CYS-57 AND TRP-67. RX PubMed=20929775; DOI=10.1126/science.1194498; RA Yamagishi Y., Honda T., Tanno Y., Watanabe Y.; RT "Two histone marks establish the inner centromere and chromosome bi- RT orientation."; RL Science 330:239-243(2010). RN [38] RP PHOSPHORYLATION AT THR-48, AND MUTAGENESIS OF THR-48. RX PubMed=21252625; DOI=10.4161/cc.10.3.14758; RA Barrett R.M., Colnaghi R., Wheatley S.P.; RT "Threonine 48 in the BIR domain of survivin is critical to its mitotic and RT anti-apoptotic activities and can be phosphorylated by CK2 in vitro."; RL Cell Cycle 10:538-548(2011). RN [39] RP INTERACTION WITH JTB. RX PubMed=21225229; DOI=10.3892/ijo.2011.900; RA Platica M., Ionescu A., Ivan E., Holland J.F., Mandeli J., Platica O.; RT "PAR, a protein involved in the cell cycle, is functionally related to RT chromosomal passenger proteins."; RL Int. J. Oncol. 38:777-785(2011). RN [40] RP FUNCTION, SUBUNIT, AND INTERACTION WITH XIAP/BIRC4 AND DIABLO/SMAC. RX PubMed=21536684; DOI=10.1074/jbc.m111.237586; RA Pavlyukov M.S., Antipova N.V., Balashova M.V., Vinogradova T.V., RA Kopantzev E.P., Shakhparonov M.I.; RT "Survivin monomer plays an essential role in apoptosis regulation."; RL J. Biol. Chem. 286:23296-23307(2011). RN [41] RP PHOSPHORYLATION AT THR-34 BY CDK15. RX PubMed=24866247; DOI=10.1016/j.bbrc.2014.05.070; RA Park M.H., Kim S.Y., Kim Y.J., Chung Y.H.; RT "ALS2CR7 (CDK15) attenuates TRAIL induced apoptosis by inducing RT phosphorylation of survivin Thr34."; RL Biochem. Biophys. Res. Commun. 450:129-134(2014). RN [42] RP UBIQUITINATION. RX PubMed=24793696; DOI=10.1016/j.molcel.2014.03.046; RA Li Z., Pei X.H., Yan J., Yan F., Cappell K.M., Whitehurst A.W., Xiong Y.; RT "CUL9 mediates the functions of the 3M complex and ubiquitylates survivin RT to maintain genome integrity."; RL Mol. Cell 54:805-819(2014). RN [43] RP FUNCTION, INTERACTION WITH FBXL7, AND MUTAGENESIS OF 90-LYS-LYS-91 AND RP GLU-126. RX PubMed=25778398; DOI=10.1074/jbc.m114.629931; RA Liu Y., Lear T., Iannone O., Shiva S., Corey C., Rajbhandari S., Jerome J., RA Chen B.B., Mallampalli R.K.; RT "The Proapoptotic F-box Protein Fbxl7 Regulates Mitochondrial Function by RT Mediating the Ubiquitylation and Proteasomal Degradation of Survivin."; RL J. Biol. Chem. 290:11843-11852(2015). RN [44] RP SUBUNIT, AND PHOSPHORYLATION AT SER-20. RX PubMed=27332895; DOI=10.1371/journal.pone.0157305; RA Sasai K., Katayama H., Hawke D.H., Sen S.; RT "Aurora-C interactions with survivin and INCENP reveal shared and distinct RT features compared with Aurora-B chromosome passenger protein complex."; RL PLoS ONE 11:E0157305-E0157305(2016). RN [45] RP FUNCTION, AND INTERACTION WITH FBXL7. RX PubMed=28218735; DOI=10.1038/oncsis.2016.80; RA Kamran M., Long Z.J., Xu D., Lv S.S., Liu B., Wang C.L., Xu J., Lam E.W., RA Liu Q.; RT "Aurora kinase A regulates Survivin stability through targeting FBXL7 in RT gastric cancer drug resistance and prognosis."; RL Oncogenesis 6:E298-E298(2017). RN [46] RP INTERACTION WITH EPSTEIN-BARR VIRUS EBNA1 (MICROBIAL INFECTION). RX PubMed=28077791; DOI=10.18632/oncotarget.14540; RA Dheekollu J., Malecka K., Wiedmer A., Delecluse H.J., Chiang A.K., RA Altieri D.C., Messick T.E., Lieberman P.M.; RT "Carcinoma-risk variant of EBNA1 deregulates Epstein-Barr Virus episomal RT latency."; RL Oncotarget 8:7248-7264(2017). RN [47] RP DEUBIQUITINATION BY USP35 AND USP38. RX PubMed=34438346; DOI=10.1016/j.bbrc.2021.08.050; RA Wang W., Lin H., Zheng E., Hou Z., Liu Y., Huang W., Chen D., Feng J., RA Li J., Li L.; RT "Regulation of survivin protein stability by USP35 is evolutionarily RT conserved."; RL Biochem. Biophys. Res. Commun. 574:48-55(2021). RN [48] RP X-RAY CRYSTALLOGRAPHY (2.71 ANGSTROMS) OF ISOFORM 1. RX PubMed=10949039; DOI=10.1016/s1097-2765(05)00020-1; RA Chantalat L., Skoufias D.A., Kleman J.P., Jung B., Dideberg O., RA Margolis R.L.; RT "Crystal structure of human survivin reveals a bow tie-shaped dimer with RT two unusual alpha-helical extensions."; RL Mol. Cell 6:183-189(2000). RN [49] RP X-RAY CRYSTALLOGRAPHY (2.58 ANGSTROMS) OF ISOFORM 1. RX PubMed=10876248; DOI=10.1038/76838; RA Verdecia M.A., Huang H., Dutil E., Kaiser D.A., Hunter T., Noel J.P.; RT "Structure of the human anti-apoptotic protein survivin reveals a dimeric RT arrangement."; RL Nat. Struct. Biol. 7:602-608(2000). RN [50] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) IN COMPLEX WITH ZINC IONS, SUBUNIT, RP AND INTERACTION WITH CDCA8 AND INCENP. RX PubMed=17956729; DOI=10.1016/j.cell.2007.07.045; RA Jeyaprakash A.A., Klein U.R., Lindner D., Ebert J., Nigg E.A., Conti E.; RT "Structure of a Survivin-Borealin-INCENP core complex reveals how RT chromosomal passengers travel together."; RL Cell 131:271-285(2007). RN [51] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS). RX PubMed=19530738; DOI=10.1021/bi900530v; RA Bourhis E., Lingel A., Phung Q., Fairbrother W.J., Cochran A.G.; RT "Phosphorylation of a borealin dimerization domain is required for proper RT chromosome segregation."; RL Biochemistry 48:6783-6793(2009). CC -!- FUNCTION: Multitasking protein that has dual roles in promoting cell CC proliferation and preventing apoptosis (PubMed:20627126, CC PubMed:21364656, PubMed:25778398, PubMed:28218735, PubMed:9859993). CC Component of a chromosome passage protein complex (CPC) which is CC essential for chromosome alignment and segregation during mitosis and CC cytokinesis (PubMed:16322459). Acts as an important regulator of the CC localization of this complex; directs CPC movement to different CC locations from the inner centromere during prometaphase to midbody CC during cytokinesis and participates in the organization of the center CC spindle by associating with polymerized microtubules (PubMed:20826784). CC Involved in the recruitment of CPC to centromeres during early mitosis CC via association with histone H3 phosphorylated at 'Thr-3' (H3pT3) CC during mitosis (PubMed:20929775). The complex with RAN plays a role in CC mitotic spindle formation by serving as a physical scaffold to help CC deliver the RAN effector molecule TPX2 to microtubules CC (PubMed:18591255). May counteract a default induction of apoptosis in CC G2/M phase (PubMed:9859993). The acetylated form represses STAT3 CC transactivation of target gene promoters (PubMed:20826784). May play a CC role in neoplasia (PubMed:10626797). Inhibitor of CASP3 and CASP7 CC (PubMed:21536684). Essential for the maintenance of mitochondrial CC integrity and function (PubMed:25778398). Isoform 2 and isoform 3 do CC not appear to play vital roles in mitosis (PubMed:12773388, CC PubMed:16291752). Isoform 3 shows a marked reduction in its anti- CC apoptotic effects when compared with the displayed wild-type isoform CC (PubMed:10626797). {ECO:0000269|PubMed:10626797, CC ECO:0000269|PubMed:12773388, ECO:0000269|PubMed:16291752, CC ECO:0000269|PubMed:16322459, ECO:0000269|PubMed:18591255, CC ECO:0000269|PubMed:20627126, ECO:0000269|PubMed:20826784, CC ECO:0000269|PubMed:20929775, ECO:0000269|PubMed:21364656, CC ECO:0000269|PubMed:21536684, ECO:0000269|PubMed:25778398, CC ECO:0000269|PubMed:28218735, ECO:0000269|PubMed:9859993}. CC -!- SUBUNIT: Monomer or homodimer. Exists as a homodimer in the apo state CC and as a monomer in the CPC-bound state. The monomer protects cells CC against apoptosis more efficiently than the dimer. Only the dimeric CC form is capable of enhancing tubulin stability in cells. When CC phosphorylated, interacts with LAMTOR5/HBXIP; the resulting complex CC binds pro-CASP9, as well as active CASP9, but much less efficiently. CC Component of the chromosomal passenger complex (CPC) composed of at CC least BIRC5/survivin, CDCA8/borealin, INCENP, AURKB or AURKC; in the CC complex forms a triple-helix bundle-based subcomplex with INCENP and CC CDCA8 (PubMed:17956729). Interacts with JTB. Interacts (via BIR domain) CC with histone H3 phosphorylated at 'Thr-3' (H3pT3). Interacts with EVI5. CC Interacts with GTP-bound RAN in both the S and M phases of the cell CC cycle. Interacts with USP9X. Interacts with tubulin. Interacts with CC BIRC2/c-IAP1. The acetylated form at Lys-129 interacts with STAT3. The CC monomeric form deacetylated at Lys-129 interacts with XPO1/CRM1. The CC monomeric form interacts with XIAP/BIRC4. Both the dimeric and CC monomeric form can interact with DIABLO/SMAC. Interacts with CC BIRC6/bruce. Interacts with FBXL7; this interaction facilitates the CC polyubiquitination and subsequent proteasomal degradation of BIRC5 by CC the SCF(FBXL7) E3 ubiquitin-protein ligase complex (PubMed:25778398, CC PubMed:28218735). {ECO:0000269|PubMed:12773388, CC ECO:0000269|PubMed:14610074, ECO:0000269|PubMed:15249581, CC ECO:0000269|PubMed:15665297, ECO:0000269|PubMed:16239925, CC ECO:0000269|PubMed:16291752, ECO:0000269|PubMed:16322459, CC ECO:0000269|PubMed:16427043, ECO:0000269|PubMed:16436504, CC ECO:0000269|PubMed:16764853, ECO:0000269|PubMed:17956729, CC ECO:0000269|PubMed:18329369, ECO:0000269|PubMed:18591255, CC ECO:0000269|PubMed:20826784, ECO:0000269|PubMed:21225229, CC ECO:0000269|PubMed:21536684, ECO:0000269|PubMed:25778398, CC ECO:0000269|PubMed:28218735}. CC -!- SUBUNIT: (Microbial infection) Interacts with Epstein-Barr virus (EBV) CC EBNA1; this interaction is probably important for EBV episome CC maintenance in Burkitt's lymphoma cells. {ECO:0000269|PubMed:28077791}. CC -!- INTERACTION: CC O15392; Q92870-2: APBB2; NbExp=3; IntAct=EBI-518823, EBI-21535880; CC O15392; P05067: APP; NbExp=3; IntAct=EBI-518823, EBI-77613; CC O15392; P05067-2: APP; NbExp=3; IntAct=EBI-518823, EBI-17264467; CC O15392; O14965: AURKA; NbExp=2; IntAct=EBI-518823, EBI-448680; CC O15392; Q96GD4: AURKB; NbExp=13; IntAct=EBI-518823, EBI-624291; CC O15392; Q9UQB9: AURKC; NbExp=10; IntAct=EBI-518823, EBI-3926851; CC O15392; Q14457: BECN1; NbExp=3; IntAct=EBI-518823, EBI-949378; CC O15392; O15392: BIRC5; NbExp=2; IntAct=EBI-518823, EBI-518823; CC O15392; Q15834: CCDC85B; NbExp=3; IntAct=EBI-518823, EBI-739674; CC O15392; Q53HL2: CDCA8; NbExp=21; IntAct=EBI-518823, EBI-979174; CC O15392; P06493: CDK1; NbExp=6; IntAct=EBI-518823, EBI-444308; CC O15392; Q14203-5: DCTN1; NbExp=3; IntAct=EBI-518823, EBI-25840379; CC O15392; Q9NR28: DIABLO; NbExp=2; IntAct=EBI-518823, EBI-517508; CC O15392; Q86XJ1: GAS2L3; NbExp=4; IntAct=EBI-518823, EBI-9248152; CC O15392; Q8TB36: GDAP1; NbExp=3; IntAct=EBI-518823, EBI-11110431; CC O15392; P42858: HTT; NbExp=15; IntAct=EBI-518823, EBI-466029; CC O15392; Q9NQS7: INCENP; NbExp=11; IntAct=EBI-518823, EBI-307907; CC O15392; O43504: LAMTOR5; NbExp=3; IntAct=EBI-518823, EBI-713382; CC O15392; Q96CV9: OPTN; NbExp=3; IntAct=EBI-518823, EBI-748974; CC O15392; Q7Z412: PEX26; NbExp=3; IntAct=EBI-518823, EBI-752057; CC O15392; Q9BXM7: PINK1; NbExp=3; IntAct=EBI-518823, EBI-2846068; CC O15392; P62826: RAN; NbExp=7; IntAct=EBI-518823, EBI-286642; CC O15392; P37840: SNCA; NbExp=3; IntAct=EBI-518823, EBI-985879; CC O15392; Q13148: TARDBP; NbExp=6; IntAct=EBI-518823, EBI-372899; CC O15392; P09936: UCHL1; NbExp=3; IntAct=EBI-518823, EBI-714860; CC O15392; O14980: XPO1; NbExp=2; IntAct=EBI-518823, EBI-355867; CC O15392-1; Q96GD4: AURKB; NbExp=2; IntAct=EBI-518838, EBI-624291; CC O15392-1; O15392-1: BIRC5; NbExp=2; IntAct=EBI-518838, EBI-518838; CC O15392-1; O15392-2: BIRC5; NbExp=2; IntAct=EBI-518838, EBI-518842; CC O15392-1; Q53HL2: CDCA8; NbExp=2; IntAct=EBI-518838, EBI-979174; CC O15392-2; Q96GD4: AURKB; NbExp=2; IntAct=EBI-518842, EBI-624291; CC O15392-2; Q53HL2: CDCA8; NbExp=2; IntAct=EBI-518842, EBI-979174; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:20627126, CC ECO:0000269|PubMed:20826784, ECO:0000269|PubMed:21364656}. Nucleus CC {ECO:0000269|PubMed:20627126, ECO:0000269|PubMed:20826784, CC ECO:0000269|PubMed:21364656}. Chromosome {ECO:0000269|PubMed:14610074}. CC Chromosome, centromere {ECO:0000269|PubMed:11084331, CC ECO:0000269|PubMed:14610074, ECO:0000269|PubMed:16322459}. Cytoplasm, CC cytoskeleton, spindle {ECO:0000269|PubMed:11084331}. Chromosome, CC centromere, kinetochore {ECO:0000269|PubMed:11084331}. Midbody CC {ECO:0000269|PubMed:15665297}. Note=Localizes at the centromeres from CC prophase to metaphase, at the spindle midzone during anaphase and a the CC midbody during telophase and cytokinesis. Accumulates in the nucleus CC upon treatment with leptomycin B (LMB), a XPO1/CRM1 nuclear export CC inhibitor (By similarity). Localizes on chromosome arms and inner CC centromeres from prophase through metaphase. Localizes to kinetochores CC in metaphase, distributes to the midzone microtubules in anaphase and CC at telophase, localizes exclusively to the midbody (PubMed:11084331). CC Colocalizes with AURKB at mitotic chromosomes (PubMed:14610074). CC Acetylation at Lys-129 directs its localization to the nucleus by CC enhancing homodimerization and thereby inhibiting XPO1/CRM1-mediated CC nuclear export (PubMed:20826784). {ECO:0000250|UniProtKB:E3SCZ8, CC ECO:0000269|PubMed:11084331, ECO:0000269|PubMed:14610074, CC ECO:0000269|PubMed:20826784}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=7; CC Name=1; Synonyms=Alpha; CC IsoId=O15392-1; Sequence=Displayed; CC Name=2; Synonyms=2B, Beta; CC IsoId=O15392-2; Sequence=VSP_002454; CC Name=3; Synonyms=DeltaEx3; CC IsoId=O15392-3; Sequence=VSP_020338; CC Name=4; Synonyms=3B; CC IsoId=O15392-4; Sequence=VSP_020342; CC Name=5; Synonyms=SI; CC IsoId=O15392-5; Sequence=VSP_020341; CC Name=6; Synonyms=3 alpha; CC IsoId=O15392-6; Sequence=VSP_020339; CC Name=7; Synonyms=2 alpha; CC IsoId=O15392-7; Sequence=VSP_020340; CC -!- TISSUE SPECIFICITY: Expressed only in fetal kidney and liver, and to CC lesser extent, lung and brain (PubMed:10626797). Abundantly expressed CC in adenocarcinoma (lung, pancreas, colon, breast, and prostate) and in CC high-grade lymphomas (PubMed:14741722, PubMed:16329164). Also expressed CC in various renal cell carcinoma cell lines (PubMed:10626797). Expressed CC in cochlea including the organ of Corti, the lateral wall, the CC interdental cells of the Limbus as well as in Schwann cells and cells CC of the cochlear nerve and the spiral ganglions (at protein level). Not CC expressed in cells of the inner and outer sulcus or the Reissner's CC membrane (at protein level) (PubMed:20627126, PubMed:21364656). CC {ECO:0000269|PubMed:10626797, ECO:0000269|PubMed:14741722, CC ECO:0000269|PubMed:16329164, ECO:0000269|PubMed:20627126, CC ECO:0000269|PubMed:21364656}. CC -!- DEVELOPMENTAL STAGE: Expression is cell cycle-dependent and peaks at CC mitosis. {ECO:0000269|PubMed:18591255}. CC -!- INDUCTION: Up-regulated by COMP. {ECO:0000269|PubMed:17993464}. CC -!- DOMAIN: The BIR repeat is necessary and sufficient for LAMTOR5 binding. CC {ECO:0000269|PubMed:12773388}. CC -!- PTM: Ubiquitinated by the Cul9-RING ubiquitin-protein ligase complex, CC leading to its degradation. Ubiquitination is required for centrosomal CC targeting. Deubiquitinated by USP35 or USP38; leading to stabilization CC (PubMed:34438346). {ECO:0000269|PubMed:16322459, CC ECO:0000269|PubMed:24793696, ECO:0000269|PubMed:34438346}. CC -!- PTM: In vitro phosphorylation at Thr-117 by AURKB prevents interaction CC with INCENP and localization to mitotic chromosomes (PubMed:14610074). CC Phosphorylation at Thr-48 by CK2 is critical for its mitotic and anti- CC apoptotic activities (PubMed:21252625). Phosphorylation at Thr-34 by CC CDK15 is critical for its anti-apoptotic activity (PubMed:24866247). CC Phosphorylation at Ser-20 by AURKC is critical for regulation of proper CC chromosome alignment and segregation, and possibly cytokinesis. CC {ECO:0000269|PubMed:11069302, ECO:0000269|PubMed:14610074, CC ECO:0000269|PubMed:21252625, ECO:0000269|PubMed:24866247, CC ECO:0000269|PubMed:27332895}. CC -!- PTM: Acetylation at Lys-129 by CBP results in its homodimerization, CC while deacetylation promotes the formation of monomers which CC heterodimerize with XPO1/CRM1 which facilitates its nuclear export. The CC acetylated form represses STAT3 transactivation. The dynamic CC equilibrium between its acetylation and deacetylation at Lys-129 CC determines its interaction with XPO1/CRM1, its subsequent subcellular CC localization, and its ability to inhibit STAT3 transactivation. CC {ECO:0000269|PubMed:20826784}. CC -!- SIMILARITY: Belongs to the IAP family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U75285; AAC51660.1; -; Genomic_DNA. DR EMBL; AF077350; AAD34226.1; -; mRNA. DR EMBL; AB154416; BAD11155.1; -; mRNA. DR EMBL; AY830084; AAW22624.1; -; mRNA. DR EMBL; AB028869; BAA93676.1; -; mRNA. DR EMBL; AY927772; AAY15202.1; -; mRNA. DR EMBL; DQ227257; ABB76601.1; -; mRNA. DR EMBL; DQ310375; ABC42341.1; -; mRNA. DR EMBL; DQ310376; ABC42342.1; -; mRNA. DR EMBL; DQ310377; ABC42343.1; -; mRNA. DR EMBL; DQ310378; ABC42344.1; -; mRNA. DR EMBL; DQ310379; ABC42345.1; -; mRNA. DR EMBL; CR541740; CAG46540.1; -; mRNA. DR EMBL; AK223428; BAD97148.1; -; mRNA. DR EMBL; AK311917; BAG34858.1; -; mRNA. DR EMBL; AY795969; AAV40840.1; -; Genomic_DNA. DR EMBL; AC087645; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471099; EAW89514.1; -; Genomic_DNA. DR EMBL; BC008718; AAH08718.1; -; mRNA. DR EMBL; BC034148; AAH34148.1; -; mRNA. DR EMBL; BC065497; AAH65497.1; -; mRNA. DR CCDS; CCDS11755.1; -. [O15392-1] DR CCDS; CCDS32751.1; -. [O15392-3] DR CCDS; CCDS32752.1; -. [O15392-2] DR RefSeq; NP_001012270.1; NM_001012270.2. [O15392-3] DR RefSeq; NP_001012271.1; NM_001012271.1. DR RefSeq; NP_001159.2; NM_001168.2. DR PDB; 1E31; X-ray; 2.71 A; A/B=1-142. DR PDB; 1F3H; X-ray; 2.58 A; A/B=1-142. DR PDB; 1XOX; NMR; -; A/B=1-117. DR PDB; 2QFA; X-ray; 1.40 A; A=1-142. DR PDB; 2RAW; X-ray; 2.40 A; A=1-142. DR PDB; 2RAX; X-ray; 3.30 A; A/E/X=1-120. DR PDB; 3UEC; X-ray; 2.18 A; A=1-142. DR PDB; 3UED; X-ray; 2.70 A; A/C=1-142. DR PDB; 3UEE; X-ray; 2.61 A; A/C=1-142. DR PDB; 3UEF; X-ray; 2.45 A; A/C=1-142. DR PDB; 3UEG; X-ray; 2.80 A; A/B=1-142. DR PDB; 3UEH; X-ray; 2.60 A; A/B=1-142. DR PDB; 3UEI; X-ray; 2.70 A; A/B=1-142. DR PDB; 3UIG; X-ray; 2.40 A; A/B=1-142. DR PDB; 3UIH; X-ray; 2.40 A; A/B=1-142. DR PDB; 3UII; X-ray; 2.60 A; A/B=1-142. DR PDB; 3UIJ; X-ray; 2.70 A; A/B=1-142. DR PDB; 3UIK; X-ray; 2.70 A; A/B=1-142. DR PDB; 4A0I; X-ray; 2.60 A; A/B=1-142. DR PDB; 4A0J; X-ray; 2.80 A; A/B=1-142. DR PDB; 4A0N; X-ray; 2.74 A; A=1-142. DR PDB; 6SHO; X-ray; 3.20 A; A/B=1-142. DR PDB; 6YIE; X-ray; 3.49 A; A/D=1-142. DR PDB; 6YIF; X-ray; 1.81 A; A=1-142. DR PDB; 6YIH; X-ray; 2.55 A; A=1-142. DR PDB; 7LBK; X-ray; 2.70 A; A/B=1-142. DR PDB; 7LBO; X-ray; 2.50 A; A/B=1-142. DR PDB; 7LBP; X-ray; 2.60 A; A/C=1-142. DR PDB; 7LBQ; X-ray; 2.69 A; A=1-142. DR PDB; 8RUP; EM; 2.42 A; K=1-142. DR PDBsum; 1E31; -. DR PDBsum; 1F3H; -. DR PDBsum; 1XOX; -. DR PDBsum; 2QFA; -. DR PDBsum; 2RAW; -. DR PDBsum; 2RAX; -. DR PDBsum; 3UEC; -. DR PDBsum; 3UED; -. DR PDBsum; 3UEE; -. DR PDBsum; 3UEF; -. DR PDBsum; 3UEG; -. DR PDBsum; 3UEH; -. DR PDBsum; 3UEI; -. DR PDBsum; 3UIG; -. DR PDBsum; 3UIH; -. DR PDBsum; 3UII; -. DR PDBsum; 3UIJ; -. DR PDBsum; 3UIK; -. DR PDBsum; 4A0I; -. DR PDBsum; 4A0J; -. DR PDBsum; 4A0N; -. DR PDBsum; 6SHO; -. DR PDBsum; 6YIE; -. DR PDBsum; 6YIF; -. DR PDBsum; 6YIH; -. DR PDBsum; 7LBK; -. DR PDBsum; 7LBO; -. DR PDBsum; 7LBP; -. DR PDBsum; 7LBQ; -. DR PDBsum; 8RUP; -. DR AlphaFoldDB; O15392; -. DR BMRB; O15392; -. DR EMDB; EMD-19513; -. DR SASBDB; O15392; -. DR SMR; O15392; -. DR BioGRID; 106829; 111. DR ComplexPortal; CPX-111; Survivin homodimer complex. DR ComplexPortal; CPX-116; Chromosomal passenger complex. DR CORUM; O15392; -. DR DIP; DIP-34662N; -. DR ELM; O15392; -. DR FunCoup; O15392; 1567. DR IntAct; O15392; 57. DR MINT; O15392; -. DR STRING; 9606.ENSP00000301633; -. DR BindingDB; O15392; -. DR ChEMBL; CHEMBL5989; -. DR DrugBank; DB16095; APG-1387. DR DrugBank; DB04115; Berberine. DR DrugBank; DB12085; LCL-161. DR DrugBank; DB05141; LY2181308. DR DrugBank; DB00206; Reserpine. DR DrugBank; DB16305; Xevinapant. DR DrugCentral; O15392; -. DR GuidetoPHARMACOLOGY; 2795; -. DR MEROPS; I32.005; -. DR iPTMnet; O15392; -. DR PhosphoSitePlus; O15392; -. DR BioMuta; BIRC5; -. DR jPOST; O15392; -. DR MassIVE; O15392; -. DR PeptideAtlas; O15392; -. DR ProteomicsDB; 48627; -. [O15392-1] DR ProteomicsDB; 48628; -. [O15392-2] DR ProteomicsDB; 48629; -. [O15392-3] DR ProteomicsDB; 48630; -. [O15392-4] DR ProteomicsDB; 48631; -. [O15392-5] DR ProteomicsDB; 48632; -. [O15392-6] DR ProteomicsDB; 48633; -. [O15392-7] DR Pumba; O15392; -. DR ABCD; O15392; 5 sequenced antibodies. DR Antibodypedia; 1073; 1831 antibodies from 53 providers. DR DNASU; 332; -. DR Ensembl; ENST00000374948.6; ENSP00000364086.1; ENSG00000089685.16. [O15392-3] DR Ensembl; ENST00000590449.1; ENSP00000465868.1; ENSG00000089685.16. [O15392-7] DR Ensembl; ENST00000590925.6; ENSP00000467336.1; ENSG00000089685.16. [O15392-4] DR Ensembl; ENST00000592734.5; ENSP00000466617.1; ENSG00000089685.16. [O15392-6] DR GeneID; 332; -. DR KEGG; hsa:332; -. DR UCSC; uc002jvh.4; human. [O15392-1] DR AGR; HGNC:593; -. DR CIViC; 332; 2 evidence items across 2 molecular profiles. DR ClinPGx; PA25362; -. DR CTD; 332; -. DR DisGeNET; 332; -. DR GeneCards; BIRC5; -. DR HGNC; HGNC:593; BIRC5. DR HPA; ENSG00000089685; Tissue enhanced (bone marrow, lymphoid tissue, testis). DR MIM; 603352; gene. DR OpenTargets; ENSG00000089685; -. DR VEuPathDB; HostDB:ENSG00000089685; -. DR GeneTree; ENSGT00510000047537; -. DR HOGENOM; CLU_1869818_0_0_1; -. DR InParanoid; O15392; -. DR OrthoDB; 2196114at2759; -. DR PAN-GO; O15392; 6 GO annotations based on evolutionary models. DR PathwayCommons; O15392; -. DR Reactome; R-HSA-141444; Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal. DR Reactome; R-HSA-2467813; Separation of Sister Chromatids. DR Reactome; R-HSA-2500257; Resolution of Sister Chromatid Cohesion. DR Reactome; R-HSA-4615885; SUMOylation of DNA replication proteins. DR Reactome; R-HSA-5663220; RHO GTPases Activate Formins. DR Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling. DR Reactome; R-HSA-6803205; TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain. DR Reactome; R-HSA-68877; Mitotic Prometaphase. DR Reactome; R-HSA-8951664; Neddylation. DR Reactome; R-HSA-9648025; EML4 and NUDC in mitotic spindle formation. DR SignaLink; O15392; -. DR SIGNOR; O15392; -. DR Agora; ENSG00000089685; -. DR BioGRID-ORCS; 332; 826 hits in 1161 CRISPR screens. DR CD-CODE; 3F4CB227; Synthetic Condensate 000322. DR CD-CODE; 45F3D8EC; Synthetic Condensate 000342. DR CD-CODE; 7230F6EA; Synthetic Condensate 000328. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; BIRC5; human. DR EvolutionaryTrace; O15392; -. DR GeneWiki; Survivin; -. DR GenomeRNAi; 332; -. DR Pharos; O15392; Tchem. DR PRO; PR:O15392; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; O15392; protein. DR Bgee; ENSG00000089685; Expressed in ventricular zone and 127 other cell types or tissues. DR ExpressionAtlas; O15392; baseline and differential. DR GO; GO:0005814; C:centriole; IDA:UniProtKB. DR GO; GO:0032133; C:chromosome passenger complex; IPI:UniProtKB. DR GO; GO:0000775; C:chromosome, centromeric region; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005881; C:cytoplasmic microtubule; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProtKB. DR GO; GO:0031021; C:interphase microtubule organizing center; IDA:UniProtKB. DR GO; GO:0000776; C:kinetochore; IDA:UniProtKB. DR GO; GO:0005874; C:microtubule; IEA:UniProtKB-KW. DR GO; GO:0015630; C:microtubule cytoskeleton; IDA:ComplexPortal. DR GO; GO:0030496; C:midbody; IDA:UniProtKB. DR GO; GO:0000228; C:nuclear chromosome; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB. DR GO; GO:0005876; C:spindle microtubule; IDA:UniProtKB. DR GO; GO:0051233; C:spindle midzone; IBA:GO_Central. DR GO; GO:1990713; C:survivin complex; IPI:ComplexPortal. DR GO; GO:0050897; F:cobalt ion binding; NAS:UniProtKB. DR GO; GO:0004869; F:cysteine-type endopeptidase inhibitor activity; IEA:UniProtKB-KW. DR GO; GO:0043027; F:cysteine-type endopeptidase inhibitor activity involved in apoptotic process; IMP:UniProtKB. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0008017; F:microtubule binding; IDA:UniProtKB. DR GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0051087; F:protein-folding chaperone binding; IPI:UniProtKB. DR GO; GO:0031267; F:small GTPase binding; IPI:UniProtKB. DR GO; GO:0015631; F:tubulin binding; IDA:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0051301; P:cell division; IMP:UniProtKB. DR GO; GO:0050000; P:chromosome localization; IMP:UniProtKB. DR GO; GO:0007059; P:chromosome segregation; IBA:GO_Central. DR GO; GO:0000086; P:G2/M transition of mitotic cell cycle; IDA:UniProtKB. DR GO; GO:0000278; P:mitotic cell cycle; TAS:UniProtKB. DR GO; GO:0000281; P:mitotic cytokinesis; IMP:UniProtKB. DR GO; GO:0090307; P:mitotic spindle assembly; NAS:ComplexPortal. DR GO; GO:0007094; P:mitotic spindle assembly checkpoint signaling; IMP:UniProtKB. DR GO; GO:0051256; P:mitotic spindle midzone assembly; NAS:ComplexPortal. DR GO; GO:0007052; P:mitotic spindle organization; IBA:GO_Central. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; IMP:UniProtKB. DR GO; GO:1902425; P:positive regulation of attachment of mitotic spindle microtubules to kinetochore; NAS:ComplexPortal. DR GO; GO:0008284; P:positive regulation of cell population proliferation; TAS:UniProtKB. DR GO; GO:0031536; P:positive regulation of exit from mitosis; IMP:UniProtKB. DR GO; GO:0045931; P:positive regulation of mitotic cell cycle; IMP:UniProtKB. DR GO; GO:0090267; P:positive regulation of mitotic cell cycle spindle assembly checkpoint; NAS:ComplexPortal. DR GO; GO:1903490; P:positive regulation of mitotic cytokinesis; NAS:ComplexPortal. DR GO; GO:1901970; P:positive regulation of mitotic sister chromatid separation; NAS:ComplexPortal. DR GO; GO:0031503; P:protein-containing complex localization; IMP:UniProtKB. DR GO; GO:0007605; P:sensory perception of sound; IEP:UniProtKB. DR CDD; cd00022; BIR; 1. DR DisProt; DP03719; -. DR FunFam; 1.10.1170.10:FF:000009; Baculoviral IAP repeat-containing protein 5; 1. DR Gene3D; 1.10.1170.10; Inhibitor Of Apoptosis Protein (2mihbC-IAP-1), Chain A; 1. DR IDEAL; IID00186; -. DR InterPro; IPR051190; Baculoviral_IAP. DR InterPro; IPR001370; BIR_rpt. DR PANTHER; PTHR46771:SF3; BACULOVIRAL IAP REPEAT-CONTAINING PROTEIN 5; 1. DR PANTHER; PTHR46771; DETERIN; 1. DR Pfam; PF00653; BIR; 1. DR SMART; SM00238; BIR; 1. DR SUPFAM; SSF57924; Inhibitor of apoptosis (IAP) repeat; 1. DR PROSITE; PS50143; BIR_REPEAT_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Apoptosis; Cell cycle; KW Cell division; Centromere; Chromosome; Chromosome partition; Cytoplasm; KW Cytoskeleton; Host-virus interaction; Kinetochore; Metal-binding; KW Microtubule; Mitosis; Nucleus; Phosphoprotein; Protease inhibitor; KW Proteomics identification; Reference proteome; Repressor; KW Thiol protease inhibitor; Transcription; Transcription regulation; KW Ubl conjugation; Zinc. FT CHAIN 1..142 FT /note="Baculoviral IAP repeat-containing protein 5" FT /id="PRO_0000122356" FT REPEAT 18..88 FT /note="BIR" FT BINDING 57 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:17956729, FT ECO:0007744|PDB:2QFA" FT BINDING 60 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:17956729, FT ECO:0007744|PDB:2QFA" FT BINDING 77 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:17956729, FT ECO:0007744|PDB:2QFA" FT BINDING 84 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:17956729, FT ECO:0007744|PDB:2QFA" FT SITE 126 FT /note="Interaction with FBXL7" FT /evidence="ECO:0000269|PubMed:25778398" FT MOD_RES 20 FT /note="Phosphoserine; by AURKC" FT /evidence="ECO:0000269|PubMed:27332895" FT MOD_RES 23 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:20826784" FT MOD_RES 34 FT /note="Phosphothreonine; by CDK1 and CDK15" FT /evidence="ECO:0000269|PubMed:11069302, FT ECO:0000269|PubMed:24866247, ECO:0007744|PubMed:18691976" FT MOD_RES 48 FT /note="Phosphothreonine; by CK2; in vitro" FT /evidence="ECO:0000269|PubMed:21252625" FT MOD_RES 90 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:20826784" FT MOD_RES 110 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:20826784" FT MOD_RES 112 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:20826784" FT MOD_RES 115 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:20826784" FT MOD_RES 117 FT /note="Phosphothreonine; by AURKB" FT /evidence="ECO:0000269|PubMed:14610074" FT MOD_RES 121 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:20826784" FT MOD_RES 129 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:20826784" FT VAR_SEQ 74..142 FT /note="IEEHKKHSSGCAFLSVKKQFEELTLGEFLKLDRERAKNKIAKETNNKKKEFE FT ETAKKVRRAIEQLAAMD -> MQRKPTIRRKNLRKLRRKCAVPSSSWLPWIEASGRSCL FT VPEWLHHFQGLFPGATSLPVGPLAMS (in isoform 3)" FT /evidence="ECO:0000303|PubMed:10626797" FT /id="VSP_020338" FT VAR_SEQ 74..142 FT /note="IEEHKKHSSGCAFLSVKKQFEELTLGEFLKLDRERAKNKIAKETNNKKKEFE FT ETAKKVRRAIEQLAAMD -> MRELC (in isoform 6)" FT /evidence="ECO:0000303|Ref.8" FT /id="VSP_020339" FT VAR_SEQ 74..142 FT /note="IEEHKKHSSGCAFLSVKKQFEELTLGEFLKLDRERAKNKIAKETNNKKKEFE FT ETAKKVRRAIEQLAAMD -> M (in isoform 7)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_020340" FT VAR_SEQ 74 FT /note="I -> IGPGTVAYACNTSTLGGRGGRITR (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10626797, ECO:0000303|Ref.6" FT /id="VSP_002454" FT VAR_SEQ 105..142 FT /note="DRERAKNKIAKETNNKKKEFEETAKKVRRAIEQLAAMD -> VRETLPPPRS FT FIR (in isoform 5)" FT /evidence="ECO:0000303|PubMed:16329164" FT /id="VSP_020341" FT VAR_SEQ 114..142 FT /note="AKETNNKKKEFEETAKKVRRAIEQLAAMD -> ERALLAE (in isoform FT 4)" FT /evidence="ECO:0000303|PubMed:14741722" FT /id="VSP_020342" FT VARIANT 129 FT /note="K -> E (loss of acetylation; localization primarily FT within the cytoplasm; increased likelihood of existing as FT monomer; stronger binding to XPO1/CRM1; dbSNP:rs2071214)" FT /evidence="ECO:0000269|PubMed:16625196, FT ECO:0000269|PubMed:20826784" FT /id="VAR_021071" FT MUTAGEN 18 FT /note="R->A: Disrupts interaction with histone H3pT3, no FT effect on interaction with INCENP." FT /evidence="ECO:0000269|PubMed:20929775" FT MUTAGEN 23 FT /note="K->R: Increases ubiquitination and blocks FT dissociation from centromeres; when associated with R-62; FT R-78 and R-79." FT /evidence="ECO:0000269|PubMed:16322459" FT MUTAGEN 25 FT /note="W->A: Disrupts interaction with histone H3pT3, no FT effect on interaction with INCENP." FT /evidence="ECO:0000269|PubMed:20929775" FT MUTAGEN 33 FT /note="C->R: Disrupts interaction with histone H3pT3, no FT effect on interaction with INCENP." FT /evidence="ECO:0000269|PubMed:20929775" FT MUTAGEN 34 FT /note="T->A: Loss of LAMTOR5 binding." FT /evidence="ECO:0000269|PubMed:12773388" FT MUTAGEN 34 FT /note="T->E: Higher affinity for LAMTOR5 binding." FT /evidence="ECO:0000269|PubMed:12773388" FT MUTAGEN 48 FT /note="T->A,E: Localizes normally during mitosis but cannot FT support cell proliferation. Increased affinity for FT CDCA8/borealin." FT /evidence="ECO:0000269|PubMed:21252625" FT MUTAGEN 57 FT /note="C->A: Disrupts interaction with histone H3pT3, no FT effect on interaction with INCENP." FT /evidence="ECO:0000269|PubMed:20929775" FT MUTAGEN 62 FT /note="K->R: Increases ubiquitination and blocks FT dissociation from centromeres; when associated with R-23; FT R-78 and R-79." FT /evidence="ECO:0000269|PubMed:16322459" FT MUTAGEN 65 FT /note="E->A: Almost abolishes RAN-binding. Does not disrupt FT binding to AURKB or CDCA8. Disrupts mitotic spindle FT assembly. Does not disrupt nuclear export." FT /evidence="ECO:0000269|PubMed:18591255" FT MUTAGEN 67 FT /note="W->A: Disrupts interaction with histone H3pT3, no FT effect on interaction with INCENP." FT /evidence="ECO:0000269|PubMed:20929775" FT MUTAGEN 70 FT /note="D->A: No change. Loss of interaction with AURKB; FT when associated with A-71." FT /evidence="ECO:0000269|PubMed:16762323" FT MUTAGEN 71 FT /note="D->A: No change. Loss of interaction with AURKB; FT when associated with A-70." FT /evidence="ECO:0000269|PubMed:16762323" FT MUTAGEN 78 FT /note="K->R: Increases ubiquitination and blocks FT dissociation from centromeres; when associated with R-23; FT R-62 and R-79." FT /evidence="ECO:0000269|PubMed:16322459" FT MUTAGEN 79 FT /note="K->R: Increases ubiquitination and blocks FT dissociation from centromeres; when associated with R-23; FT R-62 and R-78." FT /evidence="ECO:0000269|PubMed:16322459" FT MUTAGEN 84 FT /note="C->A: Loss of cytoprotection." FT MUTAGEN 90..91 FT /note="KK->RR: Loss of FBXL7 mediated polyubiquitination." FT /evidence="ECO:0000269|PubMed:25778398" FT MUTAGEN 117 FT /note="T->A: Prevents phosphorylation by AURKB. Still able FT to localize correctly but prevents interaction with FT INCENP." FT /evidence="ECO:0000269|PubMed:14610074" FT MUTAGEN 117 FT /note="T->E: Mimics phosphorylation. Disrupts subcellular FT localization during mitosis and prevents interaction with FT INCENP." FT /evidence="ECO:0000269|PubMed:14610074" FT MUTAGEN 126 FT /note="E->A: Loss of FBXL7 binding." FT /evidence="ECO:0000269|PubMed:25778398" FT MUTAGEN 129 FT /note="K->A,Q: Mimics acetylation. Localization primarily FT within the nucleus." FT /evidence="ECO:0000269|PubMed:20826784" FT MUTAGEN 129 FT /note="K->R: Loss of acetylation. Localization primarily FT within the cytoplasm." FT /evidence="ECO:0000269|PubMed:20826784" FT CONFLICT 57..58 FT /note="CF -> WV (in Ref. 5; AAW22624)" FT /evidence="ECO:0000305" FT CONFLICT 58 FT /note="F -> L (in Ref. 11; BAD97148)" FT /evidence="ECO:0000305" FT CONFLICT 128 FT /note="A -> V (in Ref. 9; CAG46540)" FT /evidence="ECO:0000305" FT TURN 8..10 FT /evidence="ECO:0007829|PDB:2QFA" FT HELIX 11..13 FT /evidence="ECO:0007829|PDB:2QFA" FT HELIX 15..20 FT /evidence="ECO:0007829|PDB:2QFA" FT STRAND 29..32 FT /evidence="ECO:0007829|PDB:6YIF" FT HELIX 35..40 FT /evidence="ECO:0007829|PDB:2QFA" FT STRAND 43..45 FT /evidence="ECO:0007829|PDB:2QFA" FT STRAND 49..51 FT /evidence="ECO:0007829|PDB:3UIG" FT STRAND 55..57 FT /evidence="ECO:0007829|PDB:2QFA" FT TURN 58..60 FT /evidence="ECO:0007829|PDB:2QFA" FT STRAND 63..65 FT /evidence="ECO:0007829|PDB:6YIF" FT HELIX 73..80 FT /evidence="ECO:0007829|PDB:2QFA" FT TURN 81..83 FT /evidence="ECO:0007829|PDB:1F3H" FT HELIX 85..88 FT /evidence="ECO:0007829|PDB:2QFA" FT HELIX 93..95 FT /evidence="ECO:0007829|PDB:2QFA" FT HELIX 98..139 FT /evidence="ECO:0007829|PDB:2QFA" SQ SEQUENCE 142 AA; 16389 MW; 9E7CADCDF2822286 CRC64; MGAPTLPPAW QPFLKDHRIS TFKNWPFLEG CACTPERMAE AGFIHCPTEN EPDLAQCFFC FKELEGWEPD DDPIEEHKKH SSGCAFLSVK KQFEELTLGE FLKLDRERAK NKIAKETNNK KKEFEETAKK VRRAIEQLAA MD // ID BRSK1_HUMAN Reviewed; 778 AA. AC Q8TDC3; F1DG44; Q5J5B5; Q8NDD0; Q8NDR4; Q8TDC2; Q96AV4; Q96JL4; DT 29-AUG-2003, integrated into UniProtKB/Swiss-Prot. DT 21-SEP-2011, sequence version 2. DT 28-JAN-2026, entry version 200. DE RecName: Full=Serine/threonine-protein kinase BRSK1; DE EC=2.7.11.1; DE AltName: Full=Brain-selective kinase 1; DE EC=2.7.11.26; DE AltName: Full=Brain-specific serine/threonine-protein kinase 1; DE Short=BR serine/threonine-protein kinase 1; DE AltName: Full=Serine/threonine-protein kinase SAD-B; DE AltName: Full=Synapses of Amphids Defective homolog 1; DE Short=SAD1 homolog; DE Short=hSAD1; GN Name=BRSK1; Synonyms=KIAA1811, SAD1, SADB; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, ACTIVITY REGULATION, RP PHOSPHORYLATION AT THR-189, AND MUTAGENESIS OF THR-189. RX PubMed=14976552; DOI=10.1038/sj.emboj.7600110; RA Lizcano J.M., Goeransson O., Toth R., Deak M., Morrice N.A., Boudeau J., RA Hawley S.A., Udd L., Maekelae T.P., Hardie D.G., Alessi D.R.; RT "LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, RT including MARK/PAR-1."; RL EMBO J. 23:833-843(2004). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBCELLULAR LOCATION, RP TISSUE SPECIFICITY, AND MUTAGENESIS OF LYS-59. RC TISSUE=Testis; RX PubMed=15150265; DOI=10.1074/jbc.m404728200; RA Lu R., Niida H., Nakanishi M.; RT "Human SAD1 kinase is involved in UV-induced DNA damage checkpoint RT function."; RL J. Biol. Chem. 279:31164-31170(2004). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=16630837; DOI=10.1016/j.neuron.2006.03.018; RA Inoue E., Mochida S., Takagi H., Higa S., Deguchi-Tawarada M., RA Takao-Rikitsu E., Inoue M., Yao I., Takeuchi K., Kitajima I., Setou M., RA Ohtsuka T., Takai Y.; RT "SAD: a presynaptic kinase associated with synaptic vesicles and the active RT zone cytomatrix that regulates neurotransmitter release."; RL Neuron 50:261-275(2006). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3). RX PubMed=19648910; DOI=10.1038/ncb1921; RA Alvarado-Kristensson M., Rodriguez M.J., Silio V., Valpuesta J.M., RA Carrera A.C.; RT "SADB phosphorylation of gamma-tubulin regulates centrosome duplication."; RL Nat. Cell Biol. 11:1081-1092(2009). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Brain; RA She X.Y., Yu L., Guo J.H.; RL Submitted (FEB-2002) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 35-778. RC TISSUE=Brain; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 64-778. RC TISSUE=Brain; RX PubMed=11347906; DOI=10.1093/dnares/8.2.85; RA Nagase T., Nakayama M., Nakajima D., Kikuno R., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XX. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 8:85-95(2001). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 287-778. RC TISSUE=Lymph; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [10] RP PHOSPHORYLATION AT THR-189, AND MUTAGENESIS OF GLY-327. RX PubMed=18339622; DOI=10.1074/jbc.m710381200; RA Bright N.J., Carling D., Thornton C.; RT "Investigating the regulation of brain-specific kinases 1 and 2 by RT phosphorylation."; RL J. Biol. Chem. 283:14946-14954(2008). RN [11] RP PHOSPHORYLATION. RX PubMed=19958286; DOI=10.1042/bj20091372; RA Fogarty S., Hawley S.A., Green K.A., Saner N., Mustard K.J., Hardie D.G.; RT "Calmodulin-dependent protein kinase kinase-beta activates AMPK without RT forming a stable complex: synergistic effects of Ca2+ and AMP."; RL Biochem. J. 426:109-118(2010). RN [12] RP FUNCTION. RX PubMed=20026642; DOI=10.1242/jcs.058230; RA Muller M., Lutter D., Puschel A.W.; RT "Persistence of the cell-cycle checkpoint kinase Wee1 in SadA- and SadB- RT deficient neurons disrupts neuronal polarity."; RL J. Cell Sci. 123:286-294(2010). RN [13] RP CATALYTIC ACTIVITY, AND FUNCTION IN MAPT PHOSPHORYLATION. RX PubMed=21985311; DOI=10.1111/j.1471-4159.2011.07523.x; RA Yoshida H., Goedert M.; RT "Phosphorylation of microtubule-associated protein tau by AMPK-related RT kinases."; RL J. Neurochem. 120:165-176(2012). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-508, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [15] RP VARIANTS [LARGE SCALE ANALYSIS] TRP-303; ILE-319; GLU-391; ASN-531; SER-749 RP AND ALA-764. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase that plays a key role in CC polarization of neurons and centrosome duplication. Phosphorylates CC CDC25B, CDC25C, MAPT/TAU, RIMS1, TUBG1, TUBG2 and WEE1. Following CC phosphorylation and activation by STK11/LKB1, acts as a key regulator CC of polarization of cortical neurons, probably by mediating CC phosphorylation of microtubule-associated proteins such as MAPT/TAU at CC 'Thr-529' and 'Ser-579'. Also regulates neuron polarization by CC mediating phosphorylation of WEE1 at 'Ser-642' in postmitotic neurons, CC leading to down-regulate WEE1 activity in polarized neurons. In CC neurons, localizes to synaptic vesicles and plays a role in CC neurotransmitter release, possibly by phosphorylating RIMS1. Also acts CC as a positive regulator of centrosome duplication by mediating CC phosphorylation of gamma-tubulin (TUBG1 and TUBG2) at 'Ser-131', CC leading to translocation of gamma-tubulin and its associated proteins CC to the centrosome. Involved in the UV-induced DNA damage checkpoint CC response, probably by inhibiting CDK1 activity through phosphorylation CC and activation of WEE1, and inhibition of CDC25B and CDC25C. CC {ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:15150265, CC ECO:0000269|PubMed:20026642, ECO:0000269|PubMed:21985311}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21985311}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21985311}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[tau protein] + ATP = O-phospho-L-seryl-[tau protein] CC + ADP + H(+); Xref=Rhea:RHEA:12801, Rhea:RHEA-COMP:13701, Rhea:RHEA- CC COMP:13702, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.26; CC Evidence={ECO:0000269|PubMed:21985311}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[tau protein] + ATP = O-phospho-L-threonyl-[tau CC protein] + ADP + H(+); Xref=Rhea:RHEA:53904, Rhea:RHEA-COMP:13703, CC Rhea:RHEA-COMP:13704, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, CC ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; CC EC=2.7.11.26; Evidence={ECO:0000269|PubMed:21985311}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250}; CC -!- ACTIVITY REGULATION: Activated by phosphorylation on Thr-189 by CC STK11/LKB1. {ECO:0000269|PubMed:14976552}. CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15150265}. Nucleus CC {ECO:0000269|PubMed:15150265}. Cytoplasm, cytoskeleton, microtubule CC organizing center, centrosome {ECO:0000250}. Synapse CC {ECO:0000250|UniProtKB:B2DD29}. Presynaptic active zone CC {ECO:0000250|UniProtKB:B2DD29}. Cytoplasmic vesicle, secretory vesicle, CC synaptic vesicle {ECO:0000250|UniProtKB:B2DD29}. Note=Nuclear in the CC absence of DNA damage. Translocated to the nucleus in response to CC UV- or MMS-induced DNA damage (By similarity). {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; Synonyms=SADB-Long, L; CC IsoId=Q8TDC3-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8TDC3-2; Sequence=VSP_008158; CC Name=3; Synonyms=SADB-short, S; CC IsoId=Q8TDC3-3; Sequence=VSP_041742; CC -!- TISSUE SPECIFICITY: Widely expressed, with highest levels in brain and CC testis. Protein levels remain constant throughout the cell cycle. CC {ECO:0000269|PubMed:15150265}. CC -!- PTM: Phosphorylated at Thr-189 by STK11/LKB1 in complex with STE20- CC related adapter-alpha (STRADA) pseudo kinase and CAB39. Not CC phosphorylated at Thr-189 by CaMKK2. In contrast, it is phosphorylated CC and activated by CaMKK1. May be inactivated via dephosphorylation of CC Thr-189 by PP2C. {ECO:0000269|PubMed:14976552, CC ECO:0000269|PubMed:18339622, ECO:0000269|PubMed:19958286}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. SNF1 subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH16681.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY458602; AAS10354.1; -; mRNA. DR EMBL; AY505124; AAS86442.1; -; mRNA. DR EMBL; HQ830199; ADX95745.1; -; mRNA. DR EMBL; AF479826; AAL87697.1; -; mRNA. DR EMBL; AF479827; AAL87698.1; -; mRNA. DR EMBL; AC008974; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC020922; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL831945; CAD38595.1; -; mRNA. DR EMBL; AL834275; CAD38950.2; -; mRNA. DR EMBL; AB058714; BAB47440.1; -; mRNA. DR EMBL; BC016681; AAH16681.1; ALT_INIT; mRNA. DR CCDS; CCDS12921.1; -. [Q8TDC3-1] DR RefSeq; NP_115806.1; NM_032430.2. [Q8TDC3-1] DR AlphaFoldDB; Q8TDC3; -. DR SMR; Q8TDC3; -. DR BioGRID; 124084; 36. DR FunCoup; Q8TDC3; 1370. DR IntAct; Q8TDC3; 29. DR MINT; Q8TDC3; -. DR STRING; 9606.ENSP00000310649; -. DR BindingDB; Q8TDC3; -. DR ChEMBL; CHEMBL5650; -. DR DrugCentral; Q8TDC3; -. DR GlyGen; Q8TDC3; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q8TDC3; -. DR PhosphoSitePlus; Q8TDC3; -. DR SwissPalm; Q8TDC3; -. DR BioMuta; BRSK1; -. DR DMDM; 347595639; -. DR jPOST; Q8TDC3; -. DR MassIVE; Q8TDC3; -. DR PaxDb; 9606-ENSP00000310649; -. DR PeptideAtlas; Q8TDC3; -. DR ProteomicsDB; 74264; -. [Q8TDC3-1] DR ProteomicsDB; 74265; -. [Q8TDC3-2] DR ProteomicsDB; 74266; -. [Q8TDC3-3] DR Antibodypedia; 19545; 448 antibodies from 37 providers. DR DNASU; 84446; -. DR Ensembl; ENST00000309383.6; ENSP00000310649.1; ENSG00000160469.17. [Q8TDC3-1] DR Ensembl; ENST00000585418.1; ENSP00000467357.1; ENSG00000160469.17. [Q8TDC3-3] DR Ensembl; ENST00000590333.5; ENSP00000468190.1; ENSG00000160469.17. [Q8TDC3-2] DR GeneID; 84446; -. DR KEGG; hsa:84446; -. DR MANE-Select; ENST00000309383.6; ENSP00000310649.1; NM_032430.2; NP_115806.1. DR UCSC; uc002qkf.4; human. [Q8TDC3-1] DR AGR; HGNC:18994; -. DR ClinPGx; PA134888976; -. DR CTD; 84446; -. DR DisGeNET; 84446; -. DR GeneCards; BRSK1; -. DR HGNC; HGNC:18994; BRSK1. DR HPA; ENSG00000160469; Group enriched (brain, pituitary gland). DR MalaCards; BRSK1; -. DR MIM; 609235; gene. DR OpenTargets; ENSG00000160469; -. DR VEuPathDB; HostDB:ENSG00000160469; -. DR eggNOG; KOG0588; Eukaryota. DR GeneTree; ENSGT00940000161254; -. DR HOGENOM; CLU_000288_156_2_1; -. DR InParanoid; Q8TDC3; -. DR OMA; QHSQRNR; -. DR OrthoDB; 193931at2759; -. DR PAN-GO; Q8TDC3; 9 GO annotations based on evolutionary models. DR PhylomeDB; Q8TDC3; -. DR PathwayCommons; Q8TDC3; -. DR SignaLink; Q8TDC3; -. DR SIGNOR; Q8TDC3; -. DR Agora; ENSG00000160469; -. DR BioGRID-ORCS; 84446; 8 hits in 1189 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; BRSK1; human. DR GeneWiki; BRSK1; -. DR GenomeRNAi; 84446; -. DR Pharos; Q8TDC3; Tchem. DR PRO; PR:Q8TDC3; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q8TDC3; protein. DR Bgee; ENSG00000160469; Expressed in right frontal lobe and 121 other cell types or tissues. DR ExpressionAtlas; Q8TDC3; baseline and differential. DR GO; GO:0030054; C:cell junction; IDA:HPA. DR GO; GO:0005813; C:centrosome; ISS:UniProtKB. DR GO; GO:0098981; C:cholinergic synapse; IEA:Ensembl. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0150034; C:distal axon; ISS:ARUK-UCL. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0014069; C:postsynaptic density; IEA:Ensembl. DR GO; GO:0048786; C:presynaptic active zone; TAS:ARUK-UCL. DR GO; GO:0008021; C:synaptic vesicle; ISS:UniProtKB. DR GO; GO:0005524; F:ATP binding; IC:UniProtKB. DR GO; GO:0043015; F:gamma-tubulin binding; ISS:UniProtKB. DR GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB. DR GO; GO:0019901; F:protein kinase binding; IEA:Ensembl. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0048156; F:tau protein binding; NAS:ARUK-UCL. DR GO; GO:0050321; F:tau-protein kinase activity; IDA:UniProtKB. DR GO; GO:0008306; P:associative learning; ISS:ARUK-UCL. DR GO; GO:0007409; P:axonogenesis; ISS:UniProtKB. DR GO; GO:0021953; P:central nervous system neuron differentiation; IEA:Ensembl. DR GO; GO:0051298; P:centrosome duplication; ISS:UniProtKB. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0030010; P:establishment of cell polarity; ISS:UniProtKB. DR GO; GO:0000086; P:G2/M transition of mitotic cell cycle; IDA:MGI. DR GO; GO:0090176; P:microtubule cytoskeleton organization involved in establishment of planar polarity; ISS:ARUK-UCL. DR GO; GO:0007095; P:mitotic G2 DNA damage checkpoint signaling; IDA:UniProtKB. DR GO; GO:0030182; P:neuron differentiation; ISS:UniProtKB. DR GO; GO:0007269; P:neurotransmitter secretion; ISS:UniProtKB. DR GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:MGI. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0050770; P:regulation of axonogenesis; ISS:ARUK-UCL. DR GO; GO:0010975; P:regulation of neuron projection development; ISS:ARUK-UCL. DR GO; GO:0048167; P:regulation of synaptic plasticity; ISS:ARUK-UCL. DR GO; GO:2000807; P:regulation of synaptic vesicle clustering; TAS:ARUK-UCL. DR GO; GO:0010807; P:regulation of synaptic vesicle priming; IEA:Ensembl. DR GO; GO:0009411; P:response to UV; IDA:UniProtKB. DR GO; GO:0099504; P:synaptic vesicle cycle; ISS:ARUK-UCL. DR CDD; cd14081; STKc_BRSK1_2; 1. DR CDD; cd14340; UBA_BRSK; 1. DR FunFam; 1.10.510.10:FF:000064; BR serine/threonine-protein kinase 2; 1. DR FunFam; 3.30.200.20:FF:000003; Non-specific serine/threonine protein kinase; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR048622; BRSK1_2-like_UBA. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR015940; UBA. DR PANTHER; PTHR24346; MAP/MICROTUBULE AFFINITY-REGULATING KINASE; 1. DR PANTHER; PTHR24346:SF36; SERINE_THREONINE-PROTEIN KINASE BRSK1 ISOFORM X1-RELATED; 1. DR Pfam; PF21122; KA1_BRSK; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF21115; UBA_BRSK; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50030; UBA; 1. PE 1: Evidence at protein level; KW Alternative splicing; ATP-binding; Cell cycle; Cell projection; Cytoplasm; KW Cytoplasmic vesicle; Cytoskeleton; DNA damage; Kinase; Magnesium; KW Metal-binding; Methylation; Neurogenesis; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Synapse; Transferase. FT CHAIN 1..778 FT /note="Serine/threonine-protein kinase BRSK1" FT /id="PRO_0000085669" FT DOMAIN 34..285 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 314..356 FT /note="UBA" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00212" FT REGION 1..29 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 362..548 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 719..778 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1..12 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 362..383 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 430..457 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 491..508 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 509..533 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 156 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 40..48 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 63 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 189 FT /note="Phosphothreonine; by LKB1" FT /evidence="ECO:0000269|PubMed:14976552, FT ECO:0000269|PubMed:18339622" FT MOD_RES 399 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 443 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 447 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 450 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 466 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 481 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 484 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 498 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 508 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 525 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 529 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 535 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 550 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 583 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 586 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:B2DD29" FT MOD_RES 587 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:B2DD29" FT MOD_RES 601 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:B2DD29" FT VAR_SEQ 1..26 FT /note="MSSGAKEGGGGSPAYHLPHPHPHPPQ -> MVAGLTLGKGPESPDGDVSVPE FT RKDEVAGGGGEEEEAEERGR (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14976552, ECO:0000303|Ref.5" FT /id="VSP_008158" FT VAR_SEQ 344..778 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:19648910" FT /id="VSP_041742" FT VARIANT 303 FT /note="R -> W (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs144130246)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040394" FT VARIANT 319 FT /note="V -> I (in a lung large cell carcinoma sample; FT somatic mutation; dbSNP:rs2088591390)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040395" FT VARIANT 391 FT /note="G -> E (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040396" FT VARIANT 531 FT /note="T -> N (in dbSNP:rs55892637)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040397" FT VARIANT 749 FT /note="G -> S (in dbSNP:rs12978445)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040398" FT VARIANT 764 FT /note="P -> A (in dbSNP:rs55796422)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040399" FT MUTAGEN 59 FT /note="K->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:15150265" FT MUTAGEN 189 FT /note="T->A: Prevents phosphorylation and activation by FT STK11/LKB1 complex." FT /evidence="ECO:0000269|PubMed:14976552" FT MUTAGEN 327 FT /note="G->A: Abolishes activation of kinase activity." FT /evidence="ECO:0000269|PubMed:18339622" FT CONFLICT 762 FT /note="G -> A (in Ref. 9; AAH16681)" FT /evidence="ECO:0000305" SQ SEQUENCE 778 AA; 85087 MW; 8D1818D4E54398BB CRC64; MSSGAKEGGG GSPAYHLPHP HPHPPQHAQY VGPYRLEKTL GKGQTGLVKL GVHCITGQKV AIKIVNREKL SESVLMKVER EIAILKLIEH PHVLKLHDVY ENKKYLYLVL EHVSGGELFD YLVKKGRLTP KEARKFFRQI VSALDFCHSY SICHRDLKPE NLLLDEKNNI RIADFGMASL QVGDSLLETS CGSPHYACPE VIKGEKYDGR RADMWSCGVI LFALLVGALP FDDDNLRQLL EKVKRGVFHM PHFIPPDCQS LLRGMIEVEP EKRLSLEQIQ KHPWYLGGKH EPDPCLEPAP GRRVAMRSLP SNGELDPDVL ESMASLGCFR DRERLHRELR SEEENQEKMI YYLLLDRKER YPSCEDQDLP PRNDVDPPRK RVDSPMLSRH GKRRPERKSM EVLSITDAGG GGSPVPTRRA LEMAQHSQRS RSVSGASTGL SSSPLSSPRS PVFSFSPEPG AGDEARGGGS PTSKTQTLPS RGPRGGGAGE QPPPPSARST PLPGPPGSPR SSGGTPLHSP LHTPRASPTG TPGTTPPPSP GGGVGGAAWR SRLNSIRNSF LGSPRFHRRK MQVPTAEEMS SLTPESSPEL AKRSWFGNFI SLDKEEQIFL VLKDKPLSSI KADIVHAFLS IPSLSHSVLS QTSFRAEYKA SGGPSVFQKP VRFQVDISSS EGPEPSPRRD GSGGGGIYSV TFTLISGPSR RFKRVVETIQ AQLLSTHDQP SVQALADEKN GAQTRPAGAP PRSLQPPPGR PDPELSSSPR RGPPKDKKLL ATNGTPLP // ID CTNB1_HUMAN Reviewed; 781 AA. AC P35222; A8K1L7; Q8NEW9; Q8NI94; Q9H391; DT 01-FEB-1994, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-1994, sequence version 1. DT 28-JAN-2026, entry version 272. DE RecName: Full=Catenin beta-1 {ECO:0000312|HGNC:HGNC:2514}; DE AltName: Full=Beta-catenin {ECO:0000303|PubMed:7806582}; GN Name=CTNNB1 {ECO:0000312|HGNC:HGNC:2514}; Synonyms=CTNNB; GN ORFNames=OK/SW-cl.35, PRO2286; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Placenta; RX PubMed=7806582; DOI=10.1083/jcb.127.6.2061; RA Huelsken J., Birchmeier W., Behrens J.; RT "E-cadherin and APC compete for the interaction with beta-catenin and the RT cytoskeleton."; RL J. Cell Biol. 127:2061-2069(1994). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Fetal liver; RA Zhang C., Yu Y., Zhang S., Wei H., Bi J., Zhou G., Dong C., Zai Y., Xu W., RA Gao F., Liu M., He F.; RT "Functional prediction of the coding sequences of 75 new genes deduced by RT analysis of cDNA clones from human fetal liver."; RL Submitted (FEB-1999) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT VAL-688. RG NIEHS SNPs program; RL Submitted (NOV-2003) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Hippocampus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16641997; DOI=10.1038/nature04728; RA Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., RA Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., RA Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A., RA Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., RA Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., RA Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., RA Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., RA Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., RA Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., RA Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., RA Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., RA Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., RA Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., RA Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., RA Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., RA Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., RA Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., RA Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., RA Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.; RT "The DNA sequence, annotation and analysis of human chromosome 3."; RL Nature 440:1194-1198(2006). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-312. RX PubMed=12019147; RA Kim J.-S., Crooks H., Dracheva T., Nishanian T.G., Singh B., Jen J., RA Waldman T.; RT "Oncogenic beta-catenin is required for bone morphogenetic protein 4 RT expression in human cancer cells."; RL Cancer Res. 62:2744-2748(2002). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 258-781. RC TISSUE=Colon adenocarcinoma; RA Shichijo S., Itoh K.; RT "Identification of immuno-peptidmics that are recognized by tumor-reactive RT CTL generated from TIL of colon cancer patients."; RL Submitted (MAY-2001) to the EMBL/GenBank/DDBJ databases. RN [10] RP IDENTIFICATION IN AN E-CADHERIN/CATENIN ADHESION COMPLEX. RX PubMed=7982500; DOI=10.1016/0014-5793(94)01205-9; RA Butz S., Kemler R.; RT "Distinct cadherin-catenin complexes in Ca(2+)-dependent cell-cell RT adhesion."; RL FEBS Lett. 355:195-200(1994). RN [11] RP CHROMOSOMAL TRANSLOCATION WITH PLAG1. RX PubMed=9020842; DOI=10.1038/ng0297-170; RA Kas K., Voz M.L., Roeijer E., Astroem A.-K., Meyen E., Stenman G., RA Van de Ven W.J.M.; RT "Promoter swapping between the genes for a novel zinc finger protein and RT beta-catenin in pleiomorphic adenomas with t(3;8)(p21;q12) RT translocations."; RL Nat. Genet. 15:170-174(1997). RN [12] RP CHROMOSOMAL TRANSLOCATION WITH PLAG1. RX PubMed=10029085; RA Astroem A.-K., Voz M.L., Kas K., Roeijer E., Wedell B., Mandahl N., RA Van de Ven W., Mark J., Stenman G.; RT "Conserved mechanism of PLAG1 activation in salivary gland tumors with and RT without chromosome 8q12 abnormalities: identification of SII as a new RT fusion partner gene."; RL Cancer Res. 59:918-923(1999). RN [13] RP STIMULATION OF TYROSINE PHOSPHORYLATION BY EGF, AND DEPHOSPHORYLATION BY RP PTPRF. RX PubMed=10187801; DOI=10.1074/jbc.274.15.10173; RA Mueller T., Choidas A., Reichmann E., Ullrich A.; RT "Phosphorylation and free pool of beta-catenin are regulated by tyrosine RT kinases and tyrosine phosphatases during epithelial cell migration."; RL J. Biol. Chem. 274:10173-10183(1999). RN [14] RP SUBCELLULAR LOCATION. RX PubMed=10725230; DOI=10.1242/jcs.113.8.1481; RA Mariner D.J., Wang J., Reynolds A.B.; RT "ARVCF localizes to the nucleus and adherens junction and is mutually RT exclusive with p120(ctn) in E-cadherin complexes."; RL J. Cell Sci. 113:1481-1490(2000). RN [15] RP INTERACTION WITH LEF1; APC; AXIN1; AXIN2 AND TCF7L2, PHOSPHORYLATION BY RP GSK3B, AND MUTAGENESIS OF PHE-253; HIS-260; LYS-292; LYS-345; TRP-383; RP ARG-386; ASN-426; LYS-435; ARG-469; HIS-470 AND LYS-508. RX PubMed=10966653; DOI=10.1038/79039; RA von Kries J.P., Winbeck G., Asbrand C., Schwarz-Romond T., Sochnikova N., RA Dell'Oro A., Behrens J., Birchmeier W.; RT "Hot spots in beta-catenin for interactions with LEF-1, conductin and RT APC."; RL Nat. Struct. Biol. 7:800-807(2000). RN [16] RP TISSUE SPECIFICITY, AND VARIANT PTR TYR-32. RX PubMed=11703283; DOI=10.1046/j.1365-2133.2001.04455.x; RA Moreno-Bueno G., Gamallo C., Perez-Gallego L., Contreras F., Palacios J.; RT "Beta-catenin expression in pilomatrixomas. Relationship with beta-catenin RT gene mutations and comparison with beta-catenin expression in normal hair RT follicles."; RL Br. J. Dermatol. 145:576-581(2001). RN [17] RP INTERACTION WITH LEF1, AND INHIBITION BY CTNNBIP1 BINDING. RX PubMed=11751639; DOI=10.1101/gad.946501; RA Tutter A.V., Fryer C.J., Jones K.A.; RT "Chromatin-specific regulation of LEF-1-beta-catenin transcription RT activation and inhibition in vitro."; RL Genes Dev. 15:3342-3354(2001). RN [18] RP RETRACTED PAPER. RX PubMed=11279024; DOI=10.1074/jbc.m100194200; RA Piedra J., Martinez D., Castano J., Miravet S., Dunach M., RA de Herreros A.G.; RT "Regulation of beta-catenin structure and activity by tyrosine RT phosphorylation."; RL J. Biol. Chem. 276:20436-20443(2001). RN [19] RP INTERACTION WITH SPN/CD43 CYTOPLASMIC TAIL. RX PubMed=15003504; DOI=10.1016/j.bbrc.2004.02.011; RA Andersson C.X., Fernandez-Rodriguez J., Laos S., Sikut R., Sikut A., RA Baeckstroem D., Hansson G.C.; RT "CD43 has a functional NLS, interacts with beta-catenin, and affects gene RT expression."; RL Biochem. Biophys. Res. Commun. 316:12-17(2004). RN [20] RP UBIQUITINATION, AND SUBCELLULAR LOCATION. RX PubMed=21118991; DOI=10.1091/mbc.e10-05-0440; RA Hay-Koren A., Caspi M., Zilberberg A., Rosin-Arbesfeld R.; RT "The EDD E3 ubiquitin ligase ubiquitinates and up-regulates beta-catenin."; RL Mol. Biol. Cell 22:399-411(2011). RN [21] RP RETRACTION NOTICE OF PUBMED:11279024. RX PubMed=27226643; DOI=10.1074/jbc.a116.100194; RA Piedra J., Martinez D., Castano J., Miravet S., Dunach M., RA de Herreros A.G.; RL J. Biol. Chem. 291:11463-11463(2016). RN [22] RP INTERACTION WITH CTNNA3. RX PubMed=11590244; DOI=10.1242/jcs.114.17.3177; RA Janssens B., Goossens S., Staes K., Gilbert B., van Hengel J., Colpaert C., RA Bruyneel E., Mareel M., van Roy F.; RT "AlphaT-catenin: a novel tissue-specific beta-catenin-binding protein RT mediating strong cell-cell adhesion."; RL J. Cell Sci. 114:3177-3188(2001). RN [23] RP INTERACTION WITH SIAH1, AND UBIQUITINATION. RX PubMed=11389839; DOI=10.1016/s1097-2765(01)00242-8; RA Matsuzawa S., Reed J.C.; RT "Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin RT degradation linked to p53 responses."; RL Mol. Cell 7:915-926(2001). RN [24] RP INTERACTION WITH SIAH1, AND UBIQUITINATION. RX PubMed=11389840; DOI=10.1016/s1097-2765(01)00241-6; RA Liu J., Stevens J., Rote C.A., Yost H.J., Hu Y., Neufeld K.L., White R.L., RA Matsunami N.; RT "Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to RT the adenomatous polyposis coli protein."; RL Mol. Cell 7:927-936(2001). RN [25] RP INVOLVEMENT IN MESOM. RX PubMed=11464291; DOI=10.1038/sj.onc.1204557; RA Shigemitsu K., Sekido Y., Usami N., Mori S., Sato M., Horio Y., RA Hasegawa Y., Bader S.A., Gazdar A.F., Minna J.D., Hida T., Yoshioka H., RA Imaizumi M., Ueda Y., Takahashi M., Shimokata K.; RT "Genetic alteration of the beta-catenin gene (CTNNB1) in human lung cancer RT and malignant mesothelioma and identification of a new 3p21.3 homozygous RT deletion."; RL Oncogene 20:4249-4257(2001). RN [26] RP INTERACTION WITH PTPRU. RX PubMed=12501215; DOI=10.1021/bi026095u; RA Yan H.-X., He Y.-Q., Dong H., Zhang P., Zeng J.-Z., Cao H.-F., Wu M.-C., RA Wang H.-Y.; RT "Physical and functional interaction between receptor-like protein tyrosine RT phosphatase PCP-2 and beta-catenin."; RL Biochemistry 41:15854-15860(2002). RN [27] RP PHOSPHORYLATION AT SER-45, CHARACTERIZATION OF VARIANT HEPATOCELLULAR RP CARCINOMA ALA-41, CHARACTERIZATION OF VARIANT DESMOID TUMOR ALA-41, AND RP CHARACTERIZATION OF VARIANT HEPATOBLASTOMA ALA-41. RX PubMed=12051714; DOI=10.1016/s0006-291x(02)00485-0; RA Hagen T., Vidal-Puig A.; RT "Characterisation of the phosphorylation of beta-catenin at the GSK-3 RT priming site Ser45."; RL Biochem. Biophys. Res. Commun. 294:324-328(2002). RN [28] RP INTERACTION WITH CXADR. RX PubMed=12297051; DOI=10.1016/s0092-8674(02)00912-1; RA Walters R.W., Freimuth P., Moninger T.O., Ganske I., Zabner J., Welsh M.J.; RT "Adenovirus fiber disrupts CAR-mediated intercellular adhesion allowing RT virus escape."; RL Cell 110:789-799(2002). RN [29] RP PHOSPHORYLATION AT SER-23 AND SER-29 BY GSK3B, PHOSPHORYLATION AT THR-41, RP MUTAGENESIS OF SER-29, CHARACTERIZATION OF VARIANTS HEPATOCELLULAR RP CARCINOMA ARG-23; ALA-37 AND ALA-41, CHARACTERIZATION OF VARIANT PTR RP TYR-33, CHARACTERIZATION OF VARIANT MDB ALA-37, CHARACTERIZATION OF VARIANT RP DESMOID TUMOR ALA-41, AND CHARACTERIZATION OF VARIANT HEPATOBLASTOMA RP ALA-41. RX PubMed=12027456; DOI=10.1006/excr.2002.5520; RA van Noort M., van de Wetering M., Clevers H.; RT "Identification of two novel regulated serines in the N-terminus of beta- RT catenin."; RL Exp. Cell Res. 276:264-272(2002). RN [30] RP INTERACTION WITH CDH1 AND PKP2, AND SUBCELLULAR LOCATION. RX PubMed=11790773; DOI=10.1074/jbc.m108765200; RA Chen X., Bonne S., Hatzfeld M., van Roy F., Green K.J.; RT "Protein binding and functional characterization of plakophilin 2. Evidence RT for its diverse roles in desmosomes and beta -catenin signaling."; RL J. Biol. Chem. 277:10512-10522(2002). RN [31] RP WNT SIGNALING MODULATES PHOSPHORYLATION. RX PubMed=11834740; DOI=10.1074/jbc.m111635200; RA van Noort M., Meeldijk J., van der Zee R., Destree O., Clevers H.; RT "Wnt signaling controls the phosphorylation status of beta-catenin."; RL J. Biol. Chem. 277:17901-17905(2002). RN [32] RP PHOSPHORYLATION, AND INTERACTION OF PHOSPHORYLATED CTNNB1 WITH BTRC. RX PubMed=12077367; DOI=10.1242/jcs.115.13.2771; RA Sadot E., Conacci-Sorrell M., Zhurinsky J., Shnizer D., Lando Z., RA Zharhary D., Kam Z., Ben-Ze'ev A., Geiger B.; RT "Regulation of S33/S37 phosphorylated beta-catenin in normal and RT transformed cells."; RL J. Cell Sci. 115:2771-2780(2002). RN [33] RP INTERACTION WITH PTPRJ. RX PubMed=12370829; DOI=10.1038/sj.onc.1205858; RA Holsinger L.J., Ward K., Duffield B., Zachwieja J., Jallal B.; RT "The transmembrane receptor protein tyrosine phosphatase DEP1 interacts RT with p120(ctn)."; RL Oncogene 21:7067-7076(2002). RN [34] RP INTERACTION WITH PCDH11Y. RX PubMed=12420223; DOI=10.1038/sj.onc.1205991; RA Chen M.-W., Vacherot F., De La Taille A., Gil-Diez-De-Medina S., Shen R., RA Friedman R.A., Burchardt M., Chopin D.K., Buttyan R.; RT "The emergence of protocadherin-PC expression during the acquisition of RT apoptosis-resistance by prostate cancer cells."; RL Oncogene 21:7861-7871(2002). RN [35] RP INTERACTION WITH NHERF1. RX PubMed=12830000; DOI=10.1053/jhep.2003.50270; RA Shibata T., Chuma M., Kokubu A., Sakamoto M., Hirohashi S.; RT "EBP50, a beta-catenin-associating protein, enhances Wnt signaling and is RT over-expressed in hepatocellular carcinoma."; RL Hepatology 38:178-186(2003). RN [36] RP REVIEW. RX PubMed=10679188; DOI=10.1006/bbrc.1999.1860; RA Kikuchi A.; RT "Regulation of beta-catenin signaling in the Wnt pathway."; RL Biochem. Biophys. Res. Commun. 268:243-248(2000). RN [37] RP PHOSPHORYLATION AT TYR-142 BY FYN. RX PubMed=12640114; DOI=10.1128/mcb.23.7.2287-2297.2003; RA Piedra J., Miravet S., Castano J., Palmer H.G., Heisterkamp N., RA Garcia de Herreros A., Dunach M.; RT "p120 Catenin-associated Fer and Fyn tyrosine kinases regulate beta-catenin RT Tyr-142 phosphorylation and beta-catenin-alpha-catenin Interaction."; RL Mol. Cell. Biol. 23:2287-2297(2003). RN [38] RP INTERACTION WITH CBY1. RX PubMed=12712206; DOI=10.1038/nature01570; RA Takemaru K., Yamaguchi S., Lee Y.S., Zhang Y., Carthew R.W., Moon R.T.; RT "Chibby, a nuclear beta-catenin-associated antagonist of the Wnt/Wingless RT pathway."; RL Nature 422:905-909(2003). RN [39] RP INTERACTION WITH AJAP1. RC TISSUE=Brain; RX PubMed=14595118; DOI=10.1091/mbc.e03-05-0281; RA Bharti S., Handrow-Metzmacher H., Zickenheiner S., Zeitvogel A., RA Baumann R., Starzinski-Powitz A.; RT "Novel membrane protein shrew-1 targets to cadherin-mediated junctions in RT polarized epithelial cells."; RL Mol. Biol. Cell 15:397-406(2004). RN [40] RP INTERACTION WITH CBY1, AND SUBCELLULAR LOCATION. RX PubMed=16424001; DOI=10.1158/0008-5472.can-05-3124; RA Jung Y., Bang S., Choi K., Kim E., Kim Y., Kim J., Park J., Koo H., RA Moon R.T., Song K., Lee I.; RT "TC1 (C8orf4) enhances the Wnt/beta-catenin pathway by relieving RT antagonistic activity of Chibby."; RL Cancer Res. 66:723-728(2006). RN [41] RP SUBCELLULAR LOCATION, AND INTERACTION WITH NANOS1. RX PubMed=17047063; DOI=10.1158/0008-5472.can-05-3096; RA Strumane K., Bonnomet A., Stove C., Vandenbroucke R., Nawrocki-Raby B., RA Bruyneel E., Mareel M., Birembaut P., Berx G., van Roy F.; RT "E-cadherin regulates human Nanos1, which interacts with p120ctn and RT induces tumor cell migration and invasion."; RL Cancer Res. 66:10007-10015(2006). RN [42] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-675, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [43] RP SUBCELLULAR LOCATION, AND INTERACTION WITH EMD. RX PubMed=16858403; DOI=10.1038/sj.emboj.7601230; RA Markiewicz E., Tilgner K., Barker N., van de Wetering M., Clevers H., RA Dorobek M., Hausmanowa-Petrusewicz I., Ramaekers F.C.S., Broers J.L.V., RA Blankesteijn W.M., Salpingidou G., Wilson R.G., Ellis J.A., Hutchison C.J.; RT "The inner nuclear membrane protein emerin regulates beta-catenin activity RT by restricting its accumulation in the nucleus."; RL EMBO J. 25:3275-3285(2006). RN [44] RP INTERACTION WITH MUC1, SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=17524503; DOI=10.1016/j.bbamcr.2007.04.009; RA Lillehoj E.P., Lu W., Kiser T., Goldblum S.E., Kim K.C.; RT "MUC1 inhibits cell proliferation by a beta-catenin-dependent mechanism."; RL Biochim. Biophys. Acta 1773:1028-1038(2007). RN [45] RP INTERACTION WITH GLIS2, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION. RX PubMed=17289029; DOI=10.1016/j.febslet.2007.01.058; RA Kim Y.-S., Kang H.S., Jetten A.M.; RT "The Kruppel-like zinc finger protein Glis2 functions as a negative RT modulator of the Wnt/beta-catenin signaling pathway."; RL FEBS Lett. 581:858-864(2007). RN [46] RP PHOSPHORYLATION AT SER-191 AND SER-246, INTERACTION WITH CDK5, SUBCELLULAR RP LOCATION, AND TISSUE SPECIFICITY. RX PubMed=17009320; DOI=10.1002/jcb.21041; RA Munoz J.P., Huichalaf C.H., Orellana D., Maccioni R.B.; RT "cdk5 modulates beta- and delta-catenin/Pin1 interactions in neuronal RT cells."; RL J. Cell. Biochem. 100:738-749(2007). RN [47] RP INTERACTION WITH FHIT, IDENTIFICATION IN A COMPLEX WITH LEF1, AND FUNCTION. RX PubMed=18077326; DOI=10.1073/pnas.0703664105; RA Weiske J., Albring K.F., Huber O.; RT "The tumor suppressor Fhit acts as a repressor of beta-catenin RT transcriptional activity."; RL Proc. Natl. Acad. Sci. U.S.A. 104:20344-20349(2007). RN [48] RP FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION, AND INTERACTION WITH NEK2. RX PubMed=18086858; DOI=10.1101/gad.1596308; RA Bahmanyar S., Kaplan D.D., Deluca J.G., Giddings T.H. Jr., O'Toole E.T., RA Winey M., Salmon E.D., Casey P.J., Nelson W.J., Barth A.I.; RT "beta-Catenin is a Nek2 substrate involved in centrosome separation."; RL Genes Dev. 22:91-105(2008). RN [49] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-556 AND SER-675, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [50] RP INTERACTION WITH SOX7. RX PubMed=18819930; DOI=10.1158/1541-7786.mcr-07-2175; RA Guo L., Zhong D., Lau S., Liu X., Dong X.Y., Sun X., Yang V.W., RA Vertino P.M., Moreno C.S., Varma V., Dong J.T., Zhou W.; RT "Sox7 Is an independent checkpoint for beta-catenin function in prostate RT and colon epithelial cells."; RL Mol. Cancer Res. 6:1421-1430(2008). RN [51] RP INTERACTION WITH CHD8. RX PubMed=18378692; DOI=10.1128/mcb.00322-08; RA Thompson B.A., Tremblay V., Lin G., Bochar D.A.; RT "CHD8 is an ATP-dependent chromatin remodeling factor that regulates beta- RT catenin target genes."; RL Mol. Cell. Biol. 28:3894-3904(2008). RN [52] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [53] RP INTERACTION WITH CBY1. RX PubMed=19435523; DOI=10.1186/1471-2199-10-41; RA Mofunanya A., Li F.Q., Hsieh J.C., Takemaru K.; RT "Chibby forms a homodimer through a heptad repeat of leucine residues in RT its C-terminal coiled-coil motif."; RL BMC Mol. Biol. 10:41-41(2009). RN [54] RP INTERACTION WITH TCF7L2 AND TNIK. RX PubMed=19816403; DOI=10.1038/emboj.2009.285; RA Mahmoudi T., Li V.S.W., Ng S.S., Taouatas N., Vries R.G.J., Mohammed S., RA Heck A.J., Clevers H.; RT "The kinase TNIK is an essential activator of Wnt target genes."; RL EMBO J. 28:3329-3340(2009). RN [55] RP FUNCTION. RX PubMed=18957423; DOI=10.1074/jbc.m805612200; RA Li H., Ray G., Yoo B.H., Erdogan M., Rosen K.V.; RT "Down-regulation of death-associated protein kinase-2 is required for beta- RT catenin-induced anoikis resistance of malignant epithelial cells."; RL J. Biol. Chem. 284:2012-2022(2009). RN [56] RP INTERACTION WITH RUVBL2; APPL2; APPL1; HDAC1 AND HDAC2. RX PubMed=19433865; DOI=10.1074/jbc.m109.007237; RA Rashid S., Pilecka I., Torun A., Olchowik M., Bielinska B., Miaczynska M.; RT "Endosomal adaptor proteins APPL1 and APPL2 are novel activators of beta- RT catenin/TCF-mediated transcription."; RL J. Biol. Chem. 284:18115-18128(2009). RN [57] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [58] RP PHOSPHORYLATION AT SER-33 AND SER-37 BY HIPK2, AND UBIQUITINATION. RX PubMed=20307497; DOI=10.1016/j.bbrc.2010.03.099; RA Kim E.-A., Kim J.E., Sung K.S., Choi D.W., Lee B.J., Choi C.Y.; RT "Homeodomain-interacting protein kinase 2 (HIPK2) targets beta-catenin for RT phosphorylation and proteasomal degradation."; RL Biochem. Biophys. Res. Commun. 394:966-971(2010). RN [59] RP INTERACTION WITH SESTD1. RX PubMed=20164195; DOI=10.1074/jbc.m109.068304; RA Miehe S., Bieberstein A., Arnould I., Ihdene O., Rutten H., Strubing C.; RT "The phospholipid-binding protein SESTD1 is a novel regulator of the RT transient receptor potential channels TRPC4 and TRPC5."; RL J. Biol. Chem. 285:12426-12434(2010). RN [60] RP INTERACTION WITH TRPC4. RX PubMed=19996314; DOI=10.1074/jbc.m109.060301; RA Graziani A., Poteser M., Heupel W.M., Schleifer H., Krenn M., RA Drenckhahn D., Romanin C., Baumgartner W., Groschner K.; RT "Cell-cell contact formation governs Ca2+ signaling by TRPC4 in the RT vascular endothelium: evidence for a regulatory TRPC4-beta-catenin RT interaction."; RL J. Biol. Chem. 285:4213-4223(2010). RN [61] RP INTERACTION WITH CDK5. RX PubMed=19693690; DOI=10.1007/s11033-009-9752-7; RA Li Q., Liu X., Zhang M., Ye G., Qiao Q., Ling Y., Wu Y., Zhang Y., Yu L.; RT "Characterization of a novel human CDK5 splicing variant that inhibits RT Wnt/beta-catenin signaling."; RL Mol. Biol. Rep. 37:2415-2421(2010). RN [62] RP PHOSPHORYLATION AT TYR-64; TYR-142; TYR-331 AND TYR-333, INTERACTION WITH RP PTK6, AND MUTAGENESIS OF TYR-64. RX PubMed=20026641; DOI=10.1242/jcs.053264; RA Palka-Hamblin H.L., Gierut J.J., Bie W., Brauer P.M., Zheng Y., Asara J.M., RA Tyner A.L.; RT "Identification of beta-catenin as a target of the intracellular tyrosine RT kinase PTK6."; RL J. Cell Sci. 123:236-245(2010). RN [63] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-675, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [64] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [65] RP FUNCTION IN INSULIN INTERNALIZATION, SUBCELLULAR LOCATION, INTERACTION WITH RP CDK2, AND PHOSPHORYLATION BY CDK2. RX PubMed=21262353; DOI=10.1016/j.cellsig.2011.01.019; RA Fiset A., Xu E., Bergeron S., Marette A., Pelletier G., Siminovitch K.A., RA Olivier M., Beauchemin N., Faure R.L.; RT "Compartmentalized CDK2 is connected with SHP-1 and beta-catenin and RT regulates insulin internalization."; RL Cell. Signal. 23:911-919(2011). RN [66] RP INTERACTION WITH PKT7. RX PubMed=21132015; DOI=10.1038/embor.2010.185; RA Puppo F., Thome V., Lhoumeau A.-C., Cibois M., Gangar A., Lembo F., RA Belotti E., Marchetto S., Lecine P., Prebet T., Sebbagh M., Shin W.-S., RA Lee S.-T., Kodjabachian L., Borg J.-P.; RT "Protein tyrosine kinase 7 has a conserved role in Wnt/beta-catenin RT canonical signalling."; RL EMBO Rep. 12:43-49(2011). RN [67] RP INTERACTION WITH NDRG2. RX PubMed=21247902; DOI=10.1074/jbc.m110.170803; RA Hwang J., Kim Y., Kang H.B., Jaroszewski L., Deacon A.M., Lee H., RA Choi W.C., Kim K.J., Kim C.H., Kang B.S., Lee J.O., Oh T.K., Kim J.W., RA Wilson I.A., Kim M.H.; RT "Crystal structure of the human N-Myc downstream-regulated gene 2 protein RT provides insight into its role as a tumor suppressor."; RL J. Biol. Chem. 286:12450-12460(2011). RN [68] RP INTERACTION WITH PKM ISOFORM M2, PHOSPHORYLATION AT TYR-333, AND RP MUTAGENESIS OF TYR-333. RX PubMed=22056988; DOI=10.1038/nature10598; RA Yang W., Xia Y., Ji H., Zheng Y., Liang J., Huang W., Gao X., Aldape K., RA Lu Z.; RT "Nuclear PKM2 regulates beta-catenin transactivation upon EGFR RT activation."; RL Nature 480:118-122(2011). RN [69] RP INTERACTION WITH AHI1. RX PubMed=21623382; DOI=10.1038/nm.2380; RA Lancaster M.A., Gopal D.J., Kim J., Saleem S.N., Silhavy J.L., Louie C.M., RA Thacker B.E., Williams Y., Zaki M.S., Gleeson J.G.; RT "Defective Wnt-dependent cerebellar midline fusion in a mouse model of RT Joubert syndrome."; RL Nat. Med. 17:726-731(2011). RN [70] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-191 AND SER-552, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [71] RP IDENTIFICATION IN A COMPLEX WITH HINT1 AND MITF, AND FUNCTION. RX PubMed=22647378; DOI=10.4161/cc.20765; RA Genovese G., Ghosh P., Li H., Rettino A., Sioletic S., Cittadini A., RA Sgambato A.; RT "The tumor suppressor HINT1 regulates MITF and beta-catenin transcriptional RT activity in melanoma cells."; RL Cell Cycle 11:2206-2215(2012). RN [72] RP FUNCTION, INTERACTION WITH FERMT2, IDENTIFICATION IN A COMPLEX WITH FERMT2 RP AND TCF7L2, AND SUBCELLULAR LOCATION. RX PubMed=22699938; DOI=10.1038/embor.2012.88; RA Yu Y., Wu J., Wang Y., Zhao T., Ma B., Liu Y., Fang W., Zhu W.G., Zhang H.; RT "Kindlin 2 forms a transcriptional complex with beta-catenin and TCF4 to RT enhance Wnt signalling."; RL EMBO Rep. 13:750-758(2012). RN [73] RP FUNCTION, AND INTERACTION WITH PML. RX PubMed=22155184; DOI=10.1053/j.gastro.2011.11.041; RA Satow R., Shitashige M., Jigami T., Fukami K., Honda K., Kitabayashi I., RA Yamada T.; RT "Beta-catenin inhibits promyelocytic leukemia protein tumor suppressor RT function in colorectal cancer cells."; RL Gastroenterology 142:572-581(2012). RN [74] RP SUBCELLULAR LOCATION. RX PubMed=22294297; DOI=10.1002/path.3982; RA Tsang S.M., Brown L., Lin K., Liu L., Piper K., O'Toole E.A., Grose R., RA Hart I.R., Garrod D.R., Fortune F., Wan H.; RT "Non-junctional human desmoglein 3 acts as an upstream regulator of Src in RT E-cadherin adhesion, a pathway possibly involved in the pathogenesis of RT pemphigus vulgaris."; RL J. Pathol. 227:81-93(2012). RN [75] RP INVOLVEMENT IN NEDSDV. RX PubMed=23033978; DOI=10.1056/nejmoa1206524; RA de Ligt J., Willemsen M.H., van Bon B.W., Kleefstra T., Yntema H.G., RA Kroes T., Vulto-van Silfhout A.T., Koolen D.A., de Vries P., Gilissen C., RA del Rosario M., Hoischen A., Scheffer H., de Vries B.B., Brunner H.G., RA Veltman J.A., Vissers L.E.; RT "Diagnostic exome sequencing in persons with severe intellectual RT disability."; RL N. Engl. J. Med. 367:1921-1929(2012). RN [76] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [77] RP SUBCELLULAR LOCATION, AND INTERACTION WITH FAM53B. RX PubMed=25183871; DOI=10.1242/dev.108415; RA Kizil C., Kuechler B., Yan J.J., Oezhan G., Moro E., Argenton F., Brand M., RA Weidinger G., Antos C.L.; RT "Simplet/Fam53b is required for Wnt signal transduction by regulating beta- RT catenin nuclear localization."; RL Development 141:3529-3539(2014). RN [78] RP GLYCOSYLATION AT SER-23, AND SUBCELLULAR LOCATION. RX PubMed=24342833; DOI=10.1016/j.yexcr.2013.11.021; RA Ha J.R., Hao L., Venkateswaran G., Huang Y.H., Garcia E., Persad S.; RT "beta-catenin is O-GlcNAc glycosylated at Serine 23: implications for beta- RT catenin's subcellular localization and transactivator function."; RL Exp. Cell Res. 321:153-166(2014). RN [79] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-191 AND SER-552, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [80] RP INTERACTION WITH RNF220. RX PubMed=25266658; DOI=10.1128/mcb.00731-14; RA Ma P., Yang X., Kong Q., Li C., Yang S., Li Y., Mao B.; RT "The ubiquitin ligase RNF220 enhances canonical Wnt signaling through USP7- RT mediated deubiquitination of beta-catenin."; RL Mol. Cell. Biol. 34:4355-4366(2014). RN [81] RP ACETYLATION AT LYS-49, AND DEACETYLATION. RX PubMed=24824780; DOI=10.1002/ijc.28967; RA Pangon L., Mladenova D., Watkins L., Van Kralingen C., Currey N., RA Al-Sohaily S., Lecine P., Borg J.P., Kohonen-Corish M.R.; RT "MCC inhibits beta-catenin transcriptional activity by sequestering DBC1 in RT the cytoplasm."; RL Int. J. Cancer 136:55-64(2015). RN [82] RP INTERACTION WITH JPT1, AND PHOSPHORYLATION AT SER-33. RX PubMed=25169422; DOI=10.1002/jcb.24956; RA Varisli L., Ozturk B.E., Akyuz G.K., Korkmaz K.S.; RT "HN1 negatively influences the beta-catenin/E-cadherin interaction, and RT contributes to migration in prostate cells."; RL J. Cell. Biochem. 116:170-178(2015). RN [83] RP INTERACTION WITH CTNND2. RX PubMed=25807484; DOI=10.1038/nature14186; RA Turner T.N., Sharma K., Oh E.C., Liu Y.P., Collins R.L., Sosa M.X., RA Auer D.R., Brand H., Sanders S.J., Moreno-De-Luca D., Pihur V., Plona T., RA Pike K., Soppet D.R., Smith M.W., Cheung S.W., Martin C.L., State M.W., RA Talkowski M.E., Cook E., Huganir R., Katsanis N., Chakravarti A.; RT "Loss of delta-catenin function in severe autism."; RL Nature 520:51-56(2015). RN [84] RP INTERACTION WITH GID8; AXIN1 AND TCF7L2, AND SUBCELLULAR LOCATION. RX PubMed=28829046; DOI=10.1038/cr.2017.107; RA Lu Y., Xie S., Zhang W., Zhang C., Gao C., Sun Q., Cai Y., Xu Z., Xiao M., RA Xu Y., Huang X., Wu X., Liu W., Wang F., Kang Y., Zhou T.; RT "Twa1/Gid8 is a beta-catenin nuclear retention factor in Wnt signaling and RT colorectal tumorigenesis."; RL Cell Res. 27:1422-1440(2017). RN [85] RP IDENTIFICATION IN A CADHERIN/CATENIN ADHESION COMPLEX. RX PubMed=28051089; DOI=10.1038/mi.2016.120; RA Caldwell J.M., Collins M.H., Kemme K.A., Sherrill J.D., Wen T., Rochman M., RA Stucke E.M., Amin L., Tai H., Putnam P.E., Jimenez-Dalmaroni M.J., RA Wormald M.R., Porollo A., Abonia J.P., Rothenberg M.E.; RT "Cadherin 26 is an alpha integrin-binding epithelial receptor regulated RT during allergic inflammation."; RL Mucosal Immunol. 10:1190-1201(2017). RN [86] RP INTERACTION WITH TCF7L2/TCF4 AND HERPES VIRUS 8 PROTEIN VPK (MICROBIAL RP INFECTION). RX PubMed=29432739; DOI=10.1016/j.bbrc.2018.02.089; RA Cha S., Kang M.S., Seo T.; RT "KSHV vPK inhibits Wnt signaling via preventing interactions between beta- RT catenin and TCF4."; RL Biochem. Biophys. Res. Commun. 497:381-387(2018). RN [87] RP SUBCELLULAR LOCATION, INTERACTION WITH TMEM170B, AND TISSUE SPECIFICITY. RX PubMed=29367600; DOI=10.1038/s41419-017-0128-y; RA Li M., Han Y., Zhou H., Li X., Lin C., Zhang E., Chi X., Hu J., Xu H.; RT "Transmembrane protein 170B is a novel breast tumorigenesis suppressor gene RT that inhibits the Wnt/beta-catenin pathway."; RL Cell Death Dis. 9:91-91(2018). RN [88] RP INVOLVEMENT IN EVR7, AND VARIANT EVR7 CYS-710. RX PubMed=28575650; DOI=10.1016/j.ajhg.2017.05.001; RA Panagiotou E.S., Sanjurjo Soriano C., Poulter J.A., Lord E.C., Dzulova D., RA Kondo H., Hiyoshi A., Chung B.H., Chu Y.W., Lai C.H.Y., Tafoya M.E., RA Karjosukarso D., Collin R.W.J., Topping J., Downey L.M., Ali M., RA Inglehearn C.F., Toomes C.; RT "Defects in the cell signaling mediator beta-catenin cause the retinal RT vascular condition FEVR."; RL Am. J. Hum. Genet. 100:960-968(2017). RN [89] RP INTERACTION WITH IRF2BPL, AND VARIANT TYR-33. RX PubMed=29374064; DOI=10.1158/0008-5472.can-17-2403; RA Higashimori A., Dong Y., Zhang Y., Kang W., Nakatsu G., Ng S.S.M., RA Arakawa T., Sung J.J.Y., Chan F.K.L., Yu J.; RT "Forkhead Box F2 Suppresses Gastric Cancer through a Novel FOXF2-IRF2BPL- RT beta-Catenin Signaling Axis."; RL Cancer Res. 78:1643-1656(2018). RN [90] RP INTERACTION WITH SOX30 AND TCF7L2, AND SUBCELLULAR LOCATION. RX PubMed=29739711; DOI=10.1016/j.ebiom.2018.04.026; RA Han F., Liu W.B., Shi X.Y., Yang J.T., Zhang X., Li Z.M., Jiang X., Yin L., RA Li J.J., Huang C.S., Cao J., Liu J.Y.; RT "SOX30 Inhibits Tumor Metastasis through Attenuating Wnt-Signaling via RT Transcriptional and Posttranslational Regulation of beta-Catenin in Lung RT Cancer."; RL EBioMedicine 31:253-266(2018). RN [91] RP INTERACTION WITH FLYWCH1. RX PubMed=30097457; DOI=10.1158/1541-7786.mcr-18-0262; RA Muhammad B.A., Almozyan S., Babaei-Jadidi R., Onyido E.K., Saadeddin A., RA Kashfi S.H., Spencer-Dene B., Ilyas M., Lourdusamy A., Behrens A., RA Nateri A.S.; RT "FLYWCH1, a Novel Suppressor of Nuclear beta-Catenin, Regulates Migration RT and Morphology in Colorectal Cancer."; RL Mol. Cancer Res. 16:1977-1990(2018). RN [92] RP FUNCTION, INTERACTION WITH DSG2, AND SUBCELLULAR LOCATION. RX PubMed=29910125; DOI=10.1016/j.stemcr.2018.05.009; RA Park J., Son Y., Lee N.G., Lee K., Lee D.G., Song J., Lee J., Kim S., RA Cho M.J., Jang J.H., Lee J., Park J.G., Kim Y.G., Kim J.S., Lee J., RA Cho Y.S., Park Y.J., Han B.S., Bae K.H., Han S., Kang B., Haam S., RA Lee S.H., Lee S.C., Min J.K.; RT "DSG2 Is a Functional Cell Surface Marker for Identification and Isolation RT of Human Pluripotent Stem Cells."; RL Stem Cell Reports 11:115-127(2018). RN [93] RP INTERACTION WITH FBXO16, SUBCELLULAR LOCATION, AND UBIQUITINATION. RX PubMed=30714168; DOI=10.1002/path.5252; RA Paul D., Islam S., Manne R.K., Dinesh U.S., Malonia S.K., Maity B., RA Boppana R., Rapole S., Shetty P.K., Santra M.K.; RT "F-box protein FBXO16 functions as a tumor suppressor by attenuating RT nuclear beta-catenin function."; RL J. Pathol. 248:266-279(2019). RN [94] RP INTERACTION WITH LMBR1L. RX PubMed=31073040; DOI=10.1126/science.aau0812; RA Choi J.H., Zhong X., McAlpine W., Liao T.C., Zhang D., Fang B., Russell J., RA Ludwig S., Nair-Gill E., Zhang Z., Wang K.W., Misawa T., Zhan X., Choi M., RA Wang T., Li X., Tang M., Sun Q., Yu L., Murray A.R., Moresco E.M.Y., RA Beutler B.; RT "LMBR1L regulates lymphopoiesis through Wnt/beta-catenin signaling."; RL Science 364:0-0(2019). RN [95] RP PHOSPHORYLATION AT THR-556 (MICROBIAL INFECTION), AND SUBCELLULAR LOCATION. RX PubMed=31801859; DOI=10.1128/jvi.01847-19; RA You H., Lin Y., Lin F., Yang M., Li J., Zhang R., Huang Z., Shen Q., RA Tang R., Zheng C.; RT "beta-Catenin Is Required for the cGAS/STING Signaling Pathway but RT Antagonized by the Herpes Simplex Virus 1 US3 Protein."; RL J. Virol. 94:0-0(2020). RN [96] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 133-664. RX PubMed=11136974; DOI=10.1016/s0092-8674(00)00192-6; RA Graham T.A., Weaver C., Mao F., Kimelman D., Xu W.; RT "Crystal structure of a beta-catenin/Tcf complex."; RL Cell 103:885-896(2000). RN [97] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 134-664 IN COMPLEX WITH TCF7L2, RP AND MUTAGENESIS OF LYS-312 AND LYS-435. RX PubMed=11713475; DOI=10.1038/nsb718; RA Graham T.A., Ferkey D.M., Mao F., Kimelman D., Xu W.; RT "Tcf4 can specifically recognize beta-catenin using alternative RT conformations."; RL Nat. Struct. Biol. 8:1048-1052(2001). RN [98] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 134-668 IN COMPLEX WITH TCF7L2. RX PubMed=11713476; DOI=10.1038/nsb720; RA Poy F., Lepourcelet M., Shivdasani R.A., Eck M.J.; RT "Structure of a human Tcf4-beta-catenin complex."; RL Nat. Struct. Biol. 8:1053-1057(2001). RN [99] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 134-664 IN COMPLEX WITH CTNNBIP1, RP AND MUTAGENESIS OF PHE-660 AND ARG-661. RX PubMed=12408824; DOI=10.1016/s1097-2765(02)00637-8; RA Graham T.A., Clements W.K., Kimelman D., Xu W.; RT "The crystal structure of the beta-catenin/ICAT complex reveals the RT inhibitory mechanism of ICAT."; RL Mol. Cell 10:563-571(2002). RN [100] RP X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 1-136 IN COMPLEX WITH BCL9 AND RP TCF7L2, INTERACTION WITH BCL9; BCL9L CDH3 AND TCF7L2, AND MUTAGENESIS OF RP TYR-142; LEU-156; LEU-159 AND LEU-178. RX PubMed=17052462; DOI=10.1016/j.molcel.2006.09.001; RA Sampietro J., Dahlberg C.L., Cho U.S., Hinds T.R., Kimelman D., Xu W.; RT "Crystal structure of a beta-catenin/BCL9/Tcf4 complex."; RL Mol. Cell 24:293-300(2006). RN [101] {ECO:0007744|PDB:3TX7} RP X-RAY CRYSTALLOGRAPHY (2.76 ANGSTROMS) OF 183-663 COMPLEX WITH NR5A2, RP FUNCTION, AND INTERACTION WITH NR5A2. RX PubMed=22187462; DOI=10.1073/pnas.1117036108; RA Yumoto F., Nguyen P., Sablin E.P., Baxter J.D., Webb P., Fletterick R.J.; RT "Structural basis of coactivation of liver receptor homolog-1 by beta- RT catenin."; RL Proc. Natl. Acad. Sci. U.S.A. 109:143-148(2012). RN [102] RP VARIANTS COLORECTAL CANCER TYR-33 AND SER-45 DEL. RX PubMed=9065402; DOI=10.1126/science.275.5307.1787; RA Morin P.J., Sparks A.B., Korinek V., Barker N., Clevers H., Vogelstein B., RA Kinzler K.W.; RT "Activation of beta-catenin-Tcf signaling in colon cancer by mutations in RT beta-catenin or APC."; RL Science 275:1787-1790(1997). RN [103] RP VARIANTS HEPATOBLASTOMA TYR-32; VAL-34; CYS-37 AND ALA-41. RX PubMed=9927029; RA Koch A., Denkhaus D., Albrecht S., Leuschner I., von Schweinitz D., RA Pietsch T.; RT "Childhood hepatoblastomas frequently carry a mutated degradation targeting RT box of the beta-catenin gene."; RL Cancer Res. 59:269-273(1999). RN [104] RP VARIANT HEPATOBLASTOMA ALA-41. RX PubMed=10398436; RX DOI=10.1002/(sici)1098-2264(199908)25:4<399::aid-gcc14>3.3.co;2-o; RA Blaeker H., Hofmann W.J., Rieker R.J., Penzel R., Graf M., Otto H.F.; RT "Beta-catenin accumulation and mutation of the CTNNB1 gene in RT hepatoblastoma."; RL Genes Chromosomes Cancer 25:399-402(1999). RN [105] RP VARIANTS OVARIAN CANCER CYS-37; ILE-41 AND ALA-41. RX PubMed=10391090; DOI=10.1111/j.1349-7006.1999.tb00777.x; RA Sagae S., Kobayashi K., Nishioka Y., Sugimura M., Ishioka S., Nagata M., RA Terasawa K., Tokino T., Kudo R.; RT "Mutational analysis of beta-catenin gene in Japanese ovarian carcinomas: RT frequent mutations in endometrioid carcinomas."; RL Jpn. J. Cancer Res. 90:510-515(1999). RN [106] RP VARIANT DESMOID TUMOR ALA-41. RX PubMed=10655994; DOI=10.1136/jcp.52.9.695; RA Shitoh K., Konishi F., Iijima T., Ohdaira T., Sakai K., Kanazawa K., RA Miyaki M.; RT "A novel case of a sporadic desmoid tumour with mutation of the beta RT catenin gene."; RL J. Clin. Pathol. 52:695-696(1999). RN [107] RP VARIANTS PTR GLY-32; TYR-32; PHE-33; TYR-33; GLU-34; CYS-37; PHE-37 AND RP ILE-41. RX PubMed=10192393; DOI=10.1038/7747; RA Chan E.F., Gat U., McNiff J.M., Fuchs E.; RT "A common human skin tumour is caused by activating mutations in beta- RT catenin."; RL Nat. Genet. 21:410-413(1999). RN [108] RP VARIANTS HEPATOCELLULAR CARCINOMA ARG-23; 25-TRP--SER-33 DEL; ALA-32; RP GLY-32; TYR-32; LEU-33; PHE-33; ARG-34; SER-35; ALA-37; 37-SER-GLY-38 RP DELINS TRP; TYR-37; ALA-41; ILE-41; PHE-45 AND PRO-45. RX PubMed=10435629; DOI=10.1038/sj.onc.1202800; RA Legoix P., Bluteau O., Bayer J., Perret C., Balabaud C., Belghiti J., RA Franco D., Thomas G., Laurent-Puig P., Zucman-Rossi J.; RT "Beta-catenin mutations in hepatocellular carcinoma correlate with a low RT rate of loss of heterozygosity."; RL Oncogene 18:4044-4046(1999). RN [109] RP VARIANTS MDB PHE-33 AND ALA-37. RX PubMed=10666372; DOI=10.1016/s0002-9440(10)64747-5; RA Huang H., Mahler-Araujo B.M., Sankila A., Chimelli L., Yonekawa Y., RA Kleihues P., Ohgaki H.; RT "APC mutations in sporadic medulloblastomas."; RL Am. J. Pathol. 156:433-437(2000). RN [110] RP VARIANT NEDSDV PRO-388. RX PubMed=25326669; DOI=10.1007/s00439-014-1498-1; RA Kuechler A., Willemsen M.H., Albrecht B., Bacino C.A., Bartholomew D.W., RA van Bokhoven H., van den Boogaard M.J., Bramswig N., Buettner C., RA Cremer K., Czeschik J.C., Engels H., van Gassen K., Graf E., van Haelst M., RA He W., Hogue J.S., Kempers M., Koolen D., Monroe G., de Munnik S., RA Pastore M., Reis A., Reuter M.S., Tegay D.H., Veltman J., Visser G., RA van Hasselt P., Smeets E.E., Vissers L., Wieland T., Wissink W., Yntema H., RA Zink A.M., Strom T.M., Luedecke H.J., Kleefstra T., Wieczorek D.; RT "De novo mutations in beta-catenin (CTNNB1) appear to be a frequent cause RT of intellectual disability: expanding the mutational and clinical RT spectrum."; RL Hum. Genet. 134:97-109(2015). RN [111] RP VARIANT NEDSDV 558-GLN--LEU-781 DEL. RX PubMed=28514307; DOI=10.1097/md.0000000000006914; RA Li N., Xu Y., Li G., Yu T., Yao R.E., Wang X., Wang J.; RT "Exome sequencing identifies a de novo mutation of CTNNB1 gene in a patient RT mainly presented with retinal detachment, lens and vitreous opacities, RT microcephaly, and developmental delay: Case report and literature review."; RL Medicine (Baltimore) 96:E6914-E6914(2017). RN [112] RP VARIANT ASN-292, AND CHARACTERIZATION OF VARIANT ASN-292. RX PubMed=38173341; DOI=10.1210/clinem/dgad757; RA Huybrechts Y., Appelman-Dijkstra N.M., Steenackers E., Van Beylen W., RA Mortier G., Hendrickx G., Van Hul W.; RT "A mosaic variant in CTNNB1/beta-catenin as a novel cause for osteopathia RT striata with cranial sclerosis."; RL J. Clin. Endocrinol. Metab. 0:0-0(2024). CC -!- FUNCTION: Key downstream component of the canonical Wnt signaling CC pathway (PubMed:17524503, PubMed:18077326, PubMed:18086858, CC PubMed:18957423, PubMed:21262353, PubMed:22155184, PubMed:22647378, CC PubMed:22699938). In the absence of Wnt, forms a complex with AXIN1, CC AXIN2, APC, CSNK1A1 and GSK3B that promotes phosphorylation on N- CC terminal Ser and Thr residues and ubiquitination of CTNNB1 via BTRC and CC its subsequent degradation by the proteasome (PubMed:17524503, CC PubMed:18077326, PubMed:18086858, PubMed:18957423, PubMed:21262353, CC PubMed:22155184, PubMed:22647378, PubMed:22699938). In the presence of CC Wnt ligand, CTNNB1 is not ubiquitinated and accumulates in the nucleus, CC where it acts as a coactivator for transcription factors of the TCF/LEF CC family, leading to activate Wnt responsive genes (PubMed:17524503, CC PubMed:18077326, PubMed:18086858, PubMed:18957423, PubMed:21262353, CC PubMed:22155184, PubMed:22647378, PubMed:22699938). Also acts as a CC coactivator for other transcription factors, such as NR5A2 CC (PubMed:22187462). Promotes epithelial to mesenchymal CC transition/mesenchymal to epithelial transition (EMT/MET) via driving CC transcription of CTNNB1/TCF-target genes (PubMed:29910125). Involved in CC the regulation of cell adhesion, as component of an E-cadherin:catenin CC adhesion complex (By similarity). Acts as a negative regulator of CC centrosome cohesion (PubMed:18086858). Involved in the CC CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization CC (PubMed:21262353). Blocks anoikis of malignant kidney and intestinal CC epithelial cells and promotes their anchorage-independent growth by CC down-regulating DAPK2 (PubMed:18957423). Disrupts PML function and PML- CC NB formation by inhibiting RANBP2-mediated sumoylation of PML CC (PubMed:22155184). Promotes neurogenesis by maintaining sympathetic CC neuroblasts within the cell cycle (By similarity). Involved in CC chondrocyte differentiation via interaction with SOX9: SOX9-binding CC competes with the binding sites of TCF/LEF within CTNNB1, thereby CC inhibiting the Wnt signaling (By similarity). Acts as a positive CC regulator of odontoblast differentiation during mesenchymal tooth germ CC formation, via promoting the transcription of differentiation factors CC such as LEF1, BMP2 and BMP4 (By similarity). Activity is repressed in a CC MSX1-mediated manner at the bell stage of mesenchymal tooth germ CC formation which prevents premature differentiation of odontoblasts (By CC similarity). {ECO:0000250|UniProtKB:Q02248, CC ECO:0000269|PubMed:17524503, ECO:0000269|PubMed:18077326, CC ECO:0000269|PubMed:18086858, ECO:0000269|PubMed:18957423, CC ECO:0000269|PubMed:21262353, ECO:0000269|PubMed:22155184, CC ECO:0000269|PubMed:22187462, ECO:0000269|PubMed:22647378, CC ECO:0000269|PubMed:22699938, ECO:0000269|PubMed:29910125}. CC -!- SUBUNIT: Two separate complex-associated pools are found in the CC cytoplasm. The majority is present as component of an E- CC cadherin:catenin adhesion complex composed of at least E-cadherin/CDH1 CC and beta-catenin/CTNNB1, and possibly alpha-catenin/CTNNA1; the complex CC is located to adherens junctions. The stable association of CTNNA1 is CC controversial as CTNNA1 was shown not to bind to F-actin when assembled CC in the complex. Alternatively, the CTNNA1-containing complex may be CC linked to F-actin by other proteins such as LIMA1. Another cytoplasmic CC pool is part of a large complex containing AXIN1, AXIN2, APC, CSNK1A1 CC and GSK3B that promotes phosphorylation on N-terminal Ser and Thr CC residues and ubiquitination of CTNNB1 via BTRC and its subsequent CC degradation by the proteasome. Wnt-dependent activation of DVL CC antagonizes the action of GSK3B. When GSK3B activity is inhibited the CC complex dissociates, CTNNB1 is dephosphorylated and is no longer CC targeted for destruction. The stabilized protein translocates to the CC nucleus, where it binds TCF/LEF-1 family members, BCL9, BCL9L and CC possibly also RUVBL1 and CHD8. Binds CTNNBIP and EP300. CTNNB1 forms a CC ternary complex with LEF1 and EP300 that is disrupted by CTNNBIP1 CC binding. Interacts with TAX1BP3 (via the PDZ domain); this interaction CC inhibits the transcriptional activity of CTNNB1. Interacts with AJAP1, CC BAIAP1, CARM1, CTNNA3, CXADR and PCDH11Y. Binds NHERF1. Interacts with CC GLIS2 and MUC1. Interacts with SLC30A9. Interacts with XIRP1. Interacts CC directly with AXIN1; the interaction is regulated by CDK2 CC phosphorylation of AXIN1. Interacts with SCRIB. Interacts with RAPGEF2. CC Interacts with PTPRU (via the cytoplasmic juxtamembrane domain). CC Interacts with EMD. Interacts with TNIK and TCF7L2. Interacts with CC SESTD1 and TRPC4. Interacts with CAV1. Interacts with TRPV4. The TRPV4 CC and CTNNB1 complex can interact with CDH1. Interacts with VCL. CC Interacts with PTPRJ. Interacts with PKT7 and CDK2. Interacts with FAT1 CC (via the cytoplasmic domain). Interacts with NANOS1 and NDRG2. CC Interacts with isoform 1 of NEK2. Interacts with both isoform 1 and CC isoform 2 of CDK5. Interacts with PTK6. Interacts with SOX7; this CC interaction may lead to proteasomal degradation of active CTNNB1 and CC thus inhibition of Wnt/beta-catenin-stimulated transcription. CC Identified in a complex with HINT1 and MITF. Interacts with FHIT. The CC CTNNB1 and TCF7L2/TCF4 complex interacts with PML (isoform PML-4). CC Interacts with FERMT2. Identified in a complex with TCF7L2/TCF4 and CC FERMT2 (PubMed:22699938, PubMed:29739711). Interacts with RORA. May CC interact with P-cadherin/CDH3. Interacts with RNF220 (PubMed:25266658). CC Interacts with CTNND2 (PubMed:25807484). Interacts (via the C-terminal CC region) with CBY1 (PubMed:12712206, PubMed:16424001, PubMed:19435523). CC The complex composed, at least, of APC, CTNNB1 and GSK3B interacts with CC JPT1; the interaction requires the inactive form of GSK3B CC (phosphorylated at 'Ser-9') (PubMed:25169422). Interacts with DLG5 (By CC similarity). Interacts with FAM53B; promoting translocation to the CC nucleus (PubMed:25183871). Interacts with TMEM170B (PubMed:29367600). CC Interacts with AHI1 (PubMed:21623382). Interacts with GID8 CC (PubMed:28829046). Component of an cadherin:catenin adhesion complex CC composed of at least of CDH26, beta-catenin/CTNNB1, alpha- CC catenin/CTNNA1 and p120 catenin/CTNND1 (PubMed:28051089). Forms a CC complex comprising APPL1, RUVBL2, APPL2, HDAC1 and HDAC2 CC (PubMed:19433865). Interacts with IRF2BPL; mediates the ubiquitination CC and degradation of CTNNB1 (PubMed:29374064). Interacts with AMFR (By CC similarity). Interacts with LMBR1L (PubMed:31073040). Interacts with CC SOX30; prevents interaction of CTNNB1 with TCF7L2/TCF4 and leads to CC inhibition of Wnt signaling (PubMed:29739711). Interacts with SOX9; CC inhibiting CTNNB1 activity by competing with the binding sites of CC TCF/LEF within CTNNB1, thereby inhibiting the Wnt signaling (By CC similarity). Interacts with SPN/CD43 cytoplasmic tail CC (PubMed:15003504). Interacts (when phosphorylated at Tyr-333) with CC isoform M2 of PKM (PKM2); promoting transcription activation CC (PubMed:22056988). Interacts with PKP2 (via HEAD domain) CC (PubMed:11790773). Interacts with CDH1 (PubMed:11790773). Interacts CC (when unphosphorylated) with FLYWCH1, perhaps preventing interaction of CC CTNNB1 with TCF4, and thereby regulating transcription activation; CC phosphorylation of CTNNB1 may inhibit the interaction CC (PubMed:30097457). Interacts (via the central armadillo domains) with CC probable transcriptional regulator ADNP (via N-terminal region); CC interaction is direct and stabilizes CTNNB1 by modulating its CC phosphorylation by glycogen synthase kinase-3 beta GSK3B (By CC similarity). Interacts with NR5A2 (PubMed:22187462). Interacts with CC DSG2; the interaction promotes localization of CTNNB1 at cell junctions CC thus reducing its nuclear localization and subsequent transcription of CC CTNNB1/TCF-target genes (PubMed:29910125). Interacts with FBXO16 CC (PubMed:30714168). {ECO:0000250|UniProtKB:Q02248, CC ECO:0000269|PubMed:10966653, ECO:0000269|PubMed:11389839, CC ECO:0000269|PubMed:11389840, ECO:0000269|PubMed:11590244, CC ECO:0000269|PubMed:11713475, ECO:0000269|PubMed:11713476, CC ECO:0000269|PubMed:11751639, ECO:0000269|PubMed:11790773, CC ECO:0000269|PubMed:12077367, ECO:0000269|PubMed:12297051, CC ECO:0000269|PubMed:12370829, ECO:0000269|PubMed:12408824, CC ECO:0000269|PubMed:12420223, ECO:0000269|PubMed:12501215, CC ECO:0000269|PubMed:12712206, ECO:0000269|PubMed:12830000, CC ECO:0000269|PubMed:14595118, ECO:0000269|PubMed:15003504, CC ECO:0000269|PubMed:16424001, ECO:0000269|PubMed:16858403, CC ECO:0000269|PubMed:17009320, ECO:0000269|PubMed:17047063, CC ECO:0000269|PubMed:17052462, ECO:0000269|PubMed:17289029, CC ECO:0000269|PubMed:17524503, ECO:0000269|PubMed:18077326, CC ECO:0000269|PubMed:18086858, ECO:0000269|PubMed:18378692, CC ECO:0000269|PubMed:18819930, ECO:0000269|PubMed:19433865, CC ECO:0000269|PubMed:19435523, ECO:0000269|PubMed:19693690, CC ECO:0000269|PubMed:19816403, ECO:0000269|PubMed:19996314, CC ECO:0000269|PubMed:20026641, ECO:0000269|PubMed:20164195, CC ECO:0000269|PubMed:21132015, ECO:0000269|PubMed:21247902, CC ECO:0000269|PubMed:21262353, ECO:0000269|PubMed:21623382, CC ECO:0000269|PubMed:22056988, ECO:0000269|PubMed:22155184, CC ECO:0000269|PubMed:22187462, ECO:0000269|PubMed:22647378, CC ECO:0000269|PubMed:22699938, ECO:0000269|PubMed:25169422, CC ECO:0000269|PubMed:25183871, ECO:0000269|PubMed:25266658, CC ECO:0000269|PubMed:25807484, ECO:0000269|PubMed:28051089, CC ECO:0000269|PubMed:28829046, ECO:0000269|PubMed:29367600, CC ECO:0000269|PubMed:29374064, ECO:0000269|PubMed:29432739, CC ECO:0000269|PubMed:29739711, ECO:0000269|PubMed:29910125, CC ECO:0000269|PubMed:30714168, ECO:0000269|PubMed:31073040, CC ECO:0000269|PubMed:7982500, ECO:0000305|PubMed:31073040}. CC -!- SUBUNIT: (Microbial infection) Interacts with herpes virus 8 protein CC vPK; this interaction inhibits the Wnt signaling pathway. CC {ECO:0000269|PubMed:29432739}. CC -!- INTERACTION: CC P35222; P01023: A2M; NbExp=3; IntAct=EBI-491549, EBI-640741; CC P35222; P00519: ABL1; NbExp=2; IntAct=EBI-491549, EBI-375543; CC P35222; O43707: ACTN4; NbExp=7; IntAct=EBI-491549, EBI-351526; CC P35222; Q02952: AKAP12; NbExp=2; IntAct=EBI-491549, EBI-2562430; CC P35222; Q5JTC6: AMER1; NbExp=9; IntAct=EBI-491549, EBI-6169747; CC P35222; P25054: APC; NbExp=22; IntAct=EBI-491549, EBI-727707; CC P35222; P10275: AR; NbExp=15; IntAct=EBI-491549, EBI-608057; CC P35222; Q5T5U3: ARHGAP21; NbExp=2; IntAct=EBI-491549, EBI-1642518; CC P35222; O15169: AXIN1; NbExp=44; IntAct=EBI-491549, EBI-710484; CC P35222; Q9Y2T1: AXIN2; NbExp=2; IntAct=EBI-491549, EBI-4400025; CC P35222; O00512: BCL9; NbExp=5; IntAct=EBI-491549, EBI-533127; CC P35222; A1Z199: BCR/ABL fusion; NbExp=2; IntAct=EBI-491549, EBI-7286259; CC P35222; P23560-2: BDNF; NbExp=3; IntAct=EBI-491549, EBI-12275524; CC P35222; Q2LD37: BLTP1; NbExp=2; IntAct=EBI-491549, EBI-2683809; CC P35222; Q9Y297: BTRC; NbExp=8; IntAct=EBI-491549, EBI-307461; CC P35222; P55212: CASP6; NbExp=3; IntAct=EBI-491549, EBI-718729; CC P35222; P35520: CBS; NbExp=3; IntAct=EBI-491549, EBI-740135; CC P35222; Q6P1J9: CDC73; NbExp=10; IntAct=EBI-491549, EBI-930143; CC P35222; P12830: CDH1; NbExp=23; IntAct=EBI-491549, EBI-727477; CC P35222; P19022: CDH2; NbExp=12; IntAct=EBI-491549, EBI-2256711; CC P35222; P33151: CDH5; NbExp=11; IntAct=EBI-491549, EBI-2903122; CC P35222; Q92793: CREBBP; NbExp=2; IntAct=EBI-491549, EBI-81215; CC P35222; P02511: CRYAB; NbExp=6; IntAct=EBI-491549, EBI-739060; CC P35222; P35221: CTNNA1; NbExp=8; IntAct=EBI-491549, EBI-701918; CC P35222; P26232: CTNNA2; NbExp=5; IntAct=EBI-491549, EBI-3953920; CC P35222; Q9UI47-1: CTNNA3; NbExp=4; IntAct=EBI-491549, EBI-21980640; CC P35222; Q9NSA3: CTNNBIP1; NbExp=19; IntAct=EBI-491549, EBI-747082; CC P35222; Q9NYF0: DACT1; NbExp=3; IntAct=EBI-491549, EBI-3951744; CC P35222; G5E9A7: DMWD; NbExp=3; IntAct=EBI-491549, EBI-10976677; CC P35222; P26358: DNMT1; NbExp=8; IntAct=EBI-491549, EBI-719459; CC P35222; Q8TEK3: DOT1L; NbExp=3; IntAct=EBI-491549, EBI-2619253; CC P35222; P18146: EGR1; NbExp=7; IntAct=EBI-491549, EBI-2834611; CC P35222; P50402: EMD; NbExp=3; IntAct=EBI-491549, EBI-489887; CC P35222; P29317: EPHA2; NbExp=2; IntAct=EBI-491549, EBI-702104; CC P35222; Q9UKB1: FBXW11; NbExp=4; IntAct=EBI-491549, EBI-355189; CC P35222; Q96AC1: FERMT2; NbExp=13; IntAct=EBI-491549, EBI-4399465; CC P35222; Q92915-2: FGF14; NbExp=3; IntAct=EBI-491549, EBI-12836320; CC P35222; P11362: FGFR1; NbExp=3; IntAct=EBI-491549, EBI-1028277; CC P35222; P49789: FHIT; NbExp=4; IntAct=EBI-491549, EBI-741760; CC P35222; Q08050: FOXM1; NbExp=16; IntAct=EBI-491549, EBI-866480; CC P35222; P04406: GAPDH; NbExp=3; IntAct=EBI-491549, EBI-354056; CC P35222; P14136: GFAP; NbExp=3; IntAct=EBI-491549, EBI-744302; CC P35222; Q9BZE0: GLIS2; NbExp=6; IntAct=EBI-491549, EBI-7251368; CC P35222; P49841: GSK3B; NbExp=20; IntAct=EBI-491549, EBI-373586; CC P35222; Q9UBN7: HDAC6; NbExp=4; IntAct=EBI-491549, EBI-301697; CC P35222; Q16665: HIF1A; NbExp=4; IntAct=EBI-491549, EBI-447269; CC P35222; O00291: HIP1; NbExp=3; IntAct=EBI-491549, EBI-473886; CC P35222; P07900: HSP90AA1; NbExp=3; IntAct=EBI-491549, EBI-296047; CC P35222; P42858: HTT; NbExp=14; IntAct=EBI-491549, EBI-466029; CC P35222; P08069: IGF1R; NbExp=3; IntAct=EBI-491549, EBI-475981; CC P35222; P46940: IQGAP1; NbExp=3; IntAct=EBI-491549, EBI-297509; CC P35222; Q8WXH2: JPH3; NbExp=3; IntAct=EBI-491549, EBI-1055254; CC P35222; O75564: JRK; NbExp=3; IntAct=EBI-491549, EBI-8607681; CC P35222; Q14678: KANK1; NbExp=2; IntAct=EBI-491549, EBI-2556221; CC P35222; P13473-2: LAMP2; NbExp=3; IntAct=EBI-491549, EBI-21591415; CC P35222; Q9UJU2: LEF1; NbExp=10; IntAct=EBI-491549, EBI-926131; CC P35222; Q8WVC0: LEO1; NbExp=2; IntAct=EBI-491549, EBI-932432; CC P35222; Q14114-3: LRP8; NbExp=3; IntAct=EBI-491549, EBI-25832196; CC P35222; Q9GZQ8: MAP1LC3B; NbExp=5; IntAct=EBI-491549, EBI-373144; CC P35222; Q9Y2H9: MAST1; NbExp=2; IntAct=EBI-491549, EBI-3385920; CC P35222; P51608: MECP2; NbExp=3; IntAct=EBI-491549, EBI-1189067; CC P35222; P55197: MLLT10; NbExp=5; IntAct=EBI-491549, EBI-1104952; CC P35222; Q92597: NDRG1; NbExp=3; IntAct=EBI-491549, EBI-716486; CC P35222; P19404: NDUFV2; NbExp=3; IntAct=EBI-491549, EBI-713665; CC P35222; P19838: NFKB1; NbExp=3; IntAct=EBI-491549, EBI-300010; CC P35222; Q15599: NHERF2; NbExp=3; IntAct=EBI-491549, EBI-1149760; CC P35222; P29474: NOS3; NbExp=4; IntAct=EBI-491549, EBI-1391623; CC P35222; O00482-1: NR5A2; NbExp=5; IntAct=EBI-491549, EBI-15960777; CC P35222; P49757: NUMB; NbExp=2; IntAct=EBI-491549, EBI-915016; CC P35222; P49757-3: NUMB; NbExp=3; IntAct=EBI-491549, EBI-10692196; CC P35222; P14618: PKM; NbExp=4; IntAct=EBI-491549, EBI-353408; CC P35222; P14618-1: PKM; NbExp=3; IntAct=EBI-491549, EBI-4304679; CC P35222; O75400-2: PRPF40A; NbExp=3; IntAct=EBI-491549, EBI-5280197; CC P35222; Q03431: PTH1R; NbExp=4; IntAct=EBI-491549, EBI-2860297; CC P35222; Q13308: PTK7; NbExp=5; IntAct=EBI-491549, EBI-2803245; CC P35222; P08575: PTPRC; NbExp=2; IntAct=EBI-491549, EBI-1341; CC P35222; P23470: PTPRG; NbExp=2; IntAct=EBI-491549, EBI-2258115; CC P35222; Q12913: PTPRJ; NbExp=2; IntAct=EBI-491549, EBI-2264500; CC P35222; P49023: PXN; NbExp=4; IntAct=EBI-491549, EBI-702209; CC P35222; P62826: RAN; NbExp=3; IntAct=EBI-491549, EBI-286642; CC P35222; Q04206: RELA; NbExp=3; IntAct=EBI-491549, EBI-73886; CC P35222; Q13761: RUNX3; NbExp=12; IntAct=EBI-491549, EBI-925990; CC P35222; Q9Y265: RUVBL1; NbExp=3; IntAct=EBI-491549, EBI-353675; CC P35222; Q01826: SATB1; NbExp=9; IntAct=EBI-491549, EBI-743747; CC P35222; Q14160: SCRIB; NbExp=4; IntAct=EBI-491549, EBI-357345; CC P35222; Q9H6I2: SOX17; NbExp=2; IntAct=EBI-491549, EBI-9106753; CC P35222; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-491549, EBI-5235340; CC P35222; P12931: SRC; NbExp=2; IntAct=EBI-491549, EBI-621482; CC P35222; O14907: TAX1BP3; NbExp=6; IntAct=EBI-491549, EBI-723259; CC P35222; P15884: TCF4; NbExp=22; IntAct=EBI-491549, EBI-533224; CC P35222; P36402: TCF7; NbExp=4; IntAct=EBI-491549, EBI-2119465; CC P35222; Q9NQB0: TCF7L2; NbExp=27; IntAct=EBI-491549, EBI-924724; CC P35222; O14746: TERT; NbExp=2; IntAct=EBI-491549, EBI-1772203; CC P35222; Q9UKE5: TNIK; NbExp=3; IntAct=EBI-491549, EBI-1051794; CC P35222; P11388: TOP2A; NbExp=5; IntAct=EBI-491549, EBI-539628; CC P35222; O14656-2: TOR1A; NbExp=3; IntAct=EBI-491549, EBI-25847109; CC P35222; Q13625: TP53BP2; NbExp=5; IntAct=EBI-491549, EBI-77642; CC P35222; O95071: UBR5; NbExp=6; IntAct=EBI-491549, EBI-358329; CC P35222; P11473: VDR; NbExp=2; IntAct=EBI-491549, EBI-286357; CC P35222; Q9GZV5: WWTR1; NbExp=4; IntAct=EBI-491549, EBI-747743; CC P35222; P46937: YAP1; NbExp=16; IntAct=EBI-491549, EBI-1044059; CC P35222; P46937-3: YAP1; NbExp=2; IntAct=EBI-491549, EBI-6558686; CC P35222; O35625: Axin1; Xeno; NbExp=4; IntAct=EBI-491549, EBI-2365912; CC P35222; Q9YGY0: axin1; Xeno; NbExp=2; IntAct=EBI-491549, EBI-1037449; CC P35222; Q67FY2: Bcl9l; Xeno; NbExp=2; IntAct=EBI-491549, EBI-5234367; CC P35222; P33724: CAV1; Xeno; NbExp=5; IntAct=EBI-491549, EBI-79998; CC P35222; P26231: Ctnna1; Xeno; NbExp=2; IntAct=EBI-491549, EBI-647895; CC P35222; P27782: Lef1; Xeno; NbExp=2; IntAct=EBI-491549, EBI-984464; CC P35222; Q01887: Ryk; Xeno; NbExp=2; IntAct=EBI-491549, EBI-16110594; CC P35222; P18012: sctB; Xeno; NbExp=4; IntAct=EBI-491549, EBI-491541; CC P35222; P40645: Sox6; Xeno; NbExp=2; IntAct=EBI-491549, EBI-3505685; CC P35222; Q9DBG9: Tax1bp3; Xeno; NbExp=3; IntAct=EBI-491549, EBI-1161647; CC P35222; Q9EPK5: Wwtr1; Xeno; NbExp=2; IntAct=EBI-491549, EBI-1211920; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:22294297, CC ECO:0000269|PubMed:25183871, ECO:0000269|PubMed:29739711, CC ECO:0000269|PubMed:29910125, ECO:0000269|PubMed:31801859}. Nucleus CC {ECO:0000269|PubMed:21118991, ECO:0000269|PubMed:24342833, CC ECO:0000269|PubMed:25183871, ECO:0000269|PubMed:28829046, CC ECO:0000269|PubMed:29367600, ECO:0000269|PubMed:29739711, CC ECO:0000269|PubMed:29910125, ECO:0000269|PubMed:30714168, CC ECO:0000269|PubMed:31801859}. Cytoplasm, cytoskeleton CC {ECO:0000250|UniProtKB:B6V8E6}. Cell junction, adherens junction CC {ECO:0000269|PubMed:10725230, ECO:0000269|PubMed:22294297}. Cell CC junction {ECO:0000250|UniProtKB:B6V8E6}. Cell membrane CC {ECO:0000269|PubMed:11790773, ECO:0000269|PubMed:24342833}. Cytoplasm, CC cytoskeleton, microtubule organizing center, centrosome. Cytoplasm, CC cytoskeleton, spindle pole. Synapse {ECO:0000250|UniProtKB:Q02248}. CC Cytoplasm, cytoskeleton, cilium basal body CC {ECO:0000250|UniProtKB:Q02248}. Note=Colocalized with RAPGEF2 and TJP1 CC at cell-cell contacts (By similarity). Cytoplasmic when it is un-stable CC (highly phosphorylated) or bound to CDH1. Translocates to the nucleus CC when it is stabilized (low level of phosphorylation). Interaction with CC GLIS2 and MUC1 promotes nuclear translocation. Interaction with EMD CC inhibits nuclear localization. The majority of CTNNB1 is localized to CC the cell membrane. In interphase, colocalizes with CROCC between CEP250 CC puncta at the proximal end of centrioles, and this localization is CC dependent on CROCC and CEP250. In mitosis, when NEK2 activity CC increases, it localizes to centrosomes at spindle poles independent of CC CROCC. Colocalizes with CDK5 in the cell-cell contacts and plasma CC membrane of undifferentiated and differentiated neuroblastoma cells. CC Interaction with FAM53B promotes translocation to the nucleus CC (PubMed:25183871). Translocates to the nucleus in the presence of CC SNAIL1 (By similarity). Ca(2+)-mediated localization to the cell CC membrane in dental epithelial cells is inhibited via WNT3A (By CC similarity). Localizes to cell-cell contacts as keratinocyte CC differentiation progresses (By similarity). CC {ECO:0000250|UniProtKB:B6V8E6, ECO:0000250|UniProtKB:Q02248, CC ECO:0000269|PubMed:25183871}. CC -!- TISSUE SPECIFICITY: Expressed in several hair follicle cell types: CC basal and peripheral matrix cells, and cells of the outer and inner CC root sheaths. Expressed in colon. Present in cortical neurons (at CC protein level). Expressed in breast cancer tissues (at protein level) CC (PubMed:29367600). {ECO:0000269|PubMed:11703283, CC ECO:0000269|PubMed:17009320, ECO:0000269|PubMed:17289029, CC ECO:0000269|PubMed:29367600}. CC -!- PTM: Phosphorylation at Ser-552 by AMPK promotes stabilization of the CC protein, enhancing TCF/LEF-mediated transcription (By similarity). CC Phosphorylation by GSK3B requires prior phosphorylation of Ser-45 by CC another kinase (PubMed:10966653, PubMed:12027456, PubMed:12051714). CC Phosphorylation proceeds then from Thr-41 to Ser-37 and Ser-33 CC (PubMed:12077367, PubMed:25169422). Phosphorylated by NEK2 CC (PubMed:18086858). EGF stimulates tyrosine phosphorylation CC (PubMed:10187801). Phosphorylated on Ser-33 and Ser-37 by HIPK2 and CC GSK3B, this phosphorylation triggers proteasomal degradation CC (PubMed:20307497). Phosphorylation on Ser-191 and Ser-246 by CDK5 CC (PubMed:17009320). Phosphorylation by CDK2 regulates insulin CC internalization (PubMed:21262353). Phosphorylation by PTK6 at Tyr-64, CC Tyr-142, Tyr-331 and/or Tyr-333 with the predominant site at Tyr-64 is CC not essential for inhibition of transcriptional activity CC (PubMed:20026641). Phosphorylation by SRC at Tyr-333 promotes CC interaction with isoform M2 of PKM (PKM2); promoting transcription CC activation (PubMed:22056988). {ECO:0000250|UniProtKB:Q02248, CC ECO:0000269|PubMed:10187801, ECO:0000269|PubMed:10966653, CC ECO:0000269|PubMed:12027456, ECO:0000269|PubMed:12051714, CC ECO:0000269|PubMed:12077367, ECO:0000269|PubMed:17009320, CC ECO:0000269|PubMed:18086858, ECO:0000269|PubMed:20026641, CC ECO:0000269|PubMed:20307497, ECO:0000269|PubMed:21262353, CC ECO:0000269|PubMed:22056988, ECO:0000269|PubMed:25169422}. CC -!- PTM: Ubiquitinated by the SCF(BTRC) E3 ligase complex when CC phosphorylated by GSK3B, leading to its degradation (PubMed:12077367). CC Ubiquitinated by a E3 ubiquitin ligase complex containing UBE2D1, CC SIAH1, CACYBP/SIP, SKP1, APC and TBL1X, leading to its subsequent CC proteasomal degradation (PubMed:11389839, PubMed:11389840, CC PubMed:20307497). Ubiquitinated and degraded following interaction with CC SOX9 (By similarity). Ubiquitinated via 'Lys-11'- and 'Lys-29'-linked CC ubiquitin chains by UBR5, leading to its stabilization CC (PubMed:21118991). Ubiquitinated by the SCF-FBXO16 E3 ubiquitin ligase, CC leading to proteasomal degradation (PubMed:30714168). CC {ECO:0000250|UniProtKB:Q02248, ECO:0000269|PubMed:11389839, CC ECO:0000269|PubMed:11389840, ECO:0000269|PubMed:12077367, CC ECO:0000269|PubMed:20307497, ECO:0000269|PubMed:21118991, CC ECO:0000269|PubMed:30714168}. CC -!- PTM: S-nitrosylation at Cys-619 within adherens junctions promotes CC VEGF-induced, NO-dependent endothelial cell permeability by disrupting CC interaction with E-cadherin, thus mediating disassembly adherens CC junctions. {ECO:0000250|UniProtKB:Q02248}. CC -!- PTM: O-glycosylation at Ser-23 decreases nuclear localization and CC transcriptional activity, and increases localization to the plasma CC membrane and interaction with E-cadherin CDH1. CC {ECO:0000269|PubMed:24342833}. CC -!- PTM: Deacetylated at Lys-49 by SIRT1. {ECO:0000269|PubMed:24824780}. CC -!- PTM: Phosphorylated at Thr-556 by herpes virus 1/HHV-1 leading to CC CTNNB1 inhibition. {ECO:0000269|PubMed:24824780}. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:9065402}. Note=The gene CC represented in this entry may be involved in disease pathogenesis. CC -!- DISEASE: Note=Activating mutations in CTNNB1 have oncogenic activity CC resulting in tumor development. Somatic mutations are found in various CC tumor types, including colon cancers, ovarian and prostate carcinomas, CC hepatoblastoma (HB), hepatocellular carcinoma (HCC). HBs are malignant CC embryonal tumors mainly affecting young children in the first three CC years of life. CC -!- DISEASE: Pilomatrixoma (PTR) [MIM:132600]: Common benign skin tumor. CC {ECO:0000269|PubMed:10192393, ECO:0000269|PubMed:11703283, CC ECO:0000269|PubMed:12027456}. Note=The gene represented in this entry CC is involved in disease pathogenesis. CC -!- DISEASE: Medulloblastoma (MDB) [MIM:155255]: Malignant, invasive CC embryonal tumor of the cerebellum with a preferential manifestation in CC children. {ECO:0000269|PubMed:10666372, ECO:0000269|PubMed:12027456}. CC Note=The gene represented in this entry may be involved in disease CC pathogenesis. CC -!- DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer CC defines malignancies originating from ovarian tissue. Although many CC histologic types of ovarian tumors have been described, epithelial CC ovarian carcinoma is the most common form. Ovarian cancers are often CC asymptomatic and the recognized signs and symptoms, even of late-stage CC disease, are vague. Consequently, most patients are diagnosed with CC advanced disease. {ECO:0000269|PubMed:10391090}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Note=A chromosomal aberration involving CTNNB1 is found in CC salivary gland pleiomorphic adenomas, the most common benign epithelial CC tumors of the salivary gland. Translocation t(3;8)(p21;q12) with PLAG1. CC {ECO:0000269|PubMed:10029085, ECO:0000269|PubMed:9020842}. CC -!- DISEASE: Mesothelioma, malignant (MESOM) [MIM:156240]: An aggressive CC neoplasm of the serosal lining of the chest. It appears as broad sheets CC of cells, with some regions containing spindle-shaped, sarcoma-like CC cells and other regions showing adenomatous patterns. Pleural CC mesotheliomas have been linked to exposure to asbestos. CC {ECO:0000269|PubMed:11464291}. Note=The gene represented in this entry CC may be involved in disease pathogenesis. CC -!- DISEASE: Neurodevelopmental disorder with spastic diplegia and visual CC defects (NEDSDV) [MIM:615075]: An autosomal dominant disorder CC characterized by global developmental delay, severe intellectual CC disability with absent or very limited speech, microcephaly, CC spasticity, and visual abnormalities. {ECO:0000269|PubMed:23033978, CC ECO:0000269|PubMed:25326669, ECO:0000269|PubMed:28514307}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Vitreoretinopathy, exudative 7 (EVR7) [MIM:617572]: An CC autosomal dominant form of exudative vitreoretinopathy, a disorder of CC the retinal vasculature characterized by an abrupt cessation of growth CC of peripheral capillaries, leading to an avascular peripheral retina. CC This may lead to compensatory retinal neovascularization, which is CC thought to be induced by hypoxia from the initial avascular insult. New CC vessels are prone to leakage and rupture causing exudates and bleeding, CC followed by scarring, retinal detachment and blindness. Clinical CC features can be highly variable, even within the same family. Patients CC with mild forms of the disease are asymptomatic, and their only disease CC related abnormality is an arc of avascular retina in the extreme CC temporal periphery. {ECO:0000269|PubMed:28575650}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the beta-catenin family. {ECO:0000305}. CC -!- CAUTION: A paper showing an interaction with TBP and phosphorylation at CC Tyr-86 and Tyr-654 has been retracted due to panel duplication in CC several figures. {ECO:0000269|PubMed:11279024, CC ECO:0000305|PubMed:27226643}. CC -!- SEQUENCE CAUTION: CC Sequence=AAG35511.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305}; CC Sequence=BAB93475.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/71/CTNNB1"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=Beta-catenin entry; CC URL="https://en.wikipedia.org/wiki/Beta-catenin"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X87838; CAA61107.1; -; mRNA. DR EMBL; Z19054; CAA79497.1; -; mRNA. DR EMBL; AF130085; AAG35511.1; ALT_SEQ; mRNA. DR EMBL; AY463360; AAR18817.1; -; Genomic_DNA. DR EMBL; AK289932; BAF82621.1; -; mRNA. DR EMBL; AC104307; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471055; EAW64625.1; -; Genomic_DNA. DR EMBL; BC058926; AAH58926.1; -; mRNA. DR EMBL; AY081165; AAL89457.1; -; Genomic_DNA. DR EMBL; AB062292; BAB93475.1; ALT_INIT; mRNA. DR CCDS; CCDS2694.1; -. DR PIR; A38973; A38973. DR RefSeq; NP_001091679.1; NM_001098209.2. DR RefSeq; NP_001091680.1; NM_001098210.2. DR RefSeq; NP_001425800.1; NM_001438871.1. DR RefSeq; NP_001425801.1; NM_001438872.1. DR RefSeq; NP_001425802.1; NM_001438873.1. DR RefSeq; NP_001895.1; NM_001904.4. DR RefSeq; XP_024309124.1; XM_024453356.2. DR RefSeq; XP_047303434.1; XM_047447478.1. DR RefSeq; XP_047303435.1; XM_047447479.1. DR RefSeq; XP_047303436.1; XM_047447480.1. DR RefSeq; XP_054201285.1; XM_054345310.1. DR RefSeq; XP_054201286.1; XM_054345311.1. DR RefSeq; XP_054201287.1; XM_054345312.1. DR RefSeq; XP_054201288.1; XM_054345313.1. DR PDB; 1G3J; X-ray; 2.10 A; A/C=133-664. DR PDB; 1JDH; X-ray; 1.90 A; A=135-663. DR PDB; 1JPW; X-ray; 2.50 A; A/B/C=131-670. DR PDB; 1LUJ; X-ray; 2.50 A; A=150-663. DR PDB; 1P22; X-ray; 2.95 A; C=19-44. DR PDB; 1QZ7; X-ray; 2.20 A; A=133-665. DR PDB; 1T08; X-ray; 2.10 A; A=146-664. DR PDB; 1TH1; X-ray; 2.50 A; A/B=133-664. DR PDB; 2G57; NMR; -; A=19-44. DR PDB; 2GL7; X-ray; 2.60 A; A/D=138-686. DR PDB; 2Z6H; X-ray; 2.20 A; A=138-781. DR PDB; 3DIW; X-ray; 2.10 A; C/D=772-781. DR PDB; 3FQN; X-ray; 1.65 A; C=30-39. DR PDB; 3FQR; X-ray; 1.70 A; C=30-39. DR PDB; 3SL9; X-ray; 2.20 A; A/B/E/G=141-305. DR PDB; 3SLA; X-ray; 2.50 A; A/B/C/D/E=141-306. DR PDB; 3TX7; X-ray; 2.76 A; A=138-663. DR PDB; 4DJS; X-ray; 3.03 A; A=148-665. DR PDB; 6M90; X-ray; 2.05 A; C=17-48. DR PDB; 6M91; X-ray; 2.40 A; C=17-48. DR PDB; 6M92; X-ray; 2.35 A; C=17-48. DR PDB; 6M93; X-ray; 2.50 A; C=17-48. DR PDB; 6M94; X-ray; 2.70 A; C=17-48. DR PDB; 6O9B; X-ray; 2.20 A; C=41-49. DR PDB; 6O9C; X-ray; 2.45 A; C=41-49. DR PDB; 6WLX; X-ray; 2.20 A; B=671-677. DR PDB; 6WNX; X-ray; 2.50 A; C/F/I=31-39. DR PDB; 7AFW; X-ray; 1.81 A; A=141-305. DR PDB; 7AR4; X-ray; 2.60 A; AAA=134-665. DR PDB; 7UWI; X-ray; 2.32 A; A=143-663. DR PDB; 7UWO; X-ray; 2.75 A; A=134-665. DR PDB; 7ZRB; X-ray; 3.43 A; A/B=133-664. DR PDB; 8EI9; X-ray; 3.90 A; A=134-665. DR PDB; 8EIA; X-ray; 3.60 A; A=134-665. DR PDB; 8EIB; X-ray; 3.76 A; A=134-665. DR PDB; 8EIC; X-ray; 2.62 A; A=134-665. DR PDB; 8RU3; X-ray; 2.00 A; A=134-665. DR PDB; 8RU4; X-ray; 2.13 A; A/B=145-665. DR PDB; 8VME; X-ray; 2.30 A; C=35-61. DR PDB; 8VMF; X-ray; 2.50 A; C=35-61. DR PDB; 8Y0G; X-ray; 2.50 A; A=138-686. DR PDB; 8Y0P; X-ray; 2.62 A; A/B=138-686. DR PDB; 8Y14; X-ray; 2.80 A; A=138-686. DR PDB; 8Z0U; X-ray; 2.21 A; A=138-686. DR PDB; 8Z10; X-ray; 2.35 A; A=138-686. DR PDB; 8Z5J; X-ray; 2.80 A; A=138-686. DR PDB; 8Z61; X-ray; 2.50 A; A=138-686. DR PDBsum; 1G3J; -. DR PDBsum; 1JDH; -. DR PDBsum; 1JPW; -. DR PDBsum; 1LUJ; -. DR PDBsum; 1P22; -. DR PDBsum; 1QZ7; -. DR PDBsum; 1T08; -. DR PDBsum; 1TH1; -. DR PDBsum; 2G57; -. DR PDBsum; 2GL7; -. DR PDBsum; 2Z6H; -. DR PDBsum; 3DIW; -. DR PDBsum; 3FQN; -. DR PDBsum; 3FQR; -. DR PDBsum; 3SL9; -. DR PDBsum; 3SLA; -. DR PDBsum; 3TX7; -. DR PDBsum; 4DJS; -. DR PDBsum; 6M90; -. DR PDBsum; 6M91; -. DR PDBsum; 6M92; -. DR PDBsum; 6M93; -. DR PDBsum; 6M94; -. DR PDBsum; 6O9B; -. DR PDBsum; 6O9C; -. DR PDBsum; 6WLX; -. DR PDBsum; 6WNX; -. DR PDBsum; 7AFW; -. DR PDBsum; 7AR4; -. DR PDBsum; 7UWI; -. DR PDBsum; 7UWO; -. DR PDBsum; 7ZRB; -. DR PDBsum; 8EI9; -. DR PDBsum; 8EIA; -. DR PDBsum; 8EIB; -. DR PDBsum; 8EIC; -. DR PDBsum; 8RU3; -. DR PDBsum; 8RU4; -. DR PDBsum; 8VME; -. DR PDBsum; 8VMF; -. DR PDBsum; 8Y0G; -. DR PDBsum; 8Y0P; -. DR PDBsum; 8Y14; -. DR PDBsum; 8Z0U; -. DR PDBsum; 8Z10; -. DR PDBsum; 8Z5J; -. DR PDBsum; 8Z61; -. DR AlphaFoldDB; P35222; -. DR SMR; P35222; -. DR BioGRID; 107880; 1008. DR ComplexPortal; CPX-316; beta1-catenin - LEF1 complex. DR CORUM; P35222; -. DR DIP; DIP-122N; -. DR FunCoup; P35222; 2315. DR IntAct; P35222; 361. DR MINT; P35222; -. DR STRING; 9606.ENSP00000495360; -. DR BindingDB; P35222; -. DR ChEMBL; CHEMBL5866; -. DR DrugBank; DB03904; Urea. DR GlyCosmos; P35222; 4 sites, 1 glycan. DR GlyGen; P35222; 5 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (4 sites). DR iPTMnet; P35222; -. DR MetOSite; P35222; -. DR PhosphoSitePlus; P35222; -. DR SwissPalm; P35222; -. DR BioMuta; CTNNB1; -. DR DMDM; 461854; -. DR CPTAC; CPTAC-1745; -. DR CPTAC; non-CPTAC-3265; -. DR CPTAC; non-CPTAC-3266; -. DR CPTAC; non-CPTAC-5365; -. DR CPTAC; non-CPTAC-5715; -. DR CPTAC; non-CPTAC-5716; -. DR jPOST; P35222; -. DR MassIVE; P35222; -. DR PaxDb; 9606-ENSP00000344456; -. DR PeptideAtlas; P35222; -. DR PRIDE; P35222; -. DR Pumba; P35222; -. DR ABCD; P35222; 7 sequenced antibodies. DR Antibodypedia; 3432; 5164 antibodies from 59 providers. DR DNASU; 1499; -. DR Ensembl; ENST00000349496.11; ENSP00000344456.5; ENSG00000168036.20. DR Ensembl; ENST00000396183.7; ENSP00000379486.3; ENSG00000168036.20. DR Ensembl; ENST00000396185.8; ENSP00000379488.3; ENSG00000168036.20. DR Ensembl; ENST00000405570.6; ENSP00000385604.1; ENSG00000168036.20. DR Ensembl; ENST00000431914.6; ENSP00000412219.2; ENSG00000168036.20. DR Ensembl; ENST00000433400.6; ENSP00000387455.2; ENSG00000168036.20. DR Ensembl; ENST00000441708.2; ENSP00000401599.2; ENSG00000168036.20. DR Ensembl; ENST00000450969.6; ENSP00000409302.2; ENSG00000168036.20. DR Ensembl; ENST00000642248.1; ENSP00000495244.1; ENSG00000168036.20. DR Ensembl; ENST00000642315.1; ENSP00000495076.1; ENSG00000168036.20. DR Ensembl; ENST00000642426.1; ENSP00000495719.1; ENSG00000168036.20. DR Ensembl; ENST00000642992.1; ENSP00000496385.1; ENSG00000168036.20. DR Ensembl; ENST00000643031.1; ENSP00000495450.1; ENSG00000168036.20. DR Ensembl; ENST00000643297.1; ENSP00000494677.1; ENSG00000168036.20. DR Ensembl; ENST00000643541.1; ENSP00000494411.1; ENSG00000168036.20. DR Ensembl; ENST00000643977.1; ENSP00000494053.1; ENSG00000168036.20. DR Ensembl; ENST00000643992.1; ENSP00000493610.1; ENSG00000168036.20. DR Ensembl; ENST00000644867.1; ENSP00000495992.1; ENSG00000168036.20. DR Ensembl; ENST00000645210.1; ENSP00000496180.1; ENSG00000168036.20. DR Ensembl; ENST00000645320.1; ENSP00000495360.1; ENSG00000168036.20. DR Ensembl; ENST00000645982.1; ENSP00000494845.1; ENSG00000168036.20. DR Ensembl; ENST00000646369.1; ENSP00000494914.1; ENSG00000168036.20. DR Ensembl; ENST00000646725.1; ENSP00000496021.1; ENSG00000168036.20. DR Ensembl; ENST00000647390.1; ENSP00000493533.1; ENSG00000168036.20. DR Ensembl; ENST00000647413.2; ENSP00000493583.2; ENSG00000168036.20. DR GeneID; 1499; -. DR KEGG; hsa:1499; -. DR MANE-Select; ENST00000349496.11; ENSP00000344456.5; NM_001904.4; NP_001895.1. DR UCSC; uc003ckp.3; human. DR AGR; HGNC:2514; -. DR CIViC; 1499; 1 clinical assertion and 42 evidence items across 16 molecular profiles. DR ClinPGx; PA27013; -. DR CTD; 1499; -. DR DisGeNET; 1499; -. DR GeneCards; CTNNB1; -. DR GeneReviews; CTNNB1; -. DR HGNC; HGNC:2514; CTNNB1. DR HPA; ENSG00000168036; Low tissue specificity. DR MalaCards; CTNNB1; -. DR MIM; 114500; phenotype. DR MIM; 116806; gene. DR MIM; 132600; phenotype. DR MIM; 155255; phenotype. DR MIM; 156240; phenotype. DR MIM; 167000; phenotype. DR MIM; 181030; phenotype. DR MIM; 615075; phenotype. DR MIM; 617572; phenotype. DR OpenTargets; ENSG00000168036; -. DR Orphanet; 952; Acrofacial dysostosis, Weyers type. DR Orphanet; 689430; Adenoid ameloblastoma. DR Orphanet; 1501; Adrenocortical carcinoma. DR Orphanet; 210159; Adult hepatocellular carcinoma. DR Orphanet; 54595; Craniopharyngioma. DR Orphanet; 873; Desmoid tumor. DR Orphanet; 891; Familial exudative vitreoretinopathy. DR Orphanet; 404473; Intellectual disability-peripheral spasticity-exudative vitreoretinopathy syndrome. DR Orphanet; 569248; Microcystic stromal tumor. DR Orphanet; 2780; Osteopathia striata-cranial sclerosis syndrome. DR Orphanet; 33402; Pediatric hepatocellular carcinoma. DR Orphanet; 91414; Pilomatrixoma. DR VEuPathDB; HostDB:ENSG00000168036; -. DR eggNOG; KOG4203; Eukaryota. DR GeneTree; ENSGT00940000155471; -. DR InParanoid; P35222; -. DR OMA; YPKLVYT; -. DR OrthoDB; 195736at2759; -. DR PAN-GO; P35222; 12 GO annotations based on evolutionary models. DR PhylomeDB; P35222; -. DR PathwayCommons; P35222; -. DR Reactome; R-HSA-195253; Degradation of beta-catenin by the destruction complex. DR Reactome; R-HSA-196299; Beta-catenin phosphorylation cascade. DR Reactome; R-HSA-201681; TCF dependent signaling in response to WNT. DR Reactome; R-HSA-201722; Formation of the beta-catenin:TCF transactivating complex. DR Reactome; R-HSA-3134973; LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production. DR Reactome; R-HSA-351906; Apoptotic cleavage of cell adhesion proteins. DR Reactome; R-HSA-3769402; Deactivation of the beta-catenin transactivating complex. DR Reactome; R-HSA-381771; Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1). DR Reactome; R-HSA-4086398; Ca2+ pathway. DR Reactome; R-HSA-418990; Adherens junctions interactions. DR Reactome; R-HSA-4411364; Binding of TCF/LEF:CTNNB1 to target gene promoters. DR Reactome; R-HSA-4641262; Disassembly of the destruction complex and recruitment of AXIN to the membrane. DR Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability. DR Reactome; R-HSA-525793; Myogenesis. DR Reactome; R-HSA-5339716; Signaling by GSK3beta mutants. DR Reactome; R-HSA-5358747; CTNNB1 S33 mutants aren't phosphorylated. DR Reactome; R-HSA-5358749; CTNNB1 S37 mutants aren't phosphorylated. DR Reactome; R-HSA-5358751; CTNNB1 S45 mutants aren't phosphorylated. DR Reactome; R-HSA-5358752; CTNNB1 T41 mutants aren't phosphorylated. DR Reactome; R-HSA-5626467; RHO GTPases activate IQGAPs. DR Reactome; R-HSA-8853884; Transcriptional Regulation by VENTX. DR Reactome; R-HSA-8876493; InlA-mediated entry of Listeria monocytogenes into host cells. DR Reactome; R-HSA-8951430; RUNX3 regulates WNT signaling. DR Reactome; R-HSA-9733709; Cardiogenesis. DR Reactome; R-HSA-9754189; Germ layer formation at gastrulation. DR Reactome; R-HSA-9762292; Regulation of CDH11 function. DR Reactome; R-HSA-9764302; Regulation of CDH19 Expression and Function. DR Reactome; R-HSA-9764561; Regulation of CDH1 Function. DR Reactome; R-HSA-9766229; Degradation of CDH1. DR Reactome; R-HSA-9768727; Regulation of CDH1 posttranslational processing and trafficking to plasma membrane. DR Reactome; R-HSA-9793380; Formation of paraxial mesoderm. DR Reactome; R-HSA-9796292; Formation of axial mesoderm. DR Reactome; R-HSA-9823730; Formation of definitive endoderm. DR Reactome; R-HSA-9824272; Somitogenesis. DR Reactome; R-HSA-9824585; Regulation of MITF-M-dependent genes involved in pigmentation. DR Reactome; R-HSA-9825892; Regulation of MITF-M-dependent genes involved in cell cycle and proliferation. DR Reactome; R-HSA-9830364; Formation of the nephric duct. DR Reactome; R-HSA-9833576; CDH11 homotypic and heterotypic interactions. DR Reactome; R-HSA-9834899; Specification of the neural plate border. DR Reactome; R-HSA-9856530; High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells. DR Reactome; R-HSA-9856649; Transcriptional and post-translational regulation of MITF-M expression and activity. DR SignaLink; P35222; -. DR SIGNOR; P35222; -. DR Agora; ENSG00000168036; -. DR BioGRID-ORCS; 1499; 103 hits in 1178 CRISPR screens. DR CD-CODE; 38EC0B30; Transcriptional condensate. DR CD-CODE; 53379B70; LEF1/Beta-catenin condensate. DR CD-CODE; 7FF4107C; Beta-Catenin Destruction Complex. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; CTNNB1; human. DR EvolutionaryTrace; P35222; -. DR GeneWiki; Beta-catenin; -. DR GenomeRNAi; 1499; -. DR Pharos; P35222; Tchem. DR PRO; PR:P35222; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; P35222; protein. DR Bgee; ENSG00000168036; Expressed in adrenal tissue and 204 other cell types or tissues. DR ExpressionAtlas; P35222; baseline and differential. DR GO; GO:0005912; C:adherens junction; IDA:UniProtKB. DR GO; GO:0045177; C:apical part of cell; IEA:Ensembl. DR GO; GO:0016327; C:apicolateral plasma membrane; IEA:Ensembl. DR GO; GO:0016323; C:basolateral plasma membrane; IDA:UniProtKB. DR GO; GO:0030877; C:beta-catenin destruction complex; IDA:BHF-UCL. DR GO; GO:1990711; C:beta-catenin-ICAT complex; IEA:Ensembl. DR GO; GO:1990907; C:beta-catenin-TCF complex; IDA:FlyBase. DR GO; GO:0070369; C:beta-catenin-TCF7L2 complex; IDA:UniProtKB. DR GO; GO:0005923; C:bicellular tight junction; IEA:Ensembl. DR GO; GO:0016342; C:catenin complex; IDA:UniProtKB. DR GO; GO:0005938; C:cell cortex; IDA:BHF-UCL. DR GO; GO:0030054; C:cell junction; IDA:BHF-UCL. DR GO; GO:0071944; C:cell periphery; IDA:BHF-UCL. DR GO; GO:0005911; C:cell-cell junction; IDA:MGI. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0005929; C:cilium; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProtKB. DR GO; GO:0000791; C:euchromatin; IDA:BHF-UCL. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005916; C:fascia adherens; IEA:Ensembl. DR GO; GO:0016600; C:flotillin complex; IEA:Ensembl. DR GO; GO:0005925; C:focal adhesion; HDA:UniProtKB. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0030027; C:lamellipodium; IEA:Ensembl. DR GO; GO:0016328; C:lateral plasma membrane; IDA:MGI. DR GO; GO:0016020; C:membrane; ISS:UniProtKB. DR GO; GO:0031528; C:microvillus membrane; IEA:Ensembl. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0099092; C:postsynaptic density, intracellular component; IEA:Ensembl. DR GO; GO:0045211; C:postsynaptic membrane; IEA:Ensembl. DR GO; GO:0098831; C:presynaptic active zone cytoplasmic component; IEA:Ensembl. DR GO; GO:0042734; C:presynaptic membrane; IEA:Ensembl. DR GO; GO:0032991; C:protein-containing complex; IDA:MGI. DR GO; GO:0032993; C:protein-DNA complex; IDA:BHF-UCL. DR GO; GO:0098685; C:Schaffer collateral - CA1 synapse; IEA:Ensembl. DR GO; GO:0034750; C:Scrib-APC-beta-catenin complex; IEA:Ensembl. DR GO; GO:0000922; C:spindle pole; IEA:UniProtKB-SubCell. DR GO; GO:0045202; C:synapse; ISS:UniProtKB. DR GO; GO:0005667; C:transcription regulator complex; IDA:BHF-UCL. DR GO; GO:1990909; C:Wnt signalosome; NAS:ParkinsonsUK-UCL. DR GO; GO:0030018; C:Z disc; IEA:Ensembl. DR GO; GO:0045294; F:alpha-catenin binding; IPI:BHF-UCL. DR GO; GO:0045296; F:cadherin binding; IPI:BHF-UCL. DR GO; GO:0003682; F:chromatin binding; ISS:ParkinsonsUK-UCL. DR GO; GO:0097718; F:disordered domain specific binding; IEA:Ensembl. DR GO; GO:0140297; F:DNA-binding transcription factor binding; IPI:BHF-UCL. DR GO; GO:0019899; F:enzyme binding; IPI:ParkinsonsUK-UCL. DR GO; GO:1990226; F:histone methyltransferase binding; ISS:ARUK-UCL. DR GO; GO:0070411; F:I-SMAD binding; IPI:BHF-UCL. DR GO; GO:0019900; F:kinase binding; IPI:BHF-UCL. DR GO; GO:0030331; F:nuclear estrogen receptor binding; IPI:BHF-UCL. DR GO; GO:0016922; F:nuclear receptor binding; IPI:BHF-UCL. DR GO; GO:0019902; F:phosphatase binding; IPI:BHF-UCL. DR GO; GO:0019901; F:protein kinase binding; IEA:Ensembl. DR GO; GO:0019903; F:protein phosphatase binding; IBA:GO_Central. DR GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IDA:UniProtKB. DR GO; GO:0005102; F:signaling receptor binding; IPI:ARUK-UCL. DR GO; GO:0046332; F:SMAD binding; IPI:BHF-UCL. DR GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB. DR GO; GO:0001221; F:transcription coregulator binding; ISS:ARUK-UCL. DR GO; GO:0001222; F:transcription corepressor binding; IPI:UniProtKB. DR GO; GO:0044325; F:transmembrane transporter binding; IPI:BHF-UCL. DR GO; GO:0031625; F:ubiquitin protein ligase binding; EXP:DisProt. DR GO; GO:0090425; P:acinar cell differentiation; IEA:Ensembl. DR GO; GO:0034333; P:adherens junction assembly; IMP:BHF-UCL. DR GO; GO:0009948; P:anterior/posterior axis specification; IEA:Ensembl. DR GO; GO:0097190; P:apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:0036520; P:astrocyte-dopaminergic neuron signaling; IEA:Ensembl. DR GO; GO:0045453; P:bone resorption; IEA:Ensembl. DR GO; GO:0001569; P:branching involved in blood vessel morphogenesis; IEA:Ensembl. DR GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; IEA:Ensembl. DR GO; GO:0007249; P:canonical NF-kappaB signal transduction; IEA:Ensembl. DR GO; GO:0060070; P:canonical Wnt signaling pathway; IDA:UniProtKB. DR GO; GO:0044338; P:canonical Wnt signaling pathway involved in mesenchymal stem cell differentiation; IEA:Ensembl. DR GO; GO:0007155; P:cell adhesion; IMP:BHF-UCL. DR GO; GO:0001708; P:cell fate specification; IEA:Ensembl. DR GO; GO:0048469; P:cell maturation; IEA:Ensembl. DR GO; GO:0098609; P:cell-cell adhesion; IBA:GO_Central. DR GO; GO:0044331; P:cell-cell adhesion mediated by cadherin; IMP:BHF-UCL. DR GO; GO:0007160; P:cell-matrix adhesion; IEA:Ensembl. DR GO; GO:0071363; P:cellular response to growth factor stimulus; IMP:BHF-UCL. DR GO; GO:0071681; P:cellular response to indole-3-methanol; IDA:UniProtKB. DR GO; GO:0022009; P:central nervous system vasculogenesis; IEA:Ensembl. DR GO; GO:0007268; P:chemical synaptic transmission; IEA:Ensembl. DR GO; GO:0002062; P:chondrocyte differentiation; IEA:Ensembl. DR GO; GO:0061550; P:cranial ganglion development; IEA:Ensembl. DR GO; GO:1904888; P:cranial skeletal system development; IEA:Ensembl. DR GO; GO:0019221; P:cytokine-mediated signaling pathway; IEA:Ensembl. DR GO; GO:0035995; P:detection of muscle stretch; TAS:BHF-UCL. DR GO; GO:1990791; P:dorsal root ganglion development; IEA:Ensembl. DR GO; GO:0009950; P:dorsal/ventral axis specification; IEA:Ensembl. DR GO; GO:0007398; P:ectoderm development; IEA:Ensembl. DR GO; GO:0000578; P:embryonic axis specification; IEA:Ensembl. DR GO; GO:1990403; P:embryonic brain development; IEA:Ensembl. DR GO; GO:0042733; P:embryonic digit morphogenesis; IEA:Ensembl. DR GO; GO:0048617; P:embryonic foregut morphogenesis; IEA:Ensembl. DR GO; GO:0035115; P:embryonic forelimb morphogenesis; IEA:Ensembl. DR GO; GO:0035050; P:embryonic heart tube development; IEA:Ensembl. DR GO; GO:0035116; P:embryonic hindlimb morphogenesis; IEA:Ensembl. DR GO; GO:0036023; P:embryonic skeletal limb joint morphogenesis; ISS:BHF-UCL. DR GO; GO:0001711; P:endodermal cell fate commitment; IEA:Ensembl. DR GO; GO:0061154; P:endothelial tube morphogenesis; IMP:BHF-UCL. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IDA:ARUK-UCL. DR GO; GO:0002064; P:epithelial cell development; IEA:Ensembl. DR GO; GO:0060742; P:epithelial cell differentiation involved in prostate gland development; IEA:Ensembl. DR GO; GO:0060767; P:epithelial cell proliferation involved in prostate gland development; IEA:Ensembl. DR GO; GO:0001837; P:epithelial to mesenchymal transition; TAS:HGNC-UCL. DR GO; GO:0060441; P:epithelial tube branching involved in lung morphogenesis; IEA:Ensembl. DR GO; GO:0060856; P:establishment of blood-brain barrier; IEA:Ensembl. DR GO; GO:1990963; P:establishment of blood-retinal barrier; IEA:Ensembl. DR GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; IEA:Ensembl. DR GO; GO:0061198; P:fungiform papilla formation; IEA:Ensembl. DR GO; GO:0001702; P:gastrulation with mouth forming second; IEA:Ensembl. DR GO; GO:0035112; P:genitalia morphogenesis; IEA:Ensembl. DR GO; GO:0007403; P:glial cell fate determination; IEA:Ensembl. DR GO; GO:0035315; P:hair cell differentiation; TAS:BHF-UCL. DR GO; GO:0031069; P:hair follicle morphogenesis; IEA:Ensembl. DR GO; GO:0060789; P:hair follicle placode formation; IEA:Ensembl. DR GO; GO:0030902; P:hindbrain development; IEA:Ensembl. DR GO; GO:0021854; P:hypothalamus development; IEA:Ensembl. DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl. DR GO; GO:0021819; P:layer formation in cerebral cortex; IEA:Ensembl. DR GO; GO:0002089; P:lens morphogenesis in camera-type eye; IEA:Ensembl. DR GO; GO:0060487; P:lung epithelial cell differentiation; IEA:Ensembl. DR GO; GO:0060492; P:lung induction; IEA:Ensembl. DR GO; GO:0060484; P:lung-associated mesenchyme development; IEA:Ensembl. DR GO; GO:0030539; P:male genitalia development; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; IEA:Ensembl. DR GO; GO:0060916; P:mesenchymal cell proliferation involved in lung development; IEA:Ensembl. DR GO; GO:0072497; P:mesenchymal stem cell differentiation; IMP:ARUK-UCL. DR GO; GO:0060231; P:mesenchymal to epithelial transition; IMP:UniProtKB. DR GO; GO:0003338; P:metanephros morphogenesis; IEA:Ensembl. DR GO; GO:1904948; P:midbrain dopaminergic neuron differentiation; ISS:ParkinsonsUK-UCL. DR GO; GO:0051450; P:myoblast proliferation; IEA:Ensembl. DR GO; GO:0016525; P:negative regulation of angiogenesis; ISS:BHF-UCL. DR GO; GO:0043066; P:negative regulation of apoptotic process; IMP:BHF-UCL. DR GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IEA:Ensembl. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:UniProtKB. DR GO; GO:0032331; P:negative regulation of chondrocyte differentiation; IEA:Ensembl. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; IMP:UniProtKB. DR GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl. DR GO; GO:0003340; P:negative regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis; IEA:Ensembl. DR GO; GO:0045976; P:negative regulation of mitotic cell cycle, embryonic; ISS:UniProtKB. DR GO; GO:0048715; P:negative regulation of oligodendrocyte differentiation; IEA:Ensembl. DR GO; GO:0045671; P:negative regulation of osteoclast differentiation; IEA:Ensembl. DR GO; GO:1903377; P:negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:0033234; P:negative regulation of protein sumoylation; IDA:UniProtKB. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IEA:Ensembl. DR GO; GO:0072079; P:nephron tubule formation; IEA:Ensembl. DR GO; GO:0001840; P:neural plate development; IEA:Ensembl. DR GO; GO:0007405; P:neuroblast proliferation; IEA:Ensembl. DR GO; GO:0048664; P:neuron fate determination; IEA:Ensembl. DR GO; GO:0001764; P:neuron migration; IEA:Ensembl. DR GO; GO:1990138; P:neuron projection extension; IMP:UniProtKB. DR GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl. DR GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl. DR GO; GO:0048599; P:oocyte development; IEA:Ensembl. DR GO; GO:0001649; P:osteoblast differentiation; IMP:ARUK-UCL. DR GO; GO:0030316; P:osteoclast differentiation; IEA:Ensembl. DR GO; GO:0003151; P:outflow tract morphogenesis; ISS:BHF-UCL. DR GO; GO:0060066; P:oviduct development; IEA:Ensembl. DR GO; GO:0031016; P:pancreas development; IEA:Ensembl. DR GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:1905555; P:positive regulation of blood vessel branching; IMP:BHF-UCL. DR GO; GO:0061047; P:positive regulation of branching involved in lung morphogenesis; IEA:Ensembl. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; IEA:Ensembl. DR GO; GO:0045597; P:positive regulation of cell differentiation; NAS:ComplexPortal. DR GO; GO:0008284; P:positive regulation of cell population proliferation; ISS:BHF-UCL. DR GO; GO:2000017; P:positive regulation of determination of dorsal identity; IEA:Ensembl. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0045603; P:positive regulation of endothelial cell differentiation; IEA:Ensembl. DR GO; GO:0060769; P:positive regulation of epithelial cell proliferation involved in prostate gland development; IEA:Ensembl. DR GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IMP:BHF-UCL. DR GO; GO:0045743; P:positive regulation of fibroblast growth factor receptor signaling pathway; IEA:Ensembl. DR GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl. DR GO; GO:0010909; P:positive regulation of heparan sulfate proteoglycan biosynthetic process; IMP:BHF-UCL. DR GO; GO:0034112; P:positive regulation of homotypic cell-cell adhesion; IGI:BHF-UCL. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IEA:Ensembl. DR GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; IEA:Ensembl. DR GO; GO:2000288; P:positive regulation of myoblast proliferation; IEA:Ensembl. DR GO; GO:0002052; P:positive regulation of neuroblast proliferation; ISS:UniProtKB. DR GO; GO:0043525; P:positive regulation of neuron apoptotic process; IDA:ParkinsonsUK-UCL. DR GO; GO:1901331; P:positive regulation of odontoblast differentiation; IEA:Ensembl. DR GO; GO:0045669; P:positive regulation of osteoblast differentiation; IEA:Ensembl. DR GO; GO:0048643; P:positive regulation of skeletal muscle tissue development; IEA:Ensembl. DR GO; GO:2000648; P:positive regulation of stem cell proliferation; IEA:Ensembl. DR GO; GO:0032212; P:positive regulation of telomere maintenance via telomerase; ISS:ARUK-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0032968; P:positive regulation of transcription elongation by RNA polymerase II; IEA:Ensembl. DR GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IDA:UniProtKB. DR GO; GO:0034394; P:protein localization to cell surface; IMP:BHF-UCL. DR GO; GO:0000209; P:protein polyubiquitination; IDA:UniProtKB. DR GO; GO:0009954; P:proximal/distal pattern formation; IEA:Ensembl. DR GO; GO:0045765; P:regulation of angiogenesis; TAS:BHF-UCL. DR GO; GO:0090279; P:regulation of calcium ion import; IDA:BHF-UCL. DR GO; GO:0030997; P:regulation of centriole-centriole cohesion; IDA:UniProtKB. DR GO; GO:0070602; P:regulation of centromeric sister chromatid cohesion; IMP:BHF-UCL. DR GO; GO:0010717; P:regulation of epithelial to mesenchymal transition; IMP:UniProtKB. DR GO; GO:0048145; P:regulation of fibroblast proliferation; TAS:BHF-UCL. DR GO; GO:0031641; P:regulation of myelination; IEA:Ensembl. DR GO; GO:0072182; P:regulation of nephron tubule epithelial cell differentiation; ISS:UniProtKB. DR GO; GO:0050767; P:regulation of neurogenesis; TAS:ParkinsonsUK-UCL. DR GO; GO:2000008; P:regulation of protein localization to cell surface; IDA:BHF-UCL. DR GO; GO:0031396; P:regulation of protein ubiquitination; IMP:DisProt. DR GO; GO:0003266; P:regulation of secondary heart field cardioblast proliferation; IEA:Ensembl. DR GO; GO:0048660; P:regulation of smooth muscle cell proliferation; IMP:BHF-UCL. DR GO; GO:0051963; P:regulation of synapse assembly; IEA:Ensembl. DR GO; GO:0042129; P:regulation of T cell proliferation; IEA:Ensembl. DR GO; GO:0051884; P:regulation of timing of anagen; IEA:Ensembl. DR GO; GO:0072053; P:renal inner medulla development; IEA:Ensembl. DR GO; GO:0072054; P:renal outer medulla development; IEA:Ensembl. DR GO; GO:0072033; P:renal vesicle formation; IEA:Ensembl. DR GO; GO:0032355; P:response to estradiol; IDA:BHF-UCL. DR GO; GO:0009410; P:response to xenobiotic stimulus; IEP:UniProtKB. DR GO; GO:0051145; P:smooth muscle cell differentiation; IEA:Ensembl. DR GO; GO:0019827; P:stem cell population maintenance; TAS:BHF-UCL. DR GO; GO:0072089; P:stem cell proliferation; IEA:Ensembl. DR GO; GO:0061549; P:sympathetic ganglion development; ISS:UniProtKB. DR GO; GO:0050808; P:synapse organization; IEA:Ensembl. DR GO; GO:0097091; P:synaptic vesicle clustering; IEA:Ensembl. DR GO; GO:0048489; P:synaptic vesicle transport; IEA:Ensembl. DR GO; GO:0033077; P:T cell differentiation in thymus; IEA:Ensembl. DR GO; GO:0048538; P:thymus development; IEA:Ensembl. DR GO; GO:0060440; P:trachea formation; IEA:Ensembl. DR GO; GO:0006366; P:transcription by RNA polymerase II; IEA:Ensembl. DR CDD; cd21724; CTNNAbd_CTNNB1; 1. DR DisProt; DP01119; -. DR FunFam; 1.25.10.10:FF:000015; Catenin beta-1; 1. DR Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 1. DR IDEAL; IID00039; -. DR InterPro; IPR011989; ARM-like. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR000225; Armadillo. DR InterPro; IPR013284; Beta-catenin. DR PANTHER; PTHR45976; ARMADILLO SEGMENT POLARITY PROTEIN; 1. DR Pfam; PF00514; Arm; 4. DR PRINTS; PR01869; BCATNINFAMLY. DR SMART; SM00185; ARM; 12. DR SUPFAM; SSF48371; ARM repeat; 1. DR PROSITE; PS50176; ARM_REPEAT; 9. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Activator; Cell adhesion; Cell junction; KW Cell membrane; Cell projection; Chromosomal rearrangement; Cytoplasm; KW Cytoskeleton; Disease variant; Glycoprotein; Host-virus interaction; KW Intellectual disability; Membrane; Neurogenesis; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; S-nitrosylation; KW Synapse; Transcription; Transcription regulation; Ubl conjugation; KW Wnt signaling pathway. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..781 FT /note="Catenin beta-1" FT /id="PRO_0000064271" FT REPEAT 151..191 FT /note="ARM 1" FT REPEAT 193..234 FT /note="ARM 2" FT REPEAT 235..276 FT /note="ARM 3" FT REPEAT 277..318 FT /note="ARM 4" FT REPEAT 319..360 FT /note="ARM 5" FT REPEAT 361..389 FT /note="ARM 6" FT REPEAT 400..441 FT /note="ARM 7" FT REPEAT 442..484 FT /note="ARM 8" FT REPEAT 489..530 FT /note="ARM 9" FT REPEAT 531..571 FT /note="ARM 10" FT REPEAT 594..636 FT /note="ARM 11" FT REPEAT 637..666 FT /note="ARM 12" FT REGION 2..23 FT /note="Interaction with VCL" FT /evidence="ECO:0000250" FT REGION 34..57 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 156..178 FT /note="Interaction with BCL9" FT /evidence="ECO:0000269|PubMed:17052462" FT REGION 705..781 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 772..781 FT /note="Interaction with SCRIB" FT /evidence="ECO:0000250" FT COMPBIAS 734..745 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 23 FT /note="Phosphoserine; by GSK3-beta; alternate" FT /evidence="ECO:0000269|PubMed:12027456" FT MOD_RES 29 FT /note="Phosphoserine; by GSK3-beta" FT /evidence="ECO:0000269|PubMed:12027456" FT MOD_RES 33 FT /note="Phosphoserine; by GSK3-beta and HIPK2" FT /evidence="ECO:0000269|PubMed:20307497, FT ECO:0000269|PubMed:25169422" FT MOD_RES 37 FT /note="Phosphoserine; by GSK3-beta and HIPK2" FT /evidence="ECO:0000269|PubMed:20307497" FT MOD_RES 41 FT /note="Phosphothreonine; by GSK3-beta" FT /evidence="ECO:0000269|PubMed:12027456, FT ECO:0000269|PubMed:30714168" FT MOD_RES 45 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:12051714" FT MOD_RES 49 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:24824780" FT MOD_RES 64 FT /note="Phosphotyrosine; by PTK6" FT /evidence="ECO:0000269|PubMed:20026641" FT MOD_RES 142 FT /note="Phosphotyrosine; by FYN and PTK6" FT /evidence="ECO:0000269|PubMed:12640114, FT ECO:0000269|PubMed:20026641" FT MOD_RES 191 FT /note="Phosphoserine; by CDK5" FT /evidence="ECO:0000269|PubMed:17009320, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:24275569" FT MOD_RES 246 FT /note="Phosphoserine; by CDK5" FT /evidence="ECO:0000269|PubMed:17009320" FT MOD_RES 331 FT /note="Phosphotyrosine; by PTK6" FT /evidence="ECO:0000269|PubMed:20026641" FT MOD_RES 333 FT /note="Phosphotyrosine; by SRC and PTK6" FT /evidence="ECO:0000269|PubMed:22056988, FT ECO:0000305|PubMed:20026641" FT MOD_RES 552 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:24275569" FT MOD_RES 556 FT /note="(Microbial infection) Phosphothreonine" FT /evidence="ECO:0000269|PubMed:31801859" FT MOD_RES 556 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18220336" FT MOD_RES 619 FT /note="S-nitrosocysteine" FT /evidence="ECO:0000250|UniProtKB:Q02248" FT MOD_RES 675 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:18220336, ECO:0007744|PubMed:20068231" FT CARBOHYD 23 FT /note="O-linked (GlcNAc) serine; alternate" FT /evidence="ECO:0000269|PubMed:24342833" FT VARIANT 23 FT /note="S -> R (in hepatocellular carcinoma; no effect; FT dbSNP:rs1413975856)" FT /evidence="ECO:0000269|PubMed:10435629, FT ECO:0000269|PubMed:12027456" FT /id="VAR_017612" FT VARIANT 25..33 FT /note="Missing (in hepatocellular carcinoma)" FT /evidence="ECO:0000269|PubMed:10435629" FT /id="VAR_017613" FT VARIANT 32 FT /note="D -> A (in hepatocellular carcinoma; FT dbSNP:rs121913396)" FT /evidence="ECO:0000269|PubMed:10435629" FT /id="VAR_017614" FT VARIANT 32 FT /note="D -> G (in PTR and hepatocellular carcinoma; FT dbSNP:rs121913396)" FT /evidence="ECO:0000269|PubMed:10192393, FT ECO:0000269|PubMed:10435629" FT /id="VAR_017615" FT VARIANT 32 FT /note="D -> Y (in PTR, hepatoblastoma and hepatocellular FT carcinoma; dbSNP:rs28931588)" FT /evidence="ECO:0000269|PubMed:10192393, FT ECO:0000269|PubMed:10435629, ECO:0000269|PubMed:11703283, FT ECO:0000269|PubMed:9927029" FT /id="VAR_017616" FT VARIANT 33 FT /note="S -> F (in PTR, MDB and hepatocellular carcinoma; FT dbSNP:rs121913400)" FT /evidence="ECO:0000269|PubMed:10192393, FT ECO:0000269|PubMed:10435629, ECO:0000269|PubMed:10666372" FT /id="VAR_017617" FT VARIANT 33 FT /note="S -> L (in hepatocellular carcinoma)" FT /evidence="ECO:0000269|PubMed:10435629" FT /id="VAR_017618" FT VARIANT 33 FT /note="S -> Y (in colorectal cancer and PTR; constitutively FT active Wnt signaling pathway; enhances transactivation of FT target genes; dbSNP:rs121913400)" FT /evidence="ECO:0000269|PubMed:10192393, FT ECO:0000269|PubMed:12027456, ECO:0000269|PubMed:29374064, FT ECO:0000269|PubMed:9065402" FT /id="VAR_017619" FT VARIANT 34 FT /note="G -> E (in PTR; dbSNP:rs28931589)" FT /evidence="ECO:0000269|PubMed:10192393" FT /id="VAR_017620" FT VARIANT 34 FT /note="G -> R (in hepatocellular carcinoma; FT dbSNP:rs121913399)" FT /evidence="ECO:0000269|PubMed:10435629" FT /id="VAR_017621" FT VARIANT 34 FT /note="G -> V (in hepatoblastoma; dbSNP:rs28931589)" FT /evidence="ECO:0000269|PubMed:9927029" FT /id="VAR_017622" FT VARIANT 35 FT /note="I -> S (in hepatocellular carcinoma)" FT /evidence="ECO:0000269|PubMed:10435629" FT /id="VAR_017623" FT VARIANT 37..38 FT /note="SG -> W (in hepatocellular carcinoma)" FT /evidence="ECO:0000269|PubMed:10435629" FT /id="VAR_017628" FT VARIANT 37 FT /note="S -> A (in MDB and hepatocellular carcinoma; FT enhances transactivation of target genes; FT dbSNP:rs121913228)" FT /evidence="ECO:0000269|PubMed:10435629, FT ECO:0000269|PubMed:10666372, ECO:0000269|PubMed:12027456" FT /id="VAR_017624" FT VARIANT 37 FT /note="S -> C (in PTR, hepatoblastoma and ovarian cancer; FT dbSNP:rs121913403)" FT /evidence="ECO:0000269|PubMed:10192393, FT ECO:0000269|PubMed:10391090, ECO:0000269|PubMed:9927029" FT /id="VAR_017625" FT VARIANT 37 FT /note="S -> F (in PTR; dbSNP:rs121913403)" FT /evidence="ECO:0000269|PubMed:10192393" FT /id="VAR_017626" FT VARIANT 37 FT /note="S -> Y (in hepatocellular carcinoma; FT dbSNP:rs121913403)" FT /evidence="ECO:0000269|PubMed:10435629" FT /id="VAR_017627" FT VARIANT 41 FT /note="T -> A (in hepatoblastoma and hepatocellular FT carcinoma; also in a desmoid tumor; strongly reduces FT phosphorylation and degradation; abolishes phosphorylation FT on Ser-33 and Ser-37 and enhances transactivation of target FT genes; dbSNP:rs121913412)" FT /evidence="ECO:0000269|PubMed:10391090, FT ECO:0000269|PubMed:10398436, ECO:0000269|PubMed:10435629, FT ECO:0000269|PubMed:10655994, ECO:0000269|PubMed:12027456, FT ECO:0000269|PubMed:12051714, ECO:0000269|PubMed:9927029" FT /id="VAR_017629" FT VARIANT 41 FT /note="T -> I (in PTR, hepatocellular carcinoma and ovarian FT cancer; dbSNP:rs121913413)" FT /evidence="ECO:0000269|PubMed:10192393, FT ECO:0000269|PubMed:10391090, ECO:0000269|PubMed:10435629" FT /id="VAR_017630" FT VARIANT 45 FT /note="S -> F (in hepatocellular carcinoma; FT dbSNP:rs121913409)" FT /evidence="ECO:0000269|PubMed:10435629" FT /id="VAR_017631" FT VARIANT 45 FT /note="S -> P (in hepatocellular carcinoma; FT dbSNP:rs121913407)" FT /evidence="ECO:0000269|PubMed:10435629" FT /id="VAR_017632" FT VARIANT 45 FT /note="Missing (in colorectal cancer)" FT /evidence="ECO:0000269|PubMed:9065402" FT /id="VAR_055430" FT VARIANT 292 FT /note="K -> N (found in a patient with features of FT osteopathia striata cranial sclerosis; uncertain FT significance; results in increased Wnt signaling)" FT /evidence="ECO:0000269|PubMed:38173341" FT /id="VAR_089205" FT VARIANT 388 FT /note="L -> P (in NEDSDV)" FT /evidence="ECO:0000269|PubMed:25326669" FT /id="VAR_072282" FT VARIANT 558..781 FT /note="Missing (in NEDSDV; the patient also manifest FT features of exudative vitreoretinopathy)" FT /evidence="ECO:0000269|PubMed:28514307" FT /id="VAR_079199" FT VARIANT 688 FT /note="M -> V (in dbSNP:rs4135384)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_018954" FT VARIANT 710 FT /note="R -> C (in EVR7; uncertain significance; FT dbSNP:rs748653573)" FT /evidence="ECO:0000269|PubMed:28575650" FT /id="VAR_079200" FT MUTAGEN 29 FT /note="S->F: No effect." FT /evidence="ECO:0000269|PubMed:12027456" FT MUTAGEN 64 FT /note="Y->F: Abolishes phosphorylation by PTK6." FT /evidence="ECO:0000269|PubMed:20026641" FT MUTAGEN 142 FT /note="Y->E: No effect on interaction with BCL9 and BCL9L." FT /evidence="ECO:0000269|PubMed:17052462" FT MUTAGEN 156 FT /note="L->A: Abolishes interaction with BCL9 but no effect FT on interaction with CDH3; when associated with A-159." FT /evidence="ECO:0000269|PubMed:17052462" FT MUTAGEN 159 FT /note="L->A: No effect on interaction with BCL9 and CDH3. FT Abolishes interaction with BCL9 but no effect on FT interaction with CDH3; when associated with A-156." FT /evidence="ECO:0000269|PubMed:17052462" FT MUTAGEN 178 FT /note="L->A: No effect on interaction with BCL9 and CDH3." FT /evidence="ECO:0000269|PubMed:17052462" FT MUTAGEN 253 FT /note="F->A: Abolishes or strongly reduces AXIN2 binding." FT /evidence="ECO:0000269|PubMed:10966653" FT MUTAGEN 260 FT /note="H->A: Abolishes or strongly reduces AXIN1 and AXIN2 FT binding. Strongly reduces phosphorylation and degradation; FT when associated with A-386 and A-383." FT /evidence="ECO:0000269|PubMed:10966653" FT MUTAGEN 292 FT /note="K->A: Abolishes or strongly reduces AXIN1 and AXIN2 FT binding." FT /evidence="ECO:0000269|PubMed:10966653" FT MUTAGEN 312 FT /note="K->E: Abolishes TCF7L2 binding." FT /evidence="ECO:0000269|PubMed:11713475" FT MUTAGEN 333 FT /note="Y->F: Abolished phosphorylation by SRC and FT interaction with isoform M2 of PKM (PKM2)." FT /evidence="ECO:0000269|PubMed:22056988" FT MUTAGEN 345 FT /note="K->A: Abolishes APC binding." FT /evidence="ECO:0000269|PubMed:10966653" FT MUTAGEN 383 FT /note="W->A: Abolishes APC binding. Strongly reduces FT phosphorylation and degradation; when associated with A-260 FT and A-386." FT /evidence="ECO:0000269|PubMed:10966653" FT MUTAGEN 386 FT /note="R->A: Strongly reduces APC binding. Strongly reduces FT phosphorylation and degradation; when associated with A-260 FT and A-383." FT /evidence="ECO:0000269|PubMed:10966653" FT MUTAGEN 426 FT /note="N->A: Abolishes TCF7L2 and LEF1 binding." FT /evidence="ECO:0000269|PubMed:10966653" FT MUTAGEN 435 FT /note="K->A: Strongly reduces or abolishes LEF1 binding." FT /evidence="ECO:0000269|PubMed:10966653, FT ECO:0000269|PubMed:11713475" FT MUTAGEN 435 FT /note="K->E: Abolishes TCF7L2 binding." FT /evidence="ECO:0000269|PubMed:10966653, FT ECO:0000269|PubMed:11713475" FT MUTAGEN 469 FT /note="R->A: Abolishes TCF7L2 binding, and strongly reduces FT or abolishes LEF1 binding." FT /evidence="ECO:0000269|PubMed:10966653" FT MUTAGEN 470 FT /note="H->A: Abolishes TCF7L2 binding, and strongly reduces FT or abolishes LEF1 binding." FT /evidence="ECO:0000269|PubMed:10966653" FT MUTAGEN 508 FT /note="K->A: Abolishes TCF7L2 and LEF1 binding." FT /evidence="ECO:0000269|PubMed:10966653" FT MUTAGEN 660 FT /note="F->A: Abolishes CTNNBIP1 binding; when associated FT with A-661." FT /evidence="ECO:0000269|PubMed:12408824" FT MUTAGEN 661 FT /note="R->A: Abolishes CTNNBIP1 binding; when associated FT with A-660." FT /evidence="ECO:0000269|PubMed:12408824" FT TURN 20..22 FT /evidence="ECO:0007829|PDB:2G57" FT STRAND 23..26 FT /evidence="ECO:0007829|PDB:2G57" FT TURN 27..29 FT /evidence="ECO:0007829|PDB:2G57" FT TURN 39..41 FT /evidence="ECO:0007829|PDB:2G57" FT HELIX 145..160 FT /evidence="ECO:0007829|PDB:7AFW" FT STRAND 161..164 FT /evidence="ECO:0007829|PDB:7UWO" FT HELIX 165..179 FT /evidence="ECO:0007829|PDB:7AFW" FT HELIX 182..189 FT /evidence="ECO:0007829|PDB:7AFW" FT HELIX 192..204 FT /evidence="ECO:0007829|PDB:7AFW" FT HELIX 208..221 FT /evidence="ECO:0007829|PDB:7AFW" FT HELIX 225..233 FT /evidence="ECO:0007829|PDB:7AFW" FT HELIX 236..243 FT /evidence="ECO:0007829|PDB:7AFW" FT HELIX 249..265 FT /evidence="ECO:0007829|PDB:7AFW" FT HELIX 269..275 FT /evidence="ECO:0007829|PDB:7AFW" FT HELIX 278..284 FT /evidence="ECO:0007829|PDB:7AFW" FT HELIX 285..287 FT /evidence="ECO:0007829|PDB:7AFW" FT HELIX 291..303 FT /evidence="ECO:0007829|PDB:7AFW" FT HELIX 309..317 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 320..330 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 334..347 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 353..359 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 362..367 FT /evidence="ECO:0007829|PDB:1JDH" FT TURN 368..371 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 375..389 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 392..394 FT /evidence="ECO:0007829|PDB:7ZRB" FT HELIX 399..408 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 414..427 FT /evidence="ECO:0007829|PDB:1JDH" FT TURN 428..430 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 432..440 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 443..454 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 458..471 FT /evidence="ECO:0007829|PDB:1JDH" FT STRAND 473..475 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 478..487 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 491..496 FT /evidence="ECO:0007829|PDB:1JDH" FT STRAND 499..501 FT /evidence="ECO:0007829|PDB:4DJS" FT HELIX 504..517 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 521..523 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 524..529 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 532..547 FT /evidence="ECO:0007829|PDB:1JDH" FT STRAND 550..552 FT /evidence="ECO:0007829|PDB:1QZ7" FT STRAND 554..557 FT /evidence="ECO:0007829|PDB:1QZ7" FT STRAND 561..563 FT /evidence="ECO:0007829|PDB:1T08" FT HELIX 566..580 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 584..592 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 596..601 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 602..604 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 608..621 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 625..633 FT /evidence="ECO:0007829|PDB:1JDH" FT TURN 634..636 FT /evidence="ECO:0007829|PDB:8Y0G" FT HELIX 637..642 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 643..645 FT /evidence="ECO:0007829|PDB:1JDH" FT HELIX 649..662 FT /evidence="ECO:0007829|PDB:1JDH" FT TURN 663..665 FT /evidence="ECO:0007829|PDB:2Z6H" FT HELIX 668..682 FT /evidence="ECO:0007829|PDB:2Z6H" FT HELIX 688..690 FT /evidence="ECO:0007829|PDB:2Z6H" FT STRAND 778..780 FT /evidence="ECO:0007829|PDB:3DIW" SQ SEQUENCE 781 AA; 85497 MW; CB78F165A3EEF86E CRC64; MATQADLMEL DMAMEPDRKA AVSHWQQQSY LDSGIHSGAT TTAPSLSGKG NPEEEDVDTS QVLYEWEQGF SQSFTQEQVA DIDGQYAMTR AQRVRAAMFP ETLDEGMQIP STQFDAAHPT NVQRLAEPSQ MLKHAVVNLI NYQDDAELAT RAIPELTKLL NDEDQVVVNK AAVMVHQLSK KEASRHAIMR SPQMVSAIVR TMQNTNDVET ARCTAGTLHN LSHHREGLLA IFKSGGIPAL VKMLGSPVDS VLFYAITTLH NLLLHQEGAK MAVRLAGGLQ KMVALLNKTN VKFLAITTDC LQILAYGNQE SKLIILASGG PQALVNIMRT YTYEKLLWTT SRVLKVLSVC SSNKPAIVEA GGMQALGLHL TDPSQRLVQN CLWTLRNLSD AATKQEGMEG LLGTLVQLLG SDDINVVTCA AGILSNLTCN NYKNKMMVCQ VGGIEALVRT VLRAGDREDI TEPAICALRH LTSRHQEAEM AQNAVRLHYG LPVVVKLLHP PSHWPLIKAT VGLIRNLALC PANHAPLREQ GAIPRLVQLL VRAHQDTQRR TSMGGTQQQF VEGVRMEEIV EGCTGALHIL ARDVHNRIVI RGLNTIPLFV QLLYSPIENI QRVAAGVLCE LAQDKEAAEA IEAEGATAPL TELLHSRNEG VATYAAAVLF RMSEDKPQDY KKRLSVELTS SLFRTEPMAW NETADLGLDI GAQGEPLGYR QDDPSYRSFH SGGYGQDALG MDPMMEHEMG GHHPGADYPV DGLPDLGHAQ DLMDGLPPGD SNQLAWFDTD L // ID DAPK3_HUMAN Reviewed; 454 AA. AC O43293; A0AVN4; B3KQE2; Q05JY4; DT 28-NOV-2003, integrated into UniProtKB/Swiss-Prot. DT 01-JUN-1998, sequence version 1. DT 28-JAN-2026, entry version 218. DE RecName: Full=Death-associated protein kinase 3; DE Short=DAP kinase 3; DE EC=2.7.11.1 {ECO:0000269|PubMed:10356987, ECO:0000269|PubMed:11384979, ECO:0000269|PubMed:11781833, ECO:0000269|PubMed:15096528, ECO:0000269|PubMed:17126281, ECO:0000269|PubMed:18995835}; DE AltName: Full=DAP-like kinase; DE Short=Dlk; DE AltName: Full=MYPT1 kinase; DE AltName: Full=Zipper-interacting protein kinase; DE Short=ZIP-kinase; GN Name=DAPK3; Synonyms=ZIPK; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=9488481; DOI=10.1128/mcb.18.3.1642; RA Kawai T., Matsumoto M., Takeda K., Sanjo H., Akira S.; RT "ZIP kinase, a novel serine/threonine kinase which mediates apoptosis."; RL Mol. Cell. Biol. 18:1642-1651(1998). RN [2] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, AND COFACTOR. RC TISSUE=Cervix carcinoma; RX PubMed=10356987; DOI=10.1016/s0014-5793(99)00550-5; RA Murata-Hori M., Suizu F., Iwasaki T., Kikuchi A., Hosoya H.; RT "ZIP kinase identified as a novel myosin regulatory light chain kinase in RT HeLa cells."; RL FEBS Lett. 451:81-84(1999). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 165-454 (ISOFORM 2), ALTERNATIVE SPLICING, RP FUNCTION IN PHOSPHORYLATION OF MYOSIN; PPP1R12A AND MYL12B, CATALYTIC RP ACTIVITY, SUBCELLULAR LOCATION, BIOPHYSICOCHEMICAL PROPERTIES, INTERACTION RP WITH PPP1R12A AND MYOSIN, AUTOPHOSPHORYLATION, AND TISSUE SPECIFICITY. RC TISSUE=Urinary bladder; RX PubMed=17126281; DOI=10.1016/j.abb.2006.09.026; RA Takamoto N., Komatsu S., Komaba S., Niiro N., Ikebe M.; RT "Novel ZIP kinase isoform lacks leucine zipper."; RL Arch. Biochem. Biophys. 456:194-203(2006). RN [6] RP FUNCTION IN PHOSPHORYLATION OF MUSCLE MYL12B, AND CATALYTIC ACTIVITY. RX PubMed=11384979; DOI=10.1074/jbc.m102753200; RA Niiro N., Ikebe M.; RT "Zipper-interacting protein kinase induces Ca(2+)-free smooth muscle RT contraction via myosin light chain phosphorylation."; RL J. Biol. Chem. 276:29567-29574(2001). RN [7] RP FUNCTION IN PHOSPHORYLATION OF NON-MUSCLE MYL12B, AND CATALYTIC ACTIVITY. RX PubMed=11781833; DOI=10.1038/sj.onc.1205055; RA Murata-Hori M., Fukuta Y., Ueda K., Iwasaki T., Hosoya H.; RT "HeLa ZIP kinase induces diphosphorylation of myosin II regulatory light RT chain and reorganization of actin filaments in nonmuscle cells."; RL Oncogene 20:8175-8183(2001). RN [8] {ECO:0000305} RP FUNCTION IN APOPTOSIS, AND INTERACTION WITH DAXX AND PAWR. RX PubMed=12917339; DOI=10.1128/mcb.23.17.6174-6186.2003; RA Kawai T., Akira S., Reed J.C.; RT "ZIP kinase triggers apoptosis from nuclear PML oncogenic domains."; RL Mol. Cell. Biol. 23:6174-6186(2003). RN [9] RP INTERACTION WITH PPP1R12A, AND TISSUE SPECIFICITY. RX PubMed=15292222; DOI=10.1074/jbc.m403676200; RA Endo A., Surks H.K., Mochizuki S., Mochizuki N., Mendelsohn M.E.; RT "Identification and characterization of zipper-interacting protein kinase RT as the unique vascular smooth muscle myosin phosphatase-associated RT kinase."; RL J. Biol. Chem. 279:42055-42061(2004). RN [10] RP FUNCTION IN PHOSPHORYLATION OF MYL12B, AND CATALYTIC ACTIVITY. RX PubMed=15096528; DOI=10.1083/jcb.200309056; RA Komatsu S., Ikebe M.; RT "ZIP kinase is responsible for the phosphorylation of myosin II and RT necessary for cell motility in mammalian fibroblasts."; RL J. Cell Biol. 165:243-254(2004). RN [11] RP FUNCTION, PHOSPHORYLATION AT THR-299; SER-309; SER-311; SER-312; SER-318 RP AND SER-326, PHOSPHORYLATION BY DAPK1, AND SUBCELLULAR LOCATION. RX PubMed=15367680; DOI=10.1128/mcb.24.19.8611-8626.2004; RA Shani G., Marash L., Gozuacik D., Bialik S., Teitelbaum L., Shohat G., RA Kimchi A.; RT "Death-associated protein kinase phosphorylates ZIP kinase, forming a RT unique kinase hierarchy to activate its cell death functions."; RL Mol. Cell. Biol. 24:8611-8626(2004). RN [12] RP INTERACTION WITH STAT3. RX PubMed=16219639; DOI=10.1093/intimm/dxh331; RA Sato N., Kawai T., Sugiyama K., Muromoto R., Imoto S., Sekine Y., RA Ishida M., Akira S., Matsuda T.; RT "Physical and functional interactions between STAT3 and ZIP kinase."; RL Int. Immunol. 17:1543-1552(2005). RN [13] RP INTERACTION WITH TCP10L, AND SUBCELLULAR LOCATION. RX PubMed=15910542; DOI=10.1111/j.1365-2605.2005.00522.x; RA Yu H., Jiang D., Guo Z., Saiyin H., Guo J., Wang X., Yu L.; RT "TCP10L is expressed specifically in spermatogenic cells and binds to death RT associated protein kinase-3."; RL Int. J. Androl. 28:163-170(2005). RN [14] RP PHOSPHORYLATION AT THR-180; THR-225; THR-265; THR-299; THR-306 AND SER-311, RP ACTIVITY REGULATION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF THR-299; RP 299-THR-THR-300; VAL-427; VAL-434 AND LEU-441. RX PubMed=15611134; DOI=10.1074/jbc.m412538200; RA Graves P.R., Winkfield K.M., Haystead T.A.; RT "Regulation of zipper-interacting protein kinase activity in vitro and in RT vivo by multisite phosphorylation."; RL J. Biol. Chem. 280:9363-9374(2005). RN [15] RP REVIEW ON FUNCTION. RX PubMed=16756490; DOI=10.1146/annurev.biochem.75.103004.142615; RA Bialik S., Kimchi A.; RT "The death-associated protein kinases: structure, function, and beyond."; RL Annu. Rev. Biochem. 75:189-210(2006). RN [16] RP FUNCTION, ACTIVITY REGULATION, AUTOPHOSPHORYLATION, PHOSPHORYLATION AT RP THR-180; THR-265 AND THR-299, AND MUTAGENESIS OF LYS-42; ASP-161; THR-225; RP THR-265 AND THR-299. RX PubMed=17158456; DOI=10.1074/jbc.m609990200; RA Hagerty L., Weitzel D.H., Chambers J., Fortner C.N., Brush M.H., RA Loiselle D., Hosoya H., Haystead T.A.; RT "ROCK1 phosphorylates and activates zipper-interacting protein kinase."; RL J. Biol. Chem. 282:4884-4893(2007). RN [17] RP SUBCELLULAR LOCATION, AND ABSENCE OF INTERACTION WITH PARW. RX PubMed=17953487; DOI=10.1371/journal.pgen.0030180; RA Shoval Y., Pietrokovski S., Kimchi A.; RT "ZIPK: a unique case of murine-specific divergence of a conserved RT vertebrate gene."; RL PLoS Genet. 3:1884-1893(2007). RN [18] RP REVIEW ON FUNCTION. RX DOI=10.1002/sita.200600112; RA Scheidtmann K.H.; RT "Dlk/ZIP kinase, a novel Ser/Thr-specific protein kinase with multiple RT functions."; RL Signal Transduct. 7:248-259(2007). RN [19] RP FUNCTION IN PHOSPHORYLATION OF RPL13A, AND CATALYTIC ACTIVITY. RX PubMed=18995835; DOI=10.1016/j.molcel.2008.09.019; RA Mukhopadhyay R., Ray P.S., Arif A., Brady A.K., Kinter M., Fox P.L.; RT "DAPK-ZIPK-L13a axis constitutes a negative-feedback module regulating RT inflammatory gene expression."; RL Mol. Cell 32:371-382(2008). RN [20] RP FUNCTION IN ANDROGEN RECEPTOR-MEDIATED TRANSCRIPTION. RX PubMed=18084323; DOI=10.1038/sj.onc.1210995; RA Leister P., Felten A., Chasan A.I., Scheidtmann K.H.; RT "ZIP kinase plays a crucial role in androgen receptor-mediated RT transcription."; RL Oncogene 27:3292-3300(2008). RN [21] RP FUNCTION AS TUMOR SUPPRESSOR, CHARACTERIZATION OF VARIANTS MET-112; ASN-161 RP AND SER-216, MUTAGENESIS OF THR-180, AND SELF-ASSOCIATION. RX PubMed=21487036; DOI=10.1158/0008-5472.can-10-3543; RA Brognard J., Zhang Y.W., Puto L.A., Hunter T.; RT "Cancer-associated loss-of-function mutations implicate DAPK3 as a tumor- RT suppressing kinase."; RL Cancer Res. 71:3152-3161(2011). RN [22] RP PHOSPHORYLATION AT THR-299, SUBCELLULAR LOCATION, AND MUTAGENESIS OF RP 294-ARG-ARG-295. RX PubMed=20854903; DOI=10.1016/j.cellsig.2010.09.016; RA Weitzel D.H., Chambers J., Haystead T.A.; RT "Phosphorylation-dependent control of ZIPK nuclear import is species RT specific."; RL Cell. Signal. 23:297-303(2011). RN [23] RP FUNCTION IN REGULATION OF AUTOPHAGY, AND INTERACTION WITH ULK1. RX PubMed=21169990; DOI=10.1038/emboj.2010.338; RA Tang H.W., Wang Y.B., Wang S.L., Wu M.H., Lin S.Y., Chen G.C.; RT "Atg1-mediated myosin II activation regulates autophagosome formation RT during starvation-induced autophagy."; RL EMBO J. 30:636-651(2011). RN [24] RP FUNCTION, AND INTERACTION WITH NLK. RX PubMed=21454679; DOI=10.1074/jbc.m110.189829; RA Togi S., Ikeda O., Kamitani S., Nakasuji M., Sekine Y., Muromoto R., RA Nanbo A., Oritani K., Kawai T., Akira S., Matsuda T.; RT "Zipper-interacting protein kinase (ZIPK) modulates canonical Wnt/beta- RT catenin signaling through interaction with Nemo-like kinase and T-cell RT factor 4 (NLK/TCF4)."; RL J. Biol. Chem. 286:19170-19177(2011). RN [25] RP FUNCTION, AND INTERACTION WITH ATF4. RX PubMed=21408167; DOI=10.1371/journal.pone.0017344; RA Shoval Y., Berissi H., Kimchi A., Pietrokovski S.; RT "New modularity of DAP-kinases: alternative splicing of the DRP-1 gene RT produces a ZIPk-like isoform."; RL PLoS ONE 6:E17344-E17344(2011). RN [26] RP FUNCTION IN REORGANIZATION OF ACTIN CYTOSKELETON, AND INTERACTION WITH RP RHOD. RX PubMed=23454120; DOI=10.1016/j.bbrc.2013.02.046; RA Nehru V., Almeida F.N., Aspenstrom P.; RT "Interaction of RhoD and ZIP kinase modulates actin filament assembly and RT focal adhesion dynamics."; RL Biochem. Biophys. Res. Commun. 433:163-169(2013). RN [27] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-312, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [28] RP FUNCTION, INTERACTION WITH LUZP1, AND SUBCELLULAR LOCATION. RX PubMed=38009294; DOI=10.1111/febs.17017; RA Hyodo T., Asano-Inami E., Ito S., Sugiyama M., Nawa A., Rahman M.L., RA Hasan M.N., Mihara Y., Lam V.Q., Karnan S., Ota A., Tsuzuki S., RA Hamaguchi M., Hosokawa Y., Konishi H.; RT "Leucine zipper protein 1 (LUZP1) regulates the constriction velocity of RT the contractile ring during cytokinesis."; RL FEBS J. 291:927-944(2024). RN [29] RP X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 1-277. RA Kursula P., Vahokoski J., Wilmanns M.; RT "Crystal structure of human ZIP kinase."; RL Submitted (JUN-2006) to the PDB data bank. RN [30] {ECO:0007744|PDB:2J90} RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 9-289 IN COMPLEX WITH PYRIDONE-6, RP ACTIVITY REGULATION, SUBUNIT, AND PHOSPHORYLATION AT SER-50 AND THR-265. RX PubMed=18239682; DOI=10.1038/emboj.2008.8; RA Pike A.C., Rellos P., Niesen F.H., Turnbull A., Oliver A.W., Parker S.A., RA Turk B.E., Pearl L.H., Knapp S.; RT "Activation segment dimerization: a mechanism for kinase RT autophosphorylation of non-consensus sites."; RL EMBO J. 27:704-714(2008). RN [31] RP VARIANTS [LARGE SCALE ANALYSIS] MET-112; ASN-161 AND SER-216. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine kinase which is involved in the regulation CC of apoptosis, autophagy, transcription, translation and actin CC cytoskeleton reorganization. Involved in the regulation of smooth CC muscle contraction. Regulates both type I (caspase-dependent) apoptotic CC and type II (caspase-independent) autophagic cell deaths signal, CC depending on the cellular setting. Involved in regulation of CC starvation-induced autophagy. Regulates myosin phosphorylation in both CC smooth muscle and non-muscle cells. In smooth muscle, regulates myosin CC either directly by phosphorylating MYL12B and MYL9 or through CC inhibition of smooth muscle myosin phosphatase (SMPP1M) via CC phosphorylation of PPP1R12A; the inhibition of SMPP1M functions to CC enhance muscle responsiveness to Ca(2+) and promote a contractile CC state. Phosphorylates MYL12B in non-muscle cells leading to CC reorganization of actin cytoskeleton. Isoform 2 can phosphorylate CC myosin, PPP1R12A and MYL12B. Overexpression leads to condensation of CC actin stress fibers into thick bundles. Involved in actin filament CC focal adhesion dynamics. The function in both reorganization of actin CC cytoskeleton and focal adhesion dissolution is modulated by RhoD. CC Positively regulates canonical Wnt/beta-catenin signaling through CC interaction with NLK and TCF7L2. Phosphorylates RPL13A on 'Ser-77' upon CC interferon-gamma activation which is causing RPL13A release from the CC ribosome, RPL13A association with the GAIT complex and its subsequent CC involvement in transcript-selective translation inhibition. Enhances CC transcription from AR-responsive promoters in a hormone- and kinase- CC dependent manner. Involved in regulation of cell cycle progression and CC cell proliferation. May be a tumor suppressor. CC {ECO:0000269|PubMed:10356987, ECO:0000269|PubMed:11384979, CC ECO:0000269|PubMed:11781833, ECO:0000269|PubMed:12917339, CC ECO:0000269|PubMed:15096528, ECO:0000269|PubMed:15367680, CC ECO:0000269|PubMed:16219639, ECO:0000269|PubMed:17126281, CC ECO:0000269|PubMed:17158456, ECO:0000269|PubMed:18084323, CC ECO:0000269|PubMed:18995835, ECO:0000269|PubMed:21169990, CC ECO:0000269|PubMed:21408167, ECO:0000269|PubMed:21454679, CC ECO:0000269|PubMed:21487036, ECO:0000269|PubMed:23454120, CC ECO:0000269|PubMed:38009294}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10356987, ECO:0000269|PubMed:11384979, CC ECO:0000269|PubMed:11781833, ECO:0000269|PubMed:15096528, CC ECO:0000269|PubMed:17126281, ECO:0000269|PubMed:18995835}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10356987, ECO:0000269|PubMed:11384979, CC ECO:0000269|PubMed:11781833, ECO:0000269|PubMed:15096528, CC ECO:0000269|PubMed:17126281, ECO:0000269|PubMed:18995835}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:10356987}; CC -!- ACTIVITY REGULATION: A sequential activation is proposed: CC autophosphorylation at consensus sites is leading to dimerization of CC the catalytic domain stabilized by phosphorylation at Ser-50 and CC activation segment exchange (producing an active confirmation of both CC kinase modules in trans) followed by phosphorylation at Thr-180 in the CC activation segment and at other regulatory sites (Probable). CC Phosphorylation at Thr-180, Thr-225 and Thr-265 is essential for CC activity. Oligomerization is required for full enzymatic activity. CC Inhibited by pyridone-6 (K00225), a potent, ATP-competitive inhibitor. CC {ECO:0000269|PubMed:15611134, ECO:0000269|PubMed:17158456, CC ECO:0000269|PubMed:18239682, ECO:0000303|PubMed:18239682}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=12 uM for myosin (isoform 2) {ECO:0000269|PubMed:17126281}; CC KM=6.2 uM for myosin (isoform 1) {ECO:0000269|PubMed:17126281}; CC KM=73 uM for MYL12B (isoform 2) {ECO:0000269|PubMed:17126281}; CC KM=10.4 uM for MYL12B (isoform 1) {ECO:0000269|PubMed:17126281}; CC Vmax=248 nmol/min/mg enzyme toward myosin (isoform 2) CC {ECO:0000269|PubMed:17126281}; CC Vmax=120 nmol/min/mg enzyme toward myosin (isoform 1) CC {ECO:0000269|PubMed:17126281}; CC Vmax=1.3 umol/min/mg enzyme toward MYL12B (isoform 2) CC {ECO:0000269|PubMed:17126281}; CC Vmax=271 nmol/min/mg enzyme toward MYL12B (isoform 1) CC {ECO:0000269|PubMed:17126281}; CC -!- SUBUNIT: Homooligomer in its kinase-active form (homotrimers and CC homodimers are reported); monomeric in its kinase-inactive form. CC Homodimerization is required for activation segment autophosphorylation CC (Probable). Isoform 1 and isoform 2 interact with myosin and PPP1R12A; CC interaction of isoform 1 with PPP1R12A is inhibited by RhoA dominant CC negative form. Interacts with NLK, DAXX, STAT3, RHOD (GTP-bound form) CC and TCP10L. Interacts with PAWR; the interaction is reported CC conflictingly: according to PubMed:17953487 does not interact with CC PAWR. Interacts with ULK1; may be a substrate of ULK1. Interacts with CC LUZP1; the interaction is likely to occur throughout the cell cycle and CC reduces the LUZP1-mediated suppression of MYL9 phosphorylation CC (PubMed:38009294). {ECO:0000269|PubMed:12917339, CC ECO:0000269|PubMed:15292222, ECO:0000269|PubMed:15910542, CC ECO:0000269|PubMed:16219639, ECO:0000269|PubMed:17126281, CC ECO:0000269|PubMed:18239682, ECO:0000269|PubMed:21169990, CC ECO:0000269|PubMed:21408167, ECO:0000269|PubMed:21454679, CC ECO:0000269|PubMed:23454120, ECO:0000269|PubMed:38009294, CC ECO:0000303|PubMed:18239682}. CC -!- INTERACTION: CC O43293; O43293: DAPK3; NbExp=3; IntAct=EBI-77293, EBI-77293; CC O43293; Q86V48: LUZP1; NbExp=3; IntAct=EBI-77293, EBI-350467; CC O43293; Q9UBE8: NLK; NbExp=3; IntAct=EBI-77293, EBI-366978; CC O43293; O14974: PPP1R12A; NbExp=5; IntAct=EBI-77293, EBI-351726; CC O43293; Q8TDR4: TCP10L; NbExp=5; IntAct=EBI-77293, EBI-3923210; CC O43293-2; Q10728: Ppp1r12a; Xeno; NbExp=2; IntAct=EBI-9691390, EBI-918263; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:15367680, CC ECO:0000269|PubMed:15910542, ECO:0000269|PubMed:20854903}. Nucleus, PML CC body {ECO:0000250|UniProtKB:O54784}. Cytoplasm, cytoskeleton, CC microtubule organizing center, centrosome CC {ECO:0000250|UniProtKB:O54784}. Chromosome, centromere CC {ECO:0000269|PubMed:38009294}. Cytoplasm {ECO:0000269|PubMed:15367680, CC ECO:0000269|PubMed:15611134, ECO:0000269|PubMed:17953487, CC ECO:0000269|PubMed:20854903}. Cytoplasm, cytoskeleton, spindle CC {ECO:0000269|PubMed:38009294}. Midbody {ECO:0000269|PubMed:38009294}. CC Note=Predominantly localizes to the cytoplasm but can shuttle between CC the nucleus and cytoplasm; cytoplasmic localization is promoted by CC phosphorylation at Thr-299 and involves Rho/Rock signaling. CC {ECO:0000269|PubMed:17953487, ECO:0000269|PubMed:20854903}. CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Nucleus CC {ECO:0000269|PubMed:17126281}. Cytoplasm {ECO:0000269|PubMed:17126281}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Nucleus CC {ECO:0000269|PubMed:17126281}. Cytoplasm {ECO:0000269|PubMed:17126281}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; Synonyms=ZIPK-L; CC IsoId=O43293-1; Sequence=Displayed; CC Name=2; Synonyms=ZIPK-S; CC IsoId=O43293-2; Sequence=VSP_042059, VSP_042060; CC -!- TISSUE SPECIFICITY: Widely expressed. Isoform 1 and isoform 2 are CC expressed in the bladder smooth muscle. {ECO:0000269|PubMed:15292222, CC ECO:0000269|PubMed:17126281}. CC -!- PTM: The phosphorylation status is critical for kinase activity, CC oligomerization and intracellular localization. Phosphorylation at Thr- CC 180, Thr-225 and Thr-265 is essential for activity. The phosphorylated CC form is localized in the cytoplasm promoted by phosphorylation at Thr- CC 299; nuclear translocation or retention is maximal when it is not CC phosphorylated. Phosphorylation increases the trimeric form, and its CC dephosphorylation favors a kinase-inactive monomeric form. Both isoform CC 1 and isoform 2 can undergo autophosphorylation. CC {ECO:0000269|PubMed:15367680, ECO:0000269|PubMed:15611134, CC ECO:0000269|PubMed:17158456, ECO:0000269|PubMed:20854903}. CC -!- MISCELLANEOUS: [Isoform 2]: The internal splice site between exon 8 and CC the 3' UTR, which yields this truncated isoform, is non-canonical. CC {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. DAP kinase subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB007144; BAA24955.1; -; mRNA. DR EMBL; AB022341; BAA81746.1; -; mRNA. DR EMBL; AK074799; BAG52004.1; -; mRNA. DR EMBL; BC126430; AAI26431.1; -; mRNA. DR EMBL; BC126432; AAI26433.1; -; mRNA. DR EMBL; AB265224; BAF34614.1; -; mRNA. DR CCDS; CCDS12116.1; -. [O43293-1] DR RefSeq; NP_001339.1; NM_001348.3. [O43293-1] DR RefSeq; NP_001362587.1; NM_001375658.1. [O43293-1] DR PDB; 1YRP; X-ray; 3.10 A; A/B=1-277. DR PDB; 2J90; X-ray; 2.00 A; A/B=9-289. DR PDB; 3BHY; X-ray; 1.24 A; A=9-289. DR PDB; 3BQR; X-ray; 1.75 A; A=9-289. DR PDB; 5A6N; X-ray; 1.70 A; A/B=9-289. DR PDB; 5A6O; X-ray; 1.60 A; A/B=9-289. DR PDB; 5VJA; X-ray; 2.46 A; A/B/C/D=9-289. DR PDBsum; 1YRP; -. DR PDBsum; 2J90; -. DR PDBsum; 3BHY; -. DR PDBsum; 3BQR; -. DR PDBsum; 5A6N; -. DR PDBsum; 5A6O; -. DR PDBsum; 5VJA; -. DR AlphaFoldDB; O43293; -. DR SMR; O43293; -. DR BioGRID; 107983; 101. DR FunCoup; O43293; 2772. DR IntAct; O43293; 75. DR MINT; O43293; -. DR STRING; 9606.ENSP00000442973; -. DR BindingDB; O43293; -. DR ChEMBL; CHEMBL2468; -. DR DrugBank; DB07242; (4R)-7,8-dichloro-1',9-dimethyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile. DR DrugBank; DB04716; 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one. DR DrugBank; DB07125; 4-(6-{[(1R)-1-(hydroxymethyl)propyl]amino}imidazo[1,2-b]pyridazin-3-yl)benzoic acid. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; O43293; -. DR GuidetoPHARMACOLOGY; 2004; -. DR GlyGen; O43293; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; O43293; -. DR PhosphoSitePlus; O43293; -. DR BioMuta; DAPK3; -. DR CPTAC; CPTAC-3091; -. DR CPTAC; CPTAC-3092; -. DR jPOST; O43293; -. DR MassIVE; O43293; -. DR PaxDb; 9606-ENSP00000442973; -. DR PeptideAtlas; O43293; -. DR ProteomicsDB; 48863; -. [O43293-1] DR ProteomicsDB; 48864; -. [O43293-2] DR Pumba; O43293; -. DR Antibodypedia; 11137; 420 antibodies from 44 providers. DR DNASU; 1613; -. DR Ensembl; ENST00000301264.7; ENSP00000301264.3; ENSG00000167657.15. [O43293-1] DR Ensembl; ENST00000545797.7; ENSP00000442973.1; ENSG00000167657.15. [O43293-1] DR GeneID; 1613; -. DR KEGG; hsa:1613; -. DR MANE-Select; ENST00000545797.7; ENSP00000442973.1; NM_001348.3; NP_001339.1. DR UCSC; uc002lzc.2; human. [O43293-1] DR AGR; HGNC:2676; -. DR ClinPGx; PA27144; -. DR CTD; 1613; -. DR DisGeNET; 1613; -. DR GeneCards; DAPK3; -. DR HGNC; HGNC:2676; DAPK3. DR HPA; ENSG00000167657; Low tissue specificity. DR MIM; 603289; gene. DR OpenTargets; ENSG00000167657; -. DR VEuPathDB; HostDB:ENSG00000167657; -. DR eggNOG; KOG0032; Eukaryota. DR GeneTree; ENSGT00940000161753; -. DR HOGENOM; CLU_000288_63_55_1; -. DR InParanoid; O43293; -. DR OMA; LWYKEEN; -. DR OrthoDB; 74764at2759; -. DR PAN-GO; O43293; 5 GO annotations based on evolutionary models. DR PhylomeDB; O43293; -. DR PathwayCommons; O43293; -. DR Reactome; R-HSA-418889; Caspase activation via Dependence Receptors in the absence of ligand. DR SABIO-RK; O43293; -. DR SignaLink; O43293; -. DR SIGNOR; O43293; -. DR Agora; ENSG00000167657; -. DR BioGRID-ORCS; 1613; 21 hits in 1190 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; DAPK3; human. DR EvolutionaryTrace; O43293; -. DR GeneWiki; DAPK3; -. DR GenomeRNAi; 1613; -. DR Pharos; O43293; Tchem. DR PRO; PR:O43293; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; O43293; protein. DR Bgee; ENSG00000167657; Expressed in apex of heart and 188 other cell types or tissues. DR ExpressionAtlas; O43293; baseline and differential. DR GO; GO:0005813; C:centrosome; IEA:UniProtKB-SubCell. DR GO; GO:0000775; C:chromosome, centromeric region; IDA:UniProtKB. DR GO; GO:0005929; C:cilium; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0030496; C:midbody; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; ISS:UniProtKB. DR GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell. DR GO; GO:0005819; C:spindle; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0008140; F:cAMP response element binding protein binding; TAS:ParkinsonsUK-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0043522; F:leucine zipper domain binding; IPI:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0031267; F:small GTPase binding; IDA:UniProtKB. DR GO; GO:0006915; P:apoptotic process; IDA:UniProtKB. DR GO; GO:0097190; P:apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:0071346; P:cellular response to type II interferon; IDA:UniProtKB. DR GO; GO:0006325; P:chromatin organization; IEA:UniProtKB-KW. DR GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB. DR GO; GO:0017148; P:negative regulation of translation; IDA:UniProtKB. DR GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IMP:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IEA:Ensembl. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0032956; P:regulation of actin cytoskeleton organization; IDA:UniProtKB. DR GO; GO:0042981; P:regulation of apoptotic process; TAS:UniProtKB. DR GO; GO:0010506; P:regulation of autophagy; TAS:UniProtKB. DR GO; GO:2000145; P:regulation of cell motility; TAS:UniProtKB. DR GO; GO:0008360; P:regulation of cell shape; IEA:Ensembl. DR GO; GO:0006355; P:regulation of DNA-templated transcription; TAS:UniProtKB. DR GO; GO:0051893; P:regulation of focal adhesion assembly; IDA:UniProtKB. DR GO; GO:0007346; P:regulation of mitotic cell cycle; IMP:UniProtKB. DR GO; GO:0007088; P:regulation of mitotic nuclear division; TAS:UniProtKB. DR GO; GO:0043519; P:regulation of myosin II filament organization; IEA:Ensembl. DR GO; GO:0006940; P:regulation of smooth muscle contraction; TAS:UniProtKB. DR CDD; cd14105; STKc_DAPK; 1. DR FunFam; 3.30.200.20:FF:000110; Death-associated kinase 3, isoform CRA_a; 1. DR FunFam; 1.10.510.10:FF:000250; Death-associated protein kinase 3; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR042870; DAPK3_STKc. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24342:SF18; DEATH-ASSOCIATED PROTEIN KINASE 3; 1. DR PANTHER; PTHR24342; SERINE/THREONINE-PROTEIN KINASE 17; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Activator; Alternative splicing; Apoptosis; ATP-binding; KW Centromere; Chromatin regulator; Chromosome; Cytoplasm; Cytoskeleton; KW Kinase; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transcription; Transcription regulation; KW Transferase; Translation regulation; Tumor suppressor. FT CHAIN 1..454 FT /note="Death-associated protein kinase 3" FT /id="PRO_0000085914" FT DOMAIN 13..275 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 161..204 FT /note="Activation segment" FT /evidence="ECO:0000250|UniProtKB:O96017" FT REGION 427..441 FT /note="Leucine-zipper" FT /evidence="ECO:0000303|PubMed:9488481" FT ACT_SITE 139 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 19..27 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 42 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305" FT BINDING 94 FT /ligand="pyridone 6" FT /ligand_id="ChEBI:CHEBI:87103" FT /ligand_note="inhibitor" FT /evidence="ECO:0000269|PubMed:18239682, FT ECO:0007744|PDB:2J90" FT BINDING 96 FT /ligand="pyridone 6" FT /ligand_id="ChEBI:CHEBI:87103" FT /ligand_note="inhibitor" FT /evidence="ECO:0000269|PubMed:18239682, FT ECO:0007744|PDB:2J90" FT MOD_RES 50 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18239682" FT MOD_RES 180 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:15611134, FT ECO:0000269|PubMed:17158456" FT MOD_RES 225 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:15611134" FT MOD_RES 265 FT /note="Phosphothreonine; by autocatalysis and ROCK1" FT /evidence="ECO:0000269|PubMed:15611134, FT ECO:0000269|PubMed:17158456, ECO:0000269|PubMed:18239682" FT MOD_RES 299 FT /note="Phosphothreonine; by autocatalysis, DAPK1 and ROCK1" FT /evidence="ECO:0000269|PubMed:15367680, FT ECO:0000269|PubMed:15611134, ECO:0000269|PubMed:17158456, FT ECO:0000269|PubMed:20854903" FT MOD_RES 306 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15611134" FT MOD_RES 309 FT /note="Phosphoserine; by DAPK1" FT /evidence="ECO:0000269|PubMed:15367680" FT MOD_RES 311 FT /note="Phosphoserine; by autocatalysis and DAPK1" FT /evidence="ECO:0000269|PubMed:15367680, FT ECO:0000269|PubMed:15611134" FT MOD_RES 312 FT /note="Phosphoserine; by DAPK1" FT /evidence="ECO:0000269|PubMed:15367680, FT ECO:0007744|PubMed:23186163" FT MOD_RES 318 FT /note="Phosphoserine; by DAPK1" FT /evidence="ECO:0000269|PubMed:15367680" FT MOD_RES 326 FT /note="Phosphoserine; by DAPK1" FT /evidence="ECO:0000269|PubMed:15367680" FT VAR_SEQ 313..322 FT /note="LPPNNSYADF -> ASPIVAPVDA (in isoform 2)" FT /evidence="ECO:0000303|PubMed:17126281" FT /id="VSP_042059" FT VAR_SEQ 323..454 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:17126281" FT /id="VSP_042060" FT VARIANT 112 FT /note="T -> M (in a colorectal adenocarcinoma sample; FT somatic mutation; greatly reduces kinase activity, FT increases cell proliferation and cell survival)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:21487036" FT /id="VAR_040438" FT VARIANT 161 FT /note="D -> N (in an ovarian mucinous carcinoma sample; FT somatic mutation; greatly reduces kinase activity, FT increases cell proliferation and cell survival)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:21487036" FT /id="VAR_040439" FT VARIANT 216 FT /note="P -> S (in a lung neuroendocrine carcinoma sample; FT somatic mutation; greatly reduces kinase activity, FT increases cell proliferation, cell adhesion and cell FT survival)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:21487036" FT /id="VAR_040440" FT MUTAGEN 42 FT /note="K->A: Loss of kinase activity at low concentrations FT of ATP." FT /evidence="ECO:0000269|PubMed:17158456" FT MUTAGEN 161 FT /note="D->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:17158456" FT MUTAGEN 180 FT /note="T->A: Greatly reduced kinase activity." FT /evidence="ECO:0000269|PubMed:21487036" FT MUTAGEN 225 FT /note="T->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:17158456" FT MUTAGEN 265 FT /note="T->A: Loss of phosphorylation by ROCK1, FT catalytically inactive." FT /evidence="ECO:0000269|PubMed:17158456" FT MUTAGEN 294..295 FT /note="RR->AA: Cytoplasmic localization." FT /evidence="ECO:0000269|PubMed:20854903" FT MUTAGEN 299..300 FT /note="TT->AA: Predominantly nuclear localization." FT /evidence="ECO:0000269|PubMed:15611134" FT MUTAGEN 299 FT /note="T->A: Loss of phosphorylation by ROCK1." FT /evidence="ECO:0000269|PubMed:17158456" FT MUTAGEN 299 FT /note="T->D: Predominantly cytoplasmic localization; FT phosphomimetic." FT /evidence="ECO:0000269|PubMed:15611134" FT MUTAGEN 427 FT /note="V->A: Predominantly nuclear localization; when FT associated with A-434 and A-441." FT /evidence="ECO:0000269|PubMed:15611134" FT MUTAGEN 434 FT /note="V->A: Predominantly nuclear localization; when FT associated with A-427 and A-441." FT /evidence="ECO:0000269|PubMed:15611134" FT MUTAGEN 441 FT /note="L->A: Predominantly nuclear localization; when FT associated with A-427 and A-434." FT /evidence="ECO:0000269|PubMed:15611134" FT HELIX 9..12 FT /evidence="ECO:0007829|PDB:3BHY" FT STRAND 13..21 FT /evidence="ECO:0007829|PDB:3BHY" FT STRAND 23..32 FT /evidence="ECO:0007829|PDB:3BHY" FT TURN 33..35 FT /evidence="ECO:0007829|PDB:3BHY" FT STRAND 38..46 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 49..51 FT /evidence="ECO:0007829|PDB:2J90" FT STRAND 53..56 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 58..70 FT /evidence="ECO:0007829|PDB:3BHY" FT STRAND 79..84 FT /evidence="ECO:0007829|PDB:3BHY" FT STRAND 86..94 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 101..108 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 113..132 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 142..144 FT /evidence="ECO:0007829|PDB:3BHY" FT STRAND 145..148 FT /evidence="ECO:0007829|PDB:3BHY" FT STRAND 150..154 FT /evidence="ECO:0007829|PDB:3BHY" FT STRAND 157..159 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 171..175 FT /evidence="ECO:0007829|PDB:5A6N" FT HELIX 176..178 FT /evidence="ECO:0007829|PDB:5A6O" FT HELIX 181..183 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 186..189 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 197..212 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 222..230 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 238..241 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 246..253 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 260..262 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 266..271 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 273..280 FT /evidence="ECO:0007829|PDB:3BHY" SQ SEQUENCE 454 AA; 52536 MW; 56773008A6A61CF0 CRC64; MSTFRQEDVE DHYEMGEELG SGQFAIVRKC RQKGTGKEYA AKFIKKRRLS SSRRGVSREE IEREVNILRE IRHPNIITLH DIFENKTDVV LILELVSGGE LFDFLAEKES LTEDEATQFL KQILDGVHYL HSKRIAHFDL KPENIMLLDK NVPNPRIKLI DFGIAHKIEA GNEFKNIFGT PEFVAPEIVN YEPLGLEADM WSIGVITYIL LSGASPFLGE TKQETLTNIS AVNYDFDEEY FSNTSELAKD FIRRLLVKDP KRRMTIAQSL EHSWIKAIRR RNVRGEDSGR KPERRRLKTT RLKEYTIKSH SSLPPNNSYA DFERFSKVLE EAAAAEEGLR ELQRSRRLCH EDVEALAAIY EEKEAWYREE SDSLGQDLRR LRQELLKTEA LKRQAQEEAK GALLGTSGLK RRFSRLENRY EALAKQVASE MRFVQDLVRA LEQEKLQGVE CGLR // ID ECT2_HUMAN Reviewed; 914 AA. AC Q9H8V3; Q0MT80; Q2M269; Q6U836; Q9NSV8; Q9NVW9; DT 26-SEP-2001, integrated into UniProtKB/Swiss-Prot. DT 16-NOV-2011, sequence version 4. DT 28-JAN-2026, entry version 195. DE RecName: Full=Protein ECT2; DE AltName: Full=Epithelial cell-transforming sequence 2 oncogene; GN Name=ECT2 {ECO:0000312|HGNC:HGNC:3155}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, PHOSPHORYLATION, AND RP SUBCELLULAR LOCATION. RX PubMed=10579713; DOI=10.1083/jcb.147.5.921; RA Tatsumoto T., Xie X., Blumenthal R., Okamoto I., Miki T.; RT "Human ECT2 is an exchange factor for Rho GTPases, phosphorylated in G2/M RT phases, and involved in cytokinesis."; RL J. Cell Biol. 147:921-928(1999). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RX PubMed=14587037; DOI=10.1002/jcb.10688; RA Saito S., Tatsumoto T., Lorenzi M.V., Chedid M., Kapoor V., Sakata H., RA Rubin J.S., Miki T.; RT "Rho exchange factor ECT2 is induced by growth factors and regulates RT cytokinesis through the N-terminal cell cycle regulator-related domains."; RL J. Cell. Biochem. 90:819-836(2003). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH PKP4, AND RP SUBCELLULAR LOCATION. RX PubMed=17115030; DOI=10.1038/ncb1504; RA Wolf A., Keil R., Gotzl O., Mun A., Schwarze K., Lederer M., RA Huttelmaier S., Hatzfeld M.; RT "The armadillo protein p0071 regulates Rho signalling during cytokinesis."; RL Nat. Cell Biol. 8:1432-1440(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Teratocarcinoma, and Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16641997; DOI=10.1038/nature04728; RA Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., RA Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., RA Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A., RA Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., RA Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., RA Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., RA Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., RA Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., RA Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., RA Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., RA Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., RA Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., RA Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., RA Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., RA Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., RA Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., RA Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., RA Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., RA Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.; RT "The DNA sequence, annotation and analysis of human chromosome 3."; RL Nature 440:1194-1198(2006). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 662-914 (ISOFORM 3). RC TISSUE=Testis; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [8] RP FUNCTION, HOMODIMERIZATION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF RP 379-ARG--ARG-381; 402-ARG--ARG-404 AND 596-PRO--ARG-599. RX PubMed=14645260; DOI=10.1074/jbc.m306725200; RA Saito S., Liu X.F., Kamijo K., Raziuddin R., Tatsumoto T., Okamoto I., RA Chen X., Lee C.C., Lorenzi M.V., Ohara N., Miki T.; RT "Deregulation and mislocalization of the cytokinesis regulator ECT2 RT activate the Rho signaling pathways leading to malignant transformation."; RL J. Biol. Chem. 279:7169-7179(2004). RN [9] RP FUNCTION, INTERACTION WITH PARD3; PARD6A; PARD6B AND PRKCQ, INDUCTION, AND RP SUBCELLULAR LOCATION. RX PubMed=15254234; DOI=10.1128/mcb.24.15.6665-6675.2004; RA Liu X.F., Ishida H., Raziuddin R., Miki T.; RT "Nucleotide exchange factor ECT2 interacts with the polarity protein RT complex Par6/Par3/protein kinase Czeta (PKCzeta) and regulates PKCzeta RT activity."; RL Mol. Cell. Biol. 24:6665-6675(2004). RN [10] RP FUNCTION, HOMODIMERIZATION, HOMOOLIGOMERIZATION, AND MUTAGENESIS OF RP TRP-336. RX PubMed=15545273; DOI=10.1074/jbc.m409298200; RA Kim J.E., Billadeau D.D., Chen J.; RT "The tandem BRCT domains of Ect2 are required for both negative and RT positive regulation of Ect2 in cytokinesis."; RL J. Biol. Chem. 280:5733-5739(2005). RN [11] RP FUNCTION. RX PubMed=15642749; DOI=10.1083/jcb.200408085; RA Oceguera-Yanez F., Kimura K., Yasuda S., Higashida C., Kitamura T., RA Hiraoka Y., Haraguchi T., Narumiya S.; RT "Ect2 and MgcRacGAP regulate the activation and function of Cdc42 in RT mitosis."; RL J. Cell Biol. 168:221-232(2005). RN [12] RP FUNCTION, INTERACTION WITH RACGAP1, MUTAGENESIS OF THR-373, AND SUBCELLULAR RP LOCATION. RX PubMed=16103226; DOI=10.1083/jcb.200501097; RA Yuce O., Piekny A., Glotzer M.; RT "An ECT2-centralspindlin complex regulates the localization and function of RT RhoA."; RL J. Cell Biol. 170:571-582(2005). RN [13] RP INTERACTION WITH RACGAP1. RX PubMed=16129829; DOI=10.1073/pnas.0504145102; RA Zhao W.-M., Fang G.; RT "MgcRacGAP controls the assembly of the contractile ring and the initiation RT of cytokinesis."; RL Proc. Natl. Acad. Sci. U.S.A. 102:13158-13163(2005). RN [14] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=16495035; DOI=10.1016/j.cellsig.2006.01.007; RA Liu X.F., Ohno S., Miki T.; RT "Nucleotide exchange factor ECT2 regulates epithelial cell polarity."; RL Cell. Signal. 18:1604-1615(2006). RN [15] RP INTERACTION WITH NEDD9, AND SUBCELLULAR LOCATION. RX PubMed=16394104; DOI=10.1091/mbc.e05-03-0237; RA Dadke D., Jarnik M., Pugacheva E.N., Singh M.K., Golemis E.A.; RT "Deregulation of HEF1 impairs M-phase progression by disrupting the RhoA RT activation cycle."; RL Mol. Biol. Cell 17:1204-1217(2006). RN [16] RP FUNCTION, IDENTIFICATION IN THE CENTRALSPINDLIN COMPLEX, INTERACTION WITH RP KIF23 AND RACGAP1, AND SUBCELLULAR LOCATION. RX PubMed=16236794; DOI=10.1091/mbc.e05-06-0569; RA Kamijo K., Ohara N., Abe M., Uchimura T., Hosoya H., Lee J.S., Miki T.; RT "Dissecting the role of Rho-mediated signaling in contractile ring RT formation."; RL Mol. Biol. Cell 17:43-55(2006). RN [17] RP FUNCTION, HOMODIMERIZATION, PHOSPHORYLATION AT THR-373, AND MUTAGENESIS OF RP THR-373. RX PubMed=16170345; DOI=10.1038/sj.onc.1209078; RA Hara T., Abe M., Inoue H., Yu L.R., Veenstra T.D., Kang Y.H., Lee K.S., RA Miki T.; RT "Cytokinesis regulator ECT2 changes its conformation through RT phosphorylation at Thr-341 in G2/M phase."; RL Oncogene 25:566-578(2006). RN [18] RP PHOSPHORYLATION AT THR-444, INTERACTION WITH PLK1, AND MUTAGENESIS OF RP THR-444 AND THR-846. RX PubMed=16247472; DOI=10.1038/sj.onc.1209124; RA Niiya F., Tatsumoto T., Lee K.S., Miki T.; RT "Phosphorylation of the cytokinesis regulator ECT2 at G2/M phase stimulates RT association of the mitotic kinase Plk1 and accumulation of GTP-bound RT RhoA."; RL Oncogene 25:827-837(2006). RN [19] RP INTERACTION WITH RAB11FIP3. RX PubMed=18511905; DOI=10.1038/emboj.2008.112; RA Simon G.C., Schonteich E., Wu C.C., Piekny A., Ekiert D., Yu X., RA Gould G.W., Glotzer M., Prekeris R.; RT "Sequential Cyk-4 binding to ECT2 and FIP3 regulates cleavage furrow RT ingression and abscission during cytokinesis."; RL EMBO J. 27:1791-1803(2008). RN [20] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-367; SER-370; THR-373; RP SER-376; SER-842 AND THR-846, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [22] RP FUNCTION. RX PubMed=19129481; DOI=10.1091/mbc.e08-01-0001; RA Asiedu M., Wu D., Matsumura F., Wei Q.; RT "Centrosome/spindle pole-associated protein regulates cytokinesis via RT promoting the recruitment of MyoGEF to the central spindle."; RL Mol. Biol. Cell 20:1428-1440(2009). RN [23] RP FUNCTION, INTERACTION WITH PARD6A AND PRKCI, SUBCELLULAR LOCATION, AND RP TISSUE SPECIFICITY. RX PubMed=19617897; DOI=10.1038/onc.2009.217; RA Justilien V., Fields A.P.; RT "Ect2 links the PKCiota-Par6alpha complex to Rac1 activation and cellular RT transformation."; RL Oncogene 28:3597-3607(2009). RN [24] RP FUNCTION, INTERACTION WITH KIF23 AND RACGAP1, SUBCELLULAR LOCATION, AND RP MUTAGENESIS OF THR-184 AND LYS-226. RX PubMed=19468300; DOI=10.1371/journal.pbio.1000110; RA Wolfe B.A., Takaki T., Petronczki M., Glotzer M.; RT "Polo-like kinase 1 directs assembly of the HsCyk-4 RhoGAP/Ect2 RhoGEF RT complex to initiate cleavage furrow formation."; RL PLoS Biol. 7:E1000110-E1000110(2009). RN [25] RP INTERACTION WITH RACGAP1. RX PubMed=19468302; DOI=10.1371/journal.pbio.1000111; RA Burkard M.E., Maciejowski J., Rodriguez-Bravo V., Repka M., Lowery D.M., RA Clauser K.R., Zhang C., Shokat K.M., Carr S.A., Yaffe M.B., RA Jallepalli P.V.; RT "Plk1 self-organization and priming phosphorylation of HsCYK-4 at the RT spindle midzone regulate the onset of division in human cells."; RL PLoS Biol. 7:E1000111-E1000111(2009). RN [26] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [27] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-359, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [28] RP FUNCTION, PHOSPHORYLATION AT THR-359, MUTAGENESIS OF THR-359, AND RP IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=21189248; DOI=10.1074/jbc.m110.196113; RA Justilien V., Jameison L., Der C.J., Rossman K.L., Fields A.P.; RT "Oncogenic activity of Ect2 is regulated through protein kinase C iota- RT mediated phosphorylation."; RL J. Biol. Chem. 286:8149-8157(2011). RN [29] RP FUNCTION, AND INDUCTION. RX PubMed=21373644; DOI=10.1371/journal.pone.0017108; RA Srougi M.C., Burridge K.; RT "The nuclear guanine nucleotide exchange factors Ect2 and Net1 regulate RT RhoB-mediated cell death after DNA damage."; RL PLoS ONE 6:E17108-E17108(2011). RN [30] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-359, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [31] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [32] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-359; SER-367; SER-716; RP SER-861 AND SER-866, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [33] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-611, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [34] RP X-RAY CRYSTALLOGRAPHY (1.48 ANGSTROMS) OF 268-361. RG Structural genomics consortium (SGC); RT "Crystal structure of the second BRCT domain of epithelial cell RT transforming 2 (ECT2)."; RL Submitted (JAN-2010) to the PDB data bank. RN [35] {ECO:0007744|PDB:4N40} RP X-RAY CRYSTALLOGRAPHY (3.11 ANGSTROMS) OF 45-356, FUNCTION, ACTIVITY RP REGULATION, INTERACTION WITH RACGAP1, AND MUTAGENESIS OF THR-184 AND RP LYS-226. RX PubMed=25068414; DOI=10.1016/j.febslet.2014.07.019; RA Zou Y., Shao Z., Peng J., Li F., Gong D., Wang C., Zuo X., Zhang Z., Wu J., RA Shi Y., Gong Q.; RT "Crystal structure of triple-BRCT-domain of ECT2 and insights into the RT binding characteristics to CYK-4."; RL FEBS Lett. 588:2911-2920(2014). RN [36] {ECO:0007744|PDB:6L30} RP X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 173-865, FUNCTION, ACTIVITY RP REGULATION, INTERACTION WITH RHOA, DOMAIN, IDENTIFICATION BY MASS RP SPECTROMETRY, AND MUTAGENESIS OF TRP-338; ARG-488; ARG-570; ALA-573; RP ARG-586; PRO-601; PHE-652; TYR-656; ARG-670; PRO-734 AND CYS-796. RX PubMed=31888991; DOI=10.1073/pnas.1913054117; RA Chen M., Pan H., Sun L., Shi P., Zhang Y., Li L., Huang Y., Chen J., RA Jiang P., Fang X., Wu C., Chen Z.; RT "Structure and regulation of human epithelial cell transforming 2 RT protein."; RL Proc. Natl. Acad. Sci. U.S.A. 117:1027-1035(2020). RN [37] RP VARIANT [LARGE SCALE ANALYSIS] PRO-833. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). CC -!- FUNCTION: Guanine nucleotide exchange factor (GEF) that catalyzes the CC exchange of GDP for GTP. Promotes guanine nucleotide exchange on the CC Rho family members of small GTPases, like RHOA, RHOC, RAC1 and CDC42. CC Required for signal transduction pathways involved in the regulation of CC cytokinesis. Component of the centralspindlin complex that serves as a CC microtubule-dependent and Rho-mediated signaling required for the CC myosin contractile ring formation during the cell cycle cytokinesis. CC Regulates the translocation of RHOA from the central spindle to the CC equatorial region. Plays a role in the control of mitotic spindle CC assembly; regulates the activation of CDC42 in metaphase for the CC process of spindle fibers attachment to kinetochores before chromosome CC congression. Involved in the regulation of epithelial cell polarity; CC participates in the formation of epithelial tight junctions in a CC polarity complex PARD3-PARD6-protein kinase PRKCQ-dependent manner. CC Plays a role in the regulation of neurite outgrowth. Inhibits CC phenobarbital (PB)-induced NR1I3 nuclear translocation. Stimulates the CC activity of RAC1 through its association with the oncogenic PARD6A- CC PRKCI complex in cancer cells, thereby acting to coordinately drive CC tumor cell proliferation and invasion. Also stimulates genotoxic CC stress-induced RHOB activity in breast cancer cells leading to their CC cell death. {ECO:0000269|PubMed:10579713, ECO:0000269|PubMed:14645260, CC ECO:0000269|PubMed:15254234, ECO:0000269|PubMed:15545273, CC ECO:0000269|PubMed:15642749, ECO:0000269|PubMed:16103226, CC ECO:0000269|PubMed:16170345, ECO:0000269|PubMed:16236794, CC ECO:0000269|PubMed:16495035, ECO:0000269|PubMed:19129481, CC ECO:0000269|PubMed:19468300, ECO:0000269|PubMed:19617897, CC ECO:0000269|PubMed:21189248, ECO:0000269|PubMed:21373644, CC ECO:0000269|PubMed:25068414, ECO:0000269|PubMed:31888991}. CC -!- ACTIVITY REGULATION: Autoinhibited by the C-terminal PH domain which CC folds back and binds to the surface of the DH domain, blocking binding CC of RHOA to the catalytic center of the DH domain (PubMed:31888991). The CC 2nd BRCT domain is also involved in inhibition, probably by helping to CC impede RHOA binding (PubMed:31888991). Allosterically activated by CC binding of activated GTP-bound RHOA to the PH domain which stimulates CC the release of PH inhibition and promotes the binding of substrate RHOA CC to the catalytic center (PubMed:31888991). Binding of phosphorylated CC RACGAP1 to the N-terminal BRCT domain-containing region also releases CC autoinhibition (PubMed:25068414). {ECO:0000269|PubMed:25068414, CC ECO:0000269|PubMed:31888991}. CC -!- SUBUNIT: Homodimer (PubMed:14645260, PubMed:15545273, PubMed:16170345). CC Homooligomer (PubMed:15545273). Found in the centralspindlin complex CC (PubMed:16236794). Interacts with NR1I3 (By similarity). Interacts CC (Thr-359 phosphorylated form) with PARD6A; the interaction is observed CC in cancer cells (PubMed:15254234, PubMed:19617897). Interacts (Thr-359 CC phosphorylated form) with PRKCI; the interaction is observed in cancer CC cells (PubMed:19617897). Interacts with PKP4; the interaction is CC observed at the midbody (PubMed:22814378). Interacts with RACGAP1/CYK4; CC the interaction is direct, occurs in a microtubule-dependent manner, CC occurs at anaphase and during cytokinesis, is inhibited in metaphase by CC phosphorylation of ECT2 on Thr-373 and is stimulated in early anaphase CC by dephosphorylation of ECT2 probably on Thr-373 through CDK1 activity CC (PubMed:16103226, PubMed:16129829, PubMed:16236794, PubMed:19468300, CC PubMed:19468302, PubMed:25068414). Interacts with PLK1; the interaction CC is stimulated upon its phosphorylation on Thr-444 (PubMed:16247472). CC Interacts with RHOA; the interaction results in allosteric activation CC of ECT2 (PubMed:31888991). Interacts with KIF23, PARD3, PARD6B and CC PRKCQ (PubMed:15254234, PubMed:16236794). Interacts with NEDD9/HEF1 CC (PubMed:16394104). {ECO:0000250|UniProtKB:Q07139, CC ECO:0000269|PubMed:14645260, ECO:0000269|PubMed:15254234, CC ECO:0000269|PubMed:15545273, ECO:0000269|PubMed:16103226, CC ECO:0000269|PubMed:16129829, ECO:0000269|PubMed:16170345, CC ECO:0000269|PubMed:16236794, ECO:0000269|PubMed:16247472, CC ECO:0000269|PubMed:16394104, ECO:0000269|PubMed:19468300, CC ECO:0000269|PubMed:19468302, ECO:0000269|PubMed:19617897, CC ECO:0000269|PubMed:22814378, ECO:0000269|PubMed:25068414, CC ECO:0000269|PubMed:31888991}. CC -!- INTERACTION: CC Q9H8V3; P12830: CDH1; NbExp=3; IntAct=EBI-1054039, EBI-727477; CC Q9H8V3; P35221: CTNNA1; NbExp=3; IntAct=EBI-1054039, EBI-701918; CC Q9H8V3; Q02241: KIF23; NbExp=2; IntAct=EBI-1054039, EBI-306852; CC Q9H8V3; P16333: NCK1; NbExp=3; IntAct=EBI-1054039, EBI-389883; CC Q9H8V3; O00444: PLK4; NbExp=3; IntAct=EBI-1054039, EBI-746202; CC Q9H8V3; Q9H0H5: RACGAP1; NbExp=15; IntAct=EBI-1054039, EBI-717233; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:10579713, CC ECO:0000269|PubMed:14645260, ECO:0000269|PubMed:15254234, CC ECO:0000269|PubMed:16103226, ECO:0000269|PubMed:16495035, CC ECO:0000269|PubMed:19617897}. Cytoplasm {ECO:0000269|PubMed:10579713, CC ECO:0000269|PubMed:16236794, ECO:0000269|PubMed:16394104}. Cytoplasm, CC cytoskeleton, spindle {ECO:0000269|PubMed:10579713, CC ECO:0000269|PubMed:16103226, ECO:0000269|PubMed:16236794, CC ECO:0000269|PubMed:17115030, ECO:0000269|PubMed:19468300}. Cleavage CC furrow {ECO:0000269|PubMed:10579713}. Midbody CC {ECO:0000269|PubMed:15254234, ECO:0000269|PubMed:16394104, CC ECO:0000269|PubMed:17115030}. Cell junction CC {ECO:0000269|PubMed:15254234, ECO:0000269|PubMed:16495035}. Cell CC junction, tight junction {ECO:0000269|PubMed:15254234}. Cytoplasm, CC cytoskeleton, microtubule organizing center, centrosome CC {ECO:0000269|PubMed:17115030}. Note=Sequestered within the nucleus CC during interphase (PubMed:10579713). Dispersed throughout the cytoplasm CC upon breakdown of the nuclear envelope during mitosis CC (PubMed:10579713). Colocalizes with the centralspindlin complex to the CC mitotic spindles during anaphase/metaphase, the cleavage furrow during CC telophase and at the midbody at the end of cytokinesis CC (PubMed:10579713). Colocalized with RhoA at the midbody CC (PubMed:10579713). Its subcellular localization to tight junction is CC increased by calcium (PubMed:15254234). {ECO:0000269|PubMed:10579713, CC ECO:0000269|PubMed:15254234}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; CC IsoId=Q9H8V3-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9H8V3-2; Sequence=VSP_041976, VSP_041977; CC Name=3; CC IsoId=Q9H8V3-3; Sequence=VSP_041978; CC Name=4; CC IsoId=Q9H8V3-4; Sequence=VSP_041977; CC -!- TISSUE SPECIFICITY: Expressed in lung epithelial cells (at protein CC level). Expressed in squamous cell carcinoma, primary non-small cell CC lung cancer tumors and lung adenocarcinoma. CC {ECO:0000269|PubMed:19617897}. CC -!- INDUCTION: Up-regulated by calcium in cells forming cell-cell contact CC sites. Up-regulated by DNA damaging agents like H(2)O(2) or ionizing CC radiation (IR). {ECO:0000269|PubMed:15254234, CC ECO:0000269|PubMed:21373644}. CC -!- DOMAIN: The BRCT domains 1 and 2 are required for intramolecular CC interaction, but not for intermolecular oligomerization CC (PubMed:15545273). The BRCT domains negatively inhibit its GEF activity CC in interphase cells (PubMed:15545273, PubMed:31888991). The same BRCT CC domains may act as a positive regulatory motif for the completion of CC cytokinesis after the breakdown of nuclear membrane during mitosis CC (PubMed:15545273). {ECO:0000269|PubMed:15545273, CC ECO:0000269|PubMed:31888991}. CC -!- PTM: Phosphorylated by PLK1 in vitro. Hyperphosphorylated during the G2 CC phase of the cell cycle. Phosphorylation at Thr-373 occurs during the CC G2/M phase, relieves its auto-inhibition status and stimulates its GEF CC activity. Phosphorylation at Thr-444 in G2/M phase is required for CC subsequent binding with PLK1 and Rho exchange activation. CC Dephosphorylated at the time of cytokinesis. Phosphorylation at Thr-359 CC is required for its transformation activity in cancer cells. CC {ECO:0000269|PubMed:10579713, ECO:0000269|PubMed:16170345, CC ECO:0000269|PubMed:16247472, ECO:0000269|PubMed:21189248}. CC -!- MISCELLANEOUS: [Isoform 3]: May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA91624.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/40400/ECT2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY376439; AAQ83675.1; -; mRNA. DR EMBL; DQ847274; ABH10140.1; -; mRNA. DR EMBL; AK001323; BAA91624.1; ALT_INIT; mRNA. DR EMBL; AK023267; BAB14498.1; -; mRNA. DR EMBL; AK314581; BAG37157.1; -; mRNA. DR EMBL; AC108667; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC112086; AAI12087.1; -; mRNA. DR EMBL; AL137710; CAB70886.1; -; mRNA. DR CCDS; CCDS3220.1; -. [Q9H8V3-4] DR CCDS; CCDS58860.1; -. [Q9H8V3-1] DR CCDS; CCDS87168.1; -. [Q9H8V3-2] DR RefSeq; NP_001245244.1; NM_001258315.2. [Q9H8V3-1] DR RefSeq; NP_001245245.1; NM_001258316.2. [Q9H8V3-4] DR RefSeq; NP_001336023.1; NM_001349094.2. [Q9H8V3-3] DR RefSeq; NP_001336024.1; NM_001349095.2. [Q9H8V3-3] DR RefSeq; NP_001336025.1; NM_001349096.2. [Q9H8V3-3] DR RefSeq; NP_001336027.1; NM_001349098.2. [Q9H8V3-1] DR RefSeq; NP_001336028.1; NM_001349099.2. [Q9H8V3-1] DR RefSeq; NP_001336029.1; NM_001349100.2. [Q9H8V3-1] DR RefSeq; NP_001336031.1; NM_001349102.2. [Q9H8V3-2] DR RefSeq; NP_060568.3; NM_018098.5. [Q9H8V3-4] DR RefSeq; XP_047303563.1; XM_047447607.1. [Q9H8V3-3] DR RefSeq; XP_047303564.1; XM_047447608.1. [Q9H8V3-3] DR RefSeq; XP_047303565.1; XM_047447609.1. [Q9H8V3-3] DR RefSeq; XP_047303573.1; XM_047447617.1. [Q9H8V3-1] DR RefSeq; XP_047303574.1; XM_047447618.1. [Q9H8V3-1] DR RefSeq; XP_047303583.1; XM_047447627.1. [Q9H8V3-4] DR RefSeq; XP_047303584.1; XM_047447628.1. [Q9H8V3-4] DR RefSeq; XP_047303585.1; XM_047447629.1. [Q9H8V3-4] DR RefSeq; XP_047303586.1; XM_047447630.1. [Q9H8V3-4] DR RefSeq; XP_054201507.1; XM_054345532.1. [Q9H8V3-3] DR RefSeq; XP_054201508.1; XM_054345533.1. [Q9H8V3-3] DR RefSeq; XP_054201509.1; XM_054345534.1. [Q9H8V3-3] DR RefSeq; XP_054201517.1; XM_054345542.1. [Q9H8V3-1] DR RefSeq; XP_054201518.1; XM_054345543.1. [Q9H8V3-1] DR RefSeq; XP_054201528.1; XM_054345553.1. [Q9H8V3-4] DR RefSeq; XP_054201529.1; XM_054345554.1. [Q9H8V3-4] DR RefSeq; XP_054201530.1; XM_054345555.1. [Q9H8V3-4] DR RefSeq; XP_054201531.1; XM_054345556.1. [Q9H8V3-4] DR PDB; 3L46; X-ray; 1.48 A; A/B=268-361. DR PDB; 4N40; X-ray; 3.11 A; A=45-356. DR PDB; 6L30; X-ray; 2.80 A; A=173-865. DR PDBsum; 3L46; -. DR PDBsum; 4N40; -. DR PDBsum; 6L30; -. DR AlphaFoldDB; Q9H8V3; -. DR SMR; Q9H8V3; -. DR BioGRID; 108223; 896. DR CORUM; Q9H8V3; -. DR DIP; DIP-47496N; -. DR FunCoup; Q9H8V3; 1534. DR IntAct; Q9H8V3; 46. DR MINT; Q9H8V3; -. DR STRING; 9606.ENSP00000376457; -. DR GlyGen; Q9H8V3; 6 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (5 sites). DR iPTMnet; Q9H8V3; -. DR MetOSite; Q9H8V3; -. DR PhosphoSitePlus; Q9H8V3; -. DR SwissPalm; Q9H8V3; -. DR BioMuta; ECT2; -. DR DMDM; 357529579; -. DR jPOST; Q9H8V3; -. DR MassIVE; Q9H8V3; -. DR PaxDb; 9606-ENSP00000376457; -. DR PeptideAtlas; Q9H8V3; -. DR ProteomicsDB; 81243; -. [Q9H8V3-1] DR ProteomicsDB; 81244; -. [Q9H8V3-2] DR ProteomicsDB; 81245; -. [Q9H8V3-3] DR Pumba; Q9H8V3; -. DR Antibodypedia; 33733; 365 antibodies from 31 providers. DR DNASU; 1894; -. DR Ensembl; ENST00000232458.9; ENSP00000232458.5; ENSG00000114346.15. [Q9H8V3-4] DR Ensembl; ENST00000392692.8; ENSP00000376457.3; ENSG00000114346.15. [Q9H8V3-1] DR Ensembl; ENST00000417960.5; ENSP00000415876.1; ENSG00000114346.15. [Q9H8V3-2] DR Ensembl; ENST00000441497.6; ENSP00000412259.2; ENSG00000114346.15. [Q9H8V3-4] DR Ensembl; ENST00000540509.5; ENSP00000443160.2; ENSG00000114346.15. [Q9H8V3-4] DR GeneID; 1894; -. DR KEGG; hsa:1894; -. DR MANE-Select; ENST00000392692.8; ENSP00000376457.3; NM_001258315.2; NP_001245244.1. DR UCSC; uc003fih.4; human. [Q9H8V3-1] DR AGR; HGNC:3155; -. DR ClinPGx; PA27600; -. DR CTD; 1894; -. DR DisGeNET; 1894; -. DR GeneCards; ECT2; -. DR HGNC; HGNC:3155; ECT2. DR HPA; ENSG00000114346; Low tissue specificity. DR MIM; 600586; gene. DR OpenTargets; ENSG00000114346; -. DR VEuPathDB; HostDB:ENSG00000114346; -. DR eggNOG; KOG3524; Eukaryota. DR GeneTree; ENSGT00940000156299; -. DR HOGENOM; CLU_008187_0_0_1; -. DR InParanoid; Q9H8V3; -. DR OMA; PIYDVHK; -. DR OrthoDB; 9997817at2759; -. DR PAN-GO; Q9H8V3; 5 GO annotations based on evolutionary models. DR PathwayCommons; Q9H8V3; -. DR Reactome; R-HSA-193648; NRAGE signals death through JNK. DR Reactome; R-HSA-416482; G alpha (12/13) signalling events. DR Reactome; R-HSA-8980692; RHOA GTPase cycle. DR Reactome; R-HSA-9013026; RHOB GTPase cycle. DR Reactome; R-HSA-9013148; CDC42 GTPase cycle. DR Reactome; R-HSA-9013149; RAC1 GTPase cycle. DR SignaLink; Q9H8V3; -. DR SIGNOR; Q9H8V3; -. DR Agora; ENSG00000114346; -. DR BioGRID-ORCS; 1894; 654 hits in 1167 CRISPR screens. DR ChiTaRS; ECT2; human. DR EvolutionaryTrace; Q9H8V3; -. DR GeneWiki; ECT2; -. DR GenomeRNAi; 1894; -. DR Pharos; Q9H8V3; Tbio. DR PRO; PR:Q9H8V3; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q9H8V3; protein. DR Bgee; ENSG00000114346; Expressed in secondary oocyte and 166 other cell types or tissues. DR ExpressionAtlas; Q9H8V3; baseline and differential. DR GO; GO:0005923; C:bicellular tight junction; IDA:UniProtKB. DR GO; GO:0005938; C:cell cortex; IBA:GO_Central. DR GO; GO:0005911; C:cell-cell junction; IDA:UniProtKB. DR GO; GO:0097149; C:centralspindlin complex; IDA:UniProtKB. DR GO; GO:0005813; C:centrosome; IEA:UniProtKB-SubCell. DR GO; GO:0032154; C:cleavage furrow; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0030496; C:midbody; IDA:UniProtKB. DR GO; GO:0072686; C:mitotic spindle; IDA:UniProtKB. DR GO; GO:0016604; C:nuclear body; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005096; F:GTPase activator activity; IMP:UniProtKB. DR GO; GO:0005085; F:guanyl-nucleotide exchange factor activity; IDA:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0031267; F:small GTPase binding; IEA:Ensembl. DR GO; GO:0090630; P:activation of GTPase activity; IDA:UniProtKB. DR GO; GO:0032147; P:activation of protein kinase activity; IDA:UniProtKB. DR GO; GO:0070830; P:bicellular tight junction assembly; IMP:UniProtKB. DR GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW. DR GO; GO:0000902; P:cell morphogenesis; IEA:Ensembl. DR GO; GO:0071277; P:cellular response to calcium ion; IDA:UniProtKB. DR GO; GO:0070301; P:cellular response to hydrogen peroxide; IDA:UniProtKB. DR GO; GO:0071479; P:cellular response to ionizing radiation; IDA:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; IEA:InterPro. DR GO; GO:0000281; P:mitotic cytokinesis; IMP:UniProtKB. DR GO; GO:0007399; P:nervous system development; IBA:GO_Central. DR GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; HMP:UniProtKB. DR GO; GO:0032467; P:positive regulation of cytokinesis; IDA:UniProtKB. DR GO; GO:0043547; P:positive regulation of GTPase activity; IDA:UniProtKB. DR GO; GO:1903438; P:positive regulation of mitotic cytokinetic process; IMP:UniProt. DR GO; GO:0045666; P:positive regulation of neuron differentiation; ISS:UniProtKB. DR GO; GO:0042307; P:positive regulation of protein import into nucleus; ISS:UniProtKB. DR GO; GO:0051260; P:protein homooligomerization; IDA:UniProtKB. DR GO; GO:0015031; P:protein transport; IEA:UniProtKB-KW. DR GO; GO:0051988; P:regulation of attachment of spindle microtubules to kinetochore; IMP:UniProtKB. DR GO; GO:2000431; P:regulation of cytokinesis, actomyosin contractile ring assembly; IEA:InterPro. DR GO; GO:0045859; P:regulation of protein kinase activity; IDA:UniProtKB. DR GO; GO:0051056; P:regulation of small GTPase mediated signal transduction; TAS:Reactome. DR CDD; cd17733; BRCT_Ect2_rpt1; 1. DR CDD; cd17732; BRCT_Ect2_rpt2; 1. DR CDD; cd01229; PH_Ect2; 1. DR CDD; cd00160; RhoGEF; 1. DR FunFam; 3.40.50.10190:FF:000058; Epithelial cell transforming 2; 1. DR FunFam; 1.20.900.10:FF:000022; protein ECT2 isoform X1; 1. DR FunFam; 3.40.50.10190:FF:000015; protein ECT2 isoform X1; 1. DR FunFam; 2.30.29.30:FF:000162; protein ECT2 isoform X2; 1. DR FunFam; 3.40.50.10190:FF:000016; protein ECT2 isoform X3; 1. DR Gene3D; 3.40.50.10190; BRCT domain; 3. DR Gene3D; 1.20.900.10; Dbl homology (DH) domain; 1. DR Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1. DR InterPro; IPR001357; BRCT_dom. DR InterPro; IPR036420; BRCT_dom_sf. DR InterPro; IPR035899; DBL_dom_sf. DR InterPro; IPR000219; DH_dom. DR InterPro; IPR026817; Ect2. DR InterPro; IPR049396; ECT2_BRCT0. DR InterPro; IPR049395; ECT2_PH. DR InterPro; IPR001331; GDS_CDC24_CS. DR InterPro; IPR011993; PH-like_dom_sf. DR PANTHER; PTHR16777; PROTEIN ECT2; 1. DR PANTHER; PTHR16777:SF2; PROTEIN ECT2; 1. DR Pfam; PF00533; BRCT; 1. DR Pfam; PF21243; ECT2_BRCT0; 1. DR Pfam; PF21242; ECT2_PH; 1. DR Pfam; PF12738; PTCB-BRCT; 1. DR Pfam; PF00621; RhoGEF; 1. DR SMART; SM00292; BRCT; 2. DR SMART; SM00325; RhoGEF; 1. DR SUPFAM; SSF52113; BRCT domain; 2. DR SUPFAM; SSF48065; DBL homology domain (DH-domain); 1. DR SUPFAM; SSF50729; PH domain-like; 1. DR PROSITE; PS50172; BRCT; 2. DR PROSITE; PS00741; DH_1; 1. DR PROSITE; PS50010; DH_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Cell cycle; Cell division; KW Cell junction; Cytoplasm; Cytoskeleton; Differentiation; KW Guanine-nucleotide releasing factor; Isopeptide bond; Neurogenesis; KW Nucleus; Oncogene; Phosphoprotein; Protein transport; KW Proteomics identification; Reference proteome; Repeat; Tight junction; KW Transport; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..914 FT /note="Protein ECT2" FT /id="PRO_0000080938" FT DOMAIN 171..260 FT /note="BRCT 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00033" FT DOMAIN 266..354 FT /note="BRCT 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00033" FT DOMAIN 452..641 FT /note="DH" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00062" FT DOMAIN 675..794 FT /note="PH" FT REGION 388..449 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 857..884 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 378..382 FT /note="Nuclear localization signal" FT MOTIF 401..405 FT /note="Nuclear localization signal" FT COMPBIAS 418..429 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 432..449 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 359 FT /note="Phosphothreonine; by PKC/PRKCI" FT /evidence="ECO:0000269|PubMed:21189248, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 367 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 370 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 373 FT /note="Phosphothreonine; by CDK1" FT /evidence="ECO:0000269|PubMed:16170345, FT ECO:0007744|PubMed:18669648" FT MOD_RES 376 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 444 FT /note="Phosphothreonine; by CDK1" FT /evidence="ECO:0000269|PubMed:16247472" FT MOD_RES 716 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 842 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 846 FT /note="Phosphothreonine; by CDK1" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 861 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 866 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT CROSSLNK 611 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VAR_SEQ 44 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10579713, FT ECO:0000303|PubMed:14587037, ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334" FT /id="VSP_041976" FT VAR_SEQ 71..101 FT /note="Missing (in isoform 2 and isoform 4)" FT /evidence="ECO:0000303|PubMed:10579713, FT ECO:0000303|PubMed:14587037, ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334" FT /id="VSP_041977" FT VAR_SEQ 886..914 FT /note="GIPSPSLVSLPSFFERRSHTLSRSTTHLI -> ITHSVSTSNVIGFTKHVYV FT QRLNSTGGRSQYSWFQSVRHSAFRASFSEILEGNTDFSNFKKVLSKSSLTFVKN (in FT isoform 3)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_041978" FT VARIANT 15 FT /note="S -> T (in dbSNP:rs34703432)" FT /id="VAR_047064" FT VARIANT 833 FT /note="T -> P (in a breast cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035975" FT MUTAGEN 184 FT /note="T->A: Inhibits interaction with RACGAP1. Abolishes FT targeting to the central spindle." FT /evidence="ECO:0000269|PubMed:19468300, FT ECO:0000269|PubMed:25068414" FT MUTAGEN 226 FT /note="K->A: Inhibits interaction with RACGAP1. Abolishes FT targeting to the central spindle." FT /evidence="ECO:0000269|PubMed:19468300, FT ECO:0000269|PubMed:25068414" FT MUTAGEN 336 FT /note="W->R: Inhibits homodimerization. Increases binding FT with RhoA and GEF activity." FT /evidence="ECO:0000269|PubMed:15545273" FT MUTAGEN 338 FT /note="W->A: 2-fold increase in GEF activity." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 359 FT /note="T->A: Inhibits its phosphorylation and anchorage- FT independent growth and invasion in cancer cells. Does not FT inhibit its GEF activity." FT /evidence="ECO:0000269|PubMed:21189248" FT MUTAGEN 373 FT /note="T->A: Does not inhibit its Rho exchange activity. FT Increases interaction with RACGAP1. Does not inhibit FT anchorage-independent growth and invasion in cancer cells." FT /evidence="ECO:0000269|PubMed:16103226, FT ECO:0000269|PubMed:16170345" FT MUTAGEN 373 FT /note="T->D: Does not inhibit subcellular localization or FT homodimerization. Enhances its Rho exchange activity." FT /evidence="ECO:0000269|PubMed:16103226, FT ECO:0000269|PubMed:16170345" FT MUTAGEN 379..381 FT /note="KRR->AAA: Shows both nuclear and cytoplasmic FT localization and activates its transforming activity." FT /evidence="ECO:0000269|PubMed:14645260" FT MUTAGEN 402..404 FT /note="RKR->AKA: Shows both nuclear and cytoplasmic FT localization and activates its transforming activity." FT /evidence="ECO:0000269|PubMed:14645260" FT MUTAGEN 444 FT /note="T->A: Diminishes its phosphorylation status. Reduces FT its interaction with PLK1 and Rho exchange activity. Does FT not change its subcellular localization. Does not inhibit FT anchorage-independent growth and invasion in cancer cells." FT /evidence="ECO:0000269|PubMed:16247472" FT MUTAGEN 444 FT /note="T->D: Does not reduce its interaction with PLK1, FT change its subcellular localization and Rho exchange FT activity." FT /evidence="ECO:0000269|PubMed:16247472" FT MUTAGEN 488 FT /note="R->C: Partially releases inhibition." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 570 FT /note="R->D: 2-fold increase in GEF activity." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 573 FT /note="A->D: 2-fold increase in GEF activity." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 586 FT /note="R->Q: Complete loss of GEF activity and failure to FT support cytokinesis." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 596..599 FT /note="PVQR->AAAA: Inhibits activation of the transforming FT activity." FT /evidence="ECO:0000269|PubMed:14645260" FT MUTAGEN 601 FT /note="P->S: Complete loss of GEF activity and failure to FT support cytokinesis." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 652 FT /note="F->A: No effect on GEF activity but severely FT decreases ECT2 activation by RHOA. Localizes correctly but FT fails to rescue the cytokinesis defect caused by knockdown FT of endogenous ECT2 in contrast to the wild-type protein FT which rescues this defect." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 656 FT /note="Y->A: No effect on GEF activity but severely FT decreases ECT2 activation by RHOA. Fails to rescue the FT cytokinesis defect caused by knockdown of endogenous ECT2 FT in contrast to the wild-type protein which rescues this FT defect." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 670 FT /note="R->Q: Marked increase in GEF activity and rescues FT the cytokinesis defect caused by depletion of endogenous FT ECT2. When expressed in a cancer cell line, causes faster FT cell proliferation than the wild-type protein." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 734 FT /note="P->D: More than 10-fold increase in GEF activity. FT Overexpression causes noticeable changes in interphase cell FT morphology such as cell rounding and formation of stress FT fibers, suggesting ectopic RhoA activation." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 796 FT /note="C->K: More than 10-fold increase in GEF activity. FT Overexpression causes noticeable changes in interphase cell FT morphology such as cell rounding and formation of stress FT fibers, suggesting ectopic RHOA activation." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 846 FT /note="T->A: Diminishes its phosphorylation status." FT /evidence="ECO:0000269|PubMed:16247472" FT CONFLICT 66 FT /note="I -> T (in Ref. 5; BAB14498)" FT /evidence="ECO:0000305" FT CONFLICT 276 FT /note="L -> F (in Ref. 5; BAB14498)" FT /evidence="ECO:0000305" FT CONFLICT 393 FT /note="E -> D (in Ref. 5; BAB14498)" FT /evidence="ECO:0000305" FT STRAND 51..56 FT /evidence="ECO:0007829|PDB:4N40" FT HELIX 57..59 FT /evidence="ECO:0007829|PDB:4N40" FT HELIX 63..70 FT /evidence="ECO:0007829|PDB:4N40" FT STRAND 107..112 FT /evidence="ECO:0007829|PDB:4N40" FT HELIX 115..119 FT /evidence="ECO:0007829|PDB:4N40" FT STRAND 124..129 FT /evidence="ECO:0007829|PDB:4N40" FT HELIX 136..143 FT /evidence="ECO:0007829|PDB:4N40" FT STRAND 147..149 FT /evidence="ECO:0007829|PDB:4N40" FT HELIX 151..159 FT /evidence="ECO:0007829|PDB:4N40" FT TURN 173..178 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 180..184 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 189..201 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 215..224 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 225..233 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 241..249 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 260..263 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 264..266 FT /evidence="ECO:0007829|PDB:6L30" FT TURN 270..273 FT /evidence="ECO:0007829|PDB:3L46" FT STRAND 278..280 FT /evidence="ECO:0007829|PDB:3L46" FT HELIX 283..295 FT /evidence="ECO:0007829|PDB:3L46" FT STRAND 309..313 FT /evidence="ECO:0007829|PDB:3L46" FT TURN 315..317 FT /evidence="ECO:0007829|PDB:3L46" FT STRAND 318..320 FT /evidence="ECO:0007829|PDB:3L46" FT STRAND 330..333 FT /evidence="ECO:0007829|PDB:3L46" FT HELIX 334..343 FT /evidence="ECO:0007829|PDB:3L46" FT HELIX 349..351 FT /evidence="ECO:0007829|PDB:3L46" FT HELIX 453..477 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 479..483 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 495..502 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 505..522 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 532..552 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 554..567 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 569..579 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 582..584 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 589..611 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 622..634 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 635..637 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 642..657 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 664..667 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 672..687 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 691..697 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 700..706 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 726..734 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 735..737 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 738..744 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 748..758 FT /evidence="ECO:0007829|PDB:6L30" FT TURN 761..763 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 767..773 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 780..795 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 803..807 FT /evidence="ECO:0007829|PDB:6L30" SQ SEQUENCE 914 AA; 103505 MW; F40FC4F982FB8C78 CRC64; MAENSVLTST TGRTSLADSS IFDSKVTEIS KENLLIGSTS YVEEEMPQIE TRVILVQEAG KQEELIKALK TIKIMEVPVI KIKESCPGKS DEKLIKSVIN MDIKVGFVKM ESVEEFEGLD SPEFENVFVV TDFQDSVFND LYKADCRVIG PPVVLNCSQK GEPLPFSCRP LYCTSMMNLV LCFTGFRKKE ELVRLVTLVH HMGGVIRKDF NSKVTHLVAN CTQGEKFRVA VSLGTPIMKP EWIYKAWERR NEQDFYAAVD DFRNEFKVPP FQDCILSFLG FSDEEKTNME EMTEMQGGKY LPLGDERCTH LVVEENIVKD LPFEPSKKLY VVKQEWFWGS IQMDARAGET MYLYEKANTP ELKKSVSMLS LNTPNSNRKR RRLKETLAQL SRETDVSPFP PRKRPSAEHS LSIGSLLDIS NTPESSINYG DTPKSCTKSS KSSTPVPSKQ SARWQVAKEL YQTESNYVNI LATIIQLFQV PLEEEGQRGG PILAPEEIKT IFGSIPDIFD VHTKIKDDLE DLIVNWDESK SIGDIFLKYS KDLVKTYPPF VNFFEMSKET IIKCEKQKPR FHAFLKINQA KPECGRQSLV ELLIRPVQRL PSVALLLNDL KKHTADENPD KSTLEKAIGS LKEVMTHINE DKRKTEAQKQ IFDVVYEVDG CPANLLSSHR SLVQRVETIS LGEHPCDRGE QVTLFLFNDC LEIARKRHKV IGTFRSPHGQ TRPPASLKHI HLMPLSQIKK VLDIRETEDC HNAFALLVRP PTEQANVLLS FQMTSDELPK ENWLKMLCRH VANTICKADA ENLIYTADPE SFEVNTKDMD STLSRASRAI KKTSKKVTRA FSFSKTPKRA LRRALMTSHG SVEGRSPSSN DKHVMSRLSS TSSLAGIPSP SLVSLPSFFE RRSHTLSRST THLI // ID ERBB2_HUMAN Reviewed; 1255 AA. AC P04626; B2RZG3; B4DHN3; Q14256; Q6LDV1; Q9UMK4; X5D2V5; DT 13-AUG-1987, integrated into UniProtKB/Swiss-Prot. DT 13-AUG-1987, sequence version 1. DT 28-JAN-2026, entry version 281. DE RecName: Full=Receptor tyrosine-protein kinase erbB-2; DE EC=2.7.10.1; DE AltName: Full=Metastatic lymph node gene 19 protein; DE Short=MLN 19; DE AltName: Full=Proto-oncogene Neu; DE AltName: Full=Proto-oncogene c-ErbB-2; DE AltName: Full=Tyrosine kinase-type cell surface receptor HER2; DE AltName: Full=p185erbB2; DE AltName: CD_antigen=CD340; DE Flags: Precursor; GN Name=ERBB2; Synonyms=HER2, MLN19, NEU, NGL; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=3003577; DOI=10.1038/319230a0; RA Yamamoto T., Ikawa S., Akiyama T., Semba K., Nomura N., Miyajima N., RA Saito T., Toyoshima K.; RT "Similarity of protein encoded by the human c-erb-B-2 gene to epidermal RT growth factor receptor."; RL Nature 319:230-234(1986). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND VARIANT ALA-1170. RX PubMed=2999974; DOI=10.1126/science.2999974; RA Coussens L., Yang-Feng T.L., Liao Y.C., Chen E., Gray A., McGrath J., RA Seeburg P.H., Libermann T.A., Schlessinger J., Francke U., Levinson A., RA Ullrich A.; RT "Tyrosine kinase receptor with extensive homology to EGF receptor shares RT chromosomal location with neu oncogene."; RL Science 230:1132-1139(1985). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS CYS-452; VAL-655 AND RP ALA-1170. RG NIEHS SNPs program; RL Submitted (DEC-2002) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4). RC TISSUE=Brain; RA Wakamatsu A., Yamamoto J., Kimura K., Ishii S., Watanabe K., Sugiyama A., RA Murakawa K., Kaida T., Tsuchiya K., Fukuzumi Y., Kumagai A., Oishi Y., RA Yamamoto S., Ono Y., Komori Y., Yamazaki M., Kisu Y., Nishikawa T., RA Sugano S., Nomura N., Isogai T.; RT "NEDO human cDNA sequencing project focused on splicing variants."; RL Submitted (OCT-2007) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-191 (ISOFORM 1). RX PubMed=3039351; DOI=10.1128/mcb.7.7.2597-2601.1987; RA Tal M., King C.R., Kraus M.H., Ullrich A., Schlessinger J., Givol D.; RT "Human HER2 (neu) promoter: evidence for multiple mechanisms for RT transcriptional initiation."; RL Mol. Cell. Biol. 7:2597-2601(1987). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-867 (ISOFORM 6). RC TISSUE=Fetal brain; RX PubMed=24722188; DOI=10.1038/ncomms4650; RA Corominas R., Yang X., Lin G.N., Kang S., Shen Y., Ghamsari L., Broly M., RA Rodriguez M., Tam S., Wanamaker S.A., Fan C., Yi S., Tasan M., Lemmens I., RA Kuang X., Zhao N., Malhotra D., Michaelson J.J., Vacic V., Calderwood M.A., RA Roth F.P., Tavernier J., Horvath S., Salehi-Ashtiani K., Korkin D., RA Sebat J., Hill D.E., Hao T., Vidal M., Iakoucheva L.M.; RT "Protein interaction network of alternatively spliced isoforms from brain RT links genetic risk factors for autism."; RL Nat. Commun. 5:3650-3650(2014). RN [9] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 737-1031. RX PubMed=2995967; DOI=10.1073/pnas.82.19.6497; RA Semba K., Kamata N., Toyoshima K., Yamamoto T.; RT "A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB- RT 1/epidermal growth factor-receptor gene and is amplified in a human RT salivary gland adenocarcinoma."; RL Proc. Natl. Acad. Sci. U.S.A. 82:6497-6501(1985). RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 832-909. RC TISSUE=Mammary carcinoma; RX PubMed=2992089; DOI=10.1126/science.2992089; RA King C.R., Kraus M.H., Aaronson S.A.; RT "Amplification of a novel v-erbB-related gene in a human mammary RT carcinoma."; RL Science 229:974-976(1985). RN [11] RP NUCLEOTIDE SEQUENCE OF 1081-1245, AND VARIANT ALA-1170. RX PubMed=8104414; DOI=10.1089/dna.1993.12.611; RA Sarkar F.H., Ball D.E., Li Y.W., Crissman J.D.; RT "Molecular cloning and sequencing of an intron of Her-2/neu (ERBB2) gene."; RL DNA Cell Biol. 12:611-615(1993). RN [12] RP INTERACTION WITH ERBB4, AND FUNCTION IN ACTIVATION OF STAT5A. RX PubMed=10358079; DOI=10.1074/jbc.274.24.17209; RA Olayioye M.A., Beuvink I., Horsch K., Daly J.M., Hynes N.E.; RT "ErbB receptor-induced activation of stat transcription factors is mediated RT by Src tyrosine kinases."; RL J. Biol. Chem. 274:17209-17218(1999). RN [13] RP IDENTIFICATION IN A COMPLEX WITH PIK3C2A AND EGFR, IDENTIFICATION IN A RP COMPLEX WITH PIK3C2B AND EGFR, AND INTERACTION WITH PIK3C2B. RX PubMed=10805725; DOI=10.1128/mcb.20.11.3817-3830.2000; RA Arcaro A., Zvelebil M.J., Wallasch C., Ullrich A., Waterfield M.D., RA Domin J.; RT "Class II phosphoinositide 3-kinases are downstream targets of activated RT polypeptide growth factor receptors."; RL Mol. Cell. Biol. 20:3817-3830(2000). RN [14] RP INTERACTION WITH MUC1. RX PubMed=12939402; RA Li Y., Yu W.-H., Ren J., Chen W., Huang L., Kharbanda S., Loda M., Kufe D.; RT "Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent RT on the DF3/MUC1 oncoprotein."; RL Mol. Cancer Res. 1:765-775(2003). RN [15] RP FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=15380516; DOI=10.1016/j.ccr.2004.07.012; RA Wang S.C., Lien H.C., Xia W., Chen I.F., Lo H.W., Wang Z., Ali-Seyed M., RA Lee D.F., Bartholomeusz G., Ou-Yang F., Giri D.K., Hung M.C.; RT "Binding at and transactivation of the COX-2 promoter by nuclear tyrosine RT kinase receptor ErbB-2."; RL Cancer Cell 6:251-261(2004). RN [16] RP INTERACTION WITH PLXNB1. RX PubMed=15210733; DOI=10.1083/jcb.200312094; RA Swiercz J.M., Kuner R., Offermanns S.; RT "Plexin-B1/RhoGEF-mediated RhoA activation involves the receptor tyrosine RT kinase ErbB-2."; RL J. Cell Biol. 165:869-880(2004). RN [17] RP INTERACTION WITH MEMO1. RX PubMed=15156151; DOI=10.1038/ncb1134; RA Marone R., Hess D., Dankort D., Muller W.J., Hynes N.E., Badache A.; RT "Memo mediates ErbB2-driven cell motility."; RL Nat. Cell Biol. 6:515-522(2004). RN [18] RP SUBCELLULAR LOCATION, NUCLEAR LOCALIZATION SIGNAL, AND INTERACTION WITH RP KPNB1; RANBP2; CRM1; EEA1 AND CLTC. RX PubMed=16314522; DOI=10.1128/mcb.25.24.11005-11018.2005; RA Giri D.K., Ali-Seyed M., Li L.Y., Lee D.F., Ling P., Bartholomeusz G., RA Wang S.C., Hung M.C.; RT "Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell RT surface receptor."; RL Mol. Cell. Biol. 25:11005-11018(2005). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1248, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [20] RP FUNCTION, ALTERNATIVE INITIATION (ISOFORMS 2 AND 3), SUBCELLULAR LOCATION, RP AND MUTAGENESIS OF MET-611; MET-687; MET-706 AND MET-712. RX PubMed=16794579; DOI=10.1038/sj.emboj.7601191; RA Anido J., Scaltriti M., Bech Serra J.J., Santiago Josefat B., Todo F.R., RA Baselga J., Arribas J.; RT "Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative RT initiation of translation."; RL EMBO J. 25:3234-3244(2006). RN [21] RP INTERACTION WITH ERBB4, AND AUTOPHOSPHORYLATION IN TRANS. RX PubMed=16978839; DOI=10.1016/j.cellsig.2006.07.020; RA Li Z., Mei Y., Liu X., Zhou M.; RT "Neuregulin-1 only induces trans-phosphorylation between ErbB receptor RT heterodimer partners."; RL Cell. Signal. 19:466-471(2007). RN [22] RP PHOSPHORYLATION AT TYR-1248. RX PubMed=17554007; DOI=10.1523/jneurosci.5381-06.2007; RA Deng S., Hirschberg A., Worzfeld T., Penachioni J.Y., Korostylev A., RA Swiercz J.M., Vodrazka P., Mauti O., Stoeckli E.T., Tamagnone L., RA Offermanns S., Kuner R.; RT "Plexin-B2, but not Plexin-B1, critically modulates neuronal migration and RT patterning of the developing nervous system in vivo."; RL J. Neurosci. 27:6333-6347(2007). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [24] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [25] RP INTERACTION WITH PTK6, AND ACTIVITY REGULATION. RX PubMed=18719096; DOI=10.1073/pnas.0805009105; RA Xiang B., Chatti K., Qiu H., Lakshmi B., Krasnitz A., Hicks J., Yu M., RA Miller W.T., Muthuswamy S.K.; RT "Brk is coamplified with ErbB2 to promote proliferation in breast cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 105:12463-12468(2008). RN [26] RP FUNCTION IN NUCLEUS. RX PubMed=19372587; DOI=10.1158/1541-7786.mcr-08-0316; RA Hawthorne V.S., Huang W.C., Neal C.L., Tseng L.M., Hung M.C., Yu D.; RT "ErbB2-mediated Src and signal transducer and activator of transcription 3 RT activation leads to transcriptional up-regulation of p21Cip1 and RT chemoresistance in breast cancer cells."; RL Mol. Cancer Res. 7:592-600(2009). RN [27] RP INTERACTION WITH CPNE3. RX PubMed=20010870; DOI=10.1038/onc.2009.456; RA Heinrich C., Keller C., Boulay A., Vecchi M., Bianchi M., Sack R., RA Lienhard S., Duss S., Hofsteenge J., Hynes N.E.; RT "Copine-III interacts with ErbB2 and promotes tumor cell migration."; RL Oncogene 29:1598-1610(2010). RN [28] RP FUNCTION. RX PubMed=20937854; DOI=10.1073/pnas.1000975107; RA Zaoui K., Benseddik K., Daou P., Salaun D., Badache A.; RT "ErbB2 receptor controls microtubule capture by recruiting ACF7 to the RT plasma membrane of migrating cells."; RL Proc. Natl. Acad. Sci. U.S.A. 107:18517-18522(2010). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1107, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [30] RP CHROMOSOMAL REARRANGEMENT WITH CDK12. RX PubMed=21097718; DOI=10.1158/0008-5472.can-10-1749; RA Zang Z.J., Ong C.K., Cutcutache I., Yu W., Zhang S.L., Huang D., Ler L.D., RA Dykema K., Gan A., Tao J., Lim S., Liu Y., Futreal P.A., Grabsch H., RA Furge K.A., Goh L.K., Rozen S., Teh B.T., Tan P.; RT "Genetic and structural variation in the gastric cancer kinome revealed RT through targeted deep sequencing."; RL Cancer Res. 71:29-39(2011). RN [31] RP FUNCTION IN NUCLEUS, INTERACTION WITH ACTB AND RPA194, AND SUBCELLULAR RP LOCATION. RX PubMed=21555369; DOI=10.1158/0008-5472.can-10-3504; RA Li L.Y., Chen H., Hsieh Y.H., Wang Y.N., Chu H.J., Chen Y.H., Chen H.Y., RA Chien P.J., Ma H.T., Tsai H.C., Lai C.C., Sher Y.P., Lien H.C., Tsai C.H., RA Hung M.C.; RT "Nuclear ErbB2 enhances translation and cell growth by activating RT transcription of ribosomal RNA genes."; RL Cancer Res. 71:4269-4279(2011). RN [32] RP INTERACTION WITH EGFR. RX PubMed=21190959; DOI=10.1210/en.2010-0940; RA Kharmate G., Rajput P.S., Watt H.L., Somvanshi R.K., Chaudhari N., Qiu X., RA Kumar U.; RT "Dissociation of epidermal growth factor receptor and ErbB2 heterodimers in RT the presence of somatostatin receptor 5 modulate signaling pathways."; RL Endocrinology 152:931-945(2011). RN [33] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [34] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-182; SER-1054; SER-1083 AND RP THR-1166, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [35] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054 AND SER-1151, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [36] RP INTERACTION WITH HSP90AA1 AND HSP90AB1. RX PubMed=26517842; DOI=10.1371/journal.pone.0141786; RA Prince T.L., Kijima T., Tatokoro M., Lee S., Tsutsumi S., Yim K., Rivas C., RA Alarcon S., Schwartz H., Khamit-Kush K., Scroggins B.T., Beebe K., RA Trepel J.B., Neckers L.; RT "Client proteins and small molecule inhibitors display distinct binding RT preferences for constitutive and stress-induced HSP90 isoforms and their RT conformationally restricted mutants."; RL PLoS ONE 10:E0141786-E0141786(2015). RN [37] RP PHOSPHORYLATION AT TYR-1112; TYR-1139; TYR-1196 AND TYR-1248, AND RP DEPHOSPHORYLATION BY PTPN12. RX PubMed=27134172; DOI=10.1016/j.celrep.2016.04.016; RA Li H., Yang F., Liu C., Xiao P., Xu Y., Liang Z., Liu C., Wang H., Wang W., RA Zheng W., Zhang W., Ma X., He D., Song X., Cui F., Xu Z., Yi F., Sun J.P., RA Yu X.; RT "Crystal structure and substrate specificity of PTPN12."; RL Cell Rep. 15:1345-1358(2016). RN [38] RP INTERACTION WITH SORL1, AND SUBCELLULAR LOCATION. RX PubMed=31138794; DOI=10.1038/s41467-019-10275-0; RA Pietilae M., Sahgal P., Peuhu E., Jaentti N.Z., Paatero I., Naervae E., RA Al-Akhrass H., Lilja J., Georgiadou M., Andersen O.M., Padzik A., Sihto H., RA Joensuu H., Blomqvist M., Saarinen I., Bostroem P.J., Taimen P., Ivaska J.; RT "SORLA regulates endosomal trafficking and oncogenic fitness of HER2."; RL Nat. Commun. 10:2340-2340(2019). RN [39] RP INTERACTION WITH SH3BGRL, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT RP TYR-877 AND TYR-1196. RX PubMed=32381043; DOI=10.1186/s13046-020-01577-z; RA Li H., Zhang M., Wei Y., Haider F., Lin Y., Guan W., Liu Y., Zhang S., RA Yuan R., Yang X., Yang S., Wang H.; RT "SH3BGRL confers innate drug resistance in breast cancer by stabilizing RT HER2 activation on cell membrane."; RL J. Exp. Clin. Cancer Res. 39:81-81(2020). RN [40] RP SUBCELLULAR LOCATION. RX PubMed=34380438; DOI=10.1186/s12860-021-00379-1; RA Di Pisa F., Pesenti E., Bono M., Mazzarello A.N., Bernardi C., RA Lisanti M.P., Renzone G., Scaloni A., Ciccone E., Fais F., Bruno S., RA Scartezzini P., Ghiotto F.; RT "SH3BGRL3 binds to myosin 1c in a calcium dependent manner and modulates RT migration in the MDA-MB-231 cell line."; RL BMC Mol. Cell Biol. 22:41-41(2021). RN [41] RP INTERACTION WITH ROR1. RX PubMed=36949068; DOI=10.1038/s41467-023-37306-1; RA Lin W., Niu R., Park S.M., Zou Y., Kim S.S., Xia X., Xing S., Yang Q., RA Sun X., Yuan Z., Zhou S., Zhang D., Kwon H.J., Park S., Il Kim C., Koo H., RA Liu Y., Wu H., Zheng M., Yoo H., Shi B., Park J.B., Yin J.; RT "IGFBP5 is an ROR1 ligand promoting glioblastoma invasion via ROR1/HER2- RT CREB signaling axis."; RL Nat. Commun. 14:1578-1578(2023). RN [42] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 654-662 IN COMPLEX WITH HLA AND RP BETA-2 MICROGLOBULIN. RX PubMed=10593938; DOI=10.1074/jbc.274.51.36422; RA Kuhns J.J., Batalia M.A., Yan S., Collins E.J.; RT "Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of RT interactions with the center of the peptide."; RL J. Biol. Chem. 274:36422-36427(1999). RN [43] RP X-RAY CRYSTALLOGRAPHY (1.25 ANGSTROMS) OF 1247-1255 IN COMPLEX WITH ERBIN, RP AND INTERACTION WITH ERBIN. RX PubMed=12444095; DOI=10.1074/jbc.c200571200; RA Birrane G., Chung J., Ladias J.A.; RT "Novel mode of ligand recognition by the Erbin PDZ domain."; RL J. Biol. Chem. 278:1399-1402(2003). RN [44] RP STRUCTURE BY NMR OF 1135-1144 IN COMPLEX WITH GRB7, AND INTERACTION WITH RP GRB7. RX PubMed=12975581; DOI=10.1023/a:1025498409113; RA Ivancic M., Daly R.J., Lyons B.A.; RT "Solution structure of the human Grb7-SH2 domain/erbB2 peptide complex and RT structural basis for Grb7 binding to ErbB2."; RL J. Biomol. NMR 27:205-219(2003). RN [45] RP X-RAY CRYSTALLOGRAPHY (2.52 ANGSTROMS) OF 23-629 IN COMPLEX WITH THE RP ANTIBODY HERCEPTIN. RX PubMed=12610629; DOI=10.1038/nature01392; RA Cho H.-S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., RA Denney D.W. Jr., Leahy D.J.; RT "Structure of the extracellular region of HER2 alone and in complex with RT the Herceptin Fab."; RL Nature 421:756-760(2003). RN [46] RP X-RAY CRYSTALLOGRAPHY (3.25 ANGSTROMS) OF 23-646 IN COMPLEX WITH THE RP ANTIBODY PERTUZUMAB, INTERACTION WITH ERBB3, MUTAGENESIS OF RP 317-LEU-HIS-318, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-187; ASN-259 AND RP ASN-530. RX PubMed=15093539; DOI=10.1016/s1535-6108(04)00083-2; RA Franklin M.C., Carey K.D., Vajdos F.F., Leahy D.J., de Vos A.M., RA Sliwkowski M.X.; RT "Insights into ErbB signaling from the structure of the ErbB2-pertuzumab RT complex."; RL Cancer Cell 5:317-328(2004). RN [47] RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 23-646 IN COMPLEX WITH THE RP ANTIBODY HERCEPTIN, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-259 AND RP ASN-530. RX PubMed=19299620; DOI=10.1126/science.1165480; RA Bostrom J., Yu S.F., Kan D., Appleton B.A., Lee C.V., Billeci K., Man W., RA Peale F., Ross S., Wiesmann C., Fuh G.; RT "Variants of the antibody herceptin that interact with HER2 and VEGF at the RT antigen binding site."; RL Science 323:1610-1614(2009). RN [48] RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 23-646 IN COMPLEX WITH ENGINEERED RP ANTIBODY ZHER2, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-68; ASN-259 AND RP ASN-571. RX PubMed=20696930; DOI=10.1073/pnas.1005025107; RA Eigenbrot C., Ultsch M., Dubnovitsky A., Abrahmsen L., Hard T.; RT "Structural basis for high-affinity HER2 receptor binding by an engineered RT protein."; RL Proc. Natl. Acad. Sci. U.S.A. 107:15039-15044(2010). RN [49] RP X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 703-1029 IN COMPLEX WITH RP INHIBITOR SYR127063, CATALYTIC ACTIVITY, SUBUNIT, AND ACTIVITY REGULATION. RX PubMed=21454582; DOI=10.1074/jbc.m110.206193; RA Aertgeerts K., Skene R., Yano J., Sang B.C., Zou H., Snell G., Jennings A., RA Iwamoto K., Habuka N., Hirokawa A., Ishikawa T., Tanaka T., Miki H., RA Ohta Y., Sogabe S.; RT "Structural analysis of the mechanism of inhibition and allosteric RT activation of the kinase domain of HER2 protein."; RL J. Biol. Chem. 286:18756-18765(2011). RN [50] RP VARIANTS VAL-654 AND VAL-655. RX PubMed=8095488; DOI=10.1006/geno.1993.1081; RA Ehsani A., Low J., Wallace R.B., Wu A.M.; RT "Characterization of a new allele of the human ERBB2 gene by allele- RT specific competition hybridization."; RL Genomics 15:426-429(1993). RN [51] RP INVOLVEMENT IN CANCER, VARIANT GASC SER-776, VARIANT OC SER-857, VARIANT RP GLM LYS-914, AND VARIANTS LNCR PRO-755; ALA-TYR-VAL-MET-774 INS AND RP VAL-GLY-SER-779 INS. RX PubMed=15457249; DOI=10.1038/431525b; RG Cancer genome project and collaborative group; RA Stephens P., Hunter C., Bignell G., Edkins S., Davies H., Teague J., RA Stevens C., O'Meara S., Smith R., Parker A., Barthorpe A., Blow M., RA Brackenbury L., Butler A., Clarke O., Cole J., Dicks E., Dike A., Drozd A., RA Edwards K., Forbes S., Foster R., Gray K., Greenman C., Halliday K., RA Hills K., Kosmidou V., Lugg R., Menzies A., Perry J., Petty R., Raine K., RA Ratford L., Shepherd R., Small A., Stephens Y., Tofts C., Varian J., RA West S., Widaa S., Yates A., Brasseur F., Cooper C.S., Flanagan A.M., RA Knowles M., Leung S.Y., Louis D.N., Looijenga L.H., Malkowicz B., RA Pierotti M.A., Teh B., Chenevix-Trench G., Weber B.L., Yuen S.T., RA Harris G., Goldstraw P., Nicholson A.G., Futreal P.A., Wooster R., RA Stratton M.R.; RT "Lung cancer: intragenic ERBB2 kinase mutations in tumours."; RL Nature 431:525-526(2004). RN [52] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-654; VAL-655; SER-768; ALA-1170 AND RP ASP-1216, VARIANT GASC SER-776, AND VARIANT OC SER-857. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [53] RP INVOLVEMENT IN VSCN2, VARIANT VSCN2 VAL-710, CHARACTERIZATION OF VARIANT RP VSCN2 VAL-710, SUBCELLULAR LOCATION, AND PHOSPHORYLATION. RX PubMed=33497358; DOI=10.1172/jci145837; RA Le T.L., Galmiche L., Levy J., Suwannarat P., Hellebrekers D.M., RA Morarach K., Boismoreau F., Theunissen T.E., Lefebvre M., Pelet A., RA Martinovic J., Gelot A., Guimiot F., Calleroz A., Gitiaux C., Hully M., RA Goulet O., Chardot C., Drunat S., Capri Y., Bole-Feysot C., Nitschke P., RA Whalen S., Mouthon L., Babcock H.E., Hofstra R., de Coo I.F., Tabet A.C., RA Molina T.J., Keren B., Brooks A., Smeets H.J., Marklund U., Gordon C.T., RA Lyonnet S., Amiel J., Bondurand N.; RT "Dysregulation of the NRG1/ERBB pathway causes a developmental disorder RT with gastrointestinal dysmotility in humans."; RL J. Clin. Invest. 131:0-0(2021). CC -!- FUNCTION: Protein tyrosine kinase that is part of several cell surface CC receptor complexes, but that apparently needs a coreceptor for ligand CC binding. Essential component of a neuregulin-receptor complex, although CC neuregulins do not interact with it alone. GP30 is a potential ligand CC for this receptor. Regulates outgrowth and stabilization of peripheral CC microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 CC signaling pathway elicits the phosphorylation and thus the inhibition CC of GSK3B at cell membrane. This prevents the phosphorylation of APC and CC CLASP2, allowing its association with the cell membrane. In turn, CC membrane-bound APC allows the localization of MACF1 to the cell CC membrane, which is required for microtubule capture and stabilization. CC {ECO:0000305}. CC -!- FUNCTION: In the nucleus is involved in transcriptional regulation. CC Associates with the 5'-TCAAATTC-3' sequence in the PTGS2/COX-2 promoter CC and activates its transcription. Implicated in transcriptional CC activation of CDKN1A; the function involves STAT3 and SRC. Involved in CC the transcription of rRNA genes by RNA Pol I and enhances protein CC synthesis and cell growth. {ECO:0000269|PubMed:10358079, CC ECO:0000269|PubMed:15380516, ECO:0000269|PubMed:21555369}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:21454582}; CC -!- ACTIVITY REGULATION: Activated by dimerization. Not activated by EGF, CC TGF-alpha and amphiregulin. Interaction with PTK6 increases its CC intrinsic kinase activity. {ECO:0000269|PubMed:18719096, CC ECO:0000269|PubMed:21454582}. CC -!- SUBUNIT: Homodimer (PubMed:21454582). Heterodimer with EGFR, ERBB3 and CC ERBB4 (PubMed:10358079, PubMed:15093539, PubMed:16978839, CC PubMed:21190959). Part of a complex with EGFR and either PIK3C2A or CC PIK3C2B. May interact with PIK3C2B when phosphorylated on Tyr-1196 CC (PubMed:10805725). Interacts with PLXNB1 (PubMed:15210733). Interacts CC (when phosphorylated on Tyr-1248) with MEMO1 (PubMed:15156151). CC Interacts with MUC1; the interaction is enhanced by heregulin (HRG) CC (PubMed:12939402). Interacts (when phosphorylated on Tyr-1139) with CC GRB7 (via SH2 domain) (PubMed:12975581). Interacts (when phosphorylated CC on Tyr-1248) with ERBIN (PubMed:12444095). Interacts with KPNB1, CC RANBP2, EEA1, CRM1 and CLTC (PubMed:16314522). Interacts with PTK6 CC (PubMed:18719096). Interacts with RPA194 and ACTB (PubMed:21555369). CC Interacts with PRKCABP, SRC and MYOC (By similarity). Interacts CC (preferentially with the tyrosine phosphorylated form) with CPNE3; this CC interaction occurs at the cell membrane and is increased in a growth CC factor heregulin-dependent manner (PubMed:20010870). Interacts with CC HSP90AA1 and HSP90AB1 in an ATP-dependent manner; the interaction CC suppresses ERBB2 kinase activity (PubMed:26517842). Interacts with CC SORL1; this interaction regulates ERBB2 subcellular distribution by CC promoting its recycling after internalization from endosomes back to CC the plasma membrane, hence stimulates ERBB2-mediated signaling CC (PubMed:31138794). Interacts with SH3BGRL (PubMed:32381043). Interacts CC with ROR1 (PubMed:36949068). {ECO:0000250|UniProtKB:P70424, CC ECO:0000269|PubMed:10358079, ECO:0000269|PubMed:10805725, CC ECO:0000269|PubMed:12939402, ECO:0000269|PubMed:12975581, CC ECO:0000269|PubMed:15093539, ECO:0000269|PubMed:15156151, CC ECO:0000269|PubMed:15210733, ECO:0000269|PubMed:16314522, CC ECO:0000269|PubMed:16978839, ECO:0000269|PubMed:18719096, CC ECO:0000269|PubMed:20010870, ECO:0000269|PubMed:21190959, CC ECO:0000269|PubMed:21454582, ECO:0000269|PubMed:21555369, CC ECO:0000269|PubMed:26517842, ECO:0000269|PubMed:31138794, CC ECO:0000269|PubMed:32381043, ECO:0000269|PubMed:36949068}. CC -!- INTERACTION: CC P04626; P00519: ABL1; NbExp=2; IntAct=EBI-641062, EBI-375543; CC P04626; P42684: ABL2; NbExp=6; IntAct=EBI-641062, EBI-1102694; CC P04626; P15309: ACP3; NbExp=2; IntAct=EBI-641062, EBI-1222012; CC P04626; P60709: ACTB; NbExp=10; IntAct=EBI-641062, EBI-353944; CC P04626; Q92625: ANKS1A; NbExp=2; IntAct=EBI-641062, EBI-1048612; CC P04626; O00213: APBB1; NbExp=2; IntAct=EBI-641062, EBI-81694; CC P04626; O75815: BCAR3; NbExp=2; IntAct=EBI-641062, EBI-702336; CC P04626; Q9HB71: CACYBP; NbExp=2; IntAct=EBI-641062, EBI-1047302; CC P04626; Q16543: CDC37; NbExp=5; IntAct=EBI-641062, EBI-295634; CC P04626; Q9NSE2: CISH; NbExp=4; IntAct=EBI-641062, EBI-617866; CC P04626; Q7Z7G1: CLNK; NbExp=2; IntAct=EBI-641062, EBI-7878194; CC P04626; P46109: CRKL; NbExp=2; IntAct=EBI-641062, EBI-910; CC P04626; Q93034: CUL5; NbExp=2; IntAct=EBI-641062, EBI-1057139; CC P04626; Q99704: DOK1; NbExp=2; IntAct=EBI-641062, EBI-1384360; CC P04626; Q8TEW6: DOK4; NbExp=2; IntAct=EBI-641062, EBI-6918542; CC P04626; Q15075: EEA1; NbExp=5; IntAct=EBI-641062, EBI-298113; CC P04626; P98172: EFNB1; NbExp=12; IntAct=EBI-641062, EBI-538287; CC P04626; P00533: EGFR; NbExp=25; IntAct=EBI-641062, EBI-297353; CC P04626; P04626: ERBB2; NbExp=12; IntAct=EBI-641062, EBI-641062; CC P04626; P21860: ERBB3; NbExp=30; IntAct=EBI-641062, EBI-720706; CC P04626; Q15303: ERBB4; NbExp=5; IntAct=EBI-641062, EBI-80371; CC P04626; Q9UJM3: ERRFI1; NbExp=4; IntAct=EBI-641062, EBI-2941912; CC P04626; P09769: FGR; NbExp=3; IntAct=EBI-641062, EBI-1383732; CC P04626; P06241: FYN; NbExp=2; IntAct=EBI-641062, EBI-515315; CC P04626; O75791: GRAP2; NbExp=2; IntAct=EBI-641062, EBI-740418; CC P04626; P62993: GRB2; NbExp=8; IntAct=EBI-641062, EBI-401755; CC P04626; Q14451: GRB7; NbExp=5; IntAct=EBI-641062, EBI-970191; CC P04626; P07900: HSP90AA1; NbExp=6; IntAct=EBI-641062, EBI-296047; CC P04626; P08238: HSP90AB1; NbExp=5; IntAct=EBI-641062, EBI-352572; CC P04626; P14625: HSP90B1; NbExp=2; IntAct=EBI-641062, EBI-359129; CC P04626; P11021: HSPA5; NbExp=3; IntAct=EBI-641062, EBI-354921; CC P04626; P46940: IQGAP1; NbExp=5; IntAct=EBI-641062, EBI-297509; CC P04626; P35568: IRS1; NbExp=2; IntAct=EBI-641062, EBI-517592; CC P04626; Q08881: ITK; NbExp=2; IntAct=EBI-641062, EBI-968552; CC P04626; P23458: JAK1; NbExp=2; IntAct=EBI-641062, EBI-1383438; CC P04626; Q14974: KPNB1; NbExp=14; IntAct=EBI-641062, EBI-286758; CC P04626; Q96JA1: LRIG1; NbExp=7; IntAct=EBI-641062, EBI-2865191; CC P04626; O75367: MACROH2A1; NbExp=6; IntAct=EBI-641062, EBI-2868511; CC P04626; O75367-3: MACROH2A1; NbExp=3; IntAct=EBI-641062, EBI-6250866; CC P04626; Q9UQF2: MAPK8IP1; NbExp=4; IntAct=EBI-641062, EBI-78404; CC P04626; Q13387: MAPK8IP2; NbExp=3; IntAct=EBI-641062, EBI-722813; CC P04626; P42679: MATK; NbExp=2; IntAct=EBI-641062, EBI-751664; CC P04626; Q9Y316: MEMO1; NbExp=6; IntAct=EBI-641062, EBI-1104564; CC P04626; O43639: NCK2; NbExp=2; IntAct=EBI-641062, EBI-713635; CC P04626; Q02297-7: NRG1; NbExp=2; IntAct=EBI-641062, EBI-2460927; CC P04626; O00750: PIK3C2B; NbExp=2; IntAct=EBI-641062, EBI-641107; CC P04626; P27986: PIK3R1; NbExp=12; IntAct=EBI-641062, EBI-79464; CC P04626; O00459: PIK3R2; NbExp=8; IntAct=EBI-641062, EBI-346930; CC P04626; Q92569: PIK3R3; NbExp=10; IntAct=EBI-641062, EBI-79893; CC P04626; P19174: PLCG1; NbExp=5; IntAct=EBI-641062, EBI-79387; CC P04626; P16885: PLCG2; NbExp=3; IntAct=EBI-641062, EBI-617403; CC P04626; O95602: POLR1A; NbExp=16; IntAct=EBI-641062, EBI-359472; CC P04626; Q13882: PTK6; NbExp=4; IntAct=EBI-641062, EBI-1383632; CC P04626; Q06124: PTPN11; NbExp=4; IntAct=EBI-641062, EBI-297779; CC P04626; Q05209: PTPN12; NbExp=4; IntAct=EBI-641062, EBI-2266035; CC P04626; Q99952: PTPN18; NbExp=6; IntAct=EBI-641062, EBI-1384210; CC P04626; Q99952-1: PTPN18; NbExp=5; IntAct=EBI-641062, EBI-12739708; CC P04626; P23467: PTPRB; NbExp=2; IntAct=EBI-641062, EBI-1265766; CC P04626; P08575: PTPRC; NbExp=2; IntAct=EBI-641062, EBI-1341; CC P04626; Q12913: PTPRJ; NbExp=2; IntAct=EBI-641062, EBI-2264500; CC P04626; Q15262: PTPRK; NbExp=2; IntAct=EBI-641062, EBI-474052; CC P04626; Q16827: PTPRO; NbExp=2; IntAct=EBI-641062, EBI-723739; CC P04626; Q15256: PTPRR; NbExp=2; IntAct=EBI-641062, EBI-2265659; CC P04626; P49792: RANBP2; NbExp=3; IntAct=EBI-641062, EBI-973138; CC P04626; P20936: RASA1; NbExp=8; IntAct=EBI-641062, EBI-1026476; CC P04626; O95980: RECK; NbExp=4; IntAct=EBI-641062, EBI-2823742; CC P04626; Q9NP31: SH2D2A; NbExp=2; IntAct=EBI-641062, EBI-490630; CC P04626; P29353: SHC1; NbExp=16; IntAct=EBI-641062, EBI-78835; CC P04626; P98077: SHC2; NbExp=3; IntAct=EBI-641062, EBI-7256023; CC P04626; Q92529: SHC3; NbExp=2; IntAct=EBI-641062, EBI-79084; CC P04626; Q9H6Q3: SLA2; NbExp=2; IntAct=EBI-641062, EBI-1222854; CC P04626; O15524: SOCS1; NbExp=2; IntAct=EBI-641062, EBI-968198; CC P04626; O43791: SPOP; NbExp=6; IntAct=EBI-641062, EBI-743549; CC P04626; P12931: SRC; NbExp=11; IntAct=EBI-641062, EBI-621482; CC P04626; P42224: STAT1; NbExp=3; IntAct=EBI-641062, EBI-1057697; CC P04626; P40763: STAT3; NbExp=9; IntAct=EBI-641062, EBI-518675; CC P04626; P31948: STIP1; NbExp=2; IntAct=EBI-641062, EBI-1054052; CC P04626; Q7KZ85: SUPT6H; NbExp=2; IntAct=EBI-641062, EBI-2515547; CC P04626; P43405: SYK; NbExp=7; IntAct=EBI-641062, EBI-78302; CC P04626; Q9Y490: TLN1; NbExp=3; IntAct=EBI-641062, EBI-2462036; CC P04626; Q63HR2: TNS2; NbExp=4; IntAct=EBI-641062, EBI-949753; CC P04626; Q68CZ2: TNS3; NbExp=2; IntAct=EBI-641062, EBI-1220488; CC P04626; Q96D37: VAV1; NbExp=2; IntAct=EBI-641062, EBI-7875353; CC P04626; P52735: VAV2; NbExp=3; IntAct=EBI-641062, EBI-297549; CC P04626; O14980: XPO1; NbExp=3; IntAct=EBI-641062, EBI-355867; CC P04626; P62258: YWHAE; NbExp=2; IntAct=EBI-641062, EBI-356498; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:32381043}; CC Single-pass type I membrane protein {ECO:0000255}. Cell projection, CC ruffle membrane {ECO:0000269|PubMed:34380438}; Single-pass type I CC membrane protein {ECO:0000255}. Note=Internalized from the cell CC membrane in response to EGF stimulation. {ECO:0000269|PubMed:32381043}. CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane CC {ECO:0000269|PubMed:31138794, ECO:0000269|PubMed:33497358}; Single-pass CC type I membrane protein {ECO:0000255}. Early endosome CC {ECO:0000269|PubMed:31138794}. Cytoplasm, perinuclear region. Nucleus. CC Note=Translocation to the nucleus requires endocytosis, probably CC endosomal sorting and is mediated by importin beta-1/KPNB1. Also CC detected in VPS35-positive endosome-to-TGN retrograde vesicles CC (PubMed:31138794). {ECO:0000269|PubMed:31138794}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Cytoplasm. Nucleus. CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Cytoplasm. Nucleus. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing, Alternative initiation; Named isoforms=6; CC Name=1; Synonyms=ERBB2, HER2; CC IsoId=P04626-1; Sequence=Displayed; CC Name=2; Synonyms=CTF-611; CC IsoId=P04626-2; Sequence=VSP_039249; CC Name=3; Synonyms=CTF-687; CC IsoId=P04626-3; Sequence=VSP_039250; CC Name=4; CC IsoId=P04626-4; Sequence=VSP_039248; CC Name=5; CC IsoId=P04626-5; Sequence=VSP_054787; CC Name=6; Synonyms=B; CC IsoId=P04626-6; Sequence=VSP_055902, VSP_055903, VSP_055904; CC -!- TISSUE SPECIFICITY: Expressed in a variety of tumor tissues including CC primary breast tumors and tumors from small bowel, esophagus, kidney CC and mouth. {ECO:0000269|PubMed:15380516}. CC -!- PTM: Autophosphorylated. Autophosphorylation occurs in trans, i.e. one CC subunit of the dimeric receptor phosphorylates tyrosine residues on the CC other subunit (Probable). Ligand-binding increases phosphorylation on CC tyrosine residues (PubMed:27134172, PubMed:33497358). Signaling via CC SEMA4C promotes phosphorylation at Tyr-1248 (PubMed:17554007). CC Dephosphorylated by PTPN12 (PubMed:27134172). CC {ECO:0000269|PubMed:17554007, ECO:0000269|PubMed:27134172, CC ECO:0000269|PubMed:33497358, ECO:0000305}. CC -!- POLYMORPHISM: There are four alleles due to the variations in positions CC 654 and 655. Allele B1 (Ile-654/Ile-655) has a frequency of 0.782; CC allele B2 (Ile-654/Val-655) has a frequency of 0.206; allele B3 (Val- CC 654/Val-655) has a frequency of 0.012. CC -!- DISEASE: Glioma (GLM) [MIM:137800]: Gliomas are benign or malignant CC central nervous system neoplasms derived from glial cells. They CC comprise astrocytomas and glioblastoma multiforme that are derived from CC astrocytes, oligodendrogliomas derived from oligodendrocytes and CC ependymomas derived from ependymocytes. {ECO:0000269|PubMed:15457249}. CC Note=The gene represented in this entry is involved in disease CC pathogenesis. CC -!- DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer CC defines malignancies originating from ovarian tissue. Although many CC histologic types of ovarian tumors have been described, epithelial CC ovarian carcinoma is the most common form. Ovarian cancers are often CC asymptomatic and the recognized signs and symptoms, even of late-stage CC disease, are vague. Consequently, most patients are diagnosed with CC advanced disease. {ECO:0000269|PubMed:15457249, CC ECO:0000269|PubMed:17344846}. Note=The gene represented in this entry CC is involved in disease pathogenesis. CC -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting CC tissues of the lung. The most common form of lung cancer is non-small CC cell lung cancer (NSCLC) that can be divided into 3 major histologic CC subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung CC cancer. NSCLC is often diagnosed at an advanced stage and has a poor CC prognosis. {ECO:0000269|PubMed:15457249}. Note=The gene represented in CC this entry is involved in disease pathogenesis. CC -!- DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which CC starts in the stomach, can spread to the esophagus or the small CC intestine, and can extend through the stomach wall to nearby lymph CC nodes and organs. It also can metastasize to other parts of the body. CC The term gastric cancer or gastric carcinoma refers to adenocarcinoma CC of the stomach that accounts for most of all gastric malignant tumors. CC Two main histologic types are recognized, diffuse type and intestinal CC type carcinomas. Diffuse tumors are poorly differentiated infiltrating CC lesions, resulting in thickening of the stomach. In contrast, CC intestinal tumors are usually exophytic, often ulcerating, and CC associated with intestinal metaplasia of the stomach, most often CC observed in sporadic disease. {ECO:0000269|PubMed:15457249, CC ECO:0000269|PubMed:17344846}. Note=The protein represented in this CC entry is involved in disease pathogenesis. CC -!- DISEASE: Note=Chromosomal aberrations involving ERBB2 may be a cause CC gastric cancer. Deletions within 17q12 region producing fusion CC transcripts with CDK12, leading to CDK12-ERBB2 fusion leading to CC truncated CDK12 protein not in-frame with ERBB2. CC {ECO:0000269|PubMed:21097718}. CC -!- DISEASE: Visceral neuropathy, familial, 2, autosomal recessive (VSCN2) CC [MIM:619465]: An autosomal recessive disorder characterized by CC intestinal dysmotility due to aganglionosis (Hirschsprung disease), CC hypoganglionosis, and/or chronic intestinal pseudoobstruction. Patients CC also show peripheral axonal neuropathy, hypotonia, mild developmental CC delay, unilateral ptosis, and sensorineural hearing loss. CC {ECO:0000269|PubMed:33497358}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform 2]: Produced by alternative initiation at Met- CC 611 of isoform 1. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 3]: Produced by alternative initiation at Met- CC 687 of isoform 1. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 4]: Produced by alternative splicing of isoform CC 1. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. EGF receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/162/ERBB2"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=ERBB2 entry; CC URL="https://en.wikipedia.org/wiki/ERBB2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AH001455; AAA35808.1; -; Genomic_DNA. DR EMBL; X03363; CAA27060.1; -; mRNA. DR EMBL; M11730; AAA75493.1; -; mRNA. DR EMBL; M12036; AAA35978.1; -; Genomic_DNA. DR EMBL; AY208911; AAO18082.1; -; Genomic_DNA. DR EMBL; AK295195; BAG58195.1; -; mRNA. DR EMBL; CH471152; EAW60597.1; -; Genomic_DNA. DR EMBL; BC167147; AAI67147.1; -; mRNA. DR EMBL; M16792; AAA58637.1; -; Genomic_DNA. DR EMBL; M16789; AAA58637.1; JOINED; Genomic_DNA. DR EMBL; M16790; AAA58637.1; JOINED; Genomic_DNA. DR EMBL; M16791; AAA58637.1; JOINED; Genomic_DNA. DR EMBL; KJ534964; AHW56604.1; -; mRNA. DR EMBL; L29395; AAA35809.1; -; Genomic_DNA. DR EMBL; M95667; AAC37531.1; -; Genomic_DNA. DR CCDS; CCDS32642.1; -. [P04626-1] DR CCDS; CCDS45667.1; -. [P04626-5] DR CCDS; CCDS74052.1; -. [P04626-4] DR PIR; A24571; A24571. DR RefSeq; NP_001005862.1; NM_001005862.3. [P04626-5] DR RefSeq; NP_001276865.1; NM_001289936.2. [P04626-4] DR RefSeq; NP_001276867.1; NM_001289938.1. DR RefSeq; NP_001369711.1; NM_001382782.1. [P04626-5] DR RefSeq; NP_001369712.1; NM_001382783.1. [P04626-5] DR RefSeq; NP_004439.2; NM_004448.4. [P04626-1] DR RefSeq; XP_047291546.1; XM_047435590.1. [P04626-4] DR PDB; 1MFG; X-ray; 1.25 A; B=1247-1255. DR PDB; 1MFL; X-ray; 1.88 A; B=1247-1255. DR PDB; 1MW4; NMR; -; B=1135-1144. DR PDB; 1N8Z; X-ray; 2.52 A; C=23-629. DR PDB; 1QR1; X-ray; 2.40 A; C/F=654-662. DR PDB; 1S78; X-ray; 3.25 A; A/B=23-646. DR PDB; 2A91; X-ray; 2.50 A; A=22-530. DR PDB; 2JWA; NMR; -; A/B=641-684. DR PDB; 2KS1; NMR; -; A=641-684. DR PDB; 2L4K; NMR; -; B=1135-1144. DR PDB; 2N2A; NMR; -; A/B=644-700. DR PDB; 3BE1; X-ray; 2.90 A; A=23-646. DR PDB; 3H3B; X-ray; 2.45 A; A/B=23-214. DR PDB; 3MZW; X-ray; 2.90 A; A=23-646. DR PDB; 3N85; X-ray; 3.20 A; A=23-646. DR PDB; 3PP0; X-ray; 2.25 A; A/B=703-1029. DR PDB; 3RCD; X-ray; 3.21 A; A/B/C/D=713-1028. DR PDB; 3WLW; X-ray; 3.09 A; A/B=23-586. DR PDB; 3WSQ; X-ray; 3.50 A; A=23-586. DR PDB; 4GFU; X-ray; 2.00 A; F=1246-1252. DR PDB; 4HRL; X-ray; 2.55 A; C=24-219. DR PDB; 4HRM; X-ray; 3.20 A; A/C=24-219. DR PDB; 4HRN; X-ray; 2.65 A; C/D=529-625. DR PDB; 4NND; X-ray; 2.50 A; C/E/F/H=1109-1114. DR PDB; 5K33; X-ray; 3.30 A; C=23-629. DR PDB; 5KWG; X-ray; 4.30 A; C=23-653. DR PDB; 5MY6; X-ray; 2.25 A; A=24-645. DR PDB; 5O4G; X-ray; 3.00 A; C=23-628. DR PDB; 5OB4; NMR; -; A/B=641-684. DR PDB; 5TQS; X-ray; 1.88 A; E/F/G/H=1218-1228. DR PDB; 6ATT; X-ray; 3.77 A; A=23-652. DR PDB; 6BGT; X-ray; 2.70 A; C=1-652. DR PDB; 6J71; X-ray; 2.92 A; A=22-639. DR PDB; 6LBX; X-ray; 2.03 A; B=531-626. DR PDB; 6OGE; EM; 4.36 A; A=23-644. DR PDB; 7JXH; X-ray; 3.27 A; A/B/C/D/E/F/G/H=703-1024. DR PDB; 7MN5; EM; 2.93 A; B=1-1029. DR PDB; 7MN6; EM; 3.09 A; B=1-1029. DR PDB; 7MN8; EM; 3.45 A; B=1-1029. DR PDB; 7PCD; X-ray; 1.77 A; A=703-1029. DR PDB; 7QVK; X-ray; 3.10 A; AAA=23-646. DR PDB; 8FFJ; EM; 7.50 A; X=23-644. DR PDB; 8HGO; EM; 3.31 A; B=1-693. DR PDB; 8HGP; EM; 4.53 A; B=1-693. DR PDB; 8JYQ; X-ray; 1.75 A; C/F=611-618. DR PDB; 8JYR; X-ray; 1.69 A; A=23-216. DR PDB; 8PWH; EM; 3.17 A; E=23-646. DR PDB; 8Q6J; EM; 3.30 A; E=23-646. DR PDB; 8U4K; EM; 4.27 A; B=24-629. DR PDB; 8U4L; EM; 3.31 A; B=24-629. DR PDB; 8U8X; X-ray; 1.69 A; A=694-1029. DR PDB; 8VB5; X-ray; 1.48 A; A=703-1029. DR PDB; 8VQD; EM; 2.61 A; A=23-652. DR PDB; 8VQE; EM; 2.67 A; A/B=23-652. DR PDB; 9IUT; X-ray; 2.09 A; C/F=611-618. DR PDB; 9L1S; EM; 3.00 A; A=23-652. DR PDBsum; 1MFG; -. DR PDBsum; 1MFL; -. DR PDBsum; 1MW4; -. DR PDBsum; 1N8Z; -. DR PDBsum; 1QR1; -. DR PDBsum; 1S78; -. DR PDBsum; 2A91; -. DR PDBsum; 2JWA; -. DR PDBsum; 2KS1; -. DR PDBsum; 2L4K; -. DR PDBsum; 2N2A; -. DR PDBsum; 3BE1; -. DR PDBsum; 3H3B; -. DR PDBsum; 3MZW; -. DR PDBsum; 3N85; -. DR PDBsum; 3PP0; -. DR PDBsum; 3RCD; -. DR PDBsum; 3WLW; -. DR PDBsum; 3WSQ; -. DR PDBsum; 4GFU; -. DR PDBsum; 4HRL; -. DR PDBsum; 4HRM; -. DR PDBsum; 4HRN; -. DR PDBsum; 4NND; -. DR PDBsum; 5K33; -. DR PDBsum; 5KWG; -. DR PDBsum; 5MY6; -. DR PDBsum; 5O4G; -. DR PDBsum; 5OB4; -. DR PDBsum; 5TQS; -. DR PDBsum; 6ATT; -. DR PDBsum; 6BGT; -. DR PDBsum; 6J71; -. DR PDBsum; 6LBX; -. DR PDBsum; 6OGE; -. DR PDBsum; 7JXH; -. DR PDBsum; 7MN5; -. DR PDBsum; 7MN6; -. DR PDBsum; 7MN8; -. DR PDBsum; 7PCD; -. DR PDBsum; 7QVK; -. DR PDBsum; 8FFJ; -. DR PDBsum; 8HGO; -. DR PDBsum; 8HGP; -. DR PDBsum; 8JYQ; -. DR PDBsum; 8JYR; -. DR PDBsum; 8PWH; -. DR PDBsum; 8Q6J; -. DR PDBsum; 8U4K; -. DR PDBsum; 8U4L; -. DR PDBsum; 8U8X; -. DR PDBsum; 8VB5; -. DR PDBsum; 8VQD; -. DR PDBsum; 8VQE; -. DR PDBsum; 9IUT; -. DR PDBsum; 9L1S; -. DR AlphaFoldDB; P04626; -. DR BMRB; P04626; -. DR EMDB; EMD-17993; -. DR EMDB; EMD-18188; -. DR EMDB; EMD-18189; -. DR EMDB; EMD-18190; -. DR EMDB; EMD-20055; -. DR EMDB; EMD-29044; -. DR EMDB; EMD-34744; -. DR EMDB; EMD-34745; -. DR EMDB; EMD-41885; -. DR EMDB; EMD-41886; -. DR EMDB; EMD-43439; -. DR EMDB; EMD-43440; -. DR EMDB; EMD-62753; -. DR SMR; P04626; -. DR BioGRID; 108376; 731. DR CORUM; P04626; -. DR DIP; DIP-8N; -. DR ELM; P04626; -. DR FunCoup; P04626; 2287. DR IntAct; P04626; 558. DR MINT; P04626; -. DR STRING; 9606.ENSP00000269571; -. DR BindingDB; P04626; -. DR ChEMBL; CHEMBL1824; -. DR DrugBank; DB08916; Afatinib. DR DrugBank; DB06021; AV-412. DR DrugBank; DB12318; BMS-599626. DR DrugBank; DB11665; BMS-690514. DR DrugBank; DB12267; Brigatinib. DR DrugBank; DB05424; Canertinib. DR DrugBank; DB12302; CP-724714. DR DrugBank; DB12174; CUDC-101. DR DrugBank; DB11963; Dacomitinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB04988; IGN311. DR DrugBank; DB01259; Lapatinib. DR DrugBank; DB14967; Margetuximab. DR DrugBank; DB00179; Masoprocol. DR DrugBank; DB04862; Merimepodib. DR DrugBank; DB12682; Mubritinib. DR DrugBank; DB06226; Nelipepimut-S. DR DrugBank; DB11828; Neratinib. DR DrugBank; DB07662; PD-168393. DR DrugBank; DB06366; Pertuzumab. DR DrugBank; DB12114; Poziotinib. DR DrugBank; DB12183; Sapitinib. DR DrugBank; DB14944; Tarloxotinib. DR DrugBank; DB11973; Tesevatinib. DR DrugBank; DB00072; Trastuzumab. DR DrugBank; DB05773; Trastuzumab emtansine. DR DrugBank; DB11652; Tucatinib. DR DrugBank; DB05944; Varlitinib. DR DrugBank; DB15471; Zanidatamab. DR DrugBank; DB15035; Zanubrutinib. DR DrugCentral; P04626; -. DR GuidetoPHARMACOLOGY; 2019; -. DR MoonDB; P04626; Predicted. DR TCDB; 8.A.23.1.39; the basigin (basigin) family. DR CarbonylDB; P04626; -. DR GlyConnect; 1710; 13 N-Linked glycans (5 sites), 1 O-Linked glycan (1 site). DR GlyCosmos; P04626; 9 sites, 13 glycans. DR GlyGen; P04626; 10 sites, 27 N-linked glycans (7 sites), 2 O-linked glycans (2 sites). DR iPTMnet; P04626; -. DR PhosphoSitePlus; P04626; -. DR SwissPalm; P04626; -. DR BioMuta; ERBB2; -. DR DMDM; 119533; -. DR CPTAC; CPTAC-192; -. DR CPTAC; CPTAC-193; -. DR CPTAC; CPTAC-194; -. DR CPTAC; CPTAC-195; -. DR CPTAC; CPTAC-3045; -. DR CPTAC; CPTAC-3046; -. DR CPTAC; CPTAC-5777; -. DR CPTAC; CPTAC-5827; -. DR CPTAC; CPTAC-5839; -. DR CPTAC; CPTAC-5864; -. DR CPTAC; CPTAC-693; -. DR CPTAC; non-CPTAC-5384; -. DR CPTAC; non-CPTAC-5385; -. DR CPTAC; non-CPTAC-5386; -. DR CPTAC; non-CPTAC-5547; -. DR CPTAC; non-CPTAC-5732; -. DR CPTAC; non-CPTAC-5733; -. DR jPOST; P04626; -. DR MassIVE; P04626; -. DR PaxDb; 9606-ENSP00000269571; -. DR PeptideAtlas; P04626; -. DR ProteomicsDB; 51718; -. [P04626-1] DR ProteomicsDB; 51719; -. [P04626-2] DR ProteomicsDB; 51720; -. [P04626-3] DR ProteomicsDB; 51721; -. [P04626-4] DR Pumba; P04626; -. DR ABCD; P04626; 341 sequenced antibodies. DR Antibodypedia; 740; 6685 antibodies from 63 providers. DR CPTC; P04626; 4 antibodies. DR DNASU; 2064; -. DR Ensembl; ENST00000269571.10; ENSP00000269571.4; ENSG00000141736.15. [P04626-1] DR Ensembl; ENST00000584601.5; ENSP00000462438.1; ENSG00000141736.15. [P04626-5] DR GeneID; 2064; -. DR KEGG; hsa:2064; -. DR MANE-Select; ENST00000269571.10; ENSP00000269571.4; NM_004448.4; NP_004439.2. DR UCSC; uc060esv.1; human. [P04626-1] DR AGR; HGNC:3430; -. DR CIViC; 2064; 2 clinical assertions and 302 evidence items across 174 molecular profiles. DR ClinPGx; PA27844; -. DR CTD; 2064; -. DR DisGeNET; 2064; -. DR GeneCards; ERBB2; -. DR HGNC; HGNC:3430; ERBB2. DR HPA; ENSG00000141736; Low tissue specificity. DR MalaCards; ERBB2; -. DR MIM; 137800; phenotype. DR MIM; 164870; gene. DR MIM; 167000; phenotype. DR MIM; 211980; phenotype. DR MIM; 613659; phenotype. DR MIM; 619465; phenotype. DR OpenTargets; ENSG00000141736; -. DR Orphanet; 99976; Adenocarcinoma of the oesophagus and oesophagogastric junction. DR Orphanet; 2800; Extramammary Paget disease. DR Orphanet; 388; Hirschsprung disease. DR Orphanet; 213726; Serous carcinoma of the corpus uteri. DR VEuPathDB; HostDB:ENSG00000141736; -. DR eggNOG; KOG1025; Eukaryota. DR GeneTree; ENSGT00940000158232; -. DR InParanoid; P04626; -. DR OMA; DRHCLPC; -. DR OrthoDB; 6219513at2759; -. DR PAN-GO; P04626; 10 GO annotations based on evolutionary models. DR PhylomeDB; P04626; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P04626; -. DR Reactome; R-HSA-1227986; Signaling by ERBB2. DR Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling. DR Reactome; R-HSA-1251932; PLCG1 events in ERBB2 signaling. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-1306955; GRB7 events in ERBB2 signaling. DR Reactome; R-HSA-1358803; Downregulation of ERBB2:ERBB3 signaling. DR Reactome; R-HSA-1963640; GRB2 events in ERBB2 signaling. DR Reactome; R-HSA-1963642; PI3K events in ERBB2 signaling. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-416572; Sema4D induced cell migration and growth-cone collapse. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6785631; ERBB2 Regulates Cell Motility. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-8847993; ERBB2 Activates PTK6 Signaling. DR Reactome; R-HSA-8863795; Downregulation of ERBB2 signaling. DR Reactome; R-HSA-8866910; TFAP2 (AP-2) family regulates transcription of growth factors and their receptors. DR Reactome; R-HSA-9634285; Constitutive Signaling by Overexpressed ERBB2. DR Reactome; R-HSA-9652282; Drug-mediated inhibition of ERBB2 signaling. DR Reactome; R-HSA-9664565; Signaling by ERBB2 KD Mutants. DR Reactome; R-HSA-9665233; Resistance of ERBB2 KD mutants to trastuzumab. DR Reactome; R-HSA-9665244; Resistance of ERBB2 KD mutants to sapitinib. DR Reactome; R-HSA-9665245; Resistance of ERBB2 KD mutants to tesevatinib. DR Reactome; R-HSA-9665246; Resistance of ERBB2 KD mutants to neratinib. DR Reactome; R-HSA-9665247; Resistance of ERBB2 KD mutants to osimertinib. DR Reactome; R-HSA-9665249; Resistance of ERBB2 KD mutants to afatinib. DR Reactome; R-HSA-9665250; Resistance of ERBB2 KD mutants to AEE788. DR Reactome; R-HSA-9665251; Resistance of ERBB2 KD mutants to lapatinib. DR Reactome; R-HSA-9665348; Signaling by ERBB2 ECD mutants. DR Reactome; R-HSA-9665686; Signaling by ERBB2 TMD/JMD mutants. DR Reactome; R-HSA-9665737; Drug resistance in ERBB2 TMD/JMD mutants. DR Reactome; R-HSA-9927432; Developmental Lineage of Mammary Gland Myoepithelial Cells. DR Reactome; R-HSA-9938206; Developmental Lineage of Mammary Stem Cells. DR SignaLink; P04626; -. DR SIGNOR; P04626; -. DR Agora; ENSG00000141736; -. DR BioGRID-ORCS; 2064; 92 hits in 1209 CRISPR screens. DR ChiTaRS; ERBB2; human. DR EvolutionaryTrace; P04626; -. DR GeneWiki; HER2/neu; -. DR GenomeRNAi; 2064; -. DR Pharos; P04626; Tclin. DR PRO; PR:P04626; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; P04626; protein. DR Bgee; ENSG00000141736; Expressed in lower esophagus mucosa and 186 other cell types or tissues. DR ExpressionAtlas; P04626; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl. DR GO; GO:0009925; C:basal plasma membrane; IBA:GO_Central. DR GO; GO:0016323; C:basolateral plasma membrane; IDA:BHF-UCL. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005769; C:early endosome; IEA:UniProtKB-SubCell. DR GO; GO:0010008; C:endosome membrane; IDA:UniProtKB. DR GO; GO:0038143; C:ERBB3:ERBB2 complex; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; NAS:UniProtKB. DR GO; GO:0043209; C:myelin sheath; IEA:Ensembl. DR GO; GO:0031594; C:neuromuscular junction; IEA:Ensembl. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0042734; C:presynaptic membrane; IEA:Ensembl. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0032587; C:ruffle membrane; IEA:UniProtKB-SubCell. DR GO; GO:0002116; C:semaphorin receptor complex; ISS:BHF-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0015026; F:coreceptor activity; ISS:BHF-UCL. DR GO; GO:0043125; F:ErbB-3 class receptor binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:UniProtKB. DR GO; GO:0046982; F:protein heterodimerization activity; IPI:BHF-UCL. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0030971; F:receptor tyrosine kinase binding; IPI:BHF-UCL. DR GO; GO:0001042; F:RNA polymerase I core binding; IDA:UniProtKB. DR GO; GO:0005102; F:signaling receptor binding; IPI:BHF-UCL. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:BHF-UCL. DR GO; GO:0004888; F:transmembrane signaling receptor activity; IDA:BHF-UCL. DR GO; GO:0008283; P:cell population proliferation; IDA:UniProt. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IDA:BHF-UCL. DR GO; GO:0007166; P:cell surface receptor signaling pathway; IDA:MGI. DR GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IMP:UniProtKB. DR GO; GO:0071363; P:cellular response to growth factor stimulus; IDA:UniProtKB. DR GO; GO:0007167; P:enzyme-linked receptor protein signaling pathway; TAS:ProtInc. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IBA:GO_Central. DR GO; GO:0038134; P:ERBB2-EGFR signaling pathway; IDA:MGI. DR GO; GO:0038133; P:ERBB2-ERBB3 signaling pathway; IEA:Ensembl. DR GO; GO:0038135; P:ERBB2-ERBB4 signaling pathway; IEA:Ensembl. DR GO; GO:0007507; P:heart development; IEA:Ensembl. DR GO; GO:0033080; P:immature T cell proliferation in thymus; IEA:Ensembl. DR GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB. DR GO; GO:0008045; P:motor neuron axon guidance; IEA:Ensembl. DR GO; GO:0042552; P:myelination; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IBA:GO_Central. DR GO; GO:0033088; P:negative regulation of immature T cell proliferation in thymus; IEA:Ensembl. DR GO; GO:0007528; P:neuromuscular junction development; IEA:Ensembl. DR GO; GO:0030182; P:neuron differentiation; IBA:GO_Central. DR GO; GO:0099645; P:neurotransmitter receptor localization to postsynaptic specialization membrane; IEA:Ensembl. DR GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl. DR GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:BHF-UCL. DR GO; GO:0045785; P:positive regulation of cell adhesion; IDA:BHF-UCL. DR GO; GO:0030307; P:positive regulation of cell growth; IMP:UniProtKB. DR GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IDA:UniProtKB. DR GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IBA:GO_Central. DR GO; GO:0090314; P:positive regulation of protein targeting to membrane; IDA:UniProtKB. DR GO; GO:0035025; P:positive regulation of Rho protein signal transduction; ISS:BHF-UCL. DR GO; GO:0045943; P:positive regulation of transcription by RNA polymerase I; IMP:UniProtKB. DR GO; GO:0045727; P:positive regulation of translation; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0045765; P:regulation of angiogenesis; NAS:UniProtKB. DR GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IMP:UniProtKB. DR GO; GO:0032886; P:regulation of microtubule-based process; IDA:UniProtKB. DR GO; GO:0014044; P:Schwann cell development; IEA:Ensembl. DR GO; GO:0071526; P:semaphorin-plexin signaling pathway; ISS:BHF-UCL. DR GO; GO:0007165; P:signal transduction; IDA:UniProtKB. DR GO; GO:0042060; P:wound healing; IDA:BHF-UCL. DR CDD; cd00064; FU; 3. DR CDD; cd05109; PTKc_HER2; 1. DR CDD; cd12094; TM_ErbB2; 1. DR DisProt; DP01484; -. DR FunFam; 1.20.5.100:FF:000007; Receptor protein-tyrosine kinase; 1. DR FunFam; 2.10.220.10:FF:000009; Receptor protein-tyrosine kinase; 1. DR FunFam; 2.10.220.10:FF:000010; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.30.200.20:FF:000184; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.80.20.20:FF:000007; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.80.20.20:FF:000008; Receptor protein-tyrosine kinase; 1. DR FunFam; 4.10.1140.10:FF:000001; Receptor protein-tyrosine kinase; 1. DR FunFam; 1.10.510.10:FF:002828; Receptor tyrosine-protein kinase erbB-2; 1. DR Gene3D; 1.20.5.100; Cytochrome c1, transmembrane anchor, C-terminal; 1. DR Gene3D; 2.10.220.10; Hormone Receptor, Insulin-like Growth Factor Receptor 1, Chain A, domain 2; 3. DR Gene3D; 4.10.1140.10; membrane-bound form of the juxtamembrane domain of the epidermal growth factor receptor like domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.80.20.20; Receptor L-domain; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00293; -. DR InterPro; IPR006211; Furin-like_Cys-rich_dom. DR InterPro; IPR006212; Furin_repeat. DR InterPro; IPR032778; GF_recep_IV. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR000494; Rcpt_L-dom. DR InterPro; IPR036941; Rcpt_L-dom_sf. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR049328; TM_ErbB1. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016245; Tyr_kinase_EGF/ERB/XmrK_rcpt. DR PANTHER; PTHR24416:SF137; RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF00757; Furin-like; 1. DR Pfam; PF14843; GF_recep_IV; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF01030; Recep_L_domain; 2. DR Pfam; PF21314; TM_ErbB1; 1. DR PIRSF; PIRSF000619; TyrPK_EGF-R; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00261; FU; 3. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF57184; Growth factor receptor domain; 2. DR SUPFAM; SSF52058; L domain-like; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Activator; Alternative initiation; Alternative splicing; KW ATP-binding; Cell membrane; Cell projection; Chromosomal rearrangement; KW Cytoplasm; Disease variant; Disulfide bond; Endosome; Glycoprotein; Kinase; KW Membrane; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Receptor; Reference proteome; Signal; KW Transcription; Transcription regulation; Transferase; Transmembrane; KW Transmembrane helix; Tyrosine-protein kinase. FT SIGNAL 1..22 FT /evidence="ECO:0000255" FT CHAIN 23..1255 FT /note="Receptor tyrosine-protein kinase erbB-2" FT /id="PRO_0000016669" FT TOPO_DOM 23..652 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 653..675 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 676..1255 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 720..987 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 676..689 FT /note="Required for interaction with KPNB1 and EEA1" FT /evidence="ECO:0000269|PubMed:16314522" FT REGION 1035..1179 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1195..1197 FT /note="Interaction with PIK3C2B" FT /evidence="ECO:0000305" FT REGION 1196..1255 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 676..689 FT /note="Nuclear localization signal" FT COMPBIAS 1146..1155 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 845 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 726..734 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 753 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 182 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 877 FT /note="Phosphotyrosine" FT /evidence="ECO:0000305|PubMed:32381043" FT MOD_RES 1054 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 1078 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P06494" FT MOD_RES 1083 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1107 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES 1112 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:27134172" FT MOD_RES 1139 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:27134172" FT MOD_RES 1151 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 1166 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1196 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:27134172, FT ECO:0000305|PubMed:32381043" FT MOD_RES 1248 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:17554007, FT ECO:0000269|PubMed:27134172, ECO:0007744|PubMed:17081983" FT CARBOHYD 68 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20696930, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3MZW" FT CARBOHYD 124 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 187 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255, ECO:0007744|PDB:1N8Z, FT ECO:0007744|PDB:1S78, ECO:0007744|PDB:2A91, FT ECO:0007744|PDB:3N85" FT CARBOHYD 259 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:15093539, FT ECO:0000269|PubMed:19299620, ECO:0000269|PubMed:20696930, FT ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85" FT CARBOHYD 530 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:15093539, FT ECO:0000269|PubMed:19299620, ECO:0007744|PDB:1S78" FT CARBOHYD 571 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20696930, FT ECO:0007744|PDB:3MZW" FT CARBOHYD 629 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 26..53 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3H3B, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRL, FT ECO:0007744|PDB:4HRM" FT DISULFID 162..192 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3H3B, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRL, FT ECO:0007744|PDB:4HRM" FT DISULFID 195..204 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3H3B, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRL, FT ECO:0007744|PDB:4HRM" FT DISULFID 199..212 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3H3B, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRL, FT ECO:0007744|PDB:4HRM" FT DISULFID 220..227 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 224..235 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 236..244 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 240..252 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 255..264 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 268..295 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 299..311 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 315..331 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 334..338 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 342..367 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 475..504 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 511..520 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 515..528 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 531..540 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:3BE1, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRN" FT DISULFID 544..560 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:3BE1, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRN" FT DISULFID 563..576 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:3BE1, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRN" FT DISULFID 567..584 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:3BE1, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRN" FT DISULFID 587..596 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:3BE1, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:4HRN" FT DISULFID 600..623 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3N85" FT DISULFID 626..634 FT /evidence="ECO:0007744|PDB:3N85" FT DISULFID 630..642 FT /evidence="ECO:0007744|PDB:3N85" FT VAR_SEQ 1..686 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000305" FT /id="VSP_039250" FT VAR_SEQ 1..610 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000305" FT /id="VSP_039249" FT VAR_SEQ 1..30 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000305" FT /id="VSP_054787" FT VAR_SEQ 1..23 FT /note="MELAALCRWGLLLALLPPGAAST -> MPRGSWKP (in isoform 4)" FT /evidence="ECO:0000303|Ref.4" FT /id="VSP_039248" FT VAR_SEQ 633..648 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000303|PubMed:24722188" FT /id="VSP_055902" FT VAR_SEQ 771..883 FT /note="AYVMAGVGSPYVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDL FT LNWCMQIAKGMSYLEDVRLVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADG FT GK -> TISNLFSNFAPRGPSACCEPTCWCHSGKGQDSLPREEWGRQRRFCLWGCRGEP FT RVLDTPGRSCPSAPPSSCLQPSLRQPLLLGPGPTRAGGSTQHLQRDTYGREPRVPGSGR FT ASVNQKAKSAEALMCPQGAGKA (in isoform 6)" FT /evidence="ECO:0000303|PubMed:24722188" FT /id="VSP_055903" FT VAR_SEQ 884..1255 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000303|PubMed:24722188" FT /id="VSP_055904" FT VARIANT 452 FT /note="W -> C (in dbSNP:rs4252633)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_016317" FT VARIANT 654 FT /note="I -> V (in allele B3; dbSNP:rs1801201)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:8095488" FT /id="VAR_004077" FT VARIANT 655 FT /note="I -> V (in allele B2 and allele B3; FT dbSNP:rs1136201)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:8095488, ECO:0000269|Ref.3" FT /id="VAR_004078" FT VARIANT 710 FT /note="A -> V (in VSCN2; almost complete loss of ERBB2 and FT ERBB3 phosphorylation in the presence or in the absence of FT NRG1 stimulation, suggesting alteration of downstream FT signaling; does not affect the subcellular localization at FT the cell membrane; dbSNP:rs2145813505)" FT /evidence="ECO:0000269|PubMed:33497358" FT /id="VAR_086107" FT VARIANT 755 FT /note="L -> P (in LNCR; uncertain significance; somatic FT mutation; dbSNP:rs121913469)" FT /evidence="ECO:0000269|PubMed:15457249" FT /id="VAR_055432" FT VARIANT 768 FT /note="L -> S (in dbSNP:rs56366519)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042097" FT VARIANT 774 FT /note="M -> MAYVM (in LNCR; uncertain significance; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:15457249" FT /id="VAR_055433" FT VARIANT 776 FT /note="G -> S (in GASC; uncertain significance; somatic FT mutation; dbSNP:rs28933369)" FT /evidence="ECO:0000269|PubMed:15457249, FT ECO:0000269|PubMed:17344846" FT /id="VAR_042098" FT VARIANT 779 FT /note="S -> SVGS (in LNCR; uncertain significance; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:15457249" FT /id="VAR_055434" FT VARIANT 857 FT /note="N -> S (in OC; uncertain significance; somatic FT mutation; dbSNP:rs28933370)" FT /evidence="ECO:0000269|PubMed:15457249, FT ECO:0000269|PubMed:17344846" FT /id="VAR_042099" FT VARIANT 914 FT /note="E -> K (in GLM; uncertain significance; somatic FT mutation; dbSNP:rs28933368)" FT /evidence="ECO:0000269|PubMed:15457249" FT /id="VAR_055435" FT VARIANT 1170 FT /note="P -> A (in dbSNP:rs1058808)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:2999974, ECO:0000269|PubMed:8104414, FT ECO:0000269|Ref.3" FT /id="VAR_016318" FT VARIANT 1216 FT /note="A -> D (in dbSNP:rs55943169)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042100" FT MUTAGEN 317..318 FT /note="LH->AA: Reduces dimerization with ERBB3." FT /evidence="ECO:0000269|PubMed:15093539" FT MUTAGEN 611 FT /note="M->A: Prevents synthesis of isoform 2." FT /evidence="ECO:0000269|PubMed:16794579" FT MUTAGEN 687 FT /note="M->A: Prevents synthesis of isoform 3." FT /evidence="ECO:0000269|PubMed:16794579" FT MUTAGEN 706 FT /note="M->A: No effect on isoform production." FT /evidence="ECO:0000269|PubMed:16794579" FT MUTAGEN 712 FT /note="M->A: No effect on isoform production." FT /evidence="ECO:0000269|PubMed:16794579" FT STRAND 25..27 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 39..50 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 55..64 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 72..74 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 79..82 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 84..88 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 92..95 FT /evidence="ECO:0007829|PDB:3H3B" FT TURN 109..111 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 112..117 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 123..125 FT /evidence="ECO:0007829|PDB:8PWH" FT TURN 130..132 FT /evidence="ECO:0007829|PDB:3H3B" FT STRAND 139..141 FT /evidence="ECO:0007829|PDB:3H3B" FT STRAND 147..150 FT /evidence="ECO:0007829|PDB:2A91" FT STRAND 152..156 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 164..166 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 169..171 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 175..177 FT /evidence="ECO:0007829|PDB:1N8Z" FT STRAND 182..184 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 200..202 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 204..208 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 209..211 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 217..219 FT /evidence="ECO:0007829|PDB:1N8Z" FT HELIX 221..223 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 227..231 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 232..234 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 240..248 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 251..260 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 263..267 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 271..274 FT /evidence="ECO:0007829|PDB:5MY6" FT TURN 276..278 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 281..283 FT /evidence="ECO:0007829|PDB:5MY6" FT TURN 284..286 FT /evidence="ECO:0007829|PDB:6J71" FT STRAND 289..291 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 294..298 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 303..305 FT /evidence="ECO:0007829|PDB:1N8Z" FT STRAND 309..314 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 319..323 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 325..327 FT /evidence="ECO:0007829|PDB:8VQD" FT STRAND 329..333 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 335..337 FT /evidence="ECO:0007829|PDB:2A91" FT HELIX 348..350 FT /evidence="ECO:0007829|PDB:5MY6" FT TURN 358..360 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 361..364 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 368..376 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 378..382 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 385..387 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 394..400 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 405..408 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 410..413 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 417..421 FT /evidence="ECO:0007829|PDB:8PWH" FT HELIX 423..425 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 430..435 FT /evidence="ECO:0007829|PDB:3WLW" FT TURN 438..440 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 441..447 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 463..469 FT /evidence="ECO:0007829|PDB:5MY6" FT TURN 476..479 FT /evidence="ECO:0007829|PDB:8VQE" FT HELIX 482..485 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 488..490 FT /evidence="ECO:0007829|PDB:8VQD" FT STRAND 493..499 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 501..506 FT /evidence="ECO:0007829|PDB:5MY6" FT TURN 507..509 FT /evidence="ECO:0007829|PDB:3N85" FT HELIX 516..518 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 520..524 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 525..527 FT /evidence="ECO:0007829|PDB:2A91" FT STRAND 532..536 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 539..542 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 545..551 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 553..556 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 559..562 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 565..567 FT /evidence="ECO:0007829|PDB:3WSQ" FT STRAND 571..573 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 575..580 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 583..592 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 595..599 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 602..604 FT /evidence="ECO:0007829|PDB:6J71" FT STRAND 605..608 FT /evidence="ECO:0007829|PDB:8PWH" FT STRAND 613..616 FT /evidence="ECO:0007829|PDB:8JYQ" FT STRAND 621..625 FT /evidence="ECO:0007829|PDB:1N8Z" FT STRAND 630..632 FT /evidence="ECO:0007829|PDB:6J71" FT STRAND 635..637 FT /evidence="ECO:0007829|PDB:6J71" FT HELIX 651..678 FT /evidence="ECO:0007829|PDB:2JWA" FT HELIX 684..690 FT /evidence="ECO:0007829|PDB:2N2A" FT HELIX 691..697 FT /evidence="ECO:0007829|PDB:2N2A" FT HELIX 717..719 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 720..729 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 732..739 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 748..755 FT /evidence="ECO:0007829|PDB:8U8X" FT TURN 762..765 FT /evidence="ECO:0007829|PDB:3RCD" FT HELIX 770..775 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 787..799 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 806..813 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 814..816 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 819..838 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 848..850 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 851..855 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 858..861 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 866..870 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 874..876 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 878..880 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 886..888 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 891..896 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 901..916 FT /evidence="ECO:0007829|PDB:8U8X" FT TURN 922..925 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 928..930 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 931..936 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 949..958 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 963..965 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 969..980 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 983..985 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 989..992 FT /evidence="ECO:0007829|PDB:3PP0" FT HELIX 1003..1007 FT /evidence="ECO:0007829|PDB:3PP0" FT TURN 1008..1011 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 1020..1022 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 1140..1142 FT /evidence="ECO:0007829|PDB:1MW4" SQ SEQUENCE 1255 AA; 137910 MW; 39E9DFDA04DCF962 CRC64; MELAALCRWG LLLALLPPGA ASTQVCTGTD MKLRLPASPE THLDMLRHLY QGCQVVQGNL ELTYLPTNAS LSFLQDIQEV QGYVLIAHNQ VRQVPLQRLR IVRGTQLFED NYALAVLDNG DPLNNTTPVT GASPGGLREL QLRSLTEILK GGVLIQRNPQ LCYQDTILWK DIFHKNNQLA LTLIDTNRSR ACHPCSPMCK GSRCWGESSE DCQSLTRTVC AGGCARCKGP LPTDCCHEQC AAGCTGPKHS DCLACLHFNH SGICELHCPA LVTYNTDTFE SMPNPEGRYT FGASCVTACP YNYLSTDVGS CTLVCPLHNQ EVTAEDGTQR CEKCSKPCAR VCYGLGMEHL REVRAVTSAN IQEFAGCKKI FGSLAFLPES FDGDPASNTA PLQPEQLQVF ETLEEITGYL YISAWPDSLP DLSVFQNLQV IRGRILHNGA YSLTLQGLGI SWLGLRSLRE LGSGLALIHH NTHLCFVHTV PWDQLFRNPH QALLHTANRP EDECVGEGLA CHQLCARGHC WGPGPTQCVN CSQFLRGQEC VEECRVLQGL PREYVNARHC LPCHPECQPQ NGSVTCFGPE ADQCVACAHY KDPPFCVARC PSGVKPDLSY MPIWKFPDEE GACQPCPINC THSCVDLDDK GCPAEQRASP LTSIISAVVG ILLVVVLGVV FGILIKRRQQ KIRKYTMRRL LQETELVEPL TPSGAMPNQA QMRILKETEL RKVKVLGSGA FGTVYKGIWI PDGENVKIPV AIKVLRENTS PKANKEILDE AYVMAGVGSP YVSRLLGICL TSTVQLVTQL MPYGCLLDHV RENRGRLGSQ DLLNWCMQIA KGMSYLEDVR LVHRDLAARN VLVKSPNHVK ITDFGLARLL DIDETEYHAD GGKVPIKWMA LESILRRRFT HQSDVWSYGV TVWELMTFGA KPYDGIPARE IPDLLEKGER LPQPPICTID VYMIMVKCWM IDSECRPRFR ELVSEFSRMA RDPQRFVVIQ NEDLGPASPL DSTFYRSLLE DDDMGDLVDA EEYLVPQQGF FCPDPAPGAG GMVHHRHRSS STRSGGGDLT LGLEPSEEEA PRSPLAPSEG AGSDVFDGDL GMGAAKGLQS LPTHDPSPLQ RYSEDPTVPL PSETDGYVAP LTCSPQPEYV NQPDVRPQPP SPREGPLPAA RPAGATLERP KTLSPGKNGV VKDVFAFGGA VENPEYLTPQ GGAAPQPHPP PAFSPAFDNL YYWDQDPPER GAPPSTFKGT PTAENPEYLG LDVPV // ID JUPI2_HUMAN Reviewed; 190 AA. AC Q9H910; B1AJY2; B4DLH4; Q6EIC7; DT 19-JUL-2005, integrated into UniProtKB/Swiss-Prot. DT 01-MAR-2001, sequence version 1. DT 28-JAN-2026, entry version 172. DE RecName: Full=Jupiter microtubule associated homolog 2 {ECO:0000312|HGNC:HGNC:14137}; DE AltName: Full=Hematological and neurological expressed 1-like protein {ECO:0000303|PubMed:15094197}; DE Short=HN1-like protein; GN Name=JPT2 {ECO:0000312|HGNC:HGNC:14137}; GN Synonyms=C16orf34, HN1L {ECO:0000303|PubMed:15094197}; ORFNames=L11; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1 AND 2), SUBCELLULAR RP LOCATION, AND TISSUE SPECIFICITY. RC TISSUE=Brain, and Liver; RX PubMed=15094197; DOI=10.1016/j.gene.2004.02.025; RA Zhou G., Wang J., Zhang Y., Zhong C., Ni J., Wang L., Guo J., Zhang K., RA Yu L., Zhao S.; RT "Cloning, expression and subcellular localization of HN1 and HN1L genes, as RT well as characterization of their orthologs, defining an evolutionarily RT conserved gene family."; RL Gene 331:115-123(2004). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INDUCTION, AND SUBCELLULAR RP LOCATION. RX PubMed=15334068; DOI=10.1038/sj.onc.1207921; RA Petroziello J., Yamane A., Westendorf L., Thompson M., McDonagh C., RA Cerveny C., Law C.-L., Wahl A., Carter P.; RT "Suppression subtractive hybridization and expression profiling identifies RT a unique set of genes overexpressed in non-small-cell lung cancer."; RL Oncogene 23:7734-7745(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3). RC TISSUE=Teratocarcinoma, and Tongue; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=11157797; DOI=10.1093/hmg/10.4.339; RA Daniels R.J., Peden J.F., Lloyd C., Horsley S.W., Clark K., Tufarelli C., RA Kearney L., Buckle V.J., Doggett N.A., Flint J., Higgs D.R.; RT "Sequence, structure and pathology of the fully annotated terminal 2 Mb of RT the short arm of human chromosome 16."; RL Hum. Mol. Genet. 10:339-352(2001). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15616553; DOI=10.1038/nature03187; RA Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X., Xie G., RA Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A., Bajorek E., RA Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J., Buckingham J.M., RA Callen D.F., Campbell C.S., Campbell M.L., Campbell E.W., Caoile C., RA Challacombe J.F., Chasteen L.A., Chertkov O., Chi H.C., Christensen M., RA Clark L.M., Cohn J.D., Denys M., Detter J.C., Dickson M., RA Dimitrijevic-Bussod M., Escobar J., Fawcett J.J., Flowers D., Fotopulos D., RA Glavina T., Gomez M., Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., RA Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., RA Huang W., Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., RA Kobayashi A., Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., RA Lowry S., Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J., RA Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D., RA Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L., Rash S., RA Retterer J., Ricke D.O., Robinson D.L., Rodriguez A., Salamov A., RA Saunders E.H., Scott D., Shough T., Stallings R.L., Stalvey M., RA Sutherland R.D., Tapia R., Tesmer J.G., Thayer N., Thompson L.S., Tice H., RA Torney D.C., Tran-Gyamfi M., Tsai M., Ulanovsky L.E., Ustaszewska A., RA Vo N., White P.S., Williams A.L., Wills P.L., Wu J.-R., Wu K., Yang J., RA DeJong P., Bruce D., Doggett N.A., Deaven L., Schmutz J., Grimwood J., RA Richardson P., Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., RA Myers R.M., Rubin E.M., Pennacchio L.A.; RT "The sequence and analysis of duplication-rich human chromosome 16."; RL Nature 432:988-994(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Skin, and Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-97, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17924679; DOI=10.1021/pr070152u; RA Yu L.R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.; RT "Improved titanium dioxide enrichment of phosphopeptides from HeLa cells RT and high confident phosphopeptide identification by cross-validation of RT MS/MS and MS/MS/MS spectra."; RL J. Proteome Res. 6:4150-4162(2007). RN [9] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-97, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-30; THR-35; SER-97 AND RP SER-144, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-97, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-97, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-132, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [16] RP ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-45; SER-69; SER-97; SER-132 RP AND SER-144, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [18] RP FUNCTION, FUNCTION (MICROBIAL INFECTION), SUBUNIT, AND INTERACTION WITH RP TPCN1. RX PubMed=33758061; DOI=10.1126/scisignal.abd5605; RA Gunaratne G.S., Brailoiu E., He S., Unterwald E.M., Patel S., Slama J.T., RA Walseth T.F., Marchant J.S.; RT "Essential requirement for JPT2 in NAADP-evoked Ca2+ signaling."; RL Sci. Signal. 14:0-0(2021). RN [19] RP FUNCTION, SUBUNIT, AND SUBCELLULAR LOCATION. RX PubMed=33758062; DOI=10.1126/scisignal.abd5647; RA Roggenkamp H.G., Khansahib I., Hernandez C.L.C., Zhang Y., Lodygin D., RA Krueger A., Gu F., Moeckl F., Loehndorf A., Wolters V., Woike D., RA Rosche A., Bauche A., Schetelig D., Werner R., Schlueter H., Failla A.V., RA Meier C., Fliegert R., Walseth T.F., Fluegel A., Diercks B.P., Guse A.H.; RT "HN1L/JPT2: A signaling protein that connects NAADP generation to Ca2+ RT microdomain formation."; RL Sci. Signal. 14:0-0(2021). CC -!- FUNCTION: Nicotinic acid adenine dinucleotide phosphate (NAADP) binding CC protein required for NAADP-evoked intracellular calcium release CC (PubMed:33758061, PubMed:33758062). Confers NAADP-sensitivity to the CC two pore channels (TPCs) complex (PubMed:33758061). Enables NAADP to CC activate Ca(2+) release from the endoplasmic reticulum through CC ryanodine receptors (PubMed:33758062). {ECO:0000269|PubMed:33758061, CC ECO:0000269|PubMed:33758062}. CC -!- FUNCTION: (Microbial infection) Involved in the endolysosomal CC trafficking of human coronavirus SARS-CoV-2. CC {ECO:0000269|PubMed:33758061}. CC -!- SUBUNIT: Monomer (PubMed:33758062). Dimer (PubMed:33758062). Interacts CC with TPCN1 (PubMed:33758061). {ECO:0000269|PubMed:33758061, CC ECO:0000269|PubMed:33758062}. CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15094197, CC ECO:0000269|PubMed:33758062}. Nucleus {ECO:0000269|PubMed:15094197}. CC Note=Colocalizes with type 1 ryanodine receptor (RYR1). CC {ECO:0000269|PubMed:33758062}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; Synonyms=HN1LA; CC IsoId=Q9H910-1; Sequence=Displayed; CC Name=2; Synonyms=HN1LB, HN1LC; CC IsoId=Q9H910-2; Sequence=VSP_014706; CC Name=3; CC IsoId=Q9H910-3; Sequence=VSP_057423; CC -!- TISSUE SPECIFICITY: Expressed in liver, kidney, prostate, testis and CC uterus. {ECO:0000269|PubMed:15094197}. CC -!- INDUCTION: Up-regulated in squamous cell carcinoma (SCC) adenocarcinoma CC (AC), adenosquamous cell carcinoma (ASCC), bronchioalveolar carcinoma CC (BAC), breast and uterus tumors. {ECO:0000269|PubMed:15334068}. CC -!- SIMILARITY: Belongs to the JUPITER family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY323831; AAP72616.1; -; Genomic_DNA. DR EMBL; AY323978; AAP83791.1; -; mRNA. DR EMBL; AY323979; AAP83792.1; -; mRNA. DR EMBL; AY598330; AAT06741.1; -; mRNA. DR EMBL; AK023154; BAB14434.1; -; mRNA. DR EMBL; AE006639; AAK61289.1; -; Genomic_DNA. DR EMBL; AK296998; BAG59536.1; -; mRNA. DR EMBL; AL031009; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL031710; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471112; EAW85635.1; -; Genomic_DNA. DR EMBL; CH471112; EAW85638.1; -; Genomic_DNA. DR EMBL; BC014438; AAH14438.1; -; mRNA. DR EMBL; BC060853; AAH60853.1; -; mRNA. DR CCDS; CCDS10441.1; -. [Q9H910-1] DR RefSeq; NP_001421594.1; NM_001434665.1. [Q9H910-3] DR RefSeq; NP_653171.1; NM_144570.3. [Q9H910-1] DR AlphaFoldDB; Q9H910; -. DR BioGRID; 124774; 60. DR FunCoup; Q9H910; 2606. DR IntAct; Q9H910; 16. DR MINT; Q9H910; -. DR STRING; 9606.ENSP00000248098; -. DR ChEMBL; CHEMBL4295946; -. DR TCDB; 8.A.242.1.1; the naadp-binding protein (jpt2) family. DR GlyGen; Q9H910; 11 sites, 2 O-linked glycans (10 sites). DR iPTMnet; Q9H910; -. DR MetOSite; Q9H910; -. DR PhosphoSitePlus; Q9H910; -. DR BioMuta; JPT2; -. DR jPOST; Q9H910; -. DR MassIVE; Q9H910; -. DR PaxDb; 9606-ENSP00000248098; -. DR PeptideAtlas; Q9H910; -. DR ProteomicsDB; 4534; -. DR ProteomicsDB; 81270; -. [Q9H910-1] DR ProteomicsDB; 81271; -. [Q9H910-2] DR Pumba; Q9H910; -. DR TopDownProteomics; Q9H910-1; -. [Q9H910-1] DR Antibodypedia; 23196; 79 antibodies from 14 providers. DR DNASU; 90861; -. DR Ensembl; ENST00000248098.8; ENSP00000248098.3; ENSG00000206053.14. [Q9H910-1] DR Ensembl; ENST00000382711.9; ENSP00000372158.5; ENSG00000206053.14. [Q9H910-2] DR Ensembl; ENST00000562684.5; ENSP00000457694.1; ENSG00000206053.14. [Q9H910-3] DR GeneID; 90861; -. DR KEGG; hsa:90861; -. DR MANE-Select; ENST00000248098.8; ENSP00000248098.3; NM_144570.3; NP_653171.1. DR UCSC; uc002cmg.4; human. [Q9H910-1] DR UCSC; uc010uvi.3; human. DR AGR; HGNC:14137; -. DR ClinPGx; PA162391043; -. DR CTD; 90861; -. DR DisGeNET; 90861; -. DR GeneCards; JPT2; -. DR HGNC; HGNC:14137; JPT2. DR HPA; ENSG00000206053; Tissue enhanced (brain). DR MIM; 619241; gene. DR OpenTargets; ENSG00000206053; -. DR VEuPathDB; HostDB:ENSG00000206053; -. DR eggNOG; ENOG502S1G7; Eukaryota. DR GeneTree; ENSGT00390000007652; -. DR HOGENOM; CLU_111612_0_0_1; -. DR InParanoid; Q9H910; -. DR OMA; RQFINPP; -. DR OrthoDB; 6367565at2759; -. DR PAN-GO; Q9H910; 1 GO annotation based on evolutionary models. DR PhylomeDB; Q9H910; -. DR PathwayCommons; Q9H910; -. DR SignaLink; Q9H910; -. DR Agora; ENSG00000206053; -. DR BioGRID-ORCS; 90861; 10 hits in 1144 CRISPR screens. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; HN1L; human. DR GeneWiki; HN1L; -. DR GenomeRNAi; 90861; -. DR Pharos; Q9H910; Tbio. DR PRO; PR:Q9H910; -. DR Proteomes; UP000005640; Chromosome 16. DR RNAct; Q9H910; protein. DR Bgee; ENSG00000206053; Expressed in epithelium of bronchus and 199 other cell types or tissues. DR ExpressionAtlas; Q9H910; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0075509; P:endocytosis involved in viral entry into host cell; IDA:UniProtKB. DR GO; GO:0050848; P:regulation of calcium-mediated signaling; IMP:UniProtKB. DR InterPro; IPR033335; JUPITER. DR PANTHER; PTHR34930; GEO05313P1; 1. DR PANTHER; PTHR34930:SF5; JUPITER MICROTUBULE ASSOCIATED HOMOLOG 2; 1. DR Pfam; PF17054; JUPITER; 1. PE 1: Evidence at protein level; KW Acetylation; Alternative splicing; Cytoplasm; Host-virus interaction; KW Nucleus; Phosphoprotein; Proteomics identification; Reference proteome. FT CHAIN 1..190 FT /note="Jupiter microtubule associated homolog 2" FT /id="PRO_0000054921" FT REGION 1..190 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 35..44 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 110..129 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 139..167 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 1 FT /note="N-acetylmethionine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 30 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 35 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 45 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 69 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 97 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17924679, FT ECO:0007744|PubMed:18220336, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163" FT MOD_RES 132 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 144 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..17 FT /note="MFQVPDSEGGRAGSRAM -> M (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15094197" FT /id="VSP_014706" FT VAR_SEQ 14 FT /note="S -> SRKWQLLTGSLASTSPSLLSGQGPWAPLQ (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_057423" SQ SEQUENCE 190 AA; 20063 MW; 9132F17687193192 CRC64; MFQVPDSEGG RAGSRAMKPP GGESSNLFGS PEEATPSSRP NRMASNIFGP TEEPQNIPKR TNPPGGKGSG IFDESTPVQT RQHLNPPGGK TSDIFGSPVT ATSRLAHPNK PKDHVFLCEG EEPKSDLKAA RSIPAGAEPG EKGSARKAGP AKEQEPMPTV DSHEPRLGPR PRSHNKVLNP PGGKSSISFY // ID KCC2B_HUMAN Reviewed; 666 AA. AC Q13554; A4D2K0; A4D2K1; A4D2K2; A4D2K3; A4D2K4; A4D2K5; A4D2K6; O95437; AC O95438; O95599; Q9UGH7; Q9UGH8; Q9UGH9; Q9UNX0; Q9UNX7; Q9UP00; Q9Y5N4; AC Q9Y6F4; DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot. DT 31-MAY-2011, sequence version 3. DT 28-JAN-2026, entry version 235. DE RecName: Full=Calcium/calmodulin-dependent protein kinase type II subunit beta; DE Short=CaM kinase II subunit beta; DE Short=CaMK-II subunit beta; DE EC=2.7.11.17 {ECO:0000269|PubMed:31930741}; GN Name=CAMK2B; Synonyms=CAM2, CAMK2, CAMKB; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 5; 6 AND 7). RC TISSUE=Brain; RX PubMed=10858498; DOI=10.1016/s0014-5793(00)01634-3; RA Wang P., Wu Y., Zhou T.H., Sun Y., Pei G.; RT "Identification of alternative splicing variants of the beta subunit of RT human Ca(2+)/calmodulin-dependent protein kinase II with different RT activities."; RL FEBS Lett. 475:107-110(2000). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4). RC TISSUE=Skeletal muscle; RA Leddy J.J., Salih M., Tuana B.S.; RL Submitted (MAR-1995) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 5). RC TISSUE=Brain; RA Li G.Y., Cooper N.G.F.; RT "Molecular cloning and sequencing of human calcium/calmodulin dependent RT protein kinase II beta subunit."; RL Submitted (DEC-1998) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3 AND 5). RC TISSUE=Insulinoma; RX PubMed=10819240; DOI=10.1007/s001250051330; RA Rochlitz H., Voigt A., Lankat-Buttgereit B., Goeke B., Heimberg H., RA Nauck M.A., Schiemann U., Schatz H., Pfeiffer A.F.; RT "Cloning and quantitative determination of the human Ca2+/calmodulin- RT dependent protein kinase II (CaMK II) isoforms in human beta cells."; RL Diabetologia 43:465-473(2000). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Testis, and Thalamus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12690205; DOI=10.1126/science.1083423; RA Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K., RA Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R., RA Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A., RA Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D., RA Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S., RA Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R., RA Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N., RA Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E., RA Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R., RA Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T., RA Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W., RA Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A., RA Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X., RA Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E., RA Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H., RA Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J., RA Adams M.D., Tsui L.-C.; RT "Human chromosome 7: DNA sequence and biology."; RL Science 300:767-772(2003). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 302-605 (ISOFORM 2). RX PubMed=9060999; DOI=10.1016/s0167-4889(96)00141-3; RA Tombes R.M., Krystal G.W.; RT "Identification of novel human tumor cell-specific CaMK-II variants."; RL Biochim. Biophys. Acta 1355:281-292(1997). RN [9] RP ACTIVITY REGULATION, SUBUNIT, AND AUTOPHOSPHORYLATION. RX PubMed=14722083; DOI=10.1074/jbc.m313597200; RA Gaertner T.R., Kolodziej S.J., Wang D., Kobayashi R., Koomen J.M., RA Stoops J.K., Waxham M.N.; RT "Comparative analyses of the three-dimensional structures and enzymatic RT properties of alpha, beta, gamma and delta isoforms of Ca2+-calmodulin- RT dependent protein kinase II."; RL J. Biol. Chem. 279:12484-12494(2004). RN [10] RP INTERACTION WITH MPDZ. RX PubMed=15312654; DOI=10.1016/j.neuron.2004.08.003; RA Krapivinsky G., Medina I., Krapivinsky L., Gapon S., Clapham D.E.; RT "SynGAP-MUPP1-CaMKII synaptic complexes regulate p38 MAP kinase activity RT and NMDA receptor-dependent synaptic AMPA receptor potentiation."; RL Neuron 43:563-574(2004). RN [11] RP FUNCTION IN SKELETAL MUSCLE, PHOSPHORYLATION AT THR-287, FUNCTION IN RP PHOSPHORYLATION OF PLN, TISSUE SPECIFICITY, AND INDUCTION. RX PubMed=16690701; DOI=10.1113/jphysiol.2006.111757; RA Rose A.J., Kiens B., Richter E.A.; RT "Ca2+-calmodulin-dependent protein kinase expression and signalling in RT skeletal muscle during exercise."; RL J. Physiol. (Lond.) 574:889-903(2006). RN [12] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [13] RP SUBCELLULAR LOCATION. RX PubMed=21529938; DOI=10.1016/j.ceca.2011.02.007; RA Wayman G.A., Tokumitsu H., Davare M.A., Soderling T.R.; RT "Analysis of CaM-kinase signaling in cells."; RL Cell Calcium 50:1-8(2011). RN [14] RP REVIEW ON FUNCTION IN SKELETAL MUSCLE. RX PubMed=15294044; DOI=10.1079/pns2004335; RA Chin E.R.; RT "The role of calcium and calcium/calmodulin-dependent kinases in skeletal RT muscle plasticity and mitochondrial biogenesis."; RL Proc. Nutr. Soc. 63:279-286(2004). RN [15] RP REVIEW ON FUNCTION IN SKELETAL MUSCLE. RA Sacchetto R., Bovo E., Damiani E.; RT "The Ca2+-calmodulin dependent protein kinase II system of skeletal muscle RT sarcoplasmic reticulum."; RL Basic Appl. Myol. 15:5-17(2005). RN [16] RP REVIEW ON FUNCTION IN NEURONAL PLASTICITY. RX PubMed=18817731; DOI=10.1016/j.neuron.2008.08.021; RA Wayman G.A., Lee Y.S., Tokumitsu H., Silva A.J., Silva A., Soderling T.R.; RT "Calmodulin-kinases: modulators of neuronal development and plasticity."; RL Neuron 59:914-931(2008). RN [17] RP REVIEW ON FUNCTION IN NEURONAL PLASTICITY. RX PubMed=19996366; DOI=10.1152/physiol.00029.2009; RA Okamoto K., Bosch M., Hayashi Y.; RT "The roles of CaMKII and F-actin in the structural plasticity of dendritic RT spines: a potential molecular identity of a synaptic tag?"; RL Physiology (Bethesda) 24:357-366(2009). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-401, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [19] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=31930741; DOI=10.15252/embj.2019102608; RA Jiang X., Wang X., Ding X., Du M., Li B., Weng X., Zhang J., Li L., RA Tian R., Zhu Q., Chen S., Wang L., Liu W., Fang L., Neculai D., Sun Q.; RT "FAM134B oligomerization drives endoplasmic reticulum membrane scission for RT ER-phagy."; RL EMBO J. 39:e102608-e102608(2020). RN [20] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 11-303 IN COMPLEX WITH INHIBITOR. RG Structural genomics consortium (SGC); RT "Crystal structure of human calcium/calmodulin-dependent protein kinase IIb RT isoform 1 (CAMK2B)."; RL Submitted (DEC-2007) to the PDB data bank. RN [21] RP VARIANTS [LARGE SCALE ANALYSIS] LEU-489 AND LYS-510. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [22] RP INVOLVEMENT IN MRD54, VARIANTS MRD54 29-ARG--GLN-666 DEL; LYS-110; LEU-139; RP LYS-237 AND GLU-301, CHARACTERIZATION OF VARIANTS MRD54 LYS-110; LEU-139; RP LYS-237 AND GLU-301, AND FUNCTION. RX PubMed=29100089; DOI=10.1016/j.ajhg.2017.10.003; RG Undiagnosed Diseases Network; RG GEM HUGO; RG Deciphering Developmental Disorders Study; RA Kuery S., van Woerden G.M., Besnard T., Proietti Onori M., Latypova X., RA Towne M.C., Cho M.T., Prescott T.E., Ploeg M.A., Sanders S., RA Stessman H.A.F., Pujol A., Distel B., Robak L.A., Bernstein J.A., RA Denomme-Pichon A.S., Lesca G., Sellars E.A., Berg J., Carre W., Busk O.L., RA van Bon B.W.M., Waugh J.L., Deardorff M., Hoganson G.E., Bosanko K.B., RA Johnson D.S., Dabir T., Holla O.L., Sarkar A., Tveten K., de Bellescize J., RA Braathen G.J., Terhal P.A., Grange D.K., van Haeringen A., Lam C., RA Mirzaa G., Burton J., Bhoj E.J., Douglas J., Santani A.B., Nesbitt A.I., RA Helbig K.L., Andrews M.V., Begtrup A., Tang S., van Gassen K.L.I., RA Juusola J., Foss K., Enns G.M., Moog U., Hinderhofer K., Paramasivam N., RA Lincoln S., Kusako B.H., Lindenbaum P., Charpentier E., Nowak C.B., RA Cherot E., Simonet T., Ruivenkamp C.A.L., Hahn S., Brownstein C.A., Xia F., RA Schmitt S., Deb W., Bonneau D., Nizon M., Quinquis D., Chelly J., RA Rudolf G., Sanlaville D., Parent P., Gilbert-Dussardier B., Toutain A., RA Sutton V.R., Thies J., Peart-Vissers L.E.L.M., Boisseau P., Vincent M., RA Grabrucker A.M., Dubourg C., Tan W.H., Verbeek N.E., Granzow M., RA Santen G.W.E., Shendure J., Isidor B., Pasquier L., Redon R., Yang Y., RA State M.W., Kleefstra T., Cogne B., Petrovski S., Retterer K., RA Eichler E.E., Rosenfeld J.A., Agrawal P.B., Bezieau S., Odent S., RA Elgersma Y., Mercier S.; RT "De Novo Mutations in Protein Kinase Genes CAMK2A and CAMK2B Cause RT Intellectual Disability."; RL Am. J. Hum. Genet. 101:768-788(2017). RN [23] RP INVOLVEMENT IN MRD54, AND VARIANTS MRD54 LEU-213 AND SER-284. RX PubMed=29560374; DOI=10.1002/acn3.528; RA Akita T., Aoto K., Kato M., Shiina M., Mutoh H., Nakashima M., Kuki I., RA Okazaki S., Magara S., Shiihara T., Yokochi K., Aiba K., Tohyama J., RA Ohba C., Miyatake S., Miyake N., Ogata K., Fukuda A., Matsumoto N., RA Saitsu H.; RT "De novo variants in CAMK2A and CAMK2B cause neurodevelopmental RT disorders."; RL Ann. Clin. Transl. Neurol. 5:280-296(2018). CC -!- FUNCTION: Calcium/calmodulin-dependent protein kinase that functions CC autonomously after Ca(2+)/calmodulin-binding and autophosphorylation, CC and is involved in dendritic spine and synapse formation, neuronal CC plasticity and regulation of sarcoplasmic reticulum Ca(2+) transport in CC skeletal muscle (PubMed:16690701). In neurons, plays an essential CC structural role in the reorganization of the actin cytoskeleton during CC plasticity by binding and bundling actin filaments in a kinase- CC independent manner. This structural function is required for correct CC targeting of CaMK2A, which acts downstream of NMDAR to promote CC dendritic spine and synapse formation and maintain synaptic plasticity CC which enables long-term potentiation (LTP) and hippocampus-dependent CC learning. In developing hippocampal neurons, promotes arborization of CC the dendritic tree and in mature neurons, promotes dendritic CC remodeling. Also regulates the migration of developing neurons CC (PubMed:29100089). Participates in the modulation of skeletal muscle CC function in response to exercise (PubMed:16690701). In slow-twitch CC muscles, is involved in regulation of sarcoplasmic reticulum (SR) CC Ca(2+) transport and in fast-twitch muscle participates in the control CC of Ca(2+) release from the SR through phosphorylation of triadin, a CC ryanodine receptor-coupling factor, and phospholamban (PLN/PLB), an CC endogenous inhibitor of SERCA2A/ATP2A2. In response to interferon-gamma CC (IFN-gamma) stimulation, catalyzes phosphorylation of STAT1, CC stimulating the JAK-STAT signaling pathway (By similarity). CC Phosphorylates reticulophagy regulator RETREG1 at 'Ser-151' under CC endoplasmic reticulum stress conditions which enhances RETREG1 CC oligomerization and its membrane scission and reticulophagy activity CC (PubMed:31930741). {ECO:0000250|UniProtKB:P08413, CC ECO:0000269|PubMed:16690701, ECO:0000269|PubMed:29100089, CC ECO:0000269|PubMed:31930741}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.17; CC Evidence={ECO:0000269|PubMed:31930741}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.17; CC -!- ACTIVITY REGULATION: Activated by Ca(2+)/calmodulin. Binding of CC calmodulin results in conformational change that relieves intrasteric CC autoinhibition and allows autophosphorylation of Thr-287 which turns CC the kinase in a constitutively active form and confers to the kinase a CC Ca(2+)-independent activity. {ECO:0000269|PubMed:14722083}. CC -!- SUBUNIT: CAMK2 is composed of 4 different chains: alpha (CAMK2A), beta CC (CAMK2B), gamma (CAMK2G), and delta (CAMK2D). The different isoforms CC assemble into homo- or heteromultimeric holoenzymes composed of 12 CC subunits with two hexameric rings stacked one on top of the other CC (PubMed:14722083, Ref.20). Interacts with SYNGAP1 and CAMK2N2 (By CC similarity). Interacts with MPDZ (PubMed:15312654). Interacts with CC FOXO3 (By similarity). Interacts (when in a kinase inactive state not CC associated with calmodulin) with ARC; leading to target ARC to inactive CC synapses (By similarity). Interacts with CAMK2N1; this interaction CC requires CAMK2B activation by Ca(2+) (By similarity). CC {ECO:0000250|UniProtKB:P08413, ECO:0000250|UniProtKB:P28652, CC ECO:0000269|PubMed:14722083, ECO:0000269|PubMed:15312654, CC ECO:0000269|Ref.20}. CC -!- INTERACTION: CC Q13554; O00154: ACOT7; NbExp=3; IntAct=EBI-1058722, EBI-948905; CC Q13554; Q2VPB7: AP5B1; NbExp=4; IntAct=EBI-1058722, EBI-5917279; CC Q13554; P62158: CALM3; NbExp=2; IntAct=EBI-1058722, EBI-397435; CC Q13554; Q9UQM7: CAMK2A; NbExp=7; IntAct=EBI-1058722, EBI-1383687; CC Q13554; Q13554: CAMK2B; NbExp=2; IntAct=EBI-1058722, EBI-1058722; CC Q13554; Q13557: CAMK2D; NbExp=6; IntAct=EBI-1058722, EBI-351018; CC Q13554; Q8N0U1: FAM171A2; NbExp=3; IntAct=EBI-1058722, EBI-10264767; CC Q13554; P60412: KRTAP10-11; NbExp=3; IntAct=EBI-1058722, EBI-10217483; CC Q13554; Q3LI72: KRTAP19-5; NbExp=3; IntAct=EBI-1058722, EBI-1048945; CC Q13554; Q3SYF9: KRTAP19-7; NbExp=3; IntAct=EBI-1058722, EBI-10241353; CC Q13554; Q9UI95: MAD2L2; NbExp=3; IntAct=EBI-1058722, EBI-77889; CC Q13554; Q9BUE0: MED18; NbExp=3; IntAct=EBI-1058722, EBI-394640; CC Q13554; Q9UBU8: MORF4L1; NbExp=3; IntAct=EBI-1058722, EBI-399246; CC Q13554; Q9UBU8-2: MORF4L1; NbExp=3; IntAct=EBI-1058722, EBI-10288852; CC Q13554; Q9Y3B7: MRPL11; NbExp=3; IntAct=EBI-1058722, EBI-5453723; CC Q13554; Q93100: PHKB; NbExp=3; IntAct=EBI-1058722, EBI-740559; CC Q13554; Q969H6: POP5; NbExp=3; IntAct=EBI-1058722, EBI-366525; CC Q13554; P61225: RAP2B; NbExp=3; IntAct=EBI-1058722, EBI-750871; CC Q13554; O43251: RBFOX2; NbExp=3; IntAct=EBI-1058722, EBI-746056; CC Q13554; Q93062: RBPMS; NbExp=3; IntAct=EBI-1058722, EBI-740322; CC Q13554; P62913: RPL11; NbExp=3; IntAct=EBI-1058722, EBI-354380; CC Q13554; Q9NTN9-3: SEMA4G; NbExp=3; IntAct=EBI-1058722, EBI-9089805; CC Q13554; Q5W111: SPRYD7; NbExp=3; IntAct=EBI-1058722, EBI-10248098; CC Q13554; Q8N0Z6: TTC5; NbExp=3; IntAct=EBI-1058722, EBI-9526213; CC Q13554; B3KWQ7; NbExp=3; IntAct=EBI-1058722, EBI-10175974; CC Q13554-3; O00154-4: ACOT7; NbExp=3; IntAct=EBI-11523526, EBI-12007918; CC Q13554-3; P15289: ARSA; NbExp=3; IntAct=EBI-11523526, EBI-2117357; CC Q13554-3; Q9UQM7: CAMK2A; NbExp=3; IntAct=EBI-11523526, EBI-1383687; CC Q13554-3; Q13557-8: CAMK2D; NbExp=4; IntAct=EBI-11523526, EBI-11534483; CC Q13554-3; Q13555-5: CAMK2G; NbExp=3; IntAct=EBI-11523526, EBI-12020154; CC Q13554-3; Q9NUG4: CCM2L; NbExp=3; IntAct=EBI-11523526, EBI-350645; CC Q13554-3; Q16543: CDC37; NbExp=3; IntAct=EBI-11523526, EBI-295634; CC Q13554-3; Q6P1R4: DUS1L; NbExp=3; IntAct=EBI-11523526, EBI-6660325; CC Q13554-3; O43790: KRT86; NbExp=3; IntAct=EBI-11523526, EBI-9996498; CC Q13554-3; Q07627: KRTAP1-1; NbExp=3; IntAct=EBI-11523526, EBI-11959885; CC Q13554-3; Q7Z4W3: KRTAP19-3; NbExp=3; IntAct=EBI-11523526, EBI-12020132; CC Q13554-3; Q3LI66: KRTAP6-2; NbExp=3; IntAct=EBI-11523526, EBI-11962084; CC Q13554-3; Q3LI67: KRTAP6-3; NbExp=3; IntAct=EBI-11523526, EBI-22311199; CC Q13554-3; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-11523526, EBI-16439278; CC Q13554-3; Q9UBU8-2: MORF4L1; NbExp=3; IntAct=EBI-11523526, EBI-10288852; CC Q13554-3; Q15014: MORF4L2; NbExp=3; IntAct=EBI-11523526, EBI-399257; CC Q13554-3; Q9Y3B7: MRPL11; NbExp=3; IntAct=EBI-11523526, EBI-5453723; CC Q13554-3; Q96T60: PNKP; NbExp=3; IntAct=EBI-11523526, EBI-1045072; CC Q13554-3; Q9BUI4: POLR3C; NbExp=3; IntAct=EBI-11523526, EBI-5452779; CC Q13554-3; P61225: RAP2B; NbExp=3; IntAct=EBI-11523526, EBI-750871; CC Q13554-3; P78317: RNF4; NbExp=3; IntAct=EBI-11523526, EBI-2340927; CC Q13554-3; O14787-2: TNPO2; NbExp=3; IntAct=EBI-11523526, EBI-12076664; CC Q13554-3; Q9Y5L0: TNPO3; NbExp=3; IntAct=EBI-11523526, EBI-1042571; CC Q13554-3; Q8N0Z6: TTC5; NbExp=3; IntAct=EBI-11523526, EBI-9526213; CC Q13554-3; P26640: VARS1; NbExp=3; IntAct=EBI-11523526, EBI-355765; CC Q13554-3; A0A0C4DGF1: ZBTB32; NbExp=3; IntAct=EBI-11523526, EBI-10188476; CC Q13554-3; Q9UJ78-2: ZMYM5; NbExp=3; IntAct=EBI-11523526, EBI-17634549; CC Q13554-3; P32502: GCD7; Xeno; NbExp=3; IntAct=EBI-11523526, EBI-6260; CC Q13554-3; P16622: HEM15; Xeno; NbExp=3; IntAct=EBI-11523526, EBI-8261; CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton CC {ECO:0000269|PubMed:21529938}. Cytoplasm, cytoskeleton, microtubule CC organizing center, centrosome {ECO:0000250}. Sarcoplasmic reticulum CC membrane {ECO:0000269|PubMed:21529938}; Peripheral membrane protein CC {ECO:0000269|PubMed:21529938}; Cytoplasmic side CC {ECO:0000269|PubMed:21529938}. Synapse {ECO:0000250|UniProtKB:P08413}. CC Note=In slow-twitch muscle, evenly distributed between longitudinal SR CC and junctional SR. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=8; CC Comment=The variable region of the CAMK2B protein is encoded by at CC least 7 exons (V1 to V7). Alternative splicing within this region CC gives rise to CAMK2B isoforms.; CC Name=4; CC IsoId=Q13554-1; Sequence=Displayed; CC Name=1; Synonyms=Beta; CC IsoId=Q13554-2; Sequence=VSP_004776; CC Name=2; Synonyms=Beta1, Beta'E; CC IsoId=Q13554-3; Sequence=VSP_004770, VSP_004771, VSP_004775, CC VSP_004776; CC Name=3; Synonyms=Beta2; CC IsoId=Q13554-4; Sequence=VSP_004770, VSP_004771, VSP_004774, CC VSP_004776; CC Name=5; Synonyms=Beta4, BetaE; CC IsoId=Q13554-5; Sequence=VSP_004770, VSP_004771, VSP_004776; CC Name=6; Synonyms=Beta6; CC IsoId=Q13554-6; Sequence=VSP_004773, VSP_004776, VSP_004777; CC Name=7; Synonyms=Beta7; CC IsoId=Q13554-7; Sequence=VSP_004770, VSP_004772; CC Name=8; CC IsoId=Q13554-8; Sequence=VSP_041219, VSP_004776; CC -!- TISSUE SPECIFICITY: Widely expressed. Expressed in adult and fetal CC brain. Expression is slightly lower in fetal brain. Expressed in CC skeletal muscle. {ECO:0000269|PubMed:16690701}. CC -!- INDUCTION: Activity is induced in skeletal muscle during exercise. CC {ECO:0000269|PubMed:16690701}. CC -!- DOMAIN: The CAMK2 protein kinases contain a unique C-terminal subunit CC association domain responsible for oligomerization. CC -!- PTM: Autophosphorylation of Thr-287 following activation by CC Ca(2+)/calmodulin. Phosphorylation of Thr-287 locks the kinase into an CC activated state. {ECO:0000269|PubMed:14722083, CC ECO:0000269|PubMed:16690701}. CC -!- DISEASE: Intellectual developmental disorder, autosomal dominant 54 CC (MRD54) [MIM:617799]: A disorder characterized by significantly below CC average general intellectual functioning associated with impairments in CC adaptive behavior and manifested during the developmental period. CC {ECO:0000269|PubMed:29100089, ECO:0000269|PubMed:29560374}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. CaMK subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC99802.1; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF078803; AAD42035.1; -; mRNA. DR EMBL; AF081572; AAD42036.1; -; mRNA. DR EMBL; AF081924; AAD42037.1; -; mRNA. DR EMBL; AF083419; AAD42038.1; -; mRNA. DR EMBL; AF140350; AAD42070.1; -; mRNA. DR EMBL; U23460; AAC99802.1; ALT_FRAME; mRNA. DR EMBL; AF112472; AAD03744.1; -; mRNA. DR EMBL; AF112471; AAD03743.1; -; mRNA. DR EMBL; AJ252236; CAB65120.1; -; mRNA. DR EMBL; AJ252237; CAB65121.1; -; mRNA. DR EMBL; AJ252238; CAB65122.1; -; mRNA. DR EMBL; AK290148; BAF82837.1; -; mRNA. DR EMBL; AK315663; BAG38029.1; -; mRNA. DR EMBL; CH236960; EAL23756.1; -; Genomic_DNA. DR EMBL; CH236960; EAL23757.1; -; Genomic_DNA. DR EMBL; CH236960; EAL23758.1; -; Genomic_DNA. DR EMBL; CH236960; EAL23759.1; -; Genomic_DNA. DR EMBL; CH236960; EAL23760.1; -; Genomic_DNA. DR EMBL; CH236960; EAL23761.1; -; Genomic_DNA. DR EMBL; CH236960; EAL23762.1; -; Genomic_DNA. DR EMBL; BC019070; AAH19070.1; -; mRNA. DR EMBL; U50358; AAB16863.1; -; mRNA. DR CCDS; CCDS43573.1; -. [Q13554-8] DR CCDS; CCDS5483.1; -. [Q13554-1] DR CCDS; CCDS5484.1; -. [Q13554-2] DR CCDS; CCDS5485.1; -. [Q13554-5] DR CCDS; CCDS5486.1; -. [Q13554-3] DR CCDS; CCDS5487.1; -. [Q13554-6] DR CCDS; CCDS5488.1; -. [Q13554-4] DR CCDS; CCDS5489.1; -. [Q13554-7] DR RefSeq; NP_001211.3; NM_001220.4. [Q13554-1] DR RefSeq; NP_001280099.1; NM_001293170.2. [Q13554-2] DR RefSeq; NP_742075.1; NM_172078.3. [Q13554-2] DR RefSeq; NP_742076.1; NM_172079.3. [Q13554-5] DR RefSeq; NP_742077.1; NM_172080.3. [Q13554-8] DR RefSeq; NP_742078.1; NM_172081.3. [Q13554-3] DR RefSeq; NP_742079.1; NM_172082.3. [Q13554-6] DR RefSeq; NP_742080.1; NM_172083.3. [Q13554-4] DR RefSeq; NP_742081.1; NM_172084.3. [Q13554-7] DR PDB; 3BHH; X-ray; 2.40 A; A/B/C/D=11-303. DR PDB; 7URW; X-ray; 3.11 A; A/B/C/D/E/F/G=534-666. DR PDB; 7URY; X-ray; 2.64 A; A/B/C/D/E/F/G=534-666. DR PDB; 7URZ; X-ray; 3.45 A; A/B/C/G=534-666. DR PDBsum; 3BHH; -. DR PDBsum; 7URW; -. DR PDBsum; 7URY; -. DR PDBsum; 7URZ; -. DR AlphaFoldDB; Q13554; -. DR SMR; Q13554; -. DR BioGRID; 107266; 186. DR DIP; DIP-39770N; -. DR FunCoup; Q13554; 2064. DR IntAct; Q13554; 131. DR MINT; Q13554; -. DR STRING; 9606.ENSP00000379098; -. DR BindingDB; Q13554; -. DR ChEMBL; CHEMBL4121; -. DR DrugBank; DB07168; [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-(methylamino)pyrimidin-2-yl}amino)phenyl]acetonitrile. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB12571; Rimacalib. DR DrugCentral; Q13554; -. DR GuidetoPHARMACOLOGY; 1556; -. DR GlyCosmos; Q13554; 2 sites, 1 glycan. DR GlyGen; Q13554; 7 sites, 1 O-linked glycan (5 sites). DR iPTMnet; Q13554; -. DR PhosphoSitePlus; Q13554; -. DR SwissPalm; Q13554; -. DR BioMuta; CAMK2B; -. DR DMDM; 334302890; -. DR jPOST; Q13554; -. DR MassIVE; Q13554; -. DR PaxDb; 9606-ENSP00000379098; -. DR PeptideAtlas; Q13554; -. DR ProteomicsDB; 59530; -. [Q13554-1] DR ProteomicsDB; 59531; -. [Q13554-2] DR ProteomicsDB; 59532; -. [Q13554-3] DR ProteomicsDB; 59533; -. [Q13554-4] DR ProteomicsDB; 59534; -. [Q13554-5] DR ProteomicsDB; 59535; -. [Q13554-6] DR ProteomicsDB; 59536; -. [Q13554-7] DR ProteomicsDB; 59537; -. [Q13554-8] DR Pumba; Q13554; -. DR Antibodypedia; 3482; 548 antibodies from 39 providers. DR DNASU; 816; -. DR Ensembl; ENST00000258682.10; ENSP00000258682.6; ENSG00000058404.22. [Q13554-8] DR Ensembl; ENST00000346990.8; ENSP00000326518.5; ENSG00000058404.22. [Q13554-7] DR Ensembl; ENST00000347193.8; ENSP00000326544.6; ENSG00000058404.22. [Q13554-6] DR Ensembl; ENST00000350811.7; ENSP00000326375.5; ENSG00000058404.22. [Q13554-2] DR Ensembl; ENST00000353625.8; ENSP00000326427.5; ENSG00000058404.22. [Q13554-4] DR Ensembl; ENST00000358707.7; ENSP00000351542.3; ENSG00000058404.22. [Q13554-3] DR Ensembl; ENST00000395747.6; ENSP00000379096.2; ENSG00000058404.22. [Q13554-5] DR Ensembl; ENST00000395749.7; ENSP00000379098.2; ENSG00000058404.22. [Q13554-1] DR Ensembl; ENST00000440254.6; ENSP00000397937.2; ENSG00000058404.22. [Q13554-2] DR Ensembl; ENST00000700285.1; ENSP00000514918.1; ENSG00000058404.22. [Q13554-2] DR GeneID; 816; -. DR KEGG; hsa:816; -. DR MANE-Select; ENST00000395749.7; ENSP00000379098.2; NM_001220.5; NP_001211.3. DR UCSC; uc003tkp.3; human. [Q13554-1] DR AGR; HGNC:1461; -. DR ClinPGx; PA91; -. DR CTD; 816; -. DR DisGeNET; 816; -. DR GeneCards; CAMK2B; -. DR HGNC; HGNC:1461; CAMK2B. DR HPA; ENSG00000058404; Group enriched (brain, heart muscle, skeletal muscle, tongue). DR MalaCards; CAMK2B; -. DR MIM; 607707; gene. DR MIM; 617799; phenotype. DR OpenTargets; ENSG00000058404; -. DR Orphanet; 178469; Autosomal dominant non-syndromic intellectual disability. DR VEuPathDB; HostDB:ENSG00000058404; -. DR eggNOG; KOG0033; Eukaryota. DR GeneTree; ENSGT00940000158973; -. DR HOGENOM; CLU_000288_71_0_1; -. DR InParanoid; Q13554; -. DR OMA; MEFHRFY; -. DR OrthoDB; 336747at2759; -. DR PAN-GO; Q13554; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q13554; -. DR BRENDA; 2.7.11.17; 2681. DR PathwayCommons; Q13554; -. DR Reactome; R-HSA-111932; CaMK IV-mediated phosphorylation of CREB. DR Reactome; R-HSA-3371571; HSF1-dependent transactivation. DR Reactome; R-HSA-399719; Trafficking of AMPA receptors. DR Reactome; R-HSA-438066; Unblocking of NMDA receptors, glutamate binding and activation. DR Reactome; R-HSA-442729; CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde. DR Reactome; R-HSA-442982; Ras activation upon Ca2+ influx through NMDA receptor. DR Reactome; R-HSA-5576892; Phase 0 - rapid depolarisation. DR Reactome; R-HSA-5578775; Ion homeostasis. DR Reactome; R-HSA-5673000; RAF activation. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants. DR Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions. DR Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF. DR Reactome; R-HSA-877300; Interferon gamma signaling. DR Reactome; R-HSA-9022692; Regulation of MECP2 expression and activity. DR Reactome; R-HSA-936837; Ion transport by P-type ATPases. DR Reactome; R-HSA-9609736; Assembly and cell surface presentation of NMDA receptors. DR Reactome; R-HSA-9617324; Negative regulation of NMDA receptor-mediated neuronal transmission. DR Reactome; R-HSA-9620244; Long-term potentiation. DR Reactome; R-HSA-9649948; Signaling downstream of RAS mutants. DR Reactome; R-HSA-9656223; Signaling by RAF1 mutants. DR SignaLink; Q13554; -. DR SIGNOR; Q13554; -. DR Agora; ENSG00000058404; -. DR BioGRID-ORCS; 816; 18 hits in 1181 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; CAMK2B; human. DR EvolutionaryTrace; Q13554; -. DR GeneWiki; CAMK2B; -. DR GenomeRNAi; 816; -. DR Pharos; Q13554; Tchem. DR PRO; PR:Q13554; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; Q13554; protein. DR Bgee; ENSG00000058404; Expressed in cerebellar cortex and 171 other cell types or tissues. DR ExpressionAtlas; Q13554; baseline and differential. DR GO; GO:0005954; C:calcium- and calmodulin-dependent protein kinase complex; IDA:BHF-UCL. DR GO; GO:0005813; C:centrosome; IEA:UniProtKB-SubCell. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0030666; C:endocytic vesicle membrane; TAS:Reactome. DR GO; GO:0043005; C:neuron projection; IBA:GO_Central. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0014069; C:postsynaptic density; IBA:GO_Central. DR GO; GO:0033017; C:sarcoplasmic reticulum membrane; IEA:UniProtKB-SubCell. DR GO; GO:0003779; F:actin binding; IEA:UniProtKB-KW. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004683; F:calcium/calmodulin-dependent protein kinase activity; IDA:UniProtKB. DR GO; GO:0005516; F:calmodulin binding; IBA:GO_Central. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW. DR GO; GO:0060291; P:long-term synaptic potentiation; TAS:BHF-UCL. DR GO; GO:0007399; P:nervous system development; IEA:UniProtKB-KW. DR GO; GO:0061003; P:positive regulation of dendritic spine morphogenesis; ISS:UniProtKB. DR GO; GO:0010976; P:positive regulation of neuron projection development; ISS:UniProtKB. DR GO; GO:0090129; P:positive regulation of synapse maturation; ISS:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0051924; P:regulation of calcium ion transport; TAS:UniProtKB. DR GO; GO:0060998; P:regulation of dendritic spine development; TAS:UniProtKB. DR GO; GO:0048169; P:regulation of long-term neuronal synaptic plasticity; TAS:UniProtKB. DR GO; GO:2001222; P:regulation of neuron migration; IMP:UniProtKB. DR GO; GO:0048168; P:regulation of neuronal synaptic plasticity; IBA:GO_Central. DR GO; GO:1903076; P:regulation of protein localization to plasma membrane; IBA:GO_Central. DR GO; GO:0014733; P:regulation of skeletal muscle adaptation; TAS:UniProtKB. DR GO; GO:0051823; P:regulation of synapse structural plasticity; TAS:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR CDD; cd14086; STKc_CaMKII; 1. DR FunFam; 1.10.510.10:FF:000001; Calcium/calmodulin-dependent protein kinase type II subunit delta; 1. DR FunFam; 3.30.200.20:FF:000002; Calcium/calmodulin-dependent protein kinase type II subunit delta isoform 2; 1. DR FunFam; 3.10.450.50:FF:000001; calcium/calmodulin-dependent protein kinase type II subunit gamma isoform X1; 1. DR Gene3D; 3.10.450.50; -; 1. DR Gene3D; 6.10.140.620; -; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR013543; Ca/CaM-dep_prot_kinase-assoc. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR032710; NTF2-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24347; SERINE/THREONINE-PROTEIN KINASE; 1. DR Pfam; PF08332; CaMKII_AD; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF54427; NTF2-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Actin-binding; Alternative splicing; ATP-binding; KW Calmodulin-binding; Cytoplasm; Cytoskeleton; Developmental protein; KW Differentiation; Intellectual disability; Kinase; Membrane; Neurogenesis; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Sarcoplasmic reticulum; KW Serine/threonine-protein kinase; Synapse; Transferase. FT CHAIN 1..666 FT /note="Calcium/calmodulin-dependent protein kinase type II FT subunit beta" FT /id="PRO_0000086096" FT DOMAIN 14..272 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 283..292 FT /note="Autoinhibitory domain" FT /evidence="ECO:0000250" FT REGION 291..301 FT /note="Calmodulin-binding" FT REGION 349..534 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 354..369 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 432..447 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 479..491 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 514..531 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 136 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 20..28 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 43 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 17 FT /note="Phosphotyrosine" FT /evidence="ECO:0000250|UniProtKB:P28652" FT MOD_RES 287 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:16690701" FT MOD_RES 306 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 307 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 367 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P08413" FT MOD_RES 394 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P28652" FT MOD_RES 397 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P08413" FT MOD_RES 400 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:P28652" FT MOD_RES 401 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:24275569" FT VAR_SEQ 316..340 FT /note="Missing (in isoform 8)" FT /evidence="ECO:0000305" FT /id="VSP_041219" FT VAR_SEQ 316 FT /note="V -> A (in isoform 2, isoform 3, isoform 5 and FT isoform 7)" FT /evidence="ECO:0000303|PubMed:10819240, FT ECO:0000303|PubMed:10858498, ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:9060999, FT ECO:0000303|Ref.3" FT /id="VSP_004770" FT VAR_SEQ 317..533 FT /note="Missing (in isoform 7)" FT /evidence="ECO:0000303|PubMed:10858498" FT /id="VSP_004772" FT VAR_SEQ 317..340 FT /note="Missing (in isoform 2, isoform 3 and isoform 5)" FT /evidence="ECO:0000303|PubMed:10819240, FT ECO:0000303|PubMed:10858498, ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:9060999, FT ECO:0000303|Ref.3" FT /id="VSP_004771" FT VAR_SEQ 354..392 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:10819240" FT /id="VSP_004774" FT VAR_SEQ 354..377 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000303|PubMed:10858498" FT /id="VSP_004773" FT VAR_SEQ 379..393 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10819240, FT ECO:0000303|PubMed:10858498, ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:9060999" FT /id="VSP_004775" FT VAR_SEQ 410..533 FT /note="Missing (in isoform 1, isoform 2, isoform 3, isoform FT 5, isoform 6 and isoform 8)" FT /evidence="ECO:0000303|PubMed:10819240, FT ECO:0000303|PubMed:10858498, ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:9060999, FT ECO:0000303|Ref.3" FT /id="VSP_004776" FT VAR_SEQ 559..584 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000303|PubMed:10858498" FT /id="VSP_004777" FT VARIANT 29..666 FT /note="Missing (in MRD54)" FT /evidence="ECO:0000269|PubMed:29100089" FT /id="VAR_080588" FT VARIANT 110 FT /note="E -> K (in MRD54; decreased protein abundance; FT increased autophosphorylation; decreased neuronal FT migration; dbSNP:rs1554402092)" FT /evidence="ECO:0000269|PubMed:29100089" FT /id="VAR_080589" FT VARIANT 139 FT /note="P -> L (in MRD54; decreased protein abundance; FT increased autophosphorylation; decreased neuronal FT migration; dbSNP:rs1554389088)" FT /evidence="ECO:0000269|PubMed:29100089" FT /id="VAR_080590" FT VARIANT 213 FT /note="P -> L (in MRD54; dbSNP:rs1554387293)" FT /evidence="ECO:0000269|PubMed:29560374" FT /id="VAR_081162" FT VARIANT 237 FT /note="E -> K (in MRD54; no effect on protein abundance; FT increased autophosphorylation; decreased neuronal FT migration; dbSNP:rs1554386687)" FT /evidence="ECO:0000269|PubMed:29100089" FT /id="VAR_080591" FT VARIANT 284 FT /note="R -> S (in MRD54; dbSNP:rs1554385203)" FT /evidence="ECO:0000269|PubMed:29560374" FT /id="VAR_081163" FT VARIANT 301 FT /note="K -> E (in MRD54; no effect on protein abundance; FT loss of autophosphorylation; changed function in neuronal FT migration; dbSNP:rs1554385111)" FT /evidence="ECO:0000269|PubMed:29100089" FT /id="VAR_080592" FT VARIANT 489 FT /note="P -> L (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs555460132)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_045581" FT VARIANT 510 FT /note="E -> K (in dbSNP:rs35452727)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_045582" FT CONFLICT 68 FT /note="L -> V (in Ref. 3; AAD03744/AAD03743)" FT /evidence="ECO:0000305" FT CONFLICT 535 FT /note="K -> N (in Ref. 8; AAB16863)" FT /evidence="ECO:0000305" FT STRAND 14..19 FT /evidence="ECO:0007829|PDB:3BHH" FT STRAND 27..33 FT /evidence="ECO:0007829|PDB:3BHH" FT TURN 34..36 FT /evidence="ECO:0007829|PDB:3BHH" FT STRAND 39..46 FT /evidence="ECO:0007829|PDB:3BHH" FT HELIX 52..67 FT /evidence="ECO:0007829|PDB:3BHH" FT STRAND 76..81 FT /evidence="ECO:0007829|PDB:3BHH" FT STRAND 83..91 FT /evidence="ECO:0007829|PDB:3BHH" FT STRAND 95..97 FT /evidence="ECO:0007829|PDB:3BHH" FT HELIX 98..102 FT /evidence="ECO:0007829|PDB:3BHH" FT HELIX 110..129 FT /evidence="ECO:0007829|PDB:3BHH" FT HELIX 139..141 FT /evidence="ECO:0007829|PDB:3BHH" FT STRAND 142..145 FT /evidence="ECO:0007829|PDB:3BHH" FT STRAND 153..155 FT /evidence="ECO:0007829|PDB:3BHH" FT HELIX 178..180 FT /evidence="ECO:0007829|PDB:3BHH" FT HELIX 183..186 FT /evidence="ECO:0007829|PDB:3BHH" FT HELIX 194..209 FT /evidence="ECO:0007829|PDB:3BHH" FT HELIX 219..228 FT /evidence="ECO:0007829|PDB:3BHH" FT TURN 235..238 FT /evidence="ECO:0007829|PDB:3BHH" FT STRAND 239..241 FT /evidence="ECO:0007829|PDB:3BHH" FT HELIX 243..252 FT /evidence="ECO:0007829|PDB:3BHH" FT TURN 257..259 FT /evidence="ECO:0007829|PDB:3BHH" FT HELIX 263..266 FT /evidence="ECO:0007829|PDB:3BHH" FT HELIX 270..273 FT /evidence="ECO:0007829|PDB:3BHH" FT HELIX 275..278 FT /evidence="ECO:0007829|PDB:3BHH" FT HELIX 285..298 FT /evidence="ECO:0007829|PDB:3BHH" FT HELIX 534..551 FT /evidence="ECO:0007829|PDB:7URY" FT HELIX 554..560 FT /evidence="ECO:0007829|PDB:7URY" FT STRAND 561..568 FT /evidence="ECO:0007829|PDB:7URY" FT HELIX 570..572 FT /evidence="ECO:0007829|PDB:7URY" FT STRAND 577..580 FT /evidence="ECO:0007829|PDB:7URY" FT HELIX 581..588 FT /evidence="ECO:0007829|PDB:7URY" FT HELIX 592..594 FT /evidence="ECO:0007829|PDB:7URY" FT STRAND 598..609 FT /evidence="ECO:0007829|PDB:7URY" FT STRAND 611..626 FT /evidence="ECO:0007829|PDB:7URY" FT STRAND 632..646 FT /evidence="ECO:0007829|PDB:7URY" FT STRAND 649..659 FT /evidence="ECO:0007829|PDB:7URY" FT CONFLICT Q13554-3:316 FT /note="A -> V (in Ref. 1; AAD42036)" FT /evidence="ECO:0000305" SQ SEQUENCE 666 AA; 72678 MW; 8CACFC3E392C3857 CRC64; MATTVTCTRF TDEYQLYEDI GKGAFSVVRR CVKLCTGHEY AAKIINTKKL SARDHQKLER EARICRLLKH SNIVRLHDSI SEEGFHYLVF DLVTGGELFE DIVAREYYSE ADASHCIQQI LEAVLHCHQM GVVHRDLKPE NLLLASKCKG AAVKLADFGL AIEVQGDQQA WFGFAGTPGY LSPEVLRKEA YGKPVDIWAC GVILYILLVG YPPFWDEDQH KLYQQIKAGA YDFPSPEWDT VTPEAKNLIN QMLTINPAKR ITAHEALKHP WVCQRSTVAS MMHRQETVEC LKKFNARRKL KGAILTTMLA TRNFSVGRQT TAPATMSTAA SGTTMGLVEQ AKSLLNKKAD GVKPQTNSTK NSAAATSPKG TLPPAALEPQ TTVIHNPVDG IKESSDSANT TIEDEDAKAP RVPDILSSVR RGSGAPEAEG PLPCPSPAPF SPLPAPSPRI SDILNSVRRG SGTPEAEGPL SAGPPPCLSP ALLGPLSSPS PRISDILNSV RRGSGTPEAE GPSPVGPPPC PSPTIPGPLP TPSRKQEIIK TTEQLIEAVN NGDFEAYAKI CDPGLTSFEP EALGNLVEGM DFHRFYFENL LAKNSKPIHT TILNPHVHVI GEDAACIAYI RLTQYIDGQG RPRTSQSEET RVWHRRDGKW QNVHFHCSGA PVAPLQ // ID KPCZ_HUMAN Reviewed; 592 AA. AC Q05513; A8K4N0; A8MU64; B7Z2J7; E9PCW2; Q15207; Q5SYT5; Q969S4; DT 01-FEB-1994, integrated into UniProtKB/Swiss-Prot. DT 21-JUN-2005, sequence version 4. DT 28-JAN-2026, entry version 253. DE RecName: Full=Protein kinase C zeta type; DE EC=2.7.11.13 {ECO:0000269|PubMed:15084291, ECO:0000269|PubMed:15324659, ECO:0000269|PubMed:36040231}; DE AltName: Full=nPKC-zeta; GN Name=PRKCZ; Synonyms=PKC2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Frontal cortex; RX PubMed=8224878; DOI=10.1016/0378-1119(93)90213-m; RA Barbee J.L., Loomis C.R., Deutscher S.L., Burns D.J.; RT "The cDNA sequence encoding human protein kinase C-zeta."; RL Gene 132:305-306(1993). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3). RC TISSUE=Brain, and Teratocarcinoma; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Colon, and Ovary; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 7-592. RC TISSUE=Hippocampus; RX PubMed=8375396; DOI=10.1111/j.1432-1033.1993.tb18179.x; RA Kochs G., Hummel R., Meyer D., Hug H., Marme D., Sarre T.F.; RT "Activation and substrate specificity of the human protein kinase C alpha RT and zeta isoenzymes."; RL Eur. J. Biochem. 216:597-606(1993). RN [7] RP SUBCELLULAR LOCATION. RX PubMed=7597083; DOI=10.1073/pnas.92.13.6072; RA Stuart R.O., Nigam S.K.; RT "Regulated assembly of tight junctions by protein kinase C."; RL Proc. Natl. Acad. Sci. U.S.A. 92:6072-6076(1995). RN [8] RP FUNCTION IN ACTIVATION OF MAP2K1/MEK1 AND MAPK1/ERK2. RX PubMed=9447975; DOI=10.1128/mcb.18.2.790; RA Schoenwasser D.C., Marais R.M., Marshall C.J., Parker P.J.; RT "Activation of the mitogen-activated protein kinase/extracellular signal- RT regulated kinase pathway by conventional, novel, and atypical protein RT kinase C isotypes."; RL Mol. Cell. Biol. 18:790-798(1998). RN [9] RP INTERACTION WITH SQSTM1, AND SUBCELLULAR LOCATION. RX PubMed=9566925; DOI=10.1128/mcb.18.5.3069; RA Sanchez P., De Carcer G., Sandoval I.V., Moscat J., Diaz-Meco M.T.; RT "Localization of atypical protein kinase C isoforms into lysosome-targeted RT endosomes through interaction with p62."; RL Mol. Cell. Biol. 18:3069-3080(1998). RN [10] RP PHOSPHORYLATION AT THR-410 BY PDPK1. RX PubMed=9768361; DOI=10.1016/s0960-9822(98)70444-0; RA Chou M.M., Hou W., Johnson J., Graham L.K., Lee M.H., Chen C.S., RA Newton A.C., Schaffhausen B.S., Toker A.; RT "Regulation of protein kinase C zeta by PI 3-kinase and PDK-1."; RL Curr. Biol. 8:1069-1077(1998). RN [11] RP INTERACTION WITH SQSTM1 AND IKBKB. RX PubMed=10356400; DOI=10.1093/emboj/18.11.3044; RA Sanz L., Sanchez P., Lallena M.-J., Diaz-Meco M.T., Moscat J.; RT "The interaction of p62 with RIP links the atypical PKCs to NF-kappaB RT activation."; RL EMBO J. 18:3044-3053(1999). RN [12] RP FUNCTION IN ACTIVATION OF MAPK1/ERK2. RX PubMed=11035106; DOI=10.4049/jimmunol.165.8.4632; RA Monick M.M., Carter A.B., Flaherty D.M., Peterson M.W., Hunninghake G.W.; RT "Protein kinase C zeta plays a central role in activation of the p42/44 RT mitogen-activated protein kinase by endotoxin in alveolar macrophages."; RL J. Immunol. 165:4632-4639(2000). RN [13] RP INTERACTION WITH PARD6A; PARD6B AND PARD6G. RC TISSUE=Neuroblastoma; RX PubMed=11260256; DOI=10.1046/j.1365-2443.2001.00404.x; RA Noda Y., Takeya R., Ohno S., Naito S., Ito T., Sumimoto H.; RT "Human homologues of the Caenorhabditis elegans cell polarity protein PAR6 RT as an adaptor that links the small GTPases Rac and Cdc42 to atypical RT protein kinase C."; RL Genes Cells 6:107-119(2001). RN [14] RP INTERACTION WITH PDPK1, AND PHOSPHORYLATION. RX PubMed=11781095; DOI=10.1021/bi010719z; RA Hodgkinson C.P., Sale G.J.; RT "Regulation of both PDK1 and the phosphorylation of PKC-zeta and -delta by RT a C-terminal PRK2 fragment."; RL Biochemistry 41:561-569(2002). RN [15] RP FUNCTION IN ACTIVATION OF AKT3. RX PubMed=12162751; DOI=10.1021/bi026065r; RA Hodgkinson C.P., Sale E.M., Sale G.J.; RT "Characterization of PDK2 activity against protein kinase B gamma."; RL Biochemistry 41:10351-10359(2002). RN [16] RP INTERACTION WITH SQSTM1 AND PAWR. RX PubMed=11755531; DOI=10.1016/s0014-5793(01)03224-0; RA Chang S., Kim J.H., Shin J.; RT "p62 forms a ternary complex with PKCzeta and PAR-4 and antagonizes PAR-4- RT induced PKCzeta inhibition."; RL FEBS Lett. 510:57-61(2002). RN [17] RP INTERACTION WITH PARD3. RX PubMed=12234671; DOI=10.1016/s0378-1119(02)00681-9; RA Gao L., Macara I.G., Joberty G.; RT "Multiple splice variants of Par3 and of a novel related gene, Par3L, RT produce proteins with different binding properties."; RL Gene 294:99-107(2002). RN [18] RP INTERACTION WITH ADAP1. RX PubMed=12893243; DOI=10.1016/s0006-291x(03)01187-2; RA Zemlickova E., Dubois T., Kerai P., Clokie S., Cronshaw A.D., RA Wakefield R.I.D., Johannes F.-J., Aitken A.; RT "Centaurin-alpha(1) associates with and is phosphorylated by isoforms of RT protein kinase C."; RL Biochem. Biophys. Res. Commun. 307:459-465(2003). RN [19] RP INTERACTION WITH SQSTM1 AND PARD6B, DOMAIN, AND MUTAGENESIS OF LYS-19; RP ASP-62 AND ASP-66. RX PubMed=12887891; DOI=10.1016/s1097-2765(03)00246-6; RA Wilson M.I., Gill D.J., Perisic O., Quinn M.T., Williams R.L.; RT "PB1 domain-mediated heterodimerization in NADPH oxidase and signaling RT complexes of atypical protein kinase C with Par6 and p62."; RL Mol. Cell 12:39-50(2003). RN [20] RP FUNCTION IN PHOSPHORYLATION OF MARK2 AND MARK3, AND CATALYTIC ACTIVITY. RX PubMed=15084291; DOI=10.1016/j.cub.2004.04.007; RA Hurov J.B., Watkins J.L., Piwnica-Worms H.; RT "Atypical PKC phosphorylates PAR-1 kinases to regulate localization and RT activity."; RL Curr. Biol. 14:736-741(2004). RN [21] RP FUNCTION IN PHOSPHORYLATION OF MARK2, AND CATALYTIC ACTIVITY. RX PubMed=15324659; DOI=10.1016/j.cub.2004.08.021; RA Suzuki A., Hirata M., Kamimura K., Maniwa R., Yamanaka T., Mizuno K., RA Kishikawa M., Hirose H., Amano Y., Izumi N., Miwa Y., Ohno S.; RT "aPKC acts upstream of PAR-1b in both the establishment and maintenance of RT mammalian epithelial polarity."; RL Curr. Biol. 14:1425-1435(2004). RN [22] RP PHOSPHORYLATION AT THR-410 BY PI3K. RX PubMed=15314172; DOI=10.1128/mcb.24.17.7643-7653.2004; RA Castoria G., Migliaccio A., Di Domenico M., Lombardi M., de Falco A., RA Varricchio L., Bilancio A., Barone M.V., Auricchio F.; RT "Role of atypical protein kinase C in estradiol-triggered G1/S progression RT of MCF-7 cells."; RL Mol. Cell. Biol. 24:7643-7653(2004). RN [23] RP INTERACTION WITH WDFY2. RX PubMed=16792529; DOI=10.1042/bj20060511; RA Fritzius T., Burkard G., Haas E., Heinrich J., Schweneker M., Bosse M., RA Zimmermann S., Frey A.D., Caelers A., Bachmann A.S., Moelling K.; RT "A WD-FYVE protein binds to the kinases Akt and PKCzeta/lambda."; RL Biochem. J. 399:9-20(2006). RN [24] RP FUNCTION, INTERACTION WITH VAMP2, COMPLEX FORMATION WITH VAMP2 AND WDFY2, RP AND SUBCELLULAR LOCATION. RX PubMed=17313651; DOI=10.1111/j.1742-4658.2007.05702.x; RA Fritzius T., Frey A.D., Schweneker M., Mayer D., Moelling K.; RT "WD-repeat-propeller-FYVE protein, ProF, binds VAMP2 and protein kinase RT Czeta."; RL FEBS J. 274:1552-1566(2007). RN [25] RP INTERACTION WITH WWC1 AND DDR1. RX PubMed=18190796; DOI=10.1016/j.bbamcr.2007.12.007; RA Hilton H.N., Stanford P.M., Harris J., Oakes S.R., Kaplan W., Daly R.J., RA Ormandy C.J.; RT "KIBRA interacts with discoidin domain receptor 1 to modulate collagen- RT induced signalling."; RL Biochim. Biophys. Acta 1783:383-393(2008). RN [26] RP RETRACTED PAPER. RX PubMed=18321849; DOI=10.1074/jbc.m708208200; RA Song P., Xie Z., Wu Y., Xu J., Dong Y., Zou M.H.; RT "Protein kinase Czeta-dependent LKB1 serine 428 phosphorylation increases RT LKB1 nucleus export and apoptosis in endothelial cells."; RL J. Biol. Chem. 283:12446-12455(2008). RN [27] RP RETRACTION NOTICE OF PUBMED:18321849. RX PubMed=31519760; DOI=10.1074/jbc.w119.010661; RA Song P., Xie Z., Wu Y., Dong Y., Zou M.H.; RT "Withdrawal: Protein kinase Czeta-dependent LKB1 serine 428 phosphorylation RT increases LKB1 nucleus export and apoptosis in endothelial cells."; RL J. Biol. Chem. 294:13831-13831(2019). RN [28] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-560, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [30] RP SUBCELLULAR LOCATION, SUBUNIT, AND PHOSPHORYLATION AT THR-410. RX PubMed=20332120; DOI=10.1242/jcs.059329; RA Lampugnani M.G., Orsenigo F., Rudini N., Maddaluno L., Boulday G., RA Chapon F., Dejana E.; RT "CCM1 regulates vascular-lumen organization by inducing endothelial RT polarity."; RL J. Cell Sci. 123:1073-1080(2010). RN [31] RP REVIEW ON FUNCTION. RX PubMed=12761192; DOI=10.1093/jb/mvg017; RA Hirai T., Chida K.; RT "Protein kinase Czeta (PKCzeta): activation mechanisms and cellular RT functions."; RL J. Biochem. 133:1-7(2003). RN [32] RP REVIEW ON FUNCTION. RX PubMed=16903823; DOI=10.1134/s0006297906070017; RA Liu L.Z., He A.B., Liu X.J., Li Y., Chang Y.S., Fang F.D.; RT "Protein kinase Czeta and glucose uptake."; RL Biochemistry (Mosc.) 71:701-706(2006). RN [33] RP REVIEW ON FUNCTION. RX PubMed=16322752; DOI=10.1038/sj.cdd.4401823; RA Moscat J., Rennert P., Diaz-Meco M.T.; RT "PKCzeta at the crossroad of NF-kappaB and Jak1/Stat6 signaling pathways."; RL Cell Death Differ. 13:702-711(2006). RN [34] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [35] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-560, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [36] RP INTERACTION WITH WWC1; WWC2 AND WWC3. RX PubMed=24682284; DOI=10.1093/molbev/msu115; RA Wennmann D.O., Schmitz J., Wehr M.C., Krahn M.P., Koschmal N., RA Gromnitza S., Schulze U., Weide T., Chekuri A., Skryabin B.V., Gerke V., RA Pavenstadt H., Duning K., Kremerskothen J.; RT "Evolutionary and Molecular Facts Link the WWC Protein Family to Hippo RT Signaling."; RL Mol. Biol. Evol. 31:1710-1723(2014). RN [37] RP INTERACTION WITH APPL1. RX PubMed=26583432; DOI=10.18632/oncotarget.6346; RA Song J., Mu Y., Li C., Bergh A., Miaczynska M., Heldin C.H., Landstroem M.; RT "APPL proteins promote TGFbeta-induced nuclear transport of the TGFbeta RT type I receptor intracellular domain."; RL Oncotarget 7:279-292(2016). RN [38] RP FUNCTION IN PHOSPHORYLATION OF LRRK1, AND CATALYTIC ACTIVITY. RX PubMed=36040231; DOI=10.1042/bcj20220308; RA Malik A.U., Karapetsas A., Nirujogi R.S., Chatterjee D., Phung T.K., RA Wightman M., Gourlay R., Morrice N., Mathea S., Knapp S., Alessi D.R.; RT "PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues RT (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain."; RL Biochem. J. 479:1941-1965(2022). RN [39] RP VARIANT [LARGE SCALE ANALYSIS] PHE-514. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [40] RP VARIANTS [LARGE SCALE ANALYSIS] HIS-84 AND CYS-519. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Calcium- and diacylglycerol-independent serine/threonine- CC protein kinase that functions in phosphatidylinositol 3-kinase (PI3K) CC pathway and mitogen-activated protein (MAP) kinase cascade, and is CC involved in NF-kappa-B activation, mitogenic signaling, cell CC proliferation, cell polarity, inflammatory response and maintenance of CC long-term potentiation (LTP). Upon lipopolysaccharide (LPS) treatment CC in macrophages, or following mitogenic stimuli, functions downstream of CC PI3K to activate MAP2K1/MEK1-MAPK1/ERK2 signaling cascade independently CC of RAF1 activation. Required for insulin-dependent activation of AKT3, CC but may function as an adapter rather than a direct activator. Upon CC insulin treatment may act as a downstream effector of PI3K and CC contribute to the activation of translocation of the glucose CC transporter SLC2A4/GLUT4 and subsequent glucose transport in CC adipocytes. In EGF-induced cells, binds and activates MAP2K5/MEK5- CC MAPK7/ERK5 independently of its kinase activity and can activate JUN CC promoter through MEF2C. Through binding with SQSTM1/p62, functions in CC interleukin-1 signaling and activation of NF-kappa-B with the specific CC adapters RIPK1 and TRAF6. Participates in TNF-dependent transactivation CC of NF-kappa-B by phosphorylating and activating IKBKB kinase, which in CC turn leads to the degradation of NF-kappa-B inhibitors. In migrating CC astrocytes, forms a cytoplasmic complex with PARD6A and is recruited by CC CDC42 to function in the establishment of cell polarity along with the CC microtubule motor and dynein. In association with FEZ1, stimulates CC neuronal differentiation in PC12 cells. In the inflammatory response, CC is required for the T-helper 2 (Th2) differentiation process, including CC interleukin production, efficient activation of JAK1 and the subsequent CC phosphorylation and nuclear translocation of STAT6. May be involved in CC development of allergic airway inflammation (asthma), a process CC dependent on Th2 immune response. In the NF-kappa-B-mediated CC inflammatory response, can relieve SETD6-dependent repression of NF- CC kappa-B target genes by phosphorylating the RELA subunit at 'Ser-311'. CC Phosphorylates VAMP2 in vitro (PubMed:17313651). Phosphorylates and CC activates LRRK1, which phosphorylates RAB proteins involved in CC intracellular trafficking (PubMed:36040231). CC {ECO:0000269|PubMed:11035106, ECO:0000269|PubMed:12162751, CC ECO:0000269|PubMed:15084291, ECO:0000269|PubMed:15324659, CC ECO:0000269|PubMed:17313651, ECO:0000269|PubMed:36040231, CC ECO:0000269|PubMed:9447975}. CC -!- FUNCTION: [Isoform 2]: Involved in late synaptic long term potention CC phase in CA1 hippocampal cells and long term memory maintenance. CC {ECO:0000250|UniProtKB:Q02956}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:15084291, ECO:0000269|PubMed:15324659, CC ECO:0000269|PubMed:36040231}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:15084291, ECO:0000269|PubMed:15324659, CC ECO:0000269|PubMed:36040231}; CC -!- ACTIVITY REGULATION: Atypical PKCs (PRKCI and PRKCZ) exhibit an CC elevated basal enzymatic activity (that may be due to the interaction CC with SMG1 or SQSTM1) and are not regulated by diacylglycerol, CC phosphatidylserine, phorbol esters or calcium ions. Two specific sites, CC Thr-410 (activation loop of the kinase domain) and Thr-560 (turn CC motif), need to be phosphorylated for its full activation. CC Phosphatidylinositol 3,4,5-trisphosphate might be a physiological CC activator (By similarity). Isoform 2: Constitutively active (By CC similarity). {ECO:0000250|UniProtKB:Q02956}. CC -!- SUBUNIT: Forms a ternary complex with SQSTM1 and KCNAB2. Forms another CC ternary complex with SQSTM1 and GABRR3. Forms a complex with SQSTM1 and CC MAP2K5 (By similarity). Interacts with PARD6A, PARD6B, PARD6G and CC SQSTM1. Part of a complex with PARD3, PARD6A or PARD6B or PARD6G and CC CDC42 or RAC1. Interacts with ADAP1/CENTA1. Forms a ternary complex CC composed of SQSTM1 and PAWR. Interacts directly with SQSTM1 (Probable). CC Interacts with IKBKB. Interacts (via the protein kinase domain) with CC WWC1. Forms a tripartite complex with WWC1 and DDR1, but predominantly CC in the absence of collagen. Component of the Par polarity complex, CC composed of at least phosphorylated PRKCZ, PARD3 and TIAM1. Interacts CC with PDPK1 (via N-terminal region). Interacts with WDFY2 (via WD CC repeats 1-3) (PubMed:16792529). Interacts with VAMP2 (PubMed:17313651). CC Forms a complex with WDFY2 and VAMP2 (PubMed:17313651). Interacts with CC APPL1 (PubMed:26583432). Interacts with WWC1, WWC2 and WWC3 CC (PubMed:24682284). {ECO:0000250|UniProtKB:P09217, CC ECO:0000269|PubMed:10356400, ECO:0000269|PubMed:11260256, CC ECO:0000269|PubMed:11755531, ECO:0000269|PubMed:11781095, CC ECO:0000269|PubMed:12234671, ECO:0000269|PubMed:12887891, CC ECO:0000269|PubMed:12893243, ECO:0000269|PubMed:16792529, CC ECO:0000269|PubMed:17313651, ECO:0000269|PubMed:18190796, CC ECO:0000269|PubMed:20332120, ECO:0000269|PubMed:24682284, CC ECO:0000269|PubMed:26583432, ECO:0000269|PubMed:9566925, ECO:0000305}. CC -!- INTERACTION: CC Q05513; Q15109: AGER; NbExp=6; IntAct=EBI-295351, EBI-1646426; CC Q05513; P31749: AKT1; NbExp=2; IntAct=EBI-295351, EBI-296087; CC Q05513; O95999: BCL10; NbExp=3; IntAct=EBI-295351, EBI-958922; CC Q05513; Q07021: C1QBP; NbExp=4; IntAct=EBI-295351, EBI-347528; CC Q05513; P08238: HSP90AB1; NbExp=2; IntAct=EBI-295351, EBI-352572; CC Q05513; P14598: NCF1; NbExp=3; IntAct=EBI-295351, EBI-395044; CC Q05513; P49757-1: NUMB; NbExp=4; IntAct=EBI-295351, EBI-7199607; CC Q05513; Q9NPB6: PARD6A; NbExp=10; IntAct=EBI-295351, EBI-81876; CC Q05513; Q9BYG5: PARD6B; NbExp=18; IntAct=EBI-295351, EBI-295391; CC Q05513; Q9BYG4: PARD6G; NbExp=9; IntAct=EBI-295351, EBI-295417; CC Q05513; P41743: PRKCI; NbExp=10; IntAct=EBI-295351, EBI-286199; CC Q05513; Q04759: PRKCQ; NbExp=3; IntAct=EBI-295351, EBI-374762; CC Q05513; P40337: VHL; NbExp=3; IntAct=EBI-295351, EBI-301246; CC Q05513; P16554: numb; Xeno; NbExp=2; IntAct=EBI-295351, EBI-429581; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17313651, CC ECO:0000269|PubMed:9566925}. Endosome {ECO:0000269|PubMed:9566925}. CC Cell junction {ECO:0000269|PubMed:7597083}. Membrane CC {ECO:0000250|UniProtKB:P09217}; Peripheral membrane protein CC {ECO:0000305}. Note=In the retina, localizes in the terminals of the CC rod bipolar cells (By similarity). Associates with endosomes CC (PubMed:9566925). Presence of KRIT1, CDH5 and RAP1B is required for its CC localization to the cell junction (PubMed:7597083). Colocalizes with CC VAMP2 and WDFY2 in intracellular vesicles (PubMed:17313651). CC Transiently translocates to the membrane of CA1 hippocampal cells in CC response to the induction of long term potentiation (By similarity). CC {ECO:0000250|UniProtKB:P09217, ECO:0000269|PubMed:17313651, CC ECO:0000269|PubMed:7597083, ECO:0000269|PubMed:9566925}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Cytoplasm CC {ECO:0000250|UniProtKB:P09217}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative promoter usage, Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q05513-1; Sequence=Displayed; CC Name=2; Synonyms=PKMzeta {ECO:0000250|UniProtKB:P09217}; CC IsoId=Q05513-2; Sequence=VSP_041904; CC Name=3; CC IsoId=Q05513-3; Sequence=VSP_046347; CC -!- TISSUE SPECIFICITY: Expressed in brain, and to a lesser extent in lung, CC kidney and testis. CC -!- DOMAIN: The PB1 domain mediate mutually exclusive interactions with CC SQSTM1 and PARD6B. {ECO:0000269|PubMed:12887891}. CC -!- DOMAIN: The C1 domain does not bind the diacylglycerol (DAG). CC {ECO:0000269|PubMed:12887891}. CC -!- PTM: CDH5 is required for its phosphorylation at Thr-410. CC Phosphorylated by protein kinase PDPK1; phosphorylation is inhibited by CC the apoptotic C-terminal cleavage product of PKN2. Phosphorylation at CC Thr-410 by PI3K activates the kinase. {ECO:0000269|PubMed:11781095, CC ECO:0000269|PubMed:15314172, ECO:0000269|PubMed:20332120, CC ECO:0000269|PubMed:9768361}. CC -!- MISCELLANEOUS: [Isoform 2]: Produced by alternative promoter usage. CC {ECO:0000250|UniProtKB:P09217}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. PKC subfamily. {ECO:0000305}. CC -!- CAUTION: Reported to phosphorylate STK11 leading to nuclear export of CC STK11, subsequent inhibition of PI3K/Akt signaling, and increased CC apoptosis in vein endothelial cells treated with the oxidant CC peroxynitrite (PubMed:18321849). However this paper was withdrawn by CC the authors due to concerns of image duplication in the figures. Its CC role in protein phosphorylation has been confirmed in other studies CC (PubMed:15084291, PubMed:15324659). {ECO:0000269|PubMed:15084291, CC ECO:0000269|PubMed:15324659, ECO:0000269|PubMed:18321849, CC ECO:0000305|PubMed:31519760}. CC -!- SEQUENCE CAUTION: CC Sequence=CAA78813.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L14283; AAA36488.1; -; mRNA. DR EMBL; BT007082; AAP35745.1; -; mRNA. DR EMBL; AK290995; BAF83684.1; -; mRNA. DR EMBL; AK294649; BAH11833.1; -; mRNA. DR EMBL; AK294782; BAH11883.1; -; mRNA. DR EMBL; AL162271; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL391845; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL590822; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL645703; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC008058; AAH08058.1; -; mRNA. DR EMBL; BC014270; AAH14270.1; -; mRNA. DR EMBL; Z15108; CAA78813.1; ALT_INIT; mRNA. DR CCDS; CCDS37.1; -. [Q05513-1] DR CCDS; CCDS41229.1; -. [Q05513-2] DR CCDS; CCDS55563.1; -. [Q05513-3] DR PIR; JN0877; JN0877. DR RefSeq; NP_001028753.1; NM_001033581.3. [Q05513-2] DR RefSeq; NP_001028754.1; NM_001033582.3. [Q05513-2] DR RefSeq; NP_001229803.1; NM_001242874.3. [Q05513-3] DR RefSeq; NP_002735.3; NM_002744.4. [Q05513-1] DR RefSeq; XP_047281304.1; XM_047425348.1. [Q05513-2] DR RefSeq; XP_054193674.1; XM_054337699.1. [Q05513-2] DR AlphaFoldDB; Q05513; -. DR SMR; Q05513; -. DR BioGRID; 111576; 381. DR ComplexPortal; CPX-6195; PAR cell polarity complex, PARD6G-PRKCZ variant. DR ComplexPortal; CPX-6196; PAR cell polarity complex, PARD6B-PRKCZ variant. DR ComplexPortal; CPX-6197; PAR cell polarity complex, PARD6A-PRKCZ variant. DR CORUM; Q05513; -. DR ELM; Q05513; -. DR FunCoup; Q05513; 1725. DR IntAct; Q05513; 231. DR MINT; Q05513; -. DR STRING; 9606.ENSP00000367830; -. DR BindingDB; Q05513; -. DR ChEMBL; CHEMBL3438; -. DR DrugBank; DB09096; Benzoyl peroxide. DR DrugBank; DB03777; Bisindolylmaleimide I. DR DrugBank; DB04209; Dequalinium. DR DrugBank; DB17029; Go-6976. DR DrugBank; DB02010; Staurosporine. DR DrugBank; DB00675; Tamoxifen. DR DrugCentral; Q05513; -. DR GuidetoPHARMACOLOGY; 1491; -. DR MoonDB; Q05513; Predicted. DR GlyGen; Q05513; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q05513; -. DR PhosphoSitePlus; Q05513; -. DR BioMuta; PRKCZ; -. DR DMDM; 68067736; -. DR jPOST; Q05513; -. DR MassIVE; Q05513; -. DR PaxDb; 9606-ENSP00000367830; -. DR PeptideAtlas; Q05513; -. DR ProteomicsDB; 19529; -. DR ProteomicsDB; 58330; -. [Q05513-1] DR ProteomicsDB; 58331; -. [Q05513-2] DR Pumba; Q05513; -. DR Antibodypedia; 3869; 858 antibodies from 46 providers. DR DNASU; 5590; -. DR Ensembl; ENST00000378567.8; ENSP00000367830.3; ENSG00000067606.18. [Q05513-1] DR Ensembl; ENST00000400921.6; ENSP00000383712.2; ENSG00000067606.18. [Q05513-2] DR Ensembl; ENST00000461106.6; ENSP00000426412.1; ENSG00000067606.18. [Q05513-3] DR GeneID; 5590; -. DR KEGG; hsa:5590; -. DR MANE-Select; ENST00000378567.8; ENSP00000367830.3; NM_002744.6; NP_002735.3. DR UCSC; uc001aiq.3; human. [Q05513-1] DR AGR; HGNC:9412; -. DR ClinPGx; PA33775; -. DR CTD; 5590; -. DR DisGeNET; 5590; -. DR GeneCards; PRKCZ; -. DR HGNC; HGNC:9412; PRKCZ. DR HPA; ENSG00000067606; Tissue enhanced (brain). DR MalaCards; PRKCZ; -. DR MIM; 176982; gene. DR OpenTargets; ENSG00000067606; -. DR Orphanet; 1606; 1p36 deletion syndrome. DR VEuPathDB; HostDB:ENSG00000067606; -. DR eggNOG; KOG0695; Eukaryota. DR GeneTree; ENSGT00940000153497; -. DR HOGENOM; CLU_000288_63_5_1; -. DR InParanoid; Q05513; -. DR OMA; DKMAGLC; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; Q05513; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q05513; -. DR BRENDA; 2.7.11.13; 2681. DR PathwayCommons; Q05513; -. DR Reactome; R-HSA-114604; GPVI-mediated activation cascade. DR Reactome; R-HSA-2173791; TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition). DR Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation. DR Reactome; R-HSA-5668599; RHO GTPases Activate NADPH Oxidases. DR Reactome; R-HSA-9634635; Estrogen-stimulated signaling through PRKCZ. DR SignaLink; Q05513; -. DR SIGNOR; Q05513; -. DR Agora; ENSG00000067606; -. DR BioGRID-ORCS; 5590; 23 hits in 1195 CRISPR screens. DR ChiTaRS; PRKCZ; human. DR GeneWiki; Protein_kinase_M_zeta/Protein_kinase_C_zeta; -. DR GenomeRNAi; 5590; -. DR Pharos; Q05513; Tchem. DR PRO; PR:Q05513; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q05513; protein. DR Bgee; ENSG00000067606; Expressed in right hemisphere of cerebellum and 168 other cell types or tissues. DR ExpressionAtlas; Q05513; baseline and differential. DR GO; GO:0045179; C:apical cortex; IEA:Ensembl. DR GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl. DR GO; GO:0043203; C:axon hillock; IEA:Ensembl. DR GO; GO:0005923; C:bicellular tight junction; IEA:Ensembl. DR GO; GO:0030054; C:cell junction; TAS:Reactome. DR GO; GO:0005911; C:cell-cell junction; IDA:UniProtKB. DR GO; GO:0005814; C:centriole; IDA:HPA. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; TAS:ProtInc. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005768; C:endosome; IEA:UniProtKB-SubCell. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0016020; C:membrane; TAS:ProtInc. DR GO; GO:0035748; C:myelin sheath abaxonal region; IEA:Ensembl. DR GO; GO:0005635; C:nuclear envelope; IEA:Ensembl. DR GO; GO:0016363; C:nuclear matrix; IEA:Ensembl. DR GO; GO:0120157; C:PAR polarity complex; ISS:ComplexPortal. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0097229; C:sperm end piece; IDA:HPA. DR GO; GO:0097225; C:sperm midpiece; IDA:HPA. DR GO; GO:0070160; C:tight junction; NAS:ComplexPortal. DR GO; GO:0031982; C:vesicle; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004697; F:diacylglycerol-dependent serine/threonine kinase activity; EXP:Reactome. DR GO; GO:0043560; F:insulin receptor substrate binding; IDA:BHF-UCL. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:BHF-UCL. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0032869; P:cellular response to insulin stimulus; IBA:GO_Central. DR GO; GO:0030010; P:establishment of cell polarity; ISS:UniProtKB. DR GO; GO:0045197; P:establishment or maintenance of epithelial cell apical/basal polarity; ISS:ComplexPortal. DR GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0060291; P:long-term synaptic potentiation; ISS:UniProtKB. DR GO; GO:0000226; P:microtubule cytoskeleton organization; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; TAS:ProtInc. DR GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; IMP:BHF-UCL. DR GO; GO:0031333; P:negative regulation of protein-containing complex assembly; IMP:BHF-UCL. DR GO; GO:1990138; P:neuron projection extension; IEA:Ensembl. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB. DR GO; GO:2000463; P:positive regulation of excitatory postsynaptic potential; ISS:UniProtKB. DR GO; GO:0046628; P:positive regulation of insulin receptor signaling pathway; ISS:UniProtKB. DR GO; GO:0032733; P:positive regulation of interleukin-10 production; ISS:UniProtKB. DR GO; GO:0032736; P:positive regulation of interleukin-13 production; ISS:UniProtKB. DR GO; GO:0032753; P:positive regulation of interleukin-4 production; ISS:UniProtKB. DR GO; GO:0032754; P:positive regulation of interleukin-5 production; ISS:UniProtKB. DR GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; ISS:UniProtKB. DR GO; GO:2000553; P:positive regulation of T-helper 2 cell cytokine production; ISS:UniProtKB. DR GO; GO:0045630; P:positive regulation of T-helper 2 cell differentiation; ISS:UniProtKB. DR GO; GO:0072659; P:protein localization to plasma membrane; IBA:GO_Central. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR CDD; cd21095; C1_aPKC_zeta; 1. DR CDD; cd06404; PB1_aPKC; 1. DR CDD; cd05617; STKc_aPKC_zeta; 1. DR FunFam; 1.10.510.10:FF:000048; Protein kinase C; 1. DR FunFam; 3.10.20.90:FF:000071; Protein kinase C; 1. DR FunFam; 3.30.200.20:FF:000070; Protein kinase C; 1. DR FunFam; 3.30.60.20:FF:000012; Protein kinase C; 1. DR Gene3D; 3.30.60.20; -; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR034662; aPKC_zeta. DR InterPro; IPR046349; C1-like_sf. DR InterPro; IPR047314; C1_aPKC_zeta. DR InterPro; IPR020454; DAG/PE-bd. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR053793; PB1-like. DR InterPro; IPR034877; PB1_aPKC. DR InterPro; IPR000270; PB1_dom. DR InterPro; IPR012233; PKC. DR InterPro; IPR002219; PKC_DAG/PE. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF00130; C1_1; 1. DR Pfam; PF00564; PB1; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00433; Pkinase_C; 1. DR PIRSF; PIRSF000554; PKC_zeta; 1. DR PRINTS; PR00008; DAGPEDOMAIN. DR SMART; SM00109; C1; 1. DR SMART; SM00666; PB1; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF54277; CAD & PB1 domains; 1. DR SUPFAM; SSF57889; Cysteine-rich domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS51745; PB1; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS00479; ZF_DAG_PE_1; 1. DR PROSITE; PS50081; ZF_DAG_PE_2; 1. PE 1: Evidence at protein level; KW Alternative promoter usage; Alternative splicing; ATP-binding; KW Cell junction; Cytoplasm; Endosome; Inflammatory response; Kinase; KW Membrane; Metal-binding; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger. FT CHAIN 1..592 FT /note="Protein kinase C zeta type" FT /id="PRO_0000055701" FT DOMAIN 15..98 FT /note="PB1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01081" FT DOMAIN 252..518 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 519..590 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT ZN_FING 130..180 FT /note="Phorbol-ester/DAG-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT REGION 79..145 FT /note="Interaction with SQSTM1" FT /evidence="ECO:0000250" FT ACT_SITE 376 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 258..266 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 281 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 410 FT /note="Phosphothreonine; by PDPK1 and PI3K" FT /evidence="ECO:0000269|PubMed:15314172, FT ECO:0000269|PubMed:20332120, ECO:0000269|PubMed:9768361" FT MOD_RES 560 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:24275569" FT MOD_RES 591 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P09217" FT VAR_SEQ 1..183 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_041904" FT VAR_SEQ 1..112 FT /note="MPSRTGPKMEGSGGRVRLKAHYGGDIFITSVDAATTFEELCEEVRDMCRLHQ FT QHPLTLKWVDSEGDPCTVSSQMELEEAFRLARQCRDEGLIIHVFPSTPEQPGLPCPGED FT K -> MLTPRTDE (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_046347" FT VARIANT 49 FT /note="R -> H (in dbSNP:rs35271800)" FT /id="VAR_050560" FT VARIANT 84 FT /note="R -> H (in dbSNP:rs56017162)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042310" FT VARIANT 514 FT /note="S -> F (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035467" FT VARIANT 519 FT /note="R -> C (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs376894109)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042311" FT MUTAGEN 19 FT /note="K->A: No effect on interaction with SQSTM1 and FT PARD6B." FT /evidence="ECO:0000269|PubMed:12887891" FT MUTAGEN 62 FT /note="D->A: Loss of interaction with SQSTM1 and PARD6B." FT /evidence="ECO:0000269|PubMed:12887891" FT MUTAGEN 66 FT /note="D->A: Loss of interaction with SQSTM1 and PARD6B." FT /evidence="ECO:0000269|PubMed:12887891" FT CONFLICT 6 FT /note="G -> D (in Ref. 1; AAA36488)" FT /evidence="ECO:0000305" FT CONFLICT 198 FT /note="K -> R (in Ref. 3; BAF83684)" FT /evidence="ECO:0000305" FT CONFLICT 262 FT /note="S -> T (in Ref. 1; AAA36488)" FT /evidence="ECO:0000305" FT CONFLICT 281 FT /note="K -> R (in Ref. 3; BAH11883)" FT /evidence="ECO:0000305" FT CONFLICT 366 FT /note="F -> L (in Ref. 3; BAF83684)" FT /evidence="ECO:0000305" FT CONFLICT 500 FT /note="R -> G (in Ref. 3; BAF83684)" FT /evidence="ECO:0000305" FT CONFLICT 522 FT /note="D -> G (in Ref. 3; BAF83684)" FT /evidence="ECO:0000305" SQ SEQUENCE 592 AA; 67660 MW; 88CCD0577E6A596C CRC64; MPSRTGPKME GSGGRVRLKA HYGGDIFITS VDAATTFEEL CEEVRDMCRL HQQHPLTLKW VDSEGDPCTV SSQMELEEAF RLARQCRDEG LIIHVFPSTP EQPGLPCPGE DKSIYRRGAR RWRKLYRANG HLFQAKRFNR RAYCGQCSER IWGLARQGYR CINCKLLVHK RCHGLVPLTC RKHMDSVMPS QEPPVDDKNE DADLPSEETD GIAYISSSRK HDSIKDDSED LKPVIDGMDG IKISQGLGLQ DFDLIRVIGR GSYAKVLLVR LKKNDQIYAM KVVKKELVHD DEDIDWVQTE KHVFEQASSN PFLVGLHSCF QTTSRLFLVI EYVNGGDLMF HMQRQRKLPE EHARFYAAEI CIALNFLHER GIIYRDLKLD NVLLDADGHI KLTDYGMCKE GLGPGDTTST FCGTPNYIAP EILRGEEYGF SVDWWALGVL MFEMMAGRSP FDIITDNPDM NTEDYLFQVI LEKPIRIPRF LSVKASHVLK GFLNKDPKER LGCRPQTGFS DIKSHAFFRS IDWDLLEKKQ ALPPFQPQIT DDYGLDNFDT QFTSEPVQLT PDDEDAIKRI DQSEFEGFEY INPLLLSTEE SV // ID LATS1_HUMAN Reviewed; 1130 AA. AC O95835; Q6PKD0; DT 27-SEP-2004, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-1999, sequence version 1. DT 28-JAN-2026, entry version 221. DE RecName: Full=Serine/threonine-protein kinase LATS1; DE EC=2.7.11.1 {ECO:0000269|PubMed:10518011, ECO:0000269|PubMed:15122335, ECO:0000269|PubMed:39173637}; DE AltName: Full=Large tumor suppressor homolog 1; DE AltName: Full=WARTS protein kinase; DE Short=h-warts; GN Name=LATS1 {ECO:0000312|EMBL:AAD16882.1}; GN Synonyms=WARTS {ECO:0000312|EMBL:AAD50272.1}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305, ECO:0000312|EMBL:AAD16882.1} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, PHOSPHORYLATION, AND RP INTERACTION WITH CDK1. RC TISSUE=Fetal brain {ECO:0000312|EMBL:AAD16882.1}; RX PubMed=9988268; DOI=10.1038/5960; RA Tao W., Zhang S., Turenchalk G.S., Stewart R.A., St John M.A., Chen W., RA Xu T.; RT "Human homologue of the Drosophila melanogaster lats tumour suppressor RT modulates CDC2 activity."; RL Nat. Genet. 21:177-181(1999). RN [2] {ECO:0000305, ECO:0000312|EMBL:AAD50272.1} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY, RP SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND PHOSPHORYLATION. RX PubMed=10518011; DOI=10.1016/s0014-5793(99)01224-7; RA Nishiyama Y., Hirota T., Morisaki T., Hara T., Marumoto T., Iida S., RA Makino K., Yamamoto H., Hiraoka T., Kitamura N., Saya H.; RT "A human homolog of Drosophila warts tumor suppressor, h-warts, localized RT to mitotic apparatus and specifically phosphorylated during mitosis."; RL FEBS Lett. 459:159-165(1999). RN [3] {ECO:0000305, ECO:0000312|EMBL:AAH02767.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Endometrium {ECO:0000312|EMBL:AAH02767.1}; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] {ECO:0000305} RP FUNCTION, AND INTERACTION WITH ZYX. RX PubMed=10831611; DOI=10.1083/jcb.149.5.1073; RA Hirota T., Morisaki T., Nishiyama Y., Marumoto T., Tada K., Hara T., RA Masuko N., Inagaki M., Hatakeyama K., Saya H.; RT "Zyxin, a regulator of actin filament assembly, targets the mitotic RT apparatus by interacting with h-warts/LATS1 tumor suppressor."; RL J. Cell Biol. 149:1073-1086(2000). RN [5] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=15144186; DOI=10.1021/ac035352d; RA Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M., RA Peters E.C.; RT "Robust phosphoproteomic profiling of tyrosine phosphorylation sites from RT human T cells using immobilized metal affinity chromatography and tandem RT mass spectrometry."; RL Anal. Chem. 76:2763-2772(2004). RN [6] {ECO:0000305} RP FUNCTION, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF RP LYS-734. RX PubMed=15122335; DOI=10.1038/sj.onc.1207623; RA Iida S., Hirota T., Morisaki T., Marumoto T., Hara T., Kuninaka S., RA Honda S., Kosai K., Kawasuji M., Pallas D.C., Saya H.; RT "Tumor suppressor WARTS ensures genomic integrity by regulating both RT mitotic progression and G1 tetraploidy checkpoint function."; RL Oncogene 23:5266-5274(2004). RN [7] {ECO:0000305} RP FUNCTION, AND INTERACTION WITH LIMK1. RX PubMed=15220930; DOI=10.1038/ncb1140; RA Yang X., Yu K., Hao Y., Li D.-M., Stewart R.A., Insogna K.L., Xu T.; RT "LATS1 tumour suppressor affects cytokinesis by inhibiting LIMK1."; RL Nat. Cell Biol. 6:609-617(2004). RN [8] RP PHOSPHORYLATION AT SER-909 AND THR-1079. RX PubMed=15688006; DOI=10.1038/sj.onc.1208445; RA Chan E.H.Y., Nousiainen M., Chalamalasetty R.B., Schaefer A., Nigg E.A., RA Sillje H.H.W.; RT "The Ste20-like kinase Mst2 activates the human large tumor suppressor RT kinase Lats1."; RL Oncogene 24:2076-2086(2005). RN [9] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-674, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [10] RP FUNCTION, INTERACTION WITH YAP1, AND MUTAGENESIS OF TYR-559. RX PubMed=18158288; DOI=10.1074/jbc.m709037200; RA Hao Y., Chun A., Cheung K., Rashidi B., Yang X.; RT "Tumor suppressor LATS1 is a negative regulator of oncogene YAP."; RL J. Biol. Chem. 283:5496-5509(2008). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-246; SER-278 AND SER-464, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [15] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [16] RP INTERACTION WITH LIMD1; WTIP AND AJUBA. RX PubMed=20303269; DOI=10.1016/j.cub.2010.02.035; RA Das Thakur M., Feng Y., Jagannathan R., Seppa M.J., Skeath J.B., RA Longmore G.D.; RT "Ajuba LIM proteins are negative regulators of the Hippo signaling RT pathway."; RL Curr. Biol. 20:657-662(2010). RN [17] RP INTERACTION WITH MOB1A AND MOB1B. RX PubMed=19739119; DOI=10.1002/ijc.24878; RA Chow A., Hao Y., Yang X.; RT "Molecular characterization of human homologs of yeast MOB1."; RL Int. J. Cancer 126:2079-2089(2010). RN [18] RP FUNCTION, PHOSPHORYLATION AT SER-464, AND MUTAGENESIS OF SER-464. RX PubMed=19927127; DOI=10.1038/emboj.2009.342; RA Humbert N., Navaratnam N., Augert A., Da Costa M., Martien S., Wang J., RA Martinez D., Abbadie C., Carling D., de Launoit Y., Gil J., Bernard D.; RT "Regulation of ploidy and senescence by the AMPK-related kinase NUAK1."; RL EMBO J. 29:376-386(2010). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-246; SER-464 AND SER-613, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [20] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [21] RP INTERACTION WITH WWC1; WWC2 AND WWC3. RX PubMed=24682284; DOI=10.1093/molbev/msu115; RA Wennmann D.O., Schmitz J., Wehr M.C., Krahn M.P., Koschmal N., RA Gromnitza S., Schulze U., Weide T., Chekuri A., Skryabin B.V., Gerke V., RA Pavenstadt H., Duning K., Kremerskothen J.; RT "Evolutionary and Molecular Facts Link the WWC Protein Family to Hippo RT Signaling."; RL Mol. Biol. Evol. 31:1710-1723(2014). RN [22] RP FUNCTION, AND PHOSPHORYLATION BY MAP4K. RX PubMed=26437443; DOI=10.1038/ncomms9357; RA Meng Z., Moroishi T., Mottier-Pavie V., Plouffe S.W., Hansen C.G., RA Hong A.W., Park H.W., Mo J.S., Lu W., Lu S., Flores F., Yu F.X., Halder G., RA Guan K.L.; RT "MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the RT Hippo pathway."; RL Nat. Commun. 6:8357-8357(2015). RN [23] RP INTERACTION WITH STK3, AND PHOSPHORYLATION AT THR-1079. RX PubMed=28087714; DOI=10.1101/gad.284539.116; RA Kwan J., Sczaniecka A., Arash E.H., Nguyen L., Chen C.C., Ratkovic S., RA Klezovitch O., Attisano L., McNeill H., Emili A., Vasioukhin V.; RT "DLG5 connects cell polarity and Hippo signaling protein networks by RT linking PAR-1 with MST1/2."; RL Genes Dev. 30:2696-2709(2016). RN [24] RP FUNCTION, AND INTERACTION WITH DCAF13; ESR1 AND DCAF1. RX PubMed=28068668; DOI=10.1038/nature20829; RA Britschgi A., Duss S., Kim S., Couto J.P., Brinkhaus H., Koren S., RA De Silva D., Mertz K.D., Kaup D., Varga Z., Voshol H., Vissieres A., RA Leroy C., Roloff T., Stadler M.B., Scheel C.H., Miraglia L.J., Orth A.P., RA Bonamy G.M., Reddy V.A., Bentires-Alj M.; RT "The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk RT with ERalpha."; RL Nature 541:541-545(2017). RN [25] RP INTERACTION WITH SCRIB. RX PubMed=28169360; DOI=10.1038/srep42125; RA Liu J., Li J., Li P., Wang Y., Liang Z., Jiang Y., Li J., Feng C., Wang R., RA Chen H., Zhou C., Zhang J., Yang J., Liu P.; RT "Loss of DLG5 promotes breast cancer malignancy by inhibiting the Hippo RT signaling pathway."; RL Sci. Rep. 7:42125-42125(2017). RN [26] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=39173637; DOI=10.1016/j.molcel.2024.08.001; RA Nie L., Fei C., Fan Y., Dang F., Zhao Z., Zhu T., Wu X., Dai T., RA Balasubramanian A., Pan J., Hu Y., Luo H.R., Wei W., Chen J.; RT "Consecutive palmitoylation and phosphorylation orchestrates NLRP3 membrane RT trafficking and inflammasome activation."; RL Mol. Cell 84:3336-3353(2024). RN [27] RP VARIANTS [LARGE SCALE ANALYSIS] TRP-96; GLY-204; GLN-237; TRP-370; SER-531; RP LEU-641; ILE-669; PRO-806 AND SER-1000. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Negative regulator of YAP1 in the Hippo signaling pathway CC that plays a pivotal role in organ size control and tumor suppression CC by restricting proliferation and promoting apoptosis (PubMed:10518011, CC PubMed:10831611, PubMed:18158288, PubMed:26437443, PubMed:28068668). CC The core of this pathway is composed of a kinase cascade wherein CC STK3/MST2 and STK4/MST1, in complex with its regulatory protein SAV1, CC phosphorylates and activates LATS1/2 in complex with its regulatory CC protein MOB1, which in turn phosphorylates and inactivates YAP1 CC oncoprotein and WWTR1/TAZ (PubMed:18158288, PubMed:26437443, CC PubMed:28068668). Phosphorylation of YAP1 by LATS1 inhibits its CC translocation into the nucleus to regulate cellular genes important for CC cell proliferation, cell death, and cell migration (PubMed:18158288, CC PubMed:26437443, PubMed:28068668). Acts as a tumor suppressor which CC plays a critical role in maintenance of ploidy through its actions in CC both mitotic progression and the G1 tetraploidy checkpoint CC (PubMed:15122335, PubMed:19927127). Negatively regulates G2/M CC transition by down-regulating CDK1 kinase activity (PubMed:9988268). CC Involved in the control of p53 expression (PubMed:15122335). Affects CC cytokinesis by regulating actin polymerization through negative CC modulation of LIMK1 (PubMed:15220930). May also play a role in CC endocrine function. Plays a role in mammary gland epithelial cell CC differentiation, both through the Hippo signaling pathway and the CC intracellular estrogen receptor signaling pathway by promoting the CC degradation of ESR1 (PubMed:28068668). Acts as an activator of the CC NLRP3 inflammasome by mediating phosphorylation of 'Ser-265' of NLRP3 CC following NLRP3 palmitoylation, promoting NLRP3 activation by NEK7 CC (PubMed:39173637). {ECO:0000269|PubMed:10518011, CC ECO:0000269|PubMed:10831611, ECO:0000269|PubMed:15122335, CC ECO:0000269|PubMed:15220930, ECO:0000269|PubMed:18158288, CC ECO:0000269|PubMed:19927127, ECO:0000269|PubMed:26437443, CC ECO:0000269|PubMed:28068668, ECO:0000269|PubMed:39173637, CC ECO:0000269|PubMed:9988268}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10518011, ECO:0000269|PubMed:15122335, CC ECO:0000269|PubMed:39173637}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10518011, ECO:0000269|PubMed:15122335}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- SUBUNIT: Complexes with CDK1 in early mitosis (PubMed:9988268). LATS1- CC associated CDK1 has no mitotic cyclin partner and no apparent kinase CC activity (PubMed:9988268). Binds phosphorylated ZYX, locating this CC protein to the mitotic spindle and suggesting a role for actin CC regulatory proteins during mitosis (PubMed:10831611). Binds to and CC colocalizes with LIMK1 at the actomyosin contractile ring during CC cytokinesis (PubMed:15220930). Interacts (via PPxY motif 2) with YAP1 CC (via WW domains) (PubMed:18158288). Interacts with MOB1A and MOB1B CC (PubMed:19739119). Interacts with LIMD1, WTIP and AJUBA CC (PubMed:20303269). Interacts with ESR1, DCAF1 and DCAF13; probably CC recruits DCAF1 and DCAF13 to ESR1 to promote ESR1 ubiquitination and CC ubiquitin-mediated proteasomal degradation (PubMed:28068668). Interacts CC with STK3/MST2; this interaction is inhibited in the presence of DLG5 CC (PubMed:28087714). Interacts with SCRIB in the presence of DLG5 CC (PubMed:28169360). Interacts with WWTR1/TAZ (By similarity). Interacts CC with WWC1, WWC2 and WWC3 (via their WW domains) (PubMed:24682284). CC {ECO:0000250|UniProtKB:Q8BYR2, ECO:0000269|PubMed:10831611, CC ECO:0000269|PubMed:15220930, ECO:0000269|PubMed:18158288, CC ECO:0000269|PubMed:19739119, ECO:0000269|PubMed:20303269, CC ECO:0000269|PubMed:24682284, ECO:0000269|PubMed:28068668, CC ECO:0000269|PubMed:28087714, ECO:0000269|PubMed:28169360, CC ECO:0000269|PubMed:9988268}. CC -!- INTERACTION: CC O95835; P06493: CDK1; NbExp=3; IntAct=EBI-444209, EBI-444308; CC O95835; P24941: CDK2; NbExp=4; IntAct=EBI-444209, EBI-375096; CC O95835; Q9Y4B6: DCAF1; NbExp=4; IntAct=EBI-444209, EBI-1996353; CC O95835; P03372: ESR1; NbExp=2; IntAct=EBI-444209, EBI-78473; CC O95835; P53667: LIMK1; NbExp=5; IntAct=EBI-444209, EBI-444403; CC O95835; Q9H8S9: MOB1A; NbExp=9; IntAct=EBI-444209, EBI-748229; CC O95835; Q7L9L4: MOB1B; NbExp=9; IntAct=EBI-444209, EBI-2558745; CC O95835; P35240: NF2; NbExp=4; IntAct=EBI-444209, EBI-1014472; CC O95835; O60285: NUAK1; NbExp=2; IntAct=EBI-444209, EBI-1046789; CC O95835; O43255: SIAH2; NbExp=2; IntAct=EBI-444209, EBI-948141; CC O95835; Q13485: SMAD4; NbExp=7; IntAct=EBI-444209, EBI-347263; CC O95835; Q15831: STK11; NbExp=2; IntAct=EBI-444209, EBI-306838; CC O95835; Q9GZV5: WWTR1; NbExp=5; IntAct=EBI-444209, EBI-747743; CC O95835; P46937: YAP1; NbExp=10; IntAct=EBI-444209, EBI-1044059; CC O95835; Q15942: ZYX; NbExp=10; IntAct=EBI-444209, EBI-444225; CC O95835; P46662: Nf2; Xeno; NbExp=5; IntAct=EBI-444209, EBI-644586; CC O95835-2; O15145: ARPC3; NbExp=3; IntAct=EBI-17978514, EBI-351829; CC O95835-2; Q9UHD9: UBQLN2; NbExp=3; IntAct=EBI-17978514, EBI-947187; CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule organizing CC center, centrosome {ECO:0000269|PubMed:10518011}. Cytoplasm, CC cytoskeleton, spindle {ECO:0000269|PubMed:10518011}. Midbody CC {ECO:0000269|PubMed:10518011}. Cytoplasm, cytoskeleton, microtubule CC organizing center, spindle pole body {ECO:0000269|PubMed:10518011}. CC Note=Localizes to the centrosomes throughout interphase but migrates to CC the mitotic apparatus, including spindle pole bodies, mitotic spindle, CC and midbody, during mitosis. {ECO:0000269|PubMed:10518011}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1 {ECO:0000269|PubMed:9988268}; CC IsoId=O95835-1; Sequence=Displayed; CC Name=2 {ECO:0000305}; CC IsoId=O95835-2; Sequence=VSP_051604, VSP_051605; CC -!- TISSUE SPECIFICITY: Expressed in all adult tissues examined except for CC lung and kidney. {ECO:0000269|PubMed:10518011}. CC -!- PTM: Autophosphorylated and phosphorylated during M-phase of the cell CC cycle (PubMed:10518011, PubMed:15122335, PubMed:9988268). CC Phosphorylated by STK3/MST2 at Ser-909 and Thr-1079, which results in CC its activation (PubMed:15688006). Phosphorylated by MAP4Ks; in parallel CC to STK3/MST2 and resulting to its activation (PubMed:26437443). CC Phosphorylation at Ser-464 by NUAK1 and NUAK2 leads to decreased CC protein level and is required to regulate cellular senescence and CC cellular ploidy (PubMed:19927127). {ECO:0000269|PubMed:10518011, CC ECO:0000269|PubMed:15122335, ECO:0000269|PubMed:15688006, CC ECO:0000269|PubMed:19927127, ECO:0000269|PubMed:26437443, CC ECO:0000269|PubMed:9988268}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/41127/LATS1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF104413; AAD16882.1; -; mRNA. DR EMBL; AF164041; AAD50272.1; -; mRNA. DR EMBL; BC002767; AAH02767.1; -; mRNA. DR CCDS; CCDS34551.1; -. [O95835-1] DR CCDS; CCDS59040.1; -. [O95835-2] DR RefSeq; NP_001257448.1; NM_001270519.2. [O95835-2] DR RefSeq; NP_004681.1; NM_004690.4. [O95835-1] DR RefSeq; XP_047275474.1; XM_047419518.1. [O95835-1] DR RefSeq; XP_054212722.1; XM_054356747.1. [O95835-1] DR PDB; 4ZRK; X-ray; 2.32 A; E/F/G/H=69-100. DR PDB; 5B5W; X-ray; 2.96 A; U=622-704. DR PDB; 5BRK; X-ray; 2.30 A; B=602-704. DR PDB; 7LWH; X-ray; 1.61 A; B=69-91. DR PDBsum; 4ZRK; -. DR PDBsum; 5B5W; -. DR PDBsum; 5BRK; -. DR PDBsum; 7LWH; -. DR AlphaFoldDB; O95835; -. DR SMR; O95835; -. DR BioGRID; 114563; 460. DR CORUM; O95835; -. DR DIP; DIP-31516N; -. DR FunCoup; O95835; 4799. DR IntAct; O95835; 114. DR MINT; O95835; -. DR STRING; 9606.ENSP00000437550; -. DR BindingDB; O95835; -. DR ChEMBL; CHEMBL6167; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; O95835; -. DR GuidetoPHARMACOLOGY; 1515; -. DR MoonProt; O95835; -. DR GlyGen; O95835; 7 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (5 sites). DR iPTMnet; O95835; -. DR PhosphoSitePlus; O95835; -. DR BioMuta; LATS1; -. DR CPTAC; CPTAC-3110; -. DR CPTAC; CPTAC-3111; -. DR jPOST; O95835; -. DR MassIVE; O95835; -. DR PaxDb; 9606-ENSP00000437550; -. DR PeptideAtlas; O95835; -. DR ProteomicsDB; 51081; -. [O95835-1] DR ProteomicsDB; 51082; -. [O95835-2] DR Pumba; O95835; -. DR Antibodypedia; 33280; 394 antibodies from 32 providers. DR DNASU; 9113; -. DR Ensembl; ENST00000253339.9; ENSP00000253339.5; ENSG00000131023.14. [O95835-1] DR Ensembl; ENST00000392273.7; ENSP00000444678.1; ENSG00000131023.14. [O95835-2] DR Ensembl; ENST00000543571.6; ENSP00000437550.1; ENSG00000131023.14. [O95835-1] DR GeneID; 9113; -. DR KEGG; hsa:9113; -. DR MANE-Select; ENST00000543571.6; ENSP00000437550.1; NM_004690.4; NP_004681.1. DR UCSC; uc003qmu.2; human. [O95835-1] DR AGR; HGNC:6514; -. DR ClinPGx; PA30301; -. DR CTD; 9113; -. DR DisGeNET; 9113; -. DR GeneCards; LATS1; -. DR HGNC; HGNC:6514; LATS1. DR HPA; ENSG00000131023; Low tissue specificity. DR MalaCards; LATS1; -. DR MIM; 603473; gene. DR OpenTargets; ENSG00000131023; -. DR VEuPathDB; HostDB:ENSG00000131023; -. DR eggNOG; KOG0608; Eukaryota. DR GeneTree; ENSGT00940000157684; -. DR HOGENOM; CLU_004885_0_0_1; -. DR InParanoid; O95835; -. DR OMA; NHHGSRQ; -. DR OrthoDB; 3638488at2759; -. DR PAN-GO; O95835; 7 GO annotations based on evolutionary models. DR PhylomeDB; O95835; -. DR PathwayCommons; O95835; -. DR Reactome; R-HSA-2028269; Signaling by Hippo. DR SignaLink; O95835; -. DR SIGNOR; O95835; -. DR Agora; ENSG00000131023; -. DR BioGRID-ORCS; 9113; 25 hits in 1204 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; LATS1; human. DR EvolutionaryTrace; O95835; -. DR GeneWiki; LATS1; -. DR GenomeRNAi; 9113; -. DR Pharos; O95835; Tchem. DR PRO; PR:O95835; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; O95835; protein. DR Bgee; ENSG00000131023; Expressed in germinal epithelium of ovary and 183 other cell types or tissues. DR ExpressionAtlas; O95835; baseline and differential. DR GO; GO:0005813; C:centrosome; IEA:UniProtKB-SubCell. DR GO; GO:0005737; C:cytoplasm; IDA:UniProt. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0005815; C:microtubule organizing center; IDA:UniProt. DR GO; GO:0030496; C:midbody; IEA:UniProtKB-SubCell. DR GO; GO:0005634; C:nucleus; ISS:UniProtKB. DR GO; GO:0098794; C:postsynapse; IEA:Ensembl. DR GO; GO:0000922; C:spindle pole; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB. DR GO; GO:0030331; F:nuclear estrogen receptor binding; IPI:UniProtKB. DR GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0051301; P:cell division; IEA:UniProtKB-KW. DR GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IBA:GO_Central. DR GO; GO:0000086; P:G2/M transition of mitotic cell cycle; IDA:UniProtKB. DR GO; GO:0035329; P:hippo signaling; IDA:BHF-UCL. DR GO; GO:0009755; P:hormone-mediated signaling pathway; ISS:UniProtKB. DR GO; GO:0001827; P:inner cell mass cell fate commitment; IEA:Ensembl. DR GO; GO:0001828; P:inner cell mass cellular morphogenesis; IEA:Ensembl. DR GO; GO:0008104; P:intracellular protein localization; IEA:Ensembl. DR GO; GO:0030216; P:keratinocyte differentiation; IEA:Ensembl. DR GO; GO:0060644; P:mammary gland epithelial cell differentiation; IMP:UniProtKB. DR GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IMP:BHF-UCL. DR GO; GO:0045736; P:negative regulation of cyclin-dependent protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:1900181; P:negative regulation of protein localization to nucleus; IMP:ARUK-UCL. DR GO; GO:0043065; P:positive regulation of apoptotic process; IBA:GO_Central. DR GO; GO:1900227; P:positive regulation of NLRP3 inflammasome complex assembly; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0030833; P:regulation of actin filament polymerization; IDA:UniProtKB. DR GO; GO:0033146; P:regulation of intracellular estrogen receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0046620; P:regulation of organ growth; IBA:GO_Central. DR GO; GO:0099151; P:regulation of postsynaptic density assembly; IEA:Ensembl. DR GO; GO:0043254; P:regulation of protein-containing complex assembly; IMP:BHF-UCL. DR GO; GO:0017015; P:regulation of transforming growth factor beta receptor signaling pathway; ISS:UniProtKB. DR GO; GO:2000058; P:regulation of ubiquitin-dependent protein catabolic process; IMP:UniProtKB. DR GO; GO:0000819; P:sister chromatid segregation; IDA:UniProtKB. DR CDD; cd21778; MobB_LATS1; 1. DR CDD; cd05625; STKc_LATS1; 1. DR CDD; cd14397; UBA_LATS1; 1. DR DisProt; DP03124; -. DR FunFam; 3.30.200.20:FF:001246; Large tumor suppressor kinase 1; 1. DR FunFam; 1.10.510.10:FF:000086; Non-specific serine/threonine protein kinase; 1. DR FunFam; 1.10.510.10:FF:000199; Non-specific serine/threonine protein kinase; 1. DR FunFam; 1.10.8.10:FF:000029; Serine/threonine-protein kinase LATS1 isoform 1; 1. DR Gene3D; 1.10.8.10; DNA helicase RuvA subunit, C-terminal domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 2. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR049761; LATS1-like_MobB. DR InterPro; IPR042706; LATS1_STKc. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR050236; Ser_Thr_kinase_AGC. DR InterPro; IPR015940; UBA. DR InterPro; IPR009060; UBA-like_sf. DR PANTHER; PTHR24356; SERINE/THREONINE-PROTEIN KINASE; 1. DR PANTHER; PTHR24356:SF138; SERINE_THREONINE-PROTEIN KINASE LATS1; 1. DR Pfam; PF00069; Pkinase; 2. DR Pfam; PF00433; Pkinase_C; 1. DR Pfam; PF00627; UBA; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF46934; UBA-like; 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50030; UBA; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell cycle; Cell division; KW Cytoplasm; Cytoskeleton; Kinase; Magnesium; Metal-binding; Mitosis; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase; KW Tumor suppressor. FT CHAIN 1..1130 FT /note="Serine/threonine-protein kinase LATS1" FT /id="PRO_0000086232" FT DOMAIN 100..141 FT /note="UBA" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00212" FT DOMAIN 705..1010 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 1011..1090 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT REGION 1..71 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 149..276 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 294..321 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 365..405 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 432..484 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 515..631 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 526..655 FT /note="Interaction with YAP1" FT /evidence="ECO:0000269|PubMed:18158288" FT REGION 1104..1130 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 373..376 FT /note="PPxY motif 1" FT MOTIF 556..559 FT /note="PPxY motif 2" FT COMPBIAS 1..11 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 19..30 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 46..64 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 167..179 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 235..268 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 300..312 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 381..405 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 434..447 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 454..482 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 579..609 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 621..630 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 828 FT /note="Proton acceptor" FT /evidence="ECO:0000250|UniProtKB:P22612, FT ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE- FT ProRule:PRU10027" FT BINDING 711..719 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000250|UniProtKB:P22612, FT ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 734 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:15122335" FT MOD_RES 246 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 278 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 464 FT /note="Phosphoserine; by NUAK1 and NUAK2" FT /evidence="ECO:0000269|PubMed:19927127, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163" FT MOD_RES 613 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 674 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17525332" FT MOD_RES 909 FT /note="Phosphoserine; by STK3/MST2" FT /evidence="ECO:0000269|PubMed:15688006" FT MOD_RES 1079 FT /note="Phosphothreonine; by STK3/MST2" FT /evidence="ECO:0000269|PubMed:15688006, FT ECO:0000269|PubMed:28087714" FT VAR_SEQ 672..690 FT /note="GLSQDAQDQMRKMLCQKES -> KPFKMSIFILNHLFAWCLF (in FT isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_051604" FT VAR_SEQ 691..1130 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_051605" FT VARIANT 96 FT /note="R -> W (in dbSNP:rs55945045)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040660" FT VARIANT 204 FT /note="S -> G (in dbSNP:rs34793526)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040661" FT VARIANT 237 FT /note="P -> Q (in dbSNP:rs56149740)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040662" FT VARIANT 370 FT /note="R -> W (in dbSNP:rs56348064)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040663" FT VARIANT 531 FT /note="P -> S (in dbSNP:rs55874734)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040664" FT VARIANT 641 FT /note="F -> L (in dbSNP:rs35163691)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040665" FT VARIANT 669 FT /note="M -> I (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs1390558952)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040666" FT VARIANT 806 FT /note="R -> P (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040667" FT VARIANT 1000 FT /note="G -> S (in dbSNP:rs56412005)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040668" FT MUTAGEN 464 FT /note="S->A: Abolishes phosphorylation by NUAK1 and NUAK2." FT /evidence="ECO:0000269|PubMed:19927127" FT MUTAGEN 559 FT /note="Y->F: Loss of interaction with YAP1." FT /evidence="ECO:0000269|PubMed:18158288" FT MUTAGEN 734 FT /note="K->A: Loss of kinase activity, autophosphorylation, FT increased ploidy, prolonged duration of mitosis and lack of FT p53 expression." FT /evidence="ECO:0000269|PubMed:15122335" FT HELIX 72..74 FT /evidence="ECO:0007829|PDB:7LWH" FT HELIX 75..85 FT /evidence="ECO:0007829|PDB:7LWH" FT HELIX 86..88 FT /evidence="ECO:0007829|PDB:7LWH" FT HELIX 637..671 FT /evidence="ECO:0007829|PDB:5BRK" FT HELIX 675..697 FT /evidence="ECO:0007829|PDB:5BRK" SQ SEQUENCE 1130 AA; 126870 MW; 11CFBCD8FD87DCD8 CRC64; MKRSEKPEGY RQMRPKTFPA SNYTVSSRQM LQEIRESLRN LSKPSDAAKA EHNMSKMSTE DPRQVRNPPK FGTHHKALQE IRNSLLPFAN ETNSSRSTSE VNPQMLQDLQ AAGFDEDMVI QALQKTNNRS IEAAIEFISK MSYQDPRREQ MAAAAARPIN ASMKPGNVQQ SVNRKQSWKG SKESLVPQRH GPPLGESVAY HSESPNSQTD VGRPLSGSGI SAFVQAHPSN GQRVNPPPPP QVRSVTPPPP PRGQTPPPRG TTPPPPSWEP NSQTKRYSGN MEYVISRISP VPPGAWQEGY PPPPLNTSPM NPPNQGQRGI SSVPVGRQPI IMQSSSKFNF PSGRPGMQNG TGQTDFMIHQ NVVPAGTVNR QPPPPYPLTA ANGQSPSALQ TGGSAAPSSY TNGSIPQSMM VPNRNSHNME LYNISVPGLQ TNWPQSSSAP AQSSPSSGHE IPTWQPNIPV RSNSFNNPLG NRASHSANSQ PSATTVTAIT PAPIQQPVKS MRVLKPELQT ALAPTHPSWI PQPIQTVQPS PFPEGTASNV TVMPPVAEAP NYQGPPPPYP KHLLHQNPSV PPYESISKPS KEDQPSLPKE DESEKSYENV DSGDKEKKQI TTSPITVRKN KKDEERRESR IQSYSPQAFK FFMEQHVENV LKSHQQRLHR KKQLENEMMR VGLSQDAQDQ MRKMLCQKES NYIRLKRAKM DKSMFVKIKT LGIGAFGEVC LARKVDTKAL YATKTLRKKD VLLRNQVAHV KAERDILAEA DNEWVVRLYY SFQDKDNLYF VMDYIPGGDM MSLLIRMGIF PESLARFYIA ELTCAVESVH KMGFIHRDIK PDNILIDRDG HIKLTDFGLC TGFRWTHDSK YYQSGDHPRQ DSMDFSNEWG DPSSCRCGDR LKPLERRAAR QHQRCLAHSL VGTPNYIAPE VLLRTGYTQL CDWWSVGVIL FEMLVGQPPF LAQTPLETQM KVINWQTSLH IPPQAKLSPE ASDLIIKLCR GPEDRLGKNG ADEIKAHPFF KTIDFSSDLR QQSASYIPKI THPTDTSNFD PVDPDKLWSD DNEEENVNDT LNGWYKNGKH PEHAFYEFTF RRFFDDNGYP YNYPKPIEYE YINSQGSEQQ SDEDDQNTGS EIKNRDLVYV // ID LATS2_HUMAN Reviewed; 1088 AA. AC Q9NRM7; B1AM47; Q9P2X1; DT 27-SEP-2004, integrated into UniProtKB/Swiss-Prot. DT 04-NOV-2008, sequence version 2. DT 28-JAN-2026, entry version 211. DE RecName: Full=Serine/threonine-protein kinase LATS2; DE EC=2.7.11.1 {ECO:0000269|PubMed:10871863, ECO:0000269|PubMed:39173637}; DE AltName: Full=Kinase phosphorylated during mitosis protein; DE AltName: Full=Large tumor suppressor homolog 2; DE AltName: Full=Serine/threonine-protein kinase kpm; DE AltName: Full=Warts-like kinase; GN Name=LATS2 {ECO:0000312|EMBL:BAA92381.1}; Synonyms=KPM; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305, ECO:0000312|EMBL:AAF80561.1} RP NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, RP AUTOPHOSPHORYLATION, AND MUTAGENESIS OF LYS-697. RC TISSUE=Myeloid {ECO:0000312|EMBL:AAF80561.1}; RX PubMed=10871863; DOI=10.1038/sj.onc.1203659; RA Hori T., Takaori-Kondo A., Kamikubo Y., Uchiyama T.; RT "Molecular cloning of a novel human protein kinase, kpm, that is homologous RT to warts/lats, a Drosophila tumor suppressor."; RL Oncogene 19:3101-3109(2000). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057823; DOI=10.1038/nature02379; RA Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L., RA Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S., RA Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P., RA Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L., RA Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P., RA Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P., RA Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C., RA Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P., RA Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L., RA Frankish A.G., Frankland J., French L., Garner P., Garnett J., RA Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M., RA Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D., RA Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D., RA Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J., RA Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S., RA Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S., RA Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R., RA Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W., RA Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P., RA Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L., RA Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R., RA Rogers J., Ross M.T.; RT "The DNA sequence and analysis of human chromosome 13."; RL Nature 428:522-528(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] {ECO:0000305, ECO:0000312|EMBL:BAA92381.1} RP NUCLEOTIDE SEQUENCE [MRNA] OF 42-1088, TISSUE SPECIFICITY, AND VARIANT RP VAL-324. RC TISSUE=Testis {ECO:0000269|PubMed:10673337}; RX PubMed=10673337; DOI=10.1006/geno.1999.6065; RA Yabuta N., Fujii T., Copeland N.G., Gilbert D.J., Jenkins N.A., RA Nishiguchi H., Endo Y., Toji S., Tanaka H., Nishimune Y., Nojima H.; RT "Structure, expression, and chromosome mapping of LATS2, a mammalian RT homologue of the Drosophila tumor suppressor gene lats/warts."; RL Genomics 63:263-270(2000). RN [6] {ECO:0000305} RP FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-697 AND SER-872. RX PubMed=12853976; DOI=10.1038/sj.onc.1206603; RA Li Y., Pei J., Xia H., Ke H., Wang H., Tao W.; RT "Lats2, a putative tumor suppressor, inhibits G1/S transition."; RL Oncogene 22:4398-4405(2003). RN [7] {ECO:0000305} RP SUBCELLULAR LOCATION, INTERACTION WITH AURKA, MUTAGENESIS OF SER-83, AND RP PHOSPHORYLATION AT SER-83. RX PubMed=15147269; DOI=10.1111/j.1356-9597.2004.00732.x; RA Toji S., Yabuta N., Hosomi T., Nishihara S., Kobayashi T., Suzuki S., RA Tamai K., Nojima H.; RT "The centrosomal protein Lats2 is a phosphorylation target of Aurora-A RT kinase."; RL Genes Cells 9:383-397(2004). RN [8] {ECO:0000305} RP FUNCTION, AND INTERACTION WITH AR. RX PubMed=15131260; DOI=10.1210/me.2004-0065; RA Powzaniuk M., McElwee-Witmer S., Vogel R.L., Hayami T., Rutledge S.J., RA Chen F., Harada S., Schmidt A., Rodan G.A., Freedman L.P., Bai C.; RT "The LATS2/KPM tumor suppressor is a negative regulator of the androgen RT receptor."; RL Mol. Endocrinol. 18:2011-2023(2004). RN [9] RP PHOSPHORYLATION. RX PubMed=15688006; DOI=10.1038/sj.onc.1208445; RA Chan E.H.Y., Nousiainen M., Chalamalasetty R.B., Schaefer A., Nigg E.A., RA Sillje H.H.W.; RT "The Ste20-like kinase Mst2 activates the human large tumor suppressor RT kinase Lats1."; RL Oncogene 24:2076-2086(2005). RN [10] RP INTERACTION WITH AJUBA. RX PubMed=16413547; DOI=10.1016/j.febslet.2005.12.096; RA Abe Y., Ohsugi M., Haraguchi K., Fujimoto J., Yamamoto T.; RT "LATS2-Ajuba complex regulates gamma-tubulin recruitment to centrosomes and RT spindle organization during mitosis."; RL FEBS Lett. 580:782-788(2006). RN [11] RP FUNCTION, AND INTERACTION WITH YAP1. RX PubMed=18158288; DOI=10.1074/jbc.m709037200; RA Hao Y., Chun A., Cheung K., Rashidi B., Yang X.; RT "Tumor suppressor LATS1 is a negative regulator of oncogene YAP."; RL J. Biol. Chem. 283:5496-5509(2008). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-279, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [13] RP INTERACTION WITH LIMD1; WTIP AND AJUBA. RX PubMed=20303269; DOI=10.1016/j.cub.2010.02.035; RA Das Thakur M., Feng Y., Jagannathan R., Seppa M.J., Skeath J.B., RA Longmore G.D.; RT "Ajuba LIM proteins are negative regulators of the Hippo signaling RT pathway."; RL Curr. Biol. 20:657-662(2010). RN [14] RP INTERACTION WITH MOB1A AND MOB1B. RX PubMed=19739119; DOI=10.1002/ijc.24878; RA Chow A., Hao Y., Yang X.; RT "Molecular characterization of human homologs of yeast MOB1."; RL Int. J. Cancer 126:2079-2089(2010). RN [15] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH SNAI1, AND PHOSPHORYLATION RP AT THR-1041. RX PubMed=21952048; DOI=10.1038/emboj.2011.357; RA Zhang K., Rodriguez-Aznar E., Yabuta N., Owen R.J., Mingot J.M., Nojima H., RA Nieto M.A., Longmore G.D.; RT "Lats2 kinase potentiates Snail1 activity by promoting nuclear retention RT upon phosphorylation."; RL EMBO J. 31:29-43(2012). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-380 AND SER-576, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [17] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [18] RP INTERACTION WITH WWC1; WWC2 AND WWC3. RX PubMed=24682284; DOI=10.1093/molbev/msu115; RA Wennmann D.O., Schmitz J., Wehr M.C., Krahn M.P., Koschmal N., RA Gromnitza S., Schulze U., Weide T., Chekuri A., Skryabin B.V., Gerke V., RA Pavenstadt H., Duning K., Kremerskothen J.; RT "Evolutionary and Molecular Facts Link the WWC Protein Family to Hippo RT Signaling."; RL Mol. Biol. Evol. 31:1710-1723(2014). RN [19] RP FUNCTION, AND PHOSPHORYLATION BY MAP4K. RX PubMed=26437443; DOI=10.1038/ncomms9357; RA Meng Z., Moroishi T., Mottier-Pavie V., Plouffe S.W., Hansen C.G., RA Hong A.W., Park H.W., Mo J.S., Lu W., Lu S., Flores F., Yu F.X., Halder G., RA Guan K.L.; RT "MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the RT Hippo pathway."; RL Nat. Commun. 6:8357-8357(2015). RN [20] RP FUNCTION, AND INTERACTION WITH AMOTL2. RX PubMed=26598551; DOI=10.15252/embr.201540809; RA Kim M., Kim M., Park S.J., Lee C., Lim D.S.; RT "Role of Angiomotin-like 2 mono-ubiquitination on YAP inhibition."; RL EMBO Rep. 17:64-78(2016). RN [21] RP PHOSPHORYLATION BY NUAK2. RX PubMed=32845958; DOI=10.1084/jem.20191561; RA Bonnard C., Navaratnam N., Ghosh K., Chan P.W., Tan T.T., Pomp O., RA Ng A.Y.J., Tohari S., Changede R., Carling D., Venkatesh B., Altunoglu U., RA Kayserili H., Reversade B.; RT "A loss-of-function NUAK2 mutation in humans causes anencephaly due to RT impaired Hippo-YAP signaling."; RL J. Exp. Med. 217:0-0(2020). RN [22] RP FUNCTION. RX PubMed=34404733; DOI=10.26508/lsa.202000953; RA Hwang D., Kim M., Kim S., Kwon M.R., Kang Y.S., Kim D., Kang H.C., RA Lim D.S.; RT "AMOTL2 mono-ubiquitination by WWP1 promotes contact inhibition by RT facilitating LATS activation."; RL Life. Sci Alliance 4:0-0(2021). RN [23] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=39173637; DOI=10.1016/j.molcel.2024.08.001; RA Nie L., Fei C., Fan Y., Dang F., Zhao Z., Zhu T., Wu X., Dai T., RA Balasubramanian A., Pan J., Hu Y., Luo H.R., Wei W., Chen J.; RT "Consecutive palmitoylation and phosphorylation orchestrates NLRP3 membrane RT trafficking and inflammasome activation."; RL Mol. Cell 84:3336-3353(2024). RN [24] RP VARIANTS [LARGE SCALE ANALYSIS] GLU-40; LEU-91; VAL-799; GLY-1014 AND RP PRO-1025. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Negative regulator of YAP1 in the Hippo signaling pathway CC that plays a pivotal role in organ size control and tumor suppression CC by restricting proliferation and promoting apoptosis (PubMed:18158288, CC PubMed:26437443, PubMed:26598551, PubMed:34404733). The core of this CC pathway is composed of a kinase cascade wherein STK3/MST2 and CC STK4/MST1, in complex with its regulatory protein SAV1, phosphorylates CC and activates LATS1/2 in complex with its regulatory protein MOB1, CC which in turn phosphorylates and inactivates YAP1 oncoprotein and CC WWTR1/TAZ (PubMed:26437443, PubMed:26598551, PubMed:34404733). CC Phosphorylation of YAP1 by LATS2 inhibits its translocation into the CC nucleus to regulate cellular genes important for cell proliferation, CC cell death, and cell migration (PubMed:26598551, PubMed:34404733). Also CC phosphorylates YAP1 in response to cell contact inhibition-driven WWP1 CC ubiquitination of AMOTL2, which results in LATS2 activation CC (PubMed:34404733). Acts as a tumor suppressor which plays a critical CC role in centrosome duplication, maintenance of mitotic fidelity and CC genomic stability (PubMed:10871863). Negatively regulates G1/S CC transition by down-regulating cyclin E/CDK2 kinase activity CC (PubMed:12853976). Negative regulator of the androgen receptor CC (PubMed:15131260). Phosphorylates SNAI1 in the nucleus leading to its CC nuclear retention and stabilization, which enhances its epithelial- CC mesenchymal transition and tumor cell invasion/migration activities CC (PubMed:21952048). This tumor-promoting activity is independent of its CC effects upon YAP1 or WWTR1/TAZ (PubMed:21952048). Acts as an activator CC of the NLRP3 inflammasome by mediating phosphorylation of 'Ser-265' of CC NLRP3 following NLRP3 palmitoylation, promoting NLRP3 activation by CC NEK7 (PubMed:39173637). {ECO:0000269|PubMed:10871863, CC ECO:0000269|PubMed:12853976, ECO:0000269|PubMed:15131260, CC ECO:0000269|PubMed:18158288, ECO:0000269|PubMed:21952048, CC ECO:0000269|PubMed:26437443, ECO:0000269|PubMed:26598551, CC ECO:0000269|PubMed:34404733, ECO:0000269|PubMed:39173637}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10871863, ECO:0000269|PubMed:39173637}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10871863}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- SUBUNIT: Interacts with and is phosphorylated by AURKA. Binds to AR. CC Interacts with AJUBA during mitosis and this complex regulates CC organization of the spindle apparatus through recruitment of gamma- CC tubulin to the centrosome. Interacts (via PPxY motif) with YAP1 (via WW CC domains). Interacts with MOB1A and MOB1B. Interacts with LIMD1, WTIP CC and AJUBA. Interacts with SNAI1. Interacts with WWC1, WWC2 and WWC3 CC (via their WW domains) (PubMed:24682284). Interacts (via UBA domain) CC with ubiquitinated AMOTL2; the interaction promotes LATS2 CC phosphorylation of YAP1 (PubMed:26598551). CC {ECO:0000269|PubMed:15131260, ECO:0000269|PubMed:15147269, CC ECO:0000269|PubMed:16413547, ECO:0000269|PubMed:18158288, CC ECO:0000269|PubMed:19739119, ECO:0000269|PubMed:20303269, CC ECO:0000269|PubMed:21952048, ECO:0000269|PubMed:24682284, CC ECO:0000269|PubMed:26598551}. CC -!- INTERACTION: CC Q9NRM7; Q96IF1: AJUBA; NbExp=7; IntAct=EBI-3506895, EBI-949782; CC Q9NRM7; Q9Y4B6: DCAF1; NbExp=2; IntAct=EBI-3506895, EBI-1996353; CC Q9NRM7; Q13643: FHL3; NbExp=4; IntAct=EBI-3506895, EBI-741101; CC Q9NRM7; Q9H8S9: MOB1A; NbExp=5; IntAct=EBI-3506895, EBI-748229; CC Q9NRM7; Q7L9L4: MOB1B; NbExp=7; IntAct=EBI-3506895, EBI-2558745; CC Q9NRM7; O43255: SIAH2; NbExp=6; IntAct=EBI-3506895, EBI-948141; CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule organizing CC center, centrosome. Cytoplasm. Cytoplasm, cytoskeleton, spindle pole. CC Nucleus. Note=Colocalizes with AURKA at the centrosomes during CC interphase, early prophase and cytokinesis. Migrates to the spindle CC poles during mitosis, and to the midbody during cytokinesis. CC Translocates to the nucleus upon mitotic stress by nocodazole CC treatment. CC -!- TISSUE SPECIFICITY: Expressed at high levels in heart and skeletal CC muscle and at lower levels in all other tissues examined. CC {ECO:0000269|PubMed:10673337, ECO:0000269|PubMed:10871863}. CC -!- PTM: Autophosphorylated and phosphorylated during M-phase and the G1/S- CC phase of the cell cycle (PubMed:15147269, PubMed:21952048). CC Phosphorylated and activated by STK3/MST2 (PubMed:15688006). CC Phosphorylated by MAP4Ks; in parallel to STK3/MST2 and resulting to its CC activation (PubMed:26437443). Phosphorylation by NUAK2 may regulate its CC activity in phosphorylation and inactivation YAP1 (PubMed:32845958). CC {ECO:0000269|PubMed:15147269, ECO:0000269|PubMed:15688006, CC ECO:0000269|PubMed:21952048, ECO:0000269|PubMed:26437443, CC ECO:0000269|PubMed:32845958}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA92381.1; Type=Frameshift; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/41128/LATS2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF207547; AAF80561.1; -; mRNA. DR EMBL; AK314235; BAG36905.1; -; mRNA. DR EMBL; AL161613; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL356285; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471075; EAX08286.1; -; Genomic_DNA. DR EMBL; AB028019; BAA92381.1; ALT_FRAME; mRNA. DR CCDS; CCDS9294.1; -. DR RefSeq; NP_055387.2; NM_014572.3. DR RefSeq; XP_005266399.1; XM_005266342.1. DR RefSeq; XP_047286222.1; XM_047430266.1. DR PDB; 4ZRI; X-ray; 2.70 A; C/D=68-99. DR PDBsum; 4ZRI; -. DR AlphaFoldDB; Q9NRM7; -. DR SMR; Q9NRM7; -. DR BioGRID; 117727; 297. DR CORUM; Q9NRM7; -. DR DIP; DIP-43883N; -. DR ELM; Q9NRM7; -. DR FunCoup; Q9NRM7; 1955. DR IntAct; Q9NRM7; 94. DR MINT; Q9NRM7; -. DR STRING; 9606.ENSP00000372035; -. DR BindingDB; Q9NRM7; -. DR ChEMBL; CHEMBL5907; -. DR DrugCentral; Q9NRM7; -. DR GuidetoPHARMACOLOGY; 1516; -. DR GlyCosmos; Q9NRM7; 1 site, 1 glycan. DR GlyGen; Q9NRM7; 9 sites, 1 O-linked glycan (8 sites). DR iPTMnet; Q9NRM7; -. DR PhosphoSitePlus; Q9NRM7; -. DR BioMuta; LATS2; -. DR DMDM; 212276441; -. DR jPOST; Q9NRM7; -. DR MassIVE; Q9NRM7; -. DR PaxDb; 9606-ENSP00000372035; -. DR PeptideAtlas; Q9NRM7; -. DR ProteomicsDB; 82392; -. DR Pumba; Q9NRM7; -. DR Antibodypedia; 22361; 321 antibodies from 32 providers. DR DNASU; 26524; -. DR Ensembl; ENST00000382592.5; ENSP00000372035.4; ENSG00000150457.10. DR GeneID; 26524; -. DR KEGG; hsa:26524; -. DR MANE-Select; ENST00000382592.5; ENSP00000372035.4; NM_014572.3; NP_055387.2. DR UCSC; uc001unr.6; human. DR AGR; HGNC:6515; -. DR ClinPGx; PA30302; -. DR CTD; 26524; -. DR DisGeNET; 26524; -. DR GeneCards; LATS2; -. DR HGNC; HGNC:6515; LATS2. DR HPA; ENSG00000150457; Low tissue specificity. DR MalaCards; LATS2; -. DR MIM; 604861; gene. DR OpenTargets; ENSG00000150457; -. DR VEuPathDB; HostDB:ENSG00000150457; -. DR eggNOG; KOG0608; Eukaryota. DR GeneTree; ENSGT00940000159161; -. DR HOGENOM; CLU_004885_1_0_1; -. DR InParanoid; Q9NRM7; -. DR OMA; FNNHQQP; -. DR OrthoDB; 3638488at2759; -. DR PAN-GO; Q9NRM7; 8 GO annotations based on evolutionary models. DR PhylomeDB; Q9NRM7; -. DR PathwayCommons; Q9NRM7; -. DR Reactome; R-HSA-2028269; Signaling by Hippo. DR SignaLink; Q9NRM7; -. DR SIGNOR; Q9NRM7; -. DR Agora; ENSG00000150457; -. DR BioGRID-ORCS; 26524; 32 hits in 1200 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; LATS2; human. DR GeneWiki; LATS2; -. DR GenomeRNAi; 26524; -. DR Pharos; Q9NRM7; Tchem. DR PRO; PR:Q9NRM7; -. DR Proteomes; UP000005640; Chromosome 13. DR RNAct; Q9NRM7; protein. DR Bgee; ENSG00000150457; Expressed in epithelial cell of pancreas and 196 other cell types or tissues. DR ExpressionAtlas; Q9NRM7; baseline and differential. DR GO; GO:0034451; C:centriolar satellite; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IDA:UniProt. DR GO; GO:0005829; C:cytosol; IDA:FlyBase. DR GO; GO:0005634; C:nucleus; IDA:MGI. DR GO; GO:0000922; C:spindle pole; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0060070; P:canonical Wnt signaling pathway; IEA:Ensembl. DR GO; GO:0051301; P:cell division; IEA:UniProtKB-KW. DR GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IDA:UniProtKB. DR GO; GO:0035329; P:hippo signaling; IDA:BHF-UCL. DR GO; GO:0009755; P:hormone-mediated signaling pathway; IDA:UniProtKB. DR GO; GO:0001827; P:inner cell mass cell fate commitment; IEA:Ensembl. DR GO; GO:0001828; P:inner cell mass cellular morphogenesis; IEA:Ensembl. DR GO; GO:0008104; P:intracellular protein localization; IEA:Ensembl. DR GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB. DR GO; GO:0030216; P:keratinocyte differentiation; IEA:Ensembl. DR GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IMP:BHF-UCL. DR GO; GO:0060243; P:negative regulation of cell growth involved in contact inhibition; IDA:UniProt. DR GO; GO:0045736; P:negative regulation of cyclin-dependent protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:1900181; P:negative regulation of protein localization to nucleus; ISS:UniProtKB. DR GO; GO:0043065; P:positive regulation of apoptotic process; IBA:GO_Central. DR GO; GO:1900227; P:positive regulation of NLRP3 inflammasome complex assembly; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0046620; P:regulation of organ growth; IBA:GO_Central. DR GO; GO:0017015; P:regulation of transforming growth factor beta receptor signaling pathway; ISS:UniProtKB. DR CDD; cd21777; MobB_LATS2; 1. DR CDD; cd05626; STKc_LATS2; 1. DR CDD; cd14398; UBA_LATS2; 1. DR FunFam; 3.30.200.20:FF:001246; Large tumor suppressor kinase 1; 1. DR FunFam; 1.10.510.10:FF:000086; Non-specific serine/threonine protein kinase; 1. DR FunFam; 1.10.510.10:FF:000199; Non-specific serine/threonine protein kinase; 1. DR FunFam; 1.10.8.10:FF:000029; Serine/threonine-protein kinase LATS1 isoform 1; 1. DR Gene3D; 1.10.8.10; DNA helicase RuvA subunit, C-terminal domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 2. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR050236; Ser_Thr_kinase_AGC. DR InterPro; IPR015940; UBA. DR InterPro; IPR009060; UBA-like_sf. DR PANTHER; PTHR24356; SERINE/THREONINE-PROTEIN KINASE; 1. DR PANTHER; PTHR24356:SF149; SERINE_THREONINE-PROTEIN KINASE LATS2; 1. DR Pfam; PF00069; Pkinase; 2. DR Pfam; PF00433; Pkinase_C; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF46934; UBA-like; 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50030; UBA; 1. PE 1: Evidence at protein level; KW 3D-structure; ATP-binding; Cell cycle; Cell division; Cytoplasm; KW Cytoskeleton; Kinase; Magnesium; Metal-binding; Mitosis; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase; KW Tumor suppressor. FT CHAIN 1..1088 FT /note="Serine/threonine-protein kinase LATS2" FT /id="PRO_0000086234" FT DOMAIN 98..139 FT /note="UBA" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00212" FT DOMAIN 668..973 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 974..1052 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT REGION 24..49 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 101..141 FT /note="Interaction with ubiquitinated AMOTL2" FT /evidence="ECO:0000269|PubMed:26598551" FT REGION 271..323 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 383..428 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 454..483 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 543..592 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 994..1022 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1056..1088 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 515..518 FT /note="PPxY motif" FT COMPBIAS 271..280 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 404..413 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 466..478 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 553..572 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 583..592 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 791 FT /note="Proton acceptor" FT /evidence="ECO:0000250|UniProtKB:P22612, FT ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE- FT ProRule:PRU10027" FT BINDING 674..682 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000250|UniProtKB:P22612, FT ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 697 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:10871863" FT MOD_RES 83 FT /note="Phosphoserine; by AURKA" FT /evidence="ECO:0000269|PubMed:15147269" FT MOD_RES 279 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 380 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 576 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1041 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:21952048" FT VARIANT 40 FT /note="G -> E (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040669" FT VARIANT 91 FT /note="S -> L (in dbSNP:rs55842804)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040670" FT VARIANT 324 FT /note="A -> V (in dbSNP:rs558614)" FT /evidence="ECO:0000269|PubMed:10673337" FT /id="VAR_019789" FT VARIANT 363 FT /note="G -> S (in dbSNP:rs2770928)" FT /id="VAR_047077" FT VARIANT 799 FT /note="I -> V (in dbSNP:rs35368391)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040671" FT VARIANT 1014 FT /note="A -> G (in dbSNP:rs45523141)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040672" FT VARIANT 1025 FT /note="L -> P (in dbSNP:rs56116059)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040673" FT MUTAGEN 83 FT /note="S->C: Fails to localize at the centromere during FT interphase." FT /evidence="ECO:0000269|PubMed:15147269" FT MUTAGEN 83 FT /note="S->E: Fails to localize at the centromere during FT interphase." FT /evidence="ECO:0000269|PubMed:15147269" FT MUTAGEN 697 FT /note="K->A: Loss of kinase activity, autophosphorylation FT and tumor suppressor activity." FT /evidence="ECO:0000269|PubMed:10871863, FT ECO:0000269|PubMed:12853976" FT MUTAGEN 872 FT /note="S->A: Loss of tumor suppressor activity." FT /evidence="ECO:0000269|PubMed:12853976" FT CONFLICT 59..61 FT /note="RQQ -> SSK (in Ref. 5; BAA92381)" FT /evidence="ECO:0000305" FT CONFLICT 436 FT /note="T -> S (in Ref. 5; BAA92381)" FT /evidence="ECO:0000305" FT CONFLICT 711 FT /note="A -> V (in Ref. 1; AAF80561)" FT /evidence="ECO:0000305" FT CONFLICT 868 FT /note="C -> S (in Ref. 5; BAA92381)" FT /evidence="ECO:0000305" FT HELIX 74..84 FT /evidence="ECO:0007829|PDB:4ZRI" FT HELIX 85..87 FT /evidence="ECO:0007829|PDB:4ZRI" SQ SEQUENCE 1088 AA; 120136 MW; 2866F6B75637AD36 CRC64; MRPKTFPATT YSGNSRQRLQ EIREGLKQPS KSSVQGLPAG PNSDTSLDAK VLGSKDATRQ QQQMRATPKF GPYQKALREI RYSLLPFANE SGTSAAAEVN RQMLQELVNA GCDQEMAGRA LKQTGSRSIE AALEYISKMG YLDPRNEQIV RVIKQTSPGK GLMPTPVTRR PSFEGTGDSF ASYHQLSGTP YEGPSFGADG PTALEEMPRP YVDYLFPGVG PHGPGHQHQH PPKGYGASVE AAGAHFPLQG AHYGRPHLLV PGEPLGYGVQ RSPSFQSKTP PETGGYASLP TKGQGGPPGA GLAFPPPAAG LYVPHPHHKQ AGPAAHQLHV LGSRSQVFAS DSPPQSLLTP SRNSLNVDLY ELGSTSVQQW PAATLARRDS LQKPGLEAPP RAHVAFRPDC PVPSRTNSFN SHQPRPGPPG KAEPSLPAPN TVTAVTAAHI LHPVKSVRVL RPEPQTAVGP SHPAWVPAPA PAPAPAPAPA AEGLDAKEEH ALALGGAGAF PLDVEYGGPD RRCPPPPYPK HLLLRSKSEQ YDLDSLCAGM EQSLRAGPNE PEGGDKSRKS AKGDKGGKDK KQIQTSPVPV RKNSRDEEKR ESRIKSYSPY AFKFFMEQHV ENVIKTYQQK VNRRLQLEQE MAKAGLCEAE QEQMRKILYQ KESNYNRLKR AKMDKSMFVK IKTLGIGAFG EVCLACKVDT HALYAMKTLR KKDVLNRNQV AHVKAERDIL AEADNEWVVK LYYSFQDKDS LYFVMDYIPG GDMMSLLIRM EVFPEHLARF YIAELTLAIE SVHKMGFIHR DIKPDNILID LDGHIKLTDF GLCTGFRWTH NSKYYQKGSH VRQDSMEPSD LWDDVSNCRC GDRLKTLEQR ARKQHQRCLA HSLVGTPNYI APEVLLRKGY TQLCDWWSVG VILFEMLVGQ PPFLAPTPTE TQLKVINWEN TLHIPAQVKL SPEARDLITK LCCSADHRLG RNGADDLKAH PFFSAIDFSS DIRKQPAPYV PTISHPMDTS NFDPVDEESP WNDASEGSTK AWDTLTSPNN KHPEHAFYEF TFRRFFDDNG YPFRCPKPSG AEASQAESSD LESSDLVDQT EGCQPVYV // ID LZTS1_HUMAN Reviewed; 596 AA. AC Q9Y250; D3DSQ6; Q9Y5V7; Q9Y5V8; Q9Y5V9; Q9Y5W0; Q9Y5W1; Q9Y5W2; DT 13-APR-2004, integrated into UniProtKB/Swiss-Prot. DT 23-JAN-2007, sequence version 3. DT 28-JAN-2026, entry version 182. DE RecName: Full=Leucine zipper putative tumor suppressor 1; DE AltName: Full=F37/esophageal cancer-related gene-coding leucine-zipper motif; DE AltName: Full=Fez1; GN Name=LZTS1; Synonyms=FEZ1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1; 2; 3; 4; 5; 6 AND 7), RP INVOLVEMENT IN ESCR, VARIANTS PRO-29 AND GLU-119, FUNCTION, AND TISSUE RP SPECIFICITY. RX PubMed=10097140; DOI=10.1073/pnas.96.7.3928; RA Ishii H., Baffa R., Numata S., Murakumo Y., Rattan S., Inoue H., Mori M., RA Fidanza V., Alder H., Croce C.M.; RT "The FEZ1 gene at chromosome 8p22 encodes a leucine-zipper protein, and its RT expression is altered in multiple human tumors."; RL Proc. Natl. Acad. Sci. U.S.A. 96:3928-3933(1999). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Fetal brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP FUNCTION, AND ALTERNATIVE SPLICING. RX PubMed=11464283; DOI=10.1038/sj.onc.1204539; RA Cabeza-Arvelaiz Y., Sepulveda J.L., Lebovitz R.M., Thompson T.C., RA Chinault A.C.; RT "Functional identification of LZTS1 as a candidate prostate tumor RT suppressor gene on human chromosome 8p22."; RL Oncogene 20:4169-4179(2001). RN [5] RP FUNCTION, PHOSPHORYLATION, SUBCELLULAR LOCATION, AND INTERACTION WITH EEF1G RP AND CDK1. RX PubMed=11504921; DOI=10.1073/pnas.181222898; RA Ishii H., Vecchione A., Murakumo Y., Baldassarre G., Numata S., RA Trapasso F., Alder H., Baffa R., Croce C.M.; RT "FEZ1/LZTS1 gene at 8p22 suppresses cancer cell growth and regulates RT mitosis."; RL Proc. Natl. Acad. Sci. U.S.A. 98:10374-10379(2001). RN [6] RP INTERACTION WITH TLK2. RX PubMed=16484223; DOI=10.1074/jbc.m513280200; RA Assmann E.M., Alborghetti M.R., Camargo M.E.R., Kobarg J.; RT "FEZ1 dimerization and interaction with transcription regulatory proteins RT involves its coiled-coil region."; RL J. Biol. Chem. 281:9869-9881(2006). RN [7] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [8] {ECO:0007744|PDB:8Y1U} RP X-RAY CRYSTALLOGRAPHY (2.41 ANGSTROMS) OF 346-368 IN COMPLEX WITH ASB7; RP ALOB AND ELOC, AND UBIQUITINATION. RX PubMed=39039081; DOI=10.1038/s41467-024-50556-x; RA Zhou M., Wang X., Li J., Ma J., Bao Z., Yan X., Zhang B., Liu T., Yu Y., RA Mi W., Dong C.; RT "Molecular insights into degron recognition by CRL5ASB7 ubiquitin ligase."; RL Nat. Commun. 15:6177-6177(2024). CC -!- FUNCTION: Involved in the regulation of cell growth. May stabilize the CC active CDC2-cyclin B1 complex and thereby contribute to the regulation CC of the cell cycle and the prevention of uncontrolled cell CC proliferation. May act as a tumor suppressor. CC {ECO:0000269|PubMed:10097140, ECO:0000269|PubMed:11464283, CC ECO:0000269|PubMed:11504921}. CC -!- SUBUNIT: Binds EEF1G, TLK2 and CDK1. CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Cell membrane CC {ECO:0000250}. Cell projection, dendritic spine {ECO:0000250}. CC Postsynaptic density {ECO:0000250}. Synapse {ECO:0000250}. CC Note=Associated with the plasma membrane and with microtubules. CC Detected in dendritic spines, especially in the postsynaptic density CC (By similarity). {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=7; CC Name=1; CC IsoId=Q9Y250-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9Y250-2; Sequence=VSP_009946; CC Name=3; CC IsoId=Q9Y250-3; Sequence=VSP_009945; CC Name=4; CC IsoId=Q9Y250-4; Sequence=VSP_009944; CC Name=5; CC IsoId=Q9Y250-5; Sequence=VSP_009943; CC Name=6; CC IsoId=Q9Y250-6; Sequence=VSP_009942; CC Name=7; CC IsoId=Q9Y250-7; Sequence=VSP_009940, VSP_009941; CC -!- TISSUE SPECIFICITY: Highly expressed in testis, prostate, spleen, CC thymus, ovary and brain. Detected at lower levels in heart, placenta, CC small intestine, colon, liver, kidney, skeletal muscle and pancreas. CC Not detectable in primary tumors from breast and prostate and in many CC cancer cell lines. {ECO:0000269|PubMed:10097140}. CC -!- PTM: Phosphorylated on serine residues. Hyperphosphorylated by the CC cAMP-dependent kinase PKA during cell-cycle progression. CC -!- PTM: Ubiquitinated by the ECS(ASB7) complex, leading to its CC degradation. {ECO:0000269|PubMed:39039081}. CC -!- DISEASE: Esophageal cancer (ESCR) [MIM:133239]: A malignancy of the CC esophagus. The most common types are esophageal squamous cell carcinoma CC and adenocarcinoma. Cancer of the esophagus remains a devastating CC disease because it is usually not detected until it has progressed to CC an advanced incurable stage. {ECO:0000269|PubMed:10097140}. Note=The CC disease may be caused by variants affecting the gene represented in CC this entry. CC -!- MISCELLANEOUS: Defects in LZTS1 are found in many types of tumors. CC -!- SIMILARITY: Belongs to the LZTS family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/367/LZTS1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF123652; AAD23833.1; -; mRNA. DR EMBL; AF123653; AAD23834.1; -; Genomic_DNA. DR EMBL; AF123654; AAD23835.1; -; mRNA. DR EMBL; AF123655; AAD23836.1; -; mRNA. DR EMBL; AF123656; AAD23837.1; -; mRNA. DR EMBL; AF123657; AAD23838.1; -; mRNA. DR EMBL; AF123658; AAD23839.1; -; mRNA. DR EMBL; AF123659; AAD23840.1; -; mRNA. DR EMBL; CH471080; EAW63753.1; -; Genomic_DNA. DR EMBL; CH471080; EAW63755.1; -; Genomic_DNA. DR EMBL; BC075006; AAH75006.1; -; mRNA. DR EMBL; BC075007; AAH75007.1; -; mRNA. DR CCDS; CCDS6015.1; -. [Q9Y250-1] DR RefSeq; NP_001349813.1; NM_001362884.2. [Q9Y250-1] DR RefSeq; NP_066300.1; NM_021020.5. [Q9Y250-1] DR RefSeq; XP_011542686.1; XM_011544384.3. [Q9Y250-1] DR RefSeq; XP_011542687.1; XM_011544385.3. [Q9Y250-1] DR RefSeq; XP_011542688.1; XM_011544386.3. [Q9Y250-1] DR RefSeq; XP_047277265.1; XM_047421309.1. [Q9Y250-1] DR RefSeq; XP_054215654.1; XM_054359679.1. [Q9Y250-1] DR RefSeq; XP_054215655.1; XM_054359680.1. [Q9Y250-1] DR RefSeq; XP_054215656.1; XM_054359681.1. [Q9Y250-1] DR PDB; 8Y1U; X-ray; 2.41 A; B=346-368. DR PDBsum; 8Y1U; -. DR AlphaFoldDB; Q9Y250; -. DR SMR; Q9Y250; -. DR BioGRID; 116348; 135. DR FunCoup; Q9Y250; 143. DR MINT; Q9Y250; -. DR STRING; 9606.ENSP00000370981; -. DR TCDB; 3.A.34.1.1; the sorting nexins of the escrt complexes (sn-escrt). DR GlyGen; Q9Y250; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q9Y250; -. DR PhosphoSitePlus; Q9Y250; -. DR BioMuta; LZTS1; -. DR DMDM; 46396556; -. DR jPOST; Q9Y250; -. DR MassIVE; Q9Y250; -. DR PaxDb; 9606-ENSP00000370981; -. DR PeptideAtlas; Q9Y250; -. DR ProteomicsDB; 85646; -. [Q9Y250-1] DR ProteomicsDB; 85647; -. [Q9Y250-2] DR ProteomicsDB; 85648; -. [Q9Y250-3] DR ProteomicsDB; 85649; -. [Q9Y250-4] DR ProteomicsDB; 85650; -. [Q9Y250-5] DR ProteomicsDB; 85651; -. [Q9Y250-6] DR ProteomicsDB; 85652; -. [Q9Y250-7] DR Antibodypedia; 1747; 241 antibodies from 27 providers. DR DNASU; 11178; -. DR Ensembl; ENST00000265801.6; ENSP00000265801.6; ENSG00000061337.16. [Q9Y250-1] DR Ensembl; ENST00000381569.5; ENSP00000370981.1; ENSG00000061337.16. [Q9Y250-1] DR Ensembl; ENST00000522290.5; ENSP00000429263.1; ENSG00000061337.16. [Q9Y250-4] DR GeneID; 11178; -. DR KEGG; hsa:11178; -. DR MANE-Select; ENST00000381569.5; ENSP00000370981.1; NM_021020.5; NP_066300.1. DR UCSC; uc003wzr.3; human. [Q9Y250-1] DR AGR; HGNC:13861; -. DR ClinPGx; PA30507; -. DR CTD; 11178; -. DR DisGeNET; 11178; -. DR GeneCards; LZTS1; -. DR HGNC; HGNC:13861; LZTS1. DR HPA; ENSG00000061337; Group enriched (brain, parathyroid gland). DR MalaCards; LZTS1; -. DR MIM; 133239; phenotype. DR MIM; 606551; gene. DR OpenTargets; ENSG00000061337; -. DR VEuPathDB; HostDB:ENSG00000061337; -. DR eggNOG; ENOG502QRU7; Eukaryota. DR GeneTree; ENSGT00940000154078; -. DR HOGENOM; CLU_026379_2_1_1; -. DR InParanoid; Q9Y250; -. DR OMA; QKTRGSH; -. DR OrthoDB; 10030037at2759; -. DR PAN-GO; Q9Y250; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q9Y250; -. DR PathwayCommons; Q9Y250; -. DR SignaLink; Q9Y250; -. DR Agora; ENSG00000061337; -. DR BioGRID-ORCS; 11178; 11 hits in 1151 CRISPR screens. DR GeneWiki; LZTS1; -. DR GenomeRNAi; 11178; -. DR Pharos; Q9Y250; Tbio. DR PRO; PR:Q9Y250; -. DR Proteomes; UP000005640; Chromosome 8. DR RNAct; Q9Y250; protein. DR Bgee; ENSG00000061337; Expressed in cortical plate and 134 other cell types or tissues. DR GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell. DR GO; GO:0043197; C:dendritic spine; IBA:GO_Central. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell. DR GO; GO:0014069; C:postsynaptic density; IEA:UniProtKB-SubCell. DR GO; GO:0016242; P:negative regulation of macroautophagy; IMP:BHF-UCL. DR GO; GO:0048814; P:regulation of dendrite morphogenesis; IBA:GO_Central. DR GO; GO:0150052; P:regulation of postsynapse assembly; IEA:Ensembl. DR GO; GO:0048167; P:regulation of synaptic plasticity; IBA:GO_Central. DR InterPro; IPR045329; LZTS. DR PANTHER; PTHR19354:SF5; ZIPPER PUTATIVE TUMOR SUPPRESSOR 1-RELATED; 1. DR PANTHER; PTHR19354; ZIPPER PUTATIVE TUMOR SUPPRESSOR 2 HOMOLOG-LIKE PROTEIN-RELATED; 1. DR Pfam; PF06818; Fez1; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Cell cycle; Cell membrane; KW Cell projection; Coiled coil; Cytoplasm; Lipoprotein; Membrane; Myristate; KW Phosphoprotein; Proteomics identification; Reference proteome; Synapse; KW Tumor suppressor; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT CHAIN 2..596 FT /note="Leucine zipper putative tumor suppressor 1" FT /id="PRO_0000182971" FT REGION 136..193 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 295..324 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 256..374 FT /evidence="ECO:0000255" FT COMPBIAS 153..162 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 178..190 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 295..310 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT LIPID 2 FT /note="N-myristoyl glycine" FT /evidence="ECO:0000250" FT VAR_SEQ 55..76 FT /note="SSSKMGKSEDFFYIKVSQKARG -> AMTRCPRASSMSGSCGRRRRRR (in FT isoform 7)" FT /evidence="ECO:0000303|PubMed:10097140" FT /id="VSP_009940" FT VAR_SEQ 77..596 FT /note="Missing (in isoform 7)" FT /evidence="ECO:0000303|PubMed:10097140" FT /id="VSP_009941" FT VAR_SEQ 186..571 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000303|PubMed:10097140" FT /id="VSP_009942" FT VAR_SEQ 454..545 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:10097140" FT /id="VSP_009943" FT VAR_SEQ 468..526 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:10097140" FT /id="VSP_009944" FT VAR_SEQ 471..503 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:10097140" FT /id="VSP_009945" FT VAR_SEQ 505..527 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10097140" FT /id="VSP_009946" FT VARIANT 29 FT /note="S -> P (found in an esophageal cancer sample; FT esophageal squamous cell carcinoma; somatic mutation; FT dbSNP:rs28937897)" FT /evidence="ECO:0000269|PubMed:10097140" FT /id="VAR_018274" FT VARIANT 50 FT /note="S -> F (in dbSNP:rs34620053)" FT /id="VAR_053490" FT VARIANT 119 FT /note="K -> E (found in an esophageal cancer sample; FT esophageal squamous cell carcinoma; somatic mutation; FT dbSNP:rs119473032)" FT /evidence="ECO:0000269|PubMed:10097140" FT /id="VAR_018275" FT VARIANT 475 FT /note="L -> V (in dbSNP:rs723874)" FT /id="VAR_018276" FT HELIX 347..363 FT /evidence="ECO:0007829|PDB:8Y1U" FT HELIX 364..367 FT /evidence="ECO:0007829|PDB:8Y1U" SQ SEQUENCE 596 AA; 66613 MW; 8ED96C707BA27659 CRC64; MGSVSSLISG HSFHSKHCRA SQYKLRKSSH LKKLNRYSDG LLRFGFSQDS GHGKSSSKMG KSEDFFYIKV SQKARGSHHP DYTALSSGDL GGQAGVDFDP STPPKLMPFS NQLEMGSEKG AVRPTAFKPV LPRSGAILHS SPESASHQLH PAPPDKPKEQ ELKPGLCSGA LSDSGRNSMS SLPTHSTSSS YQLDPLVTPV GPTSRFGGSA HNITQGIVLQ DSNMMSLKAL SFSDGGSKLG HSNKADKGPS CVRSPISTDE CSIQELEQKL LEREGALQKL QRSFEEKELA SSLAYEERPR RCRDELEGPE PKGGNKLKQA SQKSQRAQQV LHLQVLQLQQ EKRQLRQELE SLMKEQDLLE TKLRSYEREK TSFGPALEET QWEVCQKSGE ISLLKQQLKE SQTEVNAKAS EILGLKAQLK DTRGKLEGLE LRTQDLEGAL RTKGLELEVC ENELQRKKNE AELLREKVNL LEQELQELRA QAALARDMGP PTFPEDVPAL QRELERLRAE LREERQGHDQ MSSGFQHERL VWKEEKEKVI QYQKQLQQSY VAMYQRNQRL EKALQQLARG DSAGEPLEVD LEGADIPYED IIATEI // ID MARK1_HUMAN Reviewed; 795 AA. AC Q9P0L2; D3DTB0; D3DTB1; Q2HIY1; Q5VTF9; Q5VTG0; Q96SW9; Q9P251; DT 12-APR-2005, integrated into UniProtKB/Swiss-Prot. DT 23-JAN-2007, sequence version 2. DT 28-JAN-2026, entry version 205. DE RecName: Full=Serine/threonine-protein kinase MARK1; DE EC=2.7.11.1; DE EC=2.7.11.26; DE AltName: Full=MAP/microtubule affinity-regulating kinase 1; DE AltName: Full=PAR1 homolog c; DE Short=Par-1c; DE Short=Par1c; GN Name=MARK1 {ECO:0000312|HGNC:HGNC:6896}; GN Synonyms=KIAA1477 {ECO:0000312|EMBL:BAA96001.1}, GN MARK {ECO:0000312|EMBL:AAF72103.1}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), ACTIVITY REGULATION, RP PHOSPHORYLATION AT THR-215, AND MUTAGENESIS OF THR-215. RX PubMed=14976552; DOI=10.1038/sj.emboj.7600110; RA Lizcano J.M., Goeransson O., Toth R., Deak M., Morrice N.A., Boudeau J., RA Hawley S.A., Udd L., Maekelae T.P., Hardie D.G., Alessi D.R.; RT "LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, RT including MARK/PAR-1."; RL EMBO J. 23:833-843(2004). RN [2] {ECO:0000305, ECO:0000312|EMBL:AAF72103.1} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RA Zhou H.J., Huang X.W., Zhou Y., Hu S.L., Yuan J.G., Qiang B.Q.; RT "Cloning and isolating human MARK."; RL Submitted (MAY-1999) to the EMBL/GenBank/DDBJ databases. RN [3] {ECO:0000305, ECO:0000312|EMBL:BAA96001.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Brain {ECO:0000269|PubMed:10819331}; RX PubMed=10819331; DOI=10.1093/dnares/7.2.143; RA Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XVII. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 7:143-150(2000). RN [4] {ECO:0000305, ECO:0000312|EMBL:BAB55152.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [6] {ECO:0000305, ECO:0000312|EMBL:AAF72103.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] {ECO:0000305} RP TISSUE SPECIFICITY. RX PubMed=9108484; DOI=10.1016/s0092-8674(00)80208-1; RA Drewes G., Ebneth A., Preuss U., Mandelkow E.-M., Mandelkow E.; RT "MARK - a novel family of protein kinases that phosphorylate microtubule- RT associated proteins and trigger microtubule disruption."; RL Cell 89:297-308(1997). RN [9] RP NEUROFIBRILLARY TANGLES IN ALZHEIMER BRAIN. RX PubMed=11089574; DOI=10.1093/jnen/59.11.966; RA Chin J.Y., Knowles R.B., Schneider A., Drewes G., Mandelkow E.M., RA Hyman B.T.; RT "Microtubule-affinity regulating kinase (MARK) is tightly associated with RT neurofibrillary tangles in Alzheimer brain: a fluorescence resonance energy RT transfer study."; RL J. Neuropathol. Exp. Neurol. 59:966-971(2000). RN [10] RP FUNCTION. RX PubMed=11433294; DOI=10.1038/35083016; RA Sun T.-Q., Lu B., Feng J.-J., Reinhard C., Jan Y.N., Fantl W.J., RA Williams L.T.; RT "PAR-1 is a Dishevelled-associated kinase and a positive regulator of Wnt RT signalling."; RL Nat. Cell Biol. 3:628-636(2001). RN [11] RP PHOSPHORYLATION AT THR-208, ACTIVITY REGULATION, AND FUNCTION. RX PubMed=17573348; DOI=10.1074/jbc.m700590200; RA Kojima Y., Miyoshi H., Clevers H.C., Oshima M., Aoki M., Taketo M.M.; RT "Suppression of tubulin polymerization by the LKB1-microtubule-associated RT protein/microtubule affinity-regulating kinase signaling."; RL J. Biol. Chem. 282:23532-23540(2007). RN [12] RP POSSIBLE INVOLVEMENT IN AUTISM. RX PubMed=18492799; DOI=10.1093/hmg/ddn154; RA Maussion G., Carayol J., Lepagnol-Bestel A.M., Tores F., Loe-Mie Y., RA Milbreta U., Rousseau F., Fontaine K., Renaud J., Moalic J.M., Philippi A., RA Chedotal A., Gorwood P., Ramoz N., Hager J., Simonneau M.; RT "Convergent evidence identifying MAP/microtubule affinity-regulating kinase RT 1 (MARK1) as a susceptibility gene for autism."; RL Hum. Mol. Genet. 17:2541-2551(2008). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-5 AND SER-403, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-588, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [16] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [17] RP REVIEW. RX PubMed=19559622; DOI=10.1016/j.tibs.2009.03.008; RA Matenia D., Mandelkow E.M.; RT "The tau of MARK: a polarized view of the cytoskeleton."; RL Trends Biochem. Sci. 34:332-342(2009). RN [18] RP REVIEW. RX PubMed=20071654; DOI=10.1096/fj.09-148064; RA Marx A., Nugoor C., Panneerselvam S., Mandelkow E.; RT "Structure and function of polarity-inducing kinase family MARK/Par-1 RT within the branch of AMPK/Snf1-related kinases."; RL FASEB J. 24:1637-1648(2010). RN [19] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [20] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [22] RP FUNCTION, INTERACTION WITH MAPT, AND SUBCELLULAR LOCATION. RX PubMed=23666762; DOI=10.1007/s12017-013-8232-3; RA Gu G.J., Lund H., Wu D., Blokzijl A., Classon C., von Euler G., RA Landegren U., Sunnemark D., Kamali-Moghaddam M.; RT "Role of individual MARK isoforms in phosphorylation of tau at Ser262 in RT Alzheimer's disease."; RL NeuroMolecular Med. 15:458-469(2013). RN [23] RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 45-371. RX PubMed=16803889; DOI=10.1074/jbc.m604865200; RA Marx A., Nugoor C., Muller J., Panneerselvam S., Timm T., Bilang M., RA Mylonas E., Svergun D.I., Mandelkow E.M., Mandelkow E.; RT "Structural variations in the catalytic and ubiquitin-associated domains of RT microtubule-associated protein/microtubule affinity regulating kinase RT (MARK) 1 and MARK2."; RL J. Biol. Chem. 281:27586-27599(2006). RN [24] RP X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 683-795, DOMAIN KA1, SUBCELLULAR RP LOCATION, AND MUTAGENESIS OF ARG-698; ARG-701; 771-ARG--LYS-773 AND RP 773-LYS-ARG-774. RX PubMed=21145462; DOI=10.1016/j.cell.2010.11.028; RA Moravcevic K., Mendrola J.M., Schmitz K.R., Wang Y.H., Slochower D., RA Janmey P.A., Lemmon M.A.; RT "Kinase associated-1 domains drive MARK/PAR1 kinases to membrane targets by RT binding acidic phospholipids."; RL Cell 143:966-977(2010). RN [25] RP VARIANTS [LARGE SCALE ANALYSIS] CYS-233; THR-355; MET-530; LEU-578 AND RP GLY-691. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase (PubMed:23666762). Involved CC in cell polarity and microtubule dynamics regulation. Phosphorylates CC DCX, MAP2 and MAP4. Phosphorylates the microtubule-associated protein CC MAPT/TAU (PubMed:23666762). Involved in cell polarity by CC phosphorylating the microtubule-associated proteins MAP2, MAP4 and CC MAPT/TAU at KXGS motifs, causing detachment from microtubules, and CC their disassembly. Involved in the regulation of neuronal migration CC through its dual activities in regulating cellular polarity and CC microtubule dynamics, possibly by phosphorylating and regulating DCX. CC Also acts as a positive regulator of the Wnt signaling pathway, CC probably by mediating phosphorylation of dishevelled proteins (DVL1, CC DVL2 and/or DVL3). {ECO:0000269|PubMed:11433294, CC ECO:0000269|PubMed:17573348, ECO:0000269|PubMed:23666762}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:14976552}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:14976552}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[tau protein] + ATP = O-phospho-L-seryl-[tau protein] CC + ADP + H(+); Xref=Rhea:RHEA:12801, Rhea:RHEA-COMP:13701, Rhea:RHEA- CC COMP:13702, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.26; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[tau protein] + ATP = O-phospho-L-threonyl-[tau CC protein] + ADP + H(+); Xref=Rhea:RHEA:53904, Rhea:RHEA-COMP:13703, CC Rhea:RHEA-COMP:13704, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, CC ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; CC EC=2.7.11.26; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250}; CC -!- ACTIVITY REGULATION: Inhibited by phosphorylation at Ser-219 (By CC similarity). Activated by phosphorylation on Thr-215. {ECO:0000250, CC ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:17573348}. CC -!- SUBUNIT: Interacts with MAPT/TAU. {ECO:0000269|PubMed:23666762}. CC -!- INTERACTION: CC Q9P0L2; P05067: APP; NbExp=3; IntAct=EBI-968587, EBI-77613; CC Q9P0L2; P63172: DYNLT1; NbExp=3; IntAct=EBI-968587, EBI-1176455; CC Q9P0L2; Q0VD86: INCA1; NbExp=3; IntAct=EBI-968587, EBI-6509505; CC Q9P0L2; O95988: TCL1B; NbExp=5; IntAct=EBI-968587, EBI-727338; CC Q9P0L2; Q8IY57-5: YAF2; NbExp=3; IntAct=EBI-968587, EBI-12111538; CC Q9P0L2; P61981: YWHAG; NbExp=4; IntAct=EBI-968587, EBI-359832; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:21145462}; CC Peripheral membrane protein {ECO:0000269|PubMed:21145462}. Cytoplasm, CC cytoskeleton {ECO:0000250}. Cytoplasm {ECO:0000269|PubMed:23666762}. CC Cell projection, dendrite {ECO:0000269|PubMed:23666762}. Note=Appears CC to localize to an intracellular network. {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q9P0L2-1; Sequence=Displayed; CC Name=2 {ECO:0000305}; CC IsoId=Q9P0L2-2; Sequence=VSP_051702, VSP_051704; CC Name=3 {ECO:0000305}; CC IsoId=Q9P0L2-3; Sequence=VSP_051703, VSP_051704; CC -!- TISSUE SPECIFICITY: Highly expressed in heart, skeletal muscle, brain, CC fetal brain and fetal kidney. {ECO:0000269|PubMed:9108484}. CC -!- DOMAIN: The UBA domain does not seem to bind ubiquitin and ubiquitin- CC like and might play a role in regulating the enzyme conformation and CC localization. Activation of the kinase activity following CC phosphorylation at Thr-208 is accompanied by a conformational change CC that alters the orientation of the UBA domain with respect to the CC catalytic domain (By similarity). {ECO:0000250}. CC -!- DOMAIN: The KA1 domain mediates binding to phospholipids and targeting CC to membranes. Binds phosphatidic acid (PA), phosphatidylserine (PtdSer) CC and phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2). CC {ECO:0000269|PubMed:21145462}. CC -!- PTM: Phosphorylation at Thr-613 by PRKCZ/aPKC in polarized epithelial CC cells inhibits the kinase activity (By similarity). Phosphorylated at CC Thr-215 by STK11/LKB1 in complex with STE20-related adapter-alpha CC (STRADA) pseudo kinase and CAB39. Phosphorylation at Thr-215 by TAOK1 CC activates the kinase activity, leading to phosphorylation and CC detachment of MAPT/TAU from microtubules. Phosphorylation at Ser-219 by CC GSK3-beta (GSK3B) inhibits the kinase activity. {ECO:0000250, CC ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:17573348}. CC -!- DISEASE: Note=Genetic variations in MARK1 may be associated with CC susceptibility to autism. MARK1 is overexpressed in the prefrontal CC cortex of patients with autism and causes changes in the function of CC cortical dendrites. CC -!- MISCELLANEOUS: Phosphorylation of MAPT/tau by MARK1 could play a role CC in early steps of Alzheimer disease. Pathological aggregation of CC MAPT/tau to neurofibrillary tangles, filamentous structures consisting CC of paired helical filaments (PHFs), is one of the hallmarks of CC Alzheimer disease. Hyperphosphorylation by MARK1 could be the initial CC step for this abnormal aggregation of tau in Alzheimer disease and CC animal models of tauopathy (PubMed:11089574). CC {ECO:0000305|PubMed:11089574}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. SNF1 subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA96001.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC Sequence=BAB55152.1; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF154845; AAF72103.1; -; mRNA. DR EMBL; AB040910; BAA96001.1; ALT_INIT; mRNA. DR EMBL; AK027493; BAB55152.1; ALT_FRAME; mRNA. DR EMBL; AC096640; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL592406; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471100; EAW93299.1; -; Genomic_DNA. DR EMBL; CH471100; EAW93300.1; -; Genomic_DNA. DR EMBL; CH471100; EAW93302.1; -; Genomic_DNA. DR EMBL; BC113869; AAI13870.1; -; mRNA. DR EMBL; BC114478; AAI14479.1; -; mRNA. DR CCDS; CCDS31029.2; -. [Q9P0L2-1] DR CCDS; CCDS65789.1; -. [Q9P0L2-3] DR RefSeq; NP_001273057.1; NM_001286128.2. [Q9P0L2-3] DR RefSeq; NP_061120.3; NM_018650.4. [Q9P0L2-1] DR PDB; 2HAK; X-ray; 2.60 A; A/B/C/D/E/F/G/H=45-371. DR PDB; 3OSE; X-ray; 1.70 A; A=683-795. DR PDB; 6C9D; X-ray; 2.50 A; A/B=45-795. DR PDBsum; 2HAK; -. DR PDBsum; 3OSE; -. DR PDBsum; 6C9D; -. DR AlphaFoldDB; Q9P0L2; -. DR SASBDB; Q9P0L2; -. DR SMR; Q9P0L2; -. DR BioGRID; 110309; 84. DR DIP; DIP-39777N; -. DR FunCoup; Q9P0L2; 1289. DR IntAct; Q9P0L2; 53. DR MINT; Q9P0L2; -. DR STRING; 9606.ENSP00000483424; -. DR BindingDB; Q9P0L2; -. DR ChEMBL; CHEMBL5940; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q9P0L2; -. DR GuidetoPHARMACOLOGY; 2097; -. DR CarbonylDB; Q9P0L2; -. DR iPTMnet; Q9P0L2; -. DR PhosphoSitePlus; Q9P0L2; -. DR BioMuta; MARK1; -. DR DMDM; 124056494; -. DR jPOST; Q9P0L2; -. DR MassIVE; Q9P0L2; -. DR PaxDb; 9606-ENSP00000483424; -. DR PeptideAtlas; Q9P0L2; -. DR ProteomicsDB; 83571; -. [Q9P0L2-1] DR ProteomicsDB; 83572; -. [Q9P0L2-2] DR ProteomicsDB; 83573; -. [Q9P0L2-3] DR Pumba; Q9P0L2; -. DR Antibodypedia; 2072; 432 antibodies from 33 providers. DR DNASU; 4139; -. DR Ensembl; ENST00000366917.6; ENSP00000355884.5; ENSG00000116141.18. [Q9P0L2-1] DR Ensembl; ENST00000366918.8; ENSP00000355885.4; ENSG00000116141.18. [Q9P0L2-3] DR GeneID; 4139; -. DR KEGG; hsa:4139; -. DR MANE-Select; ENST00000366917.6; ENSP00000355884.5; NM_018650.5; NP_061120.3. DR UCSC; uc001hmm.6; human. [Q9P0L2-1] DR AGR; HGNC:6896; -. DR ClinPGx; PA30639; -. DR CTD; 4139; -. DR DisGeNET; 4139; -. DR GeneCards; MARK1; -. DR HGNC; HGNC:6896; MARK1. DR HPA; ENSG00000116141; Low tissue specificity. DR MIM; 606511; gene. DR OpenTargets; ENSG00000116141; -. DR VEuPathDB; HostDB:ENSG00000116141; -. DR eggNOG; KOG0586; Eukaryota. DR GeneTree; ENSGT00940000157560; -. DR InParanoid; Q9P0L2; -. DR OrthoDB; 193931at2759; -. DR PAN-GO; Q9P0L2; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q9P0L2; -. DR PathwayCommons; Q9P0L2; -. DR SignaLink; Q9P0L2; -. DR SIGNOR; Q9P0L2; -. DR Agora; ENSG00000116141; -. DR BioGRID-ORCS; 4139; 14 hits in 1190 CRISPR screens. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; MARK1; human. DR EvolutionaryTrace; Q9P0L2; -. DR GeneWiki; MARK1; -. DR GenomeRNAi; 4139; -. DR Pharos; Q9P0L2; Tchem. DR PRO; PR:Q9P0L2; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q9P0L2; protein. DR Bgee; ENSG00000116141; Expressed in cortical plate and 178 other cell types or tissues. DR ExpressionAtlas; Q9P0L2; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005856; C:cytoskeleton; ISS:UniProtKB. DR GO; GO:0030425; C:dendrite; IDA:UniProtKB. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0015630; C:microtubule cytoskeleton; TAS:ProtInc. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0098794; C:postsynapse; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB. DR GO; GO:0070300; F:phosphatidic acid binding; IDA:UniProtKB. DR GO; GO:0005546; F:phosphatidylinositol-4,5-bisphosphate binding; IDA:UniProtKB. DR GO; GO:0001786; F:phosphatidylserine binding; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0048156; F:tau protein binding; NAS:ARUK-UCL. DR GO; GO:0050321; F:tau-protein kinase activity; IMP:UniProtKB. DR GO; GO:0007010; P:cytoskeleton organization; ISS:UniProtKB. DR GO; GO:0051654; P:establishment of mitochondrion localization; ISS:ARUK-UCL. DR GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB. DR GO; GO:0000226; P:microtubule cytoskeleton organization; ISS:ARUK-UCL. DR GO; GO:0010719; P:negative regulation of epithelial to mesenchymal transition; IDA:ARUK-UCL. DR GO; GO:0010629; P:negative regulation of gene expression; IDA:ARUK-UCL. DR GO; GO:0001764; P:neuron migration; ISS:UniProtKB. DR GO; GO:0010628; P:positive regulation of gene expression; IDA:ARUK-UCL. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0050773; P:regulation of dendrite development; ISS:ARUK-UCL. DR GO; GO:0010975; P:regulation of neuron projection development; ISS:ARUK-UCL. DR GO; GO:0150052; P:regulation of postsynapse assembly; IEA:Ensembl. DR GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW. DR CDD; cd12196; MARK1-3_C; 1. DR CDD; cd14072; STKc_MARK; 1. DR CDD; cd14405; UBA_MARK1; 1. DR FunFam; 1.10.510.10:FF:001032; KP78b, isoform A; 1. DR FunFam; 1.10.8.10:FF:000011; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.200.20:FF:000003; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.310.80:FF:000001; Non-specific serine/threonine protein kinase; 1. DR Gene3D; 1.10.8.10; DNA helicase RuvA subunit, C-terminal domain; 1. DR Gene3D; 3.30.310.80; Kinase associated domain 1, KA1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR028375; KA1/Ssp2_C. DR InterPro; IPR001772; KA1_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR049508; MARK1-4_cat. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR015940; UBA. DR PANTHER; PTHR24346; MAP/MICROTUBULE AFFINITY-REGULATING KINASE; 1. DR PANTHER; PTHR24346:SF21; SERINE_THREONINE-PROTEIN KINASE MARK1; 1. DR Pfam; PF02149; KA1; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00627; UBA; 1. DR SMART; SM00220; S_TKc; 1. DR SMART; SM00165; UBA; 1. DR SUPFAM; SSF103243; KA1-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50032; KA1; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50030; UBA; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Autism; KW Autism spectrum disorder; Cell membrane; Cell projection; Cytoplasm; KW Cytoskeleton; Kinase; Lipid-binding; Magnesium; Membrane; Metal-binding; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase; KW Wnt signaling pathway. FT CHAIN 1..795 FT /note="Serine/threonine-protein kinase MARK1" FT /id="PRO_0000086298" FT DOMAIN 60..311 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 325..370 FT /note="UBA" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00212" FT DOMAIN 746..795 FT /note="KA1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00565" FT REGION 1..40 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 377..495 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 539..700 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 31..40 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 380..403 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 447..459 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 462..473 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 486..495 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 590..599 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 647..657 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 661..676 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 683..697 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 182 FT /note="Proton acceptor" FT /evidence="ECO:0000250|UniProtKB:Q9H0K1, FT ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE- FT ProRule:PRU10027" FT BINDING 66..74 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000250|UniProtKB:Q9H0K1, FT ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 89 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000250|UniProtKB:O08678, FT ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 5 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 208 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:17573348" FT MOD_RES 215 FT /note="Phosphothreonine; by LKB1 and TAOK1" FT /evidence="ECO:0000269|PubMed:14976552" FT MOD_RES 219 FT /note="Phosphoserine; by GSK3-beta" FT /evidence="ECO:0000250|UniProtKB:O08678" FT MOD_RES 382 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8VHJ5" FT MOD_RES 390 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8VHJ5" FT MOD_RES 393 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8VHJ5" FT MOD_RES 403 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 423 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8VHJ5" FT MOD_RES 444 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O08678" FT MOD_RES 475 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8VHJ5" FT MOD_RES 588 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 613 FT /note="Phosphothreonine; by PKC/PRKCZ" FT /evidence="ECO:0000250" FT MOD_RES 666 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8VHJ5" FT VAR_SEQ 1..135 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_051702" FT VAR_SEQ 120..141 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:10819331" FT /id="VSP_051703" FT VAR_SEQ 663..677 FT /note="Missing (in isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:10819331, FT ECO:0000303|PubMed:14702039" FT /id="VSP_051704" FT VARIANT 233 FT /note="Y -> C (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040760" FT VARIANT 355 FT /note="N -> T (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040761" FT VARIANT 530 FT /note="V -> M (in dbSNP:rs56212551)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040762" FT VARIANT 578 FT /note="P -> L (in dbSNP:rs55691439)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040763" FT VARIANT 645 FT /note="R -> G (in dbSNP:rs12123778)" FT /id="VAR_030018" FT VARIANT 691 FT /note="E -> G (in dbSNP:rs55688276)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040764" FT MUTAGEN 215 FT /note="T->A: Prevents phosphorylation and activation by FT STK11/LKB1 complex." FT /evidence="ECO:0000269|PubMed:14976552" FT MUTAGEN 215 FT /note="T->E: Constitutively active." FT /evidence="ECO:0000269|PubMed:14976552" FT MUTAGEN 698 FT /note="R->S: Impairs phospholipid-binding, targeting to FT membrane and vesicle-binding; when associated with S-701." FT /evidence="ECO:0000269|PubMed:21145462" FT MUTAGEN 701 FT /note="R->S: Impairs phospholipid-binding, targeting to FT membrane and vesicle-binding; when associated with S-698." FT /evidence="ECO:0000269|PubMed:21145462" FT MUTAGEN 771..773 FT /note="RFK->AFA: Impairs phospholipid-binding." FT /evidence="ECO:0000269|PubMed:21145462" FT CONFLICT 16 FT /note="E -> V (in Ref. 2; AAF72103)" FT /evidence="ECO:0000305" FT CONFLICT 20 FT /note="S -> T (in Ref. 2; AAF72103)" FT /evidence="ECO:0000305" FT CONFLICT 522 FT /note="D -> N (in Ref. 4; BAB55152)" FT /evidence="ECO:0000305" FT CONFLICT 544 FT /note="V -> A (in Ref. 4; BAB55152)" FT /evidence="ECO:0000305" FT CONFLICT 763 FT /note="P -> A (in Ref. 4; BAB55152)" FT /evidence="ECO:0000305" FT CONFLICT 794 FT /note="K -> M (in Ref. 3; BAA96001)" FT /evidence="ECO:0000305" FT STRAND 55..57 FT /evidence="ECO:0007829|PDB:6C9D" FT STRAND 60..68 FT /evidence="ECO:0007829|PDB:6C9D" FT STRAND 70..79 FT /evidence="ECO:0007829|PDB:6C9D" FT TURN 80..82 FT /evidence="ECO:0007829|PDB:6C9D" FT STRAND 85..92 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 93..95 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 98..111 FT /evidence="ECO:0007829|PDB:6C9D" FT STRAND 122..127 FT /evidence="ECO:0007829|PDB:6C9D" FT STRAND 129..136 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 146..151 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 156..175 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 185..187 FT /evidence="ECO:0007829|PDB:6C9D" FT STRAND 188..190 FT /evidence="ECO:0007829|PDB:6C9D" FT STRAND 196..198 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 201..203 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 220..222 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 225..228 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 236..252 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 262..271 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 282..291 FT /evidence="ECO:0007829|PDB:6C9D" FT TURN 296..298 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 302..305 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 309..312 FT /evidence="ECO:0007829|PDB:6C9D" FT STRAND 316..318 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 333..341 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 346..355 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 360..368 FT /evidence="ECO:0007829|PDB:6C9D" FT TURN 706..708 FT /evidence="ECO:0007829|PDB:6C9D" FT HELIX 714..727 FT /evidence="ECO:0007829|PDB:3OSE" FT STRAND 731..736 FT /evidence="ECO:0007829|PDB:3OSE" FT STRAND 739..745 FT /evidence="ECO:0007829|PDB:3OSE" FT TURN 747..750 FT /evidence="ECO:0007829|PDB:3OSE" FT STRAND 753..762 FT /evidence="ECO:0007829|PDB:3OSE" FT HELIX 763..765 FT /evidence="ECO:0007829|PDB:3OSE" FT STRAND 767..777 FT /evidence="ECO:0007829|PDB:3OSE" FT HELIX 779..792 FT /evidence="ECO:0007829|PDB:3OSE" SQ SEQUENCE 795 AA; 89003 MW; 71BF6EB76912631B CRC64; MSARTPLPTV NERDTENHTS VDGYTEPHIQ PTKSSSRQNI PRCRNSITSA TDEQPHIGNY RLQKTIGKGN FAKVKLARHV LTGREVAVKI IDKTQLNPTS LQKLFREVRI MKILNHPNIV KLFEVIETEK TLYLVMEYAS GGEVFDYLVA HGRMKEKEAR AKFRQIVSAV QYCHQKYIVH RDLKAENLLL DGDMNIKIAD FGFSNEFTVG NKLDTFCGSP PYAAPELFQG KKYDGPEVDV WSLGVILYTL VSGSLPFDGQ NLKELRERVL RGKYRIPFYM STDCENLLKK LLVLNPIKRG SLEQIMKDRW MNVGHEEEEL KPYTEPDPDF NDTKRIDIMV TMGFARDEIN DALINQKYDE VMATYILLGR KPPEFEGGES LSSGNLCQRS RPSSDLNNST LQSPAHLKVQ RSISANQKQR RFSDHAGPSI PPAVSYTKRP QANSVESEQK EEWDKDVARK LGSTTVGSKS EMTASPLVGP ERKKSSTIPS NNVYSGGSMA RRNTYVCERT TDRYVALQNG KDSSLTEMSV SSISSAGSSV ASAVPSARPR HQKSMSTSGH PIKVTLPTIK DGSEAYRPGT TQRVPAASPS AHSISTATPD RTRFPRGSSS RSTFHGEQLR ERRSVAYNGP PASPSHETGA FAHARRGTST GIISKITSKF VRRDPSEGEA SGRTDTSRST SGEPKERDKE EGKDSKPRSL RFTWSMKTTS SMDPNDMMRE IRKVLDANNC DYEQKERFLL FCVHGDARQD SLVQWEMEVC KLPRLSLNGV RFKRISGTSI AFKNIASKIA NELKL // ID MARK4_HUMAN Reviewed; 752 AA. AC Q96L34; Q8NG37; Q96JG7; Q96SQ2; Q9BYD8; DT 28-FEB-2003, integrated into UniProtKB/Swiss-Prot. DT 01-DEC-2001, sequence version 1. DT 28-JAN-2026, entry version 213. DE RecName: Full=MAP/microtubule affinity-regulating kinase 4 {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:14594945, ECO:0000269|PubMed:15009667, ECO:0000269|PubMed:23184942}; DE AltName: Full=MAP/microtubule affinity-regulating kinase-like 1 {ECO:0000303|PubMed:11326310}; GN Name=MARK4 {ECO:0000303|PubMed:14594945, ECO:0000312|HGNC:HGNC:13538}; GN Synonyms=KIAA1860 {ECO:0000303|PubMed:11347906}, GN MARKL1 {ECO:0000303|PubMed:11326310}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND TISSUE SPECIFICITY. RC TISSUE=Brain; RX PubMed=11326310; DOI=10.1038/sj.neo.7900132; RA Kato T., Satoh S., Okabe H., Kitahara O., Ono K., Kihara C., Tanaka T., RA Tsunoda T., Yamaoka Y., Nakamura Y., Furukawa Y.; RT "Isolation of a novel human gene, MARKL1, homologous to MARK3 and its RT involvement in hepatocellular carcinogenesis."; RL Neoplasia 3:4-9(2001). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY, RP COFACTOR, INTERACTION WITH GAMMA-TUBULIN, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RX PubMed=14594945; DOI=10.1074/jbc.m304528200; RA Trinczek B., Brajenovic M., Ebneth A., Drewes G.; RT "MARK4 is a novel microtubule-associated proteins/microtubule affinity- RT regulating kinase that binds to the cellular microtubule network and to RT centrosomes."; RL J. Biol. Chem. 279:5915-5923(2004). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, AND CATALYTIC RP ACTIVITY. RX PubMed=15009667; DOI=10.1046/j.1471-4159.2003.02228.x; RA Schneider A., Laage R., von Ahsen O., Fischer A., Rossner M., Scheek S., RA Grunewald S., Kuner R., Weber D., Kruger C., Klaussner B., Gotz B., RA Hiemisch H., Newrzella D., Martin-Villalba A., Bach A., Schwaninger M.; RT "Identification of regulated genes during permanent focal cerebral RT ischaemia: characterization of the protein kinase 9b5/MARKL1/MARK4."; RL J. Neurochem. 88:1114-1126(2004). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Brain; RA Beghini A., Magnani I., Roversi G., Piepoli T., DiTerlizzi S., Pollo B., RA Conti A.M.F., Cowell J.K., Finocchiaro G., Larizza L.; RT "Neural progenitor-restricted isoform of MARKL1 gene is upregulated by RT 19q13 amplification in human glioblastoma."; RL Submitted (JUN-2002) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain; RX PubMed=11347906; DOI=10.1093/dnares/8.2.85; RA Nagase T., Nakayama M., Nakajima D., Kikuno R., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XX. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 8:85-95(2001). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Thyroid; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP ACTIVITY REGULATION, PHOSPHORYLATION AT THR-214, AND MUTAGENESIS OF RP THR-214. RX PubMed=14976552; DOI=10.1038/sj.emboj.7600110; RA Lizcano J.M., Goeransson O., Toth R., Deak M., Morrice N.A., Boudeau J., RA Hawley S.A., Udd L., Maekelae T.P., Hardie D.G., Alessi D.R.; RT "LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, RT including MARK/PAR-1."; RL EMBO J. 23:833-843(2004). RN [8] RP INTERACTION WITH YWHAQ. RX PubMed=16959763; DOI=10.1074/mcp.m600147-mcp200; RA Angrand P.O., Segura I., Voelkel P., Ghidelli S., Terry R., Brajenovic M., RA Vintersten K., Klein R., Superti-Furga G., Drewes G., Kuster B., RA Bouwmeester T., Acker-Palmer A.; RT "Transgenic mouse proteomics identifies new 14-3-3-associated proteins RT involved in cytoskeletal rearrangements and cell signaling."; RL Mol. Cell. Proteomics 5:2211-2227(2006). RN [9] RP UBIQUITINATION, DEUBIQUITINATION BY USP9X, AND INTERACTION WITH USP9X. RX PubMed=18254724; DOI=10.1042/bj20080067; RA Al-Hakim A.K., Zagorska A., Chapman L., Deak M., Peggie M., Alessi D.R.; RT "Control of AMPK-related kinases by USP9X and atypical Lys(29)/Lys(33)- RT linked polyubiquitin chains."; RL Biochem. J. 411:249-260(2008). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [11] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF THR-214. RX PubMed=23184942; DOI=10.1074/jbc.c112.396903; RA Li L., Guan K.L.; RT "Microtubule-associated protein/microtubule affinity-regulating kinase 4 RT (MARK4) is a negative regulator of the mammalian target of rapamycin RT complex 1 (mTORC1)."; RL J. Biol. Chem. 288:703-708(2013). RN [12] RP FUNCTION, INTERACTION WITH ODF2, AND SUBCELLULAR LOCATION. RX PubMed=23400999; DOI=10.1083/jcb.201206013; RA Kuhns S., Schmidt K.N., Reymann J., Gilbert D.F., Neuner A., Hub B., RA Carvalho R., Wiedemann P., Zentgraf H., Erfle H., Klingmuller U., RA Boutros M., Pereira G.; RT "The microtubule affinity regulating kinase MARK4 promotes axoneme RT extension during early ciliogenesis."; RL J. Cell Biol. 200:505-522(2013). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-543, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [14] RP FUNCTION, INTERACTION WITH MAPT, AND SUBCELLULAR LOCATION. RX PubMed=23666762; DOI=10.1007/s12017-013-8232-3; RA Gu G.J., Lund H., Wu D., Blokzijl A., Classon C., von Euler G., RA Landegren U., Sunnemark D., Kamali-Moghaddam M.; RT "Role of individual MARK isoforms in phosphorylation of tau at Ser262 in RT Alzheimer's disease."; RL NeuroMolecular Med. 15:458-469(2013). RN [15] RP FUNCTION, DEVELOPMENTAL STAGE, AND PHOSPHORYLATION. RX PubMed=25123532; DOI=10.1016/j.ejcb.2014.07.004; RA Rovina D., Fontana L., Monti L., Novielli C., Panini N., Sirchia S.M., RA Erba E., Magnani I., Larizza L.; RT "Microtubule-associated protein/microtubule affinity-regulating kinase 4 RT (MARK4) plays a role in cell cycle progression and cytoskeletal dynamics."; RL Eur. J. Cell Biol. 93:355-365(2014). RN [16] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH NLRP3. RX PubMed=28656979; DOI=10.1038/ncomms15986; RA Li X., Thome S., Ma X., Amrute-Nayak M., Finigan A., Kitt L., Masters L., RA James J.R., Shi Y., Meng G., Mallat Z.; RT "MARK4 regulates NLRP3 positioning and inflammasome activation through a RT microtubule-dependent mechanism."; RL Nat. Commun. 8:15986-15986(2017). RN [17] RP VARIANTS [LARGE SCALE ANALYSIS] GLN-377 AND CYS-418. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase (PubMed:14594945, CC PubMed:15009667, PubMed:23184942, PubMed:23666762). Phosphorylates the CC microtubule-associated protein MAPT/TAU (PubMed:14594945, CC PubMed:23666762). Also phosphorylates the microtubule-associated CC proteins MAP2 and MAP4 (PubMed:14594945). Involved in regulation of the CC microtubule network, causing reorganization of microtubules into CC bundles (PubMed:14594945, PubMed:25123532). Required for the initiation CC of axoneme extension during cilium assembly (PubMed:23400999). CC Regulates the centrosomal location of ODF2 and phosphorylates ODF2 in CC vitro (PubMed:23400999). Plays a role in cell cycle progression, CC specifically in the G1/S checkpoint (PubMed:25123532). Reduces neuronal CC cell survival (PubMed:15009667). Plays a role in energy homeostasis by CC regulating satiety and metabolic rate (By similarity). Promotes CC adipogenesis by activating JNK1 and inhibiting the p38MAPK pathway, and CC triggers apoptosis by activating the JNK1 pathway (By similarity). CC Phosphorylates mTORC1 complex member RPTOR and acts as a negative CC regulator of the mTORC1 complex, probably due to disruption of the CC interaction between phosphorylated RPTOR and the RRAGA/RRAGC CC heterodimer which is required for mTORC1 activation (PubMed:23184942). CC Involved in NLRP3 positioning along microtubules by mediating NLRP3 CC recruitment to microtubule organizing center (MTOC) upon inflammasome CC activation (PubMed:28656979). {ECO:0000250|UniProtKB:Q8CIP4, CC ECO:0000269|PubMed:14594945, ECO:0000269|PubMed:15009667, CC ECO:0000269|PubMed:23184942, ECO:0000269|PubMed:23400999, CC ECO:0000269|PubMed:23666762, ECO:0000269|PubMed:25123532, CC ECO:0000269|PubMed:28656979}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:14594945, ECO:0000269|PubMed:15009667, CC ECO:0000269|PubMed:23184942}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:14594945, ECO:0000269|PubMed:15009667, CC ECO:0000269|PubMed:23184942}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:14594945}; CC -!- ACTIVITY REGULATION: Activated by phosphorylation on Thr-214. CC {ECO:0000269|PubMed:14976552}. CC -!- SUBUNIT: Interacts with MAPT/TAU (PubMed:23666762). Interacts with CC gamma-tubulin (PubMed:14594945). Interacts with ODF2 (PubMed:23400999). CC Interacts with USP9X (PubMed:18254724). Interacts with YWHAQ CC (PubMed:16959763). Interacts with NLRP3; promoting NLRP3 recruitment to CC microtubule organizing center (MTOC) (PubMed:28656979). CC {ECO:0000269|PubMed:14594945, ECO:0000269|PubMed:16959763, CC ECO:0000269|PubMed:18254724, ECO:0000269|PubMed:23400999, CC ECO:0000269|PubMed:23666762, ECO:0000269|PubMed:28656979}. CC -!- INTERACTION: CC Q96L34; Q06481-5: APLP2; NbExp=3; IntAct=EBI-302319, EBI-25646567; CC Q96L34; P05067: APP; NbExp=3; IntAct=EBI-302319, EBI-77613; CC Q96L34; P60953: CDC42; NbExp=2; IntAct=EBI-302319, EBI-81752; CC Q96L34; P48730-2: CSNK1D; NbExp=3; IntAct=EBI-302319, EBI-9087876; CC Q96L34; Q15323: KRT31; NbExp=3; IntAct=EBI-302319, EBI-948001; CC Q96L34; P07948: LYN; NbExp=3; IntAct=EBI-302319, EBI-79452; CC Q96L34; Q9BYG4: PARD6G; NbExp=2; IntAct=EBI-302319, EBI-295417; CC Q96L34; Q8ND90: PNMA1; NbExp=2; IntAct=EBI-302319, EBI-302345; CC Q96L34; P41743: PRKCI; NbExp=2; IntAct=EBI-302319, EBI-286199; CC Q96L34; Q15831: STK11; NbExp=2; IntAct=EBI-302319, EBI-306838; CC Q96L34; P23258: TUBG1; NbExp=4; IntAct=EBI-302319, EBI-302589; CC Q96L34; Q04917: YWHAH; NbExp=7; IntAct=EBI-302319, EBI-306940; CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule organizing CC center, centrosome {ECO:0000269|PubMed:14594945}. Cytoplasm, CC cytoskeleton, microtubule organizing center CC {ECO:0000269|PubMed:14594945, ECO:0000269|PubMed:28656979}. Cytoplasm, CC cytoskeleton, cilium basal body {ECO:0000269|PubMed:23400999}. CC Cytoplasm, cytoskeleton, cilium axoneme {ECO:0000269|PubMed:23400999}. CC Cytoplasm {ECO:0000269|PubMed:23400999, ECO:0000269|PubMed:23666762}. CC Cell projection, dendrite {ECO:0000269|PubMed:23666762}. Note=Localized CC at the tips of neurite-like processes in differentiated neuroblast CC cells. Detected in the cytoplasm and neuropil of the hippocampus. CC {ECO:0000269|PubMed:14594945, ECO:0000269|PubMed:23666762}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; Synonyms=MARK4L; CC IsoId=Q96L34-1; Sequence=Displayed; CC Name=2; Synonyms=MARKL1S, MARK4S; CC IsoId=Q96L34-2; Sequence=VSP_004946; CC -!- TISSUE SPECIFICITY: Ubiquitous. Isoform 2 is brain-specific CC (PubMed:11326310). Expressed at highest levels in brain and testis. CC Also expressed in heart, lung, liver, muscle, kidney and spleen CC (PubMed:14594945). {ECO:0000269|PubMed:11326310, CC ECO:0000269|PubMed:14594945}. CC -!- DEVELOPMENTAL STAGE: Expressed at all stages of the mitotic cell cycle. CC {ECO:0000269|PubMed:25123532}. CC -!- PTM: Ubiquitinated with 'Lys-29'- and 'Lys-33'-linked polyubiquitins CC which appear to impede LKB1-mediated phosphorylation. Deubiquitinated CC by USP9X. {ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:18254724}. CC -!- PTM: Phosphorylated at Thr-214 by STK11/LKB1 in complex with STE20- CC related adapter-alpha (STRADA) pseudo kinase and CAB39 CC (PubMed:14976552). Phosphorylated throughout the cell cycle CC (PubMed:25123532). {ECO:0000269|PubMed:14976552, CC ECO:0000269|PubMed:25123532}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. SNF1 subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAB47489.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAB55238.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/419/MARK4"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB049127; BAB39380.1; -; mRNA. DR EMBL; AB088047; BAC03375.1; -; mRNA. DR EMBL; AY057448; AAL23683.1; -; mRNA. DR EMBL; AX305105; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AX305106; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AY120867; AAM55491.1; -; mRNA. DR EMBL; AB058763; BAB47489.1; ALT_INIT; mRNA. DR EMBL; AK027619; BAB55238.1; ALT_INIT; mRNA. DR EMBL; AK075272; BAC11510.1; -; mRNA. DR CCDS; CCDS12658.1; -. [Q96L34-2] DR CCDS; CCDS56097.1; -. [Q96L34-1] DR RefSeq; NP_001186796.1; NM_001199867.2. [Q96L34-1] DR RefSeq; NP_113605.2; NM_031417.3. [Q96L34-2] DR PDB; 5ES1; X-ray; 2.80 A; A=44-370. DR PDB; 8XFL; X-ray; 3.00 A; A/B=44-370. DR PDBsum; 5ES1; -. DR PDBsum; 8XFL; -. DR AlphaFoldDB; Q96L34; -. DR SMR; Q96L34; -. DR BioGRID; 121760; 74. DR FunCoup; Q96L34; 1008. DR IntAct; Q96L34; 50. DR MINT; Q96L34; -. DR STRING; 9606.ENSP00000262891; -. DR BindingDB; Q96L34; -. DR ChEMBL; CHEMBL5754; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q96L34; -. DR GuidetoPHARMACOLOGY; 2100; -. DR GlyGen; Q96L34; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q96L34; -. DR PhosphoSitePlus; Q96L34; -. DR BioMuta; MARK4; -. DR DMDM; 29840797; -. DR CPTAC; non-CPTAC-5644; -. DR jPOST; Q96L34; -. DR MassIVE; Q96L34; -. DR PaxDb; 9606-ENSP00000262891; -. DR PeptideAtlas; Q96L34; -. DR ProteomicsDB; 77145; -. [Q96L34-1] DR ProteomicsDB; 77146; -. [Q96L34-2] DR Pumba; Q96L34; -. DR Antibodypedia; 31285; 373 antibodies from 36 providers. DR DNASU; 57787; -. DR Ensembl; ENST00000262891.9; ENSP00000262891.3; ENSG00000007047.17. [Q96L34-1] DR Ensembl; ENST00000300843.8; ENSP00000300843.3; ENSG00000007047.17. [Q96L34-2] DR GeneID; 57787; -. DR KEGG; hsa:57787; -. DR MANE-Select; ENST00000262891.9; ENSP00000262891.3; NM_001199867.2; NP_001186796.1. DR UCSC; uc002pba.3; human. [Q96L34-1] DR AGR; HGNC:13538; -. DR ClinPGx; PA30641; -. DR CTD; 57787; -. DR DisGeNET; 57787; -. DR GeneCards; MARK4; -. DR HGNC; HGNC:13538; MARK4. DR HPA; ENSG00000007047; Low tissue specificity. DR MalaCards; MARK4; -. DR MIM; 606495; gene. DR OpenTargets; ENSG00000007047; -. DR VEuPathDB; HostDB:ENSG00000007047; -. DR eggNOG; KOG0586; Eukaryota. DR GeneTree; ENSGT00940000159555; -. DR HOGENOM; CLU_000288_157_5_1; -. DR InParanoid; Q96L34; -. DR OMA; CHLPWDK; -. DR OrthoDB; 193931at2759; -. DR PAN-GO; Q96L34; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q96L34; -. DR PathwayCommons; Q96L34; -. DR Reactome; R-HSA-5620912; Anchoring of the basal body to the plasma membrane. DR SignaLink; Q96L34; -. DR SIGNOR; Q96L34; -. DR Agora; ENSG00000007047; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 57787; 12 hits in 1188 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; MARK4; human. DR EvolutionaryTrace; Q96L34; -. DR GeneWiki; MARK4; -. DR GenomeRNAi; 57787; -. DR Pharos; Q96L34; Tchem. DR PRO; PR:Q96L34; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q96L34; protein. DR Bgee; ENSG00000007047; Expressed in cortical plate and 200 other cell types or tissues. DR ExpressionAtlas; Q96L34; baseline and differential. DR GO; GO:0005930; C:axoneme; IEA:UniProtKB-SubCell. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0036064; C:ciliary basal body; IMP:CACAO. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0030425; C:dendrite; IDA:UniProtKB. DR GO; GO:0000930; C:gamma-tubulin complex; IDA:ARUK-UCL. DR GO; GO:0015630; C:microtubule cytoskeleton; IDA:UniProtKB. DR GO; GO:0005815; C:microtubule organizing center; IDA:UniProtKB. DR GO; GO:0030496; C:midbody; IDA:ARUK-UCL. DR GO; GO:0043005; C:neuron projection; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; NAS:UniProtKB. DR GO; GO:0008093; F:cytoskeletal anchor activity; IDA:UniProtKB. DR GO; GO:0043015; F:gamma-tubulin binding; IDA:UniProtKB. DR GO; GO:0008017; F:microtubule binding; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0048156; F:tau protein binding; NAS:ARUK-UCL. DR GO; GO:0050321; F:tau-protein kinase activity; IDA:UniProtKB. DR GO; GO:0043130; F:ubiquitin binding; NAS:UniProtKB. DR GO; GO:0051301; P:cell division; IEA:UniProtKB-KW. DR GO; GO:0044782; P:cilium organization; IGI:ARUK-UCL. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0001578; P:microtubule bundle formation; IEP:UniProtKB. DR GO; GO:0000226; P:microtubule cytoskeleton organization; IMP:UniProtKB. DR GO; GO:0007399; P:nervous system development; IDA:UniProtKB. DR GO; GO:0045787; P:positive regulation of cell cycle; IDA:ARUK-UCL. DR GO; GO:0045724; P:positive regulation of cilium assembly; IMP:ARUK-UCL. DR GO; GO:1900227; P:positive regulation of NLRP3 inflammasome complex assembly; IDA:UniProtKB. DR GO; GO:0043068; P:positive regulation of programmed cell death; NAS:UniProtKB. DR GO; GO:1904781; P:positive regulation of protein localization to centrosome; IMP:ARUK-UCL. DR GO; GO:0006468; P:protein phosphorylation; IMP:UniProtKB. DR GO; GO:0046605; P:regulation of centrosome cycle; IMP:ARUK-UCL. DR CDD; cd12197; MARK4_C; 1. DR CDD; cd14072; STKc_MARK; 1. DR CDD; cd14407; UBA_MARK3_4; 1. DR FunFam; 1.10.510.10:FF:001032; KP78b, isoform A; 1. DR FunFam; 1.10.8.10:FF:000011; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.200.20:FF:000003; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.310.80:FF:000009; Non-specific serine/threonine protein kinase; 1. DR Gene3D; 1.10.8.10; DNA helicase RuvA subunit, C-terminal domain; 1. DR Gene3D; 3.30.310.80; Kinase associated domain 1, KA1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR028375; KA1/Ssp2_C. DR InterPro; IPR001772; KA1_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR049508; MARK1-4_cat. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR015940; UBA. DR PANTHER; PTHR24346; MAP/MICROTUBULE AFFINITY-REGULATING KINASE; 1. DR PANTHER; PTHR24346:SF28; MAP_MICROTUBULE AFFINITY-REGULATING KINASE 4; 1. DR Pfam; PF02149; KA1; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00627; UBA; 1. DR SMART; SM00220; S_TKc; 1. DR SMART; SM00165; UBA; 1. DR SUPFAM; SSF103243; KA1-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50032; KA1; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50030; UBA; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell cycle; Cell division; KW Cell projection; Cilium biogenesis/degradation; Cytoplasm; Cytoskeleton; KW Kinase; Mitosis; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Ubl conjugation. FT CHAIN 1..752 FT /note="MAP/microtubule affinity-regulating kinase 4" FT /id="PRO_0000086307" FT DOMAIN 59..310 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 324..368 FT /note="UBA" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00212" FT DOMAIN 703..752 FT /note="KA1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00565" FT REGION 1..36 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 385..614 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 391..406 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 544..553 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 181 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 65..73 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 88 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 214 FT /note="Phosphothreonine; by LKB1" FT /evidence="ECO:0000269|PubMed:14976552" FT MOD_RES 423 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8CIP4" FT MOD_RES 543 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 628..752 FT /note="ADEPERIGGPEVTSCHLPWDQTETAPRLLRFPWSVKLTSSRPPEALMAALRQ FT ATAAARCRCRQPQPFLLACLHGGAGGPEPLSHFEVEVCQLPRPGLRGVLFRRVAGTALA FT FRTLVTRISNDLEL -> TLDPSKRQNSNRCVSGASLPQGSKIRSQTNLRESGDLRSQV FT AIYLGIKRKPPPGCSDSPGV (in isoform 2)" FT /evidence="ECO:0000303|PubMed:11326310, FT ECO:0000303|PubMed:11347906" FT /id="VSP_004946" FT VARIANT 377 FT /note="R -> Q (in dbSNP:rs35070611)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040766" FT VARIANT 418 FT /note="R -> C (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs780763668)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040767" FT MUTAGEN 214 FT /note="T->A: Prevents phosphorylation and activation by FT STK11/LKB1 complex." FT /evidence="ECO:0000269|PubMed:14976552" FT MUTAGEN 214 FT /note="T->E: Mimicks phosphorylation state, leading to FT increased activity. Decreases mTORC1 activity." FT /evidence="ECO:0000269|PubMed:14976552, FT ECO:0000269|PubMed:23184942" FT CONFLICT 70 FT /note="F -> S (in Ref. 1; BAB39380/BAC03375)" FT /evidence="ECO:0000305" FT CONFLICT 518 FT /note="P -> L (in Ref. 6; BAB55238)" FT /evidence="ECO:0000305" FT STRAND 59..67 FT /evidence="ECO:0007829|PDB:5ES1" FT STRAND 69..78 FT /evidence="ECO:0007829|PDB:5ES1" FT TURN 79..81 FT /evidence="ECO:0007829|PDB:5ES1" FT STRAND 84..91 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 92..94 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 97..111 FT /evidence="ECO:0007829|PDB:5ES1" FT STRAND 121..126 FT /evidence="ECO:0007829|PDB:5ES1" FT STRAND 128..135 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 143..150 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 155..174 FT /evidence="ECO:0007829|PDB:5ES1" FT STRAND 186..189 FT /evidence="ECO:0007829|PDB:5ES1" FT STRAND 195..197 FT /evidence="ECO:0007829|PDB:5ES1" FT TURN 219..221 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 224..228 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 235..251 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 261..270 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 281..290 FT /evidence="ECO:0007829|PDB:5ES1" FT TURN 295..297 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 301..304 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 308..311 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 332..339 FT /evidence="ECO:0007829|PDB:5ES1" FT TURN 340..342 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 345..352 FT /evidence="ECO:0007829|PDB:5ES1" FT TURN 353..355 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 359..366 FT /evidence="ECO:0007829|PDB:5ES1" FT TURN 367..369 FT /evidence="ECO:0007829|PDB:5ES1" SQ SEQUENCE 752 AA; 82520 MW; 4B430FFD2B150E7A CRC64; MSSRTVLAPG NDRNSDTHGT LGSGRSSDKG PSWSSRSLGA RCRNSIASCP EEQPHVGNYR LLRTIGKGNF AKVKLARHIL TGREVAIKII DKTQLNPSSL QKLFREVRIM KGLNHPNIVK LFEVIETEKT LYLVMEYASA GEVFDYLVSH GRMKEKEARA KFRQIVSAVH YCHQKNIVHR DLKAENLLLD AEANIKIADF GFSNEFTLGS KLDTFCGSPP YAAPELFQGK KYDGPEVDIW SLGVILYTLV SGSLPFDGHN LKELRERVLR GKYRVPFYMS TDCESILRRF LVLNPAKRCT LEQIMKDKWI NIGYEGEELK PYTEPEEDFG DTKRIEVMVG MGYTREEIKE SLTSQKYNEV TATYLLLGRK TEEGGDRGAP GLALARVRAP SDTTNGTSSS KGTSHSKGQR SSSSTYHRQR RHSDFCGPSP APLHPKRSPT STGEAELKEE RLPGRKASCS TAGSGSRGLP PSSPMVSSAH NPNKAEIPER RKDSTSTPNN LPPSMMTRRN TYVCTERPGA ERPSLLPNGK ENSSGTPRVP PASPSSHSLA PPSGERSRLA RGSTIRSTFH GGQVRDRRAG GGGGGGVQNG PPASPTLAHE AAPLPAGRPR PTTNLFTKLT SKLTRRVADE PERIGGPEVT SCHLPWDQTE TAPRLLRFPW SVKLTSSRPP EALMAALRQA TAAARCRCRQ PQPFLLACLH GGAGGPEPLS HFEVEVCQLP RPGLRGVLFR RVAGTALAFR TLVTRISNDL EL // ID MTOR_HUMAN Reviewed; 2549 AA. AC P42345; Q4LE76; Q5TER1; Q6LE87; Q96QG3; Q9Y4I3; DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1995, sequence version 1. DT 28-JAN-2026, entry version 243. DE RecName: Full=Serine/threonine-protein kinase mTOR {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:15268862, ECO:0000269|PubMed:15467718, ECO:0000269|PubMed:15718470, ECO:0000269|PubMed:18925875, ECO:0000269|PubMed:22343943, ECO:0000269|PubMed:22576015, ECO:0000269|PubMed:22692423}; DE AltName: Full=FK506-binding protein 12-rapamycin complex-associated protein 1; DE AltName: Full=FKBP12-rapamycin complex-associated protein; DE AltName: Full=Mammalian target of rapamycin; DE Short=mTOR; DE AltName: Full=Mechanistic target of rapamycin; DE AltName: Full=Rapamycin and FKBP12 target 1; DE AltName: Full=Rapamycin target protein 1; DE AltName: Full=Tyrosine-protein kinase mTOR {ECO:0000305}; DE EC=2.7.10.2 {ECO:0000305|PubMed:26584640}; GN Name=MTOR {ECO:0000312|HGNC:HGNC:3942}; GN Synonyms=FRAP, FRAP1, FRAP2, RAFT1, RAPT1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Brain; RX PubMed=8008069; DOI=10.1038/369756a0; RA Brown E.J., Albers M.W., Shin T.B., Ichikawa K., Keith C.T., Lane W.S., RA Schreiber S.L.; RT "A mammalian protein targeted by G1-arresting rapamycin-receptor complex."; RL Nature 369:756-758(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=9653645; DOI=10.1006/geno.1997.5186; RA Onyango P., Lubyova B., Gardellin P., Kurzbauer R., Weith A.; RT "Molecular cloning and expression analysis of five novel genes in RT chromosome 1p36."; RL Genomics 50:187-198(1998). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RA Nakajima D., Saito K., Yamakawa H., Kikuno R.F., Nakayama M., Ohara R., RA Okazaki N., Koga H., Nagase T., Ohara O.; RT "Preparation of a set of expression-ready clones of mammalian long cDNAs RT encoding large proteins by the ORF trap cloning method."; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Cerebellum; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1362-2549. RX PubMed=11426320; DOI=10.1038/sj.gene.6363745; RA Stover C., Endo Y., Takahashi M., Lynch N., Constantinescu C., RA Vorup-Jensen T., Thiel S., Friedl H., Hankeln T., Hall R., Gregory S., RA Fujita T., Schwaeble W.; RT "The human gene for mannan-binding lectin-associated serine protease-2 RT (MASP-2), the effector component of the lectin route of complement RT activation, is part of a tightly linked gene cluster on chromosome 1p36.2- RT 3."; RL Genes Immun. 2:119-127(2001). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1987-2146, AND TISSUE SPECIFICITY. RC TISSUE=B-cell; RX PubMed=7809080; DOI=10.1073/pnas.91.26.12574; RA Chiu M.I., Katz H., Berlin V.; RT "RAPT1, a mammalian homolog of yeast Tor, interacts with the RT FKBP12/rapamycin complex."; RL Proc. Natl. Acad. Sci. U.S.A. 91:12574-12578(1994). RN [8] RP SUBCELLULAR LOCATION, AND AUTOPHOSPHORYLATION. RX PubMed=9434772; DOI=10.1006/bbrc.1997.7878; RA Withers D.J., Ouwens D.M., Nave B.T., van der Zon G.C.M., Alarcon C.M., RA Cardenas M.E., Heitman J., Maassen J.A., Shepherd P.R.; RT "Expression, enzyme activity, and subcellular localization of mammalian RT target of rapamycin in insulin-responsive cells."; RL Biochem. Biophys. Res. Commun. 241:704-709(1997). RN [9] RP INTERACTION WITH UBQLN1. RX PubMed=11853878; DOI=10.1016/s0167-4889(01)00164-1; RA Wu S., Mikhailov A., Kallo-Hosein H., Hara K., Yonezawa K., Avruch J.; RT "Characterization of ubiquilin 1, an mTOR-interacting protein."; RL Biochim. Biophys. Acta 1542:41-56(2002). RN [10] RP FUNCTION IN NUTRIENT-DEPENDENT CELL GROWTH, CATALYTIC ACTIVITY, FUNCTION IN RP PHOSPHORYLATION OF RPS6KB1, AND INTERACTION WITH RPTOR. RX PubMed=12150925; DOI=10.1016/s0092-8674(02)00808-5; RA Kim D.-H., Sarbassov D.D., Ali S.M., King J.E., Latek R.R., RA Erdjument-Bromage H., Tempst P., Sabatini D.M.; RT "mTOR interacts with raptor to form a nutrient-sensitive complex that RT signals to the growth machinery."; RL Cell 110:163-175(2002). RN [11] RP FUNCTION, AND INTERACTION WITH RPTOR. RX PubMed=12150926; DOI=10.1016/s0092-8674(02)00833-4; RA Hara K., Maruki Y., Long X., Yoshino K., Oshiro N., Hidayat S., RA Tokunaga C., Avruch J., Yonezawa K.; RT "Raptor, a binding partner of target of rapamycin (TOR), mediates TOR RT action."; RL Cell 110:177-189(2002). RN [12] RP INTERACTION WITH CLIP1, FUNCTION IN PHOSPHORYLATION OF CLIP1, AND CATALYTIC RP ACTIVITY. RX PubMed=12231510; DOI=10.1093/embo-reports/kvf197; RA Choi J.H., Bertram P.G., Drenan R., Carvalho J., Zhou H.H., Zheng X.F.; RT "The FKBP12-rapamycin-associated protein (FRAP) is a CLIP-170 kinase."; RL EMBO Rep. 3:988-994(2002). RN [13] RP FUNCTION IN PHOSPHORYLATION OF RPS6KB2, AND CATALYTIC ACTIVITY. RX PubMed=12087098; DOI=10.1074/jbc.m204080200; RA Park I.H., Bachmann R., Shirazi H., Chen J.; RT "Regulation of ribosomal S6 kinase 2 by mammalian target of rapamycin."; RL J. Biol. Chem. 277:31423-31429(2002). RN [14] RP INTERACTION WITH MLST8 AND RPTOR, IDENTIFICATION IN THE MTORC1 COMPLEX, AND RP TISSUE SPECIFICITY. RX PubMed=12408816; DOI=10.1016/s1097-2765(02)00636-6; RA Loewith R., Jacinto E., Wullschleger S., Lorberg A., Crespo J.L., RA Bonenfant D., Oppliger W., Jenoe P., Hall M.N.; RT "Two TOR complexes, only one of which is rapamycin sensitive, have distinct RT roles in cell growth control."; RL Mol. Cell 10:457-468(2002). RN [15] RP SUBCELLULAR LOCATION. RX PubMed=11930000; DOI=10.1073/pnas.261702698; RA Desai B.N., Myers B.R., Schreiber S.L.; RT "FKBP12-rapamycin-associated protein associates with mitochondria and RT senses osmotic stress via mitochondrial dysfunction."; RL Proc. Natl. Acad. Sci. U.S.A. 99:4319-4324(2002). RN [16] RP ACTIVITY REGULATION, AND FUNCTION IN RESPONSE TO LOW CELLULAR ENERGY. RX PubMed=14651849; DOI=10.1016/s0092-8674(03)00929-2; RA Inoki K., Zhu T., Guan K.L.; RT "TSC2 mediates cellular energy response to control cell growth and RT survival."; RL Cell 115:577-590(2003). RN [17] RP FUNCTION, ACTIVITY REGULATION, AND INTERACTION WITH MLST8. RX PubMed=12718876; DOI=10.1016/s1097-2765(03)00114-x; RA Kim D.-H., Sarbassov D.D., Ali S.M., Latek R.R., Guntur K.V.P., RA Erdjument-Bromage H., Tempst P., Sabatini D.M.; RT "GbetaL, a positive regulator of the rapamycin-sensitive pathway required RT for the nutrient-sensitive interaction between raptor and mTOR."; RL Mol. Cell 11:895-904(2003). RN [18] RP FUNCTION IN PHOSPHORYLATION OF PRKCA, CATALYTIC ACTIVITY, FUNCTION IN RP REGULATION OF THE ACTIN CYTOSKELETON, IDENTIFICATION IN THE MTORC2 COMPLEX, RP AND INTERACTION WITH RICTOR. RX PubMed=15268862; DOI=10.1016/j.cub.2004.06.054; RA Sarbassov D.D., Ali S.M., Kim D.-H., Guertin D.A., Latek R.R., RA Erdjument-Bromage H., Tempst P., Sabatini D.M.; RT "Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive RT and raptor-independent pathway that regulates the cytoskeleton."; RL Curr. Biol. 14:1296-1302(2004). RN [19] RP ACTIVITY REGULATION, AND FUNCTION IN RESPONSE TO HYPOXIA. RX PubMed=15545625; DOI=10.1101/gad.1256804; RA Brugarolas J., Lei K., Hurley R.L., Manning B.D., Reiling J.H., Hafen E., RA Witters L.A., Ellisen L.W., Kaelin W.G. Jr.; RT "Regulation of mTOR function in response to hypoxia by REDD1 and the RT TSC1/TSC2 tumor suppressor complex."; RL Genes Dev. 18:2893-2904(2004). RN [20] RP SUBCELLULAR LOCATION. RX PubMed=14578359; DOI=10.1074/jbc.m305912200; RA Drenan R.M., Liu X., Bertram P.G., Zheng X.F.S.; RT "FKBP12-rapamycin-associated protein or mammalian target of rapamycin RT (FRAP/mTOR) localization in the endoplasmic reticulum and the Golgi RT apparatus."; RL J. Biol. Chem. 279:772-778(2004). RN [21] RP FUNCTION IN REGULATION OF THE ACTIN CYTOSKELETON, CATALYTIC ACTIVITY, RP FUNCTION IN PHOSPHORYLATION OF PXN, IDENTIFICATION IN THE MTORC2 COMPLEX, RP INTERACTION WITH RICTOR, AUTOPHOSPHORYLATION, AND ACTIVITY REGULATION. RX PubMed=15467718; DOI=10.1038/ncb1183; RA Jacinto E., Loewith R., Schmidt A., Lin S., Ruegg M.A., Hall A., Hall M.N.; RT "Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin RT insensitive."; RL Nat. Cell Biol. 6:1122-1128(2004). RN [22] RP PHOSPHORYLATION AT SER-2448. RX PubMed=15899889; DOI=10.1074/jbc.m501707200; RA Chiang G.G., Abraham R.T.; RT "Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is RT mediated by p70S6 kinase."; RL J. Biol. Chem. 280:25485-25490(2005). RN [23] RP PHOSPHORYLATION AT THR-2446 AND SER-2448. RX PubMed=15905173; DOI=10.1074/jbc.m504045200; RA Holz M.K., Blenis J.; RT "Identification of S6 kinase 1 as a novel mammalian target of rapamycin RT (mTOR)-phosphorylating kinase."; RL J. Biol. Chem. 280:26089-26093(2005). RN [24] RP FUNCTION IN PHOSPHORYLATION OF AKT1, AND CATALYTIC ACTIVITY. RX PubMed=15718470; DOI=10.1126/science.1106148; RA Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M.; RT "Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex."; RL Science 307:1098-1101(2005). RN [25] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=17517883; DOI=10.1074/jbc.m702636200; RA Oshiro N., Takahashi R., Yoshino K., Tanimura K., Nakashima A., Eguchi S., RA Miyamoto T., Hara K., Takehana K., Avruch J., Kikkawa U., Yonezawa K.; RT "The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological RT substrate of mammalian target of rapamycin complex 1."; RL J. Biol. Chem. 282:20329-20339(2007). RN [26] RP IDENTIFICATION IN THE MTORC2 COMPLEX, AND INTERACTION WITH PRR5. RX PubMed=17599906; DOI=10.1074/jbc.m704343200; RA Woo S.-Y., Kim D.-H., Jun C.-B., Kim Y.-M., Haar E.V., Lee S.-I., RA Hegg J.W., Bandhakavi S., Griffin T.J., Kim D.-H.; RT "PRR5, a novel component of mTOR complex 2, regulates platelet-derived RT growth factor receptor beta expression and signaling."; RL J. Biol. Chem. 282:25604-25612(2007). RN [27] RP INTERACTION WITH AKT1S1, AND ACTIVITY REGULATION. RX PubMed=17386266; DOI=10.1016/j.molcel.2007.03.003; RA Sancak Y., Thoreen C.C., Peterson T.R., Lindquist R.A., Kang S.A., RA Spooner E., Carr S.A., Sabatini D.M.; RT "PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase."; RL Mol. Cell 25:903-915(2007). RN [28] RP IDENTIFICATION IN THE MTORC1 AND MTORC2 COMPLEXES, CATALYTIC ACTIVITY, AND RP FUNCTION IN PHOSPHORYLATION OF RPS6KB1 AND SGK1. RX PubMed=18925875; DOI=10.1042/bj20081668; RA Garcia-Martinez J.M., Alessi D.R.; RT "mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and RT activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)."; RL Biochem. J. 416:375-385(2008). RN [29] RP FUNCTION IN LIPID SYNTHESIS AND CELL GROWTH. RX PubMed=18762023; DOI=10.1016/j.cmet.2008.07.007; RA Porstmann T., Santos C.R., Griffiths B., Cully M., Wu M., Leevers S., RA Griffiths J.R., Chung Y.L., Schulze A.; RT "SREBP activity is regulated by mTORC1 and contributes to Akt-dependent RT cell growth."; RL Cell Metab. 8:224-236(2008). RN [30] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=18372248; DOI=10.1074/jbc.m800723200; RA Wang L., Harris T.E., Lawrence J.C. Jr.; RT "Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by RT mammalian target of rapamycin complex 1 (mTORC1)-mediated RT phosphorylation."; RL J. Biol. Chem. 283:15619-15627(2008). RN [31] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-567, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [32] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2478 AND SER-2481, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [33] RP FUNCTION, ACTIVITY REGULATION, AND SUBCELLULAR LOCATION. RX PubMed=18497260; DOI=10.1126/science.1157535; RA Sancak Y., Peterson T.R., Shaul Y.D., Lindquist R.A., Thoreen C.C., RA Bar-Peled L., Sabatini D.M.; RT "The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1."; RL Science 320:1496-1501(2008). RN [34] RP INTERACTION WITH DEPTOR, AND ACTIVITY REGULATION. RX PubMed=19446321; DOI=10.1016/j.cell.2009.03.046; RA Peterson T.R., Laplante M., Thoreen C.C., Sancak Y., Kang S.A., Kuehl W.M., RA Gray N.S., Sabatini D.M.; RT "DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma RT cells and required for their survival."; RL Cell 137:873-886(2009). RN [35] RP PHOSPHORYLATION AT SER-1261, AND ACTIVITY REGULATION. RX PubMed=19487463; DOI=10.1128/mcb.01665-08; RA Acosta-Jaquez H.A., Keller J.A., Foster K.G., Ekim B., Soliman G.A., RA Feener E.P., Ballif B.A., Fingar D.C.; RT "Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and RT cell growth."; RL Mol. Cell. Biol. 29:4308-4324(2009). RN [36] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-567, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [37] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-1218, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [38] RP PHOSPHORYLATION AT SER-2448. RX PubMed=19145465; DOI=10.1007/s00726-008-0230-7; RA Rosner M., Siegel N., Valli A., Fuchs C., Hengstschlager M.; RT "mTOR phosphorylated at S2448 binds to raptor and rictor."; RL Amino Acids 38:223-228(2010). RN [39] RP SUBCELLULAR LOCATION, AND ACTIVITY REGULATION. RX PubMed=20381137; DOI=10.1016/j.cell.2010.02.024; RA Sancak Y., Bar-Peled L., Zoncu R., Markhard A.L., Nada S., Sabatini D.M.; RT "Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is RT necessary for its activation by amino acids."; RL Cell 141:290-303(2010). RN [40] RP FUNCTION IN PHOSPHORYLATION OF DAP, FUNCTION IN AUTOPHAGY, AND CATALYTIC RP ACTIVITY. RX PubMed=20537536; DOI=10.1016/j.cub.2010.04.041; RA Koren I., Reem E., Kimchi A.; RT "DAP1, a novel substrate of mTOR, negatively regulates autophagy."; RL Curr. Biol. 20:1093-1098(2010). RN [41] RP FUNCTION, CATALYTIC ACTIVITY, AND PHOSPHORYLATION AT SER-2481. RX PubMed=20022946; DOI=10.1074/jbc.m109.096222; RA Soliman G.A., Acosta-Jaquez H.A., Dunlop E.A., Ekim B., Maj N.E., Tee A.R., RA Fingar D.C.; RT "mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic RT activity and clarifies rapamycin mechanism of action."; RL J. Biol. Chem. 285:7866-7879(2010). RN [42] RP FUNCTION, AND ACTIVITY REGULATION. RX PubMed=21376236; DOI=10.1016/j.cell.2011.02.014; RA Zinzalla V., Stracka D., Oppliger W., Hall M.N.; RT "Activation of mTORC2 by association with the ribosome."; RL Cell 144:757-768(2011). RN [43] RP INTERACTION WITH TTI1. RX PubMed=20810650; DOI=10.1101/gad.1934210; RA Hurov K.E., Cotta-Ramusino C., Elledge S.J.; RT "A genetic screen identifies the Triple T complex required for DNA damage RT signaling and ATM and ATR stability."; RL Genes Dev. 24:1939-1950(2010). RN [44] RP INTERACTION WITH TELO2. RX PubMed=20801936; DOI=10.1101/gad.1956410; RA Takai H., Xie Y., de Lange T., Pavletich N.P.; RT "Tel2 structure and function in the Hsp90-dependent maturation of mTOR and RT ATR complexes."; RL Genes Dev. 24:2019-2030(2010). RN [45] RP INTERACTION WITH TELO2 AND TTI1. RX PubMed=20427287; DOI=10.1074/jbc.m110.121699; RA Kaizuka T., Hara T., Oshiro N., Kikkawa U., Yonezawa K., Takehana K., RA Iemura S., Natsume T., Mizushima N.; RT "Tti1 and Tel2 are critical factors in mammalian target of rapamycin RT complex assembly."; RL J. Biol. Chem. 285:20109-20116(2010). RN [46] RP FUNCTION IN REGULATION OF RNA POLYMERASE III TRANSCRIPTION, FUNCTION IN RP PHOSPHORYLATION OF MAF1, AND CATALYTIC ACTIVITY. RX PubMed=20516213; DOI=10.1128/mcb.00319-10; RA Michels A.A., Robitaille A.M., Buczynski-Ruchonnet D., Hodroj W., RA Reina J.H., Hall M.N., Hernandez N.; RT "mTORC1 directly phosphorylates and regulates human MAF1."; RL Mol. Cell. Biol. 30:3749-3757(2010). RN [47] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-567 AND THR-1162, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [48] RP SUBCELLULAR LOCATION. RX PubMed=21867682; DOI=10.1016/j.bbrc.2011.08.034; RA Boulbes D.R., Shaiken T., Sarbassov D.D.; RT "Endoplasmic reticulum is a main localization site of mTORC2."; RL Biochem. Biophys. Res. Commun. 413:46-52(2011). RN [49] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [50] RP PHOSPHORYLATION AT SER-2159; THR-2164 AND SER-2481, AND MUTAGENESIS OF RP SER-2159 AND THR-2164. RX PubMed=21576368; DOI=10.1128/mcb.05437-11; RA Ekim B., Magnuson B., Acosta-Jaquez H.A., Keller J.A., Feener E.P., RA Fingar D.C.; RT "mTOR kinase domain phosphorylation promotes mTORC1 signaling, cell growth, RT and cell cycle progression."; RL Mol. Cell. Biol. 31:2787-2801(2011). RN [51] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [52] RP FUNCTION IN PHOSPHORYLATION OF GRB10, CATALYTIC ACTIVITY, AND FUNCTION IN RP INSR-DEPENDENT SIGNALING. RX PubMed=21659604; DOI=10.1126/science.1199498; RA Hsu P.P., Kang S.A., Rameseder J., Zhang Y., Ottina K.A., Lim D., RA Peterson T.R., Choi Y., Gray N.S., Yaffe M.B., Marto J.A., Sabatini D.M.; RT "The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated RT inhibition of growth factor signaling."; RL Science 332:1317-1322(2011). RN [53] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=22576015; DOI=10.4161/auto.19653; RA Martina J.A., Chen Y., Gucek M., Puertollano R.; RT "MTORC1 functions as a transcriptional regulator of autophagy by preventing RT nuclear transport of TFEB."; RL Autophagy 8:903-914(2012). RN [54] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=22343943; DOI=10.1038/emboj.2012.32; RA Settembre C., Zoncu R., Medina D.L., Vetrini F., Erdin S., Erdin S., RA Huynh T., Ferron M., Karsenty G., Vellard M.C., Facchinetti V., RA Sabatini D.M., Ballabio A.; RT "A lysosome-to-nucleus signalling mechanism senses and regulates the RT lysosome via mTOR and TFEB."; RL EMBO J. 31:1095-1108(2012). RN [55] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=22692423; DOI=10.1126/scisignal.2002790; RA Roczniak-Ferguson A., Petit C.S., Froehlich F., Qian S., Ky J., RA Angarola B., Walther T.C., Ferguson S.M.; RT "The transcription factor TFEB links mTORC1 signaling to transcriptional RT control of lysosome homeostasis."; RL Sci. Signal. 5:RA42-RA42(2012). RN [56] RP INTERACTION WITH HTR6. RX PubMed=23027611; DOI=10.1002/emmm.201201410; RA Meffre J., Chaumont-Dubel S., Mannoury la Cour C., Loiseau F., Watson D.J., RA Dekeyne A., Seveno M., Rivet J.M., Gaven F., Deleris P., Herve D., RA Fone K.C., Bockaert J., Millan M.J., Marin P.; RT "5-HT(6) receptor recruitment of mTOR as a mechanism for perturbed RT cognition in schizophrenia."; RL EMBO Mol. Med. 4:1043-1056(2012). RN [57] RP ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [58] RP FUNCTION, AND INTERACTION WITH TPCN1 AND TPCN2. RX PubMed=23394946; DOI=10.1016/j.cell.2013.01.023; RA Cang C., Zhou Y., Navarro B., Seo Y.J., Aranda K., Shi L., RA Battaglia-Hsu S., Nissim I., Clapham D.E., Ren D.; RT "mTOR regulates lysosomal ATP-sensitive two-pore Na(+) channels to adapt to RT metabolic state."; RL Cell 152:778-790(2013). RN [59] RP FUNCTION. RX PubMed=23426360; DOI=10.1074/jbc.m112.441493; RA Eaton J.M., Mullins G.R., Brindley D.N., Harris T.E.; RT "Phosphorylation of lipin 1 and charge on the phosphatidic acid head group RT control its phosphatidic acid phosphatase activity and membrane RT association."; RL J. Biol. Chem. 288:9933-9945(2013). RN [60] RP INTERACTION WITH BRAT1. RX PubMed=25657994; RA So E.Y., Ouchi T.; RT "The potential role of BRCA1-associated ATM activator-1 (BRAT1) in RT regulation of mTOR."; RL J. Cancer Biol. Res. 1:0-0(2013). RN [61] RP PHOSPHORYLATION AT THR-2173, AND MUTAGENESIS OF THR-2173. RX PubMed=24247430; DOI=10.1083/jcb.201305103; RA Halova L., Du W., Kirkham S., Smith D.L., Petersen J.; RT "Phosphorylation of the TOR ATP binding domain by AGC kinase constitutes a RT novel mode of TOR inhibition."; RL J. Cell Biol. 203:595-604(2013). RN [62] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1261, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [63] RP FUNCTION IN PHOSPHORYLATION OF AMBRA1. RX PubMed=23524951; DOI=10.1038/ncb2708; RA Nazio F., Strappazzon F., Antonioli M., Bielli P., Cianfanelli V., RA Bordi M., Gretzmeier C., Dengjel J., Piacentini M., Fimia G.M., Cecconi F.; RT "mTOR inhibits autophagy by controlling ULK1 ubiquitylation, self- RT association and function through AMBRA1 and TRAF6."; RL Nat. Cell Biol. 15:406-416(2013). RN [64] RP INTERACTION WITH NBN. RX PubMed=23762398; DOI=10.1371/journal.pone.0065586; RA Wang J.Q., Chen J.H., Chen Y.C., Chen M.Y., Hsieh C.Y., Teng S.C., Wu K.J.; RT "Interaction between NBS1 and the mTOR/Rictor/SIN1 complex through specific RT domains."; RL PLoS ONE 8:E65586-E65586(2013). RN [65] RP FUNCTION, AND REGULATION OF PYRIMIDINE SYNTHESIS. RX PubMed=23429704; DOI=10.1126/science.1228771; RA Robitaille A.M., Christen S., Shimobayashi M., Cornu M., Fava L.L., RA Moes S., Prescianotto-Baschong C., Sauer U., Jenoe P., Hall M.N.; RT "Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine RT synthesis."; RL Science 339:1320-1323(2013). RN [66] RP FUNCTION, AND REGULATION OF PYRIMIDINE SYNTHESIS. RX PubMed=23429703; DOI=10.1126/science.1228792; RA Ben-Sahra I., Howell J.J., Asara J.M., Manning B.D.; RT "Stimulation of de novo pyrimidine synthesis by growth signaling through RT mTOR and S6K1."; RL Science 339:1323-1328(2013). RN [67] RP FUNCTION, AND IDENTIFICATION IN THE MTORC1 COMPLEX. RX PubMed=24403073; DOI=10.1074/jbc.m113.482067; RA Coffman K., Yang B., Lu J., Tetlow A.L., Pelliccio E., Lu S., Guo D.C., RA Tang C., Dong M.Q., Tamanoi F.; RT "Characterization of the Raptor/4E-BP1 interaction by chemical cross- RT linking coupled with mass spectrometry analysis."; RL J. Biol. Chem. 289:4723-4734(2014). RN [68] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2448, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [69] RP FUNCTION. RX PubMed=24670654; DOI=10.1038/nature13079; RA Liu P., Begley M., Michowski W., Inuzuka H., Ginzberg M., Gao D., Tsou P., RA Gan W., Papa A., Kim B.M., Wan L., Singh A., Zhai B., Yuan M., Wang Z., RA Gygi S.P., Lee T.H., Lu K.P., Toker A., Pandolfi P.P., Asara J.M., RA Kirschner M.W., Sicinski P., Cantley L., Wei W.; RT "Cell-cycle-regulated activation of Akt kinase by phosphorylation at its RT carboxyl terminus."; RL Nature 508:541-545(2014). RN [70] RP FUNCTION. RX PubMed=24448649; DOI=10.1126/scisignal.2004754; RA Martina J.A., Diab H.I., Lishu L., Jeong-A L., Patange S., Raben N., RA Puertollano R.; RT "The nutrient-responsive transcription factor TFE3 promotes autophagy, RT lysosomal biogenesis, and clearance of cellular debris."; RL Sci. Signal. 7:ra9-ra9(2014). RN [71] RP INVOLVEMENT IN SKS, VARIANT SKS LYS-1799, AND CHARACTERIZATION OF VARIANT RP SKS LYS-1799. RX PubMed=25851998; DOI=10.1002/ajmg.a.37070; RA Baynam G., Overkov A., Davis M., Mina K., Schofield L., Allcock R., RA Laing N., Cook M., Dawkins H., Goldblatt J.; RT "A germline MTOR mutation in Aboriginal Australian siblings with RT intellectual disability, dysmorphism, macrocephaly, and small thoraces."; RL Am. J. Med. Genet. A 167:1659-1667(2015). RN [72] RP FUNCTION, INVOLVEMENT IN FCORD2, VARIANTS FCORD2 ASP-1459; PRO-1460; RP PHE-2215 AND TYR-2215, AND CHARACTERIZATION OF VARIANTS FCORD2 ASP-1459; RP PRO-1460; PHE-2215 AND TYR-2215. RX PubMed=26018084; DOI=10.1002/ana.24444; RA Nakashima M., Saitsu H., Takei N., Tohyama J., Kato M., Kitaura H., RA Shiina M., Shirozu H., Masuda H., Watanabe K., Ohba C., Tsurusaki Y., RA Miyake N., Zheng Y., Sato T., Takebayashi H., Ogata K., Kameyama S., RA Kakita A., Matsumoto N.; RT "Somatic mutations in the MTOR gene cause focal cortical dysplasia type RT IIb."; RL Ann. Neurol. 78:375-386(2015). RN [73] RP INVOLVEMENT IN SKS, VARIANT SKS LYS-1799, AND CHARACTERIZATION OF VARIANT RP SKS LYS-1799. RX PubMed=26542245; DOI=10.1186/s12881-015-0240-8; RA Mroske C., Rasmussen K., Shinde D.N., Huether R., Powis Z., Lu H.M., RA Baxter R.M., McPherson E., Tang S.; RT "Germline activating MTOR mutation arising through gonadal mosaicism in two RT brothers with megalencephaly and neurodevelopmental abnormalities."; RL BMC Med. Genet. 16:102-102(2015). RN [74] RP FUNCTION IN PHOSPHORYLATION OF AMBRA1. RX PubMed=25438055; DOI=10.1038/ncb3072; RA Cianfanelli V., Fuoco C., Lorente M., Salazar M., Quondamatteo F., RA Gherardini P.F., De Zio D., Nazio F., Antonioli M., D'Orazio M., Skobo T., RA Bordi M., Rohde M., Dalla Valle L., Helmer-Citterich M., Gretzmeier C., RA Dengjel J., Fimia G.M., Piacentini M., Di Bartolomeo S., Velasco G., RA Cecconi F.; RT "AMBRA1 links autophagy to cell proliferation and tumorigenesis by RT promoting c-Myc dephosphorylation and degradation."; RL Nat. Cell Biol. 17:20-30(2015). RN [75] RP ERRATUM OF PUBMED:25438055. RX PubMed=25925585; DOI=10.1038/ncb3171; RA Cianfanelli V., Fuoco C., Lorente M., Salazar M., Quondamatteo F., RA Gherardini P.F., De Zio D., Nazio F., Antonioli M., D'Orazio M., Skobo T., RA Bordi M., Rohde M., Dalla Valle L., Helmer-Citterich M., Gretzmeier C., RA Dengjel J., Fimia G.M., Piacentini M., Di Bartolomeo S., Velasco G., RA Cecconi F.; RL Nat. Cell Biol. 17:706-706(2015). RN [76] RP FUNCTION, INVOLVEMENT IN FCORD2, VARIANTS FCORD2 HIS-624; ASP-1450; RP ARG-1483; HIS-1709; LYS-1977; CYS-2193; PHE-2215; GLN-2427 AND PRO-2427, RP AND CHARACTERIZATION OF VARIANTS FCORD2 ARG-1483; GLN-2427 AND PRO-2427. RX PubMed=25799227; DOI=10.1038/nm.3824; RA Lim J.S., Kim W.I., Kang H.C., Kim S.H., Park A.H., Park E.K., Cho Y.W., RA Kim S., Kim H.M., Kim J.A., Kim J., Rhee H., Kang S.G., Kim H.D., Kim D., RA Kim D.S., Lee J.H.; RT "Brain somatic mutations in MTOR cause focal cortical dysplasia type II RT leading to intractable epilepsy."; RL Nat. Med. 21:395-400(2015). RN [77] RP ACTIVITY REGULATION. RX PubMed=25561175; DOI=10.1038/nature14107; RA Rebsamen M., Pochini L., Stasyk T., de Araujo M.E., Galluccio M., RA Kandasamy R.K., Snijder B., Fauster A., Rudashevskaya E.L., Bruckner M., RA Scorzoni S., Filipek P.A., Huber K.V., Bigenzahn J.W., Heinz L.X., RA Kraft C., Bennett K.L., Indiveri C., Huber L.A., Superti-Furga G.; RT "SLC38A9 is a component of the lysosomal amino acid sensing machinery that RT controls mTORC1."; RL Nature 519:477-481(2015). RN [78] RP INVOLVEMENT IN FCORD2, AND VARIANT FCORD2 GLY-1456. RX PubMed=25878179; DOI=10.1212/wnl.0000000000001594; RA Leventer R.J., Scerri T., Marsh A.P., Pope K., Gillies G., Maixner W., RA MacGregor D., Harvey A.S., Delatycki M.B., Amor D.J., Crino P., Bahlo M., RA Lockhart P.J.; RT "Hemispheric cortical dysplasia secondary to a mosaic somatic mutation in RT MTOR."; RL Neurology 84:2029-2032(2015). RN [79] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [80] RP ACTIVITY REGULATION. RX PubMed=25567906; DOI=10.1126/science.1257132; RA Wang S., Tsun Z.Y., Wolfson R.L., Shen K., Wyant G.A., Plovanich M.E., RA Yuan E.D., Jones T.D., Chantranupong L., Comb W., Wang T., Bar-Peled L., RA Zoncu R., Straub C., Kim C., Park J., Sabatini B.L., Sabatini D.M.; RT "Metabolism. Lysosomal amino acid transporter SLC38A9 signals arginine RT sufficiency to mTORC1."; RL Science 347:188-194(2015). RN [81] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=26584640; DOI=10.1038/cr.2015.133; RA Yin Y., Hua H., Li M., Liu S., Kong Q., Shao T., Wang J., Luo Y., Wang Q., RA Luo T., Jiang Y.; RT "mTORC2 promotes type I insulin-like growth factor receptor and insulin RT receptor activation through the tyrosine kinase activity of mTOR."; RL Cell Res. 26:46-65(2016). RN [82] RP INTERACTION WITH WAC. RX PubMed=26812014; DOI=10.1016/j.devcel.2015.12.019; RA David-Morrison G., Xu Z., Rui Y.N., Charng W.L., Jaiswal M., Yamamoto S., RA Xiong B., Zhang K., Sandoval H., Duraine L., Zuo Z., Zhang S., Bellen H.J.; RT "WAC regulates mTOR activity by acting as an adaptor for the TTT and RT Pontin/Reptin complexes."; RL Dev. Cell 36:139-151(2016). RN [83] RP SUBCELLULAR LOCATION. RX PubMed=27623384; DOI=10.1016/j.devcel.2016.08.001; RA Krishna S., Palm W., Lee Y., Yang W., Bandyopadhyay U., Xu H., Florey O., RA Thompson C.B., Overholtzer M.; RT "PIKfyve Regulates Vacuole Maturation and Nutrient Recovery following RT Engulfment."; RL Dev. Cell 38:536-547(2016). RN [84] RP INVOLVEMENT IN FCORD2, VARIANTS GLU-1376 AND VAL-2501, VARIANTS FCORD2 RP SER-1459; PRO-1460; PHE-2215 AND TYR-2215, AND VARIANTS SKS ARG-1490; RP ILE-1595; THR-1832; CYS-1888 AND ILE-2327. RX PubMed=27830187; DOI=10.1212/nxg.0000000000000118; RA Moeller R.S., Weckhuysen S., Chipaux M., Marsan E., Taly V., Bebin E.M., RA Hiatt S.M., Prokop J.W., Bowling K.M., Mei D., Conti V., de la Grange P., RA Ferrand-Sorbets S., Dorfmueller G., Lambrecq V., Larsen L.H., Leguern E., RA Guerrini R., Rubboli G., Cooper G.M., Baulac S.; RT "Germline and somatic mutations in the MTOR gene in focal cortical RT dysplasia and epilepsy."; RL Neurol. Genet. 2:E118-E118(2016). RN [85] RP FUNCTION. RX PubMed=30171069; DOI=10.1074/jbc.ra118.005354; RA Choppara S., Ganga S., Manne R., Dutta P., Singh S., Santra M.K.; RT "The SCFFBXO46 ubiquitin ligase complex mediates degradation of the tumor RT suppressor FBXO31 and thereby prevents premature cellular senescence."; RL J. Biol. Chem. 293:16291-16306(2018). RN [86] RP SUBCELLULAR LOCATION, AND INTERACTION WITH MEAK7. RX PubMed=29750193; DOI=10.1126/sciadv.aao5838; RA Nguyen J.T., Ray C., Fox A.L., Mendonca D.B., Kim J.K., Krebsbach P.H.; RT "Mammalian EAK-7 activates alternative mTOR signaling to regulate cell RT proliferation and migration."; RL Sci. Adv. 4:EAAO5838-EAAO5838(2018). RN [87] RP FUNCTION, CATALYTIC ACTIVITY, PHOSPHORYLATION AT SER-2159, AND MUTAGENESIS RP OF SER-2159. RX PubMed=29150432; DOI=10.15252/embj.201696164; RA Bodur C., Kazyken D., Huang K., Ekim Ustunel B., Siroky K.A., Tooley A.S., RA Gonzalez I.E., Foley D.H., Acosta-Jaquez H.A., Barnes T.M., Steinl G.K., RA Cho K.W., Lumeng C.N., Riddle S.M., Myers M.G. Jr., Fingar D.C.; RT "The IKK-related kinase TBK1 activates mTORC1 directly in response to RT growth factors and innate immune agonists."; RL EMBO J. 37:19-38(2018). RN [88] RP INTERACTION WITH TM4SF5, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ASP-2357 RP AND VAL-2364. RX PubMed=30956113; DOI=10.1016/j.cmet.2019.03.005; RA Jung J.W., Macalino S.J.Y., Cui M., Kim J.E., Kim H.J., Song D.G., RA Nam S.H., Kim S., Choi S., Lee J.W.; RT "Transmembrane 4 L six family member 5 senses arginine for mTORC1 RT signaling."; RL Cell Metab. 29:1306-1319(2019). RN [89] RP FUNCTION. RX PubMed=30704899; DOI=10.1016/j.molcel.2018.12.017; RA Cheng X., Ma X., Zhu Q., Song D., Ding X., Li L., Jiang X., Wang X., RA Tian R., Su H., Shen Z., Chen S., Liu T., Gong W., Liu W., Sun Q.; RT "Pacer is a mediator of mTORC1 and GSK3-TIP60 signaling in regulation of RT autophagosome maturation and lipid metabolism."; RL Mol. Cell 73:1-15(2019). RN [90] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=31112131; DOI=10.7554/elife.43038; RA Jewell J.L., Fu V., Hong A.W., Yu F.X., Meng D., Melick C.H., Wang H., RA Lam W.M., Yuan H.X., Taylor S.S., Guan K.L.; RT "GPCR signaling inhibits mTORC1 via PKA phosphorylation of Raptor."; RL Elife 8:0-0(2019). RN [91] RP FUNCTION. RX PubMed=31695197; DOI=10.1038/s41586-019-1738-6; RA MacVicar T., Ohba Y., Nolte H., Mayer F.C., Tatsuta T., Sprenger H.G., RA Lindner B., Zhao Y., Li J., Bruns C., Krueger M., Habich M., Riemer J., RA Schwarzer R., Pasparakis M., Henschke S., Bruening J.C., Zamboni N., RA Langer T.; RT "Lipid signalling drives proteolytic rewiring of mitochondria by YME1L."; RL Nature 575:361-365(2019). RN [92] RP INTERACTION WITH GPR137B. RX PubMed=31036939; DOI=10.1038/s41556-019-0321-6; RA Gan L., Seki A., Shen K., Iyer H., Han K., Hayer A., Wollman R., Ge X., RA Lin J.R., Dey G., Talbot W.S., Meyer T.; RT "The lysosomal GPCR-like protein GPR137B regulates Rag and mTORC1 RT localization and activity."; RL Nat. Cell Biol. 21:614-626(2019). RN [93] RP FUNCTION. RX PubMed=31601708; DOI=10.1126/science.aay0166; RA Rogala K.B., Gu X., Kedir J.F., Abu-Remaileh M., Bianchi L.F., RA Bottino A.M.S., Dueholm R., Niehaus A., Overwijn D., Fils A.P., Zhou S.X., RA Leary D., Laqtom N.N., Brignole E.J., Sabatini D.M.; RT "Structural basis for the docking of mTORC1 on the lysosomal surface."; RL Science 366:468-475(2019). RN [94] RP INTERACTION WITH RICTOR. RX PubMed=33378666; DOI=10.1016/j.celrep.2020.108564; RA Wrobel L., Siddiqi F.H., Hill S.M., Son S.M., Karabiyik C., Kim H., RA Rubinsztein D.C.; RT "mTORC2 Assembly Is Regulated by USP9X-Mediated Deubiquitination of RT RICTOR."; RL Cell Rep. 33:108564-108564(2020). RN [95] RP FUNCTION, AND ACTIVITY REGULATION. RX PubMed=32612235; DOI=10.1038/s41586-020-2444-0; RA Napolitano G., Di Malta C., Esposito A., de Araujo M.E.G., Pece S., RA Bertalot G., Matarese M., Benedetti V., Zampelli A., Stasyk T., RA Siciliano D., Venuta A., Cesana M., Vilardo C., Nusco E., Monfregola J., RA Calcagni A., Di Fiore P.P., Huber L.A., Ballabio A.; RT "A substrate-specific mTORC1 pathway underlies Birt-Hogg-Dube syndrome."; RL Nature 585:597-602(2020). RN [96] RP FUNCTION. RX PubMed=32561715; DOI=10.1038/s41467-020-16886-2; RA Son S.M., Park S.J., Stamatakou E., Vicinanza M., Menzies F.M., RA Rubinsztein D.C.; RT "Leucine regulates autophagy via acetylation of the mTORC1 component RT raptor."; RL Nat. Commun. 11:3148-3148(2020). RN [97] RP INTERACTION WITH NCKAP1L. RX PubMed=32647003; DOI=10.1126/science.aay5663; RA Cook S.A., Comrie W.A., Poli M.C., Similuk M., Oler A.J., Faruqi A.J., RA Kuhns D.B., Yang S., Vargas-Hernandez A., Carisey A.F., Fournier B., RA Anderson D.E., Price S., Smelkinson M., Abou Chahla W., Forbes L.R., RA Mace E.M., Cao T.N., Coban-Akdemir Z.H., Jhangiani S.N., Muzny D.M., RA Gibbs R.A., Lupski J.R., Orange J.S., Cuvelier G.D.E., Al Hassani M., RA Al Kaabi N., Al Yafei Z., Jyonouchi S., Raje N., Caldwell J.W., Huang Y., RA Burkhardt J.K., Latour S., Chen B., ElGhazali G., Rao V.K., Chinn I.K., RA Lenardo M.J.; RT "HEM1 deficiency disrupts mTORC2 and F-actin control in inherited RT immunodysregulatory disease."; RL Science 369:202-207(2020). RN [98] RP FUNCTION. RX PubMed=34289345; DOI=10.1016/j.cell.2021.06.028; RA Evavold C.L., Hafner-Bratkovic I., Devant P., D'Andrea J.M., Ngwa E.M., RA Borsic E., Doench J.G., LaFleur M.W., Sharpe A.H., Thiagarajah J.R., RA Kagan J.C.; RT "Control of gasdermin D oligomerization and pyroptosis by the Ragulator- RT Rag-mTORC1 pathway."; RL Cell 184:4495-4511(2021). RN [99] RP INTERACTION WITH SLC38A7. RX PubMed=35561222; DOI=10.1073/pnas.2123261119; RA Meng D., Yang Q., Jeong M.H., Curukovic A., Tiwary S., Melick C.H., RA Lama-Sherpa T.D., Wang H., Huerta-Rosario M., Urquhart G., Zacharias L.G., RA Lewis C., DeBerardinis R.J., Jewell J.L.; RT "SNAT7 regulates mTORC1 via macropinocytosis."; RL Proc. Natl. Acad. Sci. U.S.A. 119:e2123261119-e2123261119(2022). RN [100] RP INTERACTION WITH TSPAN8. RX PubMed=35904232; DOI=10.1002/cbin.11870; RA Zhuang L., Jin G., Hu X., Yang Q., Pei X., Zhao W.; RT "TSPAN8 alleviates high glucose-induced apoptosis and autophagy via RT targeting mTORC2."; RL Cell Biol. Int. 46:1693-1703(2022). RN [101] RP FUNCTION. RX PubMed=36691768; DOI=10.15252/embj.2022112344; RA Shetty S., Hofstetter J., Battaglioni S., Ritz D., Hall M.N.; RT "TORC1 phosphorylates and inhibits the ribosome preservation factor Stm1 to RT activate dormant ribosomes."; RL EMBO J. 42:e112344-e112344(2023). RN [102] RP SUBCELLULAR LOCATION. RX PubMed=37057673; DOI=10.1016/j.gim.2023.100838; RA Reijnders M.R.F., Seibt A., Brugger M., Lamers I.J.C., Ott T., Klaas O., RA Horvath J., Rose A.M.S., Craghill I.M., Brunet T., Graf E., Mayerhanser K., RA Hellebrekers D., Pauck D., Neuen-Jacob E., Rodenburg R.J.T., Wieczorek D., RA Klee D., Mayatepek E., Driessen G., Bindermann R., Averdunk L., RA Lohmeier K., Sinnema M., Stegmann A.P.A., Roepman R., Poulter J.A., RA Distelmaier F.; RT "De novo missense variants in RRAGC lead to a fatal mTORopathy of early RT childhood."; RL Genet. Med. 25:100838-100838(2023). RN [103] RP FUNCTION. RX PubMed=36608670; DOI=10.1016/j.molcel.2022.12.013; RA Nardone C., Palanski B.A., Scott D.C., Timms R.T., Barber K.W., Gu X., RA Mao A., Leng Y., Watson E.V., Schulman B.A., Cole P.A., Elledge S.J.; RT "A central role for regulated protein stability in the control of TFE3 and RT MITF by nutrients."; RL Mol. Cell 83:57-73(2023). RN [104] RP FUNCTION, UBIQUITINATION AT LYS-2066, AND MUTAGENESIS OF LYS-2066. RX PubMed=37979583; DOI=10.1016/j.cmet.2023.10.016; RA Ge M.K., Zhang C., Zhang N., He P., Cai H.Y., Li S., Wu S., Chu X.L., RA Zhang Y.X., Ma H.M., Xia L., Yang S., Yu J.X., Yao S.Y., Zhou X.L., Su B., RA Chen G.Q., Shen S.M.; RT "The tRNA-GCN2-FBXO22-axis-mediated mTOR ubiquitination senses amino acid RT insufficiency."; RL Cell Metab. 35:2216-2230.e8(2023). RN [105] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=37751742; DOI=10.1016/j.molcel.2023.08.032; RA He L., Chen J., Deng P., Huang S., Liu P., Wang C., Huang X., Li Y., RA Chen B., Shi D., Xiao Y., Chen X., Ouyang Y., Song L., Lin C.; RT "Lysosomal cyst(e)ine storage potentiates tolerance to oxidative stress in RT cancer cells."; RL Mol. Cell 83:3502-3519(2023). RN [106] RP X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 2018-2112 IN COMPLEX WITH FKBP1A RP AND INHIBITOR RAPAMYCIN, AND ACTIVITY REGULATION. RX PubMed=8662507; DOI=10.1126/science.273.5272.239; RA Choi J., Chen J., Schreiber S.L., Clardy J.; RT "Structure of the FKBP12-rapamycin complex interacting with the binding RT domain of human FRAP."; RL Science 273:239-242(1996). RN [107] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 2018-2112 IN COMPLEX WITH FKBP1A RP AND INHIBITOR RAPAMYCIN, AND ACTIVITY REGULATION. RX PubMed=10089303; DOI=10.1107/s0907444998014747; RA Liang J., Choi J., Clardy J.; RT "Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2 A RT resolution."; RL Acta Crystallogr. D 55:736-744(1999). RN [108] RP 3D-STRUCTURE MODELING, HEAT-REPEATS, AND TPR-REPEATS. RX PubMed=20060908; DOI=10.1016/j.jsb.2010.01.002; RA Knutson B.A.; RT "Insights into the domain and repeat architecture of target of rapamycin."; RL J. Struct. Biol. 170:354-363(2010). RN [109] RP STRUCTURE BY ELECTRON MICROSCOPY (26 ANGSTROMS) OF MTORC1 COMPLEX, AND RP SUBUNIT. RX PubMed=20542007; DOI=10.1016/j.molcel.2010.05.017; RA Yip C.K., Murata K., Walz T., Sabatini D.M., Kang S.A.; RT "Structure of the human mTOR complex I and its implications for rapamycin RT inhibition."; RL Mol. Cell 38:768-774(2010). RN [110] RP X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 1376-2549 IN COMPLEX WITH MLST8, RP SUBUNIT, TPR-REPEATS, DOMAINS, AND MUTAGENESIS OF HIS-2340. RX PubMed=23636326; DOI=10.1038/nature12122; RA Yang H., Rudge D.G., Koos J.D., Vaidialingam B., Yang H.J., Pavletich N.P.; RT "mTOR kinase structure, mechanism and regulation."; RL Nature 497:217-223(2013). RN [111] {ECO:0007744|PDB:5H64} RP STRUCTURE BY ELECTRON MICROSCOPY (4.40 ANGSTROMS) IN COMPLEX WITH RPTOR AND RP MLST8, AND IDENTIFICATION IN THE MTORC1 COMPLEX. RX PubMed=27909983; DOI=10.1007/s13238-016-0346-6; RA Yang H., Wang J., Liu M., Chen X., Huang M., Tan D., Dong M.Q., Wong C.C., RA Wang J., Xu Y., Wang H.W.; RT "4.4 Aa Resolution Cryo-EM structure of human mTOR Complex 1."; RL Protein Cell 7:878-887(2016). RN [112] {ECO:0007744|PDB:5FLC} RP STRUCTURE BY ELECTRON MICROSCOPY (5.90 ANGSTROMS) IN COMPLEX WITH MLST8. RX PubMed=26678875; DOI=10.1126/science.aaa3870; RA Aylett C.H., Sauer E., Imseng S., Boehringer D., Hall M.N., Ban N., RA Maier T.; RT "Architecture of human mTOR complex 1."; RL Science 351:48-52(2016). RN [113] {ECO:0007744|PDB:5WBH, ECO:0007744|PDB:5WBU, ECO:0007744|PDB:5WBY, ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX} RP STRUCTURE BY ELECTRON MICROSCOPY (3.43 ANGSTROMS) IN COMPLEX WITH ATP; RP MAGNESIUM; MLST8; RPTOR; RHEB; AKT1S1; RPS6KB1 AND EIF4EBP1, FUNCTION, RP CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND IDENTIFICATION IN THE MTORC1 RP COMPLEX. RX PubMed=29236692; DOI=10.1038/nature25023; RA Yang H., Jiang X., Li B., Yang H.J., Miller M., Yang A., Dhar A., RA Pavletich N.P.; RT "Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40."; RL Nature 552:368-373(2017). RN [114] {ECO:0007744|PDB:5ZCS} RP STRUCTURE BY ELECTRON MICROSCOPY (4.90 ANGSTROMS) OF THE MTORC2 COMPLEX, RP AND IDENTIFICATION IN THE MTORC2 COMPLEX. RX PubMed=29567957; DOI=10.1038/s41422-018-0029-3; RA Chen X., Liu M., Tian Y., Li J., Qi Y., Zhao D., Wu Z., Huang M., RA Wong C.C.L., Wang H.W., Wang J., Yang H., Xu Y.; RT "Cryo-EM structure of human mTOR complex 2."; RL Cell Res. 28:518-528(2018). RN [115] RP STRUCTURE BY ELECTRON MICROSCOPY OF THE MTORC2 COMPLEX, AND IDENTIFICATION RP IN THE MTORC2 COMPLEX. RX PubMed=29424687; DOI=10.7554/elife.33101; RA Stuttfeld E., Aylett C.H., Imseng S., Boehringer D., Scaiola A., Sauer E., RA Hall M.N., Maier T., Ban N.; RT "Architecture of the human mTORC2 core complex."; RL Elife 7:0-0(2018). RN [116] {ECO:0007744|PDB:6SB0, ECO:0007744|PDB:6SB2} RP STRUCTURE BY ELECTRON MICROSCOPY (5.50 ANGSTROMS) IN COMPLEX WITH RRAGA; RP RRAGC; RPTOR; MLST8 AND AKT1S1, IDENTIFICATION IN THE MTORC1 COMPLEX, AND RP SUBCELLULAR LOCATION. RX PubMed=31601764; DOI=10.1126/science.aax3939; RA Anandapadamanaban M., Masson G.R., Perisic O., Berndt A., Kaufman J., RA Johnson C.M., Santhanam B., Rogala K.B., Sabatini D.M., Williams R.L.; RT "Architecture of human Rag GTPase heterodimers and their complex with RT mTORC1."; RL Science 366:203-210(2019). RN [117] {ECO:0007744|PDB:6ZWM, ECO:0007744|PDB:6ZWO} RP STRUCTURE BY ELECTRON MICROSCOPY (3.00 ANGSTROMS) OF THE MTORC2 COMPLEX IN RP COMPLEX WITH 1D-MYO-INOSITOL HEXAKISPHOSPHATE, AND IDENTIFICATION IN THE RP MTORC2 COMPLEX. RX PubMed=33158864; DOI=10.1126/sciadv.abc1251; RA Scaiola A., Mangia F., Imseng S., Boehringer D., Berneiser K., RA Shimobayashi M., Stuttfeld E., Hall M.N., Ban N., Maier T.; RT "The 3.2-Aa resolution structure of human mTORC2."; RL Sci. Adv. 6:0-0(2020). RN [118] {ECO:0007744|PDB:7PE7, ECO:0007744|PDB:7PE8, ECO:0007744|PDB:7PE9, ECO:0007744|PDB:7PEA, ECO:0007744|PDB:7PEB, ECO:0007744|PDB:7PEC} RP X-RAY CRYSTALLOGRAPHY (1.93 ANGSTROMS) OF 1-230 IN COMPLEX WITH DEPTOR; RP MLST8; MAPKAP1; RICTOR AND RPTOR, ACTIVITY REGULATION, IDENTIFICATION IN RP THE MTORC1 COMPLEX, AND IDENTIFICATION IN THE MTORC2 COMPLEX. RX PubMed=34519268; DOI=10.7554/elife.70871; RA Waelchli M., Berneiser K., Mangia F., Imseng S., Craigie L.M., RA Stuttfeld E., Hall M.N., Maier T.; RT "Regulation of human mTOR complexes by DEPTOR."; RL Elife 10:0-0(2021). RN [119] {ECO:0007744|PDB:7OWG} RP STRUCTURE BY ELECTRON MICROSCOPY (4.70 ANGSTROMS) IN COMPLEX WITH DEPTOR; RP MLST8 AND RPTOR, ACTIVITY REGULATION, IDENTIFICATION IN THE MTORC1 COMPLEX, RP AND FUNCTION. RX PubMed=34519269; DOI=10.7554/elife.68799; RA Heimhalt M., Berndt A., Wagstaff J., Anandapadamanaban M., Perisic O., RA Maslen S., McLaughlin S., Yu C.W., Masson G.R., Boland A., Ni X., RA Yamashita K., Murshudov G.N., Skehel M., Freund S.M., Williams R.L.; RT "Bipartite binding and partial inhibition links DEPTOR and mTOR in a RT mutually antagonistic embrace."; RL Elife 10:0-0(2021). RN [120] {ECO:0007744|PDB:7TZO} RP STRUCTURE BY ELECTRON MICROSCOPY (3.28 ANGSTROMS) OF THE MTORC2 COMPLEX, RP FUNCTION, AND IDENTIFICATION IN THE MTORC2 COMPLEX. RX PubMed=35926713; DOI=10.1016/j.jbc.2022.102288; RA Yu Z., Chen J., Takagi E., Wang F., Saha B., Liu X., Joubert L.M., RA Gleason C.E., Jin M., Li C., Nowotny C., Agard D., Cheng Y., Pearce D.; RT "Interactions between mTORC2 core subunits Rictor and mSin1 dictate RT selective and context-dependent phosphorylation of substrate kinases SGK1 RT and Akt."; RL J. Biol. Chem. 298:102288-102288(2022). RN [121] {ECO:0007744|PDB:7UXC, ECO:0007744|PDB:7UXH} RP STRUCTURE BY ELECTRON MICROSCOPY (2.90 ANGSTROMS) IN COMPLEX WITH RRAGA; RP RRAGC; LAMTOR1; LAMTOR2; LAMTOR3; LAMTOR4; LAMTOR5; RPTOR; MLST8 AND TFEB, RP FUNCTION, ACTIVITY REGULATION, AND IDENTIFICATION IN THE MTORC1 COMPLEX. RX PubMed=36697823; DOI=10.1038/s41586-022-05652-7; RA Cui Z., Napolitano G., de Araujo M.E.G., Esposito A., Monfregola J., RA Huber L.A., Ballabio A., Hurley J.H.; RT "Structure of the lysosomal mTORC1-TFEB-Rag-Ragulator megacomplex."; RL Nature 614:572-579(2023). RN [122] RP VARIANTS [LARGE SCALE ANALYSIS] SER-8; THR-135; VAL-1083; VAL-1134; RP PHE-1178; VAL-2011; TYR-2215 AND LEU-2476. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [123] RP VARIANTS PHE-2220 AND ALA-2406. RX PubMed=21248752; DOI=10.1038/nature09639; RA Varela I., Tarpey P., Raine K., Huang D., Ong C.K., Stephens P., Davies H., RA Jones D., Lin M.L., Teague J., Bignell G., Butler A., Cho J., RA Dalgliesh G.L., Galappaththige D., Greenman C., Hardy C., Jia M., RA Latimer C., Lau K.W., Marshall J., McLaren S., Menzies A., Mudie L., RA Stebbings L., Largaespada D.A., Wessels L.F.A., Richard S., Kahnoski R.J., RA Anema J., Tuveson D.A., Perez-Mancera P.A., Mustonen V., Fischer A., RA Adams D.J., Rust A., Chan-On W., Subimerb C., Dykema K., Furge K., RA Campbell P.J., Teh B.T., Stratton M.R., Futreal P.A.; RT "Exome sequencing identifies frequent mutation of the SWI/SNF complex gene RT PBRM1 in renal carcinoma."; RL Nature 469:539-542(2011). CC -!- FUNCTION: Serine/threonine protein kinase which is a central regulator CC of cellular metabolism, growth and survival in response to hormones, CC growth factors, nutrients, energy and stress signals (PubMed:12087098, CC PubMed:12150925, PubMed:12150926, PubMed:12231510, PubMed:12718876, CC PubMed:14651849, PubMed:15268862, PubMed:15467718, PubMed:15545625, CC PubMed:15718470, PubMed:18497260, PubMed:18762023, PubMed:18925875, CC PubMed:20516213, PubMed:20537536, PubMed:21659604, PubMed:23429703, CC PubMed:23429704, PubMed:25799227, PubMed:26018084, PubMed:29150432, CC PubMed:29236692, PubMed:31112131, PubMed:31601708, PubMed:32561715, CC PubMed:34519269, PubMed:37751742). MTOR directly or indirectly CC regulates the phosphorylation of at least 800 proteins CC (PubMed:15268862, PubMed:15467718, PubMed:17517883, PubMed:18372248, CC PubMed:18497260, PubMed:18925875, PubMed:20516213, PubMed:21576368, CC PubMed:21659604, PubMed:23429704, PubMed:30171069, PubMed:29236692, CC PubMed:37751742). Functions as part of 2 structurally and functionally CC distinct signaling complexes mTORC1 and mTORC2 (mTOR complex 1 and 2) CC (PubMed:15268862, PubMed:15467718, PubMed:18497260, PubMed:18925875, CC PubMed:20516213, PubMed:21576368, PubMed:21659604, PubMed:23429704, CC PubMed:29424687, PubMed:29567957, PubMed:35926713). In response to CC nutrients, growth factors or amino acids, mTORC1 is recruited to the CC lysosome membrane and promotes protein, lipid and nucleotide synthesis CC by phosphorylating key regulators of mRNA translation and ribosome CC synthesis (PubMed:12087098, PubMed:12150925, PubMed:12150926, CC PubMed:12231510, PubMed:12718876, PubMed:14651849, PubMed:15268862, CC PubMed:15467718, PubMed:15545625, PubMed:15718470, PubMed:18497260, CC PubMed:18762023, PubMed:18925875, PubMed:20516213, PubMed:20537536, CC PubMed:21659604, PubMed:23429703, PubMed:23429704, PubMed:25799227, CC PubMed:26018084, PubMed:29150432, PubMed:29236692, PubMed:31112131, CC PubMed:34519269). This includes phosphorylation of EIF4EBP1 and release CC of its inhibition toward the elongation initiation factor 4E (eiF4E) CC (PubMed:24403073, PubMed:29236692). Moreover, phosphorylates and CC activates RPS6KB1 and RPS6KB2 that promote protein synthesis by CC modulating the activity of their downstream targets including ribosomal CC protein S6, eukaryotic translation initiation factor EIF4B, and the CC inhibitor of translation initiation PDCD4 (PubMed:12087098, CC PubMed:12150925, PubMed:18925875, PubMed:29150432, PubMed:29236692). CC Stimulates the pyrimidine biosynthesis pathway, both by acute CC regulation through RPS6KB1-mediated phosphorylation of the biosynthetic CC enzyme CAD, and delayed regulation, through transcriptional enhancement CC of the pentose phosphate pathway which produces 5-phosphoribosyl-1- CC pyrophosphate (PRPP), an allosteric activator of CAD at a later step in CC synthesis, this function is dependent on the mTORC1 complex CC (PubMed:23429703, PubMed:23429704). Regulates ribosome synthesis by CC activating RNA polymerase III-dependent transcription through CC phosphorylation and inhibition of MAF1 an RNA polymerase III-repressor CC (PubMed:20516213). Activates dormant ribosomes by mediating CC phosphorylation of SERBP1, leading to SERBP1 inactivation and CC reactivation of translation (PubMed:36691768). In parallel to protein CC synthesis, also regulates lipid synthesis through SREBF1/SREBP1 and CC LPIN1 (PubMed:23426360). To maintain energy homeostasis mTORC1 may also CC regulate mitochondrial biogenesis through regulation of PPARGC1A (By CC similarity). In the same time, mTORC1 inhibits catabolic pathways: CC negatively regulates autophagy through phosphorylation of ULK1 CC (PubMed:32561715). Under nutrient sufficiency, phosphorylates ULK1 at CC 'Ser-758', disrupting the interaction with AMPK and preventing CC activation of ULK1 (PubMed:32561715). Also prevents autophagy through CC phosphorylation of the autophagy inhibitor DAP (PubMed:20537536). Also CC prevents autophagy by phosphorylating RUBCNL/Pacer under nutrient-rich CC conditions (PubMed:30704899). Prevents autophagy by mediating CC phosphorylation of AMBRA1, thereby inhibiting AMBRA1 ability to mediate CC ubiquitination of ULK1 and interaction between AMBRA1 and PPP2CA CC (PubMed:23524951, PubMed:25438055). mTORC1 exerts a feedback control on CC upstream growth factor signaling that includes phosphorylation and CC activation of GRB10 a INSR-dependent signaling suppressor CC (PubMed:21659604). Among other potential targets mTORC1 may CC phosphorylate CLIP1 and regulate microtubules (PubMed:12231510). The CC mTORC1 complex is inhibited in response to starvation and amino acid CC depletion (PubMed:12150925, PubMed:12150926, PubMed:24403073, CC PubMed:31695197). The non-canonical mTORC1 complex, which acts CC independently of RHEB, specifically mediates phosphorylation of MiT/TFE CC factors MITF, TFEB and TFE3 in the presence of nutrients, promoting CC their cytosolic retention and inactivation (PubMed:22343943, CC PubMed:22576015, PubMed:22692423, PubMed:24448649, PubMed:32612235, CC PubMed:36608670, PubMed:36697823). Upon starvation or lysosomal stress, CC inhibition of mTORC1 induces dephosphorylation and nuclear CC translocation of TFEB and TFE3, promoting their transcription factor CC activity (PubMed:22343943, PubMed:22576015, PubMed:22692423, CC PubMed:24448649, PubMed:32612235, PubMed:36608670). The mTORC1 complex CC regulates pyroptosis in macrophages by promoting GSDMD oligomerization CC (PubMed:34289345). MTOR phosphorylates RPTOR which in turn inhibits CC mTORC1 (By similarity). As part of the mTORC2 complex, MTOR transduces CC signals from growth factors to pathways involved in proliferation, CC cytoskeletal organization, lipogenesis and anabolic output CC (PubMed:15268862, PubMed:15467718, PubMed:24670654, PubMed:29424687, CC PubMed:29567957, PubMed:35926713). In response to growth factors, CC mTORC2 phosphorylates and activates AGC protein kinase family members, CC including AKT (AKT1, AKT2 and AKT3), PKC (PRKCA, PRKCB and PRKCE) and CC SGK1 (PubMed:15268862, PubMed:15467718, PubMed:21376236, CC PubMed:24670654, PubMed:29424687, PubMed:29567957, PubMed:35926713). In CC contrast to mTORC1, mTORC2 is nutrient-insensitive (PubMed:15467718). CC mTORC2 plays a critical role in AKT1 activation by mediating CC phosphorylation of different sites depending on the context, such as CC 'Thr-450', 'Ser-473', 'Ser-477' or 'Thr-479', facilitating the CC phosphorylation of the activation loop of AKT1 on 'Thr-308' by CC PDPK1/PDK1 which is a prerequisite for full activation CC (PubMed:15718470, PubMed:21376236, PubMed:24670654, PubMed:29424687, CC PubMed:29567957). mTORC2 also regulates the phosphorylation of SGK1 at CC 'Ser-422' (PubMed:18925875). mTORC2 may regulate the actin CC cytoskeleton, through phosphorylation of PRKCA, PXN and activation of CC the Rho-type guanine nucleotide exchange factors RHOA and RAC1A or CC RAC1B (PubMed:15268862). The mTORC2 complex also phosphorylates various CC proteins involved in insulin signaling, such as FBXW8 and IGF2BP1 (By CC similarity). May also regulate insulin signaling by acting as a CC tyrosine protein kinase that catalyzes phosphorylation of IGF1R and CC INSR; additional evidence are however required to confirm this result CC in vivo (PubMed:26584640). Regulates osteoclastogenesis by adjusting CC the expression of CEBPB isoforms (By similarity). Plays an important CC regulatory role in the circadian clock function; regulates period CC length and rhythm amplitude of the suprachiasmatic nucleus (SCN) and CC liver clocks (By similarity). {ECO:0000250|UniProtKB:Q9JLN9, CC ECO:0000269|PubMed:12087098, ECO:0000269|PubMed:12150925, CC ECO:0000269|PubMed:12150926, ECO:0000269|PubMed:12231510, CC ECO:0000269|PubMed:12718876, ECO:0000269|PubMed:14651849, CC ECO:0000269|PubMed:15268862, ECO:0000269|PubMed:15467718, CC ECO:0000269|PubMed:15545625, ECO:0000269|PubMed:15718470, CC ECO:0000269|PubMed:17517883, ECO:0000269|PubMed:18372248, CC ECO:0000269|PubMed:18497260, ECO:0000269|PubMed:18762023, CC ECO:0000269|PubMed:18925875, ECO:0000269|PubMed:20516213, CC ECO:0000269|PubMed:20537536, ECO:0000269|PubMed:21376236, CC ECO:0000269|PubMed:21576368, ECO:0000269|PubMed:21659604, CC ECO:0000269|PubMed:22343943, ECO:0000269|PubMed:22576015, CC ECO:0000269|PubMed:22692423, ECO:0000269|PubMed:23426360, CC ECO:0000269|PubMed:23429703, ECO:0000269|PubMed:23429704, CC ECO:0000269|PubMed:23524951, ECO:0000269|PubMed:24403073, CC ECO:0000269|PubMed:24448649, ECO:0000269|PubMed:24670654, CC ECO:0000269|PubMed:25438055, ECO:0000269|PubMed:25799227, CC ECO:0000269|PubMed:26018084, ECO:0000269|PubMed:26584640, CC ECO:0000269|PubMed:29150432, ECO:0000269|PubMed:29236692, CC ECO:0000269|PubMed:29424687, ECO:0000269|PubMed:29567957, CC ECO:0000269|PubMed:30171069, ECO:0000269|PubMed:30704899, CC ECO:0000269|PubMed:31112131, ECO:0000269|PubMed:31601708, CC ECO:0000269|PubMed:31695197, ECO:0000269|PubMed:32561715, CC ECO:0000269|PubMed:32612235, ECO:0000269|PubMed:34289345, CC ECO:0000269|PubMed:34519269, ECO:0000269|PubMed:35926713, CC ECO:0000269|PubMed:36608670, ECO:0000269|PubMed:36691768, CC ECO:0000269|PubMed:36697823, ECO:0000269|PubMed:37751742}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12087098, ECO:0000269|PubMed:12150925, CC ECO:0000269|PubMed:12231510, ECO:0000269|PubMed:15268862, CC ECO:0000269|PubMed:15467718, ECO:0000269|PubMed:15718470, CC ECO:0000269|PubMed:17517883, ECO:0000269|PubMed:18372248, CC ECO:0000269|PubMed:18925875, ECO:0000269|PubMed:20022946, CC ECO:0000269|PubMed:20516213, ECO:0000269|PubMed:20537536, CC ECO:0000269|PubMed:21659604, ECO:0000269|PubMed:22343943, CC ECO:0000269|PubMed:22576015, ECO:0000269|PubMed:22692423, CC ECO:0000269|PubMed:29150432}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12087098, ECO:0000269|PubMed:12150925, CC ECO:0000269|PubMed:12231510, ECO:0000269|PubMed:15268862, CC ECO:0000269|PubMed:15467718, ECO:0000269|PubMed:15718470, CC ECO:0000269|PubMed:18925875, ECO:0000269|PubMed:20516213, CC ECO:0000269|PubMed:20537536, ECO:0000269|PubMed:21659604, CC ECO:0000269|PubMed:29150432, ECO:0000269|PubMed:29236692, CC ECO:0000269|PubMed:37751742}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.2; CC Evidence={ECO:0000305|PubMed:26584640}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:10597; CC Evidence={ECO:0000305|PubMed:26584640}; CC -!- ACTIVITY REGULATION: The mTORC1 complex is activated in response to CC nutrients, growth factors or amino acids: activation requires CC relocalization of the mTORC1 complex to lysosomes that is mediated by CC the Ragulator complex, SLC38A9, and the Rag GTPases RagA/RRAGA, CC RagB/RRAGB, RagC/RRAGC and RagD/RRAGD (PubMed:18497260, CC PubMed:20381137, PubMed:25561175, PubMed:25567906). Activation of CC mTORC1 by growth factors such as insulin involves AKT1-mediated CC phosphorylation of TSC1-TSC2, which leads to the activation of the RHEB CC GTPase a potent activator of the protein kinase activity of mTORC1 CC (PubMed:14651849, PubMed:15545625, PubMed:29236692). Insulin-stimulated CC and amino acid-dependent phosphorylation at Ser-1261 promotes CC autophosphorylation and the activation of mTORC1 (PubMed:19487463). On CC the other hand, low cellular energy levels can inhibit mTORC1 through CC activation of PRKAA1 while hypoxia inhibits mTORC1 through a REDD1- CC dependent mechanism which may also require PRKAA1 (PubMed:14651849, CC PubMed:15545625). The kinase activity of MTOR within the mTORC1 complex CC is positively regulated by MLST8 (PubMed:12718876). The kinase activity CC of MTOR is inhibited by DEPTOR and AKT1S1 (PubMed:17386266, CC PubMed:19446321, PubMed:29236692, PubMed:34519268, PubMed:34519269). CC The non-canonical mTORC1 complex is independent of the RHEB GTPase and CC specifically mediates phosphorylation of MiT/TFE factors TFEB and TFE3 CC but not other mTORC1 substrates: it is activated by FLCN, which CC activates Rag GTPases RagC/RRAGC and RagD/RRAGD (PubMed:32612235, CC PubMed:36697823). MTOR is the target of the immunosuppressive and anti- CC cancer drug rapamycin which acts in complex with FKBP1A/FKBP12, and CC specifically inhibits its kinase activity (PubMed:10089303, CC PubMed:8662507). mTORC2 is also activated by growth factors, but seems CC to be nutrient-insensitive (PubMed:15467718). mTORC2 associates and is CC directly activated by ribosomes (PubMed:21376236). mTORC2 may also be CC regulated by RHEB but in an indirect manner through the PI3K signaling CC pathway (PubMed:15467718). {ECO:0000269|PubMed:10089303, CC ECO:0000269|PubMed:12718876, ECO:0000269|PubMed:14651849, CC ECO:0000269|PubMed:15467718, ECO:0000269|PubMed:15545625, CC ECO:0000269|PubMed:17386266, ECO:0000269|PubMed:18497260, CC ECO:0000269|PubMed:19446321, ECO:0000269|PubMed:19487463, CC ECO:0000269|PubMed:20381137, ECO:0000269|PubMed:21376236, CC ECO:0000269|PubMed:25561175, ECO:0000269|PubMed:25567906, CC ECO:0000269|PubMed:29236692, ECO:0000269|PubMed:32612235, CC ECO:0000269|PubMed:34519268, ECO:0000269|PubMed:34519269, CC ECO:0000269|PubMed:36697823, ECO:0000269|PubMed:8662507}. CC -!- SUBUNIT: Part of the mechanistic target of rapamycin complex 1 (mTORC1) CC which contains MTOR, MLST8 and RPTOR (PubMed:12150925, PubMed:12150926, CC PubMed:12408816, PubMed:12718876, PubMed:18925875, PubMed:20542007, CC PubMed:23636326, PubMed:24403073, PubMed:26678875, PubMed:27909983, CC PubMed:29236692, PubMed:31601764, PubMed:34519268, PubMed:34519269, CC PubMed:36697823). The mTORC1 complex is a 1 Md obligate dimer of two CC stoichiometric heterotetramers with overall dimensions of 290 A x 210 A CC x 135 A (PubMed:20542007, PubMed:23636326). It has a rhomboid shape and CC a central cavity, the dimeric interfaces are formed by interlocking CC interactions between the two MTOR and the two RPTOR subunits CC (PubMed:20542007, PubMed:23636326, PubMed:27909983). The MLST8 subunit CC forms distal foot-like protuberances, and contacts only one MTOR within CC the complex, while the small AKT1S1/PRAS40 localizes to the midsection CC of the central core, in close proximity to RPTOR (PubMed:20542007, CC PubMed:23636326, PubMed:27909983, PubMed:29236692). mTORC1 associates CC with AKT1S1/PRAS40, which inhibits its activity by blocking MTOR CC substrate-recruitment site (PubMed:17386266, PubMed:29236692). CC Component of the mechanistic target of rapamycin complex 2 (mTORC2), CC consisting in two heterotretramers composed of MTOR, MLST8, RICTOR and CC MAPKAP1/SIN1 (PubMed:15268862, PubMed:15467718, PubMed:17599906, CC PubMed:18925875, PubMed:29424687, PubMed:29567957, PubMed:33158864, CC PubMed:35926713). Interacts with PLPP7 and PML (By similarity). CC Interacts with PRR5 and RICTOR; the interaction is direct within the CC mTORC2 complex and interaction with RICTOR is enhanced by CC deubiquitination of RICTOR by USP9X (PubMed:17599906, PubMed:33378666, CC PubMed:29424687, PubMed:34519268). mTORC1 and mTORC2 associate with CC DEPTOR, which regulates their activity (PubMed:19446321, CC PubMed:34519268, PubMed:34519269). Interacts with WAC; WAC positively CC regulates MTOR activity by promoting the assembly of the TTT complex CC composed of TELO2, TTI1 and TTI2 and the RUVBL complex composed of CC RUVBL1 and RUVBL2 into the TTT-RUVBL complex which leads to the CC dimerization of the mTORC1 complex and its subsequent activation CC (PubMed:26812014). Interacts with UBQLN1 (PubMed:11853878). Interacts CC with TTI1 and TELO2 (PubMed:20427287, PubMed:20801936, CC PubMed:20810650). Interacts with CLIP1; phosphorylates and regulates CC CLIP1 (PubMed:12231510). Interacts with NBN (PubMed:23762398). CC Interacts with HTR6 (PubMed:23027611). Interacts with BRAT1 CC (PubMed:25657994). Interacts with MEAK7 (via C-terminal domain); the CC interaction increases upon nutrient stimulation (PubMed:29750193). CC Interacts with TM4SF5; the interaction is positively regulated by CC arginine and is negatively regulated by leucine (PubMed:30956113). CC Interacts with GPR137B (PubMed:31036939). Interacts with NCKAP1L CC (PubMed:32647003). Interacts with TPCN1 and TPCN2; the interaction is CC required for TPCN1 and TPCN2 sensitivity to ATP (PubMed:23394946). CC Interacts with ATP6V1A and with CRYAB, forming a ternary complex (By CC similarity). Interacts with SLC38A7; this interaction mediates the CC recruitment of mTORC1 to the lysosome and its subsequent activation CC (PubMed:35561222). Interacts with TSPAN8 (PubMed:35904232). CC {ECO:0000250|UniProtKB:Q9JLN9, ECO:0000269|PubMed:11853878, CC ECO:0000269|PubMed:12150925, ECO:0000269|PubMed:12150926, CC ECO:0000269|PubMed:12231510, ECO:0000269|PubMed:12408816, CC ECO:0000269|PubMed:12718876, ECO:0000269|PubMed:15268862, CC ECO:0000269|PubMed:15467718, ECO:0000269|PubMed:17386266, CC ECO:0000269|PubMed:17599906, ECO:0000269|PubMed:18925875, CC ECO:0000269|PubMed:19446321, ECO:0000269|PubMed:20427287, CC ECO:0000269|PubMed:20542007, ECO:0000269|PubMed:20801936, CC ECO:0000269|PubMed:20810650, ECO:0000269|PubMed:23027611, CC ECO:0000269|PubMed:23394946, ECO:0000269|PubMed:23636326, CC ECO:0000269|PubMed:23762398, ECO:0000269|PubMed:24403073, CC ECO:0000269|PubMed:25657994, ECO:0000269|PubMed:26678875, CC ECO:0000269|PubMed:26812014, ECO:0000269|PubMed:27909983, CC ECO:0000269|PubMed:29236692, ECO:0000269|PubMed:29424687, CC ECO:0000269|PubMed:29567957, ECO:0000269|PubMed:29750193, CC ECO:0000269|PubMed:30956113, ECO:0000269|PubMed:31036939, CC ECO:0000269|PubMed:31601764, ECO:0000269|PubMed:32647003, CC ECO:0000269|PubMed:33158864, ECO:0000269|PubMed:33378666, CC ECO:0000269|PubMed:34519268, ECO:0000269|PubMed:34519269, CC ECO:0000269|PubMed:35561222, ECO:0000269|PubMed:35904232, CC ECO:0000269|PubMed:35926713, ECO:0000269|PubMed:36697823}. CC -!- INTERACTION: CC P42345; P31749: AKT1; NbExp=6; IntAct=EBI-359260, EBI-296087; CC P42345; Q07817-1: BCL2L1; NbExp=4; IntAct=EBI-359260, EBI-287195; CC P42345; Q6UXB4: CLEC4G; NbExp=4; IntAct=EBI-359260, EBI-2114729; CC P42345; Q8TB45: DEPTOR; NbExp=5; IntAct=EBI-359260, EBI-2359040; CC P42345; Q13541: EIF4EBP1; NbExp=2; IntAct=EBI-359260, EBI-74090; CC P42345; Q969H0: FBXW7; NbExp=5; IntAct=EBI-359260, EBI-359574; CC P42345; P62942: FKBP1A; NbExp=5; IntAct=EBI-359260, EBI-1027571; CC P42345; P24522: GADD45A; NbExp=4; IntAct=EBI-359260, EBI-448167; CC P42345; Q8WUA4: GTF3C2; NbExp=3; IntAct=EBI-359260, EBI-1237062; CC P42345; Q9BVC4: MLST8; NbExp=7; IntAct=EBI-359260, EBI-1387471; CC P42345; Q9BVC4-1: MLST8; NbExp=7; IntAct=EBI-359260, EBI-16056342; CC P42345; Q13615: MTMR3; NbExp=3; IntAct=EBI-359260, EBI-371938; CC P42345; P42345: MTOR; NbExp=2; IntAct=EBI-359260, EBI-359260; CC P42345; Q9Y4G2: PLEKHM1; NbExp=6; IntAct=EBI-359260, EBI-473814; CC P42345; Q8TCU6: PREX1; NbExp=11; IntAct=EBI-359260, EBI-1046542; CC P42345; P62820: RAB1A; NbExp=4; IntAct=EBI-359260, EBI-716845; CC P42345; Q15382: RHEB; NbExp=4; IntAct=EBI-359260, EBI-1055287; CC P42345; Q6R327: RICTOR; NbExp=37; IntAct=EBI-359260, EBI-1387196; CC P42345; Q8N122: RPTOR; NbExp=48; IntAct=EBI-359260, EBI-1567928; CC P42345; Q96EB6: SIRT1; NbExp=2; IntAct=EBI-359260, EBI-1802965; CC P42345; O14894: TM4SF5; NbExp=7; IntAct=EBI-359260, EBI-19125949; CC P42345; Q92544: TM9SF4; NbExp=4; IntAct=EBI-359260, EBI-6138615; CC P42345; Q8NHX9: TPCN2; NbExp=2; IntAct=EBI-359260, EBI-5239949; CC P42345; O75385: ULK1; NbExp=7; IntAct=EBI-359260, EBI-908831; CC P42345; P63104: YWHAZ; NbExp=3; IntAct=EBI-359260, EBI-347088; CC -!- SUBCELLULAR LOCATION: Lysosome membrane {ECO:0000269|PubMed:18497260, CC ECO:0000269|PubMed:20381137, ECO:0000269|PubMed:29750193, CC ECO:0000269|PubMed:30956113, ECO:0000269|PubMed:31112131, CC ECO:0000269|PubMed:31601764, ECO:0000269|PubMed:37057673}; Peripheral CC membrane protein {ECO:0000269|PubMed:30956113, CC ECO:0000269|PubMed:31112131}; Cytoplasmic side CC {ECO:0000269|PubMed:30956113, ECO:0000269|PubMed:31112131}. Endoplasmic CC reticulum membrane {ECO:0000269|PubMed:14578359}; Peripheral membrane CC protein {ECO:0000269|PubMed:14578359}; Cytoplasmic side CC {ECO:0000269|PubMed:14578359}. Golgi apparatus membrane CC {ECO:0000269|PubMed:14578359}; Peripheral membrane protein CC {ECO:0000269|PubMed:14578359}; Cytoplasmic side CC {ECO:0000269|PubMed:14578359}. Cell membrane CC {ECO:0000269|PubMed:21867682}; Peripheral membrane protein CC {ECO:0000269|PubMed:14578359}. Mitochondrion outer membrane CC {ECO:0000269|PubMed:11930000, ECO:0000269|PubMed:14578359}; Peripheral CC membrane protein {ECO:0000269|PubMed:11930000, CC ECO:0000269|PubMed:14578359}; Cytoplasmic side CC {ECO:0000269|PubMed:11930000, ECO:0000269|PubMed:14578359}. Cytoplasm CC {ECO:0000269|PubMed:11930000, ECO:0000269|PubMed:18497260}. Nucleus CC {ECO:0000250|UniProtKB:Q9JLN9}. Nucleus, PML body CC {ECO:0000250|UniProtKB:Q9JLN9}. Microsome membrane CC {ECO:0000269|PubMed:9434772}. Cytoplasmic vesicle, phagosome CC {ECO:0000269|PubMed:27623384}. Note=Shuttles between cytoplasm and CC nucleus. Accumulates in the nucleus in response to hypoxia (By CC similarity). Targeting to lysosomes depends on amino acid availability CC and RRAGA and RRAGB (PubMed:18497260, PubMed:20381137). Lysosome CC targeting also depends on interaction with MEAK7. Translocates to the CC lysosome membrane in the presence of TM4SF5 (PubMed:30956113). The CC mTORC2 complex localizes to membranes: mTORC2 is active at the plasma CC membrane, endoplasmic reticulum membrane and lysosomes CC (PubMed:21867682). {ECO:0000250|UniProtKB:Q9JLN9, CC ECO:0000269|PubMed:18497260, ECO:0000269|PubMed:20381137, CC ECO:0000269|PubMed:21867682, ECO:0000269|PubMed:29750193, CC ECO:0000269|PubMed:30956113}. CC -!- TISSUE SPECIFICITY: Expressed in numerous tissues, with highest levels CC in testis. {ECO:0000269|PubMed:12408816, ECO:0000269|PubMed:7809080}. CC -!- DOMAIN: The kinase domain (PI3K/PI4K) is intrinsically active but has a CC highly restricted catalytic center. {ECO:0000269|PubMed:23636326}. CC -!- DOMAIN: The FAT domain forms three discontinuous subdomains of alpha- CC helical TPR repeats plus a single subdomain of HEAT repeats. The four CC domains pack sequentially to form a C-shaped a-solenoid that clamps CC onto the kinase domain (PubMed:23636326). CC {ECO:0000269|PubMed:23636326}. CC -!- PTM: Autophosphorylates when part of mTORC1 or mTORC2 (PubMed:15467718, CC PubMed:20022946, PubMed:9434772). Phosphorylation at Ser-1261, Ser-2159 CC and Thr-2164 promotes autophosphorylation (PubMed:19487463). CC Phosphorylated at Ser-2448 by RPS6KB1 (PubMed:15899889, CC PubMed:15905173, PubMed:19145465). Phosphorylation in the kinase domain CC modulates the interactions of MTOR with RPTOR and AKT1S1/PRAS40 and CC leads to increased intrinsic mTORC1 kinase activity (PubMed:15905173, CC PubMed:19145465, PubMed:21576368). Phosphorylation at Ser-2159 by TBK1 CC in response to growth factors and pathogen recognition receptors CC promotes mTORC1 activity (PubMed:29150432). Phosphorylation at Ser-2159 CC by TBK1 in response to EGF growth factor promotes mTORC2 activity, CC leading to AKT1 phosphorylation and activation (By similarity). CC Phosphorylation at Thr-2173 in the ATP-binding region by AKT1 strongly CC reduces kinase activity (PubMed:24247430). CC {ECO:0000250|UniProtKB:Q9JLN9, ECO:0000269|PubMed:15467718, CC ECO:0000269|PubMed:15905173, ECO:0000269|PubMed:19145465, CC ECO:0000269|PubMed:19487463, ECO:0000269|PubMed:20022946, CC ECO:0000269|PubMed:21576368, ECO:0000269|PubMed:24247430, CC ECO:0000269|PubMed:29150432, ECO:0000269|PubMed:9434772}. CC -!- PTM: Ubiquitinated at Lys-2066 by the SCF(FBXO22) complex via 'Lys-27'- CC linked ubiquitination prevents mTORC1 substrate recruitment. CC {ECO:0000269|PubMed:37979583}. CC -!- DISEASE: Smith-Kingsmore syndrome (SKS) [MIM:616638]: An autosomal CC dominant syndrome characterized by intellectual disability, CC macrocephaly, seizures, umbilical hernia, and facial dysmorphic CC features. {ECO:0000269|PubMed:25851998, ECO:0000269|PubMed:26542245, CC ECO:0000269|PubMed:27830187}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Focal cortical dysplasia 2 (FCORD2) [MIM:607341]: A form of CC focal cortical dysplasia, a malformation of cortical development that CC results in medically refractory epilepsy in the pediatric population CC and in adults. FCORD2 is a severe form, with onset usually in CC childhood, characterized by disrupted cortical lamination and specific CC cytological abnormalities. It is classified in 2 subtypes: type IIA CC characterized by dysmorphic neurons and lack of balloon cells; type IIB CC with dysmorphic neurons and balloon cells. CC {ECO:0000269|PubMed:25799227, ECO:0000269|PubMed:25878179, CC ECO:0000269|PubMed:26018084, ECO:0000269|PubMed:27830187}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC39933.1; Type=Frameshift; Evidence={ECO:0000305}; CC Sequence=BAE06077.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/40639/FRAP1"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=Mammalian target of rapamycin entry; CC URL="https://en.wikipedia.org/wiki/Mammalian_target_of_rapamycin"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L34075; AAA58486.1; -; mRNA. DR EMBL; U88966; AAC39933.1; ALT_FRAME; mRNA. DR EMBL; AB209995; BAE06077.1; ALT_INIT; mRNA. DR EMBL; AL109811; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL391561; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL049653; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC117166; AAI17167.1; -; mRNA. DR EMBL; AJ300188; CAC15570.1; -; Genomic_DNA. DR EMBL; L35478; AAC41713.1; -; mRNA. DR CCDS; CCDS127.1; -. DR PIR; S45340; S45340. DR RefSeq; NP_001373429.1; NM_001386500.1. DR RefSeq; NP_004949.1; NM_004958.4. DR PDB; 1AUE; X-ray; 2.33 A; A/B=2015-2114. DR PDB; 1FAP; X-ray; 2.70 A; B=2018-2112. DR PDB; 1NSG; X-ray; 2.20 A; B=2019-2112. DR PDB; 2FAP; X-ray; 2.20 A; B=2019-2112. DR PDB; 2GAQ; NMR; -; A=2015-2114. DR PDB; 2NPU; NMR; -; A=2015-2114. DR PDB; 2RSE; NMR; -; B=2019-2112. DR PDB; 3FAP; X-ray; 1.85 A; B=2019-2112. DR PDB; 3JBZ; EM; 28.00 A; A=1385-2549. DR PDB; 4DRH; X-ray; 2.30 A; B/E=2025-2114. DR PDB; 4DRI; X-ray; 1.45 A; B=2025-2114. DR PDB; 4DRJ; X-ray; 1.80 A; B=2025-2114. DR PDB; 4FAP; X-ray; 2.80 A; B=2019-2112. DR PDB; 4JSN; X-ray; 3.20 A; A/B=1376-2549. DR PDB; 4JSP; X-ray; 3.30 A; A/B=1376-2549. DR PDB; 4JSV; X-ray; 3.50 A; A/B=1376-2549. DR PDB; 4JSX; X-ray; 3.50 A; A/B=1376-2549. DR PDB; 4JT5; X-ray; 3.45 A; A/B=1376-2549. DR PDB; 4JT6; X-ray; 3.60 A; A/B=1376-2549. DR PDB; 5FLC; EM; 5.90 A; B/F=1382-2549. DR PDB; 5GPG; X-ray; 1.67 A; B=2021-2112. DR PDB; 5H64; EM; 4.40 A; A/a=1-2549. DR PDB; 5WBH; X-ray; 1.75 A; A/B/C/D/E=2018-2114. DR PDB; 5WBU; X-ray; 3.42 A; A/B=1376-2549. DR PDB; 5WBY; X-ray; 3.10 A; A/B=1376-2549. DR PDB; 5ZCS; EM; 4.90 A; A/B=1-2549. DR PDB; 6BCU; EM; 3.43 A; A/B=1-2549. DR PDB; 6BCX; EM; 3.00 A; A/B=1-2549. DR PDB; 6M4U; X-ray; 2.20 A; B/F=2021-2113. DR PDB; 6M4W; X-ray; 3.11 A; G/H/I=2021-2113. DR PDB; 6SB0; EM; 5.50 A; A/B=60-2549. DR PDB; 6SB2; EM; 6.20 A; A/B=54-2549. DR PDB; 6ZWM; EM; 3.20 A; A/B=1-2549. DR PDB; 6ZWO; EM; 3.00 A; B=1-2549. DR PDB; 7EPD; EM; 3.90 A; B=2019-2114. DR PDB; 7OWG; EM; 4.70 A; B=1-2549. DR PDB; 7PE7; EM; 3.41 A; A/B=1-2549. DR PDB; 7PE8; EM; 3.20 A; A=1-2549. DR PDB; 7PE9; EM; 3.70 A; A=1-2549. DR PDB; 7PEA; EM; 4.07 A; A/B=1-2549. DR PDB; 7PEB; EM; 3.67 A; A=1-2549. DR PDB; 7PEC; EM; 4.24 A; A=1-2549. DR PDB; 7TZO; EM; 3.28 A; A/B=1-2549. DR PDB; 7UXC; EM; 3.20 A; A=1-2549. DR PDB; 7UXH; EM; 3.20 A; A/C=1-2549. DR PDB; 8ER6; X-ray; 2.81 A; B/D/F=2019-2112. DR PDB; 8ER7; X-ray; 3.07 A; B/D/F=2019-2112. DR PDB; 8ERA; EM; 2.86 A; A=1-2549. DR PDB; 8PPZ; X-ray; 1.85 A; B=2025-2114. DR PDB; 8RCH; EM; 4.00 A; A/B=1-2549. DR PDB; 8RCK; EM; 3.40 A; B=1-2549. DR PDB; 8RCN; EM; 3.10 A; B=1-2549. DR PDB; 9F44; EM; 3.68 A; A/B=1-2549. DR PDB; 9F45; EM; 3.74 A; A/B=1-2549. DR PDBsum; 1AUE; -. DR PDBsum; 1FAP; -. DR PDBsum; 1NSG; -. DR PDBsum; 2FAP; -. DR PDBsum; 2GAQ; -. DR PDBsum; 2NPU; -. DR PDBsum; 2RSE; -. DR PDBsum; 3FAP; -. DR PDBsum; 3JBZ; -. DR PDBsum; 4DRH; -. DR PDBsum; 4DRI; -. DR PDBsum; 4DRJ; -. DR PDBsum; 4FAP; -. DR PDBsum; 4JSN; -. DR PDBsum; 4JSP; -. DR PDBsum; 4JSV; -. DR PDBsum; 4JSX; -. DR PDBsum; 4JT5; -. DR PDBsum; 4JT6; -. DR PDBsum; 5FLC; -. DR PDBsum; 5GPG; -. DR PDBsum; 5H64; -. DR PDBsum; 5WBH; -. DR PDBsum; 5WBU; -. DR PDBsum; 5WBY; -. DR PDBsum; 5ZCS; -. DR PDBsum; 6BCU; -. DR PDBsum; 6BCX; -. DR PDBsum; 6M4U; -. DR PDBsum; 6M4W; -. DR PDBsum; 6SB0; -. DR PDBsum; 6SB2; -. DR PDBsum; 6ZWM; -. DR PDBsum; 6ZWO; -. DR PDBsum; 7EPD; -. DR PDBsum; 7OWG; -. DR PDBsum; 7PE7; -. DR PDBsum; 7PE8; -. DR PDBsum; 7PE9; -. DR PDBsum; 7PEA; -. DR PDBsum; 7PEB; -. DR PDBsum; 7PEC; -. DR PDBsum; 7TZO; -. DR PDBsum; 7UXC; -. DR PDBsum; 7UXH; -. DR PDBsum; 8ER6; -. DR PDBsum; 8ER7; -. DR PDBsum; 8ERA; -. DR PDBsum; 8PPZ; -. DR PDBsum; 8RCH; -. DR PDBsum; 8RCK; -. DR PDBsum; 8RCN; -. DR PDBsum; 9F44; -. DR PDBsum; 9F45; -. DR AlphaFoldDB; P42345; -. DR BMRB; P42345; -. DR EMDB; EMD-10132; -. DR EMDB; EMD-10133; -. DR EMDB; EMD-11488; -. DR EMDB; EMD-11489; -. DR EMDB; EMD-11490; -. DR EMDB; EMD-11491; -. DR EMDB; EMD-11492; -. DR EMDB; EMD-13097; -. DR EMDB; EMD-13347; -. DR EMDB; EMD-13348; -. DR EMDB; EMD-13349; -. DR EMDB; EMD-13350; -. DR EMDB; EMD-13351; -. DR EMDB; EMD-13352; -. DR EMDB; EMD-19052; -. DR EMDB; EMD-19053; -. DR EMDB; EMD-19056; -. DR EMDB; EMD-26213; -. DR EMDB; EMD-26857; -. DR EMDB; EMD-26861; -. DR EMDB; EMD-28551; -. DR EMDB; EMD-3212; -. DR EMDB; EMD-3213; -. DR EMDB; EMD-50183; -. DR EMDB; EMD-50184; -. DR EMDB; EMD-6668; -. DR EMDB; EMD-6913; -. DR EMDB; EMD-7086; -. DR EMDB; EMD-7087; -. DR SMR; P42345; -. DR BioGRID; 108757; 392. DR ComplexPortal; CPX-4402; mTORC2 complex. DR ComplexPortal; CPX-503; mTORC1 complex. DR CORUM; P42345; -. DR DIP; DIP-790N; -. DR FunCoup; P42345; 4303. DR IntAct; P42345; 203. DR MINT; P42345; -. DR STRING; 9606.ENSP00000354558; -. DR BindingDB; P42345; -. DR ChEMBL; CHEMBL2842; -. DR DrugBank; DB12180; Apitolisib. DR DrugBank; DB12774; AZD-8055. DR DrugBank; DB14846; Bimiralisib. DR DrugBank; DB11651; Dactolisib. DR DrugBank; DB01590; Everolimus. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB13072; GDC-0349. DR DrugBank; DB11896; Gedatolisib. DR DrugBank; DB11978; Glasdegib. DR DrugBank; DB11962; GSK-1059615. DR DrugBank; DB12167; LY-3023414. DR DrugBank; DB13062; ME-344. DR DrugBank; DB19085; Novolimus. DR DrugBank; DB12843; Oleandrin. DR DrugBank; DB12570; Onatasertib. DR DrugBank; DB12387; OSI-027. DR DrugBank; DB11974; PF-04691502. DR DrugBank; DB00337; Pimecrolimus. DR DrugBank; DB08052; PP-121. DR DrugBank; DB06233; Ridaforolimus. DR DrugBank; DB04974; Rimiducid. DR DrugBank; DB12681; Salirasib. DR DrugBank; DB11836; Sapanisertib. DR DrugBank; DB05210; SF1126. DR DrugBank; DB00877; Sirolimus. DR DrugBank; DB06287; Temsirolimus. DR DrugBank; DB11925; Vistusertib. DR DrugBank; DB12400; Voxtalisib. DR DrugBank; DB12986; VS-5584. DR DrugBank; DB05241; XL765. DR DrugBank; DB18761; Zotarolimus. DR DrugCentral; P42345; -. DR GuidetoPHARMACOLOGY; 2109; -. DR GlyGen; P42345; 5 sites, 2 N-linked glycans (2 sites), 1 O-linked glycan (1 site). DR iPTMnet; P42345; -. DR MetOSite; P42345; -. DR PhosphoSitePlus; P42345; -. DR SwissPalm; P42345; -. DR BioMuta; MTOR; -. DR DMDM; 1169735; -. DR CPTAC; CPTAC-1360; -. DR CPTAC; CPTAC-1361; -. DR CPTAC; CPTAC-3133; -. DR CPTAC; CPTAC-3134; -. DR CPTAC; CPTAC-5752; -. DR CPTAC; CPTAC-5753; -. DR CPTAC; CPTAC-5754; -. DR CPTAC; CPTAC-5755; -. DR CPTAC; CPTAC-5756; -. DR CPTAC; CPTAC-5793; -. DR CPTAC; CPTAC-5794; -. DR CPTAC; CPTAC-5795; -. DR CPTAC; CPTAC-5796; -. DR CPTAC; CPTAC-5797; -. DR CPTAC; CPTAC-5798; -. DR CPTAC; CPTAC-5799; -. DR CPTAC; CPTAC-5800; -. DR CPTAC; non-CPTAC-5421; -. DR CPTAC; non-CPTAC-5422; -. DR CPTAC; non-CPTAC-5423; -. DR CPTAC; non-CPTAC-5424; -. DR CPTAC; non-CPTAC-5425; -. DR CPTAC; non-CPTAC-5560; -. DR CPTAC; non-CPTAC-5561; -. DR CPTAC; non-CPTAC-5562; -. DR CPTAC; non-CPTAC-5563; -. DR CPTAC; non-CPTAC-5709; -. DR CPTAC; non-CPTAC-5710; -. DR CPTAC; non-CPTAC-5711; -. DR CPTAC; non-CPTAC-5712; -. DR jPOST; P42345; -. DR MassIVE; P42345; -. DR PaxDb; 9606-ENSP00000354558; -. DR PeptideAtlas; P42345; -. DR ProteomicsDB; 55511; -. DR Pumba; P42345; -. DR Antibodypedia; 3566; 1829 antibodies from 54 providers. DR CPTC; P42345; 10 antibodies. DR DNASU; 2475; -. DR Ensembl; ENST00000361445.9; ENSP00000354558.4; ENSG00000198793.15. DR Ensembl; ENST00000703143.2; ENSP00000515200.2; ENSG00000198793.15. DR GeneID; 2475; -. DR KEGG; hsa:2475; -. DR MANE-Select; ENST00000361445.9; ENSP00000354558.4; NM_004958.4; NP_004949.1. DR UCSC; uc001asd.4; human. DR AGR; HGNC:3942; -. DR CIViC; 2475; 31 evidence items across 26 molecular profiles. DR ClinPGx; PA28360; -. DR CTD; 2475; -. DR DisGeNET; 2475; -. DR GeneCards; MTOR; -. DR HGNC; HGNC:3942; MTOR. DR HPA; ENSG00000198793; Low tissue specificity. DR MalaCards; MTOR; -. DR MIM; 601231; gene. DR MIM; 607341; phenotype. DR MIM; 616638; phenotype. DR OpenTargets; ENSG00000198793; -. DR Orphanet; 99802; Hemimegalencephaly. DR Orphanet; 269001; Isolated focal cortical dysplasia type IIa. DR Orphanet; 269008; Isolated focal cortical dysplasia type IIb. DR Orphanet; 457485; Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome. DR VEuPathDB; HostDB:ENSG00000198793; -. DR eggNOG; KOG0891; Eukaryota. DR GeneTree; ENSGT00930000151037; -. DR HOGENOM; CLU_000178_7_1_1; -. DR InParanoid; P42345; -. DR OMA; MRQHSAK; -. DR OrthoDB; 2250022at2759; -. DR PAN-GO; P42345; 7 GO annotations based on evolutionary models. DR PhylomeDB; P42345; -. DR PathwayCommons; P42345; -. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-1632852; Macroautophagy. DR Reactome; R-HSA-165159; MTOR signalling. DR Reactome; R-HSA-166208; mTORC1-mediated signalling. DR Reactome; R-HSA-3371571; HSF1-dependent transactivation. DR Reactome; R-HSA-380972; Energy dependent regulation of mTOR by LKB1-AMPK. DR Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling. DR Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability. DR Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes. DR Reactome; R-HSA-5674400; Constitutive Signaling by AKT1 E17K in Cancer. DR Reactome; R-HSA-6804757; Regulation of TP53 Degradation. DR Reactome; R-HSA-8943724; Regulation of PTEN gene transcription. DR Reactome; R-HSA-9639288; Amino acids regulate mTORC1. DR Reactome; R-HSA-9856530; High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells. DR SABIO-RK; P42345; -. DR SignaLink; P42345; -. DR SIGNOR; P42345; -. DR Agora; ENSG00000198793; -. DR BioGRID-ORCS; 2475; 805 hits in 1184 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; MTOR; human. DR EvolutionaryTrace; P42345; -. DR GeneWiki; Mammalian_target_of_rapamycin; -. DR GenomeRNAi; 2475; -. DR Pharos; P42345; Tclin. DR PRO; PR:P42345; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; P42345; protein. DR Bgee; ENSG00000198793; Expressed in primordial germ cell in gonad and 132 other cell types or tissues. DR ExpressionAtlas; P42345; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProt. DR GO; GO:0030425; C:dendrite; IEA:Ensembl. DR GO; GO:0012505; C:endomembrane system; IDA:UniProtKB. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB. DR GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell. DR GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB. DR GO; GO:0005764; C:lysosome; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; IDA:UniProtKB. DR GO; GO:0005741; C:mitochondrial outer membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005635; C:nuclear envelope; IDA:CACAO. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0045335; C:phagocytic vesicle; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell. DR GO; GO:0031931; C:TORC1 complex; IDA:UniProtKB. DR GO; GO:0031932; C:TORC2 complex; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0000822; F:inositol hexakisphosphate binding; IDA:UniProtKB. DR GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IEA:UniProtKB-EC. DR GO; GO:0051219; F:phosphoprotein binding; IPI:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; IDA:WormBase. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0043022; F:ribosome binding; IDA:UniProtKB. DR GO; GO:0001002; F:RNA polymerase III type 1 promoter sequence-specific DNA binding; IDA:UniProtKB. DR GO; GO:0001003; F:RNA polymerase III type 2 promoter sequence-specific DNA binding; IDA:UniProtKB. DR GO; GO:0001006; F:RNA polymerase III type 3 promoter sequence-specific DNA binding; IDA:UniProtKB. DR GO; GO:0001156; F:TFIIIC-class transcription factor complex binding; IDA:UniProtKB. DR GO; GO:0044325; F:transmembrane transporter binding; IEA:Ensembl. DR GO; GO:0006207; P:'de novo' pyrimidine nucleobase biosynthetic process; IEA:Ensembl. DR GO; GO:0043276; P:anoikis; NAS:ParkinsonsUK-UCL. DR GO; GO:0048266; P:behavioral response to pain; IEA:Ensembl. DR GO; GO:0033173; P:calcineurin-NFAT signaling cascade; IEA:Ensembl. DR GO; GO:0055013; P:cardiac muscle cell development; IEA:Ensembl. DR GO; GO:0060048; P:cardiac muscle contraction; IEA:Ensembl. DR GO; GO:0030030; P:cell projection organization; IEA:Ensembl. DR GO; GO:0034198; P:cellular response to amino acid starvation; IDA:UniProtKB. DR GO; GO:0071230; P:cellular response to amino acid stimulus; IDA:CAFA. DR GO; GO:0071456; P:cellular response to hypoxia; ISS:UniProtKB. DR GO; GO:0032869; P:cellular response to insulin stimulus; IDA:UniProt. DR GO; GO:0071233; P:cellular response to L-leucine; IDA:CAFA. DR GO; GO:1990253; P:cellular response to leucine starvation; IDA:CAFA. DR GO; GO:0061431; P:cellular response to methionine; IDA:UniProt. DR GO; GO:0031670; P:cellular response to nutrient; IDA:UniProt. DR GO; GO:0031669; P:cellular response to nutrient levels; IDA:UniProt. DR GO; GO:0071470; P:cellular response to osmotic stress; NAS:ComplexPortal. DR GO; GO:0009267; P:cellular response to starvation; IDA:UniProtKB. DR GO; GO:0007010; P:cytoskeleton organization; NAS:ComplexPortal. DR GO; GO:0006974; P:DNA damage response; NAS:ComplexPortal. DR GO; GO:0006112; P:energy reserve metabolic process; IEA:Ensembl. DR GO; GO:0007281; P:germ cell development; IEA:Ensembl. DR GO; GO:0003007; P:heart morphogenesis; IEA:Ensembl. DR GO; GO:0003179; P:heart valve morphogenesis; IEA:Ensembl. DR GO; GO:0006954; P:inflammatory response; IEA:Ensembl. DR GO; GO:0016236; P:macroautophagy; IEA:Ensembl. DR GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; NAS:ComplexPortal. DR GO; GO:0010507; P:negative regulation of autophagy; IDA:UniProtKB. DR GO; GO:0070885; P:negative regulation of calcineurin-NFAT signaling cascade; IEA:Ensembl. DR GO; GO:0045792; P:negative regulation of cell size; IEA:Ensembl. DR GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; ISS:UniProt. DR GO; GO:1905672; P:negative regulation of lysosome organization; IDA:UniProtKB. DR GO; GO:0016242; P:negative regulation of macroautophagy; IDA:MGI. DR GO; GO:1900181; P:negative regulation of protein localization to nucleus; IDA:UniProtKB. DR GO; GO:0019228; P:neuronal action potential; IEA:Ensembl. DR GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl. DR GO; GO:0030838; P:positive regulation of actin filament polymerization; IEA:Ensembl. DR GO; GO:0030307; P:positive regulation of cell growth; NAS:ComplexPortal. DR GO; GO:1904690; P:positive regulation of cytoplasmic translational initiation; TAS:ARUK-UCL. DR GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IMP:BHF-UCL. DR GO; GO:0045821; P:positive regulation of glycolytic process; NAS:ComplexPortal. DR GO; GO:0051549; P:positive regulation of keratinocyte migration; IMP:BHF-UCL. DR GO; GO:0010592; P:positive regulation of lamellipodium assembly; IEA:Ensembl. DR GO; GO:0046889; P:positive regulation of lipid biosynthetic process; IMP:UniProtKB. DR GO; GO:0010831; P:positive regulation of myotube differentiation; IEA:Ensembl. DR GO; GO:0048714; P:positive regulation of oligodendrocyte differentiation; IEA:Ensembl. DR GO; GO:1905857; P:positive regulation of pentose-phosphate shunt; NAS:ComplexPortal. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; TAS:Reactome. DR GO; GO:1900029; P:positive regulation of ruffle assembly; IEA:Ensembl. DR GO; GO:0062027; P:positive regulation of SCF-dependent proteasomal ubiquitin-dependent catabolic process; IDA:UniProt. DR GO; GO:0051496; P:positive regulation of stress fiber assembly; IEA:Ensembl. DR GO; GO:0045945; P:positive regulation of transcription by RNA polymerase III; IMP:UniProtKB. DR GO; GO:1901838; P:positive regulation of transcription of nucleolar large rRNA by RNA polymerase I; IMP:UniProtKB. DR GO; GO:0045727; P:positive regulation of translation; IDA:UniProtKB. DR GO; GO:0045948; P:positive regulation of translational initiation; IDA:UniProt. DR GO; GO:2000060; P:positive regulation of ubiquitin-dependent protein catabolic process; IDA:UniProtKB. DR GO; GO:1903691; P:positive regulation of wound healing, spreading of epidermal cells; IMP:BHF-UCL. DR GO; GO:0009791; P:post-embryonic development; IEA:Ensembl. DR GO; GO:0031648; P:protein destabilization; IDA:UniProt. DR GO; GO:0050821; P:protein stabilization; ISS:UniProt. DR GO; GO:0032956; P:regulation of actin cytoskeleton organization; IMP:UniProtKB. DR GO; GO:2000785; P:regulation of autophagosome assembly; IDA:UniProt. DR GO; GO:0001558; P:regulation of cell growth; IDA:UniProtKB. DR GO; GO:0008361; P:regulation of cell size; IMP:CAFA. DR GO; GO:1900034; P:regulation of cellular response to heat; TAS:Reactome. DR GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB. DR GO; GO:1904059; P:regulation of locomotor rhythm; ISS:UniProtKB. DR GO; GO:1905671; P:regulation of lysosome organization; IDA:UniProtKB. DR GO; GO:0016241; P:regulation of macroautophagy; TAS:Reactome. DR GO; GO:0090559; P:regulation of membrane permeability; IEA:Ensembl. DR GO; GO:0031641; P:regulation of myelination; IEA:Ensembl. DR GO; GO:0045670; P:regulation of osteoclast differentiation; ISS:UniProtKB. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0043200; P:response to amino acid; IDA:UniProtKB. DR GO; GO:0009408; P:response to heat; IEA:Ensembl. DR GO; GO:0031667; P:response to nutrient levels; IDA:UniProtKB. DR GO; GO:0009615; P:response to virus; IEA:Ensembl. DR GO; GO:0031295; P:T cell costimulation; TAS:Reactome. DR GO; GO:0002296; P:T-helper 1 cell lineage commitment; IEA:Ensembl. DR GO; GO:0031929; P:TOR signaling; IMP:UniProtKB. DR GO; GO:0038202; P:TORC1 signaling; IDA:UniProtKB. DR GO; GO:0038203; P:TORC2 signaling; IDA:UniProtKB. DR GO; GO:0097700; P:vascular endothelial cell response to laminar fluid shear stress; TAS:Reactome. DR GO; GO:0050882; P:voluntary musculoskeletal movement; IEA:Ensembl. DR CDD; cd05169; PIKKc_TOR; 1. DR DisProt; DP03874; -. DR FunFam; 1.10.1070.11:FF:000074; DJ576K7.1 (FK506 binding protein 12-rapamycin associated protein 1); 1. DR FunFam; 1.10.1070.11:FF:000058; MTOR isoform 6; 1. DR FunFam; 1.25.10.10:FF:000060; Serine/threonine-protein kinase mTOR; 1. DR FunFam; 1.25.10.10:FF:000094; Serine/threonine-protein kinase mTOR; 1. DR FunFam; 1.25.10.10:FF:000532; Serine/threonine-protein kinase mTOR; 1. DR FunFam; 1.20.120.150:FF:000001; Serine/threonine-protein kinase TOR; 1. DR FunFam; 1.25.10.10:FF:000083; Serine/threonine-protein kinase TOR; 1. DR FunFam; 3.30.1010.10:FF:000004; Serine/threonine-protein kinase TOR; 1. DR Gene3D; 1.20.120.150; FKBP12-rapamycin binding domain; 1. DR Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 4. DR Gene3D; 1.10.1070.11; Phosphatidylinositol 3-/4-kinase, catalytic domain; 1. DR Gene3D; 3.30.1010.10; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 4; 1. DR Gene3D; 1.25.40.10; Tetratricopeptide repeat domain; 1. DR IDEAL; IID00598; -. DR InterPro; IPR011989; ARM-like. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR050517; DDR_Repair_Kinase. DR InterPro; IPR003152; FATC_dom. DR InterPro; IPR009076; FRB_dom. DR InterPro; IPR036738; FRB_sf. DR InterPro; IPR057564; HEAT_ATR. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR024585; mTOR_dom. DR InterPro; IPR000403; PI3/4_kinase_cat_dom. DR InterPro; IPR036940; PI3/4_kinase_cat_sf. DR InterPro; IPR018936; PI3/4_kinase_CS. DR InterPro; IPR003151; PIK-rel_kinase_FAT. DR InterPro; IPR014009; PIK_FAT. DR InterPro; IPR026683; TOR_cat. DR InterPro; IPR011990; TPR-like_helical_dom_sf. DR PANTHER; PTHR11139; ATAXIA TELANGIECTASIA MUTATED ATM -RELATED; 1. DR PANTHER; PTHR11139:SF9; SERINE_THREONINE-PROTEIN KINASE MTOR; 1. DR Pfam; PF02259; FAT; 1. DR Pfam; PF02260; FATC; 1. DR Pfam; PF08771; FRB_dom; 1. DR Pfam; PF23593; HEAT_ATR; 1. DR Pfam; PF11865; mTOR_dom; 1. DR Pfam; PF00454; PI3_PI4_kinase; 1. DR SMART; SM01346; DUF3385; 1. DR SMART; SM01343; FATC; 1. DR SMART; SM00146; PI3Kc; 1. DR SMART; SM01345; Rapamycin_bind; 1. DR SUPFAM; SSF48371; ARM repeat; 2. DR SUPFAM; SSF47212; FKBP12-rapamycin-binding domain of FKBP-rapamycin-associated protein (FRAP); 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51189; FAT; 1. DR PROSITE; PS51190; FATC; 1. DR PROSITE; PS00915; PI3_4_KINASE_1; 1. DR PROSITE; PS00916; PI3_4_KINASE_2; 1. DR PROSITE; PS50290; PI3_4_KINASE_3; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; ATP-binding; Cell membrane; Cytoplasm; KW Cytoplasmic vesicle; Disease variant; Endoplasmic reticulum; Epilepsy; KW Golgi apparatus; Intellectual disability; Isopeptide bond; Kinase; KW Lysosome; Membrane; Microsome; Mitochondrion; Mitochondrion outer membrane; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat; Serine/threonine-protein kinase; TPR repeat; KW Transferase; Ubl conjugation. FT CHAIN 1..2549 FT /note="Serine/threonine-protein kinase mTOR" FT /id="PRO_0000088808" FT REPEAT 16..53 FT /note="HEAT 1" FT REPEAT 55..99 FT /note="HEAT 2" FT REPEAT 100..137 FT /note="HEAT 3" FT REPEAT 138..179 FT /note="HEAT 4" FT REPEAT 180..220 FT /note="HEAT 5" FT REPEAT 222..276 FT /note="HEAT 6" FT REPEAT 277..313 FT /note="HEAT 7" FT REPEAT 314..364 FT /note="HEAT 8" FT REPEAT 365..409 FT /note="HEAT 9" FT REPEAT 410..445 FT /note="HEAT 10" FT REPEAT 446..494 FT /note="HEAT 11" FT REPEAT 495..529 FT /note="HEAT 12" FT REPEAT 530..563 FT /note="HEAT 13" FT REPEAT 564..596 FT /note="HEAT 14" FT REPEAT 597..636 FT /note="HEAT 15" FT REPEAT 637..683 FT /note="HEAT 16" FT REPEAT 686..724 FT /note="HEAT 17" FT REPEAT 727..766 FT /note="HEAT 18" FT REPEAT 769..811 FT /note="HEAT 19" FT REPEAT 814..853 FT /note="HEAT 20" FT REPEAT 857..893 FT /note="HEAT 21" FT REPEAT 894..942 FT /note="HEAT 22" FT REPEAT 943..988 FT /note="HEAT 23" FT REPEAT 989..1027 FT /note="HEAT 24" FT REPEAT 1029..1068 FT /note="HEAT 25" FT REPEAT 1069..1105 FT /note="HEAT 26" FT REPEAT 1106..1144 FT /note="HEAT 27" FT REPEAT 1145..1188 FT /note="HEAT 28" FT REPEAT 1189..1225 FT /note="HEAT 29" FT REPEAT 1226..1273 FT /note="HEAT 30" FT REPEAT 1274..1311 FT /note="HEAT 31" FT REPEAT 1312..1345 FT /note="HEAT 32" FT REPEAT 1346..1382 FT /note="TPR 1" FT DOMAIN 1382..1982 FT /note="FAT" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534" FT REPEAT 1383..1408 FT /note="TPR 2" FT REPEAT 1409..1442 FT /note="TPR 3" FT REPEAT 1443..1473 FT /note="TPR 4" FT REPEAT 1474..1507 FT /note="TPR 5" FT REPEAT 1508..1541 FT /note="TPR 6" FT REPEAT 1542..1574 FT /note="TPR 7" FT REPEAT 1575..1614 FT /note="TPR 8" FT REPEAT 1615..1649 FT /note="TPR 9" FT REPEAT 1650..1693 FT /note="TPR 10" FT REPEAT 1694..1731 FT /note="TPR 11" FT REPEAT 1732..1786 FT /note="TPR 12" FT REPEAT 1787..1846 FT /note="TPR 13" FT REPEAT 1898..1930 FT /note="TPR 14" FT REPEAT 1931..1970 FT /note="TPR 15" FT REPEAT 1971..2005 FT /note="TPR 16" FT DOMAIN 2156..2469 FT /note="PI3K/PI4K catalytic" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT DOMAIN 2517..2549 FT /note="FATC" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534, FT ECO:0000255|PROSITE-ProRule:PRU00535" FT REGION 1..651 FT /note="Interaction with NBN" FT /evidence="ECO:0000269|PubMed:23762398" FT REGION 1812..1867 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2012..2144 FT /note="Sufficient for interaction with the FKBP1A/rapamycin FT complex" FT /evidence="ECO:0000250|UniProtKB:Q9JLN9" FT REGION 2162..2168 FT /note="G-loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 2258..2296 FT /note="Interaction with MLST8" FT REGION 2335..2343 FT /note="Catalytic loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 2355..2380 FT /note="Activation loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT COMPBIAS 1820..1860 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 1662 FT /ligand="1D-myo-inositol hexakisphosphate" FT /ligand_id="ChEBI:CHEBI:58130" FT /evidence="ECO:0000269|PubMed:33158864, FT ECO:0007744|PDB:6ZWM" FT BINDING 1702 FT /ligand="1D-myo-inositol hexakisphosphate" FT /ligand_id="ChEBI:CHEBI:58130" FT /evidence="ECO:0000269|PubMed:33158864, FT ECO:0007744|PDB:6ZWM" FT BINDING 1749 FT /ligand="1D-myo-inositol hexakisphosphate" FT /ligand_id="ChEBI:CHEBI:58130" FT /evidence="ECO:0000269|PubMed:33158864, FT ECO:0007744|PDB:6ZWM" FT BINDING 2165 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2167 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2185 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2187 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCX" FT BINDING 2190 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2225 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2238 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2239 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2240 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2245 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2343 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCX" FT BINDING 2345 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2356 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2357 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCX" FT MOD_RES 1 FT /note="N-acetylmethionine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 567 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:20068231" FT MOD_RES 1162 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES 1218 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 1261 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:19487463, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2159 FT /note="Phosphoserine; by TBK1" FT /evidence="ECO:0000269|PubMed:21576368, FT ECO:0000269|PubMed:29150432" FT MOD_RES 2164 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:21576368" FT MOD_RES 2173 FT /note="Phosphothreonine; by PKB/AKT1" FT /evidence="ECO:0000269|PubMed:24247430" FT MOD_RES 2446 FT /note="Phosphothreonine; by RPS6KB1" FT /evidence="ECO:0000269|PubMed:15905173" FT MOD_RES 2448 FT /note="Phosphoserine; by RPS6KB1" FT /evidence="ECO:0000269|PubMed:15899889, FT ECO:0000269|PubMed:15905173, ECO:0000269|PubMed:19145465, FT ECO:0007744|PubMed:24275569" FT MOD_RES 2478 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2481 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:20022946, FT ECO:0000269|PubMed:21576368, ECO:0007744|PubMed:18669648" FT CROSSLNK 2066 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:37979583" FT VARIANT 8 FT /note="A -> S (in a lung large cell carcinoma sample; FT somatic mutation; dbSNP:rs748801456)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041537" FT VARIANT 135 FT /note="M -> T (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041538" FT VARIANT 624 FT /note="R -> H (in FCORD2; uncertain significance; somatic FT mutation; dbSNP:rs913197212)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078824" FT VARIANT 1083 FT /note="M -> V (in dbSNP:rs56164650)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041539" FT VARIANT 1134 FT /note="A -> V (in dbSNP:rs28730685)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041540" FT VARIANT 1178 FT /note="S -> F (in dbSNP:rs55975118)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041541" FT VARIANT 1376 FT /note="D -> E (found in a patient with focal epilepsy; FT uncertain significance; dbSNP:rs975577894)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078825" FT VARIANT 1450 FT /note="Y -> D (in FCORD2; somatic mutation)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078826" FT VARIANT 1456 FT /note="W -> G (in FCORD2; somatic mutation; FT dbSNP:rs1085307114)" FT /evidence="ECO:0000269|PubMed:25878179" FT /id="VAR_078827" FT VARIANT 1459 FT /note="A -> D (in FCORD2; somatic mutation; increased TOR FT signaling; dbSNP:rs1644347782)" FT /evidence="ECO:0000269|PubMed:26018084" FT /id="VAR_078828" FT VARIANT 1459 FT /note="A -> S (in FCORD2; uncertain significance; somatic FT mutation; dbSNP:rs1644347846)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078829" FT VARIANT 1460 FT /note="L -> P (in FCORD2; somatic mutation; increased TOR FT signaling; dbSNP:rs1057519779)" FT /evidence="ECO:0000269|PubMed:26018084, FT ECO:0000269|PubMed:27830187" FT /id="VAR_078830" FT VARIANT 1483 FT /note="C -> R (in FCORD2; somatic mutation; increased TOR FT signaling; increased kinase activity; dbSNP:rs1057519914)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078831" FT VARIANT 1490 FT /note="W -> R (in SKS; dbSNP:rs2100566800)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078832" FT VARIANT 1595 FT /note="M -> I (in SKS; dbSNP:rs869312671)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078833" FT VARIANT 1709 FT /note="R -> H (in FCORD2; uncertain significance; somatic FT mutation; dbSNP:rs587777895)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078834" FT VARIANT 1799 FT /note="E -> K (in SKS; results in increased mTOR signaling; FT dbSNP:rs863225264)" FT /evidence="ECO:0000269|PubMed:25851998, FT ECO:0000269|PubMed:26542245" FT /id="VAR_075072" FT VARIANT 1832 FT /note="A -> T (in SKS; dbSNP:rs369088781)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078835" FT VARIANT 1888 FT /note="F -> C (in SKS; dbSNP:rs869312666)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078836" FT VARIANT 1977 FT /note="T -> K (in FCORD2; somatic mutation; FT dbSNP:rs587777893)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078837" FT VARIANT 2011 FT /note="M -> V (in an ovarian mucinous carcinoma sample; FT somatic mutation; dbSNP:rs2100412651)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041542" FT VARIANT 2193 FT /note="R -> C (in FCORD2; somatic mutation; FT dbSNP:rs1642723200)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078838" FT VARIANT 2215 FT /note="S -> F (in FCORD2; somatic mutation; increased TOR FT signaling; dbSNP:rs587777894)" FT /evidence="ECO:0000269|PubMed:25799227, FT ECO:0000269|PubMed:26018084, ECO:0000269|PubMed:27830187" FT /id="VAR_078839" FT VARIANT 2215 FT /note="S -> Y (in FCORD2; also found in a colorectal FT adenocarcinoma sample; somatic mutation; increased TOR FT signaling; dbSNP:rs587777894)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:26018084, ECO:0000269|PubMed:27830187" FT /id="VAR_041543" FT VARIANT 2220 FT /note="L -> F (found in a renal cell carcinoma sample; FT somatic mutation; dbSNP:rs2100381099)" FT /evidence="ECO:0000269|PubMed:21248752" FT /id="VAR_064733" FT VARIANT 2327 FT /note="M -> I (in SKS; dbSNP:rs878855328)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078840" FT VARIANT 2406 FT /note="V -> A (found in a renal cell carcinoma sample; FT somatic mutation; dbSNP:rs2100316251)" FT /evidence="ECO:0000269|PubMed:21248752" FT /id="VAR_064734" FT VARIANT 2427 FT /note="L -> P (in FCORD2; somatic mutation; increased TOR FT signaling; increased kinase activity; dbSNP:rs1085307113)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078841" FT VARIANT 2427 FT /note="L -> Q (in FCORD2; somatic mutation; increased TOR FT signaling; increased kinase activity; dbSNP:rs1085307113)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078842" FT VARIANT 2476 FT /note="P -> L (in a glioblastoma multiforme sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041544" FT VARIANT 2501 FT /note="I -> V (found in a patient with non-lesional FT nocturnal frontal epilepsy; uncertain significance; FT dbSNP:rs968817513)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078843" FT MUTAGEN 2066 FT /note="K->R: Complete loss ubiquitination by the FT SCF(FBXO22) complex." FT /evidence="ECO:0000269|PubMed:37979583" FT MUTAGEN 2159 FT /note="S->A: Reduces mTORC1-associated S-2481 FT autophosphorylation; when associated with A-2164. Reduced FT activity of the mTORC1 complex." FT /evidence="ECO:0000269|PubMed:21576368, FT ECO:0000269|PubMed:29150432" FT MUTAGEN 2159 FT /note="S->D: Mimics phosphorylation; leading to stronger FT phosphorylation of RPS6KB1; when associated with E-2164. FT Increased activity of the mTORC1 complex." FT /evidence="ECO:0000269|PubMed:21576368, FT ECO:0000269|PubMed:29150432" FT MUTAGEN 2164 FT /note="T->A: Reduces mTORC1-associated S-2481 FT autophosphorylation; when associated with A-2159." FT /evidence="ECO:0000269|PubMed:21576368" FT MUTAGEN 2164 FT /note="T->E: Stronger phosphorylation of RPS6KB1; when FT associated with D-2159." FT /evidence="ECO:0000269|PubMed:21576368" FT MUTAGEN 2173 FT /note="T->A: Increased mTOR kinase activity." FT /evidence="ECO:0000269|PubMed:24247430" FT MUTAGEN 2340 FT /note="H->A: Barely detectable kinase activity." FT /evidence="ECO:0000269|PubMed:23636326" FT MUTAGEN 2357 FT /note="D->E: Kinase-dead mutant, loss of interaction with FT TM4SF5 and loss of lysosome membrane localization; when FT associated with I-2364." FT /evidence="ECO:0000269|PubMed:30956113" FT MUTAGEN 2364 FT /note="V->I: Kinase-dead mutant, loss of interaction with FT TM4SF5 and loss of lysosome membrane localization; when FT associated with E-2357." FT /evidence="ECO:0000269|PubMed:30956113" FT CONFLICT 353 FT /note="K -> N (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 359 FT /note="S -> N (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 364 FT /note="D -> N (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 390 FT /note="M -> L (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 430 FT /note="R -> L (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 455..457 FT /note="VLD -> GVE (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 461 FT /note="A -> G (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 482..484 FT /note="VFT -> FFN (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 489 FT /note="L -> V (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 513 FT /note="L -> I (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 539 FT /note="L -> V (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 553 FT /note="R -> C (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 857 FT /note="P -> L (in Ref. 3; BAE06077)" FT /evidence="ECO:0000305" FT CONFLICT 1075 FT /note="I -> S (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT HELIX 19..29 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 38..52 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 61..73 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 83..93 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 94..96 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 102..114 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 115..117 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 123..134 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 141..155 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 165..178 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 180..183 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 184..186 FT /evidence="ECO:0007829|PDB:7UXC" FT HELIX 188..197 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 204..222 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 234..245 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 259..275 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 277..288 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 357..360 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 362..375 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 376..378 FT /evidence="ECO:0007829|PDB:7PE8" FT HELIX 380..382 FT /evidence="ECO:0007829|PDB:7UXC" FT HELIX 387..402 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 404..409 FT /evidence="ECO:0007829|PDB:7UXC" FT HELIX 413..424 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 427..443 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 446..448 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 449..451 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 452..462 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 463..465 FT /evidence="ECO:0007829|PDB:7PE8" FT HELIX 479..490 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 495..497 FT /evidence="ECO:0007829|PDB:7UXC" FT HELIX 499..510 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 517..527 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 530..532 FT /evidence="ECO:0007829|PDB:6ZWM" FT HELIX 533..548 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 580..588 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 601..611 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 616..629 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 646..648 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 649..665 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 667..669 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 670..677 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 681..683 FT /evidence="ECO:0007829|PDB:6ZWM" FT TURN 685..688 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 690..699 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 703..705 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 706..717 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 718..721 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 723..742 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 749..762 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 765..767 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 769..771 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 772..783 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 792..808 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 811..813 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 814..816 FT /evidence="ECO:0007829|PDB:6ZWO" FT HELIX 817..828 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 831..833 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 838..851 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 856..860 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 864..870 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 871..873 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 878..891 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 896..902 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 934..937 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 943..958 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 964..982 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 986..989 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 990..1002 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1006..1008 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1009..1023 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1024..1030 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1031..1040 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1046..1062 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1065..1069 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1071..1083 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1088..1090 FT /evidence="ECO:0007829|PDB:7PE8" FT HELIX 1091..1103 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1104..1107 FT /evidence="ECO:0007829|PDB:7UXC" FT TURN 1108..1110 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1111..1123 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1125..1127 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1129..1142 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1143..1145 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1150..1152 FT /evidence="ECO:0007829|PDB:6ZWO" FT HELIX 1153..1163 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1167..1169 FT /evidence="ECO:0007829|PDB:6ZWO" FT HELIX 1170..1182 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1185..1191 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1192..1202 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1207..1218 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1222..1226 FT /evidence="ECO:0007829|PDB:6ZWO" FT HELIX 1229..1237 FT /evidence="ECO:0007829|PDB:6ZWO" FT HELIX 1263..1269 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1277..1293 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1298..1301 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1304..1309 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1311..1315 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1318..1328 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1331..1347 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1351..1366 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1367..1369 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1375..1379 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1380..1390 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1393..1406 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1410..1422 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1426..1439 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1441..1444 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1447..1452 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1456..1469 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1474..1487 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1490..1499 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1501..1504 FT /evidence="ECO:0007829|PDB:6ZWO" FT HELIX 1506..1523 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1526..1533 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1538..1540 FT /evidence="ECO:0007829|PDB:5WBY" FT HELIX 1541..1553 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1557..1579 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1584..1586 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1587..1602 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1603..1605 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1606..1608 FT /evidence="ECO:0007829|PDB:4JSP" FT HELIX 1609..1611 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1612..1623 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1630..1640 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1641..1643 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1646..1648 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1650..1662 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1666..1677 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1681..1683 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1685..1687 FT /evidence="ECO:0007829|PDB:6ZWO" FT STRAND 1691..1693 FT /evidence="ECO:0007829|PDB:7UXC" FT HELIX 1694..1706 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1710..1730 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1737..1758 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1759..1762 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1766..1768 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1769..1782 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1783..1785 FT /evidence="ECO:0007829|PDB:5WBY" FT HELIX 1787..1809 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1810..1813 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1868..1877 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1878..1880 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1881..1893 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1896..1898 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1900..1913 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1917..1929 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1933..1935 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1936..1938 FT /evidence="ECO:0007829|PDB:7PE7" FT HELIX 1939..1943 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1944..1947 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1951..1966 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1970..1972 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1973..1980 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1985..1999 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2005..2019 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2020..2022 FT /evidence="ECO:0007829|PDB:2NPU" FT HELIX 2025..2039 FT /evidence="ECO:0007829|PDB:4DRI" FT HELIX 2044..2058 FT /evidence="ECO:0007829|PDB:4DRI" FT HELIX 2065..2091 FT /evidence="ECO:0007829|PDB:4DRI" FT HELIX 2094..2111 FT /evidence="ECO:0007829|PDB:4DRI" FT HELIX 2115..2117 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2120..2122 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2123..2126 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2128..2132 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2137..2139 FT /evidence="ECO:0007829|PDB:6ZWO" FT TURN 2141..2143 FT /evidence="ECO:0007829|PDB:5WBY" FT STRAND 2146..2148 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2152..2156 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2158..2162 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2164..2167 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2170..2179 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2181..2187 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2194..2210 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2213..2216 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 2217..2219 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2227..2229 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2231..2233 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2235..2238 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2241..2245 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2246..2256 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2263..2271 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 2273..2277 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2280..2292 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2298..2305 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2308..2310 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2311..2334 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2341..2343 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2344..2350 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2353..2355 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2362..2364 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 2365..2367 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2369..2371 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2381..2385 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 2392..2394 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2395..2409 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2411..2422 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 2425..2428 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2429..2432 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2433..2435 FT /evidence="ECO:0007829|PDB:5WBY" FT HELIX 2493..2509 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2512..2516 FT /evidence="ECO:0007829|PDB:4JT5" FT HELIX 2521..2532 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2535..2539 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2543..2545 FT /evidence="ECO:0007829|PDB:8ERA" SQ SEQUENCE 2549 AA; 288892 MW; 7D9AD6E784882AB4 CRC64; MLGTGPAAAT TAATTSSNVS VLQQFASGLK SRNEETRAKA AKELQHYVTM ELREMSQEES TRFYDQLNHH IFELVSSSDA NERKGGILAI ASLIGVEGGN ATRIGRFANY LRNLLPSNDP VVMEMASKAI GRLAMAGDTF TAEYVEFEVK RALEWLGADR NEGRRHAAVL VLRELAISVP TFFFQQVQPF FDNIFVAVWD PKQAIREGAV AALRACLILT TQREPKEMQK PQWYRHTFEE AEKGFDETLA KEKGMNRDDR IHGALLILNE LVRISSMEGE RLREEMEEIT QQQLVHDKYC KDLMGFGTKP RHITPFTSFQ AVQPQQSNAL VGLLGYSSHQ GLMGFGTSPS PAKSTLVESR CCRDLMEEKF DQVCQWVLKC RNSKNSLIQM TILNLLPRLA AFRPSAFTDT QYLQDTMNHV LSCVKKEKER TAAFQALGLL SVAVRSEFKV YLPRVLDIIR AALPPKDFAH KRQKAMQVDA TVFTCISMLA RAMGPGIQQD IKELLEPMLA VGLSPALTAV LYDLSRQIPQ LKKDIQDGLL KMLSLVLMHK PLRHPGMPKG LAHQLASPGL TTLPEASDVG SITLALRTLG SFEFEGHSLT QFVRHCADHF LNSEHKEIRM EAARTCSRLL TPSIHLISGH AHVVSQTAVQ VVADVLSKLL VVGITDPDPD IRYCVLASLD ERFDAHLAQA ENLQALFVAL NDQVFEIREL AICTVGRLSS MNPAFVMPFL RKMLIQILTE LEHSGIGRIK EQSARMLGHL VSNAPRLIRP YMEPILKALI LKLKDPDPDP NPGVINNVLA TIGELAQVSG LEMRKWVDEL FIIIMDMLQD SSLLAKRQVA LWTLGQLVAS TGYVVEPYRK YPTLLEVLLN FLKTEQNQGT RREAIRVLGL LGALDPYKHK VNIGMIDQSR DASAVSLSES KSSQDSSDYS TSEMLVNMGN LPLDEFYPAV SMVALMRIFR DQSLSHHHTM VVQAITFIFK SLGLKCVQFL PQVMPTFLNV IRVCDGAIRE FLFQQLGMLV SFVKSHIRPY MDEIVTLMRE FWVMNTSIQS TIILLIEQIV VALGGEFKLY LPQLIPHMLR VFMHDNSPGR IVSIKLLAAI QLFGANLDDY LHLLLPPIVK LFDAPEAPLP SRKAALETVD RLTESLDFTD YASRIIHPIV RTLDQSPELR STAMDTLSSL VFQLGKKYQI FIPMVNKVLV RHRINHQRYD VLICRIVKGY TLADEEEDPL IYQHRMLRSG QGDALASGPV ETGPMKKLHV STINLQKAWG AARRVSKDDW LEWLRRLSLE LLKDSSSPSL RSCWALAQAY NPMARDLFNA AFVSCWSELN EDQQDELIRS IELALTSQDI AEVTQTLLNL AEFMEHSDKG PLPLRDDNGI VLLGERAAKC RAYAKALHYK ELEFQKGPTP AILESLISIN NKLQQPEAAA GVLEYAMKHF GELEIQATWY EKLHEWEDAL VAYDKKMDTN KDDPELMLGR MRCLEALGEW GQLHQQCCEK WTLVNDETQA KMARMAAAAA WGLGQWDSME EYTCMIPRDT HDGAFYRAVL ALHQDLFSLA QQCIDKARDL LDAELTAMAG ESYSRAYGAM VSCHMLSELE EVIQYKLVPE RREIIRQIWW ERLQGCQRIV EDWQKILMVR SLVVSPHEDM RTWLKYASLC GKSGRLALAH KTLVLLLGVD PSRQLDHPLP TVHPQVTYAY MKNMWKSARK IDAFQHMQHF VQTMQQQAQH AIATEDQQHK QELHKLMARC FLKLGEWQLN LQGINESTIP KVLQYYSAAT EHDRSWYKAW HAWAVMNFEA VLHYKHQNQA RDEKKKLRHA SGANITNATT AATTAATATT TASTEGSNSE SEAESTENSP TPSPLQKKVT EDLSKTLLMY TVPAVQGFFR SISLSRGNNL QDTLRVLTLW FDYGHWPDVN EALVEGVKAI QIDTWLQVIP QLIARIDTPR PLVGRLIHQL LTDIGRYHPQ ALIYPLTVAS KSTTTARHNA ANKILKNMCE HSNTLVQQAM MVSEELIRVA ILWHEMWHEG LEEASRLYFG ERNVKGMFEV LEPLHAMMER GPQTLKETSF NQAYGRDLME AQEWCRKYMK SGNVKDLTQA WDLYYHVFRR ISKQLPQLTS LELQYVSPKL LMCRDLELAV PGTYDPNQPI IRIQSIAPSL QVITSKQRPR KLTLMGSNGH EFVFLLKGHE DLRQDERVMQ LFGLVNTLLA NDPTSLRKNL SIQRYAVIPL STNSGLIGWV PHCDTLHALI RDYREKKKIL LNIEHRIMLR MAPDYDHLTL MQKVEVFEHA VNNTAGDDLA KLLWLKSPSS EVWFDRRTNY TRSLAVMSMV GYILGLGDRH PSNLMLDRLS GKILHIDFGD CFEVAMTREK FPEKIPFRLT RMLTNAMEVT GLDGNYRITC HTVMEVLREH KDSVMAVLEA FVYDPLLNWR LMDTNTKGNK RSRTRTDSYS AGQSVEILDG VELGEPAHKK TGTTVPESIH SFIGDGLVKP EALNKKAIQI INRVRDKLTG RDFSHDDTLD VPTQVELLIK QATSHENLCQ CYIGWCPFW // ID NDRG1_HUMAN Reviewed; 394 AA. AC Q92597; B3KR80; B7Z446; O15207; Q6IBG2; Q9NYR6; Q9UK29; DT 15-JUL-1999, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-1997, sequence version 1. DT 28-JAN-2026, entry version 219. DE RecName: Full=Protein NDRG1; DE AltName: Full=Differentiation-related gene 1 protein; DE Short=DRG-1; DE AltName: Full=N-myc downstream-regulated gene 1 protein; DE AltName: Full=Nickel-specific induction protein Cap43; DE AltName: Full=Reducing agents and tunicamycin-responsive protein; DE Short=RTP; DE AltName: Full=Rit42; GN Name=NDRG1; Synonyms=CAP43, DRG1, RTP; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INDUCTION, AND TISSUE SPECIFICITY. RC TISSUE=Umbilical vein endothelial cell; RX PubMed=8939898; DOI=10.1074/jbc.271.47.29659; RA Kokame K., Kato H., Miyata T.; RT "Homocysteine-respondent genes in vascular endothelial cells identified by RT differential display analysis. GRP78/BiP and novel genes."; RL J. Biol. Chem. 271:29659-29665(1996). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INDUCTION, SUBCELLULAR LOCATION, RP AND TISSUE SPECIFICITY. RX PubMed=9251681; RA van Belzen N., Dinjens W.N.M., Diesveld M.P.G., Groen N.A., RA van der Made A.C.J., Nozawa Y., Vlietstra R., Trapman J., Bosman F.T.; RT "A novel gene which is up-regulated during colon epithelial cell RT differentiation and down-regulated in colorectal neoplasms."; RL Lab. Invest. 77:85-92(1997). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND INDUCTION. RC TISSUE=Lung; RX PubMed=9605764; RA Zhou D., Salnikow K., Costa M.; RT "Cap43, a novel gene specifically induced by Ni2+ compounds."; RL Cancer Res. 58:2182-2189(1998). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INDUCTION. RX PubMed=10395947; DOI=10.1016/s0167-4889(99)00056-7; RA Piquemal D., Joulia D., Balaguer P., Basset A., Marti J., Commes T.; RT "Differential expression of the RTP/Drg1/Ndr1 gene product in proliferating RT and growth arrested cells."; RL Biochim. Biophys. Acta 1450:364-373(1999). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3). RC TISSUE=Brain, and Tongue; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16421571; DOI=10.1038/nature04406; RA Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M., RA Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L., RA Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S., RA Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A., RA Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III, RA Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., RA Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P., RA Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H., RA Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B., RA O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K., RA Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L., RA Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G., RA Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W., RA Platzer M., Shimizu N., Lander E.S.; RT "DNA sequence and analysis of human chromosome 8."; RL Nature 439:331-335(2006). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Kidney; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [10] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-21 (ISOFORM 1). RC TISSUE=Brain; RA Angelicheva D., Kalaydjieva L.; RL Submitted (FEB-2000) to the EMBL/GenBank/DDBJ databases. RN [11] RP PROTEIN SEQUENCE OF 4-19; 54-70; 133-148; 199-212; 286-300; 307-322; RP 328-341 AND 364-388, AND IDENTIFICATION BY MASS SPECTROMETRY. RC TISSUE=Fetal brain cortex; RA Lubec G., Chen W.-Q., Sun Y.; RL Submitted (DEC-2008) to UniProtKB. RN [12] RP FUNCTION, AND INDUCTION. RX PubMed=9766676; RA Kurdistani S.K., Arizti P., Reimer C.L., Sugrue M.M., Aaronson S.A., RA Lee S.W.; RT "Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 RT and DNA damage."; RL Cancer Res. 58:4439-4444(1998). RN [13] RP INVOLVEMENT IN CMT4D. RX PubMed=10831399; DOI=10.1086/302978; RA Kalaydjieva L., Gresham D., Gooding R., Heather L., Baas F., de Jonge R., RA Blechschmidt K., Angelicheva D., Chandler D., Worsley P., Rosenthal A., RA King R.H.M., Thomas P.K.; RT "N-myc downstream-regulated gene 1 is mutated in hereditary motor and RT sensory neuropathy-Lom."; RL Am. J. Hum. Genet. 67:47-58(2000). RN [14] RP PHOSPHORYLATION, AND SUBCELLULAR LOCATION. RX PubMed=10860807; DOI=10.1006/bbrc.2000.2833; RA Agarwala K.L., Kokame K., Kato H., Miyata T.; RT "Phosphorylation of RTP, an ER stress-responsive cytoplasmic protein."; RL Biochem. Biophys. Res. Commun. 272:641-647(2000). RN [15] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=12432451; DOI=10.1007/s00418-002-0460-9; RA Lachat P., Shaw P., Gebhard S., van Belzen N., Chaubert P., Bosman F.T.; RT "Expression of NDRG1, a differentiation-related gene, in human tissues."; RL Histochem. Cell Biol. 118:399-408(2002). RN [16] RP PHOSPHORYLATION AT THR-328; SER-330; THR-346; THR-356 AND THR-366. RX PubMed=15461589; DOI=10.1042/bj20041057; RA Murray J.T., Campbell D.G., Morrice N., Auld G.C., Shpiro N., Marquez R., RA Peggie M., Bain J., Bloomberg G.B., Grahammer F., Lang F., Wulff P., RA Kuhl D., Cohen P.; RT "Exploitation of KESTREL to identify NDRG family members as physiological RT substrates for SGK1 and GSK3."; RL Biochem. J. 384:477-488(2004). RN [17] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=15247272; DOI=10.1074/jbc.m400781200; RA Kim K.T., Ongusaha P.P., Hong Y.K., Kurdistani S.K., Nakamura M., Lu K.P., RA Lee S.W.; RT "Function of Drg1/Rit42 in p53-dependent mitotic spindle checkpoint."; RL J. Biol. Chem. 279:38597-38602(2004). RN [18] RP FUNCTION. RX PubMed=15377670; DOI=10.1074/jbc.m400386200; RA Stein S., Thomas E.K., Herzog B., Westfall M.D., Rocheleau J.V., RA Jackson R.S. II, Wang M., Liang P.; RT "NDRG1 is necessary for p53-dependent apoptosis."; RL J. Biol. Chem. 279:48930-48940(2004). RN [19] RP INTERACTION WITH APOA1; APOA2; PRA1 AND RTN1, AND POSSIBLE FUNCTION. RX PubMed=15922294; DOI=10.1016/j.bbrc.2005.05.050; RA Hunter M., Angelicheva D., Tournev I., Ingley E., Chan D.C., Watts G.F., RA Kremensky I., Kalaydjieva L.; RT "NDRG1 interacts with APO A-I and A-II and is a functional candidate for RT the HDL-C QTL on 8q24."; RL Biochem. Biophys. Res. Commun. 332:982-992(2005). RN [20] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-330 AND SER-333, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [22] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Prostate cancer; RX PubMed=17487921; DOI=10.1002/elps.200600782; RA Giorgianni F., Zhao Y., Desiderio D.M., Beranova-Giorgianni S.; RT "Toward a global characterization of the phosphoproteome in prostate cancer RT cells: identification of phosphoproteins in the LNCaP cell line."; RL Electrophoresis 28:2027-2034(2007). RN [23] RP SUBCELLULAR LOCATION, AND INDUCTION. RX PubMed=17316623; DOI=10.1016/j.febslet.2007.01.080; RA Sibold S., Roh V., Keogh A., Studer P., Tiffon C., Angst E., RA Vorburger S.A., Weimann R., Candinas D., Stroka D.; RT "Hypoxia increases cytoplasmic expression of NDRG1, but is insufficient for RT its membrane localization in human hepatocellular carcinoma."; RL FEBS Lett. 581:989-994(2007). RN [24] RP INTERACTION WITH RAB4A, SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=17786215; DOI=10.1371/journal.pone.0000844; RA Kachhap S.K., Faith D., Qian D.Z., Shabbeer S., Galloway N.L., Pili R., RA Denmeade S.R., DeMarzo A.M., Carducci M.A.; RT "The N-Myc down regulated Gene1 (NDRG1) is a Rab4a effector involved in RT vesicular recycling of E-cadherin."; RL PLoS ONE 2:E844-E844(2007). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-326; SER-330; SER-333; RP SER-336; SER-364 AND THR-375, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [26] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [27] RP PHOSPHORYLATION AT THR-346; THR-356 AND THR-366. RX PubMed=18787837; DOI=10.1007/s00424-008-0587-1; RA Inglis S.K., Gallacher M., Brown S.G., McTavish N., Getty J., Husband E.M., RA Murray J.T., Wilson S.M.; RT "SGK1 activity in Na+ absorbing airway epithelial cells monitored by RT assaying NDRG1-Thr346/356/366 phosphorylation."; RL Pflugers Arch. 457:1287-1301(2009). RN [28] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-328 AND SER-330, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-333, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [30] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [31] RP PHOSPHORYLATION, AND SUBCELLULAR LOCATION. RX PubMed=21708134; DOI=10.1016/j.bbrc.2011.06.092; RA McCaig C., Potter L., Abramczyk O., Murray J.T.; RT "Phosphorylation of NDRG1 is temporally and spatially controlled during the RT cell cycle."; RL Biochem. Biophys. Res. Commun. 411:227-234(2011). RN [32] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2; THR-328; SER-330; SER-333; RP SER-336; SER-364; THR-366 AND THR-375, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [33] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-328; SER-332 AND SER-333, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). CC -!- FUNCTION: Stress-responsive protein involved in hormone responses, cell CC growth, and differentiation. Acts as a tumor suppressor in many cell CC types. Necessary but not sufficient for p53/TP53-mediated caspase CC activation and apoptosis. Has a role in cell trafficking, notably of CC the Schwann cell, and is necessary for the maintenance and development CC of the peripheral nerve myelin sheath. Required for vesicular recycling CC of CDH1 and TF. May also function in lipid trafficking. Protects cells CC from spindle disruption damage. Functions in p53/TP53-dependent mitotic CC spindle checkpoint. Regulates microtubule dynamics and maintains CC euploidy. {ECO:0000269|PubMed:15247272, ECO:0000269|PubMed:15377670, CC ECO:0000269|PubMed:17786215, ECO:0000269|PubMed:9766676}. CC -!- SUBUNIT: Interacts with RAB4A (membrane-bound form); the interaction CC involves NDRG1 in vesicular recycling of CDH1. CC {ECO:0000269|PubMed:15922294, ECO:0000269|PubMed:17786215}. CC -!- INTERACTION: CC Q92597; P05023: ATP1A1; NbExp=2; IntAct=EBI-716486, EBI-358778; CC Q92597; P27824: CANX; NbExp=2; IntAct=EBI-716486, EBI-355947; CC Q92597; Q9H6J7-2: CSTPP1; NbExp=3; IntAct=EBI-716486, EBI-13328871; CC Q92597; P35222: CTNNB1; NbExp=3; IntAct=EBI-716486, EBI-491549; CC Q92597; Q9H816: DCLRE1B; NbExp=3; IntAct=EBI-716486, EBI-3508943; CC Q92597; Q3SYB3: FOXD4L6; NbExp=3; IntAct=EBI-716486, EBI-6425864; CC Q92597; Q9BYZ2: LDHAL6B; NbExp=3; IntAct=EBI-716486, EBI-1108377; CC Q92597; Q9H204: MED28; NbExp=3; IntAct=EBI-716486, EBI-514199; CC Q92597; Q9Y3D2: MSRB2; NbExp=3; IntAct=EBI-716486, EBI-9092052; CC Q92597; Q6ZNA4-2: RNF111; NbExp=3; IntAct=EBI-716486, EBI-21535400; CC Q92597; Q8N488: RYBP; NbExp=3; IntAct=EBI-716486, EBI-752324; CC Q92597; O75446: SAP30; NbExp=3; IntAct=EBI-716486, EBI-632609; CC Q92597; Q99932-2: SPAG8; NbExp=3; IntAct=EBI-716486, EBI-11959123; CC Q92597; Q8IUW3: SPATA2L; NbExp=3; IntAct=EBI-716486, EBI-2510414; CC Q92597; Q6PID6: TTC33; NbExp=3; IntAct=EBI-716486, EBI-2555404; CC Q92597; P12956: XRCC6; NbExp=2; IntAct=EBI-716486, EBI-353208; CC Q92597; P61981: YWHAG; NbExp=3; IntAct=EBI-716486, EBI-359832; CC Q92597; Q96NC0: ZMAT2; NbExp=3; IntAct=EBI-716486, EBI-2682299; CC Q92597-3; Q9Y3D8: AK6; NbExp=3; IntAct=EBI-10278703, EBI-2896123; CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol. Cytoplasm, cytoskeleton, CC microtubule organizing center, centrosome. Nucleus. Cell membrane. CC Note=Mainly cytoplasmic but differentially localized to other regions. CC Associates with the plasma membrane in intestinal epithelia and CC lactating mammary gland. Translocated to the nucleus in a p53/TP53- CC dependent manner. In prostate epithelium and placental chorion, located CC in both the cytoplasm and in the nucleus. No nuclear localization in CC colon epithelium cells. In intestinal mucosa, prostate and renal CC cortex, located predominantly adjacent to adherens junctions. CC Cytoplasmic with granular staining in proximal tubular cells of the CC kidney and salivary gland ducts. Recruits to the membrane of CC recycling/sorting and late endosomes via binding to CC phosphatidylinositol 4-phosphate. Associates with microtubules. CC Colocalizes with TUBG1 in the centrosome. Cytoplasmic location CC increased with hypoxia. Phosphorylated form found associated with CC centromeres during S-phase of mitosis and with the plasma membrane. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q92597-1; Sequence=Displayed; CC Name=2; CC IsoId=Q92597-2; Sequence=VSP_045038; CC Name=3; CC IsoId=Q92597-3; Sequence=VSP_045037; CC -!- TISSUE SPECIFICITY: Ubiquitous; expressed most prominently in placental CC membranes and prostate, kidney, small intestine, and ovary tissues. CC Also expressed in heart, brain, skeletal muscle, lung, liver and CC pancreas. Low levels in peripheral blood leukocytes and in tissues of CC the immune system. Expressed mainly in epithelial cells. Also found in CC Schwann cells of peripheral neurons. Reduced expression in CC adenocarcinomas compared to normal tissues. In colon, prostate and CC placental membranes, the cells that border the lumen show the highest CC expression. {ECO:0000269|PubMed:12432451, ECO:0000269|PubMed:8939898, CC ECO:0000269|PubMed:9251681, ECO:0000269|PubMed:9605764}. CC -!- INDUCTION: By homocysteine, 2-mercaptoethanol, tunicamycin in CC endothelial cells. Induced approximately 20-fold during in vitro CC differentiation of the colon carcinoma cell lines HT-29-D4 and Caco-2. CC Induced by oxidative stress in colon cancers. Decreased expression in CC colon adenomas and adenocarcinomas. Induced by nickel compounds in all CC tested cell lines. The primary signal for its induction is an elevation CC of free intracellular calcium ion caused by nickel ion exposure. CC Okadaic acid, a serine/threonine phosphatase inhibitor, induced its CC expression more rapidly and more efficiently than nickel. CC {ECO:0000269|PubMed:10395947, ECO:0000269|PubMed:17316623, CC ECO:0000269|PubMed:8939898, ECO:0000269|PubMed:9251681, CC ECO:0000269|PubMed:9605764, ECO:0000269|PubMed:9766676}. CC -!- PTM: Under stress conditions, phosphorylated in the C-terminal on many CC serine and threonine residues. Phosphorylated in vitro by PKA. CC Phosphorylation enhanced by increased intracellular cAMP levels. CC Homocysteine induces dephosphorylation. Phosphorylation by SGK1 is cell CC cycle dependent. {ECO:0000269|PubMed:10860807, CC ECO:0000269|PubMed:15461589, ECO:0000269|PubMed:18787837, CC ECO:0000269|PubMed:21708134}. CC -!- DISEASE: Charcot-Marie-Tooth disease, demyelinating, type 4D (CMT4D) CC [MIM:601455]: A recessive demyelinating form of Charcot-Marie-Tooth CC disease, a disorder of the peripheral nervous system, characterized by CC progressive weakness and atrophy, initially of the peroneal muscles and CC later of the distal muscles of the arms. Charcot-Marie-Tooth disease is CC classified in two main groups on the basis of electrophysiologic CC properties and histopathology: primary peripheral demyelinating CC neuropathies (designated CMT1 when they are dominantly inherited) and CC primary peripheral axonal neuropathies (CMT2). Demyelinating CC neuropathies are characterized by severely reduced nerve conduction CC velocities (less than 38 m/sec), segmental demyelination and CC remyelination with onion bulb formations on nerve biopsy, slowly CC progressive distal muscle atrophy and weakness, absent deep tendon CC reflexes, and hollow feet. By convention autosomal recessive forms of CC demyelinating Charcot-Marie-Tooth disease are designated CMT4. CC {ECO:0000269|PubMed:10831399}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the NDRG family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/41512/NDRG1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D87953; BAA13505.1; -; mRNA. DR EMBL; X92845; CAA63430.1; -; mRNA. DR EMBL; AF004162; AAC13419.1; -; mRNA. DR EMBL; AF186190; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CR456842; CAG33123.1; -; mRNA. DR EMBL; AK091147; BAG52292.1; -; mRNA. DR EMBL; AK126924; BAG54400.1; -; mRNA. DR EMBL; AK296794; BAH12432.1; -; mRNA. DR EMBL; AF192304; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471060; EAW92164.1; -; Genomic_DNA. DR EMBL; BC003175; AAH03175.1; -; mRNA. DR EMBL; AF230380; AAF71305.1; -; mRNA. DR CCDS; CCDS34945.1; -. [Q92597-1] DR CCDS; CCDS59113.1; -. [Q92597-2] DR RefSeq; NP_001128714.1; NM_001135242.2. [Q92597-1] DR RefSeq; NP_001245361.1; NM_001258432.2. [Q92597-2] DR RefSeq; NP_001245362.1; NM_001258433.2. [Q92597-3] DR RefSeq; NP_001361774.1; NM_001374845.1. [Q92597-1] DR RefSeq; NP_001361775.1; NM_001374846.1. [Q92597-1] DR RefSeq; NP_001361776.1; NM_001374847.1. [Q92597-2] DR RefSeq; NP_006087.2; NM_006096.3. [Q92597-1] DR PDB; 6ZMM; X-ray; 2.96 A; A/B=31-319. DR PDBsum; 6ZMM; -. DR AlphaFoldDB; Q92597; -. DR SMR; Q92597; -. DR BioGRID; 115669; 247. DR FunCoup; Q92597; 1492. DR IntAct; Q92597; 165. DR MINT; Q92597; -. DR STRING; 9606.ENSP00000404854; -. DR ChEMBL; CHEMBL4295916; -. DR ESTHER; human-NDRG1; Ndr_family. DR MEROPS; S33.988; -. DR GlyGen; Q92597; 3 sites, 2 O-linked glycans (3 sites). DR iPTMnet; Q92597; -. DR MetOSite; Q92597; -. DR PhosphoSitePlus; Q92597; -. DR SwissPalm; Q92597; -. DR BioMuta; NDRG1; -. DR DMDM; 6166568; -. DR jPOST; Q92597; -. DR MassIVE; Q92597; -. DR PaxDb; 9606-ENSP00000404854; -. DR PeptideAtlas; Q92597; -. DR ProteomicsDB; 3585; -. DR ProteomicsDB; 6569; -. DR ProteomicsDB; 75343; -. [Q92597-1] DR Pumba; Q92597; -. DR TopDownProteomics; Q92597-1; -. [Q92597-1] DR Antibodypedia; 1521; 643 antibodies from 43 providers. DR DNASU; 10397; -. DR Ensembl; ENST00000323851.13; ENSP00000319977.8; ENSG00000104419.17. [Q92597-1] DR Ensembl; ENST00000414097.6; ENSP00000404854.2; ENSG00000104419.17. [Q92597-1] DR Ensembl; ENST00000522476.5; ENSP00000427894.1; ENSG00000104419.17. [Q92597-2] DR GeneID; 10397; -. DR KEGG; hsa:10397; -. DR MANE-Select; ENST00000323851.13; ENSP00000319977.8; NM_006096.4; NP_006087.2. DR UCSC; uc003yug.3; human. [Q92597-1] DR AGR; HGNC:7679; -. DR ClinPGx; PA31482; -. DR CTD; 10397; -. DR DisGeNET; 10397; -. DR GeneCards; NDRG1; -. DR GeneReviews; NDRG1; -. DR HGNC; HGNC:7679; NDRG1. DR HPA; ENSG00000104419; Low tissue specificity. DR MalaCards; NDRG1; -. DR MIM; 601455; phenotype. DR MIM; 605262; gene. DR OpenTargets; ENSG00000104419; -. DR Orphanet; 99950; Charcot-Marie-Tooth disease type 4D. DR VEuPathDB; HostDB:ENSG00000104419; -. DR eggNOG; KOG2931; Eukaryota. DR GeneTree; ENSGT00950000182872; -. DR HOGENOM; CLU_035361_1_0_1; -. DR InParanoid; Q92597; -. DR OMA; LVEKGEX; -. DR OrthoDB; 741027at2759; -. DR PAN-GO; Q92597; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q92597; -. DR PathwayCommons; Q92597; -. DR Reactome; R-HSA-6803205; TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain. DR SignaLink; Q92597; -. DR SIGNOR; Q92597; -. DR Agora; ENSG00000104419; -. DR BioGRID-ORCS; 10397; 11 hits in 1163 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; NDRG1; human. DR GeneWiki; NDRG1; -. DR GenomeRNAi; 10397; -. DR Pharos; Q92597; Tbio. DR PRO; PR:Q92597; -. DR Proteomes; UP000005640; Chromosome 8. DR RNAct; Q92597; protein. DR Bgee; ENSG00000104419; Expressed in olfactory bulb and 205 other cell types or tissues. DR ExpressionAtlas; Q92597; baseline and differential. DR GO; GO:0005912; C:adherens junction; IDA:UniProtKB. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005874; C:microtubule; IDA:UniProtKB. DR GO; GO:0015630; C:microtubule cytoskeleton; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0055038; C:recycling endosome membrane; IDA:UniProtKB. DR GO; GO:0097229; C:sperm end piece; IDA:HPA. DR GO; GO:0120238; C:sperm glycocalyx; IDA:HPA. DR GO; GO:0120212; C:sperm head-tail coupling apparatus; IDA:HPA. DR GO; GO:0097225; C:sperm midpiece; IDA:HPA. DR GO; GO:0097228; C:sperm principal piece; IDA:HPA. DR GO; GO:0045296; F:cadherin binding; IDA:UniProtKB. DR GO; GO:0043015; F:gamma-tubulin binding; IDA:UniProtKB. DR GO; GO:0008017; F:microtubule binding; IDA:UniProtKB. DR GO; GO:0016151; F:nickel cation binding; IPI:DisProt. DR GO; GO:0031267; F:small GTPase binding; IDA:UniProtKB. DR GO; GO:0071456; P:cellular response to hypoxia; IEP:UniProtKB. DR GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; IEP:UniProtKB. DR GO; GO:0045576; P:mast cell activation; IEA:Ensembl. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IEA:Ensembl. DR GO; GO:0032287; P:peripheral nervous system myelin maintenance; IEA:Ensembl. DR GO; GO:0010038; P:response to metal ion; TAS:ProtInc. DR GO; GO:0007165; P:signal transduction; IBA:GO_Central. DR DisProt; DP03990; -. DR FunFam; 3.40.50.1820:FF:000006; NDRG family member 3; 1. DR Gene3D; 3.40.50.1820; alpha/beta hydrolase; 1. DR InterPro; IPR029058; AB_hydrolase_fold. DR InterPro; IPR004142; NDRG. DR PANTHER; PTHR11034; N-MYC DOWNSTREAM REGULATED; 1. DR Pfam; PF03096; Ndr; 1. DR SUPFAM; SSF53474; alpha/beta-Hydrolases; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Cell membrane; KW Charcot-Marie-Tooth disease; Cytoplasm; Cytoskeleton; KW Direct protein sequencing; Membrane; Microtubule; Neurodegeneration; KW Neuropathy; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:19413330" FT CHAIN 2..394 FT /note="Protein NDRG1" FT /id="PRO_0000159573" FT REPEAT 339..348 FT /note="1" FT REPEAT 349..358 FT /note="2" FT REPEAT 359..368 FT /note="3" FT REGION 325..394 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 339..368 FT /note="3 X 10 AA tandem repeats of G-T-R-S-R-S-H-T-S-E" FT COMPBIAS 327..339 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 345..371 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:19413330" FT MOD_RES 2 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 319 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62433" FT MOD_RES 326 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 328 FT /note="Phosphothreonine; by SGK1" FT /evidence="ECO:0000269|PubMed:15461589, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 330 FT /note="Phosphoserine; by SGK1" FT /evidence="ECO:0000269|PubMed:15461589, FT ECO:0007744|PubMed:16964243, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163" FT MOD_RES 332 FT /note="Phosphoserine; by SGK1" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 333 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:16964243, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 335 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q62433" FT MOD_RES 336 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 340 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q62433" FT MOD_RES 342 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62433" FT MOD_RES 346 FT /note="Phosphothreonine; by SGK1" FT /evidence="ECO:0000269|PubMed:15461589, FT ECO:0000269|PubMed:18787837" FT MOD_RES 352 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q6JE36" FT MOD_RES 356 FT /note="Phosphothreonine; by SGK1" FT /evidence="ECO:0000269|PubMed:15461589, FT ECO:0000269|PubMed:18787837" FT MOD_RES 362 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q6JE36" FT MOD_RES 364 FT /note="Phosphoserine; by SGK1" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 366 FT /note="Phosphothreonine; by SGK1" FT /evidence="ECO:0000269|PubMed:15461589, FT ECO:0000269|PubMed:18787837, ECO:0007744|PubMed:23186163" FT MOD_RES 375 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..81 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_045037" FT VAR_SEQ 1..66 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_045038" FT VARIANT 67 FT /note="M -> V (in dbSNP:rs2233319)" FT /id="VAR_050234" FT VARIANT 111 FT /note="M -> L (in dbSNP:rs2233328)" FT /id="VAR_050235" FT CONFLICT 145 FT /note="I -> T (in Ref. 2; CAA63430)" FT /evidence="ECO:0000305" FT STRAND 33..39 FT /evidence="ECO:0007829|PDB:6ZMM" FT STRAND 42..48 FT /evidence="ECO:0007829|PDB:6ZMM" FT STRAND 58..62 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 69..72 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 74..77 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 80..82 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 83..88 FT /evidence="ECO:0007829|PDB:6ZMM" FT STRAND 90..95 FT /evidence="ECO:0007829|PDB:6ZMM" FT TURN 97..99 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 115..120 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 122..128 FT /evidence="ECO:0007829|PDB:6ZMM" FT STRAND 134..139 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 141..152 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 154..156 FT /evidence="ECO:0007829|PDB:6ZMM" FT STRAND 157..164 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 187..195 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 209..217 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 221..232 FT /evidence="ECO:0007829|PDB:6ZMM" FT STRAND 255..260 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 266..274 FT /evidence="ECO:0007829|PDB:6ZMM" FT TURN 278..280 FT /evidence="ECO:0007829|PDB:6ZMM" FT STRAND 281..286 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 293..296 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 298..311 FT /evidence="ECO:0007829|PDB:6ZMM" SQ SEQUENCE 394 AA; 42835 MW; 4C816B9C85E3756F CRC64; MSREMQDVDL AEVKPLVEKG ETITGLLQEF DVQEQDIETL HGSVHVTLCG TPKGNRPVIL TYHDIGMNHK TCYNPLFNYE DMQEITQHFA VCHVDAPGQQ DGAASFPAGY MYPSMDQLAE MLPGVLQQFG LKSIIGMGTG AGAYILTRFA LNNPEMVEGL VLINVNPCAE GWMDWAASKI SGWTQALPDM VVSHLFGKEE MQSNVEVVHT YRQHIVNDMN PGNLHLFINA YNSRRDLEIE RPMPGTHTVT LQCPALLVVG DSSPAVDAVV ECNSKLDPTK TTLLKMADCG GLPQISQPAK LAEAFKYFVQ GMGYMPSASM TRLMRSRTAS GSSVTSLDGT RSRSHTSEGT RSRSHTSEGT RSRSHTSEGA HLDITPNSGA AGNSAGPKSM EVSC // ID NEK11_HUMAN Reviewed; 645 AA. AC Q8NG66; A6NHD7; Q5JPC0; Q8NG65; Q8TBY1; Q9H5F4; DT 13-SEP-2005, integrated into UniProtKB/Swiss-Prot. DT 30-NOV-2010, sequence version 2. DT 28-JAN-2026, entry version 181. DE RecName: Full=Serine/threonine-protein kinase Nek11; DE EC=2.7.11.1 {ECO:0000269|PubMed:12154088, ECO:0000269|PubMed:15161910}; DE AltName: Full=Never in mitosis A-related kinase 11; DE Short=NimA-related protein kinase 11; GN Name=NEK11 {ECO:0000312|HGNC:HGNC:18593}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305, ECO:0000312|EMBL:BAC06350.1} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, CATALYTIC RP ACTIVITY, COFACTOR, ACTIVITY REGULATION, DEVELOPMENTAL STAGE, TISSUE RP SPECIFICITY, SUBCELLULAR LOCATION, MUTAGENESIS OF LYS-61, AND VARIANT RP VAL-488. RC TISSUE=Cervix carcinoma; RX PubMed=12154088; DOI=10.1074/jbc.m204599200; RA Noguchi K., Fukazawa H., Murakami Y., Uehara Y.; RT "Nek11, a new member of the NIMA family of kinases, involved in DNA RT replication and genotoxic stress responses."; RL J. Biol. Chem. 277:39655-39665(2002). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4), AND VARIANT VAL-488. RC TISSUE=Cervix; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16641997; DOI=10.1038/nature04728; RA Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., RA Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., RA Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A., RA Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., RA Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., RA Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., RA Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., RA Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., RA Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., RA Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., RA Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., RA Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., RA Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., RA Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., RA Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., RA Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., RA Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., RA Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., RA Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.; RT "The DNA sequence, annotation and analysis of human chromosome 3."; RL Nature 440:1194-1198(2006). RN [4] {ECO:0000305, ECO:0000312|EMBL:CAI46114.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [5] {ECO:0000305, ECO:0000312|EMBL:AAH28587.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Testis {ECO:0000312|EMBL:AAH28587.1}; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] {ECO:0000305, ECO:0000312|EMBL:BAB15672.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 162-645 (ISOFORM 1), AND VARIANT RP VAL-488. RC TISSUE=Lung {ECO:0000312|EMBL:BAB15672.1}; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] {ECO:0000305} RP CATALYTIC ACTIVITY, COFACTOR, SUBCELLULAR LOCATION, ACTIVITY REGULATION, RP AND INTERACTION WITH NEK2. RX PubMed=15161910; DOI=10.1074/jbc.m404104200; RA Noguchi K., Fukazawa H., Murakami Y., Uehara Y.; RT "Nucleolar Nek11 is a novel target of Nek2A in G1/S-arrested cells."; RL J. Biol. Chem. 279:32716-32727(2004). RN [8] RP FUNCTION, AND PHOSPHORYLATION AT SER-273. RX PubMed=19734889; DOI=10.1038/ncb1969; RA Melixetian M., Klein D.K., Soerensen C.S., Helin K.; RT "NEK11 regulates CDC25A degradation and the IR-induced G2/M checkpoint."; RL Nat. Cell Biol. 11:1247-1253(2009). RN [9] RP FUNCTION, AND PHOSPHORYLATION AT SER-273. RX PubMed=20090422; DOI=10.4161/cc.9.3.10513; RA Soerensen C.S., Melixetian M., Klein D.K., Helin K.; RT "NEK11: linking CHK1 and CDC25A in DNA damage checkpoint signaling."; RL Cell Cycle 9:450-455(2010). RN [10] RP VARIANTS [LARGE SCALE ANALYSIS] MET-108; CYS-123; LEU-213; VAL-263; RP LYS-451; VAL-488; LYS-492; THR-548; ALA-562; LYS-606 AND ASN-617. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Protein kinase which plays an important role in the G2/M CC checkpoint response to DNA damage. Controls degradation of CDC25A by CC directly phosphorylating it on residues whose phosphorylation is CC required for BTRC-mediated polyubiquitination and degradation. CC {ECO:0000269|PubMed:12154088, ECO:0000269|PubMed:19734889, CC ECO:0000269|PubMed:20090422}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12154088, ECO:0000269|PubMed:15161910}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12154088, ECO:0000269|PubMed:15161910}; CC -!- COFACTOR: CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; CC Evidence={ECO:0000269|PubMed:12154088, ECO:0000269|PubMed:15161910}; CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:12154088, ECO:0000269|PubMed:15161910}; CC -!- ACTIVITY REGULATION: Autorepressed by intramolecular binding of the C- CC terminus which dissociates following phosphorylation by NEK2 isoform 1 CC in G1/S-arrested cells. NEK2 isoform 2 is largely not present in the CC nucleolus, and does not appear to phosphorylate NEK11. Activated in CC response to DNA damage. Inhibited by zinc. CC {ECO:0000269|PubMed:12154088, ECO:0000269|PubMed:15161910}. CC -!- SUBUNIT: Interacts with isoform 1 of NEK2. CC {ECO:0000269|PubMed:15161910}. CC -!- INTERACTION: CC Q8NG66; P08238: HSP90AB1; NbExp=2; IntAct=EBI-633195, EBI-352572; CC Q8NG66; P51955: NEK2; NbExp=5; IntAct=EBI-633195, EBI-633182; CC Q8NG66; P51955-1: NEK2; NbExp=2; IntAct=EBI-633195, EBI-687792; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:12154088}. Nucleus, CC nucleolus {ECO:0000269|PubMed:15161910}. Note=Nuclear during interphase CC but moves to the polar microtubules during prometaphase and metaphase CC (PubMed:12154088). Accumulates in the nucleolus in G1/S-arrested cells CC (PubMed:15161910). {ECO:0000269|PubMed:12154088, CC ECO:0000269|PubMed:15161910}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1 {ECO:0000269|PubMed:12154088}; Synonyms=Long CC {ECO:0000303|PubMed:12154088}; CC IsoId=Q8NG66-1; Sequence=Displayed; CC Name=2 {ECO:0000269|PubMed:12154088}; Synonyms=Short CC {ECO:0000303|PubMed:12154088}; CC IsoId=Q8NG66-2; Sequence=VSP_051821, VSP_051822; CC Name=3 {ECO:0000305}; CC IsoId=Q8NG66-3; Sequence=VSP_051820, VSP_051823; CC Name=4; CC IsoId=Q8NG66-4; Sequence=VSP_040080, VSP_040081; CC -!- TISSUE SPECIFICITY: Poorly expressed in cerebellum, trachea, lung, CC appendix, and uterus. {ECO:0000269|PubMed:12154088}. CC -!- DEVELOPMENTAL STAGE: Predominantly expressed at S/G2/M phase. CC {ECO:0000269|PubMed:12154088}. CC -!- PTM: Phosphorylated by NEK2. Phosphorylation at Ser-273 is important CC for its activation. {ECO:0000269|PubMed:19734889, CC ECO:0000269|PubMed:20090422}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. NEK Ser/Thr CC protein kinase family. NIMA subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAB15672.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB071996; BAC06350.1; -; mRNA. DR EMBL; AB071997; BAC06351.1; -; mRNA. DR EMBL; AL833472; CAI46114.1; -; mRNA. DR EMBL; AC055733; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471052; EAW79213.1; -; Genomic_DNA. DR EMBL; BC028587; AAH28587.1; -; mRNA. DR EMBL; AK027148; BAB15672.1; ALT_INIT; mRNA. DR CCDS; CCDS3069.1; -. [Q8NG66-1] DR CCDS; CCDS46915.1; -. [Q8NG66-2] DR CCDS; CCDS54639.1; -. [Q8NG66-4] DR CCDS; CCDS82836.1; -. [Q8NG66-3] DR RefSeq; NP_001139475.1; NM_001146003.2. [Q8NG66-4] DR RefSeq; NP_001308149.1; NM_001321220.2. [Q8NG66-1] DR RefSeq; NP_001308150.1; NM_001321221.1. DR RefSeq; NP_001308151.1; NM_001321222.1. DR RefSeq; NP_001308152.1; NM_001321223.1. [Q8NG66-3] DR RefSeq; NP_001308153.1; NM_001321224.1. DR RefSeq; NP_001339952.1; NM_001353023.2. [Q8NG66-1] DR RefSeq; NP_001339957.1; NM_001353028.2. [Q8NG66-4] DR RefSeq; NP_001339958.1; NM_001353029.2. [Q8NG66-4] DR RefSeq; NP_079076.3; NM_024800.4. [Q8NG66-1] DR RefSeq; NP_665917.1; NM_145910.4. [Q8NG66-2] DR RefSeq; XP_047304926.1; XM_047448970.1. [Q8NG66-1] DR RefSeq; XP_047304927.1; XM_047448971.1. [Q8NG66-1] DR RefSeq; XP_047304928.1; XM_047448972.1. [Q8NG66-1] DR RefSeq; XP_047304935.1; XM_047448979.1. [Q8NG66-2] DR RefSeq; XP_054203914.1; XM_054347939.1. [Q8NG66-2] DR AlphaFoldDB; Q8NG66; -. DR SMR; Q8NG66; -. DR BioGRID; 122947; 36. DR CORUM; Q8NG66; -. DR FunCoup; Q8NG66; 986. DR IntAct; Q8NG66; 16. DR STRING; 9606.ENSP00000372857; -. DR BindingDB; Q8NG66; -. DR ChEMBL; CHEMBL5638; -. DR DrugBank; DB08912; Dabrafenib. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q8NG66; -. DR GuidetoPHARMACOLOGY; 2116; -. DR iPTMnet; Q8NG66; -. DR PhosphoSitePlus; Q8NG66; -. DR BioMuta; NEK11; -. DR DMDM; 313104142; -. DR CPTAC; non-CPTAC-5648; -. DR CPTAC; non-CPTAC-5649; -. DR jPOST; Q8NG66; -. DR MassIVE; Q8NG66; -. DR PaxDb; 9606-ENSP00000372857; -. DR PeptideAtlas; Q8NG66; -. DR ProteomicsDB; 73438; -. [Q8NG66-1] DR ProteomicsDB; 73439; -. [Q8NG66-2] DR ProteomicsDB; 73440; -. [Q8NG66-3] DR ProteomicsDB; 73441; -. [Q8NG66-4] DR Antibodypedia; 2071; 293 antibodies from 25 providers. DR DNASU; 79858; -. DR Ensembl; ENST00000356918.8; ENSP00000349389.5; ENSG00000114670.15. [Q8NG66-2] DR Ensembl; ENST00000383366.9; ENSP00000372857.4; ENSG00000114670.15. [Q8NG66-1] DR Ensembl; ENST00000507910.5; ENSP00000426662.1; ENSG00000114670.15. [Q8NG66-3] DR Ensembl; ENST00000508196.5; ENSP00000421851.1; ENSG00000114670.15. [Q8NG66-1] DR Ensembl; ENST00000510688.5; ENSP00000423458.1; ENSG00000114670.15. [Q8NG66-4] DR Ensembl; ENST00000511262.5; ENSP00000425114.1; ENSG00000114670.15. [Q8NG66-2] DR GeneID; 79858; -. DR KEGG; hsa:79858; -. DR MANE-Select; ENST00000383366.9; ENSP00000372857.4; NM_024800.5; NP_079076.3. DR UCSC; uc003enx.4; human. [Q8NG66-1] DR AGR; HGNC:18593; -. DR ClinPGx; PA38595; -. DR CTD; 79858; -. DR DisGeNET; 79858; -. DR GeneCards; NEK11; -. DR HGNC; HGNC:18593; NEK11. DR HPA; ENSG00000114670; Tissue enhanced (choroid). DR MIM; 609779; gene. DR OpenTargets; ENSG00000114670; -. DR VEuPathDB; HostDB:ENSG00000114670; -. DR eggNOG; KOG0589; Eukaryota. DR GeneTree; ENSGT00940000160525; -. DR HOGENOM; CLU_000288_63_39_1; -. DR InParanoid; Q8NG66; -. DR OrthoDB; 248923at2759; -. DR PAN-GO; Q8NG66; 8 GO annotations based on evolutionary models. DR PhylomeDB; Q8NG66; -. DR PathwayCommons; Q8NG66; -. DR SignaLink; Q8NG66; -. DR SIGNOR; Q8NG66; -. DR Agora; ENSG00000114670; -. DR BioGRID-ORCS; 79858; 11 hits in 1182 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; NEK11; human. DR GenomeRNAi; 79858; -. DR Pharos; Q8NG66; Tchem. DR PRO; PR:Q8NG66; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q8NG66; protein. DR Bgee; ENSG00000114670; Expressed in right uterine tube and 137 other cell types or tissues. DR ExpressionAtlas; Q8NG66; baseline and differential. DR GO; GO:0005730; C:nucleolus; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB. DR GO; GO:0031573; P:mitotic intra-S DNA damage checkpoint signaling; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:1901990; P:regulation of mitotic cell cycle phase transition; IMP:CACAO. DR CDD; cd08222; STKc_Nek11; 1. DR FunFam; 1.10.510.10:FF:000436; NIMA related kinase 11; 1. DR FunFam; 3.30.200.20:FF:000332; NIMA related kinase 11; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR051131; NEK_Ser/Thr_kinase_NIMA. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR44899; CAMK FAMILY PROTEIN KINASE; 1. DR PANTHER; PTHR44899:SF8; NIMA-RELATED KINASE 11; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW Alternative splicing; ATP-binding; Cell cycle; Coiled coil; Kinase; KW Magnesium; Manganese; Metal-binding; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..645 FT /note="Serine/threonine-protein kinase Nek11" FT /id="PRO_0000086438" FT DOMAIN 29..287 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 399..445 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 346..385 FT /evidence="ECO:0000250|UniProtKB:P51957, ECO:0000255" FT ACT_SITE 158 FT /note="Proton acceptor" FT /evidence="ECO:0000250|UniProtKB:P51957, FT ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE- FT ProRule:PRU10027" FT BINDING 35..43 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000250|UniProtKB:P51957, FT ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 61 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:12154088" FT MOD_RES 273 FT /note="Phosphoserine; by CHEK1" FT /evidence="ECO:0000269|PubMed:19734889, FT ECO:0000269|PubMed:20090422" FT VAR_SEQ 467..482 FT /note="EIPEDPLVAEEYYADA -> GDCNLISLDEYWKNEK (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_051820" FT VAR_SEQ 467..470 FT /note="EIPE -> ATHS (in isoform 2)" FT /evidence="ECO:0000303|PubMed:12154088" FT /id="VSP_051821" FT VAR_SEQ 471..645 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:12154088" FT /id="VSP_051822" FT VAR_SEQ 483..645 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_051823" FT VAR_SEQ 542..599 FT /note="TKTITTMAEDMSPGPPIFNSVMARTKMKRMRESAMQKLGTEVFEEVYNYLKR FT ARHQNA -> QPCRSWGQKYLKRSIITSREQGIRMLAKQRSASVWKKWCLKPATVLKWT FT SSCTLKSSC (in isoform 4)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_040080" FT VAR_SEQ 600..645 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_040081" FT VARIANT 108 FT /note="T -> M (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs200709914)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040935" FT VARIANT 123 FT /note="Y -> C (in dbSNP:rs55806123)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040936" FT VARIANT 213 FT /note="S -> L (in dbSNP:rs55920129)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040937" FT VARIANT 263 FT /note="I -> V (in dbSNP:rs35567155)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040938" FT VARIANT 451 FT /note="E -> K (in dbSNP:rs35409692)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040939" FT VARIANT 488 FT /note="E -> V (in dbSNP:rs3738000)" FT /evidence="ECO:0000269|PubMed:12154088, FT ECO:0000269|PubMed:14702039, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:17974005" FT /id="VAR_040940" FT VARIANT 492 FT /note="E -> K (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs140599545)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040941" FT VARIANT 548 FT /note="M -> T (in dbSNP:rs55813244)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040942" FT VARIANT 562 FT /note="V -> A (in dbSNP:rs16836266)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_033907" FT VARIANT 606 FT /note="E -> K (in dbSNP:rs55944737)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040943" FT VARIANT 617 FT /note="D -> N (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs765563230)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040944" FT MUTAGEN 61 FT /note="K->R: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:12154088" SQ SEQUENCE 645 AA; 74192 MW; 7D11AE1D89711DEC CRC64; MLKFQEAAKC VSGSTAISTY PKTLIARRYV LQQKLGSGSF GTVYLVSDKK AKRGEELKVL KEISVGELNP NETVQANLEA QLLSKLDHPA IVKFHASFVE QDNFCIITEY CEGRDLDDKI QEYKQAGKIF PENQIIEWFI QLLLGVDYMH ERRILHRDLK SKNVFLKNNL LKIGDFGVSR LLMGSCDLAT TLTGTPHYMS PEALKHQGYD TKSDIWSLAC ILYEMCCMNH AFAGSNFLSI VLKIVEGDTP SLPERYPKEL NAIMESMLNK NPSLRPSAIE ILKIPYLDEQ LQNLMCRYSE MTLEDKNLDC QKEAAHIINA MQKRIHLQTL RALSEVQKMT PRERMRLRKL QAADEKARKL KKIVEEKYEE NSKRMQELRS RNFQQLSVDV LHEKTHLKGM EEKEEQPEGR LSCSPQDEDE ERWQGREEES DEPTLENLPE SQPIPSMDLH ELESIVEDAT SDLGYHEIPE DPLVAEEYYA DAFDSYCEES DEEEEEIALE RPEKEIRNEG SQPAYRTNQQ DSDIEALARC LENVLGCTSL DTKTITTMAE DMSPGPPIFN SVMARTKMKR MRESAMQKLG TEVFEEVYNY LKRARHQNAS EAEIRECLEK VVPQASDCFE VDQLLYFEEQ LLITMGKEPT LQNHL // ID NEK1_HUMAN Reviewed; 1258 AA. AC Q96PY6; G5E9Z3; Q05DG5; Q14CB7; Q5H9T1; Q6PIB8; Q96SS2; Q9H6P7; Q9Y594; DT 13-AUG-2002, integrated into UniProtKB/Swiss-Prot. DT 13-AUG-2002, sequence version 2. DT 28-JAN-2026, entry version 212. DE RecName: Full=Serine/threonine-protein kinase Nek1; DE EC=2.7.11.1 {ECO:0000269|PubMed:20230784}; DE AltName: Full=Never in mitosis A-related kinase 1; DE Short=NimA-related protein kinase 1; DE AltName: Full=Renal carcinoma antigen NY-REN-55; GN Name=NEK1; Synonyms=KIAA1901; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=11572484; DOI=10.1093/dnares/8.4.179; RA Nagase T., Kikuno R., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XXI. The RT complete sequences of 60 new cDNA clones from brain which code for large RT proteins."; RL DNA Res. 8:179-187(2001). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANT GLY-724. RC TISSUE=Uterus; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4). RC TISSUE=Bone marrow, and Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 91-1258 (ISOFORM 5), AND RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 865-1258. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 444-1258 (ISOFORM 2), AND IDENTIFICATION AS A RP RENAL CANCER ANTIGEN. RC TISSUE=Renal cell carcinoma; RX PubMed=10508479; RX DOI=10.1002/(sici)1097-0215(19991112)83:4<456::aid-ijc4>3.0.co;2-5; RA Scanlan M.J., Gordan J.D., Williamson B., Stockert E., Bander N.H., RA Jongeneel C.V., Gure A.O., Jaeger D., Jaeger E., Knuth A., Chen Y.-T., RA Old L.J.; RT "Antigens recognized by autologous antibody in patients with renal-cell RT carcinoma."; RL Int. J. Cancer 83:456-464(1999). RN [8] RP SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=15604234; DOI=10.1158/0008-5472.can-04-2243; RA Polci R., Peng A., Chen P.L., Riley D.J., Chen Y.; RT "NIMA-related protein kinase 1 is involved early in the ionizing radiation- RT induced DNA damage response."; RL Cancer Res. 64:8800-8803(2004). RN [9] RP SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=18843199; DOI=10.4161/cc.7.20.6815; RA Chen Y., Chen P.L., Chen C.F., Jiang X., Riley D.J.; RT "Never-in-mitosis related kinase 1 functions in DNA damage response and RT checkpoint control."; RL Cell Cycle 7:3194-3201(2008). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-414; SER-418; SER-428; RP SER-653; SER-798; SER-834; SER-868 AND SER-881, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [13] RP FUNCTION IN PHOSPHORYLATION OF VDAC1, AND CATALYTIC ACTIVITY. RX PubMed=20230784; DOI=10.1016/j.bbrc.2010.03.077; RA Chen Y., Gaczynska M., Osmulski P., Polci R., Riley D.J.; RT "Phosphorylation by Nek1 regulates opening and closing of voltage dependent RT anion channel 1."; RL Biochem. Biophys. Res. Commun. 394:798-803(2010). RN [14] RP FUNCTION, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND INVOLVEMENT IN RP DIGENIC SHORT-RIB THORACIC DYSPLASIA 3/6 WITH POLYDACTYLY. RX PubMed=21211617; DOI=10.1016/j.ajhg.2010.12.004; RA Thiel C., Kessler K., Giessl A., Dimmler A., Shalev S.A., von der Haar S., RA Zenker M., Zahnleiter D., Stoess H., Beinder E., Abou Jamra R., Ekici A.B., RA Schroeder-Kress N., Aigner T., Kirchner T., Reis A., Brandstaetter J.H., RA Rauch A.; RT "NEK1 mutations cause short-rib polydactyly syndrome type majewski."; RL Am. J. Hum. Genet. 88:106-114(2011). RN [15] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-156; SER-428; THR-661; RP SER-664; SER-868; SER-881 AND SER-1052, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1052, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [18] RP IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN A COMPLEX WITH RP CFAP410 AND SPATA7 BY MASS SPECTROMETRY, AND INTERACTION WITH CFAP410. RX PubMed=26167768; DOI=10.1038/ncb3201; RG UK10K Consortium; RG University of Washington Center for Mendelian Genomics; RA Wheway G., Schmidts M., Mans D.A., Szymanska K., Nguyen T.M., Racher H., RA Phelps I.G., Toedt G., Kennedy J., Wunderlich K.A., Sorusch N., RA Abdelhamed Z.A., Natarajan S., Herridge W., van Reeuwijk J., Horn N., RA Boldt K., Parry D.A., Letteboer S.J., Roosing S., Adams M., Bell S.M., RA Bond J., Higgins J., Morrison E.E., Tomlinson D.C., Slaats G.G., RA van Dam T.J., Huang L., Kessler K., Giessl A., Logan C.V., Boyle E.A., RA Shendure J., Anazi S., Aldahmesh M., Al Hazzaa S., Hegele R.A., Ober C., RA Frosk P., Mhanni A.A., Chodirker B.N., Chudley A.E., Lamont R., RA Bernier F.P., Beaulieu C.L., Gordon P., Pon R.T., Donahue C., RA Barkovich A.J., Wolf L., Toomes C., Thiel C.T., Boycott K.M., McKibbin M., RA Inglehearn C.F., Stewart F., Omran H., Huynen M.A., Sergouniotis P.I., RA Alkuraya F.S., Parboosingh J.S., Innes A.M., Willoughby C.E., Giles R.H., RA Webster A.R., Ueffing M., Blacque O., Gleeson J.G., Wolfrum U., RA Beales P.L., Gibson T., Doherty D., Mitchison H.M., Roepman R., RA Johnson C.A.; RT "An siRNA-based functional genomics screen for the identification of RT regulators of ciliogenesis and ciliopathy genes."; RL Nat. Cell Biol. 17:1074-1087(2015). RN [19] RP INVOLVEMENT IN OFD2, AND VARIANTS OFD2 THR-155 AND 409-TRP--GLU-1258 DEL. RX PubMed=27530628; DOI=10.1038/ejhg.2016.103; RA Monroe G.R., Kappen I.F., Stokman M.F., Terhal P.A., van den Boogaard M.H., RA Savelberg S.M., van der Veken L.T., van Es R.J., Lens S.M., Hengeveld R.C., RA Creton M.A., Janssen N.G., Mink van der Molen A.B., Ebbeling M.B., RA Giles R.H., Knoers N.V., van Haaften G.; RT "Compound heterozygous NEK1 variants in two siblings with oral-facial- RT digital syndrome type II (Mohr syndrome)."; RL Eur. J. Hum. Genet. 24:1752-1760(2016). RN [20] RP VARIANTS [LARGE SCALE ANALYSIS] PHE-10; LYS-25; VAL-76; PRO-294; GLY-355; RP VAL-463; THR-598; GLY-724; ASN-745; GLU-883 AND ASN-1180. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [21] RP VARIANTS SRTD6 ARG-145 AND SER-253. RX PubMed=22499340; DOI=10.1136/jmedgenet-2011-100717; RA El Hokayem J., Huber C., Couve A., Aziza J., Baujat G., Bouvier R., RA Cavalcanti D.P., Collins F.A., Cordier M.P., Delezoide A.L., Gonzales M., RA Johnson D., Le Merrer M., Levy-Mozziconacci A., Loget P., RA Martin-Coignard D., Martinovic J., Mortier G.R., Perez M.J., Roume J., RA Scarano G., Munnich A., Cormier-Daire V.; RT "NEK1 and DYNC2H1 are both involved in short rib polydactyly Majewski type RT but not in Beemer Langer cases."; RL J. Med. Genet. 49:227-233(2012). RN [22] RP INVOLVEMENT IN ALS24, AND VARIANTS 784-ARG--GLU-1258 DEL AND RP 1008-SER--GLU-1258 DEL. RX PubMed=26945885; DOI=10.1093/brain/aww033; RA Brenner D., Mueller K., Wieland T., Weydt P., Boehm S., Lule D., RA Huebers A., Neuwirth C., Weber M., Borck G., Wahlqvist M., Danzer K.M., RA Volk A.E., Meitinger T., Strom T.M., Otto M., Kassubek J., Ludolph A.C., RA Andersen P.M., Weishaupt J.H.; RT "NEK1 mutations in familial amyotrophic lateral sclerosis."; RL Brain 139:E28-E28(2016). RN [23] RP INVOLVEMENT IN ALS24, AND VARIANTS HIS-261 AND 550-ARG--GLU-1258 DEL. RX PubMed=27455347; DOI=10.1038/ng.3626; RA Kenna K.P., van Doormaal P.T., Dekker A.M., Ticozzi N., Kenna B.J., RA Diekstra F.P., van Rheenen W., van Eijk K.R., Jones A.R., Keagle P., RA Shatunov A., Sproviero W., Smith B.N., van Es M.A., Topp S.D., Kenna A., RA Miller J.W., Fallini C., Tiloca C., McLaughlin R.L., Vance C., Troakes C., RA Colombrita C., Mora G., Calvo A., Verde F., Al-Sarraj S., King A., RA Calini D., de Belleroche J., Baas F., van der Kooi A.J., de Visser M., RA Ten Asbroek A.L., Sapp P.C., McKenna-Yasek D., Polak M., Asress S., RA Munoz-Blanco J.L., Strom T.M., Meitinger T., Morrison K.E., Lauria G., RA Williams K.L., Leigh P.N., Nicholson G.A., Blair I.P., Leblond C.S., RA Dion P.A., Rouleau G.A., Pall H., Shaw P.J., Turner M.R., Talbot K., RA Taroni F., Boylan K.B., Van Blitterswijk M., Rademakers R., RA Esteban-Perez J., Garcia-Redondo A., Van Damme P., Robberecht W., Chio A., RA Gellera C., Drepper C., Sendtner M., Ratti A., Glass J.D., Mora J.S., RA Basak N.A., Hardiman O., Ludolph A.C., Andersen P.M., Weishaupt J.H., RA Brown R.H. Jr., Al-Chalabi A., Silani V., Shaw C.E., van den Berg L.H., RA Veldink J.H., Landers J.E.; RT "NEK1 variants confer susceptibility to amyotrophic lateral sclerosis."; RL Nat. Genet. 48:1037-1042(2016). CC -!- FUNCTION: Phosphorylates serines and threonines, but also appears to CC possess tyrosine kinase activity (PubMed:20230784). Involved in DNA CC damage checkpoint control and for proper DNA damage repair CC (PubMed:20230784). In response to injury that includes DNA damage, NEK1 CC phosphorylates VDAC1 to limit mitochondrial cell death CC (PubMed:20230784). May be implicated in the control of meiosis (By CC similarity). Involved in cilium assembly (PubMed:21211617). CC {ECO:0000250|UniProtKB:P51954, ECO:0000269|PubMed:20230784, CC ECO:0000269|PubMed:21211617}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:20230784}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:20230784}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- SUBUNIT: Binds to CBY2 (By similarity). Found in a complex with CC CFAP410, NEK1 and SPATA7 (PubMed:26167768). Interacts with CFAP410 CC (PubMed:26167768). Interacts (via Ser-1052 phosphorylated form) with CC 14-3-3 proteins (By similarity). {ECO:0000250|UniProtKB:P51954, CC ECO:0000269|PubMed:26167768}. CC -!- INTERACTION: CC Q96PY6; Q96Q42: ALS2; NbExp=2; IntAct=EBI-373615, EBI-1044902; CC Q96PY6; Q99689: FEZ1; NbExp=2; IntAct=EBI-373615, EBI-396435; CC Q96PY6; Q9UHY8: FEZ2; NbExp=2; IntAct=EBI-373615, EBI-396453; CC Q96PY6; Q5S007: LRRK2; NbExp=2; IntAct=EBI-373615, EBI-5323863; CC Q96PY6; Q04917: YWHAH; NbExp=6; IntAct=EBI-373615, EBI-306940; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:15604234, CC ECO:0000305|PubMed:21211617}. Cytoplasm, cytoskeleton, microtubule CC organizing center, centrosome {ECO:0000250|UniProtKB:P51954}. Cytoplasm CC {ECO:0000269|PubMed:18843199}. Note=Associated with the pericentriolar CC material (PubMed:21211617). Localizes to centrosome during interphase CC and mitosis (By similarity). Translocated from cytoplasm to discrete CC nuclear foci at sites of DNA damage (PubMed:15604234). CC {ECO:0000250|UniProtKB:P51954, ECO:0000269|PubMed:15604234, CC ECO:0000269|PubMed:21211617}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=6; CC Name=1; CC IsoId=Q96PY6-1; Sequence=Displayed; CC Name=2; CC IsoId=Q96PY6-2; Sequence=VSP_004870; CC Name=3; CC IsoId=Q96PY6-3; Sequence=VSP_035439; CC Name=4; CC IsoId=Q96PY6-4; Sequence=VSP_035435, VSP_035436; CC Name=5; CC IsoId=Q96PY6-5; Sequence=VSP_035437, VSP_035438; CC Name=6; CC IsoId=Q96PY6-6; Sequence=VSP_035436, VSP_035439; CC -!- TISSUE SPECIFICITY: High fetal expression in the brain and kidney. CC {ECO:0000269|PubMed:21211617}. CC -!- DISEASE: Short-rib thoracic dysplasia 6 with or without polydactyly CC (SRTD6) [MIM:263520]: A form of short-rib thoracic dysplasia, a group CC of autosomal recessive ciliopathies that are characterized by a CC constricted thoracic cage, short ribs, shortened tubular bones, and a CC 'trident' appearance of the acetabular roof. Polydactyly is variably CC present. Non-skeletal involvement can include cleft lip/palate as well CC as anomalies of major organs such as the brain, eye, heart, kidneys, CC liver, pancreas, intestines, and genitalia. Some forms of the disease CC are lethal in the neonatal period due to respiratory insufficiency CC secondary to a severely restricted thoracic cage, whereas others are CC compatible with life. Disease spectrum encompasses Ellis-van Creveld CC syndrome, asphyxiating thoracic dystrophy (Jeune syndrome), Mainzer- CC Saldino syndrome, and short rib-polydactyly syndrome. CC {ECO:0000269|PubMed:22499340}. Note=The disease is caused by variants CC affecting the gene represented in this entry. In some cases NEK1 CC mutations result in disease phenotype in the presence of mutations in CC DYNC2H1 indicating digenic inheritance (digenic short rib-polydactyly CC syndrome 3/6 with polydactyly) (PubMed:21211617). CC {ECO:0000269|PubMed:21211617}. CC -!- DISEASE: Amyotrophic lateral sclerosis 24 (ALS24) [MIM:617892]: A form CC of amyotrophic lateral sclerosis, a neurodegenerative disorder CC affecting upper motor neurons in the brain and lower motor neurons in CC the brain stem and spinal cord, resulting in fatal paralysis. Sensory CC abnormalities are absent. The pathologic hallmarks of the disease CC include pallor of the corticospinal tract due to loss of motor neurons, CC presence of ubiquitin-positive inclusions within surviving motor CC neurons, and deposition of pathologic aggregates. The etiology of CC amyotrophic lateral sclerosis is likely to be multifactorial, involving CC both genetic and environmental factors. The disease is inherited in 5- CC 10% of the cases. {ECO:0000269|PubMed:26945885, CC ECO:0000269|PubMed:27455347}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- DISEASE: Orofaciodigital syndrome 2 (OFD2) [MIM:252100]: A form of CC orofaciodigital syndrome, a group of heterogeneous disorders CC characterized by malformations of the oral cavity, face and digits, and CC associated phenotypic abnormalities that lead to the delineation of CC various subtypes. OFD2 is an autosomal recessive form characterized by CC cleft lip/palate, lobulated tongue with nodules, dental anomalies, CC maxillary hypoplasia, conductive hearing loss, polydactyly, syndactyly, CC brachydactyly, and mesomelic lower limb shortening. CC {ECO:0000269|PubMed:27530628}. Note=The disease may be caused by CC variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. NEK Ser/Thr CC protein kinase family. NIMA subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH15147.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305}; CC Sequence=BAB15207.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAB55209.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAB67794.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB067488; BAB67794.1; ALT_INIT; mRNA. DR EMBL; CR933642; CAI45943.1; -; mRNA. DR EMBL; AC116615; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC116621; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC084724; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471056; EAX04791.1; -; Genomic_DNA. DR EMBL; BC015147; AAH15147.1; ALT_SEQ; mRNA. DR EMBL; BC037790; AAH37790.1; -; mRNA. DR EMBL; BC114491; AAI14492.1; -; mRNA. DR EMBL; AK025658; BAB15207.1; ALT_INIT; mRNA. DR EMBL; AK027580; BAB55209.1; ALT_INIT; mRNA. DR EMBL; AF155113; AAD42879.1; -; mRNA. DR CCDS; CCDS47162.1; -. [Q96PY6-1] DR CCDS; CCDS56348.1; -. [Q96PY6-4] DR CCDS; CCDS56349.1; -. [Q96PY6-2] DR CCDS; CCDS56350.1; -. [Q96PY6-6] DR CCDS; CCDS56351.1; -. [Q96PY6-3] DR RefSeq; NP_001186326.1; NM_001199397.3. [Q96PY6-3] DR RefSeq; NP_001186327.1; NM_001199398.3. [Q96PY6-6] DR RefSeq; NP_001186328.1; NM_001199399.3. [Q96PY6-4] DR RefSeq; NP_001186329.1; NM_001199400.3. [Q96PY6-2] DR RefSeq; NP_001361347.1; NM_001374418.1. [Q96PY6-3] DR RefSeq; NP_001361348.1; NM_001374419.1. [Q96PY6-1] DR RefSeq; NP_036356.1; NM_012224.4. [Q96PY6-1] DR RefSeq; XP_011530306.1; XM_011532004.2. [Q96PY6-2] DR RefSeq; XP_047271687.1; XM_047415731.1. [Q96PY6-6] DR PDB; 4APC; X-ray; 2.10 A; A/B=1-328. DR PDB; 4B9D; X-ray; 1.90 A; A/B=1-328. DR PDBsum; 4APC; -. DR PDBsum; 4B9D; -. DR AlphaFoldDB; Q96PY6; -. DR SMR; Q96PY6; -. DR BioGRID; 110825; 92. DR CORUM; Q96PY6; -. DR FunCoup; Q96PY6; 4026. DR IntAct; Q96PY6; 63. DR MINT; Q96PY6; -. DR STRING; 9606.ENSP00000424757; -. DR BindingDB; Q96PY6; -. DR ChEMBL; CHEMBL5855; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q96PY6; -. DR GuidetoPHARMACOLOGY; 2114; -. DR GlyGen; Q96PY6; 3 sites, 2 N-linked glycans (2 sites), 1 O-linked glycan (1 site). DR iPTMnet; Q96PY6; -. DR PhosphoSitePlus; Q96PY6; -. DR BioMuta; NEK1; -. DR DMDM; 22256934; -. DR jPOST; Q96PY6; -. DR MassIVE; Q96PY6; -. DR PaxDb; 9606-ENSP00000424757; -. DR PeptideAtlas; Q96PY6; -. DR ProteomicsDB; 34091; -. DR ProteomicsDB; 77788; -. [Q96PY6-1] DR ProteomicsDB; 77789; -. [Q96PY6-2] DR ProteomicsDB; 77790; -. [Q96PY6-3] DR ProteomicsDB; 77791; -. [Q96PY6-4] DR ProteomicsDB; 77792; -. [Q96PY6-5] DR Pumba; Q96PY6; -. DR TopDownProteomics; Q96PY6-3; -. [Q96PY6-3] DR Antibodypedia; 28454; 148 antibodies from 27 providers. DR DNASU; 4750; -. DR Ensembl; ENST00000439128.6; ENSP00000408020.2; ENSG00000137601.19. [Q96PY6-1] DR Ensembl; ENST00000507142.6; ENSP00000424757.2; ENSG00000137601.19. [Q96PY6-3] DR Ensembl; ENST00000510533.5; ENSP00000427653.1; ENSG00000137601.19. [Q96PY6-2] DR Ensembl; ENST00000511633.5; ENSP00000423332.1; ENSG00000137601.19. [Q96PY6-6] DR Ensembl; ENST00000512193.5; ENSP00000424938.1; ENSG00000137601.19. [Q96PY6-4] DR GeneID; 4750; -. DR KEGG; hsa:4750; -. DR MANE-Select; ENST00000507142.6; ENSP00000424757.2; NM_001199397.3; NP_001186326.1. [Q96PY6-3] DR UCSC; uc003isb.3; human. [Q96PY6-1] DR AGR; HGNC:7744; -. DR ClinPGx; PA31545; -. DR CTD; 4750; -. DR DisGeNET; 4750; -. DR GeneCards; NEK1; -. DR HGNC; HGNC:7744; NEK1. DR HPA; ENSG00000137601; Low tissue specificity. DR MalaCards; NEK1; -. DR MIM; 252100; phenotype. DR MIM; 263520; phenotype. DR MIM; 604588; gene. DR MIM; 617892; phenotype. DR OpenTargets; ENSG00000137601; -. DR Orphanet; 803; Amyotrophic lateral sclerosis. DR Orphanet; 2751; Orofaciodigital syndrome type 2. DR Orphanet; 93269; Short rib-polydactyly syndrome, Majewski type. DR VEuPathDB; HostDB:ENSG00000137601; -. DR eggNOG; KOG0589; Eukaryota. DR GeneTree; ENSGT00940000158460; -. DR HOGENOM; CLU_000288_60_1_1; -. DR InParanoid; Q96PY6; -. DR OMA; ELNEEWH; -. DR OrthoDB; 248923at2759; -. DR PAN-GO; Q96PY6; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q96PY6; -. DR PathwayCommons; Q96PY6; -. DR Reactome; R-HSA-9861718; Regulation of pyruvate metabolism. DR SignaLink; Q96PY6; -. DR SIGNOR; Q96PY6; -. DR Agora; ENSG00000137601; -. DR BioGRID-ORCS; 4750; 51 hits in 1199 CRISPR screens. DR ChiTaRS; NEK1; human. DR EvolutionaryTrace; Q96PY6; -. DR GeneWiki; NEK1; -. DR GenomeRNAi; 4750; -. DR Pharos; Q96PY6; Tchem. DR PRO; PR:Q96PY6; -. DR Proteomes; UP000005640; Chromosome 4. DR RNAct; Q96PY6; protein. DR Bgee; ENSG00000137601; Expressed in secondary oocyte and 212 other cell types or tissues. DR ExpressionAtlas; Q96PY6; baseline and differential. DR GO; GO:0034451; C:centriolar satellite; IDA:HPA. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0005929; C:cilium; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IDA:MGI. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:MGI. DR GO; GO:0000242; C:pericentriolar material; IDA:UniProtKB. DR GO; GO:0071889; F:14-3-3 protein binding; ISS:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0016301; F:kinase activity; IMP:CACAO. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0004672; F:protein kinase activity; IDA:MGI. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0004713; F:protein tyrosine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0051301; P:cell division; IEA:UniProtKB-KW. DR GO; GO:0060271; P:cilium assembly; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:CACAO. DR CDD; cd08218; STKc_Nek1; 1. DR FunFam; 3.30.200.20:FF:000097; Probable serine/threonine-protein kinase nek1; 1. DR FunFam; 1.10.510.10:FF:000172; serine/threonine-protein kinase Nek1 isoform X1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR051131; NEK_Ser/Thr_kinase_NIMA. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR44899; CAMK FAMILY PROTEIN KINASE; 1. DR PANTHER; PTHR44899:SF4; SERINE_THREONINE-PROTEIN KINASE NEK1; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Amyotrophic lateral sclerosis; KW ATP-binding; Cell cycle; Cell division; Ciliopathy; KW Cilium biogenesis/degradation; Cytoplasm; Cytoskeleton; Kinase; Magnesium; KW Metal-binding; Mitosis; Neurodegeneration; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Tyrosine-protein kinase. FT CHAIN 1..1258 FT /note="Serine/threonine-protein kinase Nek1" FT /id="PRO_0000086418" FT DOMAIN 4..258 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 330..360 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 578..600 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 648..669 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 685..704 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1118..1171 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 344..360 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 579..591 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 691..700 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 128 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 10..18 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 33 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 156 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 162 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 414 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 418 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 428 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:23186163" FT MOD_RES 438 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P51954" FT MOD_RES 653 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 661 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 664 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 798 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 834 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 868 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:23186163" FT MOD_RES 881 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1052 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 1126 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P51954" FT VAR_SEQ 398..422 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_035435" FT VAR_SEQ 477..520 FT /note="Missing (in isoform 4 and isoform 6)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_035436" FT VAR_SEQ 478..521 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10508479" FT /id="VSP_004870" FT VAR_SEQ 522..527 FT /note="QKGQLA -> LDCDDP (in isoform 5)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_035437" FT VAR_SEQ 528..1258 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_035438" FT VAR_SEQ 555 FT /note="M -> MGILQNLAAMYGGRPSSSRGGKPRNKEEE (in isoform 3 and FT isoform 6)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_035439" FT VARIANT 10 FT /note="I -> F (in dbSNP:rs34214559)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040900" FT VARIANT 25 FT /note="E -> K (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040901" FT VARIANT 76 FT /note="L -> V (in dbSNP:rs35093214)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040902" FT VARIANT 145 FT /note="G -> R (in SRTD6; dbSNP:rs431905508)" FT /evidence="ECO:0000269|PubMed:22499340" FT /id="VAR_069617" FT VARIANT 155 FT /note="S -> T (in OFD2; uncertain significance; the FT nucleotide substitution creating this missense variant may FT predominantly result in aberrant splicing, with skipping of FT exon 6 and creation of a premature stop codon, possibly FT leading to nonsense-mediated mRNA decay)" FT /evidence="ECO:0000269|PubMed:27530628" FT /id="VAR_089300" FT VARIANT 253 FT /note="L -> S (in SRTD6)" FT /evidence="ECO:0000269|PubMed:22499340" FT /id="VAR_069618" FT VARIANT 261 FT /note="R -> H (risk factor for ALS24; dbSNP:rs200161705)" FT /evidence="ECO:0000269|PubMed:27455347" FT /id="VAR_080694" FT VARIANT 294 FT /note="A -> P (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040903" FT VARIANT 355 FT /note="R -> G (in dbSNP:rs35763578)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040904" FT VARIANT 409..1258 FT /note="Missing (in OFD2; uncertain significance; the FT nucleotide substitution creating this nonsense variant may FT predominantly result in aberrant splicing)" FT /evidence="ECO:0000269|PubMed:27530628" FT /id="VAR_089301" FT VARIANT 463 FT /note="A -> V (in dbSNP:rs34540355)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040905" FT VARIANT 550..1258 FT /note="Missing (risk factor for ALS24)" FT /evidence="ECO:0000269|PubMed:27455347" FT /id="VAR_080695" FT VARIANT 598 FT /note="A -> T (in dbSNP:rs33933790)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046486" FT VARIANT 717 FT /note="N -> K (in dbSNP:rs34324114)" FT /id="VAR_061743" FT VARIANT 724 FT /note="E -> G (in dbSNP:rs34099167)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:17974005" FT /id="VAR_051651" FT VARIANT 745 FT /note="K -> N" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040906" FT VARIANT 784..1258 FT /note="Missing (risk factor for ALS24)" FT /evidence="ECO:0000269|PubMed:26945885" FT /id="VAR_080696" FT VARIANT 883 FT /note="Q -> E (in dbSNP:rs6828134)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046488" FT VARIANT 1008..1258 FT /note="Missing (risk factor for ALS24)" FT /evidence="ECO:0000269|PubMed:26945885" FT /id="VAR_080697" FT VARIANT 1180 FT /note="D -> N (in dbSNP:rs35503975)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046489" FT CONFLICT 250 FT /note="N -> D (in Ref. 2; CAI45943)" FT /evidence="ECO:0000305" FT CONFLICT 602 FT /note="R -> RK (in Ref. 2; CAI45943)" FT /evidence="ECO:0000305" FT CONFLICT 1232 FT /note="G -> E (in Ref. 7; AAD42879)" FT /evidence="ECO:0000305" FT STRAND 4..9 FT /evidence="ECO:0007829|PDB:4B9D" FT STRAND 18..23 FT /evidence="ECO:0007829|PDB:4B9D" FT TURN 24..26 FT /evidence="ECO:0007829|PDB:4B9D" FT STRAND 29..36 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 42..57 FT /evidence="ECO:0007829|PDB:4B9D" FT STRAND 66..72 FT /evidence="ECO:0007829|PDB:4B9D" FT STRAND 75..81 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 88..94 FT /evidence="ECO:0007829|PDB:4B9D" FT TURN 95..97 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 102..121 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 131..133 FT /evidence="ECO:0007829|PDB:4B9D" FT STRAND 134..136 FT /evidence="ECO:0007829|PDB:4B9D" FT STRAND 142..144 FT /evidence="ECO:0007829|PDB:4B9D" FT STRAND 149..151 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 155..164 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 172..175 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 182..198 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 208..217 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 229..238 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 243..245 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 249..253 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 256..259 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 260..264 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 268..275 FT /evidence="ECO:0007829|PDB:4B9D" SQ SEQUENCE 1258 AA; 142828 MW; 339C4BFA56612530 CRC64; MEKYVRLQKI GEGSFGKAIL VKSTEDGRQY VIKEINISRM SSKEREESRR EVAVLANMKH PNIVQYRESF EENGSLYIVM DYCEGGDLFK RINAQKGVLF QEDQILDWFV QICLALKHVH DRKILHRDIK SQNIFLTKDG TVQLGDFGIA RVLNSTVELA RTCIGTPYYL SPEICENKPY NNKSDIWALG CVLYELCTLK HAFEAGSMKN LVLKIISGSF PPVSLHYSYD LRSLVSQLFK RNPRDRPSVN SILEKGFIAK RIEKFLSPQL IAEEFCLKTF SKFGSQPIPA KRPASGQNSI SVMPAQKITK PAAKYGIPLA YKKYGDKKLH EKKPLQKHKQ AHQTPEKRVN TGEERRKISE EAARKRRLEF IEKEKKQKDQ IISLMKAEQM KRQEKERLER INRAREQGWR NVLSAGGSGE VKAPFLGSGG TIAPSSFSSR GQYEHYHAIF DQMQQQRAED NEAKWKREIY GRGLPERGIL PGVRPGFPYG AAGHHHFPDA DDIRKTLKRL KAVSKQANAN RQKGQLAVER AKQVEEFLQR KREAMQNKAR AEGHMVYLAR LRQIRLQNFN ERQQIKAKLR GEKKEANHSE GQEGSEEADM RRKKIESLKA HANARAAVLK EQLERKRKEA YEREKKVWEE HLVAKGVKSS DVSPPLGQHE TGGSPSKQQM RSVISVTSAL KEVGVDSSLT DTRETSEEMQ KTNNAISSKR EILRRLNENL KAQEDEKGKQ NLSDTFEINV HEDAKEHEKE KSVSSDRKKW EAGGQLVIPL DELTLDTSFS TTERHTVGEV IKLGPNGSPR RAWGKSPTDS VLKILGEAEL QLQTELLENT TIRSEISPEG EKYKPLITGE KKVQCISHEI NPSAIVDSPV ETKSPEFSEA SPQMSLKLEG NLEEPDDLET EILQEPSGTN KDESLPCTIT DVWISEEKET KETQSADRIT IQENEVSEDG VSSTVDQLSD IHIEPGTNDS QHSKCDVDKS VQPEPFFHKV VHSEHLNLVP QVQSVQCSPE ESFAFRSHSH LPPKNKNKNS LLIGLSTGLF DANNPKMLRT CSLPDLSKLF RTLMDVPTVG DVRQDNLEID EIEDENIKEG PSDSEDIVFE ETDTDLQELQ ASMEQLLREQ PGEEYSEEEE SVLKNSDVEP TANGTDVADE DDNPSSESAL NEEWHSDNSD GEIASECECD SVFNHLEELR LHLEQEMGFE KFFEVYEKIK AIHEDEDENI EICSKIVQNI LGNEHQHLYA KILHLVMADG AYQEDNDE // ID NEK8_HUMAN Reviewed; 692 AA. AC Q86SG6; A6NIC5; Q14CL7; Q2M1S6; Q8NDH1; DT 15-AUG-2003, integrated into UniProtKB/Swiss-Prot. DT 01-JUN-2003, sequence version 1. DT 28-JAN-2026, entry version 190. DE RecName: Full=Serine/threonine-protein kinase Nek8; DE EC=2.7.11.1; DE AltName: Full=Never in mitosis A-related kinase 8; DE Short=NimA-related protein kinase 8; DE AltName: Full=Nima-related protein kinase 12a; GN Name=NEK8; Synonyms=JCK, NEK12A; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RA Huang C.Q., Wu S.L., Yu L.; RL Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases. RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RA Nedwidek M.N., Roig J., Lenz G., Avruch J.; RT "NIMA-family kinase Nek8 complete human coding region."; RL Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 445-692. RC TISSUE=Testis; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [7] RP TISSUE SPECIFICITY. RX PubMed=15019993; DOI=10.1016/j.gene.2003.12.002; RA Bowers A.J., Boylan J.F.; RT "Nek8, a NIMA family kinase member, is overexpressed in primary human RT breast tumors."; RL Gene 328:135-142(2004). RN [8] RP INVOLVEMENT IN RHPD2, FUNCTION, AND INTERACTION WITH NPHP3. RX PubMed=23418306; DOI=10.1093/hmg/ddt070; RA Frank V., Habbig S., Bartram M.P., Eisenberger T., Veenstra-Knol H.E., RA Decker C., Boorsma R.A., Goebel H., Nuernberg G., Griessmann A., Franke M., RA Borgal L., Kohli P., Voelker L.A., Doetsch J., Nuernberg P., Benzing T., RA Bolz H.J., Johnson C., Gerkes E.H., Schermer B., Bergmann C.; RT "Mutations in NEK8 link multiple organ dysplasia with altered Hippo RT signalling and increased c-MYC expression."; RL Hum. Mol. Genet. 22:2177-2185(2013). RN [9] RP INTERACTION WITH ANKS6; INVS AND NPHP3. RX PubMed=23793029; DOI=10.1038/ng.2681; RA Hoff S., Halbritter J., Epting D., Frank V., Nguyen T.M., van Reeuwijk J., RA Boehlke C., Schell C., Yasunaga T., Helmstadter M., Mergen M., Filhol E., RA Boldt K., Horn N., Ueffing M., Otto E.A., Eisenberger T., Elting M.W., RA van Wijk J.A., Bockenhauer D., Sebire N.J., Rittig S., Vyberg M., Ring T., RA Pohl M., Pape L., Neuhaus T.J., Elshakhs N.A., Koon S.J., Harris P.C., RA Grahammer F., Huber T.B., Kuehn E.W., Kramer-Zucker A., Bolz H.J., RA Roepman R., Saunier S., Walz G., Hildebrandt F., Bergmann C., RA Lienkamp S.S.; RT "ANKS6 is a central component of a nephronophthisis module linking NEK8 to RT INVS and NPHP3."; RL Nat. Genet. 45:951-956(2013). RN [10] RP INTERACTION WITH ANKS3. RX PubMed=26188091; DOI=10.1016/j.bbrc.2015.07.063; RA Ramachandran H., Engel C., Mueller B., Dengjel J., Walz G., Yakulov T.A.; RT "Anks3 alters the sub-cellular localization of the Nek7 kinase."; RL Biochem. Biophys. Res. Commun. 464:901-907(2015). RN [11] RP VARIANTS NPHP9 PHE-330; TYR-425 AND PRO-497, CHARACTERIZATION OF VARIANTS RP NPHP9 PHE-330; TYR-425 AND PRO-497, AND SUBCELLULAR LOCATION. RX PubMed=18199800; DOI=10.1681/asn.2007040490; RA Otto E.A., Trapp M.L., Schultheiss U.T., Helou J., Quarmby L.M., RA Hildebrandt F.; RT "NEK8 mutations affect ciliary and centrosomal localization and may cause RT nephronophthisis."; RL J. Am. Soc. Nephrol. 19:587-592(2008). RN [12] RP VARIANTS RHPD2 ALA-87; 127-ARG--PRO-692 DEL; SER-416; 462-ARG--PRO-692 DEL; RP SER-580 AND TRP-602, CHARACTERIZATION OF VARIANTS RHPD2 ALA-87; RP 127-ARG--PRO-692 DEL; 462-ARG--PRO-692 DEL; SER-580 AND TRP-602, RP CHARACTERIZATION OF VARIANT NPHP9 TYR-425, INTERACTION WITH ANKS6, RP SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=26967905; DOI=10.1371/journal.pgen.1005894; RA Grampa V., Delous M., Zaidan M., Odye G., Thomas S., Elkhartoufi N., RA Filhol E., Niel O., Silbermann F., Lebreton C., Collardeau-Frachon S., RA Rouvet I., Alessandri J.L., Devisme L., Dieux-Coeslier A., Cordier M.P., RA Capri Y., Khung-Savatovsky S., Sigaudy S., Salomon R., Antignac C., RA Gubler M.C., Benmerah A., Terzi F., Attie-Bitach T., Jeanpierre C., RA Saunier S.; RT "Novel NEK8 Mutations Cause Severe Syndromic Renal Cystic Dysplasia through RT YAP Dysregulation."; RL PLoS Genet. 12:e1005894-e1005894(2016). RN [13] RP VARIANTS PKD8 TRP-45; MET-150 AND GLN-157, CHARACTERIZATION OF VARIANTS RP PKD8 TRP-45; MET-150 AND GLN-157, INVOLVEMENT IN PKD8, AND FUNCTION. RX PubMed=37598857; DOI=10.1016/j.kint.2023.07.021; RG Genomics England Research Consortium; RA Claus L.R., Chen C., Stallworth J., Turner J.L., Slaats G.G., Hawks A.L., RA Mabillard H., Senum S.R., Srikanth S., Flanagan-Steet H., Louie R.J., RA Silver J., Lerner-Ellis J., Morel C., Mighton C., Sleutels F., RA van Slegtenhorst M., van Ham T., Brooks A.S., Dorresteijn E.M., RA Barakat T.S., Dahan K., Demoulin N., Goffin E.J., Olinger E., Larsen M., RA Hertz J.M., Lilien M.R., Obeidova L., Seeman T., Stone H.K., Kerecuk L., RA Gurgu M., Yousef Yengej F.A., Ammerlaan C.M.E., Rookmaaker M.B., Hanna C., RA Rogers R.C., Duran K., Peters E., Sayer J.A., van Haaften G., Harris P.C., RA Ling K., Mason J.M., van Eerde A.M., Steet R.; RT "Certain heterozygous variants in the kinase domain of the serine/threonine RT kinase NEK8 can cause an autosomal dominant form of polycystic kidney RT disease."; RL Kidney Int. 104:995-1007(2023). RN [14] RP VARIANT PKD8 TRP-45, AND INVOLVEMENT IN PKD8. RX PubMed=36215968; DOI=10.1159/000526841; RA Mehawej C., Chouery E., Ghabril R., Tokajian S., Megarbane A.; RT "NEK8-Associated Nephropathies: Do Autosomal Dominant Forms Exist?"; RL Nephron 147:229-233(2023). CC -!- FUNCTION: Required for renal tubular integrity. May regulate local CC cytoskeletal structure in kidney tubule epithelial cells. May regulate CC ciliary biogenesis through targeting of proteins to the cilia CC (PubMed:37598857). Plays a role in organogenesis, and is involved in CC the regulation of the Hippo signaling pathway (PubMed:26967905). CC {ECO:0000269|PubMed:23418306, ECO:0000269|PubMed:26967905, CC ECO:0000269|PubMed:37598857}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250}; CC -!- SUBUNIT: Interacts with PKD2; may regulate PKD2 targeting to the cilium CC (By similarity). Interacts with ANKS6 (PubMed:26967905). Component of a CC complex containing at least ANKS6, INVS, NEK8 and NPHP3 CC (PubMed:23418306, PubMed:23793029). ANKS6 may organize complex assembly CC by linking INVS and NPHP3 to NEK8 and INVS may target the complex to CC the proximal ciliary axoneme (PubMed:23418306, PubMed:23793029). CC Interacts with ANKS3 (PubMed:26188091). {ECO:0000250|UniProtKB:Q91ZR4, CC ECO:0000269|PubMed:23418306, ECO:0000269|PubMed:23793029, CC ECO:0000269|PubMed:26188091}. CC -!- INTERACTION: CC Q86SG6; Q6UY14-3: ADAMTSL4; NbExp=3; IntAct=EBI-1752987, EBI-10173507; CC Q86SG6; Q6ZW76: ANKS3; NbExp=3; IntAct=EBI-1752987, EBI-949601; CC Q86SG6; Q68DC2: ANKS6; NbExp=5; IntAct=EBI-1752987, EBI-7054139; CC Q86SG6; P54253: ATXN1; NbExp=3; IntAct=EBI-1752987, EBI-930964; CC Q86SG6; P08238: HSP90AB1; NbExp=2; IntAct=EBI-1752987, EBI-352572; CC Q86SG6; P42858: HTT; NbExp=3; IntAct=EBI-1752987, EBI-466029; CC Q86SG6; Q52LG2: KRTAP13-2; NbExp=3; IntAct=EBI-1752987, EBI-11953846; CC Q86SG6; Q8TDX7: NEK7; NbExp=3; IntAct=EBI-1752987, EBI-1055945; CC Q86SG6; Q8WVJ2: NUDCD2; NbExp=3; IntAct=EBI-1752987, EBI-1052153; CC Q86SG6; Q8TDS5: OXER1; NbExp=3; IntAct=EBI-1752987, EBI-12813389; CC Q86SG6; O76081-6: RGS20; NbExp=3; IntAct=EBI-1752987, EBI-10178530; CC Q86SG6; P15884: TCF4; NbExp=3; IntAct=EBI-1752987, EBI-533224; CC Q86SG6; Q8IWZ5: TRIM42; NbExp=3; IntAct=EBI-1752987, EBI-5235829; CC Q86SG6; Q86WT6: TRIM69; NbExp=3; IntAct=EBI-1752987, EBI-749955; CC Q86SG6; Q86WT6-2: TRIM69; NbExp=3; IntAct=EBI-1752987, EBI-11525489; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:18199800}. CC Cytoplasm, cytoskeleton {ECO:0000250|UniProtKB:Q91ZR4}. Cell CC projection, cilium {ECO:0000269|PubMed:18199800}. Cytoplasm, CC cytoskeleton, microtubule organizing center, centrosome CC {ECO:0000269|PubMed:18199800}. Cytoplasm, cytoskeleton, cilium axoneme CC {ECO:0000269|PubMed:26967905}. Note=Predominantly cytoplasmic. CC Localizes to the proximal region of the primary cilium and is not CC observed in dividing cells. {ECO:0000250|UniProtKB:Q91ZR4}. CC -!- TISSUE SPECIFICITY: Highest expression in thyroid, adrenal gland and CC skin. Low levels in spleen, colon and uterus. Overexpressed in breast CC tumors, with highest expression in infiltrating ductal carcinomas and CC moderate levels in mucinous adenocarcinoma. CC {ECO:0000269|PubMed:15019993}. CC -!- DISEASE: Nephronophthisis 9 (NPHP9) [MIM:613824]: An autosomal CC recessive disorder resulting in end-stage renal disease. It is a CC progressive tubulo-interstitial kidney disorder histologically CC characterized by modifications of the tubules with thickening of the CC basement membrane, interstitial fibrosis and, in the advanced stages, CC medullary cysts. {ECO:0000269|PubMed:18199800, CC ECO:0000269|PubMed:26967905}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Renal-hepatic-pancreatic dysplasia 2 (RHPD2) [MIM:615415]: A CC form of renal-hepatic-pancreatic dysplasia, a disease characterized by CC cystic malformations of the kidneys, liver, and pancreas. The CC pathological findings consist of multicystic dysplastic kidneys, CC dilated and dysgenetic bile ducts, a dysplastic pancreas with dilated CC ducts, cysts, fibrosis and inflammatory infiltrates. CC {ECO:0000269|PubMed:23418306, ECO:0000269|PubMed:26967905}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Polycystic kidney disease 8 (PKD8) [MIM:620903]: A form of CC polycystic kidney disease, a disorder characterized by progressive CC formation and enlargement of cysts in both kidneys, typically leading CC to end-stage renal disease in adult life. Cysts may also occur in other CC organs, particularly the liver. PKD8 inheritance is autosomal dominant. CC {ECO:0000269|PubMed:36215968, ECO:0000269|PubMed:37598857}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. NEK Ser/Thr CC protein kinase family. NIMA subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY242354; AAO88243.1; -; mRNA. DR EMBL; AY267371; AAP04006.1; -; mRNA. DR EMBL; AC010761; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471159; EAW51136.1; -; Genomic_DNA. DR EMBL; BC112240; AAI12241.1; -; mRNA. DR EMBL; BC113705; AAI13706.1; -; mRNA. DR EMBL; AL833909; CAD38765.1; -; mRNA. DR CCDS; CCDS32597.1; -. DR RefSeq; NP_835464.1; NM_178170.3. DR AlphaFoldDB; Q86SG6; -. DR SMR; Q86SG6; -. DR BioGRID; 129755; 63. DR CORUM; Q86SG6; -. DR FunCoup; Q86SG6; 177. DR IntAct; Q86SG6; 64. DR STRING; 9606.ENSP00000268766; -. DR BindingDB; Q86SG6; -. DR ChEMBL; CHEMBL2417353; -. DR iPTMnet; Q86SG6; -. DR PhosphoSitePlus; Q86SG6; -. DR BioMuta; NEK8; -. DR DMDM; 34098463; -. DR jPOST; Q86SG6; -. DR MassIVE; Q86SG6; -. DR PaxDb; 9606-ENSP00000268766; -. DR PeptideAtlas; Q86SG6; -. DR ProteomicsDB; 69588; -. DR Pumba; Q86SG6; -. DR Antibodypedia; 26547; 285 antibodies from 26 providers. DR DNASU; 284086; -. DR Ensembl; ENST00000268766.11; ENSP00000268766.6; ENSG00000160602.15. DR GeneID; 284086; -. DR KEGG; hsa:284086; -. DR MANE-Select; ENST00000268766.11; ENSP00000268766.6; NM_178170.3; NP_835464.1. DR UCSC; uc002hcp.4; human. DR AGR; HGNC:13387; -. DR ClinPGx; PA38361; -. DR CTD; 284086; -. DR DisGeNET; 284086; -. DR GeneCards; NEK8; -. DR GeneReviews; NEK8; -. DR HGNC; HGNC:13387; NEK8. DR HPA; ENSG00000160602; Low tissue specificity. DR MalaCards; NEK8; -. DR MIM; 609799; gene. DR MIM; 613824; phenotype. DR MIM; 615415; phenotype. DR MIM; 620903; phenotype. DR OpenTargets; ENSG00000160602; -. DR Orphanet; 730; Autosomal dominant polycystic kidney disease. DR Orphanet; 93591; Infantile nephronophthisis. DR Orphanet; 294415; Renal-hepatic-pancreatic dysplasia. DR VEuPathDB; HostDB:ENSG00000160602; -. DR eggNOG; KOG0589; Eukaryota. DR GeneTree; ENSGT00940000159297; -. DR HOGENOM; CLU_000288_123_1_1; -. DR InParanoid; Q86SG6; -. DR OrthoDB; 248923at2759; -. DR PAN-GO; Q86SG6; 7 GO annotations based on evolutionary models. DR PhylomeDB; Q86SG6; -. DR PathwayCommons; Q86SG6; -. DR SignaLink; Q86SG6; -. DR SIGNOR; Q86SG6; -. DR Agora; ENSG00000160602; -. DR BioGRID-ORCS; 284086; 18 hits in 1190 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR GeneWiki; NEK8; -. DR GenomeRNAi; 284086; -. DR Pharos; Q86SG6; Tchem. DR PRO; PR:Q86SG6; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; Q86SG6; protein. DR Bgee; ENSG00000160602; Expressed in buccal mucosa cell and 133 other cell types or tissues. DR ExpressionAtlas; Q86SG6; baseline and differential. DR GO; GO:0005930; C:axoneme; IEA:UniProtKB-SubCell. DR GO; GO:0005813; C:centrosome; IEA:UniProtKB-SubCell. DR GO; GO:0097546; C:ciliary base; IEA:Ensembl. DR GO; GO:0097543; C:ciliary inversin compartment; IEA:Ensembl. DR GO; GO:0005929; C:cilium; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0009887; P:animal organ morphogenesis; IMP:UniProtKB. DR GO; GO:0007368; P:determination of left/right symmetry; IEA:Ensembl. DR GO; GO:0007507; P:heart development; IEA:Ensembl. DR GO; GO:0035330; P:regulation of hippo signaling; IDA:UniProtKB. DR CDD; cd08220; STKc_Nek8; 1. DR FunFam; 1.10.510.10:FF:000262; Serine/threonine-protein kinase Nek8; 1. DR FunFam; 2.130.10.30:FF:000017; Serine/threonine-protein kinase Nek8; 1. DR FunFam; 2.130.10.30:FF:000020; serine/threonine-protein kinase Nek8; 1. DR FunFam; 3.30.200.20:FF:000243; serine/threonine-protein kinase Nek8; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 2.130.10.30; Regulator of chromosome condensation 1/beta-lactamase-inhibitor protein II; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR058923; RCC1-like_dom. DR InterPro; IPR009091; RCC1/BLIP-II. DR InterPro; IPR000408; Reg_chr_condens. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR051997; STK_NEK. DR InterPro; IPR044120; STKc_Nek8. DR PANTHER; PTHR44535; PROTEIN CBG16200; 1. DR PANTHER; PTHR44535:SF4; SERINE_THREONINE-PROTEIN KINASE NEK8; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF25390; WD40_RLD; 1. DR PRINTS; PR00633; RCCNDNSATION. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF50985; RCC1/BLIP-II; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50012; RCC1_3; 5. PE 1: Evidence at protein level; KW ATP-binding; Cell projection; Ciliopathy; Cilium; Cytoplasm; Cytoskeleton; KW Disease variant; Kinase; Magnesium; Metal-binding; Nephronophthisis; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat; Serine/threonine-protein kinase; Transferase. FT CHAIN 1..692 FT /note="Serine/threonine-protein kinase Nek8" FT /id="PRO_0000086432" FT DOMAIN 4..258 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REPEAT 312..350 FT /note="RCC1 1" FT REPEAT 410..461 FT /note="RCC1 2" FT REPEAT 462..513 FT /note="RCC1 3" FT REPEAT 580..631 FT /note="RCC1 4" FT REPEAT 632..684 FT /note="RCC1 5" FT REGION 277..301 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 282..293 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 128 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 10..18 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 33 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 162 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000250" FT VARIANT 45 FT /note="R -> W (in PKD8; pathogenic; fails to rescue FT defective PKD2 targeting to cilia in NEK8-deficient FT epithelial renal cells; decreased autophosphorylation; FT dbSNP:rs1567759130)" FT /evidence="ECO:0000269|PubMed:36215968, FT ECO:0000269|PubMed:37598857" FT /id="VAR_089841" FT VARIANT 87 FT /note="T -> A (in RHPD2; likely pathogenic; contrary to the FT wild type, it fails to rescue body curvature defects in FT zebrafish morphants; decreased localization to cilia; FT decreased interaction with ANKS6; dbSNP:rs1555563787)" FT /evidence="ECO:0000269|PubMed:26967905" FT /id="VAR_089842" FT VARIANT 127..692 FT /note="Missing (in RHPD2; likely pathogenic; loss of FT protein expression)" FT /evidence="ECO:0000269|PubMed:26967905" FT /id="VAR_089843" FT VARIANT 150 FT /note="I -> M (in PKD8; uncertain significance; it rescues FT ciliary defects when transfected in NEK8-deficient FT epithelial renal cells)" FT /evidence="ECO:0000269|PubMed:37598857" FT /id="VAR_089844" FT VARIANT 157 FT /note="K -> Q (in PKD8; likely pathogenic; contrary to the FT wild type, it does not rescue ciliary defects when FT transfected in NEK8-deficient epithelial renal cells)" FT /evidence="ECO:0000269|PubMed:37598857" FT /id="VAR_089845" FT VARIANT 330 FT /note="L -> F (in NPHP9; a full-length mouse NEK8 construct FT containing the mutation shows a defect in ciliary FT localization with no apparent effect on ciliation, mitosis FT or centriole number; dbSNP:rs199962228)" FT /evidence="ECO:0000269|PubMed:18199800" FT /id="VAR_065769" FT VARIANT 416 FT /note="G -> S (in RHPD2; uncertain significance; FT dbSNP:rs199823733)" FT /evidence="ECO:0000269|PubMed:26967905" FT /id="VAR_089846" FT VARIANT 425 FT /note="H -> Y (in NPHP9; loss of ciliary localization; a FT full-length mouse NEK8 construct containing the mutation FT shows a defect in ciliary localization with no apparent FT effect on ciliation, mitosis or centriole number; no effect FT on interaction with ANKS6; dbSNP:rs118204032)" FT /evidence="ECO:0000269|PubMed:18199800" FT /id="VAR_065770" FT VARIANT 462..692 FT /note="Missing (in RHPD2; likely pathogenic; loss of FT protein expression)" FT /evidence="ECO:0000269|PubMed:26967905" FT /id="VAR_089847" FT VARIANT 497 FT /note="A -> P (in NPHP9; a full-length mouse NEK8 construct FT containing the mutation shows a defect in ciliary FT localization with no apparent effect on ciliation, mitosis FT or centriole number; dbSNP:rs146326420)" FT /evidence="ECO:0000269|PubMed:18199800" FT /id="VAR_065771" FT VARIANT 580 FT /note="G -> S (in RHPD2; likely pathogenic; loss of ciliary FT localization; no effect on interaction with ANKS6; FT dbSNP:rs751440831)" FT /evidence="ECO:0000269|PubMed:26967905" FT /id="VAR_089848" FT VARIANT 602 FT /note="R -> W (in RHPD2; likely pathogenic; contrary to the FT wild type, it fails to rescue body curvature defects in FT zebrafish morphants; loss of ciliary localization; no FT effect on interaction with ANKS6; dbSNP:rs773883764)" FT /evidence="ECO:0000269|PubMed:26967905" FT /id="VAR_089849" SQ SEQUENCE 692 AA; 74806 MW; 9E09820DFB3D5CA1 CRC64; MEKYERIRVV GRGAFGIVHL CLRKADQKLV IIKQIPVEQM TKEERQAAQN ECQVLKLLNH PNVIEYYENF LEDKALMIAM EYAPGGTLAE FIQKRCNSLL EEETILHFFV QILLALHHVH THLILHRDLK TQNILLDKHR MVVKIGDFGI SKILSSKSKA YTVVGTPCYI SPELCEGKPY NQKSDIWALG CVLYELASLK RAFEAANLPA LVLKIMSGTF APISDRYSPE LRQLVLSLLS LEPAQRPPLS HIMAQPLCIR ALLNLHTDVG SVRMRRAEKS VAPSNTGSRT TSVRCRGIPR GPVRPAIPPP LSSVYAWGGG LGTPLRLPML NTEVVQVAAG RTQKAGVTRS GRLILWEAPP LGAGGGSLLP GAVEQPQPQF ISRFLEGQSG VTIKHVACGD FFTACLTDRG IIMTFGSGSN GCLGHGSLTD ISQPTIVEAL LGYEMVQVAC GASHVLALST ERELFAWGRG DSGRLGLGTR ESHSCPQQVP MPPGQEAQRV VCGIDSSMIL TVPGQALACG SNRFNKLGLD HLSLGEEPVP HQQVEEALSF TLLGSAPLDQ EPLLSIDLGT AHSAAVTASG DCYTFGSNQH GQLGTNTRRG SRAPCKVQGL EGIKMAMVAC GDAFTVAIGA ESEVYSWGKG ARGRLGRRDE DAGLPRPVQL DETHPYTVTS VSCCHGNTLL AVRSVTDEPV PP // ID P53_HUMAN Reviewed; 393 AA. AC P04637; Q15086; Q15087; Q15088; Q16535; Q16807; Q16808; Q16809; Q16810; AC Q16811; Q16848; Q2XN98; Q3LRW1; Q3LRW2; Q3LRW3; Q3LRW4; Q3LRW5; Q86UG1; AC Q8J016; Q99659; Q9BTM4; Q9HAQ8; Q9NP68; Q9NPJ2; Q9NZD0; Q9UBI2; Q9UQ61; DT 13-AUG-1987, integrated into UniProtKB/Swiss-Prot. DT 24-NOV-2009, sequence version 4. DT 28-JAN-2026, entry version 313. DE RecName: Full=Cellular tumor antigen p53; DE AltName: Full=Antigen NY-CO-13; DE AltName: Full=Phosphoprotein p53; DE AltName: Full=Tumor suppressor p53; GN Name=TP53; Synonyms=P53; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=4006916; DOI=10.1002/j.1460-2075.1985.tb03768.x; RA Zakut-Houri R., Bienz-Tadmor B., Givol D., Oren M.; RT "Human p53 cellular tumor antigen: cDNA sequence and expression in COS RT cells."; RL EMBO J. 4:1251-1255(1985). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND VARIANT GLY-76. RX PubMed=2946935; DOI=10.1128/mcb.6.5.1379-1385.1986; RA Lamb P., Crawford L.; RT "Characterization of the human p53 gene."; RL Mol. Cell. Biol. 6:1379-1385(1986). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=3894933; DOI=10.1128/mcb.5.7.1601-1610.1985; RA Harlow E., Williamson N.M., Ralston R., Helfman D.M., Adams T.E.; RT "Molecular cloning and in vitro expression of a cDNA clone for human RT cellular tumor antigen p53."; RL Mol. Cell. Biol. 5:1601-1610(1985). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=3025664; DOI=10.1128/mcb.6.12.4650-4656.1986; RA Harris N., Brill E., Shohat O., Prokocimer M., Wolf D., Arai N., Rotter V.; RT "Molecular basis for heterogeneity of the human p53 protein."; RL Mol. Cell. Biol. 6:4650-4656(1986). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=2905688; DOI=10.1016/0378-1119(88)90196-5; RA Buchman V.L., Chumakov P.M., Ninkina N.N., Samarina O.P., Georgiev G.P.; RT "A variation in the structure of the protein-coding region of the human p53 RT gene."; RL Gene 70:245-252(1988). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS SPORADIC CANCERS. RX PubMed=1915267; DOI=10.1002/j.1460-2075.1991.tb07837.x; RA Farrell P.J., Allan G., Shanahan F., Vousden K.H., Crook T.; RT "p53 is frequently mutated in Burkitt's lymphoma cell lines."; RL EMBO J. 10:2879-2887(1991). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-286. RX PubMed=8316628; DOI=10.2307/3578196; RA Allalunis-Turner M.J., Barron G.M., Day R.S. III, Dobler K.D., RA Mirzayans R.; RT "Isolation of two cell lines from a human malignant glioma specimen RT differing in sensitivity to radiation and chemotherapeutic drugs."; RL Radiat. Res. 134:349-354(1993). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH WWOX. RX PubMed=11058590; DOI=10.1074/jbc.m007140200; RA Chang N.-S., Pratt N., Heath J., Schultz L., Sleve D., Carey G.B., RA Zevotek N.; RT "Hyaluronidase induction of a WW domain-containing oxidoreductase that RT enhances tumor necrosis factor cytotoxicity."; RL J. Biol. Chem. 276:3361-3370(2001). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 7; 8 AND 9), SUBCELLULAR RP LOCATION, TISSUE SPECIFICITY, ALTERNATIVE PROMOTER USAGE, ALTERNATIVE RP SPLICING, INDUCTION, AND VARIANT ARG-72. RC TISSUE=Colon; RX PubMed=16131611; DOI=10.1101/gad.1339905; RA Bourdon J.C., Fernandes K., Murray-Zmijewski F., Liu G., Diot A., RA Xirodimas D.P., Saville M.K., Lane D.P.; RT "p53 isoforms can regulate p53 transcriptional activity."; RL Genes Dev. 19:2122-2137(2005). RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Chumakov P.M., Almazov V.P., Jenkins J.R.; RL Submitted (JUN-1991) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Rozemuller E.H., Tilanus M.G.J.; RT "P53 genomic sequence. Corrections and polymorphism."; RL Submitted (MAR-1997) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-47; LYS-339 AND RP ALA-366. RG NIEHS SNPs program; RL Submitted (NOV-2004) to the EMBL/GenBank/DDBJ databases. RN [13] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-286. RX PubMed=11023613; DOI=10.1667/0033-7587(2000)154[0473:htftmg]2.0.co;2; RA Anderson C.W., Allalunis-Turner M.J.; RT "Human TP53 from the malignant glioma-derived cell lines M059J and M059K RT has a cancer-associated mutation in exon 8."; RL Radiat. Res. 154:473-476(2000). RN [14] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS HIS-273 AND SER-309. RA Azuma K., Shichijo S., Itoh K.; RT "Identification of a tumor-rejection antigen recognized by HLA-B46 RT restricted CTL."; RL Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases. RN [15] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-72. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [16] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [17] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ARG-72. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [18] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ALA-278. RC TISSUE=Kidney; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [19] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-379 (ISOFORM 1), AND VARIANTS ASN-139 AND RP PRO-155. RC TISSUE=Lung carcinoma; RX PubMed=14660794; DOI=10.1073/pnas.2536558100; RA Kanashiro C.A., Schally A.V., Groot K., Armatis P., Bernardino A.L., RA Varga J.L.; RT "Inhibition of mutant p53 expression and growth of DMS-153 small cell lung RT carcinoma by antagonists of growth hormone-releasing hormone and RT bombesin."; RL Proc. Natl. Acad. Sci. U.S.A. 100:15836-15841(2003). RN [20] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 101-393. RX PubMed=6396087; DOI=10.1002/j.1460-2075.1984.tb02287.x; RA Matlashewski G., Lamb P., Pim D., Peacock J., Crawford L., Benchimol S.; RT "Isolation and characterization of a human p53 cDNA clone: expression of RT the human p53 gene."; RL EMBO J. 3:3257-3262(1984). RN [21] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 126-185. RA Pan X.L., Zhang A.H.; RT "Study on the effect of tumor suppressor gene p53 in arsenism patients."; RL Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases. RN [22] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 261-298, AND VARIANT GLN-282. RC TISSUE=Blood; RA Nimri L.F., Owais W., Momani E.; RT "Detection of P53 gene mutations and serum p53 antibodies associated with RT cigarette smoking."; RL Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases. RN [23] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 262-306, AND VARIANT VAL-262. RC TISSUE=Ovarian adenocarcinoma; RA Filippini G., Soldati G.; RL Submitted (JUL-1996) to the EMBL/GenBank/DDBJ databases. RN [24] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 225-260. RC TISSUE=Glial cell, and Glial tumor; RA Thompson-Hehir J., Davies M.P.A., Green J.A., Halliwell N., Joyce K.A., RA Salisbury J., Sibson D.R., Vergote I., Walker C.; RT "Mutation detection utilizing a novel PCR approach for amplification of the RT p53 gene from microdissected tissue: application to archival tumor RT samples."; RL Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases. RN [25] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 225-260. RA Yavuz A.S., Farner N.L., Yavuz S., Grammer A.C., Girschick H.J., RA Lipsky P.E.; RT "Bcl6 and P53 gene mutations in tonsillar B cells."; RL Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases. RN [26] RP PROTEIN SEQUENCE OF 320-337, SUBUNIT, INTERACTION WITH PRMT5, SUBCELLULAR RP LOCATION, METHYLATION AT ARG-333; ARG-335 AND ARG-337 BY PRMT5, RP IDENTIFICATION BY MASS SPECTROMETRY, AND MUTAGENESIS OF 333-ARG--ARG-337. RX PubMed=19011621; DOI=10.1038/ncb1802; RA Jansson M., Durant S.T., Cho E.C., Sheahan S., Edelmann M., Kessler B., RA La Thangue N.B.; RT "Arginine methylation regulates the p53 response."; RL Nat. Cell Biol. 10:1431-1439(2008). RN [27] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 332-366. RA Pinto E.M., Mendonca B.B., Latronico A.C.; RT "Allelic variant in intron 9 of TP53 gene."; RL Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases. RN [28] RP INTERACTION WITH HUMAN PAPILLOMAVIRUS TYPE 6 AND 11 PROTEIN E6 (MICROBIAL RP INFECTION). RX PubMed=2175676; DOI=10.1016/0092-8674(90)90409-8; RA Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M.; RT "The E6 oncoprotein encoded by human papillomavirus types 16 and 18 RT promotes the degradation of p53."; RL Cell 63:1129-1136(1990). RN [29] RP NUCLEAR LOCALIZATION SIGNAL, AND MUTAGENESIS OF LYS-319; LYS-320 AND RP LYS-321. RX PubMed=2156209; RA Addison C., Jenkins J.R., Sturzbecher H.-W.; RT "The p53 nuclear localisation signal is structurally linked to a p34cdc2 RT kinase motif."; RL Oncogene 5:423-426(1990). RN [30] RP PHOSPHORYLATION BY P60/CDC2 AND CYCLIN B/CDC2. RX PubMed=2141171; DOI=10.1073/pnas.87.12.4766; RA Bischoff J.R., Friedman P.N., Marshak D.R., Prives C., Beach D.; RT "Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2."; RL Proc. Natl. Acad. Sci. U.S.A. 87:4766-4770(1990). RN [31] RP PHOSPHORYLATION. RX PubMed=1705009; DOI=10.1128/mcb.11.3.1598-1606.1991; RA Samad A., Carroll R.B.; RT "The tumor suppressor p53 is bound to RNA by a stable covalent linkage."; RL Mol. Cell. Biol. 11:1598-1606(1991). RN [32] RP DEPHOSPHORYLATION BY PP2A. RX PubMed=1848668; DOI=10.1128/mcb.11.4.1996-2003.1991; RA Scheidtmann K.H., Mumby M.C., Rundell K., Walter G.; RT "Dephosphorylation of simian virus 40 large-T antigen and p53 protein by RT protein phosphatase 2A: inhibition by small-t antigen."; RL Mol. Cell. Biol. 11:1996-2003(1991). RN [33] RP ALTERNATIVE SPLICING. RX PubMed=8632903; RA Flaman J.-M., Waridel F., Estreicher A., Vannier A., Limacher J.-M., RA Gilbert D., Iggo R., Frebourg T.; RT "The human tumour suppressor gene p53 is alternatively spliced in normal RT cells."; RL Oncogene 12:813-818(1996). RN [34] RP GLYCOSYLATION. RX PubMed=8632915; RA Shaw P., Freeman J., Bovey R., Iggo R.; RT "Regulation of specific DNA binding by p53: evidence for a role for O- RT glycosylation and charged residues at the carboxy-terminus."; RL Oncogene 12:921-930(1996). RN [35] RP PHOSPHORYLATION AT SER-33. RX PubMed=9372954; DOI=10.1128/mcb.17.12.7220; RA Ko L.J., Shieh S.-Y., Chen X., Jayaraman L., Tamai K., Taya Y., Prives C., RA Pan Z.-Q.; RT "p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner."; RL Mol. Cell. Biol. 17:7220-7229(1997). RN [36] RP FUNCTION, AND IDENTIFICATION IN COMPLEX WITH CAK. RX PubMed=9840937; DOI=10.1038/sj.onc.1202504; RA Schneider E., Montenarh M., Wagner P.; RT "Regulation of CAK kinase activity by p53."; RL Oncogene 17:2733-2741(1998). RN [37] RP SUMOYLATION AT LYS-386, AND MUTAGENESIS OF LYS-386. RA Gostissa M., Hengstermann A., Fogal V., Sandy P., Schwarz S.E., RA Scheffner M., Del Sal G.; RT "Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1."; RL EMBO J. 18:6462-6471(1999). RN [38] RP PHOSPHORYLATION AT THR-18 BY CSNK1D/CK1. RX PubMed=10606744; DOI=10.1016/s0014-5793(99)01647-6; RA Dumaz N., Milne D.M., Meek D.W.; RT "Protein kinase CK1 is a p53-threonine 18 kinase which requires prior RT phosphorylation of serine 15."; RL FEBS Lett. 463:312-316(1999). RN [39] RP BIPARTITE NUCLEAR LOCALIZATION SIGNAL, AND CHARACTERIZATION OF VARIANT RP ASN-305. RX PubMed=10551826; DOI=10.1074/jbc.274.46.32699; RA Liang S.H., Clarke M.F.; RT "A bipartite nuclear localization signal is required for p53 nuclear import RT regulated by a carboxyl-terminal domain."; RL J. Biol. Chem. 274:32699-32703(1999). RN [40] RP PHOSPHORYLATION AT SER-15 AND SER-20, INDUCTION BY DNA DAMAGE, RP CHARACTERIZATION OF LFS VARIANT HIS-273, MUTAGENESIS OF THR-18; SER-20 AND RP 22-LEU-TRP-23, SUBCELLULAR LOCATION, AND INTERACTION WITH PML AND MDM2. RX PubMed=10570149; DOI=10.1073/pnas.96.24.13777; RA Chehab N.H., Malikzay A., Stavridi E.S., Halazonetis T.D.; RT "Phosphorylation of Ser-20 mediates stabilization of human p53 in response RT to DNA damage."; RL Proc. Natl. Acad. Sci. U.S.A. 96:13777-13782(1999). RN [41] RP UBIQUITINATION. RX PubMed=10722742; DOI=10.1074/jbc.275.12.8945; RA Fang S., Jensen J.P., Ludwig R.L., Vousden K.H., Weissman A.M.; RT "Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and RT p53."; RL J. Biol. Chem. 275:8945-8951(2000). RN [42] RP ACETYLATION AT LYS-373 AND LYS-382. RX PubMed=10656795; DOI=10.1006/jmbi.1999.3415; RA Abraham J., Kelly J., Thibault P., Benchimol S.; RT "Post-translational modification of p53 protein in response to ionizing RT radiation analyzed by mass spectrometry."; RL J. Mol. Biol. 295:853-864(2000). RN [43] RP PHOSPHORYLATION AT SER-315 AND SER-392 BY CDK2, AND MUTAGENESIS OF LYS-382; RP LEU-383 AND PHE-385. RX PubMed=10884347; DOI=10.1006/jmbi.2000.3830; RA Luciani M.G., Hutchins J.R.A., Zheleva D., Hupp T.R.; RT "The C-terminal regulatory domain of p53 contains a functional docking site RT for cyclin A."; RL J. Mol. Biol. 300:503-518(2000). RN [44] RP FUNCTION, INTERACTION WITH PML, AND SUBCELLULAR LOCATION. RX PubMed=11025664; DOI=10.1038/35036365; RA Guo A., Salomoni P., Luo J., Shih A., Zhong S., Gu W., Pandolfi P.P.; RT "The function of PML in p53-dependent apoptosis."; RL Nat. Cell Biol. 2:730-736(2000). RN [45] RP INTERACTION WITH E4F1. RX PubMed=10644996; DOI=10.1038/sj.onc.1203250; RA Sandy P., Gostissa M., Fogal V., Cecco L.D., Szalay K., Rooney R.J., RA Schneider C., Del Sal G.; RT "p53 is involved in the p120E4F-mediated growth arrest."; RL Oncogene 19:188-199(2000). RN [46] RP PHOSPHORYLATION AT THR-18. RX PubMed=10951572; DOI=10.1038/sj.onc.1203709; RA Lopez-Borges S., Lazo P.A.; RT "The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-18 RT within the mdm-2 binding site of the p53 tumour suppressor protein."; RL Oncogene 19:3656-3664(2000). RN [47] RP REVIEW ON ZINC-BINDING PROPERTIES. RX PubMed=11554448; DOI=10.1089/15230860152542961; RA Hainaut P., Mann K.; RT "Zinc binding and redox control of p53 structure and function."; RL Antioxid. Redox Signal. 3:611-623(2001). RN [48] RP PHOSPHORYLATION AT SER-15. RX PubMed=11554766; DOI=10.1006/bbrc.2001.5627; RA Imamura K., Ogura T., Kishimoto A., Kaminishi M., Esumi H.; RT "Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated RT protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D- RT ribofuranoside, in a human hepatocellular carcinoma cell line."; RL Biochem. Biophys. Res. Commun. 287:562-567(2001). RN [49] RP DEACETYLATION AT LYS-382 BY SIRT1. RX PubMed=11672523; DOI=10.1016/s0092-8674(01)00527-x; RA Vaziri H., Dessain S.K., Ng Eaton E., Imai S., Frye R.A., Pandita T.K., RA Guarente L., Weinberg R.A.; RT "hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase."; RL Cell 107:149-159(2001). RN [50] RP MINIMAL REPRESSION DOMAIN. RX PubMed=11007800; DOI=10.1074/jbc.m008231200; RA Hong T.M., Chen J.J., Peck K., Yang P.C., Wu C.W.; RT "p53 amino acids 339-346 represent the minimal p53 repression domain."; RL J. Biol. Chem. 276:1510-1515(2001). RN [51] RP PHOSPHORYLATION AT SER-20 BY PLK3. RX PubMed=11447225; DOI=10.1074/jbc.m104157200; RA Xie S., Wang Q., Wu H., Cogswell J., Lu L., Jhanwar-Uniyal M., Dai W.; RT "Reactive oxygen species-induced phosphorylation of p53 on serine 20 is RT mediated in part by polo-like kinase-3."; RL J. Biol. Chem. 276:36194-36199(2001). RN [52] RP PHOSPHORYLATION AT SER-20 BY PLK3. RX PubMed=11551930; DOI=10.1074/jbc.m106050200; RA Xie S., Wu H., Wang Q., Cogswell J.P., Husain I., Conn C., Stambrook P., RA Jhanwar-Uniyal M., Dai W.; RT "Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at RT least in part via the p53 pathway."; RL J. Biol. Chem. 276:43305-43312(2001). RN [53] RP SUMOYLATION AT LYS-386, SUBCELLULAR LOCATION, AND MUTAGENESIS OF PHE-385; RP LYS-386; THR-387 AND GLU-388. RX PubMed=11124955; DOI=10.1074/jbc.m009476200; RA Rodriguez M.S., Dargemont C., Hay R.T.; RT "SUMO-1 conjugation in vivo requires both a consensus modification motif RT and nuclear targeting."; RL J. Biol. Chem. 276:12654-12659(2001). RN [54] RP PHOSPHORYLATION BY PRPK. RX PubMed=11546806; DOI=10.1074/jbc.m105669200; RA Abe Y., Matsumoto S., Wei S., Nezu K., Miyoshi A., Kito K., Ueda N., RA Shigemoto K., Hitsumoto Y., Nikawa J., Enomoto Y.; RT "Cloning and characterization of a p53-related protein kinase expressed in RT interleukin-2-activated cytotoxic T-cells, epithelial tumor cell lines, and RT the testes."; RL J. Biol. Chem. 276:44003-44011(2001). RN [55] RP PHOSPHORYLATION AT SER-392. RX PubMed=11239457; DOI=10.1016/s1097-2765(01)00176-9; RA Keller D.M., Zeng X., Wang Y., Zhang Q.H., Kapoor M., Shu H., Goodman R., RA Lozano G., Zhao Y., Lu H.; RT "A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, RT and SSRP1."; RL Mol. Cell 7:283-292(2001). RN [56] RP INTERACTION WITH USP7. RX PubMed=12507430; DOI=10.1016/s0092-8674(02)01199-6; RA Hu M., Li P., Li M., Li W., Yao T., Wu J.-W., Gu W., Cohen R.E., Shi Y.; RT "Crystal structure of a UBP-family deubiquitinating enzyme in isolation and RT in complex with ubiquitin aldehyde."; RL Cell 111:1041-1054(2002). RN [57] RP IDENTIFICATION IN A COMPLEX WITH CABLES1 AND TP73. RX PubMed=11706030; DOI=10.1074/jbc.m108535200; RA Tsuji K., Mizumoto K., Yamochi T., Nishimoto I., Matsuoka M.; RT "Differential effect of ik3-1/cables on p53- and p73-induced cell death."; RL J. Biol. Chem. 277:2951-2957(2002). RN [58] RP INTERACTION WITH HIPK2. RX PubMed=11925430; DOI=10.1074/jbc.m200153200; RA Kim E.-J., Park J.-S., Um S.-J.; RT "Identification and characterization of HIPK2 interacting with p73 and RT modulating functions of the p53 family in vivo."; RL J. Biol. Chem. 277:32020-32028(2002). RN [59] RP INTERACTION WITH HIPK2, PHOSPHORYLATION AT SER-46, AND MUTAGENESIS OF RP SER-46 AND LYS-382. RX PubMed=11740489; DOI=10.1038/ncb715; RA Hofmann T.G., Moeller A., Sirma H., Zentgraf H., Taya Y., Droege W., RA Will H., Schmitz M.L.; RT "Regulation of p53 activity by its interaction with homeodomain-interacting RT protein kinase-2."; RL Nat. Cell Biol. 4:1-10(2002). RN [60] RP INTERACTION WITH HIPK2, AND PHOSPHORYLATION AT SER-46. RX PubMed=11780126; DOI=10.1038/ncb714; RA D'Orazi G., Cecchinelli B., Bruno T., Manni I., Higashimoto Y., Saito S., RA Gostissa M., Coen S., Marchetti A., Del Sal G., Piaggio G., Fanciulli M., RA Appella E., Soddu S.; RT "Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and RT mediates apoptosis."; RL Nat. Cell Biol. 4:11-19(2002). RN [61] RP INTERACTION WITH ING4. RX PubMed=12750254; RA Shiseki M., Nagashima M., Pedeux R.M., Kitahama-Shiseki M., Miura K., RA Okamura S., Onogi H., Higashimoto Y., Appella E., Yokota J., Harris C.C.; RT "p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity."; RL Cancer Res. 63:2373-2378(2003). RN [62] RP ACETYLATION AT LYS-305. RX PubMed=12724314; DOI=10.1074/jbc.m212574200; RA Wang Y.H., Tsay Y.G., Tan B.C., Lo W.Y., Lee S.C.; RT "Identification and characterization of a novel p300-mediated p53 RT acetylation site, lysine 305."; RL J. Biol. Chem. 278:25568-25576(2003). RN [63] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH CHEK2 AND PML, RP UBIQUITINATION BY MDM2, AND PHOSPHORYLATION AT SER-20. RX PubMed=12810724; DOI=10.1074/jbc.m301264200; RA Louria-Hayon I., Grossman T., Sionov R.V., Alsheich O., Pandolfi P.P., RA Haupt Y.; RT "The promyelocytic leukemia protein protects p53 from Mdm2-mediated RT inhibition and degradation."; RL J. Biol. Chem. 278:33134-33141(2003). RN [64] RP INTERACTION WITH TP53INP1. RX PubMed=12851404; DOI=10.1074/jbc.m301979200; RA Tomasini R., Samir A.A., Carrier A., Isnardon D., Cecchinelli B., Soddu S., RA Malissen B., Dagorn J.-C., Iovanna J.L., Dusetti N.J.; RT "TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are RT partners in regulating p53 activity."; RL J. Biol. Chem. 278:37722-37729(2003). RN [65] RP NUCLEOCYTOPLASMIC SHUTTLING, AND NUCLEAR EXPORT SIGNAL. RX PubMed=12944468; DOI=10.1128/mcb.23.18.6396-6405.2003; RA O'Keefe K., Li H., Zhang Y.; RT "Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated RT cytoplasmic degradation but not ubiquitination."; RL Mol. Cell. Biol. 23:6396-6405(2003). RN [66] RP FUNCTION, AND INTERACTION WITH PPP1R13L; PPP1R13B AND TP53BP2. RX PubMed=12524540; DOI=10.1038/ng1070; RA Bergamaschi D., Samuels Y., O'Neil N.J., Trigiante G., Crook T., RA Hsieh J.-K., O'Connor D.J., Zhong S., Campargue I., Tomlinson M.L., RA Kuwabara P.E., Lu X.; RT "iASPP oncoprotein is a key inhibitor of p53 conserved from worm to RT human."; RL Nat. Genet. 33:162-167(2003). RN [67] RP INTERACTION WITH HIPK1. RX PubMed=12702766; DOI=10.1073/pnas.0530308100; RA Kondo S., Lu Y., Debbas M., Lin A.W., Sarosi I., Itie A., Wakeham A., RA Tuan J., Saris C., Elliott G., Ma W., Benchimol S., Lowe S.W., Mak T.W., RA Thukral S.K.; RT "Characterization of cells and gene-targeted mice deficient for the p53- RT binding kinase homeodomain-interacting protein kinase 1 (HIPK1)."; RL Proc. Natl. Acad. Sci. U.S.A. 100:5431-5436(2003). RN [68] RP INTERACTION WITH CDKN2AIP. RX PubMed=15109303; DOI=10.1042/bj20040337; RA Hasan M.K., Yaguchi T., Minoda Y., Hirano T., Taira K., Wadhwa R., RA Kaul S.C.; RT "Alternative reading frame protein (ARF)-independent function of CARF RT (collaborator of ARF) involves its interactions with p53: evidence for a RT novel p53-activation pathway and its negative feedback control."; RL Biochem. J. 380:605-610(2004). RN [69] RP INTERACTION WITH HRMT1L2; EP300 AND CARM1, AND FUNCTION. RX PubMed=15186775; DOI=10.1016/j.cell.2004.05.009; RA An W., Kim J., Roeder R.G.; RT "Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional RT activation by p53."; RL Cell 117:735-748(2004). RN [70] RP INTERACTION WITH ANKRD2. RX PubMed=15136035; DOI=10.1016/j.jmb.2004.03.071; RA Kojic S., Medeot E., Guccione E., Krmac H., Zara I., Martinelli V., RA Valle G., Faulkner G.; RT "The Ankrd2 protein, a link between the sarcomere and the nucleus in RT skeletal muscle."; RL J. Mol. Biol. 339:313-325(2004). RN [71] RP PHOSPHORYLATION AT THR-55, MUTAGENESIS OF THR-55, AND INTERACTION WITH RP TAF1. RX PubMed=15053879; DOI=10.1016/s1097-2765(04)00123-6; RA Li H.-H., Li A.G., Sheppard H.M., Liu X.; RT "Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for RT TAF1 in cell G1 progression."; RL Mol. Cell 13:867-878(2004). RN [72] RP DEUBIQUITINATION BY USP7. RX PubMed=15053880; DOI=10.1016/s1097-2765(04)00157-1; RA Li M., Brooks C.L., Kon N., Gu W.; RT "A dynamic role of HAUSP in the p53-Mdm2 pathway."; RL Mol. Cell 13:879-886(2004). RN [73] RP ALTERNATIVE SPLICING (ISOFORM 4), FUNCTION, SUBCELLULAR LOCATION, AND RP UBIQUITINATION. RX PubMed=15340061; DOI=10.1128/mcb.24.18.7987-7997.2004; RA Ghosh A., Stewart D., Matlashewski G.; RT "Regulation of human p53 activity and cell localization by alternative RT splicing."; RL Mol. Cell. Biol. 24:7987-7997(2004). RN [74] RP METHYLATION AT LYS-372, AND MUTAGENESIS OF LYS-372. RX PubMed=15525938; DOI=10.1038/nature03117; RA Chuikov S., Kurash J.K., Wilson J.R., Xiao B., Justin N., Ivanov G.S., RA McKinney K., Tempst P., Prives C., Gamblin S.J., Barlev N.A., Reinberg D.; RT "Regulation of p53 activity through lysine methylation."; RL Nature 432:353-360(2004). RN [75] RP ACETYLATION AT LYS-382. RX PubMed=15448695; DOI=10.1038/ncb1170; RA Demonacos C., Krstic-Demonacos M., Smith L., Xu D., O'Connor D.P., RA Jansson M., La Thangue N.B.; RT "A new effector pathway links ATM kinase with the DNA damage response."; RL Nat. Cell Biol. 6:968-976(2004). RN [76] RP INTERACTION WITH AURKA, AND PHOSPHORYLATION AT SER-315. RX PubMed=14702041; DOI=10.1038/ng1279; RA Katayama H., Sasai K., Kawai H., Yuan Z.M., Bondaruk J., Suzuki F., RA Fujii S., Arlinghaus R.B., Czerniak B.A., Sen S.; RT "Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization RT and inhibition of p53."; RL Nat. Genet. 36:55-62(2004). RN [77] RP INTERACTION WITH NQO1. RX PubMed=15687255; DOI=10.1101/gad.319905; RA Asher G., Tsvetkov P., Kahana C., Shaul Y.; RT "A mechanism of ubiquitin-independent proteasomal degradation of the tumor RT suppressors p53 and p73."; RL Genes Dev. 19:316-321(2005). RN [78] RP INTERACTION WITH NOC2L. RX PubMed=16322561; DOI=10.1101/gad.351205; RA Hublitz P., Kunowska N., Mayer U.P., Muller J.M., Heyne K., Yin N., RA Fritzsche C., Poli C., Miguet L., Schupp I.W., van Grunsven L.A., RA Potiers N., van Dorsselaer A., Metzger E., Roemer K., Schule R.; RT "NIR is a novel INHAT repressor that modulates the transcriptional activity RT of p53."; RL Genes Dev. 19:2912-2924(2005). RN [79] RP RETRACTED PAPER. RX PubMed=15701641; DOI=10.1074/jbc.m413200200; RA Jalota-Badhwar A., Singh K., Pavithra L., Kaul-Ghanekar R., Jameel S., RA Chattopadhyay S.; RT "Tumor suppressor SMAR1 activates and stabilizes p53 through its arginine- RT serine-rich motif."; RL J. Biol. Chem. 280:16019-16029(2005). RN [80] RP RETRACTION NOTICE OF PUBMED:15701641. RX PubMed=32144153; DOI=10.1074/jbc.w120.012894; RA Jalota A., Singh K., Pavithra L., Kaul-Ghanekar R., Jameel S., RA Chattopadhyay S.; RL J. Biol. Chem. 295:3390-3390(2020). RN [81] RP INTERACTION WITH PTK2/FAK1. RX PubMed=15855171; DOI=10.1074/jbc.m414172200; RA Golubovskaya V.M., Finch R., Cance W.G.; RT "Direct interaction of the N-terminal domain of focal adhesion kinase with RT the N-terminal transactivation domain of p53."; RL J. Biol. Chem. 280:25008-25021(2005). RN [82] RP INTERACTION WITH WWOX, AND MUTAGENESIS OF SER-46. RX PubMed=16219768; DOI=10.1074/jbc.m505590200; RA Chang N.-S., Doherty J., Ensign A., Schultz L., Hsu L.-J., Hong Q.; RT "WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, RT and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds RT and stabilizes serine 46-phosphorylated p53."; RL J. Biol. Chem. 280:43100-43108(2005). RN [83] RP PHOSPHORYLATION AT SER-15. RX PubMed=15866171; DOI=10.1016/j.molcel.2005.03.027; RA Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y., Birnbaum M.J., RA Thompson C.B.; RT "AMP-activated protein kinase induces a p53-dependent metabolic RT checkpoint."; RL Mol. Cell 18:283-293(2005). RN [84] RP INTERACTION WITH STK11/LKB1, AND PHOSPHORYLATION AT SER-15 AND SER-392. RX PubMed=17108107; DOI=10.1158/0008-5472.can-06-0999; RA Zeng P.Y., Berger S.L.; RT "LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate RT transcriptional activation."; RL Cancer Res. 66:10701-10708(2006). RN [85] RP PHOSPHORYLATION AT THR-18. RX PubMed=16704422; DOI=10.1111/j.1742-4658.2006.05256.x; RA Blanco S., Klimcakova L., Vega F.M., Lazo P.A.; RT "The subcellular localization of vaccinia-related kinase-2 (VRK2) isoforms RT determines their different effect on p53 stability in tumour cell lines."; RL FEBS J. 273:2487-2504(2006). RN [86] RP INTERACTION WITH YWHAZ. RX PubMed=16376338; DOI=10.1016/j.febslet.2005.12.024; RA Gu Y.-M., Jin Y.-H., Choi J.-K., Baek K.-H., Yeo C.-Y., Lee K.-Y.; RT "Protein kinase A phosphorylates and regulates dimerization of 14-3-3 RT epsilon."; RL FEBS Lett. 580:305-310(2006). RN [87] RP PHOSPHORYLATION AT SER-46, AND INTERACTION WITH PRKCG. RX PubMed=16377624; DOI=10.1074/jbc.m512074200; RA Yoshida K., Liu H., Miki Y.; RT "Protein kinase C delta regulates Ser46 phosphorylation of p53 tumor RT suppressor in the apoptotic response to DNA damage."; RL J. Biol. Chem. 281:5734-5740(2006). RN [88] RP FUNCTION, ACETYLATION AT LYS-120, VARIANTS ARG-120; GLU-120 AND MET-120, RP AND CHARACTERIZATION OF VARIANTS ARG-120; GLU-120 AND MET-120. RX PubMed=17189187; DOI=10.1016/j.molcel.2006.11.026; RA Sykes S.M., Mellert H.S., Holbert M.A., Li K., Marmorstein R., Lane W.S., RA McMahon S.B.; RT "Acetylation of the p53 DNA-binding domain regulates apoptosis induction."; RL Mol. Cell 24:841-851(2006). RN [89] RP METHYLATION AT LYS-370, AND MUTAGENESIS OF LYS-370. RX PubMed=17108971; DOI=10.1038/nature05287; RA Huang J., Perez-Burgos L., Placek B.J., Sengupta R., Richter M., RA Dorsey J.A., Kubicek S., Opravil S., Jenuwein T., Berger S.L.; RT "Repression of p53 activity by Smyd2-mediated methylation."; RL Nature 444:629-632(2006). RN [90] RP INTERACTION WITH DAXX. RX PubMed=16845383; DOI=10.1038/ncb1442; RA Tang J., Qu L.K., Zhang J., Wang W., Michaelson J.S., Degenhardt Y.Y., RA El-Deiry W.S., Yang X.; RT "Critical role for Daxx in regulating Mdm2."; RL Nat. Cell Biol. 8:855-862(2006). RN [91] RP MOTIF, AND METHYLATION AT LYS-372. RX PubMed=16415881; DOI=10.1038/nsmb1045; RA Couture J.-F., Collazo E., Hauk G., Trievel R.C.; RT "Structural basis for the methylation site specificity of SET7/9."; RL Nat. Struct. Mol. Biol. 13:140-146(2006). RN [92] RP INTERACTION WITH POU4F2. RX PubMed=17145718; DOI=10.1093/nar/gkl878; RA Budhram-Mahadeo V.S., Bowen S., Lee S., Perez-Sanchez C., Ensor E., RA Morris P.J., Latchman D.S.; RT "Brn-3b enhances the pro-apoptotic effects of p53 but not its induction of RT cell cycle arrest by cooperating in trans-activation of bax expression."; RL Nucleic Acids Res. 34:6640-6652(2006). RN [93] RP PHOSPHORYLATION AT SER-37, AND MUTAGENESIS OF SER-37. RX PubMed=17254968; DOI=10.1016/j.cell.2006.11.050; RA Sun P., Yoshizuka N., New L., Moser B.A., Li Y., Liao R., Xie C., Chen J., RA Deng Q., Yamout M., Dong M.Q., Frangou C.G., Yates J.R. III, Wright P.E., RA Han J.; RT "PRAK is essential for ras-induced senescence and tumor suppression."; RL Cell 128:295-308(2007). RN [94] RP INTERACTION WITH ZNF385A, AND CHARACTERIZATION OF VARIANTS ALA-143; HIS-175 RP AND PRO-175. RX PubMed=17719541; DOI=10.1016/j.cell.2007.06.013; RA Das S., Raj L., Zhao B., Kimura Y., Bernstein A., Aaronson S.A., Lee S.W.; RT "Hzf Determines cell survival upon genotoxic stress by modulating p53 RT transactivation."; RL Cell 130:624-637(2007). RN [95] RP UBIQUITINATION, INTERACTION WITH SYVN1, AND SUBCELLULAR LOCATION. RX PubMed=17170702; DOI=10.1038/sj.emboj.7601490; RA Yamasaki S., Yagishita N., Sasaki T., Nakazawa M., Kato Y., Yamadera T., RA Bae E., Toriyama S., Ikeda R., Zhang L., Fujitani K., Yoo E., RA Tsuchimochi K., Ohta T., Araya N., Fujita H., Aratani S., Eguchi K., RA Komiya S., Maruyama I., Higashi N., Sato M., Senoo H., Ochi T., RA Yokoyama S., Amano T., Kim J., Gay S., Fukamizu A., Nishioka K., Tanaka K., RA Nakajima T.; RT "Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident RT ubiquitin ligase 'Synoviolin'."; RL EMBO J. 26:113-122(2007). RN [96] RP INTERACTION WITH PPP2CA; PPP2R1A; PPP2R2A AND PPP2R5C. RX PubMed=17245430; DOI=10.1038/sj.emboj.7601519; RA Li H.H., Cai X., Shouse G.P., Piluso L.G., Liu X.; RT "A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-induced RT dephosphorylation of p53 at Thr55."; RL EMBO J. 26:402-411(2007). RN [97] RP INTERACTION WITH ARMC10. RX PubMed=17904127; DOI=10.1016/j.febslet.2007.09.025; RA Zhou X., Yang G., Huang R., Chen X., Hu G.; RT "SVH-B interacts directly with p53 and suppresses the transcriptional RT activity of p53."; RL FEBS Lett. 581:4943-4948(2007). RN [98] RP PHOSPHORYLATION AT SER-9. RX PubMed=18022393; DOI=10.1016/j.febslet.2007.11.022; RA Arai S., Matsushita A., Du K., Yagi K., Okazaki Y., Kurokawa R.; RT "Novel homeodomain-interacting protein kinase family member, HIPK4, RT phosphorylates human p53 at serine 9."; RL FEBS Lett. 581:5649-5657(2007). RN [99] RP DOMAIN. RX PubMed=17467953; DOI=10.1016/j.ygeno.2007.02.003; RA Piskacek S., Gregor M., Nemethova M., Grabner M., Kovarik P., Piskacek M.; RT "Nine-amino-acid transactivation domain: establishment and prediction RT utilities."; RL Genomics 89:756-768(2007). RN [100] RP INTERACTION WITH RFFL AND RNF34. RX PubMed=17121812; DOI=10.1074/jbc.m610793200; RA Yang W., Rozan L.M., McDonald E.R. III, Navaraj A., Liu J.J., Matthew E.M., RA Wang W., Dicker D.T., El-Deiry W.S.; RT "CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho- RT p53ser20 degradation."; RL J. Biol. Chem. 282:3273-3281(2007). RN [101] RP FUNCTION, AND INTERACTION WITH MAML1. RX PubMed=17317671; DOI=10.1074/jbc.m608974200; RA Zhao Y., Katzman R.B., Delmolino L.M., Bhat I., Zhang Y., Gurumurthy C.B., RA Germaniuk-Kurowska A., Reddi H.V., Solomon A., Zeng M.S., Kung A., Ma H., RA Gao Q., Dimri G., Stanculescu A., Miele L., Wu L., Griffin J.D., RA Wazer D.E., Band H., Band V.; RT "The notch regulator MAML1 interacts with p53 and functions as a RT coactivator."; RL J. Biol. Chem. 282:11969-11981(2007). RN [102] RP PHOSPHORYLATION AT SER-15; SER-33 AND SER-46, INTERACTION WITH CDK5, AND RP SUBCELLULAR LOCATION. RX PubMed=17591690; DOI=10.1242/jcs.03468; RA Lee J.-H., Kim H.-S., Lee S.-J., Kim K.-T.; RT "Stabilization and activation of p53 induced by Cdk5 contributes to RT neuronal cell death."; RL J. Cell Sci. 120:2259-2271(2007). RN [103] RP INTERACTION WITH MORC3. RX PubMed=17332504; DOI=10.1091/mbc.e06-08-0747; RA Takahashi K., Yoshida N., Murakami N., Kawata K., Ishizaki H., RA Tanaka-Okamoto M., Miyoshi J., Zinn A.R., Shime H., Inoue N.; RT "Dynamic regulation of p53 subnuclear localization and senescence by RT MORC3."; RL Mol. Biol. Cell 18:1701-1709(2007). RN [104] RP FUNCTION, PHOSPHORYLATION AT SER-46, AND MUTAGENESIS OF SER-46. RX PubMed=17349958; DOI=10.1016/j.molcel.2007.02.007; RA Taira N., Nihira K., Yamaguchi T., Miki Y., Yoshida K.; RT "DYRK2 is targeted to the nucleus and controls p53 via Ser46 RT phosphorylation in the apoptotic response to DNA damage."; RL Mol. Cell 25:725-738(2007). RN [105] RP DEMETHYLATION BY KDM1A. RX PubMed=17805299; DOI=10.1038/nature06092; RA Huang J., Sengupta R., Espejo A.B., Lee M.G., Dorsey J.A., Richter M., RA Opravil S., Shiekhattar R., Bedford M.T., Jenuwein T., Berger S.L.; RT "p53 is regulated by the lysine demethylase LSD1."; RL Nature 449:105-108(2007). RN [106] RP METHYLATION AT LYS-382, AND MUTAGENESIS OF LYS-382. RX PubMed=17707234; DOI=10.1016/j.molcel.2007.07.012; RA Shi X., Kachirskaia I., Yamaguchi H., West L.E., Wen H., Wang E.W., RA Dutta S., Appella E., Gozani O.; RT "Modulation of p53 function by SET8-mediated methylation at lysine 382."; RL Mol. Cell 27:636-646(2007). RN [107] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [108] RP ACETYLATION, AND DEACETYLATION BY SIRT2. RX PubMed=18249187; DOI=10.1016/j.bbrc.2008.01.114; RA Jin Y.H., Kim Y.J., Kim D.W., Baek K.H., Kang B.Y., Yeo C.Y., Lee K.Y.; RT "Sirt2 interacts with 14-3-3 beta/gamma and down-regulates the activity of RT p53."; RL Biochem. Biophys. Res. Commun. 368:690-695(2008). RN [109] RP INTERACTION WITH SETD2. RX PubMed=18585004; DOI=10.1016/j.cellsig.2008.05.012; RA Xie P., Tian C., An L., Nie J., Lu K., Xing G., Zhang L., He F.; RT "Histone methyltransferase protein SETD2 interacts with p53 and selectively RT regulates its downstream genes."; RL Cell. Signal. 20:1671-1678(2008). RN [110] RP INTERACTION WITH NUPR1. RX PubMed=18690848; DOI=10.2174/156800908785133196; RA Clark D.W., Mitra A., Fillmore R.A., Jiang W.G., Samant R.S., Fodstad O., RA Shevde L.A.; RT "NUPR1 interacts with p53, transcriptionally regulates p21 and rescues RT breast epithelial cells from doxorubicin-induced genotoxic stress."; RL Curr. Cancer Drug Targets 8:421-430(2008). RN [111] RP UBIQUITINATION, AND SUBCELLULAR LOCATION. RX PubMed=18206965; DOI=10.1016/j.molcel.2007.11.031; RA Lim S.T., Chen X.L., Lim Y., Hanson D.A., Vo T.T., Howerton K., RA Larocque N., Fisher S.J., Schlaepfer D.D., Ilic D.; RT "Nuclear FAK promotes cell proliferation and survival through FERM-enhanced RT p53 degradation."; RL Mol. Cell 29:9-22(2008). RN [112] RP INTERACTION WITH KAT7. RX PubMed=17954561; DOI=10.1128/mcb.00662-07; RA Iizuka M., Sarmento O.F., Sekiya T., Scrable H., Allis C.D., Smith M.M.; RT "Hbo1 Links p53-dependent stress signaling to DNA replication licensing."; RL Mol. Cell. Biol. 28:140-153(2008). RN [113] RP INTERACTION WITH PPP2CA; PPP2R1A AND PPP2R5C, PHOSPHORYLATION AT SER-15 BY RP ATM, AND MUTAGENESIS OF SER-15. RX PubMed=17967874; DOI=10.1128/mcb.00983-07; RA Shouse G.P., Cai X., Liu X.; RT "Serine 15 phosphorylation of p53 directs its interaction with B56gamma and RT the tumor suppressor activity of B56gamma-specific protein phosphatase RT 2A."; RL Mol. Cell. Biol. 28:448-456(2008). RN [114] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [115] RP INTERACTION WITH MKRN1, MUTAGENESIS OF 291-LYS-LYS-292, AND UBIQUITINATION RP AT LYS-291 AND LYS-292 BY MKRN1. RX PubMed=19536131; DOI=10.1038/emboj.2009.164; RA Lee E.-W., Lee M.-S., Camus S., Ghim J., Yang M.-R., Oh W., Ha N.-C., RA Lane D.P., Song J.; RT "Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell RT cycle arrest and apoptosis."; RL EMBO J. 28:2100-2113(2009). RN [116] RP UBIQUITINATION BY TOPORS. RX PubMed=19473992; DOI=10.1074/jbc.c109.001560; RA Yang X., Li H., Zhou Z., Wang W.H., Deng A., Andrisani O., Liu X.; RT "Plk1-mediated phosphorylation of Topors regulates p53 stability."; RL J. Biol. Chem. 284:18588-18592(2009). RN [117] RP UBIQUITINATION AT LYS-351 AND LYS-357, AND SUBCELLULAR LOCATION. RX PubMed=19033443; DOI=10.1074/jbc.m805658200; RA Kruse J.P., Gu W.; RT "MSL2 promotes Mdm2-independent cytoplasmic localization of p53."; RL J. Biol. Chem. 284:3250-3263(2009). RN [118] RP INTERACTION WITH MTA1 AND COP1, AND UBIQUITINATION. RX PubMed=19837670; DOI=10.1074/jbc.m109.056499; RA Li D.Q., Divijendra Natha Reddy S., Pakala S.B., Wu X., Zhang Y., RA Rayala S.K., Kumar R.; RT "MTA1 coregulator regulates p53 stability and function."; RL J. Biol. Chem. 284:34545-34552(2009). RN [119] RP INTERACTION WITH HHV-5 PROTEIN UL123 (MICROBIAL INFECTION). RX PubMed=19776115; DOI=10.1128/jvi.00304-09; RA Hwang E.S., Zhang Z., Cai H., Huang D.Y., Huong S.M., Cha C.Y., Huang E.S.; RT "Human cytomegalovirus IE1-72 protein interacts with p53 and inhibits p53- RT dependent transactivation by a mechanism different from that of IE2-86 RT protein."; RL J. Virol. 83:12388-12398(2009). RN [120] RP ACETYLATION AT LYS-120. RX PubMed=19854137; DOI=10.1016/j.molcel.2009.07.031; RA Li X., Wu L., Corsa C.A., Kunkel S., Dou Y.; RT "Two mammalian MOF complexes regulate transcription activation by distinct RT mechanisms."; RL Mol. Cell 36:290-301(2009). RN [121] RP INTERACTION WITH FBXO42. RX PubMed=19509332; DOI=10.1073/pnas.0901864106; RA Sun L., Shi L., Li W., Yu W., Liang J., Zhang H., Yang X., Wang Y., Li R., RA Yao X., Yi X., Shang Y.; RT "JFK, a Kelch domain-containing F-box protein, links the SCF complex to p53 RT regulation."; RL Proc. Natl. Acad. Sci. U.S.A. 106:10195-10200(2009). RN [122] RP FUNCTION, UBIQUITINATION, AND INTERACTION WITH TRIM24. RX PubMed=19556538; DOI=10.1073/pnas.0813177106; RA Allton K., Jain A.K., Herz H.M., Tsai W.W., Jung S.Y., Qin J., Bergmann A., RA Johnson R.L., Barton M.C.; RT "Trim24 targets endogenous p53 for degradation."; RL Proc. Natl. Acad. Sci. U.S.A. 106:11612-11616(2009). RN [123] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-381 AND LYS-382, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [124] RP INTERACTION WITH TAF6 ISOFORMS 1 AND 4. RX PubMed=20096117; DOI=10.1186/1471-2199-11-10; RA Wilhelm E., Kornete M., Targat B., Vigneault-Edwards J., Frontini M., RA Tora L., Benecke A., Bell B.; RT "TAF6delta orchestrates an apoptotic transcriptome profile and interacts RT functionally with p53."; RL BMC Mol. Biol. 11:10-10(2010). RN [125] RP UBIQUITINATION, AND DEUBIQUITINATION BY USP10. RX PubMed=20096447; DOI=10.1016/j.cell.2009.12.032; RA Yuan J., Luo K., Zhang L., Cheville J.C., Lou Z.; RT "USP10 regulates p53 localization and stability by deubiquitinating p53."; RL Cell 140:384-396(2010). RN [126] RP FUNCTION. RX PubMed=20673990; DOI=10.1016/j.cell.2010.06.040; RA Huarte M., Guttman M., Feldser D., Garber M., Koziol M.J., RA Kenzelmann-Broz D., Khalil A.M., Zuk O., Amit I., Rabani M., Attardi L.D., RA Regev A., Lander E.S., Jacks T., Rinn J.L.; RT "A large intergenic noncoding RNA induced by p53 mediates global gene RT repression in the p53 response."; RL Cell 142:409-419(2010). RN [127] RP PHOSPHORYLATION AT SER-20 BY CSNK1D/CK1. RX PubMed=20041275; DOI=10.1007/s00018-009-0236-7; RA Venerando A., Marin O., Cozza G., Bustos V.H., Sarno S., Pinna L.A.; RT "Isoform specific phosphorylation of p53 by protein kinase CK1."; RL Cell. Mol. Life Sci. 67:1105-1118(2010). RN [128] RP INTERACTION WITH SNAI1, CHARACTERIZATION OF VARIANTS LEU-110; PRO-155; RP HIS-175; SER-232; SER-249; HIS-273 AND TRP-282, AND MUTAGENESIS OF ARG-248. RX PubMed=20385133; DOI=10.1016/j.febslet.2010.04.006; RA Lim S.O., Kim H., Jung G.; RT "p53 inhibits tumor cell invasion via the degradation of snail protein in RT hepatocellular carcinoma."; RL FEBS Lett. 584:2231-2236(2010). RN [129] RP INTERACTION WITH PTK2B/PYK2 AND MDM2, UBIQUITINATION, AND SUBCELLULAR RP LOCATION. RX PubMed=19880522; DOI=10.1074/jbc.m109.064212; RA Lim S.T., Miller N.L., Nam J.O., Chen X.L., Lim Y., Schlaepfer D.D.; RT "Pyk2 inhibition of p53 as an adaptive and intrinsic mechanism facilitating RT cell proliferation and survival."; RL J. Biol. Chem. 285:1743-1753(2010). RN [130] RP METHYLATION AT LYS-373, AND MUTAGENESIS OF LYS-373. RX PubMed=20118233; DOI=10.1074/jbc.m109.062588; RA Huang J., Dorsey J., Chuikov S., Perez-Burgos L., Zhang X., Jenuwein T., RA Reinberg D., Berger S.L.; RT "G9a and Glp methylate lysine 373 in the tumor suppressor p53."; RL J. Biol. Chem. 285:9636-9641(2010). RN [131] RP ERRATUM OF PUBMED:20118233. RA Huang J., Dorsey J., Chuikov S., Perez-Burgos L., Zhang X., Jenuwein T., RA Reinberg D., Berger S.L.; RL J. Biol. Chem. 285:18122-18122(2010). RN [132] RP PHOSPHORYLATION AT THR-55, AND INTERACTION WITH GRK5. RX PubMed=20124405; DOI=10.1074/jbc.m109.094243; RA Chen X., Zhu H., Yuan M., Fu J., Zhou Y., Ma L.; RT "G-protein-coupled receptor kinase 5 phosphorylates p53 and inhibits DNA RT damage-induced apoptosis."; RL J. Biol. Chem. 285:12823-12830(2010). RN [133] RP INTERACTION WITH BRD7, AND ACETYLATION AT LYS-382. RX PubMed=20228809; DOI=10.1038/ncb2038; RA Drost J., Mantovani F., Tocco F., Elkon R., Comel A., Holstege H., RA Kerkhoven R., Jonkers J., Voorhoeve P.M., Agami R., Del Sal G.; RT "BRD7 is a candidate tumour suppressor gene required for p53 function."; RL Nat. Cell Biol. 12:380-389(2010). RN [134] RP UBIQUITINATION BY RFWD3. RX PubMed=20173098; DOI=10.1073/pnas.0912094107; RA Fu X., Yucer N., Liu S., Li M., Yi P., Mu J.J., Yang T., Chu J., Jung S.Y., RA O'Malley B.W., Gu W., Qin J., Wang Y.; RT "RFWD3-Mdm2 ubiquitin ligase complex positively regulates p53 stability in RT response to DNA damage."; RL Proc. Natl. Acad. Sci. U.S.A. 107:4579-4584(2010). RN [135] RP INTERACTION WITH BRD7. RX PubMed=20660729; DOI=10.1073/pnas.1009559107; RA Burrows A.E., Smogorzewska A., Elledge S.J.; RT "Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are RT critical regulators of p53 required for induction of replicative RT senescence."; RL Proc. Natl. Acad. Sci. U.S.A. 107:14280-14285(2010). RN [136] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [137] RP INTERACTION WITH UHRF2. RX PubMed=21952639; DOI=10.4161/cc.10.19.17176; RA Mori T., Ikeda D.D., Fukushima T., Takenoshita S., Kochi H.; RT "NIRF constitutes a nodal point in the cell cycle network and is a RT candidate tumor suppressor."; RL Cell Cycle 10:3284-3299(2011). RN [138] RP INTERACTION WITH MUL1, SUBCELLULAR LOCATION, UBIQUITINATION AT LYS-24 BY RP MUL1, AND MUTAGENESIS OF LYS-24. RX PubMed=21597459; DOI=10.1038/cdd.2011.57; RA Jung J.H., Bae S., Lee J.Y., Woo S.R., Cha H.J., Yoon Y., Suh K.S., RA Lee S.J., Park I.C., Jin Y.W., Lee K.H., An S., Lee J.H.; RT "E3 ubiquitin ligase Hades negatively regulates the exonuclear function of RT p53."; RL Cell Death Differ. 18:1865-1875(2011). RN [139] RP FUNCTION, INTERACTION WITH AURKB AND NOC2L, PHOSPHORYLATION AT SER-183; RP SER-269 AND THR-284, CHARACTERIZATION OF VARIANT ALA-284, MUTAGENESIS OF RP SER-183; SER-269 AND THR-284, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=20959462; DOI=10.1074/jbc.m110.174755; RA Wu L., Ma C.A., Zhao Y., Jain A.; RT "Aurora B interacts with NIR-p53, leading to p53 phosphorylation in its RT DNA-binding domain and subsequent functional suppression."; RL J. Biol. Chem. 286:2236-2244(2011). RN [140] RP INTERACTION WITH ALDOB AND G6PD. RX PubMed=35122041; DOI=10.1038/s43018-020-0086-7; RA Li M., He X., Guo W., Yu H., Zhang S., Wang N., Liu G., Sa R., Shen X., RA Jiang Y., Tang Y., Zhuo Y., Yin C., Tu Q., Li N., Nie X., Li Y., Hu Z., RA Zhu H., Ding J., Li Z., Liu T., Zhang F., Zhou H., Li S., Yue J., Yan Z., RA Cheng S., Tao Y., Yin H.; RT "Aldolase B suppresses hepatocellular carcinogenesis by inhibiting G6PD and RT pentose phosphate pathways."; RL Nat. Cancer 1:735-747(2020). RN [141] RP INVOLVEMENT IN BCC7. RX PubMed=21946351; DOI=10.1038/ng.926; RA Stacey S.N., Sulem P., Jonasdottir A., Masson G., Gudmundsson J., RA Gudbjartsson D.F., Magnusson O.T., Gudjonsson S.A., Sigurgeirsson B., RA Thorisdottir K., Ragnarsson R., Benediktsdottir K.R., Nexo B.A., RA Tjonneland A., Overvad K., Rudnai P., Gurzau E., Koppova K., Hemminki K., RA Corredera C., Fuentelsaz V., Grasa P., Navarrete S., Fuertes F., RA Garcia-Prats M.D., Sanambrosio E., Panadero A., De Juan A., Garcia A., RA Rivera F., Planelles D., Soriano V., Requena C., Aben K.K., RA van Rossum M.M., Cremers R.G., van Oort I.M., van Spronsen D.J., RA Schalken J.A., Peters W.H., Helfand B.T., Donovan J.L., Hamdy F.C., RA Badescu D., Codreanu O., Jinga M., Csiki I.E., Constantinescu V., Badea P., RA Mates I.N., Dinu D.E., Constantin A., Mates D., Kristjansdottir S., RA Agnarsson B.A., Jonsson E., Barkardottir R.B., Einarsson G.V., RA Sigurdsson F., Moller P.H., Stefansson T., Valdimarsson T., RA Johannsson O.T., Sigurdsson H., Jonsson T., Jonasson J.G., RA Tryggvadottir L., Rice T., Hansen H.M., Xiao Y., Lachance D.H., RA O'Neill B.P., Kosel M.L., Decker P.A., Thorleifsson G., Johannsdottir H., RA Helgadottir H.T., Sigurdsson A., Steinthorsdottir V., Lindblom A., RA Sandler R.S., Keku T.O., Banasik K., Jorgensen T., Witte D.R., Hansen T., RA Pedersen O., Jinga V., Neal D.E., Catalona W.J., Wrensch M., Wiencke J., RA Jenkins R.B., Nagore E., Vogel U., Kiemeney L.A., Kumar R., Mayordomo J.I., RA Olafsson J.H., Kong A., Thorsteinsdottir U., Rafnar T., Stefansson K.; RT "A germline variant in the TP53 polyadenylation signal confers cancer RT susceptibility."; RL Nat. Genet. 43:1098-1103(2011). RN [142] RP INTERACTION WITH NUAK1, AND PHOSPHORYLATION AT SER-15 AND SER-392. RX PubMed=21317932; DOI=10.1038/onc.2011.19; RA Hou X., Liu J.E., Liu W., Liu C.Y., Liu Z.Y., Sun Z.Y.; RT "A new role of NUAK1: directly phosphorylating p53 and regulating cell RT proliferation."; RL Oncogene 30:2933-2942(2011). RN [143] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PPIF. RX PubMed=22726440; DOI=10.1016/j.cell.2012.05.014; RA Vaseva A.V., Marchenko N.D., Ji K., Tsirka S.E., Holzmann S., Moll U.M.; RT "p53 opens the mitochondrial permeability transition pore to trigger RT necrosis."; RL Cell 149:1536-1548(2012). RN [144] RP INTERACTION WITH UBC9, PHOSPHORYLATION AT SER-392, AND SUMOYLATION AT RP LYS-386. RX PubMed=22214662; DOI=10.4161/cc.11.2.18999; RA Bennett R.L., Pan Y., Christian J., Hui T., May W.S. Jr.; RT "The RAX/PACT-PKR stress response pathway promotes p53 sumoylation and RT activation, leading to G(1) arrest."; RL Cell Cycle 11:407-417(2012). RN [145] RP INTERACTION WITH NOP53. RX PubMed=22522597; DOI=10.1038/cdd.2012.40; RA Lee S., Kim J.Y., Kim Y.J., Seok K.O., Kim J.H., Chang Y.J., Kang H.Y., RA Park J.H.; RT "Nucleolar protein GLTSCR2 stabilizes p53 in response to ribosomal RT stresses."; RL Cell Death Differ. 19:1613-1622(2012). RN [146] RP INTERACTION WITH ZNF385B. RX PubMed=22945289; DOI=10.1002/eji.201242530; RA Iijima K., Yamada H., Miharu M., Imadome K., Miyagawa Y., Akimoto S., RA Kobayashi K., Okita H., Nakazawa A., Fujiwara S., Fujimoto J., Kiyokawa N.; RT "ZNF385B is characteristically expressed in germinal center B cells and RT involved in B-cell apoptosis."; RL Eur. J. Immunol. 42:3405-3415(2012). RN [147] RP METHYLATION AT LYS-370 AND LYS-382. RX PubMed=22864287; DOI=10.1038/nsmb.2353; RA Cui G., Park S., Badeaux A.I., Kim D., Lee J., Thompson J.R., Yan F., RA Kaneko S., Yuan Z., Botuyan M.V., Bedford M.T., Cheng J.Q., Mer G.; RT "PHF20 is an effector protein of p53 double lysine methylation that RT stabilizes and activates p53."; RL Nat. Struct. Mol. Biol. 19:916-924(2012). RN [148] RP FUNCTION. RX PubMed=24051492; DOI=10.1038/ncomms3444; RA Miki T., Matsumoto T., Zhao Z., Lee C.C.; RT "p53 regulates Period2 expression and the circadian clock."; RL Nat. Commun. 4:2444-2444(2013). RN [149] RP ACETYLATION AT LYS-120 AND LYS-382. RX PubMed=23431171; DOI=10.1073/pnas.1300490110; RA Rokudai S., Laptenko O., Arnal S.M., Taya Y., Kitabayashi I., Prives C.; RT "MOZ increases p53 acetylation and premature senescence through its complex RT formation with PML."; RL Proc. Natl. Acad. Sci. U.S.A. 110:3895-3900(2013). RN [150] RP INTERACTION WITH HSPA9, AND SUBCELLULAR LOCATION. RX PubMed=24625977; DOI=10.1038/cddis.2014.100; RA Sane S., Abdullah A., Boudreau D.A., Autenried R.K., Gupta B.K., Wang X., RA Wang H., Schlenker E.H., Zhang D., Telleria C., Huang L., Chauhan S.C., RA Rezvani K.; RT "Ubiquitin-like (UBX)-domain-containing protein, UBXN2A, promotes cell RT death by interfering with the p53-Mortalin interactions in colon cancer RT cells."; RL Cell Death Dis. 5:e1118-e1118(2014). RN [151] RP INTERACTION WITH S100A4, AND SUBCELLULAR LOCATION. RX PubMed=23752197; DOI=10.1038/onc.2013.213; RA Orre L.M., Panizza E., Kaminskyy V.O., Vernet E., Graeslund T., RA Zhivotovsky B., Lehtioe J.; RT "S100A4 interacts with p53 in the nucleus and promotes p53 degradation."; RL Oncogene 32:5531-5540(2013). RN [152] RP FUNCTION. RX PubMed=24652652; DOI=10.1093/jnci/dju053; RA Polato F., Rusconi P., Zangrossi S., Morelli F., Boeri M., Musi A., RA Marchini S., Castiglioni V., Scanziani E., Torri V., Broggini M.; RT "DRAGO (KIAA0247), a new DNA damage-responsive, p53-inducible gene that RT cooperates with p53 as oncosuppressor. [Corrected]."; RL J. Natl. Cancer Inst. 106:1-10(2014). RN [153] RP INTERACTION WITH UBD. RX PubMed=25422469; DOI=10.1073/pnas.1403383111; RA Theng S.S., Wang W., Mah W.C., Chan C., Zhuo J., Gao Y., Qin H., Lim L., RA Chong S.S., Song J., Lee C.G.; RT "Disruption of FAT10-MAD2 binding inhibits tumor progression."; RL Proc. Natl. Acad. Sci. U.S.A. 111:E5282-E5291(2014). RN [154] RP INTERACTION WITH TTC5, AND SUBCELLULAR LOCATION. RX PubMed=25168243; DOI=10.1038/cdd.2014.135; RA Maniam S., Coutts A.S., Stratford M.R., McGouran J., Kessler B., RA La Thangue N.B.; RT "Cofactor Strap regulates oxidative phosphorylation and mitochondrial p53 RT activity through ATP synthase."; RL Cell Death Differ. 22:156-163(2015). RN [155] RP SUBCELLULAR LOCATION. RX PubMed=26634371; DOI=10.1007/s12192-015-0661-5; RA Sane S., Abdullah A., Nelson M.E., Wang H., Chauhan S.C., Newton S.S., RA Rezvani K.; RT "Structural studies of UBXN2A and mortalin interaction and the putative RT role of silenced UBXN2A in preventing response to chemotherapy."; RL Cell Stress Chaperones 21:313-326(2016). RN [156] RP UBIQUITINATION. RX PubMed=25591766; DOI=10.1159/000369691; RA Yang L., Zhou B., Li X., Lu Z., Li W., Huo X., Miao Z.; RT "RNF125 is a ubiquitin-protein ligase that promotes p53 degradation."; RL Cell. Physiol. Biochem. 35:237-245(2015). RN [157] RP INTERACTION WITH HADV5 E1B-55K (MICROBIAL INFECTION). RX PubMed=25772236; DOI=10.1038/onc.2015.63; RA Wimmer P., Berscheminski J., Blanchette P., Groitl P., Branton P.E., RA Hay R.T., Dobner T., Schreiner S.; RT "PML isoforms IV and V contribute to adenovirus-mediated oncogenic RT transformation by functionally inhibiting the tumor-suppressor p53."; RL Oncogene 35:69-82(2016). RN [158] RP INTERACTION WITH FBXO22, AND UBIQUITINATION. RX PubMed=26868148; DOI=10.1038/ncomms10574; RA Johmura Y., Sun J., Kitagawa K., Nakanishi K., Kuno T., Naiki-Ito A., RA Sawada Y., Miyamoto T., Okabe A., Aburatani H., Li S., Miyoshi I., RA Takahashi S., Kitagawa M., Nakanishi M.; RT "SCF(Fbxo22)-KDM4A targets methylated p53 for degradation and regulates RT senescence."; RL Nat. Commun. 7:10574-10574(2016). RN [159] RP INTERACTION WITH AFG1L, AND SUBCELLULAR LOCATION. RX PubMed=27323408; DOI=10.18632/oncotarget.9959; RA Cesnekova J., Spacilova J., Hansikova H., Houstek J., Zeman J., RA Stiburek L.; RT "LACE1 interacts with p53 and mediates its mitochondrial translocation and RT apoptosis."; RL Oncotarget 7:47687-47698(2016). RN [160] RP INTERACTION WITH DDX3X AND GAMMA-TUBULIN, SUBCELLULAR LOCATION, AND RP PHOSPHORYLATION AT SER-15. RX PubMed=28842590; DOI=10.1038/s41598-017-09779-w; RA Chen W.J., Wang W.T., Tsai T.Y., Li H.K., Lee Y.W.; RT "DDX3 localizes to the centrosome and prevents multipolar mitosis by RT epigenetically and translationally modulating p53 expression."; RL Sci. Rep. 7:9411-9411(2017). RN [161] RP DEUBIQUITINATION BY USP3. RX PubMed=28807825; DOI=10.1016/j.bbrc.2017.08.036; RA Fu S., Shao S., Wang L., Liu H., Hou H., Wang Y., Wang H., Huang X., Lv R.; RT "USP3 stabilizes p53 protein through its deubiquitinase activity."; RL Biochem. Biophys. Res. Commun. 492:178-183(2017). RN [162] RP INTERACTION WITH DAZAP2. RX PubMed=33591310; DOI=10.1093/nar/gkab084; RA Liebl M.C., Moehlenbrink J., Becker H., Raddatz G., Abdeen S.K., RA Aqeilan R.I., Lyko F., Hofmann T.G.; RT "DAZAP2 acts as specifier of the p53 response to DNA damage."; RL Nucleic Acids Res. 49:2759-2776(2021). RN [163] RP INVOLVEMENT IN BMFS5. RX PubMed=30146126; DOI=10.1016/j.ajhg.2018.07.020; RA Toki T., Yoshida K., Wang R., Nakamura S., Maekawa T., Goi K., Katoh M.C., RA Mizuno S., Sugiyama F., Kanezaki R., Uechi T., Nakajima Y., Sato Y., RA Okuno Y., Sato-Otsubo A., Shiozawa Y., Kataoka K., Shiraishi Y., Sanada M., RA Chiba K., Tanaka H., Terui K., Sato T., Kamio T., Sakaguchi H., Ohga S., RA Kuramitsu M., Hamaguchi I., Ohara A., Kanno H., Miyano S., Kojima S., RA Ishiguro A., Sugita K., Kenmochi N., Takahashi S., Eto K., Ogawa S., RA Ito E.; RT "De novo mutations activating germline TP53 in an inherited bone-marrow- RT failure syndrome."; RL Am. J. Hum. Genet. 103:440-447(2018). RN [164] RP INTERACTION WITH MORN3, DEACETYLATION AT LYS-382, AND UBQIQUITINATION. RX PubMed=29681526; DOI=10.1016/j.chembiol.2018.03.010; RA Liang L., Wang H., Shi H., Li Z., Yao H., Bu Z., Song N., Li C., Xiang D., RA Zhang Y., Wang J., Hu Y., Xu Q., Ma Y., Cheng Z., Wang Y., Zhao S., RA Qian J., Chen Y., Fang J.Y., Xu J.; RT "A Designed Peptide Targets Two Types of Modifications of p53 with Anti- RT cancer Activity."; RL Cell Chem. Biol. 25:761-774.e5(2018). RN [165] RP ACETYLATION AT LYS-381, DEACETYLATION BY SIRT6, AND MUTAGENESIS OF LYS-381. RX PubMed=29474172; DOI=10.7554/elife.32127; RA Ghosh S., Wong S.K., Jiang Z., Liu B., Wang Y., Hao Q., Gorbunova V., RA Liu X., Zhou Z.; RT "Haploinsufficiency of Trp53 dramatically extends the lifespan of Sirt6- RT deficient mice."; RL Elife 7:0-0(2018). RN [166] RP PHOSPHORYLATION AT THR-18 BY VRK1. RX PubMed=31527692; DOI=10.1038/s41598-019-49821-7; RA Martin-Doncel E., Rojas A.M., Cantarero L., Lazo P.A.; RT "VRK1 functional insufficiency due to alterations in protein stability or RT kinase activity of human VRK1 pathogenic variants implicated in neuromotor RT syndromes."; RL Sci. Rep. 9:13381-13381(2019). RN [167] RP DOMAIN, AND MUTAGENESIS OF SER-392. RX PubMed=31953488; DOI=10.1038/s41598-020-57521-w; RA Kamagata K., Kanbayashi S., Honda M., Itoh Y., Takahashi H., Kameda T., RA Nagatsugi F., Takahashi S.; RT "Liquid-like droplet formation by tumor suppressor p53 induced by RT multivalent electrostatic interactions between two disordered domains."; RL Sci. Rep. 10:580-580(2020). RN [168] RP INTERACTION WITH KAPOSI'S SARCOMA-ASSOCIATED HERPESVIRUS/HHV-8 PROTEIN RP ORF45 (MICROBIAL INFECTION). RX PubMed=34523970; DOI=10.1128/jvi.01459-21; RA Alzhanova D., Meyo J.O., Juarez A., Dittmer D.P.; RT "The ORF45 protein of Kaposi Sarcoma-associated Herpesvirus (KSHV) is an RT inhibitor of p53 signaling during viral reactivation."; RL J. Virol. 0:0-0(2021). RN [169] RP INTERACTION WITH ZNF768. RX PubMed=34404770; DOI=10.1038/s41467-021-24932-w; RA Villot R., Poirier A., Bakan I., Boulay K., Fernandez E., Devillers R., RA Gama-Braga L., Tribouillard L., Gagne A., Duchesne E., Caron D., RA Berube J.S., Berube J.C., Coulombe Y., Orain M., Gelinas Y., Gobeil S., RA Bosse Y., Masson J.Y., Elowe S., Bilodeau S., Manem V., Joubert P., RA Mallette F.A., Laplante M.; RT "ZNF768 links oncogenic RAS to cellular senescence."; RL Nat. Commun. 12:4841-4841(2021). RN [170] RP FUNCTION, DOMAIN, PHOSPHORYLATION AT SER-392, AND MUTAGENESIS OF SER-392. RX PubMed=35618207; DOI=10.1016/j.bbagrm.2022.194827; RA Dai Z., Li G., Chen Q., Yang X.; RT "Ser392 phosphorylation modulated a switch between p53 and transcriptional RT condensates."; RL Biochim. Biophys. Acta 1865:194827-194827(2022). RN [171] RP DOMAIN, SUBCELLULAR LOCATION, CHARACTERIZATION OF VARIANTS LFS CYS-337; RP HIS-337 AND PRO-344, AND CHARACTERIZATION OF VARIANT PRO-337. RX PubMed=36108750; DOI=10.1016/j.ijbiomac.2022.09.087; RA Chen C., Fu G., Guo Q., Xue S., Luo S.Z.; RT "Phase separation of p53 induced by its unstructured basic region and RT prevented by oncogenic mutations in tetramerization domain."; RL Int. J. Biol. Macromol. 222:207-216(2022). RN [172] RP FUNCTION, AND DOMAIN. RX PubMed=36634798; DOI=10.1016/j.ijbiomac.2023.123221; RA Chen Q., Wu Y., Dai Z., Zhang Z., Yang X.; RT "Phosphorylation and specific DNA improved the incorporation ability of p53 RT into functional condensates."; RL Int. J. Biol. Macromol. 230:123221-123221(2023). RN [173] RP FUNCTION, DOMAIN, LACTYLATION AT LYS-120 AND LYS-139, AND CHARACTERIZATION RP OF VARIANTS GLU-120; GLN-120; ASN-139; THR-139; GLN-139 AND GLU-139. RX PubMed=38653238; DOI=10.1016/j.cell.2024.04.002; RA Zong Z., Xie F., Wang S., Wu X., Zhang Z., Yang B., Zhou F.; RT "Alanyl-tRNA synthetase, AARS1, is a lactate sensor and lactyltransferase RT that lactylates p53 and contributes to tumorigenesis."; RL Cell 187:2375-2392(2024). RN [174] RP STRUCTURE BY NMR OF 319-360. RX PubMed=8023159; DOI=10.1126/science.8023159; RA Clore G.M., Omichinski J.G., Sakaguchi K., Zambrano N., Sakamoto H., RA Appella E., Gronenborn A.M.; RT "High-resolution structure of the oligomerization domain of p53 by RT multidimensional NMR."; RL Science 265:386-391(1994). RN [175] RP STRUCTURE BY NMR OF 325-355. RX PubMed=7773777; DOI=10.1038/nsb1294-877; RA Lee W., Harvey T.S., Yin Y., Yau P., Litchfield D., Arrowsmith C.H.; RT "Solution structure of the tetrameric minimum transforming domain of p53."; RL Nat. Struct. Biol. 1:877-890(1994). RN [176] RP STRUCTURE BY NMR OF 326-354. RX PubMed=9321402; DOI=10.1093/emboj/16.20.6230; RA McCoy M., Stavridi E.S., Waterman J.L., Wieczorek A.M., Opella S.J., RA Halazonetis T.D.; RT "Hydrophobic side-chain size is a determinant of the three-dimensional RT structure of the p53 oligomerization domain."; RL EMBO J. 16:6230-6236(1997). RN [177] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 94-289. RX PubMed=8023157; DOI=10.1126/science.8023157; RA Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P.; RT "Crystal structure of a p53 tumor suppressor-DNA complex: understanding RT tumorigenic mutations."; RL Science 265:346-355(1994). RN [178] RP X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 325-356. RX PubMed=7878469; DOI=10.1126/science.7878469; RA Jeffrey P.D., Gorina S., Pavletich N.P.; RT "Crystal structure of the tetramerization domain of the p53 tumor RT suppressor at 1.7 angstroms."; RL Science 267:1498-1502(1995). RN [179] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 13-29 IN COMPLEX WITH MDM2. RX PubMed=8875929; DOI=10.1126/science.274.5289.948; RA Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J., Levine A.J., RA Pavletich N.P.; RT "Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor RT transactivation domain."; RL Science 274:948-953(1996). RN [180] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 97-287 IN COMPLEX WITH 53BP2. RX PubMed=8875926; DOI=10.1126/science.274.5289.1001; RA Gorina S., Pavletich N.P.; RT "Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains RT of 53BP2."; RL Science 274:1001-1005(1996). RN [181] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 94-312 IN COMPLEX WITH ZINC IONS, RP AND SUBUNIT. RX PubMed=14534297; DOI=10.1074/jbc.m309732200; RA Joerger A.C., Allen M.D., Fersht A.R.; RT "Crystal structure of a superstable mutant of human p53 core domain. RT Insights into the mechanism of rescuing oncogenic mutations."; RL J. Biol. Chem. 279:1291-1296(2004). RN [182] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 94-293 IN COMPLEX WITH DNA AND RP ZINC IONS, AND SUBUNIT. RX PubMed=16793544; DOI=10.1016/j.molcel.2006.05.015; RA Kitayner M., Rozenberg H., Kessler N., Rabinovich D., Shaulov L., RA Haran T.E., Shakked Z.; RT "Structural basis of DNA recognition by p53 tetramers."; RL Mol. Cell 22:741-753(2006). RN [183] RP X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 358-367 IN COMPLEX WITH USP7, AND RP INTERACTION WITH USP7. RX PubMed=16474402; DOI=10.1038/nsmb1067; RA Sheng Y., Saridakis V., Sarkari F., Duan S., Wu T., Arrowsmith C.H., RA Frappier L.; RT "Molecular recognition of p53 and MDM2 by USP7/HAUSP."; RL Nat. Struct. Mol. Biol. 13:285-291(2006). RN [184] RP X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 360-368 IN COMPLEX WITH USP7, RP MUTAGENESIS OF PRO-359; GLY-361 AND SER-362, AND INTERACTION WITH USP7. RX PubMed=16402859; DOI=10.1371/journal.pbio.0040027; RA Hu M., Gu L., Li M., Jeffrey P.D., Gu W., Shi Y.; RT "Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: RT implications for the regulation of the p53-MDM2 pathway."; RL PLoS Biol. 4:228-239(2006). RN [185] RP X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 377-386, METHYLATION AT LYS-382, RP MUTAGENESIS OF LYS-382, AND INTERACTION WITH L3MBTL1. RX PubMed=20870725; DOI=10.1074/jbc.m110.139527; RA West L.E., Roy S., Lachmi-Weiner K., Hayashi R., Shi X., Appella E., RA Kutateladze T.G., Gozani O.; RT "The MBT repeats of L3MBTL1 link SET8-mediated p53 methylation at lysine RT 382 to target gene repression."; RL J. Biol. Chem. 285:37725-37732(2010). RN [186] RP REVIEW. RX PubMed=8266092; DOI=10.1126/science.8266092; RA Harris C.C.; RT "p53: at the crossroads of molecular carcinogenesis and risk assessment."; RL Science 262:1980-1981(1993). RN [187] RP REVIEW ON VARIANTS. RX PubMed=1905840; DOI=10.1126/science.1905840; RA Hoolstein M., Sidransky D., Vogelstein B., Harris C.C.; RT "p53 mutations in human cancers."; RL Science 253:49-53(1991). RN [188] RP REVIEW ON VARIANTS. RX PubMed=8829653; RX DOI=10.1002/(sici)1098-1004(1996)7:3<202::aid-humu4>3.0.co;2-c; RA de Vries E.M.G., Ricke D.O., de Vries T.N., Hartmann A., Blaszyk H., RA Liao D., Soussi T., Kovach J.S., Sommer S.S.; RT "Database of mutations in the p53 and APC tumor suppressor genes designed RT to facilitate molecular epidemiological analyses."; RL Hum. Mutat. 7:202-213(1996). RN [189] RP X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 94-312 IN COMPLEX WITH ZINC IONS. RX PubMed=17015838; DOI=10.1073/pnas.0607286103; RA Joerger A.C., Ang H.C., Fersht A.R.; RT "Structural basis for understanding oncogenic p53 mutations and designing RT rescue drugs."; RL Proc. Natl. Acad. Sci. U.S.A. 103:15056-15061(2006). RN [190] RP X-RAY CRYSTALLOGRAPHY (1.54 ANGSTROMS) OF 94-292 OF VARIANT GLN-282. RX PubMed=18453682; DOI=10.1107/s0907444908003338; RA Tu C., Tan Y.H., Shaw G., Zhou Z., Bai Y., Luo R., Ji X.; RT "Impact of low-frequency hotspot mutation R282Q on the structure of p53 RT DNA-binding domain as revealed by crystallography at 1.54 angstroms RT resolution."; RL Acta Crystallogr. D 64:471-477(2008). RN [191] RP X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 94-312 OF VARIANT CYS-202 IN RP COMPLEX WITH ZINC IONS AND PHIKAN083. RX PubMed=18650397; DOI=10.1073/pnas.0805326105; RA Boeckler F.M., Joerger A.C., Jaggi G., Rutherford T.J., Veprintsev D.B., RA Fersht A.R.; RT "Targeted rescue of a destabilized mutant of p53 by an in silico screened RT drug."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10360-10365(2008). RN [192] RP X-RAY CRYSTALLOGRAPHY (1.2 ANGSTROMS) OF 94-293 OF VARIANT SER-249 IN RP COMPLEX WITH DNA. RX PubMed=18996393; DOI=10.1016/j.jmb.2008.10.063; RA Suad O., Rozenberg H., Brosh R., Diskin-Posner Y., Kessler N., Shimon L.J., RA Frolow F., Liran A., Rotter V., Shakked Z.; RT "Structural basis of restoring sequence-specific DNA binding and RT transactivation to mutant p53 by suppressor mutations."; RL J. Mol. Biol. 385:249-265(2009). RN [193] RP X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 94-310 IN COMPLEX WITH ZINC IONS. RX PubMed=19515728; DOI=10.1093/protein/gzp018; RA Khoo K.H., Joerger A.C., Freund S.M., Fersht A.R.; RT "Stabilising the DNA-binding domain of p53 by rational design of its RT hydrophobic core."; RL Protein Eng. Des. Sel. 22:421-430(2009). RN [194] RP X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 94-312 OF VARIANT CYS-220 IN RP COMPLEX WITH ZINC IONS. RX PubMed=20142040; DOI=10.1016/j.chembiol.2009.12.011; RA Basse N., Kaar J.L., Settanni G., Joerger A.C., Rutherford T.J., RA Fersht A.R.; RT "Toward the rational design of p53-stabilizing drugs: probing the surface RT of the oncogenic Y220C mutant."; RL Chem. Biol. 17:46-56(2010). RN [195] RP X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 94-293 IN COMPLEX WITH DNA AND RP ZINC IONS, AND SUBUNIT. RX PubMed=20364130; DOI=10.1038/nsmb.1800; RA Kitayner M., Rozenberg H., Rohs R., Suad O., Rabinovich D., Honig B., RA Shakked Z.; RT "Diversity in DNA recognition by p53 revealed by crystal structures with RT Hoogsteen base pairs."; RL Nat. Struct. Mol. Biol. 17:423-429(2010). RN [196] {ECO:0007744|PDB:6T58} RP X-RAY CRYSTALLOGRAPHY (3.10 ANGSTROMS) OF 17-56, AND INTERACTION WITH RP S100A4. RX PubMed=32442400; DOI=10.1016/j.str.2020.05.001; RA Ecsedi P., Gogl G., Hof H., Kiss B., Harmat V., Nyitray L.; RT "Structure Determination of the Transactivation Domain of p53 in Complex RT with S100A4Using Annexin A2 as a Crystallization Chaperone."; RL Structure 28:943-953.e4(2020). RN [197] RP VARIANT ARG-72. RX PubMed=1999338; DOI=10.1007/bf00201836; RA Olschwang S., Laurent-Puig P., Vassal A., Salmon R.-J., Thomas G.; RT "Characterization of a frequent polymorphism in the coding sequence of the RT Tp53 gene in colonic cancer patients and a control population."; RL Hum. Genet. 86:369-370(1991). RN [198] RP VARIANT LFS THR-133. RX PubMed=1933902; RA Law J.C., Strong L.C., Chidambaram A., Ferrell R.E.; RT "A germ line mutation in exon 5 of the p53 gene in an extended cancer RT family."; RL Cancer Res. 51:6385-6387(1991). RN [199] RP VARIANTS LFS CYS-245; TRP-248; PRO-252 AND LYS-258. RX PubMed=1978757; DOI=10.1126/science.1978757; RA Malkin D., Li F.P., Strong L.C., Fraumeni J.F. Jr., Nelson C.E., Kim D.H., RA Kassel J., Gryka M.A., Bischoff F.Z., Tainsky M.A., Friend S.H.; RT "Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, RT and other neoplasms."; RL Science 250:1233-1238(1990). RN [200] RP VARIANT LFS ASP-245. RX PubMed=2259385; DOI=10.1038/348747a0; RA Srivastava S., Zou Z., Pirollo K., Blattner W., Chang E.H.; RT "Germ-line transmission of a mutated p53 gene in a cancer-prone family with RT Li-Fraumeni syndrome."; RL Nature 348:747-749(1990). RN [201] RP VARIANT LFS LEU-272. RX PubMed=1737852; DOI=10.1172/jci115630; RA Felix C.A., Nau M.M., Takahashi T., Mitsudomi T., Chiba I., Poplack D.G., RA Reaman G.H., Cole D.E., Letterio J.J., Whang-Peng J., Knutsen T., RA Minna J.D.; RT "Hereditary and acquired p53 gene mutations in childhood acute RT lymphoblastic leukemia."; RL J. Clin. Invest. 89:640-647(1992). RN [202] RP VARIANTS LFS HIS-273 AND VAL-325. RX PubMed=1565144; DOI=10.1056/nejm199205143262002; RA Malkin D., Jolly K.W., Barbier N., Look A.T., Friend S.H., Gebhardt M.C., RA Andersen T.I., Boerresen A.-L., Li F.P., Garber J., Strong L.C.; RT "Germline mutations of the p53 tumor-suppressor gene in children and young RT adults with second malignant neoplasms."; RL N. Engl. J. Med. 326:1309-1315(1992). RN [203] RP VARIANTS SPORADIC CANCERS GLN-132; SER-249; LYS-280 AND LYS-285. RX PubMed=1694291; RA Bartek J., Iggo R., Gannon J., Lane D.P.; RT "Genetic and immunochemical analysis of mutant p53 in human breast cancer RT cell lines."; RL Oncogene 5:893-899(1990). RN [204] RP VARIANTS SPORADIC CANCERS PHE-241 AND HIS-273. RX PubMed=1699228; DOI=10.1073/pnas.87.19.7555; RA Rodrigues N.R., Rowan A., Smith M.E.F., Kerr I.B., Bodmer W.F., RA Gannon J.V., Lane D.P.; RT "p53 mutations in colorectal cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 87:7555-7559(1990). RN [205] RP VARIANTS SPORADIC CANCER VAL-154; VAL-245; GLN-248; LEU-278 AND SER-278. RX PubMed=2263646; DOI=10.1073/pnas.87.24.9958; RA Hollstein M.C., Metcalf R.A., Welsh J.A., Montesano R., Harris C.C.; RT "Frequent mutation of the p53 gene in human esophageal cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 87:9958-9961(1990). RN [206] RP VARIANTS SPORADIC CANCERS. RX PubMed=1647768; DOI=10.1016/0006-291x(91)90623-f; RA Ishioka C., Sato T., Gamoh M., Suzuki T., Shibata H., Kanamaru R., RA Wakui A., Yamazaki T.; RT "Mutations of the P53 gene, including an intronic point mutation, in RT colorectal tumors."; RL Biochem. Biophys. Res. Commun. 177:901-906(1991). RN [207] RP VARIANTS SPORADIC CANCERS LEU-152; ALA-155; HIS-175; PHE-176 AND HIS-273. RX PubMed=1868473; RA Casson A.G., Mukhopadhyay T., Cleary K.R., Ro J.Y., Levin B., Roth J.A.; RT "p53 gene mutations in Barrett's epithelium and esophageal cancer."; RL Cancer Res. 51:4495-4499(1991). RN [208] RP VARIANTS SPORADIC CANCERS IN CHINA. RX PubMed=1849234; DOI=10.1038/350427a0; RA Hsu I.C., Metcalf R.A., Sun T., Welsh J.A., Wang N.J., Harris C.C.; RT "Mutational hotspot in the p53 gene in human hepatocellular carcinomas."; RL Nature 350:427-428(1991). RN [209] RP VARIANTS SPORADIC CANCERS IN SOUTH AFRICA. RX PubMed=1672732; DOI=10.1038/350429a0; RA Bressac B., Kew M., Wands J., Ozturk M.; RT "Selective G to T mutations of p53 gene in hepatocellular carcinoma from RT southern Africa."; RL Nature 350:429-431(1991). RN [210] RP VARIANTS SPORADIC CANCERS PHE-176; PHE-242; CYS-245; LEU-248 AND HIS-273. RX PubMed=1394225; RA Somers K.D., Merrick M.A., Lopez M.E., Incognito L.S., Schechter G.L., RA Casey G.; RT "Frequent p53 mutations in head and neck cancer."; RL Cancer Res. 52:5997-6000(1992). RN [211] RP VARIANTS SPORADIC CANCERS. RX PubMed=1327751; DOI=10.1002/j.1460-2075.1992.tb05487.x; RA Crook T., Vousden K.H.; RT "Properties of p53 mutations detected in primary and secondary cervical RT cancers suggest mechanisms of metastasis and involvement of environmental RT carcinogens."; RL EMBO J. 11:3935-3940(1992). RN [212] RP VARIANTS SPORADIC CANCERS CYS-205; GLU-281 AND LYS-285. RX PubMed=1459726; DOI=10.1002/ijc.2910520606; RA Sakai E., Rikimaru K., Ueda M., Matsumoto Y., Ishii N., Enomoto S., RA Yamamoto H., Tsuchida N.; RT "The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous- RT cell carcinoma."; RL Int. J. Cancer 52:867-872(1992). RN [213] RP VARIANT PRO-HIS-PRO-178 INS. RX PubMed=1303181; DOI=10.1093/hmg/1.3.207; RA Bhatia K., Guiterrez M.I., Magrath I.T.; RT "A novel mutation in the p53 gene in a Burkitt's lymphoma cell line."; RL Hum. Mol. Genet. 1:207-208(1992). RN [214] RP VARIANTS SPORADIC CANCERS. RX PubMed=1437144; RA Duthu A., Debuire B., Romano J.W., Ehrhart J.C., Fiscella M., May E., RA Appella E., May P.; RT "p53 mutations in Raji cells: characterization and localization relative to RT other Burkitt's lymphomas."; RL Oncogene 7:2161-2167(1992). RN [215] RP VARIANT SPORADIC CANCER THR-280. RX PubMed=1631151; DOI=10.1073/pnas.89.14.6516; RA Sun Y., Hegamyer G., Heng Y.-J., Hildesheim A., Chen J.-Y., Chen I.-H., RA Cao Y., Yao K.-T., Colburn N.H.; RT "An infrequent point mutation of the p53 gene in human nasopharyngeal RT carcinoma."; RL Proc. Natl. Acad. Sci. U.S.A. 89:6516-6520(1992). RN [216] RP VARIANTS SPORADIC CANCERS SER-151; PRO-156; LYS-174; ARG-194; CYS-220; RP GLN-248; LEU-248 AND HIS-273. RX PubMed=7682763; RA Caamano J., Zhang S.Y., Rosvold E.A., Bauer B., Klein-Szanto A.J.P.; RT "p53 alterations in human squamous cell carcinomas and carcinoma cell RT lines."; RL Am. J. Pathol. 142:1131-1139(1993). RN [217] RP VARIANTS SPORADIC CANCERS. RX PubMed=8402617; RA Boyle J.O., Hakim J., Koch W., van der Riet P., Hruban R.H., Roa R.A., RA Correo R., Eby Y.J., Ruppert J.M., Sidransky D.; RT "The incidence of p53 mutations increases with progression of head and neck RT cancer."; RL Cancer Res. 53:4477-4480(1993). RN [218] RP VARIANTS SPORADIC CANCERS. RX PubMed=8336944; RA Hamelin R., Jego N., Laurent-Puig P., Vidaud M., Thomas G.; RT "Efficient screening of p53 mutations by denaturing gradient gel RT electrophoresis in colorectal tumors."; RL Oncogene 8:2213-2220(1993). RN [219] RP VARIANTS, AND INVOLVEMENT IN LFL. RX PubMed=8118819; RA Birch J.M., Hartley A.L., Tricker K.J., Prosser J., Condie A., Kelsey A.M., RA Harris M., Jones P.H., Binchy A., Crowther D., Craft A.W., Eden O.B., RA Evans D.G.R., Thompson E., Mann J.R., Martin J., Mitchell E.L.D., RA Santibanez-Koref M.F.; RT "Prevalence and diversity of constitutional mutations in the p53 gene among RT 21 Li-Fraumeni families."; RL Cancer Res. 54:1298-1304(1994). RN [220] RP CHARACTERIZATION OF VARIANT ALA-143. RX PubMed=8013454; DOI=10.1002/j.1460-2075.1994.tb06543.x; RA Zhang W., Guo X.-Y., Hu G.-Y., Liu W.-B., Shay J.W., Deisseroth A.B.; RT "A temperature-sensitive mutant of human p53."; RL EMBO J. 13:2535-2544(1994). RN [221] RP VARIANTS LFS HIS-175; ARG-193; GLN-248; CYS-273 AND TYR-275. RX PubMed=7887414; RA Frebourg T., Barbier N., Yan Y.-X., Garber J.E., Dreyfus M., RA Fraumeni J.F. Jr., Li F.P., Friend S.H.; RT "Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome."; RL Am. J. Hum. Genet. 56:608-615(1995). RN [222] RP VARIANTS, AND INVOLVEMENT IN LFL. RX PubMed=8718514; RA Eeles R.A.; RT "Germline mutations in the TP53 gene."; RL Cancer Surv. 25:101-124(1995). RN [223] RP VARIANT LFS HIS-175. RX PubMed=8825920; DOI=10.1136/jmg.32.12.942; RA Varley J.M., McGrown G., Thorncroft M., Tricker K.J., Teare M.D., RA Santibanez-Koref M.F., Houlston R.S., Martin J., Birch J.M., Evans D.G.R.; RT "An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175 RT mutation in TP53."; RL J. Med. Genet. 32:942-945(1995). RN [224] RP VARIANTS SPORADIC CANCERS PHE-176; SER-245; TRP-248; TRP-282 AND GLN-286. RX PubMed=8829627; RX DOI=10.1002/(sici)1098-1004(1996)7:2<109::aid-humu4>3.0.co;2-7; RA Audrezet M.-P., Robaszkiewicz M., Mercier B., Nousbaum J.-B., Hardy E., RA Bail J.-P., Volant A., Lozac'H P., Gouerou H., Ferec C.; RT "Molecular analysis of the TP53 gene in Barrett's adenocarcinoma."; RL Hum. Mutat. 7:109-113(1996). RN [225] RP VARIANTS SPORADIC CANCERS. RX PubMed=9101296; RX DOI=10.1002/(sici)1098-1004(1997)9:4<348::aid-humu8>3.0.co;2-1; RA Guldberg P., Nedergaard T., Nielsen H.J., Olsen A.C., Ahrenkiel V., RA Zeuthen J.; RT "Single-step DGGE-based mutation scanning of the p53 gene: application to RT genetic diagnosis of colorectal cancer."; RL Hum. Mutat. 9:348-355(1997). RN [226] RP VARIANT SPORADIC CANCER ILE-157. RX PubMed=9419979; DOI=10.1038/sj.onc.1201668; RA Miyaki M., Nishio J., Konishi M., Kikuchi-Yanoshita R., Tanaka K., RA Muraoka M., Nagato M., Chong J.-M., Koike M., Terada T., Kawahara Y., RA Fukutome A., Tomiyama J., Chuganji Y., Momoi M., Utsunomiya J.; RT "Drastic genetic instability of tumors and normal tissues in Turcot RT syndrome."; RL Oncogene 15:2877-2881(1997). RN [227] RP VARIANTS SER-152; ILE-169; PHE-176; THR-195; CYS-220; ILE-230; CYS-273 AND RP SER-278. RX PubMed=9450901; RX DOI=10.1002/(sici)1098-1004(1998)11:1<39::aid-humu6>3.0.co;2-g; RA van Rensburg E.J., Engelbrecht S., van Heerden W.F.P., Kotze M.J., RA Raubenheimer E.J.; RT "Detection of p53 gene mutations in oral squamous cell carcinomas of a RT black African population sample."; RL Hum. Mutat. 11:39-44(1998). RN [228] RP VARIANT NON-CLASSICAL LFS CYS-337. RX PubMed=9452042; DOI=10.1002/humu.1380110121; RA Luca J.W., Strong L.C., Hansen M.F.; RT "A germline missense mutation R337C in exon 10 of the human p53 gene."; RL Hum. Mutat. Suppl. 1:S58-S61(1998). RN [229] RP VARIANT LFS ILE-292. RX PubMed=10484981; DOI=10.1016/s0165-4608(98)00276-3; RA Gueran S., Tunca Y., Imirzalioglu N.; RT "Hereditary TP53 codon 292 and somatic P16INK4A codon 94 mutations in a Li- RT Fraumeni syndrome family."; RL Cancer Genet. Cytogenet. 113:145-151(1999). RN [230] RP VARIANTS. RX PubMed=10549356; DOI=10.1016/s0065-230x(08)60785-x; RA Hainaut P., Hollstein M.; RT "p53 and human cancer: the first ten thousand mutations."; RL Adv. Cancer Res. 77:81-137(2000). RN [231] RP VARIANT ADCC HIS-337. RX PubMed=11481490; DOI=10.1073/pnas.161479898; RA Ribeiro R.C., Sandrini F., Figueiredo B., Zambetti G.P., Michalkiewicz E., RA Lafferty A.R., DeLacerda L., Rabin M., Cadwell C., Sampaio G., Cat I., RA Stratakis C.A., Sandrini R.; RT "An inherited p53 mutation that contributes in a tissue-specific manner to RT pediatric adrenal cortical carcinoma."; RL Proc. Natl. Acad. Sci. U.S.A. 98:9330-9335(2001). RN [232] RP INVOLVEMENT IN CPP. RX PubMed=12085209; DOI=10.1038/sj.bjc.6600269; RA Rutherford J., Chu C.E., Duddy P.M., Charlton R.S., Chumas P., Taylor G.R., RA Lu X., Barnes D.M., Camplejohn R.S.; RT "Investigations on a clinically and functionally unusual and novel germline RT p53 mutation."; RL Br. J. Cancer 86:1592-1596(2002). RN [233] RP VARIANTS [LARGE SCALE ANALYSIS] LEU-134; PHE-157; CYS-163; HIS-175; RP ARG-177; ARG-193; PRO-213; PHE-241; PHE-242; GLN-248; TRP-248; SER-249; RP TRP-267; LYS-271; CYS-273; HIS-273; LEU-273; SER-278; ILE-280 AND HIS-281. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [234] RP VARIANTS PRO-110; VAL-113; VAL-138; CYS-163; HIS-163; THR-195; MET-216; RP ALA-241; MET-249; SER-251; TYR-259 AND CYS-273. RX PubMed=17224074; DOI=10.1186/bcr1637; RA Chanock S.J., Burdett L., Yeager M., Llaca V., Langeroed A., Presswalla S., RA Kaaresen R., Strausberg R.L., Gerhard D.S., Kristensen V., Perou C.M., RA Boerresen-Dale A.-L.; RT "Somatic sequence alterations in twenty-one genes selected by expression RT profile analysis of breast carcinomas."; RL Breast Cancer Res. 9:R5-R5(2007). RN [235] RP VARIANTS. RX PubMed=17311302; DOI=10.1002/humu.20495; RA Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V., Hainaut P., RA Olivier M.; RT "Impact of mutant p53 functional properties on TP53 mutation patterns and RT tumor phenotype: lessons from recent developments in the IARC TP53 RT database."; RL Hum. Mutat. 28:622-629(2007). RN [236] RP CHARACTERIZATION OF VARIANT SPORADIC CANCER LYS-280, UBIQUITINATION, RP PROTEASOMAL DEGRADATION, AND INTERACTION WITH CCAR2. RX PubMed=25732823; DOI=10.1016/j.celrep.2015.01.066; RA Qin B., Minter-Dykhouse K., Yu J., Zhang J., Liu T., Zhang H., Lee S., RA Kim J., Wang L., Lou Z.; RT "DBC1 functions as a tumor suppressor by regulating p53 stability."; RL Cell Rep. 10:1324-1334(2015). RN [237] RP VARIANTS VAL-138; HIS-175; ILE-237; TRP-248 AND PRO-273. RX PubMed=27657329; DOI=10.1371/journal.pbio.1002555; RA Guan Y., Huang D., Chen F., Gao C., Tao T., Shi H., Zhao S., Liao Z., RA Lo L.J., Wang Y., Chen J., Peng J.; RT "Phosphorylation of Def Regulates Nucleolar p53 Turnover and Cell Cycle RT Progression through Def Recruitment of Calpain3."; RL PLoS Biol. 14:e1002555-e1002555(2016). CC -!- FUNCTION: Multifunctional transcription factor that induces cell cycle CC arrest, DNA repair or apoptosis upon binding to its target DNA sequence CC (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, CC PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, CC PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, CC PubMed:24652652, PubMed:35618207, PubMed:36634798, PubMed:38653238, CC PubMed:9840937). Acts as a tumor suppressor in many tumor types; CC induces growth arrest or apoptosis depending on the physiological CC circumstances and cell type (PubMed:11025664, PubMed:12524540, CC PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17189187, CC PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, CC PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, CC PubMed:38653238, PubMed:9840937). Negatively regulates cell division by CC controlling expression of a set of genes required for this process CC (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, CC PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, CC PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, CC PubMed:24652652, PubMed:9840937). One of the activated genes is an CC inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be CC mediated either by stimulation of BAX and FAS antigen expression, or by CC repression of Bcl-2 expression (PubMed:12524540, PubMed:17189187). Its CC pro-apoptotic activity is activated via its interaction with CC PPP1R13B/ASPP1 or TP53BP2/ASPP2 (PubMed:12524540). However, this CC activity is inhibited when the interaction with PPP1R13B/ASPP1 or CC TP53BP2/ASPP2 is displaced by PPP1R13L/iASPP (PubMed:12524540). In CC cooperation with mitochondrial PPIF is involved in activating oxidative CC stress-induced necrosis; the function is largely independent of CC transcription. Induces the transcription of long intergenic non-coding CC RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in CC TP53-dependent transcriptional repression leading to apoptosis and CC seems to have an effect on cell-cycle regulation. Implicated in Notch CC signaling cross-over. Prevents CDK7 kinase activity when associated to CC CAK complex in response to DNA damage, thus stopping cell cycle CC progression. Isoform 2 enhances the transactivation activity of isoform CC 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses CC transactivation activity and impairs growth suppression mediated by CC isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates CC the circadian clock by repressing CLOCK-BMAL1-mediated transcriptional CC activation of PER2 (PubMed:24051492). {ECO:0000269|PubMed:11025664, CC ECO:0000269|PubMed:12524540, ECO:0000269|PubMed:12810724, CC ECO:0000269|PubMed:15186775, ECO:0000269|PubMed:15340061, CC ECO:0000269|PubMed:17189187, ECO:0000269|PubMed:17317671, CC ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:19556538, CC ECO:0000269|PubMed:20673990, ECO:0000269|PubMed:20959462, CC ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:24051492, CC ECO:0000269|PubMed:24652652, ECO:0000269|PubMed:35618207, CC ECO:0000269|PubMed:36634798, ECO:0000269|PubMed:38653238, CC ECO:0000269|PubMed:9840937}. CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; CC Evidence={ECO:0000269|PubMed:14534297, ECO:0000269|PubMed:16793544, CC ECO:0000269|PubMed:17015838, ECO:0000269|PubMed:18650397, CC ECO:0000269|PubMed:19515728, ECO:0000269|PubMed:20142040, CC ECO:0000269|PubMed:20364130}; CC Note=Binds 1 zinc ion per subunit. {ECO:0000269|PubMed:14534297, CC ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, CC ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, CC ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130}; CC -!- SUBUNIT: Forms homodimers and homotetramers (PubMed:19011621). Binds CC DNA as a homotetramer (PubMed:36108750). Interacts with AXIN1. Probably CC part of a complex consisting of TP53, HIPK2 and AXIN1 (By similarity). CC Interacts with histone acetyltransferases EP300 and methyltransferases CC HRMT1L2 and CARM1, and recruits them to promoters. Interacts (via C- CC terminus) with TAF1; when TAF1 is part of the TFIID complex. Interacts CC with ING4; this interaction may be indirect. Found in a complex with CC CABLES1 and TP73. Interacts with HIPK1, HIPK2, and TP53INP1. Interacts CC with WWOX. May interact with HCV core protein. Interacts with USP7 and CC SYVN1. Interacts with HSP90AB1. Interacts with CHD8; leading to recruit CC histone H1 and prevent transactivation activity (By similarity). CC Interacts with ARMC10, CDKN2AIP, NUAK1, STK11/LKB1, UHRF2 and E4F1. CC Interacts with YWHAZ; the interaction enhances TP53 transcriptional CC activity. Phosphorylation of YWHAZ on 'Ser-58' inhibits this CC interaction. Interacts (via DNA-binding domain) with MAML1 (via N- CC terminus). Interacts with MKRN1. Interacts with PML (via C-terminus). CC Interacts with MDM2; leading to ubiquitination and proteasomal CC degradation of TP53. Directly interacts with FBXO42; leading to CC ubiquitination and degradation of TP53. Interacts (phosphorylated at CC Ser-15 by ATM) with the phosphatase PP2A-PPP2R5C holoenzyme; regulates CC stress-induced TP53-dependent inhibition of cell proliferation. CC Interacts with PPP2R2A. Interacts with AURKA, DAXX, BRD7 and TRIM24. CC Interacts (when monomethylated at Lys-382) with L3MBTL1. Isoform 1 CC interacts with isoform 2 and with isoform 4. Interacts with GRK5. Binds CC to the CAK complex (CDK7, cyclin H and MAT1) in response to DNA damage. CC Interacts with CDK5 in neurons. Interacts with AURKB, SETD2, UHRF2 and CC NOC2L. Interacts (via N-terminus) with PTK2/FAK1; this promotes CC ubiquitination by MDM2. Interacts with PTK2B/PYK2; this promotes CC ubiquitination by MDM2. Interacts with PRKCG. Interacts with PPIF; the CC association implicates preferentially tetrameric TP53, is induced by CC oxidative stress and is impaired by cyclosporin A (CsA). Interacts with CC SNAI1; the interaction induces SNAI1 degradation via MDM2-mediated CC ubiquitination and inhibits SNAI1-induced cell invasion. Interacts with CC UBC9. Interacts with ZNF385B; the interaction is direct. Interacts (via CC DNA-binding domain) with ZNF385A; the interaction is direct and CC enhances p53/TP53 transactivation functions on cell-cycle arrest target CC genes, resulting in growth arrest. Interacts with ANKRD2. Interacts CC with RFFL and RNF34; involved in p53/TP53 ubiquitination. Interacts CC with MTA1 and COP1. Interacts with CCAR2 (via N-terminus). Interacts CC with MORC3 (PubMed:17332504). Interacts (via C-terminus) with POU4F2 CC isoform 1 (via C-terminus) (PubMed:17145718). Interacts (via CC oligomerization region) with NOP53; the interaction is direct and may CC prevent the MDM2-mediated proteasomal degradation of TP53 CC (PubMed:22522597). Interacts with AFG1L; mediates mitochondrial CC translocation of TP53 (PubMed:27323408). Interacts with UBD CC (PubMed:25422469). Interacts with TAF6 isoform 1 and isoform 4 CC (PubMed:20096117). Interacts with C10orf90/FATS; the interaction CC inhibits binding of TP53 and MDM2 (By similarity). Interacts with CC NUPR1; interaction is stress-dependent (PubMed:18690848). Forms a CC complex with EP300 and NUPR1; this complex binds CDKN1A promoter CC leading to transcriptional induction of CDKN1A (PubMed:18690848). CC Interacts with PRMT5 in response to DNA damage; the interaction is CC TTC5/STRAP dependent (PubMed:19011621). Interacts with PPP1R13L (via CC SH3 domain and ANK repeats); the interaction inhibits pro-apoptotic CC activity of p53/TP53 (PubMed:12524540). Interacts with PPP1R13B/ASPP1 CC and TP53BP2/ASPP2; the interactions promotes pro-apoptotic activity CC (PubMed:12524540). When phosphorylated at Ser-15, interacts with DDX3X CC and gamma-tubulin (PubMed:28842590). Interacts with KAT7/HBO1; leading CC to inhibit histone acetyltransferase activity of KAT7/HBO1 CC (PubMed:17954561). Interacts (via N-terminus) with E3 ubiquitin-protein CC ligase MUL1; the interaction results in ubiquitination of cytoplasmic CC TP53 at Lys-24 and subsequent proteasomal degradation CC (PubMed:21597459). Interacts with S100A4; this interaction promotes CC TP53 degradation (PubMed:23752197, PubMed:32442400). Interacts with CC BANP (By similarity). Interacts with TTC5/STRAP; the interaction may CC result in increased mitochondrial-dependent apoptosis CC (PubMed:25168243). Interacts with NQO1; this interaction is NADH- CC dependent, stabilizes TP53 in response to oxidative stress and protects CC it from ubiquitin-independent degradation by the 20S proteasome CC (PubMed:15687255). Interacts with DAZAP2 at TP53 target gene promoters; CC the interaction is triggered by DNA damage and leads to modulation of CC the expression of a subset of TP53 target genes, reducing DNA damage- CC induced cell death by limiting the expression of cell death-mediating CC TP53 target genes (PubMed:33591310). Interacts (via N-terminus) with CC ZNF768 (via zinc-finger domains); interaction might be facilitated by CC TP53 oligomerization state (PubMed:34404770). Forms a ternary complex CC with ALDOB and G6PD; this interaction is direct. ALDOB stabilizes the CC complex inhibiting G6PD activity and keeping oxidative pentose CC phosphate metabolism in check. Interacts with MORN3; the interactions CC mediate post-transcriptional modifications of TP53 by MDM2 and SIRT1 CC (PubMed:29681526). Interacts with HSPA9/MOT-2; the interaction promotes CC the degradation of TP53 (PubMed:24625977). Interacts with FBXO22; this CC interaction promotes TP53 proteasomal degradation (PubMed:26868148). CC {ECO:0000250|UniProtKB:P02340, ECO:0000250|UniProtKB:P10361, CC ECO:0000269|PubMed:12524540, ECO:0000269|PubMed:12750254, CC ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:12851404, CC ECO:0000269|PubMed:14534297, ECO:0000269|PubMed:14702041, CC ECO:0000269|PubMed:15053879, ECO:0000269|PubMed:15109303, CC ECO:0000269|PubMed:15136035, ECO:0000269|PubMed:15186775, CC ECO:0000269|PubMed:15687255, ECO:0000269|PubMed:15855171, CC ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:16322561, CC ECO:0000269|PubMed:16376338, ECO:0000269|PubMed:16377624, CC ECO:0000269|PubMed:16402859, ECO:0000269|PubMed:16474402, CC ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:16845383, CC ECO:0000269|PubMed:17015838, ECO:0000269|PubMed:17108107, CC ECO:0000269|PubMed:17121812, ECO:0000269|PubMed:17145718, CC ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:17245430, CC ECO:0000269|PubMed:17317671, ECO:0000269|PubMed:17332504, CC ECO:0000269|PubMed:17591690, ECO:0000269|PubMed:17719541, CC ECO:0000269|PubMed:17904127, ECO:0000269|PubMed:17954561, CC ECO:0000269|PubMed:17967874, ECO:0000269|PubMed:18585004, CC ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:18690848, CC ECO:0000269|PubMed:18996393, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:19509332, ECO:0000269|PubMed:19515728, CC ECO:0000269|PubMed:19536131, ECO:0000269|PubMed:19556538, CC ECO:0000269|PubMed:19837670, ECO:0000269|PubMed:19880522, CC ECO:0000269|PubMed:20096117, ECO:0000269|PubMed:20124405, CC ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20228809, CC ECO:0000269|PubMed:20364130, ECO:0000269|PubMed:20385133, CC ECO:0000269|PubMed:20660729, ECO:0000269|PubMed:20870725, CC ECO:0000269|PubMed:20959462, ECO:0000269|PubMed:21317932, CC ECO:0000269|PubMed:21952639, ECO:0000269|PubMed:22214662, CC ECO:0000269|PubMed:22522597, ECO:0000269|PubMed:22726440, CC ECO:0000269|PubMed:22945289, ECO:0000269|PubMed:23431171, CC ECO:0000269|PubMed:23752197, ECO:0000269|PubMed:24625977, CC ECO:0000269|PubMed:25168243, ECO:0000269|PubMed:25422469, CC ECO:0000269|PubMed:25732823, ECO:0000269|PubMed:26868148, CC ECO:0000269|PubMed:27323408, ECO:0000269|PubMed:28842590, CC ECO:0000269|PubMed:29681526, ECO:0000269|PubMed:32442400, CC ECO:0000269|PubMed:33591310, ECO:0000269|PubMed:34404770, CC ECO:0000269|PubMed:35122041, ECO:0000269|PubMed:8875926, CC ECO:0000269|PubMed:8875929, ECO:0000269|PubMed:9840937}. CC -!- SUBUNIT: (Microbial infection) Interacts with cancer-associated/HPV E6 CC viral proteins leading to ubiquitination and degradation of TP53 giving CC a possible model for cell growth regulation. This complex formation CC requires an additional factor, E6-AP, which stably associates with TP53 CC in the presence of E6. {ECO:0000269|PubMed:2175676}. CC -!- SUBUNIT: (Microbial infection) Interacts with human CC cytomegalovirus/HHV-5 protein UL123. {ECO:0000269|PubMed:19776115}. CC -!- SUBUNIT: (Microbial infection) Interacts (via N-terminus) with human CC adenovirus 5 E1B-55K protein; this interaction leads to the inhibition CC of TP53 function and/or its degradation. {ECO:0000269|PubMed:25772236}. CC -!- SUBUNIT: (Microbial infection) Interacts with Kaposi's sarcoma- CC associated herpesvirus/HHV-8 protein ORF45; this interaction results in CC the cytoplasmic localization of TP53 thereby decreasing its CC transcriptional activity. {ECO:0000269|PubMed:34523970}. CC -!- INTERACTION: CC P04637; P00519: ABL1; NbExp=2; IntAct=EBI-366083, EBI-375543; CC P04637; Q13155: AIMP2; NbExp=6; IntAct=EBI-366083, EBI-745226; CC P04637; O95376: ARIH2; NbExp=5; IntAct=EBI-366083, EBI-711158; CC P04637; P49407: ARRB1; NbExp=5; IntAct=EBI-366083, EBI-743313; CC P04637; Q9UBL3: ASH2L; NbExp=8; IntAct=EBI-366083, EBI-540797; CC P04637; O95352-2: ATG7; NbExp=4; IntAct=EBI-366083, EBI-15980880; CC P04637; O15169: AXIN1; NbExp=4; IntAct=EBI-366083, EBI-710484; CC P04637; Q8N9N5: BANP; NbExp=3; IntAct=EBI-366083, EBI-744695; CC P04637; P10415: BCL2; NbExp=5; IntAct=EBI-366083, EBI-77694; CC P04637; Q07817-1: BCL2L1; NbExp=26; IntAct=EBI-366083, EBI-287195; CC P04637; O14503: BHLHE40; NbExp=11; IntAct=EBI-366083, EBI-711810; CC P04637; P15056: BRAF; NbExp=4; IntAct=EBI-366083, EBI-365980; CC P04637; P38398: BRCA1; NbExp=2; IntAct=EBI-366083, EBI-349905; CC P04637; P51587: BRCA2; NbExp=7; IntAct=EBI-366083, EBI-79792; CC P04637; Q9NPI1: BRD7; NbExp=9; IntAct=EBI-366083, EBI-711221; CC P04637; Q9BX70: BTBD2; NbExp=2; IntAct=EBI-366083, EBI-710091; CC P04637; Q9Y297: BTRC; NbExp=2; IntAct=EBI-366083, EBI-307461; CC P04637; P55212: CASP6; NbExp=3; IntAct=EBI-366083, EBI-718729; CC P04637; Q9BWC9: CCDC106; NbExp=3; IntAct=EBI-366083, EBI-711501; CC P04637; P48643: CCT5; NbExp=3; IntAct=EBI-366083, EBI-355710; CC P04637; P38936: CDKN1A; NbExp=6; IntAct=EBI-366083, EBI-375077; CC P04637; P17676: CEBPB; NbExp=4; IntAct=EBI-366083, EBI-969696; CC P04637; Q03701: CEBPZ; NbExp=2; IntAct=EBI-366083, EBI-1046778; CC P04637; O14757: CHEK1; NbExp=2; IntAct=EBI-366083, EBI-974488; CC P04637; O96017: CHEK2; NbExp=3; IntAct=EBI-366083, EBI-1180783; CC P04637; Q8NHY2: COP1; NbExp=5; IntAct=EBI-366083, EBI-1176214; CC P04637; Q92793: CREBBP; NbExp=17; IntAct=EBI-366083, EBI-81215; CC P04637; P55060: CSE1L; NbExp=5; IntAct=EBI-366083, EBI-286709; CC P04637; Q14999: CUL7; NbExp=19; IntAct=EBI-366083, EBI-308606; CC P04637; Q8IWT3: CUL9; NbExp=16; IntAct=EBI-366083, EBI-311123; CC P04637; Q9P0U4: CXXC1; NbExp=7; IntAct=EBI-366083, EBI-949911; CC P04637; Q9UER7: DAXX; NbExp=13; IntAct=EBI-366083, EBI-77321; CC P04637; Q92841: DDX17; NbExp=3; IntAct=EBI-366083, EBI-746012; CC P04637; P17844: DDX5; NbExp=6; IntAct=EBI-366083, EBI-351962; CC P04637; Q9NRR4: DROSHA; NbExp=5; IntAct=EBI-366083, EBI-528367; CC P04637; Q9BV47: DUSP26; NbExp=9; IntAct=EBI-366083, EBI-2924519; CC P04637; O14641: DVL2; NbExp=6; IntAct=EBI-366083, EBI-740850; CC P04637; Q09472: EP300; NbExp=22; IntAct=EBI-366083, EBI-447295; CC P04637; P15036: ETS2; NbExp=4; IntAct=EBI-366083, EBI-1646991; CC P04637; Q86XK2: FBXO11; NbExp=4; IntAct=EBI-366083, EBI-1047804; CC P04637; P21333-2: FLNA; NbExp=3; IntAct=EBI-366083, EBI-9641086; CC P04637; P51114: FXR1; NbExp=2; IntAct=EBI-366083, EBI-713291; CC P04637; P49841: GSK3B; NbExp=3; IntAct=EBI-366083, EBI-373586; CC P04637; P32780: GTF2H1; NbExp=12; IntAct=EBI-366083, EBI-715539; CC P04637; Q13547: HDAC1; NbExp=8; IntAct=EBI-366083, EBI-301834; CC P04637; Q86Z02: HIPK1; NbExp=2; IntAct=EBI-366083, EBI-692891; CC P04637; Q9H2X6: HIPK2; NbExp=3; IntAct=EBI-366083, EBI-348345; CC P04637; P09429: HMGB1; NbExp=9; IntAct=EBI-366083, EBI-389432; CC P04637; P41235: HNF4A; NbExp=3; IntAct=EBI-366083, EBI-1049011; CC P04637; P61978: HNRNPK; NbExp=2; IntAct=EBI-366083, EBI-304185; CC P04637; P61978-2: HNRNPK; NbExp=2; IntAct=EBI-366083, EBI-7060731; CC P04637; Q9BUJ2: HNRNPUL1; NbExp=12; IntAct=EBI-366083, EBI-1018153; CC P04637; P38646: HSPA9; NbExp=6; IntAct=EBI-366083, EBI-354932; CC P04637; P04792: HSPB1; NbExp=3; IntAct=EBI-366083, EBI-352682; CC P04637; P42858: HTT; NbExp=19; IntAct=EBI-366083, EBI-466029; CC P04637; Q7Z6Z7: HUWE1; NbExp=3; IntAct=EBI-366083, EBI-625934; CC P04637; Q16666-2: IFI16; NbExp=6; IntAct=EBI-366083, EBI-6273540; CC P04637; O14920: IKBKB; NbExp=3; IntAct=EBI-366083, EBI-81266; CC P04637; Q9UHH9: IP6K2; NbExp=4; IntAct=EBI-366083, EBI-747509; CC P04637; Q6NYC1: JMJD6; NbExp=7; IntAct=EBI-366083, EBI-8464037; CC P04637; Q92993: KAT5; NbExp=3; IntAct=EBI-366083, EBI-399080; CC P04637; Q9H7Z6: KAT8; NbExp=2; IntAct=EBI-366083, EBI-896414; CC P04637; O60341-1: KDM1A; NbExp=6; IntAct=EBI-366083, EBI-15599570; CC P04637; Q8IZD2: KMT2E; NbExp=4; IntAct=EBI-366083, EBI-2689959; CC P04637; P13473-2: LAMP2; NbExp=3; IntAct=EBI-366083, EBI-21591415; CC P04637; P43356: MAGEA2B; NbExp=7; IntAct=EBI-366083, EBI-5650739; CC P04637; Q96M61: MAGEB18; NbExp=3; IntAct=EBI-366083, EBI-741835; CC P04637; Q9UBF1: MAGEC2; NbExp=3; IntAct=EBI-366083, EBI-5651487; CC P04637; P46821: MAP1B; NbExp=6; IntAct=EBI-366083, EBI-764611; CC P04637; Q15759: MAPK11; NbExp=2; IntAct=EBI-366083, EBI-298304; CC P04637; Q8IW41: MAPKAPK5; NbExp=2; IntAct=EBI-366083, EBI-1201460; CC P04637; Q00987: MDM2; NbExp=119; IntAct=EBI-366083, EBI-389668; CC P04637; O15151: MDM4; NbExp=24; IntAct=EBI-366083, EBI-398437; CC P04637; Q15648: MED1; NbExp=3; IntAct=EBI-366083, EBI-394459; CC P04637; Q9UHC7: MKRN1; NbExp=8; IntAct=EBI-366083, EBI-373524; CC P04637; O75970: MPDZ; NbExp=3; IntAct=EBI-366083, EBI-821405; CC P04637; P04731: MT1A; NbExp=3; IntAct=EBI-366083, EBI-8045030; CC P04637; P19338: NCL; NbExp=2; IntAct=EBI-366083, EBI-346967; CC P04637; Q9Y618: NCOR2; NbExp=7; IntAct=EBI-366083, EBI-80830; CC P04637; Q99608: NDN; NbExp=4; IntAct=EBI-366083, EBI-718177; CC P04637; P23511: NFYA; NbExp=11; IntAct=EBI-366083, EBI-389739; CC P04637; P25208: NFYB; NbExp=6; IntAct=EBI-366083, EBI-389728; CC P04637; Q9Y3T9: NOC2L; NbExp=8; IntAct=EBI-366083, EBI-751547; CC P04637; O60936: NOL3; NbExp=3; IntAct=EBI-366083, EBI-740992; CC P04637; P06748: NPM1; NbExp=6; IntAct=EBI-366083, EBI-78579; CC P04637; P06748-1: NPM1; NbExp=3; IntAct=EBI-366083, EBI-354150; CC P04637; Q15466: NR0B2; NbExp=3; IntAct=EBI-366083, EBI-3910729; CC P04637; P22736: NR4A1; NbExp=6; IntAct=EBI-366083, EBI-721550; CC P04637; O43847: NRDC; NbExp=6; IntAct=EBI-366083, EBI-2371631; CC P04637; O60285: NUAK1; NbExp=5; IntAct=EBI-366083, EBI-1046789; CC P04637; P49757: NUMB; NbExp=5; IntAct=EBI-366083, EBI-915016; CC P04637; Q96FW1: OTUB1; NbExp=8; IntAct=EBI-366083, EBI-1058491; CC P04637; Q8TEW0: PARD3; NbExp=3; IntAct=EBI-366083, EBI-81968; CC P04637; P09874: PARP1; NbExp=5; IntAct=EBI-366083, EBI-355676; CC P04637; Q96KB5: PBK; NbExp=7; IntAct=EBI-366083, EBI-536853; CC P04637; Q7Z412: PEX26; NbExp=3; IntAct=EBI-366083, EBI-752057; CC P04637; P35232: PHB1; NbExp=6; IntAct=EBI-366083, EBI-354213; CC P04637; O75925: PIAS1; NbExp=4; IntAct=EBI-366083, EBI-629434; CC P04637; Q8N2W9: PIAS4; NbExp=2; IntAct=EBI-366083, EBI-473160; CC P04637; Q92569: PIK3R3; NbExp=5; IntAct=EBI-366083, EBI-79893; CC P04637; Q13526: PIN1; NbExp=14; IntAct=EBI-366083, EBI-714158; CC P04637; P53350: PLK1; NbExp=6; IntAct=EBI-366083, EBI-476768; CC P04637; P29590: PML; NbExp=4; IntAct=EBI-366083, EBI-295890; CC P04637; A0A6Q8PF08: PMP22; NbExp=3; IntAct=EBI-366083, EBI-50433196; CC P04637; P30405: PPIF; NbExp=4; IntAct=EBI-366083, EBI-5544229; CC P04637; P36873-1: PPP1CC; NbExp=2; IntAct=EBI-366083, EBI-356289; CC P04637; Q8WUF5: PPP1R13L; NbExp=12; IntAct=EBI-366083, EBI-5550163; CC P04637; P30153: PPP2R1A; NbExp=3; IntAct=EBI-366083, EBI-302388; CC P04637; Q13362: PPP2R5C; NbExp=4; IntAct=EBI-366083, EBI-1266156; CC P04637; O43741: PRKAB2; NbExp=3; IntAct=EBI-366083, EBI-1053424; CC P04637; Q05655: PRKCD; NbExp=4; IntAct=EBI-366083, EBI-704279; CC P04637; P61289: PSME3; NbExp=7; IntAct=EBI-366083, EBI-355546; CC P04637; Q05397: PTK2; NbExp=13; IntAct=EBI-366083, EBI-702142; CC P04637; Q06609: RAD51; NbExp=2; IntAct=EBI-366083, EBI-297202; CC P04637; Q06330: RBPJ; NbExp=5; IntAct=EBI-366083, EBI-632552; CC P04637; Q96PM5: RCHY1; NbExp=13; IntAct=EBI-366083, EBI-947779; CC P04637; Q6PCD5: RFWD3; NbExp=5; IntAct=EBI-366083, EBI-2129159; CC P04637; Q06587: RING1; NbExp=7; IntAct=EBI-366083, EBI-752313; CC P04637; P23396: RPS3; NbExp=4; IntAct=EBI-366083, EBI-351193; CC P04637; Q9Y265: RUVBL1; NbExp=10; IntAct=EBI-366083, EBI-353675; CC P04637; Q8N488: RYBP; NbExp=4; IntAct=EBI-366083, EBI-752324; CC P04637; P23297: S100A1; NbExp=3; IntAct=EBI-366083, EBI-743686; CC P04637; P31949: S100A11; NbExp=2; IntAct=EBI-366083, EBI-701862; CC P04637; P29034: S100A2; NbExp=4; IntAct=EBI-366083, EBI-752230; CC P04637; P33764: S100A3; NbExp=2; IntAct=EBI-366083, EBI-1044747; CC P04637; P26447: S100A4; NbExp=9; IntAct=EBI-366083, EBI-717058; CC P04637; P33763: S100A5; NbExp=2; IntAct=EBI-366083, EBI-7211732; CC P04637; P06703: S100A6; NbExp=3; IntAct=EBI-366083, EBI-352877; CC P04637; P04271: S100B; NbExp=3; IntAct=EBI-366083, EBI-458391; CC P04637; P25815: S100P; NbExp=2; IntAct=EBI-366083, EBI-743700; CC P04637; Q15424: SAFB; NbExp=5; IntAct=EBI-366083, EBI-348298; CC P04637; Q8WTS6: SETD7; NbExp=11; IntAct=EBI-366083, EBI-1268586; CC P04637; P31947: SFN; NbExp=5; IntAct=EBI-366083, EBI-476295; CC P04637; Q96ST3: SIN3A; NbExp=2; IntAct=EBI-366083, EBI-347218; CC P04637; Q96EB6: SIRT1; NbExp=18; IntAct=EBI-366083, EBI-1802965; CC P04637; Q15796: SMAD2; NbExp=7; IntAct=EBI-366083, EBI-1040141; CC P04637; Q9NRG4: SMYD2; NbExp=6; IntAct=EBI-366083, EBI-1055671; CC P04637; O95863: SNAI1; NbExp=2; IntAct=EBI-366083, EBI-1045459; CC P04637; Q06945: SOX4; NbExp=4; IntAct=EBI-366083, EBI-6672525; CC P04637; P08047: SP1; NbExp=6; IntAct=EBI-366083, EBI-298336; CC P04637; Q12772: SREBF2; NbExp=3; IntAct=EBI-366083, EBI-465059; CC P04637; Q96SB4: SRPK1; NbExp=3; IntAct=EBI-366083, EBI-539478; CC P04637; P31948: STIP1; NbExp=4; IntAct=EBI-366083, EBI-1054052; CC P04637; P63165: SUMO1; NbExp=3; IntAct=EBI-366083, EBI-80140; CC P04637; Q86TM6: SYVN1; NbExp=5; IntAct=EBI-366083, EBI-947849; CC P04637; Q9HBM6: TAF9B; NbExp=2; IntAct=EBI-366083, EBI-751601; CC P04637; P20226: TBP; NbExp=2; IntAct=EBI-366083, EBI-355371; CC P04637; P15884: TCF4; NbExp=2; IntAct=EBI-366083, EBI-533224; CC P04637; Q96GM8: TOE1; NbExp=3; IntAct=EBI-366083, EBI-717460; CC P04637; P04637: TP53; NbExp=34; IntAct=EBI-366083, EBI-366083; CC P04637; Q12888: TP53BP1; NbExp=8; IntAct=EBI-366083, EBI-396540; CC P04637; Q12888-1: TP53BP1; NbExp=17; IntAct=EBI-366083, EBI-8022649; CC P04637; Q13625: TP53BP2; NbExp=9; IntAct=EBI-366083, EBI-77642; CC P04637; Q9H3D4: TP63; NbExp=5; IntAct=EBI-366083, EBI-2337775; CC P04637; P13693: TPT1; NbExp=7; IntAct=EBI-366083, EBI-1783169; CC P04637; O15164: TRIM24; NbExp=3; IntAct=EBI-366083, EBI-2130378; CC P04637; Q15672: TWIST1; NbExp=10; IntAct=EBI-366083, EBI-1797287; CC P04637; P0CG48: UBC; NbExp=15; IntAct=EBI-366083, EBI-3390054; CC P04637; P63279: UBE2I; NbExp=5; IntAct=EBI-366083, EBI-80168; CC P04637; Q05086: UBE3A; NbExp=6; IntAct=EBI-366083, EBI-954357; CC P04637; P09936: UCHL1; NbExp=3; IntAct=EBI-366083, EBI-714860; CC P04637; Q96PU4: UHRF2; NbExp=3; IntAct=EBI-366083, EBI-625304; CC P04637; Q9H9J4: USP42; NbExp=2; IntAct=EBI-366083, EBI-2513638; CC P04637; Q9H9J4-2: USP42; NbExp=2; IntAct=EBI-366083, EBI-9118105; CC P04637; Q93009: USP7; NbExp=23; IntAct=EBI-366083, EBI-302474; CC P04637; P11473: VDR; NbExp=6; IntAct=EBI-366083, EBI-286357; CC P04637; Q99986: VRK1; NbExp=11; IntAct=EBI-366083, EBI-1769146; CC P04637; Q14191: WRN; NbExp=5; IntAct=EBI-366083, EBI-368417; CC P04637; Q9NZC7: WWOX; NbExp=2; IntAct=EBI-366083, EBI-4320739; CC P04637; O14980: XPO1; NbExp=3; IntAct=EBI-366083, EBI-355867; CC P04637; P12956: XRCC6; NbExp=2; IntAct=EBI-366083, EBI-353208; CC P04637; P61981: YWHAG; NbExp=5; IntAct=EBI-366083, EBI-359832; CC P04637; P63104: YWHAZ; NbExp=3; IntAct=EBI-366083, EBI-347088; CC P04637; Q8TAQ5: ZNF420; NbExp=4; IntAct=EBI-366083, EBI-3923307; CC P04637; Q7L7W2; NbExp=2; IntAct=EBI-366083, EBI-7210801; CC P04637; P29066: Arrb1; Xeno; NbExp=3; IntAct=EBI-366083, EBI-4303019; CC P04637; Q9ESJ1: Cables1; Xeno; NbExp=3; IntAct=EBI-366083, EBI-604411; CC P04637; P45481: Crebbp; Xeno; NbExp=10; IntAct=EBI-366083, EBI-296306; CC P04637; P03120: E2; Xeno; NbExp=3; IntAct=EBI-366083, EBI-1779322; CC P04637; P03126: E6; Xeno; NbExp=5; IntAct=EBI-366083, EBI-1177242; CC P04637; P04019: E6; Xeno; NbExp=2; IntAct=EBI-366083, EBI-1177232; CC P04637; P06463: E6; Xeno; NbExp=5; IntAct=EBI-366083, EBI-1186926; CC P04637; P02829: HSP82; Xeno; NbExp=8; IntAct=EBI-366083, EBI-8659; CC P04637; Q08619: Ifi205b; Xeno; NbExp=2; IntAct=EBI-366083, EBI-8064290; CC P04637; P89055: NSP1; Xeno; NbExp=6; IntAct=EBI-366083, EBI-9522973; CC P04637; Q923E4: Sirt1; Xeno; NbExp=4; IntAct=EBI-366083, EBI-1802585; CC P04637; Q8R5A0: Smyd2; Xeno; NbExp=3; IntAct=EBI-366083, EBI-15612527; CC P04637; P32776: TFB1; Xeno; NbExp=7; IntAct=EBI-366083, EBI-19146; CC P04637; O88898: Tp63; Xeno; NbExp=2; IntAct=EBI-366083, EBI-2338025; CC P04637; P26687: Twist1; Xeno; NbExp=4; IntAct=EBI-366083, EBI-6123119; CC P04637; Q9PST7: znf585b.S; Xeno; NbExp=3; IntAct=EBI-366083, EBI-1782562; CC P04637; P03070; Xeno; NbExp=25; IntAct=EBI-366083, EBI-617698; CC P04637; PRO_0000037536 [P26663]; Xeno; NbExp=9; IntAct=EBI-366083, EBI-6838571; CC P04637; Q8QW27; Xeno; NbExp=2; IntAct=EBI-366083, EBI-6863726; CC P04637-1; P17844: DDX5; NbExp=2; IntAct=EBI-3895849, EBI-351962; CC P04637-1; P55209: NAP1L1; NbExp=2; IntAct=EBI-3895849, EBI-356392; CC P04637-1; P03126: E6; Xeno; NbExp=2; IntAct=EBI-3895849, EBI-1177242; CC P04637-7; P17844: DDX5; NbExp=2; IntAct=EBI-3895873, EBI-351962; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15340061, CC ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:19033443, ECO:0000269|PubMed:21597459, CC ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:24625977, CC ECO:0000269|PubMed:26634371}. Nucleus {ECO:0000269|PubMed:15340061, CC ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:17591690, CC ECO:0000269|PubMed:18206965, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:21597459, ECO:0000269|PubMed:24625977, CC ECO:0000269|PubMed:26634371}. Nucleus, PML body CC {ECO:0000269|PubMed:11025664, ECO:0000269|PubMed:12810724, CC ECO:0000269|PubMed:36108750}. Endoplasmic reticulum CC {ECO:0000269|PubMed:17170702}. Mitochondrion matrix CC {ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:25168243, CC ECO:0000269|PubMed:27323408}. Cytoplasm, cytoskeleton, microtubule CC organizing center, centrosome {ECO:0000269|PubMed:28842590}. CC Note=Recruited into PML bodies together with CHEK2 (PubMed:12810724). CC Translocates to mitochondria upon oxidative stress (PubMed:22726440). CC Translocates to mitochondria in response to mitomycin C treatment CC (PubMed:27323408). Competitive inhibition of TP53 interaction with CC HSPA9/MOT-2 by UBXN2A results in increased protein abundance and CC subsequent translocation of TP53 to the nucleus (PubMed:24625977). CC {ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:22726440, CC ECO:0000269|PubMed:24625977, ECO:0000269|PubMed:27323408}. CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Nucleus CC {ECO:0000269|PubMed:23752197}. Cytoplasm. Note=Predominantly nuclear CC but localizes to the cytoplasm when expressed with isoform 4. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Nucleus. Cytoplasm. Note=Localized CC mainly in the nucleus with minor staining in the cytoplasm. CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Nucleus. Cytoplasm. Note=Localized CC in the nucleus in most cells but found in the cytoplasm in some cells. CC -!- SUBCELLULAR LOCATION: [Isoform 4]: Nucleus. Cytoplasm. CC Note=Predominantly nuclear but translocates to the cytoplasm following CC cell stress. CC -!- SUBCELLULAR LOCATION: [Isoform 7]: Nucleus. Cytoplasm. Note=Localized CC mainly in the nucleus with minor staining in the cytoplasm. CC -!- SUBCELLULAR LOCATION: [Isoform 8]: Nucleus. Cytoplasm. Note=Localized CC in both nucleus and cytoplasm in most cells. In some cells, forms foci CC in the nucleus that are different from nucleoli. CC -!- SUBCELLULAR LOCATION: [Isoform 9]: Cytoplasm. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative promoter usage, Alternative splicing; Named isoforms=9; CC Name=1; Synonyms=p53, p53alpha; CC IsoId=P04637-1; Sequence=Displayed; CC Name=2; Synonyms=I9RET, p53beta; CC IsoId=P04637-2; Sequence=VSP_006535, VSP_006536; CC Name=3; Synonyms=p53gamma; CC IsoId=P04637-3; Sequence=VSP_040560, VSP_040561; CC Name=4; Synonyms=Del40-p53, Del40-p53alpha, p47; CC IsoId=P04637-4; Sequence=VSP_040832; CC Name=5; Synonyms=Del40-p53beta; CC IsoId=P04637-5; Sequence=VSP_040832, VSP_006535, VSP_006536; CC Name=6; Synonyms=Del40-p53gamma; CC IsoId=P04637-6; Sequence=VSP_040832, VSP_040560, VSP_040561; CC Name=7; Synonyms=Del133-p53, Del133-p53alpha; CC IsoId=P04637-7; Sequence=VSP_040833; CC Name=8; Synonyms=Del133-p53beta; CC IsoId=P04637-8; Sequence=VSP_040833, VSP_006535, VSP_006536; CC Name=9; Synonyms=Del133-p53gamma; CC IsoId=P04637-9; Sequence=VSP_040833, VSP_040560, VSP_040561; CC -!- TISSUE SPECIFICITY: Ubiquitous. Isoforms are expressed in a wide range CC of normal tissues but in a tissue-dependent manner. Isoform 2 is CC expressed in most normal tissues but is not detected in brain, lung, CC prostate, muscle, fetal brain, spinal cord and fetal liver. Isoform 3 CC is expressed in most normal tissues but is not detected in lung, CC spleen, testis, fetal brain, spinal cord and fetal liver. Isoform 7 is CC expressed in most normal tissues but is not detected in prostate, CC uterus, skeletal muscle and breast. Isoform 8 is detected only in CC colon, bone marrow, testis, fetal brain and intestine. Isoform 9 is CC expressed in most normal tissues but is not detected in brain, heart, CC lung, fetal liver, salivary gland, breast or intestine. CC {ECO:0000269|PubMed:16131611}. CC -!- INDUCTION: Up-regulated in response to DNA damage. Isoform 2 is not CC induced in tumor cells in response to stress. CC {ECO:0000269|PubMed:10570149, ECO:0000269|PubMed:16131611}. CC -!- DOMAIN: The N-terminal and C-terminal disordered regions undergo CC liquid-liquid phase separation (LLPS) following homotetramerization and CC activation (PubMed:31953488, PubMed:35618207, PubMed:36108750, CC PubMed:36634798, PubMed:38653238). Post-translational modifications, CC such as phosphorylation or lactylation affect the ability to undergo CC LLPS (PubMed:31953488, PubMed:35618207, PubMed:36634798, CC PubMed:38653238). {ECO:0000269|PubMed:31953488, CC ECO:0000269|PubMed:35618207, ECO:0000269|PubMed:36108750, CC ECO:0000269|PubMed:36634798, ECO:0000269|PubMed:38653238}. CC -!- DOMAIN: The nuclear export signal acts as a transcriptional repression CC domain. The TADI and TADII motifs (residues 17 to 25 and 48 to 56) CC correspond both to 9aaTAD motifs which are transactivation domains CC present in a large number of yeast and animal transcription factors. CC {ECO:0000269|PubMed:17467953}. CC -!- PTM: Acetylation of Lys-382 by CREBBP enhances transcriptional activity CC (PubMed:10656795, PubMed:15448695, PubMed:20228809, PubMed:23431171). CC Acetylation of Lys-382 by EP300 (PubMed:10656795, PubMed:15448695, CC PubMed:20228809, PubMed:23431171). Deacetylation of Lys-382 by SIRT1 CC impairs its ability to induce proapoptotic program and modulate cell CC senescence (PubMed:10656795, PubMed:15448695, PubMed:20228809, CC PubMed:23431171). Deacetylation by SIRT2 impairs its ability to induce CC transcription activation in a AKT-dependent manner (PubMed:10656795, CC PubMed:15448695, PubMed:20228809, PubMed:23431171, PubMed:29681526). CC Acetylation at Lys-381 increases stability (PubMed:29474172). CC Deacetylation at Lys-381 by SIRT6 decreases its stability, thereby CC regulating cell senescence (PubMed:29474172). Acetylated at Lys-120 by CC KAT5, KAT6A and KAT8; regulating its ability to induce proapoptotic CC program (PubMed:17189187, PubMed:19854137, PubMed:23431171). CC {ECO:0000269|PubMed:10656795, ECO:0000269|PubMed:15448695, CC ECO:0000269|PubMed:17189187, ECO:0000269|PubMed:19854137, CC ECO:0000269|PubMed:20228809, ECO:0000269|PubMed:23431171, CC ECO:0000269|PubMed:29474172, ECO:0000269|PubMed:29681526}. CC -!- PTM: Lactylation by AARS1 prevents ability to undergo liquid-liquid CC phase separation (LLPS), thereby inhibiting transcription factor CC activity. {ECO:0000269|PubMed:38653238}. CC -!- PTM: Phosphorylation on Ser residues mediates transcriptional CC activation. Phosphorylated by HIPK1 (By similarity). Phosphorylation at CC Ser-9 by HIPK4 increases repression activity on BIRC5 promoter. CC Phosphorylated on Thr-18 by VRK1, which may prevent the interaction CC with MDM2 (PubMed:10951572, PubMed:31527692). Phosphorylated on Ser-20 CC by CHEK2 in response to DNA damage, which prevents ubiquitination by CC MDM2. Phosphorylated on Ser-20 by PLK3 in response to reactive oxygen CC species (ROS), promoting p53/TP53-mediated apoptosis. Phosphorylated on CC Thr-55 by TAF1, which promotes MDM2-mediated degradation. CC Phosphorylated on Ser-33 by CDK7 in a CAK complex in response to DNA CC damage. Phosphorylated on Ser-46 by HIPK2 upon UV irradiation. CC Phosphorylation on Ser-46 is required for acetylation by CREBBP. CC Phosphorylated on Ser-392 following UV but not gamma irradiation. CC Phosphorylated by NUAK1 at Ser-15 and Ser-392; was initially thought to CC be mediated by STK11/LKB1 but it was later shown that it is indirect CC and that STK11/LKB1-dependent phosphorylation is probably mediated by CC downstream NUAK1 (PubMed:21317932). It is unclear whether AMP directly CC mediates phosphorylation at Ser-15. Phosphorylated on Thr-18 by isoform CC 1 and isoform 2 of VRK2. Phosphorylation on Thr-18 by isoform 2 of VRK2 CC results in a reduction in ubiquitination by MDM2 and an increase in CC acetylation by EP300. Stabilized by CDK5-mediated phosphorylation in CC response to genotoxic and oxidative stresses at Ser-15, Ser-33 and Ser- CC 46, leading to accumulation of p53/TP53, particularly in the nucleus, CC thus inducing the transactivation of p53/TP53 target genes. CC Phosphorylated by DYRK2 at Ser-46 in response to genotoxic stress. CC Phosphorylated at Ser-315 and Ser-392 by CDK2 in response to DNA- CC damage. Phosphorylation at Ser-15 is required for interaction with CC DDX3X and gamma-tubulin (PubMed:28842590). Phosphorylation at Ser-392 CC regulates its ability to undergo liquid-liquid phase separation by CC increasing fluidity of TP53/p53 condensates (PubMed:35618207). CC {ECO:0000250, ECO:0000269|PubMed:10570149, ECO:0000269|PubMed:10606744, CC ECO:0000269|PubMed:10884347, ECO:0000269|PubMed:10951572, CC ECO:0000269|PubMed:11239457, ECO:0000269|PubMed:11447225, CC ECO:0000269|PubMed:11546806, ECO:0000269|PubMed:11551930, CC ECO:0000269|PubMed:11554766, ECO:0000269|PubMed:11740489, CC ECO:0000269|PubMed:11780126, ECO:0000269|PubMed:12810724, CC ECO:0000269|PubMed:14702041, ECO:0000269|PubMed:15053879, CC ECO:0000269|PubMed:15866171, ECO:0000269|PubMed:16377624, CC ECO:0000269|PubMed:16704422, ECO:0000269|PubMed:1705009, CC ECO:0000269|PubMed:17108107, ECO:0000269|PubMed:17254968, CC ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:17591690, CC ECO:0000269|PubMed:17967874, ECO:0000269|PubMed:18022393, CC ECO:0000269|PubMed:20041275, ECO:0000269|PubMed:20124405, CC ECO:0000269|PubMed:20959462, ECO:0000269|PubMed:21317932, CC ECO:0000269|PubMed:2141171, ECO:0000269|PubMed:22214662, CC ECO:0000269|PubMed:28842590, ECO:0000269|PubMed:31527692, CC ECO:0000269|PubMed:9372954}. CC -!- PTM: Dephosphorylated by PP2A-PPP2R5C holoenzyme at Thr-55. SV40 small CC T antigen inhibits the dephosphorylation by the AC form of PP2A. CC -!- PTM: May be O-glycosylated in the C-terminal basic region. Studied in CC EB-1 cell line. {ECO:0000269|PubMed:8632915}. CC -!- PTM: Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal CC degradation (PubMed:10722742, PubMed:12810724, PubMed:15340061, CC PubMed:17170702, PubMed:19880522, PubMed:29681526). Ubiquitinated by CC RFWD3, which works in cooperation with MDM2 and may catalyze the CC formation of short polyubiquitin chains on p53/TP53 that are not CC targeted to the proteasome (PubMed:10722742, PubMed:12810724, CC PubMed:20173098). Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which CC leads to proteasomal degradation (PubMed:19536131). Deubiquitinated by CC USP10, leading to its stabilization (PubMed:20096447). Ubiquitinated by CC TRIM24, RFFL, RNF34 and RNF125, which leads to proteasomal degradation CC (PubMed:19556538). Ubiquitination by TOPORS induces degradation CC (PubMed:19473992). Deubiquitination by USP7, leading to stabilization CC (PubMed:15053880). Isoform 4 is monoubiquitinated in an MDM2- CC independent manner (PubMed:15340061). Ubiquitinated by COP1, which CC leads to proteasomal degradation (PubMed:19837670). Ubiquitination and CC subsequent proteasomal degradation is negatively regulated by CCAR2 CC (PubMed:25732823). Polyubiquitinated by C10orf90/FATS, CC polyubiquitination is 'Lys-48'-linkage independent and non-proteolytic, CC leading to TP53 stabilization (By similarity). Polyubiquitinated by CC MUL1 at Lys-24 which leads to proteasomal degradation CC (PubMed:21597459). Deubiquitinated by USP3, leading to stabilization CC (PubMed:28807825). Ubiquitinated by MSL2, promoting its cytoplasmic CC localization (PubMed:19033443). Also ubiquitinated by the SCF(FBXO22)- CC KDMA4A complex; leading to proteasomal degradation (PubMed:26868148). CC {ECO:0000250|UniProtKB:P02340, ECO:0000269|PubMed:10722742, CC ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:15053880, CC ECO:0000269|PubMed:15340061, ECO:0000269|PubMed:17170702, CC ECO:0000269|PubMed:18206965, ECO:0000269|PubMed:19033443, CC ECO:0000269|PubMed:19473992, ECO:0000269|PubMed:19536131, CC ECO:0000269|PubMed:19556538, ECO:0000269|PubMed:19837670, CC ECO:0000269|PubMed:19880522, ECO:0000269|PubMed:20096447, CC ECO:0000269|PubMed:20173098, ECO:0000269|PubMed:21597459, CC ECO:0000269|PubMed:25591766, ECO:0000269|PubMed:25732823, CC ECO:0000269|PubMed:26868148, ECO:0000269|PubMed:28807825, CC ECO:0000269|PubMed:29681526}. CC -!- PTM: Monomethylated at Lys-372 by SETD7, leading to stabilization and CC increased transcriptional activation (PubMed:15525938, CC PubMed:16415881). Monomethylated at Lys-370 by SMYD2, leading to CC decreased DNA-binding activity and subsequent transcriptional CC regulation activity (PubMed:17108971). Lys-372 monomethylation prevents CC interaction with SMYD2 and subsequent monomethylation at Lys-370 CC (PubMed:17108971). Dimethylated at Lys-373 by EHMT1 and EHMT2 CC (PubMed:20118233). Monomethylated at Lys-382 by KMT5A, promoting CC interaction with L3MBTL1 and leading to repress transcriptional CC activity (PubMed:17707234). Dimethylation at Lys-370 and Lys-382 CC diminishes p53 ubiquitination, through stabilizing association with the CC methyl reader PHF20 (PubMed:22864287). Demethylation of dimethylated CC Lys-370 by KDM1A prevents interaction with TP53BP1 and represses TP53- CC mediated transcriptional activation (PubMed:17805299). Monomethylated CC at Arg-333 and dimethylated at Arg-335 and Arg-337 by PRMT5; CC methylation is increased after DNA damage and might possibly affect CC TP53 target gene specificity (PubMed:19011621). CC {ECO:0000269|PubMed:15525938, ECO:0000269|PubMed:16415881, CC ECO:0000269|PubMed:17108971, ECO:0000269|PubMed:17707234, CC ECO:0000269|PubMed:17805299, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:20118233, ECO:0000269|PubMed:22864287}. CC -!- PTM: Sumoylated with SUMO1. Sumoylated at Lys-386 by UBC9. CC {ECO:0000269|PubMed:11124955, ECO:0000269|PubMed:22214662, CC ECO:0000269|Ref.37}. CC -!- DISEASE: Note=TP53 is found in increased amounts in a wide variety of CC transformed cells. TP53 is frequently mutated or inactivated in about CC 60% of cancers. TP53 defects are found in Barrett metaplasia a CC condition in which the normally stratified squamous epithelium of the CC lower esophagus is replaced by a metaplastic columnar epithelium. The CC condition develops as a complication in approximately 10% of patients CC with chronic gastroesophageal reflux disease and predisposes to the CC development of esophageal adenocarcinoma. CC -!- DISEASE: Esophageal cancer (ESCR) [MIM:133239]: A malignancy of the CC esophagus. The most common types are esophageal squamous cell carcinoma CC and adenocarcinoma. Cancer of the esophagus remains a devastating CC disease because it is usually not detected until it has progressed to CC an advanced incurable stage. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Li-Fraumeni syndrome (LFS) [MIM:151623]: An autosomal dominant CC familial cancer syndrome that in its classic form is defined by the CC existence of a proband affected by a sarcoma before 45 years with a CC first degree relative affected by any tumor before 45 years and another CC first degree relative with any tumor before 45 years or a sarcoma at CC any age. Other clinical definitions for LFS have been proposed and CC called Li-Fraumeni like syndrome (LFL). In these families affected CC relatives develop a diverse set of malignancies at unusually early CC ages. Four types of cancers account for 80% of tumors occurring in TP53 CC germline mutation carriers: breast cancers, soft tissue and bone CC sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. CC Less frequent tumors include choroid plexus carcinoma or papilloma CC before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, CC Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers. CC {ECO:0000269|PubMed:10484981, ECO:0000269|PubMed:1565144, CC ECO:0000269|PubMed:1737852, ECO:0000269|PubMed:1933902, CC ECO:0000269|PubMed:1978757, ECO:0000269|PubMed:2259385, CC ECO:0000269|PubMed:36108750, ECO:0000269|PubMed:7887414, CC ECO:0000269|PubMed:8825920, ECO:0000269|PubMed:9452042}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) CC [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. CC The hallmark of cutaneous SCC is malignant transformation of normal CC epidermal keratinocytes. Note=The gene represented in this entry is CC involved in disease pathogenesis. CC -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting CC tissues of the lung. The most common form of lung cancer is non-small CC cell lung cancer (NSCLC) that can be divided into 3 major histologic CC subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung CC cancer. NSCLC is often diagnosed at an advanced stage and has a poor CC prognosis. Note=The disease is caused by variants affecting the gene CC represented in this entry. CC -!- DISEASE: Papilloma of choroid plexus (CPP) [MIM:260500]: A benign tumor CC of neuroectodermal origin that generally occurs in childhood, but has CC also been reported in adults. Although generally found within the CC ventricular system, choroid plexus papillomas can arise ectopically in CC the brain parenchyma or disseminate throughout the neuraxis. Patients CC present with signs and symptoms of increased intracranial pressure CC including headache, hydrocephalus, papilledema, nausea, vomiting, CC cranial nerve deficits, gait impairment, and seizures. CC {ECO:0000269|PubMed:12085209}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Adrenocortical carcinoma (ADCC) [MIM:202300]: A malignant CC neoplasm of the adrenal cortex and a rare childhood tumor. It occurs CC with increased frequency in patients with Beckwith-Wiedemann syndrome CC and Li-Fraumeni syndrome. {ECO:0000269|PubMed:11481490}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Basal cell carcinoma 7 (BCC7) [MIM:614740]: A common malignant CC skin neoplasm that typically appears on hair-bearing skin, most CC commonly on sun-exposed areas. It is slow growing and rarely CC metastasizes, but has potentialities for local invasion and CC destruction. It usually develops as a flat, firm, pale area that is CC small, raised, pink or red, translucent, shiny, and waxy, and the area CC may bleed following minor injury. Tumor size can vary from a few CC millimeters to several centimeters in diameter. CC {ECO:0000269|PubMed:21946351}. Note=Disease susceptibility is CC associated with variants affecting the gene represented in this entry. CC -!- DISEASE: Bone marrow failure syndrome 5 (BMFS5) [MIM:618165]: A form of CC bone marrow failure syndrome, a heterogeneous group of life-threatening CC disorders characterized by hematopoietic defects in association with a CC range of variable extra-hematopoietic manifestations. BMFS5 is an CC autosomal dominant form characterized by infantile onset of severe red CC cell anemia requiring transfusion. Additional features include CC hypogammaglobulinemia, poor growth with microcephaly, developmental CC delay, and seizures. {ECO:0000269|PubMed:30146126}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform 2]: Expressed in quiescent lymphocytes. Seems CC to be non-functional. May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 3]: Expressed in quiescent lymphocytes. Seems CC to be non-functional. May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 7]: Produced by alternative promoter usage. CC {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 8]: Produced by alternative promoter usage and CC alternative splicing. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 9]: Produced by alternative promoter usage and CC alternative splicing. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the p53 family. {ECO:0000305}. CC -!- CAUTION: Interaction with BANP was reported to enhance phosphorylation CC on Ser-15 upon ultraviolet irradiation (PubMed:15701641). However, the CC publication has been retracted due to image duplication and CC manipulation. Interaction with BANP has been confirmed in mouse studies CC (By similarity). Phosphorylation at Ser-15 has been confirmed by other CC studies (PubMed:10570149, PubMed:11554766, PubMed:15866171, CC PubMed:16219768, PubMed:17317671, PubMed:17954561, PubMed:20959462, CC PubMed:25772236). Its nuclear and cytoplasmic localization has been CC confirmed by other studies (PubMed:15340061, PubMed:17170702, CC PubMed:17591690, PubMed:18206965, PubMed:19011621, PubMed:21597459, CC PubMed:22726440). {ECO:0000250|UniProtKB:P02340, CC ECO:0000269|PubMed:10570149, ECO:0000269|PubMed:11554766, CC ECO:0000269|PubMed:15340061, ECO:0000269|PubMed:15701641, CC ECO:0000269|PubMed:15866171, ECO:0000269|PubMed:16219768, CC ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:17317671, CC ECO:0000269|PubMed:17591690, ECO:0000269|PubMed:17954561, CC ECO:0000269|PubMed:18206965, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:20959462, ECO:0000269|PubMed:21597459, CC ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:25772236, CC ECO:0000305|PubMed:32144153}. CC -!- WEB RESOURCE: Name=The TP53 Database; CC URL="https://tp53.cancer.gov/"; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/88/P53"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=P53 entry; CC URL="https://en.wikipedia.org/wiki/P53"; CC -!- WEB RESOURCE: Name=Protein Spotlight; Note=On the right track - Issue CC 206 of August 2018; CC URL="https://www.proteinspotlight.org/back_issues/206/"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X02469; CAA26306.1; -; mRNA. DR EMBL; M13121; AAA59987.1; -; Genomic_DNA. DR EMBL; M13112; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13113; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13114; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13115; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13116; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13117; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13118; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13119; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13120; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; K03199; AAA59989.1; -; mRNA. DR EMBL; M14694; AAA61211.1; -; mRNA. DR EMBL; M14695; AAA61212.1; -; mRNA. DR EMBL; M22898; AAA59988.1; -; Genomic_DNA. DR EMBL; M22882; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22883; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22884; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22887; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22888; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22894; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22895; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22896; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22897; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; X01405; CAA25652.1; -; mRNA. DR EMBL; X60011; CAA42626.1; -; mRNA. DR EMBL; X60012; CAA42627.1; ALT_TERM; mRNA. DR EMBL; X60013; CAA42628.1; -; mRNA. DR EMBL; X60014; CAA42629.1; -; mRNA. DR EMBL; X60015; CAA42630.1; -; mRNA. DR EMBL; X60016; CAA42631.1; -; mRNA. DR EMBL; X60017; CAA42632.1; -; mRNA. DR EMBL; X60018; CAA42633.1; -; mRNA. DR EMBL; X60019; CAA42634.1; -; mRNA. DR EMBL; X60020; CAA42635.1; -; mRNA. DR EMBL; AF307851; AAG28785.1; -; mRNA. DR EMBL; DQ186648; ABA29753.1; -; mRNA. DR EMBL; DQ186649; ABA29754.1; -; mRNA. DR EMBL; DQ186650; ABA29755.1; -; mRNA. DR EMBL; DQ186651; ABA29756.1; -; mRNA. DR EMBL; DQ186652; ABA29757.1; -; mRNA. DR EMBL; DQ191317; ABB80262.1; -; mRNA. DR EMBL; DQ286964; ABB80266.1; -; mRNA. DR EMBL; X54156; CAA38095.1; -; Genomic_DNA. DR EMBL; U94788; AAC12971.1; -; Genomic_DNA. DR EMBL; AY838896; AAV80424.1; -; Genomic_DNA. DR EMBL; AF135121; AAD28535.1; -; Genomic_DNA. DR EMBL; AF135120; AAD28535.1; JOINED; Genomic_DNA. DR EMBL; AF136271; AAD28628.1; -; Genomic_DNA. DR EMBL; AF136270; AAD28628.1; JOINED; Genomic_DNA. DR EMBL; AB082923; BAC16799.1; -; mRNA. DR EMBL; AK312568; BAG35463.1; -; mRNA. DR EMBL; AC007421; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC087388; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471108; EAW90143.1; -; Genomic_DNA. DR EMBL; CH471108; EAW90144.1; -; Genomic_DNA. DR EMBL; BC003596; AAH03596.1; -; mRNA. DR EMBL; AY429684; AAR10356.1; -; mRNA. DR EMBL; AY390341; AAQ90158.1; -; Genomic_DNA. DR EMBL; AY359814; AAR13239.1; -; Genomic_DNA. DR EMBL; U63714; AAB39322.1; -; Genomic_DNA. DR EMBL; AF209136; AAF36362.1; -; Genomic_DNA. DR EMBL; AF209128; AAF36354.1; -; Genomic_DNA. DR EMBL; AF209129; AAF36355.1; -; Genomic_DNA. DR EMBL; AF209130; AAF36356.1; -; Genomic_DNA. DR EMBL; AF209131; AAF36357.1; -; Genomic_DNA. DR EMBL; AF209132; AAF36358.1; -; Genomic_DNA. DR EMBL; AF209133; AAF36359.1; -; Genomic_DNA. DR EMBL; AF209134; AAF36360.1; -; Genomic_DNA. DR EMBL; AF209135; AAF36361.1; -; Genomic_DNA. DR EMBL; AF209148; AAF36374.1; -; Genomic_DNA. DR EMBL; AF209149; AAF36375.1; -; Genomic_DNA. DR EMBL; AF209150; AAF36376.1; -; Genomic_DNA. DR EMBL; AF209151; AAF36377.1; -; Genomic_DNA. DR EMBL; AF209152; AAF36378.1; -; Genomic_DNA. DR EMBL; AF209153; AAF36379.1; -; Genomic_DNA. DR EMBL; AF209154; AAF36380.1; -; Genomic_DNA. DR EMBL; AF209155; AAF36381.1; -; Genomic_DNA. DR EMBL; AF209156; AAF36382.1; -; Genomic_DNA. DR EMBL; AF210309; AAF63442.1; -; Genomic_DNA. DR EMBL; AF210308; AAF63442.1; JOINED; Genomic_DNA. DR EMBL; AF210310; AAF63443.1; -; Genomic_DNA. DR EMBL; AF240684; AAK76358.1; -; Genomic_DNA. DR EMBL; AF240685; AAK76359.1; -; Genomic_DNA. DR EMBL; AY270155; AAP30003.1; -; Genomic_DNA. DR CCDS; CCDS11118.1; -. [P04637-1] DR CCDS; CCDS45605.1; -. [P04637-3] DR CCDS; CCDS45606.1; -. [P04637-2] DR CCDS; CCDS73966.1; -. [P04637-7] DR CCDS; CCDS73967.1; -. [P04637-9] DR CCDS; CCDS73968.1; -. [P04637-8] DR CCDS; CCDS73969.1; -. [P04637-4] DR CCDS; CCDS73970.1; -. [P04637-6] DR CCDS; CCDS73971.1; -. [P04637-5] DR PIR; A25224; DNHU53. DR RefSeq; NP_000537.3; NM_000546.5. [P04637-1] DR RefSeq; NP_001119584.1; NM_001126112.3. [P04637-1] DR RefSeq; NP_001119585.1; NM_001126113.3. [P04637-3] DR RefSeq; NP_001119586.1; NM_001126114.3. [P04637-2] DR RefSeq; NP_001119587.1; NM_001126115.2. [P04637-7] DR RefSeq; NP_001119588.1; NM_001126116.2. [P04637-8] DR RefSeq; NP_001119589.1; NM_001126117.2. [P04637-9] DR RefSeq; NP_001119590.1; NM_001126118.2. [P04637-4] DR RefSeq; NP_001263624.1; NM_001276695.3. [P04637-6] DR RefSeq; NP_001263625.1; NM_001276696.3. [P04637-5] DR RefSeq; NP_001263626.1; NM_001276697.1. DR RefSeq; NP_001263627.1; NM_001276698.1. DR RefSeq; NP_001263628.1; NM_001276699.1. DR RefSeq; NP_001263689.1; NM_001276760.3. [P04637-4] DR RefSeq; NP_001263690.1; NM_001276761.3. [P04637-4] DR RefSeq; NP_001394191.1; NM_001407262.1. [P04637-1] DR RefSeq; NP_001394192.1; NM_001407263.1. [P04637-4] DR RefSeq; NP_001394193.1; NM_001407264.1. [P04637-1] DR RefSeq; NP_001394194.1; NM_001407265.1. [P04637-4] DR RefSeq; NP_001394195.1; NM_001407266.1. [P04637-1] DR RefSeq; NP_001394196.1; NM_001407267.1. [P04637-4] DR RefSeq; NP_001394197.1; NM_001407268.1. [P04637-2] DR RefSeq; NP_001394198.1; NM_001407269.1. [P04637-5] DR RefSeq; NP_001394199.1; NM_001407270.1. [P04637-2] DR RefSeq; NP_001394200.1; NM_001407271.1. [P04637-5] DR PDB; 1A1U; NMR; -; A/C=324-358. DR PDB; 1AIE; X-ray; 1.50 A; A=326-356. DR PDB; 1C26; X-ray; 1.70 A; A=325-356. DR PDB; 1DT7; NMR; -; X/Y=367-388. DR PDB; 1GZH; X-ray; 2.60 A; A/C=95-292. DR PDB; 1H26; X-ray; 2.24 A; E=376-386. DR PDB; 1HS5; NMR; -; A/B=324-357. DR PDB; 1JSP; NMR; -; A=367-386. DR PDB; 1KZY; X-ray; 2.50 A; A/B=95-289. DR PDB; 1MA3; X-ray; 2.00 A; B=372-389. DR PDB; 1OLG; NMR; -; A/B/C/D=319-360. DR PDB; 1OLH; NMR; -; A/B/C/D=319-360. DR PDB; 1PES; NMR; -; A/B/C/D=325-355. DR PDB; 1PET; NMR; -; A/B/C/D=325-355. DR PDB; 1SAE; NMR; -; A/B/C/D=319-360. DR PDB; 1SAF; NMR; -; A/B/C/D=319-360. DR PDB; 1SAK; NMR; -; A/B/C/D=319-360. DR PDB; 1SAL; NMR; -; A/B/C/D=319-360. DR PDB; 1TSR; X-ray; 2.20 A; A/B/C=94-312. DR PDB; 1TUP; X-ray; 2.20 A; A/B/C=94-312. DR PDB; 1UOL; X-ray; 1.90 A; A/B=94-312. DR PDB; 1XQH; X-ray; 1.75 A; B/F=369-377. DR PDB; 1YC5; X-ray; 1.40 A; B=372-389. DR PDB; 1YCQ; X-ray; 2.30 A; B=13-29. DR PDB; 1YCR; X-ray; 2.60 A; B=15-29. DR PDB; 1YCS; X-ray; 2.20 A; A=94-292. DR PDB; 2AC0; X-ray; 1.80 A; A/B/C/D=94-293. DR PDB; 2ADY; X-ray; 2.50 A; A/B=94-293. DR PDB; 2AHI; X-ray; 1.85 A; A/B/C/D=94-293. DR PDB; 2ATA; X-ray; 2.20 A; A/B/C/D=94-293. DR PDB; 2B3G; X-ray; 1.60 A; B=33-60. DR PDB; 2BIM; X-ray; 1.98 A; A/B=94-312. DR PDB; 2BIN; X-ray; 1.90 A; A=94-312. DR PDB; 2BIO; X-ray; 1.90 A; A=94-312. DR PDB; 2BIP; X-ray; 1.80 A; A=94-312. DR PDB; 2BIQ; X-ray; 1.80 A; A=94-312. DR PDB; 2F1X; X-ray; 2.30 A; A/B=359-368. DR PDB; 2FEJ; NMR; -; A=94-297. DR PDB; 2FOJ; X-ray; 1.60 A; B=361-367. DR PDB; 2FOO; X-ray; 2.20 A; B=358-363. DR PDB; 2GS0; NMR; -; B=20-73. DR PDB; 2H1L; X-ray; 3.16 A; M/N/O/P/Q/R/S/T/U/V/W/X=92-292. DR PDB; 2H2D; X-ray; 1.70 A; B=372-389. DR PDB; 2H2F; X-ray; 2.20 A; B=372-389. DR PDB; 2H4F; X-ray; 2.00 A; D=372-389. DR PDB; 2H4H; X-ray; 1.99 A; B=372-389. DR PDB; 2H4J; X-ray; 2.10 A; D=372-389. DR PDB; 2H59; X-ray; 1.90 A; D/E=372-389. DR PDB; 2J0Z; NMR; -; A/B/C/D=326-356. DR PDB; 2J10; NMR; -; A/B/C/D=326-356. DR PDB; 2J11; NMR; -; A/B/C/D=326-356. DR PDB; 2J1W; X-ray; 1.80 A; A/B=94-312. DR PDB; 2J1X; X-ray; 1.65 A; A/B=94-312. DR PDB; 2J1Y; X-ray; 1.69 A; A/B/C/D=94-293. DR PDB; 2J1Z; X-ray; 1.80 A; A/B=94-312. DR PDB; 2J20; X-ray; 1.80 A; A/B=94-312. DR PDB; 2J21; X-ray; 1.60 A; A/B=94-312. DR PDB; 2K8F; NMR; -; B=1-39. DR PDB; 2L14; NMR; -; B=13-61. DR PDB; 2LY4; NMR; -; B=1-93. DR PDB; 2MEJ; NMR; -; B=96-312. DR PDB; 2MWO; NMR; -; B=363-377. DR PDB; 2MWP; NMR; -; B=376-387. DR PDB; 2MWY; NMR; -; B=15-29. DR PDB; 2MZD; NMR; -; B=35-59. DR PDB; 2OCJ; X-ray; 2.05 A; A/B/C/D=94-312. DR PDB; 2PCX; X-ray; 1.54 A; A=94-292. DR PDB; 2RUK; NMR; -; A=41-62. DR PDB; 2VUK; X-ray; 1.50 A; A/B=94-312. DR PDB; 2WGX; X-ray; 1.75 A; A/B=94-312. DR PDB; 2X0U; X-ray; 1.60 A; A/B=94-312. DR PDB; 2X0V; X-ray; 1.80 A; A/B=94-312. DR PDB; 2X0W; X-ray; 2.10 A; A/B=94-312. DR PDB; 2XWR; X-ray; 1.68 A; A/B=89-293. DR PDB; 2YBG; X-ray; 1.90 A; A/B/C/D=94-293. DR PDB; 2YDR; X-ray; 2.75 A; P=144-154. DR PDB; 2Z5S; X-ray; 2.30 A; P/Q/R=15-29. DR PDB; 2Z5T; X-ray; 2.30 A; P/Q/R=15-29. DR PDB; 3D05; X-ray; 1.70 A; A=94-293. DR PDB; 3D06; X-ray; 1.20 A; A=94-293. DR PDB; 3D07; X-ray; 2.20 A; A/B=94-293. DR PDB; 3D08; X-ray; 1.40 A; A=94-293. DR PDB; 3D09; X-ray; 1.90 A; A=94-293. DR PDB; 3D0A; X-ray; 1.80 A; A/B/C/D=94-293. DR PDB; 3DAB; X-ray; 1.90 A; B/D/F/H=15-29. DR PDB; 3DAC; X-ray; 1.80 A; B/P=17-37. DR PDB; 3IGK; X-ray; 1.70 A; A=94-293. DR PDB; 3IGL; X-ray; 1.80 A; A=94-293. DR PDB; 3KMD; X-ray; 2.15 A; A/B/C/D=92-291. DR PDB; 3KZ8; X-ray; 1.91 A; A/B=94-293. DR PDB; 3LW1; X-ray; 1.28 A; P=385-393. DR PDB; 3OQ5; X-ray; 2.50 A; D/E=377-386. DR PDB; 3PDH; X-ray; 1.80 A; D=372-389. DR PDB; 3Q01; X-ray; 2.10 A; A/B=94-356. DR PDB; 3Q05; X-ray; 2.40 A; A/B/C/D=94-356. DR PDB; 3Q06; X-ray; 3.20 A; A/B/C/D=96-354. DR PDB; 3SAK; NMR; -; A/B/C/D=319-360. DR PDB; 3TG5; X-ray; 2.30 A; B=365-375. DR PDB; 3TS8; X-ray; 2.80 A; A/B/C/D=94-356. DR PDB; 3ZME; X-ray; 1.35 A; A/B=94-312. DR PDB; 4AGL; X-ray; 1.70 A; A/B=94-312. DR PDB; 4AGM; X-ray; 1.52 A; A/B=94-312. DR PDB; 4AGN; X-ray; 1.60 A; A/B=94-312. DR PDB; 4AGO; X-ray; 1.45 A; A/B=94-312. DR PDB; 4AGP; X-ray; 1.50 A; A/B=94-312. DR PDB; 4AGQ; X-ray; 1.42 A; A/B=94-312. DR PDB; 4BUZ; X-ray; 1.90 A; P=379-386. DR PDB; 4BV2; X-ray; 3.30 A; E/H=376-388. DR PDB; 4HFZ; X-ray; 2.69 A; B/D=15-29. DR PDB; 4HJE; X-ray; 1.91 A; A/B/C/D=92-291. DR PDB; 4IBQ; X-ray; 1.80 A; A/B/C/D=94-293. DR PDB; 4IBS; X-ray; 1.78 A; A/B/C/D=94-293. DR PDB; 4IBT; X-ray; 1.70 A; A/B/C/D=94-293. DR PDB; 4IBU; X-ray; 1.70 A; A/B/C/D=94-293. DR PDB; 4IBV; X-ray; 2.10 A; A=94-293. DR PDB; 4IBW; X-ray; 1.79 A; A=94-293. DR PDB; 4IBY; X-ray; 1.45 A; A/B=94-293. DR PDB; 4IBZ; X-ray; 1.92 A; A/B/C/D=94-293. DR PDB; 4IJT; X-ray; 1.78 A; A=94-293. DR PDB; 4KVP; X-ray; 1.50 A; A/B/C/D=94-312. DR PDB; 4LO9; X-ray; 2.50 A; A/B/C/D=94-312. DR PDB; 4LOE; X-ray; 1.85 A; A/B/C/D=94-312. DR PDB; 4LOF; X-ray; 2.00 A; A=94-312. DR PDB; 4MZI; X-ray; 1.25 A; A=94-292. DR PDB; 4MZR; X-ray; 2.90 A; A/B/C/D=94-358. DR PDB; 4QO1; X-ray; 1.92 A; B=92-312. DR PDB; 4RP6; X-ray; 1.70 A; Z=252-258. DR PDB; 4RP7; X-ray; 1.58 A; Z=253-258. DR PDB; 4X34; X-ray; 1.80 A; C/D=377-386. DR PDB; 4XR8; X-ray; 2.25 A; C/D=94-292. DR PDB; 4ZZJ; X-ray; 2.74 A; B=379-383. DR PDB; 5A7B; X-ray; 1.40 A; A/B=94-312. DR PDB; 5AB9; X-ray; 1.36 A; A/B=94-312. DR PDB; 5ABA; X-ray; 1.62 A; A/B=94-312. DR PDB; 5AOI; X-ray; 1.78 A; A/B=94-312. DR PDB; 5AOJ; X-ray; 1.47 A; A/B=94-312. DR PDB; 5AOK; X-ray; 1.35 A; A/B=94-312. DR PDB; 5AOL; X-ray; 1.50 A; A/B=94-312. DR PDB; 5AOM; X-ray; 1.74 A; A/B=94-312. DR PDB; 5BUA; X-ray; 1.81 A; A=94-293. DR PDB; 5ECG; X-ray; 3.00 A; A/B=95-312. DR PDB; 5G4M; X-ray; 1.38 A; A/B=94-312. DR PDB; 5G4N; X-ray; 1.35 A; A/B=94-312. DR PDB; 5G4O; X-ray; 1.48 A; A/B=94-312. DR PDB; 5HOU; NMR; -; A=1-61. DR PDB; 5HP0; NMR; -; A=37-61. DR PDB; 5HPD; NMR; -; A=2-61. DR PDB; 5LAP; X-ray; 1.42 A; A/B=94-312. DR PDB; 5LGY; X-ray; 2.92 A; A/B/C/D=94-291. DR PDB; 5MCT; X-ray; 1.45 A; A/B=94-293. DR PDB; 5MCU; X-ray; 1.70 A; A/B=94-293. DR PDB; 5MCV; X-ray; 1.60 A; A/B=94-293. DR PDB; 5MCW; X-ray; 1.90 A; A/B=94-293. DR PDB; 5MF7; X-ray; 1.59 A; A/B=94-293. DR PDB; 5MG7; X-ray; 1.45 A; A/B=94-293. DR PDB; 5MHC; X-ray; 1.20 A; P=382-393. DR PDB; 5MOC; X-ray; 1.80 A; P=382-393. DR PDB; 5O1A; X-ray; 1.44 A; A/B=94-312. DR PDB; 5O1B; X-ray; 1.43 A; A/B=94-312. DR PDB; 5O1C; X-ray; 1.32 A; A/B=94-312. DR PDB; 5O1D; X-ray; 1.36 A; A/B=94-312. DR PDB; 5O1E; X-ray; 1.30 A; A/B=94-312. DR PDB; 5O1F; X-ray; 1.38 A; A/B=94-312. DR PDB; 5O1G; X-ray; 1.35 A; A/B=94-312. DR PDB; 5O1H; X-ray; 1.32 A; A/B=94-312. DR PDB; 5O1I; X-ray; 1.40 A; A/B=94-312. DR PDB; 5OL0; X-ray; 1.99 A; C/D=372-389. DR PDB; 5UN8; X-ray; 2.13 A; E/F/G/H=144-154. DR PDB; 5XZC; EM; 10.70 A; B/C/D/E=92-356. DR PDB; 6FF9; X-ray; 2.00 A; A/B/C/D=97-289. DR PDB; 6FJ5; X-ray; 2.05 A; A/B/C/D=94-293. DR PDB; 6GGA; X-ray; 1.55 A; A/B=94-312. DR PDB; 6GGB; X-ray; 1.32 A; A/B=94-312. DR PDB; 6GGC; X-ray; 1.24 A; A/B=94-312. DR PDB; 6GGD; X-ray; 1.40 A; A/B=94-312. DR PDB; 6GGE; X-ray; 1.25 A; A/B=94-312. DR PDB; 6GGF; X-ray; 1.32 A; A/B=94-312. DR PDB; 6LHD; X-ray; 2.50 A; A/B=96-292. DR PDB; 6R5L; X-ray; 1.88 A; P=382-393. DR PDB; 6RJZ; X-ray; 1.58 A; P=382-393. DR PDB; 6RK8; X-ray; 1.60 A; P=382-393. DR PDB; 6RKI; X-ray; 1.88 A; P=382-393. DR PDB; 6RKK; X-ray; 1.88 A; P=382-393. DR PDB; 6RKM; X-ray; 1.88 A; P=382-393. DR PDB; 6RL3; X-ray; 1.30 A; P=382-393. DR PDB; 6RL4; X-ray; 1.60 A; P=382-393. DR PDB; 6RL6; X-ray; 1.60 A; P=382-393. DR PDB; 6RM5; X-ray; 1.88 A; P=382-393. DR PDB; 6RM7; X-ray; 1.60 A; P=382-393. DR PDB; 6RWH; X-ray; 1.68 A; P=382-393. DR PDB; 6RWI; X-ray; 1.65 A; P=382-393. DR PDB; 6RWS; X-ray; 1.53 A; P=382-393. DR PDB; 6RWU; X-ray; 1.46 A; P=382-393. DR PDB; 6RX2; X-ray; 1.82 A; P=382-393. DR PDB; 6RZ3; X-ray; 4.23 A; A=62-292. DR PDB; 6S39; X-ray; 1.88 A; P=382-393. DR PDB; 6S3C; X-ray; 2.00 A; P=382-393. DR PDB; 6S40; X-ray; 1.90 A; P=382-393. DR PDB; 6S9Q; X-ray; 1.69 A; P=382-393. DR PDB; 6SHZ; X-ray; 1.24 A; A/B=94-311. DR PDB; 6SI0; X-ray; 1.53 A; A/B=94-312. DR PDB; 6SI1; X-ray; 1.44 A; A/B=94-312. DR PDB; 6SI2; X-ray; 1.50 A; A/B=94-312. DR PDB; 6SI3; X-ray; 1.40 A; A/B=94-312. DR PDB; 6SI4; X-ray; 1.80 A; A/B=94-312. DR PDB; 6SIN; X-ray; 1.64 A; P=382-393. DR PDB; 6SIO; X-ray; 1.60 A; P=382-393. DR PDB; 6SIP; X-ray; 1.60 A; P=382-393. DR PDB; 6SIQ; X-ray; 1.60 A; P=382-393. DR PDB; 6SL6; X-ray; 1.67 A; A=89-311. DR PDB; 6SLV; X-ray; 1.90 A; P=382-393. DR PDB; 6T58; X-ray; 3.10 A; A/B=17-56. DR PDB; 6V4F; X-ray; 1.35 A; B=14-29. DR PDB; 6V4H; X-ray; 1.53 A; B/D=14-29. DR PDB; 6VQO; X-ray; 3.00 A; P/Q=168-176. DR PDB; 6VR1; X-ray; 2.37 A; P/Q=168-176. DR PDB; 6VR5; X-ray; 2.38 A; P/Q=168-176. DR PDB; 6VRM; X-ray; 2.61 A; P=168-176. DR PDB; 6VRN; X-ray; 2.46 A; P=168-176. DR PDB; 6W51; X-ray; 3.53 A; C/F/I/L=168-176. DR PDB; 6XRE; EM; 4.60 A; M=1-393. DR PDB; 6ZNC; X-ray; 1.64 A; A=94-293. DR PDB; 7B46; X-ray; 2.02 A; A/B/C/D=94-293. DR PDB; 7B47; X-ray; 1.80 A; A/B/C/D=94-293. DR PDB; 7B48; X-ray; 2.05 A; A/B/C/D=94-293. DR PDB; 7B49; X-ray; 1.42 A; A/B=94-293. DR PDB; 7B4A; X-ray; 1.90 A; A/B=94-293. DR PDB; 7B4B; X-ray; 1.76 A; A/B/C/D=94-293. DR PDB; 7B4C; X-ray; 1.71 A; A/B/C/D=94-293. DR PDB; 7B4D; X-ray; 1.85 A; A=94-293. DR PDB; 7B4E; X-ray; 1.58 A; A=94-293. DR PDB; 7B4F; X-ray; 1.78 A; A=94-293. DR PDB; 7B4G; X-ray; 1.86 A; A=94-293. DR PDB; 7B4H; X-ray; 1.39 A; A=94-293. DR PDB; 7B4N; X-ray; 1.32 A; A=94-293. DR PDB; 7BWN; X-ray; 2.40 A; B/D/G/I/K/L/N/P=326-356. DR PDB; 7DHY; X-ray; 2.15 A; A/B/C/D=94-293. DR PDB; 7DHZ; X-ray; 1.74 A; A/B=94-293. DR PDB; 7DVD; X-ray; 2.59 A; A/B/C/D=92-290. DR PDB; 7EAX; X-ray; 2.55 A; A/B/C/D=96-289. DR PDB; 7EDS; X-ray; 1.77 A; A=94-293. DR PDB; 7EEU; X-ray; 2.90 A; A/B/C/D/E/F/G/H=94-293. DR PDB; 7EL4; X-ray; 2.11 A; A=23-29. DR PDB; 7NMI; X-ray; 2.10 A; A=17-56. DR PDB; 7RM4; X-ray; 3.33 A; C/H/M/R=168-176. DR PDB; 7V97; X-ray; 2.02 A; A/B/C/D=94-293. DR PDB; 7XZX; EM; 4.53 A; K/L/M/N=94-293. DR PDB; 7XZZ; EM; 4.07 A; K/L/M/N=1-393. DR PDB; 7YGI; X-ray; 2.10 A; A/B=92-289. DR PDB; 8A31; X-ray; 1.46 A; A/B=94-312. DR PDB; 8A32; X-ray; 1.47 A; A/B=94-312. DR PDB; 8A92; X-ray; 1.37 A; A/B=94-312. DR PDB; 8CG7; X-ray; 1.53 A; A/B=94-312. DR PDB; 8DC4; X-ray; 2.40 A; A/B/C/D=94-312. DR PDB; 8DC6; X-ray; 1.60 A; A/B/C/D=94-312. DR PDB; 8DC7; X-ray; 1.99 A; A=94-312. DR PDB; 8DC8; X-ray; 1.72 A; A=94-312. DR PDB; 8E7A; X-ray; 1.30 A; A=93-312. DR PDB; 8E7B; X-ray; 2.50 A; A/B=93-312. DR PDB; 8GCR; EM; 3.38 A; B=94-312. DR PDB; 8HLL; X-ray; 2.62 A; A=95-290. DR PDB; 8HLM; X-ray; 2.52 A; A=95-290. DR PDB; 8HLN; X-ray; 2.35 A; A=95-290. DR PDB; 8J8N; EM; 9.02 A; A/B/C/D=92-292. DR PDB; 8OXM; EM; 3.30 A; E/F=11-22. DR PDB; 8OXO; EM; 3.00 A; E/F=11-22. DR PDB; 8QWK; X-ray; 1.69 A; A=94-312. DR PDB; 8QWL; X-ray; 1.65 A; A=94-312. DR PDB; 8QWM; X-ray; 1.54 A; A/B=94-312. DR PDB; 8QWN; X-ray; 1.44 A; A=94-312. DR PDB; 8QWO; X-ray; 1.38 A; A/B=94-312. DR PDB; 8QWP; X-ray; 2.10 A; A/B=94-312. DR PDB; 8R1F; EM; 3.67 A; C=1-393. DR PDB; 8R1G; EM; 3.99 A; C/F=1-393. DR PDB; 8RBA; X-ray; 1.57 A; A/B=94-312. DR PDB; 8RBB; X-ray; 1.69 A; A/B=94-312. DR PDB; 8RBC; X-ray; 2.06 A; A/B=94-312. DR PDB; 8RCI; X-ray; 1.50 A; A=94-294. DR PDB; 8UQR; X-ray; 1.22 A; A/B/C/D=326-356. DR PDB; 8WD2; X-ray; 1.85 A; A/B=94-312. DR PDB; 8XP5; X-ray; 2.55 A; A/B=95-292. DR PDB; 9BR3; X-ray; 1.90 A; A/B=94-312. DR PDB; 9BR4; X-ray; 1.70 A; A/B=94-312. DR PDB; 9C5S; X-ray; 1.01 A; A/B/C/D=17-30. DR PDB; 9CHT; EM; 3.54 A; B=1-312. DR PDB; 9FZB; X-ray; 1.44 A; A=94-294. DR PDBsum; 1A1U; -. DR PDBsum; 1AIE; -. DR PDBsum; 1C26; -. DR PDBsum; 1DT7; -. DR PDBsum; 1GZH; -. DR PDBsum; 1H26; -. DR PDBsum; 1HS5; -. DR PDBsum; 1JSP; -. DR PDBsum; 1KZY; -. DR PDBsum; 1MA3; -. DR PDBsum; 1OLG; -. DR PDBsum; 1OLH; -. DR PDBsum; 1PES; -. DR PDBsum; 1PET; -. DR PDBsum; 1SAE; -. DR PDBsum; 1SAF; -. DR PDBsum; 1SAK; -. DR PDBsum; 1SAL; -. DR PDBsum; 1TSR; -. DR PDBsum; 1TUP; -. DR PDBsum; 1UOL; -. DR PDBsum; 1XQH; -. DR PDBsum; 1YC5; -. DR PDBsum; 1YCQ; -. DR PDBsum; 1YCR; -. DR PDBsum; 1YCS; -. DR PDBsum; 2AC0; -. DR PDBsum; 2ADY; -. DR PDBsum; 2AHI; -. DR PDBsum; 2ATA; -. DR PDBsum; 2B3G; -. DR PDBsum; 2BIM; -. DR PDBsum; 2BIN; -. DR PDBsum; 2BIO; -. DR PDBsum; 2BIP; -. DR PDBsum; 2BIQ; -. DR PDBsum; 2F1X; -. DR PDBsum; 2FEJ; -. DR PDBsum; 2FOJ; -. DR PDBsum; 2FOO; -. DR PDBsum; 2GS0; -. DR PDBsum; 2H1L; -. DR PDBsum; 2H2D; -. DR PDBsum; 2H2F; -. DR PDBsum; 2H4F; -. DR PDBsum; 2H4H; -. DR PDBsum; 2H4J; -. DR PDBsum; 2H59; -. DR PDBsum; 2J0Z; -. DR PDBsum; 2J10; -. DR PDBsum; 2J11; -. DR PDBsum; 2J1W; -. DR PDBsum; 2J1X; -. DR PDBsum; 2J1Y; -. DR PDBsum; 2J1Z; -. DR PDBsum; 2J20; -. DR PDBsum; 2J21; -. DR PDBsum; 2K8F; -. DR PDBsum; 2L14; -. DR PDBsum; 2LY4; -. DR PDBsum; 2MEJ; -. DR PDBsum; 2MWO; -. DR PDBsum; 2MWP; -. DR PDBsum; 2MWY; -. DR PDBsum; 2MZD; -. DR PDBsum; 2OCJ; -. DR PDBsum; 2PCX; -. DR PDBsum; 2RUK; -. DR PDBsum; 2VUK; -. DR PDBsum; 2WGX; -. DR PDBsum; 2X0U; -. DR PDBsum; 2X0V; -. DR PDBsum; 2X0W; -. DR PDBsum; 2XWR; -. DR PDBsum; 2YBG; -. DR PDBsum; 2YDR; -. DR PDBsum; 2Z5S; -. DR PDBsum; 2Z5T; -. DR PDBsum; 3D05; -. DR PDBsum; 3D06; -. DR PDBsum; 3D07; -. DR PDBsum; 3D08; -. DR PDBsum; 3D09; -. DR PDBsum; 3D0A; -. DR PDBsum; 3DAB; -. DR PDBsum; 3DAC; -. DR PDBsum; 3IGK; -. DR PDBsum; 3IGL; -. DR PDBsum; 3KMD; -. DR PDBsum; 3KZ8; -. DR PDBsum; 3LW1; -. DR PDBsum; 3OQ5; -. DR PDBsum; 3PDH; -. DR PDBsum; 3Q01; -. DR PDBsum; 3Q05; -. DR PDBsum; 3Q06; -. DR PDBsum; 3SAK; -. DR PDBsum; 3TG5; -. DR PDBsum; 3TS8; -. DR PDBsum; 3ZME; -. DR PDBsum; 4AGL; -. DR PDBsum; 4AGM; -. DR PDBsum; 4AGN; -. DR PDBsum; 4AGO; -. DR PDBsum; 4AGP; -. DR PDBsum; 4AGQ; -. DR PDBsum; 4BUZ; -. DR PDBsum; 4BV2; -. DR PDBsum; 4HFZ; -. DR PDBsum; 4HJE; -. DR PDBsum; 4IBQ; -. DR PDBsum; 4IBS; -. DR PDBsum; 4IBT; -. DR PDBsum; 4IBU; -. DR PDBsum; 4IBV; -. DR PDBsum; 4IBW; -. DR PDBsum; 4IBY; -. DR PDBsum; 4IBZ; -. DR PDBsum; 4IJT; -. DR PDBsum; 4KVP; -. DR PDBsum; 4LO9; -. DR PDBsum; 4LOE; -. DR PDBsum; 4LOF; -. DR PDBsum; 4MZI; -. DR PDBsum; 4MZR; -. DR PDBsum; 4QO1; -. DR PDBsum; 4RP6; -. DR PDBsum; 4RP7; -. DR PDBsum; 4X34; -. DR PDBsum; 4XR8; -. DR PDBsum; 4ZZJ; -. DR PDBsum; 5A7B; -. DR PDBsum; 5AB9; -. DR PDBsum; 5ABA; -. DR PDBsum; 5AOI; -. DR PDBsum; 5AOJ; -. DR PDBsum; 5AOK; -. DR PDBsum; 5AOL; -. DR PDBsum; 5AOM; -. DR PDBsum; 5BUA; -. DR PDBsum; 5ECG; -. DR PDBsum; 5G4M; -. DR PDBsum; 5G4N; -. DR PDBsum; 5G4O; -. DR PDBsum; 5HOU; -. DR PDBsum; 5HP0; -. DR PDBsum; 5HPD; -. DR PDBsum; 5LAP; -. DR PDBsum; 5LGY; -. DR PDBsum; 5MCT; -. DR PDBsum; 5MCU; -. DR PDBsum; 5MCV; -. DR PDBsum; 5MCW; -. DR PDBsum; 5MF7; -. DR PDBsum; 5MG7; -. DR PDBsum; 5MHC; -. DR PDBsum; 5MOC; -. DR PDBsum; 5O1A; -. DR PDBsum; 5O1B; -. DR PDBsum; 5O1C; -. DR PDBsum; 5O1D; -. DR PDBsum; 5O1E; -. DR PDBsum; 5O1F; -. DR PDBsum; 5O1G; -. DR PDBsum; 5O1H; -. DR PDBsum; 5O1I; -. DR PDBsum; 5OL0; -. DR PDBsum; 5UN8; -. DR PDBsum; 5XZC; -. DR PDBsum; 6FF9; -. DR PDBsum; 6FJ5; -. DR PDBsum; 6GGA; -. DR PDBsum; 6GGB; -. DR PDBsum; 6GGC; -. DR PDBsum; 6GGD; -. DR PDBsum; 6GGE; -. DR PDBsum; 6GGF; -. DR PDBsum; 6LHD; -. DR PDBsum; 6R5L; -. DR PDBsum; 6RJZ; -. DR PDBsum; 6RK8; -. DR PDBsum; 6RKI; -. DR PDBsum; 6RKK; -. DR PDBsum; 6RKM; -. DR PDBsum; 6RL3; -. DR PDBsum; 6RL4; -. DR PDBsum; 6RL6; -. DR PDBsum; 6RM5; -. DR PDBsum; 6RM7; -. DR PDBsum; 6RWH; -. DR PDBsum; 6RWI; -. DR PDBsum; 6RWS; -. DR PDBsum; 6RWU; -. DR PDBsum; 6RX2; -. DR PDBsum; 6RZ3; -. DR PDBsum; 6S39; -. DR PDBsum; 6S3C; -. DR PDBsum; 6S40; -. DR PDBsum; 6S9Q; -. DR PDBsum; 6SHZ; -. DR PDBsum; 6SI0; -. DR PDBsum; 6SI1; -. DR PDBsum; 6SI2; -. DR PDBsum; 6SI3; -. DR PDBsum; 6SI4; -. DR PDBsum; 6SIN; -. DR PDBsum; 6SIO; -. DR PDBsum; 6SIP; -. DR PDBsum; 6SIQ; -. DR PDBsum; 6SL6; -. DR PDBsum; 6SLV; -. DR PDBsum; 6T58; -. DR PDBsum; 6V4F; -. DR PDBsum; 6V4H; -. DR PDBsum; 6VQO; -. DR PDBsum; 6VR1; -. DR PDBsum; 6VR5; -. DR PDBsum; 6VRM; -. DR PDBsum; 6VRN; -. DR PDBsum; 6W51; -. DR PDBsum; 6XRE; -. DR PDBsum; 6ZNC; -. DR PDBsum; 7B46; -. DR PDBsum; 7B47; -. DR PDBsum; 7B48; -. DR PDBsum; 7B49; -. DR PDBsum; 7B4A; -. DR PDBsum; 7B4B; -. DR PDBsum; 7B4C; -. DR PDBsum; 7B4D; -. DR PDBsum; 7B4E; -. DR PDBsum; 7B4F; -. DR PDBsum; 7B4G; -. DR PDBsum; 7B4H; -. DR PDBsum; 7B4N; -. DR PDBsum; 7BWN; -. DR PDBsum; 7DHY; -. DR PDBsum; 7DHZ; -. DR PDBsum; 7DVD; -. DR PDBsum; 7EAX; -. DR PDBsum; 7EDS; -. DR PDBsum; 7EEU; -. DR PDBsum; 7EL4; -. DR PDBsum; 7NMI; -. DR PDBsum; 7RM4; -. DR PDBsum; 7V97; -. DR PDBsum; 7XZX; -. DR PDBsum; 7XZZ; -. DR PDBsum; 7YGI; -. DR PDBsum; 8A31; -. DR PDBsum; 8A32; -. DR PDBsum; 8A92; -. DR PDBsum; 8CG7; -. DR PDBsum; 8DC4; -. DR PDBsum; 8DC6; -. DR PDBsum; 8DC7; -. DR PDBsum; 8DC8; -. DR PDBsum; 8E7A; -. DR PDBsum; 8E7B; -. DR PDBsum; 8GCR; -. DR PDBsum; 8HLL; -. DR PDBsum; 8HLM; -. DR PDBsum; 8HLN; -. DR PDBsum; 8J8N; -. DR PDBsum; 8OXM; -. DR PDBsum; 8OXO; -. DR PDBsum; 8QWK; -. DR PDBsum; 8QWL; -. DR PDBsum; 8QWM; -. DR PDBsum; 8QWN; -. DR PDBsum; 8QWO; -. DR PDBsum; 8QWP; -. DR PDBsum; 8R1F; -. DR PDBsum; 8R1G; -. DR PDBsum; 8RBA; -. DR PDBsum; 8RBB; -. DR PDBsum; 8RBC; -. DR PDBsum; 8RCI; -. DR PDBsum; 8UQR; -. DR PDBsum; 8WD2; -. DR PDBsum; 8XP5; -. DR PDBsum; 9BR3; -. DR PDBsum; 9BR4; -. DR PDBsum; 9C5S; -. DR PDBsum; 9CHT; -. DR PDBsum; 9FZB; -. DR AlphaFoldDB; P04637; -. DR BMRB; P04637; -. DR EMDB; EMD-0378; -. DR EMDB; EMD-17265; -. DR EMDB; EMD-17266; -. DR EMDB; EMD-18809; -. DR EMDB; EMD-18810; -. DR EMDB; EMD-22294; -. DR EMDB; EMD-22827; -. DR EMDB; EMD-29941; -. DR EMDB; EMD-33533; -. DR EMDB; EMD-33535; -. DR EMDB; EMD-36075; -. DR EMDB; EMD-45601; -. DR EMDB; EMD-53478; -. DR EMDB; EMD-53532; -. DR EMDB; EMD-53536; -. DR EMDB; EMD-53537; -. DR EMDB; EMD-6791; -. DR EMDB; EMD-8926; -. DR EMDB; EMD-8927; -. DR SMR; P04637; -. DR BioGRID; 113010; 2577. DR ComplexPortal; CPX-6093; p53-MDM2-MDM4 transcriptional regulation complex. DR ComplexPortal; CPX-663; p53-MDM4 transcriptional regulation complex. DR ComplexPortal; CPX-759; p53-MDM2 transcriptional regulation complex. DR CORUM; P04637; -. DR DIP; DIP-368N; -. DR ELM; P04637; -. DR FunCoup; P04637; 3248. DR IntAct; P04637; 850. DR MINT; P04637; -. DR STRING; 9606.ENSP00000269305; -. DR BindingDB; P04637; -. DR ChEMBL; CHEMBL4096; -. DR DrugBank; DB08363; 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine. DR DrugBank; DB13010; 4-isothioureidobutyronitrile. DR DrugBank; DB00945; Acetylsalicylic acid. DR DrugBank; DB17549; Alrizomadlin. DR DrugBank; DB05404; AZD 3355. DR DrugBank; DB17507; COTI-2. DR DrugBank; DB11684; Eprenetapopt. DR DrugBank; DB17039; Nutlin-3. DR DrugBank; DB12541; SAR-405838. DR DrugBank; DB16331; Siremadlin. DR DrugBank; DB16447; Thymoquinone. DR DrugBank; DB03347; Triethyl phosphate. DR DrugBank; DB01593; Zinc. DR DrugBank; DB14487; Zinc acetate. DR DrugBank; DB14533; Zinc chloride. DR DrugBank; DB14548; Zinc sulfate, unspecified form. DR MoonDB; P04637; Predicted. DR TCDB; 1.C.110.1.1; the pore-forming pnc-27 peptide of 32 aas from the p53 tumor suppressor protein (pnc-27) family. DR GlyCosmos; P04637; 1 site, 1 glycan. DR GlyGen; P04637; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; P04637; -. DR MetOSite; P04637; -. DR PhosphoSitePlus; P04637; -. DR SwissPalm; P04637; -. DR BioMuta; TP53; -. DR DMDM; 269849759; -. DR CPTAC; CPTAC-5895; -. DR CPTAC; CPTAC-5896; -. DR CPTAC; CPTAC-951; -. DR jPOST; P04637; -. DR MassIVE; P04637; -. DR PaxDb; 9606-ENSP00000269305; -. DR PeptideAtlas; P04637; -. DR ProteomicsDB; 51728; -. [P04637-1] DR ProteomicsDB; 51729; -. [P04637-2] DR ProteomicsDB; 51730; -. [P04637-3] DR ProteomicsDB; 51731; -. [P04637-4] DR ProteomicsDB; 51732; -. [P04637-5] DR ProteomicsDB; 51733; -. [P04637-6] DR ProteomicsDB; 51734; -. [P04637-7] DR ProteomicsDB; 51735; -. [P04637-8] DR ProteomicsDB; 51736; -. [P04637-9] DR Pumba; P04637; -. DR ABCD; P04637; 67 sequenced antibodies. DR Antibodypedia; 3525; 9660 antibodies from 66 providers. DR CPTC; P04637; 2 antibodies. DR DNASU; 7157; -. DR Ensembl; ENST00000269305.9; ENSP00000269305.4; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000420246.6; ENSP00000391127.2; ENSG00000141510.20. [P04637-2] DR Ensembl; ENST00000445888.6; ENSP00000391478.2; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000455263.6; ENSP00000398846.2; ENSG00000141510.20. [P04637-3] DR Ensembl; ENST00000503591.2; ENSP00000426252.2; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000504290.5; ENSP00000484409.1; ENSG00000141510.20. [P04637-9] DR Ensembl; ENST00000504937.5; ENSP00000481179.1; ENSG00000141510.20. [P04637-7] DR Ensembl; ENST00000508793.6; ENSP00000424104.2; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000509690.6; ENSP00000425104.2; ENSG00000141510.20. [P04637-7] DR Ensembl; ENST00000510385.5; ENSP00000478499.1; ENSG00000141510.20. [P04637-8] DR Ensembl; ENST00000610292.4; ENSP00000478219.1; ENSG00000141510.20. [P04637-4] DR Ensembl; ENST00000610538.4; ENSP00000480868.1; ENSG00000141510.20. [P04637-6] DR Ensembl; ENST00000619485.4; ENSP00000482537.1; ENSG00000141510.20. [P04637-4] DR Ensembl; ENST00000620739.4; ENSP00000481638.1; ENSG00000141510.20. [P04637-4] DR Ensembl; ENST00000622645.4; ENSP00000482222.1; ENSG00000141510.20. [P04637-5] DR Ensembl; ENST00000714357.1; ENSP00000519624.1; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000714359.1; ENSP00000519626.1; ENSG00000141510.20. [P04637-1] DR GeneID; 7157; -. DR KEGG; hsa:7157; -. DR MANE-Select; ENST00000269305.9; ENSP00000269305.4; NM_000546.6; NP_000537.3. DR UCSC; uc002gij.4; human. [P04637-1] DR AGR; HGNC:11998; -. DR CIViC; 7157; 387 evidence items across 280 molecular profiles. DR ClinPGx; PA36679; -. DR CTD; 7157; -. DR DisGeNET; 7157; -. DR GeneCards; TP53; -. DR GeneReviews; TP53; -. DR HGNC; HGNC:11998; TP53. DR HPA; ENSG00000141510; Low tissue specificity. DR MalaCards; TP53; -. DR MIM; 133239; phenotype. DR MIM; 151623; phenotype. DR MIM; 191170; gene+phenotype. DR MIM; 202300; phenotype. DR MIM; 211980; phenotype. DR MIM; 260500; phenotype. DR MIM; 275355; phenotype. DR MIM; 614740; phenotype. DR MIM; 618165; phenotype. DR OpenTargets; ENSG00000141510; -. DR Orphanet; 1501; Adrenocortical carcinoma. DR Orphanet; 210159; Adult hepatocellular carcinoma. DR Orphanet; 99756; Alveolar rhabdomyosarcoma. DR Orphanet; 67038; B-cell chronic lymphocytic leukemia. DR Orphanet; 585909; B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2). DR Orphanet; 667662; Breast implant-associated anaplastic large cell lymphoma. DR Orphanet; 251899; Choroid plexus carcinoma. DR Orphanet; 96253; Cushing disease. DR Orphanet; 99757; Embryonal rhabdomyosarcoma. DR Orphanet; 3318; Essential thrombocythemia. DR Orphanet; 1333; Familial pancreatic carcinoma. DR Orphanet; 251579; Giant cell glioblastoma. DR Orphanet; 251576; Gliosarcoma. DR Orphanet; 145; Hereditary breast and/or ovarian cancer syndrome. DR Orphanet; 524; Li-Fraumeni syndrome. DR Orphanet; 52688; Myelodysplastic syndrome. DR Orphanet; 668; Osteosarcoma. DR Orphanet; 2807; Papilloma of choroid plexus. DR Orphanet; 293199; Pleomorphic rhabdomyosarcoma. DR Orphanet; 70573; Small cell lung cancer. DR VEuPathDB; HostDB:ENSG00000141510; -. DR eggNOG; ENOG502QVY3; Eukaryota. DR GeneTree; ENSGT00950000183153; -. DR InParanoid; P04637; -. DR OMA; HKKGEPC; -. DR OrthoDB; 5915660at2759; -. DR PAN-GO; P04637; 3 GO annotations based on evolutionary models. DR PhylomeDB; P04637; -. DR PathwayCommons; P04637; -. DR Reactome; R-HSA-111448; Activation of NOXA and translocation to mitochondria. DR Reactome; R-HSA-139915; Activation of PUMA and translocation to mitochondria. DR Reactome; R-HSA-1912408; Pre-NOTCH Transcription and Translation. DR Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence. DR Reactome; R-HSA-2559584; Formation of Senescence-Associated Heterochromatin Foci (SAHF). DR Reactome; R-HSA-2559585; Oncogene Induced Senescence. DR Reactome; R-HSA-2559586; DNA Damage/Telomere Stress Induced Senescence. DR Reactome; R-HSA-3232118; SUMOylation of transcription factors. DR Reactome; R-HSA-349425; Autodegradation of the E3 ubiquitin ligase COP1. DR Reactome; R-HSA-390471; Association of TriC/CCT with target proteins during biosynthesis. DR Reactome; R-HSA-5620971; Pyroptosis. DR Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes. DR Reactome; R-HSA-5689880; Ub-specific processing proteases. DR Reactome; R-HSA-5689896; Ovarian tumor domain proteases. DR Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks. DR Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling. DR Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes. DR Reactome; R-HSA-6803204; TP53 Regulates Transcription of Genes Involved in Cytochrome C Release. DR Reactome; R-HSA-6803205; TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain. DR Reactome; R-HSA-6803207; TP53 Regulates Transcription of Caspase Activators and Caspases. DR Reactome; R-HSA-6803211; TP53 Regulates Transcription of Death Receptors and Ligands. DR Reactome; R-HSA-6804114; TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest. DR Reactome; R-HSA-6804115; TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain. DR Reactome; R-HSA-6804116; TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest. DR Reactome; R-HSA-6804754; Regulation of TP53 Expression. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-6804757; Regulation of TP53 Degradation. DR Reactome; R-HSA-6804758; Regulation of TP53 Activity through Acetylation. DR Reactome; R-HSA-6804759; Regulation of TP53 Activity through Association with Co-factors. DR Reactome; R-HSA-6804760; Regulation of TP53 Activity through Methylation. DR Reactome; R-HSA-6811555; PI5P Regulates TP53 Acetylation. DR Reactome; R-HSA-69473; G2/M DNA damage checkpoint. DR Reactome; R-HSA-69481; G2/M Checkpoints. DR Reactome; R-HSA-69541; Stabilization of p53. DR Reactome; R-HSA-69895; Transcriptional activation of cell cycle inhibitor p21. DR Reactome; R-HSA-8852276; The role of GTSE1 in G2/M progression after G2 checkpoint. DR Reactome; R-HSA-8853884; Transcriptional Regulation by VENTX. DR Reactome; R-HSA-8941855; RUNX3 regulates CDKN1A transcription. DR Reactome; R-HSA-8943724; Regulation of PTEN gene transcription. DR Reactome; R-HSA-9723905; Loss of function of TP53 in cancer due to loss of tetramerization ability. DR Reactome; R-HSA-9725370; Signaling by ALK fusions and activated point mutants. DR Reactome; R-HSA-9758274; Regulation of NF-kappa B signaling. DR Reactome; R-HSA-9819196; Zygotic genome activation (ZGA). DR Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production. DR Reactome; R-HSA-9833482; PKR-mediated signaling. DR SABIO-RK; P04637; -. DR SignaLink; P04637; -. DR SIGNOR; P04637; -. DR Agora; ENSG00000141510; -. DR BioGRID-ORCS; 7157; 66 hits in 1218 CRISPR screens. DR CD-CODE; 1A18FFC4; Paraspeckle. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; A1A97FAB; Synthetic Condensate 000191. DR CD-CODE; B5B9A610; PML body. DR CD-CODE; E11B6BAB; Synthetic Condensate 000195. DR ChiTaRS; TP53; human. DR EvolutionaryTrace; P04637; -. DR GeneWiki; P53; -. DR GenomeRNAi; 7157; -. DR Pharos; P04637; Tchem. DR PRO; PR:P04637; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; P04637; protein. DR Bgee; ENSG00000141510; Expressed in ventricular zone and 144 other cell types or tissues. DR ExpressionAtlas; P04637; baseline and differential. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0000785; C:chromatin; IDA:BHF-UCL. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell. DR GO; GO:0043073; C:germ cell nucleus; IEA:Ensembl. DR GO; GO:0005759; C:mitochondrial matrix; IEA:UniProtKB-SubCell. DR GO; GO:0005739; C:mitochondrion; IDA:UniProtKB. DR GO; GO:0016363; C:nuclear matrix; IDA:UniProtKB. DR GO; GO:0005730; C:nucleolus; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0016605; C:PML body; IDA:UniProtKB. DR GO; GO:0032991; C:protein-containing complex; IDA:CAFA. DR GO; GO:0005657; C:replication fork; IEA:Ensembl. DR GO; GO:0035861; C:site of double-strand break; IEA:Ensembl. DR GO; GO:0005667; C:transcription regulator complex; IGI:ARUK-UCL. DR GO; GO:0017053; C:transcription repressor complex; IPI:ComplexPortal. DR GO; GO:0071889; F:14-3-3 protein binding; EXP:DisProt. DR GO; GO:0036310; F:ATP-dependent DNA/DNA annealing activity; IDA:UniProtKB. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0000987; F:cis-regulatory region sequence-specific DNA binding; IDA:ARUK-UCL. DR GO; GO:0005507; F:copper ion binding; IDA:UniProtKB. DR GO; GO:0001046; F:core promoter sequence-specific DNA binding; IDA:CAFA. DR GO; GO:0097718; F:disordered domain specific binding; IPI:CAFA. DR GO; GO:0003677; F:DNA binding; IDA:UniProtKB. DR GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:GO_Central. DR GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB. DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IDA:UniProtKB. DR GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IDA:ARUK-UCL. DR GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL. DR GO; GO:0140296; F:general transcription initiation factor binding; IPI:BHF-UCL. DR GO; GO:0042826; F:histone deacetylase binding; IPI:CAFA. DR GO; GO:0035033; F:histone deacetylase regulator activity; IEA:Ensembl. DR GO; GO:0042802; F:identical protein binding; IPI:UniProtKB. DR GO; GO:0097371; F:MDM2/MDM4 family protein binding; IEA:Ensembl. DR GO; GO:0140693; F:molecular condensate scaffold activity; IDA:UniProtKB. DR GO; GO:0140677; F:molecular function activator activity; IPI:DisProt. DR GO; GO:0003730; F:mRNA 3'-UTR binding; IDA:CAFA. DR GO; GO:0002039; F:p53 binding; IPI:CAFA. DR GO; GO:1990841; F:promoter-specific chromatin binding; IDA:UniProtKB. DR GO; GO:0002020; F:protease binding; IPI:UniProtKB. DR GO; GO:0046982; F:protein heterodimerization activity; IPI:UniProtKB. DR GO; GO:0051721; F:protein phosphatase 2A binding; IPI:UniProtKB. DR GO; GO:0051087; F:protein-folding chaperone binding; IPI:UniProtKB. DR GO; GO:0030971; F:receptor tyrosine kinase binding; IPI:BHF-UCL. DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:ARUK-UCL. DR GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:UniProtKB. DR GO; GO:0001094; F:TFIID-class transcription factor complex binding; IPI:ParkinsonsUK-UCL. DR GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:BHF-UCL. DR GO; GO:0001223; F:transcription coactivator binding; IPI:BHF-UCL. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; TAS:UniProtKB. DR GO; GO:0006914; P:autophagy; IMP:CAFA. DR GO; GO:0002326; P:B cell lineage commitment; IEA:Ensembl. DR GO; GO:0048539; P:bone marrow development; IMP:UniProtKB. DR GO; GO:0010659; P:cardiac muscle cell apoptotic process; IEA:Ensembl. DR GO; GO:0060411; P:cardiac septum morphogenesis; IEA:Ensembl. DR GO; GO:0072717; P:cellular response to actinomycin D; IDA:CAFA. DR GO; GO:0071480; P:cellular response to gamma radiation; IDA:CAFA. DR GO; GO:0042149; P:cellular response to glucose starvation; IDA:UniProtKB. DR GO; GO:0071456; P:cellular response to hypoxia; IEP:UniProtKB. DR GO; GO:0071479; P:cellular response to ionizing radiation; IMP:BHF-UCL. DR GO; GO:0034644; P:cellular response to UV; IDA:CAFA. DR GO; GO:0071494; P:cellular response to UV-C; IEA:Ensembl. DR GO; GO:0071466; P:cellular response to xenobiotic stimulus; IEP:UniProtKB. DR GO; GO:0090398; P:cellular senescence; IMP:GO_Central. DR GO; GO:0021549; P:cerebellum development; IEA:Ensembl. DR GO; GO:0051276; P:chromosome organization; IEA:Ensembl. DR GO; GO:0048512; P:circadian behavior; ISS:UniProtKB. DR GO; GO:0008340; P:determination of adult lifespan; ISS:BHF-UCL. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; IDA:BHF-UCL. DR GO; GO:0006302; P:double-strand break repair; IEA:Ensembl. DR GO; GO:0048568; P:embryonic organ development; IEA:Ensembl. DR GO; GO:0043153; P:entrainment of circadian clock by photoperiod; ISS:UniProtKB. DR GO; GO:0006983; P:ER overload response; IDA:MGI. DR GO; GO:0048144; P:fibroblast proliferation; IEA:Ensembl. DR GO; GO:0007369; P:gastrulation; IEA:Ensembl. DR GO; GO:0014009; P:glial cell proliferation; IEA:Ensembl. DR GO; GO:0019661; P:glucose catabolic process to lactate via pyruvate; IEA:Ensembl. DR GO; GO:0002244; P:hematopoietic progenitor cell differentiation; IMP:UniProtKB. DR GO; GO:0060218; P:hematopoietic stem cell differentiation; IMP:UniProtKB. DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl. DR GO; GO:0008104; P:intracellular protein localization; IDA:UniProtKB. DR GO; GO:0097193; P:intrinsic apoptotic signaling pathway; TAS:HGNC-UCL. DR GO; GO:0072332; P:intrinsic apoptotic signaling pathway by p53 class mediator; IMP:UniProtKB. DR GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IDA:UniProtKB. DR GO; GO:0070059; P:intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress; IEA:Ensembl. DR GO; GO:1990144; P:intrinsic apoptotic signaling pathway in response to hypoxia; IEA:Ensembl. DR GO; GO:0043504; P:mitochondrial DNA repair; IEA:Ensembl. DR GO; GO:0000423; P:mitophagy; IEA:Ensembl. DR GO; GO:0031571; P:mitotic G1 DNA damage checkpoint signaling; IMP:BHF-UCL. DR GO; GO:0009299; P:mRNA transcription; IMP:UniProtKB. DR GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl. DR GO; GO:0070266; P:necroptotic process; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0030308; P:negative regulation of cell growth; IMP:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:CACAO. DR GO; GO:0008156; P:negative regulation of DNA replication; IEA:Ensembl. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0048147; P:negative regulation of fibroblast proliferation; IMP:UniProtKB. DR GO; GO:1903451; P:negative regulation of G1 to G0 transition; IDA:CAFA. DR GO; GO:0060253; P:negative regulation of glial cell proliferation; IEA:Ensembl. DR GO; GO:1904024; P:negative regulation of glucose catabolic process to lactate via pyruvate; IEA:Ensembl. DR GO; GO:0051097; P:negative regulation of helicase activity; TAS:UniProtKB. DR GO; GO:1903799; P:negative regulation of miRNA processing; IEA:Ensembl. DR GO; GO:1901525; P:negative regulation of mitophagy; IEA:Ensembl. DR GO; GO:0007406; P:negative regulation of neuroblast proliferation; IEA:Ensembl. DR GO; GO:1905856; P:negative regulation of pentose-phosphate shunt; IMP:CACAO. DR GO; GO:0045861; P:negative regulation of proteolysis; IEA:Ensembl. DR GO; GO:2000378; P:negative regulation of reactive oxygen species metabolic process; IEA:Ensembl. DR GO; GO:2000647; P:negative regulation of stem cell proliferation; IEA:Ensembl. DR GO; GO:0032211; P:negative regulation of telomere maintenance via telomerase; IDA:BHF-UCL. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:ARUK-UCL. DR GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; IEA:Ensembl. DR GO; GO:0007405; P:neuroblast proliferation; IEA:Ensembl. DR GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl. DR GO; GO:0006289; P:nucleotide-excision repair; IMP:UniProtKB. DR GO; GO:0097252; P:oligodendrocyte apoptotic process; IDA:UniProtKB. DR GO; GO:0090403; P:oxidative stress-induced premature senescence; IMP:BHF-UCL. DR GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0010666; P:positive regulation of cardiac muscle cell apoptotic process; IEA:Ensembl. DR GO; GO:2000774; P:positive regulation of cellular senescence; IDA:UniProt. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:1900119; P:positive regulation of execution phase of apoptosis; IMP:AgBase. DR GO; GO:0010628; P:positive regulation of gene expression; IDA:CAFA. DR GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; IMP:UniProtKB. DR GO; GO:1902895; P:positive regulation of miRNA transcription; IDA:BHF-UCL. DR GO; GO:0035794; P:positive regulation of mitochondrial membrane permeability; IEA:Ensembl. DR GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:0062100; P:positive regulation of programmed necrotic cell death; IEA:Ensembl. DR GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IMP:BHF-UCL. DR GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; IDA:UniProtKB. DR GO; GO:0045899; P:positive regulation of RNA polymerase II transcription preinitiation complex assembly; IDA:BHF-UCL. DR GO; GO:0070245; P:positive regulation of thymocyte apoptotic process; ISS:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0006606; P:protein import into nucleus; IEA:Ensembl. DR GO; GO:0050821; P:protein stabilization; IEA:Ensembl. DR GO; GO:0051262; P:protein tetramerization; IEA:InterPro. DR GO; GO:0065003; P:protein-containing complex assembly; IDA:UniProtKB. DR GO; GO:0007265; P:Ras protein signal transduction; IEP:BHF-UCL. DR GO; GO:0072593; P:reactive oxygen species metabolic process; IEA:Ensembl. DR GO; GO:0042981; P:regulation of apoptotic process; IDA:MGI. DR GO; GO:0051726; P:regulation of cell cycle; IDA:BHF-UCL. DR GO; GO:1902749; P:regulation of cell cycle G2/M phase transition; IMP:UniProtKB. DR GO; GO:0043516; P:regulation of DNA damage response, signal transduction by p53 class mediator; IEA:Ensembl. DR GO; GO:0006355; P:regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:2000269; P:regulation of fibroblast apoptotic process; IEA:Ensembl. DR GO; GO:1902253; P:regulation of intrinsic apoptotic signaling pathway by p53 class mediator; IEA:Ensembl. DR GO; GO:1902108; P:regulation of mitochondrial membrane permeability involved in apoptotic process; IEA:Ensembl. DR GO; GO:0034103; P:regulation of tissue remodeling; IEA:Ensembl. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:ARUK-UCL. DR GO; GO:0001836; P:release of cytochrome c from mitochondria; IEA:Ensembl. DR GO; GO:0090399; P:replicative senescence; IMP:BHF-UCL. DR GO; GO:0046677; P:response to antibiotic; IEP:UniProtKB. DR GO; GO:0010332; P:response to gamma radiation; IMP:BHF-UCL. DR GO; GO:0002931; P:response to ischemia; IEA:Ensembl. DR GO; GO:0009651; P:response to salt stress; IEA:Ensembl. DR GO; GO:0010165; P:response to X-ray; IEA:Ensembl. DR GO; GO:0009303; P:rRNA transcription; IEA:Ensembl. DR GO; GO:0072331; P:signal transduction by p53 class mediator; IDA:CAFA. DR GO; GO:0001756; P:somitogenesis; IEA:Ensembl. DR GO; GO:0072089; P:stem cell proliferation; IEA:Ensembl. DR GO; GO:0033077; P:T cell differentiation in thymus; IEA:Ensembl. DR GO; GO:0002360; P:T cell lineage commitment; IEA:Ensembl. DR GO; GO:0002309; P:T cell proliferation involved in immune response; IEA:Ensembl. DR GO; GO:0070242; P:thymocyte apoptotic process; IEA:Ensembl. DR GO; GO:0045815; P:transcription initiation-coupled chromatin remodeling; IDA:GO_Central. DR GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IEA:Ensembl. DR GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; IGI:BHF-UCL. DR GO; GO:0060333; P:type II interferon-mediated signaling pathway; IEA:Ensembl. DR GO; GO:0016032; P:viral process; IMP:CACAO. DR CDD; cd08367; P53; 1. DR DisProt; DP00086; -. DR FunFam; 2.60.40.720:FF:000003; Cellular tumor antigen p53; 1. DR FunFam; 4.10.170.10:FF:000003; Cellular tumor antigen p53; 1. DR Gene3D; 2.60.40.720; -; 1. DR Gene3D; 6.10.50.20; -; 1. DR Gene3D; 4.10.170.10; p53-like tetramerisation domain; 1. DR IDEAL; IID00015; -. DR InterPro; IPR008967; p53-like_TF_DNA-bd_sf. DR InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf. DR InterPro; IPR057064; P53_central_site. DR InterPro; IPR011615; p53_DNA-bd. DR InterPro; IPR040926; p53_TAD2. DR InterPro; IPR036674; p53_tetramer_sf. DR InterPro; IPR010991; p53_tetrameristn. DR InterPro; IPR013872; p53_transactivation_domain. DR InterPro; IPR002117; p53_tumour_suppressor. DR PANTHER; PTHR11447; CELLULAR TUMOR ANTIGEN P53; 1. DR PANTHER; PTHR11447:SF6; CELLULAR TUMOR ANTIGEN P53; 1. DR Pfam; PF00870; P53; 1. DR Pfam; PF08563; P53_TAD; 1. DR Pfam; PF07710; P53_tetramer; 1. DR Pfam; PF18521; TAD2; 1. DR PRINTS; PR00386; P53SUPPRESSR. DR SUPFAM; SSF47719; p53 tetramerization domain; 1. DR SUPFAM; SSF49417; p53-like transcription factors; 1. DR PROSITE; PS00348; P53; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Activator; Alternative promoter usage; KW Alternative splicing; Apoptosis; Biological rhythms; Cell cycle; Cytoplasm; KW Cytoskeleton; Direct protein sequencing; Disease variant; DNA-binding; KW Endoplasmic reticulum; Glycoprotein; Host-virus interaction; KW Isopeptide bond; Li-Fraumeni syndrome; Metal-binding; Methylation; KW Mitochondrion; Necrosis; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repressor; Transcription; KW Transcription regulation; Tumor suppressor; Ubl conjugation; Zinc. FT CHAIN 1..393 FT /note="Cellular tumor antigen p53" FT /id="PRO_0000185703" FT DNA_BIND 102..292 FT /evidence="ECO:0000269|PubMed:16793544, FT ECO:0000269|PubMed:18996393, ECO:0000269|PubMed:20364130" FT REGION 1..320 FT /note="Interaction with CCAR2" FT /evidence="ECO:0000269|PubMed:25732823" FT REGION 1..83 FT /note="Interaction with HRMT1L2" FT /evidence="ECO:0000269|PubMed:15186775" FT REGION 1..44 FT /note="Transcription activation (acidic)" FT REGION 50..96 FT /note="Disordered" FT /evidence="ECO:0000269|PubMed:31953488" FT REGION 66..110 FT /note="Interaction with WWOX" FT REGION 100..370 FT /note="Interaction with HIPK1" FT /evidence="ECO:0000250" FT REGION 100..300 FT /note="Required for interaction with ZNF385A" FT /evidence="ECO:0000269|PubMed:17719541" FT REGION 113..236 FT /note="Required for interaction with FBXO42" FT /evidence="ECO:0000269|PubMed:19509332" FT REGION 116..292 FT /note="Interaction with AXIN1" FT /evidence="ECO:0000250" FT REGION 241..248 FT /note="Interaction with the 53BP2 SH3 domain" FT REGION 256..294 FT /note="Interaction with E4F1" FT /evidence="ECO:0000269|PubMed:10644996" FT REGION 273..280 FT /note="Interaction with DNA" FT REGION 282..325 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 300..393 FT /note="Interaction with CARM1" FT /evidence="ECO:0000269|PubMed:15186775" FT REGION 319..360 FT /note="Interaction with HIPK2" FT REGION 325..356 FT /note="Oligomerization" FT REGION 351..393 FT /note="Disordered" FT /evidence="ECO:0000269|PubMed:31953488, FT ECO:0000269|PubMed:36108750" FT REGION 359..363 FT /note="Interaction with USP7" FT REGION 368..387 FT /note="Basic (repression of DNA-binding)" FT REGION 374..393 FT /note="Interaction with MORN3" FT /evidence="ECO:0000269|PubMed:29681526" FT MOTIF 17..25 FT /note="TADI" FT MOTIF 48..56 FT /note="TADII" FT MOTIF 305..321 FT /note="Bipartite nuclear localization signal" FT MOTIF 339..350 FT /note="Nuclear export signal" FT MOTIF 370..372 FT /note="[KR]-[STA]-K motif" FT COMPBIAS 69..90 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 282..299 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 365..384 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 176 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:14534297, FT ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, FT ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, FT ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130" FT BINDING 179 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:14534297, FT ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, FT ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, FT ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130" FT BINDING 238 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:14534297, FT ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, FT ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, FT ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130" FT BINDING 242 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:14534297, FT ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, FT ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, FT ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130" FT SITE 120 FT /note="Interaction with DNA" FT /evidence="ECO:0000269|PubMed:16793544, FT ECO:0000269|PubMed:18996393, ECO:0000269|PubMed:20364130" FT MOD_RES 9 FT /note="Phosphoserine; by HIPK4" FT /evidence="ECO:0000269|PubMed:18022393" FT MOD_RES 15 FT /note="Phosphoserine; by CDK5, PRPK, AMPK, NUAK1 and ATM" FT /evidence="ECO:0000269|PubMed:10570149, FT ECO:0000269|PubMed:11554766, ECO:0000269|PubMed:15866171, FT ECO:0000269|PubMed:17108107, ECO:0000269|PubMed:17591690, FT ECO:0000269|PubMed:17967874, ECO:0000269|PubMed:21317932, FT ECO:0000269|PubMed:28842590" FT MOD_RES 18 FT /note="Phosphothreonine; by CK1, VRK1 and VRK2" FT /evidence="ECO:0000269|PubMed:10606744, FT ECO:0000269|PubMed:10951572, ECO:0000269|PubMed:16704422, FT ECO:0000269|PubMed:31527692" FT MOD_RES 20 FT /note="Phosphoserine; by CHEK2, CK1 and PLK3" FT /evidence="ECO:0000269|PubMed:10570149, FT ECO:0000269|PubMed:11447225, ECO:0000269|PubMed:11551930, FT ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:20041275" FT MOD_RES 33 FT /note="Phosphoserine; by CDK5 and CDK7" FT /evidence="ECO:0000269|PubMed:17591690, FT ECO:0000269|PubMed:9372954" FT MOD_RES 37 FT /note="Phosphoserine; by MAPKAPK5" FT /evidence="ECO:0000269|PubMed:17254968" FT MOD_RES 46 FT /note="Phosphoserine; by CDK5, DYRK2, HIPK2 and PKC/PRKCG" FT /evidence="ECO:0000269|PubMed:11740489, FT ECO:0000269|PubMed:11780126, ECO:0000269|PubMed:16377624, FT ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:17591690" FT MOD_RES 55 FT /note="Phosphothreonine; by TAF1 and GRK5" FT /evidence="ECO:0000269|PubMed:15053879, FT ECO:0000269|PubMed:20124405" FT MOD_RES 120 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:17189187, FT ECO:0000269|PubMed:19854137, ECO:0000269|PubMed:23431171" FT MOD_RES 120 FT /note="N6-lactoyllysine" FT /evidence="ECO:0000269|PubMed:38653238" FT MOD_RES 139 FT /note="N6-lactoyllysine" FT /evidence="ECO:0000269|PubMed:38653238" FT MOD_RES 183 FT /note="Phosphoserine; by AURKB" FT /evidence="ECO:0000269|PubMed:20959462" FT MOD_RES 269 FT /note="Phosphoserine; by AURKB" FT /evidence="ECO:0000269|PubMed:20959462" FT MOD_RES 284 FT /note="Phosphothreonine; by AURKB" FT /evidence="ECO:0000269|PubMed:20959462" FT MOD_RES 305 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:12724314" FT MOD_RES 315 FT /note="Phosphoserine; by AURKA, CDK1 and CDK2" FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:14702041" FT MOD_RES 321 FT /note="N6-acetyllysine" FT /evidence="ECO:0000250|UniProtKB:P02340" FT MOD_RES 333 FT /note="Omega-N-methylarginine; by PRMT5" FT /evidence="ECO:0000269|PubMed:19011621" FT MOD_RES 335 FT /note="Symmetric dimethylarginine; by PRMT5" FT /evidence="ECO:0000269|PubMed:19011621" FT MOD_RES 337 FT /note="Symmetric dimethylarginine; by PRMT5" FT /evidence="ECO:0000269|PubMed:19011621" FT MOD_RES 370 FT /note="N6,N6-dimethyllysine; alternate" FT /evidence="ECO:0000269|PubMed:17108971, FT ECO:0000269|PubMed:22864287" FT MOD_RES 370 FT /note="N6-methyllysine; by SMYD2; alternate" FT /evidence="ECO:0000269|PubMed:17108971, FT ECO:0000269|PubMed:22864287" FT MOD_RES 372 FT /note="N6-methyllysine; by SETD7" FT /evidence="ECO:0000269|PubMed:15525938, FT ECO:0000269|PubMed:16415881" FT MOD_RES 373 FT /note="N6,N6-dimethyllysine; by EHMT1 and EHMT2; alternate" FT /evidence="ECO:0000269|PubMed:20118233" FT MOD_RES 373 FT /note="N6-acetyllysine; alternate" FT /evidence="ECO:0000269|PubMed:10656795" FT MOD_RES 381 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:29474172, FT ECO:0007744|PubMed:19608861" FT MOD_RES 382 FT /note="N6,N6-dimethyllysine; alternate" FT /evidence="ECO:0000269|PubMed:17707234, FT ECO:0000269|PubMed:20870725, ECO:0000269|PubMed:22864287" FT MOD_RES 382 FT /note="N6-acetyllysine; alternate" FT /evidence="ECO:0000269|PubMed:10656795, FT ECO:0000269|PubMed:15448695, ECO:0000269|PubMed:20228809, FT ECO:0000269|PubMed:23431171, ECO:0000269|PubMed:29681526, FT ECO:0007744|PubMed:19608861" FT MOD_RES 382 FT /note="N6-methyllysine; by KMT5A; alternate" FT /evidence="ECO:0000269|PubMed:17707234, FT ECO:0000269|PubMed:20870725, ECO:0000269|PubMed:22864287" FT MOD_RES 392 FT /note="Phosphoserine; by CK2, CDK2 and NUAK1" FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:11239457, ECO:0000269|PubMed:17108107, FT ECO:0000269|PubMed:21317932, ECO:0000269|PubMed:22214662, FT ECO:0000269|PubMed:35618207" FT CROSSLNK 24 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:21597459" FT CROSSLNK 291 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19536131" FT CROSSLNK 292 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19536131" FT CROSSLNK 351 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19033443" FT CROSSLNK 357 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19033443" FT CROSSLNK 386 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO)" FT /evidence="ECO:0000269|PubMed:11124955, FT ECO:0000269|PubMed:22214662, ECO:0000269|Ref.37" FT VAR_SEQ 1..132 FT /note="Missing (in isoform 7, isoform 8 and isoform 9)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_040833" FT VAR_SEQ 1..39 FT /note="Missing (in isoform 4, isoform 5 and isoform 6)" FT /evidence="ECO:0000305" FT /id="VSP_040832" FT VAR_SEQ 332..346 FT /note="IRGRERFEMFRELNE -> MLLDLRWCYFLINSS (in isoform 3, FT isoform 6 and isoform 9)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_040560" FT VAR_SEQ 332..341 FT /note="IRGRERFEMF -> DQTSFQKENC (in isoform 2, isoform 5 FT and isoform 8)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_006535" FT VAR_SEQ 342..393 FT /note="Missing (in isoform 2, isoform 5 and isoform 8)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_006536" FT VAR_SEQ 347..393 FT /note="Missing (in isoform 3, isoform 6 and isoform 9)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_040561" FT VARIANT 5 FT /note="Q -> H (in a sporadic cancer; somatic mutation; FT abolishes strongly phosphorylation)" FT /id="VAR_044543" FT VARIANT 6 FT /note="S -> L (in a sporadic cancer; somatic mutation; FT reduces interaction with ZNF385A)" FT /id="VAR_044544" FT VARIANT 7 FT /note="D -> H (in a sporadic cancer; somatic mutation; FT dbSNP:rs587782646)" FT /id="VAR_005851" FT VARIANT 8 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_044545" FT VARIANT 10 FT /note="V -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs535274413)" FT /id="VAR_044546" FT VARIANT 11 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs201382018)" FT /id="VAR_044547" FT VARIANT 11 FT /note="E -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs201382018)" FT /id="VAR_044548" FT VARIANT 15 FT /note="S -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044549" FT VARIANT 16 FT /note="Q -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044550" FT VARIANT 17 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044551" FT VARIANT 24 FT /note="K -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_044552" FT VARIANT 28 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044553" FT VARIANT 29..30 FT /note="NN -> KD (in a sporadic cancer; somatic mutation)" FT /id="VAR_047158" FT VARIANT 31 FT /note="V -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs201753350)" FT /id="VAR_044554" FT VARIANT 33 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044555" FT VARIANT 34 FT /note="P -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044556" FT VARIANT 35 FT /note="L -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs121912661)" FT /id="VAR_005852" FT VARIANT 36 FT /note="P -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs587781866)" FT /id="VAR_044557" FT VARIANT 37 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044558" FT VARIANT 37 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044559" FT VARIANT 39 FT /note="A -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044560" FT VARIANT 39 FT /note="A -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs1353016807)" FT /id="VAR_044561" FT VARIANT 42 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_044562" FT VARIANT 43 FT /note="L -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_005853" FT VARIANT 44 FT /note="M -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs1060501190)" FT /id="VAR_044563" FT VARIANT 44 FT /note="M -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044564" FT VARIANT 44 FT /note="M -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_044565" FT VARIANT 45 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_044566" FT VARIANT 46 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044567" FT VARIANT 46 FT /note="S -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs876659630)" FT /id="VAR_044568" FT VARIANT 47 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044569" FT VARIANT 47 FT /note="P -> S (in dbSNP:rs1800371)" FT /evidence="ECO:0000269|Ref.12" FT /id="VAR_014632" FT VARIANT 48 FT /note="D -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044570" FT VARIANT 49 FT /note="D -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs587780728)" FT /id="VAR_044571" FT VARIANT 49 FT /note="D -> N (in a sporadic cancer; somatic mutation; FT dbSNP:rs587780728)" FT /id="VAR_044572" FT VARIANT 49 FT /note="D -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044573" FT VARIANT 52 FT /note="Q -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_044574" FT VARIANT 53 FT /note="W -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_005854" FT VARIANT 53 FT /note="W -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044575" FT VARIANT 54 FT /note="F -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555526742)" FT /id="VAR_044576" FT VARIANT 54 FT /note="F -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_044577" FT VARIANT 56 FT /note="E -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044578" FT VARIANT 56 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_044579" FT VARIANT 58 FT /note="P -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044580" FT VARIANT 58 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044581" FT VARIANT 59 FT /note="G -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs1237722021)" FT /id="VAR_044582" FT VARIANT 59 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044583" FT VARIANT 59 FT /note="G -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045783" FT VARIANT 60 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044584" FT VARIANT 60 FT /note="P -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044585" FT VARIANT 60 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_005855" FT VARIANT 61 FT /note="D -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1460793472)" FT /id="VAR_044586" FT VARIANT 61 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_044587" FT VARIANT 62 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044588" FT VARIANT 63 FT /note="A -> T (in a sporadic cancer; somatic mutation; FT dbSNP:rs876658902)" FT /id="VAR_044589" FT VARIANT 63 FT /note="A -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs372201428)" FT /id="VAR_044590" FT VARIANT 65 FT /note="R -> T (in a sporadic cancer; somatic mutation; FT dbSNP:rs1060501210)" FT /id="VAR_044591" FT VARIANT 66 FT /note="M -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555526711)" FT /id="VAR_044592" FT VARIANT 66 FT /note="M -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044593" FT VARIANT 67 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044594" FT VARIANT 67 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044595" FT VARIANT 67 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044596" FT VARIANT 68 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044597" FT VARIANT 68 FT /note="E -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044598" FT VARIANT 69 FT /note="A -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044599" FT VARIANT 69 FT /note="A -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs756233241)" FT /id="VAR_044600" FT VARIANT 69 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044601" FT VARIANT 69 FT /note="A -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs756233241)" FT /id="VAR_044602" FT VARIANT 70 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044603" FT VARIANT 71 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044604" FT VARIANT 72 FT /note="P -> C (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions; dbSNP:rs730882014)" FT /id="VAR_045784" FT VARIANT 72 FT /note="P -> G (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045785" FT VARIANT 72 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1042522)" FT /id="VAR_045786" FT VARIANT 72 FT /note="P -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045787" FT VARIANT 72 FT /note="P -> R (in dbSNP:rs1042522)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:16131611, ECO:0000269|PubMed:1999338, FT ECO:0000269|Ref.17" FT /id="VAR_005856" FT VARIANT 73 FT /note="V -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_044605" FT VARIANT 73 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044606" FT VARIANT 73 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs587782423)" FT /id="VAR_044607" FT VARIANT 74 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044608" FT VARIANT 75 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044609" FT VARIANT 75 FT /note="P -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044610" FT VARIANT 75 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_044611" FT VARIANT 76 FT /note="A -> G (in a sporadic cancer; somatic mutation)" FT /evidence="ECO:0000269|PubMed:2946935" FT /id="VAR_044612" FT VARIANT 76 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044613" FT VARIANT 77 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044614" FT VARIANT 78 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044615" FT VARIANT 79 FT /note="A -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044616" FT VARIANT 79 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_005857" FT VARIANT 79 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044617" FT VARIANT 80 FT /note="P -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044618" FT VARIANT 80 FT /note="P -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs1060501204)" FT /id="VAR_044619" FT VARIANT 81 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044620" FT VARIANT 82 FT /note="P -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs534447939)" FT /id="VAR_044621" FT VARIANT 82 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044622" FT VARIANT 83 FT /note="A -> E (in a sporadic cancer; somatic mutation; FT dbSNP:rs201717599)" FT /id="VAR_044623" FT VARIANT 83 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs201717599)" FT /id="VAR_044624" FT VARIANT 84 FT /note="A -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044625" FT VARIANT 84 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044626" FT VARIANT 85 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044627" FT VARIANT 85 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044628" FT VARIANT 86 FT /note="A -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_044629" FT VARIANT 87 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_005858" FT VARIANT 88 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044630" FT VARIANT 88 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526631)" FT /id="VAR_044631" FT VARIANT 89 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs730881994)" FT /id="VAR_044632" FT VARIANT 89 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044633" FT VARIANT 90 FT /note="S -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526625)" FT /id="VAR_044634" FT VARIANT 90 FT /note="S -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_044635" FT VARIANT 91 FT /note="W -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044636" FT VARIANT 92 FT /note="P -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044637" FT VARIANT 92 FT /note="P -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs1210700121)" FT /id="VAR_044638" FT VARIANT 92 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_044639" FT VARIANT 93 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_044640" FT VARIANT 93 FT /note="L -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044641" FT VARIANT 94 FT /note="S -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044642" FT VARIANT 94 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_005859" FT VARIANT 95 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044643" FT VARIANT 95 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044644" FT VARIANT 96 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044645" FT VARIANT 96 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044646" FT VARIANT 96 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044647" FT VARIANT 97 FT /note="V -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044648" FT VARIANT 97 FT /note="V -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044649" FT VARIANT 97 FT /note="V -> I (in familial cancer not matching LFS; FT germline mutation and in a sporadic cancer; somatic FT mutation; dbSNP:rs730882023)" FT /id="VAR_044650" FT VARIANT 98 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1245723119)" FT /id="VAR_044651" FT VARIANT 98 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044652" FT VARIANT 99 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044653" FT VARIANT 99 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044654" FT VARIANT 100 FT /note="Q -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044655" FT VARIANT 101 FT /note="K -> N (in a sporadic cancer; somatic mutation; FT dbSNP:rs878854069)" FT /id="VAR_044656" FT VARIANT 101 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044657" FT VARIANT 102 FT /note="T -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs786202717)" FT /id="VAR_044658" FT VARIANT 104 FT /note="Q -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044659" FT VARIANT 104 FT /note="Q -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044660" FT VARIANT 105 FT /note="G -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_044661" FT VARIANT 105 FT /note="G -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs587781504)" FT /id="VAR_044662" FT VARIANT 105 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501195)" FT /id="VAR_044663" FT VARIANT 105 FT /note="G -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs1060501195)" FT /id="VAR_044664" FT VARIANT 105 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044665" FT VARIANT 106 FT /note="S -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044666" FT VARIANT 106 FT /note="S -> R (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs1555526581)" FT /id="VAR_044667" FT VARIANT 107 FT /note="Y -> C (in a sporadic cancer; somatic mutation; FT dbSNP:rs587782447)" FT /id="VAR_044668" FT VARIANT 107 FT /note="Y -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044669" FT VARIANT 107 FT /note="Y -> H (in a sporadic cancer; somatic mutation; FT dbSNP:rs368771578)" FT /id="VAR_044670" FT VARIANT 108 FT /note="G -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044671" FT VARIANT 108 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs587782461)" FT /id="VAR_044672" FT VARIANT 109 FT /note="F -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_044673" FT VARIANT 109 FT /note="F -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044674" FT VARIANT 109 FT /note="F -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1064796722)" FT /id="VAR_044675" FT VARIANT 110 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs587781371)" FT /id="VAR_005860" FT VARIANT 110 FT /note="R -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044676" FT VARIANT 110 FT /note="R -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs11540654)" FT /id="VAR_044677" FT VARIANT 110 FT /note="R -> L (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; does not induce SNAI1 degradation; FT dbSNP:rs11540654)" FT /evidence="ECO:0000269|PubMed:20385133" FT /id="VAR_005861" FT VARIANT 110 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs11540654)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_005862" FT VARIANT 110 FT /note="R -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs587781371)" FT /id="VAR_044678" FT VARIANT 111 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_044679" FT VARIANT 111 FT /note="L -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519997)" FT /id="VAR_044680" FT VARIANT 111 FT /note="L -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519997)" FT /id="VAR_044681" FT VARIANT 111 FT /note="L -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519997)" FT /id="VAR_044682" FT VARIANT 112 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044683" FT VARIANT 112 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1423803759)" FT /id="VAR_044684" FT VARIANT 113 FT /note="F -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_005863" FT VARIANT 113 FT /note="F -> G (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045788" FT VARIANT 113 FT /note="F -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_044685" FT VARIANT 113 FT /note="F -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044686" FT VARIANT 113 FT /note="F -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044687" FT VARIANT 113 FT /note="F -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs587781642)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033033" FT VARIANT 115 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044688" FT VARIANT 116 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_044689" FT VARIANT 116 FT /note="S -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044690" FT VARIANT 116 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044691" FT VARIANT 117 FT /note="G -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs755238756)" FT /id="VAR_044692" FT VARIANT 117 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526518)" FT /id="VAR_044693" FT VARIANT 118 FT /note="T -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044694" FT VARIANT 118 FT /note="T -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1064794141)" FT /id="VAR_044695" FT VARIANT 118 FT /note="T -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044696" FT VARIANT 119 FT /note="A -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044697" FT VARIANT 119 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044698" FT VARIANT 120 FT /note="K -> E (in sporadic cancers; somatic mutation; FT abolished acetylation; impaired ability to induce FT proapoptotic program; mimics lactylation, leading to FT decreased ability to undergo liquid-liquid phase separation FT and activate the transcription factor activity; FT dbSNP:rs121912658)" FT /evidence="ECO:0000269|PubMed:17189187, FT ECO:0000269|PubMed:38653238" FT /id="VAR_044699" FT VARIANT 120 FT /note="K -> M (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17189187" FT /id="VAR_044700" FT VARIANT 120 FT /note="K -> Q (in a sporadic cancer; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity; dbSNP:rs121912658)" FT /evidence="ECO:0000269|PubMed:38653238" FT /id="VAR_044701" FT VARIANT 120 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17189187" FT /id="VAR_044702" FT VARIANT 121 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044703" FT VARIANT 122 FT /note="V -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044704" FT VARIANT 123 FT /note="T -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555526486)" FT /id="VAR_044705" FT VARIANT 123 FT /note="T -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_044706" FT VARIANT 124 FT /note="C -> G (in a sporadic cancer; somatic mutation; FT dbSNP:rs730881997)" FT /id="VAR_044707" FT VARIANT 124 FT /note="C -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044708" FT VARIANT 124 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs730881997)" FT /id="VAR_044709" FT VARIANT 124 FT /note="C -> W (in a sporadic cancer; somatic mutation)" FT /id="VAR_044710" FT VARIANT 124 FT /note="C -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_044711" FT VARIANT 125 FT /note="T -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044712" FT VARIANT 125 FT /note="T -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs786201057)" FT /id="VAR_044713" FT VARIANT 125 FT /note="T -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs786201057)" FT /id="VAR_005864" FT VARIANT 125 FT /note="T -> P (in a sporadic cancer; somatic mutation; FT dbSNP:rs1057520003)" FT /id="VAR_044714" FT VARIANT 125 FT /note="T -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs786201057)" FT /id="VAR_044715" FT VARIANT 126 FT /note="Y -> C (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs1555526335)" FT /id="VAR_044716" FT VARIANT 126 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs886039483)" FT /id="VAR_005865" FT VARIANT 126 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044717" FT VARIANT 126 FT /note="Y -> G (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045789" FT VARIANT 126 FT /note="Y -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044718" FT VARIANT 126 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs886039483)" FT /id="VAR_005866" FT VARIANT 126 FT /note="Y -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044719" FT VARIANT 127 FT /note="S -> C (in a sporadic cancer; somatic mutation; FT dbSNP:rs730881999)" FT /id="VAR_044720" FT VARIANT 127 FT /note="S -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs730881999)" FT /id="VAR_005867" FT VARIANT 127 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044721" FT VARIANT 127 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044722" FT VARIANT 127 FT /note="S -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044723" FT VARIANT 128 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044724" FT VARIANT 128 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044725" FT VARIANT 128 FT /note="P -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044726" FT VARIANT 128 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005868" FT VARIANT 129 FT /note="A -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_005869" FT VARIANT 129 FT /note="A -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044727" FT VARIANT 129 FT /note="A -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs1438095083)" FT /id="VAR_044728" FT VARIANT 129 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs137852792)" FT /id="VAR_044729" FT VARIANT 130 FT /note="L -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs863224683)" FT /id="VAR_044730" FT VARIANT 130 FT /note="L -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044731" FT VARIANT 130 FT /note="L -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_044732" FT VARIANT 130 FT /note="L -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691013)" FT /id="VAR_044733" FT VARIANT 130 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_005870" FT VARIANT 130 FT /note="L -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs863224683)" FT /id="VAR_044734" FT VARIANT 131 FT /note="N -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044735" FT VARIANT 131 FT /note="N -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044736" FT VARIANT 131 FT /note="N -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691037)" FT /id="VAR_044737" FT VARIANT 131 FT /note="N -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs769270327)" FT /id="VAR_005872" FT VARIANT 131 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005871" FT VARIANT 131 FT /note="N -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044738" FT VARIANT 131 FT /note="N -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs587782160)" FT /id="VAR_044739" FT VARIANT 132..133 FT /note="KM -> NL (in a sporadic cancer; somatic mutation)" FT /id="VAR_047159" FT VARIANT 132 FT /note="K -> E (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs747342068)" FT /id="VAR_044740" FT VARIANT 132 FT /note="K -> L (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045790" FT VARIANT 132 FT /note="K -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519996)" FT /id="VAR_005873" FT VARIANT 132 FT /note="K -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs866775781)" FT /id="VAR_044741" FT VARIANT 132 FT /note="K -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs747342068)" FT /evidence="ECO:0000269|PubMed:1694291" FT /id="VAR_005874" FT VARIANT 132 FT /note="K -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519996)" FT /id="VAR_044742" FT VARIANT 132 FT /note="K -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519996)" FT /id="VAR_044743" FT VARIANT 132 FT /note="K -> W (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045791" FT VARIANT 133 FT /note="M -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795139)" FT /id="VAR_044744" FT VARIANT 133 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044745" FT VARIANT 133 FT /note="M -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044746" FT VARIANT 133 FT /note="M -> R (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_044747" FT VARIANT 133 FT /note="M -> T (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934873)" FT /evidence="ECO:0000269|PubMed:1933902" FT /id="VAR_005875" FT VARIANT 133 FT /note="M -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1057280220)" FT /id="VAR_044748" FT VARIANT 134 FT /note="F -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs780442292)" FT /id="VAR_044749" FT VARIANT 134 FT /note="F -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044750" FT VARIANT 134 FT /note="F -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs267605077)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036504" FT VARIANT 134 FT /note="F -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044751" FT VARIANT 134 FT /note="F -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044752" FT VARIANT 135 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs587781991)" FT /id="VAR_005877" FT VARIANT 135 FT /note="C -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519975)" FT /id="VAR_044753" FT VARIANT 135 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519975)" FT /id="VAR_044754" FT VARIANT 135 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519975)" FT /id="VAR_005876" FT VARIANT 135 FT /note="C -> T (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045792" FT VARIANT 135 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519976)" FT /id="VAR_044755" FT VARIANT 135 FT /note="C -> Y (in sporadic cancers; somatic mutation; FT decreased E6-mediated binding to E6-AP; dbSNP:rs587781991)" FT /id="VAR_044756" FT VARIANT 136 FT /note="Q -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526268)" FT /id="VAR_005878" FT VARIANT 136 FT /note="Q -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs758781593)" FT /id="VAR_044757" FT VARIANT 136 FT /note="Q -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_005879" FT VARIANT 136 FT /note="Q -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044758" FT VARIANT 136 FT /note="Q -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044759" FT VARIANT 137 FT /note="L -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044760" FT VARIANT 137 FT /note="L -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044761" FT VARIANT 137 FT /note="L -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_005880" FT VARIANT 137 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044762" FT VARIANT 138 FT /note="A -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044763" FT VARIANT 138 FT /note="A -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934875)" FT /id="VAR_005881" FT VARIANT 138 FT /note="A -> S (in LFS; germline mutation)" FT /id="VAR_044764" FT VARIANT 138 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044765" FT VARIANT 138 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs750600586)" FT /evidence="ECO:0000269|PubMed:17224074, FT ECO:0000269|PubMed:27657329" FT /id="VAR_033034" FT VARIANT 139 FT /note="K -> E (in sporadic cancers; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity; dbSNP:rs1212996409)" FT /evidence="ECO:0000269|PubMed:38653238" FT /id="VAR_044766" FT VARIANT 139 FT /note="K -> N (in sporadic cancers; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity)" FT /evidence="ECO:0000269|PubMed:14660794, FT ECO:0000269|PubMed:38653238" FT /id="VAR_005882" FT VARIANT 139 FT /note="K -> Q (in sporadic cancers; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity)" FT /evidence="ECO:0000269|PubMed:38653238" FT /id="VAR_044767" FT VARIANT 139 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044768" FT VARIANT 139 FT /note="K -> T (in sporadic cancers; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity)" FT /evidence="ECO:0000269|PubMed:38653238" FT /id="VAR_044769" FT VARIANT 140 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044770" FT VARIANT 140 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044771" FT VARIANT 140 FT /note="T -> N (in a sporadic cancer; somatic mutation; FT dbSNP:rs786202561)" FT /id="VAR_044772" FT VARIANT 140 FT /note="T -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044773" FT VARIANT 140 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044774" FT VARIANT 141 FT /note="C -> A (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045793" FT VARIANT 141 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs587781288)" FT /id="VAR_005885" FT VARIANT 141 FT /note="C -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519978)" FT /id="VAR_005884" FT VARIANT 141 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519978)" FT /id="VAR_044775" FT VARIANT 141 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519978)" FT /id="VAR_044776" FT VARIANT 141 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519977)" FT /id="VAR_044777" FT VARIANT 141 FT /note="C -> Y (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587781288)" FT /id="VAR_005886" FT VARIANT 142 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044778" FT VARIANT 142 FT /note="P -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045794" FT VARIANT 142 FT /note="P -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044779" FT VARIANT 142 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs779196500)" FT /id="VAR_044780" FT VARIANT 142 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044781" FT VARIANT 142 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044782" FT VARIANT 142 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044783" FT VARIANT 143 FT /note="V -> A (in sporadic cancers; somatic mutation; FT strong DNA binding ability at 32.5 degrees Celsius; strong FT reduction of transcriptional activity at 37.5 degrees FT Celsius; severely represses interaction with ZNF385A)" FT /evidence="ECO:0000269|PubMed:17719541, FT ECO:0000269|PubMed:8013454" FT /id="VAR_005887" FT VARIANT 143 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_044784" FT VARIANT 143 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526241)" FT /id="VAR_044785" FT VARIANT 143 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs587782620)" FT /id="VAR_044786" FT VARIANT 143 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs587782620)" FT /id="VAR_044787" FT VARIANT 144 FT /note="Q -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs786201419)" FT /id="VAR_044788" FT VARIANT 144 FT /note="Q -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044789" FT VARIANT 144 FT /note="Q -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs786203071)" FT /id="VAR_044790" FT VARIANT 144 FT /note="Q -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs786203071)" FT /id="VAR_005888" FT VARIANT 144 FT /note="Q -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044791" FT VARIANT 145 FT /note="L -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044792" FT VARIANT 145 FT /note="L -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs587782197)" FT /id="VAR_005889" FT VARIANT 145 FT /note="L -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_005890" FT VARIANT 145 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044793" FT VARIANT 145 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044794" FT VARIANT 146 FT /note="W -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044795" FT VARIANT 146 FT /note="W -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs786203064)" FT /id="VAR_044796" FT VARIANT 146 FT /note="W -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044797" FT VARIANT 146 FT /note="W -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044798" FT VARIANT 146 FT /note="W -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044799" FT VARIANT 147 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044800" FT VARIANT 147 FT /note="V -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_005891" FT VARIANT 147 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_044801" FT VARIANT 147 FT /note="V -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044802" FT VARIANT 147 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1453167097)" FT /id="VAR_005892" FT VARIANT 147 FT /note="V -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526226)" FT /id="VAR_044803" FT VARIANT 148 FT /note="D -> A (in a sporadic cancer; somatic mutation; FT dbSNP:rs1046611742)" FT /id="VAR_044804" FT VARIANT 148 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_044805" FT VARIANT 148 FT /note="D -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044806" FT VARIANT 148 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_044807" FT VARIANT 148 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044808" FT VARIANT 148 FT /note="D -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691007)" FT /id="VAR_044809" FT VARIANT 149 FT /note="S -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526214)" FT /id="VAR_044810" FT VARIANT 149 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_005893" FT VARIANT 149 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044811" FT VARIANT 150 FT /note="T -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044812" FT VARIANT 150 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044813" FT VARIANT 150 FT /note="T -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044814" FT VARIANT 150 FT /note="T -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_044815" FT VARIANT 150 FT /note="T -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044816" FT VARIANT 150 FT /note="T -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044817" FT VARIANT 151 FT /note="P -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs28934874)" FT /id="VAR_005894" FT VARIANT 151 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520000)" FT /id="VAR_044818" FT VARIANT 151 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044819" FT VARIANT 151 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520000)" FT /id="VAR_044820" FT VARIANT 151 FT /note="P -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934874)" FT /evidence="ECO:0000269|PubMed:7682763" FT /id="VAR_005895" FT VARIANT 151 FT /note="P -> T (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934874)" FT /id="VAR_005896" FT VARIANT 152 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044821" FT VARIANT 152 FT /note="P -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587782705)" FT /evidence="ECO:0000269|PubMed:1868473" FT /id="VAR_005897" FT VARIANT 152 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044822" FT VARIANT 152 FT /note="P -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044823" FT VARIANT 152 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs767328513)" FT /evidence="ECO:0000269|PubMed:9450901" FT /id="VAR_005898" FT VARIANT 152 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044824" FT VARIANT 153 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044825" FT VARIANT 153 FT /note="P -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045795" FT VARIANT 153 FT /note="P -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_044826" FT VARIANT 153 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044827" FT VARIANT 153 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044828" FT VARIANT 153 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795860)" FT /id="VAR_044829" FT VARIANT 153 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_005899" FT VARIANT 154 FT /note="G -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044830" FT VARIANT 154 FT /note="G -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044831" FT VARIANT 154 FT /note="G -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs762846821)" FT /id="VAR_044832" FT VARIANT 154 FT /note="G -> I (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045796" FT VARIANT 154 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs137852789)" FT /id="VAR_044833" FT VARIANT 154 FT /note="G -> V (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs762846821)" FT /evidence="ECO:0000269|PubMed:2263646" FT /id="VAR_005900" FT VARIANT 155 FT /note="T -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs772683278)" FT /evidence="ECO:0000269|PubMed:1868473" FT /id="VAR_005901" FT VARIANT 155 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044834" FT VARIANT 155 FT /note="T -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_044835" FT VARIANT 155 FT /note="T -> N (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs786202752)" FT /id="VAR_044836" FT VARIANT 155 FT /note="T -> P (in sporadic cancers; somatic mutation; does FT not induce SNAI1 degradation)" FT /evidence="ECO:0000269|PubMed:14660794, FT ECO:0000269|PubMed:20385133" FT /id="VAR_044837" FT VARIANT 155 FT /note="T -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs786202752)" FT /id="VAR_044838" FT VARIANT 156 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs563378859)" FT /id="VAR_044839" FT VARIANT 156 FT /note="R -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044840" FT VARIANT 156 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs371524413)" FT /id="VAR_044841" FT VARIANT 156 FT /note="R -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044842" FT VARIANT 156 FT /note="R -> P (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:7682763" FT /id="VAR_005902" FT VARIANT 156 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044843" FT VARIANT 157 FT /note="V -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691023)" FT /id="VAR_044844" FT VARIANT 157 FT /note="V -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_005903" FT VARIANT 157 FT /note="V -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs121912654)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_005904" FT VARIANT 157 FT /note="V -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044845" FT VARIANT 157 FT /note="V -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs121912654)" FT /evidence="ECO:0000269|PubMed:9419979" FT /id="VAR_012977" FT VARIANT 157 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044846" FT VARIANT 158 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs587780068)" FT /id="VAR_005905" FT VARIANT 158 FT /note="R -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045797" FT VARIANT 158 FT /note="R -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_005906" FT VARIANT 158 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587782144)" FT /id="VAR_005907" FT VARIANT 158 FT /note="R -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044847" FT VARIANT 158 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs587782144)" FT /id="VAR_044848" FT VARIANT 158 FT /note="R -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044849" FT VARIANT 158 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044850" FT VARIANT 158 FT /note="R -> Y (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045798" FT VARIANT 159 FT /note="A -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044851" FT VARIANT 159 FT /note="A -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions; dbSNP:rs730882022)" FT /id="VAR_045799" FT VARIANT 159 FT /note="A -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044852" FT VARIANT 159 FT /note="A -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs730882000)" FT /id="VAR_044853" FT VARIANT 159 FT /note="A -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044854" FT VARIANT 159 FT /note="A -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs730882000)" FT /id="VAR_044855" FT VARIANT 159 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526131)" FT /id="VAR_044856" FT VARIANT 160..161 FT /note="MA -> IP (in a sporadic cancer; somatic mutation)" FT /id="VAR_047160" FT VARIANT 160..161 FT /note="MA -> IS (in sporadic cancers; somatic mutation)" FT /id="VAR_047161" FT VARIANT 160..161 FT /note="MA -> IT (in a sporadic cancer; somatic mutation)" FT /id="VAR_047162" FT VARIANT 160 FT /note="M -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs772354334)" FT /id="VAR_005908" FT VARIANT 160 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044857" FT VARIANT 160 FT /note="M -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044858" FT VARIANT 160 FT /note="M -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs377274728)" FT /id="VAR_044859" FT VARIANT 161 FT /note="A -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795691)" FT /id="VAR_044860" FT VARIANT 161 FT /note="A -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045800" FT VARIANT 161 FT /note="A -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044861" FT VARIANT 161 FT /note="A -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044862" FT VARIANT 161 FT /note="A -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005909" FT VARIANT 161 FT /note="A -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs193920817)" FT /id="VAR_044863" FT VARIANT 161 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044864" FT VARIANT 162 FT /note="I -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044865" FT VARIANT 162 FT /note="I -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044866" FT VARIANT 162 FT /note="I -> N (in a breast cancer with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_044867" FT VARIANT 162 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs587780069)" FT /id="VAR_005910" FT VARIANT 162 FT /note="I -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044868" FT VARIANT 162 FT /note="I -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_005911" FT VARIANT 163 FT /note="Y -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs148924904)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:17224074" FT /id="VAR_033035" FT VARIANT 163 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs786203436)" FT /id="VAR_044869" FT VARIANT 163 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044870" FT VARIANT 163 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs786203436)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_005912" FT VARIANT 163 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs786203436)" FT /id="VAR_044871" FT VARIANT 163 FT /note="Y -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044872" FT VARIANT 164 FT /note="K -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs879254249)" FT /id="VAR_044873" FT VARIANT 164 FT /note="K -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044874" FT VARIANT 164 FT /note="K -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691034)" FT /id="VAR_005913" FT VARIANT 164 FT /note="K -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_005914" FT VARIANT 164 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044875" FT VARIANT 164 FT /note="K -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044876" FT VARIANT 165 FT /note="Q -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_044877" FT VARIANT 165 FT /note="Q -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_044878" FT VARIANT 165 FT /note="Q -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_005915" FT VARIANT 165 FT /note="Q -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044879" FT VARIANT 165 FT /note="Q -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_005916" FT VARIANT 166 FT /note="S -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044880" FT VARIANT 166 FT /note="S -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044881" FT VARIANT 166 FT /note="S -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526101)" FT /id="VAR_005917" FT VARIANT 166 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044882" FT VARIANT 166 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044883" FT VARIANT 167..168 FT /note="QH -> HD (in a sporadic cancer; somatic mutation)" FT /id="VAR_047163" FT VARIANT 167..168 FT /note="QH -> YL (in a sporadic cancer; somatic mutation)" FT /id="VAR_047164" FT VARIANT 167 FT /note="Q -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044884" FT VARIANT 167 FT /note="Q -> K (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation)" FT /id="VAR_044885" FT VARIANT 167 FT /note="Q -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044886" FT VARIANT 167 FT /note="Q -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044887" FT VARIANT 168..169 FT /note="HM -> LI (in a sporadic cancer; somatic mutation)" FT /id="VAR_047165" FT VARIANT 168 FT /note="H -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044888" FT VARIANT 168 FT /note="H -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044889" FT VARIANT 168 FT /note="H -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_044890" FT VARIANT 168 FT /note="H -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044891" FT VARIANT 168 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044892" FT VARIANT 168 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs867114783)" FT /id="VAR_005918" FT VARIANT 168 FT /note="H -> V (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045801" FT VARIANT 168 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044893" FT VARIANT 169..170 FT /note="MT -> IS (in a sporadic cancer; somatic mutation)" FT /id="VAR_047166" FT VARIANT 169 FT /note="M -> I (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:9450901" FT /id="VAR_005919" FT VARIANT 169 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044894" FT VARIANT 169 FT /note="M -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_005920" FT VARIANT 169 FT /note="M -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044895" FT VARIANT 170 FT /note="T -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs587780729)" FT /id="VAR_044896" FT VARIANT 170 FT /note="T -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_044897" FT VARIANT 170 FT /note="T -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs779000871)" FT /id="VAR_005921" FT VARIANT 170 FT /note="T -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044898" FT VARIANT 170 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005922" FT VARIANT 171 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044899" FT VARIANT 171 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044900" FT VARIANT 171 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044901" FT VARIANT 171 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs587781845)" FT /id="VAR_044902" FT VARIANT 171 FT /note="E -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044903" FT VARIANT 171 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044904" FT VARIANT 172 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_005923" FT VARIANT 172 FT /note="V -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044905" FT VARIANT 172 FT /note="V -> F (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1131691043)" FT /id="VAR_044906" FT VARIANT 172 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691021)" FT /id="VAR_044907" FT VARIANT 172 FT /note="V -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044908" FT VARIANT 173 FT /note="V -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519747)" FT /id="VAR_044909" FT VARIANT 173 FT /note="V -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519747)" FT /id="VAR_005924" FT VARIANT 173 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519747)" FT /id="VAR_044910" FT VARIANT 173 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs876660754)" FT /id="VAR_005925" FT VARIANT 173 FT /note="V -> M (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs876660754)" FT /id="VAR_005926" FT VARIANT 173 FT /note="V -> W (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045802" FT VARIANT 174 FT /note="R -> G (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation; dbSNP:rs864622115)" FT /id="VAR_044911" FT VARIANT 174 FT /note="R -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs1064796681)" FT /evidence="ECO:0000269|PubMed:7682763" FT /id="VAR_005927" FT VARIANT 174 FT /note="R -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044912" FT VARIANT 174 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044913" FT VARIANT 174 FT /note="R -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044914" FT VARIANT 174 FT /note="R -> W (in sporadic cancers; somatic mutation)" FT /id="VAR_044915" FT VARIANT 175 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs138729528)" FT /id="VAR_005928" FT VARIANT 175 FT /note="R -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs138729528)" FT /id="VAR_005929" FT VARIANT 175 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; does not induce SNAI1 FT degradation; reduces interaction with ZNF385A; FT dbSNP:rs28934578)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:17719541, ECO:0000269|PubMed:1868473, FT ECO:0000269|PubMed:20385133, ECO:0000269|PubMed:27657329, FT ECO:0000269|PubMed:7887414, ECO:0000269|PubMed:8825920" FT /id="VAR_005932" FT VARIANT 175 FT /note="R -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934578)" FT /id="VAR_005930" FT VARIANT 175 FT /note="R -> P (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17719541" FT /id="VAR_005931" FT VARIANT 175 FT /note="R -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044916" FT VARIANT 175 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044917" FT VARIANT 176..177 FT /note="CP -> FS (in a sporadic cancer; somatic mutation)" FT /id="VAR_047167" FT VARIANT 176 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs786202962)" FT /evidence="ECO:0000269|PubMed:1394225, FT ECO:0000269|PubMed:1868473, ECO:0000269|PubMed:8829627, FT ECO:0000269|PubMed:9450901" FT /id="VAR_005933" FT VARIANT 176 FT /note="C -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044918" FT VARIANT 176 FT /note="C -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044919" FT VARIANT 176 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs967461896)" FT /id="VAR_044920" FT VARIANT 176 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519980)" FT /id="VAR_005934" FT VARIANT 176 FT /note="C -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs786202962)" FT /id="VAR_044921" FT VARIANT 177 FT /note="P -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044922" FT VARIANT 177 FT /note="P -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045803" FT VARIANT 177 FT /note="P -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044923" FT VARIANT 177 FT /note="P -> I (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045804" FT VARIANT 177 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs751477326)" FT /id="VAR_005935" FT VARIANT 177 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs751477326)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036505" FT VARIANT 177 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs147002414)" FT /id="VAR_044924" FT VARIANT 177 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044925" FT VARIANT 178..179 FT /note="HH -> QS (in a sporadic cancer; somatic mutation)" FT /id="VAR_047168" FT VARIANT 178 FT /note="H -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044926" FT VARIANT 178 FT /note="H -> HPHP (in a Burkitt lymphoma)" FT /evidence="ECO:0000269|PubMed:1303181" FT /id="VAR_005936" FT VARIANT 178 FT /note="H -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044927" FT VARIANT 178 FT /note="H -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795203)" FT /id="VAR_044928" FT VARIANT 178 FT /note="H -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526004)" FT /id="VAR_044929" FT VARIANT 178 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044930" FT VARIANT 178 FT /note="H -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044931" FT VARIANT 178 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044932" FT VARIANT 179 FT /note="H -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs587780070)" FT /id="VAR_044933" FT VARIANT 179 FT /note="H -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519991)" FT /id="VAR_044934" FT VARIANT 179 FT /note="H -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs587780070)" FT /id="VAR_044935" FT VARIANT 179 FT /note="H -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519991)" FT /id="VAR_044936" FT VARIANT 179 FT /note="H -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs876660821)" FT /id="VAR_044937" FT VARIANT 179 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519991)" FT /id="VAR_044938" FT VARIANT 179 FT /note="H -> Y (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587780070)" FT /id="VAR_044939" FT VARIANT 180 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044940" FT VARIANT 180 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044941" FT VARIANT 180 FT /note="E -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044942" FT VARIANT 180 FT /note="E -> K (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs879253911)" FT /id="VAR_044943" FT VARIANT 180 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044944" FT VARIANT 180 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_044945" FT VARIANT 181 FT /note="R -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587782596)" FT /id="VAR_044946" FT VARIANT 181 FT /note="R -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044947" FT VARIANT 181 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs397514495)" FT /id="VAR_044948" FT VARIANT 181 FT /note="R -> L (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs397514495)" FT /id="VAR_005937" FT VARIANT 181 FT /note="R -> P (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_044949" FT VARIANT 181 FT /note="R -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs587782596)" FT /id="VAR_044950" FT VARIANT 182 FT /note="C -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044951" FT VARIANT 182 FT /note="C -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005938" FT VARIANT 182 FT /note="C -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044952" FT VARIANT 183 FT /note="S -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525970)" FT /id="VAR_044953" FT VARIANT 183 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044954" FT VARIANT 184 FT /note="D -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501209)" FT /id="VAR_044955" FT VARIANT 184 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044956" FT VARIANT 184 FT /note="D -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs72661117)" FT /id="VAR_047169" FT VARIANT 184 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044957" FT VARIANT 184 FT /note="D -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_005939" FT VARIANT 185 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044958" FT VARIANT 185 FT /note="S -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044959" FT VARIANT 185 FT /note="S -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044960" FT VARIANT 185 FT /note="S -> N (in a sporadic cancer; somatic mutation; FT dbSNP:rs150607408)" FT /id="VAR_044961" FT VARIANT 185 FT /note="S -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044962" FT VARIANT 185 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044963" FT VARIANT 186 FT /note="D -> E (in a sporadic cancer; somatic mutation; FT dbSNP:rs375275361)" FT /id="VAR_044964" FT VARIANT 186 FT /note="D -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044965" FT VARIANT 186 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044966" FT VARIANT 186 FT /note="D -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501206)" FT /id="VAR_044967" FT VARIANT 186 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044968" FT VARIANT 186 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_005940" FT VARIANT 187 FT /note="G -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_005941" FT VARIANT 187 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044969" FT VARIANT 187 FT /note="G -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045805" FT VARIANT 187 FT /note="G -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044970" FT VARIANT 187 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs776167460)" FT /id="VAR_005942" FT VARIANT 187 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044971" FT VARIANT 188 FT /note="L -> P (in a sporadic cancer; somatic mutation; FT dbSNP:rs1199893366)" FT /id="VAR_044972" FT VARIANT 188 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044973" FT VARIANT 189 FT /note="A -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044974" FT VARIANT 189 FT /note="A -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044975" FT VARIANT 189 FT /note="A -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_005943" FT VARIANT 189 FT /note="A -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555525921)" FT /id="VAR_044976" FT VARIANT 189 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044977" FT VARIANT 189 FT /note="A -> V (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs121912665)" FT /id="VAR_044978" FT VARIANT 190 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044979" FT VARIANT 190 FT /note="P -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_044980" FT VARIANT 190 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs876660825)" FT /id="VAR_005944" FT VARIANT 190 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs876660825)" FT /id="VAR_044981" FT VARIANT 190 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044982" FT VARIANT 190 FT /note="P -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs876660254)" FT /id="VAR_044983" FT VARIANT 191 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs587778718)" FT /id="VAR_044984" FT VARIANT 191 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs587778718)" FT /id="VAR_044985" FT VARIANT 191 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs587778718)" FT /id="VAR_044986" FT VARIANT 191 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs868590738)" FT /id="VAR_044987" FT VARIANT 191 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_005945" FT VARIANT 192..193 FT /note="QH -> HN (in a sporadic cancer; somatic mutation)" FT /id="VAR_047170" FT VARIANT 192..193 FT /note="QH -> HY (in a sporadic cancer; somatic mutation)" FT /id="VAR_047171" FT VARIANT 192 FT /note="Q -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044988" FT VARIANT 192 FT /note="Q -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_044989" FT VARIANT 192 FT /note="Q -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044990" FT VARIANT 192 FT /note="Q -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044991" FT VARIANT 192 FT /note="Q -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs730882002)" FT /id="VAR_005946" FT VARIANT 193 FT /note="H -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs876658468)" FT /id="VAR_005947" FT VARIANT 193 FT /note="H -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs786201838)" FT /id="VAR_044992" FT VARIANT 193 FT /note="H -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs876658468)" FT /id="VAR_044993" FT VARIANT 193 FT /note="H -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs786201838)" FT /id="VAR_044994" FT VARIANT 193 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044995" FT VARIANT 193 FT /note="H -> R (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs786201838)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:7887414" FT /id="VAR_005948" FT VARIANT 193 FT /note="H -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs876658468)" FT /id="VAR_044996" FT VARIANT 194 FT /note="L -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs587780071)" FT /id="VAR_044997" FT VARIANT 194 FT /note="L -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519998)" FT /id="VAR_044998" FT VARIANT 194 FT /note="L -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044999" FT VARIANT 194 FT /note="L -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519998)" FT /id="VAR_005949" FT VARIANT 194 FT /note="L -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519998)" FT /evidence="ECO:0000269|PubMed:7682763" FT /id="VAR_005950" FT VARIANT 194 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045000" FT VARIANT 195 FT /note="I -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs942158624)" FT /id="VAR_045001" FT VARIANT 195 FT /note="I -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_047172" FT VARIANT 195 FT /note="I -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs760043106)" FT /id="VAR_045002" FT VARIANT 195 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs760043106)" FT /id="VAR_045003" FT VARIANT 195 FT /note="I -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs760043106)" FT /evidence="ECO:0000269|PubMed:17224074, FT ECO:0000269|PubMed:9450901" FT /id="VAR_005951" FT VARIANT 195 FT /note="I -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045004" FT VARIANT 195 FT /note="I -> Y (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045806" FT VARIANT 196 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs397516435)" FT /id="VAR_045005" FT VARIANT 196 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs483352697)" FT /id="VAR_045006" FT VARIANT 196 FT /note="R -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs483352697)" FT /id="VAR_045007" FT VARIANT 196 FT /note="R -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs483352697)" FT /id="VAR_045008" FT VARIANT 196 FT /note="R -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045009" FT VARIANT 197 FT /note="V -> E (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_045010" FT VARIANT 197 FT /note="V -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045011" FT VARIANT 197 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs786204041)" FT /id="VAR_045012" FT VARIANT 197 FT /note="V -> M (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs786204041)" FT /id="VAR_045013" FT VARIANT 198 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045014" FT VARIANT 198 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045015" FT VARIANT 198 FT /note="E -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_005952" FT VARIANT 198 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045016" FT VARIANT 198 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045017" FT VARIANT 199 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045018" FT VARIANT 199 FT /note="G -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045019" FT VARIANT 199 FT /note="G -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045020" FT VARIANT 199 FT /note="G -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525857)" FT /id="VAR_045021" FT VARIANT 200 FT /note="N -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045022" FT VARIANT 200 FT /note="N -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045023" FT VARIANT 200 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045024" FT VARIANT 200 FT /note="N -> P (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045807" FT VARIANT 200 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045025" FT VARIANT 200 FT /note="N -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045026" FT VARIANT 201..202 FT /note="LR -> FC (in a sporadic cancer; somatic mutation)" FT /id="VAR_047173" FT VARIANT 201 FT /note="L -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs730882024)" FT /id="VAR_045027" FT VARIANT 201 FT /note="L -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045028" FT VARIANT 201 FT /note="L -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045029" FT VARIANT 202 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs587780072)" FT /id="VAR_045030" FT VARIANT 202 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs587780072)" FT /id="VAR_045031" FT VARIANT 202 FT /note="R -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs587778719)" FT /id="VAR_045032" FT VARIANT 202 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs587778719)" FT /id="VAR_045033" FT VARIANT 202 FT /note="R -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045034" FT VARIANT 202 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045035" FT VARIANT 203..204 FT /note="VE -> LV (in a sporadic cancer; somatic mutation)" FT /id="VAR_047174" FT VARIANT 203 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045036" FT VARIANT 203 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045037" FT VARIANT 203 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045038" FT VARIANT 203 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs730882003)" FT /id="VAR_045039" FT VARIANT 203 FT /note="V -> W (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045808" FT VARIANT 204 FT /note="E -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045040" FT VARIANT 204 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045041" FT VARIANT 204 FT /note="E -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1260903787)" FT /id="VAR_045042" FT VARIANT 204 FT /note="E -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045043" FT VARIANT 204 FT /note="E -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_045044" FT VARIANT 204 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045045" FT VARIANT 205 FT /note="Y -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520007)" FT /evidence="ECO:0000269|PubMed:1459726" FT /id="VAR_005953" FT VARIANT 205 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520008)" FT /id="VAR_005954" FT VARIANT 205 FT /note="Y -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520007)" FT /id="VAR_047175" FT VARIANT 205 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520008)" FT /id="VAR_045046" FT VARIANT 205 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520008)" FT /id="VAR_045047" FT VARIANT 205 FT /note="Y -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520007)" FT /id="VAR_045048" FT VARIANT 206 FT /note="L -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045049" FT VARIANT 206 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_045050" FT VARIANT 207..208 FT /note="DD -> EY (in a sporadic cancer; somatic mutation)" FT /id="VAR_047176" FT VARIANT 207 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045051" FT VARIANT 207 FT /note="D -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045052" FT VARIANT 207 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045053" FT VARIANT 207 FT /note="D -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs923100890)" FT /id="VAR_045054" FT VARIANT 207 FT /note="D -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045055" FT VARIANT 207 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_045056" FT VARIANT 208 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045057" FT VARIANT 208 FT /note="D -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045058" FT VARIANT 208 FT /note="D -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045059" FT VARIANT 208 FT /note="D -> I (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045809" FT VARIANT 208 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045060" FT VARIANT 208 FT /note="D -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1464727668)" FT /id="VAR_045061" FT VARIANT 208 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_045062" FT VARIANT 209 FT /note="R -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045063" FT VARIANT 209 FT /note="R -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045064" FT VARIANT 209 FT /note="R -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045065" FT VARIANT 209 FT /note="R -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045066" FT VARIANT 210 FT /note="N -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045067" FT VARIANT 210 FT /note="N -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045068" FT VARIANT 210 FT /note="N -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045069" FT VARIANT 210 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045070" FT VARIANT 210 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045071" FT VARIANT 210 FT /note="N -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045072" FT VARIANT 210 FT /note="N -> Y (in a familial cancer not matching LFS; FT germline mutation; dbSNP:rs1060501200)" FT /id="VAR_045073" FT VARIANT 211 FT /note="T -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501198)" FT /id="VAR_045074" FT VARIANT 211 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045075" FT VARIANT 211 FT /note="T -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045076" FT VARIANT 211 FT /note="T -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045077" FT VARIANT 211 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045078" FT VARIANT 212 FT /note="F -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795766)" FT /id="VAR_045079" FT VARIANT 212 FT /note="F -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045080" FT VARIANT 212 FT /note="F -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045081" FT VARIANT 212 FT /note="F -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045082" FT VARIANT 212 FT /note="F -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045083" FT VARIANT 213 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs397516436)" FT /id="VAR_045084" FT VARIANT 213 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs587778720)" FT /id="VAR_045085" FT VARIANT 213 FT /note="R -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587778720)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036506" FT VARIANT 213 FT /note="R -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587778720)" FT /id="VAR_005955" FT VARIANT 213 FT /note="R -> W (in sporadic cancers; somatic mutation)" FT /id="VAR_045086" FT VARIANT 214 FT /note="H -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045087" FT VARIANT 214 FT /note="H -> P (in a sporadic cancer; somatic mutation; FT dbSNP:rs1057519992)" FT /id="VAR_045088" FT VARIANT 214 FT /note="H -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs587781386)" FT /id="VAR_047177" FT VARIANT 214 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519992)" FT /id="VAR_045089" FT VARIANT 214 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045090" FT VARIANT 215 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045091" FT VARIANT 215 FT /note="S -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs886039484)" FT /id="VAR_045092" FT VARIANT 215 FT /note="S -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs587782177)" FT /id="VAR_045093" FT VARIANT 215 FT /note="S -> K (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045810" FT VARIANT 215 FT /note="S -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs587782177)" FT /id="VAR_045094" FT VARIANT 215 FT /note="S -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520001)" FT /id="VAR_045095" FT VARIANT 215 FT /note="S -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs587782177)" FT /id="VAR_045096" FT VARIANT 216 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045097" FT VARIANT 216 FT /note="V -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520004)" FT /id="VAR_045098" FT VARIANT 216 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520004)" FT /id="VAR_045099" FT VARIANT 216 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs730882025)" FT /id="VAR_045100" FT VARIANT 216 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs730882025)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_005956" FT VARIANT 216 FT /note="V -> W (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045811" FT VARIANT 217 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045101" FT VARIANT 217 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045102" FT VARIANT 217 FT /note="V -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045103" FT VARIANT 217 FT /note="V -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045104" FT VARIANT 217 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045105" FT VARIANT 217 FT /note="V -> M (in dbSNP:rs35163653)" FT /id="VAR_047178" FT VARIANT 218 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045106" FT VARIANT 218 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045107" FT VARIANT 218 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525743)" FT /id="VAR_045108" FT VARIANT 218 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045109" FT VARIANT 218 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs878854072)" FT /id="VAR_045110" FT VARIANT 219 FT /note="P -> C (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045812" FT VARIANT 219 FT /note="P -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045111" FT VARIANT 219 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1420675064)" FT /id="VAR_045112" FT VARIANT 219 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045113" FT VARIANT 219 FT /note="P -> S (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs879253894)" FT /id="VAR_045114" FT VARIANT 219 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045115" FT VARIANT 220 FT /note="Y -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912666)" FT /evidence="ECO:0000269|PubMed:7682763, FT ECO:0000269|PubMed:9450901" FT /id="VAR_005957" FT VARIANT 220 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs530941076)" FT /id="VAR_045116" FT VARIANT 220 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045117" FT VARIANT 220 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs530941076)" FT /id="VAR_005958" FT VARIANT 220 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs530941076)" FT /id="VAR_045118" FT VARIANT 220 FT /note="Y -> S (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs121912666)" FT /id="VAR_005959" FT VARIANT 221 FT /note="E -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045119" FT VARIANT 221 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045120" FT VARIANT 221 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045121" FT VARIANT 221 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs786201592)" FT /id="VAR_045122" FT VARIANT 221 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045123" FT VARIANT 222 FT /note="P -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045124" FT VARIANT 222 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs146340390)" FT /id="VAR_045125" FT VARIANT 222 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045126" FT VARIANT 222 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045127" FT VARIANT 222 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501203)" FT /id="VAR_045128" FT VARIANT 222 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045129" FT VARIANT 223 FT /note="P -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_047179" FT VARIANT 223 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs138983188)" FT /id="VAR_045130" FT VARIANT 223 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs138983188)" FT /id="VAR_045131" FT VARIANT 223 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045132" FT VARIANT 223 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045133" FT VARIANT 223 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045134" FT VARIANT 224 FT /note="E -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs267605076)" FT /id="VAR_045135" FT VARIANT 224 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045136" FT VARIANT 224 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525707)" FT /id="VAR_045137" FT VARIANT 224 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045138" FT VARIANT 225 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045139" FT VARIANT 225 FT /note="V -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045140" FT VARIANT 225 FT /note="V -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045141" FT VARIANT 225 FT /note="V -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045142" FT VARIANT 225 FT /note="V -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045143" FT VARIANT 225 FT /note="V -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs746504075)" FT /id="VAR_045144" FT VARIANT 226 FT /note="G -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045145" FT VARIANT 226 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_047180" FT VARIANT 226 FT /note="G -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045844" FT VARIANT 226 FT /note="G -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045146" FT VARIANT 226 FT /note="G -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs970212462)" FT /id="VAR_045147" FT VARIANT 227 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045148" FT VARIANT 227 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045149" FT VARIANT 227 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045150" FT VARIANT 227 FT /note="S -> T (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation)" FT /id="VAR_045151" FT VARIANT 228 FT /note="D -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045152" FT VARIANT 228 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_005960" FT VARIANT 228 FT /note="D -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045153" FT VARIANT 228 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045154" FT VARIANT 228 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045155" FT VARIANT 228 FT /note="D -> P (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045845" FT VARIANT 228 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045156" FT VARIANT 228 FT /note="D -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045157" FT VARIANT 229 FT /note="C -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045158" FT VARIANT 229 FT /note="C -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045846" FT VARIANT 229 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1064794312)" FT /id="VAR_045159" FT VARIANT 229 FT /note="C -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045160" FT VARIANT 229 FT /note="C -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs1064793603)" FT /id="VAR_045161" FT VARIANT 230 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045162" FT VARIANT 230 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:9450901" FT /id="VAR_005961" FT VARIANT 230 FT /note="T -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045163" FT VARIANT 230 FT /note="T -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045164" FT VARIANT 230 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045165" FT VARIANT 231 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045166" FT VARIANT 231 FT /note="T -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525564)" FT /id="VAR_045167" FT VARIANT 231 FT /note="T -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045168" FT VARIANT 231 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045169" FT VARIANT 232 FT /note="I -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045170" FT VARIANT 232 FT /note="I -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525562)" FT /id="VAR_045171" FT VARIANT 232 FT /note="I -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045172" FT VARIANT 232 FT /note="I -> S (in sporadic cancers; somatic mutation; does FT not induce SNAI1 degradation)" FT /evidence="ECO:0000269|PubMed:20385133" FT /id="VAR_045173" FT VARIANT 232 FT /note="I -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs587781589)" FT /id="VAR_005962" FT VARIANT 232 FT /note="I -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045174" FT VARIANT 233 FT /note="H -> D (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation)" FT /id="VAR_045175" FT VARIANT 233 FT /note="H -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045176" FT VARIANT 233 FT /note="H -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045177" FT VARIANT 233 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045178" FT VARIANT 233 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs879254233)" FT /id="VAR_047181" FT VARIANT 233 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045179" FT VARIANT 234 FT /note="Y -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587780073)" FT /id="VAR_005963" FT VARIANT 234 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs864622237)" FT /id="VAR_045180" FT VARIANT 234 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045181" FT VARIANT 234 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs864622237)" FT /id="VAR_005964" FT VARIANT 234 FT /note="Y -> K (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045847" FT VARIANT 234 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs864622237)" FT /id="VAR_045182" FT VARIANT 234 FT /note="Y -> Q (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045848" FT VARIANT 234 FT /note="Y -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs587780073)" FT /id="VAR_045183" FT VARIANT 235 FT /note="N -> D (in an adrenocortical carcinoma with no FT family history; germline mutation and in sporadic cancers; FT somatic mutation)" FT /id="VAR_047182" FT VARIANT 235 FT /note="N -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045184" FT VARIANT 235 FT /note="N -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs144340710)" FT /id="VAR_045185" FT VARIANT 235 FT /note="N -> M (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045849" FT VARIANT 235 FT /note="N -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs144340710)" FT /id="VAR_045186" FT VARIANT 235 FT /note="N -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045187" FT VARIANT 235 FT /note="N -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs786204145)" FT /id="VAR_045188" FT VARIANT 236 FT /note="Y -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs730882026)" FT /id="VAR_045189" FT VARIANT 236 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs587782289)" FT /id="VAR_045190" FT VARIANT 236 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045191" FT VARIANT 236 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs587782289)" FT /id="VAR_045192" FT VARIANT 236 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs587782289)" FT /id="VAR_045193" FT VARIANT 236 FT /note="Y -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs730882026)" FT /id="VAR_045194" FT VARIANT 237 FT /note="M -> I (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587782664)" FT /evidence="ECO:0000269|PubMed:27657329" FT /id="VAR_005965" FT VARIANT 237 FT /note="M -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs765848205)" FT /id="VAR_045195" FT VARIANT 237 FT /note="M -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045196" FT VARIANT 237 FT /note="M -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs765848205)" FT /id="VAR_045197" FT VARIANT 237 FT /note="M -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045198" FT VARIANT 237 FT /note="M -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs730882004)" FT /id="VAR_045199" FT VARIANT 238 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs730882005)" FT /id="VAR_005966" FT VARIANT 238 FT /note="C -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1057519981)" FT /id="VAR_045200" FT VARIANT 238 FT /note="C -> H (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045850" FT VARIANT 238 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519981)" FT /id="VAR_045201" FT VARIANT 238 FT /note="C -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs730882005)" FT /id="VAR_045202" FT VARIANT 238 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs193920789)" FT /id="VAR_045203" FT VARIANT 238 FT /note="C -> Y (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs730882005)" FT /id="VAR_005967" FT VARIANT 239 FT /note="N -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs876660807)" FT /id="VAR_045204" FT VARIANT 239 FT /note="N -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045205" FT VARIANT 239 FT /note="N -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045206" FT VARIANT 239 FT /note="N -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs1057522275)" FT /id="VAR_045207" FT VARIANT 239 FT /note="N -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519999)" FT /id="VAR_045208" FT VARIANT 239 FT /note="N -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519999)" FT /id="VAR_045209" FT VARIANT 239 FT /note="N -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045210" FT VARIANT 240 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045211" FT VARIANT 240 FT /note="S -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045212" FT VARIANT 240 FT /note="S -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_005968" FT VARIANT 240 FT /note="S -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045213" FT VARIANT 240 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045214" FT VARIANT 240 FT /note="S -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045215" FT VARIANT 240 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045216" FT VARIANT 241 FT /note="S -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520002)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033036" FT VARIANT 241 FT /note="S -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs28934573)" FT /id="VAR_045217" FT VARIANT 241 FT /note="S -> F (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934573)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:1699228" FT /id="VAR_005969" FT VARIANT 241 FT /note="S -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520002)" FT /id="VAR_045218" FT VARIANT 241 FT /note="S -> T (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_047183" FT VARIANT 241 FT /note="S -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs28934573)" FT /id="VAR_045219" FT VARIANT 242 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs121912655)" FT /evidence="ECO:0000269|PubMed:1394225, FT ECO:0000269|PubMed:16959974" FT /id="VAR_005970" FT VARIANT 242 FT /note="C -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519982)" FT /id="VAR_045220" FT VARIANT 242 FT /note="C -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045221" FT VARIANT 242 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs121912655)" FT /id="VAR_045222" FT VARIANT 242 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs375874539)" FT /id="VAR_045223" FT VARIANT 242 FT /note="C -> Y (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs121912655)" FT /id="VAR_045224" FT VARIANT 243..244 FT /note="MG -> IC (in a sporadic cancer; somatic mutation)" FT /id="VAR_047184" FT VARIANT 243..244 FT /note="MG -> IS (in a sporadic cancer; somatic mutation)" FT /id="VAR_047185" FT VARIANT 243 FT /note="M -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045225" FT VARIANT 243 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045226" FT VARIANT 243 FT /note="M -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs786203117)" FT /id="VAR_045227" FT VARIANT 243 FT /note="M -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045228" FT VARIANT 243 FT /note="M -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs730882006)" FT /id="VAR_045229" FT VARIANT 243 FT /note="M -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs786203117)" FT /id="VAR_045230" FT VARIANT 244 FT /note="G -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs985033810)" FT /id="VAR_047186" FT VARIANT 244 FT /note="G -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519989)" FT /id="VAR_045231" FT VARIANT 244 FT /note="G -> D (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1057517983)" FT /id="VAR_045232" FT VARIANT 244 FT /note="G -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_045233" FT VARIANT 244 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519989)" FT /id="VAR_045234" FT VARIANT 244 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519989)" FT /id="VAR_045235" FT VARIANT 244 FT /note="G -> V (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs985033810)" FT /id="VAR_045236" FT VARIANT 245 FT /note="G -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs121912656)" FT /id="VAR_005971" FT VARIANT 245 FT /note="G -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934575)" FT /evidence="ECO:0000269|PubMed:1394225, FT ECO:0000269|PubMed:1978757" FT /id="VAR_005972" FT VARIANT 245 FT /note="G -> D (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912656)" FT /evidence="ECO:0000269|PubMed:2259385" FT /id="VAR_005973" FT VARIANT 245 FT /note="G -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_045237" FT VARIANT 245 FT /note="G -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045851" FT VARIANT 245 FT /note="G -> H (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045852" FT VARIANT 245 FT /note="G -> L (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045853" FT VARIANT 245 FT /note="G -> N (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045854" FT VARIANT 245 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs28934575)" FT /id="VAR_045238" FT VARIANT 245 FT /note="G -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934575)" FT /evidence="ECO:0000269|PubMed:8829627" FT /id="VAR_005974" FT VARIANT 245 FT /note="G -> V (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912656)" FT /evidence="ECO:0000269|PubMed:2263646" FT /id="VAR_005975" FT VARIANT 246 FT /note="M -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1019340046)" FT /id="VAR_045239" FT VARIANT 246 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045240" FT VARIANT 246 FT /note="M -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs483352695)" FT /id="VAR_044020" FT VARIANT 246 FT /note="M -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs587780074)" FT /id="VAR_005976" FT VARIANT 246 FT /note="M -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs587780074)" FT /id="VAR_005977" FT VARIANT 246 FT /note="M -> V (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs483352695)" FT /id="VAR_005978" FT VARIANT 247..248 FT /note="NR -> IP (in a sporadic cancer; somatic mutation)" FT /id="VAR_047187" FT VARIANT 247..248 FT /note="NR -> KW (in sporadic cancers; somatic mutation)" FT /id="VAR_047188" FT VARIANT 247 FT /note="N -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1452189221)" FT /id="VAR_045241" FT VARIANT 247 FT /note="N -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045855" FT VARIANT 247 FT /note="N -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs786201762)" FT /id="VAR_005980" FT VARIANT 247 FT /note="N -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045242" FT VARIANT 247 FT /note="N -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs786201762)" FT /id="VAR_045243" FT VARIANT 247 FT /note="N -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_047189" FT VARIANT 247 FT /note="N -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045244" FT VARIANT 248 FT /note="R -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_045245" FT VARIANT 248 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs121912651)" FT /id="VAR_005981" FT VARIANT 248 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs11540652)" FT /evidence="ECO:0000269|PubMed:1394225, FT ECO:0000269|PubMed:7682763" FT /id="VAR_005982" FT VARIANT 248 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs11540652)" FT /id="VAR_045246" FT VARIANT 248 FT /note="R -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs11540652)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:2263646, ECO:0000269|PubMed:7682763, FT ECO:0000269|PubMed:7887414" FT /id="VAR_005983" FT VARIANT 248 FT /note="R -> W (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912651)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:1978757, ECO:0000269|PubMed:27657329, FT ECO:0000269|PubMed:8829627" FT /id="VAR_005984" FT VARIANT 249..250 FT /note="RP -> SA (in a sporadic cancer; somatic mutation)" FT /id="VAR_047190" FT VARIANT 249..250 FT /note="RP -> SS (in sporadic cancers; somatic mutation)" FT /id="VAR_047191" FT VARIANT 249 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs587782082)" FT /id="VAR_005985" FT VARIANT 249 FT /note="R -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045247" FT VARIANT 249 FT /note="R -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs587782329)" FT /id="VAR_045248" FT VARIANT 249 FT /note="R -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs587782329)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033037" FT VARIANT 249 FT /note="R -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045856" FT VARIANT 249 FT /note="R -> S (in sporadic cancers; somatic mutation; does FT not induce SNAI1 degradation; dbSNP:rs28934571)" FT /evidence="ECO:0000269|PubMed:1694291, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:20385133" FT /id="VAR_005986" FT VARIANT 249 FT /note="R -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs587782329)" FT /id="VAR_045249" FT VARIANT 249 FT /note="R -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs587782082)" FT /id="VAR_045250" FT VARIANT 250 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045251" FT VARIANT 250 FT /note="P -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045857" FT VARIANT 250 FT /note="P -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045252" FT VARIANT 250 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1064794311)" FT /id="VAR_047192" FT VARIANT 250 FT /note="P -> N (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045858" FT VARIANT 250 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045253" FT VARIANT 250 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045254" FT VARIANT 250 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045255" FT VARIANT 251 FT /note="I -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045256" FT VARIANT 251 FT /note="I -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs730882007)" FT /id="VAR_045257" FT VARIANT 251 FT /note="I -> M (in LFS; germline mutation; FT dbSNP:rs878854074)" FT /id="VAR_045258" FT VARIANT 251 FT /note="I -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_005987" FT VARIANT 251 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs730882027)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033038" FT VARIANT 251 FT /note="I -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045259" FT VARIANT 251 FT /note="I -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045260" FT VARIANT 252 FT /note="L -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045261" FT VARIANT 252 FT /note="L -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045262" FT VARIANT 252 FT /note="L -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045263" FT VARIANT 252 FT /note="L -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912653)" FT /evidence="ECO:0000269|PubMed:1978757" FT /id="VAR_005988" FT VARIANT 252 FT /note="L -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045264" FT VARIANT 253 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045265" FT VARIANT 253 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045266" FT VARIANT 253 FT /note="T -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525465)" FT /id="VAR_045267" FT VARIANT 253 FT /note="T -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_047193" FT VARIANT 253 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045268" FT VARIANT 254 FT /note="I -> D (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045859" FT VARIANT 254 FT /note="I -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045269" FT VARIANT 254 FT /note="I -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045270" FT VARIANT 254 FT /note="I -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_045271" FT VARIANT 254 FT /note="I -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_017908" FT VARIANT 254 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1330865474)" FT /id="VAR_045272" FT VARIANT 254 FT /note="I -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_017909" FT VARIANT 254 FT /note="I -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs746601313)" FT /id="VAR_045273" FT VARIANT 255 FT /note="I -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519995)" FT /id="VAR_045274" FT VARIANT 255 FT /note="I -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_045275" FT VARIANT 255 FT /note="I -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs876659675)" FT /id="VAR_045276" FT VARIANT 255 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs876659675)" FT /id="VAR_045277" FT VARIANT 255 FT /note="I -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs876659675)" FT /id="VAR_045278" FT VARIANT 255 FT /note="I -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045279" FT VARIANT 256 FT /note="T -> I (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_045280" FT VARIANT 256 FT /note="T -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045281" FT VARIANT 256 FT /note="T -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045282" FT VARIANT 256 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045283" FT VARIANT 257 FT /note="L -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_005989" FT VARIANT 257 FT /note="L -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934577)" FT /id="VAR_045284" FT VARIANT 257 FT /note="L -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs28934577)" FT /id="VAR_045285" FT VARIANT 257 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045286" FT VARIANT 258 FT /note="E -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045287" FT VARIANT 258 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_005990" FT VARIANT 258 FT /note="E -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501201)" FT /id="VAR_045288" FT VARIANT 258 FT /note="E -> K (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912652)" FT /evidence="ECO:0000269|PubMed:1978757" FT /id="VAR_005991" FT VARIANT 258 FT /note="E -> L (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045860" FT VARIANT 258 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045289" FT VARIANT 258 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045290" FT VARIANT 259 FT /note="D -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_047194" FT VARIANT 259 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045291" FT VARIANT 259 FT /note="D -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs745425759)" FT /id="VAR_045292" FT VARIANT 259 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045293" FT VARIANT 259 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045294" FT VARIANT 259 FT /note="D -> P (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045861" FT VARIANT 259 FT /note="D -> S (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045862" FT VARIANT 259 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045295" FT VARIANT 259 FT /note="D -> Y (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033039" FT VARIANT 260 FT /note="S -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045296" FT VARIANT 260 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045297" FT VARIANT 260 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045298" FT VARIANT 260 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045299" FT VARIANT 260 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045300" FT VARIANT 260 FT /note="S -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs876658916)" FT /id="VAR_045301" FT VARIANT 261 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_045302" FT VARIANT 261 FT /note="S -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045303" FT VARIANT 261 FT /note="S -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045304" FT VARIANT 261 FT /note="S -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045305" FT VARIANT 261 FT /note="S -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045306" FT VARIANT 262..263 FT /note="GN -> PD (in a sporadic cancer; somatic mutation)" FT /id="VAR_047195" FT VARIANT 262 FT /note="G -> C (in a sporadic cancer; somatic mutation; FT dbSNP:rs200579969)" FT /id="VAR_045307" FT VARIANT 262 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_047196" FT VARIANT 262 FT /note="G -> H (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045863" FT VARIANT 262 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs200579969)" FT /id="VAR_045308" FT VARIANT 262 FT /note="G -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691025)" FT /evidence="ECO:0000269|Ref.23" FT /id="VAR_045309" FT VARIANT 263 FT /note="N -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs72661119)" FT /id="VAR_045310" FT VARIANT 263 FT /note="N -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045311" FT VARIANT 263 FT /note="N -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045312" FT VARIANT 263 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045313" FT VARIANT 263 FT /note="N -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045314" FT VARIANT 264 FT /note="L -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045315" FT VARIANT 264 FT /note="L -> P (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555525353)" FT /id="VAR_045316" FT VARIANT 264 FT /note="L -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_045317" FT VARIANT 264 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045318" FT VARIANT 264 FT /note="L -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045319" FT VARIANT 265 FT /note="L -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_045320" FT VARIANT 265 FT /note="L -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs879253942)" FT /id="VAR_045321" FT VARIANT 265 FT /note="L -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045322" FT VARIANT 265 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_047197" FT VARIANT 266 FT /note="G -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045323" FT VARIANT 266 FT /note="G -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs193920774)" FT /id="VAR_045324" FT VARIANT 266 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519990)" FT /id="VAR_045325" FT VARIANT 266 FT /note="G -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs193920774)" FT /id="VAR_045326" FT VARIANT 267 FT /note="R -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045327" FT VARIANT 267 FT /note="R -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045328" FT VARIANT 267 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs587780075)" FT /id="VAR_045329" FT VARIANT 267 FT /note="R -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587780075)" FT /id="VAR_045330" FT VARIANT 267 FT /note="R -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs55832599)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036507" FT VARIANT 268 FT /note="N -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045864" FT VARIANT 268 FT /note="N -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045331" FT VARIANT 268 FT /note="N -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045332" FT VARIANT 268 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045333" FT VARIANT 268 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045334" FT VARIANT 268 FT /note="N -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_045335" FT VARIANT 269 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045336" FT VARIANT 269 FT /note="S -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045337" FT VARIANT 269 FT /note="S -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_047198" FT VARIANT 269 FT /note="S -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045338" FT VARIANT 269 FT /note="S -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045339" FT VARIANT 269 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045340" FT VARIANT 270 FT /note="F -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519986)" FT /id="VAR_045341" FT VARIANT 270 FT /note="F -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519988)" FT /id="VAR_045342" FT VARIANT 270 FT /note="F -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519987)" FT /id="VAR_045343" FT VARIANT 270 FT /note="F -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519986)" FT /id="VAR_045344" FT VARIANT 270 FT /note="F -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519988)" FT /id="VAR_045345" FT VARIANT 270 FT /note="F -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045346" FT VARIANT 271 FT /note="E -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045347" FT VARIANT 271 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045348" FT VARIANT 271 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045349" FT VARIANT 271 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501191)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036508" FT VARIANT 271 FT /note="E -> P (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045865" FT VARIANT 271 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045350" FT VARIANT 271 FT /note="E -> R (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045866" FT VARIANT 271 FT /note="E -> V (in an osteosarcoma with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_047199" FT VARIANT 272 FT /note="V -> A (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_045351" FT VARIANT 272 FT /note="V -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs876660333)" FT /id="VAR_045352" FT VARIANT 272 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs876660333)" FT /id="VAR_045353" FT VARIANT 272 FT /note="V -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912657)" FT /evidence="ECO:0000269|PubMed:1737852" FT /id="VAR_005992" FT VARIANT 272 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs121912657)" FT /id="VAR_045354" FT VARIANT 273 FT /note="R -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121913343)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:17224074, ECO:0000269|PubMed:7887414, FT ECO:0000269|PubMed:9450901" FT /id="VAR_005993" FT VARIANT 273 FT /note="R -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_005994" FT VARIANT 273 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; abolishes sequence-specific DNA FT binding; does not induce SNAI1 degradation; FT dbSNP:rs28934576)" FT /evidence="ECO:0000269|PubMed:10570149, FT ECO:0000269|PubMed:1394225, ECO:0000269|PubMed:1565144, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:1699228, FT ECO:0000269|PubMed:1868473, ECO:0000269|PubMed:20385133, FT ECO:0000269|PubMed:7682763, ECO:0000269|Ref.14" FT /id="VAR_005995" FT VARIANT 273 FT /note="R -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934576)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036509" FT VARIANT 273 FT /note="R -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045867" FT VARIANT 273 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs28934576)" FT /evidence="ECO:0000269|PubMed:27657329" FT /id="VAR_045355" FT VARIANT 273 FT /note="R -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045356" FT VARIANT 273 FT /note="R -> S (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs121913343)" FT /id="VAR_045357" FT VARIANT 273 FT /note="R -> Y (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045868" FT VARIANT 274 FT /note="V -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520006)" FT /id="VAR_045358" FT VARIANT 274 FT /note="V -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520006)" FT /id="VAR_045359" FT VARIANT 274 FT /note="V -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520005)" FT /id="VAR_005997" FT VARIANT 274 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520006)" FT /id="VAR_047200" FT VARIANT 274 FT /note="V -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045360" FT VARIANT 274 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520005)" FT /id="VAR_045361" FT VARIANT 275 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs863224451)" FT /id="VAR_045362" FT VARIANT 275 FT /note="C -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045363" FT VARIANT 275 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519983)" FT /id="VAR_045364" FT VARIANT 275 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs863224451)" FT /id="VAR_045365" FT VARIANT 275 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525279)" FT /id="VAR_005999" FT VARIANT 275 FT /note="C -> Y (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs863224451)" FT /evidence="ECO:0000269|PubMed:7887414" FT /id="VAR_005998" FT VARIANT 276 FT /note="A -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs786202082)" FT /id="VAR_045366" FT VARIANT 276 FT /note="A -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs786202082)" FT /id="VAR_045367" FT VARIANT 276 FT /note="A -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691029)" FT /id="VAR_045368" FT VARIANT 276 FT /note="A -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045369" FT VARIANT 276 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045370" FT VARIANT 276 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045371" FT VARIANT 277 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs763098116)" FT /id="VAR_045372" FT VARIANT 277 FT /note="C -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795369)" FT /id="VAR_006000" FT VARIANT 277 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795369)" FT /id="VAR_045373" FT VARIANT 277 FT /note="C -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045374" FT VARIANT 277 FT /note="C -> W (in sporadic cancers; somatic mutation)" FT /id="VAR_047201" FT VARIANT 277 FT /note="C -> Y (in an osteosarcoma with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs763098116)" FT /id="VAR_045375" FT VARIANT 278 FT /note="P -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs17849781)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_006001" FT VARIANT 278 FT /note="P -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045869" FT VARIANT 278 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs876659802)" FT /id="VAR_006002" FT VARIANT 278 FT /note="P -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs876659802)" FT /evidence="ECO:0000269|PubMed:2263646" FT /id="VAR_006003" FT VARIANT 278 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs876659802)" FT /id="VAR_045376" FT VARIANT 278 FT /note="P -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs17849781)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:2263646, ECO:0000269|PubMed:9450901" FT /id="VAR_006004" FT VARIANT 278 FT /note="P -> T (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs17849781)" FT /id="VAR_006005" FT VARIANT 279 FT /note="G -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1064793881)" FT /id="VAR_006006" FT VARIANT 279 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525248)" FT /id="VAR_045377" FT VARIANT 279 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045378" FT VARIANT 279 FT /note="G -> W (in sporadic cancers; somatic mutation)" FT /id="VAR_045379" FT VARIANT 280 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs753660142)" FT /id="VAR_045380" FT VARIANT 280 FT /note="R -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs121912660)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_006008" FT VARIANT 280 FT /note="R -> K (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; no effect on interaction with CCAR2; FT dbSNP:rs121912660)" FT /evidence="ECO:0000269|PubMed:1694291, FT ECO:0000269|PubMed:25732823" FT /id="VAR_006007" FT VARIANT 280 FT /note="R -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045381" FT VARIANT 280 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045382" FT VARIANT 280 FT /note="R -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs121912660)" FT /evidence="ECO:0000269|PubMed:1631151" FT /id="VAR_006009" FT VARIANT 281..282 FT /note="DR -> EW (in sporadic cancers; somatic mutation)" FT /id="VAR_047203" FT VARIANT 281 FT /note="D -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs587781525)" FT /id="VAR_006010" FT VARIANT 281 FT /note="D -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519984)" FT /evidence="ECO:0000269|PubMed:1459726" FT /id="VAR_006011" FT VARIANT 281 FT /note="D -> G (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs587781525)" FT /id="VAR_006012" FT VARIANT 281 FT /note="D -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs764146326)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_006013" FT VARIANT 281 FT /note="D -> N (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs764146326)" FT /id="VAR_047202" FT VARIANT 281 FT /note="D -> R (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045870" FT VARIANT 281 FT /note="D -> V (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs587781525)" FT /id="VAR_006014" FT VARIANT 281 FT /note="D -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs764146326)" FT /id="VAR_045383" FT VARIANT 282 FT /note="R -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934574)" FT /id="VAR_045384" FT VARIANT 282 FT /note="R -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045385" FT VARIANT 282 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs730882008)" FT /id="VAR_006015" FT VARIANT 282 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs730882008)" FT /id="VAR_045386" FT VARIANT 282 FT /note="R -> Q (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs730882008)" FT /evidence="ECO:0000269|PubMed:18453682, ECO:0000269|Ref.22" FT /id="VAR_045387" FT VARIANT 282 FT /note="R -> W (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; does not induce SNAI1 FT degradation; dbSNP:rs28934574)" FT /evidence="ECO:0000269|PubMed:20385133, FT ECO:0000269|PubMed:8829627" FT /id="VAR_006016" FT VARIANT 283 FT /note="R -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs149633775)" FT /id="VAR_006017" FT VARIANT 283 FT /note="R -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_006018" FT VARIANT 283 FT /note="R -> H (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs371409680)" FT /id="VAR_006019" FT VARIANT 283 FT /note="R -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045388" FT VARIANT 283 FT /note="R -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_006020" FT VARIANT 283 FT /note="R -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs149633775)" FT /id="VAR_045389" FT VARIANT 284 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:20959462" FT /id="VAR_006021" FT VARIANT 284 FT /note="T -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs863224685)" FT /id="VAR_045390" FT VARIANT 284 FT /note="T -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045391" FT VARIANT 284 FT /note="T -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1204379654)" FT /id="VAR_006022" FT VARIANT 285 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045392" FT VARIANT 285 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045393" FT VARIANT 285 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045394" FT VARIANT 285 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs112431538)" FT /evidence="ECO:0000269|PubMed:1459726, FT ECO:0000269|PubMed:1694291" FT /id="VAR_006023" FT VARIANT 285 FT /note="E -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_006024" FT VARIANT 285 FT /note="E -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs121912667)" FT /id="VAR_006025" FT VARIANT 286 FT /note="E -> A (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1057519985)" FT /id="VAR_006026" FT VARIANT 286 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_006027" FT VARIANT 286 FT /note="E -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519985)" FT /id="VAR_006028" FT VARIANT 286 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs786201059)" FT /evidence="ECO:0000269|PubMed:11023613, FT ECO:0000269|PubMed:8316628" FT /id="VAR_006029" FT VARIANT 286 FT /note="E -> L (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045871" FT VARIANT 286 FT /note="E -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs786201059)" FT /evidence="ECO:0000269|PubMed:8829627" FT /id="VAR_006030" FT VARIANT 286 FT /note="E -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519985)" FT /id="VAR_045395" FT VARIANT 287 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_047204" FT VARIANT 287 FT /note="E -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs748891343)" FT /id="VAR_045396" FT VARIANT 287 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045397" FT VARIANT 287 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs587782006)" FT /id="VAR_045398" FT VARIANT 287 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045399" FT VARIANT 288 FT /note="N -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045400" FT VARIANT 288 FT /note="N -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045401" FT VARIANT 288 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045402" FT VARIANT 288 FT /note="N -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045403" FT VARIANT 288 FT /note="N -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045404" FT VARIANT 289 FT /note="L -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045405" FT VARIANT 289 FT /note="L -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045406" FT VARIANT 289 FT /note="L -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045407" FT VARIANT 289 FT /note="L -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045408" FT VARIANT 289 FT /note="L -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525154)" FT /id="VAR_045409" FT VARIANT 290 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs770374782)" FT /id="VAR_045410" FT VARIANT 290 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs55819519)" FT /id="VAR_045411" FT VARIANT 290 FT /note="R -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_045412" FT VARIANT 291 FT /note="K -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525126)" FT /id="VAR_045413" FT VARIANT 291 FT /note="K -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_045414" FT VARIANT 291 FT /note="K -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs372613518)" FT /id="VAR_045415" FT VARIANT 291 FT /note="K -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_047205" FT VARIANT 291 FT /note="K -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs781490101)" FT /id="VAR_045416" FT VARIANT 291 FT /note="K -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045417" FT VARIANT 292 FT /note="K -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045418" FT VARIANT 292 FT /note="K -> G (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045872" FT VARIANT 292 FT /note="K -> I (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation; dbSNP:rs121912663)" FT /evidence="ECO:0000269|PubMed:10484981" FT /id="VAR_015819" FT VARIANT 292 FT /note="K -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045419" FT VARIANT 292 FT /note="K -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_045420" FT VARIANT 292 FT /note="K -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs121912663)" FT /id="VAR_045421" FT VARIANT 292 FT /note="K -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045422" FT VARIANT 293 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045423" FT VARIANT 293 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs587780076)" FT /id="VAR_045424" FT VARIANT 293 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045425" FT VARIANT 293 FT /note="G -> W (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs587780076)" FT /id="VAR_045426" FT VARIANT 294 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045427" FT VARIANT 294 FT /note="E -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1305324490)" FT /id="VAR_045428" FT VARIANT 294 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045429" FT VARIANT 294 FT /note="E -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_047206" FT VARIANT 294 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045430" FT VARIANT 294 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045431" FT VARIANT 295 FT /note="P -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045432" FT VARIANT 295 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs751713111)" FT /id="VAR_045433" FT VARIANT 295 FT /note="P -> R (in a sporadic cancer; somatic mutation; FT dbSNP:rs751713111)" FT /id="VAR_045434" FT VARIANT 295 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691006)" FT /id="VAR_045435" FT VARIANT 296 FT /note="H -> C (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045873" FT VARIANT 296 FT /note="H -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045436" FT VARIANT 296 FT /note="H -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_047207" FT VARIANT 296 FT /note="H -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045437" FT VARIANT 296 FT /note="H -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_006031" FT VARIANT 296 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045438" FT VARIANT 296 FT /note="H -> R (in a sporadic cancer; somatic mutation; FT dbSNP:rs483352696)" FT /id="VAR_045439" FT VARIANT 296 FT /note="H -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs672601296)" FT /id="VAR_045440" FT VARIANT 297 FT /note="H -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045441" FT VARIANT 297 FT /note="H -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045442" FT VARIANT 297 FT /note="H -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045443" FT VARIANT 297 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs876659477)" FT /id="VAR_045444" FT VARIANT 297 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045445" FT VARIANT 298 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045446" FT VARIANT 298 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045447" FT VARIANT 298 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs201744589)" FT /id="VAR_045448" FT VARIANT 298 FT /note="E -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs201744589)" FT /id="VAR_045449" FT VARIANT 298 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045450" FT VARIANT 299 FT /note="L -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045451" FT VARIANT 299 FT /note="L -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045452" FT VARIANT 299 FT /note="L -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045453" FT VARIANT 299 FT /note="L -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045454" FT VARIANT 300 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045455" FT VARIANT 300 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs909643864)" FT /id="VAR_045456" FT VARIANT 300 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_006032" FT VARIANT 300 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045457" FT VARIANT 301 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045458" FT VARIANT 301 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525067)" FT /id="VAR_006033" FT VARIANT 301 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045459" FT VARIANT 301 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045460" FT VARIANT 301 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_047208" FT VARIANT 302 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045461" FT VARIANT 302 FT /note="G -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501202)" FT /id="VAR_006034" FT VARIANT 302 FT /note="G -> R (in a sporadic cancer; somatic mutation; FT dbSNP:rs863224686)" FT /id="VAR_045462" FT VARIANT 302 FT /note="G -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_006035" FT VARIANT 303 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045463" FT VARIANT 303 FT /note="S -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045464" FT VARIANT 303 FT /note="S -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs876658714)" FT /id="VAR_045465" FT VARIANT 303 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045466" FT VARIANT 304 FT /note="T -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs587782654)" FT /id="VAR_045467" FT VARIANT 304 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045468" FT VARIANT 304 FT /note="T -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045469" FT VARIANT 304 FT /note="T -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_047209" FT VARIANT 305 FT /note="K -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_045470" FT VARIANT 305 FT /note="K -> M (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_045471" FT VARIANT 305 FT /note="K -> N (in sporadic cancers; somatic mutation; loss FT of nuclear localization)" FT /evidence="ECO:0000269|PubMed:10551826" FT /id="VAR_045472" FT VARIANT 305 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045473" FT VARIANT 305 FT /note="K -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045474" FT VARIANT 306 FT /note="R -> P (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation)" FT /id="VAR_045475" FT VARIANT 306 FT /note="R -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs1048095040)" FT /id="VAR_006036" FT VARIANT 307 FT /note="A -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045476" FT VARIANT 307 FT /note="A -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045477" FT VARIANT 307 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_006037" FT VARIANT 308 FT /note="L -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_045478" FT VARIANT 308 FT /note="L -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045479" FT VARIANT 309 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045480" FT VARIANT 309 FT /note="P -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1555525012)" FT /evidence="ECO:0000269|Ref.14" FT /id="VAR_006038" FT VARIANT 310 FT /note="N -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045481" FT VARIANT 310 FT /note="N -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045482" FT VARIANT 311 FT /note="N -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525007)" FT /id="VAR_045483" FT VARIANT 311 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045484" FT VARIANT 311 FT /note="N -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs56184981)" FT /id="VAR_045485" FT VARIANT 311 FT /note="N -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs56184981)" FT /id="VAR_045486" FT VARIANT 312 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045487" FT VARIANT 312 FT /note="T -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs145151284)" FT /id="VAR_045488" FT VARIANT 313 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_045489" FT VARIANT 313 FT /note="S -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045490" FT VARIANT 313 FT /note="S -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045491" FT VARIANT 313 FT /note="S -> R (in a sporadic cancer; somatic mutation; FT dbSNP:rs1367492395)" FT /id="VAR_045492" FT VARIANT 314 FT /note="S -> F (in a sporadic cancer; somatic mutation; FT dbSNP:rs751440465)" FT /id="VAR_045493" FT VARIANT 315 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_045494" FT VARIANT 315 FT /note="S -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045495" FT VARIANT 315 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045496" FT VARIANT 316 FT /note="P -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555524979)" FT /id="VAR_045497" FT VARIANT 316 FT /note="P -> T (in a sporadic cancer; somatic mutation; FT dbSNP:rs772773208)" FT /id="VAR_045498" FT VARIANT 317 FT /note="Q -> H (in a kidney cancer with no family history; FT germline mutation and in a sporadic cancer; somatic FT mutation; dbSNP:rs1060501199)" FT /id="VAR_045499" FT VARIANT 317 FT /note="Q -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs764735889)" FT /id="VAR_045500" FT VARIANT 317 FT /note="Q -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_047210" FT VARIANT 317 FT /note="Q -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045501" FT VARIANT 317 FT /note="Q -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1159579789)" FT /id="VAR_045502" FT VARIANT 318 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555524975)" FT /id="VAR_045503" FT VARIANT 319 FT /note="K -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045504" FT VARIANT 319 FT /note="K -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045505" FT VARIANT 319 FT /note="K -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045506" FT VARIANT 320 FT /note="K -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045507" FT VARIANT 321 FT /note="K -> E (in kidney cancer; germline mutation)" FT /id="VAR_045508" FT VARIANT 321 FT /note="K -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045509" FT VARIANT 322 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045510" FT VARIANT 322 FT /note="P -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045511" FT VARIANT 323 FT /note="L -> G (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045874" FT VARIANT 323 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_045512" FT VARIANT 323 FT /note="L -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045513" FT VARIANT 323 FT /note="L -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045514" FT VARIANT 323 FT /note="L -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs1432281680)" FT /id="VAR_047211" FT VARIANT 324 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045515" FT VARIANT 324 FT /note="D -> S (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045875" FT VARIANT 324 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_045516" FT VARIANT 325 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045517" FT VARIANT 325 FT /note="G -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045518" FT VARIANT 325 FT /note="G -> V (in LFS; germline mutation; FT dbSNP:rs121912659)" FT /evidence="ECO:0000269|PubMed:1565144" FT /id="VAR_006039" FT VARIANT 326 FT /note="E -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045519" FT VARIANT 327 FT /note="Y -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045520" FT VARIANT 327 FT /note="Y -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045521" FT VARIANT 328 FT /note="F -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045522" FT VARIANT 328 FT /note="F -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045523" FT VARIANT 328 FT /note="F -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045524" FT VARIANT 329 FT /note="T -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs969930693)" FT /id="VAR_045525" FT VARIANT 329 FT /note="T -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045526" FT VARIANT 330 FT /note="L -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045527" FT VARIANT 330 FT /note="L -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_047212" FT VARIANT 330 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045528" FT VARIANT 331 FT /note="Q -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs11575996)" FT /id="VAR_045529" FT VARIANT 331 FT /note="Q -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045530" FT VARIANT 331 FT /note="Q -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795056)" FT /id="VAR_045531" FT VARIANT 332 FT /note="I -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045532" FT VARIANT 334 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_006040" FT VARIANT 334 FT /note="G -> W (in a sporadic cancer; somatic mutation; FT dbSNP:rs730882028)" FT /id="VAR_045533" FT VARIANT 335 FT /note="R -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045534" FT VARIANT 335 FT /note="R -> H (in a sporadic cancer; somatic mutation; FT dbSNP:rs771939956)" FT /id="VAR_045535" FT VARIANT 335 FT /note="R -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045536" FT VARIANT 337 FT /note="R -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; impaired ability to tetramerize FT and undergo liquid-liquid phase separation; FT dbSNP:rs587782529)" FT /evidence="ECO:0000269|PubMed:36108750, FT ECO:0000269|PubMed:9452042" FT /id="VAR_006041" FT VARIANT 337 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; impaired ability to tetramerize FT and undergo liquid-liquid phase separation; FT dbSNP:rs121912664)" FT /evidence="ECO:0000269|PubMed:11481490, FT ECO:0000269|PubMed:36108750" FT /id="VAR_035016" FT VARIANT 337 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs121912664)" FT /id="VAR_045537" FT VARIANT 337 FT /note="R -> P (in sporadic cancers; somatic mutation; FT impaired ability to tetramerize and undergo liquid-liquid FT phase separation; dbSNP:rs121912664)" FT /evidence="ECO:0000269|PubMed:36108750" FT /id="VAR_045538" FT VARIANT 338 FT /note="F -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045539" FT VARIANT 338 FT /note="F -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs150293825)" FT /id="VAR_045540" FT VARIANT 339 FT /note="E -> K (in a sporadic cancer; somatic mutation; FT dbSNP:rs17882252)" FT /evidence="ECO:0000269|Ref.12" FT /id="VAR_022316" FT VARIANT 339 FT /note="E -> Q (in a sporadic cancer; somatic mutation; FT dbSNP:rs17882252)" FT /id="VAR_045541" FT VARIANT 341 FT /note="F -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045542" FT VARIANT 342 FT /note="R -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045543" FT VARIANT 342 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs375338359)" FT /id="VAR_045544" FT VARIANT 342 FT /note="R -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs375338359)" FT /id="VAR_047213" FT VARIANT 343 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045545" FT VARIANT 344 FT /note="L -> P (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation; impaired ability to tetramerize FT and undergo liquid-liquid phase separation; FT dbSNP:rs121912662)" FT /evidence="ECO:0000269|PubMed:36108750" FT /id="VAR_045546" FT VARIANT 344 FT /note="L -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045547" FT VARIANT 346 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045548" FT VARIANT 347 FT /note="A -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045549" FT VARIANT 347 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045550" FT VARIANT 348 FT /note="L -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045551" FT VARIANT 348 FT /note="L -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045552" FT VARIANT 349 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045553" FT VARIANT 352 FT /note="D -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045554" FT VARIANT 353 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045555" FT VARIANT 354 FT /note="Q -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_045556" FT VARIANT 354 FT /note="Q -> K (in a sporadic cancer; somatic mutation; FT dbSNP:rs755394212)" FT /id="VAR_045557" FT VARIANT 354 FT /note="Q -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs752142489)" FT /id="VAR_047214" FT VARIANT 356 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045558" FT VARIANT 356 FT /note="G -> W (in a sporadic cancer; somatic mutation)" FT /id="VAR_045559" FT VARIANT 358 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045560" FT VARIANT 358 FT /note="E -> K (in a sporadic cancer; somatic mutation; FT dbSNP:rs587782237)" FT /id="VAR_045561" FT VARIANT 360 FT /note="G -> A (in dbSNP:rs35993958)" FT /id="VAR_045562" FT VARIANT 360 FT /note="G -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs35993958)" FT /id="VAR_045563" FT VARIANT 363 FT /note="R -> K (in a sporadic cancer; somatic mutation; FT dbSNP:rs876660285)" FT /id="VAR_045564" FT VARIANT 364 FT /note="A -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045565" FT VARIANT 364 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045566" FT VARIANT 364 FT /note="A -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045567" FT VARIANT 365 FT /note="H -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_047215" FT VARIANT 365 FT /note="H -> Y (in a familial cancer not matching LFS; FT germline mutation and in a sporadic cancer; somatic FT mutation; dbSNP:rs267605075)" FT /id="VAR_045568" FT VARIANT 366 FT /note="S -> A (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs17881470)" FT /evidence="ECO:0000269|Ref.12" FT /id="VAR_022317" FT VARIANT 370 FT /note="K -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_045569" FT VARIANT 376 FT /note="S -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045570" FT VARIANT 376 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045571" FT VARIANT 379 FT /note="R -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs863224682)" FT /id="VAR_045572" FT VARIANT 385 FT /note="F -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555524094)" FT /id="VAR_045573" FT VARIANT 389 FT /note="G -> W (in a sporadic cancer; somatic mutation; FT dbSNP:rs587783064)" FT /id="VAR_045574" FT VARIANT 392 FT /note="S -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045575" FT MUTAGEN 15 FT /note="S->A: Loss of interaction with PPP2R5C, PPP2CA AND FT PPP2R1A." FT /evidence="ECO:0000269|PubMed:17967874" FT MUTAGEN 18 FT /note="T->A: No effect on interaction with MDM2 and FT increase in protein levels after DNA damage." FT /evidence="ECO:0000269|PubMed:10570149" FT MUTAGEN 20 FT /note="S->A: Abolishes phosphorylation site. Abolishes FT increase in protein levels after DNA damage." FT /evidence="ECO:0000269|PubMed:10570149" FT MUTAGEN 20 FT /note="S->D: Constitutively increased TP53 protein levels." FT /evidence="ECO:0000269|PubMed:10570149" FT MUTAGEN 22..23 FT /note="LW->QS: Loss of interaction with MDM2, leading to FT constitutively increased TP53 protein levels." FT /evidence="ECO:0000269|PubMed:10570149" FT MUTAGEN 24 FT /note="K->R: Abolishes ubiquitination by MUL1." FT /evidence="ECO:0000269|PubMed:21597459" FT MUTAGEN 37 FT /note="S->D: Abolishes phosphorylation by MAPKAPK5." FT /evidence="ECO:0000269|PubMed:17254968" FT MUTAGEN 46 FT /note="S->A: Abolishes phosphorylation by DYRK2 and HIPK2 FT and acetylation of K-382 by CREBBP." FT /evidence="ECO:0000269|PubMed:11740489, FT ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:17349958" FT MUTAGEN 46 FT /note="Missing: Alters interaction with WWOX." FT /evidence="ECO:0000269|PubMed:11740489, FT ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:17349958" FT MUTAGEN 55 FT /note="T->A: Blocks phosphorylation by TAF1." FT /evidence="ECO:0000269|PubMed:15053879" FT MUTAGEN 183 FT /note="S->A: Abolishes strongly phosphorylation." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 183 FT /note="S->E: Inhibits slightly its transcriptional FT activity." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 248 FT /note="R->S: Does not induce SNAI1 degradation." FT /evidence="ECO:0000269|PubMed:20385133" FT MUTAGEN 269 FT /note="S->A: Abolishes phosphorylation." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 269 FT /note="S->E: Inhibits strongly its transcriptional FT activity." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 284 FT /note="T->E: Inhibits strongly its transcriptional FT activity." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 291..292 FT /note="KK->RR: Abolishes polyubiquitination by MKRN1." FT /evidence="ECO:0000269|PubMed:19536131" FT MUTAGEN 319 FT /note="K->A: Loss of nuclear localization; when associated FT with A-320 and A-321." FT /evidence="ECO:0000269|PubMed:2156209" FT MUTAGEN 320 FT /note="K->A: Loss of nuclear localization; when associated FT with A-319 and A-321." FT /evidence="ECO:0000269|PubMed:2156209" FT MUTAGEN 321 FT /note="K->A: Loss of nuclear localization; when associated FT with A-319 and A-320." FT /evidence="ECO:0000269|PubMed:2156209" FT MUTAGEN 333..337 FT /note="RGRER->KGKEK: Reduced methylation by PRMT5. Reduced FT nuclear localization. Decreased binding to promoters of FT target genes. Reduced transcriptional activity. Decrease in FT cell cycle arrest." FT /evidence="ECO:0000269|PubMed:19011621" FT MUTAGEN 359 FT /note="P->D: Abolishes binding to USP7." FT /evidence="ECO:0000269|PubMed:16402859" FT MUTAGEN 361 FT /note="G->E: Abolishes binding to USP7." FT /evidence="ECO:0000269|PubMed:16402859" FT MUTAGEN 362 FT /note="S->A: Abolishes binding to USP7." FT /evidence="ECO:0000269|PubMed:16402859" FT MUTAGEN 370 FT /note="K->R: Induces a decrease in methylation by SMYD2." FT /evidence="ECO:0000269|PubMed:17108971" FT MUTAGEN 372 FT /note="K->R: Induces a decrease in protein stabilization." FT /evidence="ECO:0000269|PubMed:15525938" FT MUTAGEN 373 FT /note="K->R: Abolishes dimethylation by EHMT1 and EHMT2." FT /evidence="ECO:0000269|PubMed:20118233" FT MUTAGEN 381 FT /note="K->Q: Mimics acetylation, leading to increased FT stability." FT /evidence="ECO:0000269|PubMed:29474172" FT MUTAGEN 381 FT /note="K->R: Decreased acetylation." FT /evidence="ECO:0000269|PubMed:29474172" FT MUTAGEN 382 FT /note="K->A: Abolishes acetylation by CREBBP." FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:11740489, ECO:0000269|PubMed:17707234, FT ECO:0000269|PubMed:20870725" FT MUTAGEN 382 FT /note="K->R: Abolishes monomethylation by KMT5A." FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:11740489, ECO:0000269|PubMed:17707234, FT ECO:0000269|PubMed:20870725" FT MUTAGEN 383 FT /note="L->A: Abolishes S-315 phosphorylation by CDK2/cyclin FT A." FT /evidence="ECO:0000269|PubMed:10884347" FT MUTAGEN 385 FT /note="F->A: Reduced SUMO1 conjugation." FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:11124955" FT MUTAGEN 386 FT /note="K->A: Abolishes SUMO1 conjugation, in vitro and in FT vivo." FT /evidence="ECO:0000269|PubMed:11124955, ECO:0000269|Ref.37" FT MUTAGEN 387 FT /note="T->A: No effect SUMO1 conjugation." FT /evidence="ECO:0000269|PubMed:11124955" FT MUTAGEN 388 FT /note="E->A: Abolishes SUMO1 conjugation." FT /evidence="ECO:0000269|PubMed:11124955" FT MUTAGEN 392 FT /note="S->D: Mimics phosphorylation; promotes ability to FT undergo liquid-liquid phase separation." FT /evidence="ECO:0000269|PubMed:35618207" FT MUTAGEN 392 FT /note="S->E: Abolished ability to undergo liquid-liquid FT phase separation." FT /evidence="ECO:0000269|PubMed:31953488" FT HELIX 3..6 FT /evidence="ECO:0007829|PDB:5HOU" FT TURN 8..10 FT /evidence="ECO:0007829|PDB:5HOU" FT HELIX 19..29 FT /evidence="ECO:0007829|PDB:9C5S" FT HELIX 30..32 FT /evidence="ECO:0007829|PDB:5HPD" FT STRAND 33..35 FT /evidence="ECO:0007829|PDB:2L14" FT HELIX 36..38 FT /evidence="ECO:0007829|PDB:2B3G" FT HELIX 41..44 FT /evidence="ECO:0007829|PDB:2B3G" FT HELIX 47..55 FT /evidence="ECO:0007829|PDB:2B3G" FT STRAND 95..97 FT /evidence="ECO:0007829|PDB:7B49" FT TURN 105..108 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 110..112 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 118..120 FT /evidence="ECO:0007829|PDB:3Q05" FT TURN 121..123 FT /evidence="ECO:0007829|PDB:3Q05" FT STRAND 124..127 FT /evidence="ECO:0007829|PDB:3D06" FT TURN 128..131 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 132..135 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 141..146 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 148..150 FT /evidence="ECO:0007829|PDB:5UN8" FT STRAND 156..165 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 166..168 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 177..180 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 181..183 FT /evidence="ECO:0007829|PDB:4KVP" FT STRAND 187..189 FT /evidence="ECO:0007829|PDB:6GGC" FT STRAND 194..199 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 204..207 FT /evidence="ECO:0007829|PDB:3D06" FT TURN 209..211 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 214..219 FT /evidence="ECO:0007829|PDB:3D06" FT TURN 225..227 FT /evidence="ECO:0007829|PDB:2FEJ" FT STRAND 228..236 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 240..242 FT /evidence="ECO:0007829|PDB:3D07" FT TURN 243..248 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 251..258 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 260..262 FT /evidence="ECO:0007829|PDB:2ADY" FT STRAND 264..274 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 278..287 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 288..290 FT /evidence="ECO:0007829|PDB:4HJE" FT HELIX 322..324 FT /evidence="ECO:0007829|PDB:3Q01" FT STRAND 327..334 FT /evidence="ECO:0007829|PDB:3Q01" FT HELIX 335..354 FT /evidence="ECO:0007829|PDB:1AIE" FT HELIX 375..380 FT /evidence="ECO:0007829|PDB:1YC5" SQ SEQUENCE 393 AA; 43653 MW; AD5C149FD8106131 CRC64; MEEPQSDPSV EPPLSQETFS DLWKLLPENN VLSPLPSQAM DDLMLSPDDI EQWFTEDPGP DEAPRMPEAA PPVAPAPAAP TPAAPAPAPS WPLSSSVPSQ KTYQGSYGFR LGFLHSGTAK SVTCTYSPAL NKMFCQLAKT CPVQLWVDST PPPGTRVRAM AIYKQSQHMT EVVRRCPHHE RCSDSDGLAP PQHLIRVEGN LRVEYLDDRN TFRHSVVVPY EPPEVGSDCT TIHYNYMCNS SCMGGMNRRP ILTIITLEDS SGNLLGRNSF EVRVCACPGR DRRTEEENLR KKGEPHHELP PGSTKRALPN NTSSSPQPKK KPLDGEYFTL QIRGRERFEM FRELNEALEL KDAQAGKEPG GSRAHSSHLK SKKGQSTSRH KKLMFKTEGP DSD // ID PAK5_HUMAN Reviewed; 719 AA. AC Q9P286; A8K5T6; D3DW14; Q5W115; Q8TB93; Q9BX09; Q9ULF6; DT 24-JAN-2001, integrated into UniProtKB/Swiss-Prot. DT 01-OCT-2000, sequence version 1. DT 28-JAN-2026, entry version 227. DE RecName: Full=Serine/threonine-protein kinase PAK 5 {ECO:0000305}; DE EC=2.7.11.1; DE AltName: Full=p21-activated kinase 5; DE Short=PAK-5; DE AltName: Full=p21-activated kinase 7; DE Short=PAK-7; GN Name=PAK5 {ECO:0000312|HGNC:HGNC:15916}; Synonyms=KIAA1264, PAK7; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Brain; RX PubMed=12032833; DOI=10.1038/sj.onc.1205478; RA Pandey A., Dan I., Kristiansen T.Z., Watanabe N.M., Voldby J., Kajikawa E., RA Khosravi-Far R., Blagoev B., Mann M.; RT "Cloning and characterization of PAK5, a novel member of mammalian p21- RT activated kinase-II subfamily that is predominantly expressed in brain."; RL Oncogene 21:3939-3948(2002). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=10574462; DOI=10.1093/dnares/6.5.337; RA Nagase T., Ishikawa K., Kikuno R., Hirosawa M., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XV. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 6:337-345(1999). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ASN-511. RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=11780052; DOI=10.1038/414865a; RA Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R., RA Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L., RA Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P., RA Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D., RA Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G., RA Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E., RA Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D., RA Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P., RA Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E., RA Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J., RA Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D., RA Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S., RA Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D., RA Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A., RA Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T., RA Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I., RA Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M., RA Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D., RA Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M., RA Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A., RA Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L., RA Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L., RA Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 20."; RL Nature 414:865-871(2001). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP DOMAIN, AND MUTAGENESIS OF 19-HIS--HIS-22. RX PubMed=12860998; DOI=10.1074/jbc.c300234200; RA Ching Y.P., Leong V.Y., Wong C.M., Kung H.F.; RT "Identification of an autoinhibitory domain of p21-activated protein kinase RT 5."; RL J. Biol. Chem. 278:33621-33624(2003). RN [8] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=12897128; DOI=10.1128/mcb.23.16.5526-5539.2003; RA Cotteret S., Jaffer Z.M., Beeser A., Chernoff J.; RT "p21-Activated kinase 5 (Pak5) localizes to mitochondria and inhibits RT apoptosis by phosphorylating BAD."; RL Mol. Cell. Biol. 23:5526-5539(2003). RN [9] RP FUNCTION, AND INTERACTION WITH MARK2. RX PubMed=16014608; DOI=10.1091/mbc.e05-01-0081; RA Matenia D., Griesshaber B., Li X.Y., Thiessen A., Johne C., Jiao J., RA Mandelkow E., Mandelkow E.M.; RT "PAK5 kinase is an inhibitor of MARK/Par-1, which leads to stable RT microtubules and dynamic actin."; RL Mol. Biol. Cell 16:4410-4422(2005). RN [10] RP INTERACTION WITH RHOD AND RHOH. RX PubMed=17064668; DOI=10.1016/j.bbrc.2006.09.172; RA Wu X., Frost J.A.; RT "Multiple Rho proteins regulate the subcellular targeting of PAK5."; RL Biochem. Biophys. Res. Commun. 351:328-335(2006). RN [11] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=16581795; DOI=10.1128/mcb.26.8.3215-3230.2006; RA Cotteret S., Chernoff J.; RT "Nucleocytoplasmic shuttling of Pak5 regulates its antiapoptotic RT properties."; RL Mol. Cell. Biol. 26:3215-3230(2006). RN [12] RP FUNCTION IN PHOSPHORYLATION OF RAF1. RX PubMed=18465753; DOI=10.1002/jcb.21809; RA Wu X., Carr H.S., Dan I., Ruvolo P.P., Frost J.A.; RT "p21 activated kinase 5 activates Raf-1 and targets it to mitochondria."; RL J. Cell. Biochem. 105:167-175(2008). RN [13] RP FUNCTION IN PHOSPHORYLATION OF CTNND1. RX PubMed=20564219; DOI=10.1002/jcb.22639; RA Wong L.E., Reynolds A.B., Dissanayaka N.T., Minden A.; RT "p120-catenin is a binding partner and substrate for Group B Pak kinases."; RL J. Cell. Biochem. 110:1244-1254(2010). RN [14] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 425-719. RX PubMed=17292838; DOI=10.1016/j.str.2007.01.001; RA Eswaran J., Lee W.H., Debreczeni J.E., Filippakopoulos P., Turnbull A., RA Fedorov O., Deacon S.W., Peterson J.R., Knapp S.; RT "Crystal Structures of the p21-activated kinases PAK4, PAK5, and PAK6 RT reveal catalytic domain plasticity of active group II PAKs."; RL Structure 15:201-213(2007). RN [15] RP VARIANTS [LARGE SCALE ANALYSIS] ASP-118; ALA-187; PRO-312; PRO-335; RP ASN-511; ASN-538; SER-555; ILE-604 AND SER-704. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine protein kinase that plays a role in a CC variety of different signaling pathways including cytoskeleton CC regulation, cell migration, proliferation or cell survival. Activation CC by various effectors including growth factor receptors or active CDC42 CC and RAC1 results in a conformational change and a subsequent CC autophosphorylation on several serine and/or threonine residues. CC Phosphorylates the proto-oncogene RAF1 and stimulates its kinase CC activity. Promotes cell survival by phosphorylating the BCL2 antagonist CC of cell death BAD. Phosphorylates CTNND1, probably to regulate CC cytoskeletal organization and cell morphology. Keeps microtubules CC stable through MARK2 inhibition and destabilizes the F-actin network CC leading to the disappearance of stress fibers and focal adhesions. CC {ECO:0000269|PubMed:12897128, ECO:0000269|PubMed:16014608, CC ECO:0000269|PubMed:16581795, ECO:0000269|PubMed:18465753, CC ECO:0000269|PubMed:20564219}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- SUBUNIT: Interacts tightly with GTP-bound but not GDP-bound CDC42/p21 CC and RAC1. Interacts with MARK2, leading to inhibit MARK2 independently CC of kinase activity. Interacts with RHOD and RHOH. CC {ECO:0000269|PubMed:16014608, ECO:0000269|PubMed:17064668}. CC -!- INTERACTION: CC Q9P286; Q8IW93: ARHGEF19; NbExp=3; IntAct=EBI-741896, EBI-7799822; CC Q9P286; Q9H6L4: ARMC7; NbExp=3; IntAct=EBI-741896, EBI-742909; CC Q9P286; Q8N5M1: ATPAF2; NbExp=7; IntAct=EBI-741896, EBI-1166928; CC Q9P286; Q9H257: CARD9; NbExp=5; IntAct=EBI-741896, EBI-751319; CC Q9P286; Q9H257-2: CARD9; NbExp=3; IntAct=EBI-741896, EBI-11530605; CC Q9P286; Q8NEC5: CATSPER1; NbExp=3; IntAct=EBI-741896, EBI-744545; CC Q9P286; Q2TAC2-2: CCDC57; NbExp=3; IntAct=EBI-741896, EBI-10961624; CC Q9P286; P51959: CCNG1; NbExp=4; IntAct=EBI-741896, EBI-3905829; CC Q9P286; P60953: CDC42; NbExp=5; IntAct=EBI-741896, EBI-81752; CC Q9P286; Q96SW2: CRBN; NbExp=4; IntAct=EBI-741896, EBI-2510250; CC Q9P286; P48730: CSNK1D; NbExp=3; IntAct=EBI-741896, EBI-751621; CC Q9P286; P26196: DDX6; NbExp=3; IntAct=EBI-741896, EBI-351257; CC Q9P286; P50402: EMD; NbExp=3; IntAct=EBI-741896, EBI-489887; CC Q9P286; Q9H0I2: ENKD1; NbExp=3; IntAct=EBI-741896, EBI-744099; CC Q9P286; Q9Y3B2: EXOSC1; NbExp=3; IntAct=EBI-741896, EBI-371892; CC Q9P286; Q96CN9: GCC1; NbExp=3; IntAct=EBI-741896, EBI-746252; CC Q9P286; P42858: HTT; NbExp=3; IntAct=EBI-741896, EBI-466029; CC Q9P286; Q96EL1: INKA1; NbExp=5; IntAct=EBI-741896, EBI-10285157; CC Q9P286; Q96BZ8: LENG1; NbExp=3; IntAct=EBI-741896, EBI-726510; CC Q9P286; Q8TBB1: LNX1; NbExp=3; IntAct=EBI-741896, EBI-739832; CC Q9P286; Q96JP2: MYO15B; NbExp=3; IntAct=EBI-741896, EBI-7950783; CC Q9P286; P07196: NEFL; NbExp=3; IntAct=EBI-741896, EBI-475646; CC Q9P286; Q96HA8: NTAQ1; NbExp=3; IntAct=EBI-741896, EBI-741158; CC Q9P286; P16284: PECAM1; NbExp=3; IntAct=EBI-741896, EBI-716404; CC Q9P286; Q8WWY3: PRPF31; NbExp=6; IntAct=EBI-741896, EBI-1567797; CC Q9P286; Q92530: PSMF1; NbExp=3; IntAct=EBI-741896, EBI-945916; CC Q9P286; Q16825: PTPN21; NbExp=3; IntAct=EBI-741896, EBI-2860264; CC Q9P286; Q9H4E5: RHOJ; NbExp=3; IntAct=EBI-741896, EBI-6285694; CC Q9P286; O60504: SORBS3; NbExp=3; IntAct=EBI-741896, EBI-741237; CC Q9P286; Q9BZW7: TSGA10; NbExp=3; IntAct=EBI-741896, EBI-744794; CC Q9P286; Q9UBK9: UXT; NbExp=4; IntAct=EBI-741896, EBI-357355; CC Q9P286; O76024: WFS1; NbExp=3; IntAct=EBI-741896, EBI-720609; CC Q9P286; P62258: YWHAE; NbExp=3; IntAct=EBI-741896, EBI-356498; CC Q9P286; P47041: BIT61; Xeno; NbExp=3; IntAct=EBI-741896, EBI-25889; CC Q9P286; P32474: EUG1; Xeno; NbExp=3; IntAct=EBI-741896, EBI-2343998; CC Q9P286; P32502: GCD7; Xeno; NbExp=3; IntAct=EBI-741896, EBI-6260; CC -!- SUBCELLULAR LOCATION: Mitochondrion. Cytoplasm. Nucleus. Note=Shuttles CC between the nucleus and the mitochondria, and mitochondrial CC localization is essential for the role in cell survival. CC -!- TISSUE SPECIFICITY: Predominantly expressed in brain. CC -!- DOMAIN: An autoinhibitory domain is present in the N-terminal region of CC the protein. {ECO:0000269|PubMed:12860998}. CC -!- PTM: Autophosphorylated when activated by CDC42/p21. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr CC protein kinase family. STE20 subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA86578.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB040812; BAA94194.1; -; mRNA. DR EMBL; AB033090; BAA86578.1; ALT_INIT; mRNA. DR EMBL; AK291401; BAF84090.1; -; mRNA. DR EMBL; AL031652; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL135935; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL353612; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471133; EAX10358.1; -; Genomic_DNA. DR EMBL; CH471133; EAX10359.1; -; Genomic_DNA. DR EMBL; CH471133; EAX10360.1; -; Genomic_DNA. DR EMBL; BC024179; AAH24179.1; -; mRNA. DR CCDS; CCDS13107.1; -. DR RefSeq; NP_065074.1; NM_020341.5. DR RefSeq; NP_817127.1; NM_177990.4. DR RefSeq; XP_016883449.1; XM_017027960.2. DR RefSeq; XP_016883450.1; XM_017027961.2. DR RefSeq; XP_016883451.1; XM_017027962.2. DR RefSeq; XP_016883453.1; XM_017027964.2. DR RefSeq; XP_016883454.1; XM_017027965.2. DR RefSeq; XP_054179701.1; XM_054323726.1. DR RefSeq; XP_054179702.1; XM_054323727.1. DR RefSeq; XP_054179703.1; XM_054323728.1. DR RefSeq; XP_054179704.1; XM_054323729.1. DR RefSeq; XP_054179705.1; XM_054323730.1. DR PDB; 2F57; X-ray; 1.80 A; A/B=425-719. DR PDB; 8C12; X-ray; 1.55 A; AAA=426-719. DR PDBsum; 2F57; -. DR PDBsum; 8C12; -. DR AlphaFoldDB; Q9P286; -. DR SMR; Q9P286; -. DR BioGRID; 121402; 117. DR FunCoup; Q9P286; 2316. DR IntAct; Q9P286; 116. DR MINT; Q9P286; -. DR STRING; 9606.ENSP00000367686; -. DR BindingDB; Q9P286; -. DR ChEMBL; CHEMBL4524; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q9P286; -. DR GuidetoPHARMACOLOGY; 2138; -. DR GlyGen; Q9P286; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q9P286; -. DR PhosphoSitePlus; Q9P286; -. DR BioMuta; PAK5; -. DR DMDM; 12585290; -. DR CPTAC; non-CPTAC-2960; -. DR CPTAC; non-CPTAC-2961; -. DR jPOST; Q9P286; -. DR MassIVE; Q9P286; -. DR PaxDb; 9606-ENSP00000367686; -. DR PeptideAtlas; Q9P286; -. DR ProteomicsDB; 83751; -. DR Antibodypedia; 8792; 369 antibodies from 39 providers. DR DNASU; 57144; -. DR Ensembl; ENST00000353224.10; ENSP00000322957.5; ENSG00000101349.18. DR Ensembl; ENST00000378423.5; ENSP00000367679.1; ENSG00000101349.18. DR Ensembl; ENST00000378429.3; ENSP00000367686.3; ENSG00000101349.18. DR GeneID; 57144; -. DR KEGG; hsa:57144; -. DR MANE-Select; ENST00000353224.10; ENSP00000322957.5; NM_177990.4; NP_817127.1. DR UCSC; uc002wnj.3; human. DR AGR; HGNC:15916; -. DR ClinPGx; PA32922; -. DR CTD; 57144; -. DR DisGeNET; 57144; -. DR GeneCards; PAK5; -. DR HGNC; HGNC:15916; PAK5. DR HPA; ENSG00000101349; Group enriched (brain, retina). DR MalaCards; PAK5; -. DR MIM; 608038; gene. DR OpenTargets; ENSG00000101349; -. DR VEuPathDB; HostDB:ENSG00000101349; -. DR eggNOG; KOG0578; Eukaryota. DR GeneTree; ENSGT00940000158656; -. DR HOGENOM; CLU_000288_26_6_1; -. DR InParanoid; Q9P286; -. DR OMA; KSHPQGH; -. DR OrthoDB; 1022360at2759; -. DR PAN-GO; Q9P286; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q9P286; -. DR BRENDA; 2.7.11.1; 2681. DR BRENDA; 2.7.12.2; 2681. DR PathwayCommons; Q9P286; -. DR Reactome; R-HSA-428540; Activation of RAC1. DR Reactome; R-HSA-9013148; CDC42 GTPase cycle. DR Reactome; R-HSA-9013149; RAC1 GTPase cycle. DR Reactome; R-HSA-9013405; RHOD GTPase cycle. DR Reactome; R-HSA-9013407; RHOH GTPase cycle. DR SignaLink; Q9P286; -. DR SIGNOR; Q9P286; -. DR Agora; ENSG00000101349; -. DR BioGRID-ORCS; 57144; 9 hits in 1193 CRISPR screens. DR ChiTaRS; PAK5; human. DR EvolutionaryTrace; Q9P286; -. DR GeneWiki; PAK7; -. DR GenomeRNAi; 57144; -. DR Pharos; Q9P286; Tchem. DR PRO; PR:Q9P286; -. DR Proteomes; UP000005640; Chromosome 20. DR RNAct; Q9P286; protein. DR Bgee; ENSG00000101349; Expressed in cortical plate and 93 other cell types or tissues. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005739; C:mitochondrion; IDA:HPA. DR GO; GO:0031965; C:nuclear membrane; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005886; C:plasma membrane; TAS:Reactome. DR GO; GO:0045202; C:synapse; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0006915; P:apoptotic process; TAS:UniProtKB. DR GO; GO:0016477; P:cell migration; TAS:UniProtKB. DR GO; GO:0008283; P:cell population proliferation; TAS:UniProtKB. DR GO; GO:0009267; P:cellular response to starvation; IBA:GO_Central. DR GO; GO:0007010; P:cytoskeleton organization; TAS:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0007612; P:learning; IEA:Ensembl. DR GO; GO:0007626; P:locomotory behavior; IEA:Ensembl. DR GO; GO:0007613; P:memory; IEA:Ensembl. DR GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:0001558; P:regulation of cell growth; TAS:UniProtKB. DR GO; GO:0043408; P:regulation of MAPK cascade; IBA:GO_Central. DR GO; GO:0007165; P:signal transduction; TAS:UniProtKB. DR CDD; cd01093; CRIB_PAK_like; 1. DR CDD; cd06658; STKc_PAK5; 1. DR FunFam; 1.10.510.10:FF:000073; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.200.20:FF:000141; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.90.810.10:FF:000002; Non-specific serine/threonine protein kinase; 1. DR Gene3D; 3.90.810.10; CRIB domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000095; CRIB_dom. DR InterPro; IPR036936; CRIB_dom_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR051931; PAK3-like. DR InterPro; IPR033923; PAK_BD. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR028754; STKc_PAK5. DR PANTHER; PTHR45832:SF4; NON-SPECIFIC SERINE_THREONINE PROTEIN KINASE; 1. DR PANTHER; PTHR45832; SERINE/THREONINE-PROTEIN KINASE SAMKA-RELATED-RELATED; 1. DR Pfam; PF00786; PBD; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00285; PBD; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50108; CRIB; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW 3D-structure; Apoptosis; ATP-binding; Cytoplasm; Kinase; Mitochondrion; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase. FT CHAIN 1..719 FT /note="Serine/threonine-protein kinase PAK 5" FT /id="PRO_0000086477" FT DOMAIN 11..24 FT /note="CRIB" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00057" FT DOMAIN 449..700 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..29 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 25..448 FT /note="Linker" FT REGION 97..123 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 256..299 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 340..373 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 271..291 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 358..373 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 568 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 455..463 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 478 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 104 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8C015" FT MOD_RES 107 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q8C015" FT VARIANT 118 FT /note="G -> D (in dbSNP:rs55923311)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040978" FT VARIANT 187 FT /note="P -> A (in dbSNP:rs34280805)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040979" FT VARIANT 312 FT /note="S -> P (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs952665081)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040980" FT VARIANT 335 FT /note="R -> P (in dbSNP:rs11700112)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040981" FT VARIANT 511 FT /note="S -> N (in dbSNP:rs2297345)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:17344846" FT /id="VAR_021865" FT VARIANT 538 FT /note="T -> N (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040982" FT VARIANT 555 FT /note="A -> S (in dbSNP:rs34102290)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040983" FT VARIANT 604 FT /note="V -> I (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040984" FT VARIANT 704 FT /note="G -> S (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs1484691555)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040985" FT MUTAGEN 19..22 FT /note="HRVH->LRVL: Complete loss of CDC42 binding and FT CDC42-mediated autophosphorylation." FT /evidence="ECO:0000269|PubMed:12860998" FT CONFLICT 27 FT /note="P -> A (in Ref. 6; AAH24179)" FT /evidence="ECO:0000305" FT CONFLICT 403 FT /note="S -> Y (in Ref. 6; AAH24179)" FT /evidence="ECO:0000305" FT HELIX 429..437 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 445..447 FT /evidence="ECO:0007829|PDB:2F57" FT STRAND 449..457 FT /evidence="ECO:0007829|PDB:2F57" FT STRAND 459..468 FT /evidence="ECO:0007829|PDB:2F57" FT TURN 469..471 FT /evidence="ECO:0007829|PDB:2F57" FT STRAND 474..481 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 482..484 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 488..500 FT /evidence="ECO:0007829|PDB:2F57" FT STRAND 509..515 FT /evidence="ECO:0007829|PDB:2F57" FT STRAND 518..524 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 531..535 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 542..561 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 571..573 FT /evidence="ECO:0007829|PDB:2F57" FT STRAND 574..576 FT /evidence="ECO:0007829|PDB:2F57" FT STRAND 582..584 FT /evidence="ECO:0007829|PDB:2F57" FT STRAND 595..597 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 607..609 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 612..615 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 623..638 FT /evidence="ECO:0007829|PDB:2F57" FT TURN 642..645 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 648..657 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 666..668 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 671..680 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 685..687 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 691..695 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 698..702 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 706..708 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 710..712 FT /evidence="ECO:0007829|PDB:2F57" SQ SEQUENCE 719 AA; 80745 MW; 07A12B1EEC4E2A02 CRC64; MFGKKKKKIE ISGPSNFEHR VHTGFDPQEQ KFTGLPQQWH SLLADTANRP KPMVDPSCIT PIQLAPMKTI VRGNKPCKET SINGLLEDFD NISVTRSNSL RKESPPTPDQ GASSHGPGHA EENGFITFSQ YSSESDTTAD YTTEKYREKS LYGDDLDPYY RGSHAAKQNG HVMKMKHGEA YYSEVKPLKS DFARFSADYH SHLDSLSKPS EYSDLKWEYQ RASSSSPLDY SFQFTPSRTA GTSGCSKESL AYSESEWGPS LDDYDRRPKS SYLNQTSPQP TMRQRSRSGS GLQEPMMPFG ASAFKTHPQG HSYNSYTYPR LSEPTMCIPK VDYDRAQMVL SPPLSGSDTY PRGPAKLPQS QSKSGYSSSS HQYPSGYHKA TLYHHPSLQS SSQYISTASY LSSLSLSSST YPPPSWGSSS DQQPSRVSHE QFRAALQLVV SPGDPREYLA NFIKIGEGST GIVCIATEKH TGKQVAVKKM DLRKQQRREL LFNEVVIMRD YHHDNVVDMY SSYLVGDELW VVMEFLEGGA LTDIVTHTRM NEEQIATVCL SVLRALSYLH NQGVIHRDIK SDSILLTSDG RIKLSDFGFC AQVSKEVPKR KSLVGTPYWM APEVISRLPY GTEVDIWSLG IMVIEMIDGE PPYFNEPPLQ AMRRIRDSLP PRVKDLHKVS SVLRGFLDLM LVREPSQRAT AQELLGHPFL KLAGPPSCIV PLMRQYRHH // ID PKN1_HUMAN Reviewed; 942 AA. AC Q16512; A8K7W5; B2R9R4; B3KVN3; Q15143; Q504U4; Q8IUV5; Q9UD44; DT 15-JUL-1999, integrated into UniProtKB/Swiss-Prot. DT 22-SEP-2009, sequence version 2. DT 28-JAN-2026, entry version 251. DE RecName: Full=Serine/threonine-protein kinase N1; DE EC=2.7.11.13 {ECO:0000269|PubMed:18066052}; DE AltName: Full=Protease-activated kinase 1; DE Short=PAK-1; DE AltName: Full=Protein kinase C-like 1; DE AltName: Full=Protein kinase C-like PKN; DE AltName: Full=Protein kinase PKN-alpha; DE AltName: Full=Protein-kinase C-related kinase 1; DE AltName: Full=Serine-threonine protein kinase N; GN Name=PKN1; Synonyms=PAK1, PKN, PRK1, PRKCL1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND MUTAGENESIS OF LYS-644. RC TISSUE=Hippocampus; RX PubMed=8135837; DOI=10.1006/bbrc.1994.1313; RA Mukai H., Ono Y.; RT "A novel protein kinase with leucine zipper-like sequences: its catalytic RT domain is highly homologous to that of protein kinase C."; RL Biochem. Biophys. Res. Commun. 199:897-904(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Fetal brain; RX PubMed=7851406; DOI=10.1111/j.1432-1033.1995.tb20395.x; RA Palmer R.H., Ridden J., Parker P.J.; RT "Cloning and expression patterns of two members of a novel protein-kinase- RT C-related kinase family."; RL Eur. J. Biochem. 227:344-351(1995). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANTS RP ILE-555 AND ILE-901. RC TISSUE=Kidney, Synovium, and Thymus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3), AND VARIANT RP ILE-901. RC TISSUE=Brain, and Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 700-800 (ISOFORMS 1/2), AND VARIANT VAL-718. RX PubMed=7988719; DOI=10.1016/0014-5793(94)01202-4; RA Palmer R.H., Ridden J., Parker P.J.; RT "Identification of multiple, novel, protein kinase C-related gene RT products."; RL FEBS Lett. 356:5-8(1994). RN [7] RP FUNCTION. RX PubMed=8557118; DOI=10.1016/0014-5793(95)01454-3; RA Palmer R.H., Schonwasser D.C., Rahman D., Pappin D.J., Herget T., RA Parker P.J.; RT "PRK1 phosphorylates MARCKS at the PKC sites: serine 152, serine 156 and RT serine 163."; RL FEBS Lett. 378:281-285(1996). RN [8] RP FUNCTION. RX PubMed=8621664; DOI=10.1074/jbc.271.16.9816; RA Mukai H., Toshimori M., Shibata H., Kitagawa M., Shimakawa M., Miyahara M., RA Sunakawa H., Ono Y.; RT "PKN associates and phosphorylates the head-rod domain of neurofilament RT protein."; RL J. Biol. Chem. 271:9816-9822(1996). RN [9] RP ACTIVITY REGULATION, AND INTERACTION WITH RHOA. RX PubMed=8571126; DOI=10.1126/science.271.5249.645; RA Watanabe G., Saito Y., Madaule P., Ishizaki T., Fujisawa K., Morii N., RA Mukai H., Ono Y., Kakizuka A., Narumiya S.; RT "Protein kinase N (PKN) and PKN-related protein rhophilin as targets of RT small GTPase Rho."; RL Science 271:645-648(1996). RN [10] RP FUNCTION. RX PubMed=9175763; DOI=10.1006/bbrc.1997.6669; RA Matsuzawa K., Kosako H., Inagaki N., Shibata H., Mukai H., Ono Y., RA Amano M., Kaibuchi K., Matsuura Y., Azuma I., Inagaki M.; RT "Domain-specific phosphorylation of vimentin and glial fibrillary acidic RT protein by PKN."; RL Biochem. Biophys. Res. Commun. 234:621-625(1997). RN [11] RP SUBCELLULAR LOCATION, AND INTERACTION WITH RHOB. RX PubMed=9478917; DOI=10.1074/jbc.273.9.4811; RA Mellor H., Flynn P., Nobes C.D., Hall A., Parker P.J.; RT "PRK1 is targeted to endosomes by the small GTPase, RhoB."; RL J. Biol. Chem. 273:4811-4814(1998). RN [12] RP ACTIVITY REGULATION, PROTEOLYTIC PROCESSING, AND MUTAGENESIS OF ASP-108; RP ASP-451; ASP-454; ASP-558 AND ASP-560. RX PubMed=9751706; DOI=10.1073/pnas.95.20.11566; RA Takahashi M., Mukai H., Toshimori M., Miyamoto M., Ono Y.; RT "Proteolytic activation of PKN by caspase-3 or related protease during RT apoptosis."; RL Proc. Natl. Acad. Sci. U.S.A. 95:11566-11571(1998). RN [13] RP PHOSPHORYLATION AT THR-774 BY PDPK1, AND INTERACTION WITH PDPK1. RX PubMed=10792047; DOI=10.1073/pnas.090491897; RA Dong L.Q., Landa L.R., Wick M.J., Zhu L., Mukai H., Ono Y., Liu F.; RT "Phosphorylation of protein kinase N by phosphoinositide-dependent protein RT kinase-1 mediates insulin signals to the actin cytoskeleton."; RL Proc. Natl. Acad. Sci. U.S.A. 97:5089-5094(2000). RN [14] RP FUNCTION. RX PubMed=11104762; DOI=10.1074/jbc.m007427200; RA Taniguchi T., Kawamata T., Mukai H., Hasegawa H., Isagawa T., Yasuda M., RA Hashimoto T., Terashima A., Nakai M., Mori H., Ono Y., Tanaka C.; RT "Phosphorylation of tau is regulated by PKN."; RL J. Biol. Chem. 276:10025-10031(2001). RN [15] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH AR. RX PubMed=12514133; DOI=10.1093/emboj/cdg023; RA Metzger E., Muller J.M., Ferrari S., Buettner R., Schule R.; RT "A novel inducible transactivation domain in the androgen receptor: RT implications for PRK in prostate cancer."; RL EMBO J. 22:270-280(2003). RN [16] RP INTERACTION WITH S.TYPHIMURIUM SSPH1 (MICROBIAL INFECTION). RX PubMed=16611232; DOI=10.1111/j.1462-5822.2005.00670.x; RA Haraga A., Miller S.I.; RT "A Salmonella type III secretion effector interacts with the mammalian RT serine/threonine protein kinase PKN1."; RL Cell. Microbiol. 8:837-846(2006). RN [17] RP INTERACTION WITH CCNT2. RX PubMed=16331689; DOI=10.1002/jcp.20566; RA Cottone G., Baldi A., Palescandolo E., Manente L., Penta R., Paggi M.G., RA De Luca A.; RT "Pkn is a novel partner of cyclin T2a in muscle differentiation."; RL J. Cell. Physiol. 207:232-237(2006). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-533 AND SER-562, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [19] RP FUNCTION, PHOSPHORYLATION, AND SUBCELLULAR LOCATION. RX PubMed=17332740; DOI=10.1038/sj.emboj.7601637; RA Schmidt A., Durgan J., Magalhaes A., Hall A.; RT "Rho GTPases regulate PRK2/PKN2 to control entry into mitosis and exit from RT cytokinesis."; RL EMBO J. 26:1624-1636(2007). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-778, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-205 AND SER-537, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [22] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-644. RX PubMed=18066052; DOI=10.1038/ncb1668; RA Metzger E., Yin N., Wissmann M., Kunowska N., Fischer K., Friedrichs N., RA Patnaik D., Higgins J.M., Potier N., Scheidtmann K.H., Buettner R., RA Schule R.; RT "Phosphorylation of histone H3 at threonine 11 establishes a novel RT chromatin mark for transcriptional regulation."; RL Nat. Cell Biol. 10:53-60(2008). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-533; SER-537; SER-559; RP SER-562 AND SER-916, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [24] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-205; SER-533; SER-537; RP SER-559; SER-562; THR-914 AND SER-916, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [26] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-448, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [27] RP FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=20188095; DOI=10.1016/j.febslet.2010.02.057; RA Harrison B.C., Huynh K., Lundgaard G.L., Helmke S.M., Perryman M.B., RA McKinsey T.A.; RT "Protein kinase C-related kinase targets nuclear localization signals in a RT subset of class IIa histone deacetylases."; RL FEBS Lett. 584:1103-1110(2010). RN [28] RP INTERACTION WITH PRKCB. RX PubMed=20228790; DOI=10.1038/nature08839; RA Metzger E., Imhof A., Patel D., Kahl P., Hoffmeyer K., Friedrichs N., RA Muller J.M., Greschik H., Kirfel J., Ji S., Kunowska N., RA Beisenherz-Huss C., Gunther T., Buettner R., Schule R.; RT "Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at RT histone H3K4."; RL Nature 464:792-796(2010). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-533; SER-537 AND SER-562, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [30] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [31] RP FUNCTION, AND IDENTIFICATION IN A COMPLEX WITH AKAP13; MAPK14; ZAK AND RP MAP2K3. RX PubMed=21224381; DOI=10.1074/jbc.m110.185645; RA Cariolato L., Cavin S., Diviani D.; RT "A-kinase anchoring protein (AKAP)-Lbc anchors a PKN-based signaling RT complex involved in alpha1-adrenergic receptor-induced p38 activation."; RL J. Biol. Chem. 286:7925-7937(2011). RN [32] RP FUNCTION IN CELL MIGRATION, AND TISSUE SPECIFICITY. RX PubMed=21754995; DOI=10.1371/journal.pone.0021732; RA Lachmann S., Jevons A., De Rycker M., Casamassima A., Radtke S., RA Collazos A., Parker P.J.; RT "Regulatory domain selectivity in the cell-type specific PKN-dependence of RT cell migration."; RL PLoS ONE 6:E21732-E21732(2011). RN [33] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-562, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [34] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [35] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-69; SER-533; SER-537; RP SER-540; SER-562; SER-608 AND SER-916, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [36] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-916, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [37] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 13-98 IN COMPLEX WITH RHOA. RX PubMed=10619026; DOI=10.1016/s1097-2765(00)80389-5; RA Maesaki R., Ihara K., Shimizu T., Kuroda S., Kaibuchi K., Hakoshima T.; RT "The structural basis of Rho effector recognition revealed by the crystal RT structure of human RhoA complexed with the effector domain of PKN/PRK1."; RL Mol. Cell 4:793-803(1999). RN [38] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 13-98. RX PubMed=10388627; DOI=10.1006/jsbi.1999.4114; RA Maesaki R., Shimizu T., Ihara K., Kuroda S., Kaibuchi K., Hakoshima T.; RT "Biochemical and crystallographic characterization of a Rho effector domain RT of the protein serine/threonine kinase N in a complex with RhoA."; RL J. Struct. Biol. 126:166-170(1999). RN [39] RP STRUCTURE BY NMR OF 116-199 IN COMPLEX WITH RAC1. RX PubMed=14514689; DOI=10.1074/jbc.m304313200; RA Owen D., Lowe P.N., Nietlispach D., Brosnan C.E., Chirgadze D.Y., RA Parker P.J., Blundell T.L., Mott H.R.; RT "Molecular dissection of the interaction between the small G proteins Rac1 RT and RhoA and protein kinase C-related kinase 1 (PRK1)."; RL J. Biol. Chem. 278:50578-50587(2003). RN [40] RP STRUCTURE BY NMR OF 122-199 IN COMPLEX WITH RAC1. RX PubMed=18006505; DOI=10.1074/jbc.m706760200; RA Modha R., Campbell L.J., Nietlispach D., Buhecha H.R., Owen D., Mott H.R.; RT "The Rac1 polybasic region is required for interaction with its effector RT PRK1."; RL J. Biol. Chem. 283:1492-1500(2008). RN [41] RP X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 122-199 IN COMPLEX WITH RP SALMONELLA SSPH1, UBIQUITINATION (MICROBIAL INFECTION), MUTAGENESIS OF RP ARG-181 AND ARG-185, FUNCTION AS ANDROGEN RECEPTOR COACTIVATOR, AND RP INTERACTION WITH SALMONELLA SSPH1 (MICROBIAL INFECTION). RX PubMed=24248594; DOI=10.1128/mcb.01360-13; RA Keszei A.F., Tang X., McCormick C., Zeqiraj E., Rohde J.R., Tyers M., RA Sicheri F.; RT "Structure of an SspH1-PKN1 complex reveals the basis for host substrate RT recognition and mechanism of activation for a bacterial E3 ubiquitin RT ligase."; RL Mol. Cell. Biol. 34:362-373(2014). RN [42] RP VARIANTS [LARGE SCALE ANALYSIS] CYS-185; GLU-197; TRP-436; GLN-520; RP ILE-555; GLN-635; VAL-718; LEU-873; ILE-901 AND VAL-921. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: PKC-related serine/threonine-protein kinase involved in CC various processes such as regulation of the intermediate filaments of CC the actin cytoskeleton, cell migration, tumor cell invasion and CC transcription regulation. Part of a signaling cascade that begins with CC the activation of the adrenergic receptor ADRA1B and leads to the CC activation of MAPK14. Regulates the cytoskeletal network by CC phosphorylating proteins such as VIM and neurofilament proteins NEFH, CC NEFL and NEFM, leading to inhibit their polymerization. Phosphorylates CC 'Ser-575', 'Ser-637' and 'Ser-669' of MAPT/Tau, lowering its ability to CC bind to microtubules, resulting in disruption of tubulin assembly. Acts CC as a key coactivator of androgen receptor (AR)-dependent transcription, CC by being recruited to AR target genes and specifically mediating CC phosphorylation of 'Thr-11' of histone H3 (H3T11ph), a specific tag for CC epigenetic transcriptional activation that promotes demethylation of CC histone H3 'Lys-9' (H3K9me) by KDM4C/JMJD2C. Phosphorylates HDAC5, CC HDAC7 and HDAC9, leading to impair their import in the nucleus. CC Phosphorylates 'Thr-38' of PPP1R14A, 'Ser-159', 'Ser-163' and 'Ser-170' CC of MARCKS, and GFAP. Able to phosphorylate RPS6 in vitro. CC {ECO:0000269|PubMed:11104762, ECO:0000269|PubMed:12514133, CC ECO:0000269|PubMed:17332740, ECO:0000269|PubMed:18066052, CC ECO:0000269|PubMed:20188095, ECO:0000269|PubMed:21224381, CC ECO:0000269|PubMed:21754995, ECO:0000269|PubMed:24248594, CC ECO:0000269|PubMed:8557118, ECO:0000269|PubMed:8621664, CC ECO:0000269|PubMed:9175763}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:18066052}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:18066052}; CC -!- ACTIVITY REGULATION: Kinase activity is activated upon binding to Rho CC proteins (RHOA, RHOB and RAC1). Activated by lipids, particularly CC cardiolipin and to a lesser extent by other acidic phospholipids. CC Activated by caspase-3 (CASP3) cleavage during apoptosis. Two specific CC sites, Thr-774 (activation loop of the kinase domain) and Ser-916 (turn CC motif), need to be phosphorylated for its full activation. CC {ECO:0000269|PubMed:8571126, ECO:0000269|PubMed:9751706}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=20.6 uM for HDAC5 {ECO:0000269|PubMed:20188095}; CC -!- SUBUNIT: Interacts with ZFAND6 (By similarity). Interacts with AR CC (PubMed:12514133). Interacts with PRKCB (PubMed:20228790). Interacts CC (via REM 1 and REM 2 repeats) with RAC1 (PubMed:14514689, CC PubMed:18006505). Interacts (via REM 1 repeat) with RHOA CC (PubMed:10619026, PubMed:8571126). Interacts with RHOB CC (PubMed:9478917). Interacts (via C-terminus) with PDPK1 CC (PubMed:10792047). Interacts with CCNT2; enhances MYOD1-dependent CC transcription (PubMed:16331689). Component of a signaling complex CC containing at least AKAP13, PKN1, MAPK14, ZAK and MAP2K3. Within this CC complex, AKAP13 interacts directly with PKN1, which in turn recruits CC MAPK14, MAP2K3 and ZAK (PubMed:21224381). CC {ECO:0000250|UniProtKB:P70268, ECO:0000269|PubMed:10619026, CC ECO:0000269|PubMed:10792047, ECO:0000269|PubMed:12514133, CC ECO:0000269|PubMed:14514689, ECO:0000269|PubMed:16331689, CC ECO:0000269|PubMed:18006505, ECO:0000269|PubMed:20228790, CC ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:8571126, CC ECO:0000269|PubMed:9478917}. CC -!- SUBUNIT: (Microbial infection) Interacts (via the second REM repeat) CC with S.typhimurium E3 ubiquitin-protein ligase SspH1 (via the leucine- CC rich repeat region) (PubMed:16611232, PubMed:24248594). CC {ECO:0000269|PubMed:16611232, ECO:0000269|PubMed:24248594}. CC -!- INTERACTION: CC Q16512; Q6UY14-3: ADAMTSL4; NbExp=3; IntAct=EBI-602382, EBI-10173507; CC Q16512; Q9ULX6: AKAP8L; NbExp=3; IntAct=EBI-602382, EBI-357530; CC Q16512; Q6PJH3: AKAP9; NbExp=3; IntAct=EBI-602382, EBI-11745576; CC Q16512; P05067: APP; NbExp=3; IntAct=EBI-602382, EBI-77613; CC Q16512; P15289: ARSA; NbExp=3; IntAct=EBI-602382, EBI-2117357; CC Q16512; Q14457: BECN1; NbExp=3; IntAct=EBI-602382, EBI-949378; CC Q16512; Q9H2G9: BLZF1; NbExp=3; IntAct=EBI-602382, EBI-2548012; CC Q16512; Q8WU43: C2orf15; NbExp=3; IntAct=EBI-602382, EBI-12904676; CC Q16512; Q96M89-2: CCDC138; NbExp=3; IntAct=EBI-602382, EBI-10972887; CC Q16512; Q15834: CCDC85B; NbExp=2; IntAct=EBI-602382, EBI-739674; CC Q16512; Q8IV13: CCNJL; NbExp=3; IntAct=EBI-602382, EBI-21668062; CC Q16512; Q01850: CDR2; NbExp=6; IntAct=EBI-602382, EBI-1181367; CC Q16512; Q86XR8-3: CEP57; NbExp=3; IntAct=EBI-602382, EBI-11752486; CC Q16512; Q8IYX8-2: CEP57L1; NbExp=3; IntAct=EBI-602382, EBI-10181988; CC Q16512; Q8NHQ1: CEP70; NbExp=3; IntAct=EBI-602382, EBI-739624; CC Q16512; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-602382, EBI-3867333; CC Q16512; Q9NRI5-2: DISC1; NbExp=3; IntAct=EBI-602382, EBI-11988027; CC Q16512; Q8IW40: DNAAF19; NbExp=3; IntAct=EBI-602382, EBI-10261970; CC Q16512; Q8WWB3: DYDC1; NbExp=3; IntAct=EBI-602382, EBI-740680; CC Q16512; P26641: EEF1G; NbExp=3; IntAct=EBI-602382, EBI-351467; CC Q16512; O00303: EIF3F; NbExp=3; IntAct=EBI-602382, EBI-711990; CC Q16512; Q06547-2: GABPB1; NbExp=3; IntAct=EBI-602382, EBI-618189; CC Q16512; Q08379: GOLGA2; NbExp=6; IntAct=EBI-602382, EBI-618309; CC Q16512; A6NEM1: GOLGA6L9; NbExp=3; IntAct=EBI-602382, EBI-5916454; CC Q16512; P54257: HAP1; NbExp=3; IntAct=EBI-602382, EBI-712814; CC Q16512; Q96CS2: HAUS1; NbExp=3; IntAct=EBI-602382, EBI-2514791; CC Q16512; Q9NSC5: HOMER3; NbExp=7; IntAct=EBI-602382, EBI-748420; CC Q16512; O75031: HSF2BP; NbExp=3; IntAct=EBI-602382, EBI-7116203; CC Q16512; Q9UKT9: IKZF3; NbExp=3; IntAct=EBI-602382, EBI-747204; CC Q16512; Q5TA45: INTS11; NbExp=3; IntAct=EBI-602382, EBI-748258; CC Q16512; Q8N5Z5: KCTD17; NbExp=3; IntAct=EBI-602382, EBI-743960; CC Q16512; Q86T90: KIAA1328; NbExp=3; IntAct=EBI-602382, EBI-3437878; CC Q16512; P19012: KRT15; NbExp=3; IntAct=EBI-602382, EBI-739566; CC Q16512; P08779: KRT16; NbExp=3; IntAct=EBI-602382, EBI-356410; CC Q16512; P08727: KRT19; NbExp=3; IntAct=EBI-602382, EBI-742756; CC Q16512; Q15323: KRT31; NbExp=6; IntAct=EBI-602382, EBI-948001; CC Q16512; O76011: KRT34; NbExp=5; IntAct=EBI-602382, EBI-1047093; CC Q16512; Q92764: KRT35; NbExp=3; IntAct=EBI-602382, EBI-1058674; CC Q16512; O76013-2: KRT36; NbExp=3; IntAct=EBI-602382, EBI-11958506; CC Q16512; O76014: KRT37; NbExp=3; IntAct=EBI-602382, EBI-1045716; CC Q16512; Q9BV99: LRRC61; NbExp=3; IntAct=EBI-602382, EBI-2350424; CC Q16512; Q9NYL2-1: MAP3K20; NbExp=2; IntAct=EBI-602382, EBI-687346; CC Q16512; P53778: MAPK12; NbExp=2; IntAct=EBI-602382, EBI-602406; CC Q16512; O15344: MID1; NbExp=3; IntAct=EBI-602382, EBI-2340316; CC Q16512; Q9UJV3-2: MID2; NbExp=3; IntAct=EBI-602382, EBI-10172526; CC Q16512; Q8N108-16: MIER1; NbExp=3; IntAct=EBI-602382, EBI-25830642; CC Q16512; Q8TD10: MIPOL1; NbExp=3; IntAct=EBI-602382, EBI-2548751; CC Q16512; Q13064: MKRN3; NbExp=3; IntAct=EBI-602382, EBI-2340269; CC Q16512; Q5JR59-3: MTUS2; NbExp=3; IntAct=EBI-602382, EBI-11522433; CC Q16512; P07196: NEFL; NbExp=3; IntAct=EBI-602382, EBI-475646; CC Q16512; Q9NRD5: PICK1; NbExp=3; IntAct=EBI-602382, EBI-79165; CC Q16512; Q8ND90: PNMA1; NbExp=3; IntAct=EBI-602382, EBI-302345; CC Q16512; P78424: POU6F2; NbExp=3; IntAct=EBI-602382, EBI-12029004; CC Q16512; P28070: PSMB4; NbExp=3; IntAct=EBI-602382, EBI-603350; CC Q16512; Q96QF0-7: RAB3IP; NbExp=3; IntAct=EBI-602382, EBI-11984839; CC Q16512; Q9UJW9: SERTAD3; NbExp=3; IntAct=EBI-602382, EBI-748621; CC Q16512; Q9H7B4: SMYD3; NbExp=3; IntAct=EBI-602382, EBI-347919; CC Q16512; Q96R06: SPAG5; NbExp=3; IntAct=EBI-602382, EBI-413317; CC Q16512; Q9Y2D8: SSX2IP; NbExp=3; IntAct=EBI-602382, EBI-2212028; CC Q16512; Q9NZ72: STMN3; NbExp=3; IntAct=EBI-602382, EBI-725557; CC Q16512; O75558: STX11; NbExp=3; IntAct=EBI-602382, EBI-714135; CC Q16512; A1L190: SYCE3; NbExp=3; IntAct=EBI-602382, EBI-10283466; CC Q16512; Q8WTV1: THAP3; NbExp=3; IntAct=EBI-602382, EBI-17438286; CC Q16512; Q13077: TRAF1; NbExp=3; IntAct=EBI-602382, EBI-359224; CC Q16512; Q12933: TRAF2; NbExp=3; IntAct=EBI-602382, EBI-355744; CC Q16512; P14373: TRIM27; NbExp=3; IntAct=EBI-602382, EBI-719493; CC Q16512; Q9BZW7: TSGA10; NbExp=3; IntAct=EBI-602382, EBI-744794; CC Q16512; Q8IWV8-2: UBR2; NbExp=3; IntAct=EBI-602382, EBI-17923957; CC Q16512; Q8N6Y0: USHBP1; NbExp=3; IntAct=EBI-602382, EBI-739895; CC Q16512; P08670: VIM; NbExp=3; IntAct=EBI-602382, EBI-353844; CC Q16512; Q8TF47: ZFP90; NbExp=3; IntAct=EBI-602382, EBI-11419867; CC Q16512; Q9UNY5: ZNF232; NbExp=3; IntAct=EBI-602382, EBI-749023; CC Q16512; Q96MN9-2: ZNF488; NbExp=3; IntAct=EBI-602382, EBI-25831733; CC Q16512; Q9P0T4: ZNF581; NbExp=3; IntAct=EBI-602382, EBI-745520; CC Q16512; Q9UGI0: ZRANB1; NbExp=3; IntAct=EBI-602382, EBI-527853; CC Q16512; A1JU68: yopM; Xeno; NbExp=2; IntAct=EBI-602382, EBI-26365850; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17332740, CC ECO:0000269|PubMed:9478917}. Nucleus {ECO:0000269|PubMed:12514133}. CC Endosome {ECO:0000269|PubMed:9478917}. Cell membrane CC {ECO:0000250|UniProtKB:Q63433}; Peripheral membrane protein CC {ECO:0000250|UniProtKB:Q63433}. Cleavage furrow CC {ECO:0000269|PubMed:17332740}. Midbody {ECO:0000269|PubMed:17332740}. CC Note=Associates with chromatin in a ligand-dependent manner. CC Localization to endosomes is mediated via its interaction with RHOB. CC Association to the cell membrane is dependent on Ser-377 CC phosphorylation. Accumulates during telophase at the cleavage furrow CC and finally concentrates around the midbody in cytokinesis. CC {ECO:0000250|UniProtKB:Q63433, ECO:0000269|PubMed:17332740}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q16512-1; Sequence=Displayed; CC Name=2; CC IsoId=Q16512-2; Sequence=VSP_038143; CC Name=3; CC IsoId=Q16512-3; Sequence=VSP_039213, VSP_039214; CC -!- TISSUE SPECIFICITY: Found ubiquitously. Expressed in heart, brain, CC placenta, lung, skeletal muscle, kidney and pancreas. Expressed in CC numerous tumor cell lines, especially in breast tumor cells. CC {ECO:0000269|PubMed:21754995}. CC -!- DOMAIN: The C1 domain does not bind the diacylglycerol (DAG). CC -!- PTM: Autophosphorylated; preferably on serine. Phosphorylated during CC mitosis. {ECO:0000269|PubMed:10792047, ECO:0000269|PubMed:17332740}. CC -!- PTM: Activated by limited proteolysis with trypsin. {ECO:0000250}. CC -!- PTM: (Microbial infection) In case of infection, polyubiquitinated by CC the bacterial E3 ubiquitin-protein ligase SspH1, leading to its CC proteasomal degradation. {ECO:0000269|PubMed:24248594}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. PKC subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D26181; BAA05169.1; -; mRNA. DR EMBL; S75546; AAB33345.1; -; mRNA. DR EMBL; U33053; AAC50209.1; -; mRNA. DR EMBL; AK123007; BAG53845.1; -; mRNA. DR EMBL; AK292130; BAF84819.1; -; mRNA. DR EMBL; AK313886; BAG36611.1; -; mRNA. DR EMBL; AC008569; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC040061; AAH40061.1; -; mRNA. DR EMBL; BC094766; AAH94766.1; -; mRNA. DR CCDS; CCDS42513.1; -. [Q16512-1] DR CCDS; CCDS42514.1; -. [Q16512-2] DR PIR; JC2129; JC2129. DR PIR; S51162; S51162. DR RefSeq; NP_002732.3; NM_002741.3. [Q16512-1] DR RefSeq; NP_998725.1; NM_213560.3. [Q16512-2] DR PDB; 1CXZ; X-ray; 2.20 A; B=13-98. DR PDB; 1URF; NMR; -; A=122-199. DR PDB; 2RMK; NMR; -; B=122-199. DR PDB; 4NKG; X-ray; 2.90 A; B/D=122-199. DR PDB; 4OTD; X-ray; 2.00 A; A=605-942. DR PDB; 4OTG; X-ray; 2.60 A; A=605-942. DR PDB; 4OTH; X-ray; 1.80 A; A=605-942. DR PDB; 4OTI; X-ray; 1.93 A; A=605-942. DR PDBsum; 1CXZ; -. DR PDBsum; 1URF; -. DR PDBsum; 2RMK; -. DR PDBsum; 4NKG; -. DR PDBsum; 4OTD; -. DR PDBsum; 4OTG; -. DR PDBsum; 4OTH; -. DR PDBsum; 4OTI; -. DR AlphaFoldDB; Q16512; -. DR SMR; Q16512; -. DR BioGRID; 111571; 147. DR CORUM; Q16512; -. DR DIP; DIP-34240N; -. DR ELM; Q16512; -. DR FunCoup; Q16512; 2793. DR IntAct; Q16512; 116. DR MINT; Q16512; -. DR STRING; 9606.ENSP00000343325; -. DR BindingDB; Q16512; -. DR ChEMBL; CHEMBL3384; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q16512; -. DR GuidetoPHARMACOLOGY; 1520; -. DR GlyConnect; 1737; 1 N-Linked glycan (1 site). DR GlyCosmos; Q16512; 3 sites, 2 glycans. DR GlyGen; Q16512; 5 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (2 sites). DR iPTMnet; Q16512; -. DR MetOSite; Q16512; -. DR PhosphoSitePlus; Q16512; -. DR BioMuta; PKN1; -. DR DMDM; 259016304; -. DR CPTAC; CPTAC-3003; -. DR jPOST; Q16512; -. DR MassIVE; Q16512; -. DR PaxDb; 9606-ENSP00000343325; -. DR PeptideAtlas; Q16512; -. DR ProteomicsDB; 60877; -. [Q16512-1] DR ProteomicsDB; 60878; -. [Q16512-2] DR ProteomicsDB; 60879; -. [Q16512-3] DR Pumba; Q16512; -. DR Antibodypedia; 1296; 250 antibodies from 36 providers. DR DNASU; 5585; -. DR Ensembl; ENST00000242783.11; ENSP00000242783.7; ENSG00000123143.14. [Q16512-1] DR Ensembl; ENST00000342216.8; ENSP00000343325.4; ENSG00000123143.14. [Q16512-2] DR GeneID; 5585; -. DR KEGG; hsa:5585; -. DR MANE-Select; ENST00000242783.11; ENSP00000242783.7; NM_002741.5; NP_002732.3. DR UCSC; uc002myp.4; human. [Q16512-1] DR AGR; HGNC:9405; -. DR ClinPGx; PA33769; -. DR CTD; 5585; -. DR DisGeNET; 5585; -. DR GeneCards; PKN1; -. DR HGNC; HGNC:9405; PKN1. DR HPA; ENSG00000123143; Low tissue specificity. DR MalaCards; PKN1; -. DR MIM; 601032; gene. DR OpenTargets; ENSG00000123143; -. DR VEuPathDB; HostDB:ENSG00000123143; -. DR eggNOG; KOG0694; Eukaryota. DR GeneTree; ENSGT00940000154990; -. DR HOGENOM; CLU_000288_132_1_1; -. DR InParanoid; Q16512; -. DR OMA; CTELRIE; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; Q16512; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q16512; -. DR BRENDA; 2.7.11.13; 2681. DR PathwayCommons; Q16512; -. DR Reactome; R-HSA-5625740; RHO GTPases activate PKNs. DR Reactome; R-HSA-5625886; Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3. DR Reactome; R-HSA-8980692; RHOA GTPase cycle. DR Reactome; R-HSA-9013026; RHOB GTPase cycle. DR Reactome; R-HSA-9013106; RHOC GTPase cycle. DR Reactome; R-HSA-9013149; RAC1 GTPase cycle. DR SABIO-RK; Q16512; -. DR SignaLink; Q16512; -. DR SIGNOR; Q16512; -. DR Agora; ENSG00000123143; -. DR BioGRID-ORCS; 5585; 15 hits in 1195 CRISPR screens. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; PKN1; human. DR EvolutionaryTrace; Q16512; -. DR GeneWiki; Protein_kinase_N1; -. DR GenomeRNAi; 5585; -. DR Pharos; Q16512; Tchem. DR PRO; PR:Q16512; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q16512; protein. DR Bgee; ENSG00000123143; Expressed in apex of heart and 142 other cell types or tissues. DR ExpressionAtlas; Q16512; baseline and differential. DR GO; GO:0032154; C:cleavage furrow; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005768; C:endosome; IDA:UniProtKB. DR GO; GO:0030496; C:midbody; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0032991; C:protein-containing complex; IDA:MGI. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0004697; F:diacylglycerol-dependent serine/threonine kinase activity; EXP:Reactome. DR GO; GO:0042393; F:histone binding; IDA:UniProtKB. DR GO; GO:0042826; F:histone deacetylase binding; IDA:UniProtKB. DR GO; GO:0035402; F:histone H3T11 kinase activity; IDA:UniProtKB. DR GO; GO:0050681; F:nuclear androgen receptor binding; IDA:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; TAS:ProtInc. DR GO; GO:0005080; F:protein kinase C binding; IPI:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0031267; F:small GTPase binding; IDA:UniProtKB. DR GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB. DR GO; GO:0001783; P:B cell apoptotic process; IEA:Ensembl. DR GO; GO:0001782; P:B cell homeostasis; IEA:Ensembl. DR GO; GO:0010631; P:epithelial cell migration; IMP:UniProtKB. DR GO; GO:0006972; P:hyperosmotic response; IEA:Ensembl. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0030889; P:negative regulation of B cell proliferation; IEA:Ensembl. DR GO; GO:0043687; P:post-translational protein modification; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0060765; P:regulation of androgen receptor signaling pathway; TAS:Reactome. DR GO; GO:2000145; P:regulation of cell motility; IMP:UniProtKB. DR GO; GO:0002634; P:regulation of germinal center formation; IEA:Ensembl. DR GO; GO:0002637; P:regulation of immunoglobulin production; IEA:Ensembl. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0003014; P:renal system process; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0048536; P:spleen development; IEA:Ensembl. DR CDD; cd08687; C2_PKN-like; 1. DR CDD; cd11630; HR1_PKN1_2; 1. DR CDD; cd11636; HR1_PKN1_3; 1. DR CDD; cd11622; HR1_PKN_1; 1. DR CDD; cd05589; STKc_PKN; 1. DR FunFam; 1.10.287.160:FF:000001; Putative serine/threonine-protein kinase N2; 1. DR FunFam; 1.10.287.160:FF:000002; Putative serine/threonine-protein kinase N2; 1. DR FunFam; 1.10.287.160:FF:000003; Putative serine/threonine-protein kinase N2; 1. DR FunFam; 3.30.200.20:FF:000058; Putative serine/threonine-protein kinase N2; 1. DR FunFam; 1.10.510.10:FF:000038; serine/threonine-protein kinase N2 isoform X1; 1. DR Gene3D; 1.10.287.160; HR1 repeat; 3. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00416; -. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR000008; C2_dom. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR037784; C2_PKN. DR InterPro; IPR011072; HR1_rho-bd. DR InterPro; IPR036274; HR1_rpt_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR037317; PKN1_HR1_2. DR InterPro; IPR037313; PKN_HR1_1. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF02185; HR1; 3. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00433; Pkinase_C; 1. DR SMART; SM00742; Hr1; 3. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1. DR SUPFAM; SSF46585; HR1 repeat; 3. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS50004; C2; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS51860; REM_1; 3. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; ATP-binding; KW Cell membrane; Chromatin regulator; Coiled coil; Cytoplasm; Endosome; KW Kinase; Membrane; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transcription; Transcription regulation; KW Transferase; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:22814378" FT CHAIN 2..942 FT /note="Serine/threonine-protein kinase N1" FT /id="PRO_0000055719" FT DOMAIN 25..100 FT /note="REM-1 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01207" FT DOMAIN 112..193 FT /note="REM-1 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01207" FT DOMAIN 201..280 FT /note="REM-1 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01207" FT DOMAIN 307..470 FT /note="C2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT DOMAIN 615..874 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 875..942 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT REGION 102..121 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 181..185 FT /note="Important for interaction with bacterial SspH1 and FT SspH1-mediated polyubiquitination" FT /evidence="ECO:0000269|PubMed:24248594" FT REGION 341..363 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 553..603 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 581..596 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 740 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 621..629 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 644 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 108..109 FT /note="Cleavage; by caspase-3" FT SITE 454..455 FT /note="Cleavage; by caspase-3" FT SITE 558..559 FT /note="Cleavage; by caspase-3" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:22814378" FT MOD_RES 69 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 205 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19690332" FT MOD_RES 374 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63433" FT MOD_RES 448 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 533 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:16964243, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 537 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 540 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 559 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332" FT MOD_RES 562 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:16964243, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 608 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 774 FT /note="Phosphothreonine; by PDPK1" FT /evidence="ECO:0000269|PubMed:10792047" FT MOD_RES 778 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18220336" FT MOD_RES 914 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:19690332" FT MOD_RES 916 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT VAR_SEQ 1..7 FT /note="MASDAVQ -> MAEANNPSEQELE (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_038143" FT VAR_SEQ 603 FT /note="S -> R (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_039213" FT VAR_SEQ 604..942 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_039214" FT VARIANT 185 FT /note="R -> C (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs267605306)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042337" FT VARIANT 197 FT /note="A -> E (in dbSNP:rs1287763348)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042338" FT VARIANT 436 FT /note="R -> W (in dbSNP:rs35132656)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042339" FT VARIANT 520 FT /note="R -> Q (in dbSNP:rs56273055)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042340" FT VARIANT 555 FT /note="L -> I (in dbSNP:rs34309238)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:17344846" FT /id="VAR_042341" FT VARIANT 635 FT /note="R -> Q (in dbSNP:rs35416389)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042342" FT VARIANT 718 FT /note="I -> V (in dbSNP:rs2230539)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7988719" FT /id="VAR_042343" FT VARIANT 873 FT /note="F -> L (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042344" FT VARIANT 901 FT /note="V -> I (in dbSNP:rs10846)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17344846" FT /id="VAR_014937" FT VARIANT 921 FT /note="A -> V (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042345" FT MUTAGEN 108 FT /note="D->A: Abolishes cleavage by caspase-3 and formation FT of AF1 fragment." FT /evidence="ECO:0000269|PubMed:9751706" FT MUTAGEN 181 FT /note="R->A: Abolishes interaction with bacterial SspH1." FT /evidence="ECO:0000269|PubMed:24248594" FT MUTAGEN 181 FT /note="R->K: Decreases interaction with bacterial SspH1." FT /evidence="ECO:0000269|PubMed:24248594" FT MUTAGEN 185 FT /note="R->A: Abolishes interaction with bacterial SspH1." FT /evidence="ECO:0000269|PubMed:24248594" FT MUTAGEN 451 FT /note="D->A: Abolishes cleavage by caspase-3 and formation FT of 70 kDa fragment." FT /evidence="ECO:0000269|PubMed:9751706" FT MUTAGEN 454 FT /note="D->A: Abolishes cleavage by caspase-3 and formation FT of 70 kDa fragment." FT /evidence="ECO:0000269|PubMed:9751706" FT MUTAGEN 558 FT /note="D->A: Abolishes cleavage by caspase-3 and formation FT of AF3 fragment." FT /evidence="ECO:0000269|PubMed:9751706" FT MUTAGEN 560 FT /note="D->A: Abolishes cleavage by caspase-3 and formation FT of AF3 fragment." FT /evidence="ECO:0000269|PubMed:9751706" FT MUTAGEN 644 FT /note="K->E: Abolishes Serine/threonine-protein kinase FT activity." FT /evidence="ECO:0000269|PubMed:18066052, FT ECO:0000269|PubMed:8135837" FT MUTAGEN 644 FT /note="K->R: Substantial reduction of autophosphorylation." FT /evidence="ECO:0000269|PubMed:18066052, FT ECO:0000269|PubMed:8135837" FT CONFLICT 191 FT /note="G -> D (in Ref. 2; AAB33345/AAC50209)" FT /evidence="ECO:0000305" FT CONFLICT 562 FT /note="S -> P (in Ref. 3; BAG36611)" FT /evidence="ECO:0000305" FT CONFLICT 736 FT /note="I -> T (in Ref. 6; no nucleotide entry)" FT /evidence="ECO:0000305" FT CONFLICT 750 FT /note="T -> A (in Ref. 6; no nucleotide entry)" FT /evidence="ECO:0000305" FT CONFLICT 800 FT /note="G -> A (in Ref. 6; no nucleotide entry)" FT /evidence="ECO:0000305" FT CONFLICT 812 FT /note="E -> G (in Ref. 3; BAG36611)" FT /evidence="ECO:0000305" FT CONFLICT 887 FT /note="L -> P (in Ref. 3; BAG53845)" FT /evidence="ECO:0000305" FT HELIX 15..18 FT /evidence="ECO:0007829|PDB:1CXZ" FT HELIX 29..66 FT /evidence="ECO:0007829|PDB:1CXZ" FT HELIX 71..95 FT /evidence="ECO:0007829|PDB:1CXZ" FT TURN 122..124 FT /evidence="ECO:0007829|PDB:1URF" FT HELIX 126..151 FT /evidence="ECO:0007829|PDB:4NKG" FT TURN 157..159 FT /evidence="ECO:0007829|PDB:4NKG" FT HELIX 160..187 FT /evidence="ECO:0007829|PDB:4NKG" FT STRAND 194..196 FT /evidence="ECO:0007829|PDB:2RMK" FT HELIX 612..614 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 615..624 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 627..634 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 635..637 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 640..647 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 648..653 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 657..671 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 672..674 FT /evidence="ECO:0007829|PDB:4OTG" FT STRAND 681..686 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 688..696 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 700..702 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 703..706 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 707..709 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 714..733 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 743..745 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 746..748 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 750..752 FT /evidence="ECO:0007829|PDB:4OTG" FT STRAND 754..756 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 763..765 FT /evidence="ECO:0007829|PDB:4OTD" FT HELIX 779..781 FT /evidence="ECO:0007829|PDB:4OTD" FT HELIX 784..788 FT /evidence="ECO:0007829|PDB:4OTD" FT HELIX 794..810 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 820..829 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 840..849 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 854..856 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 862..864 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 865..869 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 872..874 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 879..883 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 906..909 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 926..930 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 931..934 FT /evidence="ECO:0007829|PDB:4OTH" SQ SEQUENCE 942 AA; 103932 MW; 61360295EC70BB8E CRC64; MASDAVQSEP RSWSLLEQLG LAGADLAAPG VQQQLELERE RLRREIRKEL KLKEGAENLR RATTDLGRSL GPVELLLRGS SRRLDLLHQQ LQELHAHVVL PDPAATHDGP QSPGAGGPTC SATNLSRVAG LEKQLAIELK VKQGAENMIQ TYSNGSTKDR KLLLTAQQML QDSKTKIDII RMQLRRALQA GQLENQAAPD DTQGSPDLGA VELRIEELRH HFRVEHAVAE GAKNVLRLLS AAKAPDRKAV SEAQEKLTES NQKLGLLREA LERRLGELPA DHPKGRLLRE ELAAASSAAF STRLAGPFPA THYSTLCKPA PLTGTLEVRV VGCRDLPETI PWNPTPSMGG PGTPDSRPPF LSRPARGLYS RSGSLSGRSS LKAEAENTSE VSTVLKLDNT VVGQTSWKPC GPNAWDQSFT LELERARELE LAVFWRDQRG LCALKFLKLE DFLDNERHEV QLDMEPQGCL VAEVTFRNPV IERIPRLRRQ KKIFSKQQGK AFQRARQMNI DVATWVRLLR RLIPNATGTG TFSPGASPGS EARTTGDISV EKLNLGTDSD SSPQKSSRDP PSSPSSLSSP IQESTAPELP SETQETPGPA LCSPLRKSPL TLEDFKFLAV LGRGHFGKVL LSEFRPSGEL FAIKALKKGD IVARDEVESL MCEKRILAAV TSAGHPFLVN LFGCFQTPEH VCFVMEYSAG GDLMLHIHSD VFSEPRAIFY SACVVLGLQF LHEHKIVYRD LKLDNLLLDT EGYVKIADFG LCKEGMGYGD RTSTFCGTPE FLAPEVLTDT SYTRAVDWWG LGVLLYEMLV GESPFPGDDE EEVFDSIVND EVRYPRFLSA EAIGIMRRLL RRNPERRLGS SERDAEDVKK QPFFRTLGWE ALLARRLPPP FVPTLSGRTD VSNFDEEFTG EAPTLSPPRD ARPLTAAEQA AFLDFDFVAG GC // ID PLK2_HUMAN Reviewed; 685 AA. AC Q9NYY3; A0A087WUH9; O60679; Q96CV7; Q9UE61; DT 11-JAN-2001, integrated into UniProtKB/Swiss-Prot. DT 02-AUG-2002, sequence version 3. DT 28-JAN-2026, entry version 207. DE RecName: Full=Serine/threonine-protein kinase PLK2; DE EC=2.7.11.21; DE AltName: Full=Polo-like kinase 2; DE Short=PLK-2; DE Short=hPlk2; DE AltName: Full=Serine/threonine-protein kinase SNK; DE Short=hSNK; DE AltName: Full=Serum-inducible kinase; GN Name=PLK2; Synonyms=SNK; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY. RX PubMed=11696980; DOI=10.3109/10425170109041337; RA Liby K., Wu H., Ouyang B., Wu S., Chen J., Dai W.; RT "Identification of the human homologue of the early-growth response gene RT Snk, encoding a serum-inducible kinase."; RL DNA Seq. 11:527-533(2001). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Colon; RA Anderson K.M., Nerurkar S.S., Hansbury M.J., Fornwald J., Scott G., RA Bouzyk M., Mui P., Imbrugia C.S., Carlson K., Marshall L.A., Roshak A.K.; RT "Identification and characterization of human serum-inducible kinase (SNK), RT a novel member of the polo-kinase family of cell cycle regulators: RT potential implication for regulation of vascular smooth muscle RT proliferation."; RL Submitted (JAN-2000) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15372022; DOI=10.1038/nature02919; RA Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S., RA Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M., RA She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S., RA Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M., RA Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M., RA Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T., RA Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., RA Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R., RA Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L., RA Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N., RA Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., RA Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., RA Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.; RT "The DNA sequence and comparative analysis of human chromosome 5."; RL Nature 431:268-274(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 110-408. RA Fidler C., Boultwood J., Wang Jabs E., Wainscoat J.S.; RL Submitted (JAN-1997) to the EMBL/GenBank/DDBJ databases. RN [6] RP INDUCTION. RX PubMed=11716500; DOI=10.1006/bbrc.2001.5993; RA Shimizu-Yoshida Y., Sugiyama K., Rogounovitch T., Ohtsuru A., Namba H., RA Saenko V., Yamashita S.; RT "Radiation-inducible hSNK gene is transcriptionally regulated by p53 RT binding homology element in human thyroid cells."; RL Biochem. Biophys. Res. Commun. 289:491-498(2001). RN [7] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=15242618; DOI=10.1016/j.cub.2004.06.059; RA Warnke S., Kemmler S., Hames R.S., Tsai H.L., Hoffmann-Rohrer U., Fry A.M., RA Hoffmann I.; RT "Polo-like kinase-2 is required for centriole duplication in mammalian RT cells."; RL Curr. Biol. 14:1200-1207(2004). RN [8] RP DOWN-REGULATION IN B-CELL LYMPHOMAS. RX PubMed=16160013; DOI=10.1182/blood-2005-03-1194; RA Syed N., Smith P., Sullivan A., Spender L.C., Dyer M., Karran L., RA O'Nions J., Allday M., Hoffmann I., Crawford D., Griffin B., Farrell P.J., RA Crook T.; RT "Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent RT event in B-cell malignancies."; RL Blood 107:250-256(2006). RN [9] RP FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ASN-210; TRP-503; RP HIS-629 AND LYS-631. RX PubMed=19001868; DOI=10.4161/cc.7.22.7071; RA Cizmecioglu O., Warnke S., Arnold M., Duensing S., Hoffmann I.; RT "Plk2 regulated centriole duplication is dependent on its localization to RT the centrioles and a functional polo-box domain."; RL Cell Cycle 7:3548-3555(2008). RN [10] RP INDUCTION. RX PubMed=18832181; DOI=10.1073/pnas.0808266105; RA Li Z., Lu J., Sun M., Mi S., Zhang H., Luo R.T., Chen P., Wang Y., Yan M., RA Qian Z., Neilly M.B., Jin J., Zhang Y., Bohlander S.K., Zhang D.E., RA Larson R.A., Le Beau M.M., Thirman M.J., Golub T.R., Rowley J.D., Chen J.; RT "Distinct microRNA expression profiles in acute myeloid leukemia with RT common translocations."; RL Proc. Natl. Acad. Sci. U.S.A. 105:15535-15540(2008). RN [11] RP FUNCTION IN PHOSPHORYLATION OF CPAP. RX PubMed=20531387; DOI=10.1038/emboj.2010.118; RA Chang J., Cizmecioglu O., Hoffmann I., Rhee K.; RT "PLK2 phosphorylation is critical for CPAP function in procentriole RT formation during the centrosome cycle."; RL EMBO J. 29:2395-2406(2010). RN [12] RP FUNCTION IN PHOSPHORYLATION OF NPM. RX PubMed=20352051; DOI=10.1371/journal.pone.0009849; RA Krause A., Hoffmann I.; RT "Polo-like kinase 2-dependent phosphorylation of NPM/B23 on serine 4 RT triggers centriole duplication."; RL PLoS ONE 5:E9849-E9849(2010). RN [13] RP DOWN-REGULATION IN ACUTE MYELOID LEUKEMIA. RX PubMed=21340720; DOI=10.1007/s00277-011-1193-4; RA Benetatos L., Dasoula A., Hatzimichael E., Syed N., Voukelatou M., RA Dranitsaris G., Bourantas K.L., Crook T.; RT "Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in RT acute myeloid leukemia and myelodysplastic syndromes: genetic and RT epigenetic interactions."; RL Ann. Hematol. 90:1037-1045(2011). RN [14] RP REVIEW ON FUNCTION. RX PubMed=20671765; DOI=10.1038/nrd3184; RA Strebhardt K.; RT "Multifaceted polo-like kinases: drug targets and antitargets for cancer RT therapy."; RL Nat. Rev. Drug Discov. 9:643-660(2010). RN [15] RP VARIANTS [LARGE SCALE ANALYSIS] THR-14; SER-92; LYS-436 AND LEU-487. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Tumor suppressor serine/threonine-protein kinase involved in CC synaptic plasticity, centriole duplication and G1/S phase transition. CC Polo-like kinases act by binding and phosphorylating proteins that are CC already phosphorylated on a specific motif recognized by the POLO box CC domains. Phosphorylates CPAP, NPM1, RAPGEF2, RASGRF1, SNCA, SIPA1L1 and CC SYNGAP1. Plays a key role in synaptic plasticity and memory by CC regulating the Ras and Rap protein signaling: required for CC overactivity-dependent spine remodeling by phosphorylating the Ras CC activator RASGRF1 and the Rap inhibitor SIPA1L1 leading to their CC degradation by the proteasome. Conversely, phosphorylates the Rap CC activator RAPGEF2 and the Ras inhibitor SYNGAP1, promoting their CC activity. Also regulates synaptic plasticity independently of kinase CC activity, via its interaction with NSF that disrupts the interaction CC between NSF and the GRIA2 subunit of AMPARs, leading to a rapid rundown CC of AMPAR-mediated current that occludes long term depression. Required CC for procentriole formation and centriole duplication by phosphorylating CC CPAP and NPM1, respectively. Its induction by p53/TP53 suggests that it CC may participate in the mitotic checkpoint following stress. CC {ECO:0000269|PubMed:15242618, ECO:0000269|PubMed:19001868, CC ECO:0000269|PubMed:20352051, ECO:0000269|PubMed:20531387}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.21; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.21; CC -!- ACTIVITY REGULATION: Activated by phosphorylation of Thr-239. Once CC activated, activity is stimulated by binding target proteins (By CC similarity). {ECO:0000250}. CC -!- SUBUNIT: Interacts with NSF; causing NSF dissociation from GRIA2. CC Interacts with CIB1 (By similarity). {ECO:0000250}. CC -!- INTERACTION: CC Q9NYY3; Q86Y33: CDC20B; NbExp=3; IntAct=EBI-721354, EBI-10260504; CC Q9NYY3; Q9HC77: CPAP; NbExp=3; IntAct=EBI-721354, EBI-946194; CC Q9NYY3; P62258: YWHAE; NbExp=2; IntAct=EBI-721354, EBI-356498; CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule organizing CC center, centrosome, centriole {ECO:0000269|PubMed:15242618, CC ECO:0000269|PubMed:19001868}. Cell projection, dendrite {ECO:0000250}. CC Note=Localizes to centrosomes during early G1 phase where it only CC associates to the mother centriole and then distributes equally to both CC mother and daughter centrioles at the onset of S phase. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q9NYY3-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9NYY3-2; Sequence=VSP_062732; CC -!- TISSUE SPECIFICITY: Expressed at higher level in the fetal lung, CC kidney, spleen and heart. {ECO:0000269|PubMed:11696980}. CC -!- INDUCTION: Directly regulated by p53/TP53. Negatively regulated by miR- CC 126. {ECO:0000269|PubMed:11716500, ECO:0000269|PubMed:18832181}. CC -!- DOMAIN: The POLO box domains act as phosphopeptide-binding module that CC recognizes and binds serine-[phosphothreonine/phosphoserine]- CC (proline/X) motifs. PLK2 recognizes and binds docking proteins that are CC already phosphorylated on these motifs, and then phosphorylates them CC (By similarity). {ECO:0000250}. CC -!- PTM: Catalytic activity is enhanced by phosphorylation of Thr-239. CC {ECO:0000250}. CC -!- MISCELLANEOUS: There are indications that PLK2 might act as a tumor CC suppressor: PLK2 is significantly down-regulated in a wide range of CC acute myeloid leukemias (AMLs) and B-cell lymphomas due to aberrant CC cytosine methylation in the CpG island located at the 5' of the PLK2 CC gene (PubMed:16160013, PubMed:21340720). Moreover, miR-126, a microRNA CC that negatively regulates PLK2 is up-regulated in AMLs, suggesting that CC PLK2 down-regulation by miR-126 could also contribute to leukemogenesis CC (PubMed:18832181). {ECO:0000305|PubMed:16160013, CC ECO:0000305|PubMed:18832181, ECO:0000305|PubMed:21340720}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. CDC5/Polo subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF059617; AAC14573.1; -; mRNA. DR EMBL; AF223574; AAF62897.1; -; mRNA. DR EMBL; U85755; AAD00575.1; -; mRNA. DR EMBL; AC008814; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC013879; AAH13879.1; -; mRNA. DR CCDS; CCDS3974.1; -. DR RefSeq; NP_001239155.1; NM_001252226.1. DR RefSeq; NP_006613.2; NM_006622.4. DR PDB; 4I5M; X-ray; 1.80 A; A=57-360. DR PDB; 4I5P; X-ray; 1.74 A; A=57-360. DR PDB; 4I6B; X-ray; 1.80 A; A=57-360. DR PDB; 4I6F; X-ray; 2.90 A; A=57-360. DR PDB; 4I6H; X-ray; 1.91 A; A=57-360. DR PDB; 4RS6; X-ray; 2.60 A; A/B=451-685. DR PDB; 4XB0; X-ray; 2.70 A; A/B=468-685. DR PDBsum; 4I5M; -. DR PDBsum; 4I5P; -. DR PDBsum; 4I6B; -. DR PDBsum; 4I6F; -. DR PDBsum; 4I6H; -. DR PDBsum; 4RS6; -. DR PDBsum; 4XB0; -. DR AlphaFoldDB; Q9NYY3; -. DR SMR; Q9NYY3; -. DR BioGRID; 115988; 72. DR DIP; DIP-48943N; -. DR FunCoup; Q9NYY3; 425. DR IntAct; Q9NYY3; 53. DR MINT; Q9NYY3; -. DR STRING; 9606.ENSP00000274289; -. DR BindingDB; Q9NYY3; -. DR ChEMBL; CHEMBL5938; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q9NYY3; -. DR GuidetoPHARMACOLOGY; 2169; -. DR iPTMnet; Q9NYY3; -. DR PhosphoSitePlus; Q9NYY3; -. DR SwissPalm; Q9NYY3; -. DR BioMuta; PLK2; -. DR DMDM; 22096374; -. DR jPOST; Q9NYY3; -. DR MassIVE; Q9NYY3; -. DR PaxDb; 9606-ENSP00000274289; -. DR PeptideAtlas; Q9NYY3; -. DR ProteomicsDB; 83299; -. DR Antibodypedia; 4042; 256 antibodies from 32 providers. DR DNASU; 10769; -. DR Ensembl; ENST00000274289.8; ENSP00000274289.3; ENSG00000145632.16. DR GeneID; 10769; -. DR KEGG; hsa:10769; -. DR MANE-Select; ENST00000274289.8; ENSP00000274289.3; NM_006622.4; NP_006613.2. DR UCSC; uc003jrn.4; human. DR AGR; HGNC:19699; -. DR ClinPGx; PA134940798; -. DR CTD; 10769; -. DR DisGeNET; 10769; -. DR GeneCards; PLK2; -. DR HGNC; HGNC:19699; PLK2. DR HPA; ENSG00000145632; Low tissue specificity. DR MalaCards; PLK2; -. DR MIM; 607023; gene. DR OpenTargets; ENSG00000145632; -. DR VEuPathDB; HostDB:ENSG00000145632; -. DR eggNOG; KOG0575; Eukaryota. DR GeneTree; ENSGT00940000158739; -. DR HOGENOM; CLU_000288_46_1_1; -. DR InParanoid; Q9NYY3; -. DR OMA; NMPESDH; -. DR OrthoDB; 408964at2759; -. DR PAN-GO; Q9NYY3; 10 GO annotations based on evolutionary models. DR PhylomeDB; Q9NYY3; -. DR BRENDA; 2.7.11.21; 2681. DR PathwayCommons; Q9NYY3; -. DR Reactome; R-HSA-6804115; TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain. DR Reactome; R-HSA-9662834; CD163 mediating an anti-inflammatory response. DR Reactome; R-HSA-9768919; NPAS4 regulates expression of target genes. DR SignaLink; Q9NYY3; -. DR SIGNOR; Q9NYY3; -. DR Agora; ENSG00000145632; -. DR BioGRID-ORCS; 10769; 13 hits in 1185 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; PLK2; human. DR EvolutionaryTrace; Q9NYY3; -. DR GeneWiki; PLK2; -. DR GenomeRNAi; 10769; -. DR Pharos; Q9NYY3; Tchem. DR PRO; PR:Q9NYY3; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; Q9NYY3; protein. DR Bgee; ENSG00000145632; Expressed in spleen and 196 other cell types or tissues. DR ExpressionAtlas; Q9NYY3; baseline and differential. DR GO; GO:0005814; C:centriole; IDA:UniProtKB. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0000785; C:chromatin; IEA:Ensembl. DR GO; GO:0005737; C:cytoplasm; IDA:ParkinsonsUK-UCL. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0030425; C:dendrite; ISS:UniProtKB. DR GO; GO:0000776; C:kinetochore; IBA:GO_Central. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0000922; C:spindle pole; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0043008; F:ATP-dependent protein binding; IDA:ParkinsonsUK-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IMP:UniProtKB. DR GO; GO:0060292; P:long-term synaptic depression; ISS:UniProtKB. DR GO; GO:0060291; P:long-term synaptic potentiation; ISS:UniProtKB. DR GO; GO:0007613; P:memory; ISS:UniProtKB. DR GO; GO:0007052; P:mitotic spindle organization; IDA:UniProtKB. DR GO; GO:0016525; P:negative regulation of angiogenesis; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; ISS:UniProtKB. DR GO; GO:0071866; P:negative regulation of apoptotic process in bone marrow cell; IEA:Ensembl. DR GO; GO:2000773; P:negative regulation of cellular senescence; IEA:Ensembl. DR GO; GO:0002862; P:negative regulation of inflammatory response to antigenic stimulus; TAS:Reactome. DR GO; GO:0010508; P:positive regulation of autophagy; IDA:ParkinsonsUK-UCL. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; HMP:UniProtKB. DR GO; GO:0090050; P:positive regulation of cell migration involved in sprouting angiogenesis; IEA:Ensembl. DR GO; GO:0045732; P:positive regulation of protein catabolic process; IDA:ParkinsonsUK-UCL. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0032486; P:Rap protein signal transduction; ISS:UniProtKB. DR GO; GO:0007265; P:Ras protein signal transduction; ISS:UniProtKB. DR GO; GO:0046599; P:regulation of centriole replication; IDA:UniProtKB. DR GO; GO:0048167; P:regulation of synaptic plasticity; ISS:UniProtKB. DR CDD; cd13118; POLO_box_1; 1. DR CDD; cd13117; POLO_box_2; 1. DR CDD; cd14188; STKc_PLK2; 1. DR FunFam; 1.10.510.10:FF:001498; Serine/threonine-protein kinase PLK; 1. DR FunFam; 3.30.1120.30:FF:000001; Serine/threonine-protein kinase PLK; 1. DR FunFam; 3.30.200.20:FF:000091; Serine/threonine-protein kinase PLK; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.30.1120.30; POLO box domain; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR042825; PLK2_STKc. DR InterPro; IPR033701; POLO_box_1. DR InterPro; IPR033695; POLO_box_2. DR InterPro; IPR000959; POLO_box_dom. DR InterPro; IPR036947; POLO_box_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24345; SERINE/THREONINE-PROTEIN KINASE PLK; 1. DR PANTHER; PTHR24345:SF44; SERINE_THREONINE-PROTEIN KINASE PLK2; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00659; POLO_box; 2. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF82615; Polo-box domain; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50078; POLO_BOX; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell projection; KW Cytoplasm; Cytoskeleton; Kinase; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase; Tumor suppressor. FT CHAIN 1..685 FT /note="Serine/threonine-protein kinase PLK2" FT /id="PRO_0000086561" FT DOMAIN 82..334 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 503..581 FT /note="POLO box 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00154" FT DOMAIN 601..685 FT /note="POLO box 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00154" FT REGION 21..70 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 406..433 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 43..52 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 205 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 88..96 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 111 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 239 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:P53351" FT VAR_SEQ 55..68 FT /note="Missing (in isoform 2)" FT /id="VSP_062732" FT VARIANT 14 FT /note="S -> T (in an ovarian endometrioid carcinoma sample; FT somatic mutation; dbSNP:rs1404394734)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041023" FT VARIANT 92 FT /note="G -> S (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041024" FT VARIANT 436 FT /note="E -> K (in dbSNP:rs55768901)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041025" FT VARIANT 487 FT /note="P -> L (in dbSNP:rs55645589)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041026" FT MUTAGEN 210 FT /note="N->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:19001868" FT MUTAGEN 503 FT /note="W->F: Impairs localization to the centrosome and FT centriole duplication; when associated with A-629 and M- FT 631." FT /evidence="ECO:0000269|PubMed:19001868" FT MUTAGEN 629 FT /note="H->A: Impairs localization to the centrosome and FT centriole duplication; when associated with F-503 and M- FT 631." FT /evidence="ECO:0000269|PubMed:19001868" FT MUTAGEN 631 FT /note="K->M: Impairs localization to the centrosome and FT centriole duplication; when associated with F-503 and A- FT 631." FT /evidence="ECO:0000269|PubMed:19001868" FT CONFLICT 28 FT /note="A -> G (in Ref. 1; AAC14573)" FT /evidence="ECO:0000305" FT STRAND 72..74 FT /evidence="ECO:0007829|PDB:4I5P" FT TURN 76..78 FT /evidence="ECO:0007829|PDB:4I5P" FT STRAND 81..91 FT /evidence="ECO:0007829|PDB:4I5P" FT STRAND 94..101 FT /evidence="ECO:0007829|PDB:4I5P" FT TURN 102..105 FT /evidence="ECO:0007829|PDB:4I5P" FT STRAND 106..114 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 115..118 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 121..134 FT /evidence="ECO:0007829|PDB:4I5P" FT STRAND 145..150 FT /evidence="ECO:0007829|PDB:4I5P" FT STRAND 152..159 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 167..174 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 179..198 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 208..210 FT /evidence="ECO:0007829|PDB:4I5P" FT STRAND 211..213 FT /evidence="ECO:0007829|PDB:4I5P" FT STRAND 219..221 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 224..226 FT /evidence="ECO:0007829|PDB:4I5M" FT TURN 233..235 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 249..252 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 259..275 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 286..288 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 289..293 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 305..314 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 319..321 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 325..329 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 332..335 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 345..348 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 471..485 FT /evidence="ECO:0007829|PDB:4RS6" FT STRAND 490..492 FT /evidence="ECO:0007829|PDB:4XB0" FT STRAND 504..510 FT /evidence="ECO:0007829|PDB:4RS6" FT TURN 511..514 FT /evidence="ECO:0007829|PDB:4RS6" FT STRAND 515..520 FT /evidence="ECO:0007829|PDB:4RS6" FT STRAND 525..529 FT /evidence="ECO:0007829|PDB:4RS6" FT STRAND 534..537 FT /evidence="ECO:0007829|PDB:4RS6" FT STRAND 541..547 FT /evidence="ECO:0007829|PDB:4RS6" FT STRAND 553..558 FT /evidence="ECO:0007829|PDB:4RS6" FT HELIX 563..582 FT /evidence="ECO:0007829|PDB:4RS6" FT STRAND 602..616 FT /evidence="ECO:0007829|PDB:4RS6" FT STRAND 621..625 FT /evidence="ECO:0007829|PDB:4RS6" FT TURN 626..628 FT /evidence="ECO:0007829|PDB:4RS6" FT STRAND 631..646 FT /evidence="ECO:0007829|PDB:4RS6" FT STRAND 652..656 FT /evidence="ECO:0007829|PDB:4RS6" FT HELIX 657..663 FT /evidence="ECO:0007829|PDB:4RS6" FT HELIX 667..680 FT /evidence="ECO:0007829|PDB:4RS6" SQ SEQUENCE 685 AA; 78237 MW; 6429F6EFD830B333 CRC64; MELLRTITYQ PAASTKMCEQ ALGKGCGADS KKKRPPQPPE ESQPPQSQAQ VPPAAPHHHH HHSHSGPEIS RIIVDPTTGK RYCRGKVLGK GGFAKCYEMT DLTNNKVYAA KIIPHSRVAK PHQREKIDKE IELHRILHHK HVVQFYHYFE DKENIYILLE YCSRRSMAHI LKARKVLTEP EVRYYLRQIV SGLKYLHEQE ILHRDLKLGN FFINEAMELK VGDFGLAARL EPLEHRRRTI CGTPNYLSPE VLNKQGHGCE SDIWALGCVM YTMLLGRPPF ETTNLKETYR CIREARYTMP SSLLAPAKHL IASMLSKNPE DRPSLDDIIR HDFFLQGFTP DRLSSSCCHT VPDFHLSSPA KNFFKKAAAA LFGGKKDKAR YIDTHNRVSK EDEDIYKLRH DLKKTSITQQ PSKHRTDEEL QPPTTTVARS GTPAVENKQQ IGDAIRMIVR GTLGSCSSSS ECLEDSTMGS VADTVARVLR GCLENMPEAD CIPKEQLSTS FQWVTKWVDY SNKYGFGYQL SDHTVGVLFN NGAHMSLLPD KKTVHYYAEL GQCSVFPATD APEQFISQVT VLKYFSHYME ENLMDGGDLP SVTDIRRPRL YLLQWLKSDK ALMMLFNDGT FQVNFYHDHT KIIICSQNEE YLLTYINEDR ISTTFRLTTL LMSGCSSELK NRMEYALNML LQRCN // ID RABL3_HUMAN Reviewed; 236 AA. AC Q5HYI8; Q8WUD3; DT 04-DEC-2007, integrated into UniProtKB/Swiss-Prot. DT 15-FEB-2005, sequence version 1. DT 28-JAN-2026, entry version 169. DE RecName: Full=Rab-like protein 3; DE EC=3.6.5.2 {ECO:0000250|UniProtKB:Q9D4V7}; GN Name=RABL3 {ECO:0000312|HGNC:HGNC:18072}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Bone marrow, Fetal skin, and Heart; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [6] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [7] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [8] RP FUNCTION, INTERACTION WITH RAB11, MUTAGENESIS OF SER-20, AND SUBCELLULAR RP LOCATION. RX PubMed=36052645; DOI=10.1242/jcs.260021; RA Kobayashi T., Ikeda T., Ota R., Yasukawa T., Itoh H.; RT "The atypical small GTPase RABL3 interacts with RAB11 to regulate early RT ciliogenesis in human cells."; RL J. Cell Sci. 135:0-0(2022). RN [9] RP FUNCTION, INTERACTION WITH RAP1GDS1, INVOLVEMENT IN PNCA5, VARIANTS PNCA5 RP 36-SER--ASP-236 DEL AND GLN-184, AND CHARACTERIZATION OF VARIANT PNCA5 RP 36-SER--ASP-236 DEL. RX PubMed=31406347; DOI=10.1038/s41588-019-0475-y; RA Nissim S., Leshchiner I., Mancias J.D., Greenblatt M.B., Maertens O., RA Cassa C.A., Rosenfeld J.A., Cox A.G., Hedgepeth J., Wucherpfennig J.I., RA Kim A.J., Henderson J.E., Gonyo P., Brandt A., Lorimer E., Unger B., RA Prokop J.W., Heidel J.R., Wang X.X., Ukaegbu C.I., Jennings B.C., RA Paulo J.A., Gableske S., Fierke C.A., Getz G., Sunyaev S.R., RA Wade Harper J., Cichowski K., Kimmelman A.C., Houvras Y., Syngal S., RA Williams C., Goessling W.; RT "Mutations in RABL3 alter KRAS prenylation and are associated with RT hereditary pancreatic cancer."; RL Nat. Genet. 51:1308-1314(2019). CC -!- FUNCTION: Small GTPase required for KRAS signaling regulation and CC modulation of cell proliferation (PubMed:31406347). Regulator of KRAS CC prenylation, and probably prenylation of other small GTPases CC (PubMed:31406347). Required for lymphocyte development and function (By CC similarity). Not required for myeloid cell development (By similarity). CC Interacts with Rab11 to promote ciliary vesicle formation at the mother CC centriole, thereby regulating early ciliogenesis. The GTP-binding CC capacity of RABL3 is essential for ciliogenesis (PubMed:36052645). CC {ECO:0000250|UniProtKB:Q9D4V7, ECO:0000269|PubMed:31406347, CC ECO:0000269|PubMed:36052645}. CC -!- CATALYTIC ACTIVITY: CC Reaction=GTP + H2O = GDP + phosphate + H(+); Xref=Rhea:RHEA:19669, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:37565, CC ChEBI:CHEBI:43474, ChEBI:CHEBI:58189; EC=3.6.5.2; CC Evidence={ECO:0000250|UniProtKB:P62493}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:19670; CC Evidence={ECO:0000250|UniProtKB:P62493}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000250|UniProtKB:Q9D4V7}; CC -!- SUBUNIT: Homodimer (By similarity). Interacts with GPR89; the CC interaction stabilizes GPR89 (By similarity). Interacts with RAP1GDS1 CC (PubMed:31406347). Interacts (GDP-bound) with RAB11A (GTP-bound); the CC interaction stabilizes RABL3 and regulates ciliary vesicle formation CC during early ciliogenesis (PubMed:36052645). CC {ECO:0000250|UniProtKB:Q9D4V7, ECO:0000269|PubMed:31406347, CC ECO:0000269|PubMed:36052645}. CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule organizing CC center, centrosome {ECO:0000269|PubMed:36052645}. Golgi apparatus CC {ECO:0000269|PubMed:36052645}. Note=Accumulates around the centrosome CC during early ciliogenesis. {ECO:0000269|PubMed:36052645}. CC -!- DOMAIN: Switch I, switch II and the interswitch regions are CC characteristic of Rab GTPases and mediate the interactions with Rab CC downstream effectors. The switch regions undergo conformational changes CC upon nucleotide binding which drive interaction with specific sets of CC effector proteins, with most effectors only binding to GTP-bound Rab. CC {ECO:0000250|UniProtKB:P62820}. CC -!- DISEASE: Pancreatic cancer 5 (PNCA5) [MIM:618680]: A malignant neoplasm CC of the pancreas. Tumors can arise from both the exocrine and endocrine CC portions of the pancreas, but 95% of them develop from the exocrine CC portion, including the ductal epithelium, acinar cells, connective CC tissue, and lymphatic tissue. {ECO:0000269|PubMed:31406347}. CC Note=Disease susceptibility is associated with variants affecting the CC gene represented in this entry. RABL3 variants have been found in CC families with a history of pancreatic ductal adenocarcinoma and CC multiple other occurrences of cancer, including melanoma, breast CC cancer, prostate cancer, and colon cancer. CC {ECO:0000269|PubMed:31406347}. CC -!- SIMILARITY: Belongs to the small GTPase superfamily. Rab family. CC {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AK293085; BAF85774.1; -; mRNA. DR EMBL; BX647664; CAI46059.1; -; mRNA. DR EMBL; BX647593; CAI46064.1; -; mRNA. DR EMBL; BX647559; CAI46095.1; -; mRNA. DR EMBL; CH471052; EAW79521.1; -; Genomic_DNA. DR EMBL; BC020832; AAH20832.1; -; mRNA. DR CCDS; CCDS3001.1; -. DR RefSeq; NP_776186.2; NM_173825.5. DR AlphaFoldDB; Q5HYI8; -. DR SMR; Q5HYI8; -. DR BioGRID; 130066; 248. DR FunCoup; Q5HYI8; 2126. DR IntAct; Q5HYI8; 118. DR MINT; Q5HYI8; -. DR STRING; 9606.ENSP00000273375; -. DR ChEMBL; CHEMBL4105853; -. DR DrugCentral; Q5HYI8; -. DR iPTMnet; Q5HYI8; -. DR PhosphoSitePlus; Q5HYI8; -. DR SwissPalm; Q5HYI8; -. DR BioMuta; RABL3; -. DR DMDM; 74762186; -. DR jPOST; Q5HYI8; -. DR MassIVE; Q5HYI8; -. DR PaxDb; 9606-ENSP00000273375; -. DR PeptideAtlas; Q5HYI8; -. DR ProteomicsDB; 62938; -. DR Pumba; Q5HYI8; -. DR TopDownProteomics; Q5HYI8; -. DR Antibodypedia; 32810; 46 antibodies from 20 providers. DR DNASU; 285282; -. DR Ensembl; ENST00000273375.8; ENSP00000273375.4; ENSG00000144840.11. DR GeneID; 285282; -. DR KEGG; hsa:285282; -. DR MANE-Select; ENST00000273375.8; ENSP00000273375.4; NM_173825.5; NP_776186.2. DR UCSC; uc003edx.3; human. DR AGR; HGNC:18072; -. DR ClinPGx; PA34161; -. DR CTD; 285282; -. DR DisGeNET; 285282; -. DR GeneCards; RABL3; -. DR HGNC; HGNC:18072; RABL3. DR HPA; ENSG00000144840; Low tissue specificity. DR MalaCards; RABL3; -. DR MIM; 618542; gene. DR MIM; 618680; phenotype. DR OpenTargets; ENSG00000144840; -. DR Orphanet; 1333; Familial pancreatic carcinoma. DR VEuPathDB; HostDB:ENSG00000144840; -. DR eggNOG; ENOG502QT3S; Eukaryota. DR GeneTree; ENSGT00390000007467; -. DR HOGENOM; CLU_084875_1_0_1; -. DR InParanoid; Q5HYI8; -. DR OMA; HIRFDME; -. DR OrthoDB; 5914890at2759; -. DR PAN-GO; Q5HYI8; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q5HYI8; -. DR PathwayCommons; Q5HYI8; -. DR SignaLink; Q5HYI8; -. DR Agora; ENSG00000144840; -. DR BioGRID-ORCS; 285282; 34 hits in 1157 CRISPR screens. DR GenomeRNAi; 285282; -. DR Pharos; Q5HYI8; Tbio. DR PRO; PR:Q5HYI8; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q5HYI8; protein. DR Bgee; ENSG00000144840; Expressed in adrenal tissue and 198 other cell types or tissues. DR ExpressionAtlas; Q5HYI8; baseline and differential. DR GO; GO:0012505; C:endomembrane system; IBA:GO_Central. DR GO; GO:0003925; F:G protein activity; IMP:UniProtKB. DR GO; GO:0005525; F:GTP binding; ISS:UniProtKB. DR GO; GO:0003924; F:GTPase activity; IBA:GO_Central. DR GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB. DR GO; GO:0030183; P:B cell differentiation; ISS:UniProtKB. DR GO; GO:0006886; P:intracellular protein transport; IBA:GO_Central. DR GO; GO:0001779; P:natural killer cell differentiation; ISS:UniProtKB. DR GO; GO:0045724; P:positive regulation of cilium assembly; IMP:UniProtKB. DR GO; GO:0050821; P:protein stabilization; ISS:UniProtKB. DR GO; GO:1903059; P:regulation of protein lipidation; IMP:UniProtKB. DR GO; GO:0046578; P:regulation of Ras protein signal transduction; IMP:UniProtKB. DR GO; GO:0033077; P:T cell differentiation in thymus; ISS:UniProtKB. DR CDD; cd04102; RabL3; 1. DR FunFam; 3.40.50.300:FF:000525; rab-like protein 3 isoform X1; 1. DR Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1. DR InterPro; IPR027417; P-loop_NTPase. DR PANTHER; PTHR24073; DRAB5-RELATED; 1. DR Pfam; PF08477; Roc; 1. DR PRINTS; PR00449; RASTRNSFRMNG. DR SMART; SM00175; RAB; 1. DR SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1. DR PROSITE; PS51419; RAB; 1. PE 1: Evidence at protein level; KW Cytoplasm; Cytoskeleton; Disease variant; Golgi apparatus; GTP-binding; KW Hydrolase; Magnesium; Metal-binding; Nucleotide-binding; KW Proteomics identification; Reference proteome. FT CHAIN 1..236 FT /note="Rab-like protein 3" FT /id="PRO_0000312166" FT REGION 1..236 FT /note="Small GTPase-like" FT REGION 33..41 FT /note="Switch-I" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00753" FT REGION 69..89 FT /note="Switch-II" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00753" FT BINDING 15 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 16 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 18 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 19 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 20 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 20 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 21 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 38 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 38 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 66 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 148 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 150 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 179 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT BINDING 180 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000250|UniProtKB:Q9D4V7" FT VARIANT 36..236 FT /note="Missing (in PNCA5; associated with disease FT susceptibility; increased KRAS signaling and cell FT proliferation; increased interaction with RAP1GDS1; FT increased KRAS prenylation)" FT /evidence="ECO:0000269|PubMed:31406347" FT /id="VAR_083453" FT VARIANT 184 FT /note="R -> Q (in PNCA5; associated with disease FT susceptibility; dbSNP:rs61756477)" FT /evidence="ECO:0000269|PubMed:31406347" FT /id="VAR_083454" FT MUTAGEN 20 FT /note="S->N: Dominant-negative mutant (GDP-bound form). FT Increased interaction with GTP-bound RAB11A. Increased FT recruitment to the centrosome. Impaired positive regulation FT of ciliary vesicle formation." FT /evidence="ECO:0000269|PubMed:36052645" FT CONFLICT 60 FT /note="Y -> C (in Ref. 4; AAH20832)" FT /evidence="ECO:0000305" FT CONFLICT 163 FT /note="R -> T (in Ref. 4; AAH20832)" FT /evidence="ECO:0000305" SQ SEQUENCE 236 AA; 26423 MW; B80898B1293C88C6 CRC64; MASLDRVKVL VLGDSGVGKS SLVHLLCQNQ VLGNPSWTVG CSVDVRVHDY KEGTPEEKTY YIELWDVGGS VGSASSVKST RAVFYNSVNG IIFVHDLTNK KSSQNLRRWS LEALNRDLVP TGVLVTNGDY DQEQFADNQI PLLVIGTKLD QIHETKRHEV LTRTAFLAED FNPEEINLDC TNPRYLAAGS SNAVKLSRFF DKVIEKRYFL REGNQIPGFP DRKRFGAGTL KSLHYD // ID RELB_HUMAN Reviewed; 579 AA. AC Q01201; Q6GTX7; Q9UEI7; DT 01-OCT-1993, integrated into UniProtKB/Swiss-Prot. DT 04-APR-2006, sequence version 2. DT 28-JAN-2026, entry version 220. DE RecName: Full=Transcription factor RelB; DE AltName: Full=I-Rel; GN Name=RELB; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=T-cell; RX PubMed=1577270; DOI=10.1101/gad.6.5.745; RA Ruben S.M., Klement J.F., Maher M., Coleman T.A., Chen C.H., Rosen C.A.; RT "I-Rel: a novel rel-related protein that inhibits NF-kappa B RT transcriptional activity."; RL Genes Dev. 6:745-760(1992). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Yoshiura K., Murray J.C.; RT "A transcriptional map in the region of 19q13 derived using direct RT sequencing and exon trapping."; RL Submitted (JAN-1998) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NHLBI resequencing and genotyping service (RS&G); RL Submitted (DEC-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Blood; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP FUNCTION, AND IDENTIFICATION IN THE NF-KAPPA-B RELB-P50 COMPLEX. RX PubMed=1732739; DOI=10.1128/mcb.12.2.674-684.1992; RA Ryseck R.P., Bull P., Takamiya M., Bours V., Siebenlist U., Dobrzanski P., RA Bravo R.; RT "RelB, a new Rel family transcription activator that can interact with p50- RT NF-kappa B."; RL Mol. Cell. Biol. 12:674-684(1992). RN [6] RP FUNCTION. RX PubMed=8441398; DOI=10.1128/mcb.13.3.1572-1582.1993; RA Dobrzanski P., Ryseck R.P., Bravo R.; RT "Both N- and C-terminal domains of RelB are required for full RT transactivation: role of the N-terminal leucine zipper-like motif."; RL Mol. Cell. Biol. 13:1572-1582(1993). RN [7] RP FUNCTION, IDENTIFICATION IN THE NF-KAPPA-B RELB-P50 COMPLEX, AND RP IDENTIFICATION IN THE NF-KAPPA-B RELB-P52 COMPLEX. RX PubMed=7925301; DOI=10.1002/j.1460-2075.1994.tb06782.x; RA Dobrzanski P., Ryseck R.P., Bravo R.; RT "Differential interactions of Rel-NF-kappa B complexes with I kappa B alpha RT determine pools of constitutive and inducible NF-kappa B activity."; RL EMBO J. 13:4608-4616(1994). RN [8] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37 AND SER-573, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [9] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-573, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [10] RP SUBCELLULAR LOCATION. RX PubMed=20873783; DOI=10.1021/pr100562w; RA Vaz Meirelles G., Ferreira Lanza D.C., da Silva J.C., Santana Bernachi J., RA Paes Leme A.F., Kobarg J.; RT "Characterization of hNek6 interactome reveals an important role for its RT short N-terminal domain and colocalization with proteins at the RT centrosome."; RL J. Proteome Res. 9:6298-6316(2010). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [12] RP FUNCTION, AND INDUCTION BY NUPR1. RX PubMed=22565310; DOI=10.1172/jci60144; RA Hamidi T., Algul H., Cano C.E., Sandi M.J., Molejon M.I., Riemann M., RA Calvo E.L., Lomberk G., Dagorn J.C., Weih F., Urrutia R., Schmid R.M., RA Iovanna J.L.; RT "Nuclear protein 1 promotes pancreatic cancer development and protects RT cells from stress by inhibiting apoptosis."; RL J. Clin. Invest. 122:2092-2103(2012). RN [13] RP METHYLATION [LARGE SCALE ANALYSIS] AT ARG-16, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Colon carcinoma; RX PubMed=24129315; DOI=10.1074/mcp.o113.027870; RA Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M., RA Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V., RA Bedford M.T., Comb M.J.; RT "Immunoaffinity enrichment and mass spectrometry analysis of protein RT methylation."; RL Mol. Cell. Proteomics 13:372-387(2014). RN [14] RP FUNCTION, INVOLVEMENT IN IMD53, AND VARIANT IMD53 397-TYR--THR-579 DEL. RX PubMed=26385063; DOI=10.1016/j.jaut.2015.09.001; RA Sharfe N., Merico D., Karanxha A., Macdonald C., Dadi H., Ngan B., RA Herbrick J.A., Roifman C.M.; RT "The effects of RelB deficiency on lymphocyte development and function."; RL J. Autoimmun. 65:90-100(2015). CC -!- FUNCTION: NF-kappa-B is a pleiotropic transcription factor which is CC present in almost all cell types and is involved in many biological CC processed such as inflammation, immunity, differentiation, cell growth, CC tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric CC complex formed by the Rel-like domain-containing proteins RELA/p65, CC RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at CC kappa-B sites in the DNA of their target genes and the individual CC dimers have distinct preferences for different kappa-B sites that they CC can bind with distinguishable affinity and specificity. Different dimer CC combinations act as transcriptional activators or repressors, CC respectively. NF-kappa-B is controlled by various mechanisms of post- CC translational modification and subcellular compartmentalization as well CC as by interactions with other cofactors or corepressors. NF-kappa-B CC complexes are held in the cytoplasm in an inactive state complexed with CC members of the NF-kappa-B inhibitor (I-kappa-B) family. In a CC conventional activation pathway, I-kappa-B is phosphorylated by I- CC kappa-B kinases (IKKs) in response to different activators, CC subsequently degraded thus liberating the active NF-kappa-B complex CC which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 CC and RelB-p52 complexes are transcriptional activators. RELB neither CC associates with DNA nor with RELA/p65 or REL. Stimulates promoter CC activity in the presence of NFKB2/p49. As a member of the CC NUPR1/RELB/IER3 survival pathway, may provide pancreatic ductal CC adenocarcinoma with remarkable resistance to cell stress, such as CC starvation or gemcitabine treatment. Regulates the circadian clock by CC repressing the transcriptional activator activity of the CLOCK-BMAL1 CC heterodimer in a CRY1/CRY2 independent manner. Increased repression of CC the heterodimer is seen in the presence of NFKB2/p52. Is required for CC both T and B lymphocyte maturation and function (PubMed:26385063). CC {ECO:0000269|PubMed:1732739, ECO:0000269|PubMed:22565310, CC ECO:0000269|PubMed:26385063, ECO:0000269|PubMed:7925301, CC ECO:0000269|PubMed:8441398}. CC -!- SUBUNIT: Component of the NF-kappa-B RelB-p50 complex. Component of the CC NF-kappa-B RelB-p52 complex. Self-associates; the interaction seems to CC be transient and may prevent degradation allowing for heterodimer CC formation with p50 or p52. Interacts with NFKB1/p50, NFKB2/p52 and CC NFKB2/p100. Interacts with NFKBID. Interacts with BMAL1 and the CC interaction is enhanced in the presence of CLOCK (By similarity). CC {ECO:0000250}. CC -!- INTERACTION: CC Q01201; Q8N668: COMMD1; NbExp=2; IntAct=EBI-357837, EBI-1550112; CC Q01201; P49841: GSK3B; NbExp=4; IntAct=EBI-357837, EBI-373586; CC Q01201; P19838: NFKB1; NbExp=8; IntAct=EBI-357837, EBI-300010; CC Q01201; Q00653: NFKB2; NbExp=6; IntAct=EBI-357837, EBI-307326; CC Q01201; Q00653-3: NFKB2; NbExp=2; IntAct=EBI-357837, EBI-50432018; CC Q01201; P25963: NFKBIA; NbExp=4; IntAct=EBI-357837, EBI-307386; CC Q01201; O00221: NFKBIE; NbExp=4; IntAct=EBI-357837, EBI-355098; CC Q01201; Q04206-2: RELA; NbExp=2; IntAct=EBI-357837, EBI-289947; CC Q01201; Q92922: SMARCC1; NbExp=2; IntAct=EBI-357837, EBI-355653; CC Q01201; Q96GM5: SMARCD1; NbExp=2; IntAct=EBI-357837, EBI-358489; CC Q01201; Q92925: SMARCD2; NbExp=2; IntAct=EBI-357837, EBI-358441; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:20873783}. Cytoplasm, CC cytoskeleton, microtubule organizing center, centrosome CC {ECO:0000269|PubMed:20873783}. Note=Colocalizes with NEK6 in the CC centrosome. CC -!- INDUCTION: Up-regulated by mitogens and NUPR1. CC {ECO:0000269|PubMed:22565310}. CC -!- DOMAIN: Both N- and C-terminal domains are required for transcriptional CC activation. CC -!- PTM: Phosphorylation at 'Thr-103' and 'Ser-573' is followed by CC proteasomal degradation. {ECO:0000250}. CC -!- DISEASE: Immunodeficiency 53 (IMD53) [MIM:617585]: An autosomal CC recessive primary immunodeficiency apparent from early infancy and CC resulting in recurrent infections, severe autoimmune skin disease CC rheumatoid arthritis, and failure to thrive. Immunologic workup shows CC increased CD4+/CD8+ ratio, impaired T-cell proliferative response to CC multiple antigen, T-cell developmental and functional defects, and CC impaired ability to produce specific immunoglobulins. CC {ECO:0000269|PubMed:26385063}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- CAUTION: Was originally thought to inhibit the transcriptional activity CC of nuclear factor NF-kappa-B. {ECO:0000305|PubMed:1577270}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/324/RELB"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M83221; AAA36127.1; -; mRNA. DR EMBL; AF043463; AAC82346.1; -; Genomic_DNA. DR EMBL; AF043454; AAC82346.1; JOINED; Genomic_DNA. DR EMBL; AF043455; AAC82346.1; JOINED; Genomic_DNA. DR EMBL; AF043456; AAC82346.1; JOINED; Genomic_DNA. DR EMBL; AF043457; AAC82346.1; JOINED; Genomic_DNA. DR EMBL; AF043458; AAC82346.1; JOINED; Genomic_DNA. DR EMBL; AF043459; AAC82346.1; JOINED; Genomic_DNA. DR EMBL; AF043460; AAC82346.1; JOINED; Genomic_DNA. DR EMBL; AF043461; AAC82346.1; JOINED; Genomic_DNA. DR EMBL; AF043462; AAC82346.1; JOINED; Genomic_DNA. DR EMBL; DQ314887; ABC40746.1; -; Genomic_DNA. DR EMBL; BC028013; AAH28013.1; -; mRNA. DR CCDS; CCDS46110.1; -. DR PIR; A42617; A42617. DR RefSeq; NP_006500.2; NM_006509.3. DR PDB; 8G8R; X-ray; 2.60 A; B=407-440. DR PDBsum; 8G8R; -. DR AlphaFoldDB; Q01201; -. DR SMR; Q01201; -. DR BioGRID; 111903; 77. DR ComplexPortal; CPX-5831; NF-kappaB DNA-binding transcription factor complex, p52/RelB. DR ComplexPortal; CPX-5833; NF-kappaB DNA-binding transcription factor complex, p50/RelB. DR CORUM; Q01201; -. DR DIP; DIP-27531N; -. DR FunCoup; Q01201; 727. DR IntAct; Q01201; 93. DR MINT; Q01201; -. DR STRING; 9606.ENSP00000221452; -. DR ChEMBL; CHEMBL4523273; -. DR DrugBank; DB01822; (4R,5R)-1,2-dithiane-4,5-diol. DR DrugBank; DB15010; Edasalonexent. DR DrugBank; DB17029; Go-6976. DR DrugBank; DB06685; Laquinimod. DR DrugBank; DB13063; Parthenolide. DR DrugBank; DB12058; Recoflavone. DR DrugBank; DB15495; Rocaglamide. DR DrugBank; DB00795; Sulfasalazine. DR DrugBank; DB18804; Tepilamide fumarate. DR DrugBank; DB12025; Triptolide. DR DrugBank; DB06439; Tyloxapol. DR DrugBank; DB06235; Vadimezan. DR GlyGen; Q01201; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q01201; -. DR PhosphoSitePlus; Q01201; -. DR BioMuta; RELB; -. DR DMDM; 92090634; -. DR jPOST; Q01201; -. DR MassIVE; Q01201; -. DR PaxDb; 9606-ENSP00000221452; -. DR PeptideAtlas; Q01201; -. DR ProteomicsDB; 57938; -. DR Pumba; Q01201; -. DR Antibodypedia; 3573; 670 antibodies from 44 providers. DR DNASU; 5971; -. DR Ensembl; ENST00000221452.13; ENSP00000221452.7; ENSG00000104856.15. DR GeneID; 5971; -. DR KEGG; hsa:5971; -. DR MANE-Select; ENST00000221452.13; ENSP00000221452.7; NM_006509.4; NP_006500.2. DR UCSC; uc060zvi.1; human. DR AGR; HGNC:9956; -. DR ClinPGx; PA34322; -. DR CTD; 5971; -. DR DisGeNET; 5971; -. DR GeneCards; RELB; -. DR HGNC; HGNC:9956; RELB. DR HPA; ENSG00000104856; Low tissue specificity. DR MalaCards; RELB; -. DR MIM; 604758; gene. DR MIM; 617585; phenotype. DR OpenTargets; ENSG00000104856; -. DR Orphanet; 688594; Combined immunodeficiency due to RELB deficiency. DR VEuPathDB; HostDB:ENSG00000104856; -. DR eggNOG; ENOG502QV8A; Eukaryota. DR GeneTree; ENSGT00940000160230; -. DR InParanoid; Q01201; -. DR OMA; NQYREGA; -. DR OrthoDB; 7881762at2759; -. DR PAN-GO; Q01201; 9 GO annotations based on evolutionary models. DR PhylomeDB; Q01201; -. DR PathwayCommons; Q01201; -. DR Reactome; R-HSA-5607761; Dectin-1 mediated noncanonical NF-kB signaling. DR Reactome; R-HSA-5621575; CD209 (DC-SIGN) signaling. DR Reactome; R-HSA-5676590; NIK-->noncanonical NF-kB signaling. DR SignaLink; Q01201; -. DR SIGNOR; Q01201; -. DR Agora; ENSG00000104856; -. DR BioGRID-ORCS; 5971; 22 hits in 1173 CRISPR screens. DR ChiTaRS; RELB; human. DR GeneWiki; RELB; -. DR GenomeRNAi; 5971; -. DR Pharos; Q01201; Tbio. DR PRO; PR:Q01201; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q01201; protein. DR Bgee; ENSG00000104856; Expressed in granulocyte and 100 other cell types or tissues. DR ExpressionAtlas; Q01201; baseline and differential. DR GO; GO:0005813; C:centrosome; IEA:UniProtKB-SubCell. DR GO; GO:0000785; C:chromatin; IDA:ARUK-UCL. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0071159; C:NF-kappaB complex; NAS:ComplexPortal. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:CACAO. DR GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB. DR GO; GO:0045202; C:synapse; IEA:Ensembl. DR GO; GO:0017053; C:transcription repressor complex; IDA:UniProtKB. DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB. DR GO; GO:0042802; F:identical protein binding; IEA:Ensembl. DR GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB. DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:ARUK-UCL. DR GO; GO:0019882; P:antigen processing and presentation; IEA:Ensembl. DR GO; GO:0007249; P:canonical NF-kappaB signal transduction; IBA:GO_Central. DR GO; GO:0071470; P:cellular response to osmotic stress; IEA:Ensembl. DR GO; GO:0032922; P:circadian regulation of gene expression; ISS:UniProtKB. DR GO; GO:0006954; P:inflammatory response; IBA:GO_Central. DR GO; GO:0045087; P:innate immune response; IBA:GO_Central. DR GO; GO:0030098; P:lymphocyte differentiation; IMP:UniProtKB. DR GO; GO:0043011; P:myeloid dendritic cell differentiation; IEA:Ensembl. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; IEA:Ensembl. DR GO; GO:0032688; P:negative regulation of interferon-beta production; IMP:CACAO. DR GO; GO:0038061; P:non-canonical NF-kappaB signal transduction; IBA:GO_Central. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IBA:GO_Central. DR GO; GO:0034097; P:response to cytokine; IBA:GO_Central. DR GO; GO:0045063; P:T-helper 1 cell differentiation; IEA:Ensembl. DR CDD; cd01177; IPT_NFkappaB; 1. DR CDD; cd07886; RHD-n_RelB; 1. DR FunFam; 2.60.40.10:FF:000046; Nuclear factor NF-kappa-B p105 subunit; 1. DR FunFam; 2.60.40.340:FF:000005; RELB proto-oncogene, NF-kB subunit; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 1. DR Gene3D; 2.60.40.340; Rel homology domain (RHD), DNA-binding domain; 1. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR014756; Ig_E-set. DR InterPro; IPR002909; IPT_dom. DR InterPro; IPR033926; IPT_NFkappaB. DR InterPro; IPR000451; NFkB/Dor. DR InterPro; IPR008967; p53-like_TF_DNA-bd_sf. DR InterPro; IPR032399; RelB_leu_zip. DR InterPro; IPR030496; RelB_RHD_N. DR InterPro; IPR032400; RelB_transact. DR InterPro; IPR030492; RHD_CS. DR InterPro; IPR032397; RHD_dimer. DR InterPro; IPR011539; RHD_DNA_bind_dom. DR InterPro; IPR037059; RHD_DNA_bind_dom_sf. DR PANTHER; PTHR24169; NUCLEAR FACTOR NF-KAPPA-B PROTEIN; 1. DR PANTHER; PTHR24169:SF18; TRANSCRIPTION FACTOR RELB; 1. DR Pfam; PF16180; RelB_leu_zip; 1. DR Pfam; PF16181; RelB_transactiv; 1. DR Pfam; PF16179; RHD_dimer; 1. DR Pfam; PF00554; RHD_DNA_bind; 1. DR PRINTS; PR00057; NFKBTNSCPFCT. DR SMART; SM00429; IPT; 1. DR SUPFAM; SSF81296; E set domains; 1. DR SUPFAM; SSF49417; p53-like transcription factors; 1. DR PROSITE; PS01204; REL_1; 1. DR PROSITE; PS50254; REL_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Activator; Biological rhythms; Cytoplasm; Cytoskeleton; KW Disease variant; DNA-binding; Methylation; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repressor; Transcription; KW Transcription regulation. FT CHAIN 1..579 FT /note="Transcription factor RelB" FT /id="PRO_0000205173" FT DOMAIN 125..440 FT /note="RHD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00265" FT REGION 1..39 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 40..68 FT /note="Leucine-zipper" FT MOTIF 433..438 FT /note="Nuclear localization signal" FT /evidence="ECO:0000255" FT MOD_RES 16 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 37 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231" FT MOD_RES 573 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332" FT VARIANT 396 FT /note="T -> M (in dbSNP:rs770682728)" FT /id="VAR_051782" FT VARIANT 397..579 FT /note="Missing (in IMD53)" FT /evidence="ECO:0000269|PubMed:26385063" FT /id="VAR_079201" FT CONFLICT 139 FT /note="R -> P (in Ref. 1; AAA36127)" FT /evidence="ECO:0000305" FT CONFLICT 411 FT /note="R -> A (in Ref. 1; AAA36127)" FT /evidence="ECO:0000305" SQ SEQUENCE 579 AA; 62134 MW; C2C61C2C8640513E CRC64; MLRSGPASGP SVPTGRAMPS RRVARPPAAP ELGALGSPDL SSLSLAVSRS TDELEIIDEY IKENGFGLDG GQPGPGEGLP RLVSRGAASL STVTLGPVAP PATPPPWGCP LGRLVSPAPG PGPQPHLVIT EQPKQRGMRF RYECEGRSAG SILGESSTEA SKTLPAIELR DCGGLREVEV TACLVWKDWP HRVHPHSLVG KDCTDGICRV RLRPHVSPRH SFNNLGIQCV RKKEIEAAIE RKIQLGIDPY NAGSLKNHQE VDMNVVRICF QASYRDQQGQ MRRMDPVLSE PVYDKKSTNT SELRICRINK ESGPCTGGEE LYLLCDKVQK EDISVVFSRA SWEGRADFSQ ADVHRQIAIV FKTPPYEDLE IVEPVTVNVF LQRLTDGVCS EPLPFTYLPR DHDSYGVDKK RKRGMPDVLG ELNSSDPHGI ESKRRKKKPA ILDHFLPNHG SGPFLPPSAL LPDPDFFSGT VSLPGLEPPG GPDLLDDGFA YDPTAPTLFT MLDLLPPAPP HASAVVCSGG AGAVVGETPG PEPLTLDSYQ APGPGDGGTA SLVGSNMFPN HYREAAFGGG LLSPGPEAT // ID TEX14_HUMAN Reviewed; 1497 AA. AC Q8IWB6; A6NH19; Q7RTP3; Q8ND97; Q9BXT9; DT 25-JUL-2006, integrated into UniProtKB/Swiss-Prot. DT 25-JUL-2006, sequence version 2. DT 28-JAN-2026, entry version 183. DE RecName: Full=Inactive serine/threonine-protein kinase TEX14; DE AltName: Full=Protein kinase-like protein SgK307; DE AltName: Full=Sugen kinase 307; DE AltName: Full=Testis-expressed sequence 14; DE AltName: Full=Testis-expressed sequence 14 protein; GN Name=TEX14; Synonyms=SGK307; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Testis; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] OF 480-1497 (ISOFORM 3), AND TISSUE SPECIFICITY. RC TISSUE=Testis; RX PubMed=11279525; DOI=10.1038/86927; RA Wang P.J., McCarrey J.R., Yang F., Page D.C.; RT "An abundance of X-linked genes expressed in spermatogonia."; RL Nat. Genet. 27:422-426(2001). RN [5] RP IDENTIFICATION, AND ALTERNATIVE SPLICING (ISOFORM 2). RX PubMed=12711554; DOI=10.1016/s1567-133x(03)00036-x; RA Wu M.-H., Rajkovic A., Burns K.H., Yan W., Lin Y.-N., Matzuk M.M.; RT "Sequence and expression of testis-expressed gene 14 (Tex14): a gene RT encoding a protein kinase preferentially expressed during RT spermatogenesis."; RL Gene Expr. Patterns 3:231-236(2003). RN [6] RP SUBCELLULAR LOCATION, AND INTERACTION WITH CEP55. RX PubMed=20176808; DOI=10.1128/mcb.01392-09; RA Iwamori T., Iwamori N., Ma L., Edson M.A., Greenbaum M.P., Matzuk M.M.; RT "TEX14 interacts with CEP55 to block cell abscission."; RL Mol. Cell. Biol. 30:2280-2292(2010). RN [7] RP PHOSPHORYLATION, AND MUTAGENESIS OF 614-SER--THR-618 AND 726-SER--THR-728. RX PubMed=22405274; DOI=10.1016/j.molcel.2012.01.013; RA Mondal G., Ohashi A., Yang L., Rowley M., Couch F.J.; RT "Tex14, a plk1-regulated protein, is required for kinetochore-microtubule RT attachment and regulation of the spindle assembly checkpoint."; RL Mol. Cell 45:680-695(2012). RN [8] RP INVOLVEMENT IN SPGF23, AND TISSUE SPECIFICITY. RX PubMed=28206990; DOI=10.1038/gim.2016.225; RA Gershoni M., Hauser R., Yogev L., Lehavi O., Azem F., Yavetz H., RA Pietrokovski S., Kleiman S.E.; RT "A familial study of azoospermic men identifies three novel causative RT mutations in three new human azoospermia genes."; RL Genet. Med. 19:998-1006(2017). RN [9] RP VARIANTS [LARGE SCALE ANALYSIS] GLY-88; GLU-321; CYS-443 AND MET-559. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [10] RP VARIANT SPGF23 1152-ARG--ASP-1497 DEL. RX PubMed=32741963; DOI=10.1038/s41436-020-0907-1; RA Krausz C., Riera-Escamilla A., Moreno-Mendoza D., Holleman K., Cioppi F., RA Algaba F., Pybus M., Friedrich C., Wyrwoll M.J., Casamonti E., RA Pietroforte S., Nagirnaja L., Lopes A.M., Kliesch S., Pilatz A., RA Carrell D.T., Conrad D.F., Ars E., Ruiz-Castane E., Aston K.I., RA Baarends W.M., Tuettelmann F.; RT "Genetic dissection of spermatogenic arrest through exome analysis: RT clinical implications for the management of azoospermic men."; RL Genet. Med. 22:1956-1966(2020). CC -!- FUNCTION: Required both for the formation of intercellular bridges CC during meiosis and for kinetochore-microtubule attachment during CC mitosis. Intercellular bridges are evolutionarily conserved structures CC that connect differentiating germ cells and are required for CC spermatogenesis and male fertility. Acts by promoting the conversion of CC midbodies into intercellular bridges via its interaction with CEP55: CC interaction with CEP55 inhibits the interaction between CEP55 and CC PDCD6IP/ALIX and TSG101, blocking cell abscission and leading to CC transform midbodies into intercellular bridges. Also plays a role CC during mitosis: recruited to kinetochores by PLK1 during early mitosis CC and regulates the maturation of the outer kinetochores and microtubule CC attachment. Has no protein kinase activity in vitro (By similarity). CC {ECO:0000250}. CC -!- SUBUNIT: Interacts with KIF23 and RBM44. Interacts with CEP55; CC inhibiting interaction between CEP55 and PDCD6IP/ALIX and TSG101 (By CC similarity). {ECO:0000250}. CC -!- INTERACTION: CC Q8IWB6; Q53EZ4: CEP55; NbExp=5; IntAct=EBI-6674697, EBI-747776; CC Q8IWB6; Q96D03: DDIT4L; NbExp=3; IntAct=EBI-6674697, EBI-742054; CC Q8IWB6; Q9UBR4-2: LHX3; NbExp=5; IntAct=EBI-6674697, EBI-12039345; CC Q8IWB6; P61968: LMO4; NbExp=3; IntAct=EBI-6674697, EBI-2798728; CC Q8IWB6; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-6674697, EBI-16439278; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Midbody {ECO:0000250}. CC Chromosome, centromere, kinetochore {ECO:0000250}. Note=Detected in the CC intercellular bridges that connect male germ cell daughter cells after CC cell division. {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q8IWB6-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8IWB6-2; Sequence=VSP_019868; CC Name=3; CC IsoId=Q8IWB6-3; Sequence=VSP_019868, VSP_019869; CC -!- TISSUE SPECIFICITY: Expression restricted to testis. CC {ECO:0000269|PubMed:11279525, ECO:0000269|PubMed:28206990}. CC -!- DOMAIN: The protein kinase domain is predicted to be catalytically CC inactive. CC -!- DOMAIN: The GPPX3Y motif mediates interaction with CEP55. CC -!- PTM: Phosphorylated on Thr residues by CDK1 during early phases of CC mitosis, promoting the interaction with PLK1 and recruitment to CC kinetochores. Phosphorylated on Ser-437 by PLK1 during late CC prometaphase promotes the rapid depletion from kinetochores and its CC subsequent degradation by the APC/C complex. CC {ECO:0000269|PubMed:22405274}. CC -!- DISEASE: Spermatogenic failure 23 (SPGF23) [MIM:617707]: An infertility CC disorder caused by spermatogenesis defects that result in non- CC obstructive azoospermia. {ECO:0000269|PubMed:28206990, CC ECO:0000269|PubMed:32741963}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. {ECO:0000305}. CC -!- CAUTION: Ser-376 is present instead of the conserved Asp which is CC expected to be an active site residue. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAK31980.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AL834143; CAD38856.2; -; mRNA. DR EMBL; AC005666; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC040526; AAH40526.1; -; mRNA. DR EMBL; AF285601; AAK31980.1; ALT_INIT; mRNA. DR EMBL; BK000998; DAA01359.1; -; mRNA. DR CCDS; CCDS32692.1; -. [Q8IWB6-3] DR CCDS; CCDS32693.1; -. [Q8IWB6-2] DR CCDS; CCDS56042.1; -. [Q8IWB6-1] DR RefSeq; NP_001188386.1; NM_001201457.2. [Q8IWB6-1] DR RefSeq; NP_112562.3; NM_031272.4. [Q8IWB6-3] DR RefSeq; NP_938207.2; NM_198393.4. [Q8IWB6-2] DR PDB; 3WUT; X-ray; 2.30 A; C/F/I/L=792-804. DR PDB; 3WUU; X-ray; 2.90 A; C/F/I/L=791-805. DR PDBsum; 3WUT; -. DR PDBsum; 3WUU; -. DR AlphaFoldDB; Q8IWB6; -. DR SMR; Q8IWB6; -. DR BioGRID; 121089; 33. DR ELM; Q8IWB6; -. DR FunCoup; Q8IWB6; 103. DR IntAct; Q8IWB6; 30. DR STRING; 9606.ENSP00000240361; -. DR TCDB; 8.A.23.1.18; the basigin (basigin) family. DR GlyGen; Q8IWB6; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q8IWB6; -. DR PhosphoSitePlus; Q8IWB6; -. DR BioMuta; TEX14; -. DR DMDM; 110816441; -. DR MassIVE; Q8IWB6; -. DR PaxDb; 9606-ENSP00000240361; -. DR PeptideAtlas; Q8IWB6; -. DR ProteomicsDB; 70835; -. [Q8IWB6-1] DR ProteomicsDB; 70836; -. [Q8IWB6-2] DR ProteomicsDB; 70837; -. [Q8IWB6-3] DR Antibodypedia; 31015; 88 antibodies from 24 providers. DR DNASU; 56155; -. DR Ensembl; ENST00000240361.12; ENSP00000240361.8; ENSG00000121101.17. [Q8IWB6-1] DR Ensembl; ENST00000349033.10; ENSP00000268910.8; ENSG00000121101.17. [Q8IWB6-3] DR Ensembl; ENST00000389934.7; ENSP00000374584.3; ENSG00000121101.17. [Q8IWB6-2] DR GeneID; 56155; -. DR KEGG; hsa:56155; -. DR MANE-Select; ENST00000349033.10; ENSP00000268910.8; NM_031272.5; NP_112562.3. [Q8IWB6-3] DR UCSC; uc002iwr.3; human. [Q8IWB6-1] DR AGR; HGNC:11737; -. DR ClinPGx; PA36454; -. DR CTD; 56155; -. DR DisGeNET; 56155; -. DR GeneCards; TEX14; -. DR HGNC; HGNC:11737; TEX14. DR HPA; ENSG00000121101; Tissue enriched (testis). DR MalaCards; TEX14; -. DR MIM; 605792; gene. DR MIM; 617707; phenotype. DR OpenTargets; ENSG00000121101; -. DR Orphanet; 399805; Male infertility with azoospermia or oligozoospermia due to single gene mutation. DR VEuPathDB; HostDB:ENSG00000121101; -. DR eggNOG; ENOG502QSZN; Eukaryota. DR GeneTree; ENSGT00390000015123; -. DR HOGENOM; CLU_004733_0_0_1; -. DR InParanoid; Q8IWB6; -. DR OMA; FGKAMPW; -. DR OrthoDB; 5962695at2759; -. DR PAN-GO; Q8IWB6; 8 GO annotations based on evolutionary models. DR PhylomeDB; Q8IWB6; -. DR PathwayCommons; Q8IWB6; -. DR SignaLink; Q8IWB6; -. DR SIGNOR; Q8IWB6; -. DR Agora; ENSG00000121101; -. DR BioGRID-ORCS; 56155; 10 hits in 1171 CRISPR screens. DR CD-CODE; 232F8A39; P-body. DR ChiTaRS; TEX14; human. DR EvolutionaryTrace; Q8IWB6; -. DR GenomeRNAi; 56155; -. DR Pharos; Q8IWB6; Tbio. DR PRO; PR:Q8IWB6; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; Q8IWB6; protein. DR Bgee; ENSG00000121101; Expressed in right testis and 97 other cell types or tissues. DR ExpressionAtlas; Q8IWB6; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0045171; C:intercellular bridge; ISS:UniProtKB. DR GO; GO:0000776; C:kinetochore; ISS:UniProtKB. DR GO; GO:0030496; C:midbody; ISS:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004672; F:protein kinase activity; IEA:InterPro. DR GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB. DR GO; GO:0008608; P:attachment of spindle microtubules to kinetochore; ISS:UniProtKB. DR GO; GO:0051301; P:cell division; IEA:UniProtKB-KW. DR GO; GO:1990830; P:cellular response to leukemia inhibitory factor; IEA:Ensembl. DR GO; GO:0043063; P:intercellular bridge organization; ISS:UniProtKB. DR GO; GO:0007140; P:male meiotic nuclear division; ISS:UniProtKB. DR GO; GO:0051306; P:mitotic sister chromatid separation; ISS:UniProtKB. DR GO; GO:0007094; P:mitotic spindle assembly checkpoint signaling; ISS:UniProtKB. DR GO; GO:0032466; P:negative regulation of cytokinesis; IEA:Ensembl. DR CDD; cd14011; PK_SCY1_like; 1. DR FunFam; 1.10.510.10:FF:000428; inactive serine/threonine-protein kinase TEX14 isoform X1; 1. DR FunFam; 1.25.40.20:FF:000153; inactive serine/threonine-protein kinase TEX14 isoform X3; 1. DR Gene3D; 1.25.40.20; Ankyrin repeat-containing domain; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR002110; Ankyrin_rpt. DR InterPro; IPR036770; Ankyrin_rpt-contain_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR039339; Tex14. DR PANTHER; PTHR23060:SF1; INACTIVE SERINE_THREONINE-PROTEIN KINASE TEX14; 1. DR PANTHER; PTHR23060; TESTIS EXPRESSED GENE 14; 1. DR Pfam; PF12796; Ank_2; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR SMART; SM00248; ANK; 3. DR SUPFAM; SSF48403; Ankyrin repeat; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50297; ANK_REP_REGION; 1. DR PROSITE; PS50088; ANK_REPEAT; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ANK repeat; ATP-binding; Cell cycle; KW Cell division; Centromere; Chromosome; Cytoplasm; Kinetochore; Mitosis; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat. FT CHAIN 1..1497 FT /note="Inactive serine/threonine-protein kinase TEX14" FT /id="PRO_0000246995" FT REPEAT 27..54 FT /note="ANK 1" FT REPEAT 55..84 FT /note="ANK 2" FT REPEAT 88..117 FT /note="ANK 3" FT DOMAIN 227..518 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 848..877 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 963..1048 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1144..1174 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1348..1470 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 795..801 FT /note="GPPX3Y" FT MOTIF 852..860 FT /note="D-box" FT COMPBIAS 989..1020 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1037..1046 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1160..1174 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1348..1360 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1368..1406 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1428..1460 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 233..241 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 273 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 175 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:F1M5M3" FT MOD_RES 437 FT /note="Phosphoserine; by PLK1" FT /evidence="ECO:0000250|UniProtKB:Q7M6U3" FT MOD_RES 567 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:F1M5M3" FT MOD_RES 665 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:F1M5M3" FT MOD_RES 1106 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q7M6U3" FT MOD_RES 1404 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q7M6U3" FT MOD_RES 1459 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q7M6U3" FT MOD_RES 1496 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q7M6U3" FT VAR_SEQ 213..218 FT /note="Missing (in isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:11279525, FT ECO:0000303|PubMed:17974005" FT /id="VSP_019868" FT VAR_SEQ 1064..1103 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:11279525, FT ECO:0000303|PubMed:17974005" FT /id="VSP_019869" FT VARIANT 88 FT /note="D -> G (in dbSNP:rs56292204)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041388" FT VARIANT 321 FT /note="K -> E (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs2045795960)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041389" FT VARIANT 443 FT /note="S -> C (in dbSNP:rs2144493686)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041390" FT VARIANT 559 FT /note="I -> M" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041391" FT VARIANT 1152..1497 FT /note="Missing (in SPGF23)" FT /evidence="ECO:0000269|PubMed:32741963" FT /id="VAR_087420" FT MUTAGEN 614..618 FT /note="SSPST->AAPAA: In PBD-1; reduced ability to interact FT with PLK1." FT /evidence="ECO:0000269|PubMed:22405274" FT MUTAGEN 726..728 FT /note="STT->AAA: In PBD-5; reduced ability to interact with FT PLK1." FT /evidence="ECO:0000269|PubMed:22405274" FT CONFLICT 1326 FT /note="H -> R (in Ref. 4; AAK31980)" FT /evidence="ECO:0000305" FT CONFLICT 1387 FT /note="L -> P (in Ref. 1; CAD38856)" FT /evidence="ECO:0000305" FT STRAND 797..800 FT /evidence="ECO:0007829|PDB:3WUT" SQ SEQUENCE 1497 AA; 167901 MW; D7DC446A1A18FC4D CRC64; MSRAVRLPVP CPVQLGTLRN DSLEAQLHEY VKQGNYVKVK KILKKGIYVD AVNSLGQTAL FVAALLGLRK FVDVLVDYGS DPNHRCFDGS TPVHAAAFSG NQWILSKLLD AGGDLRLHDE RGQNPKTWAL TAGKERSTQI VEFMQRCASH MQAIIQGFSY DLLKKIDSPQ RLVYSPSWCG GLVQGNPNGS PNRLLKAGVI SAQNIYSFGF GKAMPWFQFY LTGATQMAYL GSLPVIGEKE VIQADDEPTF SFFSGPYMVM TNLVWNGSRV TVKELNLPTH PHCSRLRLAD LLIAEQEHSS KLRHPYLLQL MAVCLSQDLE KTRLVYERIT IGTLFSVLHE RRSQFPVLHM EVIVHLLLQI SDALRYLHFQ GFIHRSLSSY AVHIISPGEA RLTNLEYMLE SEDRGVQRDL TRVPLPTQLY NWAAPEVILQ KAATVKSDIY SFSMIMQEIL TDDIPWKGLD GSVVKKAVVS GNYLEADVRL PKPYYDIVKS GIHVKQKDRT MNLQDIRYIL KNDLKDFTGA QRTQPTESPR VQRYGLHPDV NVYLGLTSEH PRETPDMEII ELKEMGSQPH SPRVHSLFTE GTLDPQAPDP CLMARETQNQ DAPCPAPFMA EEASSPSTGQ PSLCSFEINE IYSGCLILED DIEEPPGAAS SLEADGPNQV DELKSMEEEL DKMEREACCF GSEDESSSKA ETEYSFDDWD WQNGSLSSLS LPESTREAKS NLNNMSTTEE YLISKCVLDL KIMQTIMHEN DDRLRNIEQI LDEVEMKQKE QEERMSLWAT SREFTNAYKL PLAVGPPSLN YIPPVLQLSG GQKPDTSGNY PTLPRFPRML PTLCDPGKQN TDEQFQCTQG AKDSLETSRI QNTSSQGRPR ESTAQAKATQ FNSALFTLSS HRQGPSASPS CHWDSTRMSV EPVSSEIYNA ESRNKDDGKV HLKWKMEVKE MAKKAATGQL TVPPWHPQSS LTLESEAENE PDALLQPPIR SPENTDWQRV IEYHRENDEP RGNGKFDKTG NNDCDSDQHG RQPRLGSFTS IRHPSPRQKE QPEHSEAFQA SSDTLVAVEK SYSHQSMQST CSPESSEDIT DEFLTPDGEY FYSSTAQENL ALETSSPIEE DFEGIQGAFA QPQVSGEEKF QMRKILGKNA EILPRSQFQP VRSTEDEQEE TSKESPKELK EKDISLTDIQ DLSSISYEPD SSFKEASCKT PKINHAPTSV STPLSPGSVS SAASQYKDCL ESITFQVKTE FASCWNSQEF IQTLSDDFIS VRERAKKLDS LLTSSETPPS RLTGLKRLSS FIGAGSPSLV KACDSSPPHA TQRRSLPKVE AFSQHHIDEL PPPSQELLDD IELLKQQQGS STVLHENTAS DGGGTANDQR HLEEQETDSK KEDSSMLLSK ETEDLGEDTE RAHSTLDEDL ERWLQPPEES VELQDLPKGS ERETNIKDQK VGEEKRKRED SITPERRKSE GVLGTSEEDE LKSCFWKRLG WSESSRIIVL DQSDLSD // ID UBQL1_HUMAN Reviewed; 589 AA. AC Q9UMX0; A0A024R284; Q5T6J5; Q5T6J9; Q8IXS9; Q8N2Q3; Q9H0T8; Q9H3R4; Q9HAZ5; DT 29-MAR-2004, integrated into UniProtKB/Swiss-Prot. DT 01-MAR-2002, sequence version 2. DT 28-JAN-2026, entry version 218. DE RecName: Full=Ubiquilin-1; DE AltName: Full=Protein linking IAP with cytoskeleton 1; DE Short=PLIC-1; DE Short=hPLIC-1; GN Name=UBQLN1; Synonyms=DA41, PLIC1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH PSEN1 AND PSEN2, RP AND TISSUE SPECIFICITY. RC TISSUE=Brain; RX PubMed=11076969; DOI=10.1083/jcb.151.4.847; RA Mah A.L., Perry G., Smith M.A., Monteiro M.J.; RT "Identification of ubiquilin, a novel presenilin interactor that increases RT presenilin protein accumulation."; RL J. Cell Biol. 151:847-862(2000). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RA Mah A.L., Monteiro M.J.; RL Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH UBE3A; BTRC RP AND THE PROTEASOME. RC TISSUE=B-cell; RX PubMed=10983987; DOI=10.1016/s1097-2765(00)00040-x; RA Kleijnen M.F., Shih A.H., Zhou P., Kumar S., Soccio R.E., Kedersha N.L., RA Gill G., Howley P.M.; RT "The hPLIC proteins may provide a link between the ubiquitination machinery RT and the proteasome."; RL Mol. Cell 6:409-419(2000). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Lung; RX PubMed=10807547; DOI=10.1007/s100380050209; RA Hanaoka E., Ozaki T., Ohira M., Nakamura Y., Suzuki M., Takahashi E., RA Moriya H., Nakagawara A., Sakiyama S.; RT "Molecular cloning and expression analysis of the human DA41 gene and its RT mapping to chromosome 9q21.2-q21.3."; RL J. Hum. Genet. 45:188-191(2000). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA]. RA Li J.Y.; RT "Human testis protein."; RL Submitted (MAR-2010) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=11230166; DOI=10.1101/gr.gr1547r; RA Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S., RA Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H., Lauber J., RA Duesterhoeft A., Beyer A., Koehrer K., Strack N., Mewes H.-W., RA Ottenwaelder B., Obermaier B., Tampe J., Heubner D., Wambutt R., Korn B., RA Klein M., Poustka A.; RT "Towards a catalog of human genes and proteins: sequencing and analysis of RT 500 novel complete protein coding human cDNAs."; RL Genome Res. 11:422-435(2001). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164053; DOI=10.1038/nature02465; RA Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L., RA Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R., RA Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S., RA Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K., RA Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C., RA Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E., RA Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M., RA Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J., RA Frankish A., Frankland J.A., French L., Fricker D.G., Garner P., RA Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S., RA Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E., RA Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D., RA Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E., RA Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K., RA Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S., RA Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J., RA Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E., RA McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V., RA Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S., RA Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K., RA Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J., RA Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., RA West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L., RA Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M., RA Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J., RA Dunham I.; RT "DNA sequence and analysis of human chromosome 9."; RL Nature 429:369-374(2004). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Brain, and Muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-316. RC TISSUE=Embryo; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [11] RP PROTEIN SEQUENCE OF 71-83; 207-236; 244-253 AND 547-582, AND IDENTIFICATION RP BY MASS SPECTROMETRY. RC TISSUE=Fetal brain cortex; RA Lubec G., Chen W.-Q., Sun Y.; RL Submitted (DEC-2008) to UniProtKB. RN [12] RP PHOSPHORYLATION, INTERACTION WITH MTOR, AND TISSUE SPECIFICITY. RX PubMed=11853878; DOI=10.1016/s0167-4889(01)00164-1; RA Wu S., Mikhailov A., Kallo-Hosein H., Hara K., Yonezawa K., Avruch J.; RT "Characterization of ubiquilin 1, an mTOR-interacting protein."; RL Biochim. Biophys. Acta 1542:41-56(2002). RN [13] RP INTERACTION WITH P4HB. RX PubMed=12095988; DOI=10.1074/jbc.m203412200; RA Ko H.S., Uehara T., Nomura Y.; RT "Role of ubiquilin associated with protein-disulfide isomerase in the RT endoplasmic reticulum in stress-induced apoptotic cell death."; RL J. Biol. Chem. 277:35386-35392(2002). RN [14] RP FUNCTION, DOMAIN UBIQUITIN-LIKE, DOMAIN UBA, AND INTERACTION WITH UBA52; RP PSMD3 AND PSMD4. RX PubMed=15147878; DOI=10.1016/j.febslet.2004.04.031; RA Ko H.S., Uehara T., Tsuruma K., Nomura Y.; RT "Ubiquilin interacts with ubiquitylated proteins and proteasome through its RT ubiquitin-associated and ubiquitin-like domains."; RL FEBS Lett. 566:110-114(2004). RN [15] RP INTERACTION WITH EPS15; EPS15L1; HGS AND STAM2, SUBCELLULAR LOCATION, AND RP UBIQUITINATION. RX PubMed=16159959; DOI=10.1242/jcs.02571; RA Regan-Klapisz E., Sorokina I., Voortman J., de Keizer P., Roovers R.C., RA Verheesen P., Urbe S., Fallon L., Fon E.A., Verkleij A., Benmerah A., RA van Bergen en Henegouwen P.M.; RT "Ubiquilin recruits Eps15 into ubiquitin-rich cytoplasmic aggregates via a RT UIM-UBL interaction."; RL J. Cell Sci. 118:4437-4450(2005). RN [16] RP SUBUNIT, HETERODIMERIZATION WITH UBQLN2, AND INTERACTION WITH PSEN1 AND RP PSEN2. RX PubMed=16813565; DOI=10.1042/bj20060441; RA Ford D.L., Monteiro M.J.; RT "Dimerization of ubiquilin is dependent upon the central region of the RT protein: evidence that the monomer, but not the dimer, is involved in RT binding presenilins."; RL Biochem. J. 399:397-404(2006). RN [17] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17323924; DOI=10.1021/bi061994u; RA Wang X., Chen C.-F., Baker P.R., Chen P.-L., Kaiser P., Huang L.; RT "Mass spectrometric characterization of the affinity-purified human 26S RT proteasome complex."; RL Biochemistry 46:3553-3565(2007). RN [18] RP FUNCTION, AND INTERACTION WITH HERPUD1. RX PubMed=18307982; DOI=10.1016/j.bbrc.2008.02.086; RA Kim T.Y., Kim E., Yoon S.K., Yoon J.B.; RT "Herp enhances ER-associated protein degradation by recruiting RT ubiquilins."; RL Biochem. Biophys. Res. Commun. 369:741-746(2008). RN [19] RP INTERACTION WITH EPS15. RX PubMed=18199683; DOI=10.1091/mbc.e07-08-0775; RA N'Diaye E.N., Hanyaloglu A.C., Kajihara K.K., Puthenveedu M.A., Wu P., RA von Zastrow M., Brown E.J.; RT "The ubiquitin-like protein PLIC-2 is a negative regulator of G protein- RT coupled receptor endocytosis."; RL Mol. Biol. Cell 19:1252-1260(2008). RN [20] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [21] RP FUNCTION, SUBCELLULAR LOCATION, AND DOMAIN UBA. RX PubMed=19148225; DOI=10.1038/embor.2008.238; RA N'Diaye E.N., Kajihara K.K., Hsieh I., Morisaki H., Debnath J., Brown E.J.; RT "PLIC proteins or ubiquilins regulate autophagy-dependent cell survival RT during nutrient starvation."; RL EMBO Rep. 10:173-179(2009). RN [22] RP FUNCTION, INTERACTION WITH UBXN4, IDENTIFICATION IN A COMPLEX WITH UBXN4 RP AND VCP, AND SUBCELLULAR LOCATION. RX PubMed=19822669; DOI=10.1083/jcb.200903024; RA Lim P.J., Danner R., Liang J., Doong H., Harman C., Srinivasan D., RA Rothenberg C., Wang H., Ye Y., Fang S., Monteiro M.J.; RT "Ubiquilin and p97/VCP bind erasin, forming a complex involved in ERAD."; RL J. Cell Biol. 187:201-217(2009). RN [23] RP ALTERNATIVE SPLICING (ISOFORMS 1; 2; 3 AND 4), FUNCTION, AND TISSUE RP SPECIFICITY. RX PubMed=18953672; DOI=10.1007/s12031-008-9155-6; RA Lu A., Hiltunen M., Romano D.M., Soininen H., Hyman B.T., Bertram L., RA Tanzi R.E.; RT "Effects of ubiquilin 1 on the unfolded protein response."; RL J. Mol. Neurosci. 38:19-30(2009). RN [24] RP REVIEW. RX PubMed=20729634; DOI=10.4161/auto.6.7.13118; RA Rothenberg C., Monteiro M.J.; RT "Ubiquilin at a crossroads in protein degradation pathways."; RL Autophagy 6:979-980(2010). RN [25] RP FUNCTION, SUBCELLULAR LOCATION, IDENTIFICATION IN A COMPLEX WITH UBQLN2 AND RP MAP1LC3A/B/C, AND PROTEOLYTIC DEGRADATION. RX PubMed=20529957; DOI=10.1093/hmg/ddq231; RA Rothenberg C., Srinivasan D., Mah L., Kaushik S., Peterhoff C.M., RA Ugolino J., Fang S., Cuervo A.M., Nixon R.A., Monteiro M.J.; RT "Ubiquilin functions in autophagy and is degraded by chaperone-mediated RT autophagy."; RL Hum. Mol. Genet. 19:3219-3232(2010). RN [26] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [27] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [28] RP REVIEW. RX PubMed=21966562; DOI=10.4161/cib.15283; RA Haapasalo A., Viswanathan J., Kurkinen K.M., Bertram L., Soininen H., RA Dantuma N.P., Tanzi R.E., Hiltunen M.; RT "Involvement of ubiquilin-1 transcript variants in protein degradation and RT accumulation."; RL Commun. Integr. Biol. 4:428-432(2011). RN [29] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH TICAM1. RX PubMed=21695056; DOI=10.1371/journal.pone.0021153; RA Biswas N., Liu S., Ronni T., Aussenberg S.E., Liu W., Fujita T., Wang T.; RT "The ubiquitin-like protein PLIC-1 or ubiquilin 1 inhibits TLR3-Trif RT signaling."; RL PLoS ONE 6:E21153-E21153(2011). RN [30] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [31] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PSEN1. RX PubMed=21143716; DOI=10.1111/j.1600-0854.2010.01149.x; RA Viswanathan J., Haapasalo A., Bottcher C., Miettinen R., Kurkinen K.M., RA Lu A., Thomas A., Maynard C.J., Romano D., Hyman B.T., Berezovska O., RA Bertram L., Soininen H., Dantuma N.P., Tanzi R.E., Hiltunen M.; RT "Alzheimer's disease-associated ubiquilin-1 regulates presenilin-1 RT accumulation and aggresome formation."; RL Traffic 12:330-348(2011). RN [32] RP REVIEW. RX PubMed=22628307; DOI=10.1515/hsz-2012-0120; RA Lee D.Y., Brown E.J.; RT "Ubiquilins in the crosstalk among proteolytic pathways."; RL Biol. Chem. 393:441-447(2012). RN [33] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22223895; DOI=10.1074/mcp.m111.015131; RA Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T., RA Giglione C.; RT "Comparative large-scale characterisation of plant vs. mammal proteins RT reveals similar and idiosyncratic N-alpha acetylation features."; RL Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012). RN [34] RP FUNCTION, AND INTERACTION WITH BCL2L10. RX PubMed=22233804; DOI=10.1073/pnas.1119167109; RA Beverly L.J., Lockwood W.W., Shah P.P., Erdjument-Bromage H., Varmus H.; RT "Ubiquitination, localization, and stability of an anti-apoptotic BCL2-like RT protein, BCL2L10/BCLb, are regulated by Ubiquilin1."; RL Proc. Natl. Acad. Sci. U.S.A. 109:E119-E126(2012). RN [35] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH UBQLN4 AND RP MAP1LC3A/B/C. RX PubMed=23459205; DOI=10.1038/embor.2013.22; RA Lee D.Y., Arnott D., Brown E.J.; RT "Ubiquilin4 is an adaptor protein that recruits Ubiquilin1 to the autophagy RT machinery."; RL EMBO Rep. 14:373-381(2013). RN [36] RP REVIEW. RX PubMed=23600477; DOI=10.1517/14728222.2013.791284; RA Takalo M., Haapasalo A., Natunen T., Viswanathan J., Kurkinen K.M., RA Tanzi R.E., Soininen H., Hiltunen M.; RT "Targeting ubiquilin-1 in Alzheimer's disease."; RL Expert Opin. Ther. Targets 17:795-810(2013). RN [37] RP INTERACTION WITH TREX1, AND SUBCELLULAR LOCATION. RX PubMed=23979357; DOI=10.1074/jbc.m113.503391; RA Orebaugh C.D., Fye J.M., Harvey S., Hollis T., Wilkinson J.C., RA Perrino F.W.; RT "The TREX1 C-terminal region controls cellular localization through RT ubiquitination."; RL J. Biol. Chem. 288:28881-28892(2013). RN [38] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [39] RP FUNCTION, INTERACTION WITH ORAI1, AND SUBCELLULAR LOCATION. RX PubMed=23307288; DOI=10.1007/s10059-013-2268-7; RA Lee J.E., Jeon I.S., Han N.E., Song H.J., Kim E.G., Choi J.W., Song K.D., RA Lee H.K., Choi J.K.; RT "Ubiquilin 1 interacts with Orai1 to regulate calcium mobilization."; RL Mol. Cells 35:41-46(2013). RN [40] RP REVIEW. RX PubMed=24674348; DOI=10.1186/1471-2148-14-63; RA Marin I.; RT "The ubiquilin gene family: evolutionary patterns and functional RT insights."; RL BMC Evol. Biol. 14:63-63(2014). RN [41] RP STRUCTURE BY NMR OF 541-586 ALONE AND IN COMPLEX WITH UBIQUITIN. RX PubMed=18241885; DOI=10.1016/j.jmb.2007.12.029; RA Zhang D., Raasi S., Fushman D.; RT "Affinity makes the difference: nonselective interaction of the UBA domain RT of Ubiquilin-1 with monomeric ubiquitin and polyubiquitin chains."; RL J. Mol. Biol. 377:162-180(2008). CC -!- FUNCTION: Plays an important role in the regulation of different CC protein degradation mechanisms and pathways including ubiquitin- CC proteasome system (UPS), autophagy and endoplasmic reticulum-associated CC protein degradation (ERAD) pathway. Mediates the proteasomal targeting CC of misfolded or accumulated proteins for degradation by binding (via CC UBA domain) to their polyubiquitin chains and by interacting (via CC ubiquitin-like domain) with the subunits of the proteasome CC (PubMed:15147878). Plays a role in the ERAD pathway via its interaction CC with ER-localized proteins UBXN4, VCP and HERPUD1 and may form a link CC between the polyubiquitinated ERAD substrates and the proteasome CC (PubMed:18307982, PubMed:19822669). Involved in the regulation of CC macroautophagy and autophagosome formation; required for maturation of CC autophagy-related protein LC3 from the cytosolic form LC3-I to the CC membrane-bound form LC3-II and may assist in the maturation of CC autophagosomes to autolysosomes by mediating autophagosome-lysosome CC fusion (PubMed:19148225, PubMed:20529957, PubMed:23459205). Negatively CC regulates the TICAM1/TRIF-dependent toll-like receptor signaling CC pathway by decreasing the abundance of TICAM1 via the autophagic CC pathway (PubMed:21695056). Promotes the ubiquitination and lysosomal CC degradation of ORAI1, consequently down-regulating the ORAI1-mediated CC Ca2+ mobilization (PubMed:23307288). Suppresses the maturation and CC proteasomal degradation of amyloid beta A4 protein (A4) by stimulating CC the lysine 63 (K63)-linked polyubiquitination. Delays the maturation of CC A4 by sequestering it in the Golgi apparatus and preventing its CC transport to the cell surface for subsequent processing (By CC similarity). Ubiquitinates BCL2L10 and thereby stabilizes protein CC abundance (PubMed:22233804). {ECO:0000250|UniProtKB:Q9JJP9, CC ECO:0000269|PubMed:18307982, ECO:0000269|PubMed:19148225, CC ECO:0000269|PubMed:19822669, ECO:0000269|PubMed:20529957, CC ECO:0000269|PubMed:21695056, ECO:0000269|PubMed:22233804, CC ECO:0000269|PubMed:23307288, ECO:0000269|PubMed:23459205, CC ECO:0000303|PubMed:15147878}. CC -!- FUNCTION: [Isoform 1]: Plays a role in unfolded protein response (UPR) CC by attenuating the induction of UPR-inducible genes, DDTI3/CHOP, HSPA5 CC and PDIA2 during ER stress (PubMed:18953672). Plays a key role in the CC regulation of the levels of PSEN1 by targeting its accumulation to CC aggresomes which may then be removed from cells by autophagocytosis CC (PubMed:21143716). {ECO:0000269|PubMed:18953672, CC ECO:0000269|PubMed:21143716}. CC -!- FUNCTION: [Isoform 2]: Plays a role in unfolded protein response (UPR) CC by attenuating the induction of UPR-inducible genes, DDTI3/CHOP, HSPA5 CC and PDIA2 during ER stress. {ECO:0000269|PubMed:18953672}. CC -!- FUNCTION: [Isoform 3]: Plays a role in unfolded protein response (UPR) CC by attenuating the induction of UPR-inducible genes, DDTI3/CHOP, HSPA5 CC and PDIA2 during ER stress (PubMed:18953672). Plays a key role in the CC regulation of the levels of PSEN1 by targeting its accumulation to CC aggresomes which may then be removed from cells by autophagocytosis CC (PubMed:21143716). {ECO:0000269|PubMed:18953672, CC ECO:0000269|PubMed:21143716}. CC -!- SUBUNIT: Monomer and homodimer (PubMed:16813565). Heterodimer with CC UBQLN2 (PubMed:16813565). Binds CD47, NBL1, GABRA1, GABRA2, GABRA3, CC GABRA6, GABRB1, GABRB2 and GABRB3 (By similarity). Binds UBE3A, BTRC, CC P4HB and MTOR. Interacts with the proteasome 19S subunit. Interacts CC (via ubiquitin-like domain) with TREX1; the interaction is direct and CC may control TREX1 subcellular location. Forms a complex with UBXN4 and CC VCP. Interacts (via UBA domain) with UBQLN4 (via ubiquitin-like CC domain). Found in a complex with UBQLN2 and MAP1LC3A/B/C. The monomeric CC form interacts with PSEN2. The monomeric form interacts with PSEN1 CC (PubMed:11076969, PubMed:21143716). Interacts with ORAI1. Interacts CC (via UBA domain) with TICAM1. Interacts with EPS15. Interacts (via UBA CC domain) with UBA52 and (via ubiquitin-like domain) with PSMD3 and CC PSMD4. Interacts with HERPUD1. Interacts with MAP1LC3A/B/C in the CC presence of UBQLN4. Interacts (via ubiquitin-like domain) with EPS15 CC (via UIM domains) and both the ubiquitinated and non-ubiquitinated CC forms can interact with EPS15. Interacts (via ubiquitin-like domain) CC with EPS15L1, HGS (via UIM domain) and STAM2 (via UIM domain). CC Interacts with BCL2L10/BCL-B; in the cytoplasm (PubMed:22233804). CC {ECO:0000250|UniProtKB:Q8R317, ECO:0000250|UniProtKB:Q9JJP9, CC ECO:0000269|PubMed:10983987, ECO:0000269|PubMed:11076969, CC ECO:0000269|PubMed:11853878, ECO:0000269|PubMed:12095988, CC ECO:0000269|PubMed:15147878, ECO:0000269|PubMed:16159959, CC ECO:0000269|PubMed:16813565, ECO:0000269|PubMed:18199683, CC ECO:0000269|PubMed:18241885, ECO:0000269|PubMed:18307982, CC ECO:0000269|PubMed:19822669, ECO:0000269|PubMed:20529957, CC ECO:0000269|PubMed:21143716, ECO:0000269|PubMed:21695056, CC ECO:0000269|PubMed:22233804, ECO:0000269|PubMed:23307288, CC ECO:0000269|PubMed:23459205, ECO:0000269|PubMed:23979357}. CC -!- SUBUNIT: [Isoform 1]: Monomeric form interacts with PSEN1. CC {ECO:0000269|PubMed:16813565}. CC -!- SUBUNIT: [Isoform 3]: Monomeric form interacts with PSEN1. CC {ECO:0000269|PubMed:16813565}. CC -!- INTERACTION: CC Q9UMX0; O00154: ACOT7; NbExp=3; IntAct=EBI-741480, EBI-948905; CC Q9UMX0; O00154-4: ACOT7; NbExp=3; IntAct=EBI-741480, EBI-12007918; CC Q9UMX0; Q16186: ADRM1; NbExp=4; IntAct=EBI-741480, EBI-954387; CC Q9UMX0; Q9NUQ2: AGPAT5; NbExp=6; IntAct=EBI-741480, EBI-6916385; CC Q9UMX0; O95994: AGR2; NbExp=9; IntAct=EBI-741480, EBI-712648; CC Q9UMX0; Q8TD06: AGR3; NbExp=4; IntAct=EBI-741480, EBI-3925742; CC Q9UMX0; P23352: ANOS1; NbExp=3; IntAct=EBI-741480, EBI-5272188; CC Q9UMX0; P55056: APOC4; NbExp=3; IntAct=EBI-741480, EBI-18302142; CC Q9UMX0; P05067: APP; NbExp=3; IntAct=EBI-741480, EBI-77613; CC Q9UMX0; Q66PJ3-4: ARL6IP4; NbExp=3; IntAct=EBI-741480, EBI-5280499; CC Q9UMX0; P50553: ASCL1; NbExp=3; IntAct=EBI-741480, EBI-957042; CC Q9UMX0; Q6XD76: ASCL4; NbExp=3; IntAct=EBI-741480, EBI-10254793; CC Q9UMX0; P54252: ATXN3; NbExp=6; IntAct=EBI-741480, EBI-946046; CC Q9UMX0; P46379-2: BAG6; NbExp=3; IntAct=EBI-741480, EBI-10988864; CC Q9UMX0; Q8TBE0: BAHD1; NbExp=3; IntAct=EBI-741480, EBI-742750; CC Q9UMX0; Q9UQB8-6: BAIAP2; NbExp=3; IntAct=EBI-741480, EBI-9092016; CC Q9UMX0; Q9H2G9: BLZF1; NbExp=3; IntAct=EBI-741480, EBI-2548012; CC Q9UMX0; Q9NP55: BPIFA1; NbExp=3; IntAct=EBI-741480, EBI-953896; CC Q9UMX0; Q9ULD4-2: BRPF3; NbExp=3; IntAct=EBI-741480, EBI-23662416; CC Q9UMX0; Q9NSI6-4: BRWD1; NbExp=3; IntAct=EBI-741480, EBI-10693038; CC Q9UMX0; Q9BXJ3: C1QTNF4; NbExp=3; IntAct=EBI-741480, EBI-11955105; CC Q9UMX0; Q3SXR2: C3orf36; NbExp=3; IntAct=EBI-741480, EBI-18036948; CC Q9UMX0; P20807-4: CAPN3; NbExp=3; IntAct=EBI-741480, EBI-11532021; CC Q9UMX0; P10147: CCL3; NbExp=3; IntAct=EBI-741480, EBI-8459634; CC Q9UMX0; P80098: CCL7; NbExp=3; IntAct=EBI-741480, EBI-718759; CC Q9UMX0; Q8TCZ2: CD99L2; NbExp=6; IntAct=EBI-741480, EBI-2824782; CC Q9UMX0; Q9H305: CDIP1; NbExp=3; IntAct=EBI-741480, EBI-2876678; CC Q9UMX0; P38936: CDKN1A; NbExp=3; IntAct=EBI-741480, EBI-375077; CC Q9UMX0; O95674: CDS2; NbExp=3; IntAct=EBI-741480, EBI-3913685; CC Q9UMX0; Q494V2-2: CFAP100; NbExp=3; IntAct=EBI-741480, EBI-11953200; CC Q9UMX0; Q8WUX9: CHMP7; NbExp=3; IntAct=EBI-741480, EBI-749253; CC Q9UMX0; Q03692: COL10A1; NbExp=6; IntAct=EBI-741480, EBI-2528309; CC Q9UMX0; P08123: COL1A2; NbExp=6; IntAct=EBI-741480, EBI-983038; CC Q9UMX0; P02458-1: COL2A1; NbExp=3; IntAct=EBI-741480, EBI-12375799; CC Q9UMX0; Q14055: COL9A2; NbExp=3; IntAct=EBI-741480, EBI-714971; CC Q9UMX0; Q86WV2: COX4I1; NbExp=3; IntAct=EBI-741480, EBI-10260134; CC Q9UMX0; P07498: CSN3; NbExp=3; IntAct=EBI-741480, EBI-2602175; CC Q9UMX0; P33240: CSTF2; NbExp=7; IntAct=EBI-741480, EBI-711360; CC Q9UMX0; Q9H0L4: CSTF2T; NbExp=7; IntAct=EBI-741480, EBI-747012; CC Q9UMX0; P78358: CTAG1B; NbExp=6; IntAct=EBI-741480, EBI-1188472; CC Q9UMX0; O75638-2: CTAG2; NbExp=3; IntAct=EBI-741480, EBI-12265122; CC Q9UMX0; Q8TB03: CXorf38; NbExp=3; IntAct=EBI-741480, EBI-12024320; CC Q9UMX0; Q9UHQ9: CYB5R1; NbExp=3; IntAct=EBI-741480, EBI-953870; CC Q9UMX0; Q15038: DAZAP2; NbExp=3; IntAct=EBI-741480, EBI-724310; CC Q9UMX0; Q9UJU6: DBNL; NbExp=3; IntAct=EBI-741480, EBI-751783; CC Q9UMX0; Q01524: DEFA6; NbExp=4; IntAct=EBI-741480, EBI-10222451; CC Q9UMX0; Q30KQ5: DEFB115; NbExp=3; IntAct=EBI-741480, EBI-12253292; CC Q9UMX0; Q6ICB0: DESI1; NbExp=6; IntAct=EBI-741480, EBI-2806959; CC Q9UMX0; O95424: DEXI; NbExp=3; IntAct=EBI-741480, EBI-724515; CC Q9UMX0; Q8NDP9: DKFZp547K2416; NbExp=3; IntAct=EBI-741480, EBI-25842538; CC Q9UMX0; O60479: DLX3; NbExp=3; IntAct=EBI-741480, EBI-3908248; CC Q9UMX0; Q6E0U4: DMKN; NbExp=3; IntAct=EBI-741480, EBI-7943171; CC Q9UMX0; Q96EY1-3: DNAJA3; NbExp=3; IntAct=EBI-741480, EBI-11526226; CC Q9UMX0; Q9H147: DNTTIP1; NbExp=3; IntAct=EBI-741480, EBI-2795449; CC Q9UMX0; A0A0S2Z5Y1: DOLK; NbExp=3; IntAct=EBI-741480, EBI-16431159; CC Q9UMX0; Q7Z7J5: DPPA2; NbExp=3; IntAct=EBI-741480, EBI-741400; CC Q9UMX0; Q14117: DPYS; NbExp=3; IntAct=EBI-741480, EBI-12275416; CC Q9UMX0; Q9BPU6: DPYSL5; NbExp=3; IntAct=EBI-741480, EBI-724653; CC Q9UMX0; Q9BVC3: DSCC1; NbExp=3; IntAct=EBI-741480, EBI-11143782; CC Q9UMX0; Q9Y6W6: DUSP10; NbExp=3; IntAct=EBI-741480, EBI-3443946; CC Q9UMX0; A0AVK6: E2F8; NbExp=3; IntAct=EBI-741480, EBI-7779316; CC Q9UMX0; Q16610: ECM1; NbExp=3; IntAct=EBI-741480, EBI-947964; CC Q9UMX0; Q658K8: EEF1DP3; NbExp=3; IntAct=EBI-741480, EBI-10248874; CC Q9UMX0; O95967: EFEMP2; NbExp=5; IntAct=EBI-741480, EBI-743414; CC Q9UMX0; O00472: ELL2; NbExp=3; IntAct=EBI-741480, EBI-395274; CC Q9UMX0; O43768-8: ENSA; NbExp=3; IntAct=EBI-741480, EBI-25853109; CC Q9UMX0; P42566: EPS15; NbExp=5; IntAct=EBI-741480, EBI-396684; CC Q9UMX0; Q96DN0: ERP27; NbExp=4; IntAct=EBI-741480, EBI-953772; CC Q9UMX0; P30040: ERP29; NbExp=3; IntAct=EBI-741480, EBI-946830; CC Q9UMX0; Q6NXG1: ESRP1; NbExp=3; IntAct=EBI-741480, EBI-10213520; CC Q9UMX0; Q9HBU6: ETNK1; NbExp=3; IntAct=EBI-741480, EBI-2834493; CC Q9UMX0; Q96GL9: FAM163A; NbExp=3; IntAct=EBI-741480, EBI-11793142; CC Q9UMX0; P0C2L3: FAM163B; NbExp=3; IntAct=EBI-741480, EBI-11793223; CC Q9UMX0; Q8NB25: FAM184A; NbExp=3; IntAct=EBI-741480, EBI-9917523; CC Q9UMX0; Q86UY5: FAM83A; NbExp=3; IntAct=EBI-741480, EBI-1384254; CC Q9UMX0; P12318: FCGR2A; NbExp=3; IntAct=EBI-741480, EBI-1395970; CC Q9UMX0; P26885: FKBP2; NbExp=3; IntAct=EBI-741480, EBI-719873; CC Q9UMX0; P02751: FN1; NbExp=3; IntAct=EBI-741480, EBI-1220319; CC Q9UMX0; P41439: FOLR3; NbExp=3; IntAct=EBI-741480, EBI-12893875; CC Q9UMX0; P15408: FOSL2; NbExp=3; IntAct=EBI-741480, EBI-3893419; CC Q9UMX0; O75084: FZD7; NbExp=5; IntAct=EBI-741480, EBI-746917; CC Q9UMX0; Q06547-2: GABPB1; NbExp=3; IntAct=EBI-741480, EBI-618189; CC Q9UMX0; O14764: GABRD; NbExp=4; IntAct=EBI-741480, EBI-744352; CC Q9UMX0; P22466: GAL; NbExp=3; IntAct=EBI-741480, EBI-6624768; CC Q9UMX0; Q9UBU3: GHRL; NbExp=3; IntAct=EBI-741480, EBI-10319458; CC Q9UMX0; Q49A26-4: GLYR1; NbExp=3; IntAct=EBI-741480, EBI-12143817; CC Q9UMX0; Q16538: GPR162; NbExp=3; IntAct=EBI-741480, EBI-22387200; CC Q9UMX0; Q02747: GUCA2A; NbExp=3; IntAct=EBI-741480, EBI-12244272; CC Q9UMX0; Q16661: GUCA2B; NbExp=3; IntAct=EBI-741480, EBI-12349759; CC Q9UMX0; P06028: GYPB; NbExp=6; IntAct=EBI-741480, EBI-10194756; CC Q9UMX0; Q5T447-2: HECTD3; NbExp=3; IntAct=EBI-741480, EBI-25854793; CC Q9UMX0; Q8IV36: HID1; NbExp=3; IntAct=EBI-741480, EBI-743438; CC Q9UMX0; P52789: HK2; NbExp=4; IntAct=EBI-741480, EBI-741469; CC Q9UMX0; Q53GQ0: HSD17B12; NbExp=6; IntAct=EBI-741480, EBI-2963255; CC Q9UMX0; P48723: HSPA13; NbExp=8; IntAct=EBI-741480, EBI-750892; CC Q9UMX0; Q9Y5U9: IER3IP1; NbExp=3; IntAct=EBI-741480, EBI-725665; CC Q9UMX0; P24592: IGFBP6; NbExp=3; IntAct=EBI-741480, EBI-947015; CC Q9UMX0; Q6PIK1: IGL@; NbExp=3; IntAct=EBI-741480, EBI-10253735; CC Q9UMX0; Q6PIQ7: IGL@; NbExp=3; IntAct=EBI-741480, EBI-6677651; CC Q9UMX0; Q8N355: IGL@; NbExp=4; IntAct=EBI-741480, EBI-748681; CC Q9UMX0; Q9NZH6: IL37; NbExp=3; IntAct=EBI-741480, EBI-3862125; CC Q9UMX0; Q17RA0: IL6ST; NbExp=3; IntAct=EBI-741480, EBI-10238517; CC Q9UMX0; P53990: IST1; NbExp=3; IntAct=EBI-741480, EBI-945994; CC Q9UMX0; P53990-3: IST1; NbExp=3; IntAct=EBI-741480, EBI-12188567; CC Q9UMX0; Q6GPH6: ITPRIPL1; NbExp=3; IntAct=EBI-741480, EBI-953819; CC Q9UMX0; Q96JJ6: JPH4; NbExp=3; IntAct=EBI-741480, EBI-2847044; CC Q9UMX0; Q96MG2: JSRP1; NbExp=3; IntAct=EBI-741480, EBI-11305455; CC Q9UMX0; P05412: JUN; NbExp=3; IntAct=EBI-741480, EBI-852823; CC Q9UMX0; Q8N5Z5: KCTD17; NbExp=3; IntAct=EBI-741480, EBI-743960; CC Q9UMX0; Q7Z7F0-4: KHDC4; NbExp=3; IntAct=EBI-741480, EBI-9089060; CC Q9UMX0; Q9P2K6: KLHL42; NbExp=4; IntAct=EBI-741480, EBI-739890; CC Q9UMX0; Q8IUC2: KRTAP8-1; NbExp=3; IntAct=EBI-741480, EBI-10261141; CC Q9UMX0; Q6ISS4: LAIR2; NbExp=3; IntAct=EBI-741480, EBI-10250491; CC Q9UMX0; P07942: LAMB1; NbExp=3; IntAct=EBI-741480, EBI-949174; CC Q9UMX0; Q6IAA8: LAMTOR1; NbExp=3; IntAct=EBI-741480, EBI-715385; CC Q9UMX0; O43504: LAMTOR5; NbExp=3; IntAct=EBI-741480, EBI-713382; CC Q9UMX0; P80188: LCN2; NbExp=3; IntAct=EBI-741480, EBI-11911016; CC Q9UMX0; A0A0S2Z5S9: LHX4; NbExp=3; IntAct=EBI-741480, EBI-16429099; CC Q9UMX0; Q9H2C1: LHX5; NbExp=3; IntAct=EBI-741480, EBI-25835523; CC Q9UMX0; Q68G74: LHX8; NbExp=3; IntAct=EBI-741480, EBI-8474075; CC Q9UMX0; Q8N0U6: LINC00518; NbExp=3; IntAct=EBI-741480, EBI-10264791; CC Q9UMX0; Q99732: LITAF; NbExp=4; IntAct=EBI-741480, EBI-725647; CC Q9UMX0; Q9UIQ6-2: LNPEP; NbExp=3; IntAct=EBI-741480, EBI-12133176; CC Q9UMX0; P27338: MAOB; NbExp=3; IntAct=EBI-741480, EBI-3911344; CC Q9UMX0; P21741: MDK; NbExp=3; IntAct=EBI-741480, EBI-722444; CC Q9UMX0; Q14696: MESD; NbExp=3; IntAct=EBI-741480, EBI-6165891; CC Q9UMX0; Q96C03: MIEF2; NbExp=4; IntAct=EBI-741480, EBI-750153; CC Q9UMX0; Q6IN84-2: MRM1; NbExp=3; IntAct=EBI-741480, EBI-25835707; CC Q9UMX0; O60783: MRPS14; NbExp=3; IntAct=EBI-741480, EBI-1045956; CC Q9UMX0; P01106: MYC; NbExp=3; IntAct=EBI-741480, EBI-447544; CC Q9UMX0; Q969H8: MYDGF; NbExp=3; IntAct=EBI-741480, EBI-718622; CC Q9UMX0; Q8IW45: NAXD; NbExp=3; IntAct=EBI-741480, EBI-8650724; CC Q9UMX0; P41271: NBL1; NbExp=3; IntAct=EBI-741480, EBI-10208650; CC Q9UMX0; P41271-2: NBL1; NbExp=3; IntAct=EBI-741480, EBI-12135485; CC Q9UMX0; Q9GZM8: NDEL1; NbExp=3; IntAct=EBI-741480, EBI-928842; CC Q9UMX0; Q9UHB4: NDOR1; NbExp=3; IntAct=EBI-741480, EBI-10249760; CC Q9UMX0; Q8NC67-2: NETO2; NbExp=3; IntAct=EBI-741480, EBI-25852289; CC Q9UMX0; Q96IV0: NGLY1; NbExp=7; IntAct=EBI-741480, EBI-6165879; CC Q9UMX0; Q13232: NME3; NbExp=6; IntAct=EBI-741480, EBI-713684; CC Q9UMX0; P01160: NPPA; NbExp=3; IntAct=EBI-741480, EBI-953859; CC Q9UMX0; Q14995: NR1D2; NbExp=3; IntAct=EBI-741480, EBI-6144053; CC Q9UMX0; F1D8P7: NR1H2; NbExp=3; IntAct=EBI-741480, EBI-10177172; CC Q9UMX0; Q6PHZ7: NR2C2; NbExp=3; IntAct=EBI-741480, EBI-2802743; CC Q9UMX0; Q9UBU9: NXF1; NbExp=3; IntAct=EBI-741480, EBI-398874; CC Q9UMX0; A5D8V7: ODAD3; NbExp=3; IntAct=EBI-741480, EBI-8466445; CC Q9UMX0; P0C6T2: OST4; NbExp=3; IntAct=EBI-741480, EBI-18397963; CC Q9UMX0; Q6GQQ9-2: OTUD7B; NbExp=3; IntAct=EBI-741480, EBI-25830200; CC Q9UMX0; Q8IVL6-2: P3H3; NbExp=3; IntAct=EBI-741480, EBI-12149899; CC Q9UMX0; Q8N3R9: PALS1; NbExp=3; IntAct=EBI-741480, EBI-2513978; CC Q9UMX0; Q495U3: PANX2; NbExp=3; IntAct=EBI-741480, EBI-17242559; CC Q9UMX0; Q9HCL0: PCDH18; NbExp=6; IntAct=EBI-741480, EBI-2949740; CC Q9UMX0; Q9UN74-2: PCDHA4; NbExp=3; IntAct=EBI-741480, EBI-12184485; CC Q9UMX0; Q13956: PDE6H; NbExp=3; IntAct=EBI-741480, EBI-10231995; CC Q9UMX0; O15534: PER1; NbExp=3; IntAct=EBI-741480, EBI-2557276; CC Q9UMX0; O75928-2: PIAS2; NbExp=3; IntAct=EBI-741480, EBI-348567; CC Q9UMX0; Q96FE7: PIK3IP1; NbExp=3; IntAct=EBI-741480, EBI-10285708; CC Q9UMX0; P14618: PKM; NbExp=3; IntAct=EBI-741480, EBI-353408; CC Q9UMX0; Q9HDD0: PLAAT1; NbExp=3; IntAct=EBI-741480, EBI-12387058; CC Q9UMX0; Q9NWW9: PLAAT2; NbExp=3; IntAct=EBI-741480, EBI-12253270; CC Q9UMX0; P53816: PLAAT3; NbExp=7; IntAct=EBI-741480, EBI-746318; CC Q9UMX0; Q6ZR37: PLEKHG7; NbExp=3; IntAct=EBI-741480, EBI-12891828; CC Q9UMX0; Q5SXH7-1: PLEKHS1; NbExp=3; IntAct=EBI-741480, EBI-26412802; CC Q9UMX0; Q96T60: PNKP; NbExp=3; IntAct=EBI-741480, EBI-1045072; CC Q9UMX0; Q8ND90: PNMA1; NbExp=4; IntAct=EBI-741480, EBI-302345; CC Q9UMX0; P0DPB6: POLR1D; NbExp=3; IntAct=EBI-741480, EBI-359498; CC Q9UMX0; P19388: POLR2E; NbExp=3; IntAct=EBI-741480, EBI-395189; CC Q9UMX0; P23284: PPIB; NbExp=3; IntAct=EBI-741480, EBI-359252; CC Q9UMX0; P45877: PPIC; NbExp=3; IntAct=EBI-741480, EBI-953909; CC Q9UMX0; O60927: PPP1R11; NbExp=3; IntAct=EBI-741480, EBI-1048104; CC Q9UMX0; Q96I34: PPP1R16A; NbExp=3; IntAct=EBI-741480, EBI-710402; CC Q9UMX0; Q96NZ9: PRAP1; NbExp=6; IntAct=EBI-741480, EBI-2116102; CC Q9UMX0; A5D903: PRB1; NbExp=3; IntAct=EBI-741480, EBI-10173935; CC Q9UMX0; O43741: PRKAB2; NbExp=3; IntAct=EBI-741480, EBI-1053424; CC Q9UMX0; Q16378: PRR4; NbExp=3; IntAct=EBI-741480, EBI-738624; CC Q9UMX0; P49768: PSEN1; NbExp=3; IntAct=EBI-741480, EBI-297277; CC Q9UMX0; P49810: PSEN2; NbExp=3; IntAct=EBI-741480, EBI-2010251; CC Q9UMX0; P55036: PSMD4; NbExp=4; IntAct=EBI-741480, EBI-359318; CC Q9UMX0; Q15008: PSMD6; NbExp=3; IntAct=EBI-741480, EBI-359701; CC Q9UMX0; Q06323: PSME1; NbExp=3; IntAct=EBI-741480, EBI-712149; CC Q9UMX0; Q9UIG4: PSORS1C2; NbExp=3; IntAct=EBI-741480, EBI-11974061; CC Q9UMX0; P06454-2: PTMA; NbExp=3; IntAct=EBI-741480, EBI-10194874; CC Q9UMX0; Q8WUD1-2: RAB2B; NbExp=3; IntAct=EBI-741480, EBI-25835884; CC Q9UMX0; Q9UNT1-2: RABL2B; NbExp=3; IntAct=EBI-741480, EBI-12256104; CC Q9UMX0; Q9Y5P3: RAI2; NbExp=3; IntAct=EBI-741480, EBI-746228; CC Q9UMX0; Q04206: RELA; NbExp=3; IntAct=EBI-741480, EBI-73886; CC Q9UMX0; P47804-3: RGR; NbExp=3; IntAct=EBI-741480, EBI-25834767; CC Q9UMX0; Q15382: RHEB; NbExp=3; IntAct=EBI-741480, EBI-1055287; CC Q9UMX0; Q9NPQ8: RIC8A; NbExp=4; IntAct=EBI-741480, EBI-717509; CC Q9UMX0; Q9NPQ8-4: RIC8A; NbExp=3; IntAct=EBI-741480, EBI-9091816; CC Q9UMX0; Q9H0X6: RNF208; NbExp=3; IntAct=EBI-741480, EBI-751555; CC Q9UMX0; P78317: RNF4; NbExp=3; IntAct=EBI-741480, EBI-2340927; CC Q9UMX0; P62899: RPL31; NbExp=3; IntAct=EBI-741480, EBI-1053664; CC Q9UMX0; P04843: RPN1; NbExp=4; IntAct=EBI-741480, EBI-355963; CC Q9UMX0; P62979: RPS27A; NbExp=3; IntAct=EBI-741480, EBI-357375; CC Q9UMX0; Q7L4I2-2: RSRC2; NbExp=3; IntAct=EBI-741480, EBI-10256202; CC Q9UMX0; Q9BWD3: RTL8A; NbExp=4; IntAct=EBI-741480, EBI-741643; CC Q9UMX0; Q17RB0: RTL8B; NbExp=6; IntAct=EBI-741480, EBI-10238588; CC Q9UMX0; A6ZKI3: RTL8C; NbExp=6; IntAct=EBI-741480, EBI-10174072; CC Q9UMX0; P13521: SCG2; NbExp=4; IntAct=EBI-741480, EBI-947132; CC Q9UMX0; P05408: SCG5; NbExp=3; IntAct=EBI-741480, EBI-722635; CC Q9UMX0; Q96GD3: SCMH1; NbExp=3; IntAct=EBI-741480, EBI-713793; CC Q9UMX0; Q9NTN9-3: SEMA4G; NbExp=3; IntAct=EBI-741480, EBI-9089805; CC Q9UMX0; P05121: SERPINE1; NbExp=3; IntAct=EBI-741480, EBI-953978; CC Q9UMX0; O75830: SERPINI2; NbExp=10; IntAct=EBI-741480, EBI-750144; CC Q9UMX0; Q9BYH1-5: SEZ6L; NbExp=3; IntAct=EBI-741480, EBI-12012146; CC Q9UMX0; Q9H173: SIL1; NbExp=3; IntAct=EBI-741480, EBI-2840325; CC Q9UMX0; O15427: SLC16A3; NbExp=3; IntAct=EBI-741480, EBI-7600166; CC Q9UMX0; P03973: SLPI; NbExp=5; IntAct=EBI-741480, EBI-355293; CC Q9UMX0; Q96E16: SMIM19; NbExp=3; IntAct=EBI-741480, EBI-17657124; CC Q9UMX0; Q9BVW6: SMIM2; NbExp=3; IntAct=EBI-741480, EBI-10300146; CC Q9UMX0; P02814: SMR3B; NbExp=3; IntAct=EBI-741480, EBI-738612; CC Q9UMX0; Q13573: SNW1; NbExp=3; IntAct=EBI-741480, EBI-632715; CC Q9UMX0; O14544: SOCS6; NbExp=3; IntAct=EBI-741480, EBI-3929549; CC Q9UMX0; P08294: SOD3; NbExp=3; IntAct=EBI-741480, EBI-10195782; CC Q9UMX0; Q02086-2: SP2; NbExp=3; IntAct=EBI-741480, EBI-9088579; CC Q9UMX0; Q99932-2: SPAG8; NbExp=3; IntAct=EBI-741480, EBI-11959123; CC Q9UMX0; Q7Z6I5: SPATA12; NbExp=3; IntAct=EBI-741480, EBI-10696971; CC Q9UMX0; Q86W54-2: SPATA24; NbExp=3; IntAct=EBI-741480, EBI-12041693; CC Q9UMX0; Q496A3: SPATS1; NbExp=3; IntAct=EBI-741480, EBI-3923692; CC Q9UMX0; Q9C004: SPRY4; NbExp=3; IntAct=EBI-741480, EBI-354861; CC Q9UMX0; P10124: SRGN; NbExp=6; IntAct=EBI-741480, EBI-744915; CC Q9UMX0; Q99469: STAC; NbExp=3; IntAct=EBI-741480, EBI-2652799; CC Q9UMX0; O75886: STAM2; NbExp=3; IntAct=EBI-741480, EBI-373258; CC Q9UMX0; Q13586: STIM1; NbExp=3; IntAct=EBI-741480, EBI-448878; CC Q9UMX0; O95947: TBX6; NbExp=3; IntAct=EBI-741480, EBI-2824328; CC Q9UMX0; O15273: TCAP; NbExp=3; IntAct=EBI-741480, EBI-954089; CC Q9UMX0; Q86WV5: TEN1; NbExp=3; IntAct=EBI-741480, EBI-2562799; CC Q9UMX0; P54274-2: TERF1; NbExp=3; IntAct=EBI-741480, EBI-711018; CC Q9UMX0; Q9BXU0: TEX12; NbExp=3; IntAct=EBI-741480, EBI-12090309; CC Q9UMX0; Q5T0J7-2: TEX35; NbExp=3; IntAct=EBI-741480, EBI-12833746; CC Q9UMX0; P04155: TFF1; NbExp=6; IntAct=EBI-741480, EBI-743871; CC Q9UMX0; Q8WTV1: THAP3; NbExp=3; IntAct=EBI-741480, EBI-17438286; CC Q9UMX0; O60830: TIMM17B; NbExp=3; IntAct=EBI-741480, EBI-2372529; CC Q9UMX0; Q96DC7: TMCO6; NbExp=7; IntAct=EBI-741480, EBI-746174; CC Q9UMX0; Q96DC7-2: TMCO6; NbExp=3; IntAct=EBI-741480, EBI-10284552; CC Q9UMX0; Q96B77: TMEM186; NbExp=3; IntAct=EBI-741480, EBI-9089409; CC Q9UMX0; P61165: TMEM258; NbExp=3; IntAct=EBI-741480, EBI-12019210; CC Q9UMX0; Q5JXX7: TMEM31; NbExp=6; IntAct=EBI-741480, EBI-10244617; CC Q9UMX0; Q8N0U2: TMEM61; NbExp=3; IntAct=EBI-741480, EBI-25830583; CC Q9UMX0; Q53NU3: tmp_locus_54; NbExp=3; IntAct=EBI-741480, EBI-10242677; CC Q9UMX0; Q71RG4-4: TMUB2; NbExp=3; IntAct=EBI-741480, EBI-25831574; CC Q9UMX0; P36406: TRIM23; NbExp=6; IntAct=EBI-741480, EBI-740098; CC Q9UMX0; Q13049: TRIM32; NbExp=7; IntAct=EBI-741480, EBI-742790; CC Q9UMX0; Q9UPQ4-2: TRIM35; NbExp=3; IntAct=EBI-741480, EBI-17716262; CC Q9UMX0; Q9Y3Q8: TSC22D4; NbExp=3; IntAct=EBI-741480, EBI-739485; CC Q9UMX0; O60636: TSPAN2; NbExp=3; IntAct=EBI-741480, EBI-3914288; CC Q9UMX0; Q6PF05: TTC23L; NbExp=3; IntAct=EBI-741480, EBI-8656864; CC Q9UMX0; Q9UGJ1-2: TUBGCP4; NbExp=3; IntAct=EBI-741480, EBI-10964469; CC Q9UMX0; O95881: TXNDC12; NbExp=4; IntAct=EBI-741480, EBI-2564581; CC Q9UMX0; P62987: UBA52; NbExp=3; IntAct=EBI-741480, EBI-357304; CC Q9UMX0; Q5U5U6: UBB; NbExp=3; IntAct=EBI-741480, EBI-1642104; CC Q9UMX0; Q96C32: UBC; NbExp=3; IntAct=EBI-741480, EBI-745483; CC Q9UMX0; P49459: UBE2A; NbExp=3; IntAct=EBI-741480, EBI-2339348; CC Q9UMX0; Q7KZS0: UBE2I; NbExp=3; IntAct=EBI-741480, EBI-10180829; CC Q9UMX0; Q13404: UBE2V1; NbExp=9; IntAct=EBI-741480, EBI-1050671; CC Q9UMX0; Q9UMX0: UBQLN1; NbExp=3; IntAct=EBI-741480, EBI-741480; CC Q9UMX0; Q9UHD9: UBQLN2; NbExp=3; IntAct=EBI-741480, EBI-947187; CC Q9UMX0; Q9NRR5: UBQLN4; NbExp=8; IntAct=EBI-741480, EBI-711226; CC Q9UMX0; Q04323: UBXN1; NbExp=3; IntAct=EBI-741480, EBI-1058647; CC Q9UMX0; Q92575: UBXN4; NbExp=6; IntAct=EBI-741480, EBI-723441; CC Q9UMX0; O94888: UBXN7; NbExp=3; IntAct=EBI-741480, EBI-1993627; CC Q9UMX0; P22415: USF1; NbExp=3; IntAct=EBI-741480, EBI-1054489; CC Q9UMX0; Q9P1Q0-4: VPS54; NbExp=3; IntAct=EBI-741480, EBI-25835297; CC Q9UMX0; Q2TAL6: VWC2; NbExp=3; IntAct=EBI-741480, EBI-11957238; CC Q9UMX0; Q9NX94: WBP1L; NbExp=3; IntAct=EBI-741480, EBI-10316321; CC Q9UMX0; Q8WWY7: WFDC12; NbExp=3; IntAct=EBI-741480, EBI-11958577; CC Q9UMX0; O00755: WNT7A; NbExp=3; IntAct=EBI-741480, EBI-727198; CC Q9UMX0; Q0VG75: XPO4; NbExp=3; IntAct=EBI-741480, EBI-10226948; CC Q9UMX0; O43829: ZBTB14; NbExp=3; IntAct=EBI-741480, EBI-10176632; CC Q9UMX0; Q8NAP8: ZBTB8B; NbExp=3; IntAct=EBI-741480, EBI-17494306; CC Q9UMX0; Q53FD0-2: ZC2HC1C; NbExp=3; IntAct=EBI-741480, EBI-14104088; CC Q9UMX0; Q9NP64: ZCCHC17; NbExp=3; IntAct=EBI-741480, EBI-746345; CC Q9UMX0; O60844: ZG16; NbExp=10; IntAct=EBI-741480, EBI-746479; CC Q9UMX0; Q96DA0: ZG16B; NbExp=3; IntAct=EBI-741480, EBI-953824; CC Q9UMX0; Q5VZL5: ZMYM4; NbExp=3; IntAct=EBI-741480, EBI-2514659; CC Q9UMX0; Q9UJ78-2: ZMYM5; NbExp=3; IntAct=EBI-741480, EBI-17634549; CC Q9UMX0; Q8WUU4: ZNF296; NbExp=3; IntAct=EBI-741480, EBI-8834821; CC Q9UMX0; Q96JL9-2: ZNF333; NbExp=3; IntAct=EBI-741480, EBI-25835852; CC Q9UMX0; Q6P1L6: ZNF343; NbExp=3; IntAct=EBI-741480, EBI-10252492; CC Q9UMX0; Q3KNS6-3: ZNF829; NbExp=3; IntAct=EBI-741480, EBI-18036029; CC Q9UMX0; A0A1U9X8X8; NbExp=3; IntAct=EBI-741480, EBI-17234977; CC Q9UMX0; B7Z3E8; NbExp=3; IntAct=EBI-741480, EBI-25831617; CC Q9UMX0; Q8WU02; NbExp=3; IntAct=EBI-741480, EBI-747182; CC Q9UMX0; P0DTC6: 6; Xeno; NbExp=3; IntAct=EBI-741480, EBI-25475897; CC Q9UMX0; P0DTD3: 9c; Xeno; NbExp=3; IntAct=EBI-741480, EBI-25475917; CC Q9UMX0; P00431: CCP1; Xeno; NbExp=3; IntAct=EBI-741480, EBI-4389; CC Q9UMX0; P35176: CPR5; Xeno; NbExp=3; IntAct=EBI-741480, EBI-5458; CC Q9UMX0; Q04201: CUE4; Xeno; NbExp=3; IntAct=EBI-741480, EBI-27928; CC Q9UMX0; P43497: CWP2; Xeno; NbExp=3; IntAct=EBI-741480, EBI-2044078; CC Q9UMX0; P40325: HUA1; Xeno; NbExp=3; IntAct=EBI-741480, EBI-23614; CC Q9UMX0; P61829: OLI1; Xeno; NbExp=3; IntAct=EBI-741480, EBI-9016907; CC Q9UMX0; Q02771: PET117; Xeno; NbExp=3; IntAct=EBI-741480, EBI-14092; CC Q9UMX0; P38886: RPN10; Xeno; NbExp=3; IntAct=EBI-741480, EBI-15949; CC Q9UMX0; P40092: SPI1; Xeno; NbExp=3; IntAct=EBI-741480, EBI-22721; CC Q9UMX0; P13130: SPS100; Xeno; NbExp=3; IntAct=EBI-741480, EBI-11523294; CC Q9UMX0; P27654: TIP1; Xeno; NbExp=3; IntAct=EBI-741480, EBI-19268; CC Q9UMX0; P54860: UFD2; Xeno; NbExp=3; IntAct=EBI-741480, EBI-20003; CC Q9UMX0; P38868: YHR180W; Xeno; NbExp=3; IntAct=EBI-741480, EBI-24840; CC Q9UMX0-2; O00154: ACOT7; NbExp=3; IntAct=EBI-10173939, EBI-948905; CC Q9UMX0-2; O95994: AGR2; NbExp=3; IntAct=EBI-10173939, EBI-712648; CC Q9UMX0-2; Q8TD06: AGR3; NbExp=3; IntAct=EBI-10173939, EBI-3925742; CC Q9UMX0-2; Q9NP55: BPIFA1; NbExp=3; IntAct=EBI-10173939, EBI-953896; CC Q9UMX0-2; Q9BXJ5: C1QTNF2; NbExp=3; IntAct=EBI-10173939, EBI-2817707; CC Q9UMX0-2; O43852: CALU; NbExp=3; IntAct=EBI-10173939, EBI-1171069; CC Q9UMX0-2; P80098: CCL7; NbExp=3; IntAct=EBI-10173939, EBI-718759; CC Q9UMX0-2; Q8TCZ2: CD99L2; NbExp=6; IntAct=EBI-10173939, EBI-2824782; CC Q9UMX0-2; P51788-4: CLCN2; NbExp=3; IntAct=EBI-10173939, EBI-16431116; CC Q9UMX0-2; Q03692: COL10A1; NbExp=3; IntAct=EBI-10173939, EBI-2528309; CC Q9UMX0-2; A0A0S2Z3K0: COL1A2; NbExp=3; IntAct=EBI-10173939, EBI-16431143; CC Q9UMX0-2; P08123: COL1A2; NbExp=6; IntAct=EBI-10173939, EBI-983038; CC Q9UMX0-2; Q8IYK4: COLGALT2; NbExp=3; IntAct=EBI-10173939, EBI-10263496; CC Q9UMX0-2; Q86VU5: COMTD1; NbExp=3; IntAct=EBI-10173939, EBI-2836030; CC Q9UMX0-2; P33240: CSTF2; NbExp=3; IntAct=EBI-10173939, EBI-711360; CC Q9UMX0-2; Q9H0L4: CSTF2T; NbExp=3; IntAct=EBI-10173939, EBI-747012; CC Q9UMX0-2; P78358: CTAG1B; NbExp=3; IntAct=EBI-10173939, EBI-1188472; CC Q9UMX0-2; O75638: CTAG2; NbExp=3; IntAct=EBI-10173939, EBI-10188927; CC Q9UMX0-2; Q9UHQ9: CYB5R1; NbExp=3; IntAct=EBI-10173939, EBI-953870; CC Q9UMX0-2; Q01524: DEFA6; NbExp=3; IntAct=EBI-10173939, EBI-10222451; CC Q9UMX0-2; A0A0S2Z5Y1: DOLK; NbExp=3; IntAct=EBI-10173939, EBI-16431159; CC Q9UMX0-2; O95967: EFEMP2; NbExp=3; IntAct=EBI-10173939, EBI-743414; CC Q9UMX0-2; Q96DN0: ERP27; NbExp=3; IntAct=EBI-10173939, EBI-953772; CC Q9UMX0-2; Q9HBU6: ETNK1; NbExp=3; IntAct=EBI-10173939, EBI-2834493; CC Q9UMX0-2; P12318: FCGR2A; NbExp=3; IntAct=EBI-10173939, EBI-1395970; CC Q9UMX0-2; P26885: FKBP2; NbExp=3; IntAct=EBI-10173939, EBI-719873; CC Q9UMX0-2; O14764: GABRD; NbExp=3; IntAct=EBI-10173939, EBI-744352; CC Q9UMX0-2; Q9UBU3: GHRL; NbExp=3; IntAct=EBI-10173939, EBI-10319458; CC Q9UMX0-2; P22352: GPX3; NbExp=3; IntAct=EBI-10173939, EBI-2832946; CC Q9UMX0-2; Q14416: GRM2; NbExp=3; IntAct=EBI-10173939, EBI-10232876; CC Q9UMX0-2; P06028: GYPB; NbExp=3; IntAct=EBI-10173939, EBI-10194756; CC Q9UMX0-2; P52789: HK2; NbExp=3; IntAct=EBI-10173939, EBI-741469; CC Q9UMX0-2; Q53GQ0: HSD17B12; NbExp=3; IntAct=EBI-10173939, EBI-2963255; CC Q9UMX0-2; P48723: HSPA13; NbExp=4; IntAct=EBI-10173939, EBI-750892; CC Q9UMX0-2; Q6PIK1: IGL@; NbExp=3; IntAct=EBI-10173939, EBI-10253735; CC Q9UMX0-2; Q6PIQ7: IGL@; NbExp=3; IntAct=EBI-10173939, EBI-6677651; CC Q9UMX0-2; Q8N355: IGL@; NbExp=3; IntAct=EBI-10173939, EBI-748681; CC Q9UMX0-2; Q17RA0: IL6ST; NbExp=3; IntAct=EBI-10173939, EBI-10238517; CC Q9UMX0-2; Q9P2K6: KLHL42; NbExp=3; IntAct=EBI-10173939, EBI-739890; CC Q9UMX0-2; Q99732: LITAF; NbExp=7; IntAct=EBI-10173939, EBI-725647; CC Q9UMX0-2; Q9NQG1: MANBAL; NbExp=3; IntAct=EBI-10173939, EBI-3867271; CC Q9UMX0-2; P33993: MCM7; NbExp=3; IntAct=EBI-10173939, EBI-355924; CC Q9UMX0-2; Q9NQG6: MIEF1; NbExp=3; IntAct=EBI-10173939, EBI-740987; CC Q9UMX0-2; Q96C03: MIEF2; NbExp=3; IntAct=EBI-10173939, EBI-750153; CC Q9UMX0-2; P55198: MLLT6; NbExp=3; IntAct=EBI-10173939, EBI-740216; CC Q9UMX0-2; Q8IW45: NAXD; NbExp=3; IntAct=EBI-10173939, EBI-8650724; CC Q9UMX0-2; P41271: NBL1; NbExp=3; IntAct=EBI-10173939, EBI-10208650; CC Q9UMX0-2; Q96IV0: NGLY1; NbExp=3; IntAct=EBI-10173939, EBI-6165879; CC Q9UMX0-2; A0A0S2Z5K2: NLGN3; NbExp=3; IntAct=EBI-10173939, EBI-16431177; CC Q9UMX0-2; Q13232: NME3; NbExp=3; IntAct=EBI-10173939, EBI-713684; CC Q9UMX0-2; Q9BVL2: NUP58; NbExp=3; IntAct=EBI-10173939, EBI-2811583; CC Q9UMX0-2; Q96AQ6: PBXIP1; NbExp=3; IntAct=EBI-10173939, EBI-740845; CC Q9UMX0-2; Q96FE7: PIK3IP1; NbExp=3; IntAct=EBI-10173939, EBI-10285708; CC Q9UMX0-2; P53816: PLAAT3; NbExp=3; IntAct=EBI-10173939, EBI-746318; CC Q9UMX0-2; Q8ND90: PNMA1; NbExp=3; IntAct=EBI-10173939, EBI-302345; CC Q9UMX0-2; P23284: PPIB; NbExp=3; IntAct=EBI-10173939, EBI-359252; CC Q9UMX0-2; P45877: PPIC; NbExp=3; IntAct=EBI-10173939, EBI-953909; CC Q9UMX0-2; Q96NZ9: PRAP1; NbExp=3; IntAct=EBI-10173939, EBI-2116102; CC Q9UMX0-2; A5D903: PRB1; NbExp=3; IntAct=EBI-10173939, EBI-10173935; CC Q9UMX0-2; Q15008: PSMD6; NbExp=3; IntAct=EBI-10173939, EBI-359701; CC Q9UMX0-2; Q9NPQ8-4: RIC8A; NbExp=3; IntAct=EBI-10173939, EBI-9091816; CC Q9UMX0-2; P04843: RPN1; NbExp=3; IntAct=EBI-10173939, EBI-355963; CC Q9UMX0-2; Q9BWD3: RTL8A; NbExp=3; IntAct=EBI-10173939, EBI-741643; CC Q9UMX0-2; Q17RB0: RTL8B; NbExp=3; IntAct=EBI-10173939, EBI-10238588; CC Q9UMX0-2; A6ZKI3: RTL8C; NbExp=3; IntAct=EBI-10173939, EBI-10174072; CC Q9UMX0-2; P05408: SCG5; NbExp=3; IntAct=EBI-10173939, EBI-722635; CC Q9UMX0-2; Q96GD3: SCMH1; NbExp=3; IntAct=EBI-10173939, EBI-713793; CC Q9UMX0-2; P05121: SERPINE1; NbExp=3; IntAct=EBI-10173939, EBI-953978; CC Q9UMX0-2; O75830: SERPINI2; NbExp=3; IntAct=EBI-10173939, EBI-750144; CC Q9UMX0-2; Q9BVW6: SMIM2; NbExp=3; IntAct=EBI-10173939, EBI-10300146; CC Q9UMX0-2; P02814: SMR3B; NbExp=3; IntAct=EBI-10173939, EBI-738612; CC Q9UMX0-2; P10124: SRGN; NbExp=3; IntAct=EBI-10173939, EBI-744915; CC Q9UMX0-2; Q96DC7-2: TMCO6; NbExp=3; IntAct=EBI-10173939, EBI-10284552; CC Q9UMX0-2; Q5JXX7: TMEM31; NbExp=3; IntAct=EBI-10173939, EBI-10244617; CC Q9UMX0-2; A0A0S2Z5T9: TMEM67; NbExp=3; IntAct=EBI-10173939, EBI-16431189; CC Q9UMX0-2; Q71RG4: TMUB2; NbExp=3; IntAct=EBI-10173939, EBI-2820477; CC Q9UMX0-2; Q13049: TRIM32; NbExp=3; IntAct=EBI-10173939, EBI-742790; CC Q9UMX0-2; O95881: TXNDC12; NbExp=3; IntAct=EBI-10173939, EBI-2564581; CC Q9UMX0-2; Q13404: UBE2V1; NbExp=3; IntAct=EBI-10173939, EBI-1050671; CC Q9UMX0-2; Q04323: UBXN1; NbExp=3; IntAct=EBI-10173939, EBI-1058647; CC Q9UMX0-2; Q92575: UBXN4; NbExp=3; IntAct=EBI-10173939, EBI-723441; CC Q9UMX0-2; Q0VG75: XPO4; NbExp=3; IntAct=EBI-10173939, EBI-10226948; CC Q9UMX0-2; Q8WV99: ZFAND2B; NbExp=3; IntAct=EBI-10173939, EBI-747823; CC Q9UMX0-2; O60844: ZG16; NbExp=3; IntAct=EBI-10173939, EBI-746479; CC Q9UMX0-2; Q96DA0: ZG16B; NbExp=3; IntAct=EBI-10173939, EBI-953824; CC Q9UMX0-2; Q5VZL5: ZMYM4; NbExp=3; IntAct=EBI-10173939, EBI-2514659; CC Q9UMX0-2; Q8WU02; NbExp=3; IntAct=EBI-10173939, EBI-747182; CC Q9UMX0-2; Q96FB2; NbExp=3; IntAct=EBI-10173939, EBI-2857623; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:16159959, CC ECO:0000269|PubMed:23979357}. Nucleus {ECO:0000269|PubMed:23979357}. CC Endoplasmic reticulum {ECO:0000269|PubMed:19822669}. Cytoplasmic CC vesicle, autophagosome {ECO:0000269|PubMed:19148225, CC ECO:0000269|PubMed:20529957, ECO:0000269|PubMed:21143716, CC ECO:0000269|PubMed:21695056, ECO:0000269|PubMed:23307288, CC ECO:0000269|PubMed:23459205}. Cell membrane CC {ECO:0000269|PubMed:21143716, ECO:0000269|PubMed:23307288}. CC Note=Detected in neuronal processes and at synapses (By similarity). CC Recruited to the ER during ER-associated protein degradation (ERAD) CC (PubMed:19822669). Isoform 1 and isoform 3 colocalize with PSEN1 in the CC cell membrane and in cytoplasmic juxtanuclear structures called CC aggresomes (PubMed:21143716). Colocalizes with ORAI1 and TICAM1 in the CC autophagosome (PubMed:21695056, PubMed:23307288). Colocalizes with CC EPS15 and HGS in ubiquitin-rich cytoplasmic aggregates that are not CC endocytic compartments and with EPS15 also in aggresomes CC (PubMed:16159959). {ECO:0000250|UniProtKB:Q9JJP9, CC ECO:0000269|PubMed:16159959, ECO:0000269|PubMed:19822669, CC ECO:0000269|PubMed:21143716, ECO:0000269|PubMed:21695056, CC ECO:0000269|PubMed:23307288}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; CC IsoId=Q9UMX0-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9UMX0-2; Sequence=VSP_009787; CC Name=3; CC IsoId=Q9UMX0-3; Sequence=VSP_057689; CC Name=4; CC IsoId=Q9UMX0-4; Sequence=VSP_057690, VSP_057691; CC -!- TISSUE SPECIFICITY: Brain (at protein level) (PubMed:18953672). CC Ubiquitous. Highly expressed throughout the brain; detected in neurons CC and in neuropathological lesions, such as neurofibrillary tangles and CC Lewy bodies. Highly expressed in heart, placenta, pancreas, lung, CC liver, skeletal muscle and kidney. {ECO:0000269|PubMed:11076969, CC ECO:0000269|PubMed:11853878, ECO:0000269|PubMed:18953672}. CC -!- DOMAIN: The UBA domain mediates binding to PSEN1 and PSEN2. It also CC binds ubiquitin with micromolar affinity, independently of CC polyubiquitin linkage type. Essential for its association with CC microtubule-associated protein 1 light chain 3 (MAP1LC3). CC {ECO:0000269|PubMed:11076969, ECO:0000269|PubMed:15147878, CC ECO:0000269|PubMed:19148225}. CC -!- DOMAIN: The ubiquitin-like domain mediates its association with the CC subunits of the proteasome. {ECO:0000269|PubMed:15147878}. CC -!- DOMAIN: Dimerization is dependent upon the central region of the CC protein containing the STI1 domains and is independent of its CC ubiquitin-like and UBA domains. {ECO:0000269|PubMed:16813565}. CC -!- PTM: Degraded during both macroautophagy and during chaperone-mediated CC autophagy (CMA). {ECO:0000269|PubMed:20529957}. CC -!- PTM: Phosphorylated. {ECO:0000269|PubMed:11853878}. CC -!- PTM: Ubiquitinated. {ECO:0000269|PubMed:16159959}. CC -!- MISCELLANEOUS: May be a prognostic marker for lung adenocarcinoma CC patient clinical outcome. {ECO:0000269|PubMed:22233804}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF176069; AAD49751.3; -; mRNA. DR EMBL; AF293384; AAG02473.1; -; mRNA. DR EMBL; AB035275; BAB20436.1; -; mRNA. DR EMBL; HM005532; AEE61129.1; -; mRNA. DR EMBL; AL136643; CAB66578.1; -; mRNA. DR EMBL; AL354920; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471089; EAW62659.1; -; Genomic_DNA. DR EMBL; CH471089; EAW62661.1; -; Genomic_DNA. DR EMBL; CH471089; EAW62664.1; -; Genomic_DNA. DR EMBL; BC010066; AAH10066.1; -; mRNA. DR EMBL; BC039294; AAH39294.1; -; mRNA. DR EMBL; AK074535; -; NOT_ANNOTATED_CDS; mRNA. DR CCDS; CCDS6663.1; -. [Q9UMX0-1] DR CCDS; CCDS6664.1; -. [Q9UMX0-2] DR RefSeq; NP_038466.2; NM_013438.4. [Q9UMX0-1] DR RefSeq; NP_444295.1; NM_053067.3. [Q9UMX0-2] DR PDB; 2JY5; NMR; -; A=541-586. DR PDB; 2JY6; NMR; -; B=541-586. DR PDB; 2KLC; NMR; -; A=34-112. DR PDBsum; 2JY5; -. DR PDBsum; 2JY6; -. DR PDBsum; 2KLC; -. DR AlphaFoldDB; Q9UMX0; -. DR BMRB; Q9UMX0; -. DR SASBDB; Q9UMX0; -. DR SMR; Q9UMX0; -. DR BioGRID; 119007; 460. DR CORUM; Q9UMX0; -. DR DIP; DIP-41629N; -. DR FunCoup; Q9UMX0; 3499. DR IntAct; Q9UMX0; 383. DR MINT; Q9UMX0; -. DR STRING; 9606.ENSP00000365576; -. DR GlyCosmos; Q9UMX0; 5 sites, 1 glycan. DR GlyGen; Q9UMX0; 8 sites, 1 O-linked glycan (7 sites). DR iPTMnet; Q9UMX0; -. DR MetOSite; Q9UMX0; -. DR PhosphoSitePlus; Q9UMX0; -. DR BioMuta; UBQLN1; -. DR DMDM; 48475013; -. DR REPRODUCTION-2DPAGE; IPI00071180; -. DR jPOST; Q9UMX0; -. DR MassIVE; Q9UMX0; -. DR PaxDb; 9606-ENSP00000365576; -. DR PeptideAtlas; Q9UMX0; -. DR ProteomicsDB; 85215; -. [Q9UMX0-1] DR ProteomicsDB; 85216; -. [Q9UMX0-2] DR Pumba; Q9UMX0; -. DR Antibodypedia; 27540; 348 antibodies from 32 providers. DR DNASU; 29979; -. DR Ensembl; ENST00000257468.11; ENSP00000257468.7; ENSG00000135018.15. [Q9UMX0-2] DR Ensembl; ENST00000376395.9; ENSP00000365576.4; ENSG00000135018.15. [Q9UMX0-1] DR GeneID; 29979; -. DR KEGG; hsa:29979; -. DR MANE-Select; ENST00000376395.9; ENSP00000365576.4; NM_013438.5; NP_038466.2. DR UCSC; uc004amv.4; human. [Q9UMX0-1] DR AGR; HGNC:12508; -. DR ClinPGx; PA37155; -. DR CTD; 29979; -. DR DisGeNET; 29979; -. DR GeneCards; UBQLN1; -. DR HGNC; HGNC:12508; UBQLN1. DR HPA; ENSG00000135018; Low tissue specificity. DR MIM; 605046; gene. DR OpenTargets; ENSG00000135018; -. DR VEuPathDB; HostDB:ENSG00000135018; -. DR eggNOG; KOG0010; Eukaryota. DR GeneTree; ENSGT00940000156437; -. DR HOGENOM; CLU_024293_4_0_1; -. DR InParanoid; Q9UMX0; -. DR OMA; PGMDMFG; -. DR OrthoDB; 9450922at2759; -. DR PAN-GO; Q9UMX0; 6 GO annotations based on evolutionary models. DR PhylomeDB; Q9UMX0; -. DR PathwayCommons; Q9UMX0; -. DR Reactome; R-HSA-8856825; Cargo recognition for clathrin-mediated endocytosis. DR SignaLink; Q9UMX0; -. DR SIGNOR; Q9UMX0; -. DR Agora; ENSG00000135018; -. DR BioGRID-ORCS; 29979; 25 hits in 1162 CRISPR screens. DR CD-CODE; EB3EADD3; Ubqln puncta. DR ChiTaRS; UBQLN1; human. DR EvolutionaryTrace; Q9UMX0; -. DR GeneWiki; UBQLN1; -. DR GenomeRNAi; 29979; -. DR Pharos; Q9UMX0; Tbio. DR PRO; PR:Q9UMX0; -. DR Proteomes; UP000005640; Chromosome 9. DR RNAct; Q9UMX0; protein. DR Bgee; ENSG00000135018; Expressed in ileal mucosa and 196 other cell types or tissues. DR ExpressionAtlas; Q9UMX0; baseline and differential. DR GO; GO:0016235; C:aggresome; IDA:UniProtKB. DR GO; GO:0005776; C:autophagosome; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0031410; C:cytoplasmic vesicle; IEA:UniProtKB-KW. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:HGNC-UCL. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0000502; C:proteasome complex; IEA:UniProtKB-KW. DR GO; GO:0032991; C:protein-containing complex; IDA:LIFEdb. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0019900; F:kinase binding; IPI:UniProtKB. DR GO; GO:0031593; F:polyubiquitin modification-dependent protein binding; IDA:UniProtKB. DR GO; GO:0035973; P:aggrephagy; IDA:UniProtKB. DR GO; GO:0000045; P:autophagosome assembly; IMP:GO_Central. DR GO; GO:0097352; P:autophagosome maturation; IMP:GO_Central. DR GO; GO:0071456; P:cellular response to hypoxia; IMP:BHF-UCL. DR GO; GO:0036503; P:ERAD pathway; IMP:UniProtKB. DR GO; GO:0016236; P:macroautophagy; IMP:GO_Central. DR GO; GO:1901340; P:negative regulation of store-operated calcium channel activity; IMP:UniProtKB. DR GO; GO:0034140; P:negative regulation of toll-like receptor 3 signaling pathway; IEA:Ensembl. DR GO; GO:1904294; P:positive regulation of ERAD pathway; IMP:UniProtKB. DR GO; GO:0031398; P:positive regulation of protein ubiquitination; IDA:UniProtKB. DR GO; GO:0016241; P:regulation of macroautophagy; IBA:GO_Central. DR GO; GO:1902175; P:regulation of oxidative stress-induced intrinsic apoptotic signaling pathway; IMP:BHF-UCL. DR GO; GO:0031396; P:regulation of protein ubiquitination; IDA:HGNC-UCL. DR GO; GO:0034976; P:response to endoplasmic reticulum stress; IMP:BHF-UCL. DR GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IBA:GO_Central. DR CDD; cd14399; UBA_PLICs; 1. DR CDD; cd01808; Ubl_PLICs; 1. DR FunFam; 1.10.260.100:FF:000001; Ubiquilin 1; 1. DR FunFam; 1.10.260.100:FF:000003; Ubiquilin 1; 1. DR FunFam; 1.10.8.10:FF:000007; Ubiquilin 1; 1. DR FunFam; 3.10.20.90:FF:000081; ubiquilin-1 isoform X2; 1. DR Gene3D; 1.10.260.100; -; 2. DR Gene3D; 1.10.8.10; DNA helicase RuvA subunit, C-terminal domain; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 1. DR InterPro; IPR006636; STI1_HS-bd. DR InterPro; IPR015940; UBA. DR InterPro; IPR009060; UBA-like_sf. DR InterPro; IPR015496; Ubiquilin. DR InterPro; IPR000626; Ubiquitin-like_dom. DR InterPro; IPR029071; Ubiquitin-like_domsf. DR PANTHER; PTHR10677; UBIQUILIN; 1. DR PANTHER; PTHR10677:SF16; UBIQUILIN-1; 1. DR Pfam; PF00627; UBA; 1. DR Pfam; PF00240; ubiquitin; 1. DR Pfam; PF23195; UBQLN1; 1. DR SMART; SM00727; STI1; 4. DR SMART; SM00165; UBA; 1. DR SMART; SM00213; UBQ; 1. DR SUPFAM; SSF46934; UBA-like; 1. DR SUPFAM; SSF54236; Ubiquitin-like; 1. DR PROSITE; PS50030; UBA; 1. DR PROSITE; PS50053; UBIQUITIN_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Autophagy; Cell membrane; KW Cytoplasm; Cytoplasmic vesicle; Direct protein sequencing; KW Endoplasmic reticulum; Membrane; Nucleus; Phosphoprotein; Proteasome; KW Proteomics identification; Reference proteome; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:22223895" FT CHAIN 2..589 FT /note="Ubiquilin-1" FT /id="PRO_0000211008" FT DOMAIN 37..111 FT /note="Ubiquitin-like" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00214" FT DOMAIN 182..210 FT /note="STI1 1" FT /evidence="ECO:0000255" FT DOMAIN 212..251 FT /note="STI1 2" FT /evidence="ECO:0000255" FT DOMAIN 387..434 FT /note="STI1 3" FT /evidence="ECO:0000255" FT DOMAIN 438..470 FT /note="STI1 4" FT /evidence="ECO:0000255" FT DOMAIN 546..586 FT /note="UBA" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00212" FT REGION 1..35 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 110..145 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 178..428 FT /note="Interaction with UBXN4" FT /evidence="ECO:0000269|PubMed:19822669" FT REGION 295..371 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 488..520 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1..11 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 12..35 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 110..124 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 125..145 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 299..313 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 327..360 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 489..499 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 509..520 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:22223895" FT VAR_SEQ 61..237 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:18953672" FT /id="VSP_057689" FT VAR_SEQ 150..181 FT /note="GGLGGLAGLSSLGLNTTNFSELQSQMQRQLLS -> DVGTCQESSNDAGDDE FT EPGPSFEQPRKHPRGI (in isoform 4)" FT /evidence="ECO:0000303|PubMed:18953672" FT /id="VSP_057690" FT VAR_SEQ 182..589 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:18953672" FT /id="VSP_057691" FT VAR_SEQ 417..444 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:18953672" FT /id="VSP_009787" FT CONFLICT 25 FT /note="A -> T (in Ref. 9; AAH39294)" FT /evidence="ECO:0000305" FT CONFLICT 41 FT /note="V -> A (in Ref. 4; BAB20436)" FT /evidence="ECO:0000305" FT CONFLICT 61 FT /note="F -> S (in Ref. 4; BAB20436)" FT /evidence="ECO:0000305" FT CONFLICT 91 FT /note="L -> S (in Ref. 4; BAB20436)" FT /evidence="ECO:0000305" FT CONFLICT 125 FT /note="S -> G (in Ref. 6; CAB66578)" FT /evidence="ECO:0000305" FT CONFLICT 202 FT /note="P -> H (in Ref. 9; AAH39294)" FT /evidence="ECO:0000305" FT CONFLICT 537..538 FT /note="NP -> YS (in Ref. 4; BAB20436)" FT /evidence="ECO:0000305" FT STRAND 37..42 FT /evidence="ECO:0007829|PDB:2KLC" FT STRAND 47..52 FT /evidence="ECO:0007829|PDB:2KLC" FT HELIX 58..69 FT /evidence="ECO:0007829|PDB:2KLC" FT HELIX 73..75 FT /evidence="ECO:0007829|PDB:2KLC" FT STRAND 76..80 FT /evidence="ECO:0007829|PDB:2KLC" FT STRAND 83..85 FT /evidence="ECO:0007829|PDB:2KLC" FT HELIX 92..94 FT /evidence="ECO:0007829|PDB:2KLC" FT STRAND 101..106 FT /evidence="ECO:0007829|PDB:2KLC" FT TURN 543..547 FT /evidence="ECO:0007829|PDB:2JY5" FT HELIX 548..556 FT /evidence="ECO:0007829|PDB:2JY5" FT HELIX 562..572 FT /evidence="ECO:0007829|PDB:2JY5" FT HELIX 576..583 FT /evidence="ECO:0007829|PDB:2JY5" SQ SEQUENCE 589 AA; 62519 MW; 8B4756B6113B7025 CRC64; MAESGESGGP PGSQDSAAGA EGAGAPAAAA SAEPKIMKVT VKTPKEKEEF AVPENSSVQQ FKEEISKRFK SHTDQLVLIF AGKILKDQDT LSQHGIHDGL TVHLVIKTQN RPQDHSAQQT NTAGSNVTTS STPNSNSTSG SATSNPFGLG GLGGLAGLSS LGLNTTNFSE LQSQMQRQLL SNPEMMVQIM ENPFVQSMLS NPDLMRQLIM ANPQMQQLIQ RNPEISHMLN NPDIMRQTLE LARNPAMMQE MMRNQDRALS NLESIPGGYN ALRRMYTDIQ EPMLSAAQEQ FGGNPFASLV SNTSSGEGSQ PSRTENRDPL PNPWAPQTSQ SSSASSGTAS TVGGTTGSTA SGTSGQSTTA PNLVPGVGAS MFNTPGMQSL LQQITENPQL MQNMLSAPYM RSMMQSLSQN PDLAAQMMLN NPLFAGNPQL QEQMRQQLPT FLQQMQNPDT LSAMSNPRAM QALLQIQQGL QTLATEAPGL IPGFTPGLGA LGSTGGSSGT NGSNATPSEN TSPTAGTTEP GHQQFIQQML QALAGVNPQL QNPEVRFQQQ LEQLSAMGFL NREANLQALI ATGGDINAAI ERLLGSQPS //